

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7772

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GAGAGAGGAGGAGCTGG 830
||||| |||||
DB 17 GAGAGCAGAGCTGG 2

RESULT 125
US-09-480-017-8/c
; Sequence 8, Application US/09480017
; Patent No. 6388067
; GENERAL INFORMATION:
; APPLICANT: Yu, Su-May
; APPLICANT: Tong, Wu-Fu
; TITLE OF INVENTION: RICE CYSTEINE PROTEINASE GENE PROMOTER
; FILE REFERENCE: 08919-038001
; CURRENT APPLICATION NUMBER: US/09/480,017
; CURRENT FILING DATE: 2000-01-10
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: Fast-Seq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthesized primer
US-09-480-017-8

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 699 TGGAGAGTGAGCGCGA 714
||||| |||||
DB 17 TGGAGGCTGAGGCGCA 2

RESULT 126
US-09-474-432B-478
; Sequence 478, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MEHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 478
; LENGTH: 17

; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-478

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 92;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 263 CTGCACCTGCCTTCAG 278
|:|||||:|
DB 1 CUCGCGGCGCUCGAG 16

RESULT 127
US-09-474-432B-605
; Sequence 605, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MEHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 605
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-605

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 512 CTGCGGGAGGTGGAGC 527
|:|||||:|
DB 1 CUGCGGGAGCUCGAGC 16

RESULT 128
US-09-371-772B-479
; Sequence 479, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1934:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1934

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 92;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 875 AACCATCAAGCA 890
DB 1 AACUACCUAAGCA 16

RESULT 123
US-08-584-040-7615
Sequence 7615, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974

FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7615:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7615

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 92;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 875 AACCATCAAGCA 890
DB 1 AACUACCUAAGCA 16

RESULT 124
US-08-584-040-7772/c
Sequence 7772, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7772:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs

RESULT 120

US-09-071-845-1868
; Sequence 1868, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOSYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071.845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292.620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1868:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-1868

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 461 GAGAGACTCGGCTTGG 476

Db 1 GAGAACCCGCGCCUGG 16

RESULT 121

US-08-881-450A-6
; Sequence 6, Application US/08881450A
; Patent No. 6274310
; GENERAL INFORMATION:

; APPLICANT: Habener, J.F. and Stoffers, D.A.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DETECTING
; TITLE OF INVENTION: PANCREATIC DISEASE
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Inc.
; STREET: One Financial Center
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/881,450A
; FILING DATE: June 24, 1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathleen M. Williams
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: 11275/7823
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-345-9100
; TELEFAX: 617-345-9111
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; FEATURE:
; NAME/KEY: primer S17b
; US-08-881-450A-6

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 680 AGCGAGCAGCGCGGC 695

Db 1 AGCGAGCAGCGGAGGC 16

RESULT 122

US-08-584-040-1934
; Sequence 1934, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-071-845-1790

Query Match
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

1.7%; Score 12.8; DB 1; Length 17;

Qy 461 GAGAGACTCGGCTGG 476
|||||:|||||:
Db 1 GAGAACCCGCGCCUGG 16

RESULT 118
US-09-071-845-1801
; Sequence 1801, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1801:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-09-071-845-1801

Qy 461 GAGAGACTCGGCTGG 476
|||||:|||||:
Db 1 GAGAACCCGCGCCUGG 16

RESULT 119
US-09-071-845-1823
; Sequence 1823, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1823:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-09-071-845-1823

Qy 461 GAGAGACTCGGCTGG 476
|||||:|||||:
Db 1 GAGAACCCGCGCCUGG 16

Query Match
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

1.7%; Score 12.8; DB 1; Length 17;

Qy 461 GAGAGACTCGGCTGG 476
|||||:|||||:
Db 1 GAGAACCCGCGCCUGG 16

Query Match
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

1.7%; Score 12.8; DB 1; Length 17;


```

COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
PRIOR APPLICATION DATA: 08/008,895
APPLICATION NUMBER: 07/989,849
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1801:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1801

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCGCTGG 476
||| |:|||:||
DB 1 GAGAACCTCGGCCUGG 16

RESULT 114
US-08-292-620A-1823
; Sequence 1823, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOSOME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0

```

APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1639:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1639

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
|||||:|||||:
Db 1 GAGAACCCGCGCCUGG 16

RESULT 112

US-08-292-620A-1790
Sequence 1790, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1790:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1790

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
|||||:|||||:
Db 1 GAGAACCCGCGCCUGG 16

RESULT 113

US-08-292-620A-1801
Sequence 1801, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California

Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 843 TGGCCTATCACCAGCT 858
:||||: |||||:
Db 2 UGGCCUGCACCAGCU 17

RESULT 109
US-08-373-124A-176/c
; Sequence 176, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 176:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-176

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 405 AGAGGAGGAGGAGGA 420
||| ||||| |||||
Db 17 AGAAGGAGGAGGAGGA 2

RESULT 110
US-08-435-628-176/c

; Sequence 176, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 176:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-176

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 405 AGAGGAGGAGGAGGA 420
||| ||||| |||||
Db 17 AGAAGGAGGAGGAGGA 2

RESULT 111
US-08-292-620A-1639
; Sequence 1639, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen

/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/435,628
/ FILING DATE: 05-MAY-1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/373,124
/ FILING DATE: January 13, 1995
/ APPLICATION NUMBER: 08/245,466
/ FILING DATE: May 18, 1994
/ APPLICATION NUMBER: 08/192,943
/ FILING DATE: February 7, 1994
/ APPLICATION NUMBER: 07/987,132
/ FILING DATE: December 7, 1992
/ APPLICATION NUMBER: 07/936,422
/ FILING DATE: August 26, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 209/035
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 182:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-435-628-182

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 409 GGAGGAGGAGGAG 421
Db 15 GGAGGAGGAGGAG 3

RESULT 104
US-09-866-108A-7242
/ Sequence 7242, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668

/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ CLASSIFICATION: 514
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aeonica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 7242
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-09-866-108A-7242

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAG 709
Db 5 GCTGGAGAGTGAG 17

RESULT 105
US-09-866-108A-8974/c
/ Sequence 8974, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aeonica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 8974
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-09-866-108A-8974

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACGAGCTCTCC 863

; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 182:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-182

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 409 GGAGGAGGAGGAG 421
Db 15 GGAGGAGGAGGAG 3

RESULT 102
US-08-628-180/c
; Sequence 180, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 180:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-180

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 409 GGAGGAGGAGGAG 421
Db 16 GGAGGAGGAGGAG 4

RESULT 103
US-08-435-628-182/c
; Sequence 182, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1

```
US-09-685-664B-3805/c
; Sequence 3805, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MH800-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3805
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3805

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGC 710
Db 16 AGCTGGAGAGTGAGC 2

RESULT 99
US-09-811-286-11
; Sequence 11, Application US/09811286
; Patent No. 6586183
; GENERAL INFORMATION:
; APPLICANT: Drysdale, Connie M
; APPLICANT: Judson, Richard S
; APPLICANT: Liggett, Stephen B
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Stack, Catherine B
; APPLICANT: Stephens, J. Claiborne
; TITLE OF INVENTION: Association of beta2-adrenergic receptor haplotypes
; TITLE OF INVENTION: with drug response
; FILE REFERENCE: MWH-0303US1
; CURRENT APPLICATION NUMBER: US/09/811,286
; CURRENT FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-811-286-11

Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 196 CAGTGGTGGCCCG 208
Db 3 CAGTGGTGGCCCG 15

RESULT 100
US-08-373-124A-180/c
; Sequence 180, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
```

```
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 180:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-180

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 409 GGAGGAGGAGGAG 421
Db 16 GGAGGAGGAGGAG 4

RESULT 101
US-08-373-124A-182/c
; Sequence 182, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
```

;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aeomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 8419
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-8419

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAAGG 503

Db 3 TGAAGAGCGCAGAAGG 17

RESULT 96

US-09-866-108A-8420
;; Sequence 8420, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aeomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 8419
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-8419

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 98

;; SOFTWARE: Aeomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 8420
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-8420

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAAGG 503

Db 2 TGAAGAGCGCAGAAGG 16

RESULT 97

US-09-866-108A-8969/c
;; Sequence 8969, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aeomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 8969
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-8969

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 852 ACCAGCTCTTCCAAG 866

Db 17 ACCAGCTCTTCCATG 3

; Patent No. 6686188
; SEQ ID NO 7248
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7248

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 699 TGGAGAGTGAGCGCG 713
|||||
Db 1 TGGAGAGTGAGCGCG 15

RESULT 93

US-09-866-108A-7448
; Sequence 7448, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; SOFTWARE: Aecomica Sequence Listing Engine

; NUMBER OF SEQ ID NOS: 15755

; Patent No. 6686188

; SEQ ID NO 7448

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-7448

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 GGAGAGGAGGTTCTCT 426
|||||
Db 3 GGAGAGGAGGTTCTCT 17

RESULT 94

US-09-866-108A-7452

; Sequence 7452, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; SOFTWARE: Aecomica Sequence Listing Engine

; NUMBER OF SEQ ID NOS: 15755

; Patent No. 6686188

; SEQ ID NO 7452

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-7452

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCCTCA 428
|||||
Db 1 AGAAGGAGTTCCTCA 15

RESULT 95

US-09-866-108A-8419

; Sequence 8419, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6824
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6824

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 16 CACCTGCCTTCAGAA 2

RESULT 91
US-09-866-108A-6825/C
; Sequence 6825, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6824
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6824

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 16 CACCTGCCTTCAGAA 2

RESULT 92
US-09-866-108A-7248
; Sequence 7248, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine

; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8022:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-8022

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGC 710
Db 16 AGCTGGAGAGGGAGC 2

RESULT 87
US-09-474-432B-657/c
; Sequence 657, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MEH800-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 657
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-657

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 642 AGGAATGCCAGGCTC 656
Db 16 AGAAATGCCAGGCTC 2

RESULT 88
US-09-371-772B-3805/c
; Sequence 3805, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggan, Jim
; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8022:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-8022

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGC 710
Db 16 AGCTGGAGAGGGAGC 2

RESULT 89
US-09-476-387-656/c
; Sequence 656, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MEH800-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 656
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-656

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 73;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 642 AGGAATGCCAGGCTC 656
Db 16 AGAAATGCCAGGCTC 2

RESULT 90
US-09-866-108A-6824/c
; Sequence 6824, Application US/09866108A

```

RESULT 85
US-08-345-264A-1/c
; Sequence 1, Application US/08345264A
; Patent No. 5660983
; GENERAL INFORMATION:
; APPLICANT: Charles S. Levings
; APPLICANT: Ralph Dewey
; TITLE OF INVENTION: STERILITY FACTOR
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jeff Lloyd
; STREET: 2421 N.W. 41st Street, Suite A-1
; CITY: Gainesville
; STATE: FL
; COUNTRY: USA
; ZIP: 32606

```

RESULT 86
US-08-584-040-8022/c
; Sequence 8022, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327

```

; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA: US/09/038,073
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 821:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-821

```

```

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 59;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 579 CCCAGGTGACGTCT 593
Db 15 CCCAGGTGAAGTCT 1

```

```

RESULT 82
US-09-275-850-18
; Sequence 18, Application US/09275850A
; Patent No. 6261774
; GENERAL INFORMATION:
; APPLICANT: Pagratis, Nikos
; APPLICANT: Gold, Larry
; APPLICANT: Shtatland, Timur
; APPLICANT: Javornik, Brenda
; TITLE OF INVENTION: Truncation SELEX Method
; FILE REFERENCE: NEX 79
; CURRENT APPLICATION NUMBER: US/09/275,850A
; CURRENT FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 351
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 18
; LENGTH: 15
; TYPE: RNA
; ORGANISM: E. coli
; US-09-275-850-18

```

```

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 59;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 720 TGCAGCAGCAGCACA 734
Db 1 UGCAGCAGCAGCACA 15

```

```

RESULT 83
US-08-292-620A-1619

```

```

; Sequence 1619, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1619:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1619

```

```

Query Match 1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 66;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 304 GCGCTGCCTGGAGGA 318
Db 1 GCGCUGCCUGGUGGA 15

```

```

RESULT 84
US-09-071-845-1619
; Sequence 1619, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan

```


Query Match 1.8%; Score 13.6; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 68;
Matches 10; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy	315	AGGAGAATCAAGAGCT	330
		: : : : : : :	
Db	2	ARGARAAYCARGARYT	17

RESULT 79

US-09-142-080-44
; Sequence 44, Application US/09142080

FACE NO. 0515103
GENERAL INFORMATION:

GENERAL INFORMATION:
APPLICANT: Aboogadie, Fe C.
Cruz, Lourdes J.
Olivera, Baldomero M.
Walker, Craig
Colledge, Clark
Hillyard, David R.
Jimenez, Elsie
Laver, Richard T.
Zhou, Li-Ming

McCabe, R. Tyler
TITLE OF INVENTION: Conantokins
NUMBER OF SEQUENCES: 71
CORRESPONDENCE ADDRESS:
ADDRESSEE: Rothwell, Figg, Ernst & Manbeck, p.c.
STREET: 555 Thirteenth Street, N.W., Suite 701-E
CITY: Washington
STATE: D.C.
COUNTRY: USA

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

APPLICATION NUMBER: US/09/142,080
FILING DATE: 11-May-2000

FILING DATE: 11-May-2000
 PRIORITY DATA:
 APPLICATION NUMBER: WO US97/12618

FILING DATE: 21-JUL-1997
 APPLICATION NUMBER: US 08/684,742
 FILING DATE: 22-JUL-1996
 ATTORNEY/AGENT INFORMATION:
 NAME: Innen, Jeffrey L.
 REGISTRATION NUMBER: 28,957
 REFERENCE/DOCKET NUMBER: 2314-134.A
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-783-6040

TELEFAX: 202-783-6031

```

;
; INFORMATION FOR SEQ ID NO: 44:
;
; SEQUENCE CHARACTERISTICS:
;     LENGTH: 17 base pairs
;     TYPE: nucleic acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
;
; MOLECULE TYPE: other nucleic acid
;     DESCRIPTION: /desc = "probe"
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 44:
US-09-142,080-44

```

```
Query Match      1.8%; Score 13.6; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 68;
Matches 10: Conservative 6; Mismatches 0; Indels
```

Qy 315 AGGAGAATCAAGAGCT 330
 |:|:|:|:|:|:|:|:
Db 2 ARGARAAYCARGARYT 17

RESULT 80
US-08-585-684B-821/c
; Sequence 821, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:

CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

```

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:

```

CURRENT AFFIDAVIT DATA:
 APPLICATION NUMBER: US/08/585,684B
 FILING DATE: January 16, 1996
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 60/000,951
 FILING DATE: July 7, 1995
 ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

TELEX: 67-3510

```

; INFORMATION FOR SEQ ID NO: 821:
;
; SEQUENCE CHARACTERISTICS:

```

```

; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-821

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 59;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

579 CCCAGGTGACGTCCT 593 QV

db 15 CCCAGGTGAAGTCCT 1

RESULT 81

US-09-038-073-821/c
; Sequence 821, Application US/09038073

Patent No. 6194150

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T

APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT
TITLE OF INVENTION: INDUCTION OF GRAF
TITLE OF INVENTION: AND REVERSAL OF I
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street

STREET: 633 WEST FIFTH STREET
STREET: SUITE 4700

```

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:probe for
; OTHER INFORMATION: conantokin DNA
; US-09-357-141-44

Query Match      1.8%; Score 13.6; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 68;
Matches 10; Conservative 6; Mismatches 0; Indels 0;

Qy      315 AGGAGATCAAGAGCT 330
      ||:||:||:||:||
Db      2 ARGARAYCARGARYT 17

RESULT 78
US-09-533-889-44
; Sequence 44, Application US/09533889
; Patent No. 6399574
; GENERAL INFORMATION:
; APPLICANT: McCabe, R. Tyler
; APPLICANT: Zhou, Li-Ming
; APPLICANT: Layer, Richard T.
; APPLICANT: Olivera, Baldomero M.
; APPLICANT: McIntosh, J. Michael
; TITLE OF INVENTION: Use of Conantokins
; NUMBER OF SEQUENCES: 71
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rothwell, Figg, Ernst & Kurz, p.c.
; STREET: 555 Thirteenth Street, N.W., Suite 701-E
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/533,889
; FILING DATE: 22 MAR-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 09/142,078
; FILING DATE: 10-FEB-1999
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO US97/12652
; FILING DATE: 21-JUL-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/762,377
; FILING DATE: 06-DEC-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/684,750
; FILING DATE: 22-JUL-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 2314-168.A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-783-6040
; TELEFAX: 202-783-6031
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "probe"
US-09-533-889-44

```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-347-613C-38

Query Match          1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      826 GCTGGCCCGAGTTGCAGG 842
Db       1 GCTGGCCCGGCTGCAGG 17

RESULT 73
US-09-662-183A-38
; Sequence 38, Application US/09662183A
; Patent No. 6734284
; GENERAL INFORMATION:
; APPLICANT: Johansen, Teit E.
; APPLICANT: Blom, Nikola
; APPLICANT: Hansen, Claus
; TITLE OF INVENTION: No. 6734284el Neurotrophic Factors
; FILE REFERENCE: 19313-001 DIV
; CURRENT APPLICATION NUMBER: US/09/662,183A
; CURRENT FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: DANISH 1998 00904
; PRIOR FILING DATE: 1998-07-06
; PRIOR APPLICATION NUMBER: USSN 60/092,229
; PRIOR FILING DATE: 1998-07-09
; PRIOR APPLICATION NUMBER: DANISH 1998 01048
; PRIOR FILING DATE: 1998-08-19
; PRIOR APPLICATION NUMBER: USSN 60/097,774
; PRIOR FILING DATE: 1998-08-25
; PRIOR APPLICATION NUMBER: DANISH 1998 01260
; PRIOR FILING DATE: 1998-10-05
; PRIOR APPLICATION NUMBER: USSN 60/103,908
; PRIOR FILING DATE: 1998-10-13
; PRIOR APPLICATION NUMBER: DANISH 1998 01265
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 09/347,613
; PRIOR FILING DATE: 2000-07-02
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 38
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-662-183A-38

Query Match          1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      826 GCTGGCCCGAGTTGCAGG 842
Db       1 GCTGGCCCGGCTGCAGG 17

RESULT 74
US-09-685-664B-3980/c
; Sequence 3980, Application US/09685664B
; Patent No. 6819447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
```

```
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3980
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3980

Query Match          1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      688 GGCGCGCGCAGCTGGAGA 704
Db       18 GGCGCGCGCAGCTGTAGA 2

RESULT 75
US-09-396-196G-13872/c
; Sequence 13872, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13872
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-13872

Query Match          1.8%; Score 13.8; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY      823 GAAGCTGGCCCGAGTTGCAGTGGCC 847
Db       25 GCAGCTGGCCCGACCTGCAGTTGGC 1

RESULT 76
US-09-142-078-44
; Sequence 44, Application US/09142078
; Patent No. 6172041
; GENERAL INFORMATION:
; APPLICANT: McCabe, R. Tyler
; APPLICANT: Zhou, Li-Ming
; APPLICANT: Layer, Richard T.
; TITLE OF INVENTION: Use of Conantokins
; NUMBER OF SEQUENCES: 71
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rothwell, Figg, Ernst & Kurz, P.C.
; STREET: 555 Thirteenth Street, N.W., Suite 701-E
; CITY: Washington
```

SEQ ID NO 384
LENGTH: 18
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..18
OTHER INFORMATION: downstream amplification primer for SEQ 190, SEQ 267, SEQ 191, SE

US-09-218-207-384

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTG 388
DB 2 GCTGAGAGGAGCTTTTG 18

RESULT 70
US-08-584-040-8322/c
Sequence 8322, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 8322:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 688 GCGCGGCGAGCTGGAGA 704
DB 18 GGCCCGGCGAGCTGTAGA 2

RESULT 71

US-09-371-772B-3980/c
Sequence 3980, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MHB00.876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3980
LENGTH: 18
TYPE: RNA
ORGANISM: Mus sp.
US-09-371-772B-3980

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 688 GCGCGGCGAGCTGGAGA 704
DB 18 GGCCCGGCGAGCTGTAGA 2

RESULT 72

US-09-347-613C-38
Sequence 38, Application US/09347613C
Patent No. 6593133
GENERAL INFORMATION:
APPLICANT: Johansen, Teit E.
APPLICANT: Blom, Nikolaj
APPLICANT: Hansen, Claus
TITLE OF INVENTION: No. 6593133el Neurotrophic Factors
FILE REFERENCE: Neurosearch 19313-001
CURRENT APPLICATION NUMBER: US/09/347,613C
CURRENT FILING DATE: 1999-07-02
PRIOR APPLICATION NUMBER: DANISH 1998 00904
PRIOR FILING DATE: 1998-07-06
PRIOR APPLICATION NUMBER: USSN 60/092,229
PRIOR FILING DATE: 1998-07-09
PRIOR APPLICATION NUMBER: DANISH 1998 01048
PRIOR FILING DATE: 1998-08-19
PRIOR APPLICATION NUMBER: USSN 60/097,774
PRIOR FILING DATE: 1998-08-25
PRIOR APPLICATION NUMBER: DANISH 1998 01260
PRIOR FILING DATE: 1998-10-05
PRIOR APPLICATION NUMBER: USSN 60/103,908
PRIOR FILING DATE: 1998-10-13
PRIOR APPLICATION NUMBER: DANISH 1998 01265
PRIOR FILING DATE: 1998-10-06
NUMBER OF SEQ ID NOS: 43
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 38
LENGTH: 18

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/106,038A
; FILING DATE: June 26, 1998
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Laurel Spear Bernstein
; REGISTRATION NUMBER: 37,280
; REFERENCE/DOCKET NUMBER: RTS-0004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (760) 931-9200
; TELEFAX: (760) 603-3820
; INFORMATION FOR SEQ ID NO: 74:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-106-038A-74

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 302 CAGCGCTGCCTGGAGGA 318
Db 17 CTGGGCTGCCTGGAGGA 1

RESULT 66
US-09-143-212-57
; Sequence 57, Application US/09143212B
; Patent No. 6077672
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia and Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRADD EXPRESSION
; FILE REFERENCE: RTS-0005
; CURRENT APPLICATION NUMBER: US/09/143,212B
; CURRENT FILING DATE: 1998-08-28
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 57
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-143-212-57

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 AGCGCCAGCGCCCTCG 811
Db 2 AGCGCCCGGAGCCTCG 18

RESULT 67
US-08-872-917-1/c
; Sequence 1, Application US/08872917
; Patent No. 6096549
; GENERAL INFORMATION:
; APPLICANT: PELICIC, Vladimir
; APPLICANT: REVRAT, Jean-Marc
; APPLICANT: GICQUEL, Brigitte
; TITLE OF INVENTION: METHOD OF SELECTION OF ALLELIC EXCHANGE MUTANTS
; FILE REFERENCE: 03495-0148-01
; CURRENT APPLICATION NUMBER: US/08/872,917
; CURRENT FILING DATE: 1997-07-11
; EARLIER APPLICATION NUMBER: 08/661,658
; EARLIER FILING DATE: 1996-06-11
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1

; LENGTH: 18
; TYPE: DNA
; ORGANISM: Mycobacterium sp.
US-08-872-917-1

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 810 CGGAGGAGGAGGAGGAG 826
Db 17 CGGAGGAGGAGGAGGAG 1

RESULT 68
US-09-338-907-384
; Sequence 384, Application US/09338907
; Patent No. 6265546
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: PROSTATE CANCER GENE
; FILE REFERENCE: GENSET.18CFICP
; CURRENT APPLICATION NUMBER: US/09/338,907
; CURRENT FILING DATE: 1999-06-23
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658
; EARLIER FILING DATE: 1998-09-09
; EARLIER APPLICATION NUMBER: 09/218,207
; EARLIER FILING DATE: 1998-12-22
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 384
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer for SEQ 190, SEQ 267, SEQ 191, SE
US-09-338-907-384

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 372 GCTGCGGAGGAGCTTCTG 388
Db 2 GCTGAGAGGAGCTTTTG 18

RESULT 69
US-09-218-207-384
; Sequence 384, Application US/09218207
; Patent No. 6346381
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: Prostate cancer gene
; FILE REFERENCE: GENSET.018CP1
; CURRENT APPLICATION NUMBER: US/09/218,207
; CURRENT FILING DATE: 1998-12-22
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658
; EARLIER FILING DATE: 1998-09-09
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8422
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8422

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGACAGGAGC 506
Db 1 GAAGAGCGACAGGAGTGC 17

RESULT 63
US-09-685-664B-2829/c
; Sequence 2829. Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggan, Jim
; APPLICANT: Strinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 2829
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2829

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 457 GGTGAGAGACTCGGCC 473
Db 17 GGTAGACAGACTCGGCC 1

RESULT 64
US-08-470-124-56/c
; Sequence 56. Application US/08470124
; Patent No. 5849481
; GENERAL INFORMATION:
```

```

; APPLICANT: Urdea, Michael S.
; APPLICANT: Horn, Thomas
; APPLICANT: Chang, Chu-An
; APPLICANT: Warner, Brian
; APPLICANT: Fultz, Timothy J.
; TITLE OF INVENTION: LARGE COMB-TYPE BRANCHED POLYNUCLEOTIDES
; TITLE OF INVENTION: POLYNUCLEOTIDES
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/470,124
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/813,588
; FILING DATE: 23 December 1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Ciotti, Thomas E.
; REGISTRATION NUMBER: 21,013
; REFERENCE/DOCKET NUMBER: 22300-20104.20
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-813-5600
; TELEFAX: 415-327-2951
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 56:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-470-124-56

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 69;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AATACGACCAACCATC 883
Db 17 AGTACGACCAACCATC 1

RESULT 65
US-09-106-038A-74/c
; Sequence 74. Application US/09106038A
; Patent No. 6007995
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker and Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Isis Pharmaceuticals, Inc.
; STREET: 2292 Faraday Avenue
; CITY: Carlsbad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Microsoft Word 97
```


US-09-371-772B-4771

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 62;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACCAATCAAGCA 890
|||||:|||||
Db 1 CAACUACCAAGCA 17

RESULT 57

US-09-371-772B-6804/c
; Sequence 6804, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6804
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6804

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 337 TGCCATCCGCAGCA 353
|||||:|||||
Db 17 TGCCATCTGCTGAGCA 1

RESULT 58

US-09-866-108A-6823/c
; Sequence 6823, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7698
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6823
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6823

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGACA 282
|||||:|||||
Db 17 CACCTGCCTTGAGAAAA 1

RESULT 59

US-09-866-108A-7698/c
; Sequence 7698, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7698
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens


```
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 184:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-628-184

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 405 AGAGGGAGGAGGAGGAG 421
DB 17 AGGAGGAGGAGGAGGAG 1

RESULT 54
US-08-584-040-5992/c
; Sequence 592, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5992:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
```

```
; TOPOLOGY: linear
; US-08-584-040-5992

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 457 GGTGGAGAGACTCGGCC 473
DB 17 GGTAGACAGACTCGGCC 1

RESULT 55
US-09-371-772B-2829/c
; Sequence 2829, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2829
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
; US-09-371-772B-2829

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 457 GGTGGAGAGACTCGGCC 473
DB 17 GGTAGACAGACTCGGCC 1

RESULT 56
US-09-371-772B-4771
; Sequence 4771, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4771
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-09-866-108A-8973

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCACTCTTCCA 864
Db 14 CACCACTCTTCCA 1

RESULT 51

US-09-205-143-42/c
; Sequence 42, Application US/09205143
; Patent No. 6107091
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-16 EXPRESSION
; FILE REFERENCE: RTS-0032
; CURRENT APPLICATION NUMBER: US/09/205,143
; CURRENT FILING DATE: 1998-12-03
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 42
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-143-42

Query Match 1.9%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 308 TGCCTGGAGGAGAA 321
Db 14 TGCCTGGAGGAGAA 1

RESULT 52

US-08-373-124A-184/c
; Sequence 184, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943

; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 184:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-184

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 405 AGAGGAGGAGGAGGAG 421
Db 17 AGAGGAGGAGGAGGAG 1

RESULT 53

US-08-435-628-184/c
; Sequence 184, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:

```
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7243
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7243

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGC 710
DB 4 GCTGGAGAGTGAGC 17

RESULT 49
US-09-866-108A-8972/c
; Sequence 8972, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7243
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7243
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8972
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8972

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCCA 864
DB 15 CACCAGCTCTTCCA 2

RESULT 50
US-09-866-108A-8973/c
; Sequence 8973, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8973
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8973
```

```

; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 10970
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-23427 for SEQ 3105, in complete
US-09-422-978-10970

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 811 GCAGGAGAGAGAGAG 826
DB 17 GCAGGAGAGAGATGAG 2

RESULT 46
US-08-690-734A-61
; Sequence 61, Application US/08690734A
; Patent No. 5871920
; GENERAL INFORMATION:
; APPLICANT: Page, David C.
; APPLICANT: Reijo, Renee
; TITLE OF INVENTION: DAZ: A GENE ASSOCIATED WITH AZOOSPERMIA
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: US
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/690,734A
; FILING DATE: 31-JUL-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/310,429
; FILING DATE: 22-SEP-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: WH194-07A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-690-734A-61

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 811 GCAGGAGAGAGAGAG 826
DB 17 GCAGGAGAGAGATGAG 2

RESULT 46
US-08-690-734A-61
; Sequence 61, Application US/08690734A
; Patent No. 5871920
; GENERAL INFORMATION:
; APPLICANT: Page, David C.
; APPLICANT: Reijo, Renee
; TITLE OF INVENTION: DAZ: A GENE ASSOCIATED WITH AZOOSPERMIA
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: US
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/690,734A
; FILING DATE: 31-JUL-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/310,429
; FILING DATE: 22-SEP-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: WH194-07A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-690-734A-61

```

```

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 526 GCACCTGAAGAGATGC 541
DB 1 GCACCTGAAGAGCTGC 16

RESULT 47
US-08-742-185-61
; Sequence 61, Application US/08742185
; Patent No. 6020476
; GENERAL INFORMATION:
; APPLICANT: Page, David C.
; APPLICANT: Reijo, Renee
; APPLICANT: Saxena, Richa
; APPLICANT: Hawkins, Trevor
; APPLICANT: Reeve, Mary Pat
; TITLE OF INVENTION: DAZ: A GENE FAMILY ASSOCIATED WITH AZOOSPERMIA
; NUMBER OF SEQUENCES: 102
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: US
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/742,185
; FILING DATE: 30-OCT-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/690,734
; FILING DATE: 31-JUL-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/310,429
; FILING DATE: 22-SEP-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: WH194-07A2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-742-185-61

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 526 GCACCTGAAGAGATGC 541
DB 1 GCACCTGAAGAGCTGC 16

RESULT 48
US-09-866-108A-7243
; Sequence 7243, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.

```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8971
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8971

Query Match          1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      851 CACCAGCTCTTCCAAAG 866
Db      16 CACCAGCTCTTCCATG 1

RESULT 43
US-08-585-684B-2688/c
; Sequence 2688, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: July 7, 1995
; PRIOR APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2688:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-2688

Query Match          1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

US-08-585-684B-2688
```

```
QY      717 CGCTGCAGCAGCAGCA 732
Db      16 CCCTGCAGCAGCAGCA 1

RESULT 44
US-09-038-073-2688/c
; Sequence 2688, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2688:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-2688

Query Match          1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      717 CGCTGCAGCAGCAGCA 732
Db      16 CCCTGCAGCAGCAGCA 1

RESULT 45
US-09-422-978-10970/c
; Sequence 10970, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
```

```
Db      2  GGAGACGAGTTCCTC 17

RESULT 40
US-09-866-108A-7451
; Sequence 7451, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7451
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7451

Query Match      1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      413  GGAGACGAGTTCCTCA 428
Db      1  GGAGACGAGTTCCTCA 16

RESULT 41
US-09-866-108A-8970/c
; Sequence 8970, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8970
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8970

Query Match      1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      851  CACCAGCTCTTCCAG 866
Db      17  CACCAGCTCTTCCATG 2

RESULT 42
US-09-866-108A-8971/c
; Sequence 8971, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8970
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8970
```

```
RESULT 37
US-09-422-978-8682
; Sequence 8682, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8682
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-17522 for SEQ 817, in complete
US-09-422-978-8682

Query Match          2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 492 AGAGGCAGAGGACGAG 509
Db 1 AGAGGAAGAGGACGAG 18
|||||
|

RESULT 38
US-09-866-108A-7247
; Sequence 7247, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7449
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7449

Query Match          1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 412 GGAGAGGAGTTCCTC 427
|||||
|
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7247
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7247

Query Match          1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 698 CTGGAGAGTGAGCGG 713
Db 1 CTGGAGAGTGAGCGG 16
|||||
|

RESULT 39
US-09-866-108A-7449
; Sequence 7449, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7449
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7449

Query Match          1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 49;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 412 GGAGAGGAGTTCCTC 427
|||||
|
```

[illegible]


```
Db      1 CTGCTTCAGACAG 15

RESULT 31
US-09-866-108A-7244
; Sequence 7244, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7244
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7245

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      697 GCTGGAGAGTGAGCG 711
Db      2 GCTGGAGAGTGAGCG 16

RESULT 32
US-08-585-684B-2687/c
; Sequence 2687, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      697 GCTGGAGAGTGAGCG 711
Db      3 GCTGGAGAGTGAGCG 17

RESULT 32
US-09-866-108A-7245
; Sequence 7245, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
```

```

;
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FASTSEQ for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/081,385
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/964,747
; FILING DATE: 05-NOV-1997
; APPLICATION NUMBER: 60/030,761
; FILING DATE: 06-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Wu, Frank
; REGISTRATION NUMBER: 41,386
; REFERENCE/DOCKET NUMBER: 22000-20577.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 131:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-09-081-385-131

```

```

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 47;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 471 GCCTGGAGAGCTCGATCTG 490
DB 1 GCCTGGAGAGCCGCTGCTG 20

```

```

RESULT 28
US-09-608-088-16
; Sequence 16, Application US/09608088
; Patent No. 6680368
; GENERAL INFORMATION:
; APPLICANT: Mosselman, Sietse
; APPLICANT: Dijkema, Rein
; TITLE OF INVENTION: No. 6680368el Estrogen Receptor
; FILE REFERENCE: O/96193 US/D1
; CURRENT APPLICATION NUMBER: US/09/608,088
; CURRENT FILING DATE: 2000-06-30
; PRIOR FILING DATE: US 08/826,361
; PRIOR FILING DATE: 1997-03-26
; PRIOR APPLICATION NUMBER: EP 96203284.3
; PRIOR FILING DATE: 1996-11-22
; PRIOR APPLICATION NUMBER: EP 96200820.7
; PRIOR FILING DATE: 1996-03-26
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
;
; US-09-608-088-16

```

```

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 47;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 822 GGAAGCTGGCCCGATGTCAG 841
DB 1 GGAAGCTGGCTCACTGCTG 20

```

```

RESULT 29
US-09-711-288-16
; Sequence 16, Application US/09711288
; Patent No. 6713270
; GENERAL INFORMATION:
; APPLICANT: Mosselman, Sietse
; APPLICANT: Dijkema, Rein
; TITLE OF INVENTION: No. 6713270el Estrogen Receptor
; FILE REFERENCE: O/96193 US/D2
; CURRENT APPLICATION NUMBER: US/09/711,288
; CURRENT FILING DATE: 2000-11-13
; PRIOR FILING DATE: US 08/826,361
; PRIOR FILING DATE: 1997-03-26
; PRIOR APPLICATION NUMBER: EP 96203284.3
; PRIOR FILING DATE: 1996-11-22
; PRIOR APPLICATION NUMBER: EP 96200820.7
; PRIOR FILING DATE: 1996-03-26
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
;
; US-09-711-288-16

```

```

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 47;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 822 GGAAGCTGGCCCGATGTCAG 841
DB 1 GGAAGCTGGCTCACTGCTG 20

```

```

RESULT 30
US-09-863-049B-62
; Sequence 62, Application US/09863049B
; Patent No. 6824972
; GENERAL INFORMATION:
; APPLICANT: Kenwick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Aradhyo, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Asmae
; APPLICANT: Israel, Alain
; APPLICANT: Poustka, Annemarie
; APPLICANT: Lewis, Richard A
; APPLICANT: Levy, Moise
; APPLICANT: Heiss, Nina
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Defe
; FILE REFERENCE: HO-P01961US1
; CURRENT APPLICATION NUMBER: US/09/863,049B
; CURRENT FILING DATE: 2001-05-22
; PRIOR FILING DATE: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 62
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Human
;
; US-09-863-049B-62

```

```

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 269 CTGCCTTCAGACAG 283
|||||

```



```
;
; GENERAL INFORMATION:
; APPLICANT: SHERIDAN, PATRICK J.
; APPLICANT: GAGNE, JULIO C.
; APPLICANT: ANDERSON, MARY L.
; APPLICANT: LUTKE, DOUGLAS N.
; TITLE OF INVENTION: METHOD FOR DETECTING OLIGONUCLEOTIDES BY
; TITLE OF INVENTION: ENZYME INHIBITION ASSAY
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CHIRON CORPORATION
; STREET: 4560 HORTON STREET
; CITY: EMERYVILLE
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES
; ZIP: 94608
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/472,756
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: GOLDMAN ESQ., KENNETH M.
; REGISTRATION NUMBER: 34,174
; REFERENCE/DOCKET NUMBER: 1014.001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 601-2719
; TELEFAX: (510) 655-3542
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 19
; OTHER INFORMATION: /standard_name=
; OTHER INFORMATION: "N4-(6-aminocaproyl-2-aminoethyl)cytosine"
;
; US-08-472-756-1
;
; Query Match 2.0%; Score 15.4; DB 1; Length 19;
; Best Local Similarity 94.1%; Pred. No. 40;
; Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 867 AATACGACCAACCATC 883
; Db 2 AGTACGACCAACCATC 18
;
; RESULT 21
; US-08-610-955-1
; Sequence 1, Application US/08610955
; Patent No. 5853974
; GENERAL INFORMATION:
; APPLICANT: SHERIDAN, PATRICK J.
; APPLICANT: GAGNE, JULIO C.
; APPLICANT: ANDERSON, MARY L.
; APPLICANT: LUTKE, DOUGLAS N.
; TITLE OF INVENTION: METHOD FOR DETECTING OLIGONUCLEOTIDES BY
; TITLE OF INVENTION: ENZYME INHIBITION ASSAY
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CHIRON CORPORATION
; STREET: 4560 HORTON STREET
; CITY: EMERYVILLE
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES
; ZIP: 94608
```

```
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/610,955
; FILING DATE: 05-MAR-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/472,756
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: GOLDMAN ESQ., KENNETH M.
; REGISTRATION NUMBER: 34,174
; REFERENCE/DOCKET NUMBER: 1014.001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 601-2719
; TELEFAX: (510) 655-3542
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 19
; OTHER INFORMATION: /standard_name=
; OTHER INFORMATION: "N4-(6-aminocaproyl-2-aminoethyl)cytosine"
;
; US-08-610-955-1
;
; Query Match 2.0%; Score 15.4; DB 1; Length 19;
; Best Local Similarity 94.1%; Pred. No. 40;
; Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 867 AATACGACCAACCATC 883
; Db 2 AGTACGACCAACCATC 18
;
; RESULT 22
; US-09-732-199A-18
; Sequence 18, Application US/09732199A
; Patent No. 6379960
; GENERAL INFORMATION:
; APPLICANT: Ian Popoff
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF DAMAGE-SPECIFIC DNA BINDING PROTEIN 2, PAGE 1
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0214
; CURRENT APPLICATION NUMBER: US/09/732,199A
; CURRENT FILING DATE: 2000-12-06
; NUMBER OF SEQ ID NOS: 57
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;
; US-09-732-199A-18
;
; Query Match 2.0%; Score 15.4; DB 1; Length 20;
; Best Local Similarity 94.1%; Pred. No. 43;
; Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; QY 815 GAGAAGAGGAGCTGCG 831
; Db 3 GAGTAGAGGAGCTGCG 19
;
; RESULT 23
```

```
;
;
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lappin & Kusmer
; STREET: 200 State Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/08/532,979
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HYZ-050
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA/RNA
; HYPOTHEICAL: NO
; ANTI-SENSE: YES
; US-08-532-979-7

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGGAGGCGGCG 693
Db 18 GCCAGCGGAGGCGGCG 2

RESULT 18
US-09-115-566-32
; Sequence 32, Application US/09115566
; Patent No. 6232462
; GENERAL INFORMATION:
; APPLICANT: COLLINS, MARK L.
; APPLICANT: HORN, THOMAS
; APPLICANT: SHERIDAN, PATRICK E.
; APPLICANT: WARNER, BRIAN D.
; APPLICANT: URDEA, MICHAEL S.
; TITLE OF INVENTION: REDUCTION OF NONSPECIFIC HYBRIDIZATION
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CHRION CORPORATION, INTELLECTUAL PROPERTY -
; STREET: P.O. BOX 8097
; CITY: EMERYVILLE
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 94662-8097
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE:
; APPLICATION NUMBER: US/09/115,566
```

```
;
;
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/794,153
; FILING DATE: 03-FEB-1997
; APPLICATION NUMBER: US 08/298,073
; FILING DATE: 30-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: GOLDMAN, KENNETH M.
; REGISTRATION NUMBER: 34,174
; REFERENCE/DOCKET NUMBER: 0974.001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 601-2719
; TELEFAX: (510) 655-3542
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-09-115-566-32

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
Db 2 AGTACGACACACATC 18

RESULT 19
US-09-146-157-3
; Sequence 3, Application US/09146157
; Patent No. 6465175
; GENERAL INFORMATION:
; APPLICANT: HORN, Thomas
; APPLICANT: SCHROEDER, Hartmut R.
; APPLICANT: WARNER, Brian D.
; APPLICANT: FISS, Ellen
; APPLICANT: SELLS, Todd
; APPLICANT: LAW, Say-Jong
; TITLE OF INVENTION: OLIGONUCLEOTIDE PROBES BEARING QUENCHABLE FLUORESCENT LABELS,
; FILE REFERENCE: 1411.002
; CURRENT APPLICATION NUMBER: US/09/146,157
; CURRENT FILING DATE: 1998-09-03
; EARLIER APPLICATION NUMBER: 60/057,810
; EARLIER FILING DATE: 1997-09-04
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: This information
; OTHER INFORMATION: is not available.
; US-09-146-157-3

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
Db 2 AGTACGACACACATC 18

RESULT 20
US-08-472-756-1
; Sequence 1, Application US/08472756
; Patent No. 5780227
```

SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/794,153
FILING DATE: 03-FEB-1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/298,073
FILING DATE: 30-AUG-1994
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: GOLDMAN, KENNETH M.
REGISTRATION NUMBER: 34,174
REFERENCE/DOCKET NUMBER: 0974.001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 601-2719
TELEFAX: (510) 655-3542
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-794-153-32

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
Db 2 AGTACGACACACATC 18
|||||

RESULT 15
US-08-532-979-2/c
Sequence 2, Application US/08532979
Patent No. 5969117
GENERAL INFORMATION:
APPLICANT: Agrawal, Sudhir
TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC
TITLE OF INVENTION: OLIGONUCLEOTIDES AND METHODS OF THEIR USE
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lappin & Kusmer
STREET: 200 State Street
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/532,979
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Kerner, Ann-Louise
REGISTRATION NUMBER: 33,523
REFERENCE/DOCKET NUMBER: HYZ-050
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-330-1300
TELEFAX: 617-330-1311
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA

HYPOTHETICAL: NO
ANTI-SENSE: YES
US-08-532-979-2
Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 677 GCCAGCGAGGAGCGCG 693
Db 18 GCCAGCGAGGAGCGCG 2
|||||
RESULT 16
US-08-532-979-5/c
Sequence 5, Application US/08532979
Patent No. 5969117
GENERAL INFORMATION:
APPLICANT: Agrawal, Sudhir
TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC
TITLE OF INVENTION: OLIGONUCLEOTIDES AND METHODS OF THEIR USE
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lappin & Kusmer
STREET: 200 State Street
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/532,979
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Kerner, Ann-Louise
REGISTRATION NUMBER: 33,523
REFERENCE/DOCKET NUMBER: HYZ-050
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-330-1300
TELEFAX: 617-330-1311
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA/RNA
HYPOTHETICAL: NO
ANTI-SENSE: YES
US-08-532-979-5
Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 677 GCCAGCGAGGAGCGCG 693
Db 18 GCCAGCGAGGAGCGCG 2
|||||
RESULT 17
US-08-532-979-7/c
Sequence 7, Application US/08532979
Patent No. 5969117
GENERAL INFORMATION:
APPLICANT: Agrawal, Sudhir
TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC
TITLE OF INVENTION: OLIGONUCLEOTIDES AND METHODS OF THEIR USE

US-09-866-108A-7246

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 33;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 697 GCTGGAGAGTCAGCGG 713
Db 1 GCTGGAGAGTCAGCGG 17

RESULT 12

US-09-866-108A-7450
; Sequence 7450, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David R.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: A60MICA Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7450
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7450

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 33;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 412 GGAGAGGAGTTCCTCA 428
Db 1 GGAGAGGAGTTCCTCA 17

RESULT 13

US-08-298-073-32
; Sequence 32, Application US/08298073
; Patent No. 5681702
; GENERAL INFORMATION:
; APPLICANT: COLLINS, MARK L.
; APPLICANT: HORN, THOMAS

; APPLICANT: SHERIDAN, PATRICK E.
; APPLICANT: WARNER, BRIAN D.
; APPLICANT: URDEA, MICHAEL S.
; TITLE OF INVENTION: REDUCTION OF NONSPECIFIC HYBRIDIZATION
; BY USING NOVEL, BASE-PAIRING SCHEMES
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CHRION CORPORATION, INTELLECTUAL PROPERTY -
; STREET: P.O. BOX 8097
; CITY: EMERYVILLE
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 94662-8097
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/298,073
; FILING DATE: 30-AUG-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: GOLDMAN, KENNETH M.
; REGISTRATION NUMBER: 34,174
; REFERENCE/DOCKET NUMBER: 0974.001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 601-2719
; TELEFAX: (510) 655-3542
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-298-073-32

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 36;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 867 AATACGACACCATC 883
Db 2 AGTACGACACCATC 18

RESULT 14

US-08-794-153-32
; Sequence 32, Application US/08794153
; Patent No. 5780610
; GENERAL INFORMATION:
; APPLICANT: COLLINS, MARK L.
; APPLICANT: HORN, THOMAS
; APPLICANT: SHERIDAN, PATRICK E.
; APPLICANT: WARNER, BRIAN D.
; APPLICANT: URDEA, MICHAEL S.
; TITLE OF INVENTION: REDUCTION OF NONSPECIFIC HYBRIDIZATION
; BY USING NOVEL, BASE-PAIRING SCHEMES
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CHRION CORPORATION, INTELLECTUAL PROPERTY -
; STREET: P.O. BOX 8097
; CITY: EMERYVILLE
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 94662-8097
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

RESULT 9
US-08-098-942C-16/c
; Sequence 16, Application US/08098942C
; Patent No. 6410322
; GENERAL INFORMATION:
; APPLICANT: Robinson, Gregory S.
; TITLE OF INVENTION: Antisense Oligonucleotides That
; TITLE OF INVENTION: Inhibit VEGF Expression
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Michael S. Greenfield
; STREET: 10 S. Wacker Drive Suite 3000
; CITY: Chicago
; STATE: Illinois
; COUNTRY: U.S.A.
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/098,942C
; FILING DATE: July 27, 1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Greenfield, Michael S.
; REGISTRATION NUMBER: 37,142
; REFERENCE/DOCKET NUMBER: 93,538
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312)715-1000
; TELEFAX: (312)715-1234
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; HYPOTHETICAL: YES
; ANTI-SENSE: YES
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..20
; OTHER INFORMATION: /note="phosphorothioate
; OTHER INFORMATION: internucleotide linkages"
US-08-098-942C-16
Query Match 2.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 37;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 696 AGCTGGAGAGTGAGCGGA 714
Db 19 AGCCGGAGAGGGAGCGGA 1
RESULT 10
US-10-083-720A-10
; Sequence 10, Application US/10083720A
; Patent No. 6797813
; GENERAL INFORMATION:
; APPLICANT: de Waal Malefyt, Rene
; APPLICANT: Fickenscher, Helmut
; APPLICANT: Fleckenstein, Bernhard
; APPLICANT: Knappe, Andrea
; TITLE OF INVENTION: MANMALLIAN CYTOKINE; RELATED REAGENTS
; FILE REFERENCE: DX0644KBK
; CURRENT APPLICATION NUMBER: US/10/083,720A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 09/363,993
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: 08/934,959
; PRIOR FILING DATE: 1997-09-22

; PRIOR APPLICATION NUMBER: 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: 60/302,176
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: 60/027,368
; PRIOR FILING DATE: 1996-09-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: Patent In version 3.1
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: IL-10 forward.
; NAME/KEY: misc feature
; LOCATION: (1)..(21)
; OTHER INFORMATION: IL-10 forward.
US-10-083-720A-10
Query Match 2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 325 AGAGCTCCGAGATGCCATC 343
Db 2 AGATCTCCGAGATGCCCTC 20
RESULT 11
US-09-866-108A-7246
; Sequence 7246, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7246
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

FILE REFERENCE: HO-P01961US1
 CURRENT APPLICATION NUMBER: US/09/863,049B
 CURRENT FILING DATE: 2001-05-22
 PRIOR APPLICATION NUMBER: US 60/206,223
 PRIOR FILING DATE: 2000-05-22
 NUMBER OF SEQ ID NOS: 79
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO 63
 LENGTH: 25
 TYPE: DNA
 ORGANISM: Human
 US-09-863-049B-63

Query Match 2.6%; Score 19.4; DB 1; Length 25;
 Best Local Similarity 95.2%; Pred. No. 12;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 263 CTGCACCTGCCTTCAGAACAG 283
 ||| ||||| ||||| ||||| |||||
 DB 5 CTTACACCTGCCTTCAGAACAG 25

RESULT 6

US-08-745-269-5/c
 Sequence 5, Application US/08745269
 Patent No. 5763183
 GENERAL INFORMATION:
 APPLICANT: Pesonen, Ullamari
 APPLICANT: Koulou, Markku
 APPLICANT: Linnoila, Markku
 APPLICANT: Goldman, David
 APPLICANT: Virkkunen, Matti
 TITLE OF INVENTION: OF THE SH7 SEROTONIN RECEPTOR
 NUMBER OF SEQUENCES: 6
 CORRESPONDENCE ADDRESSES:
 ADDRESSEE: Knobbe, Martens, Olson and Bear
 STREET: 620 Newport Center Drive 16th Floor
 CITY: Newport Beach
 STATE: CA
 COUNTRY: USA
 ZIP: 92660
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: DOS
 SOFTWARE: FastSeq Version 1.5
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/745,269
 FILING DATE: 08-NOV-1996
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 60/006,394
 FILING DATE: 09-NOV-1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Fuller, Michael L
 REGISTRATION NUMBER: 36,516
 REFERENCE/DOCKET NUMBER: NIH126.001A
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 619-235-8550
 TELEFAX: 619-235-0176
 TELEX:
 INFORMATION FOR SEQ ID NO: 5:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 19 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: cDNA
 US-08-745-269-5

Query Match 2.1%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 34;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 441 AGGAGGCCAGGAACCTGGT 459
 ||||| ||||| ||||| ||||| |||||
 DB 19 AGGAGGCCAGGAACCTGGT 1

RESULT 7

US-09-232-468A-10
 Sequence 10, Application US/09232468A
 Patent No. 6207165
 GENERAL INFORMATION:
 APPLICANT: AUDONNET et al.
 TITLE OF INVENTION: POLYNUCLEOTIDE VACCINE FORMULA AGAINST PORCINE
 REPRODUCTIVE AND RESPIRATORY PATHOLOGIES
 FILE REFERENCE: 454313-2230
 CURRENT APPLICATION NUMBER: US/09/232,468A
 CURRENT FILING DATE: 1999-01-05
 NUMBER OF SEQ ID NOS: 54
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO 10
 LENGTH: 19
 TYPE: DNA
 ORGANISM: Aujeszky's Disease Virus (NIA3 Strain)
 US-09-232-468A-10

Query Match 2.1%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 34;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTGCA 390
 ||||| ||||| ||||| ||||| |||||
 DB 1 GCTGCGAGGAGCTTCTGCA 19

RESULT 8

US-09-784-984B-8
 Sequence 8, Application US/09784984B
 Patent No. 6576243
 GENERAL INFORMATION:
 APPLICANT: Merial Ltd.
 APPLICANT: Audonnet, Jean-Christophe
 APPLICANT: Bouchardon, Annabelle
 APPLICANT: Baudu, Philippe
 APPLICANT: Riviere, Michael
 TITLE OF INVENTION: Polynucleotide Vaccine Formula Against Porcine Reproductive and
 Respiratory Pathologies
 FILE REFERENCE: 454313-2230.1
 CURRENT APPLICATION NUMBER: US/09/784,984B
 CURRENT FILING DATE: 2001-02-16
 PRIOR APPLICATION NUMBER: FR 96/09338
 PRIOR FILING DATE: 1996-07-19
 PRIOR APPLICATION NUMBER: PCT/FR97/01313
 PRIOR FILING DATE: 1997-07-15
 PRIOR APPLICATION NUMBER: US 6,207,165
 PRIOR FILING DATE: 2001-03-27
 NUMBER OF SEQ ID NOS: 54
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO 8
 LENGTH: 19
 TYPE: DNA
 ORGANISM: Pseudorabies virus
 US-09-784-984B-8

Query Match 2.1%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 34;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTGCA 390
 ||||| ||||| ||||| ||||| |||||
 DB 1 GCTGCGAGGAGCTTCTGCA 19

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 8, 2005, 08:49:16 ; Search time 2 seconds
(without alignments)
2.698 Million cell updates/sec

Title: US-10-628-841-3

Perfect score: 755

Sequence: 1 tctggaagagccaactgtgt.....tgggcagtgcggaagcga.755

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 212 seqs, 3574 residues

Total number of hits satisfying chosen parameters: 424

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 213 summaries

Database : fetch3rni.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match %	Query Length	ID	Description
1	22	2.9	22	1	US-09-863-049B-61
2	20	2.6	21	1	US-09-863-049B-53
3	19.8	2.6	25	1	US-09-396-196G-13872
4	19.4	2.6	21	1	US-09-863-049B-55
5	19.4	2.6	25	1	US-09-863-049B-63
6	15.8	2.1	19	1	US-08-745-269-5
7	15.8	2.1	19	1	US-09-232-468A-10
8	15.8	2.1	19	1	US-09-784-984B-8
9	15.8	2.1	20	1	US-08-098-942C-16
10	15.4	2.0	21	1	US-10-083-720A-10
11	15.4	2.0	17	1	US-09-866-108A-7246
12	15.4	2.0	17	1	US-09-866-108A-7450
13	15.4	2.0	18	1	US-08-398-073-32
14	15.4	2.0	18	1	US-08-794-153-32
15	15.4	2.0	18	1	US-08-532-979-2
16	15.4	2.0	18	1	US-08-532-979-5
17	15.4	2.0	18	1	US-08-532-979-7
18	15.4	2.0	18	1	US-09-115-566-32
19	15.4	2.0	18	1	US-09-146-157-3
20	15.4	2.0	19	1	US-08-472-756-1
21	15.4	2.0	19	1	US-08-610-955-1
22	15.4	2.0	20	1	US-09-732-199A-18
23	15.4	2.0	20	1	US-09-863-049B-13
24	15.2	2.0	20	1	US-09-180-783-3
25	15.2	2.0	20	1	US-09-467-082-47
26	15.2	2.0	20	1	US-09-658-679A-61
27	15.2	2.0	20	1	US-09-081-385-131
28	15.2	2.0	20	1	US-09-608-088-16
29	15.2	2.0	20	1	US-09-711-288-16
30	15	2.0	15	1	US-09-863-049B-62
31	15	2.0	17	1	US-09-866-108A-7244
32	15	2.0	17	1	US-09-866-108A-7245
33	15	2.0	18	1	US-08-585-684B-2687

1	US-09-038-073-2687	18	2.0	15	C 34
1	US-09-045-301-3	18	2.0	14.8	C 35
1	US-09-045-301-4	18	2.0	14.8	C 36
1	US-09-422-978-8682	18	2.0	14.8	C 37
1	US-09-866-108A-7247	17	1.9	14.4	C 38
1	US-09-866-108A-7449	17	1.9	14.4	C 39
1	US-09-866-108A-7451	17	1.9	14.4	C 40
1	US-09-866-108A-8970	17	1.9	14.4	C 41
1	US-09-866-108A-8971	17	1.9	14.4	C 42
1	US-08-585-684B-2688	18	1.9	14.4	C 43
1	US-09-038-073-2688	18	1.9	14.4	C 44
1	US-09-422-978-10970	18	1.9	14.4	C 45
1	US-08-690-734A-61	19	1.9	14.4	C 46
1	US-08-742-185-61	19	1.9	14.4	C 47
1	US-09-866-108A-7243	17	1.9	14	C 48
1	US-09-866-108A-8972	17	1.9	14	C 49
1	US-09-866-108A-8973	17	1.9	14	C 50
1	US-09-205-143-42	18	1.9	14	C 51
1	US-08-373-124A-184	17	1.8	13.8	C 52
1	US-08-435-628-184	17	1.8	13.8	C 53
1	US-08-584-040-5982	17	1.8	13.8	C 54
1	US-09-371-772B-2829	17	1.8	13.8	C 55
1	US-09-371-772B-6804	17	1.8	13.8	C 56
1	US-09-866-108A-6823	17	1.8	13.8	C 57
1	US-09-866-108A-7698	17	1.8	13.8	C 58
1	US-09-866-108A-7813	17	1.8	13.8	C 59
1	US-09-866-108A-8421	17	1.8	13.8	C 60
1	US-09-866-108A-8422	17	1.8	13.8	C 61
1	US-09-685-664B-2829	17	1.8	13.8	C 62
1	US-08-470-124-56	18	1.8	13.8	C 63
1	US-09-106-038A-74	18	1.8	13.8	C 64
1	US-09-143-212-57	18	1.8	13.8	C 65
1	US-08-872-917-1	18	1.8	13.8	C 66
1	US-09-338-907-384	18	1.8	13.8	C 67
1	US-09-218-207-384	18	1.8	13.8	C 68
1	US-08-584-040-8322	18	1.8	13.8	C 69
1	US-09-371-772B-3980	18	1.8	13.8	C 70
1	US-09-347-613C-38	18	1.8	13.8	C 71
1	US-09-662-183A-38	18	1.8	13.8	C 72
1	US-09-685-664B-3980	18	1.8	13.8	C 73
1	US-09-396-196G-13872	18	1.8	13.8	C 74
1	US-09-142-078-44	17	1.8	13.6	C 75
1	US-09-357-141-44	17	1.8	13.6	C 76
1	US-09-533-889-44	17	1.8	13.6	C 77
1	US-09-142-080-44	17	1.8	13.6	C 78
1	US-08-585-684B-821	15	1.8	13.4	C 79
1	US-09-038-073-821	15	1.8	13.4	C 80
1	US-09-275-850-18	15	1.8	13.4	C 81
1	US-08-292-620A-1619	16	1.8	13.4	C 82
1	US-09-071-845-1619	16	1.8	13.4	C 83
1	US-08-245-264A-1	17	1.8	13.4	C 84
1	US-08-584-040-8022	17	1.8	13.4	C 85
1	US-09-474-432B-657	17	1.8	13.4	C 86
1	US-09-371-772B-3805	17	1.8	13.4	C 87
1	US-09-476-387-656	17	1.8	13.4	C 88
1	US-09-866-108A-6824	17	1.8	13.4	C 89
1	US-09-866-108A-7448	17	1.8	13.4	C 90
1	US-09-866-108A-7452	17	1.8	13.4	C 91
1	US-09-866-108A-8419	17	1.8	13.4	C 92
1	US-09-866-108A-8420	17	1.8	13.4	C 93
1	US-09-866-108A-8969	17	1.8	13.4	C 94
1	US-09-685-664B-3805	17	1.8	13.4	C 95
1	US-09-811-286-11	15	1.7	13	C 96
1	US-08-373-124A-180	17	1.7	13	C 97
1	US-08-373-124A-182	17	1.7	13	C 98
1	US-08-435-628-180	17	1.7	13	C 99
1	US-08-435-628-182	17	1.7	13	C 100
1	US-09-866-108A-7242	17	1.7	13	C 101
1	US-09-866-108A-8974	17	1.7	13	C 102
1	US-09-572-891-18	16	1.7	12.8	C 103
1	US-09-866-108A-7245	17	1.7	13	C 104
1	US-09-866-108A-7246	17	1.7	13	C 105
1	US-09-866-108A-7247	17	1.7	13	C 106

THIS PAGE BLANK (USPTO)

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 75.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

```

; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4770
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4770

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 92;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      874 CAACCATCATCAAGGC 889
      ||||| :|||
DB      2 CAACUACCUCAAGGC 17

RESULT 131
US-09-476-387-477
; Sequence 477, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MEHQ00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 477
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-477

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 92;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      263 CTGCACCTGCCTTCAG 278
      | : |||:|
DB      1 CUCCUCCUGCCUUCAG 16

RESULT 132
US-09-476-387-604
; Sequence 604, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides

```

; FILE REFERENCE: MEHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 604
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-604

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 92;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 512 CTGCGGAGGTGGAGC 527
|:|||||:|
Db 1 CUGCGGAGCGCAGC 16

RESULT 133
US-09-866-108A-354/c
; Sequence 354, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; NUMBER OF SEQ ID NOS: 15755
; Patent No. 6686188
; SEQ ID NO 354
; LENGTH: 17
; TYPE: DNA

; ORGANISM: Homo sapiens
US-09-866-108A-354

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTGAAGAGGC 497
|||||
Db 17 CTCGTTCTGGAGAGGC 2

RESULT 134
US-09-866-108A-355/c
; Sequence 355, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-355

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTGAAGAGGC 497
|||||
Db 16 CTCGTTCTGGAGAGGC 1

RESULT 135
US-09-866-108A-672/c
; Sequence 672, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong


```

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 686188
; SEQ ID NO 673
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-673

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
Db 16 GATGAGTCTCTCTGG 1
|||||
|||||

RESULT 137
US-09-866-108A-1523/c
; Sequence 1523, Application US/09866108A
; Patent No. 686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 686188
; SEQ ID NO 1523
; LENGTH: 17

```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1523

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      846 CCTATCACCAGCTCTT 861
Db      17 CCCATCACCCTGCTT 2

RESULT 138
US-09-866-108A-1524/c
; Sequence 1524, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1524
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1720

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      392 TTCCAAGCCAGCCAGA 407
Db      17 TTCTGAGCCAGCCAGA 2

RESULT 140
US-09-866-108A-1721/c
; Sequence 1721, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1524
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1524

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      846 CCTATCACCAGCTCTT 861
Db      16 CCCATCACCCTGCTT 1

RESULT 139
US-09-866-108A-1720/c
; Sequence 1720, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1721
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1721

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCGAGCCAGA 407
DB 16 TTCTGAGCCGAGCCAGA 1

RESULT 141
US-09-866-108A-1996/c
; Sequence 1996, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1996

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1996

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGCAATCA 324
DB 17 GCCTGGAGGAGCAATCA 2

RESULT 142
US-09-866-108A-1997/c
; Sequence 1997, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1997
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1997

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGCAATCA 324
DB 16 GCCTGGAGGAGCAATCA 1

RESULT 143
US-09-866-108A-6822/c
; Sequence 6822, Application US/09866108A
; Patent No. 6686188

GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6822
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6822

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 ACCTGCCTTCAGACA 282
DB 17 ACCTGCCTTCAGAAA 2

RESULT 144
US-09-866-108A-6890/C
; Sequence 6890, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27

GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6890
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6890

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCCTTCGAGAGAA 321
DB 17 GCGCCTTCGAGAGAA 2

RESULT 145
US-09-866-108A-6891/C
; Sequence 6891, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188

```
; SEQ ID NO 6891
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6891

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGGAGGAGAA 321
Db 16 GCCGCTGGAAGAA 1

RESULT 146
US-09-866-108A-7677
; Sequence 7677, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7678
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7678

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGAAGAGAG 505
Db 1 GAAGAAGCAGAGAAG 16

RESULT 148
US-09-866-108A-7697/c
; Sequence 7697, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/207,456
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```

```
; SEQ ID NO 6891
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6891

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGGAGGAGAA 321
Db 16 GCCGCTGGAAGAA 1

RESULT 146
US-09-866-108A-7677
; Sequence 7677, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7677
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7677

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGAAGAGAG 505
Db 2 GAAGAAGCAGAGAAG 17

RESULT 147
US-09-866-108A-7678
; Sequence 7678, Application US/09866108A
```

```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7697

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      828 TGGCCCACTGTCAGGT 843
      ||| |||| |||| |||
Db      17 TGGCCCACTGTCAGGT 2

RESULT 149
US-09-866-108A-7699/c
; Sequence 7699, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7697

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      828 TGGCCCACTGTCAGGT 843
      ||| |||| |||| |||
Db      17 TGGCCCACTGTCAGGT 2

RESULT 149
US-09-866-108A-7699/c
; Sequence 7699, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7697

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      828 TGGCCCACTGTCAGGT 843
      ||| |||| |||| |||
Db      17 TGGCCCACTGTCAGGT 2

RESULT 149
US-09-866-108A-7699/c
; Sequence 7699, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7697
```

```
; Patent No. 6686188
; SEQ ID NO 7699
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7699

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      827 CTGGCCCACTGTCAGG 842
      ||| |||| |||| |||
Db      16 CTGGCCCACTGTCAGG 1

RESULT 150
US-09-866-108A-7812
; Sequence 7812, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7812
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7812

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      493 GAGGCAGAGGAGCAG 508
      ||| |||| |||| |||
Db      2 GAAGCAAAAGGAGCAG 17

RESULT 151
US-09-866-108A-7814
```

; Sequence 7814, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Acomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 7814

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

; US-09-866-108A-7814

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 494 AGGCAAGAGGAGGAGG 509

DB 1 AAGCAAAAGGAGGAGG 16

RESULT 152

US-09-866-108A-8033

; Sequence 8033, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Acomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 8033

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

; US-09-866-108A-8033

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 92;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGAGAGTGAGCG 711

DB 2 AGCTGAGAGTGAGCG 17

RESULT 153

US-09-866-108A-8034

; Sequence 8034, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8034
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8034

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 696 AGCTGGAGATGACGC 711
Db 1 AGCTGGAGATGACGC 16

RESULT 154

; Sequence 8423, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8423
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8423

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 491 AAGAGCGAAGGAGC 506
Db 1 AAGAGCGAAGGAGC 16

RESULT 155

US-09-404-912-648
; Sequence 648, Application US/09404912
; Patent No. 670328
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest

; TITLE OF INVENTION: Methods and Products Related to
Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; CURRENT FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 648
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
; US-09-404-912-648

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 397 AGCCAGCCAGGGAG 412
Db 1 AGCCAGCCAGGGAG 16

RESULT 156

; Sequence 479, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: M06800-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-685-664B-479

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 92;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 875 AACCCATCAAGCA 890
Db 1 AACCCATCAAGCA 16

RESULT 157


```

US-09-685-664B-3556/c
; Sequence 3556, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH800-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3556
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3556

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GAGAGGAGGAAGCTGG 830
DB 17 GAGAGCAGAGCTGG 2

RESULT 158
5240847-22
; Patent No. 5240847
; APPLICANT: HECKL, KONRAD; SPEVAK, WALTER; OSTERMANN, ELINBOURG;
; ZOPHEL, ANDREAS; KRISTEK, EDELTRAUD; MAURER-FOG, INGRID;
; WITCHE-CASTANON, MARIA J.; STRATOWA, CHRISTIAN; HAUPTMANN, RUDOLF
; TITLE OF INVENTION: HUMAN MANGANESE SUPEROXIDE DISMUTASE
; (HMN-SOD)
; NUMBER OF SEQUENCES: 34
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/167,261
; FILING DATE: 11-MAR-1988
; SEQ ID NO: 22
; LENGTH: 17
5240847-22

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 GAGATGTCAGGCCCA 197
DB 2 GAGATGTTACAGGCCCA 17

RESULT 159
US-08-390-850-5/c
; Sequence 5, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John T.
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:

```

```

; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Fast-SEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-5

Query Match 1.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 79;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 380 GAGCTTCTGCATTT 393
DB 14 GAACTTCTGCATTT 1

RESULT 160
US-08-435-634-5/c
; Sequence 5, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John T.
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:

```

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-5

Query Match 1.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 79;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 380 GAGCTTCTGCATTT 393
DB 14 GAACCTTCTGCATTT 1

RESULT 161
US-08-319-492B-129/c
Sequence 129, Application US/08319492B
Patent No. 5616488
GENERAL INFORMATION:
APPLICANT: Sullivan, Sean M.
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF IL-5
NUMBER OF SEQUENCES: 751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/319,492B
FILING DATE: October 7, 1994

PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/276
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 129:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-319-492B-129

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 308 TGCCTGGAGGAGNA 321
DB 14 TGCCTGGAGGAGAAA 1

RESULT 162
US-08-307-682B-18/c
Sequence 18, Application US/08307682B
Patent No. 5665580
GENERAL INFORMATION:
APPLICANT: Crooke, Stanley T., Mirabelli,
APPLICANT: Christopher K., Ecker, David J., Cowsett, Lex M.
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE
TITLE OF INVENTION: INHIBITION OF PAPILLOMAVIRUS TRANSFORMED CELLS
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Jane Massey Licata, Esq.
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM 486
OPERATING SYSTEM: WINDOWS FOR WORKGROUPS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/307,682B
FILING DATE: October 14, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 860,925
FILING DATE: March 31, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US90/07067
FILING DATE: December 3, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 445,195
FILING DATE: December 4, 1989
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata, Esquire
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISIS-1049
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400

```

; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; ANTI-SENSE: yes
US-08-307-682B-18

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 404 CAGAGGGAGGAGAA 417
Db 14 CAGAGGTAGGAGAA 1

RESULT 163
US-08-585-684B-820/c
; Sequence 820, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 820:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-820

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 580 CCAGGTGAGCTCT 593
Db 15 CCAGGTGAGCTCT 2

RESULT 164
US-08-585-684B-885/c
; Sequence 885, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 885:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-885

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 CTTGAGAACAGGCG 286
Db 15 CTTGAGAACAGGCG 2

RESULT 165
US-08-585-684B-886/c
; Sequence 886, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 886:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-886
```

```
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 886:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-886

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 CTTGAGAACAGGGC 286
Db 14 CTTGAGAAAGGC 1

; RESULT 166
; US-09-038-073-820/c
; Sequence 820, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 885:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; FILING DATE:

; RESULT 167
; US-09-038-073-885/c
; Sequence 885, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 885:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; FILING DATE:
```

```

;
; TOPOLOGY: linear
; US-09-038-073-885

Query Match
Best Local Similarity 1.6%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 CTTGAGAACAGGCG 286
Db 15 CTTGAGAAAGGCG 2

RESULT 168
US-09-038-073-886/c
; Sequence 886, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 886:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-886

Query Match
Best Local Similarity 1.6%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 CTTGAGAACAGGCG 286
Db 14 CTTGAGAAAGGCG 1

RESULT 169
US-09-180-437-182/c
; Sequence 182, Application US/09180437
; Patent No. 6251873

```

```

;
; GENERAL INFORMATION:
; APPLICANT: FUKUSAKO, Shioji
; APPLICANT: MORISAWA, Yoshifumi
; APPLICANT: KUSUYAMA, Takeshi
; TITLE OF INVENTION: Antisense Compounds to CD14
; FILE REFERENCE: 1110-209P
; CURRENT APPLICATION NUMBER: US/09/180,437
; CURRENT FILING DATE: 1998-11-06
; EARLIER APPLICATION NUMBER: PCT/JP98/00953
; EARLIER FILING DATE: 1998-03-09
; EARLIER APPLICATION NUMBER: 09-053518 JAPAN
; EARLIER FILING DATE: 1997-03-07
; NUMBER OF SEQ ID NOS: 289
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 182
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:other nucleic
; OTHER INFORMATION: acid
; US-09-180-437-182

Query Match
Best Local Similarity 1.6%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 325 AGAGCTCCGAGATG 338
Db 14 AGCGCTCCGAGATG 1

RESULT 170
US-09-475-947A-304
; Sequence 304, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTS0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 304
; LENGTH: 15
; TYPE: DNA
; ORGANISM: human
; US-09-475-947A-304

Query Match
Best Local Similarity 1.6%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 719 CTGAGCAGCAGCA 732
Db 1 CAGCAGCAGCAGCA 14

RESULT 171
US-08-911-894-13/c
; Sequence 13, Application US/08911894
; Patent No. 6030830
; GENERAL INFORMATION:
; APPLICANT: Saxon, Andrew
; APPLICANT: Zhang, Ke
; APPLICANT: Fujieda, Shigeharu
; TITLE OF INVENTION: IMMUNOGLOBULIN TRANS-SPICED TRANSCRIPTS
; TITLE OF INVENTION: AND USES THEREOF
; NUMBER OF SEQUENCES: 90
; CORRESPONDENCE ADDRESS:

```

ADDRESSEE: Akin, Gump, Strauss, Hauer & Feld
STREET: 816 Congress Avenue, Suite 1900
CITY: Austin
STATE: Texas
COUNTRY: USA
ZIP: 78701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/911,894
FILING DATE: Concurrently Herewith
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/023,579
FILING DATE: 19-AUG-1996
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Mayfield, Denise L.
REGISTRATION NUMBER: 33,732
REFERENCE/DOCKET NUMBER: 43496.0006
TELEPHONE: (512) 499-6200
TELEFAX: (512) 499-6290
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-911-894-13

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 773 GTGGAGGCGCGCT 786
Db 15 GTGGAGGCGCTCGCT 2

RESULT 172
US-08-911-894-14
Sequence 14, Application US/08911894
Patent No. 6030830
GENERAL INFORMATION:
APPLICANT: Saxon, Andrew
APPLICANT: Zhang, Ke
APPLICANT: Fujieda, Shigeharu
TITLE OF INVENTION: IMMUNOGLOBULIN TRANS-SPLICED TRANSCRIPTS
TITLE OF INVENTION: AND USES THEREOF
NUMBER OF SEQUENCES: 90
CORRESPONDENCE ADDRESS:
ADDRESSEE: Akin, Gump, Strauss, Hauer & Feld
STREET: 816 Congress Avenue, Suite 1900
CITY: Austin
STATE: Texas
COUNTRY: USA
ZIP: 78701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/911,894
FILING DATE: Concurrently Herewith
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/023,579
FILING DATE: 19-AUG-1996

CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Mayfield, Denise L.
REGISTRATION NUMBER: 33,732
REFERENCE/DOCKET NUMBER: 43496.0006
TELEPHONE: (512) 499-6200
TELEFAX: (512) 499-6290
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-911-894-14

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 773 GTGGAGGCGCGCT 786
Db 2 GTGGAGGCGCTCGCT 15

RESULT 173
US-09-509-565-38
Sequence 38, Application US/09509565
Patent No. 6399340
GENERAL INFORMATION:
APPLICANT: SAITO, YOSHIMASA
APPLICANT: NOGUCHI, YUJI
APPLICANT: YOSHIKAWA, KOJI
APPLICANT: SOEDA, SHINSUKE
TITLE OF INVENTION: PLASMID VECTORS
FILE REFERENCE: 0018-1105-0PCT
CURRENT APPLICATION NUMBER: US/09/509,565
CURRENT FILING DATE: 2000-06-23
PRIOR APPLICATION NUMBER: PCT/JP9804611
PRIOR FILING DATE: 1998-10-13
PRIOR APPLICATION NUMBER: JP9/303395
PRIOR FILING DATE: 1997-10-16
NUMBER OF SEQ ID NOS: 42
SEQ ID NO 38
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
NAME/KEY: misc feature
OTHER INFORMATION: Description of Artificial Sequence: synthetic DNA
US-09-509-565-38

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 741 AGGTGACCAGCTG 754
Db 1 AGGTGACCAGCTG 14

RESULT 174
US-09-060-299-445/c
Sequence 445, Application US/09060299
Patent No. 6545137
GENERAL INFORMATION:
APPLICANT: Todd, John A
APPLICANT: Hess, John W
APPLICANT: Caskey, Charles T
APPLICANT: Cox, Roger D
APPLICANT: Gerhold, David
APPLICANT: Hammond, Holly

```

; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: No. 6545137el Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6545137th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/060,299
; FILING DATE: 15-APR-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-35
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 445:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; US-09-060-299-445

```

```

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 508 GGCTCTGGGGGAGG 521
Db 14 GGCTCTGGGGGAGG 1

```

```

RESULT 175
US-09-402-923A-445/c
; Sequence 445, Application US/09402923A
; Patent No. 6555654
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; Hesse, John W
; Caskey, Charles T
; Cox, Roger D
; Gerhold, David
; Hammond, Holly
; Hey, Patricia
; Kawaguchi, Yoshihiko
; Merriman, Tony R
; Metzker, Michael L
; TITLE OF INVENTION: No. 6555654el LDL-Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia

```

```

; COUNTRY: US
; ZIP: VA 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/402,923A
; FILING DATE: 14-Feb-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB98/01102
; FILING DATE: 15-APR-1998
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-81
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 445:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; US-09-402-923A-445

```

```

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 508 GGCTCTGGGGGAGG 521
Db 14 GGCTCTGGGGGAGG 1

```

```

RESULT 176
US-09-371-772B-5656/c
; Sequence 5656, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5656
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-5656

```

```

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Qy 705 GTGAGCGCGAGCG 718
|||||
Db 16 GTGAGCGCGAGCG 3

RESULT 177

US-09-544-398B-121/c
; Sequence 121, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/09/544,398B
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 121
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-544-398B-121

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 462 AGAGACTGGCGCTG 475
|||||
Db 14 AGAGACTGGCGCTG 1

RESULT 178

US-09-543-771B-121/c
; Sequence 121, Application US/09543771B
; Patent No. 6780609
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-014
; CURRENT APPLICATION NUMBER: US/09/543,771B
; CURRENT FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 121
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-543-771B-121

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 462 AGAGACTGGCGCTG 475

Db 14 AGAGACTGGCGCTG 1
|||||

RESULT 179

US-07-891-962-9/c
; Sequence 9, Application US/07891962
; Patent No. 5587308
; GENERAL INFORMATION:
; APPLICANT: Carter, Barrie J.
; APPLICANT: Flotte, Terence
; APPLICANT: Afione, Sandra
; APPLICANT: Solow, Rikki
; TITLE OF INVENTION: MODIFIED ADENO-ASSOCIATED VIRUS VECTOR
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NEEDLE & ROSENBERG
; STREET: 133 Carnegie Way, N.W., Suite 400
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30303
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/891,962
; FILING DATE: 19920602
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Pertyman, David G.
; REGISTRATION NUMBER: 33,438
; REFERENCE/DOCKET NUMBER: 1414.012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404) 688-0770
; TELEFAX: (404) 688-9880
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-07-891-962-9

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 668 GCCCGGGCGGCC 679
|||||
Db 12 GCCCGGGCGGCC 1

RESULT 180

US-08-626-953-9/c
; Sequence 9, Application US/08626953
; Patent No. 5866696
; GENERAL INFORMATION:
; APPLICANT: Carter, Barrie J.
; APPLICANT: Flotte, Terence
; APPLICANT: Afione, Sandra
; APPLICANT: Solow, Rikki
; TITLE OF INVENTION: MODIFIED ADENO-ASSOCIATED VIRUS VECTOR
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NEEDLE & ROSENBERG
; STREET: 133 Carnegie Way, N.W., Suite 400
; CITY: Atlanta

STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/626,953
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA: 07/891,962
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Perryman, David G.
REGISTRATION NUMBER: 33,438
REFERENCE/DOCKET NUMBER: 1414.012
TELEPHONE: (404) 688-0770
TELEFAX: (404) 688-9880
INFORMATION FOR SEQ ID NO: 9:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-626-953-9

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 668 GCCCGGGCGGCC 679
DB 12 GCCCGGGCGGCC 1

RESULT 181
US-08-455-231-9/c
Sequence 9, Application US/08455231
Patent No. 5989540
GENERAL INFORMATION:
APPLICANT: Carter, Barrie J.
APPLICANT: Flotte, Terence
APPLICANT: Afione, Sandra
APPLICANT: Solow, Rikki
TITLE OF INVENTION: MODIFIED ADENO-ASSOCIATED VIRUS VECTOR
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG
STREET: 133 Carnegie Way, N.W., Suite 400
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,231
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA: 07/891,962
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Perryman, David G.

REGISTRATION NUMBER: 33,438
REFERENCE/DOCKET NUMBER: 1414.012
TELEPHONE: (404) 688-0770
TELEFAX: (404) 688-9880
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-455-231-9

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 668 GCCCGGGCGGCC 679
DB 12 GCCCGGGCGGCC 1

RESULT 182
US-08-455-552A-9/c
Sequence 9, Application US/08455552A
Patent No. 5990279
GENERAL INFORMATION:
APPLICANT: Carter, Barrie J.
APPLICANT: Flotte, Terence
APPLICANT: Afione, Sandra
APPLICANT: Solow, Rikki
TITLE OF INVENTION: MODIFIED ADENO-ASSOCIATED VIRUS VECTOR
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG
STREET: 127 Peachtree Street, Suite 1200
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/455,552A
FILING DATE: 31 May 1995
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Perryman, David G.
REGISTRATION NUMBER: 33,438
REFERENCE/DOCKET NUMBER: 20094.0152
TELEPHONE: (404) 688-0770
TELEFAX: (404) 688-9880
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-455-552A-9

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 668 GCCCGGGCGGCC 679
DB 12 GCCCGGGCGGCC 1

```
Db      12 GCCCGGGCGGCC 1

RESULT 183
US-09-235-375-9/c
; Sequence 9, Application US/0923375
; Patent No. 6165781
; GENERAL INFORMATION:
; APPLICANT: Carter, Barrie J.
;             Florite, Terence
;             Afione, Sandra
;             Solow, Rikki
; TITLE OF INVENTION: MODIFIED ADENO-ASSOCIATED VIRUS VECTOR
; CAPABLE OF EXPRESSION FROM A NOVEL PROMOTER
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NEEDLE & ROSENBERG
; STREET: 133 Carnegie Way, N.W., Suite 400
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30303
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/235.375
; FILING DATE: 21-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/626,953
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Perryman, David G.
; REGISTRATION NUMBER: 33,438
; REFERENCE/DOCKET NUMBER: 1414.012
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404) 688-0770
; TELEFAX: (404) 688-9880
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-235-375-9

Query Match      1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      668 GCCCGGGCGGCC 679
        |||||
Db      12 GCCCGGGCGGCC 1

RESULT 184
US-09-213-834B-6
; Sequence 6, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; OPERATING SYSTEM: IBM P.C. DOS 5.0
```

```
; SEQ ID NO 6
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-09-213-834B-6

Query Match      1.6%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      668 GCCCGGGCGGCC 679
        |||||
Db      1 GCCCGGGCGGCC 12

RESULT 185
US-09-213-834B-7
; Sequence 7, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-09-213-834B-7

Query Match      1.6%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 92;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      668 GCCCGGGCGGCC 679
        |||||
Db      1 GCCCGGGCGGCC 12

RESULT 186
US-08-319-492B-16
; Sequence 16, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
```

```
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,492B
; FILING DATE: October 7, 1994
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/276
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-319-492B-16

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 1e+02;
Matches 6; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 382 GCTTCTGCATTT 393
||:||||:
Db 4 GCUCUGCAUU 15

RESULT 187
US-08-588-595-1/c
; Sequence 1, Application US/08588595
; Patent No. 5958769
; GENERAL INFORMATION:
; APPLICANT: Roberts, James M.
; APPLICANT: Coats, Steven R.
; APPLICANT: Fero, Matthew L.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR MEDIATING
; TITLE OF INVENTION: CELL CYCLE PROGRESSION
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew
; STREET: One Market Plaza, Steuart Street Tower
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105-1492
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/588,595
; FILING DATE: 18-JAN-1996
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 14538A-19
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
```

```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleotide
; US-08-588-595-1

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 607 GCAGGAGAGCCA 618
|||||
Db 12 GCAGGAGAGCCA 1

RESULT 188
US-09-180-437-104
; Sequence 104, Application US/09180437
; Patent No. 6251873
; GENERAL INFORMATION:
; APPLICANT: FUKUSAKO, Shioji
; APPLICANT: MORISAWA, Yoshifumi
; APPLICANT: KUSUYAMA, Takeshi
; TITLE OF INVENTION: Antisense Compounds to CD14
; FILE REFERENCE: 1110-209P
; CURRENT APPLICATION NUMBER: US/09/180,437
; CURRENT FILING DATE: 1998-11-06
; EARLIER APPLICATION NUMBER: PCT/JP98/00953
; EARLIER FILING DATE: 1998-03-09
; EARLIER APPLICATION NUMBER: 09-053518 JAPAN
; EARLIER FILING DATE: 1997-03-07
; NUMBER OF SEQ ID NOS: 289
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 104
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:other nucleic
; OTHER INFORMATION: acid
; US-09-180-437-104

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCA 732
|||||
Db 2 GCAGCAGCAGCA 13

RESULT 189
US-09-163-485-13/c
; Sequence 13, Application US/09163485
; Patent No. 6277571
; GENERAL INFORMATION:
; APPLICANT: FILLMORE, HELEN
; APPLICANT: BROADUS, WILLIAM
; APPLICANT: GILLIES, GEORGE
; TITLE OF INVENTION: SEQUENTIAL CONSENSUS REGION-DIRECTED AMPLIFICATION OF
; TITLE OF INVENTION: KNOWN AND NOVEL MEMBERS OF GENE FAMILIES
; FILE REFERENCE: VCUIP4B
; CURRENT APPLICATION NUMBER: US/09/163,485
; CURRENT FILING DATE: 1998-08-30
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 13
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide, consensus sequence from human
```

; OTHER INFORMATION: matrix metalloproteinases
US-09-163-485-13

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCA 732
Db 13 GCAGCAGCAGCA 2
|||||

RESULT 190

US-09-081-646-177

; Sequence 177, Application US/09081646

; Patent No. 6333152

; GENERAL INFORMATION:

; APPLICANT: Kinzler, Kenneth

; APPLICANT: Vogelstein, Bert

; APPLICANT: Zhang, Lin

; APPLICANT: Zhou, Wei

; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and

; FILE REFERENCE: 01107.74664

; CURRENT APPLICATION NUMBER: US/09/081,646

; CURRENT FILING DATE: 1998-05-20

; EARLIER APPLICATION NUMBER: 60/047,352

; EARLIER FILING DATE: 1997-05-21

; NUMBER OF SEQ ID NOS: 871

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 177

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-081-646-177

Query Match

Best Local Similarity 1.6%; Score 12; DB 1; Length 15;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 249 GGAAGCCAGCCA 260
Db 4 GGAAGCCAGCCA 15
|||||

RESULT 191

US-08-705-477B-49

; Sequence 49, Application US/08705477E

; Patent No. 6569432

; GENERAL INFORMATION:

; APPLICANT: Israeli, Ron S

; APPLICANT: Heston, Warren D.W.

; APPLICANT: Fair, William R.

; APPLICANT: Overfelli, Ouathak

; APPLICANT: Pinto, John

; TITLE OF INVENTION: PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF

; FILE REFERENCE: 1769/41426-G

; CURRENT APPLICATION NUMBER: US/08/705,477E

; CURRENT FILING DATE: 1996-08-29

; NUMBER OF SEQ ID NOS: 128

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 49

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Homo sapiens

US-08-705-477B-49

Query Match

Best Local Similarity 1.6%; Score 12; DB 1; Length 15;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 641 AAGGAATGCCAG 652
|||||

Db 1 AAGGAATGCCAG 12

RESULT 192

US-09-079-839-1/c

; Sequence 1, Application US/09079839

; Patent No. 6048726

; GENERAL INFORMATION:

; APPLICANT: Weltman, Joel K.

; APPLICANT: Karim, Aftab S.

; TITLE OF INVENTION: INHIBITION OF EOSINOPHILIC INFLAMMATION

; FILE REFERENCE: 09998/002001

; CURRENT APPLICATION NUMBER: US/09/079,839

; CURRENT FILING DATE: 1998-05-15

; NUMBER OF SEQ ID NOS: 2

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 1

; LENGTH: 16

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-079-839-1

Query Match

Best Local Similarity 1.6%; Score 12; DB 1; Length 16;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 382 GCTTCTGCAATT 393
Db 16 GCTTCTGCAATT 5
|||||

RESULT 193

US-09-917-907-1

; Sequence 1, Application US/09917907

; Patent No. 6653466

; GENERAL INFORMATION:

; APPLICANT: Matsuo, Masafumi

; TITLE OF INVENTION: Pharmaceutical Composition for Treatment of Muscular Dystrophy

; FILE REFERENCE: P21305

; CURRENT APPLICATION NUMBER: US/09/917,907

; CURRENT FILING DATE: 2001-07-31

; PRIOR APPLICATION NUMBER: 09/563,260

; PRIOR FILING DATE: 2000-05-01

; PRIOR APPLICATION NUMBER: JP 140930/99

; PRIOR FILING DATE: 1999-05-21

; NUMBER OF SEQ ID NOS: 2

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1

; LENGTH: 16

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-917-907-1

Query Match

Best Local Similarity 1.6%; Score 12; DB 1; Length 16;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 536 AGATGCCAGCAG 547
Db 4 AGATGCCAGCAG 15
|||||

RESULT 194

US-09-667-327-5

; Sequence 5, Application US/09667327

; Patent No. 6653467

; GENERAL INFORMATION:

; APPLICANT: JCR Pharmaceuticals Co., Ltd.

; TITLE OF INVENTION: Medicament for Treatment of Duchenne Muscular Dystrophy

; FILE REFERENCE: GP34

; CURRENT APPLICATION NUMBER: US/09/667,327

; CURRENT FILING DATE: 2000-09-22

; NUMBER OF SEQ ID NOS: 6

```
; SEQ ID NO 5
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-667-327-5

Query Match      1.6%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      536 AGATGCCAGCAG 547
Db      4 AGATGCCAGCAG 15

RESULT 195
US-09-930-251-1
; Sequence 1, Application US/09930251
; Patent No. 6727355
; GENERAL INFORMATION:
; APPLICANT: Matsuo, Masafumi; Kamei, Shoichiro
; TITLE OF INVENTION: Pharmaceutical Composition for Treatment of Duchenne Muscular Dystrophy
; FILE REFERENCE: P21360
; CURRENT APPLICATION NUMBER: US/09/930,251
; CURRENT FILING DATE: 2001-08-16
; PRIOR APPLICATION NUMBER: JP2000-256547
; PRIOR FILING DATE: 2000-08-25
; NUMBER OF SEQ ID NOS: 19
; SEQ ID NO 1
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-930-251-1

Query Match      1.6%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      536 AGATGCCAGCAG 547
Db      4 AGATGCCAGCAG 15

RESULT 196
US-08-182-968A-139/C
; Sequence 139, Application US/08182968A
; Patent No. 5610054
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR INHIBITING HEPATITIS C
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14-MAY-1992
```

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/277
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 139:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-182-968A-139

Query Match      1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      511 TCTGCGGAGGTGGA 525
Db      15 TCTGATGGAGGTGGA 1

RESULT 197
US-08-100-465-7
; Sequence 7, Application US/08100465
; Patent No. 5610137
; GENERAL INFORMATION:
; APPLICANT: TOWNES, TIM M., ET AL.
; TITLE OF INVENTION: TRANSGENIC, CROSS-LINKED HEMOGLOBIN
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 502 or 55SX
; OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
; SOFTWARE: WordPerfect (Version 5.0)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/100,465
; FILING DATE: 30-JUL-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/630,825
; FILING DATE: DECEMBER 20, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: CLARK, PAUL T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 004005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-100-465-7

Query Match      1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Qy 260 ATGCTGCACCTGCT 274
||| ||||| ||
Db 1 ATGCTGCACCTGACT 15

RESULT 198

US-08-291-932A-296/c
; Sequence 296, Application US/08291932A
; Patent No. 5658780

GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830

CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/291,932A

FILING DATE: August 15, 1994

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

; including application

PRIOR APPLICATION DATA: described below:

; APPLICATION NUMBER: 08/245,466

; FILING DATE: May 18, 1994

; APPLICATION NUMBER: 07/987,132

; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 208/157

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 296:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-291-932A-296

Query Match 1.6%; Score 11.8; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 1.1e+02;

Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 243 CTCCTGGGAGGCAG 257

Db 15 CTCCTGGGAGGCAG 1

RESULT 199

US-08-292-620A-35
; Sequence 35, Application US/08292620A
; Patent No. 5837542

GENERAL INFORMATION:

; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071-2066

COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/292,620A

FILING DATE: August 17, 1994

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

; including application

PRIOR APPLICATION DATA: described below:

; APPLICATION NUMBER: 08/008,895

; FILING DATE: January 19, 1993

; APPLICATION NUMBER: 07/989,849

; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 208/149

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 35:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-292-620A-35

Query Match 1.6%; Score 11.8; DB 1; Length 15;

Best Local Similarity 60.0%; Pred. No. 1.1e+02;

Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 416 AAGGAGTCTCATG 430

Db 1 AAGGAGTCTCATG 15

RESULT 200

US-08-292-620A-176/c

; Sequence 176, Application US/08292620A

; Patent No. 5837542

GENERAL INFORMATION:

; APPLICANT: Susan Grimm

; APPLICANT: Dan T. Stinchcomb

; APPLICANT: James McSwiggen

; APPLICANT: Sean Sullivan

; APPLICANT: Kenneth G. Draper

; TITLE OF INVENTION: RIBOZYME TREATMENT OF

; DISEASES OR CONDITIONS

two

Two

```

; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 176:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-176

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 553 GGCTGAGGACAAAGGC 567
DB 15 GACTGAGGACAAATGC 1

RESULT 201
US-08-774-306A-139/c
; Sequence 139, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:

```

```

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,306A
; FILING DATE: December 26, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/227
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 139:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-306A-139

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 511 TCTGGGGAGGTGGA 525
DB 15 TCTGATGGAGGTGGA 1

RESULT 202
US-09-064-156A-139/c
; Sequence 139, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:

```

two

```
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 139:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-064-156A-139

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 511 TCTGCGGAGGTGGA 525
   ||| |||||
Db 15 TCTGATGAGGTGGA 1

RESULT 203
US-09-071-845-35
; Sequence 35, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
```

```
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-35

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.1e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 416 AAGGAGTTCCTCATG 430
   |||||:|:|
Db 1 AAGGAGUGUCUCCUG 15

RESULT 204
US-09-071-845-176/c
; Sequence 176, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 176:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-176
```


Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 553 GGCTGAGGACAGGC 567
| | | | | | | | | | | | | | |
Db 15 GACTGAGGCAATGC 1

RESULT 205

US-09-232-468A-9/c
; Sequence 9, Application US/09232468A

; Patent No. 6207165

; GENERAL INFORMATION:

; APPLICANT: AUDONNET et al.

; TITLE OF INVENTION: POLYNUCLEOTIDE VACCINE FORMULA AGAINST PORCINE

; FILE REFERENCE: 454313-2230

; CURRENT APPLICATION NUMBER: US/09/232,468A

; CURRENT FILING DATE: 1999-01-05

; NUMBER OF SEQ ID NOS: 54

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 9

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Aujeszky's Disease Virus (NIA3 Strain)

US-09-232-468A-9

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCAGGAGGCTTC 386
| | | | | | | | | | | | | | |
Db 15 GCTGCAGGAGCATC 1

RESULT 206

US-09-275-850-21

; Sequence 21, Application US/09275850A

; Patent No. 6261774

; GENERAL INFORMATION:

; APPLICANT: Pagratis, Nikos

; APPLICANT: Gold, Larry

; APPLICANT: Shtatland, Timur

; APPLICANT: Javornik, Brenda

; TITLE OF INVENTION: Truncation SELEX Method

; FILE REFERENCE: NEX 79

; CURRENT APPLICATION NUMBER: US/09/275,850A

; CURRENT FILING DATE: 1999-03-24

; NUMBER OF SEQ ID NOS: 351

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 21

; LENGTH: 15

; TYPE: RNA

; ORGANISM: E. coli

US-09-275-850-21

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.1e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 720 TGCAGCAGCAGCACCA 734
| | | | | | | | | | | | | | |
Db 1 UGCAGCACACGCCA 15

RESULT 207

US-09-081-646-429/c

; Sequence 429, Application US/09081646

; Patent No. 6333152

; GENERAL INFORMATION:

; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 429
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-429

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 324 AAGAGCTCGGATG 338
| | | | | | | | | | | | | | |
Db 15 AACAGCTCGACATG 1

RESULT 208

US-09-081-646-468

; Sequence 468, Application US/09081646

; Patent No. 6333152

; GENERAL INFORMATION:

; APPLICANT: Kinzler, Kenneth

; APPLICANT: Vogelstein, Bert

; APPLICANT: Zhang, Lin

; APPLICANT: Zhou, Wei

; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and

; FILE REFERENCE: 01107.74664

; CURRENT APPLICATION NUMBER: US/09/081,646

; CURRENT FILING DATE: 1998-05-20

; EARLIER APPLICATION NUMBER: 60/047,352

; EARLIER FILING DATE: 1997-05-21

; NUMBER OF SEQ ID NOS: 871

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 468

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-081-646-468

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 CATGCTGCACCTGCC 273
| | | | | | | | | | | | | | |
Db 1 CATGCTGCACCTCCC 15

RESULT 209

US-09-474-432B-194

; Sequence 194, Application US/09474432B

; Patent No. 6528640

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Beigelman, Leo

; APPLICANT: Burgin, Alex

; APPLICANT: Beaudry, Amber

; APPLICANT: Karpeisky, Alex

; APPLICANT: Adamic, Jasenka

; APPLICANT: Svedler, David

```
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 194
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-194

Query Match          1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.1e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      264 TGCACCTGCCTTCAG 278
Db      : |||:|||||
        1 UCCUCCUGCCUUCAG 15

RESULT 210
US-09-784-984B-7/c
; Sequence 7, Application US/09784984B
; Patent No. 6576243
; GENERAL INFORMATION:
; APPLICANT: Merial Ltd.
; APPLICANT: Audonnet, Jean-Christophe
; APPLICANT: Bouchardon, Annabelle
; APPLICANT: Baudu, Philippe
; APPLICANT: Riviere, Michael
; TITLE OF INVENTION: Polynucleotide vaccine Formula Against Porcine Reproductive and
; TITLE OF INVENTION: Respiratory Pathologies
; FILE REFERENCE: 454313-2230.1
; CURRENT APPLICATION NUMBER: US/09/784,984B
; CURRENT FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: FR 96/09338
; PRIOR FILING DATE: 1996-07-19
; PRIOR APPLICATION NUMBER: PCT/FR97/01313
; PRIOR FILING DATE: 1997-07-15
; PRIOR APPLICATION NUMBER: US 6,207,165
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Aujeszky's Disease Virus (NIA3 Strain)
US-09-784-984B-7

Query Match          1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      372 GCTCGGAGGAGCTTC 386
Db      : |||||:|||||
        15 GCTCGGAGGAGCATC 1

RESULT 211
US-09-476-387-194
; Sequence 194, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 194
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-194

Query Match          1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.1e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      264 TGCACCTGCCTTCAG 278
Db      : |||:|||||
        1 UCCUCCUGCCUUCAG 15

RESULT 212
5182195-58
; Patent No. 5182195
; APPLICANT: NAKAHAMA, KAZUO;KAISHO, YOSHIHIKO;YOSHIMURA, KOJI
; TITLE OF INVENTION: METHOD FOR INCREASING USING PROTEASE
; DEFICIENT YEASTS
; NUMBER OF SEQUENCES: 71
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/269,140
; FILING DATE: 09-NOV-1988
; SEQ ID NO:58:
; LENGTH: 15
5182195-58

Query Match          1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      612 AGAGCCAGAGTCGCT 626
Db      : |||||:|||||
        1 AGAGCCTGGTCGCT 15

RESULT 213
5182195-58
; Patent No. 5182195
; APPLICANT: NAKAHAMA, KAZUO;KAISHO, YOSHIHIKO;YOSHIMURA, KOJI
; TITLE OF INVENTION: METHOD FOR INCREASING USING PROTEASE
; DEFICIENT YEASTS
; NUMBER OF SEQUENCES: 71
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/269,140
; FILING DATE: 09-NOV-1988
; SEQ ID NO:58:
; LENGTH: 15
```

5182195-58

Query Match 1.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 612 AGAGCCAGAGTCGCT 626
| | | | | | | | | |
Db 1 AGAGCCTGGGTCGCT 15

Search completed: April 8, 2005, 08:49:19
Job time : 3 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 8, 2005, 08:45:15 ; Search time 8 Seconds
(without alignments)
3.726 Million cell updates/sec

Title: US-10-628-841-3
Perfect score: 755
Sequence: 1 tctggaagagccaactgtgt.....tgggcagtgcggaagcga 755

Scoring table: IDENTITY NUC
Gapop 10_0 , Gapext 0.5

Searched: 1138 seqs, 19741 residues

Total number of hits satisfying chosen parameters: 2276

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1138 summaries

Database : fetchrng.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	29	3.8	29	ADA44708	PCR probe for ampl
2	27	3.6	27	ADSI7882	Human IKKGs2.1 D
3	23	3.0	23	ADG29527	IKKG siNA-target R
4	23	3.0	23	ADG29528	IKKG siNA-target R
5	22	2.9	22	ACD23070	Human NEMO exon 3
6	21	2.8	21	ADA13786	Short interfering
7	21	2.8	21	ADA13787	Short interfering
8	21	2.8	21	ADA13791	Short interfering
9	21	2.8	21	ADN75886	Human IKKGgamma sir
10	21	2.8	21	ADN75896	Human IKKGgamma sir
11	20	2.6	20	ADA44738	Antisense oligonuc
12	20	2.6	20	ADA44746	Antisense oligonuc
13	20	2.6	20	ADA44751	Antisense oligonuc
14	20	2.6	20	ADA44726	Antisense oligonuc
15	20	2.6	20	ADA44750	Antisense oligonuc
16	20	2.6	20	ADA44719	Antisense oligonuc
17	20	2.6	20	ADA44722	Antisense oligonuc
18	20	2.6	20	ADA44732	Antisense oligonuc
19	20	2.6	20	ADA44739	Antisense oligonuc
20	20	2.6	20	ADA44742	Antisense oligonuc
21	20	2.6	20	ADA44728	Antisense oligonuc
22	20	2.6	20	ADA44744	Antisense oligonuc
23	20	2.6	20	ADA44707	PCR primer for amp
24	20	2.6	20	ADA44718	Antisense oligonuc
25	20	2.6	20	ADA44734	Antisense oligonuc
26	20	2.6	20	ADA44747	Antisense oligonuc
27	20	2.6	20	ADA44730	Antisense oligonuc
28	20	2.6	20	ADA44733	Antisense oligonuc
29	20	2.6	20	ADA44741	Antisense oligonuc
30	20	2.6	20	ADA44724	Antisense oligonuc
31	20	2.6	20	ADA44727	Antisense oligonuc
32	20	2.6	20	ADA44720	Antisense oligonuc
33	20	2.6	20	ADA44740	Antisense oligonuc

Antisense oligonuc	ADA44725	20	2.6	34	C
Antisense oligonuc	ADA44731	20	2.6	35	C
Antisense oligonuc	ADA44745	20	2.6	36	C
Antisense oligonuc	ADA44723	20	2.6	37	C
Antisense oligonuc	ADA44748	20	2.6	38	C
Antisense oligonuc	ADA44721	20	2.6	39	C
Antisense oligonuc	ADA44737	20	2.6	40	C
Antisense oligonuc	ADA44749	20	2.6	41	C
Antisense oligonuc	ADA44735	20	2.6	42	C
Antisense oligonuc	ADA44743	20	2.6	43	C
Antisense oligonuc	ADA44729	20	2.6	44	C
Antisense oligonuc	ADA44736	20	2.6	45	C
Human NEMO gene RT	ACD23062	21	2.6	46	C
Short interfering	ADAI3795	21	2.6	47	C
IKKG-targeted siNA	ADG30046	23	2.6	48	C
Human NEMO gene RT	ACD23064	21	2.6	49	C
Short interfering	ADA13790	21	2.6	50	C
IKKG-targeted siNA	ADG30050	21	2.6	51	C
Human IKKGgamma sir	ADN75891	21	2.6	52	C
IKKG-targeted siNA	ADG30045	23	2.6	53	C
Human NEMO gene mu	ACD23072	25	2.6	54	C
IKK.2 associated s	ADN75887	19	2.5	55	C
IKK.2 associated s	ADN75888	19	2.5	56	C
IKK.3 associated s	ADN75892	19	2.5	57	C
IKK.1 associated s	ADN75883	19	2.5	58	C
IKK.3 associated s	ADN75893	19	2.5	59	C
IKK.1 associated s	ADN75882	19	2.5	60	C
IKK.4 associated s	ADN75898	19	2.5	61	C
IKK.4 associated s	ADN75897	19	2.5	62	C
Short interfering	ADA13794	21	2.5	63	C
IKKG-targeted siNA	ADG30049	21	2.5	64	C
IKK.4 associated s	ADN75900	21	2.5	65	C
IKK.1 associated s	ADN75884	21	2.5	66	C
IKK.3 associated s	ADN75894	21	2.5	67	C
IKK.2 associated s	ADN75890	21	2.5	68	C
Human IKKGgamma sir	ADN75881	21	2.5	69	C
IKK.4 associated s	ADN75899	21	2.5	70	C
IKK.1 associated s	ADN75885	21	2.5	71	C
IKK.2 associated s	ADN75889	21	2.5	72	C
IKK.3 associated s	ADN75895	21	2.5	73	C
Human KIAA1531 ant	ADJ46760	20	2.4	74	C
Cyclin-dependent k	ADG31926	20	2.4	75	C
Human IKK-gamma su	ADL47533	17	2.3	76	C
Human IKK-gamma su	ADL47537	17	2.3	77	C
Human IKK-gamma su	ADL47549	17	2.3	78	C
Human IKK-gamma su	ADL47744	17	2.3	79	C
Human IKK-gamma su	ADL47762	17	2.3	80	C
Human IKK-gamma su	ADL47788	17	2.3	81	C
Human IKK-gamma su	ADL47794	17	2.3	82	C
Human IKK-gamma su	ADL47821	17	2.3	83	C
Human IKK-gamma su	ADL47839	17	2.3	84	C
Human IKK-gamma su	ADL47841	17	2.3	85	C
Human IKK-gamma su	ADL47859	17	2.3	86	C
Human IKK-gamma su	ADL48207	17	2.3	87	C
Human IKK-gamma su	ADL48222	17	2.3	88	C
Human IKK-gamma su	ADL48232	17	2.3	89	C
Human IKK-gamma su	ADL48266	17	2.3	90	C
Human IKK-gamma su	ADL48275	17	2.3	91	C
Human IKK-gamma su	ADL48280	17	2.3	92	C
Human IKK-gamma su	ADL48391	17	2.3	93	C
Human IKK-gamma su	ADL48312	17	2.3	94	C
Human IKK-gamma su	ADL48482	17	2.3	95	C
Human IKK-gamma su	ADL48559	17	2.3	96	C
Human IKK-gamma su	ADL48564	17	2.3	97	C
Human IKK-gamma su	ADL48578	17	2.3	98	C
Human IKK-gamma su	ADL48600	17	2.3	99	C
Human IKK-gamma su	ADL48606	17	2.3	100	C
Human IKK-gamma su	ADL48617	17	2.3	101	C
Human IKK-gamma su	ADL48628	17	2.3	102	C
Human IKK-gamma su	ADL48630	17	2.3	103	C
Human IKK-gamma su	ADL48632	17	2.3	104	C
Human IKK-gamma su	ADL48653	17	2.3	105	C
Human IKK-gamma su	ADL48657	17	2.3	106	C

107	17	2.3	17	1	ADL48700	Human	IKK-gamma	su	180	17	2.3	17	1	ADL48215	Human	IKK-gamma	su
108	17	2.3	17	1	ADL47525	Human	IKK-gamma	su	181	17	2.3	17	1	ADL48216	Human	IKK-gamma	su
109	17	2.3	17	1	ADL47532	Human	IKK-gamma	su	182	17	2.3	17	1	ADL48227	Human	IKK-gamma	su
110	17	2.3	17	1	ADL47534	Human	IKK-gamma	su	183	17	2.3	17	1	ADL48238	Human	IKK-gamma	su
111	17	2.3	17	1	ADL47540	Human	IKK-gamma	su	184	17	2.3	17	1	ADL48273	Human	IKK-gamma	su
112	17	2.3	17	1	ADL47543	Human	IKK-gamma	su	185	17	2.3	17	1	ADL48279	Human	IKK-gamma	su
113	17	2.3	17	1	ADL47553	Human	IKK-gamma	su	186	17	2.3	17	1	ADL48296	Human	IKK-gamma	su
114	17	2.3	17	1	ADL47737	Human	IKK-gamma	su	187	17	2.3	17	1	ADL48309	Human	IKK-gamma	su
115	17	2.3	17	1	ADL47758	Human	IKK-gamma	su	188	17	2.3	17	1	ADL48313	Human	IKK-gamma	su
116	17	2.3	17	1	ADL47774	Human	IKK-gamma	su	189	17	2.3	17	1	ADL48487	Human	IKK-gamma	su
117	17	2.3	17	1	ADL47777	Human	IKK-gamma	su	190	17	2.3	17	1	ADL48595	Human	IKK-gamma	su
118	17	2.3	17	1	ADL47783	Human	IKK-gamma	su	191	17	2.3	17	1	ADL48605	Human	IKK-gamma	su
119	17	2.3	17	1	ADL47792	Human	IKK-gamma	su	192	17	2.3	17	1	ADL48610	Human	IKK-gamma	su
120	17	2.3	17	1	ADL47819	Human	IKK-gamma	su	193	17	2.3	17	1	ADL48626	Human	IKK-gamma	su
121	17	2.3	17	1	ADL47831	Human	IKK-gamma	su	194	17	2.3	17	1	ADL48678	Human	IKK-gamma	su
122	17	2.3	17	1	ADL47834	Human	IKK-gamma	su	195	17	2.3	17	1	ADL48689	Human	IKK-gamma	su
123	17	2.3	17	1	ADL47847	Human	IKK-gamma	su	196	17	2.3	17	1	ADL48702	Human	IKK-gamma	su
124	17	2.3	17	1	ADL47857	Human	IKK-gamma	su	197	17	2.3	17	1	ADL47554	Human	IKK-gamma	su
125	17	2.3	17	1	ADL47864	Human	IKK-gamma	su	198	17	2.3	17	1	ADL47558	Human	IKK-gamma	su
126	17	2.3	17	1	ADL47876	Human	IKK-gamma	su	199	17	2.3	17	1	ADL47750	Human	IKK-gamma	su
127	17	2.3	17	1	ADL47878	Human	IKK-gamma	su	200	17	2.3	17	1	ADL47752	Human	IKK-gamma	su
128	17	2.3	17	1	ADL47886	Human	IKK-gamma	su	201	17	2.3	17	1	ADL47756	Human	IKK-gamma	su
129	17	2.3	17	1	ADL48208	Human	IKK-gamma	su	202	17	2.3	17	1	ADL47773	Human	IKK-gamma	su
130	17	2.3	17	1	ADL48210	Human	IKK-gamma	su	203	17	2.3	17	1	ADL47830	Human	IKK-gamma	su
131	17	2.3	17	1	ADL48212	Human	IKK-gamma	su	204	17	2.3	17	1	ADL47850	Human	IKK-gamma	su
132	17	2.3	17	1	ADL48213	Human	IKK-gamma	su	205	17	2.3	17	1	ADL47895	Human	IKK-gamma	su
133	17	2.3	17	1	ADL48241	Human	IKK-gamma	su	206	17	2.3	17	1	ADL48251	Human	IKK-gamma	su
134	17	2.3	17	1	ADL48274	Human	IKK-gamma	su	207	17	2.3	17	1	ADL48277	Human	IKK-gamma	su
135	17	2.3	17	1	ADL48274	Human	IKK-gamma	su	208	17	2.3	17	1	ADL48289	Human	IKK-gamma	su
136	17	2.3	17	1	ADL48301	Human	IKK-gamma	su	209	17	2.3	17	1	ADL48483	Human	IKK-gamma	su
137	17	2.3	17	1	ADL48473	Human	IKK-gamma	su	210	17	2.3	17	1	ADL48492	Human	IKK-gamma	su
138	17	2.3	17	1	ADL48480	Human	IKK-gamma	su	211	17	2.3	17	1	ADL48561	Human	IKK-gamma	su
139	17	2.3	17	1	ADL48562	Human	IKK-gamma	su	212	17	2.3	17	1	ADL48571	Human	IKK-gamma	su
140	17	2.3	17	1	ADL48580	Human	IKK-gamma	su	213	17	2.3	17	1	ADL48575	Human	IKK-gamma	su
141	17	2.3	17	1	ADL48594	Human	IKK-gamma	su	214	17	2.3	17	1	ADL48633	Human	IKK-gamma	su
142	17	2.3	17	1	ADL48598	Human	IKK-gamma	su	215	17	2.3	17	1	ADL48666	Human	IKK-gamma	su
143	17	2.3	17	1	ADL48656	Human	IKK-gamma	su	216	17	2.3	17	1	ADL48680	Human	IKK-gamma	su
144	17	2.3	17	1	ADL48665	Human	IKK-gamma	su	217	17	2.3	17	1	ADL48683	Human	IKK-gamma	su
145	17	2.3	17	1	ADL47519	Human	IKK-gamma	su	218	17	2.3	17	1	ADL48687	Human	IKK-gamma	su
146	17	2.3	17	1	ADL47797	Human	IKK-gamma	su	219	17	2.3	17	1	ADL48691	Human	IKK-gamma	su
147	17	2.3	17	1	ADL47804	Human	IKK-gamma	su	220	17	2.3	17	1	ADL48694	Human	IKK-gamma	su
148	17	2.3	17	1	ADL47806	Human	IKK-gamma	su	221	17	2.3	17	1	ADL48696	Human	IKK-gamma	su
149	17	2.3	17	1	ADL47816	Human	IKK-gamma	su	222	17	2.3	17	1	ADL48698	Human	IKK-gamma	su
150	17	2.3	17	1	ADL47837	Human	IKK-gamma	su	223	17	2.3	17	1	ADL48705	Human	IKK-gamma	su
151	17	2.3	17	1	ADL47883	Human	IKK-gamma	su	224	17	2.3	17	1	ADL47520	Human	IKK-gamma	su
152	17	2.3	17	1	ADL48214	Human	IKK-gamma	su	225	17	2.3	17	1	ADL47528	Human	IKK-gamma	su
153	17	2.3	17	1	ADL48225	Human	IKK-gamma	su	226	17	2.3	17	1	ADL47530	Human	IKK-gamma	su
154	17	2.3	17	1	ADL48245	Human	IKK-gamma	su	227	17	2.3	17	1	ADL47552	Human	IKK-gamma	su
155	17	2.3	17	1	ADL48255	Human	IKK-gamma	su	228	17	2.3	17	1	ADL47736	Human	IKK-gamma	su
156	17	2.3	17	1	ADL48263	Human	IKK-gamma	su	229	17	2.3	17	1	ADL47751	Human	IKK-gamma	su
157	17	2.3	17	1	ADL48282	Human	IKK-gamma	su	230	17	2.3	17	1	ADL47764	Human	IKK-gamma	su
158	17	2.3	17	1	ADL48289	Human	IKK-gamma	su	231	17	2.3	17	1	ADL47771	Human	IKK-gamma	su
159	17	2.3	17	1	ADL48302	Human	IKK-gamma	su	232	17	2.3	17	1	ADL47776	Human	IKK-gamma	su
160	17	2.3	17	1	ADL48321	Human	IKK-gamma	su	233	17	2.3	17	1	ADL47800	Human	IKK-gamma	su
161	17	2.3	17	1	ADL48479	Human	IKK-gamma	su	234	17	2.3	17	1	ADL47803	Human	IKK-gamma	su
162	17	2.3	17	1	ADL48574	Human	IKK-gamma	su	235	17	2.3	17	1	ADL47809	Human	IKK-gamma	su
163	17	2.3	17	1	ADL48576	Human	IKK-gamma	su	236	17	2.3	17	1	ADL47810	Human	IKK-gamma	su
164	17	2.3	17	1	ADL48581	Human	IKK-gamma	su	237	17	2.3	17	1	ADL47840	Human	IKK-gamma	su
165	17	2.3	17	1	ADL48643	Human	IKK-gamma	su	238	17	2.3	17	1	ADL47851	Human	IKK-gamma	su
166	17	2.3	17	1	ADL48647	Human	IKK-gamma	su	239	17	2.3	17	1	ADL47862	Human	IKK-gamma	su
167	17	2.3	17	1	ADL48649	Human	IKK-gamma	su	240	17	2.3	17	1	ADL47873	Human	IKK-gamma	su
168	17	2.3	17	1	ADL48655	Human	IKK-gamma	su	241	17	2.3	17	1	ADL47880	Human	IKK-gamma	su
169	17	2.3	17	1	ADL47529	Human	IKK-gamma	su	242	17	2.3	17	1	ADL48217	Human	IKK-gamma	su
170	17	2.3	17	1	ADL47538	Human	IKK-gamma	su	243	17	2.3	17	1	ADL48249	Human	IKK-gamma	su
171	17	2.3	17	1	ADL47745	Human	IKK-gamma	su	244	17	2.3	17	1	ADL48252	Human	IKK-gamma	su
172	17	2.3	17	1	ADL47755	Human	IKK-gamma	su	245	17	2.3	17	1	ADL48258	Human	IKK-gamma	su
173	17	2.3	17	1	ADL47769	Human	IKK-gamma	su	246	17	2.3	17	1	ADL48265	Human	IKK-gamma	su
174	17	2.3	17	1	ADL47828	Human	IKK-gamma	su	247	17	2.3	17	1	ADL48269	Human	IKK-gamma	su
175	17	2.3	17	1	ADL47843	Human	IKK-gamma	su	248	17	2.3	17	1	ADL48270	Human	IKK-gamma	su
176	17	2.3	17	1	ADL47881	Human	IKK-gamma	su	249	17	2.3	17	1	ADL48283	Human	IKK-gamma	su
177	17	2.3	17	1	ADL47889	Human	IKK-gamma	su	250	17	2.3	17	1	ADL48295	Human	IKK-gamma	su
178	17	2.3	17	1	ADL47890	Human	IKK-gamma	su	251	17	2.3	17	1	ADL48320	Human	IKK-gamma	su
179	17	2.3	17	1	ADL48205	Human	IKK-gamma	su	252	17	2.3	17	1	ADL48478	Human	IKK-gamma	su

399	17	2.3	17	1	ADL47536	Human	IKK-gamma	su	472
400	17	2.3	17	1	ADL47753	Human	IKK-gamma	su	473
401	17	2.3	17	1	ADL47767	Human	IKK-gamma	su	474
402	17	2.3	17	1	ADL47789	Human	IKK-gamma	su	475
403	17	2.3	17	1	ADL47807	Human	IKK-gamma	su	476
404	17	2.3	17	1	ADL47811	Human	IKK-gamma	su	477
405	17	2.3	17	1	ADL47820	Human	IKK-gamma	su	478
406	17	2.3	17	1	ADL47823	Human	IKK-gamma	su	479
407	17	2.3	17	1	ADL47836	Human	IKK-gamma	su	480
408	17	2.3	17	1	ADL47845	Human	IKK-gamma	su	481
409	17	2.3	17	1	ADL47849	Human	IKK-gamma	su	482
410	17	2.3	17	1	ADL47860	Human	IKK-gamma	su	483
411	17	2.3	17	1	ADL47882	Human	IKK-gamma	su	484
412	17	2.3	17	1	ADL48204	Human	IKK-gamma	su	485
413	17	2.3	17	1	ADL48220	Human	IKK-gamma	su	486
414	17	2.3	17	1	ADL48253	Human	IKK-gamma	su	487
415	17	2.3	17	1	ADL48285	Human	IKK-gamma	su	488
416	17	2.3	17	1	ADL48304	Human	IKK-gamma	su	489
417	17	2.3	17	1	ADL48308	Human	IKK-gamma	su	490
418	17	2.3	17	1	ADL48310	Human	IKK-gamma	su	491
419	17	2.3	17	1	ADL48475	Human	IKK-gamma	su	492
420	17	2.3	17	1	ADL48481	Human	IKK-gamma	su	493
421	17	2.3	17	1	ADL48484	Human	IKK-gamma	su	494
422	17	2.3	17	1	ADL48486	Human	IKK-gamma	su	495
423	17	2.3	17	1	ADL48618	Human	IKK-gamma	su	496
424	17	2.3	17	1	ADL48641	Human	IKK-gamma	su	497
425	17	2.3	17	1	ADL48645	Human	IKK-gamma	su	498
426	17	2.3	17	1	ADL48646	Human	IKK-gamma	su	499
427	17	2.3	17	1	ADL48670	Human	IKK-gamma	su	500
428	17	2.3	17	1	ADL48676	Human	IKK-gamma	su	501
429	17	2.3	17	1	ADL48692	Human	IKK-gamma	su	502
430	17	2.3	17	1	ADL48695	Human	IKK-gamma	su	503
431	17	2.3	17	1	ADL47526	Human	IKK-gamma	su	504
432	17	2.3	17	1	ADL47738	Human	IKK-gamma	su	505
433	17	2.3	17	1	ADL47766	Human	IKK-gamma	su	506
434	17	2.3	17	1	ADL47768	Human	IKK-gamma	su	507
435	17	2.3	17	1	ADL47795	Human	IKK-gamma	su	508
436	17	2.3	17	1	ADL47817	Human	IKK-gamma	su	509
437	17	2.3	17	1	ADL47822	Human	IKK-gamma	su	510
438	17	2.3	17	1	ADL47879	Human	IKK-gamma	su	511
439	17	2.3	17	1	ADL48206	Human	IKK-gamma	su	512
440	17	2.3	17	1	ADL48233	Human	IKK-gamma	su	513
441	17	2.3	17	1	ADL48250	Human	IKK-gamma	su	514
442	17	2.3	17	1	ADL48261	Human	IKK-gamma	su	515
443	17	2.3	17	1	ADL48287	Human	IKK-gamma	su	516
444	17	2.3	17	1	ADL48306	Human	IKK-gamma	su	517
445	17	2.3	17	1	ADL48306	Human	IKK-gamma	su	518
446	17	2.3	17	1	ADL48587	Human	IKK-gamma	su	519
447	17	2.3	17	1	ADL48590	Human	IKK-gamma	su	520
448	17	2.3	17	1	ADL48642	Human	IKK-gamma	su	521
449	17	2.3	17	1	ADL48651	Human	IKK-gamma	su	522
450	17	2.3	17	1	ADL48701	Human	IKK-gamma	su	523
451	17	2.3	17	1	ADL47521	Human	IKK-gamma	su	524
452	17	2.3	17	1	ADL47527	Human	IKK-gamma	su	525
453	17	2.3	17	1	ADL47531	Human	IKK-gamma	su	526
454	17	2.3	17	1	ADL47539	Human	IKK-gamma	su	527
455	17	2.3	17	1	ADL47541	Human	IKK-gamma	su	528
456	17	2.3	17	1	ADL47548	Human	IKK-gamma	su	529
457	17	2.3	17	1	ADL47555	Human	IKK-gamma	su	530
458	17	2.3	17	1	ADL47757	Human	IKK-gamma	su	531
459	17	2.3	17	1	ADL47801	Human	IKK-gamma	su	532
460	17	2.3	17	1	ADL47813	Human	IKK-gamma	su	533
461	17	2.3	17	1	ADL47818	Human	IKK-gamma	su	534
462	17	2.3	17	1	ADL47842	Human	IKK-gamma	su	535
463	17	2.3	17	1	ADL47858	Human	IKK-gamma	su	536
464	17	2.3	17	1	ADL47865	Human	IKK-gamma	su	537
465	17	2.3	17	1	ADL47870	Human	IKK-gamma	su	538
466	17	2.3	17	1	ADL47875	Human	IKK-gamma	su	539
467	17	2.3	17	1	ADL47893	Human	IKK-gamma	su	540
468	17	2.3	17	1	ADL47894	Human	IKK-gamma	su	541
469	17	2.3	17	1	ADL48218	Human	IKK-gamma	su	542
470	17	2.3	17	1	ADL48224	Human	IKK-gamma	su	543
471	17	2.3	17	1	ADL48254	Human	IKK-gamma	su	544

545	17	2.3	17	1	ADL47742	Human IKK-gamma su	C 618	15.4	2.0	18	1	ADD10674	Protein kinase A s
546	17	2.3	17	1	ADL47749	Human IKK-gamma su	C 619	15.4	2.0	18	1	ADF77884	Human EST clone an
547	17	2.3	17	1	ADL47765	Human IKK-gamma su	C 620	15.4	2.0	19	1	AAT74056	Oligonucleotide pr
548	17	2.3	17	1	ADL47778	Human IKK-gamma su	C 621	15.4	2.0	19	1	AA28254	Probe bla3. Synth
549	17	2.3	17	1	ADL47787	Human IKK-gamma su	C 622	15.4	2.0	19	1	AA28254	Probe bla3. Synth
550	17	2.3	17	1	ADL47805	Human IKK-gamma su	C 623	15.4	2.0	19	1	AA28254	Probe bla3. Synth
551	17	2.3	17	1	ADL47854	Human IKK-gamma su	C 624	15.4	2.0	19	1	AA28254	Probe bla3. Synth
552	17	2.3	17	1	ADL47867	Human IKK-gamma su	C 625	15.4	2.0	19	1	AA28254	Probe bla3. Synth
553	17	2.3	17	1	ADL47871	Human IKK-gamma su	C 626	15.4	2.0	20	1	AA28254	Probe bla3. Synth
554	17	2.3	17	1	ADL47877	Human IKK-gamma su	C 627	15.4	2.0	20	1	AA28254	Probe bla3. Synth
555	17	2.3	17	1	ADL47885	Human IKK-gamma su	C 628	15.4	2.0	20	1	AA28254	Probe bla3. Synth
556	17	2.3	17	1	ADL48226	Human IKK-gamma su	C 629	15.4	2.0	20	1	AA28254	Probe bla3. Synth
557	17	2.3	17	1	ADL48234	Human IKK-gamma su	C 630	15.4	2.0	20	1	AA28254	Probe bla3. Synth
558	17	2.3	17	1	ADL48239	Human IKK-gamma su	C 631	15.2	2.0	20	1	AA28254	Probe bla3. Synth
559	17	2.3	17	1	ADL48240	Human IKK-gamma su	C 632	15.2	2.0	20	1	AA28254	Probe bla3. Synth
560	17	2.3	17	1	ADL48247	Human IKK-gamma su	C 633	15.2	2.0	20	1	AA28254	Probe bla3. Synth
561	17	2.3	17	1	ADL48288	Human IKK-gamma su	C 634	15.2	2.0	20	1	AA28254	Probe bla3. Synth
562	17	2.3	17	1	ADL48300	Human IKK-gamma su	C 635	15.2	2.0	20	1	AA28254	Probe bla3. Synth
563	17	2.3	17	1	ADL48317	Human IKK-gamma su	C 636	15.2	2.0	20	1	AA28254	Probe bla3. Synth
564	17	2.3	17	1	ADL48318	Human IKK-gamma su	C 637	15.2	2.0	20	1	AA28254	Probe bla3. Synth
565	17	2.3	17	1	ADL48319	Human IKK-gamma su	C 638	15.2	2.0	20	1	AA28254	Probe bla3. Synth
566	17	2.3	17	1	ADL48477	Human IKK-gamma su	C 639	15.2	2.0	20	1	AA28254	Probe bla3. Synth
567	17	2.3	17	1	ADL48573	Human IKK-gamma su	C 640	15.2	2.0	20	1	AA28254	Probe bla3. Synth
568	17	2.3	17	1	ADL48592	Human IKK-gamma su	C 641	15.2	2.0	20	1	AA28254	Probe bla3. Synth
569	17	2.3	17	1	ADL48593	Human IKK-gamma su	C 642	15.2	2.0	20	1	AA28254	Probe bla3. Synth
570	17	2.3	17	1	ADL48599	Human IKK-gamma su	C 643	15.2	2.0	20	1	AA28254	Probe bla3. Synth
571	17	2.3	17	1	ADL48635	Human IKK-gamma su	C 644	15.2	2.0	20	1	AA28254	Probe bla3. Synth
572	17	2.3	17	1	ADL48662	Human IKK-gamma su	C 645	15.2	2.0	20	1	AA28254	Probe bla3. Synth
573	17	2.3	17	1	ADL48665	Human IKK-gamma su	C 646	15.2	2.0	20	1	AA28254	Probe bla3. Synth
574	17	2.3	17	1	ADL48681	Human IKK-gamma su	C 647	15.2	2.0	20	1	AA28254	Probe bla3. Synth
575	17	2.3	17	1	ADL48706	Human IKK-gamma su	C 648	15.2	2.0	20	1	AA28254	Probe bla3. Synth
576	17	2.3	17	1	ADL48708	Human IKK-gamma su	C 649	15.2	2.0	20	1	AA28254	Probe bla3. Synth
577	17	2.3	18	1	AB292117	Streptomyces coeli	C 650	15.2	2.0	20	1	AA28254	Probe bla3. Synth
578	16.8	2.2	20	1	AB292117	Streptomyces coeli	C 651	15.2	2.0	20	1	AA28254	Probe bla3. Synth
579	16.8	2.2	20	1	AB292117	Streptomyces coeli	C 652	15.2	2.0	20	1	AA28254	Probe bla3. Synth
580	16.8	2.2	20	1	AB292117	Streptomyces coeli	C 653	15.2	2.0	20	1	AA28254	Probe bla3. Synth
581	16.8	2.2	20	1	AB292117	Streptomyces coeli	C 654	15.2	2.0	20	1	AA28254	Probe bla3. Synth
582	16.8	2.2	22	1	AA233693	S. cereale microsa	C 655	15.2	2.0	20	1	AA28254	Probe bla3. Synth
583	16.8	2.2	22	1	AA233693	S. cereale microsa	C 656	15.2	2.0	20	1	AA28254	Probe bla3. Synth
584	16.4	2.2	20	1	AAV18609	Synthetic human tu	C 657	15.2	2.0	20	1	AA28254	Probe bla3. Synth
585	16.4	2.2	20	1	AAV18609	Synthetic human tu	C 658	15.2	2.0	20	1	AA28254	Probe bla3. Synth
586	16.4	2.2	20	1	AB287729	Human oligonucleot	C 659	15.2	2.0	20	1	AA28254	Probe bla3. Synth
587	16.4	2.2	20	1	AB287729	Human oligonucleot	C 660	15.2	2.0	20	1	AA28254	Probe bla3. Synth
588	16.2	2.1	21	1	AB290611	Sca-2 siRNA duplex	C 661	15.2	2.0	20	1	AA28254	Probe bla3. Synth
589	16	2.1	17	1	ADL48709	Human IKK-gamma su	C 662	15.2	2.0	20	1	AA28254	Probe bla3. Synth
590	16	2.1	17	1	ADL48709	Human IKK-gamma su	C 663	15.2	2.0	20	1	AA28254	Probe bla3. Synth
591	15.8	2.1	19	1	AAV29497	Serotonin 5HT7 rec	C 664	15.2	2.0	20	1	AA28254	Probe bla3. Synth
592	15.8	2.1	19	1	ADL95276	Human 23S rRNA mo	C 665	15.2	2.0	20	1	AA28254	Probe bla3. Synth
593	15.8	2.1	20	1	AAQ83789	VEGF antisense oli	C 666	15.2	2.0	20	1	AA28254	Probe bla3. Synth
594	15.8	2.1	20	1	AAQ90288	16S rRNA gene PCR	C 667	15.2	2.0	20	1	AA28254	Probe bla3. Synth
595	15.8	2.1	20	1	ABQ78472	Antisense oligonuc	C 668	15.2	2.0	20	1	AA28254	Probe bla3. Synth
596	15.8	2.1	20	1	ADP11986	Set 2 right PCR pr	C 669	15.2	2.0	20	1	AA28254	Probe bla3. Synth
597	15.8	2.1	20	1	ADP11986	DNA probe used for	C 670	15.2	2.0	20	1	AA28254	Probe bla3. Synth
598	15.8	2.1	21	1	AB287729	Human polymorphis	C 671	15.2	2.0	20	1	AA28254	Probe bla3. Synth
599	15.8	2.1	21	1	AB287729	IL-10 forward prim	C 672	15.2	2.0	20	1	AA28254	Probe bla3. Synth
600	15.8	2.1	21	1	AB287729	Mouse Rab38 probe	C 673	15.2	2.0	20	1	AA28254	Probe bla3. Synth
601	15.8	2.1	21	1	AA287825	Cytokine amplifin	C 674	15.2	2.0	20	1	AA28254	Probe bla3. Synth
602	15.8	2.1	21	1	ADQ90647	Mouse Sca-2 target	C 675	15.2	2.0	20	1	AA28254	Probe bla3. Synth
603	15.8	2.1	21	1	ADQ90647	Sca-2 siRNA duplex	C 676	15.2	2.0	20	1	AA28254	Probe bla3. Synth
604	15.4	2.0	17	1	ABN07254	Human GDMPL-1 17-m	C 677	15.2	2.0	20	1	AA28254	Probe bla3. Synth
605	15.4	2.0	17	1	ABN07254	Human GDMPL-1 17-m	C 678	15.2	2.0	20	1	AA28254	Probe bla3. Synth
606	15.4	2.0	17	1	ACN70344	Human secreted pro	C 679	15.2	2.0	20	1	AA28254	Probe bla3. Synth
607	15.4	2.0	17	1	ACN70344	Human GDMPL-1 prob	C 680	15.2	2.0	20	1	AA28254	Probe bla3. Synth
608	15.4	2.0	17	1	ACN70548	Human GDMPL-1 prob	C 681	15.2	2.0	20	1	AA28254	Probe bla3. Synth
609	15.4	2.0	18	1	AA28254	Probe SEQ ID No 32	C 682	15.2	2.0	20	1	AA28254	Probe bla3. Synth
610	15.4	2.0	18	1	AA28254	Protein kinase A s	C 683	15.2	2.0	20	1	AA28254	Probe bla3. Synth
611	15.4	2.0	18	1	AA28254	Protein kinase A s	C 684	15.2	2.0	20	1	AA28254	Probe bla3. Synth
612	15.4	2.0	18	1	AA28254	Down-regulator oli	C 685	15.2	2.0	20	1	AA28254	Probe bla3. Synth
613	15.4	2.0	18	1	AA28254	Down-regulator oli	C 686	15.2	2.0	20	1	AA28254	Probe bla3. Synth
614	15.4	2.0	18	1	AA28254	Down-regulator oli	C 687	15.2	2.0	20	1	AA28254	Probe bla3. Synth
615	15.4	2.0	18	1	AA28254	Protein kinase A s	C 688	15.2	2.0	20	1	AA28254	Probe bla3. Synth
616	15.4	2.0	18	1	AA28254	Protein kinase A s	C 689	15.2	2.0	20	1	AA28254	Probe bla3. Synth
617	15.4	2.0	18	1	AA28254	Protein kinase A s	C 690	15.2	2.0	20	1	AA28254	Probe bla3. Synth

c 691	15	2.0	20	1	ADO46267	Human oligonucleot	764	13.8	1.8	17	1	ADF62162	Human PCCP1 DNA fr
c 692	14.8	2.0	18	1	AAV60911	Angiogenin antisense	765	13.8	1.8	17	1	ADF64121	Human PCCP1 DNA fr
c 693	14.8	2.0	18	1	AAV60919	Angiogenin sense o	766	13.8	1.8	17	1	ADM09541	Human NKG2 receptor
c 694	14.8	2.0	18	1	AAZ77049	PCR primer for the	767	13.8	1.8	17	1	ADL48763	Human IKK-gamma su
c 695	14.8	2.0	18	1	AAZ74326	Human biallelic ma	768	13.8	1.8	17	1	ADL49424	Human PKR substrat
c 696	14.8	2.0	19	1	AAZ33146	Treponema pallidum	769	13.8	1.8	17	1	ADL46635	Human NKG2 recepto
c 697	14.8	2.0	19	1	ABN84784	Primer useful for	770	13.8	1.8	17	1	ADL51771	Human PKR substrat
c 698	14.8	2.0	19	1	ABL31391	Human HLA genotypi	771	13.8	1.8	17	1	ADL49425	Human PKR substrat
c 699	14.8	2.0	19	1	ADF36747	Human VEGFR2 short	772	13.8	1.8	17	1	ADL87094	HCV DNasezyme substr
c 700	14.8	2.0	19	1	ADF37071	Human VEGFR2 short	773	13.8	1.8	17	1	ACN69921	Human GMPLP-1 prob
c 701	14.8	2.0	19	1	ADN75388	Human CD45 CR regi	774	13.8	1.8	17	1	ACN70796	Human GMPLP-1 prob
c 702	14.8	2.0	19	1	ADR75637	Human apolipoprote	775	13.8	1.8	17	1	ACN70911	Human GMPLP-1 prob
c 703	14.8	2.0	19	1	ADR78255	Human apolipoprote	776	13.8	1.8	17	1	ACN71520	Human GMPLP-1 prob
c 704	14.4	1.9	17	1	ABN07457	Human GMPLP-1 17-m	777	13.8	1.8	17	1	ACN71519	Human GMPLP-1 prob
c 705	14.4	1.9	17	1	ABN07459	Human GMPLP-1 17-m	778	13.8	1.8	18	1	AAZ75572	Mouse fit-1 VEGF r
c 706	14.4	1.9	17	1	ABN07255	Human GMPLP-1 17-m	779	13.8	1.8	18	1	AAZ74250	Estng primer R1.
c 707	14.4	1.9	17	1	ABN08979	Human GMPLP-1 17-m	780	13.8	1.8	18	1	AAV07833	Segment of branch
c 708	14.4	1.9	17	1	ABN08978	Human GMPLP-1 17-m	781	13.8	1.8	18	1	AAZ36676	PCR primer for mar
c 709	14.4	1.9	17	1	ACD59504	HCV DNasezyme substr	782	13.8	1.8	18	1	AAZ20075	PCR primer for hum
c 710	14.4	1.9	17	1	ACN70345	Human GMPLP-1 prob	783	13.8	1.8	18	1	AAV83062	Oligonucleotide fo
c 711	14.4	1.9	17	1	ACN70547	Human GMPLP-1 prob	784	13.8	1.8	18	1	AAZ01227	PCR primer for PGI
c 712	14.4	1.9	17	1	ACN72068	Human GMPLP-1 prob	785	13.8	1.8	18	1	AAZ48548	Human TNFR1 mRNA i
c 713	14.4	1.9	17	1	ACN70549	Human GMPLP-1 prob	786	13.8	1.8	18	1	AAZ474709	Sequencing primer
c 714	14.4	1.9	17	1	ACN72069	Human GMPLP-1 prob	787	13.8	1.8	18	1	AAZ93487	TRADD antisense ol
c 715	14.4	1.9	18	1	AAZ67194	Human CD40 hairpin	788	13.8	1.8	18	1	AAH56090	Human SCN3A PCR-SS
c 716	14.4	1.9	18	1	AAZ76614	Human biallelic ma	789	13.8	1.8	18	1	AAF89332	Sample member clus
c 717	14.4	1.9	18	1	AAH75205	Human inducible NO	790	13.8	1.8	18	1	ABT13201	Fanconi anaemia FA
c 718	14.4	1.9	18	1	AAZ55767	Fluorogenic probe	791	13.8	1.8	18	1	ABT10504	TNFR1 expression m
c 719	14.4	1.9	18	1	ADD94303	Mouse HUI77/HUIV26	792	13.8	1.8	18	1	ABT11916	Neublastin DNA rel
c 720	14.4	1.9	19	1	AAZ02688	Human papilloma vi	793	13.8	1.8	18	1	ADC42438	FANCD2 PCR primer
c 721	14.4	1.9	19	1	AAZ02696	Human papilloma vi	794	13.8	1.8	18	1	ABX34421	PCR primer #2 for
c 722	14.4	1.9	19	1	AAZ01486	Primer STS sy240 r	795	13.8	1.8	18	1	ACA58246	Human familial bip
c 723	14.4	1.9	19	1	AAZ92545	Human Y-specific S	796	13.8	1.8	18	1	ADL71979	CENP-A DNA amplif
c 724	14.4	1.9	15	1	AAZ35047	HPV ORF-Ec target	797	13.8	1.8	18	1	ADP47488	Intelligent PCR pr
c 725	14.4	1.9	17	1	ABN08981	Human GMPLP-1 17-m	798	13.8	1.8	18	1	ADQ59846	Human TNFR1 antise
c 726	14.4	1.9	17	1	ABN07251	Human GMPLP-1 17-m	799	13.8	1.8	18	1	ADRO6076	Novel mutant prote
c 727	14.4	1.9	17	1	ABN08980	Human GMPLP-1 17-m	800	13.8	1.8	18	1	ADT00917	Allele specific pr
c 728	14.4	1.9	17	1	ACC53301	Human tumour suppr	801	13.8	1.8	18	1	ADR74661	Probe for Conus ge
c 729	14.4	1.9	17	1	ACN70341	Human GMPLP-1 prob	802	13.6	1.8	17	1	AAV20512	Probe for Conus ge
c 730	14.4	1.9	17	1	ACN72070	Human GMPLP-1 prob	803	13.6	1.8	17	1	AAV17129	Probe used to isol
c 731	14.4	1.9	17	1	ACN72071	Human GMPLP-1 prob	804	13.6	1.8	17	1	AAI65365	Microsatellite seq
c 732	14.4	1.9	18	1	AAZ48792	Human G-alpha-16 a	805	13.4	1.8	15	1	AAQ33752	Apo(a) mRNA (nt. p
c 733	13.8	1.8	17	1	AAZ81047	Human c-myc hamme	806	13.4	1.8	15	1	AAZ37567	Mouse B7-1 hammerh
c 734	13.8	1.8	17	1	AAZ73242	Mouse fit-1 VEGF r	807	13.4	1.8	15	1	AAZ65327	Substrate for ham
c 735	13.8	1.8	17	1	AAZ01997	Hammerhead ribozym	808	13.4	1.8	15	1	AAZ64153	E. coli nuok RNase
c 736	13.8	1.8	17	1	AAZ01998	Hammerhead ribozym	809	13.4	1.8	15	1	AAZ69823	IGFBP2 oligonucleo
c 737	13.8	1.8	17	1	ABA80609	POE mutation corr	810	13.4	1.8	15	1	AAZ45430	IGFBP2 oligonucleo
c 738	13.8	1.8	17	1	ABA80608	POE mutation corr	811	13.4	1.8	15	1	AAZ45429	IGFBP3 oligonucleo
c 739	13.8	1.8	17	1	ABN08430	Human GMPLP-1 17-m	812	13.4	1.8	15	1	AAZ47286	Hepatitis C virus
c 740	13.8	1.8	17	1	ABN07706	Human GMPLP-1 17-m	813	13.4	1.8	15	1	ABX01206	Allele specific pr
c 741	13.8	1.8	17	1	ABN07821	Human GMPLP-1 17-m	814	13.4	1.8	15	1	ADR74748	Rat ICAM hairpin r
c 742	13.8	1.8	17	1	ABN06831	Human GMPLP-1 17-m	815	13.4	1.8	16	1	AAZ53413	Human NOV4 forward
c 743	13.8	1.8	17	1	ABN08429	Human GMPLP-1 17-m	816	13.4	1.8	16	1	ACF06258	Klebsiella oxytoca
c 744	13.8	1.8	17	1	ABV89590	Human PSHLI scann	817	13.4	1.8	16	1	ADN01434	DNA probe 1 specif
c 745	13.8	1.8	17	1	ABL31574	Human HLA genotypi	818	13.4	1.8	17	1	AAZ93742	Mouse fit-1 VEGF r
c 746	13.8	1.8	17	1	ABK56107	Human CLCA gene e	819	13.4	1.8	17	1	AAZ75272	Human GMPLP-1 17-m
c 747	13.8	1.8	17	1	ACN08336	WNV minus strand I	820	13.4	1.8	17	1	ABN07456	Human GMPLP-1 17-m
c 748	13.8	1.8	17	1	ACN10740	WNV minus strand H	821	13.4	1.8	17	1	ABN07256	Human GMPLP-1 17-m
c 749	13.8	1.8	17	1	ACN06511	WNV minus strand I	822	13.4	1.8	17	1	ABN08977	Human GMPLP-1 17-m
c 750	13.8	1.8	17	1	ACN06512	WNV Amberzyme subs	823	13.4	1.8	17	1	ABN06832	Human GMPLP-1 17-m
c 751	13.8	1.8	17	1	ACN14467	WNV minus strand A	824	13.4	1.8	17	1	ABN08427	Human GMPLP-1 17-m
c 752	13.8	1.8	17	1	ACN10741	WNV minus strand I	825	13.4	1.8	17	1	ABN08428	Human GMPLP-1 17-m
c 753	13.8	1.8	17	1	ACN02935	WNV inozyme substr	826	13.4	1.8	17	1	ABN06833	Human GMPLP-1 17-m
c 754	13.8	1.8	17	1	ACA06363	NFKB sub-unit modu	827	13.4	1.8	17	1	ABN07460	Human GMPLP-1 17-m
c 755	13.8	1.8	17	1	ACA08234	Necrosis factor ka	828	13.4	1.8	17	1	ABK25615	Stress tolerance c
c 756	13.8	1.8	17	1	ADA99740	Human MD23 scannin	829	13.4	1.8	17	1	ABK25616	Stress tolerance c
c 757	13.8	1.8	17	1	ADA99741	Human MD23 scannin	830	13.4	1.8	17	1	ACN06513	WNV Amberzyme subs
c 758	13.8	1.8	17	1	ACD65432	HCV minus strand D	831	13.4	1.8	17	1	ACN08335	WNV minus strand H
c 759	13.8	1.8	17	1	ADB40151	Tumour suppression	832	13.4	1.8	17	1	ACN10739	WNV minus strand I
c 760	13.8	1.8	17	1	ADB40733	Tumour suppression	833	13.4	1.8	17	1	ACN10739	Tumour suppression
c 761	13.8	1.8	17	1	ADF64209	Human PCCP1 DNA fr	834	13.4	1.8	17	1	ACA07656	NFKB sub-unit modu
c 762	13.8	1.8	17	1	ADF62167	Human PCCP1 DNA fr	835	13.4	1.8	17	1	ACA06305	NFKB sub-unit modu
c 763	13.8	1.8	17	1	ADF64208	Human PCCP1 DNA fr	836	13.4	1.8	17	1	ABZ64849	Human HER2 DNasezyme

837	13.4	1.8	17	1	ACD63165	HCV minus strand D	c 910	12.8	1.7	16	1	ADD20502	Oreochromis niloti
838	13.4	1.8	17	1	ADB45030	Tumour suppression	c 911	12.8	1.7	16	1	ACC43260	Nucleotide sequenc
839	13.4	1.8	17	1	ADF62873	Human PCCP1 DNA fr	c 912	12.8	1.7	16	1	ADR06457	IMAGE:2631676 mRNA
840	13.4	1.8	17	1	ADL511393	Human tumour suppr	c 913	12.8	1.7	16	1	ADR06458	Unigene cluster EN
841	13.4	1.8	17	1	ADL511695	Human PTGDR substr	c 914	12.8	1.7	17	1	AAQ52083	Breast cancer spec
842	13.4	1.8	17	1	ADL511926	Human PTGDR substr	c 915	12.8	1.7	17	1	AAQ52083	Rat ICAM hammerhea
843	13.4	1.8	17	1	ADL82133	Human ER+ breast c	c 916	12.8	1.7	17	1	AAQ53562	Rat ICAM hammerhea
844	13.4	1.8	17	1	ADL82156	Human ER+ breast c	c 917	12.8	1.7	17	1	AAQ53584	Rat ICAM hammerhea
845	13.4	1.8	17	1	ADL85947	HCV DNazyme substr	c 918	12.8	1.7	17	1	AAQ53620	Rat ICAM hammerhea
846	13.4	1.8	17	1	ADL85947	HCV DNazyme substr	c 919	12.8	1.7	17	1	AAQ53627	Rat ICAM hammerhea
847	13.4	1.8	17	1	ADL85947	Mutant cell identi	c 920	12.8	1.7	17	1	AAQ53627	Antimicrobial prot
848	13.4	1.8	17	1	ADL85947	Mutant cell identi	c 921	12.8	1.7	17	1	AAQ53627	Human c-myb hamme
849	13.4	1.8	17	1	ADL85947	Human GMPLP-1 prob	c 922	12.8	1.7	17	1	AAQ53627	Human flt1 VEGF re
850	13.4	1.8	17	1	ADL85947	Human GMPLP-1 prob	c 923	12.8	1.7	17	1	AAQ53627	Mouse flt-1 VEGF r
851	13.4	1.8	17	1	ADL85947	Human GMPLP-1 prob	c 924	12.8	1.7	17	1	AAQ53627	Mouse flt-1 VEGF r
852	13.4	1.8	17	1	ADL85947	Human GMPLP-1 prob	c 925	12.8	1.7	17	1	AAQ53627	Primer used to con
853	13.4	1.8	17	1	ADL85947	Human GMPLP-1 prob	c 926	12.8	1.7	17	1	AAQ53627	Potato citrate syn
854	13.4	1.8	17	1	ADL85947	Human GMPLP-1 prob	c 927	12.8	1.7	17	1	AAQ53627	Integrin alpha 6 s
855	13.4	1.8	17	1	ADL85947	Human GMPLP-1 prob	c 928	12.8	1.7	17	1	AAQ53627	Aryl hydrocarbon b
856	13.4	1.8	17	1	ADL85947	Human GMPLP-1 prob	c 929	12.8	1.7	17	1	AAQ53627	Integrin subunit b
857	13.4	1.8	17	1	ADL85947	Oligonucleotide SE	c 930	12.8	1.7	17	1	AAQ53627	Human BRCA2 C2192G
858	13.4	1.8	17	1	ADL85947	Oligonucleotide SE	c 931	12.8	1.7	17	1	AAQ53627	IPF1 gene exon 1 a
859	13.4	1.8	17	1	ADL85947	Oligonucleotide SE	c 932	12.8	1.7	17	1	AAQ53627	Human genomic SNP
860	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 933	12.8	1.7	17	1	AAQ53627	Hammerhead ribozym
861	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 934	12.8	1.7	17	1	AAQ53627	Hammerhead ribozym
862	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 935	12.8	1.7	17	1	AAQ53627	Hammerhead ribozym
863	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 936	12.8	1.7	17	1	AAQ53627	Hammerhead ribozym
864	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 937	12.8	1.7	17	1	AAQ53627	Sindbis-like virus
865	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 938	12.8	1.7	17	1	AAQ53627	Human Chk1 ribozym
866	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 939	12.8	1.7	17	1	AAQ53627	Human Chk1 ribozym
867	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 940	12.8	1.7	17	1	AAQ53627	Human NOGO Hamme
868	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 941	12.8	1.7	17	1	AAQ53627	Human NOGO Inozyme
869	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 942	12.8	1.7	17	1	AAQ53627	Human NOGO Zinzyme
870	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 943	12.8	1.7	17	1	AAQ53627	Human NOGO Zinzyme
871	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 944	12.8	1.7	17	1	AAQ53627	MLH1 mutation corr
872	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 945	12.8	1.7	17	1	AAQ53627	POE mutation corr
873	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 946	12.8	1.7	17	1	AAQ53627	p53 mutation corre
874	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 947	12.8	1.7	17	1	AAQ53627	CDKN2A mutation co
875	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 948	12.8	1.7	17	1	AAQ53627	p53 mutation corre
876	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 949	12.8	1.7	17	1	AAQ53627	CDKN2A mutation co
877	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 950	12.8	1.7	17	1	AAQ53627	MLH1 mutation corr
878	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 951	12.8	1.7	17	1	AAQ53627	POE mutation corr
879	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 952	12.8	1.7	17	1	AAQ53627	Rice OSEP3A gene f
880	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 953	12.8	1.7	17	1	AAQ53627	Rice cysteine prot
881	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 954	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
882	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 955	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
883	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 956	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
884	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 957	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
885	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 958	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
886	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 959	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
887	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 960	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
888	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 961	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
889	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 962	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
890	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 963	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
891	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 964	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
892	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 965	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
893	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 966	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
894	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 967	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
895	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 968	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
896	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 969	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
897	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 970	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
898	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 971	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
899	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 972	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
900	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 973	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
901	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 974	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
902	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 975	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
903	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 976	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
904	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 977	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
905	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 978	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
906	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 979	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
907	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 980	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
908	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 981	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib
909	13.4	1.8	17	1	ADL85947	Human PKR subestrat	c 982	12.8	1.7	17	1	AAQ53627	Human GRID NCH rib

1129 12.8 1.7 17 1 ACN71132 Human GMPLP-1 prob
 c1130 12.8 1.7 17 1 ACN65095 Human GMPLP-1 prob
 1131 12.8 1.7 17 1 ACN71131 Human GMPLP-1 prob
 c1132 12.8 1.7 17 1 ACN63770 Human GMPLP-1 prob
 1133 12.8 1.7 17 1 ACN70776 Human GMPLP-1 prob
 1134 12.8 1.7 17 1 ACN70910 Human GMPLP-1 prob
 c1135 12.8 1.7 17 1 ACN63453 Human GMPLP-1 prob
 1136 12.8 1.7 17 1 ACN70775 Human GMPLP-1 prob
 c1137 12.8 1.7 17 1 ACN69988 Human GMPLP-1 prob
 c1138 12.8 1.7 17 1 ADR74662 Allele specific pr

ALIGNMENTS

RESULT 1
 ADA44708
 ID ADA44708 standard; DNA; 29 BP.
 XX
 AC ADA44708;
 XX
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE PCR probe for amplifying human inhibitor-kappa B kinase-gamma #SEQ ID 6.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; PCR;
 KW probe; ss.
 XX
 OS Homo sapiens.
 XX
 XX
 FH Key Location/Qualifiers
 FT modified_base 1
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note="modified by addition of FAM fluorescent reporter
 FT dye"
 FT 29
 FT modified_base b
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note="modified by addition of TAMRA quencher dye"
 FT
 XX
 XX WO2003031576-A2.
 XX
 XX
 PD 17-APR-2003.
 XX
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Monia BP, Wyatt JR;
 PI
 XX WPI; 2003-457242/43.
 DR
 XX
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 XX
 PS Example 13; Page 74; 106pp; English.
 XX
 XX The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridising to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-phethoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a

CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. The current sequence represents a PCR
 CC probe used in an example from the invention to detect human inhibitor-
 CC kappa B kinase-gamma DNA.
 SQ Sequence 29 BP; 7 A; 4 C; 11 G; 7 T; 0 U; 0 Other;
 Query Match 3.8%; Score 29; DB 1; Length 29;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 162 TCTGGAAGAGCAACTGTGTGAGATGGTG 190
 Db 1 TCTGGAAGAGCAACTGTGTGAGATGGTG 29
 RESULT 2
 ADS17882/c
 ID ADS17882 standard; DNA; 27 BP.
 XX
 AC ADS17882;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human IKKGSv2.1 DNA specific 3' reverse RT-PCR primer.
 XX
 KW Human; kappa light polypeptide inhibitor; gene enhancer; IKKKG;
 KW I-kappa-B-kinase-gamma; IKK; I-kappa-B-kinase; rheumatoid arthritis;
 KW lupus; AIDS; acquired immunodeficiency syndrome; influenza; septic shock;
 KW atherosclerosis; oncogenesis; apoptosis; antirheumatic; antiarthritic;
 KW dermatological; antiinflammatory; immunosuppressive; virucide; anti-HIV;
 KW antibacterial; antiarteriosclerotic; cytostatic; kinase inhibitor;
 KW RT-PCR; reverse transcription; primer; IKKGS2.1; ss.
 XX
 OS Homo sapiens.
 XX
 XX US2004175797-A1.
 XX
 XX 09-SEP-2004.
 PD
 XX
 XX 03-MAR-2004; 2004US-00792063.
 PF
 XX
 XX 04-MAR-2003; 2003US-0452293P.
 PR
 XX (JOHN/) JOHNSON J M.
 PA (GARR/) GARRETT-ENGELE P W.
 PA (KANZ/) KAN Z.
 XX
 XX Johnson JM, Garrett-Engle PW, Kan Z;
 PI
 XX WPI; 2004-634849/61.
 DR
 XX
 XX New splice variant isoforms of inhibitor of kappa light polypeptide gene
 PT enhancer in B cells, useful for treating arthritis, lupus, HIV, septic
 PT shock and atherosclerosis.
 PT
 XX Example 3; SEQ ID NO 24; 27pp; English.
 PS
 XX
 XX The present invention relates to a polypeptides and nucleic acids
 CC encoding four novel splice variant isoforms of human inhibitor of kappa
 CC light polypeptide gene enhancer in B cells, kinase of, I-kappa-B-kinase-
 CC gamma (IKKKG or IKK (I-kappa-B-kinase)-gamma). The invention is useful
 CC for treatment of diseases or conditions associated with aberrant
 CC expression or activity of the IKKKG polypeptide, such as rheumatoid
 CC arthritis, lupus, human immunodeficiency virus (HIV)-acquired
 CC immunodeficiency syndrome (AIDS), influenza, septic shock,
 CC atherosclerosis, oncogenesis and apoptosis. The present sequence is the
 CC human IKKGSv2.1 DNA specific reverse transcription (RT)-PCR primer. This
 CC sequence is used in the exemplification of the invention.
 XX

SQ Sequence 27 BP; 4 A; 11 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 3.6%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 880 CATCAGAGCAGCGTGTGGCAGTGA 906
|||||
DB 27 CATCAGAGCAGCGTGTGGCAGTGA 1

RESULT 3
ADG29527
ID ADG29527 standard; RNA; 23 BP.
XX AC
AC ADG29527;
XX DT
DT 26-FEB-2004 (first entry)
XX DE
DE IKKg siNA-target RNA - SEQ ID 93.
XX DE
XX double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; target; ss; IKKg.
XX OS
OS Unidentified.
XX PN
PN WO2003074654-A2.
XX PD
PD 12-SEP-2003.
XX PF
PF 20-FEB-2003; 2003WO-US005028.
XX PR
PR 20-FEB-2002; 2002US-0359580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX PA
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX PI
PI WPI; 2003-731676/69.
XX DR
DR New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX PS
PS Example 24; SEQ ID NO 93; 593pp; English.
XX CC
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA
CC target DNA of the invention.

SQ Sequence 23 BP; 7 A; 3 C; 8 G; 0 T; 5 U; 0 Other;
Query Match 3.0%; Score 23; DB 1; Length 23;
Best Local Similarity 78.3%; Pred. No. 56;
Matches 18; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 164 TGGAGAGCCCACTGTGTGAGAT 186
:|||||
DB 1 UGGAGAGCCCACTGTGTGAGAU 23

RESULT 4
ADG29528
ID ADG29528 standard; RNA; 23 BP.
XX AC
AC ADG29528;
XX DT
DT 26-FEB-2004 (first entry)
XX DE
DE IKKg siNA-target RNA - SEQ ID 94.
XX DE
XX double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
KW amyotrophic lateral sclerosis; gene therapy; target; ss; IKKg.
XX OS
OS Unidentified.
XX PN
PN WO2003074654-A2.
XX PD
PD 12-SEP-2003.
XX PF
PF 20-FEB-2003; 2003WO-US005028.
XX PR
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX PA
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI
PI Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
PI Jamison S, Usman N, Thompson J;
XX PI
PI WPI; 2003-731676/69.
XX DR
DR New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX PS
PS Example 24; SEQ ID NO 94; 593pp; English.
XX CC
CC The invention relates to a double-stranded short interfering nucleic acid
CC (siNA) molecule that down-regulates expression of an endogenous mammalian
CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC nootropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA
CC target DNA of the invention.

Example 4; Page 135; 204pp; English.

```

XX The present invention describes a double-stranded short interfering
CC nucleic acid (siRNA) that downregulates expression of a target gene, where
CC the siRNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siRNA comprises about 21 nucleotides. Also described: (1)
CC a siRNA molecule that inhibits expression of target RNA; (2) a siRNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siRNA molecule
CC that inhibits expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siRNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siRNA
CC molecules. siRNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytosstatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siRNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. siRNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalovirus; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siRNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siRNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siRNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 4 C; 6 G; 2 T; 5 U; 0 Other;

Query Match 2.8%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 90;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCCTCATGTGCAAGTT 438
| | | | | | | | | | | | | | | | | | | | |
DB 1 GGAGUUCUCCAUUGGCAAGTT 21

RESULT 7
ADAL13787/c
ID ADAL13787 standard; RNA; 21 BP.
XX
AC ADAL13787;
XX
DT 20-NOV-2003 (first entry)
XX
DE Short interfering nucleic acid (siRNA) oligonucleotide SEQ ID NO:124.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siRNA; expression; replication;
KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW cytosstatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW herpes simplex; cytomegalovirus; human papillomavirus;
KW respiratory syncytial virus; influenza virus; restenosis;
KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW pulmonary; renal; liver; mitochondrial; reproductive disease;
KW chemical modification; ss.
XX
OS Synthetic.
XX
PN WO2003070918-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005346.

```

```

XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0385782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
PI Morrissey D, Fosnaugh K, Mokier V, Jamison S;
DR WPI; 2003-689785/65.
XX
XX New short interfering nucleic acid containing no ribonucleotides, useful
PT e.g. for treating viral infection, downregulates expression of target
PT gene or RNA.
XX
XX Example 4; Page 135; 204pp; English.
XX
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siRNA) that downregulates expression of a target gene, where
CC the siRNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siRNA comprises about 21 nucleotides. Also described: (1)
CC a siRNA molecule that inhibits expression of target RNA; (2) a siRNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siRNA molecule
CC that inhibits expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siRNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siRNA
CC molecules. siRNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytosstatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siRNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. siRNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalovirus; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siRNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siRNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siRNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 5 A; 6 C; 4 G; 2 T; 4 U; 0 Other;

Query Match 2.8%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 90;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 416 AAGGAGTTCCTCATGTGCAAG 436
| | | | | | | | | | | | | | | | | | | | |
DB 21 AAGGAGTTCCTCATGTGCAAG 1

RESULT 8
ADAL13791/c
ID ADAL13791 standard; RNA; 21 BP.
XX
AC ADAL13791;
XX
DT 20-NOV-2003 (first entry)
XX

```



```
Db 1 GGAGUCCUUGUGCAAGTT 21
RESULT 10
ADN75896/c
ID ADN75896 standard; RNA; 21 BP.
XX
XX
AC ADN75896;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human IKKgamma siRNA IKK.4.
XX
XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
XX cytosolic; immunomodulator; antimicrobial; antiinflammatory;
XX antidiabetic; anorectic; cancer; autoimmune disease; infection;
XX inflammation; diabetes; obesity; RNA interference; gene silencing; ss;
XX DNA-RNA hybrid.
XX
XX Homo sapiens.
XX
XX WO2004016735-A2.
XX
XX 26-FEB-2004.
XX
XX 23-MAY-2003; 2003WO-US016632.
XX
XX 23-MAY-2002; 2002US-0383249P.
XX
XX 14-APR-2003; 2003US-0462942P.
XX
XX (CEPT-) CEPTVR INC.
XX
XX (COLD-) COLD SPRING HARBOR LAB.
XX
XX Klinghoffer R, Lewis SP, Tonks NK, Meng T;
XX
XX WPI; 2004-203773/19.
XX
XX New isolated small interfering RNA (siRNA) polynucleotide useful for
XX treating diseases with aberrant activity of the protein tyrosine
XX phosphatase, such as cancer, autoimmune disease, infection, inflammation,
XX diabetes and obesity.
XX
XX Example 8; SEQ ID NO 721; 392pp; English.
XX
XX This invention describes novel small interfering RNA (siRNA)
XX polynucleotides capable of interfering with expression of a polypeptide
XX having protein-tyrosine-phosphatase (PTP) activity. The products of the
XX invention have cytostatic, immunomodulator, antimicrobial,
XX antiinflammatory, antidiabetic and anorectic activity. The methods and
XX conditions of the present invention are useful for treating diseases or
XX conditions associated with aberrant expression or activity of the protein
XX tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
XX inflammation, diabetes and obesity. This sequence represents a siRNA
XX directed against dual specificity phosphatase (DSP) expression.
XX
XX Sequence 21 BP; 2 A; 5 C; 6 G; 2 T; 6 U; 0 Other;
XX
XX Query Match 2.8%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 90;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 875 AACACATCAAGAGCGGTG 895
XX
XX 21 AACACATCAAGAGCGGTG 1
XX
XX
XX RESULT 11
XX ADA44738/c
XX ID ADA44738 standard; DNA; 20 BP.
XX
XX ADA44738;
XX
XX 20-NOV-2003 (first entry)
XX
```

```
XX
DE Antisense oligonucleotide #ISIS 115410 #SEQ ID 36.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= b
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages, all cytosines are 5-
XX methylcytosine"
XX modified_base 1..5
XX /*tag= a
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003031576-A2.
XX
XX 17-APR-2003.
XX
XX 03-OCT-2002; 2002WO-US031809.
XX
XX 06-OCT-2001; 2001US-00972607.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-457242/43.
XX
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX
XX Example 15; Page 77; 106pp; English.
XX
XX The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX
XX Sequence 20 BP; 1 A; 7 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.6%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 11e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 715 GGCGCTGCAGCAGCACA 734
XX
XX 20 GGCGCTGCAGCAGCACA 1
XX
XX
```

RESULT 12
ADA44746/C
ID ADA44746 standard; DNA; 20 BP.
XX AC ADA44746;
XX DT 20-NOV-2003 (first entry)
XX DE Antisense oligonucleotide #ISIS 115418 #SEQ ID 44.
XX KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-methylcytosine"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX PN WO2003031576-A2.
XX PD 17-APR-2003.
XX PF 03-OCT-2002; 2002WO-US031809.
XX PR 06-OCT-2001; 2001US-00972607.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Wyatt JR;
XX DR WPI; 2003-457242/43.
XX PS New compound having sequence targeted to nucleic acid encoding inhibitor-kappa B kinase-gamma, useful for preparing composition for treating e.g., cancer, or inflammatory or autoimmune disorder.
XX CC Claim 3; Page 77; 106pp; English.
XX CC The invention relates to an antisense compound that is targeted to a nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma and inhibiting its expression. Compounds of the invention are antisense oligonucleotides comprising at least one modified internucleoside linkage, which is a phosphorothioate linkage, at least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase, which is a 5-methylcytosine. Preferably, the antisense oligonucleotide is a chimeric oligonucleotide. The compound of the invention is useful for preparing a composition for treating a hyperproliferative disorder e.g., cancer, or an autoimmune or inflammatory disorder. The methods are useful for inhibiting the expression of inhibitor-kappa B kinase-gamma in cells or tissues, and treating an animal having a disease or condition associated with inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790 represent antisense oligonucleotides for the inhibition of human inhibitor-kappa B kinase-gamma mRNA levels.
XX Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 830 GCCCAGTTGCAGTGGCCTA 849
DB 20 GCCCAGTTGCAGTGGCCTA 1
RESULT 13
ADA44751/C
ID ADA44751 standard; DNA; 20 BP.
XX AC ADA44751;
XX DT 20-NOV-2003 (first entry)
XX DE Antisense oligonucleotide #ISIS 115423 #SEQ ID 49.
XX KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-methylcytosine"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX PN WO2003031576-A2.
XX PD 17-APR-2003.
XX PF 03-OCT-2002; 2002WO-US031809.
XX PR 06-OCT-2001; 2001US-00972607.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Wyatt JR;
XX DR WPI; 2003-457242/43.
XX PS New compound having sequence targeted to nucleic acid encoding inhibitor-kappa B kinase-gamma, useful for preparing composition for treating e.g., cancer, or inflammatory or autoimmune disorder.
XX CC Example 15; Page 77; 106pp; English.
XX CC The invention relates to an antisense compound that is targeted to a nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma and inhibiting its expression. Compounds of the invention are antisense oligonucleotides comprising at least one modified internucleoside linkage, which is a phosphorothioate linkage, at least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase, which is a 5-methylcytosine. Preferably, the antisense oligonucleotide is a chimeric oligonucleotide. The compound of the invention is useful for preparing a composition for treating a hyperproliferative disorder e.g., cancer, or an autoimmune or inflammatory disorder. The methods are useful for inhibiting the

CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 2 A; 10 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 897 TGGCAGTGGCGGAGCGA 916
Db 20 TGGCAGTGGCGGAGCGA 1

RESULT 14
ADA44726/C
ID ADA44726 standard; DNA; 20 BP.
XX
AC ADA44726;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115398 #SEQ ID 24.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
PR 06-OCT-2001; 2001US-00972607.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
PD WPI; 2003-457242/43.
XX
DR New compound having sequence targeted to nucleic acid encoding inhibitor-
PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
PT cancer, or inflammatory or autoimmune disorder.
XX
PS Claim 3; Page 76; 106pp; English.
XX
CC The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC

CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 385 TCTGCATTTCACAGCCAGCC 404
Db 20 TCTGCATTTCACAGCCAGCC 1

RESULT 15
ADA44750/C
ID ADA44750 standard; DNA; 20 BP.
XX
AC ADA44750;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115422 #SEQ ID 48.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
PR 06-OCT-2001; 2001US-00972607.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
PD WPI; 2003-457242/43.
XX
DR New compound having sequence targeted to nucleic acid encoding inhibitor-
PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
PT cancer, or inflammatory or autoimmune disorder.
XX
PS Claim 3; Page 76; 106pp; English.
XX
CC The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC

PT cancer, or inflammatory or autoimmune disorder.
 PS Claim 3; Page 77; 106pp; English.
 XX The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX Sequence 20 BP; 3 A; 10 C; 3 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 885 AGAGCAGCGTGGTGGCGACT 904
 DB 20 AGAGCAGCGTGGTGGCGACT 1
 RESULT 16
 ADA44719/C
 ID ADA44719 standard; DNA; 20 BP.
 AC ADA44719;
 XX
 XX 20-NOV-2003 (first entry)
 DE Antisense oligonucleotide #ISIS 115391 #SEQ ID 17.
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 FN WO2003031576-A2.
 XX
 PD 17-APR-2003.
 XX
 XX 03-OCT-2002; 2002WO-US031809.
 PF
 XX 06-OCT-2001; 2001US-00972607.
 PR
 XX

PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 DR WPI; 2003-457242/43.
 XX
 PT New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 XX
 PS Claim 3; Page 76; 106pp; English.
 XX
 CC The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 195 CCAGTGGTGGCCCGCAGCA 214
 DB 20 CCAGTGGTGGCCCGCAGCA 1
 RESULT 17
 ADA44722/C
 ID ADA44722 standard; DNA; 20 BP.
 AC ADA44722;
 XX
 XX 20-NOV-2003 (first entry)
 DE Antisense oligonucleotide #ISIS 115394 #SEQ ID 20.
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX

```
PN W02003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
XX 06-OCT-2001; 2001US-00972607.
PR
PA (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX
XX WPI; 2003-457242/43.
XX
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
PT cancer, or inflammatory or autoimmune disorder.
XX
XX Example 15; Page 76; 106pp; English.
XX
XX The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
XX Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
SQ
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 275 TCAGAACAGGCGCTCTCTGA 294
Db 20 TCAGAACAGGCGCTCTCTGA 1
RESULT 18
ADA44732/c
ID ADA44732 standard; DNA; 20 BP.
XX
XX ADA44732;
AC
XX 20-NOV-2003 (first entry)
DT
XX
XX Antisense oligonucleotide #ISIS 115404 #SEQ ID 30.
DE
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
XX Homo sapiens.
OS
XX
XX Location/Qualifiers
PH modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
```

```
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX W02003031576-A2.
PN
XX
XX 17-APR-2003.
XX
XX 03-OCT-2002; 2002WO-US031809.
XX
XX 06-OCT-2001; 2001US-00972607.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Monia BP, Wyatt JR;
PI
XX
XX WPI; 2003-457242/43.
XX
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
PT cancer, or inflammatory or autoimmune disorder.
XX
XX Claim 3; Page 77; 106pp; English.
XX
XX The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
XX Sequence 20 BP; 1 A; 9 C; 2 G; 8 T; 0 U; 0 Other;
SQ
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 489 TGAAGAGCGCAGAGGAGCAG 508
Db 20 TGAAGAGCGCAGAGGAGCAG 1
RESULT 19
ADA44739/c
ID ADA44739 standard; DNA; 20 BP.
XX
XX ADA44739;
AC
XX 20-NOV-2003 (first entry)
DT
XX
XX Antisense oligonucleotide #ISIS 115411 #SEQ ID 37.
DE
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
XX Homo sapiens.
OS
```

```

XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX PN WO2003031576-A2.
XX XX 17-APR-2003.
XX PF 03-OCT-2002; 2002WO-US031809.
XX PR 06-OCT-2001; 2001US-00972607.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Wyatt JR;
XX WPI; 2003-457242/43.
XX CC New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX PS Claim 3; Page 77; 106pp; English.
XX CC The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX SQ Sequence 20 BP; 1 A; 8 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 724 GCAGCAGCACAGCGTCAGG 743
DB 20 GCAGCAGCACAGCGTCAGG 1

RESULT 20
ADA44742/c
ID ADA44742 standard; DNA; 20 BP.
XX AC ADA44742;
XX DT 20-NOV-2003 (first entry)
XX

```

```

DE Antisense oligonucleotide #ISIS 115414 #SEQ ID 40.
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune, inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX human.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX PN WO2003031576-A2.
XX XX 17-APR-2003.
XX PF 03-OCT-2002; 2002WO-US031809.
XX PR 06-OCT-2001; 2001US-00972607.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Wyatt JR;
XX WPI; 2003-457242/43.
XX CC New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX PS Claim 3; Page 77; 106pp; English.
XX CC The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX SQ Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 776 GAGGCGCGCTCCGATGGA 795
DB 20 GAGGCGCGCTCCGATGGA 1

```

Best Local Similarity 100.0%; Pred. No. 1.1e+02; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 GAGTTCTCATGTGCAAGTT 438
| | | | | | | | | | | | | | | | | |
DB 20 GAGTTCTCATGTGCAAGTT 1

RESULT 22
ADA44744/c
ID ADA44744 standard; DNA; 20 BP.
XX
AC ADA44744;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115416 #SEQ ID 42.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX human.
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
PR 06-OCT-2001; 2001US-00972607.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
PS WPI; 2003-457242/43.
XX
DR The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridising to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and

RESULT 21
ADA44728/c
ID ADA44728 standard; DNA; 20 BP.
XX
AC ADA44728;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115400 #SEQ ID 26.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX human.
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
PR 06-OCT-2001; 2001US-00972607.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
PS WPI; 2003-457242/43.
XX
DR The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridising to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
SQ Sequence 20 BP; 7 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;

CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 1 A; 8 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 800 CAGGCCGCTCGAGGAGAA 819
 Db 20 CAGGCCGCTCGAGGAGAA 1
 RESULT 23
 ADA44707/c
 ID ADA44707 standard; DNA; 20 BP.
 XX
 AC ADA44707;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE PCR primer for amplifying human inhibitor-kappa B kinase-gamma #SEQ ID 5.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; PCR;
 KW primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003031576-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 DR WPI; 2003-457242/43.
 XX
 DR New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 XX
 PS Example 13; Page 74; 106pp; English.
 XX
 CC The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. The current sequence represents a reverse
 CC PCR primer used in an example from the invention to amplify human
 CC inhibitor-kappa B kinase-gamma DNA.
 XX
 SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 215 GATCAGGACGTACTGGCGGA 234
 Db 20 GATCAGGACGTACTGGCGGA 1
 RESULT 24
 ADA44718/c
 ID ADA44718 standard; DNA; 20 BP.
 XX
 AC ADA44718;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Antisense oligonucleotide #ISIS 115390 #SEQ ID 16.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 PN WO2003031576-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 DR WPI; 2003-457242/43.
 XX
 DR New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 XX
 PS Claim 3; Page 76; 106pp; English.
 XX
 CC The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the

CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 162 TCTGGAGAGCCCACTGTGT 181
 Db 20 TCTGGAGAGCCCACTGTGT 1
 RESULT 25
 ADA44734/c
 ID ADA44734 standard; DNA; 20 BP.
 XX
 AC ADA44734;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Antisense oligonucleotide #ISIS 115406 #SEQ ID 32.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT methylcytosine"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 PN WO2003031576-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 PD WPI; 2003-457242/43.
 XX
 DR New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 XX
 PS Claim 3; Page 77; 106pp; English.
 XX
 CC The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridising to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense

CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02; Mismatches 0; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 534 AGAGATGCCAGCAGCAGATG 553
 Db 20 AGAGATGCCAGCAGCAGATG 1
 RESULT 26
 ADA44747/c
 ID ADA44747 standard; DNA; 20 BP.
 XX
 AC ADA44747;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Antisense oligonucleotide #ISIS 115419 #SEQ ID 45.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 PN WO2003031576-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 PD WPI; 2003-457242/43.
 XX
 DR New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,

```

PT cancer, or inflammatory or autoimmune disorder.
PS Claim 3; Page 77; 106pp; English.
XX
CC The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a 2'-O-methoxyethyl linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 AGGTGGCCTATCACCAGCTC 859
DB 20 AGGTGGCCTATCACCAGCTC 1

RESULT 27
ADA44730/C
ID ADA44730 standard; DNA; 20 BP.
XX
AC ADA44730;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115402 #SEQ ID 28.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003031576-A2.
XX
XX
PD 17-APR-2003.
XX
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
XX
PR 06-OCT-2001; 2001US-00972607.
XX
XX

```

```

PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
DR WPI; 2003-457242/43.
XX
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
PS Claim 3; Page 77; 106pp; English.
XX
CC The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 465 GACTCGGCTGAGAGCTC 484
DB 20 GACTCGGCTGAGAGCTC 1

RESULT 28
ADA44733/C
ID ADA44733 standard; DNA; 20 BP.
XX
AC ADA44733;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115405 #SEQ ID 31.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX

```

```
PN WO2003031576-A2.
XX 17-APR-2003.
XX 03-OCT-2002; 2002WO-US031809.
XX 06-OCT-2001; 2001US-00972607.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-457242/43.
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX Claim 3; Page 77; 106pp; English.
XX The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX Sequence 20 BP; 3 A; 11 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 507 AGGCTCTGCGGGAGGTGGAG 526
DB 20 AGGCTCTGCGGGAGGTGGAG 1
RESULT 29
ADA44741/c
ID ADA44741 standard; DNA; 20 BP.
XX ADA44741;
XX 20-NOV-2003 (first entry)
XX Antisense oligonucleotide #ISIS 115413 #SEQ ID 39.
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
XX antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
XX autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX Homo sapiens.
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= b
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages, all cytosines are 5-
XX methylcytosine"
XX modified_base 1..5
```

```
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003031576-A2.
XX 17-APR-2003.
XX 03-OCT-2002; 2002WO-US031809.
XX 06-OCT-2001; 2001US-00972607.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-457242/43.
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX Claim 3; Page 77; 106pp; English.
XX The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 726 AGCAGCACAGCGTGCGAGGTG 745
DB 20 AGCAGCACAGCGTGCGAGGTG 1
RESULT 30
ADA44724/c
ID ADA44724 standard; DNA; 20 BP.
XX ADA44724;
XX 20-NOV-2003 (first entry)
XX Antisense oligonucleotide #ISIS 115396 #SEQ ID 22.
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
XX antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
XX autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX Homo sapiens.
XX modified_base 1..5
```

```

XX PH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003031576-A2.
XX 17-APR-2003.
XX 03-OCT-2002; 2002WO-US031809.
XX 06-OCT-2001; 2001US-00972607.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-457242/43.
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX Claim 3; Page 76; 106pp; English.
XX The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 2.6%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.1e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 313 GGAGGAGATCAAGAGCTCC 332
XX
XX Db 20 GGAGGAGATCAAGAGCTCC 1
XX
XX RESULT 31
XX ADA44727/c
XX ID ADA44727 standard; DNA; 20 BP.
XX AC ADA44727;
XX XX
XX XX 20-NOV-2003 (first entry)
XX
XX

```

```

DE, Antisense oligonucleotide #ISIS 115399 #SEQ ID 25.
XX
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune, inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX human.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003031576-A2.
XX 17-APR-2003.
XX 03-OCT-2002; 2002WO-US031809.
XX 06-OCT-2001; 2001US-00972607.
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Wyatt JR;
XX WPI; 2003-457242/43.
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX Claim 3; Page 76; 106pp; English.
XX The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.6%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.1e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 391 TTCCAAGCCAGCCAGAGGG 410
XX
XX Db 20 TTCCAAGCCAGCCAGAGGG 1
XX

```

Query Match

CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 725 CAGCAGCAGCGTGCAGGT 744
 DB 20 CAGCAGCAGCGTGCAGGT 1
 RESULT 34
 ADA44725/c
 ID ADA44725 standard; DNA; 20 BP.
 XX
 AC ADA44725;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Antisense oligonucleotide #ISIS 115397 #SEQ ID 23.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 XX human.
 XX Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /notes= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /notes= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /notes= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003031576-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 DR WPI; 2003-457242/43.
 XX
 PT New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 XX
 PS Claim 3; Page 76; 106pp; English.
 XX
 CC The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside

CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX
 SQ Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 344 CGGCAGCAGCACCATTTCT 363
 DB 20 CGGCAGCAGCACCATTTCT 1
 RESULT 35
 ADA44731/c
 ID ADA44731 standard; DNA; 20 BP.
 XX
 AC ADA44731;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Antisense oligonucleotide #ISIS 115403 #SEQ ID 29.
 XX
 KW Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 XX human.
 XX Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /notes= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /notes= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /notes= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003031576-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 03-OCT-2002; 2002WO-US031809.
 XX
 PR 06-OCT-2001; 2001US-00972607.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monia BP, Wyatt JR;
 XX
 DR WPI; 2003-457242/43.
 XX
 PT New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.

XX PS Claim 3; Page 77; 106pp; English.

XX CC The invention relates to an antisense compound that is targeted to a

CC CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically

CC CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma

CC CC and inhibiting its expression. Compounds of the invention are antisense

CC CC oligonucleotides comprising at least one modified internucleoside

CC CC linkage, which is a phosphorothioate linkage, at least one modified sugar

CC CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one

CC CC modified nucleobase, which is a 5-methylcytosine. Preferably, the

CC CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of

CC CC the invention is useful for preparing a composition for treating a

CC CC hyperproliferative disorder e.g., cancer, or an autoimmune or

CC CC inflammatory disorder. The methods are useful for inhibiting the

CC CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and

CC CC treating an animal having a disease or condition associated with

CC CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790

CC CC represent antisense oligonucleotides for the inhibition of human

CC CC inhibitor-kappa B kinase-gamma mRNA levels.

XX SQ Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 483 TCGATCTGAAGAGCGAGAG 502

DB 20 TCGATCTGAAGAGCGAGAG 1

RESULT 36

ADA44745/C

ID ADA44745 standard; DNA; 20 BP.

XX AC ADA44745;

XX DT 20-NOV-2003 (first entry)

XX DE Antisense oligonucleotide #ISIS 115417 #SEQ ID 43.

XX KW Antisense oligonucleotide; cytostatic; immunosuppressive;

KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;

KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX PN WO2003031576-A2.

XX PD 17-APR-2003.

XX PF 03-OCT-2002; 2002WO-US031809.

XX PR 06-OCT-2001; 2001US-00972607.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Monia BP, Wyatt JR;

XX DR WPI; 2003-457242/43.

XX PS New compound having sequence targeted to nucleic acid encoding inhibitor-

PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,

PT cancer, or inflammatory or autoimmune disorder.

XX PS Claim 3; Page 77; 106pp; English.

XX CC The invention relates to an antisense compound that is targeted to a

CC CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically

CC CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma

CC CC and inhibiting its expression. Compounds of the invention are antisense

CC CC oligonucleotides comprising at least one modified internucleoside

CC CC linkage, which is a phosphorothioate linkage, at least one modified sugar

CC CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one

CC CC modified nucleobase, which is a 5-methylcytosine. Preferably, the

CC CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of

CC CC the invention is useful for preparing a composition for treating a

CC CC hyperproliferative disorder e.g., cancer, or an autoimmune or

CC CC inflammatory disorder. The methods are useful for inhibiting the

CC CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and

CC CC treating an animal having a disease or condition associated with

CC CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790

CC CC represent antisense oligonucleotides for the inhibition of human

CC CC inhibitor-kappa B kinase-gamma mRNA levels.

XX SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 803 GCGGCTCGAGAGAGAG 822

DB 20 GCGGCTCGAGAGAGAG 1

RESULT 37

ADA44723/C

ID ADA44723 standard; DNA; 20 BP.

XX AC ADA44723;

XX DT 20-NOV-2003 (first entry)

XX DE Antisense oligonucleotide #ISIS 115395 #SEQ ID 21.

XX KW Antisense oligonucleotide; cytostatic; immunosuppressive;

KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;

KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "Phosphorothioate linkages, all cytosines are 5-

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX PN WO2003031576-A2.

XX 17-APR-2003.
 XX 03-OCT-2002; 2002WO-US031809.
 XX 06-OCT-2003; 2001US-00972607.
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-457242/43.
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-
 PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 PT cancer, or inflammatory or autoimmune disorder.
 XX Claim 3; Page 76; 106pp; English.
 XX The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 279 AACAGGGCGCTCTGTGAGACC 298
 DB 20 AACAGGGCGCTCTGTGAGACC 1
 RESULT 38
 ADA44748/c
 ID ADA44748 standard; DNA; 20 BP.
 XX ADA44748;
 AC
 XX 20-NOV-2003 (first entry)
 DT
 XX Antisense oligonucleotide #ISIS 115420 #SEQ ID 46.
 DE Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 PH modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /*tag= a

FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003031576-A2.
 PN 17-APR-2003.
 PD 03-OCT-2002; 2002WO-US031809.
 XX 06-OCT-2001; 2001US-00972607.
 XX (ISIS-) ISIS PHARM INC.
 PA Monia BP, Wyatt JR;
 PI WPI; 2003-457242/43.
 DR New compound having sequence targeted to nucleic acid encoding inhibitor-
 CC kappa B kinase-gamma, useful for preparing composition for treating e.g.,
 CC cancer, or inflammatory or autoimmune disorder.
 CC Claim 3; Page 77; 106pp; English.
 CC The invention relates to an antisense compound that is targeted to a
 CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
 CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
 CC and inhibiting its expression. Compounds of the invention are antisense
 CC oligonucleotides comprising at least one modified internucleoside
 CC linkage, which is a phosphorothioate linkage, at least one modified sugar
 CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
 CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
 CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
 CC the invention is useful for preparing a composition for treating a
 CC hyperproliferative disorder e.g., cancer, or an autoimmune or
 CC inflammatory disorder. The methods are useful for inhibiting the
 CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
 CC treating an animal having a disease or condition associated with
 CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
 CC represent antisense oligonucleotides for the inhibition of human
 CC inhibitor-kappa B kinase-gamma mRNA levels.
 XX Sequence 20 BP; 6 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 843 TGGCCTATCACCAGCTCTTC 862
 DB 20 TGGCCTATCACCAGCTCTTC 1
 RESULT 39
 ADA44721/c
 ID ADA44721 standard; DNA; 20 BP.
 XX ADA44721;
 AC
 XX 20-NOV-2003 (first entry)
 DT
 XX Antisense oligonucleotide #ISIS 115393 #SEQ ID 19.
 DE Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 PH modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /*tag= a

FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-methylcytosine"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003031576-A2.
 XX 17-APR-2003.
 XX 03-OCT-2002; 2002WO-US031809.
 XX 06-OCT-2001; 2001US-00972607.
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-457242/43.
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-kappa B kinase-gamma, useful for preparing composition for treating e.g., cancer, or inflammatory or autoimmune disorder.
 XX Claim 3; Page 76; 106pp; English.
 XX The invention relates to an antisense compound that is targeted to a nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma and inhibiting its expression. Compounds of the invention are antisense oligonucleotides comprising at least one modified internucleoside linkage, which is a phosphorothioate linkage, at least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase, which is a 5-methylcytosine. Preferably, the antisense oligonucleotide is a chimeric oligonucleotide. The compound of the invention is useful for preparing a composition for treating a hyperproliferative disorder e.g., cancer, or an autoimmune or inflammatory disorder. The methods are useful for inhibiting the expression of inhibitor-kappa B kinase-gamma in cells or tissues, and treating an animal having a disease or condition associated with inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790 represent antisense oligonucleotides for the inhibition of human inhibitor-kappa B kinase-gamma mRNA levels.
 SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 270 TGCCTTCAGACAGGGCGCT 289
 DB 20 TGCCTTCAGACAGGGCGCT 1
 RESULT 40
 ADA44737/C
 ID ADA44737 standard; DNA; 20 BP.
 XX ADA44737;
 AC
 XX 20-NOV-2003 (first entry)
 DT
 XX Antisense oligonucleotide #ISIS 115409 #SEQ ID 35.

XX Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 KW human.
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-methylcytosine"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003031576-A2.
 XX 17-APR-2003.
 XX 03-OCT-2002; 2002WO-US031809.
 XX 06-OCT-2001; 2001US-00972607.
 XX (ISIS-) ISIS PHARM INC.
 XX Monia BP, Wyatt JR;
 XX WPI; 2003-457242/43.
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-kappa B kinase-gamma, useful for preparing composition for treating e.g., cancer, or inflammatory or autoimmune disorder.
 XX Claim 3; Page 77; 106pp; English.
 XX The invention relates to an antisense compound that is targeted to a nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma and inhibiting its expression. Compounds of the invention are antisense oligonucleotides comprising at least one modified internucleoside linkage, which is a phosphorothioate linkage, at least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase, which is a 5-methylcytosine. Preferably, the antisense oligonucleotide is a chimeric oligonucleotide. The compound of the invention is useful for preparing a composition for treating a hyperproliferative disorder e.g., cancer, or an autoimmune or inflammatory disorder. The methods are useful for inhibiting the expression of inhibitor-kappa B kinase-gamma in cells or tissues, and treating an animal having a disease or condition associated with inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790 represent antisense oligonucleotides for the inhibition of human inhibitor-kappa B kinase-gamma mRNA levels.
 SQ Sequence 20 BP; 1 A; 10 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 2.6%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 686 CAGCGCGCGCAGCTGGAGAG 705
 DB 20 CAGCGCGCGCAGCTGGAGAG 1
 RESULT 41

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0

Qy 882 TCAAGAGCAGCGTGGTGGC 901
 |||||
 Db 20 TCAAGAGCAGCGTGGTGGC 1

RESULT 42
 ADA44735/c
 ID ID ADA44735 standard; DNA; 20 BP.
 XX
 AC ADA44735;
 AC
 XX 20-NOV-2003 (first entry)
 XX
 DE Antisense oligonucleotide #ISIS 115407 #SEQ ID 33.
 XX
 XX Antisense oligonucleotide; cytostatic; immunosuppressive;
 KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
 KW antitumor; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
 XX human.
 XX
 OS Homo sapiens.
 OS
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages, all cytosines are 5-methylocytosine"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 XX WO2003031576-A2.
 PN
 XX
 XX 17-APR-2003.
 PD
 XX
 XX 03-OCT-2002; 2002WO-US031809.
 XX
 XX 06-OCT-2001; 2001US-00972607.
 PR
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX
 XX Monia BP, Wyatt JR;
 PI
 PI
 DR WPI; 2003-457242/43.
 DR
 XX
 XX New compound having sequence targeted to nucleic acid encoding inhibitor-kappa B kinase-gamma, useful for preparing composition for treating e.g., cancer, or inflammatory or autoimmune disorder.
 PT
 PT
 PT
 XX
 XX
 PS Claim 3; Page 77; 106pp; English.
 XX
 CC The invention relates to an antisense compound that is targeted to a nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma and inhibiting its expression. Compounds of the invention are antisense oligonucleotides comprising at least one modified internucleoside linkage, which is a phosphorothioate linkage, at least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase, which is a 5-methylcytosine. Preferably, the antisense oligonucleotide is a chimeric oligonucleotide. The compound of the invention is useful for preparing a composition for treating a hyperproliferative disorder e.g., cancer, or an autoimmune or inflammatory disorder. The methods are useful for inhibiting the expression of inhibitor-kappa B kinase-gamma in cells or tissues, and treating an animal having a disease or condition associated with

Query Match	2.6%	Score 20;	DB 1;	Length 20;
Best Local Similarity	100.0%	Pred. No.	1.1e+02;	

CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 604 GCTGCAGGAGCCAGAGTC 623
Db 20 GCTGCAGGAGCCAGAGTC 1
RESULT 43
ADA44743/C
ID ADA44743 standard; DNA; 20 BP.
XX
AC ADA44743;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115415 #SEQ ID 41.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
PR 06-OCT-2001; 2001US-00972607.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
WPI; 2003-457242/43.
XX
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
kappa B kinase-gamma, useful for preparing composition for treating e.g.,
cancer, or inflammatory or autoimmune disorder.
PS Claim 3; Page 77; 106pp; English.
XX
CC The invention relates to an antisense compound that is targeted to a
nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
and inhibiting its expression. Compounds of the invention are antisense
oligonucleotides comprising at least one modified internucleoside
linkage, which is a phosphorothioate linkage, at least one modified sugar

CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
modified nucleobase, which is a 5-methylcytosine. Preferably, the
antisense oligonucleotide is a chimeric oligonucleotide. The compound of
the invention is useful for preparing a composition for treating a
hyperproliferative disorder e.g., cancer, or an autoimmune or
inflammatory disorder. The methods are useful for inhibiting the
expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
treating an animal having a disease or condition associated with
inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
represent antisense oligonucleotides for the inhibition of human
inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 2 A; 8 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 792 TGGAGCGCCAGCGCCGCTCG 811
Db 20 TGGAGCGCCAGCGCCGCTCG 1
RESULT 44
ADA44729/C
ID ADA44729 standard; DNA; 20 BP.
XX
AC ADA44729;
XX
DT 20-NOV-2003 (first entry)
XX
DE Antisense oligonucleotide #ISIS 115401 #SEQ ID 27.
XX
KW Antisense oligonucleotide; cytostatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
methylcytosine"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003031576-A2.
XX
PD 17-APR-2003.
XX
PF 03-OCT-2002; 2002WO-US031809.
XX
PR 06-OCT-2001; 2001US-00972607.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Wyatt JR;
XX
WPI; 2003-457242/43.
XX
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
kappa B kinase-gamma, useful for preparing composition for treating e.g.,
cancer, or inflammatory or autoimmune disorder.
XX

```

PS Claim 3; Page 77; 106pp; English.
XX
CC The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 3 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 451 GAAACTGGTGGAGAGACTCG 470
DB 20 GAAACTGGTGGAGAGACTCG 1
RESULT 45
ADA44736/c
ID ADA44736 standard; DNA; 20 BP.
XX ADA44736;
XX
XX 20-NOV-2003 (first entry)
XX
XX Antisense oligonucleotide #ISIS 115408 #SEQ ID 34.
XX
XX Antisense oligonucleotide; cytostatic; immunosuppressive;
XX antinflammatory; gene therapy; hyperproliferative disorder; cancer;
XX autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
XX human.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= b
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages, all cytosines are 5-
XX methylcytosine"
XX modified_base 1..5
XX /*tag= a
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003031576-A2.
XX
XX 17-APR-2003.
XX
XX 03-OCT-2002; 2002WO-US031809.
XX
XX 06-OCT-2001; 2001US-00972607.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX

```

```

PI Monia BP, Wyatt JR;
XX
DR WPI; 2003-457242/43.
XX
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
XX kappa B kinase-gamma, useful for preparing composition for treating e.g.,
XX cancer, or inflammatory or autoimmune disorder.
XX
XX Claim 3; Page 77; 106pp; English.
XX
XX The invention relates to an antisense compound that is targeted to a
XX nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
XX hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
XX and inhibiting its expression. Compounds of the invention are antisense
XX oligonucleotides comprising at least one modified internucleoside
XX linkage, which is a phosphorothioate linkage, at least one modified sugar
XX moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
XX modified nucleobase, which is a 5-methylcytosine. Preferably, the
XX antisense oligonucleotide is a chimeric oligonucleotide. The compound of
XX the invention is useful for preparing a composition for treating a
XX hyperproliferative disorder e.g., cancer, or an autoimmune or
XX inflammatory disorder. The methods are useful for inhibiting the
XX expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
XX treating an animal having a disease or condition associated with
XX inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
XX represent antisense oligonucleotides for the inhibition of human
XX inhibitor-kappa B kinase-gamma mRNA levels.
XX
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 616 CCAGAGTCGCTGGAGGCTG 635
DB 20 CCAGAGTCGCTGGAGGCTG 1
RESULT 46
ACD23062/c
ID ACD23062 standard; DNA; 21 BP.
XX ACD23062;
XX
XX 25-AUG-2003 (first entry)
XX
XX Human NEMO gene RT-PCR primer R1.
XX
XX Human; PCR; ss; NF-kappaB essential modulator; nuclear factor kappa B;
XX incontinentia pigmenti; X-linked disorder; chromosome Xq28; NEMO;
XX immunomodulatory; dermatological; osteopathic; neuropathic; primer;
XX apoptosis-related disease; immune-system related disease; RT-PCR;
XX blood vessel-related disease; skin defect; dental defect; osteopetrosis;
XX ophthalmologic defect; neurological defect; reverse transcriptase PCR.
XX
XX Homo sapiens.
XX
XX US2003032055-A1.
XX
XX 13-FEB-2003.
XX
XX 22-MAY-2001; 2001US-00863049.
XX
XX 22-MAY-2000; 2000US-0206223P.
XX
XX (KENW/) KENWICK S J.
XX (WOFF/) WOFFENDIN H.
XX (MUNN/) MUNNICH A.
XX (SMAH/) SMAHI A.
XX (ISRA/) ISRAEL A.
XX (POUS/) POUSTR A.
XX (HEIS/) HEISS N.

```

PA (DURS/) D'URSO M.
PA (LEWI/) LEWIS R. A.
PA (NELS/) NELSON D L.
PA (ARAD/) ARADHYA S.
PA (LEVY/) LEVY M.
XX
XX Kenrick SJ, Woffendin H, Munnich A, Smahi A, Israel A;
PI Poustka A, Heiss N, D'urso M, Lewis RA, Nelson DL, Aradhyia S;
PI Levy M;
XX
XX WPI; 2003-492063/46.
XX
XX Detection of necrosis factor-kappa B related medical condition in
PT organism, by obtaining sample from the organism, and analyzing the sample
PT for alteration in specified amino acid sequences.
XX
XX Claim 40; Page 25; 44pp; English.
XX
XX The invention relates to a nuclear factor-kappa B (NF-kappa B) related
CC medical condition in an organism being detected by obtaining a sample
CC from the organism, and analyzing the sample for an alteration in a the
CC nuclear factor kappaB essential modifier (NEMO) gene or protein sequence
CC (neither shown in the specification). The alteration results in
CC inactivation of NF-kappa B. Also included are treating or preventing NF-
CC kappa B related medical condition in an organism by administering the
CC NEMO protein to the organism and screening a test organism for a compound
CC for the treatment of NF-kappa B related medical condition (by
CC administering the compound to the organism, and assaying for an
CC improvement in the NF-kappa B related medical condition). The method
CC useful is for detecting NF-kappa B related condition, e.g. incontinentia
CC pigmenti (IP), apoptosis-related disease, immune-system related disease,
CC blood vessel-related disease, skin defect, dental defect, osteopetrosis,
CC ophthalmologic defect, or neurological defect, in an organism, i.e. human
CC including affected individual, carrier individual, or noncarrier
CC individual. The NEMO gene is located on chromosome Xq28, incontinentia
CC pigmenti being an X-linked disorder. Experiments in this study show
CC variations in exon 2, 10, 9 and particularly intron 3 to be linked to
CC familial incontinentia pigmenti The present sequence is a reverse
CC transcriptase (RT)-PCR primer used to amplify the human NEMO cDNA
XX
XX Sequence 21 BP; 4 A; 8 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 2.6%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 645 AATCCAGGCTCTCGAGGCT 664
Db 20 AATCCAGGCTCTCGAGGCT 1
RESULT 47
ADAL3795/C
ID ADAL3795 standard; RNA; 21 BP.
XX
XX ADAL3795;
AC
XX
XX 20-NOV-2003 (first entry)
DT
XX Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:132.
DE
XX double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; expression; replication;
KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW cytosolic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW herpes simplex; cytomegalovirus; human papillomavirus;
KW respiratory syncytial virus; influenza virus; restdenosis;
KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW pulmonary; renal; liver; mitochondrial; reproductive disease;
KW chemical modification; ss.
XX

OS Synthetic.
XX WO2003070918-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005346.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
PI Morrissey D, Fosnaugh K, Mokler V, Jamison S;
XX WPI; 2003-689785/65.
XX
XX New short interfering nucleic acid containing no ribonucleotides, useful
PT e.g. for treating viral infection, downregulates expression of target
PT gene or RNA.
XX
XX Example 4; Page 135; 204pp; English.
XX
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of a target gene, where
CC the siNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC that inhibits expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siNA
CC molecules. siNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. siNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalovirus; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restdenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
XX Sequence 21 BP; 2 A; 8 C; 3 G; 2 T; 6 U; 0 Other;
SQ
Query Match 2.6%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 546 AGCAGATGCTGTGAGCAAG 565
Db 20 AGCAGATGCTGTGAGCAAG 1
RESULT 48

ADG30046
ID ADG30046 standard; RNA; 23 BP.
AC
AC ADG30046;
XX
DT 26-FEB-2004 (first entry)
XX
DE IKKγ-targeted siNA DNA-RNA hybrid - SEQ ID 612.
XX
KW double-stranded short interfering nucleic acid; siNA;
KW antiarteriosclerotic; neuroprotective; nontropic; antiparkinsonian;
KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
KW Alzheimer's; Parkinson's; epilepsy; dementia; Huntington's;
KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; IKKγ.
XX
OS Unidentified.
OS Synthetic.
XX
XX WO2003074654-A2.
XX
PD 12-SEP-2003.
XX
XX 20-FEB-2003; 2003WO-US005028.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX McSwiggen J, Beigelman L, Chowrira B, Pavco P, Fossnaugh K;
PI Jamison S, Uzman N, Thompson J;
XX
XX WPI; 2003-731676/69.
XX
PT New double-stranded short interfering nucleic acid molecule, useful for
PT down-regulating the expression of an endogenous mammalian target gene or
PT for treating diseases that respond to modulation of gene expression or
PT activity.
XX
XX Example 24; SEQ ID NO 612; 593pp; English.
XX
XX The invention relates to a double-stranded short interfering nucleic acid
XX (siNA) molecule that down-regulates expression of an endogenous mammalian
XX target gene comprising one or more chemical modifications and each strand
XX of the double-stranded siNA comprises about 21 nucleotides. The siNA of
XX the invention demonstrates antiarteriosclerotic, neuroprotective,
XX nontropic, antiparkinsonian and anticonvulsant activities and may be
XX useful for down-regulating the expression of an endogenous mammalian
XX target gene and therefore in the treatment of any disease or condition
XX that responds to modulation of gene expression or activity in a cell,
XX tissue or organism. The disease or condition may include pulmonary
XX diseases such as restenosis, atherosclerosis, Alzheimer's disease,
XX Parkinson's disease, epilepsy, dementia, Huntington's disease or
XX amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
XX gene therapy applications. The current sequence is that of the siNA DNA-
XX RNA hybrid of the invention.
XX
SQ Sequence 23 BP; 6 A; 2 C; 9 G; 2 T; 2 U; 2 Other;
Query Match 2.6%; Score 20; DB 1; Length 23;
Best Local Similarity 90.0%; Pred. No. 1.4e+02;
Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 407 AGGAGGAGGAGGAGGTTCT 426
|||||
DB 2 AGGAGGAGGAGGAGGTTCT 21

RESULT 49
ACD23064/c
ID ACD23064 standard; DNA; 21 BP.
XX
XX ACD23064;
AC
XX
DT 25-AUG-2003 (first entry)
XX
DE Human NEMO gene RT-PCR primer R4.
XX
XX Human; PCR; ss; NF-kappaB essential modulator; nuclear factor kappa B;
KW incontinentia pigmenti; X-linked disorder; chromosome Xq28; NEMO;
KW immunomodulatory; dermatological; osteopathic; neuropathic; primer;
KW apoptosis-related disease; immune-system related disease; RT-PCR;
KW blood vessel-related disease; skin defect; dental defect; osteopetrosis;
KW ophthalmologic defect; neurological defect; reverse transcriptase PCR.
XX
OS Homo sapiens.
XX
XX US2003032055-A1.
XX
PD 13-FEB-2003.
XX
XX 22-MAY-2001; 2001US-00863049.
XX
XX 22-MAY-2000; 2000US-0206223P.
XX
XX (KENN/) KENNRICK S J.
PA (WOFF/) WOFFENDIN H.
PA (MUNN/) MUNNICH A.
PA (SMAH/) SMAHI A.
PA (ISRA/) ISRAEL A.
PA (POUS/) POUSTRA A.
PA (HEIS/) HEISS N.
PA (DURS/) D'URSO M.
PA (LEWI/) LEWIS R A.
PA (NELS/) NELSON D L.
PA (ARAD/) ARADHYA S.
PA (LEVY/) LEVY M.
XX
XX Kenrick SJ, Woffendin H, Munnich A, Smahi A, Israel A;
PI Poustka A, Heiss N, D'urso M, Lewis RA, Nelson DL, Aradhyia S;
PI Levy M;
XX
XX WPI; 2003-492063/46.
XX
XX Detection of necrosis factor-kappa B related medical condition in
XX organism, by obtaining sample from the organism, and analyzing the sample
XX for alteration in specified amino acid sequences.
XX
XX Claim 40; Page 25; 44pp; English.
XX
XX The invention relates to a nuclear factor-kappa B (NF-kappa B) related
XX medical condition in an organism being detected by obtaining a sample
XX from the organism, and analysing the sample for an alteration in a the
XX nuclear factor kappaB essential modifier (NEMO) gene or protein sequence
XX (neither shown in the specification). The alteration results in
XX inactivation of NF-kappa B. Also included are treating or preventing NF-
XX kappa B related medical condition in an organism by administering the
XX NEMO protein to the organism and screening a test organism for a compound
XX for the treatment of NF-kappa B related medical condition (by
XX administering the compound to the organism, and assaying for an
XX improvement in the NF-kappa B related medical condition). The method
XX useful is for detecting NF-kappa B related condition, e.g. incontinentia
XX pigmenti (IP), apoptosis-related disease, immune-system related disease,
XX blood vessel-related disease, skin defect, dental defect, osteopetrosis,
XX ophthalmologic defect, or neurological defect, in an organism, i.e. human
XX including affected individual, carrier individual, or noncarrier
XX individual. The NEMO gene is located on chromosome Xq28, incontinentia
XX pigmenti being an X-linked disorder. Experiments in this study show
XX variations in exon 2, 10, 9 and particularly intron 3 to be linked to
XX familial incontinentia pigmenti. The present sequence is a reverse
XX transcriptase (RT)-PCR primer used to amplify the human NEMO cDNA

```
XX
SQ Sequence 21 BP; 4 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match      2.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 473 CTCGAGAGCTCGATCTGAAG 493
Db 21 CTCGAGAGCTCGATCTGAAG 1

RESULT 50
ADAL3790
ID ADAL3790 standard; RNA; 21 BP.
XX
AC ADAL3790;
XX
XX 20-NOV-2003 (first entry)
XX
XX Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:127.
XX
XX double-stranded short interfering nucleic acid;
XX short interfering nucleic acid; siNA; expression; replication;
XX inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
XX antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
XX cytosolic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
XX endocrine; viral infection; hepatitis B; hepatitis C; HIV;
XX herpes simplex; cytomegalovirus; human papillomavirus;
XX respiratory syncytial virus; influenza virus; restenosis;
XX neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
XX pulmonary; renal; liver; mitochondrial; reproductive disease;
XX chemical modification; ss.
XX
OS Synthetic.
XX
XX W02003070918-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005346.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-JUN-2002; 2002US-0366782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
XX Morrissey D, Fosnaugh K, Mokler V, Jamison S;
XX
XX WPI; 2003-689785/65.
XX
XX New short interfering nucleic acid containing no ribonucleotides, useful
XX e.g. for treating viral infection, downregulates expression of target
XX gene or RNA.
XX
XX Example 4; Page 135; 204pp; English.
XX
XX The present invention describes a double-stranded short interfering
XX nucleic acid (siNA) that downregulates expression of a target gene, where
XX the siNA molecule comprises no ribonucleotides and each strand of the
XX double-stranded siNA comprises about 21 nucleotides. Also described: (1)
XX a siNA molecule that inhibits expression of target RNA; (2) a siNA
XX molecule that inhibits replication of a virus and optionally does not
XX require presence of a ribonucleotide for inhibition; (3) a siNA molecule
XX that inhibits expression of a target gene and does not require presence
XX of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
XX expression of a target gene by mediating RNA interference; and (5) a

method for modulating expression of a gene in a cell using siNA
molecules. siNA's can have virucide, anti-HIV, hepatotropic,
antiinflammatory, plant antiviral, vasotropic, neuroprotective,
cytosolic, cardiovascular, immunosuppressive, respiratory, nephrotropic
and endocrine activities. The siNA's are useful for downregulating
expression of target genes, inhibiting expression of target RNA, and
inhibiting replication of a virus. siNA molecules can be used: (a) for
therapy of any disorder that responds to modulation of gene expression,
especially animal and plant viral infections, specifically hepatitis B or
C; HIV; herpes simplex; cytomegalovirus; human papilloma; respiratory
syncytial or influenza viruses, and also many other diseases such as
restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
endocrine or reproductive diseases; and (b) for diagnosis, target
validation, genomic discovery, genetic engineering, pharmacogenomics and
analysis of gene function. Chemical modification of siNA molecules
improves interfering activity; stability; cellular uptake; binding
affinity and/or mediates increased polymerase activity. siNA may be
designed to target many related genes containing a conserved sequence.
The present sequence represents a siNA oligonucleotide sequence, which is
used in the exemplification of the present invention.

Query Match      2.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 322 TCAAGAGCTCCGAGATGCCAT 342
Db 1 UCAAGAGCTCCGAGATGCCAT 21

RESULT 51
ADG30050/C
ID ADG30050 standard; RNA; 21 BP.
XX
XX AC ADG30050;
XX
XX 26-FEB-2004 (first entry)
XX
XX IKKg-targeted siNA DNA-RNA hybrid - SEQ ID 616.
XX
XX double-stranded short interfering nucleic acid; siNA;
XX antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;
XX anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
XX Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
XX amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; IKKg.
XX
XX Unidentified.
XX OS Synthetic.
XX
XX W02003074654-A2.
XX
XX 12-SEP-2003.
XX
XX 20-FEB-2003; 2003WO-US005028.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-JUN-2002; 2002US-0366782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Mcswiggen J, Beigelman L, Chowrira B, Pavco P, Fosnaugh K;
XX Jamison S, Usman N, Thompson J;
XX
XX WPI; 2003-731676/69.
```


CC target gene comprising one or more chemical modifications and each strand
CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
CC the invention demonstrates antiarteriosclerotic, neuroprotective,
CC neurotropic, antiparkinsonian and anticonvulsant activities and may be
CC useful for down-regulating the expression of an endogenous mammalian
CC target gene and therefore in the treatment of any disease or condition
CC that responds to modulation of gene expression or activity in a cell,
CC tissue or organism. The disease or condition may include pulmonary
CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
CC Parkinson's disease, epilepsy, dementia, Huntington's disease or
CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
CC gene therapy applications. The current sequence is that of the siNA DNA-
CC RNA hybrid of the invention.

XX Sequence 23 BP; 6 A; 3 C; 7 G; 2 T; 3 U; 2 Other;
SQ Query Match 2.6%; Score 19.4; DB 1; Length 23;
Best Local Similarity 81.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 166 GAAGAGCCAACTGCTGAGAT 186
Db 2 GAAGAGCCAACTGCTGAGAT 22

RESULT 54
ACD23072
ID ACD23072 standard; DNA; 25 BP.
XX AC ACD23072;
XX AC ACD23072;
XX 25-AUG-2003 (first entry)
XX Human Nemo gene mutant exon 2 DNA sequence, family XL349.
XX Human; ds; NF-kappaB essential modulator; nuclear factor kappa B;
XX incontinentia pigmenti; X-linked disorder; chromosome Xq28; NEMO;
XX immunomodulatory; dermatological; osteopathic; neuropathic;
XX apoptosis-related disease; immune-system related disease;
XX blood vessel-related disease; skin defect; dental defect; osteopetrosis;
XX ophthalmologic defect; neurological defect.

XX Homo sapiens.
XX US2003032055-A1.
XX 13-FEB-2003.
XX 22-MAY-2001; 2001US-00863049.
XX 22-MAY-2000; 2000US-0206223P.
XX (KENW/) KENWICK S. J.
XX (WOFF/) WOFFENDIN H.
XX (MUNN/) MUNNICH A.
XX (SMAH/) SMAHI A.
XX (ISRA/) ISRAEL A.
XX (POUS/) POUTKA A.
XX (HEIS/) HEISS N.
XX (DURS/) D'URSO M.
XX (LEWI/) LEWIS R. A.
XX (NELS/) NELSON D. L.
XX (ARAD/) ARADHYA S.
XX (LEVY/) LEVY M.

XX Kenrick SJ, Woffendin H, Munnich A, Smahi A, Israel A;
XX Poustka A, Heiss N, D'urso M, Lewis RA, Nelson DL, Aradhyha S;
XX Levy M;
XX WPI; 2003-492063/46.
XX P-PSDB; ABO17487.
XX Detection of necrosis factor-kappa B related medical condition in

PT organism, by obtaining sample from the organism, and analyzing the sample
PT for alteration in specified amino acid sequences.
XX Claim 41; Fig 5; 44pp; English.
XX The invention relates to a nuclear factor-kappa B (NF-kappa B) related
CC medical condition in an organism being detected by obtaining a sample
CC from the organism, and analysing the sample for an alteration in a the
CC nuclear factor kappaB essential modifier (NEMO) gene or protein sequence
CC (neither shown in the specification). The alteration results in
CC inactivation of NF-kappa B. Also included are treating or preventing NF-
CC kappa B related medical condition in an organism by administering the
CC NEMO protein to the organism and screening a test organism for a compound
CC for the treatment of NF-kappa B related medical condition (by
CC administering the compound to the organism, and assaying for an
CC improvement in the NF-kappa B related medical condition). The method
CC useful is for detecting NF-kappa B related condition, e.g. incontinentia
CC pigmenti (IP), apoptosis-related disease, immune-system related disease,
CC blood vessel-related disease, skin defect, dental defect, osteopetrosis,
CC ophthalmologic defect, or neurological defect, in an organism, i.e. human
CC including affected individual, carrier individual, or noncarrier
CC individual. The NEMO gene is located on chromosome Xq28, incontinentia
CC pigmenti being an X-linked disorder. Experiments in this study show
CC variations in exon 2, 10, 9 and particularly intron 3 to be linked to
CC familial incontinentia pigmenti. The present sequence is a mutant region
CC of the human NEMO gene found to be associated with familial incontinentia
CC pigmenti.

XX Sequence 25 BP; 5 A; 10 C; 4 G; 6 T; 0 U; 0 Other;
SQ Query Match 2.6%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 263 CTGCACCTGCCTTCAGACAG 283
Db 5 CTTACCTGCCTTCAGACAG 25

RESULT 55
ADN75887
ID ADN75887 standard; RNA; 19 BP.
XX AC ADN75887;
XX 01-JUL-2004 (first entry)
XX IKK.2 associated siRNA #1.
XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
XX cytostatic; immunomodulator; antimicrobial; antiinflammatory;
XX antidiabetic; anorectic; cancer; autoimmune disease; infection;
XX inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
XX Homo sapiens.
XX WO2004016735-A2.
XX 26-FEB-2004.
XX 23-MAY-2003; 2003WO-US016632.
XX 23-MAY-2002; 2002US-0383249P.
XX 14-APR-2003; 2003US-0462942P.
XX (CEPT-) CEPTVR INC.
XX (COLD-) COLD SPRING HARBOR LAB.
XX Klinghoffer R, Lewis SP, Tonks NK, Meng T;
XX WPI; 2004-203773/19.
XX New isolated small interfering RNA (siRNA) polynucleotide useful for

PT treating diseases with aberrant activity of the protein tyrosine
PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
PT diabetes and obesity.
XX Disclosure; SEQ ID NO 712; 392pp; English.

XX This invention describes novel small interfering RNA (siRNA)
CC polynucleotides capable of interfering with expression of a polypeptide
CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
CC invention have cytosolic, immunomodulator, antimicrobial,
CC antiinflammatory, antidiabetic and anorectic activity. The methods and
CC compositions of the present invention are useful for treating diseases or
CC conditions associated with aberrant expression or activity of the protein
CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
CC inflammation, diabetes and obesity. This sequence represents a siRNA
CC directed against dual specificity phosphatase (DSP) expression.

XX Sequence 19 BP; 4 A; 4 C; 6 G; 0 T; 5 U; 0 Other;

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.4e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCTCATGTGCAAG 436
DB 1 GGAGUCCUUGUGCAAG 19

RESULT 56
ADN75888/C
ID ADN75888 standard; RNA; 19 BP.
XX AC ADN75888;
XX 01-JUL-2004 (first entry)
XX IKK.2 associated siRNA #2.
XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
XX cytosolic; immunomodulator; antimicrobial; antiinflammatory;
XX antidiabetic; anorectic; cancer; autoimmune disease; infection;
XX inflammation; diabetes; obesity; RNA interference; gene silencing; ss.

OS Homo sapiens.

XX WO2004016735-A2.

XX 26-FEB-2004.

XX 23-MAY-2003; 2003WO-US016632.

XX 23-MAY-2002; 2002US-0383249P.

XX 14-APR-2003; 2003US-0462942P.

XX (CEPT-) CEPTYR INC.

XX (COLD-) COLD SPRING HARBOR LAB.

XX Klinghoffer R, Lewis SP, Tonks NK, Meng T;

XX WPI; 2004-203773/19.

XX New isolated small interfering RNA (siRNA) polynucleotide useful for
PT treating diseases with aberrant activity of the protein tyrosine
PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
PT diabetes and obesity.

XX Disclosure; SEQ ID NO 713; 392pp; English.

XX This invention describes novel small interfering RNA (siRNA)
CC polynucleotides capable of interfering with expression of a polypeptide
CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
CC invention have cytosolic, immunomodulator, antimicrobial,
CC antiinflammatory, antidiabetic and anorectic activity. The methods and

CC compositions of the present invention are useful for treating diseases or
CC conditions associated with aberrant expression or activity of the protein
CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
CC inflammation, diabetes and obesity. This sequence represents a siRNA
CC directed against dual specificity phosphatase (DSP) expression.

XX Sequence 19 BP; 5 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCTCATGTGCAAG 436
DB 19 GGAGTTCTCATGTGCAAG 1

RESULT 57

ADN75892

ID ADN75892 standard; RNA; 19 BP.

XX AC ADN75892;

XX 01-JUL-2004 (first entry)

XX IKK.3 associated siRNA #1.

XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
XX cytosolic; immunomodulator; antimicrobial; antiinflammatory;
XX antidiabetic; anorectic; cancer; autoimmune disease; infection;
XX inflammation; diabetes; obesity; RNA interference; gene silencing; ss.

OS Homo sapiens.

XX WO2004016735-A2.

XX 26-FEB-2004.

XX 23-MAY-2003; 2003WO-US016632.

XX 23-MAY-2002; 2002US-0383249P.

XX 14-APR-2003; 2003US-0462942P.

XX (CEPT-) CEPTYR INC.

XX (COLD-) COLD SPRING HARBOR LAB.

XX Klinghoffer R, Lewis SP, Tonks NK, Meng T;

XX WPI; 2004-203773/19.

XX New isolated small interfering RNA (siRNA) polynucleotide useful for
PT treating diseases with aberrant activity of the protein tyrosine
PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
PT diabetes and obesity.

XX Disclosure; SEQ ID NO 717; 392pp; English.

XX This invention describes novel small interfering RNA (siRNA)
CC polynucleotides capable of interfering with expression of a polypeptide
CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
CC invention have cytosolic, immunomodulator, antimicrobial,
CC antiinflammatory, antidiabetic and anorectic activity. The methods and
CC compositions of the present invention are useful for treating diseases or
CC conditions associated with aberrant expression or activity of the protein
CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
CC inflammation, diabetes and obesity. This sequence represents a siRNA
CC directed against dual specificity phosphatase (DSP) expression.

XX Sequence 19 BP; 4 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.4e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY	565	GGCCTCTGTGAAGCCGAG 583	
DB	1	GGCCUCUGUGAAGCCGAG 19	
ADN75893/c			
ID	ADN75893	standard; RNA; 19 BP.	
XX	AC	ADN75893;	
XX	DT	01-JUL-2004 (first entry)	
XX	DE	IKK.1 associated siRNA #2.	
XX	KW	small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;	
XX	KW	cytostatic; immunomodulator; antimicrobial; antiinflammatory;	
XX	KW	antidiabetic; anorectic; cancer; autoimmune disease; infection;	
XX	KW	inflammation; diabetes; obesity; RNA interference; gene silencing; ss.	
OS	Homo sapiens.		
XX	PN	WO2004016735-A2.	
XX	PD	26-FEB-2004.	
XX	PF	23-MAY-2003; 2003WO-US016632.	
XX	PR	23-MAY-2002; 2002US-0383249P.	
XX	PR	14-APR-2003; 2003US-0462942P.	
XX	PA	(CEPT-) CEPTVR INC.	
XX	PA	(COLD-) COLD SPRING HARBOR LAB.	
XX	PI	Klinghoffer R, Lewis SP, Tonks NK, Meng T;	
XX	DR	WPI; 2004-203773/19.	
XX	PT	New isolated small interfering RNA (siRNA) polynucleotide useful for	
XX	PT	treating diseases with aberrant activity of the protein tyrosine	
XX	PT	phosphatase, such as cancer, autoimmune disease, infection, inflammation,	
XX	PT	diabetes and obesity.	
XX	PS	Disclosure; SEQ ID NO 718; 392pp; English.	
XX	CC	This invention describes novel small interfering RNA (siRNA)	
XX	CC	polynucleotides capable of interfering with expression of a polypeptide	
XX	CC	having protein-tyrosine-phosphatase (PTP) activity. The products of the	
XX	CC	invention have cytostatic, immunomodulator, antimicrobial,	
XX	CC	antiinflammatory, antidiabetic and anorectic activity. The methods and	
XX	CC	compositions of the present invention are useful for treating diseases or	
XX	CC	conditions associated with aberrant expression or activity of the protein	
XX	CC	tyrosine phosphatase, such as cancer, autoimmune diseases, infection,	
XX	CC	inflammation, diabetes and obesity. This sequence represents a siRNA	
XX	CC	directed against dual specificity phosphatase (DSP) expression.	
XX	SQ	Sequence 19 BP; 3 A; 6 C; 6 G; 0 T; 4 U; 0 Other;	
	Query Match	2.5%; Score 19; DB 1; Length 19;	
	Best Local Similarity	100.0%; Pred. No. 1.4e+02;	
	Matches 19; Conservative	0; Mismatches 0; Indels 0; Gaps 0;	
QY	565	GGCCTCTGTGAAGCCGAG 583	
DB	19	GGCCTCTGTGAAGCCGAG 1	
RESULT 60			
ADN75893			
ID	ADN75893	standard; RNA; 19 BP.	
XX	AC	ADN75893;	
XX	DT	01-JUL-2004 (first entry)	
XX	DE	IKK.1 associated siRNA #1.	
XX	KW	small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;	
XX	KW	cytostatic; immunomodulator; antimicrobial; antiinflammatory;	
XX	KW	antidiabetic; anorectic; cancer; autoimmune disease; infection;	
XX	KW	inflammation; diabetes; obesity; RNA interference; gene silencing; ss.	
OS	Homo sapiens.		

QY	236	GAGTCTCTCTGGGGAAGC 254	
DB	19	GAGTCTCTCTGGGGAAGC 1	
RESULT 59			
ADN75893/c			
ID	ADN75893	standard; RNA; 19 BP.	
XX	AC	ADN75893;	

XX	PN	WO2004016735-A2.
XX	PD	26-FEB-2004.
XX	PB	23-MAY-2003; 2003WO-US016632.
XX	PF	23-MAY-2002; 2002US-0383249P.
XX	PR	14-APR-2003; 2003US-0462942P.
XX	PP	(CEPT-) CEPTYR INC.
PA	PA	(COLD-) COLD SPRING HARBOR LAB.
XX	PI	Klinghoffer R, Lewis SP, Tonks NK, Meng T;
XX	DR	WPI; 2004-203773/19.
XX	PT	New isolated small interfering RNA (siRNA) polynucleotide useful for treating diseases with aberrant activity of the protein tyrosine phosphatase, such as cancer, autoimmune disease, infection, inflammation, diabetes and obesity.
XX	PS	Disclosure; SEQ ID NO 707; 392pp; English.
XX	CC	This invention describes novel small interfering RNA (siRNA) polynucleotides capable of interfering with expression of a polypeptide having protein-tyrosine-phosphatase (PTP) activity. The products of the invention have cytostatic, immunomodulator, antimicrobial, antiinflammatory, antidiabetic and anorectic activity. The methods and compositions of the present invention are useful for treating diseases or conditions associated with aberrant expression or activity of the protein tyrosine phosphatase, such as cancer, autoimmune diseases, infection, inflammation, diabetes and obesity. This sequence represents a siRNA directed against dual specificity phosphatase (DSP) expression.
XX	SQ	Sequence 19 BP; 3 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
XX	QY	Query Match 2.5%; Score 19; DB 1; Length 19; Best Local Similarity 78.9%; Pred. No. 1.4e+02; Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
DG	DB	236 GAGTCCTCCTGGGAAC 254 : : 1 GAGUCUCCUGGGGAAC 19
XX	PN	RESULT 61
XX	ADN75898	ID ADN75898 standard; RNA; 19 BP.
XX	OS	Homo sapiens.
XX	AC	ADN75898;
XX	DT	01-JUL-2004 (first entry)
XX	DE	IKK.4 associated siRNA #2.
XX	KK	small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP; cytostatic; immunomodulator; antimicrobial; antiinflammatory; antidiabetic; anorectic; cancer; autoimmune disease; infection; inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
XX	OS	Homo sapiens.
XX	PA	WO2004016735-A2.
XX	PI	26-FEB-2004.
XX	PP	23-MAY-2003; 2003WO-US016632.
XX	PR	23-MAY-2002; 2002US-0383249P.
XX	PR	14-APR-2003; 2003US-0462942P.
XX	PA	(CEPT-) CEPTYR INC.
XX	PN	(COLD-) COLD SPRING HARBOR LAB.
XX	PI	Klinghoffer R, Lewis SP, Tonks NK, Meng T;
XX	DR	WPI; 2004-203773/19.
XX	PT	New isolated small interfering RNA (siRNA) polynucleotide useful for treating diseases with aberrant activity of the protein tyrosine phosphatase, such as cancer, autoimmune disease, infection, inflammation, diabetes and obesity.
XX	PS	Disclosure; SEQ ID NO 707; 392pp; English.
XX	CC	This invention describes novel small interfering RNA (siRNA) polynucleotides capable of interfering with expression of a polypeptide having protein-tyrosine-phosphatase (PTP) activity. The products of the invention have cytostatic, immunomodulator, antimicrobial, antiinflammatory, antidiabetic and anorectic activity. The methods and compositions of the present invention are useful for treating diseases or conditions associated with aberrant expression or activity of the protein tyrosine phosphatase, such as cancer, autoimmune diseases, infection, inflammation, diabetes and obesity. This sequence represents a siRNA directed against dual specificity phosphatase (DSP) expression.
XX	SQ	Sequence 19 BP; 3 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
XX	QY	Query Match 2.5%; Score 19; DB 1; Length 19; Best Local Similarity 78.9%; Pred. No. 1.4e+02; Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
DG	DB	236 GAGTCCTCCTGGGAAC 254 : : 1 GAGUCUCCUGGGGAAC 19
XX	PN	RESULT 61
XX	ADN75898	ID ADN75898 standard; RNA; 19 BP.
XX	OS	Homo sapiens.
XX	AC	ADN75898;
XX	DT	01-JUL-2004 (first entry)
XX	DE	IKK.4 associated siRNA #2.
XX	KK	small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP; cytostatic; immunomodulator; antimicrobial; antiinflammatory; antidiabetic; anorectic; cancer; autoimmune disease; infection; inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
XX	OS	Homo sapiens.
XX	PA	WO2004016735-A2.
XX	PI	26-FEB-2004.
XX	PP	23-MAY-2003; 2003WO-US016632.
XX	PR	23-MAY-2002; 2002US-0383249P.
XX	PR	14-APR-2003; 2003US-0462942P.
XX	PA	(CEPT-) CEPTYR INC.
XX	PN	(COLD-) COLD SPRING HARBOR LAB.
XX	PI	Klinghoffer R, Lewis SP, Tonks NK, Meng T;
XX	DR	WPI; 2004-203773/19.
XX	PT	New isolated small interfering RNA (siRNA) polynucleotide useful for treating diseases with aberrant activity of the protein tyrosine phosphatase, such as cancer, autoimmune disease, infection, inflammation, diabetes and obesity.
XX	PS	Disclosure; SEQ ID NO 723; 392pp; English.
XX	CC	This invention describes novel small interfering RNA (siRNA) polynucleotides capable of interfering with expression of a polypeptide having protein-tyrosine-phosphatase (PTP) activity. The products of the invention have cytostatic, immunomodulator, antimicrobial, antiinflammatory, antidiabetic and anorectic activity. The methods and compositions of the present invention are useful for treating diseases or conditions associated with aberrant expression or activity of the protein tyrosine phosphatase, such as cancer, autoimmune diseases, infection, inflammation, diabetes and obesity. This sequence represents a siRNA directed against dual specificity phosphatase (DSP) expression.
XX	SQ	Sequence 19 BP; 6 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
XX	QY	Query Match 2.5%; Score 19; DB 1; Length 19; Best Local Similarity 89.5%; Pred. No. 1.4e+02; Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
DG	DB	877 CCACATCAAGAGCGGTG 895 : : 1 CCACAUCAAGAGCGGTG 19
XX	PN	RESULT 62
XX	ADN75897/c	ID ADN75897 standard; RNA; 19 BP.
XX	OS	Homo sapiens.
XX	AC	ADN75897;
XX	DT	01-JUL-2004 (first entry)
XX	DE	IKK.4 associated siRNA #1.
XX	KK	small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP; cytostatic; immunomodulator; antimicrobial; antiinflammatory; antidiabetic; anorectic; cancer; autoimmune disease; infection; inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
XX	OS	Homo sapiens.
XX	PA	WO2004016735-A2.
XX	PI	26-FEB-2004.
XX	PP	23-MAY-2003; 2003WO-US016632.
XX	PR	23-MAY-2002; 2002US-0383249P.
XX	PR	14-APR-2003; 2003US-0462942P.
XX	PA	(CEPT-) CEPTYR INC.
XX	PN	(COLD-) COLD SPRING HARBOR LAB.
XX	PI	Klinghoffer R, Lewis SP, Tonks NK, Meng T;
XX	DR	WPI; 2004-203773/19.
XX	PT	New isolated small interfering RNA (siRNA) polynucleotide useful for treating diseases with aberrant activity of the protein tyrosine phosphatase, such as cancer, autoimmune disease, infection, inflammation, diabetes and obesity.
XX	PS	Disclosure; SEQ ID NO 723; 392pp; English.
XX	CC	This invention describes novel small interfering RNA (siRNA) polynucleotides capable of interfering with expression of a polypeptide having protein-tyrosine-phosphatase (PTP) activity. The products of the invention have cytostatic, immunomodulator, antimicrobial, antiinflammatory, antidiabetic and anorectic activity. The methods and compositions of the present invention are useful for treating diseases or conditions associated with aberrant expression or activity of the protein tyrosine phosphatase, such as cancer, autoimmune diseases, infection, inflammation, diabetes and obesity. This sequence represents a siRNA directed against dual specificity phosphatase (DSP) expression.
XX	SQ	Sequence 19 BP; 6 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
XX	QY	Query Match 2.5%; Score 19; DB 1; Length 19; Best Local Similarity 89.5%; Pred. No. 1.4e+02; Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
DG		

PS Disclosure; SEQ ID NO 722; 392pp; English.

XX This invention describes novel small interfering RNA (siRNA)

CC polynucleotides capable of interfering with expression of a polypeptide

CC having protein-tyrosine-phosphatase (PTP) activity. The products of the

CC invention have cytosolic, immunomodulatory, antimicrobial,

CC antiinflammatory, antidiabetic and anorectic activity. The methods and

CC compositions of the present invention are useful for treating diseases or

CC conditions associated with aberrant expression or activity of the protein

CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,

CC inflammation, diabetes and obesity. This sequence represents a siRNA

CC directed against dual specificity phosphatase (DSP) expression.

XX

SQ Sequence 19 BP; 2 A; 5 C; 6 G; 0 T; 6 U; 0 Other;

Query Match 2.5%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 877 CCACATCAAGCAGCGCTG 895

DB 19 CCACATCAAGCAGCGCTG 1

RESULT 63

ID ADAL13794

AD ADAL13794 standard; RNA; 21 BP.

XX

AC ADAL13794;

XX

XX

DT 20-NOV-2003 (first entry)

XX

DE Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:131.

XX

XX double-stranded short interfering nucleic acid;

XX short interfering nucleic acid; siNA; expression; replication;

KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;

KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;

KW cytosolic; cardiovascular; immunosuppressive; respiratory; nephrotropic;

KW endocrine; viral infection; hepatitis B; hepatitis C; HIV;

KW herpes simplex; cytomegalovirus; human papillomavirus;

KW respiratory syncytial virus; influenza virus; restenosis;

KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;

KW pulmonary; renal; liver; mitochondrial; reproductive disease;

KW chemical modification; ss.

XX

OS Synthetic.

XX

XX WO2003070918-A2.

XX

XX

PD 28-AUG-2003.

XX

XX

PF 20-FEB-2003; 2003WO-US005346.

XX

XX

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

XX

XX (RIBO-) RIBOZYME PHARM INC.

XX

XX Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;

PI Morrissey D, Fornaugh K, Mokler V, Jamison S;

XX

XX WPI; 2003-689785/65.

XX

XX New short interfering nucleic acid containing no ribonucleotides, useful

PT e.g. for treating viral infection, downregulates expression of target

PT gene or RNA.

XX

PS Example 4; Page 135; 204pp; English.

XX The present invention describes a double-stranded short interfering

CC nucleic acid (siNA) that downregulates expression of a target gene, where

CC the siNA molecule comprises no ribonucleotides and each strand of the

CC double-stranded siNA comprises about 21 nucleotides. Also described: (1)

CC a siNA molecule that inhibits expression of target RNA; (2) a siNA

CC molecule that inhibits replication of a virus and optionally does not

CC require presence of a ribonucleotide for inhibition; (3) a siNA molecule

CC that inhibits expression of a target gene and does not require presence

CC of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits

CC expression of a target gene by mediating RNA interference; and (5) a

CC method for modulating expression of a gene in a cell using siNA

CC molecules. siNA's can have virucide, anti-HIV, neuroprotective,

CC antiinflammatory, plant antiviral, vasotropic, hepatotropic,

CC cytosolic, cardiovascular, immunosuppressive, respiratory, nephrotropic

CC and endocrine activities. The siNA's are useful for downregulating

CC expression of target genes, inhibiting expression of target RNA, and

CC inhibiting replication of a virus. siNA molecules can be used: (a) for

CC therapy of any disorder that responds to modulation of gene expression,

CC especially animal and plant viral infections, specifically hepatitis B or

CC C; HIV; herpes simplex; cytomegalovirus; human papilloma; respiratory

CC syncytial or influenza viruses, and also many other diseases such as

CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,

CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,

CC endocrine or reproductive diseases; and (b) for diagnosis, target

CC validation, genomic discovery, genetic engineering, pharmacogenomics and

CC analysis of gene function. Chemical modification of siNA molecules

CC improves interfering activity; stability; cellular uptake; binding

CC affinity and/or mediates increased polymerase activity. siNA may be

CC designed to target many related genes containing a conserved sequence.

CC The present sequence represents a siNA oligonucleotide sequence, which is

CC used in the exemplification of the present invention.

XX

SQ Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;

Query Match 2.5%; Score 19; DB 1; Length 21;

Best Local Similarity 89.5%; Pred. No. 1.6e+02;

Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 547 GCAGATGGCTGAGCACAAG 565

DB 1 GCAGATGGCTGAGCACAAG 19

RESULT 64

ADG30049/c

ID ADG30049 standard; RNA; 21 BP.

XX

AC ADG30049;

XX

XX

DT 26-FEB-2004 (first entry)

XX

DE IKKg-targeted siNA DNA-RNA hybrid - SEQ ID 615.

XX

XX double-stranded short interfering nucleic acid; siNA;

KW antiarteriosclerotic; neuroprotective; nootropic; antiparkinsonian;

KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;

KW Alzheimer's; Parkinson's; epilepsy; dementia; Huntington's;

KW amyotrophic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; IKKg.

XX

OS Unidentified.

OS Synthetic.

XX

XX WO2003074654-A2.

XX

XX

PD 12-SEP-2003.

XX

XX

PF 20-FEB-2003; 2003WO-US005028.

XX

XX 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 06-JUN-2002; 2002US-0386782P.

PS Disclosure; SEQ ID NO 709; 392pp; English.

XX This invention describes novel small interfering RNA (siRNA)

CC polynucleotides capable of interfering with expression of a polypeptide

CC having protein-tyrosine-phosphatase (PTP) activity. The products of the

CC invention have cytostatic, immunomodulator, antimicrobial,

CC antiinflammatory, antidiabetic and anorectic activity. The methods and

CC compositions of the present invention are useful for treating diseases or

CC conditions associated with aberrant expression or activity of the protein

CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,

CC inflammation, diabetes and obesity. This sequence represents a siRNA

CC directed against dual specificity phosphatase (DSP) expression.

XX

SQ Sequence 21 BP; 3 A; 5 C; 7 G; 0 T; 4 U; 2 Other;

Query Match 2.5%; Score 19; DB 1; Length 21;

Best Local Similarity 78.9%; Pred. No. 1.6e+02;

Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 236 GAGTCTCTCTGGGAGC 254

Db 1 GAGUCUCUCUGGGAGC 19

RESULT 67

ADN75894

ID ADN75894 standard; RNA; 21 BP.

XX

XX ADN75894;

XX

DT 01-JUL-2004 (first entry)

XX

DE IKK.3 associated siRNA #3.

XX

XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;

KW cytosatic; immunomodulator; antimicrobial; antiinflammatory;

KW antidiabetic; anorectic; cancer; autoimmune disease; infection;

KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.

XX

XX Homo sapiens.

OS

XX WO2004016735-A2.

XX

PD 26-FEB-2004.

XX

XX 23-MAY-2003; 2003WO-US016632.

PF

XX 23-MAY-2002; 2002US-0383249P.

XX

PR 14-APR-2003; 2003US-0462942P.

XX

XX (CEPT-) CEPTVR INC.

PA

PA (COLD-) COLD SPRING HARBOR LAB.

XX

XX Klinghoffer R, Lewis SP, Tonks NK, Meng T;

XX

XX WPI; 2004-203773/19.

XX

XX New isolated small interfering RNA (siRNA) polynucleotide useful for

PT treating diseases with aberrant activity of the protein tyrosine

PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,

PT diabetes and obesity.

XX

XX Disclosure; SEQ ID NO 719; 392pp; English.

PS

XX This invention describes novel small interfering RNA (siRNA)

CC polynucleotides capable of interfering with expression of a polypeptide

CC having protein-tyrosine-phosphatase (PTP) activity. The products of the

CC invention have cytostatic, immunomodulator, antimicrobial,

CC antiinflammatory, antidiabetic and anorectic activity. The methods and

CC compositions of the present invention are useful for treating diseases or

CC conditions associated with aberrant expression or activity of the protein

CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,

CC inflammation, diabetes and obesity. This sequence represents a siRNA

CC directed against dual specificity phosphatase (DSP) expression.

XX

SQ Sequence 21 BP; 3 A; 5 C; 7 G; 0 T; 4 U; 2 Other;

Query Match 2.5%; Score 19; DB 1; Length 21;

Best Local Similarity 78.9%; Pred. No. 1.6e+02;

Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 236 GAGTCTCTCTGGGAGC 254

Db 1 GAGUCUCUCUGGGAGC 19

RESULT 68

ADN75890/c

ID ADN75890 standard; RNA; 21 BP.

XX

XX ADN75890;

XX

DT 01-JUL-2004 (first entry)

XX

DE IKK.2 associated siRNA #4.

XX

XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;

KW cytosatic; immunomodulator; antimicrobial; antiinflammatory;

KW antidiabetic; anorectic; cancer; autoimmune disease; infection;

KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.

XX

XX Homo sapiens.

OS

XX WO2004016735-A2.

XX

PD 26-FEB-2004.

XX

XX 23-MAY-2003; 2003WO-US016632.

PF

XX 23-MAY-2002; 2002US-0383249P.

XX

PR 14-APR-2003; 2003US-0462942P.

XX

XX (CEPT-) CEPTVR INC.

PA

PA (COLD-) COLD SPRING HARBOR LAB.

XX

XX Klinghoffer R, Lewis SP, Tonks NK, Meng T;

XX

XX WPI; 2004-203773/19.

XX

XX New isolated small interfering RNA (siRNA) polynucleotide useful for

PT treating diseases with aberrant activity of the protein tyrosine

PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,

PT diabetes and obesity.

XX

XX Disclosure; SEQ ID NO 715; 392pp; English.

PS

XX This invention describes novel small interfering RNA (siRNA)

CC polynucleotides capable of interfering with expression of a polypeptide

CC having protein-tyrosine-phosphatase (PTP) activity. The products of the

CC invention have cytostatic, immunomodulator, antimicrobial,

CC antiinflammatory, antidiabetic and anorectic activity. The methods and

CC compositions of the present invention are useful for treating diseases or

CC conditions associated with aberrant expression or activity of the protein

CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,

CC inflammation, diabetes and obesity. This sequence represents a siRNA

CC directed against dual specificity phosphatase (DSP) expression.

XX

SQ Sequence 21 BP; 5 A; 6 C; 4 G; 0 T; 4 U; 2 Other;

Query Match 2.5%; Score 19; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 418 GGAGTTCTCTATGCGCAG 436

Db 21 GGAGTTCTCTATGCGCAG 3

CC directed against dual specificity phosphatase (DSP) expression.

XX

SQ Sequence 21 BP; 4 A; 6 C; 6 G; 0 T; 3 U; 2 Other;

Query Match 2.5%; Score 19; DB 1; Length 21;

Best Local Similarity 84.2%; Pred. No. 1.6e+02;

Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 565 GGCTCTCTGGAAGCCAG 583

Db 1 GGCCUCUGUGAAGCCAG 19

RESULT 68

ADN75890/c

ID ADN75890 standard; RNA; 21 BP.

XX

XX ADN75890;

XX

DT 01-JUL-2004 (first entry)

XX

DE IKK.2 associated siRNA #4.

XX

XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;

KW cytosatic; immunomodulator; antimicrobial; antiinflammatory;

KW antidiabetic; anorectic; cancer; autoimmune disease; infection;

KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.

XX

XX Homo sapiens.

OS

XX WO2004016735-A2.

XX

PD 26-FEB-2004.

XX

XX 23-MAY-2003; 2003WO-US016632.

PF

XX 23-MAY-2002; 2002US-0383249P.

XX

PR 14-APR-2003; 2003US-0462942P.

XX

XX (CEPT-) CEPTVR INC.

PA

PA (COLD-) COLD SPRING HARBOR LAB.

XX

XX Klinghoffer R, Lewis SP, Tonks NK, Meng T;

XX

XX WPI; 2004-203773/19.

XX

XX New isolated small interfering RNA (siRNA) polynucleotide useful for

PT treating diseases with aberrant activity of the protein tyrosine

PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,

PT diabetes and obesity.

XX

XX Disclosure; SEQ ID NO 715; 392pp; English.

PS

XX This invention describes novel small interfering RNA (siRNA)

CC polynucleotides capable of interfering with expression of a polypeptide

CC having protein-tyrosine-phosphatase (PTP) activity. The products of the

CC invention have cytostatic, immunomodulator, antimicrobial,

CC antiinflammatory, antidiabetic and anorectic activity. The methods and

CC compositions of the present invention are useful for treating diseases or

CC conditions associated with aberrant expression or activity of the protein

CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,

CC inflammation, diabetes and obesity. This sequence represents a siRNA

CC directed against dual specificity phosphatase (DSP) expression.

XX

SQ Sequence 21 BP; 5 A; 6 C; 4 G; 0 T; 4 U; 2 Other;

Query Match 2.5%; Score 19; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 418 GGAGTTCTCTATGCGCAG 436

Db 21 GGAGTTCTCTATGCGCAG 3

CC polynucleotides capable of interfering with expression of a polypeptide
CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
CC invention have cytostatic, immunomodulator, antimicrobial,
CC antiinflammatory, antidiabetic and anorectic activity. The methods and
CC conditions of the present invention are useful for treating diseases or
CC conditions associated with aberrant expression or activity of the protein
CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
CC inflammation, diabetes and obesity. This sequence represents a siRNA
CC directed against dual specificity phosphatase (DSP) expression.
XX
SQ Sequence 21 BP; 3 A; 6 C; 6 G; 0 T; 4 U; 2 Other;

Query Match 2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAGCCAC 583
DB 21 GGCCTCTGTGAAGCCAC 3

RESULT 74
ADJ46760/C
ID ADJ46760 standard; DNA; 20 BP.

XX ADJ46760;

XX 06-MAY-2004 (first entry)

XX Human KIAA1531 antisense oligonucleotide ISIS #208184.

XX human; KIAA1531; hyperproliferative disorder; cancer;
XX angiogenesis hyperactivation; chronic inflammation; ss; antisense.

XX Homo sapiens.

XX Synthetic.

XX US2004023378-A1.

XX 05-FEB-2004.

XX 31-JUL-2002; 2002US-00210290.

XX 31-JUL-2002; 2002US-00210290.

XX (ISIS-) ISIS PHARM INC.

XX Chiang M, Marcusson EG, Dobie KW;

XX WPI; 2004-142659/14.

XX New compound, particularly an antisense oligonucleotide targeted to a
XX nucleic acid encoding KIAA1531, useful for treating cancer, chronic
XX inflammation or conditions involving hyperactivation of angiogenesis.

XX Example 15; SEQ ID NO 37; 65pp; English.

XX The invention relates to a compound targeted to and which specifically
XX hybridizes with a nucleic acid molecule encoding KIAA1531 and inhibits
XX the expression of KIAA1531. The compound, composition and methods are
XX useful for treating a disease or condition associated with KIAA1531, such
XX as a hyperproliferative disorder, e.g. cancer, a disease or condition
XX involving hyperactivation of angiogenesis, or chronic inflammation. They
XX are also useful in research and diagnostics for modulating the expression
XX of KIAA1531. The present sequence represents a human KIAA1531 antisense
XX oligonucleotide.

XX Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 2.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 877 CCACATCAAGACGCGTGG 896
DB 20 CCACATCAAGACGCGTGG 1

RESULT 75

AD031926/C

ID ADO31926 standard; DNA; 20 BP.

XX ADO31926;

XX 29-JUL-2004 (first entry)

XX Cyclin-dependent kinase 6, antisense oligonucleotide #23.

XX antisense therapy; cyclin-dependent kinase 6;

XX hyperproliferative disorder; cancer; bacterial infection;

XX viral infection; apoptosis; ss; probe; human.

XX Homo sapiens.

XX US2004087523-A1.

XX 06-MAY-2004.

XX 31-JUL-2002; 2002US-00210802.

XX 31-JUL-2002; 2002US-00210802.

XX (ISIS-) ISIS PHARM INC.

XX Freier SM, Dobie KW;

XX WPI; 2004-356241/33.

XX New compounds, particularly antisense oligonucleotides targeted to a
XX nucleic acid encoding cyclin-dependent kinase 6, useful for treating
XX cancer, bacterial/viral infection or conditions involving aberrant
XX apoptosis.

XX Disclosure; SEQ ID NO 37; 69pp; English.

XX The invention relates to antisense oligonucleotides targeted to cyclin-
XX dependent kinase 6, and which inhibit the expression of cyclin-dependent
XX kinase 6. The antisense oligonucleotides are useful for treating a
XX disease or condition associated with cyclin-dependent kinase 6, such as a
XX hyperproliferative disorder (e.g. cancer), or conditions arising from
XX bacterial or viral infections, or involving aberrant apoptosis. They are
XX also useful in research and diagnostics for modulating the expression of
XX cyclin-dependent kinase 6. The present sequence represents a cyclin-
XX dependent kinase 6 antisense oligonucleotide. Note: Seqid 15-134 are also
XX used in Tables 1 and 2 (page 30-34) but these sequences do not match
XX seqid 15-134 of the seq list.

XX Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 2.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 877 CCACATCAAGACGCGTGG 896
DB 20 CCACATCAAGACGCGTGG 1

RESULT 76

ADL47533

ID ADL47533 standard; RNA; 17 BP.

XX ADL47533;

XX 20-MAY-2004 (first entry)

XX


```

DE Human IKK-gamma substrate sequence #59.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1082; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 1 A; 4 C; 10 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 657 TGGAGGTCGGCCCGG 673
Db 1 UGAGGGGCGGCCCGG 17
|||||:|||||
|||||:|||||

RESULT 79
ADL47744
ID ADL47744 standard; RNA; 17 BP.
XX
XX AC ADL47744;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #254.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1277; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 203 GGCCCGGCGAGCATCA 219
Db 1 GGCCCGGCGAGCAUCA 17
|||||:|||||
|||||:|||||

RESULT 80
ADL47762
ID ADL47762 standard; RNA; 17 BP.
XX
XX AC ADL47762;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```
DE Human IKK-gamma substrate sequence #272.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 1295; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 269 CTGCTTCAGACACGGG 285
DB 1 CUGCCUUCAGACACGGG 17

RESULT 81
ADL47788
ID ADL47788 standard; RNA; 17 BP.
XX
XX AC ADL47788;
XX DT 20-MAY-2004 (first entry)
XX
```

```
DE Human IKK-gamma substrate sequence #298.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 1321; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX SQ Sequence 17 BP; 2 A; 5 C; 4 G; 0 T; 6 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 379 GGAGCTTCTGCATTTC 395
DB 1 GGAGCUUCUCAUUUC 17

RESULT 82
ADL47794
ID ADL47794 standard; RNA; 17 BP.
XX
XX AC ADL47794;
XX DT 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #304.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1327; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 7 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 396 AAGCCAGCCAGAGGGAG 412
 DB 1 AAGCCAGCCAGAGGGAG 17
 RESULT 83
 ID ADL47821
 ADL47821 standard; RNA; 17 BP.
 XX
 AC ADL47821;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #331.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1354; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 548 CAGATGGCTGAGGACAA 564
 DB 1 CAGATGGCTGAGGACAA 17
 RESULT 84
 ID ADL47839
 ADL47839 standard; RNA; 17 BP.
 XX
 AC ADL47839;
 XX
 DT 20-MAY-2004 (first entry)
 XX

Human IKK-gamma substrate sequence #349.

antisense oligonucleotide; neurite growth inhibitor; NOGO; prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK; protein kinase PKR; cerebrovascular accident; central nervous system injury; CNS injury; spinal cord injury; cancer; melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis; restenosis; asthma; Crohn's disease; diabetes; obesity; autoimmune disease; lupus; multiple sclerosis; transplant rejection; graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis; allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma; substrate; ds.

Unidentified.

WO200281628-A2.

17-OCT-2002.

03-APR-2002; 2002WO-US010512.

05-APR-2001; 2001US-00827395.

29-MAY-2001; 2001US-0294412P.

28-AUG-2001; 2001US-0315315P.

(RIBO-) RIBOZYME PHARM INC.

Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K; WPI; 2003-058513/05.

Novel enzymatic nucleic acid that down-regulates expression of neurite growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or protein kinase PKR genes, for treating cancer and inflammatory disease.

Claim 59; SEQ ID NO 1372; 317pp; English.

The invention comprises nucleic acids (e.g. antisense oligonucleotides) that down regulate the expression or inhibit the function of a receptor for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR), IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the invention are useful for treating: cerebrovascular accident, central nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma, lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis, restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The nucleic acids of the invention are also useful for down-regulating the expression of a target gene and as a diagnostic tool to examine genetic drifts and mutations within diseased cells or to detect the presence of a target RNA in a cell. The present RNA sequence represents a human IKK-gamma substrate sequence.

Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 630 AGGCTGCCACTAAGGAA 646
|||||:|||||:|||||
Db 1 AGGCTGCCACTAAGGAA 17

RESULT 85
ADL47841
ID ADL47841 standard; RNA; 17 BP.
XX
AC ADL47841;
XX
DT 20-MAY-2004 (first entry)
XX

Human IKK-gamma substrate sequence #351.

antisense oligonucleotide; neurite growth inhibitor; NOGO; prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK; protein kinase PKR; cerebrovascular accident; central nervous system injury; CNS injury; spinal cord injury; cancer; melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis; restenosis; asthma; Crohn's disease; diabetes; obesity; autoimmune disease; lupus; multiple sclerosis; transplant rejection; graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis; allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma; substrate; ds.

Unidentified.

WO200281628-A2.

17-OCT-2002.

03-APR-2002; 2002WO-US010512.

05-APR-2001; 2001US-00827395.

29-MAY-2001; 2001US-0294412P.

28-AUG-2001; 2001US-0315315P.

(RIBO-) RIBOZYME PHARM INC.

Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K; WPI; 2003-058513/05.

Novel enzymatic nucleic acid that down-regulates expression of neurite growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or protein kinase PKR genes, for treating cancer and inflammatory disease.

Claim 59; SEQ ID NO 1374; 317pp; English.

The invention comprises nucleic acids (e.g. antisense oligonucleotides) that down regulate the expression or inhibit the function of a receptor for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR), IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the invention are useful for treating: cerebrovascular accident, central nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma, lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis, restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The nucleic acids of the invention are also useful for down-regulating the expression of a target gene and as a diagnostic tool to examine genetic drifts and mutations within diseased cells or to detect the presence of a target RNA in a cell. The present RNA sequence represents a human IKK-gamma substrate sequence.

Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 642 AGGAATGCCAGGCTCTG 658
|||||:|||||:|||||
Db 1 AGGAATGCCAGGCTCTG 17

RESULT 86
ADL47859
ID ADL47859 standard; RNA; 17 BP.
XX
AC ADL47859;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #369.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1392; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 741 AGGTGACCACTGCGC 757
 Db 1 AGGUGGACCACTGCGC 17
 RESULT 87
 ID ADL48207
 XX ADL48207 standard; RNA; 17 BP.
 AC
 XX ADL48207;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #717.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1740; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 180 GTGAGATGTCGAGCCC 196
 Db 1 GUGAGAGTCGAGCCC 17
 RESULT 88
 ID ADL48222
 XX ADL48222 standard; RNA; 17 BP.
 AC
 XX ADL48222;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #732.	DE	Human IKK-gamma substrate sequence #742.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
XX		XX	
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
XX		XX	
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
XX		XX	
PS	Claim 59; SEQ ID NO 1755; 317pp; English.	PS	Claim 59; SEQ ID NO 1765; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
XX		XX	
SQ	Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 76.5%; Pred. No. 2.2e+02;		Best Local Similarity 82.4%; Pred. No. 2.2e+02;
	Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;		Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY	263 CTGCACCTGCTTCAGA 279	QY	356 CAGATTCTCGCGGAGCG 372
	:		:
Db	1 CUGCACCUGCCUUCAGA 17	Db	1 CAGAUCUCGCGGAGCG 17
RESULT 89		RESULT 90	
ADL48232		ADL48266	
ID	ADL48232 standard; RNA; 17 BP.	ID	ADL48266 standard; RNA; 17 BP.
XX		XX	
AC	ADL48232;	AC	ADL48266;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #776.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 1799; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 607 GCAGGAGAGCCAGAGTC 623
 DB 1 GCAGGAGAGCCAGAGUC 17
 RESULT 91
 ADL48275
 ID ADL48275 standard; RNA; 17 BP.
 XX
 AC ADL48275;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #785.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 1808; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 1 A; 7 C; 9 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 666 GGGCCCGGGCGGCCAGC 682
 DB 1 GGGCCCGGGCGGCCAGC 17
 RESULT 92
 ADL48280
 ID ADL48280 standard; RNA; 17 BP.
 XX
 AC ADL48280;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE	Human IKK-gamma substrate sequence #790.	DE	Human IKK-gamma substrate sequence #801.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
XX		XX	
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
XX		XX	
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1813; 317pp; English.	PS	Claim 59; SEQ ID NO 1824; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;	SQ	Sequence 17 BP; 5 A; 6 C; 5 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 94.1%; Pred. No. 2.2e+02;		Best Local Similarity 94.1%; Pred. No. 2.2e+02;	
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;		Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;	
QY	683 GAGCAGCGCGGCGAGCT 699	QY	722 CAGCAGCAGCAGCGCT 738
DB	1 GAGCAGCGCGGCGAGCU 17	DB	1 CAGCAGCAGCAGCGCU 17
RESULT 93		RESULT 94	
ADL48291		ADL48312	
ID ADL48291 standard; RNA; 17 BP.		ID ADL48312 standard; RNA; 17 BP.	
XX		XX	
AC ADL48291;		AC ADL48312;	
XX		XX	
DT 20-MAY-2004 (first entry)		DT 20-MAY-2004 (first entry)	
XX		XX	

DE Human IKK-gamma substrate sequence #822.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1845; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 822 GGAAGCTGCCCGGTTG 838
 DB 1 GGAAGCTGCCCGGTTG 17
 RESULT 95
 ADL48482
 ID ADL48482 standard; RNA; 17 BP.
 XX
 AC ADL48482;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #992.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1015; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 351 GCAACGAGATTCTCGG 367
 DB 1 GCAACGAGATTCTCGG 17
 RESULT 96
 ADL48559
 ID ADL48559 standard; RNA; 17 BP.
 XX
 AC ADL48559;
 XX
 DT 20-MAY-2004 (first entry)
 XX


```

DE XX Human IKK-gamma substrate sequence #1088.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2111; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 276 CAGAACAGGCGGCTCTT 292
Db 1 CAGAACAGGCGGCUCCU 17

RESULT 99
ADL48600
ID ADL48600 standard; RNA; 17 BP.
XX
AC ADL48600;
XX
DT 20-MAY-2004 (first entry)
XX

DE XX Human IKK-gamma substrate sequence #1110.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2133; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 7 A; 2 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 401 AGCCAGAGGAGGAGAA 417
Db 1 AGCCAGAGGAGGAGAA 17

RESULT 100
ADL48606
ID ADL48606 standard; RNA; 17 BP.
XX
AC ADL48606;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE	Human IKK-gamma substrate sequence #1116.	DE	Human IKK-gamma substrate sequence #1127.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
XX	Unidentified.	XX	Unidentified.
OS		OS	
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
XX		XX	
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
XX		XX	
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
XX	(RIBO-) RIBOZYME PHARM INC.	XX	(RIBO-) RIBOZYME PHARM INC.
PA		PA	
XX		XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
XX	WPI; 2003-058513/05.	XX	WPI; 2003-058513/05.
DR		DR	
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 2139; 317pp; English.	PS	Claim 59; SEQ ID NO 2150; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;	SQ	Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 82.4%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	411 AGGAGAAGGAGTTCCTC 427	QY	462 AGAGACTCGCGCTGGAG 478
	: :		: :
DB	1 AGGAGAAGGAGUUCUC 17	DB	1 AGAGACUCGCGCCUGGAG 17
RESULT 101		RESULT 102	
ADL48617		ADL48628	
ID	ADL48617 standard; RNA; 17 BP.	ID	ADL48628 standard; RNA; 17 BP.
XX		XX	
AC	ADL48617;	AC	ADL48628;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #1138.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 PR 29-MAY-2001; 2001US-0294412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2161; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 500 AAGGAGCAGGCTCTGCG 516
 Db 1 AAGGAGCAGGCTCTGCG 17
 RESULT 103
 ADL48630
 ID ADL48630 standard; RNA; 17 BP.
 XX
 AC ADL48630;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1140.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 PR 29-MAY-2001; 2001US-0294412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2163; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 509 GCTCTGCGGAGGTGGA 525
 Db 1 GCUCUGCGGAGGUGGA 17
 RESULT 104
 ADL48632
 ID ADL48632 standard; RNA; 17 BP.
 XX
 AC ADL48632;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1167.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 XX
 PR 29-MAY-2001; 2001US-0294412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2190; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 623 CGCTTGAGGCTGCCAC 639
 DB 1 CGCTUGGAGGCGGCCAC 17
 RESULT 107
 ADL48700
 ID ADL48700 standard; RNA; 17 BP.
 XX
 AC ADL48700;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1210.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 XX
 PR 29-MAY-2001; 2001US-0294412P.
 PR
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2233; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 833 CAGTTGCGAGGTGGCCTA 849
 DB 1 CAGUUGCAGGUGGCCUA 17
 RESULT 108
 ADL47525
 ID ADL47525 standard; RNA; 17 BP.
 XX
 AC ADL47525;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE	Human IKK-gamma substrate sequence #44.	DE	Human IKK-gamma substrate sequence #50.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1067; 317pp; English.	PS	Claim 59; SEQ ID NO 1073; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 4 A; 4 C; 4 G; 0 T; 5 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 70.6%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	419 GAGTTCCTCATGTGCA 435	QY	504 AGCAGGCTCTCGGAG 520
DB	1 GAGUUCUCAUGGCA 17	DB	1 AGCAGGCTCTCGGAG 17
	:		:
RESULT 111		RESULT 112	
ADL47540		ADL47543	
ID	ADL47540 standard; RNA; 17 BP.	ID	ADL47543 standard; RNA; 17 BP.
XX		XX	
AC	ADL47540;	AC	ADL47543;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

```

DE Human IKK-gamma substrate sequence #53.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX OS Unidentified.
XX PN W0200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1076; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
    Query Match 2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 76.5%; Pred. No. 2.2e+02;
    Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 586 GACGTCCTTGCTCGGG 602
Db 1 GACGUCCUUGCUCGGG 17
    |||:|:|:|:|:|
    1 GACGUCCUUGCUCGGG 17

RESULT 113
ADL47553
ID ADL47553 standard; RNA; 17 BP.
XX
XX AC ADL47553;
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #63.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX OS Unidentified.
XX PN W0200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1086; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 6 C; 5 G; 0 T; 3 U; 0 Other;
    Query Match 2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 2.2e+02;
    Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 841 GGTCGCTATCACCAGC 857
Db 1 GGUGCCUACUACCAGC 17
    |||:|:|:|:|
    1 GGUGCCUACUACCAGC 17

RESULT 114
ADL47737
ID ADL47737 standard; RNA; 17 BP.
XX
XX AC ADL47737;
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #247.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1270; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 169 GAGCCAACTGTGTGAGA 185
 Db 1 GAGCCAACTGTGTGAGA 17
 RESULT 115
 ADL47758
 ID ADL47758 standard; RNA; 17 BP.
 XX
 AC ADL47758;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #268.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1291; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 261 TGCTGCACCTGCCTTCA 277
 Db 1 UGCUGCACCUGCCUCCA 17
 RESULT 116
 ADL47774
 ID ADL47774 standard; RNA; 17 BP.
 XX
 AC ADL47774;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```
DE Human IKK-gamma substrate sequence #284.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1307; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 304 GCGCTGCTGGAGGAGA 320
Db 1 GCGCTGCTGGAGGAGA 17
|||||:|||||:|||||
1 GCGCTGCTGGAGGAGA 17
RESULT 117
ADL47777
ID ADL47777 standard; RNA; 17 BP.
XX
XX AC ADL47777;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #287.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 23-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1310; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 5 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 324 AAGAGCTCCGAGATGCC 340
Db 1 AAGAGCTCCGAGATGCC 17
|||||:|||||:|||||
1 AAGAGCTCCGAGATGCC 17
RESULT 118
ADL47783
ID ADL47783 standard; RNA; 17 BP.
XX
XX AC ADL47783;
XX
XX DT 20-MAY-2004 (first entry)
XX
```



```

DE  Human IKK-gamma substrate sequence #293.
XX  antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW  prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW  protein kinase PKR; cerebrovascular accident;
KW  central nervous system injury; CNS injury; spinal cord injury; cancer;
KW  melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW  restenosis; asthma; Crohn's disease; diabetes; obesity;
KW  autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW  graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW  allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW  substrate; ds.
XX
OS  Unidentified.
XX
PN  WO200281628-A2.
XX
PD  17-OCT-2002.
XX
PF  03-APR-2002; 2002WO-US010512.
XX
PR  05-APR-2001; 2001US-00827395.
PR  29-MAY-2001; 2001US-0294412P.
PR  28-AUG-2001; 2001US-0315315P.
XX
PA  (RIBO-) RIBOZYME PHARM INC.
XX
PI  Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX  WPI; 2003-058513/05.
DR
XX
PT  Novel enzymatic nucleic acid that down-regulates expression of neurite
PT  growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT  protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS  Claim 59; SEQ ID NO 1316; 317pp; English.
XX
CC  The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC  that down regulate the expression or inhibit the function of a receptor
CC  for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC  IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC  invention are useful for treating: cerebrovascular accident, central
CC  nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC  lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC  restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC  disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC  ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC  conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC  nucleic acids of the invention are also useful for down-regulating the
CC  expression of a target gene and as a diagnostic tool to examine genetic
CC  drifts and mutations within diseased cells or to detect the presence of a
CC  target RNA in a cell. The present RNA sequence represents a human IKK-
CC  gamma substrate sequence.
XX
SQ  Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY  348 AGAGCAACCAAGATTCG 364
DB  1 AGAGCAACCAAGAUUCUG 17
      |||||
RESULT 119
ADL47792
ID  ADL47792 standard; RNA; 17 BP.
XX
AC  ADL47792;
XX
DT  20-MAY-2004 (first entry)
XX

DE  Human IKK-gamma substrate sequence #302.
XX  antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW  prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW  protein kinase PKR; cerebrovascular accident;
KW  central nervous system injury; CNS injury; spinal cord injury; cancer;
KW  melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW  restenosis; asthma; Crohn's disease; diabetes; obesity;
KW  autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW  graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW  allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW  substrate; ds.
XX
OS  Unidentified.
XX
PN  WO200281628-A2.
XX
PD  17-OCT-2002.
XX
PF  03-APR-2002; 2002WO-US010512.
XX
PR  05-APR-2001; 2001US-00827395.
PR  29-MAY-2001; 2001US-0294412P.
PR  28-AUG-2001; 2001US-0315315P.
XX
PA  (RIBO-) RIBOZYME PHARM INC.
XX
PI  Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX  WPI; 2003-058513/05.
DR
XX
PT  Novel enzymatic nucleic acid that down-regulates expression of neurite
PT  growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT  protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS  Claim 59; SEQ ID NO 1325; 317pp; English.
XX
CC  The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC  that down regulate the expression or inhibit the function of a receptor
CC  for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC  IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC  invention are useful for treating: cerebrovascular accident, central
CC  nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC  lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC  restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC  disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC  ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC  conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC  nucleic acids of the invention are also useful for down-regulating the
CC  expression of a target gene and as a diagnostic tool to examine genetic
CC  drifts and mutations within diseased cells or to detect the presence of a
CC  target RNA in a cell. The present RNA sequence represents a human IKK-
CC  gamma substrate sequence.
XX
SQ  Sequence 17 BP; 5 A; 6 C; 4 G; 0 T; 2 U; 0 Other;

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY  392 TTCCAAGCCAGCCAGAG 408
DB  1 UUCCAAGCCAGCCAGAG 17
      ::|||
RESULT 120
ADL47819
ID  ADL47819 standard; RNA; 17 BP.
XX
AC  ADL47819;
XX
DT  20-MAY-2004 (first entry)
XX

```

```
DE Human IKK-gamma substrate sequence #329.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1352; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 538 ATGCCAGCAGCAGATGG 554
Db 1 AUGCCAGCAGCAGGAUGG 17
:|||||
RESULT 121
ADL47831
ID ADL47831 standard; RNA; 17 BP.
XX
XX AC ADL47831;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

```
DE Human IKK-gamma substrate sequence #341.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1364; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 589 GTCCTTGTCTCGGGAGC 605
Db 1 GUCCUUGUCUGGGAGC 17
:|||||
RESULT 122
ADL47834
ID ADL47834 standard; RNA; 17 BP.
XX
XX AC ADL47834;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

DE	Human IKK-gamma substrate sequence #344.	DE	Human IKK-gamma substrate sequence #357.																																
XX		XX																																	
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;																																
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;																																
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;																																
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;																																
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;																																
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;																																
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;																																
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;																																
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;																																
KW	substrate; ds.	KW	substrate; ds.																																
XX		XX																																	
OS	Unidentified.	OS	Unidentified.																																
XX		XX																																	
PN	WO200281628-A2.	PN	WO200281628-A2.																																
XX		XX																																	
PD	17-OCT-2002.	PD	17-OCT-2002.																																
XX		XX																																	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.																																
XX		XX																																	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.																																
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.																																
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.																																
XX		XX																																	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.																																
XX		XX																																	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;																																
XX		XX																																	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.																																
XX		XX																																	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite																																
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or																																
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.																																
XX		XX																																	
PS	Claim 59; SEQ ID NO 1367; 317pp; English.	PS	Claim 59; SEQ ID NO 1380; 317pp; English.																																
XX		XX																																	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)																																
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor																																
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),																																
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the																																
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central																																
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,																																
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,																																
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune																																
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,																																
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic																																
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The																																
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the																																
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic																																
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a																																
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-																																
CC	gamma substrate sequence.	CC	gamma substrate sequence.																																
XX		XX																																	
SQ	Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 6 C; 8 G; 0 T; 0 U; 0 Other;																																
<table><tr><td>Query Match</td><td>2.3%;</td><td>Score 17;</td><td>DB 1;</td><td>Length 17;</td></tr><tr><td>Best Local Similarity</td><td>94.1%;</td><td>Pred. No. 2.2e+02;</td><td></td><td></td></tr><tr><td>Matches</td><td>16;</td><td>Conservative</td><td>1;</td><td>Mismatches 0; Indels 0; Gaps 0;</td></tr></table>				Query Match	2.3%;	Score 17;	DB 1;	Length 17;	Best Local Similarity	94.1%;	Pred. No. 2.2e+02;			Matches	16;	Conservative	1;	Mismatches 0; Indels 0; Gaps 0;																	
Query Match	2.3%;	Score 17;	DB 1;	Length 17;																															
Best Local Similarity	94.1%;	Pred. No. 2.2e+02;																																	
Matches	16;	Conservative	1;	Mismatches 0; Indels 0; Gaps 0;																															
QY	609 AGGAGAGCCAGAGTCGC 625	QY	671 CGGGCGGCAGCGAGCA 687																																
DB	1 AGGAGAGCCAGAGTCGC 17	DB	1 CGGGCGGCAGCGAGCA 17																																
<table><tr><td>RESULT 123</td><td></td><td>RESULT 124</td><td></td></tr><tr><td>ADL47847</td><td></td><td>ADL47857</td><td></td></tr><tr><td>ID ADL47847 standard; RNA; 17 BP.</td><td></td><td>ID ADL47857 standard; RNA; 17 BP.</td><td></td></tr><tr><td>XX</td><td></td><td>XX</td><td></td></tr><tr><td>AC ADL47847;</td><td></td><td>AC ADL47857;</td><td></td></tr><tr><td>XX</td><td></td><td>XX</td><td></td></tr><tr><td>DT 20-MAY-2004 (first entry)</td><td></td><td>DT 20-MAY-2004 (first entry)</td><td></td></tr><tr><td>XX</td><td></td><td>XX</td><td></td></tr></table>				RESULT 123		RESULT 124		ADL47847		ADL47857		ID ADL47847 standard; RNA; 17 BP.		ID ADL47857 standard; RNA; 17 BP.		XX		XX		AC ADL47847;		AC ADL47857;		XX		XX		DT 20-MAY-2004 (first entry)		DT 20-MAY-2004 (first entry)		XX		XX	
RESULT 123		RESULT 124																																	
ADL47847		ADL47857																																	
ID ADL47847 standard; RNA; 17 BP.		ID ADL47857 standard; RNA; 17 BP.																																	
XX		XX																																	
AC ADL47847;		AC ADL47857;																																	
XX		XX																																	
DT 20-MAY-2004 (first entry)		DT 20-MAY-2004 (first entry)																																	
XX		XX																																	

DE Human IKK-gamma substrate sequence #367.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX W0200281628-A2.
PN
XX 17-OCT-2002.
PD
XX 03-APR-2002; 2002WO-US010512.
PF
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1390; 317pp; English.
PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 5 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 726 AGCAGCACAGCGTCAG 742
Db 1 AGCAGCACAGCGTCAG 17
RESULT 125
ADL47864
ID ADL47864 standard; RNA; 17 BP.
XX
XX AC ADL47864;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #374.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX W0200281628-A2.
PN
XX 17-OCT-2002.
PD
XX 03-APR-2002; 2002WO-US010512.
PF
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1397; 317pp; English.
PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 759 TGCAGGGCCAGCGTG 775
Db 1 UGCAGGGCCAGCGUG 17
RESULT 126
ADL47876
ID ADL47876 standard; RNA; 17 BP.
XX
XX AC ADL47876;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #386.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1409; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection.
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 824 AAGCTGGCCCGAGTGGCA 840
 DB 1 AAGCTGGCCCGAGTGGCA 17
 RESULT 127
 ADL47878
 ID ADL47878 standard; RNA; 17 BP.
 XX
 AC ADL47878;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #388.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1411; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection.
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 826 GCTGCCCGAGTGGCAG 842
 DB 1 GCTGCCCGAGTGGCAG 17
 RESULT 128
 ADL47886
 ID ADL47886 standard; RNA; 17 BP.
 XX
 AC ADL47886;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #396.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1419; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 6 C; 2 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 852 ACCAGCTCTCCCAAGAA 868
 Db 1 ACCAGCUCUCCCAAGAA 17
 |||||:|||||
 |||||:|||||
 RESULT 129
 ADL48208
 ID ADL48208 standard; RNA; 17 BP.
 XX
 AC ADL48208;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #718.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1741; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 182 GAGATGGTGCAGCCGAG 198
 Db 1 GAGAGUGGUGCAGCCGAG 17
 |||||:|||||
 |||||:|||||
 RESULT 130
 ADL48210
 ID ADL48210 standard; RNA; 17 BP.
 XX
 AC ADL48210;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #720.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1743; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 190 GCAGCCAGTGGTGGCC 206
 DB 1 GCAGCCAGTGGTGGCC 17
 RESULT 131
 ID ADL48212
 XX ADL48212 standard; RNA; 17 BP.
 AC ADL48212;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #722.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1745; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 196 CAGTGGTGGCCGGCAG 212
 DB 1 CAGTGGTGGCCGGCAG 17
 RESULT 132
 ID ADL48213
 XX ADL48213 standard; RNA; 17 BP.
 AC ADL48213;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #784.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1807; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 660 AGGGTCGGGCCCGGGCG 676
 DB 1 AGGGTCGGGCCCGGGCG 17
 RESULT 135
 ADL48298
 ID ADL48298 standard; RNA; 17 BP.
 XX
 AC ADL48298;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #808.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1831; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 748 CCAGTCGGCGATGCAGG 764
 DB 1 CCAGTCGGCGATGCAGG 17
 RESULT 136
 ADL48301
 ID ADL48301 standard; RNA; 17 BP.
 XX
 AC ADL48301;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE	Human IKK-gamma substrate sequence #811.	DE	Human IKK-gamma substrate sequence #983.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1834; 317pp; English.	PS	Claim 59; SEQ ID NO 2006; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 3 A; 3 C; 10 G; 0 T; 1 U; 0 Other;	SQ	Sequence 17 BP; 6 A; 3 C; 5 G; 0 T; 3 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 94.1%; Pred. No. 2.2e+02;		Best Local Similarity 82.4%; Pred. No. 2.2e+02;
	Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;		Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY	763 GGGCCAGAGCGTGAGG 779	QY	167 AGAGCCCAACTGTGTGA 183
Db	1 GGGCCAGAGCGTGAGG 17	Db	1 AAGAGCCCAACUGUGUGA 17
RESULT 137		RESULT 138	
ADL48473		ADL48480	
ID	ADL48473 standard; RNA; 17 BP.	ID	ADL48480 standard; RNA; 17 BP.
XX		XX	
AC	ADL48473;	AC	ADL48480;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #990.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2013; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 7 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 328 GCTCCGAGATGCCATCC 344
 DB 1 GCUCGAGAUCCCAUCC 17
 RESULT 139
 ADL48562
 ID ADL48562 standard; RNA; 17 BP.
 XX
 AC ADL48562;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1072.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2095; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 192 AGCCCGAGTGGTGGCCG 208
 DB 1 AGCCCGAGUGGUGGCCG 17
 RESULT 140
 ADL48580
 ID ADL48580 standard; RNA; 17 BP.
 XX
 AC ADL48580;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE Human IKK-gamma substrate sequence #1090.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 2113; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX
XX Sequence 17 BP; 3 A; 8 C; 3 G; 0 T; 3 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 287 GCTCTGAGACCTCCCA 303
DB 1 GCUCUGAGACCCUCCA 17
RESULT 141
ADL48594
ID ADL48594 standard; RNA; 17 BP.
XX
XX ADL48594;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #1104.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 2127; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX
XX Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 360 TTCTGCGGAGCGCTGC 376
DB 1 UUCUGCGGAGCGCUGC 17
RESULT 142
ADL48598
ID ADL48598 standard; RNA; 17 BP.
XX
XX ADL48598;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE Human IKK-gamma substrate sequence #1108.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 PD 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT Claim 59; SEQ ID NO 2131; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 5 A; 4 C; 8 G; 0 T; 0 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 398 GCCAGCCAGGAGGAGGA 414
 Db 1 GCCAGCCAGGAGGAGGA 17
 RESULT 143
 ADL48656
 ID ADL48656 standard; RNA; 17 BP.
 XX AC ADL48656;
 XX 20-MAY-2004 (first entry)
 DT XX

DE Human IKK-gamma substrate sequence #1166.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 PD 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT Claim 59; SEQ ID NO 2189; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 621 GTCGCTTGAGGCTGCC 637
 Db 1 GUCGCTUGGAGGCGGCC 17
 RESULT 144
 ADL48685
 ID ADL48685 standard; RNA; 17 BP.
 XX AC ADL48685;
 XX 20-MAY-2004 (first entry)
 DT XX

DE Human IKK-gamma substrate sequence #1195.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 23-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 2218; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 767 CAGAGCGTGAGGCGCG 783
 Db 1 CAGAGCGTGAGGCGCG 17
 |||:|||||
 |||:|||||
 RESULT 145
 ADL47519
 ID ADL47519 standard; RNA; 17 BP.
 XX
 XX AC ADL47519;
 XX
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #29.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 23-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1052; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 4 A; 6 C; 4 G; 0 T; 3 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 268 CCTGCCTTCAGAACAGG 284
 Db 1 CCUGCCUUCAGAACAGG 17
 |||:|||||
 |||:|||||
 RESULT 146
 ADL47797
 ID ADL47797 standard; RNA; 17 BP.
 XX
 XX AC ADL47797;
 XX
 XX DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #307.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.
XX	Unidentified.
OS	XX
PN	WO200281628-A2.
XX	XX
PD	17-OCT-2002.
XX	XX
Pf	03-APR-2002; 2002WO-US010512.
XX	XX
PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
XX	XX
PA	(RIBO-) RIBOZYME PHARM INC.
XX	XX
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI	WPI; 2003-058513/05.
DR	XX
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
PS	Claim 59; SEQ ID NO 1330; 317pp; English.
XX	XX
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
XX	XX
SQ	Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 70.6%; Pred. No. 2.2e+02;
	Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
OY	418 GGAGTTCCTCATGTGCA 434 :: :
Db	1 CGAGUUCUCAUGUCA 17
RESULT 147	
ADL47804	
ID	ADL47804 standard; RNA; 17 BP.
XX	XX
AC	ADL47804;
XX	XX
DT	20-MAY-2004 (first entry)
XX	XX

DE	Human IKK-gamma substrate sequence #314.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.
XX	Unidentified.
OS	XX
PN	WO200281628-A2.
XX	XX
PD	17-OCT-2002.
XX	XX
Pf	03-APR-2002; 2002WO-US010512.
XX	XX
PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
XX	XX
PA	(RIBO-) RIBOZYME PHARM INC.
XX	XX
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI	WPI; 2003-058513/05.
DR	XX
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
PS	Claim 59; SEQ ID NO 1337; 317pp; English.
XX	XX
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
XX	XX
SQ	Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY	448 CAGGAACCTGGTGAGA 464 :: :
Db	1 CAGGAACCTGGTGAGA 17
RESULT 148	
ADL47806	
ID	ADL47806 standard; RNA; 17 BP.
XX	XX
AC	ADL47806;
XX	XX
DT	20-MAY-2004 (first entry)
XX	XX

DE Human IKK-gamma substrate sequence #316.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 1339; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 465 GACTCGGCCTGGAGAAG 481
 Db 1 GACUCGGCCUGGAGAAG 17
 |||:|||||:|||||:
 1 GACUCGGCCUGGAGAAG 17
 RESULT 149
 ADL47816
 ID ADL47816 standard; RNA; 17 BP.
 XX
 XX AC ADL47816;
 XX
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #326.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 XX
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 1349; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 523 GGAGCACCCTGAAGAGAT 539
 Db 1 GGAGCACCCTGAAGAGAU 17
 |||:|||||:|||||:
 1 GGAGCACCCTGAAGAGAU 17
 RESULT 150
 ADL47837
 ID ADL47837 standard; RNA; 17 BP.
 XX
 XX AC ADL47837;
 XX
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #347.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1370; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 626 TTGGAGGCTGCCACTAA 642
 DB 1 UUGGAGGCGGCCACUAA 17
 RESULT 151
 ADL47883
 ID ADL47883 standard; RNA; 17 BP.
 XX
 AC ADL47883;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #393.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1416; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 8 C; 1 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 846 CCTATCACGCTCTTC 862
 DB 1 CCUAUCACGCTCTTC 17
 RESULT 152
 ADL48214
 ID ADL48214 standard; RNA; 17 BP.
 XX
 AC ADL48214;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #755.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 PD 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT Claim 59; SEQ ID NO 1778; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Query Match 2.3%; Score 17; DB 1; Length 17;
 XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 450 GGAAACTGTGGAGAGA 466
 Db 1 GGAAACUGGGGAGAGA 17
 RESULT 155
 ADL48255
 ID ADL48255 standard; RNA; 17 BP.
 XX AC ADL48255;
 XX AC ADL48255;
 XX 20-MAY-2004 (first entry)
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #765.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 PD 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT Claim 59; SEQ ID NO 1788; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Query Match 2.3%; Score 17; DB 1; Length 17;
 XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 536 AGATCCGACGACGAT 552
 Db 1 AGAUGCCAGCAGCAU 17
 RESULT 156
 ADL48263
 ID ADL48263 standard; RNA; 17 BP.
 XX AC ADL48263;
 XX AC ADL48263;
 XX 20-MAY-2004 (first entry)
 DT 20-MAY-2004 (first entry)
 XX


```

DE XX Human IKK-gamma substrate sequence #809.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1832; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 6 G; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 752 CTCGCATCGAGGCCA 768
DB 1 CUGCGCAUGCAGGCCA 17
|||||
|:|||||:|

RESULT 159
ADL48302
ID ADL48302 standard; RNA; 17 BP.
XX
AC ADL48302;
XX
AC ADL48302;
XX
DT 20-MAY-2004 (first entry)
XX

DE XX Human IKK-gamma substrate sequence #812.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1835; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 765 GCCAGAGCGTGAGGCC 781
DB 1 GCCAGAGCGUGGAGGCC 17
|||||
|:|||||:|

RESULT 160
ADL48321
ID ADL48321 standard; RNA; 17 BP.
XX
AC ADL48321;
XX
AC ADL48321;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #831.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 XX WO200281628-A2.
 PN
 XX
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 1854; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 888 GCAGCGTGGTGGCAGT 904
 DB 1 GCAGCGUGGUGGCGAGU 17
 |||||:|||||:
 1 GCAGCGUGGUGGCGAGU 17
 RESULT 161
 ADL48479
 ID ADL48479 standard; RNA; 17 BP.
 XX
 AC ADL48479;
 XX
 DT 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #989.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 XX WO200281628-A2.
 PN
 XX
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 XX Claim 59; SEQ ID NO 1012; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 7 A; 2 C; 7 G; 0 T; 1 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 313 GCAGGAGATCAAGAGC 329
 DB 1 GCAGGAGAGCAAGAGC 17
 |||||:|||||:
 1 GCAGGAGAGCAAGAGC 17
 RESULT 162
 ADL48574
 ID ADL48574 standard; RNA; 17 BP.
 XX
 AC ADL48574;
 XX
 DT 20-MAY-2004 (first entry)
 DT
 XX

```

DE Human IKK-gamma substrate sequence #1084.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2107; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 241 TCCTCTGGGAGCCAG 257
DB 1 UCCUCUGGGAGCCAG 17
:|||||
:|||||

RESULT 163
ADL48576
ID ADL48576 standard; RNA; 17 BP.
XX
AC ADL48576;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1086.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2109; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 270 TGCCTTCAGACAGGC 286
DB 1 UGCCUUCAGACAGGC 17
:|||||
:|||||

RESULT 164
ADL48581
ID ADL48581 standard; RNA; 17 BP.
XX
AC ADL48581;
XX
DT 20-MAY-2004 (first entry)
XX

```



```

DE Human IKK-gamma substrate sequence #1157.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
PR 29-MAY-2001; 2001US-0294412P.
PR
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2180; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 591 CCTTGCTCGGGAGCTG 607
DB 1 CCUUGCUCGGGAGCTG 17
:::|||||:|

RESULT 167
ADL48649
ID ADL48649 standard; RNA; 17 BP.
XX
XX AC ADL48649;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #1159.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
PR 29-MAY-2001; 2001US-0294412P.
PR
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2182; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 4 C; 7 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 593 TTGCTCGGGAGCTGCA 609
DB 1 UUGCUCGGGAGCTGCA 17
:::|||||:|

RESULT 168
ADL48655
ID ADL48655 standard; RNA; 17 BP.
XX
XX AC ADL48655;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE	Human IKK-gamma substrate sequence #1165.	DE	Human IKK-gamma substrate sequence #39.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 2188; 317pp; English.	PS	Claim 59; SEQ ID NO 1062; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 2 A; 4 C; 7 G; 0 T; 4 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 6 C; 2 G; 0 T; 6 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 76.5%; Pred. No. 2.2e+02;		Best Local Similarity 64.7%; Pred. No. 2.2e+02;
	Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;		Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY	620 AGTCGCTGGAGGCTGC 636	QY	384 TTCTGCGATTCCCAAGCC 400
	:		: : : : : :
Db	1 AGUCGCUVGAGGCGUC 17	Db	1 UUCUGCAUUUCCAGCC 17
RESULT 169		RESULT 170	
ADL47529		ADL47538	
ID	ADL47529 standard; RNA; 17 BP.	ID	ADL47538 standard; RNA; 17 BP.
XX		XX	
AC	ADL47529;	AC	ADL47538;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #48.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 PS Claim 59; SEQ ID NO 1071; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred.No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 476 GAGAGCTCGATCTGAA 492
 Db 1 GAGAGCTCGATCTGAA 17
 |||||:||||:||||
 RESULT 171
 ADL47745
 ID ADL47745 standard; RNA; 17 BP.
 XX
 AC ADL47745;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #255.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX
 PS Claim 59; SEQ ID NO 1278; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 5 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred.No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 206 CCGGCAGCAGATCAGGA 222
 Db 1 CCGGCAGCAGATCAGGA 17
 |||||:||||:||||
 RESULT 172
 ADL47755
 ID ADL47755 standard; RNA; 17 BP.
 XX
 AC ADL47755;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #265.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1288; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 252 AGCCAGCCATGCTGCAC 268
 Db 1 AGCCAGCCATGCTGCAC 17
 RESULT 173
 ADL47769
 ID ADL47769 standard; RNA; 17 BP.
 XX
 AC ADL47769;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #279.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1302; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 7 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 292 TGAGACCTTCAGCGCT 308
 Db 1 UGAGACCTTCAGCGCT 17
 RESULT 174
 ADL47828
 ID ADL47828 standard; RNA; 17 BP.
 XX
 AC ADL47828;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE XX Human IKK-gamma substrate sequence #338.
KW antisease oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowwira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1361; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 574 GAAAGCCAGGTGACGT 590
DB 1 GAAAGCCAGGTGACGU 17

RESULT 175
ADL47843
ID ADL47843 standard; RNA; 17 BP.
XX
AC ADL47843;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE XX Human IKK-gamma substrate sequence #353.
KW antisease oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowwira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1376; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 647 TGCCAGGCTCTGGAGGG 663
DB 1 UGCCAGGCUCUGAGGG 17

RESULT 176
ADL47881
ID ADL47881 standard; RNA; 17 BP.
XX
AC ADL47881;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #391.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1414; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 840 AGGTGGCCTATCACCAG 856
DB 1 AGGUGGCCUACUACCAG 17
|||||:|||||
1 AGGUGGCCUACUACCAG 17

RESULT 177
ADL47889
ID ADL47889 standard; RNA; 17 BP.
XX
XX ADL47889;
XX
XX 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #399.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1422; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 8 A; 6 C; 1 G; 0 T; 2 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 867 AATACGACACCAATC 883
DB 1 AAUACGACCAACCAUC 17
|||||:|||||
1 AAUACGACCAACCAUC 17

RESULT 178
ADL47890
ID ADL47890 standard; RNA; 17 BP.
XX
XX ADL47890;
XX
XX 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #400.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1423; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 8 A; 6 C; 2 G; 0 T; 1 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 870 AGCACAACCAATCAAG 886
DB 1 AGCACAACCAUCAAG 17
|||||:|||||:|||||:
1 AGCACAACCAUCAAG 17

RESULT 179
ADL48205
ID ADL48205 standard; RNA; 17 BP.
XX
XX AC ADL48205;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #715.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1738; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 3 C; 5 G; 0 T; 4 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 170 AGCCAACTGTGTGAGAT 186
DB 1 AGCCAACTGTGTGAGAU 17
|||||:|||||:|||||:
1 AGCCAACTGTGTGAGAU 17

RESULT 180
ADL48215
ID ADL48215 standard; RNA; 17 BP.
XX
XX AC ADL48215;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE XX Human IKK-gamma substrate sequence #725.
KW XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW KW protein kinase PKR; cerebrovascular accident;
KW KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW KW substrate; ds.
XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 1748; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 216 ATCAGGACGTACTGGGC 232
Db 1 AUCAGGACGACUGGCG 17
RESULT 181
ADL48216
ID ADL48216 standard; RNA; 17 BP.
XX AC ADL48216;
XX DT 20-MAY-2004 (first entry)
XX
DE XX Human IKK-gamma substrate sequence #726.
KW XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW KW protein kinase PKR; cerebrovascular accident;
KW KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW KW substrate; ds.
XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 1749; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX SQ Sequence 17 BP; 4 A; 3 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 223 CGTACTGGGCGAAGAGT 239
Db 1 CGUACUGGCGAGAGU 17
RESULT 182
ADL48227
ID ADL48227 standard; RNA; 17 BP.
XX AC ADL48227;
XX DT 20-MAY-2004 (first entry)
XX

```



```

DE  Human IKK-gamma substrate sequence #737.
XX  antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW  prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW  protein kinase PKR; cerebrovascular accident;
KW  central nervous system injury; CNS injury; spinal cord injury; cancer;
KW  melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW  restenosis; asthma; Crohn's disease; diabetes; obesity;
KW  autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW  graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW  allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX  substrate; ds.
XX  Unidentified.
OS
XX
XX  WO200281628-A2.
PN
XX
XX  17-OCT-2002.
PD
XX
XX  03-APR-2002; 2002WO-US010512.
PF
XX
XX  05-APR-2001; 2001US-00827395.
PR
XX  29-MAY-2001; 2001US-0294412P.
PR
XX  28-AUG-2001; 2001US-0315315P.
XX
XX  (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX  Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI  WPI; 2003-058513/05.
XX
XX  Novel enzymatic nucleic acid that down-regulates expression of neurite
PT  growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT  protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX  Claim 59; SEQ ID NO 1760; 317pp; English.
XX
XX  The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC  that down regulate the expression or inhibit the function of a receptor
CC  for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC  IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC  invention are useful for treating: cerebrovascular accident, central
CC  nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC  lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC  restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC  disease, lupus, multiple sclerosis, transplant/graft rejection,
CC  ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC  conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC  nucleic acids of the invention are also useful for down-regulating the
CC  expression of a target gene and as a diagnostic tool to examine genetic
CC  drifts and mutations within diseased cells or to detect the presence of a
CC  target RNA in a cell. The present RNA sequence represents a human IKK-
CC  gamma substrate sequence.
XX
SQ  Sequence 17 BP; 2 A; 6 C; 7 G; 0 T; 2 U; 0 Other;
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 88.2%; Pred. No. 2.2e+02;
    Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY  301 CCAGCGCTCCCTGGAGG 317
DB  1 CCAGCGCTCCCTGGAGG 17
    |||||:|||||
    |||||:|||||

RESULT 183
ADL48238
ID  ADL48238 standard; RNA; 17 BP.
XX
XX  ADL48238;
AC
XX
XX  20-MAY-2004 (first entry)
DT
XX

```

```

DE  Human IKK-gamma substrate sequence #748.
XX  antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW  prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW  protein kinase PKR; cerebrovascular accident;
KW  central nervous system injury; CNS injury; spinal cord injury; cancer;
KW  melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW  restenosis; asthma; Crohn's disease; diabetes; obesity;
KW  autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW  graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW  allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX  substrate; ds.
XX  Unidentified.
OS
XX
XX  WO200281628-A2.
PN
XX
XX  17-OCT-2002.
PD
XX
XX  03-APR-2002; 2002WO-US010512.
PF
XX
XX  05-APR-2001; 2001US-00827395.
PR
XX  29-MAY-2001; 2001US-0294412P.
PR
XX  28-AUG-2001; 2001US-0315315P.
XX
XX  (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX  Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI  WPI; 2003-058513/05.
XX
XX  Novel enzymatic nucleic acid that down-regulates expression of neurite
PT  growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT  protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX  Claim 59; SEQ ID NO 1771; 317pp; English.
XX
XX  The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC  that down regulate the expression or inhibit the function of a receptor
CC  for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC  IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC  invention are useful for treating: cerebrovascular accident, central
CC  nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC  lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC  restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC  disease, lupus, multiple sclerosis, transplant/graft rejection,
CC  ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC  conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC  nucleic acids of the invention are also useful for down-regulating the
CC  expression of a target gene and as a diagnostic tool to examine genetic
CC  drifts and mutations within diseased cells or to detect the presence of a
CC  target RNA in a cell. The present RNA sequence represents a human IKK-
CC  gamma substrate sequence.
XX
SQ  Sequence 17 BP; 5 A; 6 C; 3 G; 0 T; 3 U; 0 Other;
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 2.2e+02;
    Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY  390 ATTTCACAGCCAGCCAG 406
DB  1 AUUCCAGCCAGCCAG 17
    |||||:|||||
    |||||:|||||

RESULT 184
ADL48273
ID  ADL48273 standard; RNA; 17 BP.
XX
XX  ADL48273;
AC
XX
XX  20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #783.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1806; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 1 A; 5 C; 8 G; 0 T; 3 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
OY 655 TCTGAGGGTCGGGCC 671
D:|||||:|||||
Db 1 UCUGAGGGCGCGGCC 17
RESULT 185
ADL48279
ID ADL48279 standard; RNA; 17 BP.
XX
XX AC ADL48279;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #789.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1812; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 5 C; 9 G; 0 T; 0 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 681 GCGAGCAGCGCGCGCAG 697
D:|||||:|||||
Db 1 GCGAGCAGCGCGCGCAG 17
RESULT 186
ADL48296
ID ADL48296 standard; RNA; 17 BP.
XX
XX AC ADL48296;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #806.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1829; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred.No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 743 GTGACACGACGTGGCAT 759
 Db 1 GUGGACCAGCGGCGCAU 17
 RESULT 187
 ID ADL48309
 ADL48309 standard; RNA; 17 BP.
 XX
 AC ADL48309;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #819.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1842; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 8 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred.No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 795 AGCGCCAGCGCGCTCG 811
 Db 1 AGCGCCAGCGCGCTCG 17
 RESULT 188
 ID ADL48313
 ADL48313 standard; RNA; 17 BP.
 XX
 AC ADL48313;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE	Human IKK-gamma substrate sequence #823.	DE	Human IKK-gamma substrate sequence #997.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
XX		XX	
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
XX		XX	
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1846; 317pp; English.	PS	Claim 59; SEQ ID NO 2020; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;	SQ	Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 76.5%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	827 CTTGCCCCAGTTCAGGT 843	QY	543 AGCAGCAGATGGCTGAG 559
	: :		: :
Db	1 CUGGCCAGUGCAGGU 17	Db	1 AGCAGCAGUGGUGAG 17
RESULT 189		RESULT 190	
ADL48487		ADL48595	
ID	ADL48487 standard; RNA; 17 BP.	ID	ADL48595 standard; RNA; 17 BP.
XX		XX	
AC	ADL48487;	AC	ADL48595;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE	XX	Human IKK-gamma substrate sequence #1105.
DE	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX	XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX	XX	protein kinase PKR; cerebrovascular accident;
XX	XX	central nervous system injury; CNS injury; spinal cord injury; cancer;
XX	XX	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX	XX	restenosis; asthma; Crohn's disease; diabetes; obesity;
XX	XX	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX	XX	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX	XX	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	XX	substrate; ds.
XX	XX	Unidentified.
XX	XX	WO200281628-A2.
XX	XX	17-OCT-2002.
XX	XX	03-APR-2002; 2002WO-US010512.
XX	XX	05-APR-2001; 2001US-00827395.
XX	XX	29-MAY-2001; 2001US-0294412P.
XX	XX	28-AUG-2001; 2001US-0315315P.
XX	XX	(RIBO-) RIBOZYME PHARM INC.
XX	XX	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX	XX	WPI; 2003-058513/05.
XX	XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
XX	XX	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX	XX	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	XX	Claim 59; SEQ ID NO 2128; 317pp; English.
XX	XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX	XX	that down regulate the expression or inhibit the function of a receptor
XX	XX	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX	XX	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX	XX	invention are useful for treating: cerebrovascular accident, central
XX	XX	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX	XX	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX	XX	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX	XX	disease, lupus, multiple sclerosis, transplant/graft rejection,
XX	XX	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX	XX	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX	XX	nucleic acids of the invention are also useful for down-regulating the
XX	XX	expression of a target gene and as a diagnostic tool to examine genetic
XX	XX	drifts and mutations within diseased cells or to detect the presence of a
XX	XX	target RNA in a cell. The present RNA sequence represents a human IKK-
XX	XX	gamma substrate sequence.
XX	XX	Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
XX	XX	Query Match 2.3%; Score 17; DB 1; Length 17;
XX	XX	Best Local Similarity 82.4%; Pred. No. 2.2e+02;
XX	XX	Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX	XX	QY 369 AGCGTTCGAGGAGCTT 385
XX	XX	: :
XX	XX	1 AGCGTTCGAGGAGCTT 17
XX	XX	Db
XX	XX	RESULT 191
XX	XX	ADL48605
XX	XX	ID ADL48605 standard; RNA; 17 BP.
XX	XX	XX
XX	XX	AC ADL48605;
XX	XX	XX
XX	XX	DT 20-MAY-2004 (first entry)
XX	XX	XX

```
DE Human IKK-gamma substrate sequence #1120.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-059513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2143; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
SQ Sequence 17 BP; 5 A; 3 C; 8 G; 0 T; 1 U; 0 Other;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 442 GGAGGCCAGGAACCTGG 458
DB 1 GGAGGCCAGGAACCTGG 17
|||||
|||||

RESULT 193
ADL48626
ID ADL48626 standard; RNA; 17 BP.
XX
XX AC ADL48626;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1136.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-059513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2159; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
SQ Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 494 AGGCAGAGGAGCAGCG 510
DB 1 AGGCAGAGGAGCAGCG 17
|||||
|||||

RESULT 194
ADL48678
ID ADL48678 standard; RNA; 17 BP.
XX
XX AC ADL48678;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #1188.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2211; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 707 GAGCGCGAGCGCTGCA 723
 Db 1 GAGCGCGAGCGCTGCA 17
 RESULT 195
 ADL48689
 ID ADL48689 standard; RNA; 17 BP.
 XX
 AC ADL48689;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1199.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2222; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 invention are useful for treating: cerebrovascular accident, central
 nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 disease, lupus, multiple sclerosis, transplant/graft rejection,
 ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 nucleic acids of the invention are also useful for down-regulating the
 expression of a target gene and as a diagnostic tool to examine genetic
 drifts and mutations within diseased cells or to detect the presence of a
 target RNA in a cell. The present RNA sequence represents a human IKK-
 gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 786 TCCGATGAGCGCCAG 802
 Db 1 UCCGCAUGGAGCGCCAG 17
 RESULT 196
 ADL48702
 ID ADL48702 standard; RNA; 17 BP.
 XX
 AC ADL48702;
 XX
 DT 20-MAY-2004 (first entry)
 XX


```

DE Human IKK-gamma substrate sequence #68.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1091; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 8 A; 6 C; 2 G; 0 T; 1 U; 0 Other;
  Query Match 2.3%; Score 17; DB 1; Length 17;
  Best Local Similarity 94.1%; Pred. No. 2.2e+02;
  Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 862 CCAAGAAATACGACAC 878
DB 1 CCAAGAAATACGACAC 17
  |||||:|||||
  |||||:|||||

RESULT 199
ADL47750
ID ADL47750 standard; RNA; 17 BP.
XX
AC ADL47750;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #260.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1283; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
  Query Match 2.3%; Score 17; DB 1; Length 17;
  Best Local Similarity 76.5%; Pred. No. 2.2e+02;
  Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 236 GAGTCTCTCTGGGAA 252
DB 1 GAGUCUCUCUGGGAA 17
  |||||:|||||
  |||||:|||||

RESULT 200
ADL47752
ID ADL47752 standard; RNA; 17 BP.
XX
AC ADL47752;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```



```

DE Human IKK-gamma substrate sequence #283.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1306; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 303 AGCGCTGCTGGAGGAG 319
Db 1 AGCGGCGCCUGGAGGAG 17
|||||:|||||
1 AGCGGCGCCUGGAGGAG 17

RESULT 203
ADL47830
ID ADL47830 standard; RNA; 17 BP.
XX
XX AC ADL47830;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #340.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1363; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 5 C; 6 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 585 TGACGTCCTGCTGCGG 601
Db 1 UGACGCGCCUGGCGGG 17
|||||:|||||
1 UGACGCGCCUGGCGGG 17

RESULT 204
ADL47850
ID ADL47850 standard; RNA; 17 BP.
XX
XX AC ADL47850;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```
DE Human IKK-gamma substrate sequence #360.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1383; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 4 C; 9 G; 0 T; 1 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 688 GCGCGGCGAGCTGGAGA 704
DB 1 GCGCGGCGAGCTGGAGA 17
RESULT 205
ADL47895
ID ADL47895 standard; RNA; 17 BP.
XX
XX AC ADL47895;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #405.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1428; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 2 A; 2 C; 10 G; 0 T; 3 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 894 TGGTGGGCGAGTGGAGCGG 910
DB 1 UGGUGGCGAGUGAGCGG 17
RESULT 206
ADL48251
ID ADL48251 standard; RNA; 17 BP.
XX
XX AC ADL48251;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #761.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1784; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 506 CAGGCTCTCGGGAGGT 522
 DB 1 CAGGCUCUGCGGAGGU 17
 RESULT 207
 ADL48277
 ID ADL48277 standard; RNA; 17 BP.
 XX
 AC ADL48277;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #787.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1810; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 9 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 673 GCGCGCCAGCGAGCAGG 689
 DB 1 GCGCGCCAGCGAGCAGG 17
 RESULT 208
 ADL48289
 ID ADL48289 standard; RNA; 17 BP.
 XX
 AC ADL48289;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE XX Human IKK-gamma substrate sequence #799.
KW XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW XX protein kinase PKR; cerebrovascular accident;
KW XX central nervous system injury; CNS injury; spinal cord injury; cancer;
KW XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW XX restenosis; asthma; Crohn's disease; diabetes; obesity;
KW XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW XX substrate; ds.
OS XX Unidentified.
XX XX
XX XX WO200281628-A2.
XX XX
XX XX 17-OCT-2002.
XX XX
XX XX 03-APR-2002; 2002WO-US010512.
XX XX
XX XX 05-APR-2001; 2001US-00827395.
XX XX 29-MAY-2001; 2001US-0294412P.
XX XX 28-AUG-2001; 2001US-0315315P.
XX XX
XX XX (RIBO-) RIBOZYME PHARM INC.
XX XX
XX XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX XX WPI; 2003-058513/05.
XX XX
XX XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX XX
XX XX Claim 59; SEQ ID NO 1822; 317pp; English.
XX XX
XX XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX XX that down regulate the expression or inhibit the function of a receptor
XX XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX XX invention are useful for treating: cerebrovascular accident, central
XX XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX XX nucleic acids of the invention are also useful for down-regulating the
XX XX expression of a target gene and as a diagnostic tool to examine genetic
XX XX drifts and mutations within diseased cells or to detect the presence of a
XX XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX XX gamma substrate sequence.
XX XX
XX XX Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
XX XX
XX XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX XX Best Local Similarity 94.1%; Pred. No. 2.2e+02;
XX XX Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX XX
XX XX 716 GCGCTGCGAGCAGCAGCA 732
XX XX |||||:|||||
XX XX 1 GCGCUGCAGCAGCAGCA 17
XX XX
XX XX RESULT 209
XX XX ADL48483
XX XX ID ADL48483 standard; RNA; 17 BP.
XX XX
XX XX AC ADL48483;
XX XX
XX XX DT 20-MAY-2004 (first entry)
XX XX
DE XX Human IKK-gamma substrate sequence #799.
KW XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW XX protein kinase PKR; cerebrovascular accident;
KW XX central nervous system injury; CNS injury; spinal cord injury; cancer;
KW XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW XX restenosis; asthma; Crohn's disease; diabetes; obesity;
KW XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW XX substrate; ds.
OS XX Unidentified.
XX XX
XX XX WO200281628-A2.
XX XX
XX XX 17-OCT-2002.
XX XX
XX XX 03-APR-2002; 2002WO-US010512.
XX XX
XX XX 05-APR-2001; 2001US-00827395.
XX XX 29-MAY-2001; 2001US-0294412P.
XX XX 28-AUG-2001; 2001US-0315315P.
XX XX
XX XX (RIBO-) RIBOZYME PHARM INC.
XX XX
XX XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX XX WPI; 2003-058513/05.
XX XX
XX XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX XX
XX XX Claim 59; SEQ ID NO 1822; 317pp; English.
XX XX
XX XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX XX that down regulate the expression or inhibit the function of a receptor
XX XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX XX invention are useful for treating: cerebrovascular accident, central
XX XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX XX nucleic acids of the invention are also useful for down-regulating the
XX XX expression of a target gene and as a diagnostic tool to examine genetic
XX XX drifts and mutations within diseased cells or to detect the presence of a
XX XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX XX gamma substrate sequence.
XX XX
XX XX Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
XX XX
XX XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX XX Best Local Similarity 94.1%; Pred. No. 2.2e+02;
XX XX Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX XX
XX XX 716 GCGCTGCGAGCAGCAGCA 732
XX XX |||||:|||||
XX XX 1 GCGCUGCAGCAGCAGCA 17
XX XX
XX XX RESULT 210
XX XX ADL48492
XX XX ID ADL48492 standard; RNA; 17 BP.
XX XX
XX XX AC ADL48492;
XX XX
XX XX DT 20-MAY-2004 (first entry)
XX XX
DE XX Human IKK-gamma substrate sequence #993.
KW XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW XX protein kinase PKR; cerebrovascular accident;
KW XX central nervous system injury; CNS injury; spinal cord injury; cancer;
KW XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW XX restenosis; asthma; Crohn's disease; diabetes; obesity;
KW XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW XX substrate; ds.
OS XX Unidentified.
XX XX
XX XX WO200281628-A2.
XX XX
XX XX 17-OCT-2002.
XX XX
XX XX 03-APR-2002; 2002WO-US010512.
XX XX
XX XX 05-APR-2001; 2001US-00827395.
XX XX 29-MAY-2001; 2001US-0294412P.
XX XX 28-AUG-2001; 2001US-0315315P.
XX XX
XX XX (RIBO-) RIBOZYME PHARM INC.
XX XX
XX XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX XX WPI; 2003-058513/05.
XX XX
XX XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX XX
XX XX Claim 59; SEQ ID NO 2016; 317pp; English.
XX XX
XX XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX XX that down regulate the expression or inhibit the function of a receptor
XX XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX XX invention are useful for treating: cerebrovascular accident, central
XX XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX XX nucleic acids of the invention are also useful for down-regulating the
XX XX expression of a target gene and as a diagnostic tool to examine genetic
XX XX drifts and mutations within diseased cells or to detect the presence of a
XX XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX XX gamma substrate sequence.
XX XX
XX XX Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
XX XX
XX XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;
XX XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX XX
XX XX 446 GCCAGGAAGAACTGGTGGGA 462
XX XX |||||:|||||
XX XX 1 GCCAGGAAGAACTGGTGGGA 17
XX XX
XX XX RESULT 210
XX XX ADL48492
XX XX ID ADL48492 standard; RNA; 17 BP.
XX XX
XX XX AC ADL48492;
XX XX
XX XX DT 20-MAY-2004 (first entry)
XX XX

```

DE Human IKK-gamma substrate sequence #1002.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2025; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 8 A; 4 C; 2 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 860 TTCCAAGAAATACGACAA 876
 Db 1 UUCCAAGAAUACGACAA 17
 :|||||:|||||
 RESULT 211
 ADL48561
 ID ADL48561 standard; RNA; 17 BP.
 XX
 AC ADL48561;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1071.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2094; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 179 TGTGAGATGTCAGCC 195
 Db 1 UGUGAGAUUGGUGCAGCC 17
 :|||||:|||||
 RESULT 212
 ADL48571
 ID ADL48571 standard; RNA; 17 BP.
 XX
 AC ADL48571;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1143.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

PD 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2166; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 515 CGGGAGGTGGAGCACCT 531

DB 1 CGGGAGGTGGAGCACCU 17

RESULT 215

ADL48666

ID ADL48666 standard; RNA; 17 BP.

XX AC ADL48666;

XX 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1176.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

PD 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2199; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.2e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 659 GAGGTCGCGGCCCGGC 675

DB 1 GAGGTCGCGGCCCGGC 17

RESULT 216

ADL48680

ID ADL48680 standard; RNA; 17 BP.

XX AC ADL48680;

XX 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1190.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2213; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 737 GTGACGGTGACAGCT 753

Db 1 GUGCAGGUGGACGACGU 17

RESULT 217

ADL48683

ID ADL48683 standard; RNA; 17 BP.

XX AC ADL48683;

XX 20-MAY-2004 (first entry)

DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1193.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2216; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.2e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 756 GCATGCAGGCGCCAGAGC 772

Db 1 GCAUGCAGGCGCCAGAGC 17

RESULT 218

ADL48687

ID ADL48687 standard; RNA; 17 BP.

XX AC ADL48687;

XX 20-MAY-2004 (first entry)

DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #1197.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2220; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 770 AGCGTCGAGCGCGCT 786
 Db 1 AGCGUGGAGCGCGCU 17
 RESULT 219
 ADL48691
 ID ADL48691 standard; RNA; 17 BP.
 XX
 AC ADL48691;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1201.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2224; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 803 GCCGCTCGGAGGAGAA 819
 Db 1 GCCGCTCGGAGGAGAA 17
 RESULT 220
 ADL48694
 ID ADL48694 standard; RNA; 17 BP.
 XX
 AC ADL48694;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```
DE Human IKK-gamma substrate sequence #1204.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2227; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 3 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 807 CCTCGAGGAGAGAGG 823
Db 1 CCUCGAGGAGAGAGG 17
|||||
1 CCUCGAGGAGAGAGG 17

RESULT 221
ADL48696
ID ADL48696 standard; RNA; 17 BP.
XX
XX AC ADL48696;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1206.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2229; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 7 A; 1 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 812 GAGGAGAGGAGGAGCT 828
Db 1 GAGGAGAGGAGGAGCT 17
|||||
1 GAGGAGAGGAGGAGCT 17

RESULT 222
ADL48698
ID ADL48698 standard; RNA; 17 BP.
XX
XX AC ADL48698;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #1208.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2231; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 815 GAGAGAGGAGGCTGGC .831
 Db 1 GAGAGAGGAGGCTGGC 17
 |||||
 RESULT 223
 ADL48705
 ID ADL48705 standard; RNA; 17 BP.
 XX
 AC ADL48705;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1215.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2238; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 887 AGCAGCGTGGTGGCAG 903
 Db 1 AGCAGCGTGGTGGCAG 17
 |||||
 RESULT 224
 ADL47520
 ID ADL47520 standard; RNA; 17 BP.
 XX
 AC ADL47520;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #30.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 23-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1053; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 282 AGGCGCTCTGTGAGACC 298
Db 1 AGGCGCGCTCTGTGAGACC 17
RESULT 225
ADL47528
ID ADL47528 standard; RNA; 17 BP.
XX
XX AC ADL47528;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #38.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 23-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1061; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 4 G; 0 T; 6 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 378 AGGAGCTTCTGATTC 394
Db 1 AGGAGCTTCTGATTC 17
RESULT 226
ADL47530
ID ADL47530 standard; RNA; 17 BP.
XX
XX AC ADL47530;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE	Human IKK-gamma substrate sequence #40.	DE	Human IKK-gamma substrate sequence #62.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1063; 317pp; English.	PS	Claim 59; SEQ ID NO 1085; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 4 A; 6 C; 2 G; 0 T; 5 U; 0 Other;	SQ	Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 70.6%; Pred. No. 2.2e+02;		Best Local Similarity 82.4%; Pred. No. 2.2e+02;
	Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;		Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY	385 TCTGCAATTCACGCCA 401	QY	829 GGCCCGATTCAGGTGG 845
DB	1 UCUGCAUUCACGCCA 17	DB	1 GGCCCGATTCAGGTGG 17
RESULT 227		RESULT 228	
ADL47552		ADL47736	
ID	ADL47552 standard; RNA; 17 BP.	ID	ADL47736 standard; RNA; 17 BP.
XX		XX	
AC	ADL47552;	AC	ADL47736;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #246.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX

XX WO200281628-A2.

PN

XX

XX 17-OCT-2002.

PD

XX

XX 03-APR-2002; 2002WO-US010512.

PF

XX

XX 05-APR-2001; 2001US-00827395.

PR

XX 29-MAY-2001; 2001US-0294412P.

PR

XX 28-AUG-2001; 2001US-0315315P.

PR

XX

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-058513/05.

DR

XX

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PT

XX

XX Claim 59; SEQ ID NO 1269; 317pp; English.

PS

XX

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 166 GAAGAGCCAACTGTGTG 182

|||||

Db 1 GAAGAGCCAACTGTGTG 17

RESULT 229

ADL47751

ID ADL47751 standard; RNA; 17 BP.

XX

XX AC ADL47751;

XX

XX 20-MAY-2004 (first entry)

DT

XX

DE Human IKK-gamma substrate sequence #261.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX

XX WO200281628-A2.

PN

XX

XX 17-OCT-2002.

PD

XX

XX 03-APR-2002; 2002WO-US010512.

PF

XX

XX 05-APR-2001; 2001US-00827395.

PR

XX 29-MAY-2001; 2001US-0294412P.

PR

XX 28-AUG-2001; 2001US-0315315P.

PR

XX

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-058513/05.

DR

XX

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PT

XX

XX Claim 59; SEQ ID NO 1284; 317pp; English.

PS

XX

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 2.2e+02;

Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 238 GTCTCTCTGGGGAAGC 254

|||||

Db 1 GUCUCUCUGGGAAGC 17

RESULT 230

ADL47764

ID ADL47764 standard; RNA; 17 BP.

XX

XX AC ADL47764;

XX

XX 20-MAY-2004 (first entry)

DT

XX


```

DE Human IKK-gamma substrate sequence #274.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1297; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 281 CAGGGCGCTCTGAGAC 297
DB 1 CAGGGCGCTCTGAGAC 17
|||||:|||||:|||||
1 CAGGGCGCTCTGAGAC 17

RESULT 231
ADL47771
ID ADL47771 standard; RNA; 17 BP.
XX
AC ADL47771;
XX
XX 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #281.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1304; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 295 GACCCTCCAGCGCTGCC 311
DB 1 GACCCTCCAGCGCTGCC 17
|||||:|||||:|||||
1 GACCCTCCAGCGCTGCC 17

RESULT 232
ADL47776
ID ADL47776 standard; RNA; 17 BP.
XX
AC ADL47776;
XX
XX 20-MAY-2004 (first entry)
XX

```

```
DE Human IKK-gamma substrate sequence #286.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1309; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 322 TCAAGAGCTCCGAGATG 338
DB 1 UCAAGAGCUCGAGAUG 17
RESULT 233
ADL47800
ID ADL47800 standard; RNA; 17 BP.
XX
XX AC ADL47800;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #310.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1333; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 432 GCAAGTTCACGAGGCC 448
DB 1 GCAAGUUCGAGAGGCC 17
RESULT 234
ADL47803
ID ADL47803 standard; RNA; 17 BP.
XX
XX AC ADL47803;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

DE	Human IKK-gamma substrate sequence #313.	DE	Human IKK-gamma substrate sequence #319.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
XX		XX	
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
XX		XX	
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
XX	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	XX	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1336; 317pp; English.	PS	Claim 59; SEQ ID NO 1342; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 6 A; 3 C; 7 G; 0 T; 1 U; 0 Other;	SQ	Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 94.1%; Pred. No. 2.2e+02;		Best Local Similarity 82.4%; Pred. No. 2.2e+02;
	Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;		Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY	441 AGAGGCCAGGAACTG 457	QY	481 GCTCGATCTGAAGGC 497
DB	1 AGGAGGCCAGGAACUG 17	DB	1 GCUCGAUCUGAAGGC 17
RESULT 235		RESULT 236	
ID ADL47809		ID ADL47810	
XX ADL47809 standard; RNA; 17 BP.		XX ADL47810 standard; RNA; 17 BP.	
AC ADL47809;		AC ADL47810;	
XX ADL47809;		XX ADL47810;	
DT 20-MAY-2004 (first entry)		DT 20-MAY-2004 (first entry)	
XX		XX	

```

DE Human IKK-gamma substrate sequence #320.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1343; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 7 A; 2 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 490 GAGAGGCGAGGAGGAGC 506
DB 1 GAAGAGGCGAGGAGGAGC 17
RESULT 237
ADL47840
ID ADL47840 standard; RNA; 17 BP.
XX
AC ADL47840;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #350.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1373; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 632 GCTGCCCACTAAGGAATG 648
DB 1 GCUGCCACUAAGGAUG 17
RESULT 238
ADL47851
ID ADL47851 standard; RNA; 17 BP.
XX
AC ADL47851;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE	Human IKK-gamma substrate sequence #361.	DE	Human IKK-gamma substrate sequence #372.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1384; 317pp; English.	PS	Claim 59; SEQ ID NO 1395; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	691 GCGGAGCTGGAGAGTG 707	QY	750 AGCTGCGCATGCAGGCG 766
	: :		: :
Db	1 GCGGAGCTGGAGAGTG 17	Db	1 AGCUGCGCAUGCAGGCG 17
RESULT 239		RESULT 240	
ADL47862		ADL47873	
ID ADL47862 standard; RNA; 17 BP.		ID ADL47873 standard; RNA; 17 BP.	
XX		XX	
AC ADL47862;		AC ADL47873;	
XX		XX	
DT 20-MAY-2004 (first entry)		DT 20-MAY-2004 (first entry)	
XX		XX	

DE Human IKK-gamma substrate sequence #727.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1750; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred.No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 230 GGCGAAGAGTCTCTCTCT 246
 DB 1 GGCGAAGAGTCTCTCTCTCT 17
 RESULT 243
 ID ADL48249
 ADL48249 standard; RNA; 17 BP.
 XX
 AC ADL48249;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #759.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1782; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred.No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 497 CAGAAGGAGCAGGCTCT 513
 DB 1 CAGAAGGAGCAGGCTCT 17
 RESULT 244
 ID ADL48252
 ADL48252 standard; RNA; 17 BP.
 XX
 AC ADL48252;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```
DE Human IKK-gamma substrate sequence #762.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1785; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 89.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 513 TGGCGGAGGTGGAGCAC 529
Db :|||||:|||||
1 UGCGGAGGUGGAGCAC 17

RESULT 245
ADL48258
ID ADL48258 standard; RNA; 17 BP.
XX
XX AC ADL48258;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #768.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1791; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 558 AGGACAAGGCTCTGTG 574
Db :|||||:|||||
1 AGGACAAGGCCUCUG 17

RESULT 246
ADL48265
ID ADL48265 standard; RNA; 17 BP.
XX
XX AC ADL48265;
XX
XX DT 20-MAY-2004 (first entry)
XX
```


DE Human IKK-gamma substrate sequence #775.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1798; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 2 C; 10 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 599 GGGGAGTCGACGAGAG 615
 DB 1 GGGGAGTCGACGAGAG 17
 |||||:|||||
 RESULT 247
 ID ADL48269
 ADL48269 standard; RNA; 17 BP.
 XX
 AC ADL48269;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #779.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1802; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 624 GCTTGAGGCTGCCACT 640
 DB 1 GCUUGAGGCGGCCACU 17
 |||||:|||||
 RESULT 248
 ID ADL48270
 ADL48270 standard; RNA; 17 BP.
 XX
 AC ADL48270;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE Human IKK-gamma substrate sequence #780.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1803; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 627 TGAGGGTGCCTAAG 643
Db :|||||:|||||:
1 UGGAGGCGGCCACUAAG 17

RESULT 249
ADL48283
ID ADL48283 standard; RNA; 17 BP.
XX
XX AC ADL48283;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #793.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1816; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCGG 713
Db ||:|||||:|||||:
1 GCTGGAGAGTGAGCGG 17

RESULT 250
ADL48295
ID ADL48295 standard; RNA; 17 BP.
XX
XX AC ADL48295;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #805.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PS Claim 59; SEQ ID NO 1828; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 735 GCCTGACGGTGGACACG 751
 Db 1 GCUGCAGGUGGACACG 17
 RESULT 251
 ADL48320
 ID ADL48320 standard; RNA; 17 BP.
 XX
 AC ADL48320;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #830.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PS Claim 59; SEQ ID NO 1853; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 885 AGAGCAGCGTGTGGGC 901
 Db 1 AGAGCAGCGTGTGGGC 17
 RESULT 252
 ADL48478
 ID ADL48478 standard; RNA; 17 BP.
 XX
 AC ADL48478;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE Human IKK-gamma substrate sequence #988.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX
XX 29-MAY-2001; 2001US-0294412P.
PR
XX
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1011; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 8 C; 3 G; 0 T; 3 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 288 CTCCTGAGACCCCTCAG 304
Db 1 CUCCUGAGACCCUCCAG 17

RESULT 253
ADL48485
ID ADL48485 standard; RNA; 17 BP.
XX
XX ADL48485;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #995.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX
XX 29-MAY-2001; 2001US-0294412P.
PR
XX
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1018; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 3 C; 5 G; 0 T; 3 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 478 GAAGCTCGATCTGAAGA 494
Db 1 GAAGCUCGACUUGAAGA 17

RESULT 254
ADL48583
ID ADL48583 standard; RNA; 17 BP.
XX
XX ADL48583;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE Human IKK-gamma substrate sequence #1093.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2116; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 308 TGCCTGGAGGAGGAATCA 324
 Db 1 UGCCUGGAGGAGGAUUA 17
 RESULT 255
 ID ADL48589
 ADL48589 standard; RNA; 17 BP.
 XX
 AC ADL48589;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1099.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2122; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 337 TGCCATCCGGCAGAGCA 353
 Db 1 UGCCAUCGGCAGAGCA 17
 RESULT 256
 ID ADL48644
 ADL48644 standard; RNA; 17 BP.
 XX
 AC ADL48644;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```
DE Human IKK-gamma substrate sequence #1154.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2177; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 6 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy 566 GCCTCTGTGAAGCCCA 582
Db 1 GCCUCUGAAGGCCCA 17
||||:|||||
1 GCCUCUGAAGGCCCA 17
RESULT 257
ADL48654
ID ADL48654 standard; RNA; 17 BP.
XX
XX AC ADL48654;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

```
DE Human IKK-gamma substrate sequence #1164.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2187; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy 611 GAGAGCCAGAGTCGCTT 627
Db 1 GAGAGCCAGAGTCGCUU 17
||||:|||||
1 GAGAGCCAGAGTCGCUU 17
RESULT 258
ADL48686
ID ADL48686 standard; RNA; 17 BP.
XX
XX AC ADL48686;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #1196.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX Unidentified.
 PN WO200281628-A2.
 XX 17-OCT-2002.
 PD 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI WPI; 2003-058513/05.
 DR WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2219; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 3 A; 4 C; 9 G; 0 T; 1 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 768 AGAGCGTGGAGGCGCG 784
 DB 1 AGAGCGTGGAGGCGCG 17
 RESULT 259
 ADL48699
 ID ADL48699 standard; RNA; 17 BP.
 XX AC ADL48699;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1209.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX Unidentified.
 PN WO200281628-A2.
 XX 17-OCT-2002.
 PD 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI WPI; 2003-058513/05.
 DR WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2232; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 821 AGGAAGCTGGCCAGTT 837
 DB 1 AGGAAGCTGGCCAGTT 17
 RESULT 260
 ADL47559
 ID ADL47559 standard; RNA; 17 BP.
 XX AC ADL47559;
 XX DT 20-MAY-2004 (first entry)
 XX

```

DE Human IKK-gamma substrate sequence #69.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
PN WO200281628-A2.
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1092; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 8 A; 5 C; 3 G; 0 T; 1 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 875 AACACATCAGAGCAG 891
DB 1 AACCAUCAAGAGCAG 17
RESULT 261
ADL47761
ID ADL47761 standard; RNA; 17 BP.
XX
XX ADL47761;
AC
XX 20-MAY-2004 (first entry)
DT
XX
DE Human IKK-gamma substrate sequence #271.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
PN WO200281628-A2.
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1294; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 7 C; 2 G; 0 T; 3 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 266 CACCTGCCTTCAGAACCA 282
DB 1 CACCGCCUUCAGAACCA 17
RESULT 262
ADL47781
ID ADL47781 standard; RNA; 17 BP.
XX
XX ADL47781;
AC
XX 20-MAY-2004 (first entry)
DT
XX

```


DE Human IKK-gamma substrate sequence #291.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1314; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 7 C; 4 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 340 CATCCGCGAGAGCAACC 356
 Db 1 CAUCCGCGAGAGCAACC 17
 RESULT 263
 ADL47782
 ID ADL47782 standard; RNA; 17 BP.
 XX
 AC ADL47782;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #292.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1315; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 345 GCGAGAGCAACAGATT 361
 Db 1 GCGAGAGCAACAGATT 17
 RESULT 264
 ADL47785
 ID ADL47785 standard; RNA; 17 BP.
 XX
 AC ADL47785;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #295.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PA
XX (RIBO-) RIBOZYME PHARM INC.
XX PI
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1318; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 355 CCAGATTCGCGGAGC 371
DB 1 CCAGAUUCUGCGGAGC 17
RESULT 265
ADL47815
ID ADL47815 standard; RNA; 17 BP.
XX AC
XX ADL47815;
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #325.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PA
XX (RIBO-) RIBOZYME PHARM INC.
XX PI
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1348; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 0 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 522 TGGAGCACCTGAGAGA 538
DB 1 UGGAGCACCTGAGAGA 17
RESULT 266
ADL47825
ID ADL47825 standard; RNA; 17 BP.
XX AC
XX ADL47825;
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #335.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1358; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 563 AAGGCCTCTGTGAAGC 579
Db 1 AAGGCCUCUGAAGC 17
|||||:|:|:|:|:|:|
1 AAGGCCUCUGAAGC 17

RESULT 267
ADL47829
ID ADL47829 standard; RNA; 17 BP.
XX
AC ADL47829;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #339.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1362; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 5 C; 6 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred.No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 584 GTGACGTCCTTGCTCGG 600
Db 1 GUGACGUCUUGCUCGG 17
|||||:|:|:|:|:|:|
1 GUGACGUCUUGCUCGG 17

RESULT 268
ADL47838
ID ADL47838 standard; RNA; 17 BP.
XX
AC ADL47838;
XX
DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #348.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX OS Unidentified.
XX
XX PN WO200281628-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1371; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 629 GAGGCTGCCTAAGGA 645
DB 1 GAGGCTGCCTAAGGA 17
RESULT 269
ADL47848
ID ADL47848 standard; RNA; 17 BP.
XX
XX AC ADL47848;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #358.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX OS Unidentified.
XX
XX PN WO200281628-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1381; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 5 C; 9 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 672 GGGCGGCCGAGCAGCAG 688
DB 1 GGGCGGCCGAGCAGCAG 17
RESULT 270
ADL47853
ID ADL47853 standard; RNA; 17 BP.
XX
XX AC ADL47853;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #363.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1386; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 715 GCGGTCGACGACGACG 731
DB 1 GCGGTCGACGACGACG 17

RESULT 271
ADL47856
ID ADL47856 standard; RNA; 17 BP.
XX
AC ADL47856;
XX
DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #366.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1389; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCGTC 740
DB 1 GCAGCAGCAGCAGCGTC 17

RESULT 272
ADL47868
ID ADL47868 standard; RNA; 17 BP.
XX
AC ADL47868;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE	Human IKK-gamma substrate sequence #378.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.
OS	Unidentified.
OS	WO200281628-A2.
PN	17-OCT-2002.
PD	03-APR-2002; 2002WO-US010512.
PF	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
XX	(RIBO-) RIBOZYME PHARM INC.
PA	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX	WPI; 2003-058513/05.
DR	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	Claim 59; SEQ ID NO 1401; 317pp; English.
PS	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
XX	Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
SQ	Query Match 2.3%; Score 17; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 2.2e+02; Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	780 CCAGCGTCGCATGGAG 796 : : 1 CCAGCGTCCGCAUGGAG 17
DB	
RESULT 273	
ADL47888	
ID ADL47888 standard; RNA; 17 BP.	
XX AC ADL47888;	
XX DT 20-MAY-2004 (first entry)	
XX	

DE	Human IKK-gamma substrate sequence #398.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.
OS	Unidentified.
OS	WO200281628-A2.
PN	17-OCT-2002.
PD	03-APR-2002; 2002WO-US010512.
PF	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
XX	(RIBO-) RIBOZYME PHARM INC.
PA	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX	WPI; 2003-058513/05.
DR	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	Claim 59; SEQ ID NO 1421; 317pp; English.
PS	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
XX	Sequence 17 BP; 5 A; 5 C; 3 G; 0 T; 4 U; 0 Other;
SQ	Query Match 2.3%; Score 17; DB 1; Length 17; Best Local Similarity 76.5%; Pred. No. 2.2e+02; Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY	856 GCTTTCCCAAGAATACG 872 ::: :: 1 GCUCUCCAAGAAUACG 17
DB	
RESULT 274	
ADL48235	
ID ADL48235 standard; RNA; 17 BP.	
XX AC ADL48235;	
XX DT 20-MAY-2004 (first entry)	
XX	

```

DE Human IKK-gamma substrate sequence #745.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1768; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 9 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 367 GGAGCGCTCGGAGGAGC 383
Db 1 GGAGCGCGGAGGAGC 17
|||||:|||||
1 GGAGCGCGGAGGAGC 17

RESULT 275
ADL48237
ID ADL48237 standard; RNA; 17 BP.
XX
XX ADL48237;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #747.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1770; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 3 G; 0 T; 6 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 380 GAGCTTCGCAVTTCCA 396
Db 1 GAGCUUCUGCAUUGCA 17
|||||:|||||
1 GAGCUUCUGCAUUGCA 17

RESULT 276
ADL48244
ID ADL48244 standard; RNA; 17 BP.
XX
XX ADL48244;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```
DE XX Human IKK-gamma substrate sequence #754.
KW XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW KW protein kinase PKR; cerebrovascular accident;
KW KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW KW substrate; ds.
XX OS Unidentified.
XX XX WO200281628-A2.
XX PN 17-OCT-2002.
XX PD
XX PF 03-APR-2002; 2002WO-US010512.
XX PP 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX PS Claim 59; SEQ ID NO 1777; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX CC
XX SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 438 TCCAGGAGGCCAGGAAA 454
Db 1 UCCAGGAGGCCAGGAAA 17
RESULT 277
ADL48259
ID ADL48259 standard; RNA; 17 BP.
XX AC ADL48259;
XX XX
XX DT 20-MAY-2004 (first entry)
XX XX
DE XX Human IKK-gamma substrate sequence #769.
KW XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW KW protein kinase PKR; cerebrovascular accident;
KW KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW KW substrate; ds.
XX OS Unidentified.
XX XX WO200281628-A2.
XX PN 17-OCT-2002.
XX PD
XX PF 03-APR-2002; 2002WO-US010512.
XX PP 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX PS Claim 59; SEQ ID NO 1792; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX CC
XX SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 564 AGGCCTCTGTGAAAGCC 580
Db 1 AGGCCUCUGUGAAGCC 17
RESULT 278
ADL48271
ID ADL48271 standard; RNA; 17 BP.
XX AC ADL48271;
XX XX
XX DT 20-MAY-2004 (first entry)
XX XX
```



```

DE Human IKK-gamma substrate sequence #781.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1804; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 640 TAAAGGAATCCAGGCTC 656
DB 1 UAAAGGAATCCAGGCTC 17
:|||||:|||||:|

RESULT 279
ADL48322
ID ADL48322 standard; RNA; 17 BP.
XX
AC ADL48322;
XX
XX 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #832.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1855; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 892 COTGCTGGCGACTGAGC 908
DB 1 CGUGGUGGGCAGUGAGC 17
:|||||:|||||:|

RESULT 280
ADL48474
ID ADL48474 standard; RNA; 17 BP.
XX
AC ADL48474;
XX
XX 20-MAY-2004 (first entry)
XX

```

DE	Human IKK-gamma substrate sequence #1075.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX	protein kinase PKR; cerebrovascular accident;
XX	central nervous system injury; CNS injury; spinal cord injury; cancer;
XX	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX	restenosis; asthma; Crohn's disease; diabetes; obesity;
XX	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.
OS	Unidentified.
OS	WO200281628-A2.
XX	17-OCT-2002.
XX	03-APR-2002; 2002WO-US010512.
XX	05-APR-2001; 2001US-00827395.
XX	29-MAY-2001; 2001US-0294412P.
XX	28-AUG-2001; 2001US-0315315P.
XX	(RIBO-) RIBOZYME PHARM INC.
XX	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX	WPI; 2003-058513/05.
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
XX	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	Claim 59; SEQ ID NO 2098; 317pp; English.
XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX	that down regulate the expression or inhibit the function of a receptor
XX	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX	invention are useful for treating: cerebrovascular accident, central
XX	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX	disease, lupus, multiple sclerosis, transplant/graft rejection,
XX	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX	nucleic acids of the invention are also useful for down-regulating the
XX	expression of a target gene and as a diagnostic tool to examine genetic
XX	drifts and mutations within diseased cells or to detect the presence of a
XX	target RNA in a cell. The present RNA sequence represents a human IKK-
XX	gamma substrate sequence.
XX	Sequence 17 BP; 5 A; 5 C; 6 G; 0 T; 1 U; 0 Other;
XX	Query Match 2.3%; Score 17; DB 1; Length 17;
XX	Best Local Similarity 94.1%; Pred. No. 2.2e+02;
XX	Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY	207 CGGCAGCAGATCAGGAC 223
DB	1 CGGCAGCAGCAUAGGAC 17
DB	:
RESULT 282	
ADL48601	
ID	ADL48601 standard; RNA; 17 BP.
XX	ADL48601;
AC	
XX	20-MAY-2004 (first entry)
DT	
XX	

DE Human IKK-gamma substrate sequence #1111.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2134; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 9 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 402 GCCAGAGGAGGAGGAG 418
 Db 1 GCCAGAGGAGGAGGAG 17
 RESULT 283
 ADL48609
 ID ADL48609 standard; RNA; 17 BP.
 XX
 AC ADL48609;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1119.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2142; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 437 TTCACAGGAGGAGGAG 453
 Db 1 UUCACAGGAGGAGGAG 17
 RESULT 284
 ADL48620
 ID ADL48620 standard; RNA; 17 BP.
 XX
 AC ADL48620;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```
DE Human IKK-gamma substrate sequence #1130.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2153; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 470 GGCCTGGAGAGCTCGA 486
DB 1 GGCCUGGAGAGCUCGA 17
RESULT 285
ADL48623
ID ADL48623 standard; RNA; 17 BP.
XX
XX AC ADL48623;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

```
DE Human IKK-gamma substrate sequence #1133.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2156; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 7 A; 2 C; 6 G; 0 T; 2 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 485 GATCTGAAGAGCGAGAA 501
DB 1 GAUCUGAAGAGCGAGAA 17
RESULT 286
ADL48639
ID ADL48639 standard; RNA; 17 BP.
XX
XX AC ADL48639;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

```
DE Human IKK-gamma substrate sequence #1149.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2172; 317pp; English.
PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 545 CAGCAGATCGCTGAGGA 561
DB 1 CAGCAGATCGCTGAGGA 17
|||||:|||||
1 CAGCAGATCGCTGAGGA 17

RESULT 287
ADL48640
ID ADL48640 standard; RNA; 17 BP.
XX
XX AC ADL48640;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #1150.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2173; 317pp; English.
PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 549 AGATCGCTGAGGACAAG 565
DB 1 AGAUGGUGGAGGACAAG 17
|||||:|||||
1 AGAUGGUGGAGGACAAG 17

RESULT 288
ADL48650
ID ADL48650 standard; RNA; 17 BP.
XX
XX AC ADL48650;
XX
XX 20-MAY-2004 (first entry)
DT
XX
```

```
DE Human IKK-gamma substrate sequence #1160.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2183; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 2.2e+02;
XX Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 594 TGCTGGGGAGCTGCAG 610
XX :||:|||||:|||||
XX 1 UGUCUGGGGAGCUGCAG 17
XX
XX Db
XX
XX RESULT 289
XX ADL48672
XX ID ADL48672 standard; RNA; 17 BP.
XX
XX AC ADL48672;
XX
XX XX 20-MAY-2004 (first entry)
XX
XX DT
XX
```

```
DE Human IKK-gamma substrate sequence #1182.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2205; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 2 A; 5 C; 9 G; 0 T; 1 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 94.1%; Pred. No. 2.2e+02;
XX Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 685 GCAGGCGCGCAGCTGG 701
XX :|||||:|||||:|
XX 1 GCAGGCGCGCAGCUGG 17
XX
XX Db
XX
XX RESULT 290
XX ADL48703
XX ID ADL48703 standard; RNA; 17 BP.
XX
XX AC ADL48703;
XX
XX XX 20-MAY-2004 (first entry)
XX
XX DT
XX
```

```

DE Human IKK-gamma substrate sequence #1213.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2236; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 9 A; 5 C; 2 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 864 AAGATACGACCAACCAC 880
DB 1 AAGAAUACGACCAACCAC 17
|||||:|||||
1 AAGAAUACGACCAACCAC 17

RESULT 291
ADL47513
ID ADL47513 standard; RNA; 17 BP.
XX
AC ADL47513;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #23.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1046; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 210 CAGCAGATCAGGACGTA 226
DB 1 CAGCAUACGAGGACGTA 17
|||||:|||||
1 CAGCAUACGAGGACGTA 17

RESULT 292
ADL47517
ID ADL47517 standard; RNA; 17 BP.
XX
AC ADL47517;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE	Human IKK-gamma substrate sequence #27.	
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	
KW	protein kinase PKR; cerebrovascular accident;	
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	
KW	substrate; ds.	
XX	Unidentified.	
OS		
XX	WO200281628-A2.	
PN		
XX	17-OCT-2002.	
XX		
XX	03-APR-2002; 2002WO-US010512.	
PF		
XX		
PR	05-APR-2001; 2001US-00827395.	
PR	23-MAY-2001; 2001US-0294412P.	
PR	28-AUG-2001; 2001US-0315315P.	
PR		
XX	(RIBO-) RIBOZYME PHARM INC.	
PA		
XX	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	
PI		
XX	WPI; 2003-058513/05.	
DR		
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite	
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	
PT		
XX	Claim 59; SEQ ID NO 1050; 317pp; English.	
PS		
XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	
CC	that down regulate the expression or inhibit the function of a receptor	
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	
CC	invention are useful for treating: cerebrovascular accident, central	
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	
CC	ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	
CC	nucleic acids of the invention are also useful for down-regulating the	
CC	expression of a target gene and as a diagnostic tool to examine genetic	
CC	drifts and mutations within diseased cells or to detect the presence of a	
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	
CC	gamma substrate sequence.	
XX	Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;	
SQ		
	Query Match 2.3%; Score 17; DB 1; Length 17;	
	Best Local Similarity 76.5%; Pred. No. 2.2e+02;	
	Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;	
Qy	237 AGTCTCTCTGGGGAAG 253	
	: : : : :	
Db	1 AGUCCUCCUGGGGAAG 17	
	: : : : :	
RESULT 293		
ADL47542		
ID	ADL47542 standard; RNA; 17 BP.	
XX		
AC	ADL47542;	
XX		
DT	20-MAY-2004 (first entry)	
XX		

DE Human IKK-gamma substrate sequence #54.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1077; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 6 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 590 TCCTGCTCGGGAGCT 606
 Db 1 UCCUUGCUGGGAGCU 17
 RESULT 295
 ID ADL47546
 ADL47546 standard; RNA; 17 BP.
 XX
 AC ADL47546;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #56.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1079; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 3 C; 8 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 619 GAGTCGCTGGAGGCTG 635
 Db 1 GAGUCGCUUGGAGGCU 17
 RESULT 296
 ID ADL47550
 ADL47550 standard; RNA; 17 BP.
 XX
 AC ADL47550;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #60.	DE	Human IKK-gamma substrate sequence #250.
XX	antisenase oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
XX	Unidentified.	XX	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1083; 317pp; English.	PS	Claim 59; SEQ ID NO 1273; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;	SQ	Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 88.2%; Pred. No. 2.2e+02;		Best Local Similarity 82.4%; Pred. No. 2.2e+02;	
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;		Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;	
QY	779 GCCGCGCTCCGATGGA 795	QY	188 GTCGAGCCGAGTGGTGG 204
DB	1 GCCGCGCTCCGATGGA 17	DB	1 GUGCAGCCGAGUGUGG 17
RESULT 297		RESULT 298	
ADL47740		ADL47741	
ID	ADL47740 standard; RNA; 17 BP.	ID	ADL47741 standard; RNA; 17 BP.
XX		XX	
AC	ADL47740;	AC	ADL47741;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

```

DE Human IKK-gamma substrate sequence #251.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1274; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 5 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 189 TGCAGCCCGAGTGGTGGC 205
DB 1 UGCAGCCCGAGUGGUGGC 17

RESULT 299
ADL47763
ID ADL47763 standard; RNA; 17 BP.
XX
AC ADL47763;
XX
DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #273.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1296; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 274 TTCAGAACAGGCGCTC 290
DB 1 UUCAGAACAGGCGGCGUC 17

RESULT 300
ADL47772
ID ADL47772 standard; RNA; 17 BP.
XX
AC ADL47772;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #282.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 23-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1305; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy 300 TCCAGCGCTGCTGGAG 316
:|||||:|||||:
Db 1 UCCAGCGCTGCTGGAG 17
RESULT 301
ADL47802
ID ADL47802 standard; RNA; 17 BP.
XX
AC ADL47802;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #312.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1335; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 440 CAGGAGGCCAGAAACT 456
:|||||:|||||:
Db 1 CAGGAGGCCAGAAACU 17
RESULT 302
ADL47824
ID ADL47824 standard; RNA; 17 BP.
XX
AC ADL47824;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #334.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1357; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 561 ACAAGCCCTCTGTGAAA 577
DB 1 ACAAGGCCUCUGGAAA 17

RESULT 303
ADL47846
ID ADL47846 standard; RNA; 17 BP.
XX
AC ADL47846;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #356.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1379; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 0 A; 7 C; 9 G; 0 T; 1 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 663 GTCGGGCCCGCGGCC 679
DB 1 GUCGGGCCCGCGGCC 17

RESULT 304
ADL47852
ID ADL47852 standard; RNA; 17 BP.
XX
AC ADL47852;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```
DE Human IKK-gamma substrate sequence #362.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1385; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 712 CGAGGCGTGCAGCAGC 728
DB 1 CGAGGCGTGCAGCAGC 17
RESULT 305
ADL47861
ID ADL47861 standard; RNA; 17 BP.
XX
XX ADL47861;
AC
XX 20-MAY-2004 (first entry)
DT
XX
```

```
DE Human IKK-gamma substrate sequence #371.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1394; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 745 GGACCAGCTCGCATGC 761
DB 1 GGACCAGCTCGCATGC 17
RESULT 306
ADL47863
ID ADL47863 standard; RNA; 17 BP.
XX
XX ADL47863;
AC
XX 20-MAY-2004 (first entry)
DT
XX
```

DE Human IKK-gamma substrate sequence #373.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1396; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 754 GCGCATGCGAGGCCAGA 770
 DB 1 GCGCAUGCAGGCCAGA 17
 RESULT 307
 ADL47874
 ID ADL47874 standard; RNA; 17 BP.
 XX
 AC ADL47874;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #384.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1407; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 801 AGGCCGCTCGGAGGAG 817
 DB 1 AGGCCGCCCGGAGGAG 17
 RESULT 308
 ADL48209
 ID ADL48209 standard; RNA; 17 BP.
 XX
 AC ADL48209;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #719.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS Unidentified.

XX WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1742; 317pp; English.

PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)

XX that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 185 ATGGTGCAGCCAGTGG 201

Db 1 AUGGUGCAGCCAGUGG 17

RESULT 309

ADL48228

ID ADL48228 standard; RNA; 17 BP.

XX AC ADL48228;

XX 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #738.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS Unidentified.

XX WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1761; 317pp; English.

PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)

XX that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 7 A; 4 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 320 AATCAAGAGCTCCGAGA 336

Db 1 AAUCAAGAGCTCCGAGA 17

RESULT 310

ADL48247

ID ADL48247 standard; RNA; 17 BP.

XX AC ADL48247;

XX 20-MAY-2004 (first entry)

XX


```

DE Human IKK-gamma substrate sequence #757.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1780; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 5 G; 0 T; 4 U; 0 Other;
  Query Match 2.3%; Score 17; DB 1; Length 17;
  Best Local Similarity 76.5%; Pred. No. 2.2e+02;
  Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 473 CTGGAGAAGCTCGATCT 489
Db 1 CUGGAGAAGCUCGAUCU 17
  |||||:|||||:|||||:
  1 CUGGAGAAGCUCGAUCU 17

RESULT 311
ADL48257
ID ADL48257 standard; RNA; 17 BP.
XX
XX AC ADL48257;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #767.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1790; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
  Query Match 2.3%; Score 17; DB 1; Length 17;
  Best Local Similarity 88.2%; Pred. No. 2.2e+02;
  Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 546 AGCAGATGGCTGAGGAC 562
Db 1 AGCAGAGUGGCGAGGAC 17
  |||||:|||||:|||||:
  1 AGCAGAGUGGCGAGGAC 17

RESULT 312
ADL48324
ID ADL48324 standard; RNA; 17 BP.
XX
XX AC ADL48324;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #834.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1857; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 4 A; 3 C; 9 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 899 GCAGTGGAGCGGACG 915
DB 1 GCAGTGGAGCGGACG 17
RESULT 313
ADL48563
ID ADL48563 standard; RNA; 17 BP.
XX
XX AC ADL48563;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #1073.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2096; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 2 A; 6 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 195 CCAGTGGTGGCCCGGCA 211
DB 1 CCAGUGGUGGCCCGGCA 17
RESULT 314
ADL48579
ID ADL48579 standard; RNA; 17 BP.
XX
XX AC ADL48579;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #1089.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 XX
 PR 29-MAY-2001; 2001US-0294412P.
 XX
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Meswigen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2112; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 8 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred.No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 285 GCGCTCCTGTGAGACCCCTC 301
 Db 1 GCGCTCCTGAGACCCCTC 17
 RESULT 315
 ID ADL48585
 AC ADL48585 standard; RNA; 17 BP.
 XX
 AC ADL48585;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1095.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 XX
 PR 29-MAY-2001; 2001US-0294412P.
 XX
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Meswigen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2118; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 7 A; 2 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred.No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 311 CTGGAGGAGGAATCAAGA 327
 Db 1 CUGGAGGAGGAUCAAGA 17
 RESULT 316
 ID ADL48604
 AC ADL48604 standard; RNA; 17 BP.
 XX
 AC ADL48604;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1114.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2137; 317pp; English.
 XX
 SS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 0 C; 9 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 407 AGGAGGAGAGAGGAGTT 423
 Db 1 AGGAGGAGAGAGGAGUU 17
 RESULT 317
 ADL48607
 ID ADL48607 standard; RNA; 17 BP.
 XX
 AC ADL48607;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1117.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2140; 317pp; English.
 XX
 SS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 434 AGTTCAGAGGCCAG 450
 Db 1 AAGUCCAGAGGCCAG 17
 RESULT 318
 ADL48613
 ID ADL48613 standard; RNA; 17 BP.
 XX
 AC ADL48613;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1123.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2146; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 OY 452 AAACUGGUGGAGAGACU 468
 Db 1 AAACUGGUGGAGAGACU 17
 |||:|||||:
 RESULT 319
 ID ADL48616
 XX ADL48616 standard; RNA; 17 BP.
 AC ADL48616;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1126.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2149; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 OY 457 GGTGGAGAGACTCGGCC 473
 Db 1 GGUGGAGAGACUCGGCC 17
 |||:|||||:
 RESULT 320
 ID ADL48621
 XX ADL48621 standard; RNA; 17 BP.
 AC ADL48621;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```

DE Human IKK-gamma substrate sequence #1131.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW central kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 23-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2154; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 3 C; 5 G; 0 T; 3 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 477 AGAAGCTCGATCTGAAG 493
DB 1 AGAAGCTCGATCTGAAG 17
|||||:|||||
1 AGAAGCTCGATCTGAAG 17

RESULT 321
ADL48622
ID ADL48622 standard; RNA; 17 BP.
XX
XX ADL48622;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #1132.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW central kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 23-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2155; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 482 CTCGATCTGAAGAGGCA 498
DB 1 CUCGATCUGAAGAGGCA 17
|||||:|||||
1 CUCGATCUGAAGAGGCA 17

RESULT 322
ADL48624
ID ADL48624 standard; RNA; 17 BP.
XX
XX ADL48624;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE	Human IKK-gamma substrate sequence #1134.	DE	Human IKK-gamma substrate sequence #1137.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 2157; 317pp; English.	PS	Claim 59; SEQ ID NO 2160; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 2 U; 0 Other;	SQ	Sequence 17 BP; 5 A; 3 C; 8 G; 0 T; 1 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 2.2e+02;		Best Local Similarity 94.1%; Pred. No. 2.2e+02;
	Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;		Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY	487 TCTGAGAGGAGGAGG 503	QY	495 GGCAGAGGAGGAGGCT 511
	: :		
Db	1 UCUGAAGAGGAGGAGG 17	Db	1 GGCAGAGGAGGAGGAGGCU 17
RESULT 323		RESULT 324	
ADL48627		ADL48664	
ID	ADL48627 standard; RNA; 17 BP.	ID	ADL48664 standard; RNA; 17 BP.
XX		XX	
AC	ADL48627;	AC	ADL48664;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

```

DE XX Human IKK-gamma substrate sequence #1174.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2197; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 1 A; 5 C; 8 G; 0 T; 3 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
QY 654 CTCTGGAGGTCGGGCC 670
DB 1 CUCUGGAGGUCGGGCC 17
XX
RESULT 325
ADL48668
ID ADL48668 standard; RNA; 17 BP.
XX
XX ADL48668;
XX
XX 20-MAY-2004 (first entry)
XX
DE XX Human IKK-gamma substrate sequence #1178.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2201; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 1 A; 7 C; 9 G; 0 T; 0 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 665 CGGGCCGGCGGCCGAG 681
DB 1 CGGGCCGGCGGCCGAG 17
XX
RESULT 326
ADL48669
ID ADL48669 standard; RNA; 17 BP.
XX
XX ADL48669;
XX
XX 20-MAY-2004 (first entry)
XX

```


DE Human IKK-gamma substrate sequence #1179.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2202; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 668 GCCCGGGCGCGCAGCGA 684
 DB 1 GCCCGGGCGCGCAGCGA 17
 RESULT 327
 ADL48684
 ID ADL48684 standard; RNA; 17 BP.
 XX
 AC ADL48684;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1194.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2217; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 761 CAGGCCCGCAGCGTGA 777
 DB 1 CAGGCCCGCAGCGTGA 17
 RESULT 328
 ADL48697
 ID ADL48697 standard; RNA; 17 BP.
 XX
 AC ADL48697;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```
DE Human IKK-gamma substrate sequence #1207.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 23-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 2230; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 1 C; 9 G; 0 T; 1 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 814 GGAGAGAGGAGCTGG 830
Db 1 GGAGAGAGGAGGCTGG 17
|||||:|||||:|
1 GGAGAGAGGAGGCTGG 17

RESULT 329
ADL47523
ID ADL47523 standard; RNA; 17 BP.
XX
XX ADL47523;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
```

```
DE Human IKK-gamma substrate sequence #33.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 23-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 1056; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 5 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 323 CAAGAGCTCGAGATGC 339
Db 1 CAAGAGCTCGAGATGC 17
|||||:|||||:|
1 CAAGAGCTCGAGATGC 17

RESULT 330
ADL47739
ID ADL47739 standard; RNA; 17 BP.
XX
XX ADL47739;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
```


DE Human IKK-gamma substrate sequence #289.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1312; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 OY 333 GAGATGCCATCCGGCAG 349
 Db 1 GAGAUCCCAUCCGGCAG 17
 |||:|||||:
 RESULT 333
 ADL47798
 ID ADL47798 standard; RNA; 17 BP.
 XX
 AC ADL47798;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #308.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1331; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 OY 420 AGTTCTCTCATGTGCAAG 436
 Db 1 AGUUCUCCAUUGUGCAAG 17
 |||:|||||:
 RESULT 334
 ADL47808
 ID ADL47808 standard; RNA; 17 BP.
 XX
 AC ADL47808;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #318.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1341; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 475 GGAGAAGCTCGATCTGA 491
 Db 1 GGAGAAGCTCGAUCUGA 17
 RESULT 335
 ADL47827
 ID ADL47827 standard; RNA; 17 BP.
 XX
 AC ADL47827;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #337.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1360; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 573 TGAAGAGCCGAGTGACG 589
 Db 1 UGAAGAGCCGAGGUGACG 17
 RESULT 336
 ADL47844
 ID ADL47844 standard; RNA; 17 BP.
 XX
 AC ADL47844;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE XX Human IKK-gamma substrate sequence #354.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1377; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 2 A; 5 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 649 CCAGGCTCTCGAGGGTC 665
||| ||| ||| ||| ||| |||
Db 1 CCAGGCTCUGGAGGGUC 17

RESULT 337
ADL47884
ID ADL47884 standard; RNA; 17 BP.
XX
XX AC ADL47884;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE XX Human IKK-gamma substrate sequence #394.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1417; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 8 C; 1 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 847 CTATCACCAGCTCTTCC 863
||| ||| ||| ||| ||| |||
Db 1 CUAUCACCAGCUCUCC 17

RESULT 338
ADL47887
ID ADL47887 standard; RNA; 17 BP.
XX
XX AC ADL47887;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #397.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX WO200281628-A2.
XX PD
XX 17-OCT-2002.
XX PF
XX 03-APR-2002; 2002WO-US010512.
XX PR
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1420; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 5 C; 2 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred.No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 855 AGCTCTTCCAAGAAATAC 871
DB 1 AGCTCUUCCAAGAAUAC 17
||||:|||||:|||||
1 AGCTCUUCCAAGAAUAC 17

RESULT 339
ADL48221
ID ADL48221 standard; RNA; 17 BP.
XX
XX AC
XX ADL48221;
XX
XX 20-MAY-2004 (first entry)
XX DT
XX

DE Human IKK-gamma substrate sequence #731.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX WO200281628-A2.
XX PD
XX 17-OCT-2002.
XX PF
XX 03-APR-2002; 2002WO-US010512.
XX PR
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1754; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 8 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 257 GCCATGCTGCACCTGCC 273
DB 1 GCCAUGCUGCACCUGCC 17
||||:|||||:|||||
1 GCCAUGCUGCACCUGCC 17

RESULT 340
ADL48242
ID ADL48242 standard; RNA; 17 BP.
XX
XX AC
XX ADL48242;
XX
XX 20-MAY-2004 (first entry)
XX DT
XX

```

DE Human IKK-gamma substrate sequence #752.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1775; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 424 CCTCATGTGCAAGTTCC 440
 Db 1 CCUCGUGCAAGUCC 17
 RESULT 341
 ADL48243
 ID ADL48243 standard; RNA; 17 BP.
 XX
 AC ADL48243;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #753.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1776; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 428 ATGTGCAAGTTCCAGGA 444
 Db 1 AUGUGCAAGUCCAGGA 17
 RESULT 342
 ADL48246
 ID ADL48246 standard; RNA; 17 BP.
 XX
 AC ADL48246;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #756.	DE	Human IKK-gamma substrate sequence #777.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1779; 317pp; English.	PS	Claim 59; SEQ ID NO 1800; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQL	Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;	SQL	Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
<p>Query Match 2.3%; Score 17; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 2.2e+02; Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;</p>		<p>Query Match 2.3%; Score 17; DB 1; Length 17; Best Local Similarity 82.4%; Pred. No. 2.2e+02; Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;</p>	
QY	463 GAGACTCGCGCTGGAGA 479	QY	613 GAGCCAGAGTCGCTGG 629
DB	1 GAGACUCGCGCUGGAGA 17	DB	1 GAGCCAGAGUCGCUUGG 17
<p>RESULT 343 ADL48267 ID ADL48267 standard; RNA; 17 BP. XX AC ADL48267; XX XX 20-MAY-2004 (first entry) DT XX</p>		<p>RESULT 344 ADL48281 ID ADL48281 standard; RNA; 17 BP. XX AC ADL48281; XX XX 20-MAY-2004 (first entry) DT XX</p>	

DE Human IKK-gamma substrate sequence #791.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 PF 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1814; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 686 CAGGCGCGGAGCTGGA 702
 DB 1 CAGGCGCGGAGCTGGA 17
 |||||:|||||:
 RESULT 345
 ADL48284
 ID ADL48284 standard; RNA; 17 BP.
 XX
 AC ADL48284;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #794.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 PF 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1817; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 4 A; 3 C; 9 G; 0 T; 1 U; 0 Other;
 SQ
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 701 GAGAGTGAGCGGAGGC 717
 DB 1 GAGAGTGAGCGGAGGC 17
 |||||:|||||:
 RESULT 346
 ADL48290
 ID ADL48290 standard; RNA; 17 BP.
 XX
 AC ADL48290;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #800.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1823; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 5 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 719 CTGCAGCAGCAGCAGCAG 735
 DB 1 CUGCAGCAGCAGCAGCAG 17
 RESULT 347
 ID ADL48297
 XX ADL48297 standard; RNA; 17 BP.
 AC
 AC ADL48297;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #807.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1830; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 746 GACCAGCTGCCATGCA 762
 DB 1 GACCAGCTGCCATGCA 17
 RESULT 348
 ID ADL48311
 XX ADL48311 standard; RNA; 17 BP.
 AC
 AC ADL48311;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE XX Human IKK-gamma substrate sequence #821.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-059513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1844; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX restenosis or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX disease, lupus, multiple sclerosis, diabetes, obesity, autoimmune
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 94.1%; Pred. No. 2.2e+02;
XX Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 818 AAGAGGAAGCTGGCCCA 834
XX |||||:|||||
XX 1 AAGAGGAAGCTGGCCCA 17
XX
XX RESULT 349
XX ADL48488
XX ID ADL48488 standard; RNA; 17 BP.
XX
XX AC ADL48488;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE XX Human IKK-gamma substrate sequence #998.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2021; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX restenosis or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX disease, lupus, multiple sclerosis, diabetes, obesity, autoimmune
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;
XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 553 GGCTGAGGACAGGCCT 569
XX |||||:|||||
XX 1 GGCUGAGGACAGGCCU 17
XX
XX RESULT 350
XX ADL48572
XX ID ADL48572 standard; RNA; 17 BP.
XX
XX AC ADL48572;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #1082.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2105; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred.No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 239 TCTCTCTCTGGGAAGCC 255
Db 1 UCUCUCUGGGAAGCC 17
|||||:|||||
1 UCUCUCUGGGAAGCC 17

RESULT 351
ADL48588
ID ADL48588 standard; RNA; 17 BP.
XX
AC ADL48588;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #1098.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2121; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 6 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred.No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 327 AGCTCCGAGATGCCATC 343
Db 1 AGCUCGCGAGGCAUC 17
|||||:|||||
1 AGCUCGCGAGGCAUC 17

RESULT 352
ADL48591
ID ADL48591 standard; RNA; 17 BP.
XX
AC ADL48591;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #1101.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2124; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 5 A; 5 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 350 AGCAACAGATTCGCG 366
Db 1 AGCAACAGATTCGCG 17

RESULT 353
ADL48602
ID ADL48602 standard; RNA; 17 BP.
XX
XX AC ADL48602;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1112.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2135; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 7 A; 1 C; 9 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 404 CAGAGGAGGAGGAGGA 420
Db 1 CAGAGGAGGAGGAGGA 17

RESULT 354
ADL48608
ID ADL48608 standard; RNA; 17 BP.
XX
XX AC ADL48608;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #1118.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2141; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 435 AGTTCAGGAGGCCAGG 451
 Db 1 AGUUCAGGAGGCCAGG 17
 ||:|||||
 ||:|||||
 RESULT 355
 ADL48615
 ID ADL48615 standard; RNA; 17 BP.
 XX
 AC ADL48615;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1125.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2148; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 8 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 455 CTGGTGGAGAGACTCGG 471
 Db 1 CUGGUGGAGAGACUCGG 17
 ||:|||||
 ||:|||||
 RESULT 356
 ADL48634
 ID ADL48634 standard; RNA; 17 BP.
 XX
 AC ADL48634;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1144.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS Unidentified.

XX WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2167; 317pp; English.

PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)

XX that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 516 GGGAGGTCGAGCAGCTG 532

DB 1 GGGAGGTCGAGCAGCTG 17

RESULT 357

ADL48637

ID ADL48637 standard; RNA; 17 BP.

XX AC ADL48637;

XX 20-MAY-2004 (first entry)

DT XX

DE Human IKK-gamma substrate sequence #1147.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS Unidentified.

XX WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2170; 317pp; English.

PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)

XX that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 5 A; 5 C; 5 G; 0 T; 2 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 529 CCTGAGAGATGCCAGC 545

DB 1 CCUGAGAGAGGCCAGC 17

RESULT 358

ADL48648

ID ADL48648 standard; RNA; 17 BP.

XX AC ADL48648;

XX 20-MAY-2004 (first entry)

DT XX

DE	Human IKK-gamma substrate sequence #1158.	DE	Human IKK-gamma substrate sequence #1168.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 2181; 317pp; English.	PS	Claim 59; SEQ ID NO 2191; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;	SQ	Sequence 17 BP; 6 A; 5 C; 4 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 76.5%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	592 CTTGCTCGGGAGCTGC 608	QY	635 GCCACTAAGGAATGCCA 651
DB	1 CUUGCUCGGGAGCUGC 17	DB	1 GCCACUAAGGAUGCCA 17
RESULT 359		RESULT 360	
ADL48658		ADL48667	
ID	ADL48658 standard; RNA; 17 BP.	ID	ADL48667 standard; RNA; 17 BP.
XX		XX	
AC	ADL48658;	AC	ADL48667;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

```
DE Human IKK-gamma substrate sequence #1177.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 23-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2200; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 1 A; 7 C; 8 G; 0 T; 1 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 664 TCGGCCCGCGCGGCCA 680
Db :|||||
1 UCGGCCCGCGCGGCCA 17

RESULT 361
ADL48677
ID ADL48677 standard; RNA; 17 BP.
XX
XX AC ADL48677;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1187.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 23-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2210; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 2 A; 4 C; 9 G; 0 T; 2 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 705 GTCAGCGCGAGCGCTG 721
Db :|||||
1 GUGAGCGCGAGCGCTG 17

RESULT 362
ADL48690
ID ADL48690 standard; RNA; 17 BP.
XX
XX AC ADL48690;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #1200.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2223; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 8 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 794 GAGCGCCAGCGCGCCTC 810
 DB 1 GAGCGCCAGCGCGCCTC 17
 RESULT 363
 ID ADL47547
 ID ADL47547 standard; RNA; 17 BP.
 XX
 AC ADL47547;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #57.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1080; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 5 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 633 CTGCCACTAAGGAATGC 649
 DB 1 CUGCCACUAGGAATGC 17
 RESULT 364
 ID ADL47556
 ID ADL47556 standard; RNA; 17 BP.
 XX
 AC ADL47556;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #66.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 XX 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 1089; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 2 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 OY 853 CCAGCTCTTCCAGAAAT 869
 Db 1 CCAGCUCUCCCAAGAAU 17
 RESULT 365
 ADL47557
 ID ADL47557 standard; RNA; 17 BP.
 XX
 AC ADL47557;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #67.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 XX 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 1090; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 5 C; 2 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 OY 854 CAGCTCTTCCCAAGAAAT 870
 Db 1 CAGCUCUCCCAAGAAU 17
 RESULT 366
 ADL47743
 ID ADL47743 standard; RNA; 17 BP.
 XX
 AC ADL47743;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```

DE XX Human IKK-gamma substrate sequence #253.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1276; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 5 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 199 TGGTGGCCCGGCGAG 215
DB 1 UGGUGGCGCGGCGAG 17

RESULT 367
ADL47754
ID ADL47754 standard; RNA; 17 BP.
XX
AC ADL47754;
XX
XX 20-MAY-2004 (first entry)
XX

```

```

DE XX Human IKK-gamma substrate sequence #264.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1287; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 6 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 251 AAGCCAGCATGCTGCA 267
DB 1 AAGCCAGCAUGCUGCA 17

RESULT 368
ADL47775
ID ADL47775 standard; RNA; 17 BP.
XX
AC ADL47775;
XX
XX 20-MAY-2004 (first entry)
XX

```


DE Human IKK-gamma substrate sequence #296.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1319; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 10 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 366 GGGAGCGCTCGAGGAG 382
 DB 1 GGGAGCGCTCGAGGAG 17
 RESULT 371
 ID ADL47799
 XX ADL47799 standard; RNA; 17 BP.
 AC ADL47799;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #309.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1332; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 426 TCATGTGCAAGTCCAG 442
 DB 1 UCAUGUGCAAGUCCAG 17
 RESULT 372
 ID ADL47814
 XX ADL47814 standard; RNA; 17 BP.
 AC ADL47814;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE	Human IKK-gamma substrate sequence #324.	DE	Human IKK-gamma substrate sequence #379.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
XX	Unidentified.	XX	Unidentified.
OS		OS	
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
XX	03-APR-2002; 2002WO-US010512.	XX	03-APR-2002; 2002WO-US010512.
PF		PF	
XX	05-APR-2001; 2001US-00827395.	XX	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
XX	(RIBO-) RIBOZYME PHARM INC.	XX	(RIBO-) RIBOZYME PHARM INC.
PA		PA	
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
XX	WPI; 2003-058513/05.	XX	WPI; 2003-058513/05.
DR		DR	
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite	XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
XX	Claim 59; SEQ ID NO 1347; 317pp; English.	XX	Claim 59; SEQ ID NO 1402; 317pp; English.
PS		PS	
XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;	SQ	Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	520 GGTGGAGCACCTGAAGA 536	QY	783 CGCTCCGCGATGGAGCGC 799
	:		:
Db	1 GGUGGAGCACCUAGA 17	Db	1 CGCUCGCGAUGGAGCGC 17
RESULT 373		RESULT 374	
ADL47869		ADL47892	
ID ADL47869 standard; RNA; 17 BP.		ID ADL47892 standard; RNA; 17 BP.	
XX		XX	
AC ADL47869;		AC ADL47892;	
XX		XX	
XX 20-MAY-2004 (first entry)		XX 20-MAY-2004 (first entry)	
DT		DT	
XX		XX	

DE Human IKK-gamma substrate sequence #402.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1425; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 8 A; 6 C; 2 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 873 ACAACCAATCATCAAGAGC 889
 DB 1 ACAACCAATCAAGAGC 17
 RESULT 375
 ID ADL48223
 XX ADL48223 standard; RNA; 17 BP.
 AC ADL48223;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #733.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1756; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 277 AGAACAGGGCGCTCTG 293
 DB 1 AGAACAGGGCGCTCTG 17
 RESULT 376
 ID ADL48229
 XX ADL48229 standard; RNA; 17 BP.
 AC ADL48229;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #739.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 23-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1762; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Query Match 2.3%; Score 17; DB 1; Length 17;

XX Best Local Similarity 82.4%; Pred. No. 2.2e+02;

XX Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 330 TCCGAGATGCCATCCGG 346

DB 1 UCCGAGAUCCGCAUCCGG 17

RESULT 377

ADL48230

ID ADL48230 standard; RNA; 17 BP.

XX ADL48230;

XX 20-MAY-2004 (first entry)

XX DT

DE Human IKK-gamma substrate sequence #740.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1763; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Query Match 2.3%; Score 17; DB 1; Length 17;

XX Best Local Similarity 94.1%; Pred. No. 2.2e+02;

XX Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 338 GCCATCCGCGCAGAGCAA 354

DB 1 GCCAUCGCGCAGAGCAA 17

RESULT 378

ADL48231

ID ADL48231 standard; RNA; 17 BP.

XX ADL48231;

XX 20-MAY-2004 (first entry)

XX DT

```

DE Human IKK-gamma substrate sequence #741.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1764; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 6 C; 5 G; 0 T; 0 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 343 CCGGCAGACGACACCGA 359
DB 1 CCGGCAGACGACACCGA 17
|||||
|||||

RESULT 379
ADL48262
ID ADL48262 standard; RNA; 17 BP.
XX
XX AC ADL48262;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #772.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1795; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 2 A; 5 C; 5 G; 0 T; 5 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 581 CAGGTGACGTCTTCTCT 597
DB 1 CAGGTGACGTCTTCTCT 17
|||||
|||||

RESULT 380
ADL48276
ID ADL48276 standard; RNA; 17 BP.
XX
XX AC ADL48276;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #786.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 23-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1809; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 2 A; 7 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 669 CCGCGGCGCGCGAG 685
Db 1 CCGCGGCGCGCGAG 17
RESULT 381
ADL48286
ID ADL48286 standard; RNA; 17 BP.
XX
XX AC ADL48286;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #796.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 23-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1819; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 708 AGCGCGAGCGCGAG 724
Db 1 AGCGCGAGCGCGAG 17
RESULT 382
ADL48292
ID ADL48292 standard; RNA; 17 BP.
XX
XX AC ADL48292;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #802.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1825; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 727 GCAGCACAGCGTGCAGG 743
 DB 1 GCAGCACAGCGTGCAGG 17
 RESULT 383
 ADL48305
 ID ADL48305 standard; RNA; 17 BP.
 XX
 AC ADL48305;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #815.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1838; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 776 GAGCGCGCGTCCGCAT 792
 DB 1 GAGCGCGCGTCCGCAT 17
 RESULT 384
 ADL48566
 ID ADL48566 standard; RNA; 17 BP.
 XX
 AC ADL48566;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1076.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI Novel enzymatic nucleic acid that down-regulates expression of neurite
 DR growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 XX protein kinase PKR genes, for treating cancer and inflammatory disease.
 PS Claim 59; SEQ ID NO 2099; 317pp; English.
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 212 GCAGATCAGGACGTACT 228
 Db 1 GCAGAUCAAGGACGUACU 17
 RESULT 385
 ADL48567
 ID ADL48567 standard; RNA; 17 BP.
 XX AC ADL48567;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1077.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI Novel enzymatic nucleic acid that down-regulates expression of neurite
 DR growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 XX protein kinase PKR genes, for treating cancer and inflammatory disease.
 PS Claim 59; SEQ ID NO 2100; 317pp; English.
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 213 CAGATCAGGACGTACTG 229
 Db 1 CAGAUCAGGACGUACUG 17
 RESULT 386
 ADL48568
 ID ADL48568 standard; RNA; 17 BP.
 XX AC ADL48568;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1078.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2101; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 221 GACGTACTGGCGGAAGA 237
 Db 1 GACGUACUGGCGGAAGA 17
 RESULT 387
 ID ADL48577
 XX ADL48577 standard; RNA; 17 BP.
 AC ADL48577;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1087.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2110; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 275 TCAGAACAGGGCGCTCC 291
 Db 1 UCAGAACAGGGCGCUCC 17
 RESULT 388
 ID ADL48586
 XX ADL48586 standard; RNA; 17 BP.
 AC ADL48586;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE	Human IKK-gamma substrate sequence #1096.	DE	Human IKK-gamma substrate sequence #1113.
XX		XX	
KW	antisense oligonucleotide; neurite growth inhibitor; NOGO;	KW	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 2119; 317pp; English.	PS	Claim 59; SEQ ID NO 2136; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 7 A; 4 C; 4 G; 0 T; 2 U; 0 Other;	SQ	Sequence 17 BP; 7 A; 0 C; 10 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 88.2%; Pred. No. 2.2e+02;		Best Local Similarity 100.0%; Pred. No. 2.2e+02;	
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;		Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	318 AGAATCAAGAGCTCCGA 334	QY	405 AGAGGGAGGAGAGGAG 421
DB	1 AGAAUCRAGAGCUCGGA 17	DB	1 AGAGGGAGGAGAGGAG 17
RESULT 389		RESULT 390	
ADL48603		ADL48612	
ID	ADL48603 standard; RNA; 17 BP.	ID	ADL48612 standard; RNA; 17 BP.
XX		XX	
AC	ADL48603;	AC	ADL48612;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	


```

DE XX Human IKK-gamma substrate sequence #1122.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2145; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 1 C; 8 G; 0 T; 2 U; 0 Other;
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 88.2%; Pred. No. 2.2e+02;
    Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 449 AGGAAACTGGTGAGAG 465
DB 1 AGGAACTGGTGAGAG 17
    |||||:|||||
    1 AGGAACTGGTGAGAG 17

RESULT 391
ADL48629
ID ADL48629 standard; RNA; 17 BP.
XX
AC ADL48629;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE XX Human IKK-gamma substrate sequence #1139.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2162; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 3 C; 10 G; 0 T; 3 U; 0 Other;
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 2.2e+02;
    Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 508 GGCTCTGGCGGAGGTGG 524
DB 1 GGCTCTGGCGGAGGTGG 17
    |||||:|||||
    1 GGCTCTGGCGGAGGTGG 17

RESULT 392
ADL48631
ID ADL48631 standard; RNA; 17 BP.
XX
AC ADL48631;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE		Human IKK-gamma substrate sequence #1141.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	
KW	protein kinase PKR; cerebrovascular accident;	
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	
KW	substrate; ds.	
OS	Unidentified.	
XX		
PX	WO200281628-A2.	
PD	17-OCT-2002.	
PF	03-APR-2002; 2002WO-US010512.	
PR	05-APR-2001; 2001US-00827395.	
PR	29-MAY-2001; 2001US-0294412P.	
PR	28-AUG-2001; 2001US-0315315P.	
XX	(RIBO-) RIBOZYME PHARM INC.	
PA		
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	
PI	WPI; 2003-058513/05.	
DR		
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	
XX		
PS	Claim 59; SEQ ID NO 2164; 317pp; English.	
XX		
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	
CC	that down regulate the expression or inhibit the function of a receptor	
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	
CC	invention are useful for treating: cerebrovascular accident, central	
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	
CC	disease, lupus, multiple sclerosis, transplant/grraft rejection,	
CC	ischaeamia/reperfusion injury, glomerulonephritis, sepsis, and allergic	
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	
CC	nucleic acids of the invention are also useful for down-regulating the	
CC	expression of a target gene and as a diagnostic tool to examine genetic	
CC	drifts and mutations within diseased cells or to detect the presence of a	
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	
CC	gamma substrate sequence.	
XX		
SQ	Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;	
	Query Match 2.3%; Score 17; DB 1; Length 17;	
	Best Local Similarity 82.4%; Pred. No. 2.2e+02;	
	Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;	
QY	510 CTCGTGGCGAGGTGGAG 526 : : : :	
Db	1 CUCUGCGGAGGUGGAG 17	
	RESULT 393	
ID	ADL48661	
ID	ADL48661 standard; RNA; 17 BP.	
AC	ADL48661;	
XX		
DT	20-MAY-2004 (first entry)	
XX		
XX		

DE		Human IKK-gamma substrate sequence #1171.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	
KW	protein kinase PKR; cerebrovascular accident;	
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	
KW	substrate; ds.	
OS	Unidentified.	
XX		
PX	WO200281628-A2.	
PD	17-OCT-2002.	
PF	03-APR-2002; 2002WO-US010512.	
PR	05-APR-2001; 2001US-00827395.	
PR	29-MAY-2001; 2001US-0294412P.	
PR	28-AUG-2001; 2001US-0315315P.	
XX	(RIBO-) RIBOZYME PHARM INC.	
PA		
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	
PI	WPI; 2003-058513/05.	
DR		
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	
XX		
PS	Claim 59; SEQ ID NO 2194; 317pp; English.	
XX		
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	
CC	that down regulate the expression or inhibit the function of a receptor	
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	
CC	invention are useful for treating: cerebrovascular accident, central	
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	
CC	disease, lupus, multiple sclerosis, transplant/grraft rejection,	
CC	ischaeamia/reperfusion injury, glomerulonephritis, sepsis, and allergic	
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	
CC	nucleic acids of the invention are also useful for down-regulating the	
CC	expression of a target gene and as a diagnostic tool to examine genetic	
CC	drifts and mutations within diseased cells or to detect the presence of a	
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	
CC	gamma substrate sequence.	
XX		
SQ	Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;	
	Query Match 2.3%; Score 17; DB 1; Length 17;	
	Best Local Similarity 82.4%; Pred. No. 2.2e+02;	
	Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;	
QY	650 CAGGCCTCTGGAGGTCG 666 : : : : : : : :	
Db	1 CAGGCUCUAGGAGGU CG 17	
	RESULT 394	
ID	ADL48674	
ID	ADL48674 standard; RNA; 17 BP.	
AC	ADL48674;	
XX		
DT	20-MAY-2004 (first entry)	
XX		

```

DE Human IKK-gamma substrate sequence #1184.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2207; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 2 C; 9 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 693 GGCAGCTGGAGAGTGAG 709
Db 1 GGCAGCTGGAGAGTGAG 17

RESULT 395
ADL48679
ID ADL48679 standard; RNA; 17 BP.
XX
AC ADL48679;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #1189.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2212; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 734 AGCGTGCAGGTGGACCA 750
Db 1 AGCGTGCAGGTGGACCA 17

RESULT 396
ADL48693
ID ADL48693 standard; RNA; 17 BP.
XX
AC ADL48693;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE Human IKK-gamma substrate sequence #1203.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2226; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 5 A; 3 C; 8 G; 0 T; 1 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 806 GCCTCGGAGGAGAGAG 822
 |||:|||||
 Db 1 GCCUCGGAGGAGAGAG 17
 RESULT 397
 ADL48707
 ID ADL48707 standard; RNA; 17 BP.
 XX AC ADL48707;
 XX AC ADL48707;
 XX DT 20-MAY-2004 (first entry)
 XX DT 20-MAY-2004 (first entry)

DE Human IKK-gamma substrate sequence #1217.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 DR Novel enzymatic nucleic acid that down-regulates expression of neurite
 XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2240; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 2 A; 2 C; 10 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 891 GCCTGGTGGCAGTGAG 907
 |||:|||||
 Db 1 GCGUGGGGCGAGAG 17
 RESULT 398
 ADL47515
 ID ADL47515 standard; RNA; 17 BP.
 XX AC ADL47515;
 XX AC ADL47515;
 XX DT 20-MAY-2004 (first entry)
 XX DT 20-MAY-2004 (first entry)

```

DE Human IKK-gamma substrate sequence #25.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1048; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 232 CGAAGAGTCTCTCTGG 248
Db 1 CGAAGAGUCUCCUUG 17

RESULT 399
ADL47536
ID ADL47536 standard; RNA; 17 BP.
XX
AC ADL47536;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #46.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1069; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 431 TGCAAGTTCAGGAGGC 447
Db 1 UGCAAGUUCAGGAGGC 17

RESULT 400
ADL47753
ID ADL47753 standard; RNA; 17 BP.
XX
AC ADL47753;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```
DE XX Human IKK-gamma substrate sequence #263.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 1286; 317pp; English.
XX SS
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 248 GGGAGGCGAGCCATGCT 264
Db 1 GGGAGGCGAGCCATGCT 17
RESULT 401
ADL47767
ID ADL47767 standard; RNA; 17 BP.
XX AC ADL47767;
XX DT 20-MAY-2004 (first entry)
XX
```

```
DE XX Human IKK-gamma substrate sequence #277.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 1300; 317pp; English.
XX SS
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX SQ Sequence 17 BP; 3 A; 8 C; 4 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 290 CCTGAGACCTCCAGCG 306
Db 1 CCUGAGACCTCCAGCG 17
RESULT 402
ADL47789
ID ADL47789 standard; RNA; 17 BP.
XX AC ADL47789;
XX DT 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #299.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1322; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 3 G; 0 T; 6 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred.No. 2.2e+02;
 Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
 QY 382 GCTTCTGCAATTTCCCAAG 398
 DB 1 GCUUCUGCAUUCCAAG 17
 RESULT 403
 ID ADL47807
 XX ADL47807 standard; RNA; 17 BP.
 AC ADL47807;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #317.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1340; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred.No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 466 ACTCGCGCTGGAGAGC 482
 DB 1 ACUCGCGCUGGAGAGC 17
 RESULT 404
 ID ADL47811
 XX ADL47811 standard; RNA; 17 BP.
 AC ADL47811;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE Human IKK-gamma substrate sequence #321.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1344; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;
XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 499 GAAGGAGCAGGCTCTGC 515
XX |||||:|||||:|
XX Db 1 GAAGGAGCAGGCTCTGC 17
XX
XX RESULT 405
XX ADL47820
XX ID ADL47820 standard; RNA; 17 BP.
XX
XX AC ADL47820;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX

```

```

DE Human IKK-gamma substrate sequence #330.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1353; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;
XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 541 CCAGCAGCAGATGGCTG 557
XX |||||:|||||:|
XX Db 1 CCAGCAGCAGATGGCTG 17
XX
XX RESULT 406
XX ADL47823
XX ID ADL47823 standard; RNA; 17 BP.
XX
XX AC ADL47823;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX

```


DE Human IKK-gamma substrate sequence #333.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

PN

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

PF

XX 05-APR-2001; 2001US-00827395.

XX

PR 29-MAY-2001; 2001US-0294412P.

PR

XX 28-AUG-2001; 2001US-0315315P.

XX

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-058513/05.

DR

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX

PS Claim 59; SEQ ID NO 1356; 317pp; English.

XX

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 560 GACAAGGCTCTGTGTGAA 576

DB 1 GACAAGGCTCTGTGTGAA 17

RESULT 407

ADL47836

ID ADL47836 standard; RNA; 17 BP.

XX

AC ADL47836;

XX

XX 20-MAY-2004 (first entry)

DT

XX

DE Human IKK-gamma substrate sequence #346.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

PN

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

PF

XX 05-APR-2001; 2001US-00827395.

XX

PR 29-MAY-2001; 2001US-0294412P.

PR

XX 28-AUG-2001; 2001US-0315315P.

XX

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-058513/05.

DR

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX

PS Claim 59; SEQ ID NO 1369; 317pp; English.

XX

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 2.2e+02;

Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 618 AGAGTCGCTTGAGGCT 634

DB 1 AGAGTCGCTTGAGGCT 17

RESULT 408

ADL47845

ID ADL47845 standard; RNA; 17 BP.

XX

AC ADL47845;

XX

XX 20-MAY-2004 (first entry)

DT

XX

DE Human IKK-gamma substrate sequence #355.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 1378; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 0 A; 6 C; 10 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 662 GGTCTGGGCCCCGGCGGC 678
 Db 1 GGUCGGGCCCCGGCGGC 17
 RESULT 409
 ADL47849
 ID ADL47849 standard; RNA; 17 BP.
 XX
 AC ADL47849;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #359.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 1382; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 679 CAGCGAGCGGCGCGGC 695
 Db 1 CAGCGAGCGGCGCGGC 17
 RESULT 410
 ADL47860
 ID ADL47860 standard; RNA; 17 BP.
 XX
 AC ADL47860;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```

DE Human IKK-gamma substrate sequence #370.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1393; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02; Indels 0; Gaps 0;
Matches 15; Conservative 2; Mismatches 0;

QY 742 GGTGGACCACTGCGCA 758
DB 1 GGUGGACCACTGCGCA 17
|||||:|||||:|||||:|

RESULT 411
ADL47882
ID ADL47882 standard; RNA; 17 BP.
XX
AC ADL47882;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #392.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1415; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02; Indels 0; Gaps 0;
Matches 13; Conservative 4; Mismatches 0;

QY 844 GGCCTATCACCAGCTCT 860
DB 1 GGCCUACACACGAGCUCU 17
|||||:|||||:|||||:|

RESULT 412
ADL48204
ID ADL48204 standard; RNA; 17 BP.
XX
AC ADL48204;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```



```

DE Human IKK-gamma substrate sequence #763.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor. IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1786; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 518 GAGGTGGAGCACTGAA 534
DB 1 GAGGUGGAGCACCUGAA 17
|||||:|||||:|||||

RESULT 415
ADL48285
ID ADL48285 standard; RNA; 17 BP.
XX
AC ADL48285;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #795.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor. IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1818; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 9 G; 0 T; 1 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 703 GAGTGAGCGCGAGCGGC 719
DB 1 GAGUGAGCGCGAGCGGC 17
|||||:|||||:|||||

RESULT 416
ADL48304
ID ADL48304 standard; RNA; 17 BP.
XX
AC ADL48304;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #814.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX
PN WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX
PS Claim 59; SEQ ID NO 1837; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 7 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 774 TGGAGGCGCGCTCCGC 790
Db 1 UGGAGGCGCGCTCCGC 17
RESULT 417
ADL48308
ID ADL48308 standard; RNA; 17 BP.
XX
AC ADL48308;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #818.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX
PN WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX
PS Claim 59; SEQ ID NO 1841; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 790 CATGAGCGCCAGCGCG 806
Db 1 CAUGGAGCGCCAGCGCG 17
RESULT 418
ADL48310
ID ADL48310 standard; RNA; 17 BP.
XX
AC ADL48310;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #820.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1843; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 798 GCCAGCCGCCCTCGGAG 814
 DB 1 GCCAGCCGCCCTCGGAG 17
 RESULT 419
 ADL48475
 ID ADL48475 standard; RNA; 17 BP.
 XX
 AC ADL48475;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #985.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2008; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 208 GGCAGCAGATCAGGACG 224
 DB 1 GGCAGCAGATCAGGACG 17
 RESULT 420
 ADL48481
 ID ADL48481 standard; RNA; 17 BP.
 XX
 AC ADL48481;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #991.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2014; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 6 A; 5 C; 4 G; 0 T; 2 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 OY 346 GCAGAGCAACAGATTC 362
 DB 1 GCAGAGCAACAGAUUC 17
 RESULT 421
 ADL48484
 ID ADL48484 standard; RNA; 17 BP.
 XX AC ADL48484;
 XX AC ADL48484;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #994.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS Unidentified.
 XX WO200281628-A2.
 PN 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 PF 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 PI Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2017; 317pp; English.
 PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 XX that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 OY 458 GTGAGAGACTCGGCT 474
 DB 1 GUGGAGAGACUCGGCCU 17
 RESULT 422
 ADL48486
 ID ADL48486 standard; RNA; 17 BP.
 XX AC ADL48486;
 XX AC ADL48486;
 XX DT 20-MAY-2004 (first entry)
 XX


```

DE Human IKK-gamma substrate sequence #996.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2019; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 530 CTGAGAGATGCCAGCA 546
DB 1 CUGAGAGAGGCCAGCA 17
RESULT 423
ADL48618
ID ADL48618 standard; RNA; 17 BP.
XX
AC ADL48618;
XX
XX 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #1128.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2151; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 467 CTCGGCCTGGAGAGCT 483
DB 1 CUCGGCCUGGAGAGCU 17
RESULT 424
ADL48641
ID ADL48641 standard; RNA; 17 BP.
XX
AC ADL48641;
XX
XX 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #1151.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2174; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 551 ATGGCTGAGGACAAAGGC 567
 Db :|||||:|||||:|||||
 1 AUGGCGAGGACAAAGGC 17
 RESULT 425
 ADL48645
 ID ADL48645 standard; RNA; 17 BP.
 XX
 AC ADL48645;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1155.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2178; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 575 AAAGCCAGGTGACGTC 591
 Db :|||||:|||||:|||||
 1 AAAGCCAGGTGACGTC 17
 RESULT 426
 ADL48646
 ID ADL48646 standard; RNA; 17 BP.
 XX
 AC ADL48646;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #1180.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.
XX	Unidentified.
OS	Unidentified.
XX	WO200281628-A2.
PN	17-OCT-2002.
XX	03-APR-2002; 2002WO-US010512.
XX	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
XX	(RIBO-) RIBOZYME PHARM INC.
PA	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX	WPI; 2003-058513/05.
DR	Novel enzymatic nucleic acid that down-regulates expression of neurite
XX	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	Claim 59; SEQ ID NO 2179; 317pp; English.
PS	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
XX	Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
SQ	Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 76.5%; Pred. No. 2.2e+02;
	Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY	578 GCCCAGGTGACGTCCTT 594
DB	1 GCCCAGGTGACGUCCUU 17
RESULT 427	
ADL48670	
ID	ADL48670 standard; RNA; 17 BP.
XX	
AC	ADL48670;
XX	
DT	20-MAY-2004 (first entry)
XX	

DE Human IKK-gamma substrate sequence #1186.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Meswigen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 2209; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 2 C; 9 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 699 TGGAGAGTGAGCGCGAG 715
 Db :|||||:|||||
 1 UGGAGAGUGAGCGCGAG 17
 RESULT 429
 ADL48692
 ID ADL48692 standard; RNA; 17 BP.
 XX
 AC ADL48692;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1202.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Meswigen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 2225; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 804 CCGCTCGGAGGAGAG 820
 Db :|||||:|||||
 1 CCGCTCGGAGGAGAG 17
 RESULT 430
 ADL48695
 ID ADL48695 standard; RNA; 17 BP.
 XX
 AC ADL48695;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```

DE Human IKK-gamma substrate sequence #1205.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2228; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 7 A; 1 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 809 TCGGAGGAGAGAGGAA 825
DB 1 UCGGAGGAGAGAGGAA 17
:|||||:|||||
:|||||:|||||

RESULT 431
ADL47526
ID ADL47526 standard; RNA; 17 BP.
XX
AC ADL47526;
XX
DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #36.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1059; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 354 ACCAGATTCTCGGAG 370
DB 1 ACCAGAUUCUGCGGAG 17
:|||||:|||||
:|||||:|||||

RESULT 432
ADL47738
ID ADL47738 standard; RNA; 17 BP.
XX
AC ADL47738;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #248.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 1271; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 184 GATGGTCAGCCAGTG 200
Db 1 GAUGGUCAGCCAGUG 17
RESULT 433
ADL47766
ID ADL47766 standard; RNA; 17 BP.
XX
XX ADL47766;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE Human IKK-gamma substrate sequence #276.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 1299; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 284 GGCGTCCTGAGACCCCT 300
Db 1 GGCGTCCTGAGACCCCT 17
RESULT 434
ADL47768
ID ADL47768 standard; RNA; 17 BP.
XX
XX ADL47768;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE Human IKK-gamma substrate sequence #278.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1301; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 8 C; 4 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 291 CTGAGACCTCCAGCGC 307
Db 1 CUGAGACCTCCAGCGC 17

RESULT 435
ADL47795
ID ADL47795 standard; RNA; 17 BP.
XX
AC ADL47795;
XX
XX 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #305.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1328; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 4 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 397 AGCCAGCCAGAGGAGG 413
Db 1 AGCCAGCCAGAGGAGG 17

RESULT 436
ADL47817
ID ADL47817 standard; RNA; 17 BP.
XX
AC ADL47817;
XX
XX 20-MAY-2004 (first entry)
XX

```

DE	Human IKK-gamma substrate sequence #327.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.
XX	Unidentified.
OS	WO200281628-A2.
PN	17-OCT-2002.
XX	03-APR-2002; 2002WO-US010512.
PF	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PP	28-AUG-2001; 2001US-0315315P.
XX	(RIBO-) RIBOZYME PHARM INC.
PA	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI	WPI; 2003-058513/05.
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	Claim 59; SEQ ID NO 1350; 317pp; English.
PS	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
XX	Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
SQ	Query Match 2.3%; Score 17; DB 1; Length 17; Best Local Similarity 94.1%; Pred. No. 2.2e+02; Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY	534 AGAGATGCCAGCGACG 550 : 1 AGAGAUGCAGCGACG 17
DB	ADL47822 standard; RNA; 17 BP. ADL47822; 20-MAY-2004 (first entry)
RESULT 437	
ID	ADL47822
XX	ADL47822;
XX	ADL47822;
XX	ADL47822;
DT	20-MAY-2004 (first entry)
XX	

DE	Human IKK-gamma substrate sequence #332.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.
XX	Unidentified.
OS	WO200281628-A2.
PN	17-OCT-2002.
XX	03-APR-2002; 2002WO-US010512.
PF	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PP	28-AUG-2001; 2001US-0315315P.
XX	(RIBO-) RIBOZYME PHARM INC.
PA	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI	WPI; 2003-058513/05.
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX	Claim 59; SEQ ID NO 1355; 317pp; English.
PS	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
XX	Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
SQ	Query Match 2.3%; Score 17; DB 1; Length 17; Best Local Similarity 82.4%; Pred. No. 2.2e+02; Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY	555 CTCGAGCACAAAGGCCTCT 571 : : 1 CUGAGGACAAGGCCUCU 17
DB	ADL47879 standard; RNA; 17 BP. ADL47879; 20-MAY-2004 (first entry)
RESULT 438	
ID	ADL47879
XX	ADL47879;
XX	ADL47879;
XX	ADL47879;
DT	20-MAY-2004 (first entry)
XX	


```

DE XX Human IKK-gamma substrate sequence #389.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
XX
PR 29-MAY-2001; 2001US-0294412P.
XX
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1412; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 832 CCAGTTGCAGGTGGCCT 848
DB 1 CCAGUUGCAGGUGCCU 17
|||||:|||||:
1 CCAGUUGCAGGUGCCU 17

RESULT 439
ADL48206
ID ADL48206 standard; RNA; 17 BP.
XX
AC ADL48206;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE XX Human IKK-gamma substrate sequence #716.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
XX
PR 29-MAY-2001; 2001US-0294412P.
XX
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1739; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 3 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 172 CCAACTGTGTGAGATGG 188
DB 1 CCAACUGUGAGAGUGG 17
|||||:|||||:
1 CCAACUGUGAGAGUGG 17

RESULT 440
ADL48233
ID ADL48233 standard; RNA; 17 BP.
XX
AC ADL48233;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

```
DE Human IKK-gamma substrate sequence #743.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD
XX PF 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 23-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 1766; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX SQ Sequence 17 BP; 2 A; 5 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 362 CTCGGGAGGCTCTCGCA 378
Db 1 CUGCGGAGGCTCTCGCA 17
RESULT 441
ADL48250
ID ADL48250 standard; RNA; 17 BP.
XX AC ADL48250;
XX AC ADL48250;
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #760.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD
XX PF 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 23-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 1783; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 501 AGGAGGAGGCTCTCGCG 517
Db 1 AGGAGGAGGCTCTCGCG 17
RESULT 442
ADL48261
ID ADL48261 standard; RNA; 17 BP.
XX AC ADL48261;
XX AC ADL48261;
XX DT 20-MAY-2004 (first entry)
XX
```

```

DE XX Human IKK-gamma substrate sequence #771.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1794; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 576 AAGCCGAGTGACGTCC 592
DB 1 AAGCCGAGTGACGTCC 17

RESULT 443
ADL48287
ID ADL48287 standard; RNA; 17 BP.
XX
AC ADL48287;
XX
XX 20-MAY-2004 (first entry)
XX

```

```

DE XX Human IKK-gamma substrate sequence #797.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1820; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 710 CGCGAGGCGCTGCAGCA 726
DB 1 CGCGAGGCGCTGCAGCA 17

RESULT 444
ADL48306
ID ADL48306 standard; RNA; 17 BP.
XX
AC ADL48306;
XX
XX 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #816.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN W0200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1839; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 781 CGCGCTCCGATGGAGC 797
 |||||:|||||:
 Db 1 CGCGCUCGCGAUGGAGC 17
 RESULT 445
 ADL48584
 ID ADL48584 standard; RNA; 17 BP.
 XX
 AC ADL48584;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1094.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN W0200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2117; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 309 GCCTGAGGAGAAATCAA 325
 |||||:|||||:
 Db 1 GCCUGGAGGAGAAUCA 17
 RESULT 446
 ADL48587
 ID ADL48587 standard; RNA; 17 BP.
 XX
 AC ADL48587;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1097.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2120; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 325 AGAGCTCCGAGATGCCA 341
 DB 1 AGAGCTCCGAGATGCCA 17
 RESULT 447
 ADL48590
 ID ADL48590 standard; RNA; 17 BP.
 XX
 AC ADL48590;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1100.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2123; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 6 C; 4 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 341 ATCCGCGAGACCA 357
 DB 1 ATCCGCGAGACCA 17
 RESULT 448
 ADL48642
 ID ADL48642 standard; RNA; 17 BP.
 XX
 AC ADL48642;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1152.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 23-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2175; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 552 TGCGTGGAGGACAGGCC 568
:|||||:|||||
Db 1 UGCGUGAGGACAGGCC 17
RESULT 449
ADL48651
ID ADL48651 standard; RNA; 17 BP.
XX
AC ADL48651;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1161.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 23-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2184; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 602 GAGCTGCAGGAGGCCA 618
:|||||:|||||
Db 1 GAGCUGAGGAGGCCA 17
RESULT 450
ADL48701
ID ADL48701 standard; RNA; 17 BP.
XX
AC ADL48701;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1211.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2234; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 836 TTGACGTCGGCTATCA 852
 DB 1 UUGCAGGUGGCUAUA 17
 RESULT 451
 ADL47521
 ID ADL47521 standard; RNA; 17 BP.
 XX
 AC ADL47521;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #31.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1054; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 7 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 293 GAGACCCCTCCAGCGCTG 309
 DB 1 GAGACCCUCCAGCGCUG 17
 RESULT 452
 ADL47527
 ID ADL47527 standard; RNA; 17 BP.
 XX
 AC ADL47527;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE	Human IKK-gamma substrate sequence #37.	DE	Human IKK-gamma substrate sequence #41.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
XX		XX	
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
XX		XX	
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1060; 317pp; English.	PS	Claim 59; SEQ ID NO 1064; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 3 A; 3 C; 5 G; 0 T; 6 U; 0 Other;	SQ	Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 64.7%; Pred. No. 2.2e+02;		Best Local Similarity 76.5%; Pred. No. 2.2e+02;	
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;		Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;	
QY	377 GAGGAGCTTCGCAATTT 393	QY	386 CTGCATTTCACAGCCAG 402
DB	1 GAGGAGCUUCUGCAUUU 17	DB	1 CUGCAUUUCCAGCCAG 17
RESULT 453		RESULT 454	
ADL47531		ADL47539	
ID	ADL47531 standard; RNA; 17 BP.	ID	ADL47539 standard; RNA; 17 BP.
XX		XX	
AC	ADL47531;	AC	ADL47539;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #49.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1072; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 480 AGCTCGATCTGAAGAGG 496
 DB 1 AGCTCGAUCUGAAGAGG 17
 RESULT 455
 ID ADL47541
 ADL47541 standard; RNA; 17 BP.
 XX
 AC ADL47541;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #51.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1074; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 562 CAAGGCCCTCTGTGAAG 578
 DB 1 CAAGGCCCTCTGTGAAG 17
 RESULT 456
 ID ADL47548
 ADL47548 standard; RNA; 17 BP.
 XX
 AC ADL47548;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX


```

DE DE Human IKK-gamma substrate sequence #267.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
OS
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1290; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.8%; Pred. No. 2.2e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 259 CATGCTGCACCTGCTT 275
Db 1 CAUGCUGACCUGCCUU 17

RESULT 459
ADL47801
ID ADL47801 standard; RNA; 17 BP.
XX
XX AC ADL47801;
XX
XX 20-MAY-2004 (first entry)
XX

DE DE Human IKK-gamma substrate sequence #311.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
OS
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1334; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 5 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 433 CAAGTTCAGGAGGCCA 449
Db 1 CAAGUCCAGGAGGCCA 17

RESULT 460
ADL47813
ID ADL47813 standard; RNA; 17 BP.
XX
XX AC ADL47813;
XX
XX 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #323.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1346; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 9 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 505 GCAGGCTCTCGGGAGG 521
 DB 1 GCAGGCTCTCGGGAGG 17
 RESULT 461
 ADL47818
 ID ADL47818 standard; RNA; 17 BP.
 XX
 AC ADL47818;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #328.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1351; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 535 GAGATGCCAGCAGCAGA 551
 DB 1 GAGATGCCAGCAGCAGA 17
 RESULT 462
 ADL47842
 ID ADL47842 standard; RNA; 17 BP.
 XX
 AC ADL47842;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```

DE Human IKK-gamma substrate sequence #352.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX
XX Claim 59; SEQ ID NO 1375; 317pp; English.
XX PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX CC
XX
XX Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
XX SQ
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 2.2e+02;
XX Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 643 GGAATGCCAGGCTCTGG 659
XX Db 1 GGAATGCCAGGCTCTGG 17
XX
XX
XX RESULT 463
XX ADL47858
XX ID ADL47858 standard; RNA; 17 BP.
XX AC
XX ADL47858;
XX XX
XX 20-MAY-2004 (first entry)
XX DT
XX

```

```

DE Human IKK-gamma substrate sequence #368.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX
XX Claim 59; SEQ ID NO 1391; 317pp; English.
XX PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX CC
XX
XX Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
XX SQ
XX
XX Query Match 2.3%; Score 17; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 2.2e+02;
XX Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 733 CAGCGTCGAGGTGACC 749
XX Db 1 CAGCGTCGAGGTGACC 17
XX
XX
XX RESULT 464
XX ADL47865
XX ID ADL47865 standard; RNA; 17 BP.
XX AC
XX ADL47865;
XX XX
XX 20-MAY-2004 (first entry)
XX DT
XX

```

DE	Human IKK-gamma substrate sequence #375.	DE	Human IKK-gamma substrate sequence #380.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
XX	Unidentified.	XX	Unidentified.
XX	WO200281628-A2.	XX	WO200281628-A2.
XX	17-OCT-2002.	XX	17-OCT-2002.
XX	03-APR-2002; 2002WO-US010512.	XX	03-APR-2002; 2002WO-US010512.
XX	05-APR-2001; 2001US-00827395.	XX	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX	(RIBO-) RIBOZYME PHARM INC.	XX	(RIBO-) RIBOZYME PHARM INC.
PA	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PA	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI	WPI; 2003-058513/05.	PI	WPI; 2003-058513/05.
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite	XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
XX	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	XX	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
PT	Claim 59; SEQ ID NO 1398; 317pp; English.	PT	Claim 59; SEQ ID NO 1403; 317pp; English.
XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX	Sequence 17 BP; 3 A; 4 C; 9 G; 0 T; 1 U; 0 Other;	XX	Sequence 17 BP; 2 A; 7 C; 7 G; 0 T; 1 U; 0 Other;
SQ	Query Match 2.3%; Score 17; DB 1; Length 17;	SQ	Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 94.1%; Pred. No. 2.2e+02;		Best Local Similarity 94.1%; Pred. No. 2.2e+02;
	Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;		Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY	760 GCAGGGCCAGAGCGTGG 776	QY	792 TGGAGCGCCAGCGCGCC 808
DB	1 GCAGGGCCAGAGCGUGG 17	DB	1 UGGAGCGCCAGCGCGCC 17
RESULT 465		RESULT 466	
ADL47870		ADL47875	
ID	ADL47870 standard; RNA; 17 BP.	ID	ADL47875 standard; RNA; 17 BP.
XX	ADL47870;	XX	ADL47875;
AC	20-MAY-2004 (first entry)	AC	20-MAY-2004 (first entry)
XX		XX	
DT		DT	
XX		XX	

DE Human IKK-gamma substrate sequence #385.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 1408; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 820 GAGGAAGCTGGCCAGT 836
 DB 1 GAGGAAGCTGGCCAGU 17
 |||||:|||||
 1 GAGGAAGCTGGCCAGU 17
 RESULT 467
 ADL47893
 ID ADL47893 standard; RNA; 17 BP.
 XX
 AC ADL47893;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #403.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 1426; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 7 A; 6 C; 3 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 876 ACCACATCAAGAGCAGC 892
 DB 1 ACCACATCAAGAGCAGC 17
 |||||:|||||
 1 ACCACATCAAGAGCAGC 17
 RESULT 468
 ADL47894
 ID ADL47894 standard; RNA; 17 BP.
 XX
 AC ADL47894;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #734.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1757; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 279 AACAGGGCGCTCTGTAG 295
 DB 1 AACAGGGCGCTCTGTAG 17
 |||||:|||||
 RESULT 471
 ADL48254
 ID ADL48254 standard; RNA; 17 BP.
 XX
 AC ADL48254;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #764.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1787; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 532 GAAGAGATGCCAGCAGC 548
 DB 1 GAAGAGATGCCAGCAGC 17
 |||||:|||||
 RESULT 472
 ADL48256
 ID ADL48256 standard; RNA; 17 BP.
 XX
 AC ADL48256;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```
DE Human IKK-gamma substrate sequence #766.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX
XX 23-MAY-2001; 2001US-0294412P.
PR
XX
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 1789; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 539 TGCCAGCAGCAGATGGC 555
DB 1 UGCCAGCAGCAGATGGC 17
:|||||:|||||:|||||
1 UGCCAGCAGCAGATGGC 17

RESULT 473
ADL48268
ID ADL48268 standard; RNA; 17 BP.
XX
XX ADL48268;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
```

```
DE Human IKK-gamma substrate sequence #778.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX
XX 23-MAY-2001; 2001US-0294412P.
PR
XX
XX 28-AUG-2001; 2001US-0315315P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
XX Claim 59; SEQ ID NO 1801; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 616 CCAGAGTCGCTTGAGG 632
DB 1 CCAGAGUCGUUGGAGG 17
:|||||:|||||:|||||
1 CCAGAGUCGUUGGAGG 17

RESULT 474
ADL48272
ID ADL48272 standard; RNA; 17 BP.
XX
XX ADL48272;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
```

```

DE XX Human IKK-gamma substrate sequence #782.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX PF
XX 03-APR-2002; 2002WO-US010512.
XX XX
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX
XX Claim 59; SEQ ID NO 1805; 317pp; English.
XX PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX CC
XX SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 645 AATGCCAGGCTCTGGAG 661
DB 1 AAUGCCAGGCUCUGGAG 17
|||||:|||||
1 AAUGCCAGGCUCUGGAG 17

RESULT 475
ADL48293
ID ADL48293 standard; RNA; 17 BP.
XX
XX AC ADL48293;
XX AC
XX 20-MAY-2004 (first entry)
XX DT
XX

DE XX Human IKK-gamma substrate sequence #803.
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX PF
XX 03-APR-2002; 2002WO-US010512.
XX XX
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX
XX Claim 59; SEQ ID NO 1826; 317pp; English.
XX PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX CC
XX SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 729 AGCACAGCGTGCAGGTG 745
DB 1 AGCACAGCGTGCAGGTG 17
|||||:|||||
1 AGCACAGCGTGCAGGTG 17

RESULT 476
ADL48323
ID ADL48323 standard; RNA; 17 BP.
XX
XX AC ADL48323;
XX AC
XX 20-MAY-2004 (first entry)
XX DT
XX

```

DE Human IKK-gamma substrate sequence #833.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1856; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 2 C; 10 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 895 GGTGGGCGAGTGAGCGGA 911
Db 1 GGUGGGCAGUGAGCGGA 17
RESULT 477
ADL48476
ID ADL48476 standard; RNA; 17 BP.
XX
AC ADL48476;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #986.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2009; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 214 AGATCAGGACGACTCG 230
Db 1 AGAUCAGGACGACUGG 17
RESULT 478
ADL48569
ID ADL48569 standard; RNA; 17 BP.
XX
AC ADL48569;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #1079.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX
PF 03-APR-2002; 2002WO-US010512.
XX
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX
PS Claim 59; SEQ ID NO 2102; 317pp; English.
XX
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 222 ACGTACTGCGCGAAGAG 238
DB 1 ACGUACUGGCGAAGAG 17
|||||
1 ACGUACUGGCGAAGAG 17

RESULT 479
ADL48582
ID ADL48582 standard; RNA; 17 BP.
XX
XX
AC ADL48582;
XX
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1092.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX
PF 03-APR-2002; 2002WO-US010512.
XX
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX
PS Claim 59; SEQ ID NO 2115; 317pp; English.
XX
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 3 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 306 GCTGCTCGGAGGAGAAAT 322
DB 1 GCUGCCUGGAGGAGAAU 17
|||||
1 GCUGCCUGGAGGAGAAU 17

RESULT 480
ADL48596
ID ADL48596 standard; RNA; 17 BP.
XX
XX
AC ADL48596;
XX
XX
DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #1106.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-059513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2129; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 371 CGTCGCGAGGAGCTTCT 387
Db 1 CGCUGCGAGGAGCUUCU 17
RESULT 481
ADL48619
ID ADL48619 standard; RNA; 17 BP.
XX
XX AC ADL48619;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #1129.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-059513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2152; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy 468 TCGCGCTGGAGAGCTC 484
Db 1 UCGCGCTGGAGAGCUC 17
RESULT 482
ADL48636
ID ADL48636 standard; RNA; 17 BP.
XX
XX AC ADL48636;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE	Human IKK-gamma substrate sequence #1146.	DE	Human IKK-gamma substrate sequence #1169.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX	substrate; ds.	XX	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 2169; 317pp; English.	PS	Claim 59; SEQ ID NO 2192; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 6 A; 5 C; 4 G; 0 T; 2 U; 0 Other;	SQ	Sequence 17 BP; 6 A; 5 C; 4 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	527 CACCTGAAGAGATGCCA 543	QY	636 CCACCTAAGGAATGCCAG 652
DB	1 CACCTGAAGAGATGCCA 17	DB	1 CCACUAGGAAUGCCAG 17
	: :		: :
RESULT 483		RESULT 484	
ADL48659		ADL48660	
ID	ADL48659 standard; RNA; 17 BP.	ID	ADL48660 standard; RNA; 17 BP.
XX		XX	
AC	ADL48659;	AC	ADL48660;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #1170.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

PN

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

PF

XX 05-APR-2001; 2001US-00827395.

XX

PR 29-MAY-2001; 2001US-0294412P.

PR

PR 28-AUG-2001; 2001US-0315315P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-058513/05.

XX

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PT

XX Claim 59; SEQ ID NO 2193; 317pp; English.

PS

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident; central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 644 GAATGCCAGGCTGTGA 660

Db 1 GAAUGCCAGGCTUGGA 17

RESULT 485

ADL48663

ID ADL48663 standard; RNA; 17 BP.

XX

AC ADL48663;

XX

XX 20-MAY-2004 (first entry)

DT

XX

DE Human IKK-gamma substrate sequence #1173.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX WO200281628-A2.

PN

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

PF

XX 05-APR-2001; 2001US-00827395.

XX

PR 29-MAY-2001; 2001US-0294412P.

PR

PR 28-AUG-2001; 2001US-0315315P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-058513/05.

XX

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PT

XX Claim 59; SEQ ID NO 2196; 317pp; English.

PS

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident; central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 1 A; 4 C; 9 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 653 GCTCTGGAGGTCGGGC 669

Db 1 GCUCUGAGGCGCGGC 17

RESULT 486

ADL48673

ID ADL48673 standard; RNA; 17 BP.

XX

AC ADL48673;

XX

XX 20-MAY-2004 (first entry)

DT

XX

DE Human IKK-gamma substrate sequence #1183.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2206; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 692 CGGACGCTGGAGAGTGA 708
 DB 1 CGGACGCTGGAGAGTGA 17
 RESULT 487
 ADL48704
 ID ADL48704 standard; RNA; 17 BP.
 XX
 AC ADL48704;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1214.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2237; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 5 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 878 CACATCAAGAGCAGCGT 894
 DB 1 CACATCAAGAGCAGCGT 17
 RESULT 488
 ADL47524
 ID ADL47524 standard; RNA; 17 BP.
 XX
 AC ADL47524;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #34.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX Unidentified.
XX OS
XX PN W0200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L., Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1057; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 335 GATGCCATCCGCGCAGAG 351
||:||||:|||||
Db 1 GAUGCCAUCGCGCAGAG 17
RESULT 489
ADL47535
ID ADL47535 standard; RNA; 17 BP.
XX
XX AC ADL47535;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #45.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX Unidentified.
XX OS
XX PN W0200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L., Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1068; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX SQ Sequence 17 BP; 4 A; 3 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 430 GTCCAAGTTCAGGAGG 446
||:||||:|||||
Db 1 GUGCAAGUCCAGGAGG 17
RESULT 490
ADL47545
ID ADL47545 standard; RNA; 17 BP.
XX
XX AC ADL47545;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #55.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1078; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 615 GCCAGAGTCGCTTGAG 631
 DB 1 GCCAGAGCGCCTTGAG 17
 RESULT 491
 ADL47735
 ID ADL47735 standard; RNA; 17 BP.
 XX
 AC ADL47735;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #245.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1268; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 165 GGAAGAGGCAACTGTGT 181
 DB 1 GGAAGAGGCAACUGUGU 17
 RESULT 492
 ADL47746
 ID ADL47746 standard; RNA; 17 BP.
 XX
 AC ADL47746;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```
DE Human IKK-gamma substrate sequence #256.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Posnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1279; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 211 AGCAGATCAGGACGTAC 227
Db 1 AGCAGATCAGGACGTAC 17
|||||:|||||:|
1 AGCAGATCAGGACGTAC 17

RESULT 493
ADL47748
ID ADL47748 standard; RNA; 17 BP.
XX
XX ADL47748;
XX
XX 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #258.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Posnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1281; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 233 GAAGAGTCCTCTGGG 249
Db 1 GAAGAGTCCTCTGGG 17
|||||:|||||:|
1 GAAGAGTCCTCTGGG 17

RESULT 494
ADL47760
ID ADL47760 standard; RNA; 17 BP.
XX
XX ADL47760;
XX
XX 20-MAY-2004 (first entry)
XX
```

DE Human IKK-gamma substrate sequence #270.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowira B, Haerberli P, Meswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1293; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 4 A; 7 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred.No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 265 GCACCTGCTTCAGAAC 281

|||||:|||||

Db 1 GCACCGCCUUCAGAAC 17

RESULT 495

ADL47770

ID ADL47770 standard; RNA; 17 BP.

XX AC ADL47770;

XX 20-MAY-2004 (first entry)

DT XX

DE Human IKK-gamma substrate sequence #280.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowira B, Haerberli P, Meswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1303; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 3 A; 8 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred.No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 294 AGACCTTCAGCGCTGC 310

|||||:|||||

Db 1 AGACCCUCCAGCGCTGC 17

RESULT 496

ADL47780

ID ADL47780 standard; RNA; 17 BP.

XX AC ADL47780;

XX 20-MAY-2004 (first entry)

DT XX

DE Human IKK-gamma substrate sequence #290.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX

XX WO200281628-A2.

PN

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

PF

XX 05-APR-2001; 2001US-00827395.

PR

XX 29-MAY-2001; 2001US-0294412P.

PR

XX 28-AUG-2001; 2001US-0315315P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-059513/05.

DR

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PT

XX Claim 59; SEQ ID NO 1313; 317pp; English.

PS

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 336 ATGCCATCCGCGAGC 352

Db 1 AUGGCAUCCGCGAGC 17

RESULT 497

ADL47790

ID ADL47790 standard; RNA; 17 BP.

XX

XX AC ADL47790;

XX

XX 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #300.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS

XX

XX WO200281628-A2.

PN

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

PF

XX 05-APR-2001; 2001US-00827395.

PR

XX 29-MAY-2001; 2001US-0294412P.

PR

XX 28-AUG-2001; 2001US-0315315P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI

XX WPI; 2003-059513/05.

DR

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PT

XX Claim 59; SEQ ID NO 1323; 317pp; English.

PS

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 2.2e+02;

Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 387 TGCATTCGAGCCAGC 403

Db 1 UGCAUUCGAGCCAGC 17

RESULT 498

ADL47791

ID ADL47791 standard; RNA; 17 BP.

XX

XX AC ADL47791;

XX

XX 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #301.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1324; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 3 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 388 GCATTTCACGACGCC 404
 DB 1 GCAUUUCCAAGCCAGCC 17
 RESULT 499
 ID ADL47793
 XX ADL47793 standard; RNA; 17 BP.
 AC ADL47793;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #303.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1326; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 5 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 393 TCCAAGCCAGCCAGG 409
 DB 1 UCCAAGCCAGCCAGG 17
 RESULT 500
 ID ADL47833
 XX ADL47833 standard; RNA; 17 BP.
 AC ADL47833;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE Human IKK-gamma substrate sequence #343.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1366; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 8 G; 0 T; 1 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 601 GGAGCTGCAGGAGGCC 617
DB 1 GGAGCTGCAGGAGGCC 17
RESULT 501
ADL47835
ID ADL47835 standard; RNA; 17 BP.
XX
XX ADL47835;
AC
XX 20-MAY-2004 (first entry)
DT
XX

```

```

DE Human IKK-gamma substrate sequence #345.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
OS
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1368; 317pp; English.
PS
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
SQ
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 610 GGAGGCCAGAGTCGCT 626
DB 1 GGAGGCCAGAGTCGCT 17
RESULT 502
ADL47855
ID ADL47855 standard; RNA; 17 BP.
XX
XX ADL47855;
AC
XX 20-MAY-2004 (first entry)
DT
XX

```



```

DE Human IKK-gamma substrate sequence #365.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD
XX PF 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor. IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1388; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 6 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 GCACGACGACGACGACG 737
DB 1 GCACGACGACGACGACG 17

RESULT 503
ADL47866
ID ADL47866 standard; RNA; 17 BP.
XX
AC ADL47866;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #376.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX PN WO200281628-A2.
XX PD
XX PF 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor. IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1399; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 6 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 773 GTGAGAGCGCGCTCCG 789
DB 1 GUGGAGCGCGCUCG 17

RESULT 504
ADL48219
ID ADL48219 standard; RNA; 17 BP.
XX
AC ADL48219;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

```
DE Human IKK-gamma substrate sequence #729.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 23-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1752; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 249 GGAAGCCAGCATGCTG 265
DB 1 GGAAGCCAGCCAGCUG 17
|||||
|||||
RESULT 505
ADL48236
ID ADL48236 standard; RNA; 17 BP.
XX
XX AC ADL48236;
XX
XX DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #746.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 23-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1769; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 374 TGCAGGAGCTTCTGCA 390
DB 1 UGCAGGAGCUCUGCA 17
|||||
|||||
RESULT 506
ADL48260
ID ADL48260 standard; RNA; 17 BP.
XX
XX AC ADL48260;
XX
XX DT 20-MAY-2004 (first entry)
XX
```

```

DE Human IKK-gamma substrate sequence #770.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1793; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 570 CTGTGAAGCCAGGTG 586
DB 1 CUGUGAAGCCAGGUG 17

RESULT 507
ADL48294
ID ADL48294 standard; RNA; 17 BP.
XX
AC ADL48294;
XX
DT 20-MAY-2004 (first entry)
XX

```

```

DE Human IKK-gamma substrate sequence #804.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1827; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 731 CACAGCGTCAGGTGA 747
DB 1 CACAGCGTCAGGTGA 17

RESULT 508
ADL48303
ID ADL48303 standard; RNA; 17 BP.
XX
AC ADL48303;
XX
DT 20-MAY-2004 (first entry)
XX

```


DE Human IKK-gamma substrate sequence #825.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1848; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.2e+02;
 Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 834 AGTTCAGGTGGCCTAT 850
 DB 1 AGUUGCAGGUGGCUAU 17
 RESULT 511
 ADL48490
 ID ADL48490 standard; RNA; 17 BP.
 XX
 AC ADL48490;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1000.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2023; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 638 ACTAAGGAATGCCAGGC 654
 DB 1 ACUAAGGAUAGCCAGGC 17
 RESULT 512
 ADL48491
 ID ADL48491 standard; RNA; 17 BP.
 XX
 AC ADL48491;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE Human IKK-gamma substrate sequence #1001.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2024; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 739 GCAGGTGCACGAGTGC 755
Db 1 GCAGGUGGACGAGCUGC 17
|||||:|||||:|
1 GCAGGUGGACGAGCUGC 17

RESULT 513
ADL48493
ID ADL48493 standard; RNA; 17 BP.
XX
XX AC ADL48493;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1003.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2026; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 9 A; 5 C; 2 G; 0 T; 1 U; 0 Other;
XX
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 865 AGAATACGACACACCACA 881
Db 1 AGAAUACGACACACCACA 17
|||||:|||||:|
1 AGAAUACGACACACCACA 17

RESULT 514
ADL48494
ID ADL48494 standard; RNA; 17 BP.
XX
XX AC ADL48494;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #1004.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2027; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 8 A; 6 C; 1 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 868 ATACGACACCAACATCA 884
 Db 1 AUAACGACACCAACCAUCA 17
 RESULT 515
 ID ADL48597
 ADL48597 standard; RNA; 17 BP.
 XX
 AC ADL48597;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1107.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2130; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 7 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 372 GCTCGAGGAGCTTCTG 388
 Db 1 GCUGCGAGGAGCUCUG 17
 RESULT 516
 ID ADL48611
 ADL48611 standard; RNA; 17 BP.
 XX
 AC ADL48611;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1121.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

OS Unidentified.

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2144; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 5 A; 3 C; 7 G; 0 T; 2 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 443 GAGGCCAGGAACCTGGT 459

Db 1 GAGGCCAGGAACCTGGU 17

RESULT 517

ADL48638

ID ADL48638 standard; RNA; 17 BP.

XX AC ADL48638;

XX 20-MAY-2004 (first entry)

DT

XX

DE Human IKK-gamma substrate sequence #1148.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

OS Unidentified.

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2171; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 542 CAGCAGCAGATGGCTGA 558

Db 1 CAGCAGCAGATGGCTGA 17

RESULT 518

ADL48652

ID ADL48652 standard; RNA; 17 BP.

XX AC ADL48652;

XX 20-MAY-2004 (first entry)

DT

XX

DE Human IKK-gamma substrate sequence #1162.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2185; 317pp; English.
 XX
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 603 AGCTGAGGAGGAGCCAG 619
 DB 1 AGCTGAGGAGGAGCCAG 17
 RESULT 519
 ADL48688
 ID ADL48688 standard; RNA; 17 BP.
 XX
 AC ADL48688;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1198.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.
 DR
 XX
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2221; 317pp; English.
 XX
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 7 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 785 CTCGCGATGAGGAGCCCA 801
 DB 1 CUCGCGAUGGAGGAGCCCA 17
 RESULT 520
 ADL47514
 ID ADL47514 standard; RNA; 17 BP.
 XX
 AC ADL47514;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

```

DE Human IKK-gamma substrate sequence #24.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 23-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1047; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX CC
XX Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 218 CAGGACGCTACTGGCGGA 234
Db |||||:|||||
1 CAGGACGCTACTGGCGGA 17

RESULT 521
ADL47518
ID ADL47518 standard; RNA; 17 BP.
XX
XX AC ADL47518;
XX AC
XX DT 20-MAY-2004 (first entry)
XX DT
XX

DE Human IKK-gamma substrate sequence #28.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1051; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX CC
XX Sequence 17 BP; 5 A; 6 C; 3 G; 0 T; 3 U; 0 Other;
SQ Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 267 ACCTGCTTCAGAACAG 283
Db |||||:|||||
1 ACCUGCCUUCAGAACAG 17

RESULT 522
ADL47522
ID ADL47522 standard; RNA; 17 BP.
XX
XX AC ADL47522;
XX AC
XX DT 20-MAY-2004 (first entry)
XX DT
XX

```

```

DE XX Human IKK-gamma substrate sequence #32.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX OS Unidentified.
XX
XX PN WO200281628-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX
XX PR 05-APR-2001; 2001US-00827395.
XX
XX PR 29-MAY-2001; 2001US-0294412P.
XX
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX DR WPI; 2003-058513/05.
XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1055; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 7 A; 3 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 315 AGGAGAAATCAAGAGCTC 331
Db 1 AGGAGAAATCAAGAGCTC 17
|||||:|||||:|

RESULT 523
ADL47759
ID ADL47759 standard; RNA; 17 BP.
XX
XX AC ADL47759;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE XX Human IKK-gamma substrate sequence #32.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX OS Unidentified.
XX
XX PN WO200281628-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX
XX PR 05-APR-2001; 2001US-00827395.
XX
XX PR 29-MAY-2001; 2001US-0294412P.
XX
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX DR WPI; 2003-058513/05.
XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 1055; 317pp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX
XX SQ Sequence 17 BP; 7 A; 3 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 315 AGGAGAAATCAAGAGCTC 331
Db 1 AGGAGAAATCAAGAGCTC 17
|||||:|||||:|

RESULT 524
ADL47796
ID ADL47796 standard; RNA; 17 BP.
XX
XX AC ADL47796;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE	Human IKK-gamma substrate sequence #306.	DE	Human IKK-gamma substrate sequence #322.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
XX	05-APR-2001; 2001US-00827395.	XX	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
XX	(RIBO-) RIBOZYME PHARM INC.	XX	(RIBO-) RIBOZYME PHARM INC.
PA		PA	
XX		XX	
PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
XX	WPI; 2003-058513/05.	XX	WPI; 2003-058513/05.
DR		DR	
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
XX	Claim 59; SEQ ID NO 1329; 317pp; English.	XX	Claim 59; SEQ ID NO 1345; 317pp; English.
PS		PS	
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;	SQ	Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 70.6%; Pred. No. 2.2e+02;		Best Local Similarity 88.2%; Pred. No. 2.2e+02;
	Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	417 AGGAGTTCTCATGTGC 433	QY	503 GAGCAGGCTCTGCGGGA 519
	: : : : :		: : : : :
Db	1 AGGAGUUCUCAUGUC 17	Db	1 GAGCAGGCTCTGCGGGA 17
RESULT 525		RESULT 526	
ADL47812		ADL47826	
ID	ADL47812 standard; RNA; 17 BP.	ID	ADL47826 standard; RNA; 17 BP.
XX		XX	
AC	ADL47812;	AC	ADL47826;
XX		XX	
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #336.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1359; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 OY 572 GTGAAGCCAGGTGAC 588
 Db :|||||:|||||:
 1 GUGAAGCCAGGTGAC 17
 RESULT 527
 ADL47832
 ID ADL47832 standard; RNA; 17 BP.
 XX
 AC ADL47832;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #342.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1365; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 9 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 OY 598 CGGGAGCTGCAGGAGA 614
 Db :|||||:|||||:
 1 CGGGAGCTGCAGGAGA 17
 RESULT 528
 ADL47872
 ID ADL47872 standard; RNA; 17 BP.
 XX
 AC ADL47872;
 XX
 DT 20-MAY-2004 (first entry)
 XX

```
DE Human IKK-gamma substrate sequence #382.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1405; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX CC
SQ Sequence 17 BP; 2 A; 8 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 797 CGCCAGGCGCCCTCGGA 813
Db 1 CGCCAGGCGCCCTCGGA 17
|||||
RESULT 529
ADL47891
ID ADL47891 standard; RNA; 17 BP.
XX AC
XX ADL47891;
XX AC
XX 20-MAY-2004 (first entry)
XX DT
XX
```

```
DE Human IKK-gamma substrate sequence #401.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX 17-OCT-2002.
XX PD
XX 03-APR-2002; 2002WO-US010512.
XX PF
XX 05-APR-2001; 2001US-00827395.
XX PR
XX 29-MAY-2001; 2001US-0294412P.
XX PR
XX 28-AUG-2001; 2001US-0315315P.
XX PR
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX PI
XX WPI; 2003-058513/05.
XX DR
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PT
XX Claim 59; SEQ ID NO 1424; 317pp; English.
XX PS
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX CC
SQ Sequence 17 BP; 8 A; 6 C; 2 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 871 CGACACCAACATCAAGA 887
Db 1 CGACACCAACATCAAGA 17
|||||
RESULT 530
ADL48211
ID ADL48211 standard; RNA; 17 BP.
XX AC
XX ADL48211;
XX AC
XX 20-MAY-2004 (first entry)
XX DT
XX
```

```

DE Human IKK-gamma substrate sequence #721.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1744; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 6 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 193 GCCCAGTGCGTCCCGG 209
Db 1 GCCCAGUGGCGCCCG 17

RESULT 531
ADL48248
ID ADL48248 standard; RNA; 17 BP.
XX
XX AC ADL48248;
XX
XX DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #758.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX OS
XX WO200281628-A2.
XX PN
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1781; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 7 A; 2 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 488 CTGAAGAGCGCAGAGGA 504
Db 1 CUGAAGAGCGCAGAGGA 17

RESULT 532
ADL48264
ID ADL48264 standard; RNA; 17 BP.
XX
XX AC ADL48264;
XX
XX DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #774.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

PD 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1797; 317pp; English.

PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)

XX that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 596 CTCGGGGAGCTGCAGGA 612

Db 1 CUCGGGGAGCTGCAGGA 17

RESULT 533

ADL48314

ID ADL48314 standard; RNA; 17 BP.

XX AC ADL48314;

XX DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #824.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS WO200281628-A2.

XX 17-OCT-2002.

PD 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

DR Novel enzymatic nucleic acid that down-regulates expression of neurite

XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1847; 317pp; English.

PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)

XX that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX SQ Sequence 17 BP; 2 A; 5 C; 7 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.2e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 830 GCCCAGTTCAGCTGGC 846

Db 1 GCCCAGUUGCAGGUGGC 17

RESULT 534

ADL48316

ID ADL48316 standard; RNA; 17 BP.

XX AC ADL48316;

XX DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #826.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1849; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 837 TGCAGGTGCCTATCAC 853
 Db 1 UGCAGGUGGCCUAUCAC 17
 :||||:||||:||||:
 RESULT 535
 ADL48489
 ID ADL48489 standard; RNA; 17 BP.
 XX
 AC ADL48489;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #999.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2022; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 579 CCCAGGTGACGTCCTTG 595
 Db 1 CCCAGGUGACGUCUUG 17
 :||||:||||:||||:
 RESULT 536
 ADL48560
 ID ADL48560 standard; RNA; 17 BP.
 XX
 AC ADL48560;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1124.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2147; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 453 AACTGGTGGAGACTC 469
 Db 1 AACUGGUGGAGAGACUC 17
 |||:|||||:|
 RESULT 539
 ADL48625
 ID ADL48625 standard; RNA; 17 BP.
 XX
 AC ADL48625;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1135.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2158; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 491 AAGAGCGAGAGGACGA 507
 Db 1 AAGAGCGAGAGGACGA 17
 |||:|||||:|
 RESULT 540
 ADL48671
 ID ADL48671 standard; RNA; 17 BP.
 XX
 AC ADL48671;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1181.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 XX OS
 XX PN WO200281628-A2.
 XX PD 17-OCT-2002.
 XX PF 03-APR-2002; 2002WO-US010512.
 XX PR 05-APR-2001; 2001US-00827395.
 XX PR 29-MAY-2001; 2001US-0294412P.
 XX PR 28-AUG-2001; 2001US-0315315P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX DR
 XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 2204; 317pp; English.
 XX PS
 XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 680 AGCGAGCAGCGCGGCA 696
 Db 1 AGCGAGCAGCGCGGCA 17
 RESULT 541
 ADL48675
 ID ADL48675 standard; RNA; 17 BP.
 XX AC
 XX ADL48675;
 XX 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1185.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 XX OS
 XX PN WO200281628-A2.
 XX PD 17-OCT-2002.
 XX PF 03-APR-2002; 2002WO-US010512.
 XX PR 05-APR-2001; 2001US-00827395.
 XX PR 29-MAY-2001; 2001US-0294412P.
 XX PR 28-AUG-2001; 2001US-0315315P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX DR
 XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 2208; 317pp; English.
 XX PS
 XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 695 CAGCTGGAGAGTGAGCG 711
 Db 1 CAGCTGGAGAGTGAGCG 17
 RESULT 542
 ADL48682
 ID ADL48682 standard; RNA; 17 BP.
 XX AC
 XX ADL48682;
 XX 20-MAY-2004 (first entry)
 XX

DE XX Human IKK-gamma substrate sequence #1192.

KW antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS OS

XX XX

PN WO200281628-A2.

XX

PD 17-OCT-2002.

XX

PF 03-APR-2002; 2002WO-US010512.

XX

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

XX

DR WPI; 2003-058513/05.

XX

PT Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX

PS Claim 59; SEQ ID NO 2215; 317pp; English.

XX

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.2e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 755 CCATGCGAGGCCAGAG 771

DB 1 CGCAUGCAGGCCAGAG 17

||||:|||||

RESULT 543

ADL47516

ID ADL47516 standard; RNA; 17 BP.

XX

AC ADL47516;

XX

XX 20-MAY-2004 (first entry)

DT

XX

DE XX Human IKK-gamma substrate sequence #26.

KW antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS OS

XX XX

PN WO200281628-A2.

XX

PD 17-OCT-2002.

XX

PF 03-APR-2002; 2002WO-US010512.

XX

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

XX

DR WPI; 2003-058513/05.

XX

PT Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX

PS Claim 59; SEQ ID NO 1049; 317pp; English.

XX

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX

SQ Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 2.2e+02;

Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 234 AAGAGTCTCTCTGGG 250

DB 1 AAGAGTCTCTCTGGG 17

||||:|||||

RESULT 544

ADL47551

ID ADL47551 standard; RNA; 17 BP.

XX

AC ADL47551;

XX

XX 20-MAY-2004 (first entry)

DT

XX

DE	Human IKK-gamma substrate sequence #61.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.
XX	Unidentified.
OS	WO200281628-A2.
PN	17-OCT-2002.
XX	
XX	03-APR-2002; 2002WO-US010512.
PF	
XX	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
PR	
XX	(RIBO-) RIBOZYME PHARM INC.
PA	
XX	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI	WPI; 2003-058513/05.
XX	
DR	
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
PT	
XX	Claim 59; SEQ ID NO 1084; 317bp; English.
PS	
XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.
CC	
XX	Sequence 17 BP; 3 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
SQ	
Query Match	2.3%; Score 17; DB 1; Length 17;
Best Local Similarity	94.1%; Pred. No. 2.2e+02;
Matches	16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy	802 GGCGGCTCGGAGGAGA 818
Db	1 GGCGGCTCGGAGGAGA 17
RESULT 545	
ADL47742	
ID	ADL47742 standard; RNA; 17 BP.
XX	
AC	ADL47742;
XX	
XX	20-MAY-2004 (first entry)
DT	
XX	

```

DE Human IKK-gamma substrate sequence #259.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1282; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
  Query Match          2.3%; Score 17; DB 1; Length 17;
  Best Local Similarity 76.5%; Pred. No. 2.2e+02;
  Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 235 AGAGTCCTCTGGGGA 251
DB 1 AGAGUCUCUUGGGGA 17
  |||||:|:|:|:|:|
  |||||:|:|:|:|:|

RESULT 547
ADL47765
ID ADL47765 standard; RNA; 17 BP.
XX
XX AC ADL47765;
XX
XX 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #275.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1298; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
  Query Match          2.3%; Score 17; DB 1; Length 17;
  Best Local Similarity 88.2%; Pred. No. 2.2e+02;
  Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 283 GGGCGCTCTGAGACCC 299
DB 1 GGGCGCUCUGAGACCC 17
  |||||:|:|:|:|:|
  |||||:|:|:|:|:|

RESULT 548
ADL47778
ID ADL47778 standard; RNA; 17 BP.
XX
XX AC ADL47778;
XX
XX 20-MAY-2004 (first entry)
XX

```


DE Human IKK-gamma substrate sequence #315.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 PI Blatt L, Chowira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1338; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 460 GGAGAGACTCGGCTGG 476
 Db 1 GGAGAGACUCCGCCUGG 17
 |||||:|||||
 RESULT 551
 ADL47854
 ID ADL47854 standard; RNA; 17 BP.
 XX
 AC ADL47854;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #364.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 PI Blatt L, Chowira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1387; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 5 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 718 GCTGCAGCAGCAGCACA 734
 Db 1 GCUGCAGCAGCAGCACA 17
 |||||:|||||
 RESULT 552
 ADL47867
 ID ADL47867 standard; RNA; 17 BP.
 XX
 AC ADL47867;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #377.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 1400; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 1 A; 7 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 778 GGCGCGCTCGCATGG 794
 Db 1 GGCGCGCTCGCATGG 17
 |||||:|||||:
 RESULT 553
 ADL47871
 ID ADL47871 standard; RNA; 17 BP.
 XX
 AC ADL47871;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #381.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 OS
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 XX 03-APR-2002; 2002WO-US010512.
 XX
 XX 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 PT
 XX Claim 59; SEQ ID NO 1404; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 793 GGAGCGCCAGCGCGCT 809
 Db 1 GGAGCGCCAGCGCGCT 17
 |||||:|||||:
 RESULT 554
 ADL47877
 ID ADL47877 standard; RNA; 17 BP.
 XX
 AC ADL47877;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #387.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1410; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 825 AGCTGCCCGCCAGTTGCGAG 841
 Db 1 AGCUGGCCCGCCAGUUGCAG 17
 RESULT 555
 ADL47885
 ID ADL47885 standard; RNA; 17 BP.
 XX
 AC ADL47885;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #395.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1418; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 2 G; 0 T; 4 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.2e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 850 TCACCAGCTCTTCCCAAG 866
 Db 1 UCACCAGCUCUCCCAAG 17
 RESULT 556
 ADL48226
 ID ADL48226 standard; RNA; 17 BP.
 XX
 AC ADL48226;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #736.	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO; prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK; protein kinase PKR; cerebrovascular accident; central nervous system injury; CNS injury; spinal cord injury; cancer; melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis; restenosis; asthma; Crohn's disease; diabetes; obesity; autoimmune disease; lupus; multiple sclerosis; transplant rejection; graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis; allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma; substrate; ds.
XX	Unidentified.	OS	
XX		XX	
XX	WO200281628-A2.	PN	
XX	17-OCT-2002.	PD	
XX		XX	
XX	03-APR-2002; 2002WO-US010512.	PF	
XX		XX	
XX	05-APR-2001; 2001US-00827395.	PR	
XX	29-MAY-2001; 2001US-0294412P.	PR	
XX	28-AUG-2001; 2001US-0315315P.	PR	
XX		XX	
XX	(RIBO-) RIBOZYME PHARM INC.	PA	
XX		XX	
XX	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	PI	
XX	WPI; 2003-058513/05.	XX	
XX		DR	
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	
XX		PT	
XX	Claim 59; SEQ ID NO 1759; 317pp; English.	PS	
XX		XX	
XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides) that down regulate the expression or inhibit the function of a receptor for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR), IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the invention are useful for treating: cerebrovascular accident, central nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma, lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis, restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The nucleic acids of the invention are also useful for down-regulating the expression of a target gene and as a diagnostic tool to examine genetic drifts and mutations within diseased cells or to detect the presence of a target RNA in a cell. The present RNA sequence represents a human IKK-gamma substrate sequence.	CC	
XX		CC	
XX	Sequence 17 BP; 1 A; 8 C; 5 G; 0 T; 3 U; 0 Other;	SQ	
XX		XX	
XX	Query Match 2.3%; Score 17; DB 1; Length 17;		
XX	Best Local Similarity 82.4%; Pred. No. 2.2e+02;		
XX	Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;		
QY	298 CCTCCAGCGCTGCTGG 314		
DB	1 CCUCCAGCGCGCCUGG 17		
XX			
XX	RESULT 557		
XX	ADL48234		
XX	ID ADL48234 standard; RNA; 17 BP.		
XX	XX ADL48234;		
XX	XX ADL48234;		
XX	XX 20-MAY-2004 (first entry)		
XX	DT		
XX	XX		

```

DE XX Human IKK-gamma substrate sequence #749.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
PR 29-MAY-2001; 2001US-0294412P.
PR
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1772; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 6 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 394 CCAAGCCAGCCAGAGGG 410
DB 1 CCAAGCCAGCCAGAGGG 17
|||||
RESULT 559
ADL48240
ID ADL48240 standard; RNA; 17 BP.
XX
AC ADL48240;
XX
XX 20-MAY-2004 (first entry)
DT
XX

DE XX Human IKK-gamma substrate sequence #750.
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
PR 29-MAY-2001; 2001US-0294412P.
PR
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1773; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 413 GAGAGGAGGATTCCTCAT 429
DB 1 GAGAGGAGGUUCCUCAU 17
|||||
RESULT 560
ADL48278
ID ADL48278 standard; RNA; 17 BP.
XX
AC ADL48278;
XX
XX 20-MAY-2004 (first entry)
DT
XX

```

DE Human IKK-gamma substrate sequence #788.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1811; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 677 GCCAGCGAGCAGCGCG 693
 Db 1 GCCAGCGAGCAGCGCG 17
 RESULT 561
 ID ADL48288
 ADL48288 standard; RNA; 17 BP.
 XX
 AC ADL48288;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #798.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 1821; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 that down regulate the expression or inhibit the function of a receptor
 for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 713 GAGCGCTGCAGCAGCA 729
 Db 1 GAGCGCTGCAGCAGCA 17
 RESULT 562
 ID ADL48300
 ADL48300 standard; RNA; 17 BP.
 XX
 AC ADL48300;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #810.	DE	Human IKK-gamma substrate sequence #827.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
XX	Unidentified.	XX	Unidentified.
OS		OS	
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
PA	(RIBO-) RIBOZYME PHARM INC.	PA	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
DR	WPI; 2003-058513/05.	DR	WPI; 2003-058513/05.
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 1833; 317pp; English.	PS	Claim 59; SEQ ID NO 1850; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;	SQ	Sequence 17 BP; 4 A; 7 C; 1 G; 0 T; 5 U; 0 Other;
	Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;
	Best Local Similarity 94.1%; Pred. No. 2.2e+02;		Best Local Similarity 70.6%; Pred. No. 2.2e+02;
	Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;		Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY	757 CATGCAGGCGCAGAGCG 773	QY	848 TATCACCAGCTTCTCCA 864
DB	1 CAUGCAGGCGCAGAGCG 17	DB	1 UAUACACCGCUCUCCA 17
RESULT 563		RESULT 564	
ADL48317		ADL48318	
ID ADL48317 standard; RNA; 17 BP.		ID ADL48318 standard; RNA; 17 BP.	
XX		XX	
AC ADL48317;		AC ADL48318;	
XX		XX	
DT 20-MAY-2004 (first entry)		DT 20-MAY-2004 (first entry)	
XX		XX	

DE Human IKK-gamma substrate sequence #828.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS Unidentified.

XX WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

PF 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

PR (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1851; 317pp; English.

PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)

XX that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 890 CATCAAGACGACGCTGG 896

Db 1 CAUCAAGACGACGCTGG 17

RESULT 565

ADL48319

ID ADL48319 standard; RNA; 17 BP.

XX AC ADL48319;

XX DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #829.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;

KW substrate; ds.

XX Unidentified.

OS Unidentified.

XX WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

PF 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

PR (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 1852; 317pp; English.

PS The invention comprises nucleic acids (e.g. antisense oligonucleotides)

XX that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-

CC gamma substrate sequence.

XX Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;

SQ Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 883 CAAGACGACGCTGG 899

Db 1 CAAGACGACGCTGG 17

RESULT 566

ADL48477

ID ADL48477 standard; RNA; 17 BP.

XX AC ADL48477;

XX DT 20-MAY-2004 (first entry)

XX

DE Human IKK-gamma substrate sequence #987.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-031531SP.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2010; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 272 CCTTCAGAACAGGGCGC 288
 Db 1 CCUUCAGAACAGGGCGC 17
 ||:|||||
 RESULT 567
 ADL48573
 ID ADL48573 standard; RNA; 17 BP.
 XX
 AC ADL48573;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1083.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-031531SP.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2106; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 240 CTCCTCTGGGGAAGCCA 256
 Db 1 CUCCUCUGGGGAAGCCA 17
 ||:|||||
 RESULT 568
 ADL48592
 ID ADL48592 standard; RNA; 17 BP.
 XX
 AC ADL48592;
 XX
 DT 20-MAY-2004 (first entry)
 XX

DE	Human IKK-gamma substrate sequence #1102.	DE	Human IKK-gamma substrate sequence #1103.
XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;	XX	antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;	KW	prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW	protein kinase PKR; cerebrovascular accident;	KW	protein kinase PKR; cerebrovascular accident;
KW	central nervous system injury; CNS injury; spinal cord injury; cancer;	KW	central nervous system injury; CNS injury; spinal cord injury; cancer;
KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;	KW	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;	KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;	KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;	KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;	KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW	substrate; ds.	KW	substrate; ds.
OS	Unidentified.	OS	Unidentified.
XX		XX	
PN	WO200281628-A2.	PN	WO200281628-A2.
XX		XX	
PD	17-OCT-2002.	PD	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	PF	03-APR-2002; 2002WO-US010512.
XX		XX	
PR	05-APR-2001; 2001US-00827395.	PR	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.	PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.	PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
XX	(RIBO-) RIBOZYME PHARM INC.	XX	(RIBO-) RIBOZYME PHARM INC.
PA		PA	
XX		XX	
PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;	PI	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX		XX	
XX	WPI; 2003-058513/05.	XX	WPI; 2003-058513/05.
DR		DR	
XX		XX	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite	PT	Novel enzymatic nucleic acid that down-regulates expression of neurite
PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or	PT	growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT	protein kinase PKR genes, for treating cancer and inflammatory disease.	PT	protein kinase PKR genes, for treating cancer and inflammatory disease.
XX		XX	
PS	Claim 59; SEQ ID NO 2125; 317pp; English.	PS	Claim 59; SEQ ID NO 2126; 317pp; English.
XX		XX	
CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	CC	The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC	that down regulate the expression or inhibit the function of a receptor	CC	that down regulate the expression or inhibit the function of a receptor
CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	CC	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	CC	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC	invention are useful for treating: cerebrovascular accident, central	CC	invention are useful for treating: cerebrovascular accident, central
CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	CC	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	CC	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	CC	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC	disease, lupus, multiple sclerosis, transplant/graft rejection,	CC	disease, lupus, multiple sclerosis, transplant/graft rejection,
CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	CC	ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	CC	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC	nucleic acids of the invention are also useful for down-regulating the	CC	nucleic acids of the invention are also useful for down-regulating the
CC	expression of a target gene and as a diagnostic tool to examine genetic	CC	expression of a target gene and as a diagnostic tool to examine genetic
CC	drifts and mutations within diseased cells or to detect the presence of a	CC	drifts and mutations within diseased cells or to detect the presence of a
CC	target RNA in a cell. The present RNA sequence represents a human IKK-	CC	target RNA in a cell. The present RNA sequence represents a human IKK-
CC	gamma substrate sequence.	CC	gamma substrate sequence.
XX		XX	
SQ	Sequence 17 BP; 2 A; 4 C; 7 G; 0 T; 4 U; 0 Other;	SQ	Sequence 17 BP; 2 A; 4 C; 7 G; 0 T; 4 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;		Query Match 2.3%; Score 17; DB 1; Length 17;	
Best Local Similarity 76.5%; Pred. No. 2.2e+02;		Best Local Similarity 76.5%; Pred. No. 2.2e+02;	
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;		Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;	
QY	358 GATTCTGCGGAGCGCT 374	QY	359 ATTCTGCGGAGCGCTG 375
DB	1 GAUUCUGCGGAGCGCU 17	DB	1 AUUCUGCGGAGCGCUG 17
RESULT 569		RESULT 570	
ADL48593		ADL48599	
ID	ADL48593 standard; RNA; 17 BP.	ID	ADL48599 standard; RNA; 17 BP.
XX		XX	
AC	ADL48593;	AC	ADL48599;
DT	20-MAY-2004 (first entry)	DT	20-MAY-2004 (first entry)
XX		XX	

DE Human IKK-gamma substrate sequence #1109.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2132; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 400 CAGCCAGAGGGAGGAGA 416
 Db 1 CAGCCAGAGGGAGGAGA 17
 RESULT 571
 ADL48635
 ID ADL48635 standard; RNA; 17 BP.
 XX
 AC ADL48635;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1145.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2168; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 524 GAGCACCTTGAGAGATG 540
 Db 1 GAGCACCTTGAGAGATG 17
 RESULT 572
 ADL48662
 ID ADL48662 standard; RNA; 17 BP.
 XX
 AC ADL48662;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX

DE Human IKK-gamma substrate sequence #1172.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 XX WO200281628-A2.
 XX 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 XX 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-059513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2195; 317pp; English.
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.2e+02;
 Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 Qy 651 AGGCTCTGGAGGGTCGG 667
 |||||:|||||:
 Db 1 AGGCUCUGAGGGUCGG 17
 RESULT 573
 ADL48665
 ID ADL48665 standard; RNA; 17 BP.
 XX AC ADL48665;
 XX DT 20-MAY-2004 (first entry)
 XX

DE Human IKK-gamma substrate sequence #1175.
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.
 XX Unidentified.
 XX WO200281628-A2.
 XX 17-OCT-2002.
 XX 03-APR-2002; 2002WO-US010512.
 XX 05-APR-2001; 2001US-00827395.
 XX 29-MAY-2001; 2001US-0294412P.
 XX 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2198; 317pp; English.
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX Sequence 17 BP; 1 A; 4 C; 11 G; 0 T; 1 U; 0 Other;
 SQ Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.2e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 Qy 658 GGAGGTCGGGCCCGGG 674
 |||||:|||||:
 Db 1 GGAGGGUCGGGCCCGGG 17
 RESULT 574
 ADL48681
 ID ADL48681 standard; RNA; 17 BP.
 XX AC ADL48681;
 XX DT 20-MAY-2004 (first entry)
 XX

```

DE Human IKK-gamma substrate sequence #1191.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2214; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 738 TGCAGGTGGACCGCTG 754
Db :||||:|||||:|
1 UGCAGGUGGACGACGUG 17

RESULT 575
ADL48706
ID ADL48706 standard; RNA; 17 BP.
XX
AC ADL48706;
XX
DT 20-MAY-2004 (first entry)
XX

DE Human IKK-gamma substrate sequence #1216.
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2239; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK) or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 2 C; 9 G; 0 T; 3 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.2e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 890 AGCGTGGTGGCAGTGA 906
Db :||||:|||||:|
1 AGCGUGGUGGCGACUGA 17

RESULT 576
ADL48708
ID ADL48708 standard; RNA; 17 BP.
XX
AC ADL48708;
XX
DT 20-MAY-2004 (first entry)
XX

```

DE Human IKK-gamma substrate sequence #1218.
XX
KW antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
OS Unidentified.
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcawiggen J, Fosnaugh K;
PI
XX WPI; 2003-059513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2241; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
SQ Sequence 17 BP; 4 A; 2 C; 9 G; 0 T; 2 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 897 TGGCAGTGAGCGGAAG 913
:|||||:|||||:
Db 1 UGGGACAGUGAGCGGAAG 17
RESULT 577
ADI39139
ID ADI39139 standard; DNA; 18 BP.
XX
XX AC ADI39139;
XX
XX DT 22-APR-2004 (first entry)
XX

DE Streptomyces coelicolor meth PCR primer #5.
XX
KW fermentation; methionine; Coryneform bacterium; methionine synthase;
KW Meth; animal feed additive; sulphur; human nutrition; animal nutrition;
KW cosmetic; pharmaceutical; PCR; primer; ss.
XX
OS Streptomyces coelicolor.
OS Synthetic.
XX
XX WO2003087386-A2.
PN
XX
XX 23-OCT-2003.
PD
XX
XX 16-APR-2003; 2003WO-EP004010.
PF
XX
XX 17-APR-2002; 2002DE-01017058.
PR
XX
XX (BADI) BASF AG.
PA
XX
XX Kroeger B, Zelder O, Klopprogge C, Schroeder H, Haefner S;
PI
XX WPI; 2003-877106/81.
DR
XX
XX Permentative production of sulfur-containing compounds, particularly L-
XX methionine, useful as feed additives, by using Coryneform bacteria that
XX overexpress methionine synthase.
XX
XX Example 7; SEQ ID NO 73; 304pp; German.
XX
XX This invention describes a novel method for the fermentative production
XX of methionine by growing a sulphur-producing Coryneform bacteria that
XX expresses at least one heterologous nucleic acid encoding a protein with
XX methionine synthase (Meth) activity. Methionine accumulates in the medium
XX or the cells. The method can be used to produce an L-methionine-
XX containing animal feed additive by culturing an L-Met-producing
XX microorganism, removing water from the resulting broth, removing 0-100%
XX of the biomass formed and drying the product to produce the feed additive
XX in powdered or granular form. The nucleic acid encoding Meth has sequence
XX homology less than 100% with respect to the meth coding sequence of
XX Corynebacterium glutamicum ATCC 13032. Optionally at least one other gene
XX in the methionine biosynthesis pathway (e.g. aspartate kinase,
XX glyceraldehyde-3-phosphate dehydrogenase or 3-phosphoglycerate kinase) is
XX also amplified or mutated so that it is not affected by metabolites. Also
XX at least one metabolic pathway that reduces production of methionine is
XX at least partly switched off (e.g. homoserine kinase, threonine
XX dehydratase or threonine synthase). The method is especially used to
XX produce L-methionine, useful as an additive for animal feeds. More
XX generally sulphur-containing fine chemicals are useful in human and
XX animal nutrition, cosmetics and pharmaceuticals. This sequence represents
XX a PCR primer used to amplify the S. coelicolor meth gene for inclusion
XX into the construct pCPhsdh meth_Sc.
SQ Sequence 18 BP; 3 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 2.3%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 469 CGGCCTGGAGAGCTCG 485
:|||||:|||||:
Db 2 CGGCCTGGAGAGAGCTCG 18
RESULT 578
ABZ92117/C
ID ABZ92117 standard; DNA; 20 BP.
XX
XX AC ABZ92117;
XX
XX DT 17-OCT-2003 (first entry)
XX
XX DE Human oligonucleotide sequence.
XX

Human; antisense; lung dysfunction; nasal airway dysfunction;
 antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 antisense gene therapy; respiratory; lung; adenosine sensitivity;
 adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 lung inflammation; respiratory disease; ds.
 OS Homo sapiens.
 XX WO200285308-A2.
 PN 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013135.
 PF 24-APR-2001; 2001US-0286137P.
 PR (EPIC-) EPIGENESIS PHARM INC.
 XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 DR Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX Disclosure; SEQ ID NO 7359; 872pp; English.
 PS The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 20 BP; 0 A; 9 C; 2 G; 9 T; 0 U; 0 Other;
 SQ Query Match 2.2%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 2.9e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 402 GCCAGAGGGAGGAGGAGGAG 421
 DB 20 GCCAGAGGAGGAGGAGGAGGAG 1
 RESULT 579
 ABD28347/C
 ID ABD28347 standard; DNA; 20 BP.
 XX ABD28347;
 AC 29-JUL-2004 (first entry)
 DT AA463610-derived oligonucleotide SEQ ID 7359.
 XX

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS WO200285309-A2.
 PN 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013143.
 PF 24-APR-2001; 2001US-0286036P.
 PR (EPIC-) EPIGENESIS PHARM INC.
 XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 7359; 763pp; English.
 PS This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 0 A; 9 C; 2 G; 9 T; 0 U; 0 Other;
 SQ Query Match 2.2%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 2.9e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 402 GCCAGAGGGAGGAGGAGGAG 421
 DB 20 GCCAGAGGAGGAGGAGGAGGAG 1

```
RESULT 580
ACC79548/c
ID ACC79548 standard; DNA; 21 BP.
XX
XX
AC ACC79548;
XX
XX
DT 05-AUG-2003 (first entry)
XX
DE Human TCH169 PCR primer SEQ ID NO:12.
XX
KW Human; TCH169; dicarboxylate transport; hepatotropic; cytostatic;
KW nephrotropic; vasotropic; antidiabetic; liver disease; hepatitis;
KW hepatic sclerosis; alcohol-related liver disease; prostate disease;
KW prostatitis; prostatic hypertrophy; spleen disease; hyperactivity;
KW kidney disease; nephritis; kidney failure; nephritis; dropsy; diabetes;
KW diabetes-associated renal disease; metabolic disease; hyperlipaemia;
KW circulatory disease; arteriosclerosis; cancer; PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2003025168-A1.
XX
PD 27-MAR-2003.
XX
PF 13-SEP-2002; 2002WO-JP009444.
XX
PR 17-SEP-2001; 2001JP-00281992.
PR 02-OCT-2001; 2001JP-00306873.
PR 16-APR-2002; 2002JP-00113279.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX Nakanishi A, Uno Y, Sagiya Y;
XX WPI; 2003-313352/30.
XX
PT Protein TCH169 with dicarboxylate transport activity for treatment and
PT diagnosis of diseases including liver disease, cancer and circulatory
PT disorders.
XX
PS Example 1; Page 107; 132pp; Japanese.
XX
CC The present invention describes protein TCH169 and its salts having
CC dicarboxylate transport activity. TCH169 has hepatotropic, cytostatic,
CC nephrotropic, vasotropic and antidiabetic activities. The TCH169 protein
CC and polynucleotide can be used in the treatment, prevention and diagnosis
CC of liver disease (such as hepatitis, hepatic sclerosis and alcohol-
CC related liver disease); prostate disease (such as prostatitis and
CC prostatic hypertrophy); spleen disease (such as spleen hyperactivity);
CC kidney disease (such as nephritis, kidney failure, nephritis, dropsy and
CC diabetes-associated renal disease); metabolic disease (such as diabetes);
CC circulatory disease (such as hyperlipaemia and arteriosclerosis); and
CC cancer (such as non-small cell lung cancer, liver cancer, renal cancer,
CC ovarian cancer, prostate cancer, stomach cancer, pancreatic cancer,
CC breast cancer, colon cancer, bladder cancer and womb cancer). The present
CC sequence represents a PCR primer for human TCH169, which is used in an
CC example from the present invention
XX
SQ Sequence 21 BP; 7 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 423 TCCTCATGTGCAAGTTCAG 442
Db 20 TCCTCTTGTCAGGTTCCAG 1
RESULT 581
```

```
ACC79554
ID ACC79554 standard; DNA; 21 BP.
XX
XX
AC ACC79554;
XX
XX
DT 05-AUG-2003 (first entry)
XX
DE Human TCH169 PCR primer SEQ ID NO:18.
XX
KW Human; TCH169; dicarboxylate transport; hepatotropic; cytostatic;
KW nephrotropic; vasotropic; antidiabetic; liver disease; hepatitis;
KW hepatic sclerosis; alcohol-related liver disease; prostate disease;
KW prostatitis; prostatic hypertrophy; spleen disease; hyperactivity;
KW kidney disease; nephritis; kidney failure; nephritis; dropsy; diabetes;
KW diabetes-associated renal disease; metabolic disease; hyperlipaemia;
KW circulatory disease; arteriosclerosis; cancer; PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2003025168-A1.
XX
PD 27-MAR-2003.
XX
PF 13-SEP-2002; 2002WO-JP009444.
XX
PR 17-SEP-2001; 2001JP-00281992.
PR 02-OCT-2001; 2001JP-00306873.
PR 16-APR-2002; 2002JP-00113279.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX Nakanishi A, Uno Y, Sagiya Y;
XX WPI; 2003-313352/30.
XX
PT Protein TCH169 with dicarboxylate transport activity for treatment and
PT diagnosis of diseases including liver disease, cancer and circulatory
PT disorders.
XX
PS Example 1; Page 109; 132pp; Japanese.
XX
CC The present invention describes protein TCH169 and its salts having
CC dicarboxylate transport activity. TCH169 has hepatotropic, cytostatic,
CC nephrotropic, vasotropic and antidiabetic activities. The TCH169 protein
CC and polynucleotide can be used in the treatment, prevention and diagnosis
CC of liver disease (such as hepatitis, hepatic sclerosis and alcohol-
CC related liver disease); prostate disease (such as prostatitis and
CC prostatic hypertrophy); spleen disease (such as spleen hyperactivity);
CC kidney disease (such as nephritis, kidney failure, nephritis, dropsy and
CC diabetes-associated renal disease); metabolic disease (such as diabetes);
CC circulatory disease (such as hyperlipaemia and arteriosclerosis); and
CC cancer (such as non-small cell lung cancer, liver cancer, renal cancer,
CC ovarian cancer, prostate cancer, stomach cancer, pancreatic cancer,
CC breast cancer, colon cancer, bladder cancer and womb cancer). The present
CC sequence represents a PCR primer for human TCH169, which is used in an
CC example from the present invention
XX
SQ Sequence 21 BP; 3 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 423 TCCTCATGTGCAAGTTCAG 442
Db 2 TCCTCTTGTCAGGTTCCAG 21
RESULT 582
AA336938
ID AAX36938 standard; DNA; 22 BP.
XX
```


AA36938;
 02-JUL-1999 (first entry)
 S. cereale microsatellite marker PCR primer 37.
 Microsatellite; marker; PCR primer; rye; plant; Triticeae; Poae;
 simple sequence repeat; SSR; sequence tag site; STS; genetic analysis;
 DNA fingerprinting; variety identification; self fertilization;
 detection; cross fertilization; cytological line; gene mapping;
 monogenic trait; polygenic trait; ss.
 Synthetic.
 Secale cereale.
 DE19835109-A1.
 15-APR-1999.
 04-AUG-1998; 98DE-01035109.
 02-OCT-1997; 97DE-01043671.
 (GVSE-) GVS GES ERWERB & VERWERTUNG LANDWIRTSCHA.
 Wricke G, Saal B;
 WPI; 1999-245522/21.
 Microsatellite markers derived from the genome of rye, useful for genetic
 mapping as markers of monogenic or polygenic traits.
 Claim 6; Page 19; 28pp; German.
 This invention describes Secale cereale microsatellite markers based on
 hypervariable genomic segments of Secale cereale and plants of the tribes
 Triticeae and Poae. The microsatellite markers comprise a simple
 sequence repeat (SSR) marker as sequence tag site (STS), defined by two
 specific S. cereale defined primers, of mean length 18-26 bases and
 flanking the microsatellite sequence (MSS). Such markers are useful for
 genetic analysis of rye, triticale and other species of the tribes
 Triticeae and Poae, e.g. for DNA fingerprinting; identification of
 varieties; detecting self or cross fertilization; studying similarity and
 relatedness; characterization of cytological lines, or generally any sort
 of gene mapping. Particularly, they are useful for genetic mapping and
 marking of mono- or poly-genic traits, selection and evaluation of
 varietal purity or checking culture stages (particularly in hybrid
 culture methods), purity of propagative materials, success of self-
 fertilization and required ratio of components in populations and
 hybrids. AAX36902-X36965 represent PCR primers used in the method of the
 invention
 Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 2.2%; Score 16.8; DB 1; Length 22;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 543 AGCAGCAGATGGCTGAGGAC 562
 Db 3 AGCCGAGATGGTTGAGGAC 22
 RESULT 583
 AA23863
 ID AA23863 standard; DNA; 22 BP.
 XX
 AC AA23863;
 XX
 21-JAN-2000 (first entry)
 Rye microsatellite marker 19 PCR primer 1.
 XX

KW Microsatellite marker; rye; hypervariable genomic region; Poae;
 KW Triticeae; breeding program; DNA fingerprinting; variety; detection;
 KW self pollination; cross pollination; cytoplasmic line; genetic mapping;
 KW polymorphism; PCR primer; ss.
 XX
 OS Synthetic.
 OS Secale cereale.
 XX
 PN DE19811506-A1.
 XX
 PD 21-OCT-1999.
 XX
 PF 17-MAR-1998; 98DE-01011506.
 XX
 PR 17-MAR-1998; 98DE-01011506.
 XX
 PA (GVSE-) GVS GES ERWERB & VERW LANDWIRTSCHAFTLICH.
 XX
 DR WPI; 1999-591715/51.
 XX
 XX New microsatellite markers for rye and closely related grasses, used for
 PT genetic analysis and in breeding.
 XX
 PS Claim 6; Page 27; 28pp; German.
 XX
 CC This invention describes novel microsatellite markers (MSM), based on the
 CC hypervariable genomic regions of rye (Secale cereale) and of plants from
 CC the tribes Triticeae and Poae. MSM, which are new genetic markers for
 CC rye and closely related species, are used for genetic analysis and in
 CC breeding programs. Typical applications are in DNA fingerprinting;
 CC identification of varieties; detection of self and cross pollination;
 CC characterization of cytoplasmic lines, and genetic mapping (of mono- or
 CC poly-genic traits). MSM show a higher degree of polymorphism than known
 CC markers (both within and between different rye varieties and lines); can
 CC be detected by polymerase chain reaction, so that even very small samples
 CC may be analyzed, and generate many alleles per marker locus. AA23827-
 CC 223886 represent the microsatellite marker PCR primers described in the
 CC method of the invention
 XX
 SQ Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 2.2%; Score 16.8; DB 1; Length 22;
 Best Local Similarity 90.0%; Pred. No. 3.3e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 543 AGCAGCAGATGGCTGAGGAC 562
 Db 3 AGCCGAGATGGTTGAGGAC 22
 RESULT 584
 AA23863
 ID AA23863 standard; DNA; 20 BP.
 XX
 AC AA23863;
 XX
 21-JUL-1998 (first entry)
 XX
 DE Synthetic human tumour necrosis factor related ligand PCR primer.
 XX
 KW TRELL; tumour necrosis factor related ligand; tnfr; treatment; cancer;
 KW autoimmune disease; immune system; stimulation; suppression;
 KW graft rejection; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9805783-A1.
 XX
 PD 12-FEB-1998.
 XX
 XX 07-AUG-1997; 97WO-US013945.
 XX

PR 07-AUG-1996; 96US-0023541P.
PR 18-OCT-1996; 96US-0028515P.
PR 18-MAR-1997; 97US-0040820P.
XX
PA (BIOJ) BIOGEN INC.
PA (UYGE-) UNIV GENEVA FACULTY MEDICINE.
XX Chicheportiche Y, Browning JL;
XX WPI; 1998-145619/13.
XX Tumour necrosis factor related ligand - useful for, e.g. treating cancer,
PT auto-immune disease and immune responses to tissue grafts.
XX
PS Example 2; Page 34; 69pp; English.
XX The sequence is that of a PCR primer which was used in the cloning of
CC cDNA coding for human tumour necrosis factor related ligand (TRELL). The
CC sequence was derived from human EST R55379 (Genbank)
XX
XX Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
SQ Query Match 2.2%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 301 CCAGCGCTGCTGGAGGA 318
DB 2 CCTGGCTGCTGGAGGA 19
RESULT 585
AAV18602
ID AAV18602 standard; DNA; 20 BP.
XX
AC AAV18602;
XX
XX 21-JUL-1998 (first entry)
XX Synthetic human tumour necrosis factor related ligand PCR primer.
DE
XX
XX TRELL; tumour necrosis factor related ligand; tnf; treatment; cancer;
XX autoimmune disease; immune system; stimulation; suppression;
XX graft rejection; ss.
XX Synthetic.
OS
OS Homo sapiens.
XX
XX W09805783-A1.
PN
XX
XX 12-FEB-1998.
PD
XX
XX 07-AUG-1997; 97WO-US013945.
PF
XX
XX 07-AUG-1996; 96US-0023541P.
PR
XX 18-OCT-1996; 96US-0028515P.
PR
XX 18-MAR-1997; 97US-0040820P.
XX
XX (BIOJ) BIOGEN INC.
PA (UYGE-) UNIV GENEVA FACULTY MEDICINE.
XX Chicheportiche Y, Browning JL;
XX WPI; 1998-145619/13.
XX Tumour necrosis factor related ligand - useful for, e.g. treating cancer,
PT auto-immune disease and immune responses to tissue grafts.
XX
PS Example 1; Page 29; 69pp; English.
XX The sequence is that of PCR primer LTB-065 which was used in the
XX isolation of cDNA coding for human tumour necrosis factor related ligand
CC (TRELL). The sequence was derived from human EST AAR55379
CC

XX
SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 2.2%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 301 CCAGCGCTGCTGGAGGA 318
DB 2 CCTGGCTGCTGGAGGA 19
RESULT 586
ABZ87729
ID ABZ87729 standard; DNA; 20 BP.
XX
XX ABZ87729;
AC
XX
XX 17-OCT-2003 (first entry)
DT
XX Human oligonucleotide sequence.
DE
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX
XX W0200285308-A2.
PN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013135.
PF
XX
XX 24-APR-2001; 2001US-0286137P.
PR
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX WPI; 2003-229219/22.
DR
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiqunone.
XX
XX Disclosure; SEQ ID NO 2971; 872pp; English.
PS
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiqunone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiqunone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 20 BP; 5 A; 3 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 2.2%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 897 TGGGCAGTGAGCGGAAGC 914
|||||
Db 2 TGGGCAGTGAGCGGAAGC 19
RESULT 587
ID ABD23959 standard; DNA; 20 BP.
XX ABD23959;
XX
DT 29-JUL-2004 (first entry)
XX Human calmodulin 2-derived oligonucleotide SEQ ID 2971.
DE
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 2971; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The

CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 5 A; 3 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 2.2%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 897 TGGGCAGTGAGCGGAAGC 914
|||||
Db 2 TGGGCAGTGAGCGGAAGC 19
RESULT 588
ID ADQ90611/c
XX ADQ90611 standard; DNA; 21 BP.
XX ADQ90611;
XX
DT 21-OCT-2004 (first entry)
XX
DE Sca-2 siRNA duplex sense oligonucleotide SEQ ID NO:8.
XX
KW lentiviral vector; small interference RNA; siRNA; cytostatic; virucide;
KW gene therapy; Sca-2; ss.
XX
OS Mus musculus.
OS Synthetic.
XX
XX WO2004065549-A2.
XX
XX 05-AUG-2004.
XX
XX 15-JAN-2004; 2004WO-US001320.
XX
XX 17-JAN-2003; 2003US-0440987P.
XX
XX (UYFL) UNIV FLORIDA.
XX
XX Chang L, He J;
XX
XX WPI; 2004-562155/54.
XX
XX New lentiviral vector comprising a nucleotide sequence encoding a small
PT interference RNA, useful for reducing expression of a target gene in a
PT cell.
XX
XX Example 1; SEQ ID NO 8; 51pp; English.
XX
XX The present invention describes a lentiviral vector comprising a
CC nucleotide sequence encoding a small interference RNA (siRNA). Also
CC described is a method of reducing expression of a target gene in a cell
CC comprising: (a) introducing into the cell a lentiviral vector encoding a
CC siRNA specific for the gene; and (b) placing the cell under conditions,
CC where the siRNA specific for the gene is expressed to cause a detectable
CC decrease in expression of the gene. The siRNA has cytostatic and virucide
CC activities, and can be used in gene therapy. The vector is useful for
CC reducing expression of a target gene in a cell. The present sequence
CC represents a Sca-2 siRNA duplex oligonucleotide, which is used in an
CC example from the present invention.
XX
XX Sequence 21 BP; 3 A; 7 C; 3 G; 8 T; 0 U; 0 Other;


```

Query Match      2.1%; Score 16; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 901 CAGTGAGCGGAGCGGA 916
DB 1 CAGUGAGCGGAGCGGA 16

RESULT 591
AAV29497/c
ID AAV29497 standard; DNA; 19 BP.
XX
AC AAV29497;
XX
DT 05-AUG-1998 (first entry)
XX
DE Serotonin 5HT7 receptor allelic variant amplifying ASA upper primer.
XX
KW Allelic variant; serotonin 5HT7 receptor; alcoholic offender; 5HT7leu;
KW neuropsychiatric drug; screening; allele specific amplification; ASA;
KW PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
PN US5763183-A.
XX
PD 09-JUN-1998.
XX
PF 08-NOV-1996; 96US-00745269.
XX
PR 09-NOV-1995; 95US-0006394P.
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Virkkunen M, Goldman D, Pesonen U, Koulu M, Linnoila M;
XX
WPI; 1998-347310/30.
DR
AL Allelic variant of serotonin 5HT7 receptor gene - is associated with
PT alcoholic offenders and is useful for screening neuropsychiatric drugs.
XX
PS Example 2; Col 7; 11pp; English.
XX
CC This PCR primer is used for allele specific amplification (ASA) of the
CC allelic variant of the serotonin 5HT7 receptor (5HT7leu). This is used
CC for screening large numbers of samples for 5HT7leu variant. The invention
CC provides a method for detecting DNA that codes for a 5HT7leu allelic
CC variant which comprises amplifying human DNA with primers capable of
CC amplifying a sequence encoding the third intracellular loop of the human
CC 5HT7 gene and determining if the amplified DNA comprises a sequence in
CC which a C-to-T alteration converts a Pro codon to a Leu codon. The
CC 5HT7leu variant and associated DNA and assays provide important
CC investigative tools for both behavioural research and the screening of
CC neuropsychiatric drug candidates
XX
SQ Sequence 19 BP; 3 A; 6 C; 3 G; 7 T; 0 U; 0 Other;

Query Match      2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 441 AGGAGCCGAGAACTGGT 459
DB 19 AGGAGCCGAGAACTGT 1

RESULT 592
ADL95276
ID ADL95276 standard; RNA; 19 BP.
XX

```

```

AC ADL95276;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human 23S rRNA molecular interaction site SeqID 290.
XX
KW molecular interaction site; 23S rRNA; combinatorial library;
KW antimicrobial; prokaryotic cell growth; ss; human.
XX
OS Homo sapiens.
XX
PN WO2003018750-A2.
XX
PD 06-MAR-2003.
XX
PF 21-AUG-2002; 2002WO-US026582.
XX
PR 22-AUG-2001; 2001US-0314251P.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ;
XX
WPI; 2003-457183/43.
XX
CC New polynucleotides comprising molecular interaction sites of 23S rRNA
CC that have secondary structures, useful for virtual or actual screening of
CC compounds that bind to it, and the modulation of the activity of the 23S
CC rRNA.
XX
Example 3; SEQ ID NO 290; 148pp; English.
XX
CC This invention relates to a novel polynucleotides that comprise molecular
CC interaction sites of 23S rRNA secondary structure. Specifically, it
CC refers to the virtual or actual screening of combinatorial libraries of
CC compounds that can bind to and modulate the activity of 23S rRNA, and as
CC such affect interactions with factors and proteins required for
CC translation and other cellular processes. The present invention describes
CC the identification of molecular interactions. The present invention describes
CC rRNA (and their secondary structures) that can be used as antimicrobial
CC targets for compounds that modulate, inhibit or stimulate prokaryotic
CC cell growth, and thus are useful as novel drugs, agricultural chemicals
CC and industrial chemicals that operate through the modulation of 23S rRNA.
CC This oligonucleotide sequence is a 23S rRNA oligo, a targeted molecular
CC interaction site of the invention.
XX
SQ Sequence 19 BP; 1 A; 6 C; 10 G; 0 T; 2 U; 0 Other;

Query Match      2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 3.6e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 652 GCCTCTGAGGTCGGGCC 670
DB 1 GCGCGUGGAGCGUCGGGCC 19

RESULT 593
AAQ83789/c
ID AAQ83789 standard; DNA; 20 BP.
XX
AC AAQ83789;
XX
DT 25-MAR-2003 (revised)
DT 05-SEP-1995 (first entry)
XX
DE VEGF antisense oligonucleotide.
XX
KW Vascular endothelial growth factor; VEGF; antisense; phosphorothioate;
KW oligonucleotide; angiogenesis; diabetes; retinopathy; atherosclerosis;
KW wound healing; vulnery; tumor; metastasis; ss.
XX
OS Synthetic.

```

```
XX Key Location/Qualifiers
FH msc_feature 1. .20
FT /*tag= a
FT /note= "phosphorothioate internucleotide linkages"
XX
XX WO9504142-A2.
XX
XX 09-FEB-1995.
XX
XX 26-JUL-1994; 94WO-US0009537.
XX
XX 27-JUL-1993; 93US-00098942.
XX
XX (HYBR-) HYBRIDON INC.
XX
XX Robinson GS;
XX
XX WPI; 1995-082226/11.
XX
XX New antisense oligo-nucleotide(s) inhibiting vascular endothelial growth
PT factor - for treating abnormal angiogenesis in cases of e.g. diabetic
PT retinopathy or tumour.
XX
XX Example 5; Page 35; 45pp; English.
XX
XX Inhibition of vascular endothelial growth factor (VEGF) expression, as a
CC means of controlling angiogenesis, is obtained using antisense
CC oligonucleotides (AODN) complementary to portions of VEGF RNA. The AODN
CC given in AAQ83789 is targeted against sequences in the 5'UTR of the human
CC VEGF molecule. It had no effect on VEGF protein production. (Updated on
CC 25-MAR-2003 to correct PN field.)
XX
XX Sequence 20 BP; 0 A; 11 C; 4 G; 5 T; 0 U; 0 Other;
SQ
Query Match 2.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 696 AGCTGGAGAGTGAGCGCGA 714
DB |||||
19 AGCGGAGAGGAGCGCGA 1
XX
RESULT 594
AAQ90288
ID AAQ90288 standard; DNA; 20 BP.
XX
XX AAQ90288;
XX
XX 11-JAN-1996 (first entry)
XX
XX 16S rRNA gene PCR detection primer ER6.
XX
XX Primer; PCR; amplification; microorganism; bacterium; virus; fungus;
KW actinomycete; unicellular parasite; 16S; 23S; rRNA gene;
KW fluorescein isothiocyanate; gel electrophoresis; ss.
XX
XX Synthetic.
XX
XX WO9513396-A2.
XX
XX 18-MAY-1995.
XX
XX 11-NOV-1994; 94WO-NL000283.
XX
XX 11-NOV-1993; 93NL-00001957.
XX
XX (UGEN-) U GENE RES BV.
XX
XX Fluit AC, Widjoatmodjo MN;
XX
XX WPI; 1995-194113/25.
DR
```

```
XX Identification of microorganisms by nucleic acid amplification - using
PT universal primers and comparison of electrophoretic sepn. patterns, esp.
PT for rapid species specific identification of bacteria.
XX
XX Claim 5; Page 31; 34pp; English.
XX
XX The primers AAQ90283-94 are used in a PCR amplification method for the
CC detection of microorganisms esp. bacteria, but also for viruses, fungi,
CC actinomycetes, unicellular parasites, etc. The primers are based on the
CC sequences of the 16S and 23S rRNA genes but can also include other
CC species and gene specific primers. This primer corresponds to bases 1041-
CC 60 of the 16S rRNA gene. The primers can be labelled for ease of
CC detection by e.g. fluorescein isothiocyanate (FITC). The amplification
CC products are converted to a single strand form and separated by gel
CC electrophoresis, based on sequence-dependent differences in mobility
CC (SDDM) of the single stranded DNA or RNA. The band pattern generated by
CC the electrophoresis can be used to identify the species or strain of
CC microorganism when compared to a set of electrophoresis patterns for
CC known microorganisms
XX
XX Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
SQ
Query Match 2.1%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 256 AGCCATGCTGCACCTGCCT 274
DB |||||
1 AGCCATGCTGCACCTGCCT 19
XX
RESULT 595
ABQ78472/C
ID ABQ78472 standard; DNA; 20 BP.
XX
XX ABQ78472;
XX
XX 05-NOV-2002 (first entry)
XX
XX Antisense oligonucleotide targeted to VEGF 3' untranslated region..
XX
XX Antisense oligonucleotide; vascular endothelial growth factor; VEGF;
KW vascular permeability factor; VPF; angiogenesis; phosphorothioate;
KW angiogenic disorder; diabetic retinopathy; tumour angiogenesis;
KW atherosclerotic plaque formation; wound healing; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH modified_base 1. .20
FT /*tag= a
FT /note= "phosphorothioate internucleotide linkages"
XX
XX US6410322-B1.
XX
XX 25-JUN-2002.
XX
XX 27-JUL-1993; 93US-00098942.
XX
XX 27-JUL-1993; 93US-00098942.
XX
XX (ROBI/) ROBINSON G S.
XX
XX Robinson GS;
XX
XX WPI; 2002-588990/63.
XX
XX New antisense oligonucleotides that bind to Vascular Endothelial Growth
PT Factor (VEGF) RNA and inhibit production of the VEGF protein, useful for
PT treating angiogenic disorders, e.g. diabetic retinopathy and tumor
PT angiogenesis.
PT
```

XX Example 5; Col 12; 16pp; English.

XX The present sequence represents an antisense oligonucleotides which is

XX targeted to vascular endothelial growth factor (VEGF) RNA. While the

XX present oligonucleotide did not inhibit VEGF protein production, other

XX antisense oligonucleotides (see ABQ78459-62 and ABQ78467-69) did. VEGF,

XX also known as vascular permeability factor (VPF), has been shown to play

XX an integral role in abnormal angiogenesis associated with a variety of

XX pathological states. These antisense oligonucleotides are useful in the

XX treatment of pathological states in which VEGF expression plays a role,

XX especially angiogenic disorders, e.g. diabetic retinopathy,

XX atherosclerotic plaque formation, wound healing and tumour angiogenesis.

XX Inhibition of VEGF expression by antisense oligonucleotide technology

XX will also be useful in determining the role of this cytokine in processes

XX where angiogenesis is involved. In vitro systems which mimic blood vessel

XX formation/permeability have been developed. The role of VEGF in these

XX systems can be determined using antisense oligonucleotides

XX

SQ Sequence 20 BP; 0 A; 11 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.1%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 3.9e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGAGAGTGTGAGCGCA 714

DB 19 AGCCGAGAGGAGCGCGA 1

RESULT 596

ADP11986

ID ADP11986 standard; DNA; 20 BP.

XX ADP11986;

AC ADP11986;

DT 12-AUG-2004 (first entry)

XX

DE Set 2 right PCR primer for marker probe #92.

XX

KW transplant rejection; immune system; rheumatoid arthritis; lupus;

KW inflammatory bowel disease; multiple sclerosis; HIV; AIDS; ss; primer.

XX Homo sapiens.

XX WO2004042346-A2.

XX

PD 21-MAY-2004.

XX

PF 24-APR-2003; 2003WO-US012946.

XX

PR 24-APR-2002; 2002US-00131831.

PR 20-DEC-2002; 2002US-00325899.

XX (EXPR-) EXPRESSION DIAGNOSTICS INC.

PA Wohlgemuth J, Fry K, Woodward R, Ly N, Prentice J, Morris M;

PI Rosenberg S;

XX WPI; 2004-400724/37.

XX

PT Diagnosing or monitoring transplant rejection, e.g. heart, kidney, liver,

PT pancreas, pancreatic islet, lung, bone marrow or stem cell transplant

PT rejection, in an individual, comprises detecting the expression level of

PT the genes.

XX

PS Claim 58; SEQ ID NO 1995; 1762pp; English.

XX

CC The present invention relates to diagnosing or monitoring transplant

CC rejection, e.g. cardiac or kidney transplant rejection, in an individual

CC comprises detecting the expression level of one or more genes. The

CC methods, system and kits are useful in diagnosing or monitoring

CC transplant rejection, e.g. heart, kidney, liver, pancreas, pancreatic

CC islet, lung, bone marrow or stem cell transplant rejection,

CC xenotransplant rejection or mechanical organ replacement rejection, in an

CC individual. The method is also useful in assessing the immune status of

CC an individual. The methods are also useful in diagnosing and monitoring

CC diseases that involve the immune system, e.g. rheumatoid arthritis,

CC lupus, inflammatory bowel diseases, multiple sclerosis, HIV/AIDS or

CC viral, bacterial or fungal infection. The present sequence represents a

CC primer for a 50 mer oligonucleotide marker for diagnosis and monitoring

CC of allograft rejection and other disorders.

XX

SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 2.1%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 3.9e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 510 CTCTCGGAGGTGAGCA 528

DB 2 CTCTCGGAGGTGAGCA 20

RESULT 597

ADOI5339/c

ID ADOI5339 standard; DNA; 20 BP.

XX ADOI5339;

AC ADOI5339;

DT 12-AUG-2004 (first entry)

XX

DE DNA probe used for one-step real-time RT-PCR detection SeqID 15.

XX

KW one step real-time RT-PCR; pharmaceutical; cosmetic; bacteria;

KW fungus-yeast; probe; ss.

XX

OS Synthetic.

XX

PN WO2004044247-A2.

XX

PD 27-MAY-2004.

XX

PF 03-NOV-2003; 2003WO-IB005312.

XX

PR 12-NOV-2002; 2002US-0425327P.

XX (GENO-) GENOLIFE.

PA

XX

PI Chaubron F, Martin-Minvielle AC, Groulon S;

XX

DR WPI; 2004-411742/38.

XX

PT Determining presence of bacteria or fungus-yeast RNA in sample involves

PT carrying out reverse transcriptase-PCR reaction of fungus-yeast RNA and

PT treating amplified DNA with probes which hybridize to amplified DNA.

XX

PS Claim 1; SEQ ID NO 15; 31pp; English.

XX

CC This invention relates to a novel method for one step real-time RT-PCR

CC kits useful for the detection of microorganisms occurring within

CC industrial products such as pharmaceuticals, cosmetic and non-clinical

CC samples. Specifically, it refers to determining the presence of bacteria

CC or fungus-yeast RNA in a sample suspected of containing such

CC contaminants. The present invention describes oligonucleotide primers and

CC probes that are natural nucleic acid or peptide nucleic acid (PNA)

CC molecules that can hybridize to the target nucleic acid (DNA and RNA).

CC Accordingly, the method enables rapid and simultaneous detection and

CC quantification of RNA from bacteria and fungus-yeast in either sterile or

CC non-sterile products in less than 24 hours. Furthermore, the one step

CC process reduces the risk of environmental contamination that could occur

CC when the reaction tubes are opened during the PCR procedure. This

CC oligonucleotide sequence is a PCR primer used in one-step real time RT-

CC PCR to amplify bacteria and fungus-yeast RNA, given in an exemplification

CC of the invention.

XX

New cells recombinantly altered to express an exogenous AK155 cytokine receptor, useful for identifying agents for treating AK155-mediated diseases, e.g. inflammation, angiogenesis or cancer.

XX Example 2; Page 51; 100pp; English.

XX The present invention relates to a cell recombinantly altered to express

CC an exogenous AK155 cytokine receptor comprising alpha and beta subunits.

CC The cytokine receptor, when expressed in Ba/F3 cells, binds to AK155 and

CC stimulates binding of STAT3 to interferon (IFN) gamma-activated

CC sequences. The cell is useful in expressing AK155 cytokine receptor which

CC may be used for identifying therapeutic agents useful for treating AK155-

CC mediated conditions or diseases, such as inflammation (e.g. Crohn's

CC disease), autoimmune diseases (e.g. multiple sclerosis, rheumatoid

CC arthritis, psoriasis, asthma, allergies, diabetes mellitus, Sjogren's

CC syndrome), transplant rejection, angiogenesis, and cancer. The current

XX sequence represents an IL-10 forward primer sequence

XX Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.1%; Score 15.8; DB 1; Length 21;

Best Local Similarity 89.5%; Pred. No. 4.1e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 325 AGAGTCCGAGATGCCATC 343

DB 2 AGATCTCCGAGATGCCCTC 20

|||||

RESULT 600

ACC79905/c

ID ACC79905 standard; DNA; 21 BP.

XX ACC79905;

AC ACC79905;

DT 08-SEP-2003 (first entry)

DE Mouse Rab38 probe SEQ ID NO:20.

XX

KW Malic enzyme; Men; F-box; ABC50; VhaPp1-1; vacuolar ATPase; Sec61 alpha;

KW glutathione S-transferase 2; GST2; Rab-Rp1 family; Csp; coronin;

KW cysteine string protein; actin-associated protein; antidiabetic;

KW hypotensive; cardiac; anorectic; antiinflammatory; cytostatic;

KW gene therapy; obesity; eating disorder; cachexia; diabetes mellitus;

KW hypertension; coronary heart disease; hypercholesterolaemia; cancer;

KW dyslipidaemia; osteoarthritis; gallstone; sleep apnea; PCR primer; ss.

XX Mus sp.

OS Synthetic.

XX

PN WO2003040296-A2.

XX

PD 15-MAY-2003.

XX

PF 08-NOV-2002; 2002WO-EP012518.

XX

PR 08-NOV-2001; 2001EP-00126681.

PR 09-NOV-2001; 2001EP-00126804.

PR 13-NOV-2001; 2001EP-00126967.

PR 20-NOV-2001; 2001EP-00127669.

PR 23-NOV-2001; 2001EP-00127959.

PR 23-NOV-2001; 2001EP-00127960.

PR 28-NOV-2001; 2001EP-00128254.

PR 13-DEC-2001; 2001EP-00129727.

PR 19-DEC-2001; 2001EP-00130310.

PR 14-JAN-2002; 2002EP-00000819.

XX (DEVE-) DEVELOPUNG ENTWICKLUNGSBIOLOGISCHE FORSCH.

PA (HAED/) HAEDER T.

XX

PI Eulenber K, Steuernagel A, Broenner G;

XX

DR WPI; 2003-441537/41.

XX

PT New pharmaceutical composition comprising a nucleic acid molecule of the

PT malic enzyme, ABC50, VhaPp1-1, Sec61 alpha, glutathione S-transferase 2,

PT Rab-Rp1, F-box protein Lilina/FBL7, useful treating e.g., obesity.

XX Example 4; Page 73; 158pp; English.

XX

CC The present invention describes a pharmaceutical composition comprising a

CC nucleic acid molecule of the malic enzyme (Men), F-box, ABC50, VhaPp1-1,

CC vacuolar ATPase, Sec61 alpha or glutathione S-transferase 2 (GST2) gene

CC family, Rab-Rp1 family of proteins, cysteine string protein (Csp) family

CC of proteins, F-box protein Lilina/FBL7, coronin family of actin-

CC associated proteins, or other polypeptides and a carrier. Also described:

CC (1) a non-human transgenic animal exhibiting a modified expression of the

CC polypeptide; (2) a recombinant host cell exhibiting the modified

CC expression of the homologous polypeptide; (3) a method of identifying a

CC polypeptide involved in regulation of the energy homeostasis and/or the

CC metabolism of triglycerides in a mammal; and (4) a method for screening

CC for an agent that modulates the activity of the homologous polypeptide or

CC interaction of the homologous polypeptide with a binding target/agent.

CC The pharmaceutical composition has anorectic, antidiabetic, hypotensive,

CC cardiant, antiinflammatory and cytostatic activities, and can be used in

CC gene therapy. The pharmaceutical composition is useful for preparing a

CC composition for diagnosing or treating, evaluating treatment of obesity,

CC eating disorders, cachexia, diabetes mellitus, hypertension, coronary

CC heart disease, hypercholesterolaemia, dyslipidaemia, osteoarthritis,

CC gallstones, cancer or sleep apnea. The present sequence is used in the

CC exemplification of the present invention

XX

QY 839 CAGGTGGCTATCACCAGC 857

DB 20 CAGGTGGCGATCACCAGC 2

|||||

RESULT 601

AAD58225/c

ID AAD58225 standard; DNA; 21 BP.

XX AAD58225;

AC AAD58225;

XX

DT 20-NOV-2003 (first entry)

XX

DE Cytokine amplifying RT-PCR primer, IFN-alphaR.

XX

KW Virus suppressing factor protein; VSP; immune cell; proteinase K;

KW immunoprecipitation; immunoneutralisation; viral infection; virucide;

KW RT-PCR; primer; ss.

XX

OS Unidentified.

XX

PN WO2003064461-A1.

XX

PD 07-AUG-2003.

XX

PF 30-JAN-2003; 2003WO-KR000231.

XX

PR 01-FEB-2002; 2002KR-00005969.

XX

PA (IMMU-) IMMUNEMED INC.

XX

PI Kim Y, Kim Y, Choi Y, Ahn J, Woo S, Sin S, Cho M, Byun Y;

PI Kang J;

XX

DR WPI; 2003-618354/58.

XX

PT New virus suppressing factor protein having antiviral activity produced

PT in immune cell stimulated by encephalomyocarditis virus variant, useful

PT for suppressing proliferation or replication of virus e.g. herpes virus.

XX Example 4; Page 22; 95pp; English.

XX The invention relates to a virus suppressing factor (VSF) protein
 CC increasingly produced in an immune cell stimulated by
 CC encephalomyocarditis virus variant. The protein has antiviral activity
 CC unchanged by immunoprecipitation and immunoneutralisation, is inactivated
 CC by proteinase K, is not chosen from antiviral cytokines. The invention is
 CC useful for preventing or treating viral infections by administering the
 CC protein to a subject suffering from a viral infection. The invention has
 CC antiviral activity which is to suppress proliferation or replication of a
 CC virus belonging to Orthomyxoviridae, Picornaviridae, Retroviridae or
 CC Herpes. The present sequence is a RT-PCR primer used in the amplification
 CC of cytokines of the invention
 XX
 SQ Sequence 21 BP; 3 A; 10 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 404 CAGAGGAGGAGGAGGAGT 422
 DB 21 CTGAGTGAGGAGGAGGAGT 3
 RESULT 602
 ADQ90647/C
 ID ADQ90647 standard; mRNA; 21 BP.
 XX AC
 XX ADQ90647;
 DT 21-OCT-2004 (first entry)
 DE Mouse Sca-2 target oligonucleotide SEQ ID NO:44.
 XX lentiviral vector; small interference RNA; siRNA; cytostatic; virucide;
 KW gene therapy; Sca-2; ss.
 XX Mus musculus.
 OS Synthetic.
 XX WO2004065549-A2.
 FN 05-AUG-2004.
 PD 15-JAN-2004; 2004WO-US001320.
 PF 17-JAN-2003; 2003US-0440987P.
 PR (UYFL) UNIV FLORIDA.
 PA Chang L, He J;
 PI WPI; 2004-562155/54.
 DR New lentiviral vector comprising a nucleotide sequence encoding a small
 PT interference RNA, useful for reducing expression of a target gene in a
 PT cell.
 XX Example 1; SEQ ID NO 44; 51pp; English.
 The present invention describes a lentiviral vector comprising a
 CC nucleotide sequence encoding a small interference RNA (siRNA). Also
 CC described is a method of reducing expression of a target gene in a cell
 CC comprising: (a) introducing into the cell a lentiviral vector encoding a
 CC siRNA specific for the gene; and (b) placing the cell under conditions,
 CC where the siRNA specific for the gene is expressed to cause a detectable
 CC decrease in expression of the gene. The siRNA has cytostatic and virucide
 CC activities, and can be used in gene therapy. The vector is useful for
 CC reducing expression of a target gene in a cell. The present sequence
 CC represents a mouse Sca-2 target oligonucleotide, which is used in an
 CC example from the present invention.
 XX Sequence 21 BP; 5 A; 7 C; 3 G; 0 T; 6 U; 0 Other;
 Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 404 CAGAGGAGGAGGAGGAGT 422
 DB 21 CTGAGTGAGGAGGAGGAGT 3
 RESULT 603
 ADQ90612
 ID ADQ90612 standard; DNA; 21 BP.
 XX AC
 XX ADQ90612;
 DT 21-OCT-2004 (first entry)
 DE Sca-2 siRNA duplex antisense oligonucleotide SEQ ID NO:9.
 XX lentiviral vector; small interference RNA; siRNA; cytostatic; virucide;
 KW gene therapy; Sca-2; ss.
 XX Mus musculus.
 OS Synthetic.
 XX WO2004065549-A2.
 FN 05-AUG-2004.
 PD 15-JAN-2004; 2004WO-US001320.
 PF 17-JAN-2003; 2003US-0440987P.
 PR (UYFL) UNIV FLORIDA.
 PA Chang L, He J;
 PI WPI; 2004-562155/54.
 DR New lentiviral vector comprising a nucleotide sequence encoding a small
 PT interference RNA, useful for reducing expression of a target gene in a
 PT cell.
 XX Example 1; SEQ ID NO 9; 51pp; English.
 The present invention describes a lentiviral vector comprising a
 CC nucleotide sequence encoding a small interference RNA (siRNA). Also
 CC described is a method of reducing expression of a target gene in a cell
 CC comprising: (a) introducing into the cell a lentiviral vector encoding a
 CC siRNA specific for the gene; and (b) placing the cell under conditions,
 CC where the siRNA specific for the gene is expressed to cause a detectable
 CC decrease in expression of the gene. The siRNA has cytostatic and virucide
 CC activities, and can be used in gene therapy. The vector is useful for
 CC reducing expression of a target gene in a cell. The present sequence
 CC represents a mouse Sca-2 target oligonucleotide, which is used in an
 CC example from the present invention.
 XX Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 488 CTGAAGAGGAGGAGGAGGAGC 506
 DB 1 CTGAAGTTGCAGAGGAGGAGC 19
 RESULT 604
 ABN07458
 ID ABN07458 standard; DNA; 17 BP.
 XX

Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 488 CTGAAGAGGAGGAGGAGC 506
 DB 21 CTGAAGTTGCAGAGGAGGAGC 3
 RESULT 603
 ADQ90612
 ID ADQ90612 standard; DNA; 21 BP.
 XX AC
 XX ADQ90612;
 DT 21-OCT-2004 (first entry)
 DE Sca-2 siRNA duplex antisense oligonucleotide SEQ ID NO:9.
 XX lentiviral vector; small interference RNA; siRNA; cytostatic; virucide;
 KW gene therapy; Sca-2; ss.
 XX Mus musculus.
 OS Synthetic.
 XX WO2004065549-A2.
 FN 05-AUG-2004.
 PD 15-JAN-2004; 2004WO-US001320.
 PF 17-JAN-2003; 2003US-0440987P.
 PR (UYFL) UNIV FLORIDA.
 PA Chang L, He J;
 PI WPI; 2004-562155/54.
 DR New lentiviral vector comprising a nucleotide sequence encoding a small
 PT interference RNA, useful for reducing expression of a target gene in a
 PT cell.
 XX Example 1; SEQ ID NO 9; 51pp; English.
 The present invention describes a lentiviral vector comprising a
 CC nucleotide sequence encoding a small interference RNA (siRNA). Also
 CC described is a method of reducing expression of a target gene in a cell
 CC comprising: (a) introducing into the cell a lentiviral vector encoding a
 CC siRNA specific for the gene; and (b) placing the cell under conditions,
 CC where the siRNA specific for the gene is expressed to cause a detectable
 CC decrease in expression of the gene. The siRNA has cytostatic and virucide
 CC activities, and can be used in gene therapy. The vector is useful for
 CC reducing expression of a target gene in a cell. The present sequence
 CC represents a Sca-2 siRNA duplex oligonucleotide, which is used in an
 CC example from the present invention.
 XX Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 488 CTGAAGAGGAGGAGGAGGAGC 506
 DB 1 CTGAAGTTGCAGAGGAGGAGC 19
 RESULT 604
 ABN07458
 ID ABN07458 standard; DNA; 17 BP.
 XX

AC ABN07458;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7450.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 OS Homo sapiens.
 XX
 XX WO200192524-A2.
 PN
 PD 06-DEC-2001.
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 PS Disclosure; SEQ ID NO 7450; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at fip.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 412 GGAGGAGGAGGTTCTCA 428
 DB 1 GGAGGAGGAGGTTCTCA 17
 RESULT 605
 ABN07254
 ID ABN07254 standard; DNA; 17 BP.
 XX
 AC ABN07254;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7246.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 OS Homo sapiens.
 XX
 XX WO200192524-A2.
 PN
 PD 06-DEC-2001.
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 PS Disclosure; SEQ ID NO 7246; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at fip.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence

XX Sequence 17 BP; 3 A; 2 C; 10 G; 2 T; 0 U; 0 Other;
 SQ Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTACGGCG 713
 DB 1 GCTGGAGAGTACGGCG 17

RESULT 606
 ADJ34447/C
 ID ADJ34447 standard; DNA; 17 BP.
 AC ADJ34447;
 XX 06-MAY-2004 (first entry)
 DT Human secreted protein NOV17a/b RTQ PCR primer #2.
 DE Human; ss; PCR; NOVX; secreted protein; cancer; diabetes; obesity;
 KW endocrine disorder; CNS disorder; inflammatory disorder; gene therapy;
 KW primer; RTQ PCR; real time quantitative PCR.
 XX Homo sapiens.
 OS Homo sapiens.
 XX WO200400997-A2.
 FN 31-DEC-2003.
 PD 04-JUN-2003; 2003WO-US017512.
 PF 19-MAR-2002; 2002US-0365491P.
 PR 04-JUN-2002; 2002US-0385504P.
 PR 05-JUN-2002; 2002US-0386041P.
 PR 06-JUN-2002; 2002US-0386453P.
 PR 07-JUN-2002; 2002US-0386974P.
 PR 07-JUN-2002; 2002US-0386816P.
 PR 07-JUN-2002; 2002US-0387002P.
 PR 10-JUN-2002; 2002US-0387540P.
 PR 11-JUN-2002; 2002US-0387659P.
 PR 12-JUN-2002; 2002US-0387934P.
 PR 13-JUN-2002; 2002US-0389123P.
 PR 17-JUN-2002; 2002US-0389729P.
 PR 17-JUN-2002; 2002US-0389742P.
 PR 19-JUN-2002; 2002US-0390006P.
 PR 17-JUL-2002; 2002US-0396706P.
 PR 12-AUG-2002; 2002US-0402832P.
 PR 13-AUG-2002; 2002US-0403486P.
 PR 14-AUG-2002; 2002US-0403522P.
 PR 15-AUG-2002; 2002US-0403748P.
 PR 06-NOV-2002; 2002US-0387037P.
 PR 03-JUN-2003; 2003US-00454246.
 XX (CURA-) CURAGEN CORP.
 PA Anderson DM, Boldog FL, Burgess CE, Casman SJ, Edinger SR;
 PI Eisen A, Ellerman K, Gerlach VL, Gorman L, Guo X, Gusev VY, Ji W;
 PI Li L, Macdougall JR, Malyankar UM, Millet I, Ort T, Padigaru M;
 PI Prayaga SK, Patturajan M, Pena CEA, Peyman JA, Rieger DK;
 PI Rothenberg ME, Sciore P, Shenoy SG, Smithson G, Stone DJ;
 PI Taupier RJ, Tchernev VT, Vernet CAM, Voss EZ, Zerhusen BD, Zhong M;
 XX WPT; 2004-082483/08.

PT New isolated NOVX polypeptides useful for treating, preventing and
 PT diagnosing pathological conditions with NOVX-associated disorders, such
 PT as cancer, obesity, diabetes and inflammatory or CNS diseases.
 XX Example D; SEQ ID NO 336; 418pp; English.
 XX The invention relates to a new isolated polypeptide (designated NOVX)
 CC comprising one of 141 fully defined sequences, their mature forms, a
 CC protein comprising one or more conservative substitutions or having at
 CC least 95% identity to one of the 141 proteins. Also included are a
 CC composition comprising NOVX (or a NOVX nucleic acid molecule (NA)), a kit
 CC comprising the composition of NOVX in one or more containers, an isolated
 CC nucleic acid molecule encoding a NOVX protein, producing NOVX (comprising
 CC culturing a cell under conditions that lead to expression of the
 CC polypeptide, where the cell comprises a vector comprising NOVX NA),
 CC identifying an agent that binds to NOVX, identifying a potential
 CC therapeutic agent for use in the treatment of a pathology that is related
 CC to aberrant expression or physiological interactions of NOVX, screening
 CC for a modulator of activity of or latency or predisposition to a
 CC pathology associated with NOVX, modulating the activity of NOVX, treating
 CC or preventing a pathology associated with NOVX, treating a pathological
 CC state in a mammal, a vector comprising the NOVX nucleic acid molecule, a
 CC cell comprising the vector, an antibody that immunospecifically binds to
 CC NOVX, determining the presence or amount of NOVX or the nucleic acid
 CC molecule in a sample, and determining the presence of or predisposition
 CC to a disease associated with altered levels of expression of NOVX or the
 CC nucleic acid molecule in a first mammalian subject. The methods and
 CC compositions of the present invention are useful for the diagnosis and
 CC treatment of disorders associated with aberrant expression or activity of
 CC the NOVX polypeptide, such as cancer, diabetes, obesity, and endocrine,
 CC CNS and inflammatory disorders. They can also be used in various
 CC detection and screening assays, chromosome mapping, tissue typing, gene
 CC therapy and predictive medicine. The present sequence is an RTQ (real
 CC time quantitative) PCR primer for an mRNA encoding a NOVX protein.

XX Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
 SQ Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 556 TGAGGACAGGCGCTCTG 572
 DB 17 TGAGGACAGGCGCTCTG 1

RESULT 607
 ACN70344
 ID ACN70344 standard; DNA; 17 BP.
 AC ACN70344;
 XX 02-DEC-2004 (first entry)
 DT Human GDMPLP-1 probe SEQ ID NO:7246.
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX Homo sapiens.
 OS Homo sapiens.
 XX US2004137589-A1.
 PN 15-JUL-2004.
 PD 26-NOV-2003; 2003US-00723361.
 PF 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 7246; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 10 G; 2 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 697 GCTGGAGAGTGAGCGCG 713
 DB 1 GCTGGAGAGTGAGCGCG 17
 RESULT 608
 ACN70548
 ID ACN70548 standard; DNA; 17 BP.
 XX
 AC ACN70548;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:7450.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 XX US2004137589-A1.
 PN
 XX 15-JUL-2004.
 PD

XX 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 7450; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 412 GGAGAGGAGTGCTCTCA 428
 DB 1 GGAGAGGAGTGCTCTCA 17
 RESULT 609
 AAX79593
 ID AAX79593 standard; DNA; 18 BP.
 XX
 AC AAX79593;
 XX
 DT 12-AUG-1999 (first entry)
 XX
 DE Probe SEQ ID No 32 for hybridisation assay.
 KW Hybridisation assay; nucleic acid analyte; detection; therapy; probe;
 XX

nonspecific hybridisation reduction; ss.

XX Synthetic.
XX WO9606950-A1.
XX 07-MAR-1996.
XX 30-AUG-1995; 95WO-US011115.
XX 30-AUG-1994; 94US-00298073.
XX (CHIR) CHIRON CORP.
XX Collins ML, Horn T, Sheridan PE, Warner BD, Urdea MS;
XX WPI; 1996-160381/16.
XX Reducing non-specific hybridisation - by using non-natural nucleotide
XX units in hybridisation assays, aptamers or anti-sense molecules.
XX Example 5; Page 43; 67pp; English.
XX This sequence represents a probe oligonucleotide used in a nucleic acid
XX hybridisation assay. The invention relates to an improvement in a nucleic
XX acid (NA) hybridisation assay for detecting a NA analyte in a sample
XX using assay components each of which comprises at least 1 hybridising
XX oligonucleotide (ON) segment, the improvement comprises incorporating
XX into at least 1 hybridising ON segment a 1st nucleotidic unit which will
XX not effectively base pair with adenosine (A), thymidine (T), cytidine
XX (C), guanosine (G) or uridine (U) under conditions in which A-T and G-C
XX base pairs are formed. Preferably the first nucleotidic unit can form a
XX non-natural base pair is formed between isocytosine and isoguanosine. The
XX assay methods reduce nonspecific hybridisation to reduce background noise
XX and increase sensitivity and specificity in the detection and
XX quantitation of analytes. The aptamers and antisense molecules containing
XX them prepared using the non-natural nucleotidic units can also have
XX minimised nonspecific hybridisation when used, e.g. in therapy
XX
XX Sequence 18 BP; 8 A; 6 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
Db 2 AGTACGACACACATC 18

RESULT 610
AAT64410/C
ID AAT64410 standard; DNA; 18 BP.

XX AAT64410;
XX 02-FEB-1998 (first entry)
XX Protein kinase A subunit RI-alpha synthetic oligonucleotide #169.
XX DNA/RNA hybrid; antisense; hybrid; inverted hybrid; mitogenicity;
XX inverted chimeric hybrid; protein kinase A subunit RI-alpha gene;
XX anti-thrombotic; cancer cell proliferation; tumour; ribonucleotide; ss.
XX Synthetic.
XX Key Location/Qualifiers
XX misc_RNA 7. .11
XX /tag= a
XX /note= "ribonucleotide"
XX WO9711171-A1.

XX 27-MAR-1997.
XX 19-SEP-1996; 96WO-US015084.
XX 22-SEP-1995; 95US-00532979.
XX (HYBR-) HYBRIDON INC.
XX Agrawal S;
XX WPI; 1997-202880/18.
XX Modified protein kinase A specific oligonucleotide(s) - are useful for
XX the treatment of cancer.
XX Example 10; Page 17; 66pp; English.
XX This sequence represents a synthetic, modified antisense oligonucleotide
XX (#169) which was designed to be a mismatched inverted hybrid control. The
XX modified oligonucleotide types used in this study were hybrid, inverted
XX hybrid or inverted chimeric hybrid and have been found to down regulate
XX protein kinase A subunit RI-alpha gene expression while producing fewer
XX side effects than conventional oligonucleotides e.g. reduced
XX mitogenicity, reduced activation of complement and reduced anti-
XX thrombotic properties. By controlling the regulation of protein kinase A
XX subunit RI-alpha inhibition of the proliferation of cancer cells and
XX tumour growth is possible. This is a novel method for the treatment of
XX disease and disorders caused by the overexpression or inappropriate
XX expression of the gene
XX
XX Sequence 18 BP; 0 A; 9 C; 6 G; 1 T; 2 U; 0 Other;

QY 677 GCCAGCGACGCGCG 693
Db 18 GCCAGCGAGGCGCG 2

RESULT 611
AAT64405/C
ID AAT64405 standard; DNA; 18 BP.

XX AAT64405;
XX 02-FEB-1998 (first entry)
XX Protein kinase A subunit RI-alpha synthetic oligonucleotide #167.
XX Antisense; hybrid; inverted hybrid; mitogenicity;
XX inverted chimeric hybrid; protein kinase A subunit RI-alpha gene;
XX anti-thrombotic; cancer cell proliferation; tumour; ss.
XX Synthetic.
XX Key Location/Qualifiers
XX modified_base 7. .12
XX /tag= a
XX /note= "Methylphosphonate nucleotides. Modification only
XX applicable to mismatched inverted chimeric
XX oligonucleotide."
XX WO9711171-A1.

XX 27-MAR-1997.
XX 19-SEP-1996; 96WO-US015084.
XX 22-SEP-1995; 95US-00532979.

```

PA (HYBR-) HYBRIDON INC.
XX
XX PI Agrawal S;
XX
XX WPI; 1997-202880/18.
XX
XX Modified protein kinase A specific oligo:nucleotide(s) - are useful for
XX the treatment of cancer.
XX
XX PS Disclosure; Page 17; 66pp; English.
XX
XX This sequence represents a synthetic, modified antisense oligonucleotide
XX which has been designed to act as a mismatched control (#167) or as a
XX mismatched inverted chimeric oligonucleotide if bases 7 to 12 contain
XX methylphosphonate nucleotides (#191). Modified oligonucleotide types used
XX in this study included hybrid, inverted hybrid or inverted chimeric
XX hybrid and have been found to down regulate protein kinase A subunit RI-
XX alpha gene expression while producing fewer side effects than
XX conventional oligonucleotides e.g. reduced mitogenicity, reduced
XX activation of complement and reduced anti-thrombotic properties. By
XX controlling the regulation of protein kinase A subunit RI-alpha
XX inhibition of the proliferation of cancer cells and tumour growth is
XX possible. This is a novel method for the treatment of disease and
XX disorders caused by the overexpression or inappropriate expression of the
XX gene
XX
XX SQ Sequence 18 BP; 0 A; 9 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGGCGG 693
DB 18 GCCAGCGAGCGGCGG 2

RESULT 612
AAV55622/c
ID AAV55622 standard; DNA; 18 BP.
XX
XX AAV55622;
XX
XX 15-MAR-1999 (first entry)
XX
XX Down-regulator oligo #168 for protein kinase A subunit R1a gene.
XX
XX Down-regulator; protein kinase A subunit R1a gene; reduced mitogenicity;
XX reduced activation of complement; reduced antithrombotic; cancer cell;
XX growth inhibitor; uncontrolled cell proliferation; therapy;
XX RNA-DNA hybrid; ss.
XX
XX OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..4
FT /*tag= a
FT /*notes= "ribonucleotides"
FT modified_base 15..18
FT /*tag= b
FT /*notes= "ribonucleotides"
FT
XX
XX WO9840479-A1.
XX
XX 17-SEP-1998.
XX
XX 12-FEB-1998; 98WO-US003003.
XX
XX 12-MAR-1997; 97US-0040740P.
XX
XX (HYBR-) HYBRIDON INC.
XX
XX PI Agrawal S;
XX
XX WPI; 1999-059623/05.
XX
XX New modified antisense oligonucleotides - which down-regulate the
XX expression of protein kinase A subunit R1a, used for inhibiting cancer
XX cell growth and treating cancers.
XX
XX PS Example 10; Page 17; 85pp; English.
XX
XX This sequence represents a example of a synthetic modified
XX oligonucleotide (ON) of the invention. The ONs are complementary to, and
XX capable of down-regulating the expression of nucleic acid encoding
XX protein kinase A (PKA) subunit R1a, the modified ON has from 15 to 30
XX nucleotides and is a hybrid, inverted hybrid, or inverted chimeric ON,
XX the hybrid ON comprising a region of at least 2 deoxyribonucleotides
XX flanked by 3' and 5' flanking ribonucleotide regions each having at least
XX 4 ribonucleotides, the inverted hybrid ON comprising a region of at least
XX 4 ribonucleotide regions flanked by 3' and 5' flanking ribonucleotide
XX regions of at least 2 deoxyribonucleotides, and the inverted chimeric ON
XX comprising an ON nonionic region of at least 4 nucleotides flanked by 2
XX ON phosphorothioate regions. The ONs down-regulate the expression of the
XX PKA R1a gene while producing fewer side effects than conventional ONs,
XX e.g. reduced mitogenicity, reduced activation of complement and reduced
XX antithrombotic properties, relative to conventional ONs. They can be used
XX for inhibiting the growth of cancer cells and for treating cancers or
XX uncontrolled cell proliferation in humans
XX
XX SQ Sequence 18 BP; 0 A; 9 C; 6 G; 2 T; 1 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGGCGG 693
DB 18 GCCAGCGAGCGGCGG 2

RESULT 613
AAV55623/c
ID AAV55623 standard; DNA; 18 BP.
XX
XX AAV55623;
XX
XX 15-MAR-1999 (first entry)
XX
XX Down-regulator oligo #169 for protein kinase A subunit R1a gene.
XX
XX Down-regulator; protein kinase A subunit R1a gene; reduced mitogenicity;
XX reduced activation of complement; reduced antithrombotic; cancer cell;
XX growth inhibitor; uncontrolled cell proliferation; therapy;
XX RNA-DNA hybrid; ss.
XX
XX OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 7..11
FT /*tag= a
FT /*notes= "ribonucleotides"
FT
XX
XX WO9840479-A1.
XX
XX 17-SEP-1998.
XX
XX 12-FEB-1998; 98WO-US003003.
XX
XX 12-MAR-1997; 97US-0040740P.
XX
XX (HYBR-) HYBRIDON INC.
XX
XX PI Agrawal S;
XX
XX WPI; 1999-059623/05.

```


PT synthetic, modified oligonucleotide, and an antibody that binds to
PT epidermal growth factor receptor or a cytotoxic agent.
PS Example 10; SEQ ID NO 7; 46pp; English.
XX
CC The invention describes a method of inhibiting proliferation of cancer
CC cells comprising administering a synthetic, modified oligonucleotide (I)
CC to the cells, where the oligonucleotide is complementary to and capable
CC of down-regulating the expression of nucleic acid encoding protein kinase
CC A subunit Rialpha and then administering an antibody (II) that binds to
CC epidermal growth factor receptor (EGFR) or a cytotoxic agent (III). The
CC method is used to inhibit the proliferation of cancer cells. (I), (II)
CC And (III) are used in a pharmaceutical composition for treating cancer in
CC an afflicted individual. (I) demonstrate reduced mitogenicity, reduced
CC activation of complement and reduced antithrombic properties, relative to
CC conventional oligonucleotides. This sequence represents an
CC oligonucleotide associated with down-regulation of protein kinase A
CC subunit Rialpha expression.
XX
SQ Sequence 18 BP; 0 A; 9 C; 6 G; 1 T; 2 U; 0 Other;
Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 677 GCCAGCGAGCGCGCG 693
DB 18 GCCAGCGAGCGCGCG 2
RESULT 616
ADD10682/c
ID ADD10682 standard; DNA; 18 BP.
XX
AC ADD10682;
XX
DT 01-JAN-2004 (first entry)
DE Protein kinase A subunit Rialpha down-regulation related DNA #2.
XX
KW cytostatic; gene therapy; antisense therapy;
KW protein kinase A subunit Rialpha-antagonist; cancer;
KW cancer cell proliferation; protein kinase A subunit Rialpha;
KW antisense technology; epidermal growth factor receptor; EGFR;
KW gene down-regulation;
KW protein kinase A subunit Rialpha expression reduction; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_RNA 7..11
FT /*tag= a
FT /*note= "Ribonucleotide"
XX
PN US2003105035-A1.
XX
PD 05-JUN-2003.
PF 05-OCT-1999; 99US-00412947.
PP 05-OCT-1999; 99US-00412947.
PR 05-OCT-1999; 98US-0103098P.
XX
PA (AGRA/) AGRAWAL S.
XX
PI Agrawal S;
XX
DR WPI; 2003-801243/75.
XX
PT Inhibiting proliferation of cancer cells comprises administering a
PT synthetic, modified oligonucleotide, and an antibody that binds to
PT epidermal growth factor receptor or a cytotoxic agent.
XX
PS Disclosure; Page 5; 46pp; English.
XX
CC The invention describes a method of inhibiting proliferation of cancer
CC cells comprising administering a synthetic, modified oligonucleotide (I)
CC to the cells, where the oligonucleotide is complementary to and capable
CC of down-regulating the expression of nucleic acid encoding protein kinase
CC A subunit Rialpha and then administering an antibody (II) that binds to
CC epidermal growth factor receptor (EGFR) or a cytotoxic agent (III). The

CC A subunit Rialpha and then administering an antibody (II) that binds to
CC epidermal growth factor receptor (EGFR) or a cytotoxic agent (III). The
CC method is used to inhibit the proliferation of cancer cells. (I), (II)
CC And (III) are used in a pharmaceutical composition for treating cancer in
CC an afflicted individual. (I) demonstrate reduced mitogenicity, reduced
CC activation of complement and reduced antithrombic properties, relative to
CC conventional oligonucleotides. This sequence represents an
CC oligonucleotide associated with down-regulation of protein kinase A
CC subunit Rialpha expression. Note: This sequence differs from ADD10673
CC shown in the sequence listing.
XX
SQ Sequence 18 BP; 0 A; 9 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 677 GCCAGCGAGCGCGCG 693
DB 18 GCCAGCGAGCGCGCG 2
RESULT 617
ADD10677/c
ID ADD10677 standard; DNA; 18 BP.
XX
AC ADD10677;
XX
DT 01-JAN-2004 (first entry)
DE Protein kinase A subunit Rialpha down-regulation related DNA seq id 5.
XX
KW cytostatic; gene therapy; antisense therapy;
KW protein kinase A subunit Rialpha-antagonist; cancer;
KW cancer cell proliferation; protein kinase A subunit Rialpha;
KW antisense technology; epidermal growth factor receptor; EGFR;
KW gene down-regulation;
KW protein kinase A subunit Rialpha expression reduction; ss;
KW DNA-RNA hybrid.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_RNA 7..11
FT /*tag= a
FT /*note= "Ribonucleotide"
XX
PN US2003105035-A1.
XX
PD 05-JUN-2003.
PF 05-OCT-1999; 99US-00412947.
PP 05-OCT-1999; 98US-0103098P.
PR 05-OCT-1999; 98US-0103098P.
XX
PA (AGRA/) AGRAWAL S.
XX
PI Agrawal S;
XX
DR WPI; 2003-801243/75.
XX
PT Inhibiting proliferation of cancer cells comprises administering a
PT synthetic, modified oligonucleotide, and an antibody that binds to
PT epidermal growth factor receptor or a cytotoxic agent.
XX
PS Example 10; SEQ ID NO 5; 46pp; English.
XX
CC The invention describes a method of inhibiting proliferation of cancer
CC cells comprising administering a synthetic, modified oligonucleotide (I)
CC to the cells, where the oligonucleotide is complementary to and capable
CC of down-regulating the expression of nucleic acid encoding protein kinase
CC A subunit Rialpha and then administering an antibody (II) that binds to
CC epidermal growth factor receptor (EGFR) or a cytotoxic agent (III). The

CC method is used to inhibit the proliferation of cancer cells. (I), (II)
 CC And (III) are used in a pharmaceutical composition for treating cancer in
 CC an afflicted individual. (I) demonstrate reduced mitogenicity, reduced
 CC activation of complement and reduced antithrombic properties, relative to
 CC conventional oligonucleotides. This sequence represents an
 CC oligonucleotide associated with down-regulation of protein kinase A
 CC subunit R1alpha expression.
 XX
 SQ Sequence 18 BP; 0 A; 9 C; 6 G; 2 T; 1 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGGAGCGCG 693
 |||||
 Db 18 GCCAGCGAGGAGCGCG 2

RESULT 618
 ADD10674/c
 ID ADD10674 standard; DNA; 18 BP.
 XX
 AC ADD10674;
 XX
 DT 01-JAN-2004 (first entry)
 XX
 DE Protein kinase A subunit R1alpha down-regulation related DNA seq id 2.
 XX
 KW cytostatic; gene therapy; antisense therapy;
 KW protein kinase A subunit R1alpha-antagonist; cancer;
 KW cancer cell proliferation; protein kinase A subunit R1alpha;
 KW antisense technology; epidermal growth factor receptor; EGFR;
 KW gene down-regulation;
 KW protein kinase A subunit R1alpha expression reduction; ss.
 XX
 OS Synthetic.

US2003105035-A1.
 PD 05-JUN-2003.
 XX
 PF 05-OCT-1999; 99US-00412947.
 XX
 PR 05-OCT-1998; 98US-0103098P.
 XX
 PA (AGRA/) AGRAWAL S.
 XX
 PI Agrawal S;
 XX
 XX WPI; 2003-801243/75.
 XX
 PS Inhibiting proliferation of cancer cells comprises administering a
 PT synthetic, modified oligonucleotide, and an antibody that binds to
 PT epidermal growth factor receptor or a cytotoxic agent.
 XX
 PS Disclosure; SEQ ID NO 2; 46pp; English.

CC The invention describes a method of inhibiting proliferation of cancer
 CC cells comprising administering a synthetic, modified oligonucleotide (I)
 CC to the cells, where the oligonucleotide is complementary to and capable
 CC of down-regulating the expression of nucleic acid encoding protein kinase
 CC A subunit R1alpha and then administering an antibody (II) that binds to
 CC epidermal growth factor receptor (EGFR) or a cytotoxic agent (III). The
 CC method is used to inhibit the proliferation of cancer cells. (I), (II)
 CC And (III) are used in a pharmaceutical composition for treating cancer in
 CC an afflicted individual. (I) demonstrate reduced mitogenicity, reduced
 CC activation of complement and reduced antithrombic properties, relative to
 CC conventional oligonucleotides. This sequence represents an
 CC oligonucleotide associated with down-regulation of protein kinase A
 CC subunit R1alpha expression.
 XX
 SQ Sequence 18 BP; 0 A; 9 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGGAGCGCG 693
 |||||
 Db 18 GCCAGCGAGGAGCGCG 2

RESULT 619
 ADF77884/c
 ID ADF77884 standard; DNA; 18 BP.
 XX
 AC ADF77884;
 XX
 DT 26-FEB-2004 (first entry)
 XX
 DE Human EST clone antisense oligonucleotide #12.
 XX
 KW reporter construct; reporter element; effective analysis;
 KW high-throughput; microtitre well format; light emission;
 KW primary cell screening; low level mRNA expression; ss; human; antisense;
 KW EST; expressed sequence tag.
 XX
 OS Synthetic.
 OS Homo sapiens.

US2003124523-A1.
 PD 03-JUL-2003.
 XX
 PF 18-JUN-2001; 2001US-00883573.
 XX
 PR 22-JUN-2000; 2000US-0213132P.
 PR 07-FEB-2001; 2001US-0266949P.
 XX
 PA (ASSE/) ASSELBERGS F A M.
 PA (HALL/) HALL J.
 PA (HUES/) HUESKEN D.
 PA (KINZ/) KINZEL B.
 PA (NATT/) NATT F.
 PA (WEILL/) WEILLER J.

Asselbergs FAM, Hall J, Huesken D, Kinzel B, Natt F, Weiller J;
 WPI; 2004-009138/01.
 XX
 PT Reporter construct, useful for identifying potential therapeutic oligo-
 PT or poly-nucleotides, comprises target nucleic acid inserted 3' to a
 PT reporter element.
 XX

Example 4; Page 7; 22pp; English.

CC The invention relates to a reporter construct (RC) comprises a reporter
 CC element (RE) and a target nucleic acid, inserted 3' to RE, in the
 CC untranslated region. RC are used to identify, particularly in screening
 CC assays, oligo- or poly-nucleotides that modulate expression of a target
 CC sequence, particularly antisense sequences and ribozymes, potentially
 CC useful as pharmaceuticals. RC provide (a) effective analysis of
 CC biological activity of many test sequences against specific targets; (b)
 CC monitoring of mRNA levels without the cost and extensive pipetting
 CC required in reverse transcription PCR; and (c) use of high-throughput,
 CC microtitre well formats for screening, with the reaction (light emission)
 CC read directly from the wells, with exactly the same conditions for each
 CC well (no need for a set of probes as in e.g. the Tagman assay). The
 CC method is especially useful for screening primary cells (or other cells
 CC that are difficult to obtain) or where target mRNA is expressed at very
 CC low levels. The present sequence is used in the exemplification of the
 CC present invention.
 XX
 SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

RESULT 621
AAX28254

XX AAS17227;
AC 12-MAR-2002 (first entry)
DT
DE
DE BLA3 probe, used to produce probes with multiple acridinium ester labels.
XX
XX Probe; multiple acridinium ester label; gene probe assay sensitivity; ss.
KW
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 19
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Primary amine group present at 3' end"
XX
XX EF1136569-A2.
XX
XX 26-SEP-2001.
XX
XX 13-MAR-2001; 2001EP-00105433.
XX
XX 24-MAR-2000; 2000US-0192026P.
XX
XX (FARB) BAYER CORP.
XX
XX Yang G, Ford DM, Law S, Monahan JE, Sells TB;
XX WPI; 2002-063391/09.
XX
XX New probes comprising a nucleic acid group and at least one tag group,
PT useful in hybridization reactions requiring highly labeled probes, for
PT detecting target sequences, or in reducing non-specific binding in
PT hybridization assays.
XX
XX Example 9; Page 10; 15pp; English.
XX
XX The present invention relates to new probes comprising a nucleic acid
CC group and at least one tag group. The probes are useful in hybridisation
CC reactions and assays where a highly labelled probe is desired, as a means
CC of detecting the presence of target sequences, in reducing non-specific
CC binding in hybridisation assays and in polymerase chain reaction assays.
CC The present nucleic acid sequence represents the BLA3 probe that was used
CC in the invention to produce probes with multiple acridinium ester labels
CC that allow greater gene probe assay sensitivity to be achieved
XX
XX Sequence 19 BP; 8 A; 6 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 867 AATACGACACACATC 883
Db 2 AGTACGACACACATC 18
RESULT 623
ADE29788/c
ID ADE29788 standard; RNA; 19 BP.
XX
XX ADE29788;
AC
XX
XX 29-JAN-2004 (first entry)
DT
XX Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:410.
DE
XX short interfering nucleic acid; siNA; downregulation; inhibition;
KW Mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW cytosolic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW antipsoriatic; gastrointestinal; obesity; diabetes; tumour;

KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW psoriasis; inflammatory bowel disease; drug screening;
KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
XX WO2003072590-A1.
PN
XX
PD 04-SEP-2003.
XX
XX 28-JAN-2003; 2003WO-US002510.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR
XX 11-MAR-2002; 2002US-0363124P.
PR
XX 06-JUN-2002; 2002US-0386782P.
PR
XX 29-AUG-2002; 2002US-0408784P.
PR
XX 05-SEP-2002; 2002US-0408378P.
PR
XX 09-SEP-2002; 2002US-0409293P.
PR
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX
XX Mcswiggen J, Beigelman L, Usman N, Haerberli P, Chowrira B;
PI
XX
XX WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
PT
XX
XX Example 3; SEQ ID NO 410; 164pp; English.
XX
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) genes by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNAs
CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC siNAs can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents a MAPK siNA which is used
CC in the exemplification of the present invention.
XX
XX Sequence 19 BP; 0 A; 9 C; 6 G; 0 T; 4 U; 0 Other;
SQ
Query Match 2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 4.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 715 GCGGCTGCAGCAGCAGC 731
Db 19 GCGGCTGCAGCAGCAGC 3
RESULT 624
ADE29893
ID ADE29893 standard; RNA; 19 BP.
XX
XX ADE29893;
AC
XX
XX 29-JAN-2004 (first entry)
DT
XX Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:515.
DE
XX


```
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Claim 15; SEQ ID NO 837; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 0 A; 5 C; 7 G; 8 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 718 GCTGAGCAGCAGCACA 734
DB 18 GCAGCAGCAGCAGCACA 2

RESULT 629
ADJ72244/c
ID ADJ72244 standard; DNA; 20 BP.
XX
XX AC ADJ72244;
XX
XX DT 06-MAY-2004 (first entry)
XX
XX DE Streptomyces roseosporus daptomycin biosynthesis gene cluster primer P92.
```

```
XX antibacterial; gene therapy; daptomycin biosynthesis gene cluster;
KW daptomycin non-ribosomal peptide synthetase; DptBC;
KW gram-positive bacterial infection; ss; primer.
XX
OS Streptomyces roseosporus.
XX
PN WO2003014297-A2.
XX
PD 20-FEB-2003.
XX
PF 31-JUL-2002; 2002WO-US024310.
XX
PR 06-AUG-2001; 2001US-0310385P.
PR 17-OCT-2001; 2001WO-US032354.
PR 10-MAY-2002; 2002US-0379866P.
XX
PA (CUBI-) CUBIST PHARM INC.
XX
PI Miao VPW, Brian P, Baltz RH, Coeffet-Legal MF;
XX
DR WPI; 2003-268192/26.
XX
XX New isolated nucleic acid molecule encoding a daptomycin non-ribosomal
PT peptide synthetase, useful for treatment of a gram-positive bacterial
PT infection of skeletal muscle, skin, bloodstream, kidneys, heart, lung and
PT bone.
XX
XX Example 2; SEQ ID NO 145; 292pp; English.
XX
CC The invention relates to new isolated nucleic acid (NA) molecules from
CC the Streptomyces roseosporus daptomycin biosynthesis gene cluster,
CC especially a daptomycin non-ribosomal peptide synthetase (NRPS) or its
CC subunit, where the (NA) molecule encodes DptBC, and is not pRB159. The
CC methods and compositions of the present invention are useful for
CC treatment of a gram-positive bacterial infection of any organ or tissue
CC in the body, including skeletal muscle, skin, bloodstream, kidneys,
CC heart, lung and bone. This sequence represents a PCR primer used to
CC isolate and amplify the daptomycin biosynthesis gene cluster (ADJ72363).
XX
SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 546 ACCAGATGCTGAGGAC 562
DB 18 AGGAGATGCTGAGGAC 2

RESULT 630
ABD21825/c
ID ABD21825 standard; DNA; 20 BP.
XX
XX AC ABD21825;
XX
XX DT 29-JUL-2004 (first entry)
XX
XX DE Human stanniocalcin-derived oligo SEQ ID 837.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX OS Homo sapiens.
XX
XX PN WO200285309-A2.
```

XX 31-OCT-2002.
 PD 23-APR-2002; 2002WO-US013143.
 XX 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 837; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating or lung
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 0 A; 5 C; 7 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 2.0%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 4.3e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 718 GCTGCAGCAGCAGCACA 734
 DB 18 GCAGCAGCAGCAGCACA 2
 RESULT 631
 AAT90087
 ID AAT90087 standard; DNA; 20 BP.
 AC AAT90087;
 XX 20-APR-1998 (first entry)
 DT Human oestrogen receptor protein PCR primer 10.
 DE
 XX

KW Oestrogen receptor protein; steroid; alternative splicing; estradiol;
 XX estone; estriol; screening; PCR primer; ss.
 OS Synthetic.
 OS Homo sapiens.
 XX EP798378-A2.
 PN 01-OCT-1997.
 PD 25-MAR-1997; 97EP-00200903.
 XX 26-MAR-1996; 96EP-00200820.
 PR 22-NOV-1996; 96EP-00203284.
 XX (ALKU) AKZO NOBEL NV.
 PA Mosselman S, Dijkema R;
 PI WPI; 1997-473188/44.
 XX
 DR DNA encoding estrogen receptor - useful in screening assay to identify
 XX novel ligands or hormonal analogues.
 PT Example A; Page 8; 45pp; English.
 PS
 CC AAT90087 and AAT90086 are PCR primers used to amplify a region of a novel
 CC oestrogen receptor protein downstream of exon 7 using testis cDNA as a
 CC template. AAT90087 is a gene specific primer and AAT90086 is designed
 CC from the A1-2 region of the classical oestrogen receptor. This primer is
 CC also used with AAT88405 and AAT90081 to detect splice variants of the
 CC receptor. This receptor is able to bind and be activated by estradiol,
 CC estone and estriol, can be used in a screening assay for the
 CC identification of new drugs e.g. novel ligands or hormonal analogues
 XX
 XX Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 822 GGAAGCTGGCCCACTGTCAG 841
 DB 1 GGAAGCTGGCTCACTGTCG 20
 RESULT 632
 AAT96747
 ID AAT96747 standard; DNA; 20 BP.
 XX AAT96747;
 AC
 XX 19-MAY-1998 (first entry)
 DT Human G protein beta-3 subunit PCR primer 1.
 XX
 XX G protein beta-3 subunit; variant; mutation; hypertension; diagnosis;
 KW cardiovascular disease; metabolic disorder; immunological disorder; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX DE19619362-A1.
 PN 20-NOV-1997.
 PD 14-MAY-1996; 96DE-01019362.
 PF 14-MAY-1996; 96DE-01019362.
 PR (BADI) BASF AG.
 XX Siffert W;
 XX

XX WPI; 1998-000675/01.
 XX Assessing risk of disease, especially hypertension - by detecting
 PT mutation in human G-protein beta-3 sub:unit gene.
 XX
 XX Example 1; Page 3; 8pp; German.
 XX PCR primers AAT96747 and AAT96748 are used to amplify the gene encoding
 CC human G-protein beta-3 subunit. A variant of this gene can be used for
 CC diagnosis of diseases or assessing the risk of a disease associated with
 CC G-protein misregulation. G-protein misregulation is associated with
 CC hypertension, cardiovascular diseases e.g. coronary heart disease,
 CC atherosclerosis, restenosis, stroke and thrombosis, metabolic disorders
 CC such as diabetes, diabetic complications, disorders of lipid metabolism
 CC and central chemoreception dysfunction (e.g. sudden infant death
 CC syndrome), and immunological disorders such as impaired wound healing,
 CC tumours, AIDS, cirrhosis and transplant rejection
 XX
 XX Sequence 20 BP; 5 A; 2 C; 10 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 513 TGGGGGAGTGGGACACCTG 532
 Db 1 TGGGGGAGATGGGCACTG 20
 RESULT 633
 AAZ57079/c
 ID AAZ57079 standard; DNA; 20 BP.
 XX
 AC AAZ57079;
 XX
 DT 19-MAY-2000 (first entry)
 XX
 DE Murine melanocortin receptor MC5-R amplifying primer.
 XX
 KW Medicament; agonist; melanocortin receptor type 3; ACTH; PMN; MC3-R;
 KW adrenocorticotrophic hormone; neutrophil chemoattractant; antigout;
 KW polymorphonuclear cell; septic shock; skin disorder; antiarthritic;
 KW melanocortin receptor; anti-inflammatory; antiasmatic; PCR primer; ss.
 XX
 OS Mus sp.
 XX
 PN WO200005263-A2.
 XX
 PD 03-FEB-2000.
 XX
 PF 22-JUL-1999; 99WO-GB002392.
 XX
 PR 24-JUL-1998; 98GB-00016234.
 XX
 PA (HARV-) HARVEY RES LTD WILLIAM.
 XX
 PI Perretti M, Getting S, Flower R;
 XX
 XX WPI; 2000-182651/16.
 DR
 XX Inhibition of neutrophil chemoattractant production, inhibition of
 PT polymorphonuclear cell accumulation or reduction/treatment of
 PT inflammation using compounds comprising the peptide sequence HFRW.
 PT
 XX Disclosure; Page 8; 20pp; English.
 XX
 CC The invention relates to the use of a compound comprising an amino acid
 CC sequence His-Phe-Arg-Tip (HFRW) in the manufacture of a medicament and/or
 CC an agonist of melanocortin receptor type 3 (MC3-R) where the compound is
 CC not adrenocorticotrophic hormone (ACTH)1-39. The compounds are used to
 CC inhibit neutrophil chemoattractant production, polymorphonuclear cell
 CC (PMN) accumulation or reduction/treatment of inflammation. Especially,

CC these compounds are agonists of the MC3-R. The inflammatory response/
 CC disease is selected from gout, gouty arthritis, rheumatoid arthritis,
 CC asthma, reperfusion injury or damage, stroke, myocardial infarction,
 CC septic shock, or a skin disorder. Sequences AAZ57073-80 represent PCR
 CC primers used for amplifying murine melanocortin receptors
 XX
 SQ Sequence 20 BP; 4 A; 10 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 407 AGGGAGGAGAGGAGTCTCT 426
 Db 20 AGGGTGGAGGAGGAGTCTAT 1
 RESULT 634
 AAZ43563
 ID AAZ43563 standard; DNA; 20 BP.
 XX
 AC AAZ43563;
 XX
 DT 21-FEB-2000 (first entry)
 XX
 DE Psychrotolerant Bacillus cereus detecting PCR primer Rps2.
 XX
 KW Psychrotolerance; mesophilic; detection; pasteurization; endospore;
 KW cold storage; lytic enzyme; toxin; food; spoilage; PCR primer; ss.
 XX
 OS Synthetic.
 OS Bacillus cereus.
 XX
 PN DE19824317-A1.
 XX
 PD 09-DEC-1999.
 XX
 PF 02-JUN-1998; 98DE-01024317.
 XX
 PR 02-JUN-1998; 98DE-01024317.
 XX
 PA (SCHE/) SCHERER S.
 XX
 PI Von Stetten F, Francis K, Lechner S, Scherer S, Mayr R;
 XX
 DR WPI; 2000-040061/04.
 XX
 PT Detecting psychrotolerance and mesophilia in Bacillus, from presence of
 PT signature sequences in ribosomal nucleic acid, for identifying food-
 PT spoilage strains.
 XX
 PS Example; Page 3; 6pp; German.
 XX
 CC This invention describes a novel method for determining psychrotolerance
 CC and mesophilia in Bacillus by using, as indicator, signature bases to
 CC present in ribosomal (deoxy)ribonucleic acids. The method is used to
 CC identify psychrotolerant strains, i.e. those that survive pasteurization
 CC as endospores and germinate and grow subsequently, even during cold
 CC storage, with production of lytic enzymes and toxins, resulting in
 CC spoilage of foods. This method allows rapid differentiation between
 CC psychrotolerant strains and mesophilic strains (which do not grow during
 CC cold storage), typically in 2 hr, compared with 14 days required for the
 CC conventional growth test. AAZ43561-243564 represent PCR primers used in
 CC the method of the invention
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 475 GGAGAGCTCGATCTGAGA 494
 |||||

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 599 GGGGAGCTCGAGAGCCCA 618
 DB 20 GGGGAGCGCTGGGAGCCCA 1

RESULT 637
 AAS0873/C
 ID AAS0873 standard; DNA; 20 BP.
 XX
 AC AAS0873;
 DT 26-SEP-2001 (first entry)
 XX
 DE Human PD-ABC form 2 DNA exon 32 3' splice site.
 KW PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
 KW peripheral blood leukocyte; bone marrow; lymph node; dyslipidaemia;
 KW cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
 KW epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
 KW familial high-density lipoprotein deficiency; fatty liver disease;
 KW atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
 KW alcoholism; retinal degeneration; hypertension; vascular disease.
 OS Homo sapiens.
 XX
 PN WO200153490-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 23-JAN-2001; 2001WO-US002191.
 XX
 PR 24-JAN-2000; 2000US-0177889P.
 PR 30-JUN-2000; 2000US-0215405P.
 XX
 PA (WARN) WARNER LAMBERT CO.
 XX
 PI Johns MA, Tafuri SR, Wang M;
 XX
 DR WPI; 2001-442259/47.
 XX
 PT New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
 of dyslipidemia, epilepsy and diseases related to abnormal calcium flux.
 XX
 PS Disclosure; Page 40; 77pp; English.
 XX
 CC The sequence represents a splice site within a DNA molecule encoding
 human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
 19p13.3 and is expressed in various tissues including spleen, thymus, DNA
 peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA
 molecules and proteins are used to diagnose and treat cardiovascular
 disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases
 related to abnormal calcium flux, coronary artery disease, Tangier's
 disease, familial high-density lipoprotein deficiency, atherosclerosis,
 diabetes, fatty liver disease, insulin resistance, obesity, alcoholism,
 retinal degeneration, hypertension and vascular disease. The sequences
 are also used in drug screening assays
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 292 TGAGACCTCCAGCGTGC 311
 DB 20 TGAGTCCCTCCAGTGAGCC 1

RESULT 638
 AAI72138
 ID AAI72138 standard; DNA; 20 BP.
 XX
 AC AAI72138;
 DT 25-MAR-2002 (first entry)
 XX
 DE Primer #10 based on ER gene.
 XX
 KW DNA binding domain; DBD; ligand binding domain; LBD; chimeric receptor;

AAS08782/c
 ID AAS08782 standard; DNA; 20 BP.
 XX
 AC AAS08782;
 DT 26-SEP-2001 (first entry)
 XX
 DE Human PD-ABC form 1 DNA exon 32 3' splice site.
 KW PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
 KW peripheral blood leukocyte; bone marrow; lymph node; dyslipidaemia;
 KW cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
 KW epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
 KW familial high-density lipoprotein deficiency; fatty liver disease;
 KW atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
 KW alcoholism; retinal degeneration; hypertension; vascular disease.
 XX
 OS Homo sapiens.
 XX
 PN WO200153490-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 23-JAN-2001; 2001WO-US002191.
 XX
 PR 24-JAN-2000; 2000US-0177889P.
 PR 30-JUN-2000; 2000US-0215405P.
 XX
 PA (WARN) WARNER LAMBERT CO.
 XX
 PI Johns MA, Tafuri SR, Wang M;
 XX
 DR WPI; 2001-442259/47.
 XX
 PT New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
 of dyslipidemia, epilepsy and diseases related to abnormal calcium flux.
 XX
 PS Disclosure; Page 38; 77pp; English.
 XX
 CC The sequence represents a splice site within a DNA molecule encoding
 human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
 19p13.3 and is expressed in various tissues including spleen, thymus,
 peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA
 molecules and proteins are used to diagnose and treat cardiovascular
 disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases
 related to abnormal calcium flux, coronary artery disease, Tangier's
 disease, familial high-density lipoprotein deficiency, atherosclerosis,
 diabetes, fatty liver disease, insulin resistance, obesity, alcoholism,
 retinal degeneration, hypertension and vascular disease. The sequences
 are also used in drug screening assays
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 292 TCAGACCTCCAGCGTGC 311
 DB 20 TGAGTCCCTCCAGTGAGCC 1

RESULT 639
 AAI72138
 ID AAI72138 standard; DNA; 20 BP.
 XX
 AC AAI72138;
 DT 25-MAR-2002 (first entry)
 XX
 DE Primer #10 based on ER gene.
 XX
 KW DNA binding domain; DBD; ligand binding domain; LBD; chimeric receptor;

KW estrogen receptor; ER; chromosome 14; ER-alpha; ER-beta; exon 8; PCR;
KW estradiol; nuclear receptor; progesterone receptor; amplify; primer;
KW polymerase chain reaction; ss.
XX Synthetic.
XX EP1162264-A2.
XX 12-DEC-2001.
XX 25-MAR-1997; 2001EP-00202021.
XX 26-MAR-1996; 96EP-00200820.
XX 22-NOV-1996; 96EP-00203284.
XX 25-MAR-1997; 97EP-00200903.
XX (ALKU) AKZO NOBEL NV.
XX Mosselman S, Dijkema R;
XX WPI; 2002-084414/12.
XX New isolated chimeric receptor comprising a DNA binding domain and/or
XX ligand binding domain of a new estrogen receptor, for identifying
XX functional ligands or hormonal analogs for the receptor.
XX Example A; Page 8; 35pp; English.
XX The sequences given in AAI71219-43 are primers which were used in the
XX amplification and cloning of a novel estrogen receptor (ER). The gene
XX encoding this new ER is located on chromosome 14 and has a different
XX tissue distribution from classical ER. This ER also has two orphan ER's,
XX ER-alpha and ER-beta. These orphan receptors have estrogen receptor
XX related structure but do not appear to be able to bind estradiol or other ER
XX ligands. The DNA binding domain (DBD) and ligand binding domain (LBD)
XX from this ER may be used in the chimeric receptor of the invention which
XX also has an N-terminal domain. The chimeric receptor, or DNA encoding it,
XX is useful in a screening assay for identification of new drugs. Similar
XX chimeric receptors comprising the LBD of the new ER, and also comprising
XX the DBD and an N-terminal domain derived from another nuclear receptor
XX e.g., progesterone receptor, are useful for the screening of compounds to
XX identify new ligands or hormone analogs which are able to activate the
XX new ER. Chimeric receptors comprising a DBD of the new ER, and LBD and an
XX N-terminal domain derived from another nuclear receptor, can be used to
XX identify new ligands or hormone analogs for the nuclear receptors
XX Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
SQ Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 822 GGAAGCTGGCCAGTTGCAG 841
Db 1 GGAAGCTGGCTCACTGCTG 20
RESULT 640
AAD34914/C
ID AAD34914 standard; DNA; 20 BP.
XX AAD34914;
XX 16-JUL-2002 (first entry)
XX Human E2F transcription factor 2 antisense oligo, ISIS #114111.
XX Human; E2F transcription factor 2; hyperproliferative disorder; cancer;
XX developmental disorder; antisense; therapy; phosphorothioate backbone;
XX cytosatic; ss.
XX Homo sapiens.
XX Synthetic.

XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 2
FT /tag= c
FT /mod_base= m5c
FT modified_base 3
FT /tag= d
FT /mod_base= m5c
FT modified_base 8
FT /tag= e
FT /mod_base= m5c
FT modified_base 9
FT /tag= f
FT /mod_base= m5c
FT modified_base 11
FT /tag= g
FT /mod_base= m5c
FT modified_base 15
FT /tag= h
FT /mod_base= m5c
FT modified_base 16..20
FT /tag= i
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO200220551-A1.
XX 14-MAR-2002.
XX 07-SEP-2001; 2001WO-US028202.
XX 08-SEP-2000; 2000US-00658679.
XX (ISIS-) ISIS PHARM INC.
XX Popoff I, Wyatt JR;
XX WPI; 2002-329864/36.
XX New antisense oligonucleotides targeted to a nucleic acid encoding E2F
XX transcription factor 2, useful for treating a disease or condition
XX associated with E2F transcription factor 2, e.g. hyperproliferative
XX disorders, such as cancer.
XX Claim 3; Page 92; 120pp; English.
XX The present invention relates to antisense oligonucleotides, compounds
XX and methods for modulating the expression of E2F transcription factor 2.
XX The antisense oligonucleotides specifically hybridise with and inhibit
XX the expression of E2F transcription factor 2. They are useful for
XX inhibiting the expression of E2F transcription factor 2 and for treating
XX diseases or conditions associated with E2F transcription factor 2, such
XX as hyperproliferative disorders, particularly cancer and developmental
XX disorders. They may also be used as research reagents and diagnostics, to
XX distinguish between functions of various members of a biological pathway
XX and in the treatment of a disease or disorder which can be treated by
XX modulating the expression of E2F transcription factor 2. The oligomeric
XX compounds, particularly the antisense oligonucleotides may be used to
XX modulate the function of nucleic acid molecules encoding E2F
XX transcription factor 2, ultimately modulating the amount of E2F
XX transcription factor produced. Sequences of the invention are also used
XX in antisense therapy. The present DNA sequence is human E2F transcription
XX factor 2 antisense oligonucleotide with a phosphorothioate backbone. This
XX sequence is targeted to the coding region of human E2F transcription
XX factor 2

```
XX
SQ Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;
    Query Match      2.0%; Score 15.2; DB 1; Length 20;
    Best Local Similarity 85.0%; Pred. No. 4.6e+02;
    Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 548 CAGATGGCTGAGGACAAAGGC 567
    |||||
Db 20 CACCTGACTGAGGACAAAGGC 1

RESULT 641
ABI96876/C
ID ABI96876 standard; DNA; 20 BP.
XX
AC ABI96876;
XX
DT 16-FEB-2002 (first entry)
XX
DE Capture oligonucleotide Zip ID#3963 oligo #9.
XX
KW Human; K-ras; PCR primer; probe; capture probe; mutation detection;
KW ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
KW infection; 21 hydroxylase deficiency; Turner Syndrome; obesity; cancer;
KW oncogene; tumour suppressor; human papillomavirus; forensic;
KW environmental monitoring; food industry; feed industry; ss.
XX
OS Synthetic.
XX
PN WO200179548-A2.
XX
PD 25-OCT-2001.
XX
PF 04-APR-2001; 2001WO-US010958.
XX
PR 14-APR-2000; 2000US-0197271P.
XX
PA (CORR ) CORNELL RES FOUND INC.
XX
PI Barany F, Zirvi M, Gerry NP, Favis R, Kliman R;
XX
WPI; 2002-034366/04.
XX
PT Designing capture oligonucleotide probes for use on a support to which
PT complementary oligonucleotides hybridize with little mismatch.
XX
PS Example 5; Fig 29; 300pp; English.
XX
CC The present invention describes a method (M1) for designing capture
CC oligonucleotide probes (I) for use on a support to which complementary
CC oligonucleotide probes (II) will hybridise with little mismatch, where
CC (I) have melting temperatures within a narrow range. The method is useful
CC for detecting infectious diseases caused by bacterial infectious agents
CC e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and
CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,
CC Epstein-Barr virus and polio virus, and parasitic infectious agents
CC selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus
CC medinensis. The method is also useful for detecting genetic diseases such
CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
CC Detecting cancer involving oncogenes, tumour suppressor genes, or genes
CC involved in DNA amplification, replication, recombination or repair, the
CC cancer is specifically associated with a gene selected from BRCA1 gene,
CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
CC method is also used for environmental monitoring, forensics and the food
CC and feed industry, detecting comprises scanning (using e.g. a scanning
CC electron microscope and infrared microscope) the support at the
CC particular sites and identifying if ligation of the oligonucleotide probe
CC sets occurred and correlating (using a computer) identified ligation to a
CC presence or absence of the target nucleotide sequences. ABI82074 to
CC ABI97546 represent oligonucleotide sequences used in the exemplification
CC of the present invention

XX
SQ Sequence 20 BP; 6 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
    Query Match      2.0%; Score 15.2; DB 1; Length 20;
    Best Local Similarity 85.0%; Pred. No. 4.6e+02;
    Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 828 TGGCCCAAGTTGCAGGTGGCC 847
    |||||
Db 20 TTGCCCAAGTTGCAGGTGTCC 1

RESULT 642
ADB39025
ID ADB39025 standard; DNA; 20 BP.
XX
AC ADB39025;
XX
DT 04-DEC-2003 (first entry)
XX
DE PCR primer B-V3 AS related to microorganism identification.
XX
KW microorganism identification; electronic sequence analysis;
KW sequence library; PCR; primer; B-V3 AS; ss.
XX
OS Unidentified.
XX
PN WO2003066888-A2.
XX
PD 14-AUG-2003.
XX
PF 07-FEB-2003; 2003WO-GB000562.
XX
PR 07-FEB-2002; 2002GB-00002891.
XX
PA (PYRO-) PYROSEQUENCING AB.
XX
PI (SAMU/) SAMUELS A J.
XX
PI Jonasson J;
XX
WPI; 2003-636965/60.
XX
PT Identifying a microorganism by generating a sample sequence comprising
PT letters representing nucleic acid bases and identifying one or more
PT library sequences having the greatest degree of agreement with the sample
PT sequence.
XX
PS Disclosure; Page 11; 31pp; English.
XX
CC This invention relates to a novel method for the identification of a
CC microorganism through electronic sequence analysis. The method compares
CC an input sequence from the organism of interest to a library of sequences
CC from microorganisms of known identity. The method is useful for
CC identifying a microorganism. The present sequence is that of PCR primer B
CC -V3 AS related to the invention.
XX
SQ Sequence 20 BP; 6 A; 8 C; 4 G; 2 T; 0 U; 0 Other;
    Query Match      2.0%; Score 15.2; DB 1; Length 20;
    Best Local Similarity 85.0%; Pred. No. 4.6e+02;
    Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 251 AAGCCAGCCATGCTGCACCT 270
    |||||
Db 1 ACGACAGCCATGCGACCACT 20

RESULT 643
ADD14252
ID ADD14252 standard; DNA; 20 BP.
XX
AC ADD14252;
XX
```

DT 01-JAN-2004 (first entry)
XX Human src biomarker forward PCR primer SEQ ID NO:441.
DE
XX
KW predictor set; protein tyrosine kinase activity modulator;
KW protein tyrosine kinase pathway; protein tyrosine kinase; cytostatic;
KW gene therapy; drug sensitivity; genetic profile; cancer; human;
KW PCR primer; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO2003062395-A2.
XX
XX
XX 31-JUL-2003.
XX
XX 17-JAN-2003; 2003WO-US001981.
XX
XX 18-JAN-2002; 2002US-0350061P.
XX
XX (BRIM) BRISTOL-MYERS SQUIBB CO.
XX
XX Huang F, Fairchild CR, Lee FY, Shaw P;
XX WPI; 2003-636735/60.
XX
XX New polynucleotides and polypeptides for predicting the activity of
PT compounds that interact with protein tyrosine kinases and/or protein
PT tyrosine kinase pathways.
XX
XX Example 2; SEQ ID NO 441; 139pp; English.
XX
XX The present invention describes a predictor set comprising a plurality of
CC polynucleotides or polypeptides whose expression pattern is predictive of
CC the response of cells to treatment with a compound that modulates protein
CC tyrosine kinase activity or members of the protein tyrosine kinase
CC pathway. Also described: (1) predicting whether a compound is capable of
CC modulating the activity of cells, comprising obtaining a sample of cells,
CC determining whether the cells express a plurality of markers, and
CC correlating the expression of the markers to the compound's ability to
CC modulate the activity of the cells; (2) a plurality of cell lines for
CC identifying polynucleotides and polypeptides whose expression levels
CC correlate with compound sensitivity or resistance of cells associated
CC with a disease state; and (3) identifying polynucleotides and
CC polypeptides that predict compound sensitivity or resistance of cells
CC associated with a disease state, comprising subjecting the plurality of
CC cell lines to one or more compounds, analysing the expression pattern of
CC a microarray of polynucleotides or polypeptides, and selecting
CC polynucleotides or polypeptides that predict the sensitivity or
CC resistance of cells associated with a disease state by using the
CC expression pattern of the microarray. The polynucleotides and
CC polypeptides have cytostatic activities, and can be used in gene therapy.
CC The polynucleotides and polypeptides are useful in predicting the
CC activity of compounds that interact with protein tyrosine kinases and/or
CC protein tyrosine kinase pathways. These may be used in determining drug
CC sensitivity in patients to allow the development of individualized
CC genetic profiles which aid in treating diseases and disorders (e.g.
CC cancer) based on patient response at a molecular level. The present
CC sequence is used in the exemplification of the present invention.
XX
SQ Sequence 20 BP; 8 A; 3 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 549 AGATGGCTGAGGACAGGCC 568
Db 1 AGAAGGCTGAGGACAGGCC 20
|||||

RESULT 644
ABZ93298

ID ABZ93298 standard; DNA; 20 BP.
XX
AC ABZ93298;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasegna A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 8540; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 3 C; 11 G; 2 T; 0 U; 0 Other;
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 400 CAGCCAGAGGAGGAGGAGG 419
Db 1 CAGCCTGAGGAGGAGGAGG 20
|||||

RESULT 645
ABZ99074/c

ID ABZ99074 standard; DNA; 20 BP.
XX
AC ABZ99074;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human PDE4C oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; anti-allergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmacological composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 14316; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, anti-allergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 516 GGCAGGTGGAGCAGCTGAG 535
DB 20 GGCAGGTGGATCAGCTGAGS 1
XX
RESULT 646
ADM96498

ID ADM96498 standard; DNA; 20 BP.
XX
AC ADM96498;
XX
DT 17-JUN-2004 (first entry)
XX
DE PCR primer of the invention B-V3.ASSEQ ID NO:7.
XX
KW ss; microorganism; signature sequence; microorganism identification;
KW pathogenic; commonal; saphorophyte; PCR; primer.
OS Synthetic.
PN CA2363938-A1.
XX
PD 28-MAY-2003.
XX
PF 28-NOV-2001; 2001CA-02363938.
XX
PR 28-NOV-2001; 2001CA-02363938.
XX
PA (PYRO-) PYROSEQUENCING AB.
XX
PI Jonasson J;
PI WPI; 2003-845757/79.
XX
DR Identification of microorganism in biological sample, by determining
PT sequence of region of preset nucleotides in predetermined site in gene of
PT microorganism to obtain signature sequence and analyzing sequencing
PT information.
XX
PS Disclosure; SEQ ID NO 7; 78pp; English.
XX
CC The invention relates to a novel method for identifying a microorganism
CC in a sample, comprising determining the sequence of a region of up to 50
CC nucleotides in a predetermined site (PS) in a gene of a microorganism, to
CC obtain a signature sequence (SS), and analysing sequencing information in
CC SS. The sequence is determined by detecting the nucleotides incorporated
CC in a primer extension reaction performed using a primer binding at a PS
CC in a gene. The method is useful for identifying a microorganism such as
CC bacteria, fungi, algae or protozoa in a sample such as samples of
CC cellular or tissue material, body fluids like blood, saliva, urine or
CC semen and microbial isolates or cultures, water, food samples and soil.
CC The method allows pathogenic microorganisms to be distinguished from
CC commonals or saphorophytes in the same sample, permits molecular
CC identification of microorganisms and therefore genotypic is achieved. The
CC method enables high capacity and convenient procedure for screening large
CC numbers of samples. The present sequence is used in the exemplification
CC of the invention.
XX
SQ Sequence 20 BP; 6 A; 8 C; 4 G; 2 T; 0 U; 0 Other;
XX
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 251 AAGCCAGCCATGCTGCACCT 270
DB 1 ACGACAGCCATGACGACCT 20
XX
RESULT 647
ABD32105/c
ID ABD32105 standard; DNA; 20 BP.
XX
AC ABD32105;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human PDE4C-derived oligonucleotide SEQ ID 14316.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW	respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW	surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW	analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW	beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW	respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW	emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW	pulmonary transplantation rejection; ss; primer.
XX	
OS	Homo sapiens.
OS	
PN	WO200285309-A2.
PN	
PD	31-OCT-2002.
PF	
PP	23-APR-2002; 2002WO-US013143.
PR	
PR	24-APR-2001; 2001US-0286036P.
XX	
XX	(EPIG-) EPIGENESIS PHARM INC.
PA	
PI	Nyce JW, Li Y, Sandrasagra A, Katz E, Fabalan J, Aguilar D;
PI	Miller S, Tang L, Shahabuddin S;
XX	
DR	WPI; 2003-093058/08.
XX	
XX	Pharmaceutical composition for treating asthma, has antisense
PT	oligonucleotide containing less percentage of adenosine, targeted to
PT	nucleic acids associated with lung airway or lung dysfunction, and
PT	bronchodilating agent.
XX	
XX	Claim 15; SEQ ID NO 14316; 763pp; English.
XX	
CC	This invention describes a novel composition (a) a first active agent,
CC	comprising oligonucleotides, effective for alleviating
CC	bronchoconstriction, respiratory tract inflammation, allergies and
CC	reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC	surfactant depletion or hyposecretion, when administered to a mammal. The
CC	oligonucleotides are derived from a gene encoding or regulating
CC	expression of a target polypeptide associated with lung airway or lung
CC	dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC	The invention also describes a kit, that comprises: (a) a delivery
CC	device, in separate containers, (b) the oligonucleotides, (c)
CC	instructions for adding a carrier and for use of the kit. The composition
CC	of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC	analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC	beta-adrenergic agonist. The composition is useful for preventing or
CC	treating a respiratory, lung or malignant disease. The administered
CC	composition comprises oligo and is administered to reduce the production
CC	or availability, or to increase the degradation of the target mRNA or to
CC	reduce the amount of target polypeptide present in the lungs. The
CC	pulmonary obstruction, and/or bronchoconstriction and/or lung
CC	inflammation, allergies and/or surfactant hypoproduction are associated
CC	with a disease or condition such as pulmonary vasoconstriction,
CC	inflammation, allergies, asthma, impeded respiration, respiratory
CC	distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC	hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC	transplantation rejection, pulmonary infections, bronchitis or cancer.
CC	The reduced adenosine content of the anti-sense oligos corresponding to
CC	thymidines present in the target RNA serves to prevent the breakdown of
CC	the oligonucleotides into products that free adenosine into the system
CC	e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC	prevent any unwanted effects due to it
XX	
SQ	Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;

RESULT 648
ABD29528
ID ABD29528 standard; DNA; 20 BP.
XX AC
XX ABD29528;
XX AC
XX 29-JUL-2004 (first entry)
XX DT
XX AA664176-derived oligonucleotide SEQ ID 8540.
XX DE
XX OS Homo sapiens.
XX KW Human; antitense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX KW
XX OS
XX DE
XX WO200285309-A2.
XX FN
XX 31-OCT-2002.
XX PD
XX 23-APR-2002; 2002WO-US013143.
XX PF
XX 24-APR-2001; 2001US-0286036P.
XX PR
XX (EPIG-) EPIGENESIS PHARM INC.
XX PA
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX
XX WPI; 2003-093058/08.
XX DR
XX Pharmaceutical composition for treating asthma, has antitense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 8540; 763pp; English.
XX PS
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC

CC prevent any unwanted effects due to it
XX Sequence 20 BP; 4 A; 3 C; 11 G; 2 T; 0 U; 0 Other;
SQ

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 400 CAGCCAGAGGAGGAGG 419
||||| ||||| ||||| |||||
Db 1 CAGCCAGAGGAGGAGG 20

RESULT 649
ADG86886/c
ID ADG86886 standard; DNA; 20 BP.
XX
AC ADG86886;
XX
XX 11-MAR-2004 (first entry)
XX Mouse PPAR antisense oligonucleotide ISIS 221093.
DE
XX Mouse; ss; PPAR delta; peroxisome proliferative activated receptor delta;
KW antisense gene therapy; cytostatic; osteopathic; antidiabetic; cancer;
KW osteoporosis; diabetes; endocrine disorder.
XX
OS Mus musculus.
XX

FH Key Location/Qualifiers
FT modified_base 1..20 /*tag= b
FT /*mod_base= OTHER
FT /*note= "Phosphorothioate linkages and all cytidines are 5
FT -methylcytidines"
FT modified_base 1..5 /*tag= a
FT /*mod_base= OTHER
FT /*note= "2'-methoxyethyl residue"
FT modified_base 16..20 /*tag= c
FT /*mod_base= OTHER
FT /*note= "2'-methoxyethyl residue"
XX
XX US2003224514-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160807.
XX
XX 31-MAY-2002; 2002US-00160807.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Gaarde W, Freier SM, Watt AT;
XX WPI; 2004-022078/02.
XX
XX New antisense oligonucleotides of 8-80 nucleobases, useful for treating
PT cancer, diabetes, osteoporosis or various endocrine disorders.
XX
XX Example 16; SEQ ID NO 122; 155pp; English.
XX
XX The invention relates to an antisense oligonucleotide comprising 8-80
CC nucleobases in length targeted to the coding region of a nucleic acid
CC molecule encoding PPAR-delta (peroxisome proliferative activated receptor
CC delta), where the antisense compound inhibits the expression of the PPAR-
CC delta and has any of the 66 sequences of 20 amino acids fully defined in
CC the specification. Also included are a compound of 8-80 nucleobases in
CC length that specifically hybridizes with at least an 8-nucleobase portion
CC of a preferred target region on a nucleic acid molecule encoding PPAR-
CC delta and a composition comprising the antisense oligonucleotide and a
CC carrier. The antisense oligonucleotide comprises at least one modified
CC internucleoside linkage (preferably a phosphorothioate linkage), at least
CC one sugar moiety (preferably 2'-O-methoxyethyl moiety) and at least one
CC modified nucleobase (which is a 5-methyl cytosine). The antisense
CC compounds are useful for treating cancer, osteoporosis, diabetes or
CC various endocrine disorders. The Human PPAR delta gene is located on
CC chromosome 6p21. The present sequence is a mouse PPAR delta cDNA target
CC sequence for the antisense oligonucleotides of the invention.

CC internucleoside linkage (preferably a phosphorothioate linkage), at least
CC one sugar moiety (preferably 2'-O-methoxyethyl moiety) and at least one
CC modified nucleobase (which is a 5-methyl cytosine). The antisense
CC compounds are useful for treating cancer, osteoporosis, diabetes or
CC various endocrine disorders. The Human PPAR delta gene is located on
CC chromosome 6p21. The present sequence is an antisense oligonucleotide of
CC the invention targeting mouse PPAR delta.
XX
SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 826 GCTGGCCAGTTCAGGTGG 845
||||| ||||| ||||| |||||
Db 20 GCTGGACCAGCTGCAGATGG 1

RESULT 650
ADG87025
ID ADG87025 standard; cDNA; 20 BP.
XX
XX ADG87025;
AC
XX 11-MAR-2004 (first entry)
DT
XX Mouse PPAR antisense oligonucleotide target sequence #21.
DE
XX Mouse; ss; PPAR delta; peroxisome proliferative activated receptor delta;
KW antisense gene therapy; cytostatic; osteopathic; antidiabetic; cancer;
KW osteoporosis; diabetes; endocrine disorder.
XX
OS Mus musculus.
XX
XX US2003224514-A1.
XX
XX 04-DEC-2003.
XX
XX 31-MAY-2002; 2002US-00160807.
XX
XX 31-MAY-2002; 2002US-00160807.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Gaarde W, Freier SM, Watt AT;
XX WPI; 2004-022078/02.
XX
XX New antisense oligonucleotides of 8-80 nucleobases, useful for treating
PT cancer, diabetes, osteoporosis or various endocrine disorders.
XX
XX Example 16; SEQ ID NO 261; 155pp; English.
XX
XX The invention relates to an antisense oligonucleotide comprising 8-80
CC nucleobases in length targeted to the coding region of a nucleic acid
CC molecule encoding PPAR-delta (peroxisome proliferative activated receptor
CC delta), where the antisense compound inhibits the expression of the PPAR-
CC delta and has any of the 66 sequences of 20 amino acids fully defined in
CC the specification. Also included are a compound of 8-80 nucleobases in
CC length that specifically hybridizes with at least an 8-nucleobase portion
CC of a preferred target region on a nucleic acid molecule encoding PPAR-
CC delta and a composition comprising the antisense oligonucleotide and a
CC carrier. The antisense oligonucleotide comprises at least one modified
CC internucleoside linkage (preferably a phosphorothioate linkage), at least
CC one sugar moiety (preferably 2'-O-methoxyethyl moiety) and at least one
CC modified nucleobase (which is a 5-methyl cytosine). The antisense
CC compounds are useful for treating cancer, osteoporosis, diabetes or
CC various endocrine disorders. The Human PPAR delta gene is located on
CC chromosome 6p21. The present sequence is a mouse PPAR delta cDNA target
CC sequence for the antisense oligonucleotides of the invention.
XX
SQ Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 826 GCTGCGCCAGTTCAGGTGG 845
 ||||| ||||| ||||| ||||| |||||
 Db 1 GCTGCGCCAGTTCAGGTGG 20

RESULT 651
 ADH44404
 ID ADH44404 standard; DNA; 20 BP.
 XX
 AC ADH44404;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human Rb2/p130 DNA, antisense oligonucleotide #5.
 XX
 KW Antisense therapy; human; Rb2/p130; hyperproliferative disorder;
 KW breast cancer; ovarian cancer; hepatocellular cancer; prostate cancer;
 KW developmental disorder; aberrant apoptosis; cytostatic; antiinflammatory;
 KW antimicrobial; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "This oligonucleotide has a phosphorothioate
 FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
 FT and 3' ends, which are 5 nucleotides in length at each
 FT end. All cytidine residues are 5-methylcytidines"
 FT
 PN US2003225015-A1.
 XX
 XX 04-DEC-2003.
 PD
 XX 31-MAY-2002; 2002US-00161983.
 PF
 XX 31-MAY-2002; 2002US-00161983.
 PR
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX Ward DT, Freier SM;
 PI
 XX WPI; 2004-042170/04.
 DR
 XX
 XX New antisense oligonucleotides inhibiting the expression of Rb2/p130,
 XX useful for preventing or treating diseases associated with Rb2/p130, such
 XX as developmental or hyperproliferative disorders, infection or
 XX PT inflammation.
 PT
 XX Example 15; SEQ ID NO 15; 47pp; English.
 PS
 CC The present invention relates to antisense compounds targeted to a
 CC nucleic acid encoding Rb2/p130. The antisense compound comprises an
 CC antisense oligonucleotide that specifically hybridizes with the nucleic
 CC acid and inhibits the expression of Rb2/p130. The antisense
 CC oligonucleotide is a chimeric oligonucleotide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE) sugar
 CC moiety. The antisense oligonucleotide further comprises at least one
 CC modified nucleobase, preferably a 5-methylcytosine. The antisense
 CC oligonucleotides are useful for the treatment of diseases such as
 CC hyperproliferative disorders, preferably cancer (particularly breast
 CC cancer, ovarian cancer, hepatocellular cancer or prostate cancer),
 CC developmental disorders, and disorders associated with aberrant
 CC apoptosis. The present sequence represents an antisense oligonucleotide
 CC used in the examples of the present invention.

XX
 SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCCTCATGTGC 433
 ||||| ||||| ||||| ||||| |||||
 Db 1 AGTAGGAGTTTCTCTGTGC 20

RESULT 652
 ADH44441/C
 ID ADH44441 standard; DNA; 20 BP.
 XX
 AC ADH44441;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human Rb2/p130 DNA target sequence #5.
 XX
 KW Antisense therapy; human; Rb2/p130; hyperproliferative disorder;
 KW breast cancer; ovarian cancer; hepatocellular cancer; prostate cancer;
 KW developmental disorder; aberrant apoptosis; cytostatic; antiinflammatory;
 KW antimicrobial; ds.
 XX
 OS Homo sapiens.
 XX
 FN US2003225015-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 31-MAY-2002; 2002US-00161983.
 XX
 XX 31-MAY-2002; 2002US-00161983.
 PR
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Ward DT, Freier SM;
 PI
 XX WPI; 2004-042170/04.
 DR
 XX
 XX New antisense oligonucleotides inhibiting the expression of Rb2/p130,
 XX useful for preventing or treating diseases associated with Rb2/p130, such
 XX as developmental or hyperproliferative disorders, infection or
 XX PT inflammation.
 PT
 XX Example 15; SEQ ID NO 52; 47pp; English.
 PS
 CC The present invention relates to antisense compounds targeted to a
 CC nucleic acid encoding Rb2/p130. The antisense compound comprises an
 CC antisense oligonucleotide that specifically hybridizes with the nucleic
 CC acid and inhibits the expression of Rb2/p130. The antisense
 CC oligonucleotide is a chimeric oligonucleotide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage,
 CC preferably a phosphorothioate linkage. It also comprises at least one
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE) sugar
 CC moiety. The antisense oligonucleotide further comprises at least one
 CC modified nucleobase, preferably a 5-methylcytosine. The antisense
 CC oligonucleotides are useful for the treatment of diseases such as
 CC hyperproliferative disorders, preferably cancer (particularly breast
 CC cancer, ovarian cancer, hepatocellular cancer or prostate cancer),
 CC developmental disorders, and disorders associated with aberrant
 CC apoptosis. The present sequence represents a human Rb2/p130 DNA target
 CC sequence for an antisense oligonucleotide.

SQ Sequence 20 BP; 7 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCCTCATGTCC 433
 Db 20 ACTAGGAGTTCTCCTGTCC 1

RESULT 653
 ADJ60959/c
 ID ADJ60959 standard; DNA; 20 BP.
 AC ADJ60959;
 XX
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to PDE4C #25.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIC-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1815; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 516 GCGAGGTGGAGCCTTGAG 535
 Db 20 GCGAGGTGGATCACCCTGAG 1

RESULT 654
 ADL34824/c
 ID ADL34824 standard; DNA; 20 BP.
 XX
 AC ADL34824;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE Antisense oligonucleotide ISIS 221093.
 KW antisense; PPAR-delta; hybridisation; inhibitor;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; cytostatic; gene therapy; ss;
 KW primer.
 XX
 OS Synthetic.
 XX US2004063129-A1.
 PN
 XX 01-APR-2004.
 PD
 PF 05-SEP-2003; 2003US-00655847.
 XX
 PR 31-MAY-2002; 2002US-00160807.
 XX
 PA (GAAR/) GAARDE W.
 PA (FREI/) FREIER S M.
 PA (WATT/) WATT A T.
 XX
 PI Gaarde W, Freier SM, Watt AT;
 XX WPI; 2004-282460/26.
 DR
 XX New antisense oligonucleotide, having a sequence targeted to a nucleic
 PT acid encoding PPAR-delta, useful for preparing a composition for treating
 PT hyperproliferative disorder, e.g., cancer.
 XX
 PS Example 16; SEQ ID NO 122; Opp; English.
 XX
 CC This invention describes novel antisense oligonucleotides targeted to a
 CC nucleic acid encoding PPAR-delta, which specifically hybridise to and
 CC inhibit expression of PPAR-delta. The oligonucleotide specifically
 CC hybridises with at least an 8-nucleobase portion of an active site on the
 CC nucleic acid molecule encoding the PPAR-delta and comprises at least one
 CC modified internucleoside linkage, which is a phosphorothioate linkage, at
 CC least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar
 CC moiety or at least one modified nucleobase, which is a 5-methylcytosine.
 CC The antisense oligonucleotides are useful for preparing a composition for
 CC treating hyperproliferative disorders, e.g., cancer. The oligonucleotides
 CC of the invention have cytostatic activity and can be used for gene
 CC therapy.
 XX
 SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 826 GCTGGCCAGTTGTCAGGTGG 845
 Db 20 GCTGGACCAGCTGCAGATGG 1

RESULT 655
 ADL34963
 ID ADL34963 standard; DNA; 20 BP.
 XX
 AC ADL34963;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE Murine PPAR-delta target site ID 137747.
 XX

KW antisense; PPAR-delta; hybridisation; inhibitor;
 KW phosphorothioate linkage; 2'-O-methoxyethyl sugar; 5-methylcytosine;
 KW hyperproliferative disorder; cancer; cytostatic; gene therapy; ds.
 XX Mus sp.
 OS
 PN US2004063129-A1.
 XX
 PN 01-APR-2004.
 XX
 PD
 XX 05-SEP-2003; 2003US-00655847.
 XX
 PF 31-MAY-2002; 2002US-00160807.
 XX
 PR (GAAR/) GAARDE W.
 XX (FREI/) FREIER S M.
 PA (WATT/) WATT A T.
 PA
 PA Gaarde W, Freier SM, Watt AT;
 PI WPI; 2004-282460/26.
 DR
 XX New antisense oligonucleotide, having a sequence targeted to a nucleic
 PT acid encoding PPAR-delta, useful for preparing a composition for treating
 PT hyperproliferative disorder, e.g., cancer.
 XX
 XX Example 16; SEQ ID NO 261; Opp; English.
 PS
 XX This invention describes novel antisense oligonucleotides targeted to a
 CC nucleic acid encoding PPAR-delta, which specifically hybridise to and
 CC inhibit expression of PPAR-delta. The oligonucleotide specifically
 CC hybridises with at least an 8-nucleobase portion of an active site on the
 CC nucleic acid molecule encoding the PPAR-delta and comprises at least one
 CC modified internucleoside linkage, which is a phosphorothioate linkage, at
 CC least one modified sugar moiety, which is a 2'-O-methoxyethyl sugar
 CC moiety or at least one modified nucleobase, which is a 5-methylcytosine.
 CC The antisense oligonucleotides are useful for preparing a composition for
 CC treating hyperproliferative disorders, e.g., cancer. The oligonucleotides
 CC of the invention have cytostatic activity and can be used for gene
 CC therapy.
 XX
 XX Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 826 GCTGGCCCGAGTTCAGGTGG 845
 Db 1 GCTGGACCGAGTTCAGATGG 20
 RESULT 656
 ADO46448/C
 ID ADO46448 standard; DNA; 20 BP.
 XX
 AC ADO46448;
 XX
 XX 15-JUL-2004 (first entry)
 DT
 XX Human oligonucleotide #1814.
 DE
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.

XX US2004049022-A1.
 PN
 XX 11-MAR-2004.
 PD
 XX 25-JUL-2003; 2003US-00627930.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 PR
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1815; 174pp; English.
 PS
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 516 GCGAGGTGAGCAGCTGAAG 535
 Db 20 GCGAGGTGATCAGCTGAGG 1
 RESULT 657
 ADP78915
 ID ADP78915 standard; DNA; 20 BP.
 XX
 XX ADP78915;
 AC
 XX

DT 12-AUG-2004 (first entry)
 XX Chimeric phosphorothioate oligonucleotide #2714.
 DE GFAT; Antidiabetic; Cardiant;
 XX Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
 KW reperfusion; ss.
 XX Synthetic.
 OS
 XX
 PH Key Location/Qualifiers
 FT modified_base 1..4
 FT /*tag= a
 FT /mod_base= other
 FT /note= "2-methoxyethyl wing"
 FT modified_base 17..20
 FT /*tag= b
 FT /mod_base= other
 FT /note= "2-methoxyethyl wing"
 XX
 XX WO2004035763-A2.
 PN
 XX
 XX 29-APR-2004.
 PD
 XX
 XX 02-OCT-2003; 2003WO-US033332.
 PF
 XX
 XX 17-OCT-2002; 2002US-0419268P.
 PR
 XX
 XX (PHAA) PHARMACIA CORP.
 PA
 XX
 XX Broschat KO, Crosby SD;
 PI
 XX
 XX WPI; 2004-348453/32.
 DR
 XX
 XX New compounds, particularly antisense oligonucleotides targeted to a
 PT nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
 PT (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
 PT ischemia/reperfusion injury.
 XX
 PS Claim 4; SEQ ID NO 2714; 175pp; English.
 XX
 CC The present invention relates to a compound which specifically hybridizes
 CC with a nucleic acid molecule encoding GFAT, and inhibits the expression
 CC of GFAT. Specifically claimed are antisense oligonucleotides capable of
 CC modulating the expression of GFAT, and which comprise any of the 3063
 CC sequences of 20 base pairs, given in the specification. The compound,
 CC composition and methods are useful for treating a disease or condition
 CC associated with GFAT, such as a disease or condition, e.g. diabetes, a
 CC cardiovascular or neurological disorder, ischemia/reperfusion injury.
 CC They are also useful in research and diagnostics for modulating the
 CC expression of GFAT. The present sequence represents a chimeric
 CC phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
 CC oligonucleotides inhibit human GFAT expression.
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 162 TCTGGAAGACCAACTGTGT 181
 Db 1 TATGGAACCTGCCAATGTGT 20
 RESULT 658
 ID AC23071
 XX AC23071 standard; DNA; 15 BP.
 AC
 XX
 XX AC23071;
 XX
 XX 25-AUG-2003 (first entry)
 DT

DE Human Nemo gene wild type exon 2 DNA sequence.
 XX
 XX Human; ds; NF-kappaB essential modulator; nuclear factor kappa B;
 KW incontinentia pigmenti; X-linked disorder; chromosome Xq28; NEMO;
 KW immunomodulatory; dermatological; osteopathic; neuropathic;
 KW apoptosis-related disease; immune-system related disease;
 KW blood vessel-related disease; skin defect; dental defect; osteopetrosis;
 KW ophthalmologic defect; neurological defect.
 XX
 XX Homo sapiens.
 OS
 XX
 XX US2003032055-A1.
 PN
 XX
 XX 13-FEB-2003.
 PD
 XX
 XX 22-MAY-2001; 2001US-00863049.
 PF
 XX
 XX 22-MAY-2000; 2000US-0206223P.
 PR
 XX
 XX (KENN/) KENNRICK S J.
 PA (WOF/) WOFFENDIN H.
 PA (MUNN/) MUNNICH A.
 PA (SMAH/) SMAHI A.
 PA (ISRA/) ISRAEL A.
 PA (POUS/) POUSTRKA A.
 PA (HEIS/) HEISS N.
 PA (DURS/) D'URSO M.
 PA (LEWI/) LEWIS R A.
 PA (NELS/) NELSON D L.
 PA (ARAD/) ARADHYA S.
 PA (LEVY/) LEVY M.
 XX
 XX Kenrick SJ, Woffendin H, Munnich A, Smahi A, Israel A;
 PI Poustra A, Heiss N, D'urso M, Lewis RA, Nelson DL, Aradhy S;
 PI Levy M;
 XX
 XX WPI; 2003-492063/46.
 DR
 XX P-PSDB; ABO17486.
 PT
 PT Detection of necrosis factor-kappa B related medical condition in
 PT organism, by obtaining sample from the organism, and analyzing the sample
 PT for alteration in specified amino acid sequences.
 XX
 XX Claim 4; Fig 5; 44pp; English.
 CC
 CC The invention relates to a nuclear factor-kappa B (NF-kappa B) related
 CC medical condition in an organism being detected by obtaining a sample
 CC from the organism, and analysing the sample for an alteration in a the
 CC nuclear factor kappaB essential modifier (NEMO) gene or protein sequence
 CC (neither shown in the specification). The alteration results in
 CC inactivation of NF-kappa B. Also included are treating or preventing NF-
 CC kappa B related medical condition in an organism by administering the
 CC NEMO protein to the organism and screening a test organism for a compound
 CC for the treatment of NF-kappa B related medical condition (by
 CC administering the compound to the organism, and assaying for an
 CC improvement in the NF-kappa B related medical condition). The method
 CC useful is for detecting NF-kappa B related condition, e.g. incontinentia
 CC pigmenti (IP), apoptosis-related disease, immune-system related disease,
 CC blood vessel-related disease, skin defect, dental defect, osteopetrosis,
 CC ophthalmologic defect, or neurological defect, in an organism, i.e. human
 CC including affected individual, carrier individual, or noncarrier
 CC individual. The NEMO gene is located on chromosome Xq28, incontinentia
 CC pigmenti being an X-linked disorder. Experiments in this study show
 CC variations in exon 2, 10, 9 and particularly intron 3 to be linked to
 CC familial incontinentia pigmenti. The present sequence is a wild-type
 CC region of the human NEMO gene found to be associated with familial
 CC incontinentia pigmenti
 XX
 XX Sequence 15 BP; 4 A; 5 C; 3 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 269 CTGCTTCAGAACAG 283
 Db 1 CTGCTTCAGAACAG 15

RESULT 659
 ADL50826
 ID ADL50826 standard; RNA; 15 BP.
 XX AC ADL50826;
 XX DT 20-MAY-2004 (first entry)
 XX DE Human PKR substrate sequence #1940.
 XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX OS Unidentified.
 XX PN WO200281628-A2.
 XX PD 17-OCT-2002.
 XX PF 03-APR-2002; 2002WO-US010512.
 XX PR 05-APR-2001; 2001US-00827395.
 XX PR 29-MAY-2001; 2001US-0294412P.
 XX PR 28-AUG-2001; 2001US-0315315P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX PS Claim 59; SEQ ID NO 4359; 317pp; English.
 XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX SQ Sequence 15 BP; 5 A; 2 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 549 AGATGCTGAGGACA 563
 Db 1 AGAUGGCTUGAGGACA 15

RESULT 660
 ADL50845
 ID ADL50845 standard; RNA; 15 BP.
 XX AC ADL50845;
 XX DT 20-MAY-2004 (first entry)
 XX DE Human PKR substrate sequence #1959.
 XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX OS Unidentified.
 XX PN WO200281628-A2.
 XX PD 17-OCT-2002.
 XX PF 03-APR-2002; 2002WO-US010512.
 XX PR 05-APR-2001; 2001US-00827395.
 XX PR 29-MAY-2001; 2001US-0294412P.
 XX PR 28-AUG-2001; 2001US-0315315P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX PS Claim 59; SEQ ID NO 4378; 317pp; English.
 XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX SQ Sequence 15 BP; 1 A; 9 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QV 297 CCTCAGCGCTGCC 311
    |||:|||||:||||
Db 1 CCUCAGCGCUGCC 15

RESULT 661
ADL50849
ID ADL50849 standard; RNA; 15 BP.
XX
AC ADL50849;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1963.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4382; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 15 BP; 5 A; 4 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QV 321 ATCAAGAGCTCCGAG 335
    |:|||||:|||||
Db 1 AUCAGAGCUCGAG 15

RESULT 662
ADL50864
ID ADL50864 standard; RNA; 15 BP.
XX
AC ADL50864;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1978.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4397; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 15 BP; 3 A; 3 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```

QY 734 AGCGTGCAGGTGAC 748
 Db 1 AGCGGCGAGGUGAC 15

RESULT 663
 ADL50859
 ID ADL50859 standard; RNA; 15 BP.
 XX
 AC ADL50859;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PKR substrate sequence #1973.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 4392; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX
 SQ Sequence 15 BP; 4 A; 3 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 3.3e+02;
 Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 431 TGCAAGTTCAGGAG 445
 Db 1 UGCAGGUCCAGGAG 15

RESULT 664
 ADL50876
 ID ADL50876 standard; RNA; 15 BP.
 XX
 AC ADL50876;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PKR substrate sequence #1990.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 4409; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX
 SQ Sequence 15 BP; 7 A; 4 C; 2 G; 0 T; 2 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.3e+02;
 Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 861 TCCAGGAATACGACA 875
:|||||:|||||
Db 1 UCCAGAAUACGACA 15

RESULT 665
ADL50879
ID ADL50879 standard; RNA; 15 BP.

XX AC ADL50879;
XX DT 20-MAY-2004 (first entry)
XX DE Human PKR substrate sequence #1993.

XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX OS Unidentified.

XX XX

PN WO200281628-A2.

XX PD 17-OCT-2002.

XX PF 03-APR-2002; 2002WO-US010512.

XX PR 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

XX XX

DR WPI; 2003-058513/05.

XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX PS Claim 59; SEQ ID NO 4412; 317pp; English.

XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.

XX SQ Sequence 15 BP; 6 A; 1 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 810 CGGAGGAGAGAGGA 824
:|||||:|||||
Db 1 CGGAGGAGAGAGGA 15

RESULT 666
ADL50874
ID ADL50874 standard; RNA; 15 BP.

XX AC ADL50874;
XX DT 20-MAY-2004 (first entry)
XX DE Human PKR substrate sequence #1988.

XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX OS Unidentified.

XX XX

PN WO200281628-A2.

XX PD 17-OCT-2002.

XX PF 03-APR-2002; 2002WO-US010512.

XX PR 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

XX XX

DR WPI; 2003-058513/05.

XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX PS Claim 59; SEQ ID NO 4407; 317pp; English.

XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.

XX SQ Sequence 15 BP; 5 A; 4 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
QY      209 GCAGCAGATCAGGAC 223
Db      1 GCAGCAGATCAGGAC 15
|||:|||||:|||||
|||:|||||:|||||

RESULT 667
ADL50811
ID ADL50811 standard; RNA; 15 BP.
XX
AC ADL50811;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1925.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4344; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 15 BP; 3 A; 4 C; 3 G; 0 T; 5 U; 0 Other;
Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 3.3e+02;
Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      420 AGTTCCTCATGTGCA 434
Db      1 AGUUCUCAUGUGCA 15
|||:|||||:|||||
|||:|||||:|||||

RESULT 668
ADL50829
ID ADL50829 standard; RNA; 15 BP.
XX
AC ADL50829;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1943.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4362; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 15 BP; 5 A; 3 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

QY 573 TGAAGCCCGAGGTGA 587
 |||||:|||||:
 Db 1 UGAAGCCCGAGGUGA 15

RESULT 669

ADL50851
 ID ADL50851 standard; RNA; 15 BP.

XX
 AC ADL50851;

XX
 DT 20-MAY-2004 (first entry)

XX
 DE Human PKR substrate sequence #1965.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.

XX Unidentified.

OS
 PN WO200281628-A2.

XX
 PD 17-OCT-2002.

XX
 PF 03-APR-2002; 2002WO-US010512.

XX
 PR 05-APR-2001; 2001US-00827395.

PR
 PR 29-MAY-2001; 2001US-0294412P.

PR
 PR 28-AUG-2001; 2001US-0315315P.

XX
 PA (RIBO-) RIBOZYME PHARM INC.

XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

XX
 DR WPI; 2003-058513/05.

XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX
 PS Claim 59; SEQ ID NO 4384; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.

XX
 SQ Sequence 15 BP; 3 A; 4 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 3.3e+02;
 Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCTCTGTGAAGC 579
 |||||:|||||:
 Db 1 GGCCUCUGAAGC 15

RESULT 670

ADL50827
 ID ADL50827 standard; RNA; 15 BP.

XX
 AC ADL50827;

XX
 DT 20-MAY-2004 (first entry)

XX
 DE Human PKR substrate sequence #1941.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.

XX Unidentified.

OS
 PN WO200281628-A2.

XX
 PD 17-OCT-2002.

XX
 PF 03-APR-2002; 2002WO-US010512.

XX
 PR 05-APR-2001; 2001US-00827395.

PR
 PR 29-MAY-2001; 2001US-0294412P.

PR
 PR 28-AUG-2001; 2001US-0315315P.

XX
 PA (RIBO-) RIBOZYME PHARM INC.

XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

XX
 DR WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX
 PS Claim 59; SEQ ID NO 4360; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.

XX
 SQ Sequence 15 BP; 4 A; 4 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 3.3e+02;
 Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 561 ACAAGGCTCTGTGA 575
 |||||:|:|:
 Db 1 ACAAGGCCUCUGUGA 15

RESULT 671
 ADL50846
 ID ADL50846 standard; RNA; 15 BP.
 XX
 AC ADL50846;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PKR substrate sequence #1960.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 4379; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX
 SQ Sequence 15 BP; 1 A; 7 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred.No. 3.3e+02;
 Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 299 CTCACGGCTGCTG 313
 |:|:|:|:|:|:
 Db 1 CUCCAGCGCGCCUG 15

RESULT 672
 ADL50878
 ID ADL50878 standard; RNA; 15 BP.
 XX
 AC ADL50878;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PKR substrate sequence #1992.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; ikappab kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, ikappab kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 4411; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX
 SQ Sequence 15 BP; 5 A; 3 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred.No. 3.3e+02;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 208 GGCAGCAGATCAGGA 222
 |||||:|||||
 Db 1 GGCAGCAGAUCAAGGA 15

RESULT 673

ADL50824

ID ADL50824 standard; RNA; 15 BP.

XX

AC ADL50824;

XX

DT 20-MAY-2004 (first entry)

XX

DE Human PKR substrate sequence #1938.

XX

KW antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;

KW substrate; ds.

XX

OS Unidentified.

XX

PN WO200281628-A2.

XX

PD 17-OCT-2002.

XX

PF 03-APR-2002; 2002WO-US010512.

XX

PR 05-APR-2001; 2001US-00827395.

XX

PR 29-MAY-2001; 2001US-0294412P.

XX

PR 28-AUG-2001; 2001US-0315315P.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;

XX

DR WPI; 2003-058513/05.

XX

PT Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX

PS Claim 59; SEQ ID NO 4357; 317pp; English.

XX

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human PKR

CC substrate sequence.

XX

SQ Sequence 15 BP; 6 A; 3 C; 4 G; 0 T; 2 U; 0 Other;

Query Match

Best Local Similarity 2.0%; Score 15; DB 1; Length 15;

Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY; 317 GAGAATCAAGAGCTC 331
 |||||:|||||
 Db 1 GAGAATCAAGAGCTC 15

RESULT 674

ADL50875

ID ADL50875 standard; RNA; 15 BP.

XX

AC ADL50875;

XX

DT 20-MAY-2004 (first entry)

XX

DE Human PKR substrate sequence #1989.

XX

KW antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;

KW substrate; ds.

XX

OS Unidentified.

XX

PN WO200281628-A2.

XX

PD 17-OCT-2002.

XX

PF 03-APR-2002; 2002WO-US010512.

XX

PR 05-APR-2001; 2001US-00827395.

XX

PR 29-MAY-2001; 2001US-0294412P.

XX

PR 28-AUG-2001; 2001US-0315315P.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Blatt L, Chowrira B, Haeblerli P, Mcswiggen J, Fosnaugh K;

XX

DR WPI; 2003-058513/05.

XX

PT Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX

PS Claim 59; SEQ ID NO 4408; 317pp; English.

XX

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human PKR

CC substrate sequence.

XX

SQ Sequence 15 BP; 5 A; 3 C; 5 G; 0 T; 2 U; 0 Other;

Query Match

Best Local Similarity 2.0%; Score 15; DB 1; Length 15;

Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 531 TGAAGAGATGCCAGC 545
 Db :|||||:|||||
 1 UGAAGAGAUGCCAGC 15

RESULT 675
 ABN07253
 ID ABN07253 standard; DNA; 17 BP.
 AC ABN07253;
 XX
 XX
 XX 29-MAY-2002 (first entry)
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7245.
 DE
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200192524-A2.
 PN
 XX
 XX 06-DEC-2001.
 PD
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI
 XX WPI; 2002-179446/23.
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 7245; 214pp; English.
 PS
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognize hGDMPLP-
 CC -1 proteins, as standards in assays used to determine the concentration
 CC of or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 0;
 QY 697 GCTGGAGAGTGAGCG 711
 Db 2 GCTGGAGAGTGAGCG 16
 RESULT 676
 ABN07252
 ID ABN07252 standard; DNA; 17 BP.
 XX
 AC ABN07252;
 XX
 XX 29-MAY-2002 (first entry)
 DT
 XX
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7244.
 DE
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200192524-A2.
 PN
 XX
 XX 06-DEC-2001.
 PD
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI
 XX WPI; 2002-179446/23.
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 7244; 214pp; English.
 PS
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognize hGDMPLP-
 CC -1 proteins, as standards in assays used to determine the concentration
 CC of or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.

CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence

SQ Sequence 17 BP; 3 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCG 711
 |||||
 DB 3 GCTGGAGAGTGAGCG 17

RESULT 677
 ADB45431
 ID ADB45431 standard; DNA; 17 BP.

XX AC ADB45431;

XX DT 12-JUN-2003 (first entry)

XX DE Tumour suppression related human fukutin oligo SEQ ID No 2021.

XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.

XX OS Homo sapiens.

XX PN WO2003025175-A2.

XX PD 27-WAR-2003.

XX PF 17-SEP-2002; 2002WO-IB004208.

XX PR 17-SEP-2001; 2001FR-00011978.

XX PA (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX DR WPI; 2003-313353/30.

XX PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.

XX PS Disclosure; Page 269; 720pp; French.

CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one

CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention

SQ Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 241 TCCTCTGGGAGGCC 255

DB 3 TCCTCTGGGAGGCC 17

RESULT 678

ADB45431

ID ADB45431 standard; DNA; 17 BP.

XX AC ADB45431;

XX DT 18-DEC-2003 (first entry)

XX DE Tumour suppression/reversion associated nucleotide #5754.

XX KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KW diagnosis.

XX OS Homo sapiens.

XX PN WO2003040369-A2.

XX PD 15-MAY-2003.

XX PF 17-SEP-2002; 2002WO-IB004219.

XX PR 17-SEP-2001; 2001FR-00011981.

XX PA (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX DR WPI; 2003-441574/41.

XX PT New nucleic acid encoding human prostate membrane-specific antigen,
 PT useful e.g. for treatment of tumors and viral infection, also related
 PT polypeptide and antibodies.

XX PS Disclosure; Page 704; 771pp; French.

CC The invention relates to the isolation of 6327 nucleotide sequences,
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
 CC sequence having at least 80% identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as

CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.
 XX
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 241 TCCTCTGGGGAAGCC 255
 |||||
 Db 3 TCCTCTGGGGAAGCC 17

RESULT 679
 ADI49287
 ID ADI49287 standard; DNA; 17 BP.

AC ADI49287;

DT 15-APR-2004 (first entry)

DE Human tumour suppression/reversion-related DNA sequence SeqID1790.

XX tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
 KW primer; PCR; gene chip; antisense; viral disease; tumour;
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX Homo sapiens.

XX WO2003025177-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004523.

XX 17-SEP-2001; 2001FR-00011980.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313354/30.

XX New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.

XX Disclosure; SEQ ID NO 1790; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis
 CC and/or resistance to viruses. The invention may be useful for the
 CC development of compounds with a cytostatic, virucide, neuroprotective,
 CC neurotropic or neuroleptic activity. The DNA sequences may be useful as
 CC probes and primers for detecting, identifying, quantifying and/or
 CC amplifying nucleic acid, for example as one component of a gene chip, in
 CC vitro as antisense reagents and for production of recombinant
 CC polypeptides. The invention may therefore be useful for preparation of
 CC pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The
 CC present sequence is that of a nucleic acid sequence of the invention.
 CC Note: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/publishedpct_sequences
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 241 TCCTCTGGGGAAGCC 255
 |||||
 Db 3 TCCTCTGGGGAAGCC 17

RESULT 680
 ADL48710
 ID ADL48710 standard; RNA; 17 BP.

XX ADL48710;

XX 20-MAY-2004 (first entry)

XX Human IKK-gamma substrate sequence #1220.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.

XX Unidentified.

XX WO200281628-A2.

XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

XX 29-MAY-2001; 2001US-0294412P.

XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Meswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 2243; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 2 C; 9 G; 0 T; 1 U; 0 Other;
 Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 3.9e+02;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 902 AGTGAGCGGAGCGA 916
 Db 1 AGUGAGCGGAGCGA 15
 RESULT 681
 ACN70343
 ID ACN70343 standard; DNA; 17 BP.
 XX
 AC ACN70343;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:7245.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX
 PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 7245; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence

CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 697 GCTGGAGAGTGAGCG 711
 Db 2 GCTGGAGAGTGAGCG 16
 RESULT 682
 ACN70342
 ID ACN70342 standard; DNA; 17 BP.
 XX
 AC ACN70342;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:7244.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX

XX New single stranded oligonucleotides comprising a DNA domain having at
PT least one mismatch with respect to the genetic sequence of the
PT Huntington's disease gene to be altered, useful for treating or
PT preventing Huntington's disease.
XX
PS Example 7; Fig 20; 133pp; English.
XX
CC The present sequence is that of a portion of a mutated glutamine (CAG)
CC triplet repeat region of exon 1 of the human Huntington's disease (HD)
CC gene (see also AB281760). The triplet repeat region is mutated following
CC treatment with single-stranded phosphorothioate-containing HD gene-
CC targeted oligonucleotide HD3S/52 (see AB281756). The second glutamine
CC (CAG) repeat triplet is converted to CTG, creating a restriction fragment
CC length polymorphism site that enables cleavage by PvuII. HD3S/25 is an
CC example of oligonucleotides of the invention for targeted alteration of
CC the HD gene. Such oligonucleotides can be used for the treatment or
CC prevention of HD
XX
SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
XX
Query Match 2.0%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 718 GCTGCAGCAGCAGCA 732
Db 3 GCTGCAGCAGCAGCA 17
XX
RESULT 685
AB281779
ID AB281779 standard; DNA; 18 BP.
XX
AC AB281779;
XX
DT 11-JUN-2003 (first entry)
XX
DE Huntington's disease gene mutated exon 1 region.
XX
DE Huntington's disease; nootropic; anticonvulsant; huntingtin; human;
KW Huntington's disease; mutant; ds.
XX
KW Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH mutation replace(5,A)
FT /*tag= a
XX
XX WO2003013437-A2.
XX
XX 20-FEB-2003.
XX
XX 07-AUG-2002; 2002WO-US025352.
XX
XX 07-AUG-2001; 2001US-0310757P.
XX
XX 08-AUG-2001; 2001US-0310770P.
XX
XX 08-AUG-2001; 2001US-0310889P.
XX
XX 04-DEC-2001; 2001US-0337219P.
XX
XX (UYDE) UNIV DELAWARE.
XX
XX Kmiec EB, Parekh-Olmedo H;
XX
XX WPI; 2003-256478/25.
XX
XX New single stranded oligonucleotides comprising a DNA domain having at
PT least one mismatch with respect to the genetic sequence of the
PT Huntington's disease gene to be altered, useful for treating or
PT preventing Huntington's disease.
XX
PS Example 7; Fig 20; 133pp; English.

XX The present sequence is that of a portion of a mutated glutamine (CAG)
CC triplet repeat region of exon 1 of the human Huntington's disease (HD)
CC gene (see also AB281760). The triplet repeat region is mutated following
CC treatment with single-stranded phosphorothioate-containing HD gene-
CC targeted oligonucleotide HD3S/25 (see AB281755). The second glutamine
CC (CAG) repeat triplet is converted to CTG, creating a restriction fragment
CC length polymorphism site that enables cleavage by PvuII. HD3S/25 is an
CC example of oligonucleotides of the invention for targeted alteration of
CC the HD gene. Such oligonucleotides can be used for the treatment or
CC prevention of HD
XX
SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
XX
Query Match 2.0%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 718 GCTGCAGCAGCAGCA 732
Db 3 GCTGCAGCAGCAGCA 17
XX
RESULT 686
AAH48698
ID AAH48698 standard; DNA; 19 BP.
XX
AC AAH48698;
XX
DT 19-OCT-2001 (first entry)
XX
DE E. coli 16S rRNA primer RP.
XX
XX 16S rDNA; amplification; PCR primer; bacterial contamination;
KW food industry; bacterial quantification; pathogen detection;
KW water protection; ss.
XX
XX Escherichia coli.
XX
XX DE10004147-A1.
XX
XX 09-AUG-2001.
XX
XX 31-JAN-2000; 2000DE-01004147.
XX
XX 31-JAN-2000; 2000DE-01004147.
XX
XX (GSFU-) GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT.
XX
XX Bach HJ, Schlöter M, Munch J, Tomanova J;
XX WPI; 2001-489825/54.
XX
XX Oligonucleotides for the amplification and qualitative and quantitative
PT detection of bacterial 16S rRNA useful to determine bacterial
PT contamination of foodstuffs, waters, and in clinical microbiology.
XX
XX Claim 1; Page 12; 16pp; German.
XX
XX This invention describes a novel oligonucleotide for the amplification
CC and qualitative and quantitative detection of RNA sequences derived from
CC 16S rRNA genes or gene fragments. The oligonucleotide is used to quantify
CC bacterial contamination, particularly using TagMan (RTM) PCR. The
CC invention can be used in the foodstuffs industry, to quantify bacteria
CC particularly human pathogens, in water protection, to determine bacterial
CC titer in drinking water, natural waters and public swimming pools, in
CC clinical microbiology to determine non-specific infection in humans and
CC animals, and in laboratory diagnostics. Unlike prior art, this invention
CC is useful to detect not only known species but also unknown bacteria of
CC differing physiological groups, and does not require bacterial
CC cultivation. The invention also allows quantification of all 16S RNA
CC using a single DNA extraction. This sequence represents a PCR primer used
CC to illustrate the method of the invention

```

XX SQ Sequence 19 BP; 5 A; 7 C; 3 G; 2 T; 0 U; 2 Other;
Query Match 2.0%; Score 15; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 253 GCCAGCCTGCTGACCTG 271
Db 1 GACARCCATGCACCTG 19

RESULT 687
ABK81885/C
ID ABK81885 standard; DNA; 20 BP.
XX
AC ABK81885;
XX
DT 13-AUG-2002 (first entry)
XX
DE Lung specific gene PCR primer #35.
XX
KW Lung specific gene; gene therapy; vaccine; lung cancer; cancer staging;
KW cancer monitoring; cancer diagnosis; imaging lung cancer; metastases;
KW PCR; primer; ss.
XX
OS Synthetic.
XX
FN WO200218576-A2.
XX
PD 07-MAR-2002.
XX
PF 27-AUG-2001; 2001WO-US026684.
XX
PR 28-AUG-2000; 2000US-0228378P.
XX
PA (DIAD-) DIADEXUS INC.
XX
PI Chen S, Macina RA, Sun Y, Recipon H;
XX
WPI; 2002-434904/46.
XX
New lung specific genes and their encoded proteins, useful in gene
therapy or as a vaccine for treating lung cancer, as well as for
measuring metastases of lung cancer, or staging, monitoring, diagnosing
or imaging lung cancer.
XX
Example 18; Page 153; 206pp; English.
XX
The invention describes a new lung specific gene and its variants. The
lung specific gene proteins and genes are useful in gene therapy or as a
vaccine for treating lung cancer. Lung specific genes are also useful for
staging, monitoring, diagnosing or imaging lung cancer, as well as for
measuring metastases of lung cancer. This sequence represents a PCR
primer used in microarray analysis to isolate a lung specific gene
thought to be involved in development of lung cancer
XX
SQ Sequence 20 BP; 5 A; 8 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 2.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 890 AGCGTGTGGGCACT 904
Db 15 AGCGTGTGGGCACT 1

RESULT 688
ABZ98895/C
ID ABZ98895 standard; DNA; 20 BP.
XX
AC ABZ98895;

```

```

XX DT 17-OCT-2003 (first entry)
XX DE Human PDE4A oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubinone; immunosuppressive; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
Pharmaceutical composition for treating ailments associated with impaired
respiration, has oligo(s) antisense to specific gene(s) or its
corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
ubinone.
XX
Disclosure; SEQ ID NO 14137; 872pp; English.
XX
The invention relates to a novel pharmaceutical composition, which has a
first active agent comprising an oligonucleotide antisense to the
initiation codon, coding region, 5' or 3' end genomic flanking regions,
5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
junctions of genes encoding a polypeptide associated with lung and/or
nasal airway dysfunction and a second active agent comprising an
antiinflammatory steroid and ubinone. A composition of the invention
has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
immunosuppressive, and cytostatic activity. The composition may have a
use in antisense gene therapy. The composition is useful for treating or
preventing a respiratory, lung or malignant disease or condition, also
for enhancing the prophylactic or therapeutic respiratory effect of an
antiinflammatory steroid in a subject, for reducing or depleting levels
of, or reducing sensitivity to adenosine, reducing levels of adenosine
receptor, producing bronchodilation, increasing levels of ubinone or
lung surfactant in a subject's tissue, or treating bronchoconstriction,
lung inflammation, lung allergies, or a respiratory disease or condition.
Note: The sequence data for this patent is not represented in the printed
specification, but was obtained in electronic format directly from WIPO
at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 1 A; 6 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 2.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 338 GCCATCGGCAGAGC 352
Db 18 GCCATCGGCAGAGC 4

RESULT 689
ABD31926/C
ID ABD31926 standard; DNA; 20 BP.
XX
AC ABD31926;

```

XX
DT 29-JUL-2004 (first entry)
DE Human PDE4A-derived oligonucleotide SEQ ID 14137.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPITG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 14137; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiasthmatic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 1 A; 6 C; 9 G; 4 T; 0 U; 0 Other;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 338 GCCATCCGCGAGC 352
DB 18 GCCATCCGCGAGC 4
RESULT 690
ADJ60778/c
ID ADJ60778 standard; DNA; 20 BP.
XX
AC ADJ60778;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to PDE4A #61.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPITG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCRI, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1634; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 1 A; 6 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 2.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 338 GCCATCCGCGAGC 352
DB 18 GCCATCCGCGAGC 4

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 6 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 2.0%; Score 15; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 4.8e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 338 GCATCCGCGCAGC 352
 Db 18 GCATCCGCGCAGC 4
 RESULT 692
 AAV60911
 ID AAV60911 standard; DNA; 18 BP.
 XX AAV60911;
 AC AAV60911;
 XX
 XX 11-JAN-1999 (first entry)
 DT
 XX
 DE Angiogenin antisense oligonucleotide JF2S.
 XX
 KW Angiogenin; antisense; inhibitor; cancer; metastasis; angiogenesis;
 KW therapy; diagnosis; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..18
 FT /*tag= a
 FT /note= "phosphorothioate linkages"
 XX
 PN WO9842722-A1.
 PD 01-OCT-1998.
 XX
 PF 20-MAR-1998; 98WO-US005651.
 XX
 PR 21-MAR-1997; 97US-0041182P.
 XX
 PA (HARD) HARVARD COLLEGE.
 XX
 PI Pett JW, Olson KA;
 XX
 DR WPI; 1998-531944/45.
 XX
 PT New oligo-nucleotide(s) that inhibit expression of angiogenin - for
 PT treatment of tumours and metastases, or other conditions involving
 PT abnormal angiogenesis.
 XX
 PS Claim 10; Page 38; 71pp; English.
 CC
 CC Antisense phosphorothioate oligonucleotide JF2S encompasses the AUG
 CC initiation codon of the human angiogenin gene (see AAV60918). JF2S, and
 CC other claimed antisense oligonucleotides (see AAV60912-17) with base
 CC sequences complementary to a target region of the angiogenin gene, are
 CC able to inhibit expression of angiogenin. They are used in claimed
 CC methods to decrease production of angiogenin, particularly to reduce the
 CC size of tumours associated with angiogenesis, to inhibit metastases,
 CC establishment of tumour cells or growth of tumours and, when labelled, to
 CC detect angiogenin for diagnosis of conditions associated with abnormal
 CC angiogenesis. They can also be used to treat a wide range of non-cancer
 CC conditions that involve angiogenesis, e.g. age-related macular
 CC degeneration, diabetic retinopathy, bacterial or fungal ulcers,
 CC rheumatoid arthritis, Paget's disease, Crohn's disease, haemangioma and
 CC many others listed
 XX
 SQ Sequence 18 BP; 3 A; 9 C; 1 G; 5 T; 0 U; 0 Other;

AD046267/c
 ID ADO46267 standard; DNA; 20 BP.
 XX
 AC ADO46267;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1633.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE// NYCE J W.
 PA (SAND// SANDRASAGRA A.
 PA (TANG// TANG L.
 PA (AGUI// AGUILAR D.
 PA (MILL// MILLER S.
 PA (SHAH// SHAHABUDDIN S.
 PA (LUHH// LU H.
 PA (CONG// CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1634; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC 5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,

Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 GCCTATCACCAGCTCTTC 862
DB 1 GCCCATCACCATCTCTTC 18

RESULT 693
AAV60919/c
ID AAV60919 standard; DNA; 18 BP.

AC AAV60919;
XX
DT 11-JAN-1999 (first entry)
XX
DE Angiogenin sense oligonucleotide JF1S.
XX
KW Angiogenin; antisense; inhibitor; cancer; metastasis; angiogenesis;
KW therapy; diagnosis; ss.
XX
OS Synthetic.
XX
PN WO9842722-A1.
XX
PD 01-OCT-1998.
XX
PF 20-MAR-1998; 98WO-US005651.
XX
PR 21-MAR-1997; 97US-0041182P.
XX
PA (HARD) HARVARD COLLEGE.
XX
PI Fett JW, Olson KA;
XX
DR WPI; 1998-531944/45.
XX
PT New oligo:nucleotide(s) that inhibit expression of angiogenin - for
PT treatment of tumours and metastases, or other conditions involving
PT abnormal angiogenesis.
XX
PS Example 4; Page 26; 71pp; English.
XX

CC Sense oligonucleotide JF1S encompasses the AUG initiation codon of the
CC human angiogenin gene (see AAV60918). Its sequence is complementary to
CC claimed antisense phosphorothioate oligonucleotide JF2S, and other
CC claimed antisense oligonucleotides (see AAV60912-17) with base sequences
CC complementary to target regions of the angiogenin gene, are able to
CC inhibit expression of angiogenin. JF1S is used as a control
CC oligonucleotide in experiments with these antisense sequences. The
CC antisense oligonucleotides are used in claimed methods to decrease
CC production of angiogenin, particularly to reduce the size of tumours
CC associated with angiogenesis, to inhibit metastases, establishment of
CC tumour cells or growth of tumours and, when labelled, to detect
CC angiogenin for diagnosis of conditions associated with abnormal
CC angiogenesis
XX

QY 845 GCCTATCACCAGCTCTTC 862
DB 18 GCCCATCACCATCTCTTC 1

RESULT 694
AAAX77049
ID AAX77049 standard; DNA; 18 BP.

Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 GCCTATCACCAGCTCTTC 862
DB 18 GCCCATCACCATCTCTTC 1

RESULT 694
AAAX77049
ID AAX77049 standard; DNA; 18 BP.

Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 GCCTATCACCAGCTCTTC 862
DB 18 GCCCATCACCATCTCTTC 1

RESULT 694
AAAX77049
ID AAX77049 standard; DNA; 18 BP.

Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 GCCTATCACCAGCTCTTC 862
DB 18 GCCCATCACCATCTCTTC 1

XX AAX77049;
AC 10-AUG-1999 (first entry)
DT PCR primer for the pericentrin gene.
DE
XX PCR primer; proto-oncogene; oncogene; nucleic acid synthesis; ultrasound;
KW stress protein; repair protein; phenylketonuria; p53 tumour suppressor;
KW phenylalanine hydroxylase; IL-2 production; cancer; AIDS; haemophilia;
KW autoimmune disease; chronic viral infection; cystic fibrosis; therapy;
KW ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9925385-A1.
XX
PD 27-MAY-1999.
XX
PF 11-NOV-1998; 98WO-US023843.
XX
PR 17-NOV-1997; 97US-00971540.
XX
PA (IMAR-) IMARX PHARM CORP.
XX
PI Unger EC, McCreery T, Sadewasser D;
XX
DR WPI; 1999-370731/31.
XX
PT Increasing nucleic acid synthesis by ultrasonic treatment of cells.
XX
PS Example 1; Page 107; 124pp; English.
XX

CC This sequence represents a PCR primer for a proto-oncogene/oncogene, and
CC was used to test the method of the invention. The method is for
CC increasing synthesis of nucleic acid (I) in a cell by exposing it to
CC ultrasound, where (I) is: (a) an endogenous sequence (Ia) encoding a
CC stress or repair protein; or (b) an introduced exogenous sequence (Ib).
CC The method is specifically used therapeutically: (i) to treat
CC phenylketonuria (following introduction of (Ib) for phenylalanine
CC hydroxylase); (ii) to increase expression of the p53 tumour suppressor;
CC (iii) to increase production of IL-2, particularly associated with
CC natural killer cells; and (iv) for treating cancer by administering a
CC sequence antisense to initiation factor 3 and/or tRNA synthase. More
CC generally, (Ib) may include one or more genes or fragments, or even
CC complete chromosomes, for delivery (in vivo, in vitro or ex vivo) to
CC animal or plant cells for treating a very wide range of conditions, e.g.
CC acquired immune deficiency syndrome, autoimmune diseases, chronic viral
CC infections, haemophilia, cystic fibrosis, and cancer. Ultrasonic
CC treatment increases expression of (I) and increases uptake of (Ib),
CC particularly of 4-6 kb
XX
SQ Sequence 18 BP; 5 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 542 CAGCAGCAGATCGCTGAG 559
DB 1 CAGCGCGCAGATGACTGAG 18
RESULT 695
AAZ74326
ID AAZ74326 standard; DNA; 18 BP.
XX
AC AAZ74326;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker downstream amplification primer SEQ ID NO:8682.

Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 542 CAGCAGCAGATCGCTGAG 559
DB 1 CAGCGCGCAGATGACTGAG 18

RESULT 695
AAZ74326
ID AAZ74326 standard; DNA; 18 BP.
XX
AC AAZ74326;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker downstream amplification primer SEQ ID NO:8682.

Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 542 CAGCAGCAGATCGCTGAG 559
DB 1 CAGCGCGCAGATGACTGAG 18

RESULT 695
AAZ74326
ID AAZ74326 standard; DNA; 18 BP.
XX
AC AAZ74326;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker downstream amplification primer SEQ ID NO:8682.

```

XX Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
XX Homo sapiens.
XX
XX WO9954500-A2.
XX
XX 28-OCT-1999.
XX
XX 21-APR-1999; 99WO-IB000822.
XX
XX 21-APR-1998; 98US-0082614P.
XX
XX 23-NOV-1998; 98US-0109732P.
XX
XX (GEST ) GENSET.
XX
XX Cohen D, Blumenfeld M, Chumakov I;
XX
XX WPI; 2000-013267/01.
XX
XX Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome.
XX
XX Claim 8; Page 2081; 2745pp; English.
XX
XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
XX primers for the biallelic markers. The biallelic markers of the invention
XX have a variety of uses: they can be used for high density mapping of the
XX human genome, and in complex association studies and haplotyping studies
XX which are useful in determining the genetic basis for disease states.
XX Compositions and methods of the invention can also be useful for the
XX identification of the targets for the development of pharmaceutical
XX agents and diagnostic methods, as well as the characterisation of the
XX differential efficacious responses to and side effects from
XX pharmaceutical agents acting on a disease as well as other treatment.
XX N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
XX 3367, are not actually given a sequence in the Sequence Listing from the
XX present invention
XX
XX SQ Sequence 18 BP; 9 A; 1 C; 8 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 2.0%; Score 14.8; DB 1; Length 18;
XX Best Local Similarity 88.9%; Pred. No. 4.5e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 492 AGAGGCAGAGGAGCAGG 509
XX ||||| ||||| |||||
XX DB 1 AGAGGAGAGGAGCAGG 18
XX
XX RESULT 696
XX AAZ33146/C
XX ID AAZ33146 standard; DNA; 19 BP.
XX
XX AC AAZ33146;
XX
XX 26-JAN-2000 (first entry)
XX
XX Treponema pallidum Msp homologue PCR primer INT-S.
XX
XX Treponema pallidum; syphilis; vaccine; treponemal disease; Msp;
KW major sheath protein; bejal; gingivitis; periodontal disease; pinta;
KW yaws; PCR primer; ss.
XX
XX Synthetic.
XX
XX Treponema pallidum.
XX

```

```

PN WO9953099-A1.
XX
XX 21-OCT-1999.
XX
XX 09-APR-1999; 99WO-US007886.
XX
XX 10-APR-1998; 98US-00058968.
XX
XX (UNIW ) UNIV WASHINGTON.
XX
XX Van Voorhis WC, Lukehart SA, Centurion-Lara GA, Cameron CBS;
XX
XX WPI; 1999-620445/53.
XX
XX Novel proteins useful in vaccines against syphilis and other treponemal
XX diseases.
XX
XX Example 5; Page 34; 200pp; English.
XX
XX The present invention describes novel Treponema pallidum genes. These
XX genes encode a glycerophosphodiester phosphodiesterase (Gpd), a D15/Oma87
XX homologue, and proteins with homology to major outer sheath (Msp)
XX proteins of T. denticola. Also described are: (1) an isolated protein
XX capable of inducing a protective immunologic response to T. p. pallidum,
XX T. p. pertenuis, or T. p. endemicum, when administered in an effective
XX amount to an animal host; (2) a method of identifying a T. p. pallidum
XX vaccine candidate; (3) a method for analysing a sample of DNA to
XX determine whether it originated from T. p. subspecies pallidum, T. p.
XX subspecies pertenuis or T. p. subspecies endemicum; and (5) a method of
XX determining whether a first and a second clinical isolate of T. p.
XX pallidum are the same or different. The proteins are used, either alone
XX or in combination, in vaccines against Treponemal diseases, e.g.
XX syphilis, bejal, pinta, yaws, gingivitis, and periodontal disease. They
XX may also provide protection against other Treponemal diseases. The
XX methods may be used to identify vaccine candidates, and to determine the
XX origin of a treponemal nucleic acid. AAZ33104 to AAZ33156, and AAZ52773
XX to AAZ52831, represent sequences used in the exemplification of the
XX present invention
XX
XX SQ Sequence 19 BP; 0 A; 8 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 2.0%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 88.9%; Pred. No. 4.8e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 810 CGGAGGAGAGGAGGAGC 827
XX ||||| ||||| |||||
XX DB 19 CGAGGAGAGGAGGAGC 2
XX
XX RESULT 697
XX ABN84784
XX ID ABN84784 standard; DNA; 19 BP.
XX
XX AC ABN84784;
XX
XX 05-NOV-2002 (first entry)
XX
XX Primer useful for familial dysautonomia allele genotype analysis.
XX
XX Familial dysautonomia; Riley-Day syndrome;
KW hereditary sensory neuropathy III; human; carrier; diagnosis;
KW IkappaB kinase-complex associated protein; primer; SSCP;
KW single-strand conformational polymorphism; ss.
XX
XX Homo sapiens.
XX
XX EP1225232-A2.
XX
XX 24-JUL-2002.
XX
XX 17-JAN-2002; 2002EP-00001232.
XX

```


XX 17-JAN-2001; 2001US-0262284P.
 XX (RUBI/) RUBIN B Y.
 PA (ANDE/) ANDERSON S L.
 XX
 PI Rubin BY, Anderson SL;
 XX WPI; 2002-601228/65.
 XX
 PT Detecting a polymorphism in a gene encoding the IkappaB kinase-complex-associated protein is used to diagnose and identify carriers of familial dysautonomia.
 PT
 PS Claim 7; Page 9; 16pp; English.
 XX
 CC The invention provides a method for detecting a polymorphism linked to a gene associated with familial dysautonomia (FD). This involves detecting a disruptive mutation in a gene encoding the IkappaB kinase-complex-associated protein (IKAP) on chromosome 9q31. Sequence analysis of the IKAP-encoding gene showed, in chromosomes with the major FD haplotype, a T to C transition in position 6 of the donor splice site of intron 20.
 CC This mutation (2507+6T to C) results in the generation of an IKAP mRNA in which exon 20 is spliced out along with intron 20. Sequence analysis of the IKAP gene of individuals heterozygous for the FD chromosome with the most common minor haplotype (minor 2) showed a G to C transversion of nucleotide 2390 in exon 19 of the reported IKAP cDNA, resulting in an Arg696Pro amino acid substitution and disruption of a consensus Ser/Thr kinase phosphorylation site. The present sequence is a primer that can be used in a claimed method for detecting a disruptive mutation in the IKAP gene, using single-strand conformational polymorphism (SSCP) analysis. The primer was used in the genotype analysis of FD alleles. Use with the primer given in ABN84785 yielded a 244 bp fragment. In a family with probands homozygous for the major haplotype, all affected individuals were homoallelic for 2507+6C to C and all the parents were heterozygous. In families with probands heterozygous for the major and minor 2 FD haplotypes, 1 parent and the proband were heterozygous for R696P and the other parent and the proband were heterozygous for 2507+6T to C. Analysis of 31 probands homozygous for the major FD haplotype showed that 100% of the probands were homozygous for 2507+6T to C, 100% of the parents were heterozygous for this mutation, and 4 siblings of the probands had FD and were homozygous for the FD haplotype and the 2507+6T to C mutation. Study of a random group of 619 individuals of Ashkenazi Jewish descent revealed the presence of 25 carriers of 2507+6T to C and 2 individuals with R696P. The method is useful for FD diagnosis and for identifying carriers of the condition
 XX
 SQ Sequence 19 BP; 8 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 2.0%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 4.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 348 AGAGCAACAGATTCTGC 365
 DB 2 AGAACCAACAGATTCTGC 19
 RESULT 698
 ID ABL31191
 XX ABL31391 standard; DNA; 19 BP.
 AC ABL31391;
 XX
 DT 21-MAR-2002 (first entry)
 DE Human HLA genotyping oligonucleotide SEQ ID NO 880.
 XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 XX Homo sapiens.
 OS
 XX

PN WO200192572-A1.
 XX
 PD 06-DEC-2001.
 XX
 PF 01-JUN-2001; 2001WO-JP004662.
 XX
 PR 01-JUN-2000; 2000JP-00164798.
 XX
 PA (NISN) NISSHINBO IND INC.
 XX (SYST-) SYSTEM RES INC.
 PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX
 PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of individuals e.g. by determining immunogenetic differences when transplanting between them.
 PT
 PS Claim 10; Page 260; 345pp; Japanese.
 XX
 CC The invention relates to a typing kit for judging human leukocyte antigen (HLA) genotype of a sample by hybridising a substrate on which 10-24 base oligonucleotides (ABU30512-ABU31809) originating in the sequences of genes e.g. belonging to HLA class I antigens on human genome and containing gene polymorphisms as alloantigens have been immobilised as primers for amplification of cleaved nucleic acids relating to gene polymorphisms. The method is useful for judging HLA genotypes of individuals by determining immunogenetic differences before transplanting between them, providing genetic information to decide compatibility of organ and tissue for transplantation e.g. of bone marrow, kidney, liver, pancreas, Langerhans islet in pancreas and cornea, susceptibility diagnosis of genetic diseases and identifying individuals
 XX
 SQ Sequence 19 BP; 5 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 2.0%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 4.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 310 CCTGGAGGAGGATCAAGA 327
 DB 1 CCTGGAGGAGGATCGGA 18
 RESULT 699
 ID ADF36747 standard; RNA; 19 BP.
 XX
 AC ADF36747;
 XX
 DT 12-FEB-2004 (first entry)
 DE Human VEGFR2 short interfering nucleic acid (siNA) SEQ ID NO:1036.
 XX
 KW double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cytostatic; antidiabetic; ophthalmological; anarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO2003070910-A2.
 XX
 PD 28-AUG-2003.
 XX
 XX 20-FEB-2003; 2003WO-US005022.
 XX

PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-0409293P.
PR 27-NOV-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.
PA Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 1036; 207pp; English.
XX
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 19 BP; 8 A; 2 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 4.8e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 811 GGAGGAGAGAGGAGCT 828
Db 1 GUAGAAGAGAGGAGCT 18
RESULT 700
ADF37071/c
ID ADF37071 standard; RNA; 19 BP.
XX ADF37071;
AC ADF37071;
XX 12-FEB-2004 (first entry)
XX Human VEGFR2 short interfering nucleic acid (siNA) SEQ ID NO:1360.
XX double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytosolic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.

XX Synthetic.
OS Homo sapiens.
XX WO2003070910-A2.
XX 28-AUG-2003.
XX 20-FEB-2003; 2003WO-US005022.
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-0409293P.
PR 27-NOV-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.
PA Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 1360; 207pp; English.
XX
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 19 BP; 2 A; 7 C; 2 G; 0 T; 8 U; 0 Other;
Query Match 2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 811 GGAGGAGAGAGGAGCT 828
Db 19 GTAGAAGAGAGGAGCT 2
RESULT 701
ADN75388/c
ID ADN75388 standard; RNA; 19 BP.
XX ADN75388;
AC ADN75388;
XX 01-JUL-2004 (first entry)
DT 01-JUL-2004 (first entry)
XX

DE Human CD45 CR region siRNA oligonucleotide SEQ ID 213.
 XX small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
 KW cytosolic; immunomodulator; antimicrobial; antiinflammatory;
 KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
 KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004016735-A2.
 XX
 PD 26-FEB-2004.
 XX
 XX 23-MAY-2003; 2003WO-US016632.
 XX
 XX 23-MAY-2002; 2002US-0383249P.
 PR
 PR 14-APR-2003; 2003US-0462942P.
 XX
 XX (CEPT-) CEPTYR INC.
 PA (COLD-) COLD SPRING HARBOR LAB.
 XX
 PI Klinghoffer R, Lewis SP, Tonks NK, Meng T;
 XX
 XX WPI; 2004-203773/19.
 XX
 XX New isolated small interfering RNA (siRNA) polynucleotide useful for
 PT treating diseases with aberrant activity of the protein tyrosine
 PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
 PT diabetes and obesity.
 XX
 PS Example 2; SEQ ID NO 213; 392pp; English.
 XX
 CC This invention describes novel small interfering RNA (siRNA)
 CC polynucleotides capable of interfering with expression of a polypeptide
 CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
 CC invention have cytostatic, immunomodulator, antimicrobial,
 CC antiinflammatory, antidiabetic and anorectic activity. The methods and
 CC compositions of the present invention are useful for treating diseases or
 CC conditions associated with aberrant expression or activity of the protein
 CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
 CC inflammation, diabetes and obesity. This sequence represents a siRNA
 CC directed against dual specificity phosphatase (DSP) expression.
 XX
 SQ Sequence 19 BP; 4 A; 6 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 2.0%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 4.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 215 GATCAGGACGTACTGGGC 232
 Db 19 GATCAAGATGTTACTGGGC 2
 RESULT 702
 AD75637/C
 ID AD75637 standard; DNA; 19 BP.
 XX
 AC AD75637;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX
 DE Human apolipoprotein B (ApoB) oligonucleotide seqid 122.
 XX
 KW antilipemic; cardiatic; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytosolic; anticonvulsant; nootropic; muscular; anti-HIV;
 KW RNA interference; siRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.

XX
 OS Homo sapiens.
 XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 XX 08-MAR-2004; 2004WO-US007070.
 XX
 XX 07-MAR-2003; 2003US-0452682P.
 PR
 PR 12-MAR-2003; 2003US-0454265P.
 PR
 PR 13-MAR-2003; 2003US-0454962P.
 PR
 PR 13-MAR-2003; 2003US-0455050P.
 PR
 PR 14-APR-2003; 2003US-0462894P.
 PR
 PR 17-APR-2003; 2003US-0463772P.
 PR
 PR 25-APR-2003; 2003US-0465665P.
 PR
 PR 25-APR-2003; 2003US-0465802P.
 PR
 PR 09-MAY-2003; 2003US-0469612P.
 PR
 PR 08-AUG-2003; 2003US-0493986P.
 PR
 PR 11-AUG-2003; 2003US-0494597P.
 PR
 PR 26-SEP-2003; 2003US-0506341P.
 PR
 PR 09-OCT-2003; 2003US-0510246P.
 PR
 PR 10-OCT-2003; 2003US-0510318P.
 PR
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 XX (ALNY-) ALNYLAM PHARM.
 PA
 PA Manoharan M, Bumcrot D;
 XX
 PI WPI; 2004-677362/66.
 DR
 XX
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX
 PS Example 5; SEQ ID NO 122; 378pp; English.
 XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.
 XX
 SQ Sequence 19 BP; 0 A; 7 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 2.0%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 4.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 718 GCTGCAGCAGCAGCAG 735

Db 18 GCAGCAGCAGCAGCGCAG 1
 RESULT 703
 ADR78255/c
 ID ADR78255 standard; DNA; 19 BP.
 AC ADR78255;
 XX
 XX 16-DEC-2004 (first entry)
 XX Human apolipoprotein B (ApoB) oligonucleotide seqid 2740.
 XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytosclastic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
 XX Homo sapiens.
 XX WO2004080406-A2.
 XX 23-SEP-2004.
 XX 08-MAR-2004; 2004WO-US007070.
 XX 07-MAR-2003; 2003US-0452682P.
 XX 12-MAR-2003; 2003US-0454285P.
 XX 13-MAR-2003; 2003US-0454962P.
 XX 13-MAR-2003; 2003US-0455050P.
 XX 14-APR-2003; 2003US-0462894P.
 XX 17-APR-2003; 2003US-0463772P.
 XX 25-APR-2003; 2003US-0465665P.
 XX 25-APR-2003; 2003US-0465802P.
 XX 09-MAY-2003; 2003US-0469612P.
 XX 08-AUG-2003; 2003US-0493986P.
 XX 11-AUG-2003; 2003US-0494597P.
 XX 26-SEP-2003; 2003US-0506341P.
 XX 09-OCT-2003; 2003US-0510246P.
 XX 10-OCT-2003; 2003US-0510318P.
 XX 07-NOV-2003; 2003US-0518453P.
 XX (ALNY-) ALNYLAM PHARM.
 XX Manoharan M, Bumcrot D;
 XX WPI; 2004-677362/66.
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX Example 5; SEQ ID NO 2740; 378pp; English.
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (MI) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (MI)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.
 XX
 SQ Sequence 19 BP; 0 A; 7 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 2.0%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 4.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 718 GCTGCAGCAGCAGCAGCAG 735
 Db 18 GCAGCAGCAGCAGCGCAG 1
 RESULT 704
 ADR78255
 ID ADR78255 standard; DNA; 17 BP.
 AC ADR78255;
 XX
 XX 29-MAY-2002 (first entry)
 XX Human GDMPL-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7449.
 DE Human; genome-derived myosin-like protein 1; GDMPL-1; hGDMPL-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 KW Homo sapiens.
 OS WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 XX 21-SEP-2000; 2000US-0234687P.
 XX 27-SEP-2000; 2000US-0236359P.
 XX 04-OCT-2000; 2000GB-00024263.
 XX 30-JAN-2001; 2001WO-US000661.
 XX 30-JAN-2001; 2001WO-US000662.
 XX 30-JAN-2001; 2001WO-US000663.
 XX 30-JAN-2001; 2001WO-US000664.
 XX 30-JAN-2001; 2001WO-US000665.
 XX 30-JAN-2001; 2001WO-US000666.
 XX 30-JAN-2001; 2001WO-US000667.
 XX 30-JAN-2001; 2001WO-US000668.
 XX 30-JAN-2001; 2001WO-US000669.
 XX 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPL-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser

PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 7449; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 412 GGAGAGGAGTTCCTC 427
 Db 2 GGAGAACGAGTTCCTC 17
 RESULT 705
 ABN07459
 ID ABN07459 standard; DNA; 17 BP.
 XX AC ABN07459;
 XX
 DT 29-MAY-2002 (first entry)
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7451.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 OS
 XX WO200192524-A2.
 PN
 XX 06-DEC-2001.
 PD
 XX 25-MAY-2001; 2001WO-US016981.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
 XX WPI; 2002-179446/23.
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 7451; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 413 GAGAGGAGTTCCTCA 428
 Db 1 GAGAACGAGTTCCTCA 16
 RESULT 706
 ABN07255
 ID ABN07255 standard; DNA; 17 BP.
 XX AC ABN07255;
 XX
 DT 29-MAY-2002 (first entry)
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7247.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 OS Homo sapiens.
 XX WO200192524-A2.
 PN
 XX 06-DEC-2001.
 PD
 XX 25-MAY-2001; 2001WO-US016981.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.

PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 7247; 214pp; English.
 PS
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 3 A; 3 C; 9 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 698 CTGAGAGTGCAGCGG 713
 Db 1 CTGAGAGTGCAGCGG 16
 RESULT 707
 ID ABN08979/c
 ID ABN08979 standard; DNA; 17 BP.
 XX
 AC ABN08979;
 XX
 XX 29-MAY-2002 (first entry)
 DT
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8971.
 DE
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.
 OS
 XX WO200192524-A2.
 PN
 XX
 XX 06-DEC-2001.
 PD
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 PF
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR
 XX 21-SEP-2000; 2000US-0234687P.
 PR
 XX 27-SEP-2000; 2000US-0236359P.
 PR
 XX 04-OCT-2000; 2000GB-00024263.
 PR
 XX 30-JAN-2001; 2001WO-US000661.
 PR
 XX 30-JAN-2001; 2001WO-US000662.
 PR
 XX 30-JAN-2001; 2001WO-US000663.
 PR
 XX 30-JAN-2001; 2001WO-US000664.
 PR
 XX 30-JAN-2001; 2001WO-US000665.
 PR
 XX 30-JAN-2001; 2001WO-US000666.
 PR
 XX 30-JAN-2001; 2001WO-US000667.
 PR
 XX 30-JAN-2001; 2001WO-US000668.
 PR
 XX 30-JAN-2001; 2001WO-US000669.
 PR
 XX 30-JAN-2001; 2001WO-US000670.
 PR
 XX 05-FEB-2001; 2001US-0266860P.
 PR
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 8971; 214pp; English.
 PS
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 851 CACGAGCTCTTCCAG 866
 Db 16 CACGAGCTCTTCCATG 1
 RESULT 708
 ABN08978/c

ID ABN08978 standard; DNA; 17 BP.
 AC ABN08978;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8970.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
 XX
 DR WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 PS Disclosure; SEQ ID NO 8970; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

*Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 851 CACCAGCTCTTCCAAG 866
 DB 17 CACCAGCTCTTCCATG 2
 RESULT 709
 ACD59504/C
 ID ACD59504 standard; RNA; 17 BP.
 XX
 AC ACD59504;
 XX
 DT 24-SEP-2003 (first entry)
 XX
 DE HCV DNAzyme substrate sequence #1362.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
 KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY J.
 PA (PAVC/) PAVCO P.
 PA (LEEF/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey J, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX
 DR WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 PS Claim 1; Page 258; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening

CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 4.7e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 594 TGCTCGGGGAGCTGCA 609

DB 16 TGCTCGGGGAGCTGCA 1

RESULT 710

ACN70345

ID ACN70345 standard; DNA; 17 BP.

XX AC ACN70345;

XX AC ACN70345;

DT 02-DEC-2004 (first entry)

XX Human GDMPL-1 probe SEQ ID NO:7247.

XX Human; ss; probe; myosin-like protein-1; hGDMPL-1;

KW hGDMPL-1 agonist hGDMPL antagonist; hGDMPL inhibitor; heart disorder;

KW skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 05-FEB-2001; 2001WO-US000670.

XX 25-MAY-2001; 2001US-0266860P.

XX 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.

XX (JIY/) JI Y.

XX (PENN/) PENN S G.

XX (HANZ/) HANZEL D K.

XX (RANK/) RANK D.

XX (CHEN/) CHEN W.

XX (SHAN/) SHANNON M E.

PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.

XX Disclosure; SEQ ID NO 7247; Opp; English.

CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPL-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPL-1, or as an inhibitor of hGDMPL-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPL-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103

XX SQ Sequence 17 BP; 3 A; 3 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 4.7e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 698 CTGGAGAGTGAGCGG 713

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

DB 1 CTGGAGAGTGAGCGG 16

PA (SHAN/) SHANNON M E.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI: 2004-533378/51.
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX Disclosure; SEQ ID NO 7449; Opp; English.
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 412 GGAGAGAGGAGTTCCTC 427
 Db 2 GGAGACGAGTTCCTC 17
 RESULT 712
 ACN72068/C
 ID ACN72068 standard; DNA; 17 BP.
 XX ACN72068;
 XX 02-DEC-2004 (first entry)
 DE Human GDMPLP-1 probe SEQ ID NO:8970.
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX Homo sapiens.
 OS US2004137589-A1.
 PN 15-JUL-2004.
 PD 26-NOV-2003; 2003US-00723361.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.

PR 25-MAY-2001; 2001US-00866108.
 XX (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI: 2004-533378/51.
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX Disclosure; SEQ ID NO 8970; Opp; English.
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 851 CACCAGCTCTTCCAG 866
 Db 17 CACCAGCTCTTCCATG 2
 RESULT 713
 ACN70549
 ID ACN70549 standard; DNA; 17 BP.
 XX ACN70549;
 XX 02-DEC-2004 (first entry)
 DE Human GDMPLP-1 probe SEQ ID NO:7451.
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX Homo sapiens.
 OS US2004137589-A1.
 PN 15-JUL-2004.
 PD 26-NOV-2003; 2003US-00723361.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.

```

PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 7451; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 4.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 413 GAGAGGAGTCTCTCA 428
DB 1 GAGACGAGTCTCTCA 16
RESULT 714
ACN72069/C
ID ACN72069 standard; DNA; 17 BP.
XX
AC ACN72069;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMLP-1 probe SEQ ID NO:8971.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
XX US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000SB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 8971; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 4.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 851 CACCAGCTCTTCAAG 866
DB 16 CACCAGCTCTTCAATG 1
RESULT 715
AAAX67194/C
ID AAX67194 standard; RNA; 18 BP.
XX
AC AAX67194;
XX
DT 20-JUL-1999 (first entry)
XX
DE Human CD40 hairpin ribozyme target SEQ ID NO:3826.
XX
KW Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;

```

KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX Homo sapiens.
 XX WO9618736-A2.
 XX 20-JUN-1996.
 XX 22-NOV-1995; 95WO-US015516.
 XX 13-DEC-1994; 94US-00354920.
 PR 23-DEC-1994; 94US-00363253.
 PR 23-DEC-1994; 94US-00363254.
 PR 17-FEB-1995; 95US-00390850.
 PR 20-APR-1995; 95US-00426124.
 PR 02-MAY-1995; 95US-00432874.
 PR 04-MAY-1995; 95US-00434509.
 PR 07-JUL-1995; 95US-0000951P.
 PR 07-JUL-1995; 95US-0000974P.
 PR 07-AUG-1995; 95US-00512861.
 PR 05-OCT-1995; 95US-00541365.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
 PI McSwiggan J, Gustofson J, Usman N, Wincott P, Matulic-Adamic J;
 PI Karpeisky A, Thompson JD, Modak A, Burgin A;
 XX WPI; 1996-300653/30.
 XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 XX Claim 10; Page 218; 307pp; English.
 XX The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 XX Sequence 18 BP; 1 A; 4 C; 8 G; 0 T; 5 U; 0 Other;
 SQ Query Match 1.9%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 717 CGCTGCAGCAGCAGCA 732
 DB 16 CCCTGCAGCAGCAGCA 1
 RESULT 716
 AAZ76614/c
 ID AAZ76614 standard; DNA; 18 BP.
 XX AAZ76614;
 AC AAZ76614;
 KW

DT 10-SEP-2001 (first entry)
 XX Human biallelic marker downstream amplification primer SEQ ID NO:10970.
 XX Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX Homo sapiens.
 XX WO9954500-A2.
 XX 28-OCT-1999.
 XX 21-APR-1999; 99WO-IB000822.
 XX 21-APR-1999; 98US-0082614P.
 PR 23-NOV-1998; 98US-0109732P.
 XX (GEST) GENSET.
 XX Cohen D, Blumenfeld M, Chumakov I;
 PI WPI; 2000-013267/01.
 XX Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome.
 XX Claim 9; Page 2569; 2745pp; English.
 XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the invention
 CC have a variety of uses: they can be used for high density mapping of the
 CC human genome, and in complex association studies and haplotyping studies
 CC which are useful in determining the genetic basis for disease states.
 CC Compositions and methods of the invention can also be useful for the
 CC identification of the targets for the development of pharmaceutical
 CC agents and diagnostic methods, as well as the characterisation of the
 CC differential efficacious responses to and side effects from
 CC pharmaceutical agents acting on a disease as well as other treatment.
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention
 XX Sequence 18 BP; 1 A; 9 C; 0 G; 8 T; 0 U; 0 Other;
 SQ Query Match 1.9%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 811 GGAGGAGAGAGGAGAG 826
 DB 17 GGAGGAGAGAGATGAAG 2
 RESULT 717
 AAH75205/c
 ID AAH75205 standard; DNA; 18 BP.
 XX AAH75205;
 AC AAH75205;
 XX 02-OCT-2001 (first entry)
 XX Human inducible NOS antisense oligonucleotide SEQ ID NO 49.
 DE Antisense oligonucleotide; inducible nitric oxide synthase; NOS;
 KW modulate expression; immunomodulator; antidiabetic; cardiovascular;
 KW cardiant; neuroprotective; vasotropic; ischaemia; reperfusion injury;
 KW 2'-O-methoxyethyl; phosphorothioate; human; ss.

XX OS Homo sapiens.

XX PH Key Location/Qualifiers

FT modified_base 1..18

FT /*tag= a

FT /mod_base= OTHER

FT /note= "phosphorothioate backbone, 5' and 3' four

FT nucleotide 2'-MOE (2'-O-methoxyethyl) wings (the cytidine

FT residues in the 2'-MOE wings are 5-methylcytidines) and a

FT deoxy gap"

XX PN W0200152902-A1.

XX XX

XX PD 26-JUL-2001.

XX XX

XX PF 15-JAN-2001; 2001WO-US001381.

XX XX

XX PR 24-JAN-2000; 2000US-00490208.

XX XX

XX PA (ISIS-) ISIS PHARM INC.

XX XX

XX PI Bennett CF, Dean NM, Cowser LM;

XX XX

XX DR WPI; 2001-465340/50.

XX XX

XX PT New antisense oligonucleotides for modulating the expression of inducible

XX nitric oxide synthase in cells or tissues, particularly useful for

XX treating e.g. immunological, cardiovascular or neurological disorders, or

XX ischemia.

XX PS Claim 3; Page 84; 144pp; English.

XX XX

XX CC The invention relates to antisense compounds, especially

XX oligonucleotides, which are targeted to a nucleic acid encoding inducible

XX nitric oxide synthase and which specifically hybridize to and modulate

XX expression of inducible nitric oxide synthase. The antisense compounds

XX have immunomodulator, antidiabetic, cardiovascular, cardiac,

XX neuroprotective, disorder and vasotropic activity. The antisense

XX oligonucleotides are useful for inhibiting the expression of inducible

XX nitric oxide synthase in cells or tissues. In particular, the antisense

XX oligonucleotides are useful for treating diseases or disorders associated

XX with inducible nitric oxide synthase, e.g. diabetes, immunological

XX disorder, cardiovascular disorder, neurological disorder or

XX ischemia/reperfusion injury. The antisense oligonucleotides are also

XX useful for research and diagnostics. The present sequence is that of an

XX antisense 2'-O-methoxyethyl gapmer oligonucleotide with a

XX phosphorothioate backbone, a central "gap" region of ten nucleotides

XX flanked by four nucleotide 2'-MOE (2'-methoxyethyl) wings (cytidine

XX residues in the 2'-MOE wings are 5-methylcytidines) and targeted to human

XX inducible nitric oxide synthase (NOS) mRNA (AAH47959)

XX XX

XX SQ Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 5e+02; Mismatches 0; Gaps 0;

Matches 15; Conservative 0; Indels 1; Indels 0; Gaps 0;

QY 306 GCTGCTGGAGGAGAA 321

Db 17 GCTGCTGGAGGAGGA 2

|||||

|||||

RESULT 718

AAL55767/C

ID AAL55767 standard; DNA; 18 BP.

XX AC AAL55767;

XX XX

XX DT 17-SEP-2003 (first entry)

XX XX

XX DE Fluorogenic probe used to isolate human Her2 RNA.

XX XX

KW Biological array; frozen; breast cancer; Her2; ErbB2; VEGF; human;

KW microarray; ss; vascular endothelial growth factor; probe.

XX OS Homo sapiens.

XX OS Synthetic.

XX PH Key Location/Qualifiers

FT modified_base 1

FT /*tag= a

FT /mod_base= FAM tag

FT /note= "FAM = 6-carboxyfluorescein"

FT modified_base 18

FT /*tag= b

FT /mod_base= TAMRA tag

FT /note= "TAMRA = 6-carboxytetramethylrhodamine"

XX PN W02003044213-A2.

XX XX

XX PD 30-MAY-2003.

XX XX

XX PF 20-NOV-2002; 2002WO-US037054.

XX XX

XX PR 20-NOV-2001; 2001US-0332293P.

XX PR 21-NOV-2001; 2001US-0332635P.

XX PR 07-FEB-2002; 2002US-0355205P.

XX PR 22-FEB-2002; 2002US-0359563P.

XX PR 17-JUN-2002; 2002US-0389610P.

XX PR 02-JUL-2002; 2002US-0393551P.

XX XX

XX PA (GETH) GENENTECH INC.

XX XX

XX PI Frantz G, Landon T, Peale FV, Pham TQ, Stephan JF, Dunlap DY;

XX PI Hillan KJ;

XX DR WPI; 2003-513598/48.

XX XX

XX PT Biological array for analyzing biological molecules, has frozen matrix

XX formed from a temperature-sensitive material with several wells in it,

XX and biological samples and internal standard preparations contained in

XX the wells.

XX PS Example 4; Page 45; 111pp; English.

XX XX

XX CC The invention relates to a novel biological array or microarray

XX comprising a frozen matrix formed of a temperature-sensitive material

XX which has a number of wells disposed in it. One or more biological

XX samples may be disposed within the wells and retained by the frozen

XX matrix surrounding the wells. Optionally, one or more internal standard

XX preparations may be contained within one or more of the wells. The

XX biological array of the invention may be useful for the detection of a

XX biological molecule i.e. a polynucleotide or a polypeptide, such as a

XX soluble receptor or extracellular domain (ECD) of a receptor. Such

XX including normal, diseased or treated cells or tissues of blood, muscle

XX or breast. The biological array may be useful during detection of disease

XX within a biological sample, for example, breast cancer may be detected

XX via the identification of Her2 (ErbB2) or VEGF (vascular endothelial

XX growth factor) overexpression within a sample. Furthermore, the method of

XX array construction disclosed herein eliminates the need for a barrier

XX material between an array matrix and a biological sample and also the

XX need to chemically process a sample before use. This allows the integrity

XX of array samples to be maintained and makes the process of constructing a

XX biological array more cost effective and less time consuming. The current

XX sequence is that of the fluorogenic probe of the invention which was used

XX to isolate the human Her2 RNA

XX SQ Sequence 18 BP; 1 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 5e+02; Mismatches 1; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 207 CGGCAGCAGATCAGGA 222


```

FH Key          Location/Qualifiers
FT misc_feature 12..14
FT FT           /*tag= a
FT FT           /note= "codon complementary to HPV E2 translation
FT FT           initiation codon"
XX WO9528942-A1.
XX PD 02-NOV-1995.
XX PF 25-APR-1995; 95WO-US0005179.
XX PR 26-APR-1994; 94US-002333778.
XX PR 04-MAY-1994; 94US-002381777.
XX PR 16-NOV-1994; 94WO-US013387.
XX PR 03-DEC-1994; 94US-00350431.
XX PA (GENT-) GENTA INC.
XX PI Giachetti C, Marich JE, Jaeger JA;
XX WI; 1995-382836/49.
XX New anti-sense oligomers for inhibiting human papilloma:virus - having
PT sequence complementary to target region of mRNA or pre-mRNA coding for
PT E1, E2, E6 or E7.
XX Example S; Page 94; 130pp; English.
XX The present oligonucleotide is an antisense oligomer complementary to the
CC area near the human papilloma virus (HPV)-11 E2 mRNA translation
CC initiation codon (N2705-N2749), designed to interfere with, and/or
CC prevent the expression of a HPV E2 mRNA. The CAT inhibition of this
CC protein is 0%, and therefore it is not effective in the treatment and/or
CC diagnosis of HPV infections
XX SQ Sequence 19 BP; 1 A; 9 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 1.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 494 AGCGAAGGAGCAGG 509
DB 16 AGGTAGAAGGAGCAGG 1
RESULT 722
AA01486
ID AAX01486 standard; DNA; 19 BP.
XX AC AAX01486;
XX DT 28-APR-1999 (first entry)
XX DE Primer STS sY240 right primer used to isolate DAZ gene.
XX DAZ gene; interval 6D; Y chromosome; reduced sperm count; oligospermia;
XX azoospermia; gene therapy; fertility disorder; spermatogenesis;
XX PCR primer; sequence tagged site; STS; ss.
XX Synthetic.
XX OS Homo sapiens.
XX PN US5871920-A.
XX PD 16-FEB-1999.
XX PF 31-JUL-1996; 96US-00690734.
XX PR 22-SEP-1994; 94US-00310429.
XX PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.

```

```

XX ReiJo R, Page DC;
XX WPI; 1999-166623/14.
XX DAZ genes associated with reduced sperm counts - useful for diagnosing
PT and treating azoospermia or oligospermia.
XX Example; Col 9-10; 25pp; English.
XX This sequence is a PCR primer for a sequence tagged site (STS) present on
CC the Y chromosome. This primer was used to isolate the DAZ gene of the
CC invention, which is part of the DAZ family of genes, and was isolated
CC from interval 6D and/or 6E of the distal portion of the long arm of the Y
CC chromosome. Alteration of the DAZ gene (A) is known to be associated with
CC reduced sperm counts. Hence, the invention may be used to diagnostically
CC identify males with a condition that results in a reduced sperm count
CC such as oligospermia or azoospermia (i.e. where sperm count= 0 to 20
CC million semen per ml), in whom the gene (A) has been altered. It may also
CC be used therapeutically in gene therapy treatments to remedy fertility
CC disorders associated with the alteration or deletion of (A).
CC Additionally, (A) may be useful in designing or identifying agents which
CC may function as a male contraceptive by inducing reduced sperm count. It
CC also has an application as a research tool, as the DNA has been localised
CC to interval 6E of the distal portion of the long arm of the human Y
CC chromosome, it can, therefore, function as a marker for that interval.
CC Little is known about the causes of reduced spermatogenesis, especially
CC among the 10% of men who visit fertility clinics and are diagnosed as
CC having oligospermia (or azoospermia) of unknown origin. Although various
CC diagnostic tests and treatments are currently available, improved methods
CC are still needed. The invention provides new diagnostic methods and
CC treatments for oligospermia resulting from alteration or deletion of (A)
XX SQ Sequence 19 BP; 4 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 1.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 526 GCACCTGAAGAGATGC 541
DB 1 GCACCTGAAGAGATGC 16
RESULT 723
AAZ92545
ID AAZ92545 standard; DNA; 19 BP.
XX AC AAZ92545;
XX DT 05-JUN-2000 (first entry)
XX DE Human Y-specific STS PCR primer, SEQ ID NO:61.
XX DAZ gene; chromosome Y; male infertility; sperm count; diagnosis;
XX sequence-tagged site; STS; treatment; gene therapy; PCR primer; ss.
XX OS Homo sapiens.
XX PN US6020476-A.
XX PD 01-FEB-2000.
XX PF 30-OCT-1996; 96US-00742185.
XX PR 22-SEP-1994; 94US-00310429.
XX PR 31-JUL-1996; 96US-00690734.
XX PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX PI Hawkins T, Reeve MP, Saxena R, Page DC, ReiJo R;
XX WPI; 2000-181393/16.

```

XX New nucleic acid, useful for diagnosis and treatment of reduced sperm
PT count, is derived from the human DAZ or DAZH genes.
XX
XX Claim 12; Col 17-18; 110pp; English.
XX
XX The invention relates to a family of human genes referred to as the DAZ
CC gene family, and to a functional DAZ homologue, DAZH. Members of the DAZ
CC gene family are clustered in the same region of the Y chromosome. In
CC particular, the invention relates to an isolated DAZ gene (AAZ929499)
CC present in interval 6D and/or 8S of the distal portion of Yq, mutations
CC in which are associated with reduced sperm count. The DAZH gene
CC (AAZ92580) is located on chromosome 3; however, the entire DAZ gene
CC family, including DAZH is expressed in germ cells. DAZ and DAZH
CC nucleotide sequences may be used as a source of primers and probes for
CC the diagnosis of cases of reduced sperm count associated with alteration
CC or deletion of the DAZ gene. They are also used as human chromosome Y
CC markers. Functional DAZ genes can be used in gene therapy for treating
CC reduced sperm counts. Sequences AAZ92502-292573 represent PCR primers
CC used in the exemplifications of the invention to test for Y-specific STSs
CC (sequence tagged sites)
XX
XX Sequence 19 BP; 4 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 526 GCACCTGAAGAGTGC 541
DB 1 GCACCTGAAGAGTGC 16
RESULT 724
AAT35047
ID AAT35047 standard; DNA; 15 BP.
XX
XX AAT35047;
AC
XX
XX 18-FEB-1997 (first entry)
DT
XX
XX HPV ORF-Ec target for triplex-forming oligo.
DE
XX
XX HBV; oligodeoxyribonucleotide; homopurine-homopyrimidine target; block;
KW in vitro; DNA synthesis; DNA polymerase; Sequenase3; Taq; Vent; Pol I;
KW accessory replication protein; SSB protein; sequence-specific;
KW triplex-forming oligonucleotide; exon 3; inverted repeat; IR110;
KW hepatitis B virus; P gene; ss.
XX
XX Synthetic.
XX
XX WO9618732-A2.
PN
XX
XX 20-JUN-1996.
PD
XX
XX 14-DEC-1995; 95WO-US016368.
PF
XX
XX 15-DEC-1994; 94US-00358089.
PR
XX
XX (UNII) UNIV ILLINOIS FOUND.
PA
XX
XX Mirkin SM, Samadashwily GM;
PI
XX
XX WPI; 1996-300649/30.
DR
XX
XX Sequence specific inhibition of DNA synthesis - by triplex-forming
PT oligonucleotide(s), for detection of oncogene mutation(s) and treatment
PT of e.g. HSV, Hepatitis C and Papillomavirus infection.
XX
XX Example 4; Page 42; 78pp; English.
XX
XX Specifically designed oligodeoxyribonucleotides form triplexes in single-
CC or double-strand DNA at homopurine-homopyrimidine targets. These

CC triplexes block in vitro DNA synthesis by all DNA polymerases studied,
CC including Sequenase3, Taq, Vent, and Pol I. A similar phenomenon occurs
CC when DNA polymerases are supplemented with accessory replication
CC proteins, including SSB protein. Replication blockage is highly sequence-
CC specific and even one or two point substitutions within either the target
CC sequence or the oligonucleotide abolish the effect. Sequence-specific
CC blocking of DNA replication in vivo is facilitated by the methods and
CC compositions of the present invention. The present sequence is the ORF-Ec
CC human papilloma virus (HPV) target (position 436-452 in HPV57 and 438-452
CC in HPV2) for triplex-forming oligonucleotides AAT35030-31
XX
XX Sequence 15 BP; 5 A; 0 C; 10 G; 0 T; 0 U; 0 Other;
SQ
Query Match 1.9%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 408 GCGAGGAGAGGAG 421
DB 1 GCGAGGAGAGGAG 14
RESULT 725
ABN08981/C
ID ABN08981 standard; DNA; 17 BP.
XX
XX AC ABN08981;
AC
XX
XX 29-MAY-2002 (first entry)
DT
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8973.
DE
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200192524-A2.
PN
XX
XX 06-DEC-2001.
PD
XX
XX 25-MAY-2001; 2001WO-US016981.
PF
XX
XX 26-MAY-2000; 2000US-0207456P.
PR
XX
XX 21-SEP-2000; 2000US-0234687P.
PR
XX
XX 27-SEP-2000; 2000US-0236359P.
PR
XX
XX 04-OCT-2000; 2000GB-00024263.
PR
XX
XX 30-JAN-2001; 2001WO-US000661.
PR
XX
XX 30-JAN-2001; 2001WO-US000662.
PR
XX
XX 30-JAN-2001; 2001WO-US000663.
PR
XX
XX 30-JAN-2001; 2001WO-US000664.
PR
XX
XX 30-JAN-2001; 2001WO-US000665.
PR
XX
XX 30-JAN-2001; 2001WO-US000666.
PR
XX
XX 30-JAN-2001; 2001WO-US000667.
PR
XX
XX 30-JAN-2001; 2001WO-US000668.
PR
XX
XX 30-JAN-2001; 2001WO-US000669.
PR
XX
XX 30-JAN-2001; 2001WO-US000670.
PR
XX
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
PA
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
PI
XX
XX WPI; 2002-179446/23.
DR
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 8973; 214pp; English.
PS
XX
XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 4 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 1.9%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACACGCTCTTCCA 864
 DB 14 CACACGCTCTTCCA 1

RESULT 726
 ABN07251
 ID ABN07251 standard; DNA; 17 BP.
 XX
 AC ABN07251;
 XX
 XX 29-MAY-2002 (first entry)
 DT
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7243.
 DE
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 XX Homo sapiens.

OS
 XX WO200192524-A2.
 PN
 XX 06-DEC-2001.
 PD
 XX 25-MAY-2001; 2001WO-US016981.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 XX (AEOM-) AEOMICA INC.

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 7243; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 3 A; 2 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 1.9%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGC 710
 DB 4 GCTGGAGAGTGAGC 17

RESULT 727
 ABN08980/c
 ID ABN08980 standard; DNA; 17 BP.
 XX
 AC ABN08980;

XX
 XX 29-MAY-2002 (first entry)
 DT
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8972.
 DE
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO200192524-A2.
 PN
 XX 06-DEC-2001.
 PD
 XX 25-MAY-2001; 2001WO-US016981.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.


```

PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 7243; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 3 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 697 GCTGGAGAGTGAGC 710
DB 4 GCTGGAGAGTGAGC 17
RESULT 730
ACN72070/C
ID ACN72070 standard; DNA; 17 BP.
XX
XX ACN72070;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMLP-1 probe SEQ ID NO:8972.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 8972; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 851 CACCAGCTCTTCCA 864
DB 15 CACCAGCTCTTCCA 2
RESULT 731
ACN72071/C
ID ACN72071 standard; DNA; 17 BP.
XX
XX ACN72071;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMLP-1 probe SEQ ID NO:8973.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX

```

```
PF 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 8973; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGMLP-1, or as an inhibitor of hGMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 4 A; 2 C; 8 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. NO. 5.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 851 CACCAGCTCTTCCA 864
DB 14 CACCAGCTCTTCCA 1
RESULT 732
ID AAA48792/c
XX AAA48792 standard; DNA; 18 BP.
XX
XX AAA48792;
AC
XX
XX 08-SEP-2000 (first entry)
DT
XX
XX Human G-alpha-16 antisense oligonucleotide ISIS# 20849.
DE
XX
XX Human; G-alpha-16; G protein; cytostatic; hyperproliferative disorder;
KW cancer; inflammation; infection; antisense inhibition; ss.
KW
```

```
XX Homo sapiens.
OS
XX WO200032817-A1.
PN
XX 08-JUN-2000.
PD
XX 25-AUG-1999; 99WO-US019613.
PF
XX 03-DEC-1998; 98US-00205143.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Cowser LM;
PI
XX WPI; 2000-412354/35.
DR
XX
XX A new antisense compound for inhibiting the expression of human G-alpha-
PT 16 and treating, preventing or delaying infections, inflammation or
PT hyperproliferative disorders such as cancer.
XX
XX Example 15; Page 73; 100pp; English.
PS
XX
XX The present sequence is an antisense oligonucleotide used to modulate
CC expression of G-alpha-16. G-alpha-16 is a human G protein which interacts
CC differentially with several receptor types including members of the
CC opiod and chemokine receptor families. A series of antisense
CC oligonucleotides have been designed to target different regions of the
CC human G-alpha-16 RNA. They may be used to inhibit the expression of G-
CC alpha-16 in human cells and tissues and thus to treat diseases associated
CC with G-alpha-16, such as hyperproliferative disorders, especially cancer.
CC Infections, inflammation or tumour formation can be prevented or delayed.
CC The compounds can be used in research and diagnostics in sandwich and
CC other assays. Note: The sequence has a phosphorothioate backbone and may
CC be either an oligodeoxynucleotide or a chimeric oligonucleotide
CC containing 2'-methoxyethyl (2'-MOE) wings and a deoxy gap. The ISIS
CC number given above corresponds to the oligodeoxynucleotide sequence
XX
XX Sequence 18 BP; 2 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
SQ
Query Match 1.9%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 308 TGCCTGGAGGAGAA 321
DB 14 TGCCTGGAGGAGAA 1
RESULT 733
AAT81047/c
ID AAT81047 standard; RNA; 17 BP.
XX
XX AAT81047;
AC
XX
XX 26-SEP-1997 (first entry)
DT
XX
XX Human c-myc hammerhead ribozyme target sequence (nt. position 31).
DE
XX
XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myc;
KW coronary angioplasty; ss.
XX
XX Homo sapiens.
OS
XX WO9531541-A2.
PN
XX
XX 23-NOV-1995.
PD
XX
XX 18-MAY-1995; 95WO-US006368.
PF
XX
XX 18-MAY-1994; 94US-00245466.
PR
XX 13-JAN-1995; 95US-00373124.
PR
```

XX (RIBO-) RIBOZYME PHARM INC.
 XX Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
 XX WPI; 1996-010927/01.
 XX New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myc,
 XX for treating restenosis or cancer.
 XX Claim 1; Page 64; 128pp; English.
 XX The present sequence represents the preferred target sequence for an
 XX enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 XX the human c-myc sequence at the base position indicated in the descriptor
 XX line. The c-myc sequence was screened for optimal ribozyme target sites
 XX using a computer folding algorithm, and regions of the mRNA which did not
 XX form secondary folding structures and contained potential ribozyme
 XX cleavage sites were identified. Ribozymes were synthesised and their
 XX activities optimised by either varying the length of the binding arms or
 XX by modification to prevent degradation by nucleases. The ribozymes cleave
 XX the c-myc sequence and can be used to prevent smooth muscle cell
 XX hyperproliferation in restenosis, especially after coronary angioplasty,
 XX and in cancers
 XX Sequence 17 BP; 0 A; 10 C; 0 G; 0 T; 7 U; 0 Other;
 XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
 XX Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 405 AGAGGGGAGGAGGAGG 421
 DB 17 AGGAGGGGAGGAGG 1
 RESULT 734
 AAX73242/c
 ID AAX73242 standard; RNA; 17 BP.
 XX AAX73242;
 XX 28-JUL-1999 (first entry)
 XX Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #675.
 XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 XX KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 XX fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 XX foetal liver kinase 1; ss.
 XX Mus sp.
 XX WO9715662-A2.
 XX 01-MAY-1997.
 XX 25-OCT-1996; 96WO-US017480.
 XX 26-OCT-1995; 95US-0005974P.
 XX 11-JAN-1996; 96US-00584040.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (CHIR) CHIRON CORP.
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 XX rheumatoid arthritis, etc., in a human patient.

XX Claim 4; Page 144; 218pp; English.
 XX The present invention describes nucleic acid molecules which modulate the
 XX synthesis, expression and/or stability of a mRNA encoding 1 or more
 XX receptors of vascular endothelial growth factor (VEGF). A patient
 XX (preferably human) having a condition associated with the level of the
 XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 XX angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 XX treated by administering the nucleic acid molecule or the expression
 XX vector to the patient. AAX67275 to AAX75752 represent specific examples
 XX of nucleic acid molecules from the present invention
 XX Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
 XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
 XX Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 457 GGTGGAGAGACTCGGCC 473
 DB 17 GGTAGACAGACTCGGCC 1
 RESULT 735
 AAF01997
 ID AAF01997 standard; DNA; 17 BP.
 XX AAF01997;
 XX 16-FEB-2001 (first entry)
 XX Hammerhead ribozyme substrate #292.
 XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 XX interferon alpha; ss.
 XX Homo sapiens.
 XX WO2000061729-A2.
 XX 19-OCT-2000.
 XX 11-APR-2000; 2000WO-US009721.
 XX 12-APR-1999; 99US-0129390P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX WPI; 2000-647423/62.
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 XX useful for producing e.g. granulocyte colony stimulating factor protein,
 XX interferon alpha and erythropoietin.
 XX Claim 37; Page 62; 164pp; English.
 XX The present invention relates to enzymatic and antisense nucleic acid
 XX molecules that act as inhibitors of the expression of repressor genes
 XX encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 XX factor gene, IRP-2 and/or the CAAT Displacement Protein (CDP).
 XX Inhibition of the repressors removes prevents inhibition (and
 XX consequently increases expression of) genes involved in the production of
 XX erythropoietin, granulocyte colony stimulating factor protein and
 XX interferon alpha
 XX Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
 XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
 XX Best Local Similarity 88.2%; Pred. No. 5.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 367 GGAGCGCTCGAGGAGC 383
 ||||| ||||| ||||| |||||
 Db 1 GGAGTCTTCGAGGAGC 17

RESULT 736
 AAF01998
 ID AAF01998 standard; DNA; 17 BP.
 XX
 AC AAF01998;
 XX
 DT 16-FEB-2001 (first entry)
 XX
 DE Hammerhead ribozyme substrate #293.
 XX
 KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200061729-A2.
 XX
 PD 19-OCT-2000.
 XX
 PF 11-APR-2000; 2000WO-US0009721.
 XX
 PR 12-APR-1999; 99US-0129390P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX
 DR WPI; 2000-647423/62.
 XX
 PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 XX
 PS Claim 37; Page 62; 164pp; English.
 XX
 CC The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 368 GAGCGCTCGAGGAGCT 384
 ||||| ||||| ||||| |||||
 Db 1 GAGTCTTCGAGGAGCT 17

RESULT 737
 ABA80609
 ID ABA80609 standard; DNA; 17 BP.
 XX
 AC ABA80609;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE APOE mutation correcting oligonucleotide SEQ ID NO: 3455.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;

KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US0009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kmiec EB, Gamper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 233; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase; p53; beta-globin, inhibitor 2A
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TCGGAGGAGCTTCTGCA 390
 ||||| ||||| ||||| |||||
 Db 1 TGCAGGCGCTTCTGCA 17

RESULT 738
 ABA80608/C
 ID ABA80608 standard; DNA; 17 BP.
 XX
 AC ABA80608;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE APOE mutation correcting oligonucleotide SEQ ID NO: 3454.
 XX

KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antileptic; ss.
 OS Homo sapiens.
 XX
 XX WO200173002-A2.
 XX 04-OCT-2001.
 XX 27-MAR-2001; 2001WO-US009761.
 XX 27-MAR-2000; 2000US-0192176P.
 XX 27-MAR-2000; 2000US-0192179P.
 XX 01-JUN-2000; 2000US-0208538P.
 XX 30-OCT-2000; 2000US-0244989P.
 XX (UYDE) UNIV DELAWARE.
 XX Kmiec EB, Camper HB, Rice MC;
 XX WPI; 2001-639230/73.
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 XX treating cystic fibrosis, comprises at least one mismatch and chemical
 XX modification.
 XX Claim 7; Page 233; 294pp; English.
 XX The present invention provides single-stranded oligonucleotides which can
 XX be used for the targeted alteration of genomic sequences, where the
 XX oligonucleotide has at least one mismatch compared with the genomic
 XX sequence to be altered. In particular, these sequences are directed at
 XX the following genes: adenosine deaminase, p53, beta-globin,
 XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 XX haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
 XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 XX various syndromes. The present sequence is one of the gene correcting
 XX oligonucleotides of the invention
 SQ Sequence 17 BP; 4 A; 5 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 374 TGCAGGAGCTTCGCA 390
 Db 17 TGCAGGAGCTTCGCA 1
 RESULT 739
 ABN08430
 ID ABN08430 standard; DNA; 17 BP.
 XX AC
 XX ABN08430;
 XX 29-MAY-2002 (first entry)
 XX Human GMMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8422.

XX Human; genome-derived myosin-like protein 1; GMMLP-1; hGDMMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 OS
 XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 XX 21-SEP-2000; 2000US-0234687P.
 XX 27-SEP-2000; 2000US-0236359P.
 XX 04-OCT-2000; 2000GB-00024263.
 XX 30-JAN-2001; 2001WO-US000661.
 XX 30-JAN-2001; 2001WO-US000662.
 XX 30-JAN-2001; 2001WO-US000663.
 XX 30-JAN-2001; 2001WO-US000664.
 XX 30-JAN-2001; 2001WO-US000665.
 XX 30-JAN-2001; 2001WO-US000666.
 XX 30-JAN-2001; 2001WO-US000667.
 XX 30-JAN-2001; 2001WO-US000668.
 XX 30-JAN-2001; 2001WO-US000669.
 XX 30-JAN-2001; 2001WO-US000670.
 XX 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMMLP-1 proteins,
 XX or as specific biomolecule capture probes for surface-enhanced laser
 XX desorption ionization, comprises human myosin-like protein hGDMMLP-1.
 XX Disclosure; SEQ ID NO 8422; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMMLP-1). The protein and polynucleotide sequences of hGDMMLP-
 XX 1 can be used in gene therapy and vaccine production. The hGDMMLP-1
 XX nucleic acids can be used as probes to detect, characterise and quantify
 XX hGDMMLP-1 nucleic acids in samples, as amplification substrates, to
 XX provide initial substrates for the recombinant engineering of hGDMMLP-1
 XX protein variants having desired phenotypic improvements, and for
 XX expressing the proteins. The hGDMMLP-1 proteins or polypeptides may be
 XX used as immunogens to raise antibodies that specifically recognise hGDMMLP-
 XX -1 proteins, as standards in assays used to determine the concentration
 XX and/or amount specifically of hGDMMLP proteins, as specific biomolecule
 XX capture probes for surface-enhanced laser desorption/ionisation, as
 XX therapeutic supplement in patients having specific deficiency in hGDMMLP-1
 XX production, and in vaccines or for replacement therapy. The
 XX polynucleotide sequences encoding hGDMMLP-1 may be used for diagnosing a
 XX disorder associated with the expression of hGDMMLP-1, in particular heart
 XX and skeletal muscle disorders. hGDMMLP-1 is localised to chromosome 22.
 XX The present sequence represents an oligomer used in the screening of the
 XX hGDMMLP-1 sequence in the exemplification of the present invention. N.B.
 XX The sequence data for this patent did not form part of the printed
 XX specification, but was obtained in electronic format directly from WIPO
 XX at ftp.wipo.int/pub/published_pct_sequence
 SQ Sequence 17 BP; 6 A; 3 C; 7 G; 1 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 490 GAAGAGGCGAGAGGAGC 506
 Db 1 GAAGAGGCGAGAGGAGC 17

RESULT 740	
ABN07706/C	
ID	ABN07706 standard; DNA; 17 BP.
XX	
XX	ABN07706;
XX	
XX	29-MAY-2002 (first entry)
XX	
XX	Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7698.
DE	
XX	Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW	skeletal muscle disorder; amplicon; screening; ss.
KW	
XX	
OS	Homo sapiens.
XX	
XX	WO200192524-A2.
XX	
XX	06-DEC-2001.
XX	
XX	25-MAY-2001; 2001WO-US016981.
XX	
XX	26-MAY-2000; 2000US-0207456P.
XX	
XX	21-SEP-2000; 2000US-0234687P.
PR	
PR	27-SEP-2000; 2000US-0236359P.
PR	
PR	04-OCT-2000; 2000GB-00024263.
PR	
PR	30-JAN-2001; 2001WO-US000661.
PR	
PR	30-JAN-2001; 2001WO-US000662.
PR	
PR	30-JAN-2001; 2001WO-US000663.
PR	
PR	30-JAN-2001; 2001WO-US000664.
PR	
PR	30-JAN-2001; 2001WO-US000665.
PR	
PR	30-JAN-2001; 2001WO-US000667.
PR	
PR	30-JAN-2001; 2001WO-US000668.
PR	
PR	30-JAN-2001; 2001WO-US000669.
PR	
PR	30-JAN-2001; 2001WO-US000670.
PR	
PR	05-FEB-2001; 2001US-0266860P.
XX	
XX	(AEOM-) AEOMICA INC.
PA	
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX	
XX	WPI; 2002-179446/23.
XX	
XX	New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT	or as specific biomolecule capture probes for surface-enhanced laser
PT	desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX	
XX	Disclosure; SEQ ID NO 7698; 214pp; English.
XX	
XX	The present invention describes a human genome-derived myosin-like
CC	protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC	1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC	nucleic acids can be used as probes to detect, characterise and quantify
CC	hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC	provide initial substrates for the recombinant engineering, and for
CC	protein variants having desired phenotypic improvements, and for
CC	expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC	used as immunogens to raise antibodies that specifically recognise hGDMPLP-
CC	-1 proteins, as standards in assays used to determine the concentration
CC	and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC	capture probes for surface-enhanced laser desorption ionisation, as
CC	therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC	production, and in vaccines or for replacement therapy. The
CC	polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC	disorder associated with the expression of hGDMPLP-1, in particular heart
CC	and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC	The present sequence represents an oligomer used in the screening of the
CC	hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC	The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 827 CTGCCCCAGTTCGAGGT 843
|||||
Db 17 CTGGCCAGCTGCAGGT 1
RESULT 741
ABN07821
ID ABN07821 standard; DNA; 17 BP.
XX
AC ABN07821;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7813.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US0016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
FT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 7813; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC of hGDMPLP-1 proteins in samples.

CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionization, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 493 GAGCGACAGGACGAG 509
 Db 1 GAAGCAAAAGGACGAG 17
 RESULT 742
 ABN06831/C
 ID ABN06831 standard; DNA; 17 BP.
 XX AC ABN06831;
 XX DT 29-MAY-2002 (first entry)
 XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6823.
 XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX OS Homo sapiens.
 XX WO200192524-A2.
 XX PD 06-DEC-2001.
 XX PF 25-MAY-2001; 2001WO-US016981.
 XX PR 26-MAY-2000; 2000US-0207456P.
 XX PR 21-SEP-2000; 2000US-0234687P.
 XX PR 27-SEP-2000; 2000US-0236359P.
 XX PR 04-OCT-2000; 2000GB-00024263.
 XX PR 30-JAN-2001; 2001WO-US000661.
 XX PR 30-JAN-2001; 2001WO-US000662.
 XX PR 30-JAN-2001; 2001WO-US000663.
 XX PR 30-JAN-2001; 2001WO-US000664.
 XX PR 30-JAN-2001; 2001WO-US000665.
 XX PR 30-JAN-2001; 2001WO-US000666.
 XX PR 30-JAN-2001; 2001WO-US000667.
 XX PR 30-JAN-2001; 2001WO-US000668.
 XX PR 30-JAN-2001; 2001WO-US000669.
 XX PR 05-FEB-2001; 2001US-0266860P.
 XX PA (AEOM-) AEOMICA INC.
 XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 6823; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 3 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 266 CACCTGCCTTCAGACA 282
 Db 17 CACCTGCCTTCAGAAAA 1
 RESULT 743
 ABN08429
 ID ABN08429 standard; DNA; 17 BP.
 XX AC ABN08429;
 XX DT 29-MAY-2002 (first entry)
 XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8421.
 XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX OS Homo sapiens.
 XX WO200192524-A2.
 XX PD 06-DEC-2001.
 XX PF 25-MAY-2001; 2001WO-US016981.
 XX PR 26-MAY-2000; 2000US-0207456P.
 XX PR 21-SEP-2000; 2000US-0234687P.
 XX PR 27-SEP-2000; 2000US-0236359P.
 XX PR 04-OCT-2000; 2000GB-00024263.
 XX PR 30-JAN-2001; 2001WO-US000661.
 XX PR 30-JAN-2001; 2001WO-US000662.
 XX PR 30-JAN-2001; 2001WO-US000663.
 XX PR 30-JAN-2001; 2001WO-US000664.
 XX PR 30-JAN-2001; 2001WO-US000665.
 XX PR 30-JAN-2001; 2001WO-US000666.
 XX PR 30-JAN-2001; 2001WO-US000667.
 XX PR 30-JAN-2001; 2001WO-US000668.
 XX PR 30-JAN-2001; 2001WO-US000669.
 XX PR 05-FEB-2001; 2001US-0266860P.
 XX

(AEOM-) AEOMICA INC.
Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
WPI; 2002-179446/23.
New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
or as specific biomolecule capture probes for surface-enhanced laser
desorption ionization, comprises human myosin-like protein hGDMPLP-1.
Disclosure; SEQ ID NO 8421; 214pp; English.
The present invention describes a human genome-derived myosin-like
protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
1 can be used in gene therapy and vaccine production. The hGDMPLP-1
nucleic acids can be used as probes to detect, characterise and quantify
hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
provide initial substrates for the recombinant engineering of hGDMPLP-1
protein variants having desired phenotypic improvements, and for
expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
used as immunogens to raise antibodies that specifically recognise hGDMPLP
-1 proteins, as standards in assays used to determine the concentration
and/or amount specifically of hGDMPLP proteins, as specific biomolecule
capture probes for surface-enhanced laser desorption ionisation, as
therapeutic supplement in patients having specific deficiency in hGDMPLP-1
production, and in vaccines or for replacement therapy. The
polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
disorder associated with the expression of hGDMPLP-1, in particular heart
and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
The present sequence represents an oligomer used in the screening of the
hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
The sequence data for this patent did not form part of the printed
specification, but was obtained in electronic format directly from WIPO
at ftp.wipo.int/pub/published_pct_sequence
Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 489 TGAAGAGCGAGAGGAG 505
DB 1 TGAAGAGCGAGAGGAG 17
RESULT 744
ABV89590
ID ABV89590 standard; DNA; 17 BP.
AC ABV89590;
XX 23-DEC-2002 (first entry)
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 303.
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
XX Rho GTPase; signal transduction; gene expression; cancer; vaccine;
XX gene therapy; transgenic; ss.
XX Homo sapiens.
XX EP1239051-A2.
XX 11-SEP-2002.
XX 28-JAN-2002; 2002EP-00001165.
XX 30-JAN-2001; 2001WO-US0000663.
XX 30-JAN-2001; 2001WO-US0000664.
XX 30-JAN-2001; 2001WO-US0000665.
XX 30-JAN-2001; 2001WO-US0000666.
XX 30-JAN-2001; 2001WO-US0000667.
PR 30-JAN-2001; 2001WO-US0000668.
PR 30-JAN-2001; 2001WO-US0000669.
PR 30-JAN-2001; 2001WO-US0000670.
PR 23-MAY-2001; 2001US-0084761.
PR 10-OCT-2001; 2001US-0328205P.
XX (AEOM-) AEOMICA INC.
XX Shannon M;
XX WPI; 2002-684061/74.
XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
-1, useful for treating disorders associated with decreased expression or
activity of human POSHL1.
XX Example 2; SEQ ID NO 303; 60pp + Sequence Listing; English.
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
acids (S1, AB883999), a sequence having 65% sequence identity to (S1),
(S1) having 95% deviations, especially conservative substitutions or a
fragment of the sequences comprising at least 8 contiguous amino acids.
XX Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
adaptor protein that interacts with Rho family small GTPases as well as
downstream components of the signal transduction pathway. (I) is useful
for identifying a specific binding partner. (II) and nucleic acids (II)
encoding (I) are useful for diagnosing, monitoring disease and treating
caused by altered expression of human POSHL1 including diagnosing and
treating cancer, they useful in the development of vaccines and (II) is
useful in gene therapy. (II) is useful for constructing microarrays which
are useful for measuring and for surveying gene expression and creating
transgenic non-human animals capable of producing the proteins. The
present sequence is that of a scanning oligonucleotide useful in examples
of the invention. Note: The present sequence did not form part of the
printed specification, but is based on sequence information supplied to
Derwent by the European Patent Office
Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 471 GCCTGAGAGAGCTCGAT 487
DB 1 GCCTGAGAGAGCTCGAT 17
RESULT 745
ABL31574
ID ABL31574 standard; DNA; 17 BP.
XX ABL31574;
XX 21-MAR-2002 (first entry)
XX Human HLA genotyping oligonucleotide SEQ ID NO 1063.
XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
XX immunogenetic; transplantation; genetic disease; ss.
XX Homo sapiens.
XX WO200192572-A1.
XX 06-DEC-2001.
XX 01-JUN-2001; 2001WO-JP004662.
XX 01-JUN-2000; 2000JP-00164798.
XX (N1SN) NISSHINBO IND INC.
PR 30-JAN-2001; 2001WO-US0000668.
PR 30-JAN-2001; 2001WO-US0000669.
PR 30-JAN-2001; 2001WO-US0000670.
PR 23-MAY-2001; 2001US-0084761.
PR 10-OCT-2001; 2001US-0328205P.
XX (AEOM-) AEOMICA INC.
XX Shannon M;
XX WPI; 2002-684061/74.
XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
-1, useful for treating disorders associated with decreased expression or
activity of human POSHL1.
XX Example 2; SEQ ID NO 303; 60pp + Sequence Listing; English.
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
acids (S1, AB883999), a sequence having 65% sequence identity to (S1),
(S1) having 95% deviations, especially conservative substitutions or a
fragment of the sequences comprising at least 8 contiguous amino acids.
XX Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
adaptor protein that interacts with Rho family small GTPases as well as
downstream components of the signal transduction pathway. (I) is useful
for identifying a specific binding partner. (II) and nucleic acids (II)
encoding (I) are useful for diagnosing, monitoring disease and treating
caused by altered expression of human POSHL1 including diagnosing and
treating cancer, they useful in the development of vaccines and (II) is
useful in gene therapy. (II) is useful for constructing microarrays which
are useful for measuring and for surveying gene expression and creating
transgenic non-human animals capable of producing the proteins. The
present sequence is that of a scanning oligonucleotide useful in examples
of the invention. Note: The present sequence did not form part of the
printed specification, but is based on sequence information supplied to
Derwent by the European Patent Office
Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 471 GCCTGAGAGAGCTCGAT 487
DB 1 GCCTGAGAGAGCTCGAT 17
RESULT 745
ABL31574
ID ABL31574 standard; DNA; 17 BP.
XX ABL31574;
XX 21-MAR-2002 (first entry)
XX Human HLA genotyping oligonucleotide SEQ ID NO 1063.
XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
XX immunogenetic; transplantation; genetic disease; ss.
XX Homo sapiens.
XX WO200192572-A1.
XX 06-DEC-2001.
XX 01-JUN-2001; 2001WO-JP004662.
XX 01-JUN-2000; 2000JP-00164798.
XX (N1SN) NISSHINBO IND INC.

PA (SYST-) SYSTEM RES INC.
XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX WPI; 2002-122074/16.
XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
PT individuals e.g. by determining immunogenetic differences when
PT transplanting between them.
XX Claim 10; Page 294; 345pp; Japanese.
XX The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC organ and tissue, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals
XX
SQ Sequence 17 BP; 1 A; 4 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 760 GCAGGGCCGAGCGGTGG 776
DB 1 GCAGGGCCGCGGTGG 17
RESULT 746
ABK56107
ID ABK56107 standard; RNA; 17 BP.
XX
AC ABK56107;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #478.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX
PN WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US024970.
XX
PR 09-AUG-2000; 2000US-0224383P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTEX USA LLC.
PA (THOM/) THOMPSON J.
XX
PI Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
XX WPI; 2002-217145/27.
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
channel calcium activated gene, useful for treating Chronic obstructive

PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX Claim 4; Page 61; 152pp; English.
XX The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
XX
SQ Sequence 17 BP; 6 A; 2 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 476 GAGAGCTCGATCTGAA 492
DB 1 GAUAAAGGUCGUCUGAA 17
RESULT 747
ACN08336/C
ID ACN08336 standard; RNA; 17 BP.
XX
AC ACN08336;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8339.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 8339; 495pp; English.
XX

CC The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

XX Sequence 17 BP; 1 A; 7 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 5.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 804 CCGCTCGGAGGAGAG 820

DB 17 CCGCTCAGAGGAGAG 1

RESULT 748

ACN10740/C

ID ACN10740 standard; RNA; 17 BP.

XX ACN10740;

DT 22-APR-2004 (first entry)

DE WNV minus strand Inozyme substrate SEQ ID NO 10743.

KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.

OS West Nile Virus.

PN WO200268637-A2.

XX 06-SEP-2002.

PF 19-OCT-2001; 2001WO-US048350.

PR 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

PI Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus
 CC (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PS Claim 23; SEQ ID NO 10743; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The

CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

XX Sequence 17 BP; 1 A; 8 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 5.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 806 GCGCTCGGAGGAGAG 822

DB 17 GCGCTCAGAGGAGAG 1

RESULT 749

ACN06511

ID ACN06511 standard; RNA; 17 BP.

XX ACN06511;

DT 22-APR-2004 (first entry)

DE WNV Amberzyme substrate SEQ ID NO 6514.

KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.

OS West Nile Virus.

PN WO200268637-A2.

PD 06-SEP-2002.

PF 19-OCT-2001; 2001WO-US048350.

PR 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

PI Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus
 CC (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PS Claim 23; SEQ ID NO 6514; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

XX SQ Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.5e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 804 CCGCTCGGAGGAGAG 820
||| | | | | | | | |
Db 1 CCGCUCAGGAGAG 17

RESULT 750
ACN06512
ID ACN06512 standard; RNA; 17 BP.
XX ACN06512;
XX ACN06512;
XX 22-APR-2004 (first entry)
XX WNV Amberzyme substrate SEQ ID NO 6515.
DE XX
DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX
XX West Nile Virus.
OS
XX
XX WO200268637-A2.
XX 06-SEP-2002.
XX 19-OCT-2001; 2001WO-US048350.
XX 20-OCT-2000; 2000US-0242411P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 6515; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 6 A; 2 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.5e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 806 GCCTCGGAGGAGAG 822
||| | | | | | | | |
Db 1 GGCUCAGGAGAGAG 17

RESULT 751
ACN14467
ID ACN14467 standard; RNA; 17 BP.
XX ACN14467;
XX ACN14467;
XX 22-APR-2004 (first entry)
XX WNV minus strand Amberzyme substrate SEQ ID NO 14470.
DE XX
DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyne; ss.
XX
XX West Nile Virus.
OS
XX
XX WO200268637-A2.
XX 06-SEP-2002.
XX 19-OCT-2001; 2001WO-US048350.
XX 20-OCT-2000; 2000US-0242411P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 14470; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.5e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 756 GCATGAGGCGCAGAGC 772
||| | | | | | | | |
Db 1 GCAUGAGGCGCAGAGC 17

RESULT 752
ACN10741/C

```

ID ACN10741 standard; RNA; 17 BP.
XX
AC ACN10741;
XX
DT 22-APR-2004 (first entry)
XX
XX WNV minus strand Inozyme substrate SEQ ID NO 10744.
DE
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
XX WO200268637-A2.
PN
XX 06-SEP-2002.
PD
XX 19-OCT-2001; 2001WO-US048350.
PF
XX 20-OCT-2000; 2000US-0242411P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
DR
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 10744; 495pp; English.
PS
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 1 A; 7 C; 3 G; 0 T; 6 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 805 CGCCTCGGAGGAGAAGA 821
DB 17 CGGCTCAGAGGAGAAGA 1
RESULT 753
ACN02935/c
ID ACN02935 standard; RNA; 17 BP.
XX
AC ACN02935;
XX
XX 22-APR-2004 (first entry)
DT
XX WNV Inozyme substrate SEQ ID NO 2938.
DE
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
XX WO200268637-A2.
PN
XX 06-SEP-2002.
PD
XX 19-OCT-2001; 2001WO-US048350.
PF
XX 20-OCT-2000; 2000US-0242411P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
DR
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 10744; 495pp; English.
PS
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 1 A; 7 C; 3 G; 0 T; 6 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 805 CGCCTCGGAGGAGAAGA 821
DB 17 CGGCTCAGAGGAGAAGA 1
RESULT 753
ACN02935/c
ID ACN02935 standard; RNA; 17 BP.
XX
AC ACN02935;
XX
XX 22-APR-2004 (first entry)
DT
XX WNV Inozyme substrate SEQ ID NO 2938.
DE
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
XX WO200268637-A2.
PN
XX 06-SEP-2002.
PD
XX 19-OCT-2001; 2001WO-US048350.
PF
XX 20-OCT-2000; 2000US-0242411P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
DR
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 2938; 495pp; English.
PS
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 8 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 756 GCATCGAGGGCAGAGC 772
DB 17 GCATGTAGGGCAGAGC 1
RESULT 754
ACN06363
ID ACN06363 standard; RNA; 17 BP.
XX
AC ACN06363;
XX
XX 03-JUN-2003 (first entry)
DT
XX NFKB sub-unit modulating inozyme substrate #182.
DE
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
```

chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 transplant/graft rejection; reperfusion injury; glomerulonephritis;
 allergic airway inflammation; inflammatory bowel disease; infection; ss.

OS Homo sapiens.
 XX
 XX
 PN US2002177568-A1.
 XX
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-00864785.
 XX
 XX 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 XX (STIN/) STINCHCOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 XX Claim 3; Page 30; 72pp; English.

The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule

XX
 XX Sequence 17 BP; 4 A; 2 C; 7 G; 0 T; 4 U; 0 Other;
 SQ

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 5.5e+02;
 Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 177 TGTGTGAGATGGTCAG 193
 :||:| | | | |
 Db 1 UGUGUCACAGGUCAG 17

RESULT 755
 ACA08234

ID ACA08234 standard; DNA; 17 BP.
 XX
 AC ACA08234;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE Necrosis factor kappa B (NFkB) sub-unit modulating DNazyme #3.
 XX
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; lung cancer;
 KW prostate cancer; colorectal cancer; brain cancer; pancreatic cancer;
 KW stomach cancer; bladder cancer; ovarian cancer; melanoma; glioma;
 KW head and neck cancer; Crohn's disease; obesity; ischaemia;
 KW multidrug resistant cancer; REL-A-specific inhibitor; chemotherapy;
 KW paclitaxel; docetaxel; cisplatin; methotrexate; cyclophosphamide;
 KW doxorubicin; fluorouracil carboplatin; edatrexate; gencitabine;
 KW radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Synthetic.
 XX
 XX US2002177568-A1.
 PN
 XX 28-NOV-2002.
 PD
 XX 23-MAY-2001; 2001US-00864785.
 XX
 XX 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 XX (STIN/) STINCHCOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 XX Claim 3; Page 44; 72pp; English.

The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule

XX
 XX Sequence 17 BP; 4 A; 2 C; 7 G; 0 T; 4 U; 0 Other;
 SQ

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 5.5e+02;
 Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 177 TGTGTGAGATGGTCAG 193
 :||:| | | | |
 Db 1 UGUGUCACAGGUCAG 17

RESULT 755
 ACA08234

```

XX SQ Sequence 17 BP; 4 A; 3 C; 6 G; 0 T; 4 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 5.5e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

OY 175 ACTGTGTGAGATGGTC 191
DB 1 ACUGUGACAGGUGC 17

RESULT 756
ADA99740/c
ID ADA99740 standard; DNA; 17 BP.
XX ADA99740;
AC ADA99740;
XX 20-NOV-2003 (first entry)
XX Human MDZ3 scanning oligonucleotide SEQ ID 729.
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX Homo sapiens.
XX EP1281758-A2.
XX 05-FEB-2003.
XX 30-JUL-2002; 2002EP-00016874.
XX 02-AUG-2001; 2001US-00922181.
XX (AEOM-) AEOMICA INC.
XX Shannon M, Gu Y, Nguyen C;
XX WPI; 2003-423107/40.
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MDZ3,
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX Example 8; SEQ ID NO 729; 103pp; English.
XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MDZ3,
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX SQ Sequence 17 BP; 1 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 268 CCTGCCTTCAGAACAGG 284
DB 17 ACCCGCTGCAGAACAGG 1

RESULT 758
ACD65432
ID ACD65432 standard; RNA; 17 BP.
XX

```


XX OS Homo sapiens.
 XX PN WO2003050284-A1.
 XX PD 19-JUN-2003.
 XX PF 22-NOV-2002; 2002WO-US037506.
 XX PR 10-DEC-2001; 2001US-0339764P.
 XX PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 XX PI Guo J;
 XX WIPI; 2003-532916/50.
 XX PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.
 XX PS Example 2; SEQ ID NO 71; 164pp; English.
 XX CC The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the WipoWeb
 CC database.
 XX SQ Sequence 17 BP; 4 A; 5 C; 8 G; 0 T; 0 U; 0 Other;
 CC Query Match 1.8%; Score 13.8; DB 1; Length 17;
 CC Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 CC Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 677 GCCAGCGAGCAGCGCG 693
 Db 1 GCCAGCGAGCAGCGCG 17
 RESULT 763
 ADF64208
 ID ADF64208 standard; DNA; 17 BP.
 AC ADF64208;
 XX 12-FEB-2004 (first entry)
 DT Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2112.
 DE chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.
 XX Homo sapiens.
 XX WO2003050284-A1.
 XX PD 19-JUN-2003.
 XX PF 22-NOV-2002; 2002WO-US037506.
 XX PR 10-DEC-2001; 2001US-0339764P.
 XX PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 XX PI Guo J;

XX WIPI; 2003-532916/50.
 XX PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.
 XX PS Example 2; SEQ ID NO 2112; 164pp; English.
 XX CC The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the WipoWeb
 CC database.
 XX SQ Sequence 17 BP; 6 A; 3 C; 5 G; 3 T; 0 U; 0 Other;
 CC Query Match 1.8%; Score 13.8; DB 1; Length 17;
 CC Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 CC Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 413 GAGAGGAGTCTCTCAT 429
 Db 1 GAGAGGAGTCTCTCAT 17
 RESULT 764
 ADF62162
 ID ADF62162 standard; DNA; 17 BP.
 AC ADF62162;
 XX 12-FEB-2004 (first entry)
 DT Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 66.
 DE chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.
 XX Homo sapiens.
 XX WO2003050284-A1.
 XX PD 19-JUN-2003.
 XX PF 22-NOV-2002; 2002WO-US037506.
 XX PR 10-DEC-2001; 2001US-0339764P.
 XX PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 XX PI Guo J;
 XX WIPI; 2003-532916/50.
 XX PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.
 XX PS Example 2; SEQ ID NO 66; 164pp; English.
 XX CC The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the WipoWeb
 CC database.

CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the WipoWeb
 CC database.
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 672 GGGCGCGCCAGCGAGCAG 688
 1 GGGCTGCGAGCGAGCAG 17

RESULT 765
 ADF64121
 ID ADF64121 standard; DNA; 17 BP.
 XX
 AC ADF64121;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2025.
 XX
 KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.
 XX
 OS Homo sapiens.
 XX
 PN WO2003050284-A1.
 XX
 PD 19-JUN-2003.
 XX
 PF 22-NOV-2002; 2002WO-US037506.
 XX
 PR 10-DEC-2001; 2001US-0339764P.
 XX
 PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.

PI Guo J;
 XX
 DR WPI; 2003-532916/50.
 XX
 PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.
 XX
 PS Example 2; SEQ ID NO 2025; 164pp; English.
 XX

CC The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the WipoWeb
 CC database.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 333 GAGATGCCATCCGAGCAG 349

Db 1 GAGATGCCATCCGAGCAG 17

RESULT 766
 ADM09541/C
 ID ADM09541 standard; RNA; 17 BP.
 XX
 AC ADM09541;
 XX

DT 20-MAY-2004 (first entry)
 XX
 DE Human NOGO receptor amberyyme substrate sequence #96.
 XX

KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis;
 KW NOGO receptor amberyyme; substrate; ss.

OS Unidentified.
 XX
 PN WO200281628-A2.
 XX

PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX

PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX

PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX

PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 9; SEQ ID NO 936; 317pp; English.

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human NOGO
 CC receptor amberyyme substrate sequence.

XX
 SQ Sequence 17 BP; 1 A; 7 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 800 CAGGCCCGCTCGAGGAG 816

Db 17 CAGGGCACCTCGGAGGA 1

RESULT 767
ADL48763
ID ADL48763 standard; RNA; 17 BP.
XX
AC ADL48763;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #1273.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 28-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2296; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 5.5e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 410 GAGGAGGAGGAGTTCCT 426

Db 1 GAGAGAGAGGAGCUCCU 17

RESULT 768
ADL49424/C
ID ADL49424 standard; RNA; 17 BP.
XX
AC ADL49424;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #538.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2957; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 7 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 492 AGAGGAGGAGGAGCAG 508

|||||
17 AGAGGCGAGGAGTTCAG 1

Db RESULT 769
ADL46635/C
ID ADL46635 standard; RNA; 17 BP.
XX
AC ADL46635;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human NOGO receptor inozyme substrate sequence #68.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor inozyme; substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 9; SEQ ID NO 168; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor inozyme substrate sequence.
XX
SQ Sequence 17 BP; 1 A; 8 C; 4 G; 0 T; 4 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 685 GCAGGCGGCGAGTTCG 701

|||||
17 GCAGGCGAGGAGTTCG 1

Db RESULT 770
ADL51771/C
ID ADL51771 standard; RNA; 17 BP.
XX
AC ADL51771;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PTGDR substrate sequence #890.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 161; SEQ ID NO 5304; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 8 C; 5 G; 0 T; 1 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 705 GTGAGCGGAGGCGTGG 721

KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX Homo sapiens.
XX US2004137589-A1.
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001WO-US000670.
XX 25-MAY-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX Disclosure; SEQ ID NO 6823; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX (S1) identity to (S1). A polypeptide of the invention acts as a agonist or
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 3 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 5.5e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 266 CACCTGCGCTTCAGACA 282
Db 17 CACCTGCGCTTCAGAAAA 1
RESULT 774
ACN70796/c

ID ACN70796 standard; DNA; 17 BP.
XX ACN70796;
XX 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO: 7698.
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX Homo sapiens.
XX US2004137589-A1.
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX Disclosure; SEQ ID NO 7698; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX (S1) identity to (S1). A polypeptide of the invention acts as a agonist or
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 5.5e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 266 CACCTGCGCTTCAGACA 282
Db 17 CACCTGCGCTTCAGAAAA 1
RESULT 774
ACN70796/c

QY 827 CTGGCCAGTTCAGGT 843
Db 17 CTGGCCAGTTCAGGT 1

RESULT 775
ACN70911
ID ACN70911 standard; DNA; 17 BP.
XX ACN70911;
DT 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:7813.
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX Homo sapiens.
XX US2004137589-A1.
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX Disclosure; SEQ ID NO 7813; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.

CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 493 GAGGCAGAGGAGGAGG 509
Db 1 GAAGCAAAAGGAGGAGG 17

RESULT 776
ACN71520
ID ACN71520 standard; DNA; 17 BP.
XX ACN71520;
XX 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:8422.
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX Homo sapiens.
XX US2004137589-A1.
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX Disclosure; SEQ ID NO 8422; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence

CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 7 G; 1 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 490 GAAGAGCGCAGAGGAGC 506
 DB 1 GAAGAGCGCAGAGGAGC 17
 RESULT 777
 ACN71519
 ID ACN71519 standard; DNA; 17 BP.
 XX
 AC ACN71519;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:8421.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001WO-US000670.
 PR 25-MAY-2001; 2001US-0266860P.
 XX
 (GUYY/) GU Y.
 PA (JIVY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX

PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX Disclosure; SEQ ID NO 8421; Opp; English.
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 489 TGAAGAGCGCAGAGGAG 505
 DB 1 TGAAGAGCGCAGAGGAG 17
 RESULT 778
 AAX75572/c
 ID AAX75572 standard; RNA; 18 BP.
 XX
 AC AAX75572;
 XX
 DT 28-JUL-1999 (first entry)
 XX
 DE Mouse flt-1 VEGF receptor hairpin ribozyme substrate #31.
 XX
 KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX Mus sp.
 OS WO9715662-A2.
 PN 01-MAY-1997.
 PD 25-OCT-1996; 96WO-US017480.
 XX
 PR 26-OCT-1995; 95US-0005974P.
 PR 11-JAN-1996; 96US-00584040.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (CHIR) CHIRON CORP.
 XX
 PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 DR
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.
 XX
 PS Claim 4; Page 185; 218pp; English.
 XX The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention

XX
 SQ Sequence 18 BP; 3 A; 7 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 688 GCGCGCGCAGCTGGAGA 704

DB 18 GCGCGCGCAGCTGTAGA 2

RESULT 779

AAT74250

ID AAT74250 standard; DNA; 18 BP.

XX AC

AC AAT74250;

XX DT 10-FEB-1998 (first entry)

XX DE Estm9 primer R1.

XX LYst1; mouse; lysosomal trafficking regulator; beige; bg gene;
 KW Chediak-Higashi syndrome; CH syndrome; Estm9; PCR; primer; ss.
 KW Synthetic.

OS

XX WO9728262-A1.

PN 07-AUG-1997.

XX 31-JAN-1997; 97WO-US001748.

XX 01-FEB-1996; 96US-0011146P.

PR 20-DEC-1996; 96US-0033599P.

PR 23-DEC-1996; 96US-0034346P.

XX (UYFL) UNIV FLORIDA.

XX Kingmore SF, Barbosa-Alleyne WDFS;

XX WPI; 1997-402616/37.

XX Mammalian lysosomal trafficking regulators LYST1, LYST1, LYST2 and LYST2

PT - useful to diagnose Chediak-Higashi syndrome.

XX Example 2; Page 71; 237pp; English.

XX Estm9 primers R1 (AAT74250) and R2 (AAT74252) correspond to the 3' end of
 CC an Estm9 cDNA. Estm9 primers F1 (AAT74249) and F2 (AAT74251) correspond
 CC to the 3' end of an Estm9 cDNA. RT-PCR products were amplified from
 CC mouse bg, bgu, bgu2 and +/ RNA with Nid primers or Estm9 primers F1-R1
 CC or F2-R2. The RT-PCR analysis was used in the mapping of the bg (beige)
 CC locus to mouse chromosome 13 to provide a foundation for yeast artificial
 CC chromosome contig development and screening of candidate genes for bg.
 CC Characterisation of the bg critical region in murine chromosome 13 and
 CC positional cloning of bg were performed as an antecedent to
 CC identification of the homologous human gene LYST1 (see AAT74201), which
 CC is mutated in human Chediak-Higashi syndrome

XX SQ Sequence 18 BP; 4 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 333 GAGATGCCATCGGCAG 349

DB 1 GAGATGCCATCGGCAG 17

RESULT 780

AAV07833/C

ID AAV07833 standard; DNA; 18 BP.

XX AC

AC AAV07833;

XX DT 25-MAR-2003 (revised)

DT 10-DEC-1998 (first entry)

XX Segment of branched nucleic acid polymer with two 5' ends.

XX Comb-type branched polynucleotide; amplification multimer; analyte;
 KW hybridisation assay; hepatitis b virus; HBV; amplifier probe; ss.

XX Synthetic.

XX US5710264-A.

XX 20-JAN-1998.

XX 07-JUN-1995; 95US-00478085.

XX 27-JUL-1990; 90US-00558897.

PR 23-DEC-1991; 91US-00813586.

XX (CHIR) CHIRON CORP.

XX Chang C, Fultz TJ, Warner B, Urdea MS, Horn T;

XX WPI; 1998-109872/10.

XX New large comb-type branched polynucleotides - useful as amplification
 PT multimers in nucleic acid hybridisation assays.

XX Example 6; Col 24; 33pp; English.

XX The invention relates to a large comb-type branched polynucleotide of
 CC formula: 3'-A-S-(S'-X')^m-S''-5', where X' is a branched site joined to -
 CC (R)n-S''-E-L; A is an oligonucleotide complementary to an analyte nucleic
 CC acid sequence; S is a first spacer segment of 1-50 linked monomers where
 CC each monomer is selected from nucleotides and a cleavable linker R; S' =
 CC a branching site spacer segment of 0-15 linked monomers where each of the
 CC monomers is selected from nucleotides and cleavable linker R; X' = a
 CC multifunctional nucleotide that provides a branch site; m = 1-100; S'' =
 CC a second spacer segment of 0-10 linked monomers where each of the
 CC monomers is selected from nucleotides and cleavable linker R; R = a
 CC cleavable linker molecule; n = 0 or 1; S''' = a third spacer segment of 0
 CC -10 linked monomers where each of the monomers is selected from
 CC nucleotides and cleavable linker R; E is an oligonucleotide segment of 5-
 CC 10 nucleotides; L is an oligonucleotide containing 2-10 iterations of a
 CC nucleotide sequence complementary to a labelled nucleic acid probe. The
 CC invention also relates to a branched nucleic acid polymer. The poly-
 CC nucleotides are useful as amplification multimers in nucleic acid
 CC hybridisation assays used for genetic research, biomedical research and
 CC clinical diagnostics. Since the polynucleotide multimers include a large
 CC number (at least 20) iterations of a sequence that are available for
 CC specific hybridisation, they permit a greater degree of amplification and
 CC decrease the threshold level of a detectable analyte. The present
 CC sequence is shown in the specification. (Updated on 25-MAR-2003 to
 CC correct PF field.)

XX SQ Sequence 18 BP; 2 A; 3 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883

XX 27-JUL-1990; 90US-00558897.
 PR 23-DEC-1991; 91US-00813588.
 XX (CHIR) CHIRON CORP.
 PA Warner B, Horn T, Fultz TJ, Urdea MS, Chang C;
 XX WPI; 1999-069715/06.
 XX Improved nucleic acid hybridisation assays - using large comb-type
 PT polypeptide(s).
 XX Example 6; Col 23; 31pp; English.
 XX The present sequence is used in the synthesis of a comb-type branched
 CC polynucleotide. The large comb-type branched polynucleotide of the
 CC invention comprises a polynucleotide backbone having at least 15
 CC multifunctional nucleotides each defining a sidechain site and pendant
 CC polynucleotide sidechains extending from the multifunctional nucleotides,
 CC each comprising iterations of an single stranded oligonucleotide unit
 CC capable of binding specifically to a second single-stranded
 CC polynucleotide sequence. The total number of iterations in all sidechains
 CC is at least 20. The first single-stranded polynucleotide sequence is a
 CC labelled polynucleotide, directly or indirectly linked to a nucleic acid
 CC analyte. In the nucleic acid hybridisation assay of the invention, the
 CC labelled nucleic acid probe is hybridised to the branched polymeric
 CC nucleotide via the second single-stranded oligonucleotide unit. The comb-
 CC type branched polynucleotides are used as amplification multimers in
 CC nucleic acid hybridisation assays and other assays such as direct,
 CC indirect and sandwich assays
 XX Sequence 18 BP; 2 A; 3 C; 6 G; 7 T; 0 U; 0 Other;
 SQ Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 867 AATGACGACACCATC 883
 DB 17 AGTACGACACCATC 1
 RESULT 784
 AAZ01227
 ID AAZ01227 standard; DNA; 18 BP.
 XX AAZ01227;
 AC AAZ01227;
 XX 27-SEP-1999 (first entry)
 DT PCR primer for PGI biallelic markers 4-22-174 and 4-22-176.
 XX PGI gene; biallelic marker; PCR primer; PGI-related biallelic marker;
 KW cancer; prostate cancer; diagnosis; therapy; prostate specific antigen;
 KW PSA; human; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9932644-A2.
 PN 01-JUL-1999.
 XX 22-DEC-1998; 98WO-IB002133.
 XX 22-DEC-1997; 97US-00996306.
 PR 09-SEP-1998; 98US-0099658P.
 XX (GEST) GENSET.
 PA Cohen D, Blumenfeld M, Chumakov I, Bougueleret L;
 PI WPI; 1999-405178/34.
 XX Use of a prostate cancer associated gene and biallelic markers derived
 PT from it.
 XX Claim 4; Page 353; 385pp; English.
 XX The invention relates to a mammalian PGI gene and protein, and a set of
 CC PGI biallelic markers. The PGI polynucleotide and biallelic markers are
 CC used in a hybridisation assay, a sequencing assay, or in an allele-
 CC specific amplification assay for determining the identity of a nucleotide
 CC at a PGI-related biallelic marker. The methods can be used to detect and
 CC to assess the risk of developing cancer or prostate cancer. Early-stage
 CC diagnosis of prostate cancer relies on prostate specific antigen (PSA)
 CC dosage. However, the effectiveness of this is limited due to its
 CC inability to discriminate between malignant and non-malignant affections
 CC of the organ. A need exists for both a reliable diagnostic procedure
 CC which would enable early-stage diagnosis, and for preventative and
 CC curative treatments of the disease. The PGI gene can be used for
 CC detection of prostate cancer, and the risk of developing it in the
 CC future, and can also be used to determine therapies for the disease
 XX Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 U; 0 Other;
 SQ Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 372 GCTGCGAGGAGCTTCG 388
 DB 2 GCTGCGAGGAGCTTCG 18
 RESULT 785
 AAZ48548/C
 ID AAZ48548 standard; DNA; 18 BP.
 XX AAZ48548;
 AC AAZ48548;
 XX 31-MAR-2000 (first entry)
 DT Human TNFR1 mRNA inhibiting antisense oligo ISIS# 18941.
 XX Tumour necrosis factor receptor type 1; TNFR1; antisense; infection;
 KW inflammation; tumour formation; TNFR1; anticancer; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX US6007995-A.
 PN 28-DEC-1999.
 XX 26-JUN-1998; 98US-00106038.
 XX 26-JUN-1998; 98US-00106038.
 XX (ISIS-) ISIS PHARM INC.
 PA Baker BF, Cowse LM;
 PI WPI; 2000-105333/09.
 XX Antisense inhibition of tumor necrosis factor type 1 expression for
 PT diagnosis, treatment and prevention of disease, particularly tumors.
 XX Claim 1; Col 25; 34pp; English.
 XX The invention provides antisense compounds targeted to human tumour
 CC necrosis factor receptor type 1 (TNFR1) RNA. These antisense compounds
 CC can be used in a method of inhibiting the expression of TNFR1 human cells
 CC or tissues. The antisense compounds specifically hybridize with one or
 CC more nucleic acids encoding TNFR1 modulating the function of nucleic acid

CC molecules encoding TNFR1, ultimately modulating the amount of TNFR1
CC produced. The antisense compounds and method are useful as research
CC reagents and diagnostics, and in the treatment and prophylaxis of
CC infection, inflammation or tumour formation. Sequences AA248482-565
CC represent antisense oligos used for inhibition of the human TNFR1 mRNA
XX
SQ Sequence 18 BP; 3 A; 9 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 302 CAGCGCTGCTGGAGGA 318
Db 17 CTGGCTGCTGGAGGA 1
RESULT 786
AAA74709/c
ID AAA74709 standard; DNA; 18 BP.
XX
AC AAA74709;
XX
DT 12-JAN-2001 (first entry)
XX
DE Sequencing primer alpha.
XX
KW Mycobacterium bovis; Mycobacterium tuberculosis; SacB; levane saccharase;
KW transposon mutagenesis; transposon IS1096; sequencing primer; ss.
XX
OS Mycobacterium sp.
XX
PN US6096549-A.
XX
PD 01-AUG-2000.
XX
PF 11-JUN-1997; 97US-00872917.
XX
PR 11-JUN-1996; . 96US-00661658.
XX
PA (INSP) INST PASTEUR.
XX
PI Gicquel B, Guillhot C, Jackson M, Pellicic V, Reytrat J;
XX
DR WPI; 2000-542306/49.
XX
PT Transforming Mycobacterium strains for positive selection of allelic
PT exchange mutants, involves transfecting cells with vector comprising
PT marker gene and transposon and selecting in medium containing sucrose.
XX
PS Disclosure; Col 16; 29pp; English.
XX
CC The present sequence is a sequencing primer based on transposon IS1096.
CC It was used to sequence double-stranded plasmid DNA in a process for
CC replacing a nucleotide sequence in the genome of a slow growing
CC Mycobacterium strain. The process comprises transfecting Mycobacterium
CC with a vector containing SacB gene coding for levane saccharase enzyme
CC and selecting clones of transformed Mycobacteria by propagating the
CC clones in a culture medium supplemented with sucrose. The method is
CC useful for inserting a transposon in the genome of a Mycobacterium
CC strain. Protective antigens, e.g. for use in BCG vaccine strains, may be
CC cloned into the Mycobacterium genome. The process is also useful for
CC random inactivation of genes coding for a protein involved in the
CC virulence of a pathogenic mycobacterium strain. The method facilitates an
CC increase of the proportion of allelic exchange mutants, making the
CC screening of transformants easier
XX
SQ Sequence 18 BP; 0 A; 8 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 810 CGGAGGAGGAGGAGGAG 826
XX
Db 17 CGGAGGAGGAGGAGGAG 1
RESULT 787
AAZ93487
ID AAZ93487 standard; DNA; 18 BP.
XX
AC AAZ93487;
XX
DT 24-JUL-2000 (first entry)
XX
DE TRADD antisense oligonucleotide.
XX
KW TRADD; TNF; tumour necrosis factor; NF-kappa-B; apoptosis;
KW programmed cell death; antisense; inhibition; treatment; therapy;
KW septic shock; inflammation; cancer; antiinflammatory; human; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_binding complement(1..18)
FT /tag= a
FT /note= "Complementary to bases 780-763 of the human TRADD
FT sequence described in GENESEQ record AAZ93431"
XX
PN WO200012527-A1.
XX
PD 09-MAR-2000.
XX
PF 25-AUG-1999; 99WO-US019614.
XX
PR 28-AUG-1998; 98US-00143212.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Cowser LM;
XX
DR WPI; 2000-237846/20.
XX
PT New antisense compounds that limit the expression of human TRADD protein,
PT useful in the treatment and diagnosis of cancer, inflammation and septic
PT shock.
XX
PS Claim 3; Page 52; 85pp; English.
XX
CC The intracellular protein TRADD has been identified as a critical link
CC between tumour necrosis factor (TNF) receptor binding and downstream
CC activation of NF-kappa-B. Overexpression of native TRADD activates NF-
CC kappa-B in the absence of TNF and dominant negative mutants of TRADD
CC block TNF-induced NF-kappa-B activation. A second effect of TNF in many
CC cell types is the induction of apoptosis (programmed cell death). TRADD
CC overexpression has been shown to mimic TNF induction of apoptosis as
CC well. Data indicates that TRADD and other downstream effector proteins
CC are the rate limiting step of TNF action and would therefore serve as the
CC most efficient targets for inhibition of TNF-induced events. Antisense
CC oligonucleotides capable of inhibiting TRADD function may therefore be
CC useful in a number of therapeutic, diagnostic and research applications.
CC Inhibiting expression of TRADD by contacting human cells or tissues with
CC the antisense compound may be used to treat a disease or condition
CC associated with TRADD expression, for example, septic shock,
CC inflammation, or cancer. TRADD antisense oligonucleotides of varying
CC inhibitory capabilities are listed in GENESEQ records AAZ93438-293517.
CC The antisense oligonucleotides exhibit enhanced inhibitory capabilities
CC when they have 2'-MOE wings and a deoxy gap
XX
SQ Sequence 18 BP; 2 A; 9 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 795 AGCGCCAGCGCGCTCG 811
 Db ||||| ||||| ||||| |||||
 2 AGCGCCCGGAGCCTCG 18

RESULT 788
 AAH56090/c
 ID AAH56090 standard; DNA; 18 BP.
 XX
 AC AAH56090;
 XX
 XX 04-SEP-2001 (first entry)
 XX
 DE Human SCN3A PCR-SSCP PCR primer SEQ ID NO:334.
 XX
 KW Human; epilepsy; chromosome 2; SCN1A; SCN2A; SCN3A; identification;
 KW diagnosis; mutation; chromosome 2q23-q31; neurological disorder;
 KW anticonvulsant; neuroprotective; PCR primer; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200138564-A2.
 XX
 XX 31-MAY-2001.
 XX
 XX 24-NOV-2000; 2000WO-CA001404.
 XX
 XX 26-NOV-1999; 99US-0167623P.
 XX
 XX (UVMC-) UNIV MCGILL.
 XX
 XX Rouleau GA, Lafreniere RG, Rochefort D, Cossette P, Ragsdale D;
 XX WPI; 2001-355945/37.
 XX
 XX Determining a predisposition to epilepsy and/or development of epilepsy
 XX comprises determining the genotype of SCN1A, SCN2A and/or SCN3A, or a DNA
 XX variant, equivalent, or mutation which shows a linkage disequilibrium.
 XX
 XX Example 5; Fig 6; 268pp; English.
 XX
 XX The present invention describes a method (M1) of determining an
 XX individual's predisposition to epilepsy and/or development of epilepsy,
 XX as well as predicting the individual's response to medication. The method
 XX comprises determining the genotype of at least one gene selected from
 XX SCN1A, SCN2A or SCN3A, or a DNA variant, equivalent, or mutation which
 XX shows a linkage disequilibrium. SCN1A, SCN2A and SCN3A are all sodium
 XX channel genes located on chromosome 2. The idiopathic generalised
 XX epilepsy (IGE) gene is more specifically localised on chromosome 2q23-
 XX q31. Compounds identified as modulators of the biological activity of
 XX SCN1A, SCN2A or SCN3A proteins or genes, are useful for treating epilepsy
 XX or other neurological disorders. They have anticonvulsant and
 XX neuroprotective activities. AAH5763 to AAH56164 and AAH99674 to AAH99679
 XX represent SCN1A, SCN2A, and SCN3A cDNAs, gene fragments, PCR primers,
 XX oligonucleotides and proteins given in the exemplification of the present
 XX invention
 XX
 XX Sequence 18 BP; 3 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 1.8%; Score 13.8; DB 1; Length 18;
 XX Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 617 CAGAGTCGCTGGAGGC 633
 Db ||||| ||||| ||||| |||||
 18 CAGAATCGCTGGGGGC 2

RESULT 789
 AAF89332
 ID AAF89332 standard; DNA; 18 BP.
 XX

AC AAF89332;
 XX
 DT 10-DEC-2001 (first entry)
 XX
 DE Sample member clustering method related human DNA PCR primer #69.
 XX
 KW Cluster; hierarchical clustering algorithm; population based study;
 KW clinical trial; DNA fingerprint; genetic profile analysis; PCR primer;
 KW SNP; single nucleotide polymorphism; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200129257-A2.
 XX
 XX 26-APR-2001.
 XX
 XX 20-OCT-2000; 2000WO-IB001632.
 XX
 XX 22-OCT-1999; 99US-0161231P.
 XX
 XX 07-JUL-2000; 2000US-0216897P.
 XX
 XX (GEST) GENSET.
 XX
 XX Schork N, Skierczynski B;
 XX WPI; 2001-316248/33.
 XX
 XX Genetic clustering by distributing members into optimal numbers of
 XX clusters determined by a hierarchical clustering algorithm or by paired-
 XX pair analysis of homozygous pairs in clusters got from non-hierarchical
 XX clustering.
 XX
 XX Claim 61; Page 88; 100pp; English.
 XX
 XX The present invention describes methods of clustering members of a
 XX sample, involving applying a hierarchical clustering algorithm to the
 XX sample members, determining the optimal number of clusters based on this
 XX and distributing the sample members into clusters using non-hierarchical
 XX clustering. The methods are useful in population based studies such as
 XX clinical trials, DNA fingerprinting and genetic profile analyses. The
 XX present sequence was used to demonstrate the method of the invention
 XX
 XX Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 U; 0 Other;
 XX
 XX Query Match 1.8%; Score 13.8; DB 1; Length 18;
 XX Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 372 GCTGCGAGGAGCTTCG 388
 Db ||||| ||||| ||||| |||||
 2 GCTGAGGAGGAGCTTTG 18

RESULT 790
 ABT13201
 ID ABT13201 standard; DNA; 18 BP.
 XX
 XX ABT13201;
 XX
 XX 30-JAN-2003 (first entry)
 XX
 XX Fanconi anaemia FANCD2 related PCR primer SEQ ID NO 104.
 XX
 XX Cystostatic; dermatological; vasotropic; anti-anaemic; FA pathway defect;
 XX Fanconi anaemia protein complex; FANCD2; DNA repair; Cockayne's syndrome;
 XX cell cycle abnormality; Fanconi anaemia; ataxia telangiectasia; cancer;
 XX Bloom's syndrome; Hereditary non-polyposis colon cancer; gene therapy;
 XX Xeroderma pigmentosum; PCR; primer; ss.
 XX
 XX Unidentified.
 XX
 XX WO200236761-A2.
 XX
 XX

PT amino acids of a mature neublastin polypeptide useful for treating
PT neurodegenerative disorders, e.g. peripheral neuropathy, neuropathic
PT pain, brain injury.
XX
XX Disclosure; Fig 8; 138pp; English.
XX
XX The invention relates to a truncated neublastin polypeptide comprising an
XX amino acid terminus that lacks one or more amino-terminal amino acids of
XX a mature neublastin polypeptide. The polypeptides and nucleic acids are
XX useful for treating neurodegenerative disorders such as ischemic neuronal
XX damage, traumatic brain injury, peripheral neuropathy, neuropathic pain,
XX Alzheimer's disease, Huntington's disease, Parkinson's disease,
XX amyotrophic lateral sclerosis, memory impairment, diabetes, renal
XX diseases, or glaucoma by moderating metabolism, growth, differentiation
XX or survival of a nerve or neuronal cell. This polynucleotide sequence is
XX a neublastin PCR primer of the invention
XX
SQ Sequence 18 BP; 1 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 GCTGGCCCGCTGCAGG 842
DB 1 GCTGGCCCGCTGCAGG 17

RESULT 793
ADC42438
ID ADC42438 standard; DNA; 18 BP.
XX
AC ADC42438;
XX
XX 18-DEC-2003 (first entry)
XX
XX FANCD2 PCR primer MG476 SEQ ID NO:104.
XX
XX cancer; Fanconi Anemia; FA; BRCA; cytostatic; microarray;
XX chemosensitising; ss; PCR; primer.
XX
XX Synthetic.
XX
XX WO2003039327-A2.
XX
XX 15-MAY-2003.
XX
XX 06-JUN-2002; 2002WO-US018153.
XX
XX 02-NOV-2001; 2001US-00998027.
XX
XX 02-NOV-2001; 2001WO-US045561.
XX
XX (DAND) DANA FARBER CANCER INST.
XX (UYOR-) UNIV OREGON HEALTH SCI.
XX
XX D'andrea AD, Taniguchi T, Timmers C, Grompe M, Fox EA;
XX
XX WPI; 2003-441436/41.
XX
XX Diagnosing or determining cancer or increased risk of cancer in a
XX patient, by testing Fanconi Anemia/BRCA pathway gene or protein for a
XX cancer-associated defect, that indicates cancer or increased risk of
XX cancer.
XX
XX Example 9; SEQ ID NO 104; 160pp; English.
XX
XX The invention relates to a novel method of diagnosing or determining if a
XX patient has cancer or is at increased risk of cancer, involving testing a
XX Fanconi Anemia (FA)/BRCA pathway gene or protein for the presence of a
XX cancer-associated defect, where the presence of one or more cancer-
XX associated defects is indicative of cancer or an increased risk of cancer
XX in the patient. The method of the invention has cytostatic activity. The
XX method is useful for determining if a patient has cancer, or is at

CC increased risk of developing cancer, e.g. breast, ovarian or prostate
CC cancer. A microarray of the invention is useful for determining if a
CC patient has cancer, or is at increased risk of developing cancer, by
CC hybridising a nucleic acid sample to the nucleic acid sequences from the
CC array, and detecting the presence of mutations in FA/BRCA pathway genes
CC in the nucleic acid sample from the patient, where detecting the presence
CC of mutations is indicative of a patient who has cancer, or is at
CC increased risk of developing cancer. A method of the invention is useful
CC for screening a chemosensitising agent, and the agent obtained is useful
CC for treating a patient having a cancer. The present sequence is used in
CC the exemplification of the invention.
XX
SQ Sequence 18 BP; 2 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 647 TGCACGCTCTGGAGGG 663
DB 2 TGCACGCTCTGGAGGG 18

RESULT 794
ABX34421
ID ABX34421 standard; DNA; 18 BP.
XX
AC ABX34421;
XX
XX 11-FEB-2003 (first entry)
XX
XX PCR primer #2 for S. atroolivaceus leinamycin gene cluster ORF+4.
XX
XX Leinamycin biosynthesis gene cluster; Lmn; open reading frame; ORF;
XX anti-tumour antibiotic; broad spectrum antimicrobial activity;
XX Gram-positive; Gram-negative bacteria; chemical modification; metabolite;
XX apo-carrier protein; holo-carrier protein; tumour; polypeptide;
XX hybrid polypeptide/polypeptide metabolite; Lmn production; cytostatic;
XX PCR; primer; ss.
XX
XX Streptomyces atroolivaceus.
XX
XX WO200277179-A2.
XX
XX 03-OCT-2002.
XX
XX 22-MAR-2002; 2002WO-US008937.
XX
XX 26-MAR-2001; 2001US-0278935P.
XX (REGC) UNIV CALIFORNIA.
XX (KYOW) KYOWA HAKKO KOGYO KK.
XX
XX Shen B, Cheng Y, Tang G;
XX
XX WPI; 2003-018907/01.
XX
XX Novel gene cluster responsible for synthesis of leinamycin in
XX Streptomyces atroolivaceus useful for making various peptide and/or
XX polypeptide, and/or hybrid polypeptide/polypeptide metabolites.
XX
XX Claim 1; Page 29; 185pp; English.
XX
XX The present invention relates to the isolation of the Streptomyces
XX atroolivaceus leinamycin (Lmn) biosynthesis gene cluster containing 71
XX open reading frames (ORFs) (ORFs -35 through -1, ORFs lnmA through lnmZ,
XX and ORFs +1 through +9). Leinamycin is a novel anti-tumour antibiotic
XX produced by several Streptomyces species. It exhibits broad spectrum
XX antimicrobial activity against Gram-positive and Gram-negative bacteria,
XX but not against fungi. The polypeptides encoded by the lnm biosynthesis
XX gene cluster ORFs are useful for chemically modifying a molecule in a
XX host cell. The host cell is a bacterium or eukaryotic cell, including a
XX mammalian, yeast, plant, fungal, or insect cell. The molecule is an

CC endogenous metabolite produced by the host cell or exogenously supplied
 CC metabolite, or an amino acid, and the polypeptide is a peptide synthetase
 CC or amino transferase. The polypeptides encoded by the lmm gene cluster
 CC are useful for converting an apo-carrier protein to a holo-carrier
 CC protein. lmm shows potent antitumour activity in tumour models in vivo.
 CC The lmm gene cluster modules and/or catalytic domains are useful for
 CC making various peptide modules and/or polyketide, and/or hybrid
 CC polypeptide/polyketide metabolites. The proteins encoded by the ORFs are
 CC useful alone, or in combination with other active domains to modify
 CC various target substrates. The lmm gene cluster is useful to upregulate
 CC endogenous lmm production to permit lmm production in cells and/or to
 CC make various modified lmm. lmm, its analogue, or other polyketide,
 CC peptide or hybrid polyketide/peptide metabolites are useful as
 CC therapeutic agents, to treat a number of disorders, depending upon the
 CC type of metabolites. ABX34290-ABX34431 represent PCR primers used to
 CC amplify individual ORFs of the S. atroolivaceus leinamycin biosynthesis
 CC gene cluster
 XX
 SQ Sequence 18 BP; 3 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 275 TCAGACAGGCGCTCC 291
 Db 1 TCAGATCAGGCGCGCC 17
 RESULT 795
 ACA58246
 ID ACA58246 standard; DNA; 18 BP.
 XX
 AC ACA58246;
 AC
 DT 09-JUN-2003 (first entry)
 XX
 DE Human familial bipolar affective disorder chromosome marker #194.
 XX
 KW Human; genotype determination; familial bipolar affective disorder;
 KW chromosomal region linked; locus associated with resistance; D4S402;
 KW D4S424; D4S431; D4S404; D11S394; D11S29; chromosome marker; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002192655-A1.
 XX
 PD 19-DEC-2002.
 XX
 PF 13-JUN-2001; 2001US-00881012.
 XX
 PR 29-MAR-1996; 96US-0014334P.
 PR 20-OCT-1997; 97US-0062924P.
 PR 19-OCT-1998; 98US-00175158.
 XX
 PA (GINN/) GINN E I.
 PA (EGEL/) EGELAND J A.
 PA (PAUL/) PAUL S M.
 XX
 PI Ginn EI, Egeland JA, Paul SM;
 XX
 DR WPI; 2003-352708/33.
 XX
 XX Determining a genotype associated with increased or decreased resistance
 PT to familial bipolar affective disorder in a family comprises determining
 PT the genotype of e.g., chromosomal regions D4S402 and D4S424.
 XX
 PS Disclosure; Page 12; 79pp; English.
 XX
 XX The present invention relates to a method of determining a genotype
 CC associated with increased or decreased resistance to familial bipolar
 CC affective disorder. The method comprises determining the genotype with at
 CC least one marker of at least one chromosomal region linked to a locus

CC associated with resistance to bipolar affective disorder, where the
 CC chromosomal regions are included of and localised between D4S402 and
 CC D4S424, D4S431 and D4S404, or D11S394 and D11S29. The invention also
 CC discloses a kit for determining a genotype associated with increased or
 CC decreased resistance to familial bipolar affective disorder, where the
 CC kit comprises markers for two or more of the chromosomal regions cited.
 CC The method and kit are useful for determining a genotype associated with
 CC increased or decreased resistance to familial bipolar affective disorder
 CC in a family affected by bipolar affective disorder, for determining the
 CC contribution of these chromosomal regions to bipolar affective disorder
 CC in an affective family member, and for assessing an increased or
 CC decreased risk of developing bipolar illness for a tested individual from
 CC an affected family. ACA58053-ACA58292 represent primers used in the
 CC present invention
 XX
 SQ Sequence 18 BP; 4 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 558 AGGACAAGGCTCTGTG 574
 Db 1 AGGCCAAGACCTCTGTG 17
 RESULT 796
 ADL71979/C
 ID ADL71979 standard; DNA; 18 BP.
 XX
 AC ADL71979;
 AC
 DT 20-MAY-2004 (first entry)
 XX
 DE CENP-A DNA amplifying PCR primer.
 XX
 KW FIR; CENP-A; cancer antigen peptide;
 KW far-upstream binding protein interacting receptor;
 KW centromere-specific protein A; cancer; PCR; primer; ss.
 XX
 OS Synthetic.
 XX
 PN WO2004018679-A1.
 XX
 PD 04-MAR-2004.
 XX
 PF 22-AUG-2003; 2003WO-JP010676.
 XX
 PR 23-AUG-2002; 2002JP-00244249.
 XX
 XX (NISC-) JAPAN SCI & TECHNOLOGY CORP.
 PA
 PI Shimada H, Tomonaga T, Matsushita K, Ochiai T, Nomura F;
 XX
 DR WPI; 2004-238979/22.
 XX
 XX Cancer antigen polypeptides, nucleic acids encoding them and antibodies
 PT recognising them for specific and sensitive diagnosis of colon and rectal
 PT cancer.
 XX
 PS Example 3; SEQ ID NO 24; 323pp; Japanese.
 XX
 XX The invention relates to novel polynucleotides encoding all or part of
 CC cancer antigen peptide FIR (far-upstream binding protein interacting
 CC receptor) or peptides derived from it and polynucleotides encoding all or
 CC part of cancer antigen peptide CENP-A (centromere-specific protein A) or
 CC a peptide derived from it. The polynucleotides or primers, probes and
 CC substances containing them are use in a method for cancer diagnosis and
 CC especially diagnosis of colorectal cancer. Sequences ADL71978-ADL71981
 CC represent PCR primers for amplifying the human CENP-A DNA.
 XX
 SQ Sequence 18 BP; 1 A; 6 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 491 AAGAGGAGGAGGAGCA 507
 |||||
 Db 18 AAGAGGAGGAGGAGCA 2

RESULT 797
 ADP47488
 ID ADP47488 standard; DNA; 18 BP.
 XX
 AC ADP47488;
 XX
 DT 09-SEP-2004 (first entry)
 XX
 DE Intelligent PCR primer for the identification of bacteria SeqID 143.
 XX
 KW PCR; ss; primer; pharmacogenetic analysis; medical diagnosis; cancer;
 KW blood typing; virus stereotyping; pathogen, mass spectroscopy;
 KW etiologic agent.
 XX
 OS Synthetic.
 XX
 PN WO2004052175-A2.
 XX
 PD 24-JUN-2004.
 XX
 PF 05-DEC-2003; 2003WO-US038830.
 XX
 PR 06-DEC-2002; 2002US-0431319P.
 PR 18-DEC-2002; 2002US-00323233.
 PR 18-DEC-2002; 2002US-00325526.
 PR 18-DEC-2002; 2002US-00325527.
 PR 18-DEC-2002; 2002US-00326051.
 PR 29-JAN-2003; 2003US-0443443P.
 PR 30-JAN-2003; 2003US-0443788P.
 PR 14-FEB-2003; 2003US-0447529P.
 PR 11-SEP-2003; 2003US-00660122.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Ecker DJ, Griffey RH, Hofstadler SA, Sampath R, Mcneil J;
 PI Crooke ST;
 PI
 XX
 DR WPI; 2004-468672/44.
 XX
 PT Identifying a pathogen in a biological sample, useful in medical
 PT diagnosis, comprises amplifying a nucleic acid from the sample with a
 PT pair of intelligent primers, and determining the molecular mass of the
 PT amplification product.
 XX
 PS Example 15; SEQ ID NO 143; 228pp; English.
 XX
 CC This invention relates to a novel method for the rapid identification of
 CC pathogens occurring in environmental samples or biological samples
 CC derived from humans and animals. Specifically, it refers to using
 CC intelligent primers to obtain an amplification product in order that the
 CC molecular mass of the amplicon can be determined by mass spectroscopy,
 CC which in turn identifies the pathogen found in the sample. The present
 CC invention describes the rapid detection and identification of an
 CC etiologic agent that does not require nucleic acid sequencing, and
 CC instead relies on the use of intelligent primers to target ribosomal RNA
 CC or housekeeping genes. Accordingly, this method can be used to identify a
 CC pathogen or infectious agent in a biological sample, which is useful in
 CC pharmacogenetic analysis and medical diagnosis (including cancer
 CC diagnosis based on mutations and polymorphisms), or for detecting single
 CC nucleotide polymorphisms in blood typing or stereotyping of viruses. This
 CC oligonucleotide sequence is an intelligent PCR primer used to identify
 CC different bacterial strains, given in an exemplification of the
 CC invention.

SQL Sequence 18 BP; 3 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 258 CCATGCTGCACCTGCT 274
 |||||
 Db 1 CCATGCTGCACCTGCT 17

RESULT 798
 ADQ59846
 ID ADQ59846 standard; DNA; 18 BP.
 XX
 AC ADQ59846;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE Intelligent PCR primer 16S_EC_326_1058 reverse SEQ ID NO:143.
 XX
 KW ss; etiologic agent; disease; intelligent primer;
 KW pathogen identification; PCR; primer.
 XX
 OS Synthetic.
 XX
 PN WO2004060278-A2.
 XX
 PD 22-JUL-2004.
 XX
 PF 05-DEC-2003; 2003WO-US038761.
 XX
 PR 06-DEC-2002; 2002US-0431319P.
 PR 18-DEC-2002; 2002US-00323233.
 PR 18-DEC-2002; 2002US-00325526.
 PR 18-DEC-2002; 2002US-00325527.
 PR 18-DEC-2002; 2002US-00326051.
 PR 29-JAN-2003; 2003US-0443443P.
 PR 30-JAN-2003; 2003US-0443788P.
 PR 14-FEB-2003; 2003US-0447529P.
 PR 11-SEP-2003; 2003US-0501926P.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Ecker DJ, Griffey RH, Sampath R, Hofstadler SA, Mcneil J;
 PI Crooke ST, Blyn LB, Ranken R, Hall TA;
 PI
 XX
 DR WPI; 2004-534302/51.
 XX
 PT Identifying pathogens in humans or animals comprises amplifying a nucleic
 PT acid molecule from the individual with intelligent primers to obtain
 PT amplification products, and determining molecular masses of the
 PT amplification products.
 XX
 PS Claim 40; SEQ ID NO 143; 184pp; English.
 XX
 CC The invention relates to a novel method for identifying etiologic agents
 CC of disease in an individual comprising amplifying a nucleic acid from a
 CC biological sample of the individual with intelligent primers to obtain
 CC amplification products corresponding to the etiologic agents, and
 CC determining the molecular masses of the amplification products. The
 CC composition and methods of the invention are useful for identifying
 CC pathogens in biological samples from humans and animals, resolving
 CC etiologic agents present in samples obtained from humans and animals,
 CC determining detailed genetic information about such pathogens or
 CC etiologic agents, and for rapidly detecting and identifying bioagents
 CC from environmental, clinical or other samples. The present sequence
 CC represents an intelligent PCR primer of the invention.

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 258 CCATGCTGCACCTGCT 274
 ||||| ||||| |||||
 Db 1 CCATGAGCAGCCTGCT 17

RESULT 799
 ADR06076/c
 ID ADR06076 standard; DNA; 18 BP.
 XX
 AC ADR06076;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human TNFR1 antisense oligonucleotide seqid 74.
 XX
 KW cytostatic; gene therapy; apoptosis inhibitor;
 KW radiation-induced apoptosis; tumour necrosis factor receptor 1; TNFR1;
 KW human; antisense oligonucleotide; antisense technology; ss.
 OS Homo sapiens.
 XX

Key Location/Qualifiers
 modified_base 1..18
 /*tag= b
 /mod_base= OTHER
 /note= "OTHER= Phosphorothioate backbone"
 modified_base 1..14
 /*tag= a
 /mod_base= OTHER
 /note= "OTHER= Optionally 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 modified_base 15..18
 /*tag= c
 /mod_base= OTHER
 /note= "OTHER= Optionally 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 US2004147471-A1.
 29-JUL-2004.
 06-NOV-2003; 2003US-00702817.
 26-JUN-1998; 98US-00106038.
 17-JUN-1999; 99WO-US013763.
 24-OCT-2000; 2000US-00695451.
 (ZHAN/) ZHANG H.
 Zhang H;
 WPI; 2004-561407/54.
 Inhibiting radiation-induced apoptosis in a cell or tissue comprises administering to the cell or tissue an antisense oligonucleotide targeted to a nucleic acid molecule encoding tumor necrosis factor receptor 1.
 Example 10; SEQ ID NO 74; 24pp; English.
 The invention describes a method of inhibiting radiation-induced apoptosis in a cell or tissue comprising administering to the cell or tissue an antisense oligonucleotide of 8-30 nucleotides in length targeted to a nucleic acid molecule encoding tumor necrosis factor receptor 1 (TNFR1). The method and antisense oligonucleotides are useful for inhibiting radiation-induced apoptosis in a cell or tissue, and for treating diseases associated with the expression of TNFR1. This sequence represents a human tumour necrosis factor receptor 1 (TNFR1) antisense oligonucleotide.
 Sequence 18 BP; 3 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 302 CAGCGCTGCTGGAGGA 318
 ||||| ||||| |||||
 Db 17 CTGGGCTGCTGGAGGA 1

RESULT 800
 ADR00917
 ID ADR00917 standard; DNA; 18 BP.
 XX
 AC ADR00917;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID905.
 XX
 KW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
 KW tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
 KW GUCY2F; MCKK; MLK4; kinase domain; cytostatic; tyrosine kinase inhibitor;
 KW guanylate cyclase stimulator; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004082458-A2.
 XX
 PD 30-SEP-2004.
 XX
 PF 18-FEB-2004; 2004WO-US004452.
 XX
 PR 21-FEB-2003; 2003US-0448537P.
 PR 29-MAY-2003; 2003US-0473895P.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
 DR WPI; 2004-718702/70.
 XX
 PT Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCKK) and associated methods for diagnosing cancer and screening for anti-cancer agents.
 PT
 PS Disclosure; SEQ ID NO 905; 363pp; English.
 XX
 CC This invention relates to a novel activated mutant protein tyrosine kinases and associated methods for diagnosing cancer and screening for anti-cancer agents. Protein kinases are signalling molecules involved in tumorigenesis. Mutational analysis of the human tyrosine kinase gene family identified somatic alteration sin 1 in 5 colorectal cancers, with the majority of mutations occurring in the NTRK3, FES, GUCY2F and MCKK/MLK4 genes. Most were identified in the kinase domain. The invention may be useful for the production of compounds with a cytostatic activity acting as protein tyrosine kinase inhibitors or guanylate cyclase stimulators. The invention may be useful for developing methods for detecting mutations involved in cancer or screening for anti-cancer agents. The present sequence is that of a human-derived oligonucleotide which is related to the invention.
 XX
 SQ Sequence 18 BP; 6 A; 2 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 5.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 402 GCCAGAGGGAGGAGAG 418
 ||||| ||||| |||||
 Db 2 GCCAGAGGGAGGAGAG 18

RESULT 801

ADR74661/c
ID ADR74661 standard; DNA; 18 BP.
XX
AC ADR74661;
XX
DT 16-DEC-2004 (first entry)
XX
DE Allele specific primer A for human stenosis associated marker hCV1997488.
XX
DE Human; ss; PCR; primer; Allele specific primer; coronary stenosis;
KW angina; ischaemic chest pain; myocardial infarction;
KW sudden cardiac death; SNP; single nucleotide polymorphism.
XX
OS Homo sapiens.
XX
XX W02004081186-A2.
XX
XX 23-SEP-2004.
XX
XX 10-MAR-2004; 2004WO-US007140.
XX
XX 10-MAR-2003; 2003US-0453050P.
PR 30-APR-2003; 2003US-0466437P.
XX
XX (APPL-) APPLERA CORP.
XX
XX Cargill M, Devlin JJ, Luke MW;
PI
XX WPI; 2004-668949/65.
DR
XX
XX Identifying an individual who has altered risk for developing stenosis
PT comprises detecting single nucleotide polymorphism (SNP), in the
PT individual's nucleic acids.
XX
XX Claim 19; SEQ ID NO 67973; 146pp; English.
PS
XX
XX The invention relates to identifying an individual who has altered risk
CC for developing coronary stenosis comprising detecting a single nucleotide
CC polymorphism (SNP) in any one of the 67073 nucleotide sequences (not
CC given in the specification), in the individual's nucleic acids, where the
CC presence of the SNP is correlated with an altered risk for stenosis in
CC the individual. Also included are an isolated nucleic acid molecule
CC (comprising at least 8 contiguous nucleotides where one of the
CC nucleotides is an SNP as cited above, or their complement), an isolated
CC polypeptide comprising an amino acid sequence selected from any of the
CC 696 amino acid sequences (not defined in the specification), an antibody
CC that specifically binds to the polypeptide (or its antigen-binding
CC fragment), an amplified polynucleotide containing the SNP as cited (where
CC the amplified polynucleotide is between about 16 and about 1,000
CC nucleotides in length), an isolated polynucleotide which specifically
CC hybridises to a nucleic acid molecule containing the SNP, a kit for
CC detecting a SNP in a nucleic acid, detecting a SNP in a nucleic acid
CC molecule, detecting a variant polypeptide and identifying an agent useful
CC in therapeutically or prophylactically treating stenosis. The detection
CC step of the method is carried out by a process selected from allele-
CC specific probe hybridisation, allele-specific primer extension, allele-
CC specific amplification, sequencing, 5' nuclease digestion, molecular
CC beacon assay, oligonucleotide ligation assay, size analysis, and single-
CC stranded conformation polymorphism. The method is useful for identifying
CC an individual who has altered risk for developing coronary stenosis,
CC which can lead to angina (ischaemic chest pain), myocardial infarction
CC and ultimately sudden cardiac death. The present sequence is an allele
CC specific primer for amplifying a SNP-containing region of a human marker
CC gene associated with stenosis. NOTE: SEQ ID 1-67771 are not shown in the
CC specification but are provided on a CD-R named CL001510CDR which was not
CC supplied with the specification.
XX
XX Sequence 18 BP; 3 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 89.2%; Pred. No. 5.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 603 AGCTGCAGGAGAGCCAG 619
Db ||||| ||||| ||||| |||||
17 AGCTTCAGCAGAGCCAG 1
RESULT 802
AAV20512
ID AAV20512 standard; DNA; 17 BP.
XX
AC AAV20512;
XX
DT 30-JUN-1998 (first entry)
XX
DE Probe for Conus geographus conantokin DNA.
XX
DE Conantokin; predatory cone snail; treatment; neurologic disorder;
KW psychiatric disorder; anticonvulsant; neuroprotective; analgesic;
KW HIV infection; ophthalmic indication; memory; learning defect;
KW cognitive defect; probe; ss.
XX
OS Synthetic.
OS Conus geographus.
XX
XX W09803541-A1.
PN
XX 29-JAN-1998.
PD
XX 21-JUL-1997; 97WO-US012618.
PF
XX 22-JUL-1996; 96US-00684742.
PR
XX (UTAH) UNIV UTAH RES FOUND.
PA (COGN-) COGNETIX INC.
XX
XX Abogadie FC, Cruz LJ, Olivera BM, Walker C, Colledge C;
PI Hillyard DR, Jimenez E, Laver RT, Zhou L, Shen GS, McCabe RT;
PI Rivier JE;
XX
XX WPI; 1998-120694/11.
DR
XX
XX New conantokin peptide(s) - useful for e.g. treating neurologic or
PT psychiatric disorders, or the management of pain.
XX
XX Claim 20; Page 79; 122pp; English.
PS
XX
XX The present sequence is a probe for the DNA encoding Conus geographus
CC conantokin, peptide derivatives of which can be used to treat neurologic
CC and psychiatric disorders, e.g. as an anticonvulsant, neuroprotective or
CC analgesic agent. Neurologic and psychiatric disorders include epilepsy,
CC convulsions, neurotoxic injury (associated with conditions of hypoxia,
CC anoxia or ischaemia, which typically follow stroke, cerebrovascular
CC accident, brain or spinal cord trauma, myocardial infarct, physical
CC trauma, drowning, suffocation, perinatal asphyxia or hypoglycaemic
CC events), neurodegeneration (associated with Alzheimer's disease, senile
CC dementia, Amyotrophic lateral Sclerosis, Multiple Sclerosis, Parkinson's
CC disease, Huntington's disease, Down's Syndrome, Korsakoff's disease,
CC schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia
CC and neuronal damage associated with uncontrolled seizures), chemical
CC toxicity (such as addiction, and morphine, opiate, opioid and barbiturate
CC tolerance), pain (acute, chronic, migraine), anxiety, major depression,
CC manic-depressive illness, obsessive-compulsive disorder, schizophrenia,
CC and mood disorders (such as bipolar disorder, unipolar depression,
CC dysthymia and seasonal affective disorder) and dystonia (movement
CC disorder), sleep disorder, muscle relaxation and urinary incontinence.
CC The peptide can also be used to treat HIV infection, ophthalmic
CC indication and memory, learning or cognitive defects
XX
XX Sequence 17 BP; 6 A; 2 C; 2 G; 1 T; 0 U; 6 Other;

Query Match 1.8%; Score 13.6; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 5.8e+02;
Matches 10; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy	315	AGGAGAATCAAGAGCT	330
		: : : : : : :	
Db	2	ARGARAAYCARGARYT	17

RESULT 803
AAV17129
ID AAV17129 standard; DNA; 17 BP.
XX
XX AAV17129;
XX AC
XX AC
XX DT
XX DT
XX DT
30-JUN-1998 (first entry)
Probe for *Conus geographus* conantokin DNA.

Conantokin; predatory cone snail; treatment; neurologic disorder;
KW psychiatric disorder; anticonvulsant; neuroprotective; analgesic;
KW HIV infection; ophtalmic indication; memory; learning defect;
KW coagitive defect; probe; ss.

OS Synthetic.
OS *Conus geographus*.

PN WO9803189-A1.

29-JAN-1998.

21-JUL-1997; 97WO-US012652.

PR 22-JUL-1996; 96US-00684750.

XX
XX

XX
XX

XX

XX XX

excitation of nerve cells by excitatory amino acids or agonists of the N-methyl-D-aspartate receptor.

PS Example 4: Page 79; 122pp; English.

The present sequence is a probe for the DNA encoding *Conus geographus* conotoxin, peptide derivatives of which can be used to treat neurologic and psychiatric disorders, e.g. as an anticonvulsant, neuroprotective or analgesic agent. Neurologic and psychiatric disorders include epilepsy, convulsions, neurotoxic injury (associated with conditions of hypoxia, anoxia or ischaemia, which typically follow stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia or hypoglycaemic events), neurodegeneration (associated with Alzheimer's disease, senile dementia, Amyotrophic lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease, schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia) and neuronal damage associated with uncontrolled seizures), chemical toxicity (such as addiction, and morphine, opiate, opioid and barbiturate tolerance), pain (acute, chronic, migraine), anxiety, major depression, manic-depressive illness, obsessive-compulsive disorder, schizophrenia and mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal affective disorder) and dystonia (movement disorder), sleep disorder, muscle relaxation and urinary incontinence. The peptide can also be used to treat HIV infection, ophthalmic indication and memory, learning or cognitive defects

SQ Sequence 17 BP; 6 A; 2 C; 2 G; 1 T; 0 U; 6 Other;

Query Match	1.8%	Score	13.6	DB 1	Length	17	
Best Local Similarity	62.5%	Pred. No.	5.8e+02				
Matches	10	Conservative	6	Mismatches	0	Gaps	0

315 AGGAGAA TCAAGAGCT 330
QY

Db . 2 ARGAPAAYCARGARYT 17

RESULT 804

AAI65365

ID AAI65365 standard; DNA; 17 BP.

AC AAI65365;

DT 10-DEC-2001 (first entry)

DE Probe used to isolate DNA encoding conantokin G.

Nicotin; cone snail; nerve cell excitation; NMDA receptor; epilepsy; N-methyl-D-aspartate receptor; pain; psychiatric disorder; neurotoxic injury; hypoxia; anxiety; ischemia; neurodegeneration; chemical toxicity; addiction; drug craving; psychiatric disorder; anxiety; depression; obsessive compulsive disorder; schizophrenia; mood disorder; ophthalmic disorder; neurological disorder; dystonia; sleep disorder; muscle relaxation; urinary incontinence; cognition enhancement; HIV infection; probe; ss.

OS Conus geographus.

PN US6277825-B1.

PD 21-AUG-2001.

20-JUL-1999; 99US-00357141.

PR 22-JUL-1996; 96US-00684750.

PR 21-JUL-1997; 97WO-US012652.

PR 01-APR-1999; 99US-00283277.

PA (UTAH) UNIV UTAH RES FOUND.

XX
XXXXXXXXXXXXX

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

XX
XX

PT chimera for treating disorders e.g. migraine.

PS Example 4; Col 21; 6

CC The present sequence represents a probe used to isolate DNA encoding

CC contain gamma-carboxyglutamic aci

which the pathophysiology involves excessive excitation of nerve cells by excitatory amino acids or agonist of N-methyl-D-aspartate (NMDA) receptor. The conantokin peptides are used for the treatment of disorders such as pain; neurologic or psychiatric disorders such as epilepsy; for reducing neurotoxic injury associated with conditions of hypoxia, anoxia or ischemia; for treating neurodegeneration; for treating chemical toxicity such as addiction, drug craving, alcohol abuse, morphine, opioïd and barbiturate tolerance; for treating psychiatric disorders such as anxiety, major depression, manic-depression illness, obsessive compulsive disorder, schizophrenia or mood disorder; for treating ophthalmic disorder; for treating additional neurological disorders e.g. dystonia, sleep disorder, muscle relaxation and urinary incontinence; for memory/coaction enhancement; for treating HIV infection

Sequence 17 BP: 6 A: 2 C: 2 G: 1 T: 0 U: 6 Other; SO

Query Match	1.8%	Score 13.6;	DB 1;	Length 17;
Best Local Similarity	62.5%;	Pred. No. 5.8e+02;		
Matches	10;	Conservative	6;	Mismatches 0;
				Indels 0;
				Gaps 0;

```

QY 315 AGGAGAAATCAAGAGCT 330
   ||:||||:||||:|
Db 2 ARGARAAACAGARYT 17

RESULT 805
ID AAQ33752 standard; DNA; 15 BP.
XX AAQ33752;
AC AAQ33752;
XX
XX 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
DE Microsatellite sequence from clone TGLA162.
XX
XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
XX Bos taurus.
OS
XX
XX W09213102-A1.
PN
XX 06-AUG-1992.
PD
XX
XX 15-JAN-1992; 92WO-US000340.
PF
XX
XX 15-JAN-1991; 91US-00642342.
PR
XX (GENM-) GENMARK.
PA
XX
XX Georges M, Massey JM;
PI
XX
XX WPI; 1992-284684/34.
DR
XX
XX Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.
PS
XX Table 7; Page 231; 517pp; English.
XX
XX The sequence is that of a bovine microsatellite sequence obt'd. by
CC screening a library of bovine MboI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC in the bovine genome is estimated at >100, 000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be
CC used to identify individuals for parentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved in the determination of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
XX Sequence 15 BP; 5 A; 5 C; 5 G; 0 T; 0 U; 0 Other;
QY Query Match 1.8%; Score 13.4; DB 1; Length 15;
   Best Local Similarity 93.3%; Pred. No. 5.3e+02;
   Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 1 GCAGCAGCAGCAGCA 15

RESULT 806
AAT37567/c
ID AAT37567 standard; mRNA; 15 BP.
XX
XX AAT37567;
AC

QY 718 GCTGCAGCAGCAGCA 732
   ||| ||||| ||||| |||||
Db 1 GCAGCAGCAGCAGCA 15

RESULT 807
AA65327/c
ID AA65327 standard; RNA; 15 BP.
XX
XX AA65327;
AC
XX
XX 20-JUL-1999 (first entry)
DT
XX
XX Mouse B7-1 hammerhead ribozyme target SEQ ID NO:1959.
DE
XX
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.

```

```

XX 11-NOV-1996 (first entry)
DT
XX
XX Apo(a) mRNA (nt. pos. 11423) hammerhead ribozyme target sequence.
DE
XX
XX Enzymatic RNA molecule; cleavage; apolipoprotein (a); apo(a);
KW hammerhead ribozyme; target sequence; diagnosis; treatment;
KW lipoprotein (a); atherosclerosis; myocardial infarction; stroke;
KW restenosis; heart disease; human; ss.
XX
XX Homo sapiens.
OS
XX
XX W09609392-A1.
PN
XX
XX 28-MAR-1996.
PD
XX
XX 21-SEP-1995; 95WO-US011995.
PF
XX
XX 23-SEP-1994; 94US-00311760.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Stinchcomb DT, Mcswiggen J, Newton RS, Ramharack R;
PI
XX
XX WPI; 1996-188454/19.
DR
XX
XX Enzymatic RNA mols. which cleave apo(a) mRNA - useful in diagnosis and
PT treatment of conditions related to lip(a) levels, e.g. atherosclerosis,
PT myocardial infarction, and heart diseases.
XX
XX Claim 2; Page 18; 37pp; English.
XX
XX A claimed enzymatic RNA mol. for the cleavage of apolipoprotein (a)
CC (apo(a)) mRNA, specifically a hammerhead ribozyme, has binding arms
CC complementary to the present sequence (nucleotide position 11423). The
CC ribozyme blocks to some extent apo(a) expression, and can therefore be
CC used to diagnose or treat conditions related to lipoprotein (a) levels,
CC e.g. atherosclerosis, myocardial infarction, stroke, restenosis and heart
CC disease. PCR was used to generate a substrate for T7 RNA polymerase
CC transcription from human apo(a) cDNA clones. Labelled transcripts were
CC synthesised in vitro to form 2 templates. The oligonucleotides and
CC labelled transcripts were annealed, RNaseH added and the mixes.
CC incubated. After a designated time the reactions were stopped, and RNA
CC sepd. on sequencing polyacrylamide gels. The percentage of substrate
CC cleaved was determined by autoradiographic quantification, and the most
CC accessible ribozyme target sites chosen
XX
XX Sequence 15 BP; 3 A; 7 C; 3 G; 0 T; 2 U; 0 Other;
QY Query Match 1.8%; Score 13.4; DB 1; Length 15;
   Best Local Similarity 93.3%; Pred. No. 5.3e+02;
   Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Db 456 TGCTGCAGCAGACTCG 470
   ||||| ||||| |||||
   15 TGCTGCAGCAGCTCG 1

RESULT 807
AA65327/c
ID AA65327 standard; RNA; 15 BP.
XX
XX AA65327;
AC
XX
XX 20-JUL-1999 (first entry)
DT
XX
XX Mouse B7-1 hammerhead ribozyme target SEQ ID NO:1959.
DE
XX
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.

```


XX PN WO200056930-A1.
XX PD 28-SEP-2000.
XX PF 20-MAR-2000; 2000WO-US007486.
XX PR 24-MAR-1999; 99US-00275850.
XX PA (NEXS-) NEXSTAR PHARM INC.
XX PI Pagratis N, Gold L, Shatland T, Javornik B;
XX DR WPI; 2000-594583/56.
XX PT Identifying nucleic acid ligands of a target molecule comprises annealing
XX PT complementary oligonucleotides, partitioning the nucleic acids and
XX PT amplifying the nucleic acids exhibiting increased affinity.
XX PS Example 2; Page 76; 264pp; English.
XX CC The invention relates to a method of identifying nucleic acid ligands of
XX CC a target molecule from a candidate mixture composed of single stranded
XX CC nucleic acids, each having a region of randomised sequence and a region
XX CC of fixed sequence. The method uses modified versions of the SELEX
XX CC (systematic evolution of ligands by exponential enrichment) method in
XX CC which the participation of fixed sequences is minimised or eliminated.
XX CC This method comprises annealing complementary oligonucleotides to the
XX CC fixed sequences of the candidate molecule mixture, contacting the
XX CC candidate mixture with the target molecule, partitioning the nucleic
XX CC acids which have increased affinity relative to the candidate mixture,
XX CC and amplifying the nucleic acids exhibiting increased affinity to yield a
XX CC ligand enriched mixture of nucleic acids. In one embodiment of the
XX CC invention, one or more regions of fixed sequences is replaced with
XX CC different fixed sequences, and the binding, partitioning and
XX CC amplification steps are repeated. In another embodiment, the partitioned
XX CC nucleic acids are hybridised with a library of single stranded
XX CC complementary nucleic acids, are then amplified, and the fixed regions of
XX CC the increased affinity nucleic acids cleaved. In the exemplifications of
XX CC the invention, a consensus binding site for MS2 CP (bacteriophage MS2
XX CC replicase fragment was identified by SELEX. MS2 CP binding sites were
XX CC then identified in the Escherichia coli genomic library by SELEX or by
XX CC the RNAMOT program. The present sequence represents an E. coli MS2 CP
XX CC binding site identified by the RNAMOT program
XX SQ Sequence 15 BP; 4 A; 5 C; 5 G; 0 T; 1 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 5.3e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 720 TGCAGCAGCAGCACA 734
DB 1 UGCAGCAGCAGCGCA 15
RESULT 810
AAF45430
ID AAF45430 standard; DNA; 15 BP.
XX AC AAF45430;
XX DT 30-MAR-2001 (first entry)
XX DE IGFBP2 oligonucleotide #269.
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;

KW neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX PN WO200078341-A1.
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wright CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX XX Example 6; Page 35; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, [for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3], which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX CC r45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, ptyriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 1 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 795 AGCGCCAGCGCGCT 809
DB 1 AGCGCCTGCGCGCT 15
RESULT 811
AAF45429
ID AAF45429 standard; DNA; 15 BP.
XX AC AAF45429;
XX DT 30-MAR-2001 (first entry)
XX DE IGFBP2 oligonucleotide #268.
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW neovascular condition of the retina; ss.
XX OS Homo sapiens.

PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 PR 21-JUN-1999; 99US-0140345P.
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 XX Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antiseNSE nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 XX Example 6; Page 35; 201pp; English.
 PS
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antiseNSE oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antiseNSE
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 1 A; 7 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 5.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 794 GAGCGCCGAGCGCC 808
 DB 1 GAGCGCCGAGCGCC 15
 RESULT 812
 ID AAF47286/C
 XX AAF47286 standard; DNA; 15 BP.
 XX
 AC AAF47286;
 XX
 XX 30-MAR-2001 (first entry)
 XX
 XX IGFBP3 oligonucleotide #706.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200078341-A1.
 PN
 XX 28-DEC-2000.
 PD
 XX

PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA
 XX Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antiseNSE nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 XX Example 7; Page 48; 201pp; English.
 PS
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antiseNSE oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antiseNSE
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 1 A; 7 C; 2 G; 5 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 5.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 806 GCCTCGGAGGAGAAG 820
 DB 15 GACTCGGAGGAGAAG 1
 RESULT 813
 ID ABX01206/C
 XX ABX01206 standard; RNA; 15 BP.
 XX
 AC ABX01206;
 XX
 XX 23-DEC-2002 (first entry)
 DT
 XX
 XX Hepatitis C virus substrate #988 for HCV hammerhead ribozyme #988.
 DE
 XX
 XX Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
 KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
 KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
 KW type I interferon; interferon alpha; interferon beta; cytostatic;
 KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
 KW substrate; hammerhead ribozyme; HH ribozyme; ss.
 XX
 XX Hepatitis C virus.
 OS
 XX
 XX US2002082225-A1.
 PN
 XX 27-JUN-2002.
 PD
 XX
 XX 23-MAR-1999; 99US-00274553.
 PF
 XX
 XX 23-MAR-1999; 99US-00274553.
 PR
 XX
 XX (BLAT/) BLATT L.
 PA
 XX (MCSW/) MCSWIGGEN J A.

PN	W05923225-A2.	ACF06258 standard; DNA; 16 BP.	ID	ACF06258 standard; DNA; 16 BP.
XX			XX	
PD	31-AUG-1995.		AC	ACF06258;
XX			XX	
PF			DT	06-OCT-2003 (first entry)
XX	23-FEB-1995; 95WO-1B000156.		XX	
PR	23-FEB-1994; 94US-00201109.	Human NOV4 forward PCR primer SEQ ID NO:36.	DE	
PR	29-MAR-1994; 94US-00218934.	Human; NOVX; cytostatic; antidiabetic; neuroprotective; antiparkinsonian;	XX	
PR	04-APR-1994; 94US-00222795.	antididiabetic; gene therapy; vaccine; cancer; neurodegenerative disorder;	XX	
PR	07-APR-1994; 94US-00224483.	Parkinson's disease; metabolic disorder; diabetes; obesity;	KW	
PR	15-APR-1994; 94US-00227958.	tissue typing; PCR primer; ss.	KW	
PR	15-APR-1994; 94US-00228041.		XX	
PR	18-MAY-1994; 94US-00245736.	Homo sapiens.	OS	
PR	06-JUL-1994; 94US-00271280.	Synthetic.	OS	
PR	16-AUG-1994; 94US-00291433.		XX	
PR	17-AUG-1994; 94US-00292620.		XX	
PR	19-AUG-1994; 94US-00293520.	WO2003052061-A2.	PN	
PR	02-SEP-1994; 94US-00300000.		XX	
PR	08-SEP-1994; 94US-00303039.	26-JUN-2003.	PD	
PR	23-SEP-1994; 94US-00311486.	03-DEC-2002; 2002WO-US038821.	XX	
PR	23-SEP-1994; 94US-00311749.		PF	
PR	28-SEP-1994; 94US-00314397.	17-DEC-2001; 2001US-0341477P.	XX	
PR	03-OCT-1994; 94US-00316771.	17-DEC-2001; 2001US-0341540P.	PR	
PR	07-OCT-1994; 94US-00319492.	20-DEC-2001; 2001US-0342592P.	PR	
PR	11-OCT-1994; 94US-00321993.	31-DEC-2001; 2001US-0344903P.	PR	
PR	04-NOV-1994; 94US-00334847.	17-APR-2002; 2002US-0373288P.	PR	
PR	10-NOV-1994; 94US-00337608.	15-MAY-2002; 2002US-0380981P.	PR	
PR	28-NOV-1994; 94US-00345516.	17-MAY-2002; 2002US-0381495P.	PR	
PR	16-DEC-1994; 94US-00357577.	28-MAY-2002; 2002US-0383744P.	PR	
PR	23-DEC-1994; 94US-00363233.	29-MAY-2002; 2002US-0384024P.	PR	
PR	30-JAN-1995; 95US-00380734.	07-AUG-2002; 2002US-0401788P.	PR	
XX		26-AUG-2002; 2002US-0406353P.	PR	
PA	(RIBO-) RIBOZYME PHARM INC.	31-OCT-2002; 2002US-0422756P.	PR	
XX		02-DEC-2002; 2002US-00307928.	XX	
PI	Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;	(CURA-) CURAGEN CORP.	PA	
PI	Grimm S, Karpeisky A, Kisch K, Matulic-Adamic J, Mcswiggen JA;	Alsobrook JP, Anderson DW, Boldog FL, Burgess CE, Catterton E;	XX	
PI	Modak A, Pavco P, Reigleman L, Sullivan SM, Sweedler D, Thompson JD;	Edinger SR, Gorman L, Guo X, Ji W, Kekuda R, Li L, Patturajan M;	PI	
PI	Tracz D, Usman N, Wincott FE, Woolf T;	Rieger DK, Shenoy SG, Spytek KA, Vernet CAM, Voss EZ, Zhong M;	PI	
XX	WPI; 1995-351090/45.		XX	
XX		WPI; 2003-533005/50.	XX	
PT	Ribozymes having modified bases and methods for producing them - for use	New NOVX polypeptide, useful for preparing a composition for treating or	PT	
PT	in inhibiting disease related genes.	preventing e.g. cancer, neurodegenerative disorders such as Parkinson's	PT	
XX		disease, or metabolic disorders such as diabetes or obesity, or for	PT	
PS	Claim 2; Page 200; 407pp; English.	tissue typing.	PT	
XX		Example C; Page 159; 190pp; English.	PS	
CC	The present sequence represents a preferred target sequence for an	ACF06233 to ACF06242 encode the human NOVX proteins given in ABR83334 to	CC	
CC	enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the	ABR83343, designated NOV1a, NOV2a, NOV3a, NOV4a, NOV4b, NOV5a, NOV6a,	CC	
CC	nucleotide base position indicated in the DE line. Regions of the mRNA	NOV7a, NOV8a and NOV9a respectively. NOVX sequences can have cytostatic,	CC	
CC	that do not form secondary folding structures and that contain potential	antidiabetic, neuroprotective, antiparkinsonian and anorectic activities,	CC	
CC	hammerhead and hairpin ribozyme cleavage sites were identified by	and can be used in vaccines and gene therapy. The NOVX polypeptides can	CC	
CC	computer analysis. Ribozymes directed against these mRNA sequences were	be used for preparing a composition for treating or preventing a	CC	
CC	designed and synthesised with modifications that improve their nuclease	pathology associated with the NOVX-polypeptides e.g. cancer, or	CC	
CC	resistance. The ribozymes cleave the ICAM-1 target sequences and thereby	neurodegenerative disorders such as Parkinson's disease, or metabolic	CC	
CC	inhibit ICAM-1 expression, making them useful for reducing transplant	disorders such as diabetes or obesity, or for tissue typing. The present	CC	
CC	rejection and alleviating symptoms in patients with rheumatoid arthritis,	sequence represents a PCR primer for human NOV4, which is used in an	CC	
CC	asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to	example from the present invention	CC	
CC	correct PI field.)		CC	
XX			XX	
SQ	Sequence 16 BP; 2 A; 4 C; 7 G; 0 T; 3 U; 0 Other;	Sequence 16 BP; 2 A; 6 C; 5 G; 3 T; 0 U; 0 Other;	SQ	
	Query Match 1.8%; Score 13.4; DB 1; Length 16;	Query Match 1.8%; Score 13.4; DB 1; Length 16;		
	Best Local Similarity 80.0%; Pred. No. 5.7e+02;	Best Local Similarity 93.3%; Pred. No. 5.7e+02;		
	Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;	Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		
QY	304 GCCTGCTGGAGGA 318	201 GTGGCCCGCAGCAG 215	QY	
DB	1 GCCTGCTGGAGGA 15	15 GTGGCCCTGCAGCAG 1	DB	
RESULT 816				
ACF06258/c				

RESULT 817
ADN01434/c
ID ADN01434 standard; DNA; 16 BP.
XX
XX ADN01434;
AC
XX
XX 01-JUL-2004 (first entry)
DT
XX
XX Klebsiella oxytoca probe.
DE
XX
XX detection; bacteria; hybridisation; probe; DNA chip; blood culture; ss.
KW
XX
XX Klebsiella oxytoca.
OS
XX
XX W02004029299-A2.
PN
XX
XX 08-APR-2004.
PD
XX
XX 23-SEP-2003; 2003MO-EP010584.
PF
XX
XX 24-SEP-2002; 2002DE-01044456.
PR
XX
XX (HAIN-) HAIN LIFESCENCE GMBH.
PA
XX
XX Weizenegger M, Bollen M;
PI
XX
XX WPI; 2004-340440/31.
DR
XX
XX Detecting clinically important bacteria, useful for diagnosis,
PT particularly in blood cultures, comprises hybridization to sequence- or
PT species-specific probes.
PT
XX
XX Claim 1; SEQ ID NO 27; 90pp; German.
PS
XX
XX This invention describes a novel method for detecting clinically relevant
CC bacteria which comprises hybridisation in which a target nucleic acid,
CC representing part of the genome of the bacteria or its complement, is
CC hybridised under stringent conditions to a sequence- and/or species-
CC specific probe, then the nucleic acid, or its hybridisation to the probe,
CC is detected. Either the probes are immobilized (particularly to a solid
CC phase through a linker, e.g. on a DNA chip) and the nucleic acid is
CC labelled, or the probe is labelled. The method is useful for diagnostic
CC detection of bacteria, particularly in blood cultures, including
CC differentiation between species. A typical self-amplifying chip supported
CC 12 pairs of immobilized primers, each pair specific for a particular
CC species of bacterium, at different locations. It was used to perform a
CC solid-phase PCR (15 minutes at 95degC, then 40 cycles of 15 seconds at
CC 95degC and 45 seconds at 58degC, in presence of Cy5-labelled
CC deoxycytosine triphosphate), then washed and fluorescence at each
CC location measured using a confocal laser scanner. ADN01408-ADN01573
CC represent probes used in the method of the invention.
XX
SQ Sequence 16 BP; 5 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 5.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 592 CTTGCTCGGGAGCT 606
DB 15 CTTGCTCGTGAGCT 1
RESULT 818
AAT93742/c
ID AAT93742 standard; DNA; 17 BP.
XX
XX AAT93742;
AC
XX
XX 25-MAR-2003 (revised)
DT 06-FEB-1998 (first entry)
XX

DE DNA probe 1 specific for type-T cytoplasmic male sterility in Zea mays.
XX
XX TURF 2H3; maize; cytoplasm male sterility; cms; type T; cms-T;
KW open reading frame 13; probe; restriction fragment; mitochondrial DNA;
KW sterility test; ss.
XX
XX Zea mays.
OS
XX
XX US5660983-A.
PN
XX
XX 26-AUG-1997.
PD
XX
XX 23-NOV-1994; 94US-00345264.
PF
XX
XX 04-DEC-1986; 86US-00937926.
PR
XX
XX 17-JUN-1991; 91US-00716645.
PR
XX
XX (MYCO) MYCOGEN PLANT SCI INC.
PA (UYNC-) UNIV NORTH CAROLINA STATE.
PA
XX
XX Dewey R, Levings CS;
PI
XX
XX WPI; 1997-434374/40.
DR
XX
XX DNA probes specific for mitochondrial DNA associated with type-T
PT cytoplasmic male sterility - for detecting male sterility in maize
PT plants.
PT
XX
XX Claim 4; Col 23; 16pp; English.
PS
XX
XX This DNA fragment is part of the TURF 2H3 region of Zea Mays. TURF 2H3
CC (3547 nucleotides long) is found in mitochondrial DNA, and is uniquely
CC arranged in maize affected by cytoplasm male sterility type T (cms-T).
CC The present sequence corresponds to positions 1400-1416 of TURF 2H3, and
CC is located in the middle of open reading frame 13. A synthetic
CC oligonucleotide whose sequence is complementary to the present sequence
CC has also been claimed. Both oligonucleotides can be used as probes to
CC identify a restriction fragment whose size in cms-T mitochondrial DNA is
CC different from the corresponding fragment in normal mitochondrial DNA.
CC They are useful for rapidly and specifically testing maize plants for T-
CC type cytoplasmic male sterility. (Updated on 25-MAR-2003 to correct PF
CC field.)
XX
SQ Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 754 GCGCATGCGAGGCCA 768
DB 17 GCTCATGCGAGGCCA 3
RESULT 819
AAAT75272/c
ID AAAT75272 standard; RNA; 17 BP.
XX
XX
XX
XX AAT75272;
AC
XX
XX 28-JUL-1999 (first entry)
DT
XX
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #800.
DE
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage; ocular disease;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
XX Mus sp.
OS
XX
XX W09715662-A2.
PN

XX 01-MAY-1997.
PD
XX
PP 25-OCT-1996; 96WO-US017480.
XX
XX 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
PI WPI; 1997-359017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 179; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patent
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 3 A; 8 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGC 710
DB 16 AGCTGGAGAGGGAGC 2

RESULT 820
ABN07456
ID ABN07456 standard; DNA; 17 BP.
XX
AC ABN07456;
XX
XX 29-MAY-2002 (first entry)
DT
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7448.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
PN
XX 06-DEC-2001.
PD
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 7448; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 protein, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 GGAGAAGAGGAGTTCCT 426
DB 3 GGAGAAGAGGAGTTCCT 17

RESULT 821
ABN07256
ID ABN07256 standard; DNA; 17 BP.
XX
AC ABN07256;
XX
XX 29-MAY-2002 (first entry)
DT
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7248.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
PN
XX 06-DEC-2001.
PD

XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 XX 21-SEP-2000; 2000US-0234687P.
 XX 27-SEP-2000; 2000US-0236359P.
 XX 04-OCT-2000; 2000GB-00024263.
 XX 30-JAN-2001; 2001WO-US000661.
 XX 30-JAN-2001; 2001WO-US000662.
 XX 30-JAN-2001; 2001WO-US000663.
 XX 30-JAN-2001; 2001WO-US000664.
 XX 30-JAN-2001; 2001WO-US000665.
 XX 30-JAN-2001; 2001WO-US000666.
 XX 30-JAN-2001; 2001WO-US000667.
 XX 30-JAN-2001; 2001WO-US000668.
 XX 30-JAN-2001; 2001WO-US000669.
 XX 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 XX or as specific biomolecule capture probes for surface-enhanced laser
 XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 7248; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 XX nucleic acids can be used as probes to detect, characterise and quantify
 XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 XX provide initial substrates for the recombinant engineering of hGDMPLP-1
 XX protein variants having desired phenotypic improvements, and for
 XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
 XX -1 proteins, as standards in assays used to determine the concentration
 XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 XX capture probes for surface-enhanced laser desorption ionisation, as
 XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 XX production, and in vaccines or for replacement therapy. The
 XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 XX disorder associated with the expression of hGDMPLP-1, in particular heart
 XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 XX The present sequence represents an oligomer used in the screening of the
 XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 XX The sequence data for this patent did not form part of the printed
 XX specification, but was obtained in electronic format directly from WIPO
 XX at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 4 A; 2 C; 9 G; 2 T; 0 U; 0 Other;
 XX
 XX Query Match 1.8%; Score 13.4; DB 1; Length 17;
 XX Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX QY 699 TGGAGAGTGAGCGG 713
 XX |||||||||
 XX Db 1 TGGAGAGTGAGCGG 15
 XX
 XX RESULT 822
 XX ID ABN08977/c
 XX AC ABN08977 standard; DNA; 17 BP.
 XX AC ABN08977;
 XX DT 29-MAY-2002 (first entry)
 XX

DE XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8969.
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 XX skeletal muscle disorder; amplicon; screening; ss.
 OS Homo sapiens.
 XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 XX 21-SEP-2000; 2000US-0234687P.
 XX 27-SEP-2000; 2000US-0236359P.
 XX 04-OCT-2000; 2000GB-00024263.
 XX 30-JAN-2001; 2001WO-US000661.
 XX 30-JAN-2001; 2001WO-US000662.
 XX 30-JAN-2001; 2001WO-US000663.
 XX 30-JAN-2001; 2001WO-US000664.
 XX 30-JAN-2001; 2001WO-US000665.
 XX 30-JAN-2001; 2001WO-US000666.
 XX 30-JAN-2001; 2001WO-US000667.
 XX 30-JAN-2001; 2001WO-US000668.
 XX 30-JAN-2001; 2001WO-US000669.
 XX 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 XX or as specific biomolecule capture probes for surface-enhanced laser
 XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 8969; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 XX nucleic acids can be used as probes to detect, characterise and quantify
 XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 XX provide initial substrates for the recombinant engineering of hGDMPLP-1
 XX protein variants having desired phenotypic improvements, and for
 XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
 XX -1 proteins, as standards in assays used to determine the concentration
 XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 XX capture probes for surface-enhanced laser desorption ionisation, as
 XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 XX production, and in vaccines or for replacement therapy. The
 XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 XX disorder associated with the expression of hGDMPLP-1, in particular heart
 XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 XX The present sequence represents an oligomer used in the screening of the
 XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 XX The sequence data for this patent did not form part of the printed
 XX specification, but was obtained in electronic format directly from WIPO
 XX at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 1.8%; Score 13.4; DB 1; Length 17;
 XX Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX QY 852 ACCAGCTCTTCCAG 866
 XX |||||||||
 XX

Db 17 ACCAGCTCTTCCATG 3

RESULT 823
ABN06832/C
ID ABN06832 standard; DNA; 17 BP.
XX
AC ABN06832;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6824.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 6824; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-1.
CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 266 CACCTGCCTTCAGAA 280
Db 16 CACCTGCCTTCAGAA 2

RESULT 824
ABN08427
ID ABN08427 standard; DNA; 17 BP.
XX
AC ABN08427;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8419.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 8419; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-1.

CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGG 503

Db 3 TGAAGAGCGCAGAGG 17

RESULT 825

ABN08428

ID ABN08428 standard; DNA; 17 BP.

XX AC ABN08428;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8420.

XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US016981.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

XX PR 30-JAN-2001; 2001WO-US000661.

XX PR 30-JAN-2001; 2001WO-US000662.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000666.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 30-JAN-2001; 2001WO-US000669.

XX PR 05-FEB-2001; 2001US-0266860P.

XX PA (AEOM-) AEOMICA INC.

XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX XX WPI; 2002-179446/23.

XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 FT or as specific biomolecule capture probes for surface-enhanced laser
 FT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
 XX

PS Disclosure; SEQ ID NO 8420; 214pp; English.

XX CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGG 503

Db 2 TGAAGAGCGCAGAGG 16

RESULT 826

ABN06833/c

ID ABN06833 standard; DNA; 17 BP.

XX AC ABN06833;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6825.

XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US016981.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

XX PR 30-JAN-2001; 2001WO-US000661.

XX PR 30-JAN-2001; 2001WO-US000662.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000666.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 30-JAN-2001; 2001WO-US000669.

XX PR 05-FEB-2001; 2001WO-US000670.

XX PR 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 XX or as specific biomolecule capture probes for surface-enhanced laser
 XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 6825; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 XX nucleic acids can be used as probes to detect, characterize and quantify
 XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 XX provide initial substrates for the recombinant engineering of hGDMPLP-1
 XX protein variants having desired phenotypic improvements, and for
 XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
 XX -1 proteins, as standards in assays used to determine the concentration
 XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 XX capture probes for surface-enhanced laser desorption/ionisation, as
 XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 XX production, and in vaccines or for replacement therapy. The
 XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 XX disorder associated with the expression of hGDMPLP-1, in particular heart
 XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 XX The present sequence represents an oligomer used in the screening of the
 XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 XX The sequence data for this patent did not form part of the printed
 XX specification, but was obtained in electronic format directly from WIPO
 XX at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 3 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 1.8%; Score 13.4; DB 1; Length 17;
 XX Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 266 CACCTGCTTCAGAA 280
 Db |||||
 15 CACCTGCTTCAGAA 1
 RESULT 827
 ABN07460
 ID ABN07460 standard; DNA; 17 BP.
 XX
 AC ABN07460;
 XX
 XX 29-MAY-2002 (first entry)
 XX
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7452.
 DE
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 XX skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200192524-A2.
 PN
 XX 06-DEC-2001.
 PD
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 PP
 XX 26-MAY-2000; 2000US-0207456P.
 PR
 XX 21-SEP-2000; 2000US-0234687P.
 PR
 XX 27-SEP-2000; 2000US-0236359P.
 PR
 XX 04-OCT-2000; 2000GB-00024263.
 PR

PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0268660P.
 XX
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 XX or as specific biomolecule capture probes for surface-enhanced laser
 XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 7452; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 XX nucleic acids can be used as probes to detect, characterize and quantify
 XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 XX provide initial substrates for the recombinant engineering of hGDMPLP-1
 XX protein variants having desired phenotypic improvements, and for
 XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
 XX -1 proteins, as standards in assays used to determine the concentration
 XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 XX capture probes for surface-enhanced laser desorption/ionisation, as
 XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 XX production, and in vaccines or for replacement therapy. The
 XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 XX disorder associated with the expression of hGDMPLP-1, in particular heart
 XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 XX The present sequence represents an oligomer used in the screening of the
 XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 XX The sequence data for this patent did not form part of the printed
 XX specification, but was obtained in electronic format directly from WIPO
 XX at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 1.8%; Score 13.4; DB 1; Length 17;
 XX Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 414 AGAAGGAGTTCCTCA 428
 Db |||||
 1 AGAAGGAGTTCCTCA 15
 RESULT 828
 ABK25615
 ID ABK25615 standard; DNA; 17 BP.
 XX
 AC ABK25615;
 XX
 XX 09-APR-2002 (first entry)
 XX
 XX Stress tolerance conferring genome altering oligonucleotide #83.
 DE
 XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
 XX o-methyl modification; LNA modification; phosphorothioate linkage;
 XX DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
 XX abiotic stress tolerance; improved nutritional value; hygromycin; primer;
 XX amino acid over production; herbicide resistance; glyphosate resistance;
 XX

KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyrin herbicide resistance; triazine resistance; disease resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; male-sterile plant; albino mutant;
KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.
XX Oryza sativa.
OS Synthetic.
XX W0200192512-A2.
XX 06-DEC-2001.
XX 01-JUN-2001; 2001WO-US017672.
XX 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
XX (UYDE) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC, Kim J;
XX WPI; 2002-106307/14.
XX New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX Claim 7; Page 101; 220pp; English.
XX The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an RNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC disease resistance, porphyrin herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention
XX Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 U; 0 Other;
SQ Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 899 GGCACTGAGCGGAAG 913
DB 1 GGCACTGAGCGGAAG 15
RESULT 829
ABK25616/C
ID ABK25616 standard; DNA; 17 BP.
XX
AC ABK25616;

XX 09-APR-2002 (first entry)
XX Stress tolerance conferring genome altering oligonucleotide #84.
XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
KW o-methyl modification; LNA modification; phosphorothioate linkage;
KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
KW abiotic stress tolerance; improved nutritional value; hygromycin-B;
KW amino acid over production; herbicide resistance; glyphosate resistance;
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyrin herbicide resistance; triazine resistance; disease resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; male-sterile plant; albino mutant;
KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.
XX Oryza sativa.
OS Synthetic.
XX W0200192512-A2.
XX 06-DEC-2001.
XX 01-JUN-2001; 2001WO-US017672.
XX 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
XX (UYDE) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC, Kim J;
XX WPI; 2002-106307/14.
XX New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX Claim 7; Page 101; 220pp; English.
XX The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an RNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC disease resistance, porphyrin herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention
XX Sequence 17 BP; 1 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
SQ Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 899 GGCAGTGCAGCGAAG 913
Db 17 GGCAGTGCAGCGAAG 3

RESULT 830
ACN06513
ID ACN06513 standard; RNA; 17 BP.
XX
AC ACN06513;
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
DE WNV Amberzyme substrate SEQ ID NO 6516.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 6516; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 7 A; 2 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 808 CTCGAGGAGAGAG 822
Db 2 CUCAGAGAGAGAG 16

RESULT 831
ACN08335
ID ACN08335 standard; RNA; 17 BP.
XX
AC ACN08335;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8338.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 8338; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 1 A; 7 C; 2 G; 0 T; 7 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 808 CTCGAGGAGAGAG 822
Db 16 CTCAGAGAGAGAG 2

RESULT 832
ACN10739/C
ID ACN10739 standard; RNA; 17 BP.
XX
AC ACN10739;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Inozyme substrate SEQ ID NO 10742.

```

XX MNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 10742; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
SQ Sequence 17 BP; 1 A; 7 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 808 CTCGAGGAGAGAG 822
||| ||||| ||||| |||||
Db 17 CTCAGAGGAGAGAG 3

RESULT 833
ABT35244/c
ID ABT35244 standard; DNA; 17 BP.
XX
XX AC ABT35244;
XX
XX 12-JUN-2003 (first entry)
XX
XX Tumour suppression related human fukutin oligo SEQ ID No 881.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
XX Homo sapiens.
OS

XX WO2003025175-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004208.
XX
XX 17-SEP-2001; 2001FR-00011978.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313353/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX Disclosure; Page 136; 720pp; French.
XX
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15 consecutive
XX nucleotides from the 17 mer sequence, a sequence with, after optimal
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX hybridizes to them under highly stringent conditions, or the complement
XX of any of them, or the corresponding RNA. The novel isolated nucleic
XX acids of the invention are useful as probes and primers for detecting,
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX component of a gene chip, in vitro as (anti)sense reagents, and for
XX production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and
XX schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX patient samples is useful for diagnosis and/or prognosis of these
XX diseases. The polypeptides can also be used to generate antibodies, and
XX both the polypeptide and antibodies are useful as components of protein
XX chips. The nucleic acid sequences of the invention can be used in gene
XX therapy. This polynucleotide sequence represents a tumour suppression
XX related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 1 A; 8 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 493 GAGGCAGAGAGGACA 507
||||| ||||| ||||| |||||
Db 17 GAGGCAGAGAGGAGA 3

RESULT 834
ACA07656
ID ACA07656 standard; RNA; 17 BP.
XX
XX ACA07656;
XX
XX 03-JUN-2003 (first entry)
XX
XX NFkB sub-unit modulating zinzyme substrate #55.
XX
XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
KW

KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Homo sapiens.
 XX
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-00864785.
 XX
 XX 07-DEC-1992; 92US-00987132.
 XX
 XX 18-MAY-1994; 94US-00245466.
 XX
 XX 15-AUG-1994; 94US-00291932.
 XX
 XX 23-DEC-1996; 96US-00777916.
 XX
 XX (STIN/) STINCHOMB D T.
 XX (MCSW/) MCSWIGGEN J.
 XX (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX
 XX WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression of
 XX a sequence encoding a subunit of nuclear factor kappa B useful for
 XX treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 XX Claim 3; Page 38; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 XX regulates expression of a sequence encoding a subunit of nuclear factor
 XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 XX configuration. The enzymatic nucleic acid molecule is adapted to treat
 XX cancer and is useful for down-regulating REL-A activity in a cell, for
 XX treating a patient having a condition associated with the level of REL-A.
 XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 XX the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 XX antisenase nucleic acid molecules are useful for treating breast, lung,
 XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 XX multidrug resistant cancer. The method involves use of other drug
 XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 XX gemcitabine or radiation therapy. The enzymatic and antisenase nucleic
 XX acid molecules are also useful for treating inflammatory disease such as
 XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 XX rejection, gene therapy applications, ischaemia/reperfusion injury
 XX (central nervous system (CNS) and myocardial), glomerulonephritis,
 XX sepsis, allergic airway inflammation, inflammatory bowel disease or
 XX infection. This sequence represents the substrate of a novel enzymatic
 XX nucleic acid molecule
 XX
 XX Sequence 17 BP; 5 A; 2 C; 9 G; 0 T; 1 U; 0 Other;
 XX
 XX Query Match 1.8%; Score 13.4; DB 1; Length 17;
 XX Best Local Similarity 86.7%; Pred. No. 6.1e+02;
 XX Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX Qy 884 AAGAGCAGCGTGGG 898
 XX |||||:|:|:
 XX 2 AAGAGCAGCGTGGG 16
 XX
 XX RESULT 835
 XX ACA06305
 XX ID ACA06305 standard; RNA; 17 BP.
 XX

AC ACA06305;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 XX NFkB sub-unit modulating inozyme substrate #124.
 DE
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-00864785.
 XX
 XX 07-DEC-1992; 92US-00987132.
 XX
 XX 18-MAY-1994; 94US-00245466.
 XX
 XX 15-AUG-1994; 94US-00291932.
 XX
 XX 23-DEC-1996; 96US-00777916.
 XX
 XX (STIN/) STINCHOMB D T.
 XX (MCSW/) MCSWIGGEN J.
 XX (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX
 XX WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression of
 XX a sequence encoding a subunit of nuclear factor kappa B useful for
 XX treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 XX Claim 3; Page 29; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 XX regulates expression of a sequence encoding a subunit of nuclear factor
 XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 XX configuration. The enzymatic nucleic acid molecule is adapted to treat
 XX cancer and is useful for down-regulating REL-A activity in a cell, for
 XX treating a patient having a condition associated with the level of REL-A.
 XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 XX the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 XX antisenase nucleic acid molecules are useful for treating breast, lung,
 XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 XX multidrug resistant cancer. The method involves use of other drug
 XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 XX gemcitabine or radiation therapy. The enzymatic and antisenase nucleic
 XX acid molecules are also useful for treating inflammatory disease such as
 XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 XX rejection, gene therapy applications, ischaemia/reperfusion injury
 XX (central nervous system (CNS) and myocardial), glomerulonephritis,
 XX sepsis, allergic airway inflammation, inflammatory bowel disease or
 XX infection. This sequence represents the substrate of a novel enzymatic
 XX nucleic acid molecule
 XX
 XX Sequence 17 BP; 5 A; 2 C; 9 G; 0 T; 1 U; 0 Other;
 XX

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 86.7%; Pred. No. 6.1e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 884 AAGACGACGCTGGTG 898
 |||||
 Db 3 AAGACGACGUGGG 17

RESULT 836
 ABZ64849/c
 ID ABZ64849 standard; RNA; 17 BP.
 XX
 AC ABZ64849;
 XX
 DT 21-MAR-2003 (first entry)
 XX
 DE Human HER2 DNzyme substrate #306.
 XX
 KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200297114-A2.
 XX
 PD 05-DEC-2002.
 XX
 PF 29-MAY-2002; 2002WO-US016940.
 XX
 PR 29-MAY-2001; 2001US-0294140P.
 PR 06-JUN-2001; 2001US-0296249P.
 PR 10-SEP-2001; 2001US-0318471P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J;
 XX
 DR WPI; 2003-140484/13.
 XX

Novel short interfering RNA and enzymatic nucleic acid useful for
 treating cancer, modulates the expression of a nucleic acid encoding
 HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
 Claim 4; Page 138; 185pp; English.

The invention relates to a novel short interfering RNA (siRNA) nucleic
 acid molecule or an enzymatic nucleic acid molecule, that modulates
 expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 acid molecule of the invention has cytostatic, anti-HIV, and anti-
 rheumatic activity. The nucleic acid molecules are useful for reducing
 HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
 also useful for treating breast, ovarian, colorectal, lung, prostate,
 bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
 shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
 ABZ66530 - ABZ66585 represent substrate/target sequences for the human
 ribozymes of the invention

Sequence 17 BP; 2 A; 4 C; 6 G; 0 T; 5 U; 0 Other;
 Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 642 AGGAATCCAGGCTC 656
 |||||
 Db 16 AGAAATCCAGGCTC 2

RESULT 837

ACD63165
 ID ACD63165 standard; RNA; 17 BP.
 XX
 AC ACD63165;
 XX
 DT 24-SEP-2003 (first entry)
 XX
 DE HCV minus strand DNzyme substrate sequence #916.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNzymes; inozyme; zinzyme;
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytosolic;
 KW virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX
 DR WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 infection.
 XX
 PS Claim 1; Page 291; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,
 CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNzyme or minus strand DNzyme sequences disclosed in the present
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 6.1e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 594 TGCTCGGGGAGTGC 608
DB 3 UGCUCGCGAGCUGC 17

RESULT 838
ADB45030
ID ADB45030 standard; DNA; 17 BP.
XX AC ADB45030;
XX DT 18-DEC-2003 (first entry)
XX DE Tumour suppression/reversion associated nucleotide #5353.
XX KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
XX KW primer; probe; tumour suppression; tumour reversion; apoptosis;
XX KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
XX KW diagnosis.
XX OS Homo sapiens.
XX PN WO2003040369-A2.
XX PD 15-MAY-2003.
XX PF 17-SEP-2002; 2002WO-IB004219.
XX PR 17-SEP-2001; 2001FR-00011981.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-441574/41.

New nucleic acid encoding human prostate membrane-specific antigen, PT useful e.g. for treatment of tumors and viral infection, also related PT polypeptide and antibodies.
PS Disclosure; Page 657; 771pp; French.
XX The invention relates to the isolation of 6327 nucleotide sequences, CC fragments of at least 15 consecutive nucleotides of these nucleotides, a CC sequence having at least 80% identity, after optimal alignment, with the CC nucleotides, a sequence that hybridizes under stringent conditions with CC the nucleotides, or the complement, or corresponding RNA, of the CC nucleotides. The nucleotides are used as probes or primers for detecting, CC identifying, quantifying and/or amplifying nucleic acids, as in vitro CC sense and antisense sequences, of nucleotides involved in tumour CC suppression or reversion, apoptosis and or viral resistance, to produce CC recombinant polypeptides, and to prepare transgenic animals, as CC experimental models. The nucleotides (also vectors containing them and CC cells containing the vectors), the encoded polypeptides and antibodies CC (Ab) against the polypeptide are useful for prevention and/or treatment CC of viral infections or diseases characterized by development of tumours CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia). CC Analysis of the expression of the nucleotides can be used for diagnosis CC and/or prognosis of these diseases. The nucleotides and polypeptides can CC also be used to screen for their specific interactive molecules, CC potentially useful for treating diseases associated with abnormal CC expression of the nucleotides.

Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 594 TGCTCGGGGAGTGC 608
DB 3 UGCUCGCGAGCUGC 17

QY 215 GATCAGGACCTACTG 229
DB 1 GATCAGGACCTACTG 15

RESULT 839
ADF62873
ID ADF62873 standard; DNA; 17 BP.
XX AC ADF62873;
XX DT 12-FEB-2004 (first entry)
XX DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 777.
XX KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
XX KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
XX KW human; ss; probe.
XX OS Homo sapiens.
XX PN WO2003050284-A1.
XX PD 19-JUN-2003.
XX PF 22-NOV-2002; 2002WO-US037506.
XX PR 10-DEC-2001; 2001US-0339764P.
XX PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX PI Guo J;
XX WPI; 2003-532916/50.

New prostate cancer candidate protein 1 (PCCP1), useful for preparing a PT composition for treating or preventing a disorder associated with PT decreased or increased expression or activity of PCCP1 e.g., tumor.
PS Example 2; SEQ ID NO 777; 164pp; English.
XX The invention relates to a novel isolated nucleic acid that encodes a CC protein with a chromatin organisation modifier (CHROMO) domain. The CC polynucleotide of the invention demonstrates cytostatic activity and may CC be useful for preparing a composition for treating or preventing a CC disorder associated with decreased or increased expression or activity of CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as CC during gene therapy and vaccine production procedures. The current CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-directed probe of the invention. Note: The current sequence is not shown CC within the specification per se but was retrieved from the WipoWeb CC database.

Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 GAGAAGAGGAGCTG 829
DB 3 GTGAGAGGAGCTG 17

RESULT 840
ADI51393
ID ADI51393 standard; DNA; 17 BP.
XX AC ADI51393;
XX DT 15-APR-2004 (first entry)
XX

XX The invention relates to a composition which contains at least one vector
 CC (B) containing a nucleic acid (I) associated with breast cancer. The
 CC vector (B), also polypeptides (II) encoded by (I), are used for treatment
 CC of breast cancer. Arrays based on (I), (II), or their fragments, and (II)
 CC -specific antibodies (Ab) are used to predict characteristics (e.g.
 CC invasiveness or stage) of breast cancer, and (I), or its fragments, are
 CC used to modulate characteristics of such cells; to identify breast cancer
 CC genes and to detect breast cancer (by detecting polymorphic nucleic acid
 CC or its products). The present sequence represents a human ER+ breast
 CC cancer differentially expressed sequence.

XX SQ Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 241 TCCTCTGGGGAAGCC 255
 Db 3 TCCTGTGGGGAAGCC 17
 |||||

RESULT 845
 ADI85947
 ID ADI85947 standard; RNA; 17 BP.
 XX AC ADI85947;
 XX DT 03-JUN-2004 (first entry)
 DE HCV DNazyme substrate sequence #3193.
 XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
 KW HCV infection; type I interferon; DNazyme.
 XX Hepatitis C virus.
 OS US2003125270-A1.
 PN 03-JUL-2003.
 PD 18-DEC-2000; 2000US-00740332.
 PF 18-DEC-2000; 2000US-00740332.
 PR (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (ROBE/) ROBERTS E.
 PA (PAVC/) PAVCO P A.
 PA (MACE/) MACEJACK D.
 XX Blatt L, Meswiggen J, Roberts E, Pavco PA, Macejack D;
 XX WPI; 2004-031273/03.
 XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
 PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
 PT especially in combination with type I interferon therapy.
 XX Claim 1; SEQ ID NO 3193; 198pp; English.
 PS The invention relates to an enzymatic nucleic acid molecule which
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
 CC the binding arms of the enzymatic nucleic acid molecule comprises
 CC sequences complementary to any of the defined substrate sequences given
 CC in the specification. The nucleic acid molecule may be administered for
 CC the treatment of HCV infections, especially in combination with type I
 CC interferons. The present sequence represents a HCV DNazyme substrate
 CC sequence.

XX SQ Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 73.3%; Pred. No. 6.1e+02;
 Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 594 TCCTCGGGGAGCTGC 608
 Db 3 UGCUCGGCGAGCTGC 17
 :||:|||||

RESULT 846
 ADN44307/C
 ID ADN44307 standard; DNA; 17 BP.
 XX AC ADN44307;
 XX DT 15-JUL-2004 (first entry)
 DE Mutant cell identification-related mutagenic oligonucleotide SeqID976.
 XX cell identification; oligonucleotide-directed sequence alteration;
 KW selectable phenotype; transgenic plant; herbicide resistance;
 KW sterile plant; abiotic stress tolerance; albino plant;
 KW amino acid production; ss.
 XX Oryza sativa.
 OS Synthetic.
 OS WO2004033708-A2.
 PN 22-APR-2004.
 PD 07-OCT-2003; 2003WO-US031862.
 PF 07-OCT-2002; 2002US-0416983P.
 PR 07-MAR-2003; 2003US-0453360P.
 XX (UYDE) UNIV DELAWARE.
 PA (NAPR-) NAPRO BIO THERAPEUTICS INC.
 XX Kmiec EB, Van Brabant A;
 XX WPI; 2004-340941/31.
 XX Identifying a cell with a desired oligonucleotide-directed sequence
 PT alteration at a nucleic acid target site within the cell by identifying
 PT the desired sequence alteration in cells selected for the presence of a
 PT selectable phenotype.

XX Example 25; SEQ ID NO 976; 303pp; English.

XX This invention relates to a novel method of identifying a cell having a
 CC desired oligonucleotide-directed sequence alteration at a first nucleic
 CC acid target site within the cell. The method comprises identifying the
 CC desired sequence alteration in cells that have been selected for the
 CC presence of a selectable phenotype conferred by a concurrent
 CC oligonucleotide-directed sequence alteration at a second nucleic acid
 CC target site within the cells. The method is useful in identifying a cell
 CC having a desired oligonucleotide-directed sequence alteration at a first
 CC nucleic acid target site within the cell. The method may be useful for
 CC the production of plants with herbicide resistance, male or female
 CC sterile plants, abiotic stress tolerance, albino plants or plants with
 CC altered amino acid production as well as for use in mammalian cell lines.
 CC The present sequence is that of a mutagenic oligonucleotide which was
 CC used in the exemplification of the invention.

XX SQ Sequence 17 BP; 1 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 899 GCGAGTGAGCGGAG 913
 |||||

```

Db      17 GGCAGTGAGCGCAAG 3

RESULT 847
ADNA44306
XX      AC      ADN44306 standard; DNA; 17 BP.
XX      AC      ADN44306;
XX      DT      15-JUL-2004 (first entry)
XX      DE      Mutant cell identification-related mutagenic oligonucleotide SeqID975.
XX      KW      cell identification; oligonucleotide-directed sequence alteration;
XX      KW      selectable phenotype; transgenic plant; herbicide resistance;
XX      KW      sterile plant; abiotic stress tolerance; albino plant;
XX      KW      amino acid production; ss.
XX      OS      Oryza sativa.
XX      OS      Synthetic.
XX      PN      WO2004033708-A2.
XX      PD      22-APR-2004.
XX      PF      07-OCT-2003; 2003WO-US031862.
XX      PR      07-OCT-2002; 2002US-0416983P.
XX      PR      07-MAR-2003; 2003US-0453360P.
XX      PA      (UYDE ) UNIV DELAWARE.
XX      PA      (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX      PI      Kmiec EB, Van Brabant A;
XX      PI      WPI; 2004-340941/31.
XX      PT      Identifying a cell with a desired oligonucleotide-directed sequence
XX      PT      alteration at a nucleic acid target site within the cell by identifying
XX      PT      the desired sequence alteration in cells selected for the presence of a
XX      PT      selectable phenotype.
XX      PS      Example 25; SEQ ID NO 975; 303pp; English.
XX      CC      This invention relates to a novel method of identifying a cell having a
XX      CC      desired oligonucleotide-directed sequence alteration at a first nucleic
XX      CC      acid target site within the cell. The method comprises identifying the
XX      CC      desired sequence alteration in cells that have been selected for the
XX      CC      presence of a selectable phenotype conferred by a concurrent
XX      CC      oligonucleotide-directed sequence alteration at a second nucleic acid
XX      CC      target site within the cells. The method is useful in identifying a cell
XX      CC      having a desired oligonucleotide-directed sequence alteration at a first
XX      CC      nucleic acid target site within the cell. The method may be useful for
XX      CC      the production of plants with herbicide resistance, male or female
XX      CC      sterile plants, abiotic stress tolerance, albino plants or plants with
XX      CC      altered amino acid production as well as for use in mammalian cell lines.
XX      CC      The present sequence is that of a mutagenic oligonucleotide which was
XX      CC      used in the exemplification of the invention.
XX      SQ      Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 U; 0 Other;

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      899 GGCAGTGAGCGCAAG 913
          |||||
          1 GGCAGTGAGCGCAAG 15

Db      17 GGCAGTGAGCGCAAG 15

RESULT 848
ACN69922/c
XX      AC      ACN69922 standard; DNA; 17 BP.
XX      DT      02-DEC-2004 (first entry)
XX      DE      Human GDMPLP-1 probe SEQ ID NO:6824.
XX      KW      Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX      KW      hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX      KW      skeletal muscle function.
XX      OS      Homo sapiens.
XX      PN      US2004137589-A1.
XX      PD      15-JUL-2004.
XX      PF      26-NOV-2003; 2003US-00723361.
XX      PR      26-MAY-2000; 2000US-0207456P.
XX      PR      21-SEP-2000; 2000US-0234687P.
XX      PR      27-SEP-2000; 2000US-0236359P.
XX      PR      04-OCT-2000; 2000GB-00024263.
XX      PR      30-JAN-2001; 2001WO-US000661.
XX      PR      30-JAN-2001; 2001WO-US000662.
XX      PR      30-JAN-2001; 2001WO-US000663.
XX      PR      30-JAN-2001; 2001WO-US000664.
XX      PR      30-JAN-2001; 2001WO-US000665.
XX      PR      30-JAN-2001; 2001WO-US000666.
XX      PR      30-JAN-2001; 2001WO-US000667.
XX      PR      30-JAN-2001; 2001WO-US000668.
XX      PR      30-JAN-2001; 2001WO-US000669.
XX      PR      30-JAN-2001; 2001WO-US000670.
XX      PR      05-FEB-2001; 2001US-0266860P.
XX      PR      25-MAY-2001; 2001US-00866108.
XX      PA      (GUY/) GU Y.
XX      PA      (JIY/) JI Y.
XX      PA      (PENN/) PENN S G.
XX      PA      (HANZ/) HANZEL D K.
XX      PA      (RANK/) RANK D.
XX      PA      (CHEN/) CHEN W.
XX      PA      (SHAN/) SHANNON M E.
XX      PI      Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX      PI      WPI; 2004-533378/51.
XX      PT      Novel myosin-like protein-1, useful for treating or preventing disorder
XX      PT      associated with decreased expression or activity of human genome-derived
XX      PT      myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX      PT      function.
XX      PS      Disclosure; SEQ ID NO 6824; 0pp; English.
XX      CC      The invention relates to a novel polypeptide (I) comprising a sequence
XX      CC      (SI) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX      CC      defined in the specification, a fragment of at least 8 amino acids of
XX      CC      (SI), 95% deviation from (SI) which are conservative substitutions, and
XX      CC      65% identity to (SI). A polypeptide of the invention acts as a agonist or
XX      CC      antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX      CC      pharmaceutical composition of the invention is useful for treating or
XX      CC      preventing a disorder associated with decreased expression or activity of
XX      CC      hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX      CC      The present sequence represents a 17-mer nucleotide, used in the
XX      CC      invention for scanning the sequence represented in ACN63103
XX      SQ      Sequence 17 BP; 3 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 266 CACCTGCTTCAGAA 280
 Db 16 CACCTGCTTCAGAA 2

RESULT 849
 ACN70550
 ID ACN70550 standard; DNA; 17 BP.
 XX ACN70550;
 AC ACN70550;
 XX DT 02-DEC-2004 (first entry)
 XX DE Human GDMPLP-1 probe SEQ ID NO:7452.
 XX KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX OS Homo sapiens.
 XX PN US2004137589-A1.
 XX PD 15-JUL-2004.
 XX PF 26-NOV-2003; 2003US-00723361.
 XX PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX (GUYI/) GU Y.
 XX (JIYY/) JI Y.
 XX (PENN/) PENN S G.
 XX (HANZ/) HANZEL D K.
 XX (RANK/) RANK D.
 XX (CHEN/) CHEN W.
 XX (SHAN/) SHANNON M E.

Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 WPI; 2004-533378/51.
 Novel myosin-like protein-1, useful for treating or preventing disorder
 associated with decreased expression or activity of human genome-derived
 myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 function.
 Disclosure; SEQ ID NO 7452; Opp; English.

The invention relates to a novel polypeptide (I) comprising a sequence
 (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 defined in the specification, a fragment of at least 8 amino acids of
 (S1), 95% deviation from (S1) which are conservative substitutions, and
 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 pharmaceutical composition of the invention is useful for treating or
 preventing a disorder associated with decreased expression or activity of
 hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63103
 XX Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 AGAAGAGTTCCTCA 428
 Db 1 AGAAGAGTTCCTCA 15

RESULT 850
 ACN71517
 ID ACN71517 standard; DNA; 17 BP.
 XX ACN71517;
 AC ACN71517;
 XX DT 02-DEC-2004 (first entry)
 XX DE Human GDMPLP-1 probe SEQ ID NO:8419.
 XX KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX OS Homo sapiens.
 XX PN US2004137589-A1.
 XX PD 15-JUL-2004.
 XX PF 26-NOV-2003; 2003US-00723361.
 XX PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX (GUYI/) GU Y.
 XX (JIYY/) JI Y.
 XX (PENN/) PENN S G.
 XX (HANZ/) HANZEL D K.
 XX (RANK/) RANK D.
 XX (CHEN/) CHEN W.
 XX (SHAN/) SHANNON M E.

Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 WPI; 2004-533378/51.
 Novel myosin-like protein-1, useful for treating or preventing disorder
 associated with decreased expression or activity of human genome-derived
 myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 function.
 Disclosure; SEQ ID NO 8419; Opp; English.

The invention relates to a novel polypeptide (I) comprising a sequence
 (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully

PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX Disclosure; SEQ ID NO 8969; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 852 ACCAGCTCTTCCAG 866
DB 17 ACCAGCTCTTCCATG 3
RESULT 853
ACN71518
ID ACN71518 standard; DNA; 17 BP.
AC ACN71518;
XX
XX 02-DEC-2004 (first entry)
DE Human GDMPLP-1 probe SEQ ID NO:8420.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX Homo sapiens.
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
PA (GUY/) GU Y.
XX (JIY/) JI Y.
PA (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
XX (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX Disclosure; SEQ ID NO 8420; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 6 A; 2 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 489 TGAAGAGGCGCAGAGG 503
DB 2 TGAAGAGCGCAGAGG 16
RESULT 854
ACN70346
ID ACN70346 standard; DNA; 17 BP.
XX ACN70346;
XX
XX 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:7248.
DE
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX Homo sapiens.
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.

PR 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.
 PR 30-JAN-2001; 2001WO-US0000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUYV/) GU Y.
 PA (JIYV/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 DR WPI; 2004-533378/51.
 XX
 Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 7248; Opp; English.
 XX
 The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 4 A; 2 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 699 TGGAGAGTGAGCGCG 713
 DB 1 TGGAGAGTGAGCGCG 15
 RESULT 855
 ACN70546
 ID ACN70546 standard; DNA; 17 BP.
 XX
 AC ACN70546;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:7448.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX

PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US0000661.
 PR 30-JAN-2001; 2001WO-US0000662.
 PR 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.
 PR 30-JAN-2001; 2001WO-US0000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUYV/) GU Y.
 PA (JIYV/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX
 DR WPI; 2004-533378/51.
 XX
 Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 7448; Opp; English.
 XX
 The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 412 GGAGAAGGAGTTCCT 426
 DB 3 GGAGAAGGAGTTCCT 17
 RESULT 856
 ABE30519/C
 ID ABE30519 standard; DNA; 13 BP.
 XX
 AC ABE30519;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 130516 for detecting SNP TSC0032599.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW

```
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 130516; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 8 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 4.9e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Oy 407 AGGGAGGAGAAGG 419
Db 13 AGGGAGGAGAAGG 1
|||||
RESULT 857
ABF29699
ID ABF29699 standard; DNA; 13 BP.
XX
XX AC ABF29699;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 129696 for detecting SNP TSC0032456.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 129696; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 8 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 4.9e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Oy 407 AGGGAGGAGAAGG 419
Db 13 AGGGAGGAGAAGG 1
|||||
RESULT 857
ABF29699
ID ABF29699 standard; DNA; 13 BP.
XX
XX AC ABF29699;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 129696 for detecting SNP TSC0032456.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 129696; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 4.9e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Oy 873 ACAACCAACATCAA 885
Db 1 ACAACCAACATCAA 13
|||||
RESULT 858
ABF29698/c
ID ABF29698 standard; DNA; 13 BP.
XX
XX AC ABF29698;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 129695 for detecting SNP TSC0032456.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 129695; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
```


CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 4.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 ACAACACATCA 885
 DB 13 ACAACACATCA 1

RESULT 859
 ID ABF30518
 AC ABF30518;
 DT 21-FEB-2002 (first entry)

OS Homo sapiens.
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 130515; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 13 BP; 5 A; 0 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 4.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 AGGGAGGAGGAGG 419
 DB 1 AGGGAGGAGGAGG 13

RESULT 860
 ID ADL50821 standard; RNA; 13 BP.
 XX
 AC ADL50821;
 DT 20-MAY-2004 (first entry)

DE Human PKR substrate sequence #1935.

XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.

XX
 OS Unidentified.

XX
 PN WO200281628-A2.
 PD 17-OCT-2002.

XX
 PF 03-APR-2002; 2002WO-US010512.
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.

XX
 PA (RIBO-) RIBOZYME PHARM INC.

XX
 PI Blatt L, Chowrita B, Haeberli P, Mcswiggen J, Fosnaugh K;
 DR WPI; 2003-058513/05.

XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX
 PS Claim 59; SEQ ID NO 4354; 317pp; English.

XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.

XX
 SQ Sequence 13 BP; 2 A; 4 C; 5 G; 0 T; 2 U; 0 Other;

Sequence 13 BP; 3 A; 3 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 4.9e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 566 GCCTCTGTGAAG 578
Db 1 GCCUCUGGAAAG 13
|||||:|||||

RESULT 863
ADL50830
ID ADL50830 standard; RNA; 13 BP.
XX
AC ADL50830;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1944.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX Unidentified.
OS
XX WO200281628-A2.
PN
XX 17-OCT-2002.
PD
XX

XX 03-APR-2002; 2002WO-US010512.
PF
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 4363; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.

XX Sequence 13 BP; 2 A; 4 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 743 GTGACCACTGCTGC 755
Db 1 GUGGACCACGCGC 13
|:|||||:|||||

RESULT 864
ADL50823
ID ADL50823 standard; RNA; 13 BP.
XX
AC ADL50823;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1937.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX Unidentified.
OS
XX WO200281628-A2.
PN
XX 17-OCT-2002.
PD
XX

XX 03-APR-2002; 2002WO-US010512.
PF
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI
XX WPI; 2003-058513/05.
DR
XX

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 4356; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.

XX Sequence 13 BP; 6 A; 2 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 318 AGAATCAAGAGCT 330
||||:|||||:
Db 1 AGAAUCAAAGAGCU 13

RESULT 865
ADL50848
ID ADL50848 standard; RNA; 13 BP.
XX AC ADL50848;
XX DT 20-MAY-2004 (first entry)
XX DE Human PKR substrate sequence #1962.
XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
XX KW substrate; ds.
XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 4381; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human PKR
XX CC substrate sequence.
XX SQ Sequence 13 BP; 4 A; 4 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 318 AGAATCAAGAGCT 330
||||:|||||:
Db 1 AGAAUCAAAGAGCU 13

RESULT 866
ADL50822
ID ADL50822 standard; RNA; 13 BP.
XX AC ADL50822;
XX DT 20-MAY-2004 (first entry)
XX DE Human PKR substrate sequence #1936.
XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
XX KW substrate; ds.
XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 4355; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human PKR
XX CC substrate sequence.
XX SQ Sequence 13 BP; 1 A; 7 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 297 CCCTCCAGCGCTG 309
Db 1 CCCTCCAGCGCTG 13

RESULT 867
ADL50828
ID ADL50828 standard; RNA; 13 BP.
XX
AC ADL50828;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1942.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX Unidentified.
OS
XX WO200281628-A2.
XX
XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 4361; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.

XX Sequence 13 BP; 3 A; 3 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 4.9e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAA 577
Db 1 GGCCTCTGTGAAA 13

RESULT 868
ADL50852
ID ADL50852 standard; RNA; 13 BP.
XX
AC ADL50852;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1966.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX Unidentified.
OS
XX WO200281628-A2.
XX
XX 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 4385; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.

XX Sequence 13 BP; 3 A; 1 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 699 TGGAGAGTGGAGCG 711
Db :||||:|||||
1 UGGAGAGGAGGAC 13

RESULT 869

ADL50825
ID ADL50825 standard; RNA; 13 BP.

XX AC ADL50825;

XX DT 20-MAY-2004 (first entry)

XX DE Human PKR substrate sequence #1939.

XX antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX OS Unidentified.

XX PN WO200281628-A2.

XX PD 17-OCT-2002.

XX PF 03-APR-2002; 2002WO-US010512.

XX PR 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX DR WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or protein kinase PKR genes, for treating cancer and inflammatory disease.

XX PS Claim 59; SEQ ID NO 4358; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides) that down regulate the expression or inhibit the function of a receptor for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR), IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the invention are useful for treating: cerebrovascular accident, central nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma, lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis, restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The nucleic acids of the invention are also useful for down-regulating the expression of a target gene and as a diagnostic tool to examine genetic drifts and mutations within diseased cells or to detect the presence of a target RNA in a cell. The present RNA sequence represents a human PKR substrate sequence.

XX Sequence 13 BP; 3 A; 2 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 550 GATGGCTGAGGAC 562
Db :||||:|||||
1 GAUGGCGAGGAC 13

RESULT 870

ADL50847
ID ADL50847 standard; RNA; 13 BP.

XX AC ADL50847;

XX DT 20-MAY-2004 (first entry)

XX DE Human PKR substrate sequence #1961.

XX antisenase oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX OS Unidentified.

XX PN WO200281628-A2.

XX PD 17-OCT-2002.

XX PF 03-APR-2002; 2002WO-US010512.

XX PR 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX DR WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or protein kinase PKR genes, for treating cancer and inflammatory disease.

XX PS Claim 59; SEQ ID NO 4380; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides) that down regulate the expression or inhibit the function of a receptor for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR), IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the invention are useful for treating: cerebrovascular accident, central nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma, lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis, restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The nucleic acids of the invention are also useful for down-regulating the expression of a target gene and as a diagnostic tool to examine genetic drifts and mutations within diseased cells or to detect the presence of a target RNA in a cell. The present RNA sequence represents a human PKR substrate sequence.

XX Sequence 13 BP; 2 A; 4 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 4.9e+02;
 Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 303 AGCGTGCTGGG 315
 Db 1 AGCGGUGCCUGGA 13
 |||||:|||||
 1 AGCGGUGCCUGGA 13

RESULT 871
 AAS02960
 ID AAS02960 standard; DNA; 15 BP.
 XX AC AAS02960;
 XX DT 29-AUG-2001 (first entry)
 XX DE Human CHMR1 allele specific oligonucleotide probe #20.
 XX KW Human; m1 acetylcholine receptor; CHRM1; immunogen; antibody;
 KW Alzheimer's disease; dementia with Lewy bodies; DLB;
 KW allele specific oligonucleotide probe; ss.
 XX OS Homo sapiens.
 XX PN WO200127312-A2.
 XX PD 19-APR-2001.
 XX PF 12-OCT-2000; 2000WO-US028211.
 XX PR 13-OCT-1999; 99US-0159269P.
 XX PA (GENA-) GENAISSANCE PHARM INC.
 XX PI Choi JY, Denton RR, Nandabalan K, Stephens JC;
 XX WPI; 2001-282046/29.
 XX PT New variants of the m1 muscarinic acetylcholine receptor gene, useful to
 PT find treatment for Alzheimer's and dementia, have single nucleotide
 PT variations at one or more of five polymorphic sites.
 XX PS Claim 15; Page 19; 52pp; English.
 XX CC The sequence represents an allele specific oligonucleotide probe for
 CC genotyping individuals using the Human gene encoding the m1 muscarinic
 CC acetylcholine receptor, CHMR1. CHMR1 is one subtype of a family of 5
 CC genetically distinct muscarinic acetylcholine receptors, mAChR, that play
 CC important roles in higher brain function such as learning and memory. The
 CC protein is a possible drug target for treatments for Alzheimer's disease
 CC and dementia with Lewy bodies (DLB). The gene, polypeptide, haplotypes
 CC and antibodies raised against the protein are useful for diagnosing and
 CC developing treatments for diseases associated with the abnormal
 CC expression of the gene or activity of the protein, e.g. Alzheimer's
 CC disease and dementia with Lewy bodies
 XX Sequence 15 BP; 2 A; 6 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 203 GGCCCGGCGAGCAG 215
 Db 2 GGCCCGGCGAGCAG 14
 |||||:|||||
 2 GGCCCGGCGAGCAG 14

RESULT 872
 AAF47284/C
 ID AAF47284 standard; DNA; 15 BP.
 XX AC AAF47284;

XX 30-MAR-2001 (first entry)
 XX IGFBP3 oligonucleotide #704.
 XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX OS Homo sapiens.
 XX PN WO200078341-A1.
 XX PD 28-DEC-2000.
 XX PF 21-JUN-2000; 2000WO-AU000693.
 XX PR 21-JUN-1999; 99US-0140345P.
 XX PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX PI Wright CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX PS Example 7; Page 48; 201pp; English.
 XX CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX Sequence 15 BP; 3 A; 6 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 808 CTCGGAGGAGAG 820
 Db 15 CTCGGAGGAGAG 3
 |||||:|||||
 15 CTCGGAGGAGAG 3

RESULT 873
 AAF51567
 ID AAF51567 standard; DNA; 15 BP.
 XX AC AAF51567;
 XX DT 30-MAR-2001 (first entry)
 XX DE IGF-I oligonucleotide #2527.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX Homo sapiens.
 OS
 XX
 XX WO200078341-A1.
 PN
 XX
 XX 28-DEC-2000.
 PD
 XX
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 XX
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA
 XX
 XX Wright CJ, Werther GA, Edmondson SR;
 PI
 XX
 XX WPI; 2001-041421/05.
 DR
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 XX Example 8; Page 77; 201pp; English.
 PS
 XX
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation.
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 XX Sequence 15 BP; 6 A; 2 C; 6 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 496 GCAGAGGAGCAG 508
 Db 1 GCAGAGGAGCAG 13
 RESULT 874
 AAF51526/c
 ID AAF51526 standard; DNA; 15 BP.
 XX
 XX AAF51526;
 AC
 XX
 XX 30-MAR-2001 (first entry)
 DT
 XX
 XX IGF-I oligonucleotide #2486.
 DE
 XX
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 XX

KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX Homo sapiens.
 OS
 XX
 XX WO200078341-A1.
 PN
 XX
 XX 28-DEC-2000.
 PD
 XX
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 XX
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA
 XX
 XX Wright CJ, Werther GA, Edmondson SR;
 PI
 XX
 XX WPI; 2001-041421/05.
 DR
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 XX Example 8; Page 77; 201pp; English.
 PS
 XX
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 XX Sequence 15 BP; 2 A; 7 C; 4 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 713 GAGGCGCTGCAGC 725
 Db 13 GAGGCGCTGCAGC 1
 RESULT 875
 AAF51524/c
 ID AAF51524 standard; DNA; 15 BP.
 XX
 XX AAF51524;
 AC
 XX
 XX 30-MAR-2001 (first entry)
 DT
 XX
 XX IGF-I oligonucleotide #2484.
 DE
 XX
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 XX

DR WPI; 2001-041421/05.
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisenescence nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX Example 8; Page 77; 201pp; English.
PS The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisenescence oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisenescence
XX oligonucleotides of the present invention (see AAP45151 and AAP45153-
XX P45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 5 A; 4 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 496 GCAGAGGAGGAGCAG 508
DB 3 GCAGAGGAGGAGCAG 15
RESULT 880
AAS95379
ID AAS95379 standard; DNA; 15 BP.
XX
XX AAS95379;
XX
XX 14-FEB-2002 (first entry)
XX Human ICAM2 gene allele-specific oligonucleotide sequencing primer #6.
XX Human; intercellular adhesion molecule 2; ICAM2; haplotyping; ss;
XX haplotype pair; single nucleotide polymorphism; genotyping; PCR primer;
XX gene therapy; drug screening; anti-HIV; antiinflammatory; probe;
XX human immunodeficiency virus; sequencing primer.
XX Homo sapiens.
XX WO200185918-A1.
XX
XX 15-NOV-2001.
XX
XX 07-MAY-2001; 2001WO-US014714.
XX
XX 05-MAY-2000; 2000US-0201946P.
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Chew A, Choi JY, Denton RR, Kliem SE, Lee HH, Nandabalan K;
XX WPI; 2002-055590/07.
XX Novel polynucleotide containing polymorphisms in intercellular adhesion
XX molecule 2 gene, useful in developing drugs for treating human
XX immunodeficiency virus infection and inflammatory diseases.
XX Claim 16; Page 13; 81pp; English.
XX

The invention relates to single nucleotide polymorphisms in the gene encoding human intercellular adhesion molecule 2 (ICAM2). A method for haplotyping the ICAM2 gene in an individual comprises identifying the nucleotide at one or more polymorphic sites and determining whether one of the copies of the gene is defined by one of the ICAM2 haplotypes given in the specification or whether both copies are defined by a haplotype pair. This method is useful in genotyping, whereby all possible haplotype pairs can be assigned to specific genotypes. An association between a trait and a haplotype or haplotype pair of the ICAM2 gene can be identified by comparing the frequency of the haplotype or haplotype pair in a population exhibiting the trait with the frequency of the haplotype or haplotype pair in a reference population, where a higher haplotype frequency in the trait population indicates the trait is associated with the haplotype or haplotype pair. ICAM2 and its corresponding DNA are used for studying the expression and function of ICAM2, for use in screening for candidate drugs to treat diseases related to ICAM2 activity, such as HIV infection and inflammatory diseases. The sequences are also useful for studying the effect of variation on the biological activity of ICAM2 as well as on the binding affinity of candidate drugs targeting ICAM2. Sequences AAS95362-AAS95417 and AAS95419-AAS95442 represent allele-specific oligonucleotide probes, sequencing primers, PCR primers and cDNA encoding human ICAM2
XX Sequence 15 BP; 4 A; 3 C; 6 G; 1 T; 0 U; 1 Other;
Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 5.9e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 210 CAGCAGATCAGGACG 224
DB 1 CAGCAGATCAGGGYG 15
RESULT 891
ABR98359/C
ID ABR98359 standard; DNA; 15 BP.
XX
XX ABR98359;
XX
XX 30-JUL-2002 (first entry)
XX SCN2B gene polymorphisms ASO primer #3.
XX Human; sodium channel voltage gated type 2 beta polypeptide; SCN2B; ds;
XX gene therapy; neuroprotective; demyelinating disease.
XX Homo sapiens.
XX WO200179547-A1.
XX
XX 25-OCT-2001.
XX
XX 03-APR-2001; 2001WO-US010743.
XX
XX 13-APR-2000; 2000US-0196597P.
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Chew A, Choi JY, Koshy B;
XX WPI; 2002-075072/10.
XX New polynucleotide containing polymorphisms in the human sodium channel
XX voltage gated type 2 beta polypeptide (SCN2B) gene, for developing drugs
XX for treating demyelinating diseases.
XX Claim 15; Page 13; 63pp; English.
XX This invention relates to an isolated polynucleotide which is a
XX polymorphic variant of a reference sequence for sodium channel voltage
XX gated type 2 beta polypeptide (SCN2B) gene. The methods have
XX applicability in developing diagnostic tests and therapeutic treatments
XX

CC for demyelinating diseases. The protein is useful for studying the
 CC expression and function of SCN2B and expressing SCN2B protein for use in
 CC screening for candidate drugs to treat diseases related to SCN2B
 CC activity. The polymorphism and haplotype data are useful for validating
 CC whether SCN2B is a suitable target for drugs to treat demyelinating
 CC diseases, screening for such drugs and reducing bias in clinical trials.
 CC The haplotyping method is useful to validate SCN2B as a candidate target
 CC for treating a specific condition or disease predicted to be associated
 CC with SCN2B activity. A recombinant non-human organism transformed or
 CC transfected with the polypeptide is useful for studying expression of the
 CC SCN2B isogenes in vivo, for in vivo screening and testing of drugs
 CC against SCN2B protein and for testing the efficacy of therapeutic agents
 CC and compounds for demyelinating diseases in a biological system. This
 CC sequence is used during the detection of polymorphisms of the SCN2B gene
 XX
 SQ Sequence 15 BP; 3 A; 2 C; 8 G; 1 T; 0 U; 1 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 5.9e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 263 CTGCACCTGCCTTCA 277
 Db 15 CTGCCCTGCCTTCA 1

RESULT 882
 AAS18453
 ID AAS18453 standard; DNA; 15 BP.
 XX
 AC AAS18453;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE ASO primer #5 to detect human beta2AR gene polymorphisms.
 XX
 KW Human; beta2-adrenergic receptor; beta2AR polymorphism; asthma;
 KW chromosome 5q31-32; migraine; congestive heart failure; hypertension;
 KW ischaemic heart disease; chronic obstructive pulmonary disease; COPD;
 KW obesity; diabetes mellitus; premature labour; vasotropic; cardiant;
 KW allele-specific oligonucleotide; ASO; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200179252-A1.
 XX
 PD 25-OCT-2001.
 XX
 PF 13-APR-2000; 2000WO-US010125.
 XX
 PR 13-APR-2000; 2000WO-US010125.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 PA (UYCI-) UNIV CINCINNATI.
 XX
 PI Stack CB, Drysdale CM, Stephens JC, Nandabalan K, Judson RS;
 PI Liggett SB;
 PI WPI; 2002-061968/08.
 DR
 XX
 PT New isolated beta 2-adrenergic receptor polynucleotide, useful for
 PT studying expression and biological function of receptor and for
 PT developing drugs targeting receptor, comprises polymorphism of adenosine
 PT at P82 and thymine at P85.
 XX
 PS Disclosure; Page 19; 67pp; English.
 XX
 CC The present invention relates to polymorphisms and haplotypes of the
 CC human beta2-adrenergic receptor (beta2-AR) gene located on chromosome
 CC 5q31-32, and methods for haplotyping and/or genotyping the beta2AR gene
 CC in an individual. The methods of the invention make use of allele-
 CC specific oligonucleotides (ASOs) as probes and primers for detecting the
 CC beta2AR gene polymorphisms. The beta2AR gene polymorphisms are useful in

CC studying the expression and biological function of beta2AR, and for
 CC developing drugs targeting this receptor. They are also useful for
 CC therapeutic purposes such as treating disorders affected by expression or
 CC function of beta2AR such as congestive heart failure, arrhythmia,
 CC ischaemic heart disease, hypertension, migraine, asthma, chronic
 CC obstructive pulmonary disease (COPD), obesity, diabetes and premature
 CC labour. The method is useful for determining the frequency of a beta2AR
 CC genotype or haplotype in a population. AAS18449-AAS18456 represent ASO
 CC forward primers for detecting human beta2AR gene polymorphisms
 XX
 SQ Sequence 15 BP; 2 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.9e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 196 CAGTGGTGGCCCG 208
 Db 3 CAGTGGTGGCCCG 15

RESULT 883
 AAS95907/C
 ID AAS95907 standard; DNA; 15 BP.
 XX
 AC AAS95907;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Human CALM1 gene allele-specific oligonucleotide #16.
 XX
 KW Calmodulin 1; CALM1; human; single nucleotide polymorphism; SNP;
 KW haplotyping; SCYA3; Alzheimer's disease; drug screening;
 KW calcium-dependent signal transduction; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200179218-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 09-APR-2001; 2001WO-US011509.
 XX
 PR 12-APR-2000; 2000US-0196340P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Bentivegna SC, Chew A, Choi JY, Koshy B, Stephens JC;
 XX WPI; 2002-049190/06.
 DR
 XX
 PT New calmodulin-1 (CALM-1) isogene polymorphic variants, useful in
 PT expressing CALM1 protein for use in screening for candidate drugs to
 PT treat diseases related to CALM1 activity such as Alzheimer's disease.
 XX
 PS Claim 15; Page 13; 82pp; English.
 XX
 CC The invention relates to an isolated polynucleotide comprising a sequence
 CC selected from a polymorphic variant of calmodulin 1 (CALM1). The
 CC polymorphic variant comprises an CALM1 isogene defined by a haplotype
 CC selected from haplotypes 1-21 given in the specification. The
 CC polymorphisms are useful for studying the biological function of CALM1 as
 CC well as in identifying drugs targeting this protein for the treatment of
 CC a disorder related to its abnormal expression or function. The
 CC polymorphic variants may also be used in screening for compounds
 CC targeting CALM1 to treat a specific condition or disease predicted to be
 CC associated with CALM1 activity. Establishing CALM1 haplotype or haplotype
 CC pair of an individual is useful for improving the efficiency and
 CC reliability of several steps in the discovery and development of drugs
 CC for treating diseases associated with SCYA3 activity, e.g. Alzheimer's
 CC disease and diseases involving defects in calcium-dependent signal
 CC transduction. Haplotyping the CALM1 gene in an individual is also useful
 CC in the design of clinical trials of candidate drugs for treating a

CC specific condition or disease predicted to be associated with CALM1
CC activity. AAS95892-AAS96018 represent human CALM1 allele- specific
CC oligonucleotides and PCR primers of the invention
XX
SQ Sequence 15 BP; 1 A; 6 C; 6 G; 1 T; 0 U; 1 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 5.9e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 716 GCGCTGCAGCAG 730
DB 15 GCGCTGCAGCAG 1

RESULT 884
AAS95951/C
ID AAS95951 standard; DNA; 15 BP.
XX
AC AAS95951;
DT 26-FEB-2002 (first entry)
XX
DE Human CALM1 gene allele-specific oligonucleotide #60.
XX
KW Calmodulin 1; CALM1; human; single nucleotide polymorphism; SNP;
KW haplotyping; SCY3; Alzheimer's disease; drug screening;
KW calcium-dependent signal transduction; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200179218-A2.
XX
PD 25-OCT-2001.
XX
PF 09-APR-2001; 2001WO-US011509.
XX
PR 12-APR-2000; 2000US-0196340P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Bentivegna SC, Chew A, Choi JY, Koshiy B, Stephens JC;
XX
DR WPI; 2002-049190/06.
XX
XX
PT New calmodulin-1 (CALM-1) isogene polymorphic variants, useful in
PT expressing CALM1 protein for use in screening for candidate drugs to
PT treat diseases related to CALM1 activity such as Alzheimer's disease.
XX
PS Claim 15; Page 13; 82pp; English.
XX
CC The invention relates to an isolated polynucleotide comprising a sequence
CC selected from a polymorphic variant of calmodulin 1 (CALM1). The
CC polymorphic variant comprises an CALM1 isogene defined by a haplotype
CC selected from haplotypes 1-21 given in the specification. The
CC polymorphisms are useful for studying the biological function of CALM1 as
CC well as in identifying drugs targeting this protein for the treatment of
CC a disorder related to its abnormal expression or function. The
CC polymorphic variants may also be used in screening for compounds
CC targeting CALM1 to treat a specific condition or disease predicted to be
CC associated with CALM1 activity. Establishing CALM1 haplotype or haplotype
CC pair of an individual is useful for improving the efficiency and
CC reliability of several steps in the discovery and development of drugs
CC for treating diseases associated with SCY3 activity, e.g. Alzheimer's
CC disease and diseases involving defects in calcium-dependent signal
CC transduction. Haplotyping the CALM1 gene in an individual is also useful
CC in the design of clinical trials of candidate drugs for treating a
CC specific condition or disease predicted to be associated with CALM1
CC activity. AAS95892-AAS96018 represent human CALM1 allele- specific
CC oligonucleotides and PCR primers of the invention
XX
SQ Sequence 15 BP; 1 A; 8 C; 4 G; 1 T; 0 U; 1 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 5.9e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 713 GAGGCGCTGCAGCAG 727
DB 15 GMGGCGCTGCAGCAG 1

RESULT 895
AAT81046/C
ID AAT81046 standard; RNA; 17 BP.
XX
AC AAT81046;
DT 26-SEP-1997 (first entry)
XX
DE Human c-myb hammerhead ribozyme target sequence (nt. position 29).
XX
KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW coronary angioplasty; ss.
XX
OS Homo sapiens.
XX
PN WO9531541-A2.
XX
PD 23-NOV-1995.
XX
PF 18-MAY-1995; 95WO-US006368.
XX
PR 18-MAY-1994; 94US-00245466.
XX
PR 13-JAN-1995; 95US-00373124.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
XX
DR WPI; 1996-010927/01.
XX
PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT for treating restenosis or cancer.
XX
PS Claim 1; Page 64; 128pp; English.
XX
CC The present sequence represents the preferred target sequence for an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the human c-myb sequence at the base position indicated in the descriptor
CC line. The c-myb sequence was screened for optimal ribozyme target sites
CC using a computer folding algorithm, and regions of the mRNA which did not
CC form secondary folding structures and contained potential ribozyme
CC cleavage sites were identified. Ribozymes were synthesised and their
CC activities optimised by either varying the length of the binding arms or
CC by modification to prevent degradation by nucleases. The ribozymes cleave
CC the c-myb sequence and can be used to prevent smooth muscle cell
CC hyperproliferation in restenosis, especially after coronary angioplasty,
CC and in cancers
XX
SQ Sequence 17 BP; 0 A; 10 C; 0 G; 0 T; 7 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 409 GGAGGAGAGAGGAG 421
DB 15 GGAGGAGAGAGGAG 3

RESULT 886
AAT81045/C
ID AAT81045 standard; RNA; 17 BP.
XX

AC AAT81045;
 XX
 DT 26-SEP-1997 (first entry)
 XX
 DE Human c-myb hammerhead ribozyme target sequence (nt. position 28).
 XX
 XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
 KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
 KW coronary angioplasty; ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO9531541-A2.
 XX
 XX 23-NOV-1995.
 XX
 XX 18-MAY-1995; 95WO-US006368.
 XX
 PR 18-MAY-1994; 94US-00245466.
 PR 13-JAN-1995; 95US-00373124.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
 XX WPI; 1996-010927/01.
 DR
 XX New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
 PT for treating restenosis or cancer.
 PT
 XX Claim 1; Page 64; 128pp; English.
 PS
 XX The present sequence represents the preferred target sequence for an
 CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 CC the human c-myb sequence at the base position indicated in the descriptor
 CC line. The c-myb sequence was screened for optimal ribozyme target sites
 CC using a computer folding algorithm, and regions of the mRNA which did not
 CC form secondary folding structures and contained potential ribozyme
 CC cleavage sites were identified. Ribozymes were synthesised and their
 CC activities optimised by either varying the length of the binding arms or
 CC by modification to prevent degradation by nucleases. The ribozymes cleave
 CC the c-myb sequence and can be used to prevent smooth muscle cell
 CC hyperproliferation in restenosis, especially after coronary angioplasty,
 CC and in cancers
 XX
 SQ Sequence 17 BP; 0 A; 10 C; 0 G; 0 T; 7 U; 0 Other;
 XX
 Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 409 GGAGGAGAGGAG 421
 Db 16 GGAGGAGAGGAG 4
 XX
 RESULT 887
 AAX22405
 ID AAX22405 standard; DNA; 17 BP.
 XX
 AC AAX22405;
 XX
 DT 19-MAY-1999 (first entry)
 XX
 DE Human live cytosolic beta-glucosidase PCR primer #4.
 XX
 KW Human; liver; cytosolic; beta-glucosidase; transplant; immunoassay;
 KW glucosylated produg; antibody; detection; ischaemic liver damage;
 KW reperfusion injury; hepatocyte; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX

PN WO9903874-A1.
 XX
 PD 28-JAN-1999.
 XX
 PF 15-JUL-1998; 98WO-US014422.
 XX
 PR 15-JUL-1997; 97US-0052598P.
 XX
 PA (UYNE-) UNIV NEW MEXICO STATE.
 XX
 PI Hays WS, Vander Jagt DJ, Glew RH;
 XX WPI; 1999-132151/11.
 DR
 XX Recombinant cDNA encoding human liver cytosolic beta-glucosidase - useful
 PT as marker of hepatocyte injury in liver transplant patients.
 PT
 XX Disclosure; Page 5; 22pp; English.
 PS
 XX This sequence is a PCR primer used in the isolation of a novel beta-
 CC glucosidase from human liver cytosol. Antibodies generated from this
 CC protein can be used in immunoassays to detect the protein, specifically
 CC for evaluating ischaemic liver damage in transplant patients, i.e.
 CC monitoring reperfusion injury and for prognosis of transplant failure.
 CC They may also be used, when conjugated with an enzyme, for enzymatic
 CC activation or cleavage of e.g. glucosylated produgs in the liver. The
 CC protein is an early and sensitive marker of hepatocyte injury in
 CC transplants
 XX
 SQ Sequence 17 BP; 1 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 647 TGCACGGCTCTGG 659
 Db 4 TGCACGGCTCTGG 16
 XX
 RESULT 888
 AAC66348
 ID AAC66348 standard; DNA; 17 BP.
 XX
 AC AAC66348;
 XX
 DT 21-FEB-2001 (first entry)
 XX
 DE Adaptor KpnI SfiI SEQ ID 4.
 XX
 KW Experimental mice; Alzheimer's disease; tau; Wortmannin; adaptor; ds.
 XX
 OS Synthetic.
 OS
 XX JP2000253774-A.
 PN
 XX 19-SEP-2000.
 XX
 PF 12-MAR-1999; 99JP-00067445.
 XX
 PR 12-MAR-1999; 99JP-00067445.
 XX
 PA (MITU) MITSUBISHI CHEM CORP.
 XX
 XX WPI; 2000-608045/59.
 DR
 XX Experimental mice with stimulated phosphorylation of tau-protein.
 PT
 XX Example 1; Page 4; 13pp; Japanese.
 PS
 XX This invention relates to experimental mice which are used for the
 CC development of agents for treating Alzheimer's disease. Phosphorylation
 CC of the tau-protein in the modified mice is stimulated through fasting or

CC by the administration of a drug such as Wortmannin. The mice are used for
 CC screening drugs for the inhibition of phosphorylation of the tau-protein.
 CC Inhibitors of the phosphorylation may be used to treat Alzheimer's
 CC disease. Adapters AAC66345 - AAC66348 and PCR primers AAC66349 - AAC66354
 CC are used during the genetic modification of the mice and in the analysis
 CC of their DNA
 XX
 SQ Sequence 17 BP; 1 A; 7 C; 8 G; 1 T; 0 U; 0 Other;
 Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 667 GCGCCGGCGGCC 679
 DB 1 GCGCCGGCGGCC 13
 RESULT 889
 AAA24913/C
 ID AAA24913 standard; DNA; 17 BP.
 XX
 AC AAA24913;
 XX
 DT 19-JUL-2000 (first entry)
 DE
 DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1411.
 XX
 KW Oestrogen receptor; c-rafi; k-raa; bcl-2; ribozyme; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
 KW Gene expression modification; cancer; phosphorothioate; endonuclease;
 KW anticancer; breast cancer; endometrium cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO954459-A2.
 XX
 PD 28-OCT-1999.
 XX
 PF 19-APR-1999; 99WO-US008547.
 XX
 PR 20-APR-1998; 98US-0082404P.
 PR 23-JUN-1998; 98US-00103636.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
 PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerl P;
 PI Matulic-Adamic J;
 XX
 DR WPI; 2000-013248/01.
 XX
 PT New nucleic acids that interact, and optionally cleave, target sequences,
 PT used to treat cancer.
 XX
 PS Claim 77; Page 62; 148pp; English.
 XX
 CC The present invention describes nucleic acids (A) that interact stably
 CC with a target sequence and contain at least one phosphorodithioate
 CC link, having endonuclease activity. (A), and more generally any catalytic
 CC nucleic acid (A') that modulates expression of the oestrogen receptor
 CC gene, are used to treat cancer (particularly of breast or endometrium),
 CC in vivo or by transforming cells ex vivo and implanting treated cells, or
 CC for other conditions associated with levels of oestrogen receptor.
 CC Because of the high selectivity for targeted RNA, (A) can also be used to
 CC correlate inhibition of gene expression with alterations in phenotype,
 CC particularly for identification of therapeutic targets, and as research
 CC reagents (for RNA, in the same way that restriction endonucleases are
 CC used with DNA). The combination of modifications in (A) improves
 CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
 CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
 CC AAA24748 to AAA25992 represent their corresponding target sequences.
 CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme

CC sequences, and AAA26107 to AAA26218 represent their corresponding target
 CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
 CC antisense oligonucleotides used in the exemplification of the present
 CC invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 790 CATGGAGCGCCAG 802
 DB 13 CATGGAGCGCCAG 1
 RESULT 890
 ABN08982/C
 ID ABN08982 standard; DNA; 17 BP.
 XX
 AC ABN08982;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8974.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-0004263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
 XX
 DR WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 PS Disclosure; SEQ ID NO 8974; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 851 CACACGCTCTTCC 863
 Db 13 CACACGCTCTTCC 1

RESULT 891
 ABN07250
 ID ABN07250 standard; DNA; 17 BP.
 XX
 AC ABN07250;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7242.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.

PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser

PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 PS Disclosure; SEQ ID NO 7242; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 4 A; 1 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 697 GCTGGAGAGTGAG 709
 Db 5 GCTGGAGAGTGAG 17

RESULT 892
 ACA07655
 ID ACA07655 standard; RNA; 17 BP.
 XX
 AC ACA07655;

XX 03-JUN-2003 (first entry)
 XX
 DE NFkB sub-unit modulating zinnzyme substrate #54.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinnzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-00864785.
 XX
 PR 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.

PR	23-DEC-1996;	96US-00777916.
XX	(STIN/) STINCHOMB D T.	
PA	(MCSW/) MCSWIGGEN J.	
BA	(DRAP/) DRAPER K G.	
XX	Stinchcomb DT, Mcswiggen J, Draper KG;	
PI	WPI; 2003-340953/32.	
XX	Novel enzymatic nucleic acid molecules which down regulates expression of	
PT	a sequence encoding a subunit of nuclear factor kappa B useful for	
PT	treating cancer, inflammatory disorders and autoimmune diseases.	
XX	Claim 3; Page 38; 72pp; English.	
XX	The invention describes an enzymatic nucleic acid molecule (I) which down	
CC	regulates expression of a sequence encoding a subunit of nuclear factor	
CC	kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme	
CC	configuration. The enzymatic nucleic acid molecule is adapted to treat	
CC	cancer and is useful for down-regulating REL-A activity in a cell, for	
CC	treating a patient having a condition associated with the level of REL-A.	
CC	(I) is useful for cleaving RNA comprising a sequence of REL-A gene, in	
CC	the presence of a divalent cation, especially Mg ²⁺ . The enzymatic and	
CC	antisense nucleic acid molecules are useful for treating breast, lung,	
CC	prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,	
CC	cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or	
CC	multidrug resistant cancer. The method involves use of other drug	
CC	therapies such as monoclonal antibodies, REL-A-specific inhibitors or	
CC	chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,	
CC	cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,	
CC	gemcitabine or radiation therapy. The enzymatic and antisense nucleic	
CC	acid molecules are also useful for treating inflammatory disease such as	
CC	rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,	
CC	obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft	
CC	rejection, gene therapy applications, ischaemia/reperfusion injury,	
CC	(central nervous system (CNS) and myocardial), glomerulonephritis,	
CC	sepsis, allergic airway inflammation, inflammatory bowel disease or	
CC	infection. This sequence represents the substrate of a novel enzymatic	
CC	nucleic acid molecule	
XX	Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 2 U; 0 Other;	
SQ	Query Match 1.7%; Score 13; DB 1; Length 17;	
	Best Local Similarity 92.3%; Pred. No. 6.8e+02;	
	Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;	
QY	884 AAGACGCGTGG 896	
DB	5 AAGACGCGGUGG 17	
RESULT 893		
ACD59950/c		
ID	ACD59950 standard; RNA; 17 BP.	
AC	ACD59950;	
XX	24-SEP-2003 (first entry)	
DT	HCV DNAzyme substrate sequence #1584.	
XX	Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;	
KW	RNA stability; RNA expression; RNA synthesis; antisense;	
KW	enzymatic nucleic acid; hammerhead ribozyme; DNAAzyme; inozyme; zinzyme;	
KW	amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;	
KW	HBV reverse transcriptase; Enhancer I region; viral replication;	
KW	degenerative; disease state; HBV infection; HCV infection; cirrhosis;	
KW	liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;	
KW	virucide; antiinflammatory; substrate; ss.	
XX	Hepatitis C virus.	
OS		
DE		
XX		
XX		
PN	WO200281494-A1.	
XX	17-OCT-2002.	
XX	26-MAR-2002; 2002WO-US009187.	
PF		
XX	26-MAR-2001; 2001US-00817879.	
PR	08-JUN-2001; 2001US-00877478.	
PR	08-JUN-2001; 2001US-0296876P.	
PR	24-OCT-2001; 2001US-0335059P.	
PR	05-DEC-2001; 2001US-0337055P.	
XX	(RIBO-) RIBOZYME PHARM INC.	
PA	(BLAT/) BLATT L.	
PA	(MACE/) MACEJAK D.	
PA	(MCSW/) MCSWIGGEN J.	
PA	(MORR/) MORRISSEY D.	
PA	(PAVC/) PAVCO P.	
PA	(LEEP/) LEE P.	
PA	(DRAP/) DRAPER K.	
PA	(ROBE/) ROBERTS E.	
XX	Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;	
PI	Draper K, Roberts E;	
PI	WPI; 2003-229207/22.	
DR	Novel compound useful for treating cirrhosis, liver failure,	
PT	hepatocellular carcinoma, or condition associated with hepatitis C virus	
PT	infection.	
XX	Claim 1; Page 262; 387pp; English.	
XX	The present invention relates to nucleic acid molecules which modulate	
CC	the synthesis, expression and/or stability of Hepatitis C virus (HCV) or	
CC	Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense	
CC	and enzymatic nucleic acids such as hammerhead ribozymes, DNAAzymes,	
CC	inozymes, zinzymes, amberyms, and G-cleaver ribozymes. Also disclosed	
CC	are nucleic acid decoy molecules and aptamers that bind to HBV reverse	
CC	transcriptase and/or HBV reverse transcriptase primer sequences, as well	
CC	as oligonucleotides that specifically bind the Enhancer I region of HBV	
CC	DNA. The nucleic acids may be used to modulate the expression of HBV	
CC	genes and HBV viral replication. Also disclosed is a method for screening	
CC	compounds and/or potential therapies directed against HBV, and compounds	
CC	that modulate the expression and/or replication of HCV. The compounds and	
CC	methods of the invention are useful for the treatment of degenerative and	
CC	disease states related to HBV and HCV infection, replication and gene	
CC	expression such as cirrhosis, liver failure, and hepatocellular	
CC	carcinoma. The present sequence represents a substrate for one of the HCV	
CC	DNAzyme or minus strand DNAAzyme sequences disclosed in the present	
CC	invention	
XX	Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;	
SQ	Query Match 1.7%; Score 13; DB 1; Length 17;	
	Best Local Similarity 100.0%; Pred. No. 6.8e+02;	
	Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	782 GCGCTCCGCATGG 794	
DB	17 GCGCTCCGCATGG 5	
RESULT 894		
ACD62719		
ID	ACD62719 standard; RNA; 17 BP.	
XX	ACD62719;	
AC	ACD62719;	
XX	24-SEP-2003 (first entry)	
DT	HCV minus strand DNAAzyme substrate sequence #694.	
XX		
OS		
DE		
XX		

KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
XX WO200281494-A1.
XX
XX 17-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORE/) MORRISSEY D.
PA (PVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Claim 1; Page 287; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNzyme or minus strand DNzyme sequences disclosed in the present
XX invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 6.8e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 782 GCCTCCGTCATGG 794
|||||:|||||:
DB 2 GCCTCCGTCATGG 14

RESULT 895
ADL48557
ID ADL48557 standard; RNA; 17 BP.
XX
AC ADL48557;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #1067.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
PD 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2090; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 6 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 6.8e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 162 TCTGGAAGGCCA 174
:|:|||||:
DB 5 UCUGGAAGGCCA 17

```

RESULT 896
ADI85725
ID ADI85725 standard; RNA; 17 BP.
XX
AC ADI85725;
XX
DT 03-JUN-2004 (first entry)
XX
DE HCV DNzyme substrate sequence #2971.
XX
KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNzyme.
XX
OS Hepatitis C virus.
XX
PN US2003125270-A1.
XX
PD 03-JUL-2003.
XX
PF 18-DEC-2000; 2000US-00740332.
XX
PR 18-DEC-2000; 2000US-00740332.
XX
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX
WPI; 2004-031273/03.
XX
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
PS Claim 1; SEQ ID NO 2971; 198pp; English.
XX
CC The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNzyme substrate
CC sequence.
XX
SQ Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
XX
Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 6.8e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 782 GGCCTCCGCATGG 794
DB 2 GGCUCGCCAUGG 14
||||:||||:|

RESULT 897
ADI84338/c
ID ADI84338 standard; RNA; 17 BP.
XX
AC ADI84338;
XX
DT 03-JUN-2004 (first entry)
XX
DE HCV DNzyme substrate sequence #1584.
XX
KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNzyme.
XX

```

```

OS Hepatitis C virus.
XX
PN US2003125270-A1.
XX
PD 03-JUL-2003.
XX
PF 18-DEC-2000; 2000US-00740332.
XX
PR 18-DEC-2000; 2000US-00740332.
XX
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX
WPI; 2004-031273/03.
XX
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
PS Claim 1; SEQ ID NO 1584; 198pp; English.
XX
CC The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNzyme substrate
CC sequence.
XX
SQ Sequence 17 BP; 2 A; 7 C; 6 G; 0 T; 2 U; 0 Other;
XX
Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 782 GGCCTCCGCATGG 794
DB 17 GGCCTCCGCATGG 5
||||:||||:|

RESULT 898
ACN70340
ID ACN70340 standard; DNA; 17 BP.
XX
AC ACN70340;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMPL-1 probe SEQ ID NO:7242.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMPL-1;
KW hGDMPL-1 agonist hGDMPL antagonist; hGDMPL inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
PN US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.

```

PR 30-JAN-2001; 2001WO-US0000662.
 PR 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.
 PR 30-JAN-2001; 2001WO-US0000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 7242; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 4 A; 1 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 697 GCTGGAGAGTGAG 709
 Db 5 GCTGGAGAGTGAG 17
 RESULT 899
 ACN72072/c
 ID ACN72072 standard; DNA; 17 BP.
 XX
 AC ACN72072;
 XX
 XX 02-DEC-2004 (first entry)
 DT
 XX Human GDMPLP-1 probe SEQ ID NO:8974.
 DE
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 XX US2004137589-A1.
 PN
 XX 15-JUL-2004.
 PD

XX 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234887P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US0000661.
 PR 30-JAN-2001; 2001WO-US0000662.
 PR 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.
 PR 30-JAN-2001; 2001WO-US0000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 8974; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 851 CACGAGCTCTTC 863
 Db 13 CACGAGCTCTTC 1
 RESULT 900
 AAQ24927/c
 ID AAQ24927 standard; DNA; 16 BP.
 XX
 AC AAQ24927;
 XX
 XX 25-MAR-2003 (revised)
 DT
 DT 19-NOV-1992 (first entry)
 DT
 XX Homeo box consensus sequence primer (250).
 DE
 XX

KW Single primer amplification; SPAR; ss.
 XX Synthetic.
 XX WO9207948-A1.
 PN
 XX
 PD 14-MAY-1992.
 XX
 XX
 PF 05-NOV-1991; 91WO-US008233.
 XX
 PR 06-NOV-1990; 90US-00610973.
 PR 29-JUL-1991; 91US-00737919.
 XX
 PA (LUBR) LUBRIZOL CORP.
 XX
 XX Cardineau GA, Filner P;
 PI
 XX
 DR WPI; 1992-183683/22.
 XX
 XX Nucleic acid sequence single primer amplification - useful for genomic
 PT variation analysis and polymorphism detection for restriction fragment
 PT length data.
 PT
 XX
 PS Claim 16; Page 39; 65pp; English.
 XX
 CC The selected primer is used in practice of the single primer
 CC amplification reaction (SPAR). (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 XX Sequence 16 BP; 1 A; 8 C; 2 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 694 GCAGCTGGAGAGTGAG 709
 DB 16 GCAGCTGGAGAGGAG 1
 RESULT 901
 AAV14335/C
 ID AAV14335 standard; DNA; 16 BP.
 XX
 AC AAV14335;
 XX
 XX 27-AUG-2003 (revised)
 DT 19-MAY-1998 (first entry)
 XX
 XX Probe HBPr242 for Hepatitis b virus.
 DE
 XX Probe; hepatitis b virus; HBV detection; RT pol region; genetic analysis;
 KW preCore region; HBsAg region; genotype specific target;
 KW mutation detection; ss.
 XX
 OS Synthetic.
 OS Hepatitis B virus.
 XX
 PN WO9740193-A2.
 XX
 XX 30-OCT-1997.
 PD
 XX 21-APR-1997; 97WO-EP002002.
 PF
 XX 19-APR-1996; 96EP-00870053.
 PR
 XX (INNO-) INNOGENETICS NV.
 PA
 XX Stuyver L, Rossau R, Maertens G;
 PI
 XX WPI; 1997-535867/49.
 DR
 XX Detection and/or genetic analysis of hepatitis B virus - specifically

PT genotype, preCore mutations, vaccine escape mutations and RT gene
 PT mutations selected by treatment with drugs.
 XX
 PS Disclosure; Page 32; 80pp; English.
 XX
 CC This sequence represents a probe for hepatitis b virus (HBV), used in the
 CC method of the invention for detection and/or genetic analysis of
 CC hepatitis B virus (HBV) in a sample. The method comprises: (a) optionally
 CC releasing, isolating or concentrating polynucleic acids (I) in the
 CC sample, and amplifying the relevant part of a suitable HBV gene in the
 CC sample with at least 1 suitable primer pair; (b) hybridising (I) with a
 CC combination of at least 2 nucleotide probes, which are applied to known
 CC locations on a solid support and hybridise specifically to mutant target
 CC sequences chosen from the HBV RT pol gene region, HBV preCore region,
 CC HBsAg region and/or HBV genotype specific target sequences, or their
 CC complements or U for T homologues; (c) detecting the hybrids formed in the
 CC sample from the differential hybridisation signal(s). The composition can
 CC be used to diagnose and/or monitor HBV mutations and/or genotypes in a
 CC sample, specifically genotype, preCore mutations, vaccine escape
 CC mutations and RT gene mutations selected by treatment with drugs, e.g.
 CC lamivudine and penciclovir. (Updated on 27-AUG-2003 to correct OS field.)
 XX
 SQ Sequence 16 BP; 1 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 395 CAAGCCAGCCAGAGGG 410
 DB 16 CAAGCCAGCAGAGTGGG 1
 RESULT 902
 AAZ91311
 ID AAZ91311 standard; DNA; 16 BP.
 XX
 AC AAZ91311;
 XX
 DT 17-MAY-2000 (first entry)
 XX
 DE IL-6R and IL-6 fusion protein related oligonucleotide SEQ ID NO:10.
 XX
 KW Interleukin 6 receptor; IL-6R; interleukin 6; IL-6; fusion protein;
 KW antianaemic; haematopoietic stem cell; platelet; blood; primer; ss.
 XX
 OS Synthetic.
 OS
 PN WO200001731-A1.
 XX
 XX 13-JAN-2000.
 PD
 XX 01-JUL-1999; 99WO-JP003554.
 PF
 XX 06-JUL-1998; 98JP-00190597.
 PR 29-JAN-1999; 99JP-00021788.
 PR 30-APR-1999; 99JP-00123411.
 XX
 PA (TOYJ) TOSOH CORP.
 XX
 XX Ekida T, Yagame H, Iida H, Yasukawa K, Tauchiya S, Ide T;
 PI
 XX WPI; 2000-182106/16.
 DR
 XX Fusion protein containing IL-6 receptor directly bonded to IL-6 useful
 PT for stimulating hematopoietic stem cell and blood platelet augmentation.
 PT
 XX Example 2; Page 60; 83pp; Japanese.
 PS
 XX The present invention describes a fusion protein (I) comprising an
 CC interleukin-6 receptor (IL-6R) directly linked to interleukin 6 (IL-6),
 CC where an amino acid residue of the IL-6R is directly bonded to an amino

CC acid residue of the IL-6. (I) is useful for the augmentation of
CC haematopoietic stem cells ex vivo, and augmentation of blood platelets
CC either ex vivo or therapeutically. AA291302 to AA291360 and AA291360 to
CC represent sequences used in the exemplification of the present invention
XX
SQ Sequence 16 BP; 2 A; 3 C; 10 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 690 CGCGGAGCTGGAGAG 705
||| ||||| ||||| |||||
Db 1 CGGGGAGCTGGAGGG 16

RESULT 903
AA282828/c
ID AAX282828 standard; DNA; 16 BP.
XX
AC AAX282828;
XX
DT 30-JUN-2000 (first entry)
XX
DE Human ApoE gene probe #3.
XX
KW ApoE; detection; polymorphism; apolipoprotein; alpha-1 antichymotrypsin;
KW diagnosis; Alzheimer's disease; PCR primer; probe; human; ss.
XX
OS Homo sapiens.
XX
PN JP2000050898-A.
XX
PD 22-FEB-2000.
XX
PF 06-AUG-1998; 98JP-00235033.
XX
PR 06-AUG-1998; 98JP-00235033.
XX
PA (NISS-) NISSHO KK.
XX
DR WPI; 2000-353229/31.
XX
PT A reagent for the detection of gene polymorphism of apolipoprotein E gene
PT and alpha-1 antichymotrypsin gene and the detecting method.
XX
PS Claim 2; Page 7; 9pp; Japanese.

XX This invention describes a novel reagent for the detection of
XX polymorphism in the apolipoprotein (Apo) E gene and alpha-1
XX antichymotrypsin (ACT) gene. The method involves primers specific to ApoE
XX gene, primers specific to the ACT gene, detection probes for detecting
XX ApoE gene polymorphisms and detection probes for detecting ACT gene
XX polymorphisms. The method of the invention can be used in the diagnosis
XX of Alzheimer's disease in which the combination between the gene
XX polymorphism of ApoE gene and the gene polymorphism of ACT gene detected
XX by the described detection method is connected to the contraction of
XX Alzheimer's disease. The method is used for the estimation of the level of
XX Alzheimer's disease in the population. The reagent can amplify the two
XX genes simultaneously and detect the gene polymorphism of the two genes in
XX one step. AAX282828-X82831 represent PCR primers and probes used to
XX illustrate the method of the invention
XX
SQ Sequence 16 BP; 4 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 373 CTGCGAGGAGCTTCTG 388
||||| ||||| ||||| |||||
Db 16 CTGCCAGGCGCTTCTG 1

RESULT 904
AAC83935/c
ID AAC83935 standard; DNA; 16 BP.
XX
AC AAC83935;
XX
DT 02-MAR-2001 (first entry)
XX
DE ApoE gene polymorphism detection probe #3.

XX Osteoporosis; human; polymorphism; vitamin D receptor; VDR;
KW oestrogen receptor; apolipoprotein E; ApoE; PCR primer; detection probe;
KW ss.
XX Homo sapiens.
XX
PN EP1054066-A2.
XX
PD 22-NOV-2000.
XX
PF 18-MAY-2000; 2000EP-00110219.
XX
PR 18-MAY-1999; 99JP-00136653.
PR 11-JUN-1999; 99JP-00165642.
XX
PA (NISS-) NISSHO CORP.
XX
PI Shiraki M, Ouchi Y, Hosoi T, Kusaba N, Baba T, Yoshida H;
XX WPI; 2001-018132/03.
XX
DR Diagnosing sensitivity to a medicine for osteoporosis involves analyzing
PT genetic polymorphisms of vitamin D receptor gene, estrogen receptor gene
PT and apolipoprotein E gene.
XX
PS Claim 22; Page 44; 51pp; English.

XX The present invention relates to a method for anticipating the
XX sensitivity to a medicine for osteoporosis. The method involves analysing
XX combinations of genetic polymorphisms of a vitamin D receptor gene (VDR),
XX an oestrogen receptor (ER) gene, and an apolipoprotein E (ApoE) gene from
XX a human genome DNA sample. PCR primers AAC83918-C83926 and AAC83937-
XX C83942 were used in the method of the present invention to amplify the
XX VDR, ER and ApoE genes, and detection probes AAC83927-C83936 were used
XX for detecting VDR, ER and ApoE genetic polymorphism. By relating a
XX combination of the genetic polymorphisms detected using the detection
XX probes described in AAC83927-C83936, a remedy for a bone-associated
XX disease can be selected
XX
SQ Sequence 16 BP; 4 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 373 CTGCGAGGAGCTTCTG 388
||||| ||||| ||||| |||||
Db 16 CTGCCAGGCGCTTCTG 1

RESULT 905
AAD04745/c
ID AAD04745 standard; DNA; 16 BP.
XX
AC AAD04745;
XX
DT 17-JUL-2001 (first entry)
XX
DE Sindbis virus erythropoietin DNA amplifying Epo-3' RT-PCR primer.

XX Alphaviral vector; vaccine; therapy; cancer; antiparasitic; antimalarial;
KW anticancer; anti-HIV; antiviral; infectious disease;

KW Human immunodeficiency virus; HIV; influenza; passive immunisation;
 KW carcinoma; liver; skin; stomach; ovarian tumour; RT-PCR primer;
 KW erythropoietin; ss.
 XX
 XX Sindbis virus.
 XX WO200130989-A2.
 XX
 XX 03-MAY-2001.
 XX
 XX 26-OCT-2000; 2000WO-IB001557.
 XX
 XX 27-OCT-1999; 99US-0161796P.
 XX
 XX (CYTO-) CYTOS BIOTECHNOLOGY AG.
 XX (RENN/) RENNER W A.
 XX (NIEB/) NIEBA L.
 XX
 XX Renner WA, Nieba L;
 XX WPI; 2001-308631/32.
 XX
 XX Preparing alphaviral vectors with mutations in a selected gene, for use
 XX as vaccines, particularly against pathogens that mutate rapidly,
 XX comprises replicating in the presence of a nucleoside analog.
 XX
 XX Example 3; Page 59; 103pp; English.
 XX
 XX The present invention relates to a method for preparing viral vectors
 XX which comprises inserting a gene of interest into an alphaviral vector
 XX such as pCytts, pSInkP5 and replicating the vector in the presence of
 XX alphaviral replicase and nucleoside analogues (5'-azacytidine (AZT), FU-
 XX 5'-fluorouridine) to produce a modified gene of interest. The replication
 XX is repeated until the modified gene in 90 % of the vector population
 XX contain a mutation in the modified gene which is 90-99 % identical with
 XX the gene of interest. The vector populations are used in vaccines for
 XX treatment or prevention of a wide variety of infectious diseases (viral
 XX or parasitic, e.g. human immuno deficiency virus (HIV), influenza,
 XX Trypanosoma or Plasmodium) and cancers such as liver carcinoma, stomach
 XX carcinoma, skin carcinoma and ovarian tumours. Vaccines containing the
 XX mutant populations will therefore be effective against viral escape
 XX mutants. Mutagenesis in a eukaryotic cell ensures that expressed proteins
 XX are correctly glycosylated. Antisera raised against the vaccines can be
 XX used for passive immunisation. The present sequence is Epo-3' RT (reverse
 XX transcription) PCR primer used for amplifying erythropoietin DNA from
 XX Sindbis virus which is an alphavirus. Erythropoietin is the gene of
 XX interest
 XX
 XX Sequence 16 BP; 2 A; 6 C; 3 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 749 CAGCTGGCATGCAGG 764
 DB 16 CAGATGATGCATGCAGG 1
 RESULT 906
 ABA93196/c
 ID ABA93196 standard; DNA; 16 BP.
 XX
 XX ABA93196;
 XX
 XX 17-APR-2002 (first entry)
 XX
 XX Human apolipoprotein E gene probe SEQ ID NO:5.
 DE
 DE Human; vitamin D receptor; apolipoprotein E; oestrogen receptor; VDR;
 KW ApoE; bone-related disease; polymorphism; detection; probe; ss.
 KW
 XX Homo sapiens.
 OS

XX JP2001333798-A.
 XX 04-DEC-2001.
 XX
 XX 26-MAY-2000; 2000JP-00155871.
 XX
 XX 26-MAY-2000; 2000JP-00155871.
 XX
 XX (NISS-) NISSHO KK.
 XX
 XX WPI; 2002-135948/18.
 XX
 XX A reagent for detecting simultaneously a gene polymorphism of the vitamin
 XX D receptor gene, apolipoprotein E gene and estrogen receptor gene.
 XX
 XX Claim 1; Page 2; 13pp; Japanese.
 XX
 XX The present invention describes a reagent for detecting simultaneously
 XX the gene polymorphism of the vitamin D receptor (VDR) gene,
 XX apolipoprotein E (ApoE) gene and estrogen receptor (ER) gene. Also
 XX described is a method for detecting simultaneously the gene polymorphism
 XX of VDR gene, ApoE gene and ER gene in which the reagent is used to detect
 XX the gene polymorphism of VDR, ApoE and ER in a sample. The reagent can be
 XX used for selecting a treating agent for bone-related diseases. The
 XX present sequence represents a specifically claimed probe for the human
 XX ApoE gene, for use in a reagent of the present invention
 XX
 XX Sequence 16 BP; 4 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 373 CTGCGAGGAGCTTCG 388
 DB 16 CTGCCAGGCGCTTCG 1
 RESULT 907
 ABS98216/c
 ID ABS98216 standard; DNA; 16 BP.
 XX
 XX ABS98216;
 XX
 XX 23-DEC-2002 (first entry)
 XX
 XX Human lactoferrin (LTF) gene PCR primer #31.
 DE
 XX
 KW Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1; PCR;
 KW cytochrome P450 A2; CYP4501A2; cytochrome P450 O2E; CYP45002B1; LTF;
 KW adrenergic receptor beta1; ADBR1; aryl hydrocarbon; AHR; MRP3; NR112;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
 KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
 KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 KW NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile; STW;
 KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KW multidrug resistance associated protein 3; cancer; prostate;
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR5;
 KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; pulmonary; immunological.
 XX
 XX Homo sapiens.
 OS
 XX WO200257410-A2.
 XX
 XX 25-JUL-2002.
 XX
 XX 28-NOV-2001; 2001WO-US044838.

```

XX 28-NOV-2000; 2000US-00724389.
XX (DNAS-) DNA SCI LAB INC.
XX Guida M, Hall J;
XX WPI; 2002-698522/75.
XX Isolated nucleic acid molecules having polymorphisms in known human genes
XX e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
XX for locating, identifying and characterizing the genes responsible for
XX disorder-related traits.
XX Example 23; Page 146; 714pp; English.
XX This invention relates to the sequence of an isolated nucleic acid
XX molecule comprising at least one base variation from that of a known
XX human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),
XX cytochrome P450 2E1 (CYP4502E1), adrenergic receptor beta1 (ADRB1),
XX aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
XX (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
XX inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
XX protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
XX transferase (HNMT), (kallikrein 2) Kk2, nicotinamide -N-methyl
XX transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
XX sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
XX (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
XX transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
XX (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
XX (MRP3), orphan nuclear receptor (NRI12), or acetylcholine muscarinic
XX receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
XX The polymorphisms in the human genes cited in the invention are useful as
XX genetic linkage markers for locating and characterizing the genes that
XX are responsible for specific traits within the genome and eventually
XX identifying the genes responsible for a variety of disorder-related
XX traits as a result of their e.g., overexpression, constitutive
XX expression, mutation or underexpression, which may be used in diagnosing
XX and/or treating the disorders. The nucleic acid molecules comprising the
XX polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502E1,
XX ARNT, EPHX2, GST12, NNMT, NQO2, NRI12, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
XX MDR1 and/or MDR3 are useful for screening individuals for altered drug
XX metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,
XX AHR, MDR1 and/or MDR3 may also be used to screen individuals for
XX susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
XX used to screen for altered cardiovascular function, in COX2 for altered
XX susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
XX nervous system function, in FLAP and HNMT for altered pulmonary,
XX immunological or haematological function, in Kk2 for altered serine
XX protease activity in the prostate, in LTF for altered immunological or
XX haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
XX peripheral nervous system function. The present sequence represents a PCR
XX primer used to amplify the sequences of the invention
XX
XX Sequence 16 BP; 1 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 608 CAGGAGAGCCGAGTC 623
Db 16 CAAGGAGCCGAGTC 1
RESULT 908
ABA93184/C
ID ABA93184 standard; DNA; 16 BP.
XX ABA93184;
XX 17-APR-2002 (first entry)
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 16;
XX Best Local Similarity 87.5%; Pred. No. 6.7e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX Qy 373 CTCGAGGAGCTTCG 388
XX Db 16 CTCGAGGAGCTTCG 1
XX
XX RESULT 909
XX ADC98479
XX ID ADC98479 standard; DNA; 16 BP.
XX
XX AC ADC98479;
XX
XX DT 01-JAN-2004 (first entry)
XX
XX DE KJ1311 polymorphism marker PCR primer S primer seq.
XX
XX KW low bone mineral density; BMD; bone damage; polymorphism; osteoporosis;
XX single nucleotide polymorphism; SNP; PCR primer; ss; human.
XX
XX OS Synthetic.
XX OS Homo sapiens.
XX
XX PN WC2003054218-A2.
XX
XX PD 03-JUL-2003.
XX
XX PF 19-DEC-2002; 2002WO-US040948.
XX
XX PR 20-DEC-2001; 2001US-0342711P.
XX 04-NOV-2002; 2002US-0423559P.
XX

```

```

DE Human apolipoprotein E gene PCR primer SEQ ID NO:18.
XX
XX KW Human; vitamin D receptor; apolipoprotein E; oestrogen receptor; VDR;
XX ApoE; osteoporosis; polymorphism; allele; PCR primer; ss.
XX
XX OS Homo sapiens.
XX
XX PN JF2001333799-A.
XX
XX PD 04-DEC-2001.
XX
XX PF 26-MAY-2000; 2000JP-00155993.
XX
XX PR 26-MAY-2000; 2000JP-00155993.
XX
XX PA (NISS-) NISSHO KK.
XX
XX DR WPI; 2002-135949/18.
XX
XX FT Estimate of sensitivity to drugs for osteoporosis and a reagent kit.
XX
XX PS Example 1; Page 7; 13pp; Japanese.
XX
XX CC The present invention describes a method for the estimation of
XX sensitivity to drugs for osteoporosis in which each gene polymorphism of
XX vitamin D receptor (VDR) gene, oestrogen receptor (ER) gene and
XX apolipoprotein E3 (ApoE3) allele (2/2, 2/3, 2/4, 3/3, 3/4 or 4/4) are
XX analysed from the genomic DNA contained in a sample collected from a
XX human and, based on these combinations of gene polymorphisms, it is
XX estimated that the sample is derived from an individual showing a
XX specific priority on the sensitivity against a plural of treating agents
XX for osteoporosis. Also described is a reagent kit for analysing gene
XX polymorphisms of VDR, ApoE and ER genes containing primers specific to
XX each of the genes and detecting probes for detecting each gene
XX polymorphisms. The reagent can be used for selecting an effective drug
XX for osteoporosis. The present sequence represents a PCR primer for human
XX ApoE which is used in the exemplification of the present invention
XX
XX Sequence 16 BP; 4 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 373 CTCGAGGAGCTTCG 388
XX Db 16 CTCGAGGAGCTTCG 1
XX
XX RESULT 909
XX ADC98479
XX ID ADC98479 standard; DNA; 16 BP.
XX
XX AC ADC98479;
XX
XX DT 01-JAN-2004 (first entry)
XX
XX DE KJ1311 polymorphism marker PCR primer S primer seq.
XX
XX KW low bone mineral density; BMD; bone damage; polymorphism; osteoporosis;
XX single nucleotide polymorphism; SNP; PCR primer; ss; human.
XX
XX OS Synthetic.
XX OS Homo sapiens.
XX
XX PN WC2003054218-A2.
XX
XX PD 03-JUL-2003.
XX
XX PF 19-DEC-2002; 2002WO-US040948.
XX
XX PR 20-DEC-2001; 2001US-0342711P.
XX 04-NOV-2002; 2002US-0423559P.
XX

```


XX PA (INCYTE-) INCYTE GENOMICS INC.

XX PI Jones KA, Valdes A, Townley DJ, Mangion J, Galwey N, Bennett S;

XX PI McKay I, Schafer A;

XX DR WPI; 2003-559156/52.

XX DR

XX PT Determining whether an individual is predisposed to susceptibility to low

XX PT bone mineral density (BMD) and/or bone damage, involves identifying

XX PT polymorphisms in associated genes.

XX PS Example 8; Page 238; 246pp; English.

XX CC The present invention describes a method of determining whether an

XX CC individual is predisposed to susceptibility to low bone mineral density

XX CC (BMD) and/or bone damage comprising identifying whether the individual

XX CC has at least one polymorphism in a polynucleotide encoding a protein,

XX CC where the polynucleotide is one of 81 200-500 nucleotide sequences (S1,

XX CC see ADC98235 to ADC98315). An agent identified in an method from the

XX CC present invention which can be used for the prevention or treatment of a

XX CC disease resulting in susceptibility to low BMD and/or bone damage is

XX CC useful in the manufacture of a medicament for use in modulating the

XX CC susceptibility to low BMD and/or bone damage. The disease associated with

XX CC low BMD and/or bone damage is osteoporosis. The present PCR primer

XX CC sequence is used in the exemplification of the present invention.

XX SQ Sequence 16 BP; 7 A; 4 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 6.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 532 GAAGAGATGCCAGAC 547

Db 1 GAAAGATCCAGAC 16

RESULT 910

ID ADD20502/c

XX ID ADD20502 standard; DNA; 16 BP.

XX AC ADD20502;

XX DT 15-JAN-2004 (first entry)

XX DE Oreochromis niloticus microsatellite primer SEQ ID NO:1137.

XX KW single nucleotide polymorphism; SNP; fish; Salmo salar;

XX KW Oreochromis niloticus; Atlantic halibut; microsatellite; cod;

XX KW polymorphic site; seabass; salmonidae; Tilapia; rainbow trout; halibut;

XX KW detection; primer; ss.

XX OS Synthetic.

XX OS Oreochromis niloticus.

XX PN WO2003060160-A2.

XX PD 24-JUL-2003.

XX PF 17-JAN-2003; 2003WO-IB000112.

XX PR 18-JAN-2002; 2002US-0349950P.

XX PR 16-AUG-2002; 2002US-0404200P.

XX PA (GENO-) GENOMAR ASA.

XX PI Lie O, Slettan A, Hoyum M, Lingaas F;

XX DR WPI; 2003-627388/59.

XX PT Novel isolated nucleic acid molecule comprising single nucleotide

XX PT polymorphism associated with fish, useful for forming PCR primers which

PT are used for detecting single nucleotide polymorphisms in fish nucleic

PT acids.

XX Claim 18; SEQ ID NO 1137; 233pp; English.

XX CC The present invention describes an isolated nucleic acid (I) comprising a

XX CC single nucleotide polymorphism (SNP) chosen from: (i) a nucleic acid of

XX CC Salmo salar SNPs, Oreochromis niloticus SNPs or Atlantic halibut SNPs;

XX CC and (ii) a nucleic acid having nucleotide sequence that hybridises to

XX CC (i), or its complement under highly stringent hybridisation conditions.

XX CC Also described: (1) an isolated oligonucleotide (II) comprising at least

XX CC 17 contiguous nucleotides of a nucleotide sequence of S. salar SNPs, O.

XX CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod

XX CC polymorphic sites and seabass polymorphic sites, or their complement; (2)

XX CC a primer pair (III) suitable for use in PCR, comprising two (II) capable

XX CC of amplifying a nucleotide sequence chosen from S. salar SNPs and, O.

XX CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod

XX CC polymorphic sites and seabass polymorphic sites; and determining (M1) the

XX CC origin of fish sample comprising providing a parentage genotype database

XX CC comprising a collection of candidate parent genotypes, where each of the

XX CC candidate parent genotype represents a distinct origin, and comparing a

XX CC sample genotype to the parentage genotype database, where a match between

XX CC the sample genotype and one of the candidate parent genotype identifies

XX CC to the origin of the sample. (M1) is useful for determining the origin of

XX CC a fish sample such as family salmonidae, S. salar, Tilapia, O. niloticus,

XX CC rainbow trout, halibut, seabass and Atlantic cod. (II) is useful for

XX CC detecting nucleic acid molecule comprising SNP in a sample, which

XX CC involves contacting the sample containing nucleic acids with one or more

XX CC (II) derived from nucleotide sequence of S. salar SNPs and O. niloticus

XX CC SNPs, and identifying nucleic acid that hybridises to (II). (II) is

XX CC useful for detecting nucleic acid molecule comprising a polymorphic

XX CC sequence in a sample, comprising contacting the sample containing nucleic

XX CC acids with one or more (II) which is derived from O. niloticus

XX CC microsatellite, O. niloticus SNPs, Atlantic halibut SNPs, cod polymorphic

XX CC sites or seabass polymorphic sites, and identifying a nucleic acid that

XX CC hybridises to (II). (III) is useful for detecting nucleic acid molecule

XX CC comprising a microsatellite sequence in sample. The present sequence is

XX CC used in the exemplification of the present invention.

XX SQ Sequence 16 BP; 5 A; 5 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 6.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 622 TCGCTTGAGGTGCC 637

Db 16 TTGCTTGAGGTGCC 1

RESULT 911

ID ACC43260/c

XX ID ACC43260 standard; DNA; 16 BP.

XX AC ACC43260;

XX DT 11-AUG-2003 (first entry)

XX DE Nucleotide sequence of a fragment from an actin binding protein exon.

XX KW Sequence tag; trapped gene; gene-trap vector; actin binding protein; ss.

XX OS Mus musculus.

XX PN WO2003018765-A2.

XX PD 06-MAR-2003.

XX PF 26-AUG-2002; 2002WO-US027102.

XX PR 24-AUG-2001; 2001US-0314991P.

XX PA (HEAL-) HEALTH RES INC.

XX Pruitt SC, Mielnicki LM;
 XX WPI; 2003-300726/29.
 XX Identifying Sequence Tags from trapped genes, useful for diagnostic
 PT applications, comprises using a gene-trap vector having a splice donor, a
 PT type IIS restriction endonuclease cleavage site and a splice donor or
 PT polyadenylation site.
 XX Example 3; Page 25; 51pp; English.
 XX The specification describes a method of identifying sequence tags from
 CC trapped genes. The method comprises using a gene-trap vector that has a
 CC splice donor, a type IIS restriction endonuclease cleavage site and a
 CC splice donor or a polyadenylation site. mRNA is prepared from cells
 CC stably transfected with the gene-trap vector; first and second cDNA
 CC strands are synthesised from the mRNA; the cDNA strands are digested with
 CC restriction endonucleases including the type IIS restriction
 CC endonucleases to produce assay tags, where each assay tag comprises a
 CC sequence Tag and a portion of the gene-trap vector; the assay tags are
 CC concatenated; and the concatamers are amplified and sequenced to identify
 CC the sequence of the assay tags and the sequence tags. The method is
 CC useful for high throughput sequence tag identification based on
 CC modifications of the serial analysis of gene expression technology, which
 CC may be used in diagnosing or in finding cures for various pathological
 CC conditions. The present sequence represents a sequence tag, identified
 CC using the method of the invention
 XX
 SQ Sequence 16 BP; 3 A; 8 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 407 AGGAGGAGGAGGAGT 422
 Db 16 AGGAGGAGGAGTGTAGT 1
 RESULT 912
 ADR06457
 ID ADR06457 standard; DNA; 16 BP.
 XX
 AC ADR06457;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE IMAGE:2631676 mRNA sequence tag.
 XX
 KW Identification; gene expression; cell differentiation;
 KW stem cell differentiation; murine; ss.
 XX
 OS Mus musculus.
 XX
 PN WO2004065553-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001482.
 XX
 PR 16-JAN-2003; 2003US-0440510P.
 XX
 PA (HEAL-) HEALTH RES INC.
 XX
 PI Pruitt SC, Maslov A;
 XX
 DR WPI; 2004-571677/55.
 XX
 DR Identifying genes expressed during differentiation of a cell, useful,
 PT e.g. in research into mechanisms leading to differentiation of stem
 PT cells, comprises integrating a cell lineage targeting vector into the
 PT genome of a host cell.

XX Example 5; SEQ ID NO 8; 45pp; English.
 XX The present invention relates to a method (M1) for identifying genes
 CC expressed during cell differentiation. The method is useful in research
 CC into the mechanisms that lead to differentiation of stem cells. Knowledge
 CC of these mechanisms is important in understanding embryonic development
 CC and homeostasis within somatic tissues, and is also relevant to the
 CC therapeutic use of stem cells. The method comprises: integrating into a
 CC site in a host cell genome, a cell lineage targeting vector comprising a
 CC pair of recombinase recognition sites flanking one or more
 CC polyadenylation sites, a first selectable marker placed downstream or
 CC between the two recombinase recognition sites, a reporter gene placed
 CC downstream of the recombinase recognition sites, and a cell lineage
 CC specific gene promoter placed upstream of the recombinase recognition
 CC sites or a cell specific lineage gene placed downstream of the
 CC recombinase recognition sites; amplifying cells generated from the host
 CC cell; integrating into the genome of a plurality of the amplified cells,
 CC a gene-trap vector comprising a splice acceptor, a type IIS restriction
 CC endonuclease cleavage site, one or more polyadenylation sites, a second
 CC selectable marker and a splice donor; allowing the cells to differentiate
 CC; isolating cells in which the reporter gene is expressed indicating
 CC expression of the cell lineage specific gene; and identifying trapped
 CC genes in the isolated cells. The present sequence was used to illustrate
 CC the invention.
 XX
 SQ Sequence 16 BP; 5 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 6.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 407 AGGAGGAGGAGGAGT 422
 Db 1 AGGAGGAGGAGTGTAGT 16
 RESULT 913
 ADR06458/c
 ID ADR06458 standard; DNA; 16 BP.
 XX
 AC ADR06458;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Unigene cluster ENCL sequence tag.
 XX
 KW Identification; gene expression; cell differentiation;
 KW stem cell differentiation; murine; ss.
 XX
 OS Mus musculus.
 XX
 PN WO2004065553-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001482.
 XX
 PR 16-JAN-2003; 2003US-0440510P.
 XX
 PA (HEAL-) HEALTH RES INC.
 XX
 PI Pruitt SC, Maslov A;
 XX
 DR WPI; 2004-571677/55.
 XX
 DR Identifying genes expressed during differentiation of a cell, useful,
 PT e.g. in research into mechanisms leading to differentiation of stem
 PT cells, comprises integrating a cell lineage targeting vector into the
 PT genome of a host cell.
 XX
 XX Example 5; SEQ ID NO 9; 45pp; English.

CC The present invention relates to a method (M1) for identifying genes
 CC expressed during cell differentiation. The method is useful in research
 CC into the mechanisms that lead to differentiation of stem cells. Knowledge
 CC of these mechanisms is important in understanding embryonic development
 CC and homeostasis within somatic tissues, and is also relevant to the
 CC therapeutic use of stem cells. The method comprises: integrating into a
 CC site in a host cell genome, a cell lineage targeting vector comprising a
 CC pair of recombinase recognition sites flanking one or more
 CC polyadenylation sites, a first selectable marker placed downstream or
 CC between the two recombinase recognition sites, a reporter gene placed
 CC downstream of the recombinase recognition sites, and a cell lineage
 CC specific gene promoter placed upstream of the recombinase recognition
 CC sites or a cell specific lineage gene placed downstream of the
 CC recombinase recognition sites; amplifying cells generated from the host
 CC cell; integrating into the genome of a plurality of the amplified cells,
 CC a gene-trap vector comprising a splice acceptor, a type IIS restriction
 CC endonuclease cleavage site, one or more polyadenylation sites, a second
 CC selectable marker and a splice donor; allowing the cells to differentiate
 CC; isolating cells in which the reporter gene is expressed indicating
 CC expression of the cell lineage specific gene; and identifying trapped
 CC genes in the isolated cells. The present sequence was used to illustrate
 CC the invention.

XX Sequence 16 BP; 3 A; 8 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 6.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 407 AGGAGAGAGAGAGT 422

DB 16 AGGAGAGAGATGTAGT 1

RESULT 914

AAQ52083
 ID AAQ52083 standard; RNA; 17 BP.

XX AAQ52083;

DT 25-MAR-2003 (revised)

DT 26-MAY-1994 (first entry)

XX Breast cancer specific mRNA ribozyme cleavable nucleotide (1699).
 XX Multiple drug resistance; mdr-1; ribozyme; membrane protein; liver;
 XX resistance; chemotherapeutic agent; colchicine; doxorubicin; colon;
 XX actinomycin D; vinblastine; small intestine; kidney; adrenal gland;
 XX adenocarcinoma; bowel; transformed phenotype; promyelocytic leukemia;
 XX human; chronic myelogenous leukemia; CML; follicular lymphoma;
 XX B-cell acute lymphocytic leukemia; breast cancer; colon carcinoma;
 XX neuroblastoma; lung cancer; genetic drift; mutation; hammerhead motif;
 XX hairpin; hepatitis delta virus; group I intron; RNaseP; ss.

XX Homo sapiens.

OS WO9323057-A1.

PN 25-NOV-1993.

PD 13-MAY-1993;

XX 93WO-US0004573.

XX 14-MAY-1992;

XX 92US-00882822.

XX 14-MAY-1992;

XX 92US-00882885.

XX 26-AUG-1992;

XX 92US-00936110.

XX 26-AUG-1992;

XX 92US-00936421.

XX 26-AUG-1992;

XX 92US-00936531.

XX 26-AUG-1992;

XX 92US-00936532.

XX 07-DEC-1992;

XX 92US-00987131.

XX 19-JAN-1993;

XX 93US-00006122.

XX 19-JAN-1993;

XX 93US-00008910.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX Thompson JD, Draper KG;

XX WPI; 1993-386203/48.

XX New enzymatic RNA molecules (ribozymes) - which cleave mRNA associated

PT with tumours or mRNA expressed from gene encoding multiple drug

PT resistance.

XX Claim 3; Fig 8; 69pp; English.

XX The sequences given in AAQ51825-2266 represent areas of mRNAs which are

CC associated with development or maintenance of chronic myelogenous

CC leukemia (CML), promyelocytic leukemia, Burkitt's lymphoma, or acute

CC lymphocytic leukemia, follicular lymphoma, B-cell acute lymphocytic

CC leukemia, breast cancer, colon carcinoma, neuroblastoma and lung cancer.

CC The full length mRNAs containing these target sequences, encode aberrant

CC cellular proteins which are able to control cellular proliferation and

CC are directly linked to a leukemic phenotype. These target sequences are

CC identified by the ribozyme of the invention. The ribozymes is formed in a

CC hammerhead motif, but may also be formed in the motif of a hairpin,

CC hepatitis delta virus, group I intron or RNaseP-like RNA. These ribozymes

CC may be used to inhibit the development or expression of a transformed

CC phenotype in man and other animals by modulating expression of the

CC corresponding gene. Cleavage of target mRNAs expressed in pre-neoplastic

CC and transformed cells elicits inhibition of the transformed state.

CC Multiple drug resistance (mdr-1) mRNA specific ribozymes remove the

CC mechanism of drug resistance used by transformed cells and thus enhances

CC drug therapies for tumours. The ribozymes may also be used to study

CC genetic drift and mutations within cells. (Updated on 25-MAR-2003 to

CC correct PN field.)

XX Sequence 17 BP; 2 A; 8 C; 4 G; 0 T; 3 U; 0 Other;

QY Query Match 1.7%; Score 12.8; DB 1; Length 17;

DB Best Local Similarity 68.8%; Pred. No. 7.2e+02;

Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 843 TGGCCTATCACCAGCT 858

DB 2 UGGCCUGCCACCAGCU 17

RESULT 915

AAQ53562

ID AAT53562 standard; RNA; 17 BP.

XX AAT53562;

AC AAT53562;

DT 25-MAR-2003 (revised)

DT 27-MAR-1997 (first entry)

XX Rat ICAM hammerhead ribozyme target sequence (nt. position 1678).

XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;

XX gene expression; downregulation; interleukin-5; IL-5; ICAM-1;

XX intercellular adhesion molecule; rel A; tumour necrosis factor;

XX TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;

XX translocation; chronic myelogenous leukaemia; CML; cancer;

XX Philadelphia chromosome; inflammation; autoimmune disease;

XX atherosclerosis; myocardial infarction; stroke; restenosis;

XX transplant rejection; rheumatoid arthritis; psoriasis;

XX myocardial ischaemia; Kawasaki disease; septic shock; HIV;

XX human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;

XX ss.

XX Rattus rattus.

XX WO9523225-A2.

XX 31-AUG-1995.

XX

```

PF 23-FEB-1995; 95WO-IB000156.
XX
XX 23-FEB-1994; 94US-002011109.
PR 29-MAR-1994; 94US-00218934.
PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 15-AUG-1994; 94US-00291433.
PR 15-AUG-1994; 94US-00294620.
PR 17-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, McSwiggen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Usman N, Wincott FE, Woolf T;
XX WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
XX in inhibiting disease related genes.
XX
XX Claim 2; Page 202; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
XX enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
XX nucleotide base position indicated in the DE line. Regions of the mRNA
XX that do not form secondary folding structures and that contain potential
XX hammerhead and hairpin ribozyme cleavage sites were identified by
XX computer analysis. Ribozymes directed against these mRNA sequences were
XX designed and synthesised with modifications that improve their nuclease
XX resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
XX inhibit ICAM-1 expression, making them useful for reducing transplant
XX rejection and alleviating symptoms in patients with rheumatoid arthritis,
XX asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
XX correct PI field.)
XX
XX Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 75.0%; Pred. No. 7.2e+02;
XX Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
XX
XX Qy 461 GAGAGACTCGGCTGG 476
XX ||||| :|||:|
XX 1 GAGAACCGGCCUGG 16
XX
XX RESULT 916
XX AAT53584
XX ID AAT53584 standard; RNA; 17 BP.
XX
XX AC AAT53584;
XX

```

25-MAR-2003 (revised)
 27-MAR-1997 (first entry)
 Rat ICAM hammerhead ribozyme target sequence (nt. position 1787).
 Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 intercellular adhesion molecule; rel A; tumour necrosis factor;
 TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 translocation; chronic myelogenous leukaemia; CML; cancer;
 Philadelphia chromosome; inflammation; autoimmune disease;
 atherosclerosis; myocardial infarction; stroke; restenosis;
 transplant rejection; rheumatoid arthritis; psoriasis;
 myocardial ischaemia; Kawasaki disease; septic shock; HIV;
 human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
 ss.
 Rattus rattus.
 WO9523225-A2.
 31-AUG-1995.
 23-FEB-1995; 95WO-IB000156.
 23-FEB-1994; 94US-002011109.
 29-MAR-1994; 94US-00218934.
 04-APR-1994; 94US-00222795.
 07-APR-1994; 94US-00224483.
 15-APR-1994; 94US-00227958.
 15-APR-1994; 94US-00228041.
 18-MAY-1994; 94US-00245736.
 06-JUL-1994; 94US-00271280.
 15-AUG-1994; 94US-00291932.
 15-AUG-1994; 94US-00291433.
 15-AUG-1994; 94US-00294620.
 17-AUG-1994; 94US-00293520.
 02-SEP-1994; 94US-00300000.
 08-SEP-1994; 94US-00303039.
 23-SEP-1994; 94US-00311486.
 23-SEP-1994; 94US-00311749.
 28-SEP-1994; 94US-00314397.
 03-OCT-1994; 94US-00316771.
 07-OCT-1994; 94US-00319492.
 11-OCT-1994; 94US-00321993.
 04-NOV-1994; 94US-00334847.
 10-NOV-1994; 94US-00337608.
 28-NOV-1994; 94US-00345516.
 16-DEC-1994; 94US-00357577.
 23-DEC-1994; 94US-00363233.
 30-JAN-1995; 95US-00380734.
 (RIBO-) RIBOZYME PHARM INC.
 Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
 Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, McSwiggen JA;
 Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
 Tracz D, Usman N, Wincott FE, Woolf T;
 WPI; 1995-351090/45.
 Ribozymes having modified bases and methods for producing them - for use
 in inhibiting disease related genes.
 Claim 2; Page 202; 407pp; English.
 The present sequence represents a preferred target sequence for an
 enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
 nucleotide base position indicated in the DE line. Regions of the mRNA
 that do not form secondary folding structures and that contain potential
 hammerhead and hairpin ribozyme cleavage sites were identified by
 computer analysis. Ribozymes directed against these mRNA sequences were
 designed and synthesised with modifications that improve their nuclease
 resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
 inhibit ICAM-1 expression, making them useful for reducing transplant
 rejection and alleviating symptoms in patients with rheumatoid arthritis,
 asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
 correct PI field.)
 Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 461 GAGAGACTCGGCTGG 476
 ||||| :|||:|
 1 GAGAACCGGCCUGG 16
 RESULT 916
 AAT53584
 ID AAT53584 standard; RNA; 17 BP.
 AC AAT53584;

CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
SQ Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
DB 1 GAGAACCCUGGCCUGG 16
||||| |:|||||
1 GAGAACCCUGGCCUGG 16

RESULT 917
AAT53620
ID AAT53620 standard; RNA; 17 BP.
XX
AC AAT53620;
XX
DT 25-MAR-2003 (revised)
DT 27-MAR-1997 (first entry)
DE
DE Rat ICAM hammerhead ribozyme target sequence (nt. position 2220).
XX
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW translocation; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW ss.
XX
OS Rattus rattus.
XX
PN WO9523225-A2.
XX
PD 31-AUG-1995.
XX
PF 23-FEB-1995; 95WO-IB000156.
XX
PR 23-FEB-1994; 94US-00201109.
PR 29-MAR-1994; 94US-00218934.
PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 18-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.

PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Chowrira B, Direnzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, McSwiggen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Usman N, Wincott FE, Woolf T;
XX WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
XX in inhibiting disease related genes.
PT
XX
PS Claim 2; Page 203; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesised with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
SQ Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
DB 1 GAGAACCCUGGCCUGG 16
||||| |:|||||
1 GAGAACCCUGGCCUGG 16

RESULT 918
AAT53439
ID AAT53439 standard; RNA; 17 BP.
XX
AC AAT53439;
XX
DT 25-MAR-2003 (revised)
DT 27-MAR-1997 (first entry)
DE
DE Rat ICAM hammerhead ribozyme target sequence (nt. position 48).
XX
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW translocation; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW ss.
XX
OS Rattus rattus.
XX
PN WO9523225-A2.
XX
PD 31-AUG-1995.
XX
PF 23-FEB-1995; 95WO-IB000156.
XX
PR 23-FEB-1994; 94US-00201109.
PR 29-MAR-1994; 94US-00218934.

```

PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00271280.
PR 16-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Ueman N, Wincott FE, Woolf T;
XX
XX WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
XX in inhibiting disease related genes.
XX
XX Claim 2; Page 201; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
XX enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
XX nucleotide base position indicated in the DE line. Regions of the mRNA
XX that do not form secondary folding structures and that contain potential
XX hammerhead and hairpin ribozyme cleavage sites were identified by
XX computer analysis. Ribozymes directed against these mRNA sequences were
XX designed and synthesised with modifications that improve their nuclease
XX resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
XX inhibit ICAM-1 expression, making them useful for reducing transplant
XX rejection and alleviating symptoms in patients with rheumatoid arthritis,
XX asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
XX correct PI field.)
XX
XX Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 75.0%; Pred. No. 7.2e+02;
XX Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCCGCGCCUGG 16
XX
RESULT 919
AAT53627
ID AAT53627 standard; RNA; 17 BP.
XX
XX AAT53627;
AC
XX
XX 25-MAR-2003 (revised)
DT
DT 27-MAR-1997 (first entry)
XX
XX Rat ICAM hammerhead ribozyme target sequence (nt. position 1983).
DE

```

Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition; gene expression; downregulation; interleukin-5; IL-5; ICAM-1; intercellular adhesion molecule; rel A; tumour necrosis factor; TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene; translocation; chronic myelogenous leukaemia; CML; cancer; Philadelphia chromosome; inflammation; autoimmune disease; atherosclerosis; myocardial infarction; stroke; restenosis; transplant rejection; rheumatoid arthritis; psoriasis; myocardial ischaemia; Kawasaki disease; septic shock; HIV; human immunodeficiency virus; acquired immune deficiency syndrome; AIDS; ss.

Rattus rattus.

WO9523225-A2.

31-AUG-1995.

23-FEB-1995; 95WO-IB000156.

23-FEB-1994; 94US-00201109.

29-MAR-1994; 94US-00218934.

04-APR-1994; 94US-00222795.

07-APR-1994; 94US-00224483.

15-APR-1994; 94US-00227958.

15-APR-1994; 94US-00228041.

18-MAY-1994; 94US-00245736.

06-JUL-1994; 94US-00271280.

16-AUG-1994; 94US-00291932.

16-AUG-1994; 94US-00291433.

17-AUG-1994; 94US-00292620.

19-AUG-1994; 94US-00293520.

02-SEP-1994; 94US-00300000.

08-SEP-1994; 94US-00303039.

23-SEP-1994; 94US-00311486.

23-SEP-1994; 94US-00311749.

28-SEP-1994; 94US-00314397.

03-OCT-1994; 94US-00316771.

07-OCT-1994; 94US-00319492.

11-OCT-1994; 94US-00321993.

04-NOV-1994; 94US-00334847.

10-NOV-1994; 94US-00337608.

28-NOV-1994; 94US-00345516.

16-DEC-1994; 94US-00357577.

23-DEC-1994; 94US-00363233.

30-JAN-1995; 95US-00380734.

(RIBO-) RIBOZYME PHARM INC.

Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW; Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA; Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD; Tracz D, Ueman N, Wincott FE, Woolf T;

WPI; 1995-351090/45.

Ribozymes having modified bases and methods for producing them - for use in inhibiting disease related genes.

Claim 2; Page 201; 407pp; English.

The present sequence represents a preferred target sequence for an enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the nucleotide base position indicated in the DE line. Regions of the mRNA that do not form secondary folding structures and that contain potential hammerhead and hairpin ribozyme cleavage sites were identified by computer analysis. Ribozymes directed against these mRNA sequences were designed and synthesised with modifications that improve their nuclease resistance. The ribozymes cleave the ICAM-1 target sequences and thereby inhibit ICAM-1 expression, making them useful for reducing transplant rejection and alleviating symptoms in patients with rheumatoid arthritis, asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to correct PI field.)

Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17; Best Local Similarity 75.0%; Pred. No. 7.2e+02; Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

461 GAGAGACTCGGCTGG 476
1 GAGAACCCGCGCCUGG 16

RESULT 919
AAT53627
ID AAT53627 standard; RNA; 17 BP.
AAT53627;
25-MAR-2003 (revised)
DT 27-MAR-1997 (first entry)
Rat ICAM hammerhead ribozyme target sequence (nt. position 1983).

```

CC correct PI field.)
SQ Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
   ||| | : ||| | : |||
Db 1 GAGAACCCGCGCCUGG 16

RESULT 920
AAT04961/c
ID AAT04961 standard; cDNA; 17 BP.
XX AC AAT04961;
XX DT 30-JAN-1996 (first entry)
XX DE Antimicrobial protein Ib-AMPI PCR primer IbAMP1-B.
XX KW Antimicrobial protein 1; Ib-AMPI; antifungal; fungicide; antibacterial;
KW phytocinide; disease-resistance; antibiotic; preservative;
KW Impatiens balsamina; PCR; primer; polymerase chain reaction; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 6 /*tag= a
FT /*mod_base= i
FT modified_base 9 /*tag= b
FT /*mod_base= i
XX PN WO9524486-A1.
XX PD 14-SEP-1995.
XX PF 09-MAR-1995; 95WO-GB000509.
XX PR 11-MAR-1994; 94GB-00004807.
XX PA (ZENE ) ZENECA LTD.
XX PI Attenborough S, Broekaert WF, Osborn RW, Ray JA, Rees SB;
PI Tailor RH;
XX DR WPI; 1995-328277/42.
XX PT New antimicrobial proteins from Aralia and Impatiens seeds - useful as
PT fungicides or antibiotics in agricultural or pharmaceutical applications.
XX PS Example 8; Page 27; 64pp; English.
XX CC An Impatiens balsamina (Ib) seed cDNA library in lambda ZAP11 was
CC screened with a DNA probe generated using 2 degenerate PCR primers
CC (AAT04960-61) based on the available peptide sequence for antimicrobial
CC protein Ib-AMPI (AAR82938). cDNA clone Ib22 was obt'd. that encoded Ib-AMP
CC (AAR82942)
XX SQ Sequence 17 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 5 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.2e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 175 ACTGTGTGAGATGGT 190
   | : | : | : | : |
Db 16 AYTGTGTMGNTGGT 1

RESULT 921
AAT81043/c
ID AAT81043 standard; RNA; 17 BP.
XX AC AAT81043;
XX DT 26-SEP-1997 (first entry)
XX DE Human c-myb hammerhead ribozyme target sequence (nt. position 22).
XX KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW coronary angioplasty; ss.
XX OS Homo sapiens.
XX PN WO9531541-A2.
XX PD 23-NOV-1995.
XX PF 18-MAY-1995; 95WO-US006368.
XX PR 18-MAY-1994; 94US-00245466.
XX PR 13-JAN-1995; 95US-00373124.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
XX DR WPI; 1996-010927/01.
XX PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT for treating restenosis or cancer.
XX PS Claim 1; Page 64; 128pp; English.
XX CC The present sequence represents the preferred target sequence for an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the human c-myb sequence at the base position indicated in the descriptor
CC line. The c-myb sequence was screened for optimal ribozyme target sites
CC using a computer folding algorithm, and regions of the mRNA which did not
CC form secondary folding structures and contained potential ribozyme
CC cleavage sites were identified. Ribozymes were synthesised and their
CC activities optimised by either varying the length of the binding arms or
CC by modification to prevent degradation by nucleases. The ribozymes cleave
CC the c-myb sequence and can be used to prevent smooth muscle cell
CC hyperproliferation in restenosis, especially after coronary angioplasty,
CC and in cancers
XX SQ Sequence 17 BP; 0 A; 9 C; 0 G; 0 T; 8 U; 0 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 405 ACAGGAGGAGGAGGA 420
   ||| | ||| | ||| | |||
Db 17 AGAAGGAGGAGGAGGA 2

RESULT 922
AAX69184
ID AAX69184 standard; RNA; 17 BP.
XX AC AAX69184;
XX DT 28-JUL-1999 (first entry)
XX DE Human flt1 VEGF receptor hammerhead ribozyme substrate #479.
XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;

```


PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 167; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 8 A; 5 C; 2 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 875 AACCAATCAGACCA 890
DB 1 AACUACCUCAAGACCA 16
|||||:|||||
1 AACUACCUCAAGACCA 16

RESULT 925
AAV17893/C
ID AAV17893 standard; DNA; 17 BP.
XX
AC AAV17893;
XX
DT 15-JUL-1998 (first entry)
XX
DE Primer used to construct a hybrid endoglucanase.
XX
KW Endo-beta-1,4-glucanase; degradation; plant; cellulose; PCR primer; ss.
XX
OS Synthetic.
XX
PN WO9808940-A1.
XX
PD 05-MAR-1998.
XX
PF 26-AUG-1997; 97WO-DK000348.
XX
PR 26-AUG-1996; 96DK-00000893.
PR 17-SEP-1996; 96DK-00001015.
XX
PA (NOVO) NOVO-NORDISK AS.
XX
PI Bjornvad ME, Nielsen P;
XX
DR WPI; 1998-179431/16.
XX
PT New endo-glucanase from Cellvibrio species and related DNA, vectors and
PT transformed cells - used to degrade plant material, treat fabrics or
PT paper pulp, and to clarify colours on laundry.
XX
XX Example 8; Page 77; 117pp; English.
XX
CC PCR primers AAV17899-96 were used to construct a hybrid endoglucanase,
CC which comprises the Humicola insolens family 45 endonuclease signal
CC peptide and the Pseudomonas fluorescens family 45 endoglucanase catalytic
CC domain and the linker cellulose binding domain of H. insolens
CC endoglucanase. The endoglucanase is used for degrading and modifying
CC plant materials such as cell walls, e.g. for production of wine or fruit
CC or vegetable juices to increase yield, to hydrolyse waste products, for
CC isolation of beta-glucans, to improve feed efficiency or ensilaging and
CC to decrease water binding capacity. It can also be used in the treatment
CC of fabrics and textiles, for biopolishing, for "stone washing"

CC cellulose, and for treating paper pulp
XX
SQ Sequence 17 BP; 2 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 707 GAGCGGAGCGCTGC 722
DB 16 GAGCGGATGAGCTGC 1
|||||:|||||
16 GAGCGGATGAGCTGC 1

RESULT 926
AAV96651
ID AAV96651 standard; RNA; 17 BP.
XX
AC AAV96651;
XX
DT 01-MAR-1999 (first entry)
XX
DE Potato citrate synthase target sequence position 1373.
XX
KW Solanidine; glucosyltransferase; potato; citrate synthase; target;
KW hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
KW flower formation; cleavage; solanaceous plant; ss.
XX
OS Solanum tuberosum.
XX
PN WO9832843-A2.
XX
PD 30-JUL-1998.
XX
PF 14-JAN-1998; 98WO-US000738.
XX
PR 28-JAN-1997; 97US-0036545P.
PR 28-JAN-1997; 97US-0036599P.
PR 24-NOV-1997; 97US-00979416.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Zwick MG, Mcswiggen JA;
XX
DR WPI; 1998-427939/36.
XX
PT New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
PT biosynthesis or regulating flowering.
XX
PS Claim 53; Page 56; 79pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules with RNA
CC -cleaving activity (e.g. ribozymes) which are capable of modulating the
CC expression of plant genes: (i) involved in biosynthesis of alkaloids; or
CC (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to
CC AAV96354 represent potato solanidine glucosyltransferase hammerhead and
CC hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to
CC AAV96734 represent potato solanidine glucosyltransferase target
CC sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195 represent
CC potato citrate synthase hammerhead and hairpin ribozymes, respectively.
CC AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate
CC synthase target sequences. Ribozymes of the present invention can be used
CC to inhibit the synthesis of toxic alkaloids in solanaceous plants,
CC particularly potato but also tomato, pepper, aubergine and ditura or to
CC inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,
CC arugula, kale, collards, chard, beet, turnip, sweet potato and turf
CC grass. Also the ribozymes can be used for RNA manipulation in the same
CC way that restriction endonucleases are for DNA, as well as to examine
CC genetic drift and mutations in plants and to detect specific RNA. The
CC ribozymes can be targeted to specific genes or to consensus sequences
CC within a family of related genes, and being catalytic need to be present
CC at only very low concentrations
XX
SQ Sequence 17 BP; 4 A; 4 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 316 GGAGATCAAGAGCTC 331
 |||||:|||||:
 Db 2 GGCGAUCAAGAGCUC 17

RESULT 927
 AAA20387/C
 ID AAA20387 standard; RNA; 17 BP.
 XX
 AC AAA20387;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:3613.
 XX
 DE Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW age related macular degeneration; cancer; diabetic retinopathy; arthritis;
 KW myopic degeneration; psoriasis; verruca vulgaris; neovascular glaucoma;
 KW tuberculous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 OS WO9950403-A2.
 XX
 PN 07-OCT-1999.
 XX
 PD 24-MAR-1999; 99WO-US006507.
 XX
 PF 27-MAR-1998; 98US-0079678P.
 XX
 PR (RIBO-) RIBOZYME PHARM INC.
 XX
 PA Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 XX WPI; 1999-591315/50.
 XX
 PT Novel ribozymes for modulating the synthesis, expression and/or stability
 of an mRNA encoding an angiogenic factors.
 XX
 PS Claim 55; Page 142; 305pp; English.

The present invention describes enzymatic cleavage of RNA molecules with RNA
 cleaving activity, which specifically cleave RNA encoded by an aryl
 hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 and AAA19155 to AAA19222 represent their corresponding target sequences;
 AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 AAA21596 to AAA21688 represent their corresponding target sequences;
 AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme
 sequences for integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 especially used to treat cancer, diabetic retinopathy, age related
 macular degeneration (ARMD), inflammation, and arthritis, as well as
 neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber

CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 SQ Sequence 17 BP; 1 A; 7 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 676 GGCCAGCGAGGCG 691
 |||||:|||||:
 Db 16 GGCCAGCGAGGCG 1

RESULT 928
 AAA17439/C
 ID AAA17439 standard; RNA; 17 BP.
 XX
 AC AAA17439;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Aryl hydrocarbon nuclear transport substrate sequence SEQ ID NO:665.
 XX
 DE Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW age related macular degeneration; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; psoriasis; verruca vulgaris; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberculous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 OS WO9950403-A2.
 XX
 PN 07-OCT-1999.
 XX
 PD 24-MAR-1999; 99WO-US006507.
 XX
 PF 27-MAR-1998; 98US-0079678P.
 XX
 PR (RIBO-) RIBOZYME PHARM INC.
 XX
 PA Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 XX WPI; 1999-591315/50.
 XX
 PT Novel ribozymes for modulating the synthesis, expression and/or stability
 of an mRNA encoding an angiogenic factors.
 XX
 PS Claim 53; Page 80; 305pp; English.

The present invention describes enzymatic cleavage of RNA molecules with RNA
 cleaving activity, which specifically cleave RNA encoded by an aryl
 hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 and AAA19155 to AAA19222 represent their corresponding target sequences;
 AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 AAA21596 to AAA21688 represent their corresponding target sequences;
 AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme
 sequences for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 AAA23422 represent their corresponding target sequences. The ribozymes of
 the invention are used for modulating the synthesis, expression and/or
 stability of an mRNA encoding angiogenic factor, especially ARNT,

CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 SQ Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 542 CAGCAGCAGTGGCTG 557
 DB 17 CAGAGCTGATGGCTG 2
 AC AAA22723;
 RESULT 929
 AAA22723/C
 ID AAA22723 standard; RNA; 17 BP.
 XX
 XX
 XX 19-JUN-2000 (first entry)
 XX Integrin subunit beta 3 substrate sequence SEQ ID NO:5949.
 DE
 XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX Homo sapiens.
 OS
 XX WO9950403-A2.
 PN
 XX
 XX 07-OCT-1999.
 PD
 XX
 XX 24-MAR-1999; 99WO-US006507.
 PF
 XX
 XX 27-MAR-1998; 98US-0079678P.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 PI
 XX WPI; 1999-591315/50.
 DR
 XX Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 XX
 XX Claim 54; Page 238; 305pp; English.
 PS
 XX The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC and AAA1768 to AAA17623 represent ribozyme sequences for ARNT,
 CC and AAA1768 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;

CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT.
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 SQ Sequence 17 BP; 2 A; 8 C; 2 G; 0 T; 5 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 493 GAGGCAGAGGAGGAGCAG 508
 DB 16 GAGGCAGAGGAGGAGCAG 1
 AC AAX78357;
 RESULT 930
 AAX78357
 ID AAX78357 standard; DNA; 17 BP.
 XX
 XX AAX78357;
 AC
 XX 25-AUG-1999 (first entry)
 DT
 XX Human BRCA2 C2192G mutation allele specific probe 1.
 DE
 XX BRCA2; breast cancer; PCR primer; mutation; detection; human; cancer;
 KW susceptibility; predisposition; ovarian cancer; assay; allele specific;
 KW sequence variation; probe; ss.
 XX
 XX Synthetic.
 OS
 XX Homo sapiens.
 XX WO9928506-A2.
 PN
 XX
 XX 10-JUN-1999.
 PD
 XX
 XX 02-DEC-1998; 98WO-US025511.
 PF
 XX
 XX 02-DEC-1997; 97US-00984034.
 PR
 XX
 XX (GENE-) GENE LOGIC.
 PA
 XX
 XX Lescallett JL, Lawrence T, Allen AP, Olson SJ, Thurber DB;
 PI White MB;
 XX
 XX WPI; 1999-371141/31.
 DR
 XX Detecting mutations in the BRCA2 gene.
 PT
 XX
 XX Claim 3; Page 58; 76pp; English.
 PS
 XX This invention describes novel primers and probes (AAX78355-X78378) which
 CC are used to detect novel mutations in the human BRCA2 gene at nucleotide
 CC positions 2192, 3772, 5193, 5374, 6495 or 6909. The products of the
 CC invention are used for detecting in an individual a predisposition or
 CC higher susceptibility to cancers such as breast or ovarian cancer. The
 CC invention describes a process for the accurate identification of sequence
 CC variation in a BRCA2 polynucleotide and the identification process
 CC includes allele-specific sequence based assays of known sequence
 CC variations
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

```
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 166 GAAGAGCCCACTGTGT 181
    ||||| ||||| |||
Db 2 GAAGAACCACACTTGT 17

RESULT 931
AAAX01065
ID AAAX01065 standard; DNA; 17 BP.
XX
AC AAAX01065;
XX
DT 06-APR-1999 (first entry)
XX
DE IPF1 gene exon 1 amplifying primer S17b.
XX
KW Mature onset diabetes of the young; MODY; insulin promoter factor 1;
KW IPF1; mutation; MODY4; pancreatic disorder; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO9859078-A1.
XX
XX 30-DEC-1998.
XX
XX 24-JUN-1998; 98WO-US013467.
XX
XX 24-JUN-1997; 97US-00881450.
XX
PA (GEO ) GEN HOSPITAL CORP.
XX
PI Habener JF, Stoffers DA;
XX
XX WPI; 1999-105636/09.
XX
XX Detecting heterozygosity for insulin promoter factor 1 - useful to detect
XX the presence of, or predisposition for, mature onset diabetes of the
XX young.
XX
XX Example 1; Page 9; 46pp; English.
XX
XX The invention relates to a new method to screen for mature onset diabetes
XX of the young (MODY). The method comprises detecting a mutation in the
XX gene encoding insulin promoter factor 1 (IPF1), wherein heterozygosity
XX for the mutation is indicative of MODY. The method may be used to
XX determine if a patient with MODY symptoms has MODY4, to assess patients
XX risk of developing MODY4, to assess the risk of a couple's progeny of
XX inheriting MODY, and to assist in determining the genetic basis for other
XX pancreatic disorders that might result from IPF-1 deficiency. Sequences
XX AAAX01063-66 represent primers used for amplifying the exon 1 of the IPF1
XX gene using a nested PCR priming scheme
XX
XX Sequence 17 BP; 4 A; 3 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 680 AGCGAGCAGCGCGGC 695
    ||||| ||||| |||
Db 1 AGCGAGCAGCGGAGGC 16

RESULT 932
AAA36589
ID AAA36589 standard; DNA; 17 BP.
XX
XX AAA36589;
AC
XX
```

```
DT 26-JUL-2000 (first entry)
XX
DE Human genomic SNP allele specific oligonucleotide SEQ ID NO:654.
XX
XX Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
KW allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
KW genomic classification; identification; DNA fingerprinting;
KW tumour characterisation; hybridisation; ss.
XX
XX Homo sapiens.
XX
XX WO200018960-A2.
XX
XX 06-APR-2000.
XX
XX 24-SEP-1999; 99WO-US022283.
XX
XX 25-SEP-1998; 98US-0101757P.
XX
XX (MASI ) MASSACHUSETTS INST TECHNOLOGY.
XX
XX Landers JE, Jordan B, Housman DE, Charest A;
XX
XX WPI; 2000-293181/25.
XX
XX Detection of single nucleotide polymorphisms in genomes by preparation
XX and analysis of reduced complexity genomes, useful for genotyping,
XX fingerprinting and determining allele frequency of SNPs.
XX
XX Disclosure; Page 72; 111pp; English.
XX
XX A method has been developed for detecting the presence or absence of a
XX single nucleotide polymorphism (SNP) allele in a genomic sample. The
XX method comprises preparing a reduced complexity genome (RCG) from the
XX genomic sample and analysing the RCG for the presence or absence of a SNP
XX allele. The method can be used to characterise a tumour, to generate a
XX genomic pattern for an individual genome or to generate a genomic
XX classification code for a genome. The method can be used to assess
XX whether a subject is at risk for developing a disease or to identify a
XX set of SNP alleles associated with a disease. The method can also be used
XX to perform linkage analysis. AAA35944 to AAA35947 represent sequences
XX used in the exemplification of the present invention. AAA35948 to
XX AAA36632 represent nucleotide sequences containing SNPs
XX
XX Sequence 17 BP; 6 A; 2 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 397 AGCCAGCCAGGGGAG 412
    ||||| ||||| |||
Db 1 AGGCAGCTAGAGGGAG 16

RESULT 933
AAAF01886/C
ID AAFA01886 standard; DNA; 17 BP.
XX
XX AAFA01886;
AC
XX
XX 16-FEB-2001 (first entry)
XX
XX Hammerhead ribozyme substrate #181.
XX
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX interferon alpha; ss.
XX
XX Homo sapiens.
XX
XX WO200061729-A2.
XX
XX 19-OCT-2000.
```

```
XX 11-APR-2000; 2000WO-US009721.
XX
XX
PR 12-APR-1999; 99US-0129390P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
XX WPI; 2000-647423/62.
XX
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 37; Page 60; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
XX Sequence 17 BP; 1 A; 9 C; 4 G; 3 T; 0 U; 0 Other;
SQ
Query Match: 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 458 GTGGAGAGACTCGGCC 473
DB 16 GGGGAGGAGCTCGGCC 1
RESULT 934
AAAF05278/c
ID AAF05278 standard; DNA; 17 BP.
XX
XX AAF05278;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #2497.
XX
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
XX Homo sapiens.
XX
XX WO200061729-A2.
XX
PD 19-OCT-2000.
XX
XX 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
XX WPI; 2000-647423/62.
XX
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 18; Page 113; 164pp; English.
XX
XX The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
XX Sequence 17 BP; 1 A; 9 C; 4 G; 3 T; 0 U; 0 Other;
SQ
Query Match: 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 458 GTGGAGAGACTCGGCC 473
DB 16 GGGGAGGAGCTCGGCC 1
RESULT 934
AAAF05278/c
ID AAF05278 standard; DNA; 17 BP.
XX
XX AAF05278;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #2497.
XX
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
XX Homo sapiens.
XX
XX WO200061729-A2.
XX
PD 19-OCT-2000.
XX
XX 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
XX WPI; 2000-647423/62.
XX
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 18; Page 113; 164pp; English.
XX
XX The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
XX Sequence 17 BP; 0 A; 12 C; 0 G; 5 T; 0 U; 0 Other;
SQ
Query Match: 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 811 GGAGGAGAGAGGAG 826
DB 16 GGAGGAGAGGAGGAG 1
RESULT 935
AAAF02085/c
ID AAF02085 standard; DNA; 17 BP.
XX
XX AAF02085;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #380.
XX
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
XX Homo sapiens.
XX
XX WO200061729-A2.
XX
PD 19-OCT-2000.
XX
XX 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
XX WPI; 2000-647423/62.
XX
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 37; Page 64; 164pp; English.
XX
XX The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
XX Sequence 17 BP; 1 A; 9 C; 1 G; 6 T; 0 U; 0 Other;
SQ
Query Match: 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 812 GAGGAGAGGAGGAGC 827
DB 17 GAGGAGAGAGGGTGC 2
```

RESULT 936
 AAF02618/c
 ID AAF02618 standard; DNA; 17 BP.
 XX AC AAF02618;
 XX AC AAF02618;
 DT DT 16-FEB-2001 (first entry)
 XX XX Hammerhead ribozyme substrate #913.
 DE XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW KW interferon alpha; ss.
 XX OS Homo sapiens.
 XX OS Homo sapiens.
 PN WO200061729-A2.
 XX 19-OCT-2000.
 XX 11-APR-2000; 2000WO-US009721.
 PF 12-APR-1999; 99US-0129390P.
 PR (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX WPI; 2000-647423/62.
 DR Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 XX Claim 37; Page 76; 164pp; English.
 XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX Sequence 17 BP; 1 A; 9 C; 5 G; 2 T; 0 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 510 CTCGCGGAGGTGGA 525
 Db |||||
 17 CTCGCGGAGGTGGA 2
 RESULT 937
 AAA70589
 ID AAA70589 standard; DNA; 17 BP.
 XX AC AAA70589;
 XX 15-SEP-2003 (revised)
 DT 06-DEC-2000 (first entry)
 DE Sindbis-like virus strain YN87448 complete genome primer R5810-5826.
 XX Genome; Sindbis-like virus strain YN87448; primer; RT-PCR; vaccine;
 KW epidemic; Sindbis encephalitis; evolution; epidemiology; ss.
 XX Sindbis-like virus; strain YN87448.
 OS CN1252445-A.
 PN

XX 10-MAY-2000.
 PD 27-OCT-1998; 98CN-00120694.
 PF 27-OCT-1998; 98CN-00120694.
 PR (VIRO-) INST VIROLOGY CHINESE ACAD PREVENTIVE ME.
 XX Liang G, Zhou G, Li L;
 PI WPI; 2000-443226/39.
 DR Whole genome sequence of YN87448 virus strain and its cloning method.
 XX Claim 3; Page 10; 24pp; Chinese.
 PS Primers AAA70578-A70603 were used to RT-PCR amplify the complete genome
 CC of the Sindbis-like virus strain YN87448 (AAA70577). The genome was
 CC cloned as 15 fragments using these PCR primers for inclusion into the
 CC plasmid pGEM-T. The invention relates to the isolation and method of
 CC cloning the complete genome for the Sindbis-like virus strain YN87448 by
 CC a RT-PCR process. The YN87448 strain virus appears to be the optimal
 CC candidate for a vaccine to prevent epidemics of Sindbis encephalitis. The
 CC sequence of this strain's genome shows the difference between this viral
 CC strain and other epidemic Sindbis virus strains at the molecular level
 CC and is useful for understanding the source, evolution and molecular
 CC epidemiology of Sindbis viruses. (Updated on 15-SEP-2003 to standardise
 CC OS field)
 XX Sequence 17 BP; 4 A; 7 C; 3 G; 3 T; 0 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 276 CAGACAGGCGGTCC 291
 Db |||||
 2 CAGACAGTTCGCGTCC 17
 RESULT 938
 AAH94701/c
 ID AAH94701 standard; RNA; 17 BP.
 XX AC AAH94701;
 XX 09-OCT-2001 (first entry)
 DT Human Chk1 ribozyme substrate SEQ ID NO: 126.
 DE Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
 XX RNA cleavage; cancer; ss.
 KW Homo sapiens.
 XX WO200157206-A2.
 PN 09-AUG-2001.
 PD 02-FEB-2001; 2001WO-US003504.
 PF 03-FEB-2000; 2000US-0179983P.
 PR (RIBO-) RIBOZYME PHARM INC.
 XX (FATT/) FATTAEY A R.
 XX Fattaey AR, Jarvis T, Mcswiggen J, Booher RN, Holman PS;
 XX WPI; 2001-496922/54.
 DR Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
 PT molecules, which downregulates expression of a checkpoint kinase-1 gene,

PT useful for treating colorectal, lung, breast or prostate cancers.
 PS Claim 4; Page 54; 115pp; English.
 XX
 CC The present invention provides nucleic acid molecules capable of
 CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
 CC gene. These may be antisense or ribozyme sequences, and are useful in the
 CC treatment of diseases associated with conditions affected by Chk1 levels,
 CC including cancer. The present sequence is an oligonucleotide described in
 CC the exemplification of the invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 3 G; 0 T; 6 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 606 TGCAGGAGCCAGAG 621
 DB 16 TGCAGGAGCCAGAG 1
 RESULT 939
 AAH95054/C
 ID AAH95054 standard; RNA; 17 BP.
 XX
 AC AAH95054;
 XX
 DT 09-OCT-2001 (first entry)
 XX
 DE Human Chk1 ribozyme substrate SEQ ID NO: 479.
 XX
 KW Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
 KW RNA cleavage; cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200157206-A2.
 PD 09-AUG-2001.
 XX
 PF 02-FEB-2001; 2001WO-US003504.
 XX
 PR 03-FEB-2000; 2000US-0179983P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (PATT/) PATTAY A R.
 XX
 PI Fattaey AR, Jarvis T, Mcswiggen J, Booher RN, Holman PS;
 XX WPI; 2001-496922/54.
 DR
 XX Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
 PT molecules, which downregulates expression of a checkpoint kinase-1 gene,
 PT useful for treating colorectal, lung, breast or prostate cancers.
 XX
 PS Claim 4; Page 62; 115pp; English.
 XX
 CC The present invention provides nucleic acid molecules capable of
 CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
 CC gene. These may be antisense or ribozyme sequences, and are useful in the
 CC treatment of diseases associated with conditions affected by Chk1 levels,
 CC including cancer. The present sequence is an oligonucleotide described in
 CC the exemplification of the invention
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 606 TGCAGGAGCCAGAG 621
 DB 16 TGCAGGAGCCAGAG 1

Db 17 TGCAGGAGCCAGAG 2
 RESULT 940
 ABK00015
 ID ABK00015 standard; RNA; 17 BP.
 XX
 AC ABK00015;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NOGO Hammerhead Ribozyme #15.
 XX
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 DR
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 66; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-

CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 7.2e+02;
 Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 233 GAAGAGTCTCTCTGG 248
 Db 2 GACCAGUCUCCUGG 17
 |||||:|:|:|:
 |||||:|:|:|:
 RESULT 941
 ABK00785
 ID ABK00785 standard; RNA; 17 BP.
 XX
 AC ABK00785;
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NOGO Inozyme #55.
 XX
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberszyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowira BM;
 XX WPI; 2001-607195/69.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and

PT central nervous system injury.
 XX
 PS Claim 88; Page 78; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNazyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberszyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a VGY motif). The CD20-targetting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic leukaemia,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
 CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an inozyme of the invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 7.2e+02;
 Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 233 GAAGAGTCTCTCTGG 248
 Db 1 GACCAGUCUCCUGG 16
 |||||:|:|:|:
 |||||:|:|:|:
 RESULT 942
 ABK01938
 ID ABK01938 standard; RNA; 17 BP.
 XX
 AC ABK01938;
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NOGO Zinzyme #260.
 XX
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberszyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX

PN	WO200159103-A2.	AC	ABK02540;
XX	16-AUG-2001.	XX	12-MAR-2002 (first entry)
XX	09-FEB-2001; 2001WO-US004273.	XX	Human NOGO Amberyze #212.
XX	11-FEB-2000; 2000US-0181797P.	XX	Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
PR	28-FEB-2000; 2000US-0185516P.	KW	cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
XX	06-MAR-2000; 2000US-0187128P.	KW	muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX	(RIBO-) RIBOZYME PHARM INC.	KW	DNAzyme; inozyme; G-cleaver; amberyze; zinzyme; lymphoma; leukaemia;
PA	(BLAT/) BLATT L.	KW	B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
PA	(MCSW/) MCSWIGGEN J.	KW	human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
PA	(CHOW/) CHOWRIRA B M.	KW	MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
XX	Blatt L, Mcswiggen J, Chowrira BM;	KW	inflammatory arthropathy; central nervous system injury;
XX	WPI; 2001-607195/69.	KW	cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
DR	Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense	KW	chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX	constructs, which down regulate expression of a CD20 gene or neurite	KW	Parkinson's disease; ataxia; Huntington's disease;
PT	growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and	KW	Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
PT	central nervous system injury.	XX	
XX	Claim 88; Page 100; 200pp; English.	OS	Homo sapiens.
XX	The invention relates to a nucleic acid molecule which down regulates	OS	Synthetic.
CC	expression of a CD20 gene and a nucleic acid molecule which down	XX	
CC	regulates expression of a neurite growth inhibitor gene (NOGO). The	PN	WO200159103-A2.
CC	nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a	XX	16-AUG-2001.
CC	DNAzyme) an inozyme (an endolytic nucleic acid cleaving a RNA molecule	XX	09-FEB-2001; 2001WO-US004273.
CC	possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr	PR	11-FEB-2000; 2000US-0181797P.
CC	an amberyze (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA	PR	28-FEB-2000; 2000US-0185516P.
CC	with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA	PR	06-MAR-2000; 2000US-0187128P.
CC	of CD20 in the presence of a divalent cation that is preferably Mg ²⁺ .	XX	(RIBO-) RIBOZYME PHARM INC.
CC	Furthermore, it may be contacted with a cell to reduce CD20 activity of	PA	(BLAT/) BLATT L.
CC	the cell and treat a patient having a condition associated with the level	PA	(MCSW/) MCSWIGGEN J.
CC	of CD20. The treatment may further comprise the use of one or more	PA	(CHOW/) CHOWRIRA B M.
CC	therapies. In particular, the CD20 targetting nucleic acid may be used to	XX	Blatt L, Mcswiggen J, Chowrira BM;
CC	treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-	XX	WPI; 2001-607195/69.
CC	Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic	DR	Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
CC	leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell	XX	constructs, which down regulate expression of a CD20 gene or neurite
CC	lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,	XX	growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
CC	immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-	XX	central nervous system injury.
CC	targetting nucleic acid is used to cleave RNA of the NOGO gene in the		
CC	presence of a divalent cation that is preferably Mg ²⁺ . Furthermore, the		
CC	nucleic acid may be contacted with a cell to reduce NOGO activity of the		
CC	cell and treat a patient having a condition associated with the level of		
CC	NOGO. The treatment may further comprise the use of one or more		
CC	therapies. In particular, the NOGO-targetting nucleic acid may be used to		
CC	treat central nervous system (CNS) injury and cerebrovascular accident		
CC	(CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),		
CC	chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),		
CC	Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob		
CC	disease, muscular dystrophy, and/or other neurodegenerative disease		
CC	states which respond to the modulation of NOGO expression. The present		
CC	sequence is a zinzyme molecule of the invention		
XX			
SQ	Sequence 17 BP; 6 A; 2 C; 5 G; 0 T; 4 U; 0 Other;		
	Query Match 1.7%; Score 12.8; DB 1; Length 17;		
	Best Local Similarity 75.0%; Pred. No. 7.2e+02;		
	Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;		
QY	487 TCTGAGAGGCGACGAG 502		
	: :		
Db	1 UUGAAGAGUCAGACGAG 16		
RESULT 943			
ABK02540			
ID	ABK02540 standard; RNA; 17 BP.		
XX			

CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an amberzyme molecule of the invention
 XX
 SQ Sequence 17 BP; 7 A; 2 C; 4 G; 0 T; 4 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 QY 486 ATCTGAAGAGCAGAA 501
 |: :||| |||||
 Db 2 AUUUGAAGAGUCAGAA 17
 RESULT 944
 ABA80257/C
 ID ABA80257 standard; DNA; 17 BP.
 XX AC ABA80257;
 XX DT 24-JAN-2002 (first entry)
 XX DE MLH1 mutation correcting oligonucleotide SEQ ID NO: 3103.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antitickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX Homo sapiens.
 OS
 XX WO200173002-A2.
 PN
 XX 04-OCT-2001.
 PD
 XX 27-MAR-2001; 2001WO-US009761.
 PF
 XX 27-MAR-2000; 2000US-0192176P.
 PR
 XX 27-MAR-2000; 2000US-0192176P.
 PR
 XX 01-JUN-2000; 2000US-0208538P.
 PR
 XX 30-OCT-2000; 2000US-0244989P.
 PR
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 PI
 XX WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 215; 294pp; English.
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase

CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSN1) and
 CC presenilin-2 (PSN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 724 GCAGCAGCAGCAGCGTG 739
 ||||| |||||
 Db 17 GCAGCAGCAGCATCGAG 2
 RESULT 945
 ABA80568
 ID ABA80568 standard; DNA; 17 BP.
 XX AC ABA80568;
 XX DT 24-JAN-2002 (first entry)
 XX DE APOE mutation correcting oligonucleotide SEQ ID NO: 3414.
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antitickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX Homo sapiens.
 OS
 XX WO200173002-A2.
 PN
 XX 04-OCT-2001.
 PD
 XX 27-MAR-2001; 2001WO-US009761.
 PF
 XX 27-MAR-2000; 2000US-0192176P.
 PR
 XX 27-MAR-2000; 2000US-0192176P.
 PR
 XX 01-JUN-2000; 2000US-0208538P.
 PR
 XX 30-OCT-2000; 2000US-0244989P.
 PR
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 PI
 XX WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 232; 294pp; English.
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase

CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 757 CATGCAGGCCAGAGC 772
 ||||| |||||
 Db 1 CATGCTGGCCAGAGC 16
 RESULT 946
 ABA77505
 ID ABA77505 standard; DNA; 17 BP.
 XX
 AC ABA77505;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE p53 mutation correcting oligonucleotide SEQ ID NO: 351.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antitickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 XX Kmiec EB, Gamper HB, Rice MC;
 XX WPI; 2001-639230/73.
 DR
 PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 63; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus

CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 364 GCGGAGCGCTCGAG 379
 ||||| |||||
 Db 2 GCGTGAGCGCTTCGAG 17
 RESULT 947
 ABA78530
 ID ABA78530 standard; DNA; 17 BP.
 XX
 AC ABA78530;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE CDKN2A mutation correcting oligonucleotide SEQ ID NO: 1376.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antitickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 XX Kmiec EB, Gamper HB, Rice MC;
 XX WPI; 2001-639230/73.
 DR
 PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 128; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A

CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 3 A; 8 C; 5 G; 1 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 721 GCAGCAGCAGCAGC 736
 DB 1 GCAGCAGCAGCCTCCG 16
 RESULT 948
 ABA77506/C
 ID ABA77506 standard; DNA; 17 BP.
 XX
 AC ABA77506;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE p53 mutation correcting oligonucleotide SEQ ID NO: 352.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 XX Kmiec EB, Gamper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 63; 294pp; English.
 PS
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,

CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 364 GCGGAGCGCTGCGAG 379
 DB 16 GCGTGGCGCTTCGAG 1
 RESULT 949
 ABA78529/C
 ID ABA78529 standard; DNA; 17 BP.
 XX
 AC ABA78529;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE CDKN2A mutation correcting oligonucleotide SEQ ID NO: 1375.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 XX Kmiec EB, Gamper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 128; 294pp; English.
 PS
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at

CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 721 GCAGCAGCAGCAGCAGC 736
 DB 17 GCAGCAGCAGCAGCAGC 2
 RESULT 950
 ABA80256
 ID ABA80256 standard; DNA; 17 BP.
 XX
 AC ABA80256;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE MLH1 mutation correcting oligonucleotide SEQ ID NO: 3102.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antiseizure;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192176P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kniec EB, Gamper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 215; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic

CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 6 A; 5 C; 5 G; 1 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 724 GCAGCAGCAGCAGCGTG 739
 DB 1 GCAGCAGCAGCAGCGTG 16
 RESULT 951
 ABA80569/C
 ID ABA80569 standard; DNA; 17 BP.
 XX
 AC ABA80569;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE APOE mutation correcting oligonucleotide SEQ ID NO: 3415.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antiseizure;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192176P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kniec EB, Gamper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 232; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the

CC oligonucleotide has at least one mismatch compared with the genomic
sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention

SQ Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 757 CATGCGGCCGAGGC 772

Db 17 CATGCTCGGCAGAGC 2

RESULT 952

ABL58272/c

ID ABL58272 standard; DNA; 17 BP.

XX

AC ABL58272;

XX

DT 15-JUL-2002 (first entry)

XX

DE Rice OsEP3A gene fragment amplifying primer P1.

XX

KW Rice; cysteine proteinase; CysP; OsEP3A; plant; transgenic; promoter;
KW aleurone; germination; nitrogen; senescence; PCR; primer; ss.

XX

OS Oryza sativa.

XX

XX USG388067-B1.

XX

PD 14-MAY-2002.

XX

XX 10-JAN-2000; 2000US-00480017.

XX

PR 12-FEB-2000; 2000CA-02296052.

XX

PA (SINI-) ACAD SINICA.

XX

PI Yu S, Tong W;

XX

DR WPI; 2001-597345/68.

XX

PT New rice cysteine proteinase gene promoter, useful in stress-induced
PT regulation of heterologous proteins in plants or plant cells, or as
PT probes for isolating promoters or genes whose expression stress-induced
PT or during senescence.

XX

PS Disclosure; Col 6; 10pp; English.

XX

CC The invention relates to a new promoter derived from rice cysteine
CC proteinase (CysP) gene (OsEP3A). The promoter directs the expression of a
CC heterologous protein in the aleurone layer of transgenic rice seeds
CC during germination and in cultured rice suspension cells under nitrogen
CC starvation. The nucleic acids can be used as probes to isolate other
CC promoters and/or genes whose expression is induced under stress or during
CC senescence, and in stress-induced regulation of heterologous proteins in
CC plants (including embryos, organs and seeds) or plant cells. The present
CC sequence represents a PCR primer for amplifying a OsEP3A DNA fragment

XX Sequence 17 BP; 3 A; 10 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 699 TGGAGAGTGAGCGCGA 714

Db 17 TGGAGGCTGAGGCGCA 2

RESULT 953

ABN87370/c

ID ABN87370 standard; DNA; 17 BP.

XX

AC ABN87370;

XX

DT 01-AUG-2002 (first entry)

XX

DE Rice cysteine proteinase OsEP3A PCR primer SEQ ID NO:8.

XX

KW Rice; cysteine proteinase; OsEP3A; CysP; enzyme; promoter; plant;
KW aleurone layer; transgenic rice; seed; germination; nitrogen starvation;
KW stress; senescence; stress-induced regulation; PCR primer; ss.

XX

OS Oryza sativa.

XX

PN CA2296052-A1.

XX

PD 12-AUG-2001.

XX

PF 12-FEB-2000; 2000CA-02296052.

XX

PR 12-FEB-2000; 2000CA-02296052.

XX

PA (SINI-) ACAD SINICA.

XX

PI Tong W, Yu S;

XX

DR WPI; 2001-597345/68.

XX

PT New rice cysteine proteinase gene promoter, useful in stress-induced
PT regulation of heterologous proteins in plants or plant cells, or as
PT probes for isolating promoters or genes whose expression stress-induced
PT or during senescence.

XX

PS Example; Page 9; 27pp; English.

XX

CC The present invention describes a rice cysteine proteinase (OsEP3A, also
CC known as CysP) gene promoter. The promoter directs the expression of a
CC heterologous protein in the aleurone layer of transgenic rice seeds
CC during germination and in cultured rice suspension cells under nitrogen
CC starvation. The promoter nucleic acid sequence can be used as a probe to
CC isolate other promoters and/or genes whose expression is induced under
CC stress or during senescence, and in stress-induced regulation of
CC heterologous proteins in plants (including embryos, organs and seeds) or
CC plant cells. The present sequence represents a PCR primer for rice
CC OsEP3A, which is used in an example from the present invention

XX Sequence 17 BP; 3 A; 10 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 699 TGGAGAGTGAGCGCGA 714

Db 17 TGGAGGCTGAGGCGCA 2

RESULT 954

ABL46638

ID ABL46638 standard; RNA; 17 BP.

XX

AC ABL46638;
 XX
 DT 27-JUN-2003 (first entry)
 XX
 DE Human GR1D NCH ribozyme substrate oligonucleotide #92.
 XX
 KW Human; Grb2-related with Insert Domain; GR1D; T-cell;
 KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
 KW leukaemia; cytostatic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200162911-A2.
 XX
 PD 30-AUG-2001.
 XX
 PF 23-FEB-2001; 2001WO-US005957.
 XX
 PR 24-FEB-2000; 2000US-0184594P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 XX
 PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
 XX WPI; 2001-550088/61.
 XX
 XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
 PT (GR1D) gene comprises using antisense and enzymatic nucleic acid
 PT molecules such as hammerhead ribozymes.
 XX
 PS Claim 4; Page 64; 108pp; English.
 XX
 CC The present invention relates to oligonucleotides that downregulate the
 CC expression of human Grb2-related with Insert Domain (GR1D) gene. GR1D is
 CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
 CC for modulating the expression of GR1D, to treat conditions such as
 CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
 CC administered in conjunction with other therapies such as radiation,
 CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
 CC used to illustrate the invention
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
 XX
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 7.2e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 393 TCCAGCCGACGACGAG 408
 DB :|| |||||
 2 UCGGGCCGACGACGAG 17
 XX
 RESULT 955
 ABL46974
 ID ABL46974 standard; RNA; 17 BP.
 XX
 AC ABL46974;
 XX
 DT 27-JUN-2003 (first entry)
 XX
 DE Human GR1D zinzyme substrate oligonucleotide #58.
 XX
 KW Human; Grb2-related with Insert Domain; GR1D; T-cell;
 KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
 KW leukaemia; cytostatic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200162911-A2.
 XX
 PD 30-AUG-2001.
 XX

PF 23-FEB-2001; 2001WO-US005957.
 XX
 PR 24-FEB-2000; 2000US-0184594P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 XX
 PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
 XX WPI; 2001-550088/61.
 XX
 XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
 PT (GR1D) gene comprises using antisense and enzymatic nucleic acid
 PT molecules such as hammerhead ribozymes.
 XX
 PS Claim 4; Page 72; 108pp; English.
 XX
 CC The present invention relates to oligonucleotides that downregulate the
 CC expression of human Grb2-related with Insert Domain (GR1D) gene. GR1D is
 CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
 CC for modulating the expression of GR1D, to treat conditions such as
 CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
 CC administered in conjunction with other therapies such as radiation,
 CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
 CC used to illustrate the invention
 XX
 SQ Sequence 17 BP; 4 A; 9 C; 3 G; 0 T; 1 U; 0 Other;
 XX
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 7.2e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 717 CGCTGCAGCAGCAGCA 732
 DB :|| |||||
 2 CCUGCAGCAGCAGCA 17
 XX
 RESULT 956
 ABL47241
 ID ABL47241 standard; RNA; 17 BP.
 XX
 AC ABL47241;
 XX
 DT 27-JUN-2003 (first entry)
 XX
 DE Human GR1D Amberzyme substrate oligonucleotide #141.
 XX
 KW Human; Grb2-related with Insert Domain; GR1D; T-cell;
 KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
 KW leukaemia; cytostatic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200162911-A2.
 XX
 PD 30-AUG-2001.
 XX
 PF 23-FEB-2001; 2001WO-US005957.
 XX
 PR 24-FEB-2000; 2000US-0184594P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 XX
 PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
 XX WPI; 2001-550088/61.
 XX
 XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
 PT (GR1D) gene comprises using antisense and enzymatic nucleic acid
 PT molecules such as hammerhead ribozymes.
 XX
 PS Claim 4; Page 88; 108pp; English.

XX The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
XX Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;
SQ

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 731 CACAGCGTGCAGGTGG 746
Db ||||| :|||
1 CACAGCGGGAGGUGG 16

RESULT 957
ABL46728
ID ABL46728 standard; RNA; 17 BP.
XX
AC ABL46728;
XX
DT 27-JUN-2003 (first entry)
XX Human GRID NCH ribozyme substrate oligonucleotide #182.
DE
DE Human; Grb2-related with Insert Domain; GRID; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX Homo sapiens.
OS
XX WO200162911-A2.
PN
PD 30-AUG-2001.
XX
XX 23-FEB-2001; 2001WO-US005957.
XX
XX 24-FEB-2000; 2000US-0184594P.
XX (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
XX Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
PI WPI; 2001-550088/61.
XX
XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
PT (GRID) gene comprises using antisense and enzymatic nucleic acid
PT molecules such as hammerhead ribozymes.
XX
XX Claim 4; Page 66; 108pp; English.
XX
XX The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
XX Sequence 17 BP; 5 A; 8 C; 4 G; 0 T; 0 U; 0 Other;
SQ

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 731 CACAGCGTGCAGGTGG 746
Db ||||| :|||
1 CACAGCGGGAGGUGG 16

RESULT 957
ABL46728
ID ABL46728 standard; RNA; 17 BP.
XX
AC ABL46728;
XX
DT 27-JUN-2003 (first entry)
XX Human GRID NCH ribozyme substrate oligonucleotide #182.
DE
DE Human; Grb2-related with Insert Domain; GRID; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX Homo sapiens.
OS
XX WO200162911-A2.
PN
PD 30-AUG-2001.
XX
XX 23-FEB-2001; 2001WO-US005957.
XX
XX 24-FEB-2000; 2000US-0184594P.
XX (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
XX Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
PI WPI; 2001-550088/61.
XX
XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
PT (GRID) gene comprises using antisense and enzymatic nucleic acid
PT molecules such as hammerhead ribozymes.
XX
XX Claim 4; Page 66; 108pp; English.
XX
XX The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
XX Sequence 17 BP; 5 A; 8 C; 4 G; 0 T; 0 U; 0 Other;
SQ

QY 718 GCTGCAGCAGCAGCAC 733
Db ||||| :|||
1 GCAGCAGCAGCAGCAC 16

RESULT 958
ABL46639
ID ABL46639 standard; RNA; 17 BP.
XX
AC ABL46639;
XX
DT 27-JUN-2003 (first entry)
XX Human GRID NCH ribozyme substrate oligonucleotide #93.
DE
DE Human; Grb2-related with Insert Domain; GRID; T-cell;
KW co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW leukaemia; cytostatic; ss.
XX Homo sapiens.
OS
XX WO200162911-A2.
PN
PD 30-AUG-2001.
XX
XX 23-FEB-2001; 2001WO-US005957.
XX
XX 24-FEB-2000; 2000US-0184594P.
XX (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
XX Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
PI WPI; 2001-550088/61.
XX
XX New nucleic acid(s) for regulating the Grb2-related with Insert Domain
PT (GRID) gene comprises using antisense and enzymatic nucleic acid
PT molecules such as hammerhead ribozymes.
XX
XX Claim 4; Page 64; 108pp; English.
XX
XX The present invention relates to oligonucleotides that downregulate the
CC expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC for modulating the expression of GRID, to treat conditions such as
CC tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC administered in conjunction with other therapies such as radiation,
CC chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC used to illustrate the invention
XX Sequence 17 BP; 3 A; 7 C; 6 G; 0 T; 1 U; 0 Other;
SQ

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 393 TCCAAGCCAGCCAGAG 408
Db ||||| :|||
1 UCCGGCCAGCCAGAG 16

RESULT 959
ABL47240
ID ABL47240 standard; RNA; 17 BP.
XX
AC ABL47240;
XX
DT 27-JUN-2003 (first entry)
XX Human GRID Amberzyme substrate oligonucleotide #140.
DE
DE Human; Grb2-related with Insert Domain; GRID; T-cell;
KW

PN WO200192524-A2.
 XX 06-DEC-2001.
 PD
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 XX
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 FT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 PT
 XX Disclosure; SEQ ID NO 673; 214pp; English.
 PS
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 6 A; 6 C; 3 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 233 GAAGAGTCTCTCTGG 248
 DB 16 GATGAGTCTCTCTGG 1
 RESULT 962
 ABN07707/c
 ID ABN07707 standard; DNA; 17 BP.
 XX
 AC ABN07707;

XX 29-MAY-2002 (first entry)
 DT Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7699.
 XX
 DE
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 XX
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 FT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 PT
 XX Disclosure; SEQ ID NO 7699; 214pp; English.
 PS
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 827 CTGCGCCAGTTCGAGG 842
 Db 16 CTGCGCCAGTTCGAGG 1

RESULT 963
 ABN08041
 ID ABN08041 standard; DNA; 17 BP.
 AC ABN08041;
 XX
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8033.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 XX
 PN WO200192524-A2.
 XX
 XX
 PD 06-DEC-2001.
 XX
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001WO-US000670.
 XX
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 XX WPI; 2002-179446/23.
 DR
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 8033; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence

XX Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGCG 711
 Db 2 AGCTGGAGATCGAGCG 17

RESULT 964
 ABN06898/c
 ID ABN06898 standard; DNA; 17 BP.

XX
 AC ABN06898;

XX
 DT 29-MAY-2002 (first entry)

XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6890.

XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

XX
 OS Homo sapiens.

XX
 PN WO200192524-A2.

XX
 PD 06-DEC-2001.

XX
 PF 25-MAY-2001; 2001WO-US016981.

XX
 PR 26-MAY-2000; 2000US-0207456P.

XX
 PR 21-SEP-2000; 2000US-0234687P.

XX
 PR 27-SEP-2000; 2000US-0236359P.

XX
 PR 04-OCT-2000; 2000GB-00024263.

XX
 PR 30-JAN-2001; 2001WO-US000661.

XX
 PR 30-JAN-2001; 2001WO-US000662.

XX
 PR 30-JAN-2001; 2001WO-US000663.

XX
 PR 30-JAN-2001; 2001WO-US000664.

XX
 PR 30-JAN-2001; 2001WO-US000665.

XX
 PR 30-JAN-2001; 2001WO-US000666.

XX
 PR 30-JAN-2001; 2001WO-US000667.

XX
 PR 30-JAN-2001; 2001WO-US000668.

XX
 PR 30-JAN-2001; 2001WO-US000669.

XX
 PR 30-JAN-2001; 2001WO-US000670.

XX
 PR 05-FEB-2001; 2001US-0266860P.

XX
 PA (AEOM-) AEOMICA INC.

XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX
 XX WPI; 2002-179446/23.

XX
 PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 6890; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1

CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 1 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 306 GCTGCTGGAGGAGAA 321
 || ||||| |||||
 Db 17 GCCGCTGGAAGAGA 2

RESULT 965
 ABN07685
 ID ABN07685 standard; DNA; 17 BP.
 XX
 AC ABN07685;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7677.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT

or as specific biomolecule capture probes for surface-enhanced laser
 desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
 Disclosure; SEQ ID NO 7677; 214pp; English.

The present invention describes a human genome-derived myosin-like
 protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 nucleic acids can be used as probes to detect, characterise and quantify
 hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 provide initial substrates for the recombinant engineering of hGDMPLP-1
 protein variants having desired phenotypic improvements, and for
 expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 used as immunogens to raise antibodies that specifically recognise hGDMPLP
 -1 proteins, as standards in assays used to determine the concentration
 and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 capture probes for surface-enhanced laser desorption/ionisation, as
 therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX

SQ Sequence 17 BP; 10 A; 1 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 490 GAGAGGCGAGAGGAG 505
 ||||| ||||| |||||
 Db 2 GAAGAAGCAGAGAGAG 17

RESULT 966
 ABN08431
 ID ABN08431 standard; DNA; 17 BP.
 XX
 AC ABN08431;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8423.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.

30-JAN-2001; 2001WO-US000669.
 30-JAN-2001; 2001WO-US000670.
 05-FEB-2001; 2001US-026686P.
 (AEOM-) AEOMICA INC.
 Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 WPI; 2002-179446/23.
 New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 or as specific biomolecule capture probes for surface-enhanced laser
 desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 Disclosure; SEQ ID NO 8423; 214pp; English.
 The present invention describes a human genome-derived myosin-like
 protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 nucleic acids can be used as probes to detect, characterise and quantify
 hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 provide initial substrates for the recombinant engineering of hGDMPLP-1
 protein variants having desired phenotypic improvements, and for
 expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 used as immunogens to raise antibodies that specifically recognise hGDMPLP
 -1 proteins, as standards in assays used to determine the concentration
 and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 capture probes for surface-enhanced laser desorption ionisation, as
 therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 production, and in vaccines or for replacement therapy. The
 polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 disorder associated with the expression of hGDMPLP-1, in particular heart
 and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 The present sequence represents an oligomer used in the screening of the
 hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 The sequence data for this patent did not form part of the printed
 specification, but was obtained in electronic format directly from WIPO
 at ftp.wipo.int/pub/published_pct_sequence
 Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 491 AGAGGCGAGGAGGAGC 506
 Db 1 AGAGCGAGGAGGAGTC 16
 RESULT 967
 ABN00680/c
 ID ABN00680 standard; DNA; 17 BP.
 AC ABN00680;
 XX 29-MAY-2002 (first entry)
 DT Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:672.
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KM skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 OS WO200192524-A2.
 XX 06-DEC-2001.
 PD 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.

21-SEP-2000; 2000US-0234687P.
 27-SEP-2000; 2000US-0236359P.
 04-OCT-2000; 2000GB-00024263.
 30-JAN-2001; 2001WO-US000661.
 30-JAN-2001; 2001WO-US000662.
 30-JAN-2001; 2001WO-US000663.
 30-JAN-2001; 2001WO-US000664.
 30-JAN-2001; 2001WO-US000665.
 30-JAN-2001; 2001WO-US000666.
 30-JAN-2001; 2001WO-US000667.
 30-JAN-2001; 2001WO-US000668.
 30-JAN-2001; 2001WO-US000669.
 30-JAN-2001; 2001WO-US000670.
 05-FEB-2001; 2001US-026686P.
 (AEOM-) AEOMICA INC.
 Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 WPI; 2002-179446/23.
 New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 or as specific biomolecule capture probes for surface-enhanced laser
 desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 Disclosure; SEQ ID NO 672; 214pp; English.
 The present invention describes a human genome-derived myosin-like
 protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 nucleic acids can be used as probes to detect, characterise and quantify
 hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 provide initial substrates for the recombinant engineering of hGDMPLP-1
 protein variants having desired phenotypic improvements, and for
 expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 used as immunogens to raise antibodies that specifically recognise hGDMPLP
 -1 proteins, as standards in assays used to determine the concentration
 and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 capture probes for surface-enhanced laser desorption ionisation, as
 therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 production, and in vaccines or for replacement therapy. The
 polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 disorder associated with the expression of hGDMPLP-1, in particular heart
 and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 The present sequence represents an oligomer used in the screening of the
 hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 The sequence data for this patent did not form part of the printed
 specification, but was obtained in electronic format directly from WIPO
 at ftp.wipo.int/pub/published_pct_sequence
 Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 233 GAAGAGTCTCTCTCTGG 248
 Db 17 GATGAGTCTCTCTCTGG 2
 RESULT 968
 ABN02004/c
 ID ABN02004 standard; DNA; 17 BP.
 AC ABN02004;
 XX 29-MAY-2002 (first entry)
 DT Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1996.
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 1996; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
 SQ Best Match 1.7%; Score 12.8; DB 1; Length 17;
 Query Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 309 GCCTGGAGGAGCAATCA 324
 Db 17 GCCTGGAGGAGCAATCA 2
 RESULT 969

ABN01729/c
 ID ABN01729 standard; DNA; 17 BP.
 XX
 AC ABN01729;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1721.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 1721; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCAGCCAGCA 407
DB 16 TTCTGAGCCAGCCAGA 1

RESULT 970
ABN07686
ID ABN07686 standard; DNA; 17 BP.
XX AC ABN07686;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7678.
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX PS Disclosure; SEQ ID NO 7678; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1
XX CC can be used in gene therapy and vaccine production. The hGDMPLP-1
XX CC nucleic acids can be used as probes to detect, characterize and quantify
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1

CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence

SQ Sequence 17 BP; 9 A; 1 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGGCGCAGAGGAG 505
DB 1 GAAGGCGCAGAGGAG 16

RESULT 971
ABN08042
ID ABN08042 standard; DNA; 17 BP.
XX AC ABN08042;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8034.
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX PS Disclosure; SEQ ID NO 8034; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1

CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTCGAGCG 711
Db 1 AGCTGGAGATCGAGCG 16

RESULT 972
ABN07705/C
ID ABN07705 standard; DNA; 17 BP.
XX
AC ABN07705;
XX
XX 29-MAY-2002 (first entry)
DT
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7697.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
FN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (ABOM-) ABOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX

XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 7697; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 828 TGGCCCGAGTTGCAGGT 843
Db 17 TGGCCCGAGTCGAGGT 2

RESULT 973
ABN01531/C
ID ABN01531 standard; DNA; 17 BP.
XX
AC ABN01531;
XX
XX 29-MAY-2002 (first entry)
DT
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1523.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
FN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
XX

PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 1523; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering, and for
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 5 A; 2 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 846 CCTATCACCAGCTCTT 861
 Db 17 CCCATCACCTGCTCTT 2
 RESULT 974
 ABN01532/c
 ID ABN01532 standard; DNA; 17 BP.
 XX
 AC ABN01532;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1524.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN W0200192524-A2.
 XX
 PD 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234587P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 1524; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering, and for
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 5 A; 1 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 846 CCTATCACCAGCTCTT 861
 Db 16 CCCATCACCTGCTCTT 1
 RESULT 975
 ABN01728/c
 ID ABN01728 standard; DNA; 17 BP.
 XX
 AC ABN01728;
 XX
 DT 29-MAY-2002 (first entry)
 XX

DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1720.
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0268686P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 1720; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 392 TTCTGAGCCAGCCAGA 407
 ||| |||||

Db 17 TTCTGAGCCAGCCAGA 2
 RESULT 976
 ABNO2005/C
 ID ABNO2005 standard; DNA; 17 BP.
 XX AC ABNO2005;
 XX 29-MAY-2002 (first entry)
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1997.
 DS Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 OS WO200192524-A2.
 PN 06-DEC-2001.
 PD 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0268686P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 1997; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the present invention. N.B.
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed

CC	-1 proteins, as standards in assays used to determine the concentration	CC	Sequence 17 BP; 8 A; 2 C; 6 G; 1 T; 0 U; 0 Other;
CC	and/or amount specifically of hGDMPLP proteins, as specific biomolecule	CC	Query Match 1.7%; Score 12.8; DB 1; Length 17;
CC	capture probes for surface-enhanced laser desorption/ionization, as	CC	Best Local Similarity 87.5%; Pred. No. 7.2e+02;
CC	therapeutic supplement in patients having specific deficiency in hGDMPLP-1	CC	Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0.
CC	production, and in vaccines or for replacement therapy. The	CC	
CC	polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a	CC	
CC	disorder associated with the expression of hGDMPLP-1, in particular heart	CC	
CC	and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.	CC	
CC	The present sequence represents an oligomer used in the screening of the	CC	
CC	hGDMPLP-1 sequence in the exemplification of the present invention. N.B.	CC	
CC	The sequence data for this patent did not form part of the printed	CC	
CC	specification, but was obtained in electronic format directly from WIPO	CC	
CC	at ftp.wipo.int/pub/published_pct_sequence	CC	
XX		XX	
SQ		SQ	
QY	493 GAGGCAGAAAGGAGCAG 508	DB	2 GAAGCAAAAGGAGCAG 17
DB			
RESULT 978			
ABN00362/c			
ID	ABN00362 standard; DNA; 17 BP.		
XX			
AC	ABN00362;		
XX			
DT	29-MAY-2002 (first entry)		
DE	Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:354.		
XX			
KW	Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;		
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;		
KW	skeletal muscle disorder; amplicon; screening; ss.		
XX			
OS	Homo sapiens.		
XX			
PN	WO200192524-A2.		
XX			
PD	06-DEC-2001.		
XX			
PF	25-MAY-2001; 2001WO-US0016981.		
XX			
PR	26-MAY-2000; 2000US-0207456P.		
PR	21-SEP-2000; 2000US-0234687P.		
PR	27-SEP-2000; 2000US-0236359P.		
PR	04-OCT-2000; 2000GB-00024263.		
PR	30-JAN-2001; 2001WO-US000661.		
PR	30-JAN-2001; 2001WO-US000662.		
PR	30-JAN-2001; 2001WO-US000663.		
PR	30-JAN-2001; 2001WO-US000664.		
PR	30-JAN-2001; 2001WO-US000665.		
PR	30-JAN-2001; 2001WO-US000666.		
PR	30-JAN-2001; 2001WO-US000667.		
PR	30-JAN-2001; 2001WO-US000668.		
PR	30-JAN-2001; 2001WO-US000669.		
PR	05-FEB-2001; 2001US-0266860P.		
XX			
PA	(AEOM-) AEOMICA INC.		
XX			
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;		
XX			
DR	WPI; 2002-179446/23.		
XX			
PT	New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,		
PT	or as specific biomolecule capture probes for surface-enhanced laser		
PT	desorption/ionization, comprises human myosin-like protein hGDMPLP-1.		
XX			

PS Disclosure; SEQ ID NO 354; 214pp; English.

XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-

CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMPLP-1

CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGDMPLP

CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption/ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1

CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMPLP-1, in particular heart

CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the

CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.

CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 4 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTGAAGAGGC 497

DB 17 CTCGTTCTGGAAGGC 2

|||||

RESULT 979

ID ABN06899/c

XX ABN06899 standard; DNA; 17 BP.

XX AC ABN06899;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6891.

XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;

XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

XX KW skeletal muscle disorder; amplicon; screening; ss.

XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US016981.

XX PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.

XX PA (AEOM-) AEOMICA INC.

XX GU Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,

XX or as specific biomolecule capture probes for surface-enhanced laser

XX desorption/ionization, comprises human myosin-like protein hGDMPLP-1.

XX Disclosure; SEQ ID NO 6891; 214pp; English.

XX The present invention describes a human genome-derived myosin-like

XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-

XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1

XX nucleic acids can be used as probes to detect, characterise and quantify

XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to

XX provide initial substrates for the recombinant engineering of hGDMPLP-1

XX protein variants having desired phenotypic improvements, and for

XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be

XX used as immunogens to raise antibodies that specifically recognise hGDMPLP

XX -1 proteins, as standards in assays used to determine the concentration

XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule

XX capture probes for surface-enhanced laser desorption/ionisation, as

XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1

XX production, and in vaccines or for replacement therapy. The

XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a

XX disorder associated with the expression of hGDMPLP-1, in particular heart

XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.

XX The present sequence represents an oligomer used in the screening of the

XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.

XX The sequence data for this patent did not form part of the printed

XX specification, but was obtained in electronic format directly from WIPO

XX at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 1 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTCTGAGAGGAA 321

DB 16 GCCGCTTGAAGAGAA 1

|||||

RESULT 980

ID ABN07822

XX ABN07822 standard; DNA; 17 BP.

XX AC ABN07822;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7814.

XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;

XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

XX KW skeletal muscle disorder; amplicon; screening; ss.

XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US016981.

XX PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.

```

PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 7814; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 494 AGCAGAGAGGAGGAGG 509
XX
XX DB 1 AAGCAAAAGGAGGAGG 16
XX
XX
XX RESULT 981
XX ID ABN06830/c
XX AC ABN06830;
XX
XX DT 29-MAY-2002 (first entry)
XX
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6822.
XX
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX OS Homo sapiens.

```

```

XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 6822; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 3 A; 3 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 267 ACCTGCCTTCAGAAC 282
XX
XX DB 17 ACCTGCCTTCAGAAAA 2
XX
XX
XX RESULT 982
XX ABQ63785/c
XX ID ABQ63785 standard; DNA; 17 BP.
XX
XX

```

AC	ABQ63785;	XX
XX		AC
DT	20-AUG-2002 (first entry)	XX
XX		DT
DE	Human KTOM1a portion (ABQ63232) probe # 498.	XX
XX		DE
KW	Human; KTOM1a; KTOM1; kidney tumor overexpressed membrane; cytostatic;	XX
KW	gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;	KW
KW	kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.	KW
XX		XX
OS	Homo sapiens.	OS
XX		XX
PN	WO200224750-A2.	XX
XX		PN
PD	28-MAR-2002.	XX
XX		PD
PF	21-SEP-2001; 2001WO-US029656.	XX
XX		PF
PR	21-SEP-2000; 2000US-0234687P.	XX
PR	27-SEP-2000; 2000US-0236359P.	PR
PR	04-OCT-2000; 2000GB-00024263.	PR
PR	30-JAN-2001; 2001WO-US000661.	PR
PR	30-JAN-2001; 2001WO-US000662.	PR
PR	30-JAN-2001; 2001WO-US000663.	PR
PR	30-JAN-2001; 2001WO-US000664.	PR
PR	30-JAN-2001; 2001WO-US000665.	PR
PR	30-JAN-2001; 2001WO-US000666.	PR
PR	30-JAN-2001; 2001WO-US000667.	PR
PR	30-JAN-2001; 2001WO-US000668.	PR
PR	30-JAN-2001; 2001WO-US000669.	PR
PR	30-JAN-2001; 2001WO-US000670.	PR
PR	23-MAY-2001; 2001US-00864761.	PR
PR	28-AUG-2001; 2001US-0315676P.	PR
XX		XX
PA	(AEOM-) ABOMICA INC.	PA
XX		XX
PI	Zhang J;	XX
XX		PI
XX	WPI; 2002-479509/51.	XX
DR		XX
XX	New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic	XX
PT	acids encoding the protein, useful for treating subjects having defects	PT
PT	in KTOM1 which can manifest as cancer of the kidney, or as a disorder of	PT
PT	e.g., liver or bone.	PT
XX		XX
PS	Example 2; Page 223; 418pp; English.	XX
XX		PS
CC	The invention relates to a novel isolated nucleic acid encoding human	XX
CC	KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the	CC
CC	invention has cytostatic activity. The nucleotide may have a use in gene	CC
CC	therapy. The KTOM1 nucleic acids may be used to diagnose, treat or	CC
CC	monitor a disease caused by altered expression of human KTOM1.	CC
CC	Compositions comprising the nucleic acids, proteins or antibodies may be	CC
CC	used to treat subjects having defects in KTOM1 which can manifest as	CC
CC	cancer of the kidney, as well as a disorder of liver, bone marrow, brain,	CC
CC	heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta	CC
CC	function. The sequence represents a probe used in the invention to scan	CC
CC	the nt 1-1001 portion of human KTOM1a (ABQ63232)	CC
XX		XX
SQ	Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;	SQ
	Query Match 1.7%; Score 12.8; DB 1; Length 17;	
	Best Local Similarity 87.5%; Pred. No. 7.2e+02;	
	Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Qy	372 GCTCGAGGAGCTCTCT 387	Qy
Db	17 GCTGAGAGGAGCTCCT 2	Db
RESULT 983		
ABQ63786/c		
ID	ABQ63786-standard; DNA; 17 BP.	

ABQ63786;	XX
	AC
20-AUG-2002 (first entry)	XX
	DT
Human KTOM1a portion (ABQ63232) probe # 499.	XX
	DE
Human; KTOM1a; KTOM1; kidney tumor overexpressed membrane; cytostatic;	XX
gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;	KW
kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.	KW
	XX
Homo sapiens.	OS
	XX
WO200224750-A2.	XX
	PN
28-MAR-2002.	XX
	PD
21-SEP-2001; 2001WO-US029656.	XX
	PF
21-SEP-2000; 2000US-0234687P.	XX
27-SEP-2000; 2000US-0236359P.	PR
04-OCT-2000; 2000GB-00024263.	PR
30-JAN-2001; 2001WO-US000661.	PR
30-JAN-2001; 2001WO-US000662.	PR
30-JAN-2001; 2001WO-US000663.	PR
30-JAN-2001; 2001WO-US000664.	PR
30-JAN-2001; 2001WO-US000665.	PR
30-JAN-2001; 2001WO-US000666.	PR
30-JAN-2001; 2001WO-US000667.	PR
30-JAN-2001; 2001WO-US000668.	PR
30-JAN-2001; 2001WO-US000669.	PR
30-JAN-2001; 2001WO-US000670.	PR
23-MAY-2001; 2001US-00864761.	PR
28-AUG-2001; 2001US-0315676P.	PR
	XX
(AEOM-) ABOMICA INC.	PA
	XX
Zhang J;	XX
	PI
WPI; 2002-479509/51.	XX
	DR
New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic	XX
acids encoding the protein, useful for treating subjects having defects	PT
in KTOM1 which can manifest as cancer of the kidney, or as a disorder of	PT
e.g., liver or bone.	PT
	XX
Example 2; Page 223; 418pp; English.	XX
	PS
The invention relates to a novel isolated nucleic acid encoding human	XX
KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the	CC
invention has cytostatic activity. The nucleotide may have a use in gene	CC
therapy. The KTOM1 nucleic acids may be used to diagnose, treat or	CC
monitor a disease caused by altered expression of human KTOM1.	CC
Compositions comprising the nucleic acids, proteins or antibodies may be	CC
used to treat subjects having defects in KTOM1 which can manifest as	CC
cancer of the kidney, as well as a disorder of liver, bone marrow, brain,	CC
heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta	CC
function. The sequence represents a probe used in the invention to scan	CC
the nt 1-1001 portion of human KTOM1a (ABQ63232)	CC
	XX
Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;	SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;	
Best Local Similarity 87.5%; Pred. No. 7.2e+02;	
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Qy 372 GCTCGAGGAGCTCTCT 387	Qy
Db 16 GCTGAGAGGAGCTCCT 1	Db
RESULT 984	
ABQ63786/c	
ID	ABK26264/c

ID ABK26264 standard; DNA; 17 BP.
 AC ABK26264;
 XX
 XX
 XX 09-APR-2002 (first entry)
 XX
 XX Increased starch production genome altering oligonucleotide #116.
 XX
 XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
 KW o-methyl modification; LNA modification; phosphorothioate linkage;
 KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
 KW abiotic stress tolerance; improved nutritional value; hygromycin-B;
 KW amino acid over production; herbicide resistance; glyphosate resistance;
 KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
 KW porphyrin herbicide resistance; triazine resistance; disease resistance;
 KW modified oil production; modified starch production; waxy starch;
 KW altered floral morphology; male-sterile plant; albino mutant;
 KW modified fatty acid content; reduced palmitate production; albino plant;
 KW increased stearate production; reduced linolenic acid production;
 KW photosynthetic process.
 XX
 OS Oryza sativa.
 OS Synthetic.
 XX
 XX WO200192512-A2.
 XX
 XX 06-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-US017672.
 XX
 XX 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 PR 27-MAR-2001; 2001US-00818875.
 XX
 XX (UYDE) UNIV DELAWARE.
 XX
 XX Kmiec EB, Gamper HB, Rice MC, Kim J;
 PI WPI; 2002-106307/14.
 DR
 XX
 XX New oligonucleotides with modified nuclease-resistant termini, useful for
 PT creating plants with desired phenotypes, e.g. stress tolerance, improved
 PT nutritional value, herbicide or disease resistance, or modified oil
 PT production.
 XX
 XX Claim 7; Page 141; 220pp; English.
 PS
 XX The invention relates to an oligonucleotide for targeted alteration of a
 CC genetic sequence, which comprises a single-stranded oligonucleotide
 CC having a DNA domain. The DNA domain has at least one mismatch with
 CC respect to the genetic sequence to be altered and further comprises
 CC chemical modifications of the oligonucleotide. The chemical modifications
 CC consist of o-methyl modification, an LNA modification, two or more
 CC phosphorothioate linkages on a terminus, or a combination of any two or
 CC more of these modifications. The oligonucleotides are useful for
 CC directing repair or alteration of plant genetic information. The
 CC oligonucleotides are particularly useful for creating plants with desired
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
 CC nutritional value (e.g. altering amino acid content of plants or
 CC conferring amino acid over production), herbicide resistance (e.g.
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
 CC resistance, porphyrin herbicide resistance or triazine resistance),
 CC disease resistance, modified oil production, modified starch production
 CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 3 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 409 GGAGGAGAGGAGTTC 424
 ||||| |||||
 DB 16 GGAGGAGAGGAGTTC 1
 RESULT 985
 ABK26263
 ID ABK26263 standard; DNA; 17 BP.
 XX
 AC ABK26263;
 XX
 XX 09-APR-2002 (first entry)
 DT
 DE Increased starch production genome altering oligonucleotide #115.
 XX
 XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
 KW o-methyl modification; LNA modification; phosphorothioate linkage;
 KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
 KW abiotic stress tolerance; improved nutritional value; hygromycin-B;
 KW amino acid over production; herbicide resistance; glyphosate resistance;
 KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
 KW porphyrin herbicide resistance; triazine resistance; disease resistance;
 KW modified oil production; modified starch production; waxy starch;
 KW altered floral morphology; male-sterile plant; albino mutant;
 KW modified fatty acid content; reduced palmitate production; albino plant;
 KW increased stearate production; reduced linolenic acid production;
 KW photosynthetic process.
 XX
 OS Oryza sativa.
 OS Synthetic.
 XX
 XX WO200192512-A2.
 XX
 XX 06-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-US017672.
 XX
 XX 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 PR 27-MAR-2001; 2001US-00818875.
 XX
 XX (UYDE) UNIV DELAWARE.
 XX
 XX Kmiec EB, Gamper HB, Rice MC, Kim J;
 PI WPI; 2002-106307/14.
 DR
 XX
 XX New oligonucleotides with modified nuclease-resistant termini, useful for
 PT creating plants with desired phenotypes, e.g. stress tolerance, improved
 PT nutritional value, herbicide or disease resistance, or modified oil
 PT production.
 XX
 XX Claim 7; Page 141; 220pp; English.
 PS
 XX The invention relates to an oligonucleotide for targeted alteration of a
 CC genetic sequence, which comprises a single-stranded oligonucleotide
 CC having a DNA domain. The DNA domain has at least one mismatch with
 CC respect to the genetic sequence to be altered and further comprises
 CC chemical modifications of the oligonucleotide. The chemical modifications
 CC consist of o-methyl modification, an LNA modification, two or more
 CC phosphorothioate linkages on a terminus, or a combination of any two or
 CC more of these modifications. The oligonucleotides are useful for
 CC directing repair or alteration of plant genetic information. The
 CC oligonucleotides are particularly useful for creating plants with desired
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
 CC nutritional value (e.g. altering amino acid content of plants or
 CC conferring amino acid over production), herbicide resistance (e.g.
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
 CC resistance, porphyrin herbicide resistance or triazine resistance),
 CC disease resistance, modified oil production, modified starch production
 CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 3 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention

XX SQ Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 409 GGAGGAGAGGAGTTC 424

DB 2 GGAGCAAGGAGTTC 17

RESULT 986

ABK19193

ID ABK19193 standard; RNA; 17 BP.

XX AC ABK19193;

XX DT 09-APR-2002 (first entry)

XX DE Human ERG Amberzyme target sequence Seq ID No 1840.

XX KW Human; hammerhead ribozyme; cytotostatic; antitumour; antidiabetic;
XX KW Ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
XX KW vulvular; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
XX KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
XX KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
XX KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
XX KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
XX KW Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;
XX KW amberzyme.

XX OS Homo sapiens.

XX PN WO200188124-A2.

XX XX 22-NOV-2001.

XX PF 16-MAY-2001; 2001WO-US015866.

XX PR 16-MAY-2000; 2000US-00572021.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PA (GLAX) GLAXO GROUP LTD.

XX PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;

XX DR WPI; 2002-082995/11.

XX PT Novel polynucleotide which down regulates expression of Ets-related gene,
XX useful for treating cancer, diabetic retinopathy, macular degeneration,
XX arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.

XX PS Claim 4; Page 122; 149pp; English.

XX CC The invention relates to a nucleic acid molecule (I) which down regulates
XX expression of an Ets-related gene (ERG). (I) is useful for treating
XX conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
XX tumour angiogenesis, diabetic retinopathy, macular degeneration,
XX neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
XX vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
XX Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
XX syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
XX treating a patient having a condition associated with the level of ERG,
XX by contacting cells of the patient with (I) under conditions suitable for
XX the treatment. The method comprises the use of one or more therapies
XX under conditions suitable for the treatment. Leukaemia or tumour

CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ASK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention

XX SQ Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 7.2e+02;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGGAGGAGAA 321

DB 1 GCUCAUGGAGGAGAA 16

RESULT 987

ABK18809/c

ID ABK18809 standard; RNA; 17 BP.

XX AC ABK18809;

XX DT 09-APR-2002 (first entry)

XX DE Human ERG DNAzyme target sequence Seq ID No 1456.

XX KW Human; hammerhead ribozyme; cytotostatic; antitumour; antidiabetic;
XX KW Ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
XX KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
XX KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
XX KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
XX KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
XX KW Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;
XX KW amberzyme.

XX OS Homo sapiens.

XX PN WO200188124-A2.

XX XX 22-NOV-2001.

XX PF 16-MAY-2001; 2001WO-US015866.

XX PR 16-MAY-2000; 2000US-00572021.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PA (GLAX) GLAXO GROUP LTD.

XX PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;

XX DR WPI; 2002-082995/11.

XX PT Novel polynucleotide which down regulates expression of Ets-related gene,
XX useful for treating cancer, diabetic retinopathy, macular degeneration,
XX arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.

XX PS Claim 4; Page 92; 149pp; English.

XX CC The invention relates to a nucleic acid molecule (I) which down regulates
XX expression of an Ets-related gene (ERG). (I) is useful for treating
XX conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
XX tumour angiogenesis, diabetic retinopathy, macular degeneration,
XX neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca

CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Oslar-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 796 GCGCCAGGCGCCTCG 811
 DB 17 GCGCCGCGCACCTCG 2
 RESULT 988
 ABK19192
 ID ABK19192 standard; RNA; 17 BP.
 XX
 AC ABK19192;
 XX
 DT 09-APR-2002 (first entry)
 DE Human ERG Amberzyme target sequence Seq ID No 1839.
 XX
 KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Oslar-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
 KW amberzyme.
 XX
 OS Homo sapiens.
 XX
 PN WO200188124-A2.
 XX
 PD 22-NOV-2001.
 XX
 PF 16-MAY-2001; 2001WO-US015866.
 XX
 PR 16-MAY-2000; 2000US-00572021.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 XX
 XX
 PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 XX WPI; 2002-082995/11.
 XX
 XX Novel polynucleotide which down regulates expression of Ets-related gene,
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 XX

PS Claim 4; Page 122; 149pp; English.
 XX
 CC The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic degeneration, arthritis, psoriasis, verruca
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Oslar-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX
 SQ Sequence 17 BP; 7 A; 2 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 QY 306 GCTGCTCGAGGAGAA 321
 DB 2 GCUACAGGAGGAGAA 17
 RESULT 989
 ABK18232
 ID ABK18232 standard; RNA; 17 BP.
 XX
 AC ABK18232;
 XX
 DT 09-APR-2002 (first entry)
 DE Human ERG hammerhead ribozyme target sequence, Seq ID No 879.
 XX
 KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Oslar-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
 KW amberzyme.
 XX
 OS Homo sapiens.
 XX
 PN WO200188124-A2.
 XX
 PD 22-NOV-2001.
 XX
 PF 16-MAY-2001; 2001WO-US015866.
 XX
 PR 16-MAY-2000; 2000US-00572021.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 XX
 XX
 PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;

OS Homo sapiens.
 PN WO200188124-A2.
 XX
 XX
 PD 22-NOV-2001.
 XX
 XX
 PF 16-MAY-2001; 2001WO-US015866.
 XX
 PR 16-MAY-2000; 2000US-00572021.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (GLAXO) GLAXO GROUP LTD.
 XX
 XX
 PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 XX WPI; 2002-082995/11.
 DR
 XX
 XX Novel polynucleotide which down regulates expression of Ets-related gene,
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 XX
 PS Claim 4; Page 73; 149pp; English.
 XX
 CC The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiobroma of tuberosus sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting the cell with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 9 G; 0 T; 2 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 795 AGCGCCAGCGCCCTC 810
 DB 16 AGCGCCGGCCACCTC 1
 RESULT 992
 ID ABK18826
 XX ABK18826 standard; RNA; 17 BP.
 XX
 AC ABK18826;
 XX
 XX 09-APR-2002 (first entry)
 DT Human ERG DNAzyme target sequence Seq ID No 1473.
 DE
 DE Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnarary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW

KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiobroma of tuberosus sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
 KW amberzyme.
 XX
 OS Homo sapiens.
 XX
 PN WO200188124-A2.
 XX
 XX 22-NOV-2001.
 PD
 XX
 PF 16-MAY-2001; 2001WO-US015866.
 XX
 PR 16-MAY-2000; 2000US-00572021.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (GLAXO) GLAXO GROUP LTD.
 XX
 XX
 PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 XX WPI; 2002-082995/11.
 DR
 XX
 XX Novel polynucleotide which down regulates expression of Ets-related gene,
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 XX
 PS Claim 4; Page 92; 149pp; English.
 XX
 CC The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiobroma of tuberosus sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting the cell with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX
 SQ Sequence 17 BP; 2 A; 12 C; 1 G; 0 T; 2 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 QY 296 ACCCTCCAGCGCTGCC 311
 DB 1 ACCCTCCAGCCCCC 16
 RESULT 993
 ID ABV90334
 XX ABV90334 standard; DNA; 17 BP.
 XX
 AC ABV90334;
 XX

```
DT 23-DEC-2002 (first entry)
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 1047.
DE
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EPI239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 1047; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (SI, AB883999), a sequence having 65% sequence identity to (SI),
CC (SI) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
XX Sequence 17 BP; 4 A; 7 C; 3 G; 3 T; 0 U; 0 Other;
SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 253 GCCAGCCATGCTGCAC 268
DB 1 GCCAGTCATCTGCAC 16
RESULT 994
ABV89595
ID ABV89595 standard; DNA; 17 BP.
```

```
XX
AC ABV89595;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 308.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EPI239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 308; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (SI, AB883999), a sequence having 65% sequence identity to (SI),
CC (SI) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
XX Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 476 GAGAGCTCGATCTGA 491
DB 1 GAGAGCTCGATGTCA 16
```

```

RESULT 995
ABV89594
ID ABV89594 standard; DNA; 17 BP.
XX
AC ABV89594;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 307.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
PT Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 307; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoded by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC caused by altered expression of human POSHL1 including diagnosing and
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 996
ABV89339
ID ABV89339 standard; DNA; 17 BP.
XX
AC ABV89339;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 52.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
PT Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 52; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoded by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC caused by altered expression of human POSHL1 including diagnosing and
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 3 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```


CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office
 CC
 XX Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 471 GCCTGGAGAGCTCGA 486
 ||| ||||| |||||
 Db 2 GCTTTGAGAGCTCGA 17

RESULT 1001

ABV89593

ID ABV89593 standard; DNA; 17 BP.

XX AC ABV89593;

XX DT 23-DEC-2002 (first entry)

XX DE Human POSHL1 scanning oligonucleotide SEQ ID NO 306.

XX DE Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;

XX KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;

XX KW gene therapy; transgenic; ss.

XX KW Homo sapiens.

XX OS

XX PN EP1239051-A2.

XX PD 11-SEP-2002.

XX PF 28-JAN-2002; 2002EP-00001165.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000666.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 30-JAN-2001; 2001WO-US000669.

XX PR 30-JAN-2001; 2001WO-US000670.

XX PR 23-MAY-2001; 2001US-00864761.

XX PR 10-OCT-2001; 2001US-0328205P.

XX PA (AEOM-) AEOMICA INC.

XX PI Shannon M;

XX WPI; 2002-684061/74.

XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL

PT -1, useful for treating disorders associated with decreased expression or

PT activity of human POSHL1.

PS Example 2; SEQ ID NO 306; 60pp + Sequence Listing; English.

XX The invention relates to an isolated SH3 domain (POSH)-like signalling

CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino

CC acids (SI, AB883999), a sequence having 65% sequence identity to (SI),

CC (SI) having 95% deviations, especially conservative substitutions or a

CC fragment of the sequences comprising at least 8 contiguous amino acids.

CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an

CC adaptor protein that interacts with Rho family small GTPases as well as

CC downstream components of the signal transduction pathway. (I) is useful

CC for identifying a specific binding partner. (I) and nucleic acids (II)

CC encoding (I) are useful for diagnosing, monitoring disease and treating

CC caused by altered expression of human POSHL1 including diagnosing and

CC treating cancer, they useful in the development of vaccines and (II) is

CC useful in gene therapy. (II) is useful for constructing microarrays which

CC are useful for measuring and for surveying gene expression and creating

CC transgenic non-human animals capable of producing the proteins. The

CC present sequence is that of a scanning oligonucleotide useful in examples

CC of the invention. Note: The present sequence did not form part of the

CC printed specification, but is based on sequence information supplied to

CC Derwent by the European Patent Office

XX Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 474 TCGAGAGCTCGATCT 489

Db 1 TTGAGAGCTCGATGT 16

RESULT 1002

ABV89338

ID ABV89338 standard; DNA; 17 BP.

XX AC ABV89338;

XX DT 23-DEC-2002 (first entry)

XX DE Human POSHL1 scanning oligonucleotide SEQ ID NO 51.

XX DE Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;

XX KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;

XX KW gene therapy; transgenic; ss.

XX KW Homo sapiens.

XX OS

XX PN EP1239051-A2.

XX PD 11-SEP-2002.

XX PF 28-JAN-2002; 2002EP-00001165.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000666.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 30-JAN-2001; 2001WO-US000669.

XX PR 30-JAN-2001; 2001WO-US000670.

XX PR 23-MAY-2001; 2001US-00864761.

XX PR 10-OCT-2001; 2001US-0328205P.

XX PA (AEOM-) AEOMICA INC.

XX PI Shannon M;

XX WPI; 2002-684061/74.

XX Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL

PT -1, useful for treating disorders associated with decreased expression or

PT activity of human POSHL1.

PS Example 2; SEQ ID NO 51; 60pp + Sequence Listing; English.

XX The invention relates to an isolated SH3 domain (POSH)-like signalling

CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino

CC acids (SI, AB883999), a sequence having 65% sequence identity to (SI),

CC (SI) having 95% deviations, especially conservative substitutions or a

CC fragment of the sequences comprising at least 8 contiguous amino acids.

CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an

CC adaptor protein that interacts with Rho family small GTPases as well as

CC downstream components of the signal transduction pathway. (I) is useful

CC for identifying a specific binding partner. (I) and nucleic acids (II)

CC encoding (I) are useful for diagnosing, monitoring disease and treating

CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office

XX Sequence 17 BP; 2 A; 4 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 617 CAGAGTCGCTTGAGG 632
||| |||||
Db 2 CAGCGGCGCTTGAGG 17

RESULT 1003
ABK56982
ID ABK56982 standard; RNA; 17 BP.

XX AC ABK56982;

XX DT 02-JUL-2002 (first entry)

XX DE Human CLCA1 gene enzymatic nucleic acid #1353.

XX KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
XX KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
XX KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
XX KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
XX KW acetylcysteine.

XX OS Homo sapiens.

XX PN WO200211674-A2.

XX PD 14-FEB-2002.

XX PF 09-AUG-2001; 2001WO-US024970.

XX PR 09-AUG-2000; 2000US-0224383P.

XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (SYNT) SYNTEX USA LLC.
XX PA (THOM/) THOMPSON J.

XX PI Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
XX PI Grupe A;

XX DR WPI; 2002-217145/27.

XX PT Enzymatic polynucleotide that down regulates expression of chloride
XX PT channel calcium activated gene, useful for treating Chronic obstructive
XX PT pulmonary disease (COPD), chronic bronchitis and asthma.

XX PS Claim 4; Page 88; 152pp; English.

XX CC The invention relates to enzymatic nucleic acid molecules that down
XX CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
XX CC by cleaving RNA derived from the genes. The nucleic acid sequences are
XX CC useful as pharmaceutical agents for treating conditions such as chronic
XX CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
XX CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
XX CC that are related to or will respond to the levels of CLCA1 in a cell or
XX CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,

CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
XX enzymatic nucleic acid molecule of the invention

XX Sequence 17 BP; 7 A; 2 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.2e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 477 AGAAGTCGATCTGAA 492
||| |||||
Db 1 AUAAGUCGCAUCGAA 16

RESULT 1004

ACN06154

ID ACN06154 standard; RNA; 17 BP.

XX AC ACN06154;

XX DT 22-APR-2004 (first entry)

XX DE WNV Amberzyme substrate SEQ ID NO 6157.

XX KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX KW viricide; neuroprotective; antibacterial; replication; pancreatitis;
XX KW encephalitis; myocarditis; meningitis; infection; hepatitis;
XX KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
XX KW Amberzyme; Zinzyme; ss.

XX OS West Nile Virus.

XX PN WO200268637-A2.

XX PD 06-SEP-2002.

XX PF 19-OCT-2001; 2001WO-US048350.

XX PR 20-OCT-2000; 2000US-0242411P.

XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.

XX PA (MCSW/) MCSWIGGEN J A.

XX PI Blatt L, Mcswiggen JA;

XX DR WPI; 2002-706994/76.

XX PT New nucleic acid molecule that modulates replication of West Nile Virus
XX PT (WNV), useful for treating a condition related to WNV infection e.g.
XX PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX PS Claim 23; SEQ ID NO 6157; 495pp; English.

XX CC The invention relates to nucleic acid molecules that modulate replication
XX CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX CC treating a condition related to WNV infection e.g. pancreatitis,
XX CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX CC molecule is selected from the group of ribozymes consisting of
XX CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
XX CC nucleic acid molecules further comprise at least five ribose residues, at
XX CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX CC least three of the 5' terminal nucleotides and a 3' end modification of a
XX CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX Sequence 17 BP; 6 A; 3 C; 5 G; 0 T; 3 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 530 CTGAAGAGATGCCAGC 545
 Db 2 CUGAAGUGAUGACAGC 17

RESULT 1005
 ACN10742/c
 ID ACN10742 standard; RNA; 17 BP.
 XX ACN10742;
 AC ACN10742;
 XX 22-APR-2004 (first entry)
 DT WNV minus strand Inozyme substrate SEQ ID NO 10745.
 DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
 KW Amberzyme; Zinzyme; ss.
 XX West Nile Virus.
 OS WO200268637-A2.
 XX 06-SEP-2002.
 PD 19-OCT-2001; 2001WO-US048350.
 PF 20-OCT-2000; 2000US-0242411P.
 PR (RIBO-) RIBOZYME PHARM INC.
 XX (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 PI WPI; 2002-706994/76.
 DR New nucleic acid molecule that modulates replication of West Nile Virus
 XX (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 PS Claim 23; SEQ ID NO 10745; 495pp; English.
 XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX Sequence 17 BP; 1 A; 6 C; 4 G; 0 T; 6 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 804 CCGCCTCGAGGAGAA 819
 Db 16 CCGCTCAGAGAGAA 1

RESULT 1006
 ACN12591
 ID ACN12591 standard; RNA; 17 BP.
 XX ACN12591;
 AC ACN12591;
 XX 22-APR-2004 (first entry)
 DT WNV minus strand Zinzyme substrate SEQ ID NO 12594.
 DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
 KW Amberzyme; Zinzyme; ss.
 XX West Nile Virus.
 OS WO200268637-A2.
 XX 06-SEP-2002.
 PD 19-OCT-2001; 2001WO-US048350.
 PF 20-OCT-2000; 2000US-0242411P.
 PR (RIBO-) RIBOZYME PHARM INC.
 XX (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 PI WPI; 2002-706994/76.
 DR New nucleic acid molecule that modulates replication of West Nile Virus
 XX (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 PS Claim 23; SEQ ID NO 12594; 495pp; English.
 XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 7.2e+02;
 Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 474 TGGAGAGCTCGATCT 489
 Db 2 UGGAGAGCUCCAUCU 17

XX	Result 1007
DE	ACN05002
ID	ACN05002 standard; RNA; 17 BP.
XX	
AC	ACN05002;
AC	
XX	
DT	22-APR-2004 (first entry)
XX	
XX	WNV DNazyme substrate SEQ ID NO 5005.
DE	
XX	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW	virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW	encephalitis; myocarditis; meningitis; infection; hepatitis;
KW	liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW	Amberzyme; Zinzyme; ss.
XX	
OS	West Nile Virus.
XX	
PN	WO200268637-A2.
XX	
PD	06-SEP-2002.
XX	
Pf	19-OCT-2001; 2001WO-US048350.
XX	
PR	20-OCT-2000; 2000US-0242411P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(BLAT/) BLATT L.
PA	(MCSW/) MCSWIGGEN J A.
XX	
PI	Blatt L, Mcswiggen JA;
XX	
DR	WPI; 2002-706994/76.
XX	
PT	New nucleic acid molecule that modulates replication of West Nile Virus
PT	(WNV), useful for treating a condition related to WNV infection e.g.
PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX	
PS	Claim 23; SEQ ID NO 5005; 495pp; English.
XX	
CC	The invention relates to nucleic acid molecules that modulate replication
CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC	treating a condition related to WNV infection e.g. pancreatitis,
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC	molecule is selected from the group of ribozymes consisting of
CC	Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC	nucleic acid molecules further comprise at least five ribose residues, at
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC	least three of the 5' terminal nucleotides and a 3' end modification of a
CC	3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC	in the specification. The present sequence is that of a nucleic acid
CC	molecule of the invention
XX	
SQ	Sequence 17 BP; 5 A; 3 C; 5 G; 0 T; 4 U; 0 Other;
	Query Match 1.7%; Score 12.8; DB 1; Length 17;
	Best Local Similarity 75.0%; Pred. No. 7.2e+02;
	Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY	530 CTGAAGATGCCGAC 545
	: :
DB	1 CUGAAGUAGCAGC 16
	RESULT 1008
	ACN06034
ID	ACN06034 standard; RNA; 17 BP.
XX	
AC	ACN06034;
XX	
DT	22-APR-2004 (first entry)
XX	
XX	WNV DNazyme substrate SEQ ID NO 5005.
DE	
XX	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW	virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW	encephalitis; myocarditis; meningitis; infection; hepatitis;
KW	liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW	Amberzyme; Zinzyme; ss.
XX	
OS	West Nile Virus.
XX	
PN	WO200268637-A2.
XX	
PD	06-SEP-2002.
XX	
Pf	19-OCT-2001; 2001WO-US048350.
XX	
PR	20-OCT-2000; 2000US-0242411P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(BLAT/) BLATT L.
PA	(MCSW/) MCSWIGGEN J A.
XX	
PI	Blatt L, Mcswiggen JA;
XX	
DR	WPI; 2002-706994/76.
XX	
PT	New nucleic acid molecule that modulates replication of West Nile Virus
PT	(WNV), useful for treating a condition related to WNV infection e.g.
PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX	
PS	Claim 23; SEQ ID NO 5005; 495pp; English.
XX	
CC	The invention relates to nucleic acid molecules that modulate replication
CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC	treating a condition related to WNV infection e.g. pancreatitis,
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC	molecule is selected from the group of ribozymes consisting of
CC	Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC	nucleic acid molecules further comprise at least five ribose residues, at
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC	least three of the 5' terminal nucleotides and a 3' end modification of a
CC	3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC	in the specification. The present sequence is that of a nucleic acid
CC	molecule of the invention
XX	
SQ	Sequence 17 BP; 5 A; 3 C; 5 G; 0 T; 4 U; 0 Other;
	Query Match 1.7%; Score 12.8; DB 1; Length 17;
	Best Local Similarity 75.0%; Pred. No. 7.2e+02;
	Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY	530 CTGAAGATGCCGAC 545
	: :
DB	1 CUGAAGUAGCAGC 16
	RESULT 1008
	ACN06034
ID	ACN06034 standard; RNA; 17 BP.
XX	
AC	ACN06034;
XX	
DT	22-APR-2004 (first entry)
XX	
XX	WNV DNazyme substrate SEQ ID NO 5005.
DE	
XX	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW	virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW	encephalitis; myocarditis; meningitis; infection; hepatitis;
KW	liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW	Amberzyme; Zinzyme; ss.
XX	
OS	West Nile Virus.
XX	
PN	WO200268637-A2.
XX	
PD	06-SEP-2002.
XX	
Pf	19-OCT-2001; 2001WO-US048350.
XX	
PR	20-OCT-2000; 2000US-0242411P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(BLAT/) BLATT L.
PA	


```

PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 7599; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.2e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 238 GTCTCTCTCGGGAAG 253
Db 2 GUCUCUCUGGGAAG 17
||:|:|:|:|:|
|:|:|:|:|:|

RESULT 1012
ID ACN14468 standard; RNA; 17 BP.
XX
AC ACN14468;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV minus strand Amberzyme substrate SEQ ID NO 14471.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 7599; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.2e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 238 GTCTCTCTCGGGAAG 253
Db 2 GUCUCUCUGGGAAG 17
||:|:|:|:|:|
|:|:|:|:|:|

RESULT 1012
ID ACN14468 standard; RNA; 17 BP.
XX
AC ACN14468;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV minus strand Amberzyme substrate SEQ ID NO 14471.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 7599; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.2e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 238 GTCTCTCTCGGGAAG 253
Db 2 GUCUCUCUGGGAAG 17
||:|:~|:~|:~|:~|
|:~|:~|:~|:~|

RESULT 1013
ID ACN02562 standard; RNA; 17 BP.
XX
AC ACN02562;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV Inozyme substrate SEQ ID NO 2565.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 2565; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for

```

CC treating a condition related to WNv infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
XX

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 804 CCGCCTCGAGGAGAA 819
DB 2 CCGCCTCGAGGAGAA 17
||||| ||||| |||||

RESULT 1014
ID ACN08730/C
XX ACN08730 standard; RNA; 17 BP.
XX ACN08730;
XX

DT 22-APR-2004 (first entry)
XX

DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8733.
XX

KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX

OS West Nile Virus.
XX

XX WO200268637-A2.
XX

XX 06-SEP-2002.
XX

XX 19-OCT-2001; 2001WO-US048350.
XX

XX 20-OCT-2000; 2000US-0242411P.
XX

XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX

PI Blatt L, Mcswiggen JA;
XX

XX WPI; 2002-706994/76.
XX

XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX

XX Claim 23; SEQ ID NO 8733; 495pp; English.
XX

XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX SQ Sequence 17 BP; 3 A; 5 C; 3 G; 0 T; 6 U; 0 Other;
XX

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 530 CTGAAGAGATGCCAGC 545
DB 16 CTGAGTGATGACAGC 1
||||| ||||| |||||

RESULT 1015
ID ACN11414/C
XX ACN11414 standard; RNA; 17 BP.
XX ACN11414;
XX

DT 22-APR-2004 (first entry)
XX

DE WNV minus strand Inozyme substrate SEQ ID NO 11417.
XX

KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX

OS West Nile Virus.
XX

XX WO200268637-A2.
XX

XX 06-SEP-2002.
XX

XX 19-OCT-2001; 2001WO-US048350.
XX

XX 20-OCT-2000; 2000US-0242411P.
XX

XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX

PI Blatt L, Mcswiggen JA;
XX

XX WPI; 2002-706994/76.
XX

XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX

XX Claim 23; SEQ ID NO 11417; 495pp; English.
XX

XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention

XX SQ Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
XX

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 718 GCTGCAGGAGCTGCAC 733
 DB 17 GCTGCAGGAGCTGCAC 2

RESULT 1016
 ACN12508/c
 ID ACN12508 standard; RNA; 17 BP.

XX ACN12508;
 XX 22-APR-2004 (first entry)
 XX WNV minus strand Zinzyne substrate SEQ ID NO 12511.
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyne; ss.
 XX West Nile Virus.
 XX WO200268637-A2.
 XX 06-SEP-2002.
 XX 19-OCT-2001; 2001WO-US048350.
 XX 20-OCT-2000; 2000US-0242411P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (BLAT/) BLATT L.
 XX (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX Claim 23; SEQ ID NO 12511; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

XX Sequence 17 BP; 1 A; 8 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 606 TGCAGGAGCCGACAG 621
 DB 17 TGCAGGAGCCGACAG 2

RESULT 1018
 ACN14466
 ID ACN14466 standard; RNA; 17 BP.

XX TGCAGGAGCCGACAG 733
 DB 16 GCTGCAGGAGCTGCAC 1

XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

XX Sequence 17 BP; 3 A; 6 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 718 GCTGCAGGAGCTGCAC 733
 DB 16 GCTGCAGGAGCTGCAC 1

XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

XX Sequence 17 BP; 3 A; 6 C; 5 G; 0 T; 3 U; 0 Other;

Db 17 TGCAGGAGCCGACAG 2

RESULT 1017
 ACN08869/c
 ID ACN08869 standard; RNA; 17 BP.

XX ACN08869;
 XX 22-APR-2004 (first entry)
 XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8872.
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyne; ss.
 XX West Nile Virus.
 XX WO200268637-A2.
 XX 06-SEP-2002.
 XX 19-OCT-2001; 2001WO-US048350.
 XX 20-OCT-2000; 2000US-0242411P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (BLAT/) BLATT L.
 XX (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX Claim 23; SEQ ID NO 8872; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

XX Sequence 17 BP; 3 A; 6 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 718 GCTGCAGGAGCTGCAC 733
 DB 16 GCTGCAGGAGCTGCAC 1

XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

XX Sequence 17 BP; 3 A; 6 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 1018
 ACN14466
 ID ACN14466 standard; RNA; 17 BP.

XX TGCAGGAGCCGACAG 733
 DB 16 GCTGCAGGAGCTGCAC 1

DR WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus

PT (WNV), useful for treating a condition related to WNV infection e.g.

PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX

PS Claim 23; SEQ ID NO 3273; 495pp; English.

XX

CC The invention relates to nucleic acid molecules that modulate replication

CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for

CC treating a condition related to WNV infection e.g. pancreatitis,

CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

CC molecule is selected from the group of ribozymes consisting of

CC Hammerhead, Inozyme, G-cleaver, DNazyme, and Zinzyme. The

CC nucleic acid molecules further comprise at least five ribose residues, at

CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a

CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080

CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

CC in the specification. The present sequence is that of a nucleic acid

CC molecule of the invention

XX

SQ Sequence 17 BP; 7 A; 5 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 238 GTCTCTCTCTGGGAAG 253

DB 17 GTCTCTCTCTGGGAAG 2

|||||

RESULT 1023

ACN07198/C

ID ACN07198 standard; RNA; 17 BP.

XX

AC ACN07198;

XX

DT 22-APR-2004 (first entry)

XX

DE WNV Amberszyme substrate SEQ ID NO 7201.

DE

DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

KW virucide; neuroprotective; antibacterial; replication; pancreatitis;

KW encephalitis; myocarditis; meningitis; infection; hepatitis;

KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;

KW Amberszyme; Zinzyme; ss.

XX

OS West Nile Virus.

XX

XX WO200268637-A2.

PN

XX

PD 06-SEP-2002.

XX

XX

PF 19-OCT-2001; 2001WO-US048350.

XX

XX

PR 20-OCT-2000; 2000US-0242411P.

XX

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

XX

XX Blatt L, Mcswiggen JA;

PI

XX

XX WPI; 2002-706994/76.

DR

XX

PT New nucleic acid molecule that modulates replication of West Nile Virus

PT (WNV), useful for treating a condition related to WNV infection e.g.

PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX

PS Claim 23; SEQ ID NO 7201; 495pp; English.

XX

CC The invention relates to nucleic acid molecules that modulate replication

CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for

CC treating a condition related to WNV infection e.g. pancreatitis,

CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

CC molecule is selected from the group of ribozymes consisting of

CC Hammerhead, Inozyme, G-cleaver, DNazyme, and Zinzyme. The

CC nucleic acid molecules further comprise at least five ribose residues, at

CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a

CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080

CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

CC in the specification. The present sequence is that of a nucleic acid

CC molecule of the invention

XX

SQ Sequence 17 BP; 6 A; 6 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 238 GTCTCTCTCTGGGAAG 253

DB 16 GTCTCTCTCTGGGAAG 1

|||||

RESULT 1024

ABT35838/C

ID ABT35838 standard; DNA; 17 BP.

XX

AC ABT35838;

XX

DT 12-JUN-2003 (first entry)

XX

DE Tumour suppression related human fukutin oligo SEQ ID NO 1475.

DE

DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;

KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; protein chip; gene therapy; tumour suppression;

KW human fukutin; ds.

XX

OS Homo sapiens.

XX

XX WO2003025175-A2.

PN

XX

PD 27-MAR-2003.

XX

PF 17-SEP-2002; 2002WO-IB004208.

XX

PR 17-SEP-2001; 2001FR-00011978.

XX

XX (MOLE-) MOLECULAR ENGINES LAB.

PA

XX

PI Telerman A, Amson R, Tuijnder M;

XX

XX WPI; 2003-313353/30.

DR

XX

PT New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX

PS Disclosure; Page 205; 720pp; French.

XX

CC The invention relates to a novel isolated 17 mer nucleic acid sequence,

CC given in the specification, a sequence containing at least 15 consecutive

CC nucleotides from the 17 mer sequence, a sequence with, after optimal

CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that

CC hybridizes to them under highly stringent conditions, or the complement

CC of any of them, or the corresponding RNA. The novel isolated nucleic

CC acids of the invention are useful as probes and primers for detecting,

CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one

CC component of a gene chip, in vitro as (anti)sense reagents, and for

CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 601 GGAGCTGCAGCAGC 616
 |||||
 DB 16 GGAGCTGCAGTAGATC 1
 RESULT 1025
 ABT36928
 ID ABT36928 standard; DNA; 17 BP.
 XX
 AC ABT36928;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 2565.
 XX
 KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 332; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the

CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 881 ATCAAGAGCAGCGTGG 896
 |||||
 DB 2 ATCTAGAGCAGCATGG 17
 RESULT 1026
 ABT37923/C
 ID ABT37923 standard; DNA; 17 BP.
 XX
 AC ABT37923;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 3560.
 XX
 KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 450; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 203 GGCCCGGCGACGATC 218
Db 16 GGGCTGGCAGCAGATC 1
RESULT 1027
ACA07771
ID ACA07771 standard; RNA; 17 BP.
AC ACA07771;
AC ACA07771;
DT 03-JUN-2003 (first entry)
XX
DE NFKB sub-unit modulating zinzyme substrate #170.
XX
KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotheraphy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW gencitabine; radiation therapy; fluorouracil carboplatin; edatrexate;
KW rheumatoid arthritis; restenosis; Crohn's disease; asthma; diabetes;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS Homo sapiens.
XX
XX US2002177568-A1.
XX
XX 28-NOV-2002.
XX
XX 23-MAY-2001; 2001US-00864785.
XX
XX 07-DEC-1992; 92US-00987132.
XX
XX 18-MAY-1994; 94US-00245466.
XX
XX 15-AUG-1994; 94US-00291932.
XX
XX 23-DEC-1996; 96US-00777916.
XX
XX (STIN/) STINCHOMB D T.
XX
XX (MCSW/) MCSWIGGEN J.
XX
XX (DRAP/) DRAPER K G.
XX
XX Stinchcomb DT, Mcswiggen J, Draper KG;
XX
XX WPT; 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression of
XX a sequence encoding a subunit of nuclear factor kappa B useful for
XX treating cancer, inflammatory disorders and autoimmune diseases.
XX
XX Claim 3; Page 40; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down

CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
CC antisense nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
CC gencitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.2e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 257 GCCATGCTGCACCTGC 272
Db 1 GCCCCGCGCAGCAGC 16
RESULT 1028
ACA07885/C
ID ACA07885 standard; RNA; 17 BP.
AC ACA07885;
AC ACA07885;
XX
XX 03-JUN-2003 (first entry)
XX
DE NFKB sub-unit modulating zinzyme substrate #284.
XX
KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotheraphy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
KW gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
XX Homo sapiens.
XX
XX US2002177568-A1.
XX
XX 28-NOV-2002.
XX
XX 23-MAY-2001; 2001US-00864785.
XX
XX 07-DEC-1992; 92US-00987132.
XX
XX 18-MAY-1994; 94US-00245466.
XX
XX 15-AUG-1994; 94US-00291932.
XX
XX 23-DEC-1996; 96US-00777916.
XX
XX (STIN/) STINCHOMB D T.
XX
XX (MCSW/) MCSWIGGEN J.
XX
XX (DRAP/) DRAPER K G.
XX
XX Stinchcomb DT, Mcswiggen J, Draper KG;
XX
XX WPT; 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression of
XX a sequence encoding a subunit of nuclear factor kappa B useful for
XX treating cancer, inflammatory disorders and autoimmune diseases.
XX
XX Claim 3; Page 40; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down

Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme; G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human; lung cancer; prostate cancer; colorectal cancer; brain cancer; oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer; cervical cancer; head and neck cancer; ovarian cancer; melanoma; lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor; chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate; cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate; gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes; rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia; gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis; transplant/graft rejection; reperfusion injury; glomerulonephritis; allergic airway inflammation; inflammatory bowel disease; infection; ss.

Homo sapiens.

US2002177568-A1.

28-NOV-2002.

23-MAY-2001; 2001US-00864785.

07-DEC-1992; 92US-00987132.

18-MAY-1994; 94US-00245466.

15-AUG-1994; 94US-00291932.

23-DEC-1996; 96US-00777916.

(STIN/) STINCHOMB D T.

(MCSW/) MCSWIGGEN J.

(DRAP/) DRAPER K G.

Stinchcomb DT, Mcswiggen J, Draper KG;

WPI; 2003-340953/32.

Novel enzymatic nucleic acid molecules which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B useful for treating cancer, inflammatory disorders and autoimmune diseases.

Claim 3; Page 40; 72pp; English.

The invention describes an enzymatic nucleic acid molecule (I) which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme configuration. The enzymatic nucleic acid molecule is adapted to treat cancer and is useful for down-regulating REL-A activity in a cell, for treating a patient having a condition associated with the level of REL-A. (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in the presence of a divalent cation, especially Mg²⁺. The enzymatic and antisense nucleic acid molecules are useful for treating breast, lung, prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic, cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or multidrug resistant cancer. The method involves use of other drug therapies such as monoclonal antibodies, REL-A-specific inhibitors or chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate, cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate, gemcitabine or radiation therapy. The enzymatic and antisense nucleic acid molecules are also useful for treating inflammatory disease such as rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, gene therapy applications, ischaemia/reperfusion injury (central nervous system (CNS) and myocardial), glomerulonephritis, sepsis, allergic airway inflammation, inflammatory bowel disease or infection. This sequence represents the substrate of a novel enzymatic nucleic acid molecule

Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 7.2e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

713 GAGGCGCTCAGCAGC 728

Db 1 GAGGCGCTCAGCAGC 16

RESULT 1031
 ACA06585
 ID ACA06585 standard; RNA; 17 BP.
 XX ACA06585;
 AC ACA06585;
 XX 03-JUN-2003 (first entry)
 DE NFkB sub-unit modulating inozyme substrate #404.

Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme; G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human; lung cancer; prostate cancer; colorectal cancer; brain cancer; oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer; cervical cancer; head and neck cancer; ovarian cancer; melanoma; lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor; chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate; cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate; gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes; rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia; gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis; transplant/graft rejection; reperfusion injury; glomerulonephritis; allergic airway inflammation; inflammatory bowel disease; infection; ss.

Homo sapiens.

US2002177568-A1.

28-NOV-2002.

23-MAY-2001; 2001US-00864785.

07-DEC-1992; 92US-00987132.

18-MAY-1994; 94US-00245466.

15-AUG-1994; 94US-00291932.

23-DEC-1996; 96US-00777916.

(STIN/) STINCHOMB D T.

(MCSW/) MCSWIGGEN J.

(DRAP/) DRAPER K G.

Stinchcomb DT, Mcswiggen J, Draper KG;

WPI; 2003-340953/32.

Novel enzymatic nucleic acid molecules which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B useful for treating cancer, inflammatory disorders and autoimmune diseases.

Claim 3; Page 33; 72pp; English.

The invention describes an enzymatic nucleic acid molecule (I) which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme configuration. The enzymatic nucleic acid molecule is adapted to treat cancer and is useful for down-regulating REL-A activity in a cell, for treating a patient having a condition associated with the level of REL-A. (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in the presence of a divalent cation, especially Mg²⁺. The enzymatic and antisense nucleic acid molecules are useful for treating breast, lung, prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic, cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or multidrug resistant cancer. The method involves use of other drug therapies such as monoclonal antibodies, REL-A-specific inhibitors or chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate, cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate, gemcitabine or radiation therapy. The enzymatic and antisense nucleic acid molecules are also useful for treating inflammatory disease such as rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,

CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 7.2e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 713 GAGGCGCTGCAGCAGC 728
 Db 2 GAGGCGCTGCAGCAGC 17
 RESULT 1032
 ACA06586
 ID ACA06586 standard; RNA; 17 BP.
 XX
 AC ACA06586;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating inozyme substrate #405.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Homo sapiens.
 XX
 US2002177568-A1.
 XX
 PN 28-NOV-2002.
 XX
 PD 23-MAY-2001; 2001US-00864785.
 XX
 PF 07-DEC-1992; 92US-00987132.
 XX
 PR 18-MAY-1994; 94US-00245466.
 PR
 PR 15-AUG-1994; 94US-00291932.
 PR
 PR 23-DEC-1996; 96US-00777916.
 XX
 (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 PI Stinchcomb DT, Mcswiggen J, Draper KG;
 XX
 DR WPI; 2003-340953/32.
 XX
 DR Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 PS Claim 3; Page 33; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat

CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisenase nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisenase nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 SQ Sequence 17 BP; 1 A; 7 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 7.2e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 QY 257 GCCATGCTGCACCTGC 272
 Db 2 GCCCTGCTGCACCTGC 17
 RESULT 1033
 ADA99742/c
 ID ADA99742 standard; DNA; 17 BP.
 XX
 AC ADA99742;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human MDZ3 scanning oligonucleotide SEQ ID 731.
 XX
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1281758-A2.
 XX
 PD 05-FEB-2003.
 XX
 XX 30-JUL-2002; 2002EP-00016874.
 PF
 PR 02-AUG-2001; 2001US-00922181.
 PR
 XX (AEOM-) AEOMICA INC.
 XX
 PI Shannon M, Gu Y, Nguyen C;
 XX
 DR WPI; 2003-423107/40.
 XX
 DR New zinc finger-containing proteins and nucleic acids, useful in
 PT manufacturing a medicament for treating or preventing a disorder
 PT associated with decreased or increased expression or activity of MDZ3,
 PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
 XX
 PS Example 8; SEQ ID NO 731; 103pp; English.
 XX
 CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences; MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
 CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,

CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy, or in manufacturing a medicament for treating or preventing a disorder, or associated with decreased or increased expression or activity of MD23, MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic acids and proteins are also useful for diagnosing or monitoring a disease caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic acids can also be used as probes to detect and characterize gross alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are useful in constructing microarrays for measuring gene expression. The proteins are useful as therapeutic agents for gene therapy or as vaccines. The present sequence was used to illustrate the invention.

XX
XX
SQ Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 ACCTGCCTTCAGAAC 282
Db 16 ACCGCTTCAGAAC 1

RESULT 1034

ADA99739/C
ID ADA99739 standard; DNA; 17 BP.

XX
XX
AC ADA99739;

XX
XX
DT 20-NOV-2003 (first entry)

XX
XX
DE Human MD23 scanning oligonucleotide SEQ ID 728.

XX
XX
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.

XX
XX
OS Homo sapiens.

XX
XX
FN EP1281758-A2.

XX
XX
PD 05-FEB-2003.

XX
XX
PF 30-JUL-2002; 2002EP-00016874.

XX
XX
PR 02-AUG-2001; 2001US-00922181.

XX
XX
PA (ABOM-) ABOMICA INC.

XX
XX
PI Shannon M, Gu Y, Nguyen C;

XX
XX
DR WPI; 2003-423107/40.

XX
XX
PT New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. Cancer.

XX
XX
PS Example 8; SEQ ID NO 728; 103pp; English.

XX
XX
CC The present invention relates to novel human zinc finger-containing
XX proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
XX encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
XX MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
XX 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
XX or in manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
XX acids and proteins are also useful for diagnosing or monitoring a disease
XX caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
XX acids can also be used as probes to detect and characterize gross

CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.

XX
XX
SQ Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 269 CTGCCTTCAGACAGG 284
Db 17 CCGCTTCAGACAGG 2

RESULT 1035

ABZ65413
ID ABZ65413 standard; RNA; 17 BP.

XX
XX
AC ABZ65413;

XX
XX
DT 21-MAR-2003 (first entry)

XX
XX
DE Human HER2 DNAzyme substrate #870.

XX
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.

XX
XX
OS Homo sapiens.

XX
XX
FN WC200297114-A2.

XX
XX
PD 05-DEC-2002.

XX
XX
PF 29-MAY-2002; 2002WO-US016840.

XX
XX
PR 29-MAY-2001; 2001US-0294140P.

XX
XX
PR 06-JUN-2001; 2001US-0296249P.

XX
XX
PR 10-SEP-2001; 2001US-0318471P.

XX
XX
PA (RIBO-) RIBOZYME PHARM INC.

XX
XX
PI Mcswiggen J;

XX
XX
DR WPI; 2003-140484/13.

XX
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.

XX
XX
PS Claim 4; Page 149; 185pp; English.

XX
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX acid molecule or an enzymatic nucleic acid molecule, that modulates
XX expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX acid molecule of the invention has cytostatic, anti-HIV, and anti-
XX rheumatic activity. The nucleic acid molecules are useful for reducing
XX HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
XX also useful for treating breast, ovarian, colorectal, lung, prostate,
XX bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
XX shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
XX ABZ66530 - ABZ66585 represent substrate/target sequences for the human
XX ribozymes of the invention

XX
XX
SQ Sequence 17 BP; 1 A; 9 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.2e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;


```

QY      263 CTGCACCTGCCTTCAG 278
Db      1 CUCUCCUGCCUUCAG 16

RESULT 1036
ID      ABZ61885 standard; RNA; 17 BP.
XX
AC      ABZ61885;
XX
DT      21-MAR-2003 (first entry)
XX
DE      Human H-Ras DNazyme target #676.
XX
KW      Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW      enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW      anti-rheumatic; cancer; AIDS; ss.
XX
OS      Homo sapiens.
XX
PN      WO200297114-A2.
XX
PD      05-DEC-2002.
XX
PF      29-MAY-2002; 2002WO-US016840.
XX
PR      29-MAY-2001; 2001US-0294140P.
PR      06-JUN-2001; 2001US-0296249P.
PR      10-SEP-2001; 2001US-0318471P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
XX
PI      Mcswiggen J;
XX
DR      WPI; 2003-140484/13.
XX
PT      Novel short interfering RNA and enzymatic nucleic acid useful for
PT      treating cancer, modulates the expression of a nucleic acid encoding
PT      HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS      Claim 58; Page 124; 185pp; English.
XX
CC      The invention relates to a novel short interfering RNA (siRNA) nucleic
CC      acid molecule or an enzymatic nucleic acid molecule, that modulates
CC      expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC      human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC      acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC      rheumatic activity. The nucleic acid molecules are useful for reducing
CC      HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC      also useful for treating breast, ovarian, colorectal, lung, prostate,
CC      bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC      shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC      ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC      ribozymes of the invention
XX
SQ      Sequence 17 BP; 2 A; 8 C; 3 G; 0 T; 4 U; 0 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      571 TGTGAAGCCAGGTG 586
Db      17 TGTGAAGCCAGGAG 2

RESULT 1037
ID      ABZ61923/c
XX
AC      ABZ61923 standard; RNA; 17 BP.
XX
XX      ABZ61923;
XX

QY      263 CTGCACCTGCCTTCAG 278
Db      1 CUCUCCUGCCUUCAG 16

RESULT 1036
ID      ABZ61885 standard; RNA; 17 BP.
XX
AC      ABZ61885;
XX
DT      21-MAR-2003 (first entry)
XX
DE      Human H-Ras DNazyme target #676.
XX
KW      Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW      enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW      anti-rheumatic; cancer; AIDS; ss.
XX
OS      Homo sapiens.
XX
PN      WO200297114-A2.
XX
PD      05-DEC-2002.
XX
PF      29-MAY-2002; 2002WO-US016840.
XX
PR      29-MAY-2001; 2001US-0294140P.
PR      06-JUN-2001; 2001US-0296249P.
PR      10-SEP-2001; 2001US-0318471P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
XX
PI      Mcswiggen J;
XX
DR      WPI; 2003-140484/13.
XX
PT      Novel short interfering RNA and enzymatic nucleic acid useful for
PT      treating cancer, modulates the expression of a nucleic acid encoding
PT      HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS      Claim 58; Page 124; 185pp; English.
XX
CC      The invention relates to a novel short interfering RNA (siRNA) nucleic
CC      acid molecule or an enzymatic nucleic acid molecule, that modulates
CC      expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC      human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC      acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC      rheumatic activity. The nucleic acid molecules are useful for reducing
CC      HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC      also useful for treating breast, ovarian, colorectal, lung, prostate,
CC      bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC      shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC      ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC      ribozymes of the invention
XX
SQ      Sequence 17 BP; 2 A; 8 C; 3 G; 0 T; 4 U; 0 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      571 TGTGAAGCCAGGTG 586
Db      17 TGTGAAGCCAGGAG 2

RESULT 1037
ID      ABZ61923/c
XX
AC      ABZ61923 standard; RNA; 17 BP.
XX
XX      ABZ61923;
XX

QY      263 CTGCACCTGCCTTCAG 278
Db      1 CUCUCCUGCCUUCAG 16

RESULT 1036
ID      ABZ61885 standard; RNA; 17 BP.
XX
AC      ABZ61885;
XX
DT      21-MAR-2003 (first entry)
XX
DE      Human H-Ras DNazyme target #676.
XX
KW      Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW      enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW      anti-rheumatic; cancer; AIDS; ss.
XX
OS      Homo sapiens.
XX
PN      WO200297114-A2.
XX
PD      05-DEC-2002.
XX
PF      29-MAY-2002; 2002WO-US016840.
XX
PR      29-MAY-2001; 2001US-0294140P.
PR      06-JUN-2001; 2001US-0296249P.
PR      10-SEP-2001; 2001US-0318471P.
XX
PA      (RIBO-) RIBOZYME PHARM INC.
XX
PI      Mcswiggen J;
XX
DR      WPI; 2003-140484/13.
XX
PT      Novel short interfering RNA and enzymatic nucleic acid useful for
PT      treating cancer, modulates the expression of a nucleic acid encoding
PT      HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS      Claim 58; Page 124; 185pp; English.
XX
CC      The invention relates to a novel short interfering RNA (siRNA) nucleic
CC      acid molecule or an enzymatic nucleic acid molecule, that modulates
CC      expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC      human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC      acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC      rheumatic activity. The nucleic acid molecules are useful for reducing
CC      HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC      also useful for treating breast, ovarian, colorectal, lung, prostate,
CC      bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC      shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC      ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC      ribozymes of the invention
XX
SQ      Sequence 17 BP; 1 A; 5 C; 7 G; 0 T; 4 U; 0 Other;

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      740 CAGGTGGACGAGTGC 755
Db      17 CAGACGACGAGTGC 2

RESULT 1038
ABZ64678
ID      ABZ64678 standard; RNA; 17 BP.
XX
AC      ABZ64678;
XX
DT      21-MAR-2003 (first entry)
XX
DE      Human HER2 DNazyme substrate #135.
XX
KW      Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW      enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW      anti-rheumatic; cancer; AIDS; ss.
XX
OS      Homo sapiens.
XX
PN      WO200297114-A2.

```

```

XX 05-DEC-2002.
XX 29-MAY-2002; 2002WO-US016840.
XX 29-MAY-2001; 2001US-0294140P.
XX 06-JUN-2001; 2001US-0296249P.
XX 10-SEP-2001; 2001US-0318471P.
XX (RIBO-) RIBOZYME PHARM INC.
XX Mcswiggen J;
XX WPI; 2003-140484/13.
XX Novel short interfering RNA and enzymatic nucleic acid useful for
XX treating cancer, modulates the expression of a nucleic acid encoding
XX HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX Claim 4; Page 135; 185pp; English.
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
XX acid molecule or an enzymatic nucleic acid molecule, that modulates
XX expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX acid molecule of the invention has cytostatic, anti-HIV, and anti-
XX rheumatic activity. The nucleic acid molecules are useful for reducing
XX HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
XX also useful for treating breast, ovarian, colorectal, lung, prostate,
XX bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
XX shown in ABZ59899 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
XX ABZ66530 - ABZ66585 represent substrate/target sequences for the human
XX ribozymes of the invention
XX Sequence 17 BP; 2 A; 5 C; 7 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 75.0%; Pred. No. 7.2e+02;
XX Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 512 CTGCGGGAGGTGGAGC 527
XX |:|||||:|
XX 1 CUGCGGGAGCGCAGC 16
XX
XX RESULT 1039
XX ACDS1596/C
XX ID ACDS1596 standard; RNA; 17 BP.
XX AC ACDS1596;
XX
XX DT 24-SEP-2003 (first entry)
XX
XX DE HBV hammerhead ribozyme substrate sequence #654.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;
XX enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX HBV reverse transcriptase; Enhancer I region; viral replication;
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX virucide; antiinflammatory; substrate; ss.
XX
XX OS Hepatitis B virus.
XX
XX PN WO200281494-A1.
XX
XX PD 17-OCT-2002.
XX
XX PF 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.

```

```

PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MACE/) MACEJAK D.
XX (MCSW/) MCSWIGGEN J.
XX (MORR/) MORRISSEY D.
XX (PAVC/) PAVCO P.
XX (LEER/) LEE P.
XX (DRAP/) DRAPER K.
XX (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX Draper K, Roberts E;
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
XX hepatocellular carcinoma, or condition associated with hepatitis C virus
XX infection.
XX Example 1; Page 148; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
XX Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
XX and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,
XX inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
XX are nucleic acid decoy molecules and aptamers that bind to HBV reverse
XX transcriptase and/or HBV reverse transcriptase primer sequences, as well
XX as oligonucleotides that specifically bind the Enhancer I region of HBV
XX DNA. The nucleic acids may be used to modulate the expression of HBV
XX genes and HBV viral replication. Also disclosed is a method for screening
XX compounds and/or potential therapies directed against HBV and compounds
XX that modulate the expression and/or replication of HCV. The compounds and
XX methods of the invention are useful for the treatment of degenerative and
XX disease states related to HBV and HCV infection, replication and gene
XX expression such as cirrhosis, liver failure, and hepatocellular
XX carcinoma. The present sequence represents a substrate for one of the HBV
XX ribozyme, inozyme, G-cleaver, zinzyme, DNzyme or amberzyme sequences
XX disclosed in the present invention
XX
XX SQ Sequence 17 BP; 0 A; 11 C; 1 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 406 GAGGAGGAGGAGGAG 421
XX |||||
XX 16 GAGGAGGAGGAGGAG 1
XX
XX RESULT 1040
XX ACDS64419/C
XX ID ACDS64419 standard; RNA; 17 BP.
XX
XX AC ACDS64419;
XX
XX DT 30-SEP-2003 (first entry)
XX
XX DE HCV minus strand DNzyme substrate sequence #1554.
XX
XX KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;
XX enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX HBV reverse transcriptase; Enhancer I region; viral replication;
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX

```

KW virucide; antiinflammatory; substrate; ss.
 XX Hepatitis C virus.
 OS WO200281494-A1.
 XX 17-OCT-2002.
 XX 26-MAR-2002; 2002WO-US009187.
 XX 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 PI WPI; 2003-229207/22.
 XX Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX Claim 1; Page 302; 387pp; English.
 XX The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 829 GGCCAGTTCAGGTG 844
 DB 16 GGCGAGTTCAGGTG 1
 RESULT 1041
 ACD63931
 ID ACD63931 standard; RNA; 17 BP.
 XX
 AC ACD63931;
 XX

DT 30-SEP-2003 (first entry)
 XX HCV minus strand DNazyme substrate sequence #1290.
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 XX RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; HCV infection; cirrhosis;
 KW degenerative; disease state; HBV infection; liver failure; hepatocellular
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX Hepatitis C virus.
 OS WO200281494-A1.
 XX 17-OCT-2002.
 XX 26-MAR-2002; 2002WO-US009187.
 XX 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 PI WPI; 2003-229207/22.
 XX Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX Claim 1; Page 298; 387pp; English.
 XX The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
 SQ Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 QY 829 GGCCAGTTCAGGTG 844
 DB 16 GGCGAGTTCAGGTG 1
 RESULT 1041
 ACD63931
 ID ACD63931 standard; RNA; 17 BP.
 XX
 AC ACD63931;
 XX

QY 735 GCGTGCAGGTGGACCA 750
|||:| |||:| |||
Db 1 GCGUGUAGGUGGGCCA 16

RESULT 1042
ACD53095/C
ID ACD53095 standard; RNA; 17 BP.
XX
AC ACD53095;
XX
DT 24-SEP-2003 (first entry)
XX
DE HBV inozyme substrate sequence #715.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis B virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Example 1; Page 164; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene

CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNzyme or amberzyme sequences
CC disclosed in the present invention
XX
XX Sequence 17 BP; 0 A; 10 C; 2 G; 0 T; 5 U; 0 Other;
QY Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 406 GAGGAGGAGAGAGGAG 421
||||| ||||| |||||
Db 17 GAGGCAGGAGGAGGAG 2

RESULT 1043
ACD59033
ID ACD59033 standard; RNA; 17 BP.
XX
AC ACD59033;
XX
DT 24-SEP-2003 (first entry)
XX
DE HCV DNzyme substrate sequence #1115.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Claim 1; Page 254; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene

CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 2 G; 0 T; 5 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 56.2%; Pred. No. 7.2e+02;
 Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
 QY 383 CTTCTGCAATTCACAG 398
 Db 1 CUUCUGCCAUUCCAG 16
 RESULT 1044
 ACDS7181/C
 ID ACDS7181 standard; RNA; 17 BP.
 XX AC ACDS7181;
 XX
 DT 23-SEP-2003 (first entry)
 XX
 DE HCV DNazyme substrate sequence #215.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; zinzyme;
 KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 XX 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (NACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX

DR WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 XX Claim 1; Page 237; 387pp; English.
 PS
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 181 TGAGATGGTGACGCC 196
 Db 17 TGACATGGTACGCC 2
 RESULT 1045
 ACC66800/C
 ID ACC66800 standard; DNA; 17 BP.
 XX AC ACC66800;
 XX
 DT 01-JUL-2003 (first entry)
 XX
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 4047.
 XX
 KW Cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; murine;
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; ss.
 XX
 OS Mus musculus.
 XX
 PN WO2003025176-A2.
 XX
 PD 27-MAR-2003.
 XX
 XX 17-SEP-2002; 2002WO-IB004210.
 PF
 XX 17-SEP-2001; 2001FR-00011979.
 PR
 XX (MOLE-) MOLECULAR ENGINES LAB.
 PA
 XX Telerman A, Anson R, Tuijnder M;
 PI WPI; 2003-333167/31.
 DR
 XX New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX

Matches	14;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	874	CAACCATCATCAGAGC	889						
Db	16	CACCCATCATCAGATC	1						
RESULT 1048									
ADB43479/C									
ID	ADB43479	standard; DNA; 17 BP.							
XX	AC	ADB43479;							
XX	AC	ADB43479;							
XX	DT	18-DEC-2003 (revised)							
XX	DT	04-DEC-2003 (first entry)							
XX	DE	Tumour suppression/reversion associated nucleotide #3802.							
XX	KW	cytostatic; antiviral; neuroprotective; nontropic; neuroleptic; ss;							
XX	KW	primer; probe; tumour suppression; tumour reversion; apoptosis;							
XX	KW	virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;							
XX	KW	diagnosis.							
XX	OS	Homo sapiens.							
XX	OS	WO2003040369-A2.							
XX	PN	15-MAY-2003.							
XX	PD	17-SEP-2002; 2002WO-IB004219.							
XX	PF	17-SEP-2001; 2001FR-00011981.							
XX	PR	17-SEP-2001; 2001FR-00011981.							
XX	PR	(MOLE-) MOLECULAR ENGINES LAB.							
XX	PA	Telerman A, Amson R, Tuijnder M;							
XX	PI	WPI; 2003-441574/41.							
XX	DR	New nucleic acid encoding human prostate membrane-specific antigen,							
XX	XX	useful e.g. for treatment of tumors and viral infection, also related							
XX	PT	polypeptide and antibodies.							
XX	PT	Disclosure; Page 476; 771pp; French.							
XX	PS	The invention relates to the isolation of 6327 nucleotide sequences,							
XX	CC	fragments of at least 15 consecutive nucleotides of these nucleotides, a							
XX	CC	sequence having at least 80% identity, after optimal alignment, with the							
XX	CC	nucleotides, a sequence that hybridizes under stringent conditions with							
XX	CC	the nucleotides, or the complement, or corresponding RNA, of the							
XX	CC	nucleotides. The nucleotides are used as probes or primers for detecting,							
XX	CC	identifying, quantifying and/or amplifying nucleic acids, as in vitro							
XX	CC	sense and antisense sequences, of nucleotides involved in tumour							
XX	CC	suppression or reversion, apoptosis and or viral resistance, to produce							
XX	CC	recombinant polypeptides, and to prepare transgenic animals, as							
XX	CC	experimental models. The nucleotides (also vectors containing them and							
XX	CC	cells containing the vectors), the encoded polypeptides and antibodies							
XX	CC	(Ab) against the polypeptide are useful for prevention and/or treatment							
XX	CC	of viral infections or diseases characterized by development of tumours							
XX	CC	or cell degeneration (e.g. Alzheimer's disease or schizophrenia).							
XX	CC	Analysis of the expression of the nucleotides can be used for diagnosis							
XX	CC	and/or prognosis of these diseases. The nucleotides and polypeptides can							
XX	CC	also be used to screen for their specific interactive molecules,							
XX	CC	potentially useful for treating diseases associated with abnormal							
XX	CC	expression of the nucleotides.							
XX	SQ	Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;							
Query Match		1.7%; Score 12.8; DB 1; Length 17;							
Best Local Similarity		87.5%; Pred. No. 7.2e+02;							
Matches	14;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	203	GGCCCGGCAGATC	218						

Db	16	GGCTGGCAGATC	1						
RESULT 1049									
ADB42794/C									
ID	ADB42794	standard; DNA; 17 BP.							
XX	AC	ADB42794;							
XX	AC	ADB42794;							
XX	DT	18-DEC-2003 (revised)							
XX	DT	04-DEC-2003 (first entry)							
XX	DE	Tumour suppression/reversion associated nucleotide #3117.							
XX	KW	cytostatic; antiviral; neuroprotective; nontropic; neuroleptic; ss;							
XX	KW	primer; probe; tumour suppression; tumour reversion; apoptosis;							
XX	KW	virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;							
XX	KW	diagnosis.							
XX	OS	Homo sapiens.							
XX	OS	WO2003040369-A2.							
XX	PN	15-MAY-2003.							
XX	PD	17-SEP-2002; 2002WO-IB004219.							
XX	PF	17-SEP-2001; 2001FR-00011981.							
XX	PR	17-SEP-2001; 2001FR-00011981.							
XX	PR	(MOLE-) MOLECULAR ENGINES LAB.							
XX	PA	Telerman A, Amson R, Tuijnder M;							
XX	PI	WPI; 2003-441574/41.							
XX	DR	New nucleic acid encoding human prostate membrane-specific antigen,							
XX	XX	useful e.g. for treatment of tumors and viral infection, also related							
XX	PT	polypeptide and antibodies.							
XX	PT	Disclosure; Page 396; 771pp; French.							
XX	PS	The invention relates to the isolation of 6327 nucleotide sequences,							
XX	CC	fragments of at least 15 consecutive nucleotides of these nucleotides, a							
XX	CC	sequence having at least 80% identity, after optimal alignment, with the							
XX	CC	nucleotides, a sequence that hybridizes under stringent conditions with							
XX	CC	the nucleotides, or the complement, or corresponding RNA, of the							
XX	CC	nucleotides. The nucleotides are used as probes or primers for detecting,							
XX	CC	identifying, quantifying and/or amplifying nucleic acids, as in vitro							
XX	CC	sense and antisense sequences, of nucleotides involved in tumour							
XX	CC	suppression or reversion, apoptosis and or viral resistance, to produce							
XX	CC	recombinant polypeptides, and to prepare transgenic animals, as							
XX	CC	experimental models. The nucleotides (also vectors containing them and							
XX	CC	cells containing the vectors), the encoded polypeptides and antibodies							
XX	CC	(Ab) against the polypeptide are useful for prevention and/or treatment							
XX	CC	of viral infections or diseases characterized by development of tumours							
XX	CC	or cell degeneration (e.g. Alzheimer's disease or schizophrenia).							
XX	CC	Analysis of the expression of the nucleotides can be used for diagnosis							
XX	CC	and/or prognosis of these diseases. The nucleotides and polypeptides can							
XX	CC	also be used to screen for their specific interactive molecules,							
XX	CC	potentially useful for treating diseases associated with abnormal							
XX	CC	expression of the nucleotides.							
XX	SQ	Sequence 17 BP; 1 A; 6 C; 3 G; 7 T; 0 U; 0 Other;							
Query Match		1.7%; Score 12.8; DB 1; Length 17;							
Best Local Similarity		87.5%; Pred. No. 7.2e+02;							
Matches	14;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	345	GGCAGGCAACAGAT	360						
Db	17	GGAAGAGCAACAGAT	2						


```
PF 25-JAN-2002; 2002EP-00001160.
XX
PR 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX
PA (AEOM-) AEOMICA INC.
XX
XX Gu Y;
XX
XX WPI; 2003-302724/30.
XX
XX New human sodium-hydrogen exchanger like protein 1 (NHEP1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHEP1.
XX
XX Example 2; SEQ ID NO 1476; 468pp; English.
XX
XX The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHEP1). The NHEP1 nucleic acid molecule, NHEP1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHEP1 nucleic acid molecule, NHEP1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHEP1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHEP1. The NHEP1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHEP1 gene (ADC03514).
XX
XX Sequence 17 BP; 3 A; 8 C; 2 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 884 AAGAGCAGCGTGTGG 899
DB 17 AGGAGCAGCGTAGTGG 2
RESULT 1053
ADC03750
ID ADC03750 standard; DNA; 17 BP.
XX
AC ADC03750;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human Na/H exchanger-like protein 1 gene oligonucleotide #197.
DE
XX
XX ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
XX NHEP1; passive replacement therapy; vaccine; diagnosis.
XX
XX Homo sapiens.
XX
XX EP1273660-A2.
XX
XX 08-JAN-2003.
XX
XX 25-JAN-2002; 2002EP-00001160.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX 23-MAY-2001; 2001US-00864761.
XX 21-DEC-2001; 2001US-0343331P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y;
XX
XX The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHEP1). The NHEP1 nucleic acid molecule, NHEP1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHEP1 nucleic acid molecule, NHEP1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHEP1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHEP1. The NHEP1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHEP1 gene (ADC03514).
XX
XX Sequence 17 BP; 3 A; 8 C; 2 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 884 AAGAGCAGCGTGTGG 899
DB 17 AGGAGCAGCGTAGTGG 2
RESULT 1054
ADB44625/C
ID ADB44625 standard; DNA; 17 BP.
XX
AC ADB44625;
XX
XX 18-DEC-2003 (first entry)
XX
XX Tumour suppression/reversion associated nucleotide #4948.
XX
XX cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
XX primer; probe; tumour suppression; tumour reversion; apoptosis;
XX virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
XX diagnosis.
XX
XX Homo sapiens.
XX
XX WO2003040369-A2.
XX
XX 15-MAY-2003.
XX
XX 17-SEP-2002; 2002WO-IB004219.
XX
XX 17-SEP-2001; 2001FR-00011981.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-441574/41.
XX
XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
XX Disclosure; Page 610; 771pp; French.
XX
XX The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
```

CC sequence having at least 80% identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as
 CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 537 GATGCCAGCAGCAGAT 552
 Db 17 GCTGCCAGCAGCAGAT 2

RESULT 1055
 ADC35279/c
 ID ADC35279 standard; DNA; 17 BP.
 XX
 AC ADC35279;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE MaSpII silk protein PCR primer SEQ ID 40.
 XX
 KW Silk; biofilament; spider; lepidopteran insect; ADF-3; ss; MaSpII; PCR;
 KW primer.
 XX
 OS Unidentified.
 XX
 PN WO2003057727-A1.
 XX
 PD 17-JUL-2003.
 XX
 PF 13-JAN-2003; 2003WO-IB000346.
 XX
 PR 11-JAN-2002; 2002US-0347509P.
 XX
 PA (NEXI-) NEXIA BIOTECHNOLOGIES INC.
 XX
 PI Karatzas CN, Turcotte C;
 XX
 DR WPI; 2003-721511/68.
 XX

PT New silk polypeptide for producing biofilaments having useful properties
 PT similar to those of natural spider or lepidopteran insect silks, e.g.
 PT strength, comprises repetitive units and a non-repetitive hydrophilic
 PT amino acid domain.
 XX
 XX Example 1; Page 38; 77pp; English.

XX The present invention relates to novel silk polypeptides (ADC35240-
 CC ADC35242). The polypeptides are useful in producing biofilaments having
 CC useful properties similar or superior to those of natural spider and
 CC lepidopteran insect silks, such as strength and elasticity. The present
 CC sequence is a PCR primer, which was used in an example from the
 CC invention.
 XX

SQ Sequence 17 BP; 0 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 718 GCTGCAGCAGCAGCAC 733
 Db 16 GCCGCAGCAGCAGCCCC 1

RESULT 1056
 ADF62166
 ID ADF62166 standard; DNA; 17 BP.
 XX
 AC ADF62166;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 70.
 XX
 KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.
 XX
 OS Homo sapiens.
 XX
 PN WO2003050284-A1.
 XX
 PD 19-JUN-2003.
 XX
 PF 22-NOV-2002; 2002WO-US037506.
 XX
 PR 10-DEC-2001; 2001US-0339764P.
 XX
 PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 XX
 PI Guo J;
 XX
 DR WPI; 2003-532916/50.
 XX

PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.
 XX
 XX Example 2; SEQ ID NO 70; 164pp; English.

CC The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the Wipoweb
 CC database.
 XX

SQ Sequence 17 BP; 4 A; 5 C; 7 G; 1 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 677 GCCAGCAGCAGCAGCGC 692
 Db 2 GCCAGCAGCAGCAGCGC 17

RESULT 1057
 ADF64207
 ID ADF64207 standard; DNA; 17 BP.


```

RESULT 1062
ADF62168
ID ADF62168 standard; DNA; 17 BP.
XX
AC ADF62168;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 72.
XX
KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
OS Homo sapiens.
XX
PN WO2003050284-A1.
XX
PD 19-JUN-2003.
XX
PF 22-NOV-2002; 2002WO-US037506.
XX
PR 10-DEC-2001; 2001US-0339764P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Guo J;
XX
WPI; 2003-532916/50.
XX
New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
composition for treating or preventing a disorder associated with
decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
Example 2; SEQ ID NO 72; 164pp; English.
XX
The invention relates to a novel isolated nucleic acid that encodes a
protein with a chromatin organisation modifier (CHROMO) domain. The
polynucleotide of the invention demonstrates cytostatic activity and may
be useful for preparing a composition for treating or preventing a
disorder associated with decreased or increased expression or activity of
PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
during gene therapy and vaccine production procedures. The current
sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
directed probe of the invention. Note: The current sequence is not shown
within the specification per se but was retrieved from the WipoWeb
database.
XX
SQ Sequence 17 BP; 4 A; 6 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 678 CCAGCGAGCAGCGCG 693
DB 1 CGAGCGAGCAGCGCG 16
|||||
1 CGAGCGAGCAGCGCG 16

RESULT 1063
ADF64210
ID ADF64210 standard; DNA; 17 BP.
XX
AC ADF64210;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2114.
XX
KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX

OS Homo sapiens.
XX
PN WO2003050284-A1.
XX
PD 19-JUN-2003.
XX
PF 22-NOV-2002; 2002WO-US037506.
XX
PR 10-DEC-2001; 2001US-0339764P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Guo J;
XX
WPI; 2003-532916/50.
XX
New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
composition for treating or preventing a disorder associated with
decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
Example 2; SEQ ID NO 72; 164pp; English.
XX
The invention relates to a novel isolated nucleic acid that encodes a
protein with a chromatin organisation modifier (CHROMO) domain. The
polynucleotide of the invention demonstrates cytostatic activity and may
be useful for preparing a composition for treating or preventing a
disorder associated with decreased or increased expression or activity of
PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
during gene therapy and vaccine production procedures. The current
sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
directed probe of the invention. Note: The current sequence is not shown
within the specification per se but was retrieved from the WipoWeb
database.
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 415 GAAGGAGTTCCTCATG 430
DB 1 GAAGGAATGCTCATG 16
|||||
1 GAAGGAATGCTCATG 16

RESULT 1064
ADF87667
ID ADF87667 standard; DNA; 17 BP.
XX
AC ADF87667;
XX
DT 26-FEB-2004 (first entry)
XX
DE Single nucleotide polymorphism detection primer, SEQ ID No 1250.
XX
KW human; single nucleotide polymorphism; microarray; side effect; ss;
KW primer; PCR.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN JP2003235571-A.
XX
PD 26-AUG-2003.
XX
PF 12-FEB-2002; 2002JP-00034717.
XX
PR 12-FEB-2002; 2002JP-00034717.
XX
PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
WPI; 2003-820454/77.
XX

```

PT Novel polynucleotide useful for detecting single nucleotide polymorphisms
PT in human gene.
PS Claim 2; SEQ ID NO 1250; 704pp; Japanese.
XX
CC The invention relates to a novel polynucleotide isolated and purified
CC from a human gene having any one of 935 fully defined sequences as given
CC in specification, or a sequence having a base substitution. The invention
CC further relates to: an oligonucleotide containing single nucleotide
CC polymorphisms; a PCR primer set chosen from the combination of two DNA
CC fragments from any one of 1220 fully defined sequences as given in
CC specification; a labelling probe containing the SNP containing oligo; and
CC a microarray equipped with the SNP containing oligo. The isolated human
CC gene of the invention is useful for detecting the single nucleotide
CC polymorphisms in human gene. The isolated human gene is also useful for
CC diagnosis of disease and determination of side effect to a medical agent.
CC The isolated human gene is also effective in detecting single nucleotide
CC polymorphisms in a human gene. This polynucleotide sequence represents
CC one of the PCR primers used in the single nucleotide polymorphism
CC detection method of the invention.
XX
SQ Sequence 17 BP; 3 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 517 GGAGTGGAGCCTG 532
DB 2 GGAGTGGAGCCTG 17
|||||

RESULT 1065
ADI49767/C
ID ADI49767 standard; DNA; 17 BP.
XX AC ADI49767;
XX
DT 15-APR-2004 (first entry)
XX
DE Human tumour suppression/reversion-related DNA sequence SeqID2270.
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
PN WO2003025177-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004523.
XX
PR 17-SEP-2001; 2001FR-00011980.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313354/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; SEQ ID NO 2270; 30pp; French.
XX
CC This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC probes and primers for detecting, indentifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration. The
CC specifically cancer but also Alzheimer's disease and schizophrenia. The

CC nontropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, indentifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration. The
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 473 CTGGAGAAGCTCGATC 488
DB 16 CTGGAGAAGCTAGATC 1
|||||

RESULT 1066
ADI51254
ID ADI51254 standard; DNA; 17 BP.
XX AC ADI51254;
XX
DT 15-APR-2004 (first entry)
XX
DE Human tumour suppression/reversion-related DNA sequence SeqID3757.
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
PN WO2003025177-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004523.
XX
PR 17-SEP-2001; 2001FR-00011980.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313354/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; SEQ ID NO 3757; 30pp; French.
XX
CC This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC probes and primers for detecting, indentifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration. The
CC specifically cancer but also Alzheimer's disease and schizophrenia. The

KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
 KW tumour regression; apoptosis; virus resistance; diagnosis;
 KW cellular degeneration.
 XX
 OS Homo sapiens.
 XX
 PN FR2826373-A1.
 XX
 PD 27-DEC-2002.
 XX
 PF 20-JUN-2001; 2001FR-00008139.
 XX
 PR 20-JUN-2001; 2001FR-00008139.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB SA.
 XX
 PI Tuijnder M, Telerman A, Amson R;
 XX WPI; 2003-250498/25.
 DR
 XX New nucleic acid sequences associated with tumor suppression, regression,
 PT apoptosis or virus resistance are useful to diagnose and treat viral
 PT disease, development of tumor cells and cell degeneration.
 XX
 PS Claim 1; Page 692; 798pp; French.
 XX
 CC This sequence represents an isolated nucleic acid sequence associated
 CC with tumour suppression or regression, apoptosis or virus resistance. The
 CC invention relates to these sequences or sequences having at least 80%
 CC identity to them, and polypeptides encoded by the sequences or
 CC polypeptides having 80% identity to the polypeptide sequences. The
 CC invention is used to diagnose or treat viral disease or disease
 CC characterized by development of tumour cells or cellular degeneration
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 537 GATGCCAGCAGCAGAT 552
 | | | | | | | | | | | | | | | | | | | | | |
 Db 17 GCTGCCAGAGCAGAT 2

RESULT 1070
 ADL46532/C
 ID ADL46532 standard; RNA; 17 BP.
 XX
 AC ADL46532;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human NOGO receptor hammerhead ribozyme substrate sequence #65.

antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis;
 KW NOGO receptor hammerhead ribozyme; substrate; ds.

XX Unidentified.
 OS
 XX
 XX WO200281628-A2.
 PN
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.

XX
 PR 05-APR-2001; 2001US-00827395.
 PR 23-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 9; SEQ ID NO 65; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human NOGO
 CC receptor hammerhead ribozyme substrate sequence.
 XX
 SQ Sequence 17 BP; 1 A; 8 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 CGCTCGGAGGAGAAG 820
 | | | | | | | | | | | | | | | | | | | | | |
 Db 16 CACCTCGGAGGAGAG 1

RESULT 1071
 ADL49918/C
 ID ADL49918 standard; RNA; 17 BP.
 XX
 AC ADL49918;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PKR substrate sequence #1032.

antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.

XX Unidentified.
 OS
 XX
 XX WO200281628-A2.
 PN
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.


```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 3451; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 7 C; 2 G; 0 T; 5 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 493 GAGGCGAGAGGAGCAG 508
Db |||||
17 GAGGCGAGAGGAGGAGCAG 2
RESULT 1072
ADL51337/c
ID ADL51337 standard; RNA; 17 BP.
XX
XX ADL51337;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PTGDR substrate sequence #456.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; glomerulonephritis;
KW graft rejection; ischaemia; reperfusion; transplant rejection;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
```

```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 161; SEQ ID NO 4870; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 0 A; 8 C; 4 G; 0 T; 5 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 677 GCCAGCGAGCAGCGC 692
Db |||||
16 GCCAGCGAGCAGCGC 1
RESULT 1073
ADL47063/c
ID ADL47063 standard; RNA; 17 BP.
XX
XX ADL47063;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human NOGO receptor zinzyme substrate sequence #50.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; ikappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; glomerulonephritis;
KW graft rejection; ischaemia; reperfusion; transplant rejection;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor zinzyme; substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
```

```

XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX DR WPI; 2003-058513/05.
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 9; SEQ ID NO 596; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human NOGO
XX CC receptor zymase substrate sequence.
XX SQ Sequence 17 BP; 1 A; 8 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 685 GCAGGCGGGCAGCTG 700
Db 16 GCAGGCACGGAAGCTG 1

RESULT 1074
ADL48356
ID ADL48356 standard; RNA; 17 BP.
XX AC ADL48356;
XX DT 20-MAY-2004 (first entry)
XX DE Human IKK-gamma substrate sequence #866.
XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX KW protein kinase PKR; cerebrovascular accident;
XX KW central nervous system injury; CNS injury; spinal cord injury; cancer;
XX KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX KW restenosis; asthma; Crohn's disease; diabetes; obesity;
XX KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX KW substrate; ds.
XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.

```

```

XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX DR WPI; 2003-058513/05.
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 59; SEQ ID NO 1889; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human IKK-
XX CC gamma substrate sequence.
XX SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 740 CAGGTGGACCCAGCTGC 755
Db 1 CAGCUGGAGCAGCUGC 16

RESULT 1075
ADL49919/C
ID ADL49919 standard; RNA; 17 BP.
XX AC ADL49919;
XX DT 20-MAY-2004 (first entry)
XX DE Human PKR substrate sequence #1033.
XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX KW protein kinase PKR; cerebrovascular accident;
XX KW central nervous system injury; CNS injury; spinal cord injury; cancer;
XX KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX KW restenosis; asthma; Crohn's disease; diabetes; obesity;
XX KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
XX KW substrate; ds.
XX OS Unidentified.
XX PN WO200281628-A2.
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.

```

```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 3452; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 6 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 491 AGAGGCGAGAGGAGC 506
DB 16 AGAGGCGAGAGGAGTGC 1

RESULT 1076
ADL51141/C
ID ADL51141 standard; RNA; 17 BP.
XX
XX ADL51141;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PTGDR substrate sequence #260.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 161; SEQ ID NO 4674; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC ikappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 8 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 706 TGAGCGCGAGCGCTG 721
DB 17 TGAGCGCGCTGCGCTG 2

RESULT 1077
ADL51504/C
ID ADL51504 standard; RNA; 17 BP.
XX
XX ADL51504;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PTGDR substrate sequence #623.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 161; SEQ ID NO 5037; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX
 SQ Sequence 17 BP; 3 A; 8 C; 5 G; 0 T; 1 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 705 GTGAGCGCGGCGCT 720
 Db ||||| |||||
 16 GTGAGCGCTGGCGCT 1
 RESULT 1078
 ADL46486/c
 ID ADL46486 standard; RNA; 17 BP.
 XX
 AC ADL46486;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human NOGO receptor hammerhead ribozyme substrate sequence #19.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis;
 KW NOGO receptor hammerhead ribozyme; substrate; ds.
 XX
 OS Unidentified.
 XX
 XX WO200281628-A2.
 XX
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 9; SEQ ID NO 19; 317pp; English.
 XX
 CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human NOGO
 CC receptor hammerhead ribozyme substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 604 GCTCGAGGAGGCCAG 619
 Db ||||| |||||
 16 GCTCCAGGAGGCCAG 1
 RESULT 1079
 ADL46844/c
 ID ADL46844 standard; RNA; 17 BP.
 XX
 AC ADL46844;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human NOGO receptor inozyme substrate sequence #277.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis;
 KW NOGO receptor inozyme; substrate; ds.
 XX
 OS Unidentified.
 XX
 XX WO200281628-A2.
 XX
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.

```

XX PR 05-APR-2001; 2001US-00827395.
XX PR 23-MAY-2001; 2001US-0294112P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX DR
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX PS Claim 9; SEQ ID NO 377; 317pp; English.
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX CC that down regulate the expression or inhibit the function of a receptor
XX CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX CC invention are useful for treating: cerebrovascular accident, central
XX CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX CC disease, lupus, multiple sclerosis, transplant/graft rejection,
XX CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX CC nucleic acids of the invention are also useful for down-regulating the
XX CC expression of a target gene and as a diagnostic tool to examine genetic
XX CC drifts and mutations within diseased cells or to detect the presence of a
XX CC target RNA in a cell. The present RNA sequence represents a human NOGO
XX CC receptor inozyme substrate sequence.
XX SQ Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 506 CAGGCTCTCGGGAGG 521
DB 16 CAGGCTTGGGGAGG 1

RESULT 1080
ADL48057/C
ID ADL48057 standard; RNA; 17 BP.
XX AC ADL48057;
XX AC
XX DT 20-MAY-2004 (first entry)
XX DE Human IKK-gamma substrate sequence #567.
XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX KW protein kinase PKR; cerebrovascular accident;
XX KW central nervous system injury; CNS injury; spinal cord injury; cancer;
XX KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX KW restenosis; asthma; Crohn's disease; diabetes; obesity;
XX KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX KW substrate; ds.
XX OS Unidentified.
XX OS
XX PN WO200281628-A2.
XX XX
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 190 GCAGCCCACTGGTGGC 205
DB 16 GCATCCCACTGGTGGC 1

RESULT 1081
ADL48768
ID ADL48768 standard; RNA; 17 BP.
XX AC ADL48768;
XX AC
XX DT 20-MAY-2004 (first entry)
XX DE Human IKK-gamma substrate sequence #1278.
XX KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX KW protein kinase PKR; cerebrovascular accident;
XX KW central nervous system injury; CNS injury; spinal cord injury; cancer;
XX KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX KW restenosis; asthma; Crohn's disease; diabetes; obesity;
XX KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX KW substrate; ds.
XX OS Unidentified.
XX OS
XX PN WO200281628-A2.
XX XX
XX PD 17-OCT-2002.
XX PF 03-APR-2002; 2002WO-US010512.

```

```

XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2301; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 739 GCAGGTGGACGAGCTG 754
DB 2 GCAGCUGGAGCAGCUG 17

RESULT 1082
ADL48354/c
ID ADL48354 standard; RNA; 17 BP.
XX
AC ADL48354;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #864.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; db.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.

```

```

XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1887; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 748 CCAGCTGGCGATGCAG 763
DB 16 CCAGCTGCTCCTGCAG 1

RESULT 1083
ADL48766/c
ID ADL48766 standard; RNA; 17 BP.
XX
AC ADL48766;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #1276.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; db.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.

```

```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2299; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 749 CAGCTGGCATGCAGG 764
DB 17 CAGCTGCTCTGCAGG 2

RESULT 1084
ADL47943
ID ADL47943 standard; RNA; 17 BP.
XX
XX ADL47943;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #453.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2299; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 3 A; 5 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 749 CAGCTGGCATGCAGG 764
DB 17 CAGCTGCTCTGCAGG 2

RESULT 1085
ADL48357
ID ADL48357 standard; RNA; 17 BP.
XX
XX ADL48357;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #867.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
```

```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1890; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 522 TGGAGCACCCTGAGAG 537
Db :||||| |:|||||
2 UGGAGCAGCUGCAGAG 17

RESULT 1086
ADL46662/C
ID ADL46662 standard; RNA; 17 BP.
XX
XX ADL46662;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human NOGO receptor inozyme substrate sequence #95.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor inozyme; substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 9; SEQ ID NO 195; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor inozyme substrate sequence.
XX
XX Sequence 17 BP; 1 A; 8 C; 5 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGGCCAG 619
Db :||||| |:|||||
17 GCTCCAGAGGGCCAG 2

RESULT 1087
ADL48764
ID ADL48764 standard; RNA; 17 BP.
XX
XX ADL48764;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #1274.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX

```



```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2297; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 411 AGGAGAGGAGGTTCTCT 426
DB 1 AGAAGAGGAGGCUCCU 16
||| ||||| ||| :||:
1 AGAAGAGGAGGCUCCU 16
RESULT 1088
ADL47162/C
ID ADL47162 standard; RNA; 17 BP.
XX
XX ADL47162;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human NOGO receptor zinzyme substrate sequence #149.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor zinzyme, substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

```

XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 9; SEQ ID NO 695; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor zinzyme substrate sequence.
XX
XX Sequence 17 BP; 1 A; 8 C; 5 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 800 CAGGCGCCTCGGAGG 815
DB 16 CAGGCGCCTCGGAGG 1
||| ||| ||| ||| ||| |||
16 CAGGCGCCTCGGAGG 1
RESULT 1089
ADL48783
ID ADL48783 standard; RNA; 17 BP.
XX
XX ADL48783;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human IKK-gamma substrate sequence #1293.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

```

XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 2316; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human IKK-
XX gamma substrate sequence.
XX
XX Sequence 17 BP; 6 A; 2 C; 8 G; 0 T; 1 U; 0 Other;
XX
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 812 GAGGAGAAGGAGGAGC 827
DB ||||| ||||| ||||| ||||| |||||
1 GAGGACAUGAGGAGAGC 16
XX
RESULT 1090
ADL51594
ID ADL51594 standard; RNA; 17 BP.
XX
XX ADL51594;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PTGDR substrate sequence #713.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

```

XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 161; SEQ ID NO 5127; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human PKR
XX substrate sequence.
XX
XX Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
XX
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
XX
QY 353 AACCCAGATTCGCGGG 368
DB ||||| ||||| ||||| ||||| |||||
2 AACCCGAGUCUCGCGG 17
XX
RESULT 1091
ADL51909
ID ADL51909 standard; RNA; 17 BP.
XX
XX ADL51909;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PTGDR substrate sequence #1028.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```



```

XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 161; SEQ ID NO 4521; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human PKR
XX substrate sequence.
XX
XX Sequence 17 BP; 1 A; 8 C; 4 G; 0 T; 4 U; 0 Other;
XX
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 677 GCCAGCGAGCAGCGGC 692
DB 17 GCCAGGAGGAGCGGC 2
||||| | | |
|:|||||:|:|
|:|||||:|:|
|:|||||:|:|

RESULT 1094
ADL51681
ID ADL51681 standard; RNA; 17 BP.
XX
XX ADL51681;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PTGDR substrate sequence #800.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
XX substrate; db.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

```

XX 05-APR-2001; 2001US-00827395.
XX 29-MAY-2001; 2001US-0294412P.
XX 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 161; SEQ ID NO 5214; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human PKR
XX substrate sequence.
XX
XX Sequence 17 BP; 4 A; 3 C; 7 G; 0 T; 3 U; 0 Other;
XX
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.2e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 473 CTGGAGAAGCTCGATC 488
DB 1 CUGGAGGAGCUGGAUC 16
||||| | | |
|:|||||:|:|
|:|||||:|:|
|:|||||:|:|

RESULT 1095
ADM09540/C
ID ADM09540 standard; RNA; 17 BP.
XX
XX ADM09540;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human NOGO receptor amberzyme substrate sequence #95.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis;
XX NOGO receptor amberzyme; substrate; ss.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.

```

```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 9; SEQ ID NO 935; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor amberzyme substrate sequence.
XX
XX Sequence 17 BP; 1 A; 9 C; 4 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 802 GGCGGCTCGGAGGAG 817
DB 17 GGGCACCTCGGAGGAG 2
RESULT 1096
ADL46479/C
ID ADL46479 standard; RNA; 17 BP.
XX
XX ADL46479;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Human NOGO receptor hammerhead ribozyme substrate sequence #12.
DE
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor hammerhead ribozyme; substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
```

```
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 9; SEQ ID NO 12; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor hammerhead ribozyme substrate sequence.
XX
XX Sequence 17 BP; 1 A; 7 C; 5 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 686 CAGGCGCGCAGCTGG 701
DB 17 CAGGCGCGGAGCTGG 2
RESULT 1097
ADL48516/C
ID ADL48516 standard; RNA; 17 BP.
XX
XX ADL48516;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Human IKK-gamma substrate sequence #1026.
DE
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW substrate; ds.
XX
XX Unidentified.
OS
XX
XX WO200281628-A2.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 03-APR-2002; 2002WO-US010512.
PF
```

XX 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
 PR WPI; 2003-058513/05.
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX Claim 59; SEQ ID NO 2049; 317pp; English.
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/perfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 191 CAGCCAGTGTGGCC 206
 || ||||| |||||
 DB 17 CATCCAGTTGTGGCC 2
 RESULT 1098
 ADM53997
 ID ADM53997 standard; mRNA; 17 BP.
 XX AC ADM53997;
 XX 03-JUN-2004 (first entry)
 XX Human GRID mRNA substrate sequence #272.
 XX Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
 KW NCH ribozyme; G-cleaver ribozyme; Zinzyne; DNazyme; amberzyme; Inozyme;
 KW hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
 XX Homo sapiens.
 XX US2003134806-A1.
 XX 17-JUL-2003.
 XX 23-FEB-2001; 2001US-00792818.
 XX 10-FEB-2000; 2000US-0181594P.
 XX (JARV/) JARVIS T.
 PA (CARL/) CARLOWITZ I V.
 PA (MCSW/) MCSWIGGEN J.
 PA (HAMB/) HAMBLIN P A.
 PA (ELLI/) ELLIS J H.

PA (ELLI/) ELLIS J H.
 XX Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;
 XX WPI; 2003-829646/77.
 XX New nucleic acid molecule that down-regulates expression of Grb2-related
 PT with insert domain (GRID) gene, useful for treating a condition
 PT associated with the level of GRID, e.g. tissue/graft rejection and
 PT leukemia.
 XX Claim 4; SEQ ID NO 272; 74pp; English.
 XX The invention relates to a nucleic acid molecule that down-regulates
 CC expression of Grb2-related with insert domain (GRID) gene, e.g. a
 CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyne, DNazyme,
 CC amberzyme, Inozyme or hairpin ribozyme. Also include are a mammalian cell
 CC including the novel nucleic acid molecule, reducing GRID activity in a
 CC cell by contacting the cell with the novel nucleic acid molecule,
 CC treating a patient having a condition associated with the level of GRID
 CC (e.g. tissue/graft rejection or leukaemia) by contacting the cell with
 CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by
 CC contacting the cell with the novel nucleic acid molecule, an expression
 CC vector comprising a nucleic acid sequences (encoding at least the novel
 CC nucleic acid molecule in a manner that allows its expression), a
 CC mammalian cell including the expression vector and an enzymatic nucleic
 CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid
 CC molecule is useful for treating a condition associated with the level of
 CC GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is
 CC a target region for the enzymatic nucleic acids of the invention.
 XX SQ Sequence 17 BP; 3 A; 7 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 7.2e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 393 TCCAAGCCAGCCAGAG 408
 :|| ||||| |||||
 DB 1 UCCGGGCCAGCCAGAG 16
 RESULT 1099
 ADM53996
 ID ADM53996 standard; mRNA; 17 BP.
 XX AC ADM53996;
 XX 03-JUN-2004 (first entry)
 XX Human GRID mRNA substrate sequence #271.
 XX Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
 KW NCH ribozyme; G-cleaver ribozyme; Zinzyne; DNazyme; amberzyme; Inozyme;
 KW hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
 XX Homo sapiens.
 XX US2003134806-A1.
 XX 17-JUL-2003.
 XX 23-FEB-2001; 2001US-00792818.
 XX 10-FEB-2000; 2000US-0181594P.
 XX (JARV/) JARVIS T.
 PA (CARL/) CARLOWITZ I V.
 PA (MCSW/) MCSWIGGEN J.
 PA (HAMB/) HAMBLIN P A.
 PA (ELLI/) ELLIS J H.
 XX Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;

XX	WPI; 2003-829646/77.
XX	New nucleic acid molecule that down-regulates expression of Grb2-related
XX	with insert domain (GRID) gene, useful for treating a condition
PT	associated with the level of GRID, e.g. tissue/graft rejection and
PT	leukemia.
PT	
XX	Claim 4; SEQ ID NO 271; 74pp; English.
XX	The invention relates to a nucleic acid molecule that down-regulates
CC	expression of Grb2-related with insert domain (GRID) gene, e.g. a
CC	hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNazyme,
CC	amberzyme, inozyme or hairpin ribozyme. Also include are a mammalian cell
CC	including the novel nucleic acid molecule, reducing GRID activity in a
CC	cell by contacting the cell with the novel nucleic acid molecule,
CC	treating a patient having a condition associated with the level of GRID
CC	(e.g. tissue/graft rejection or leukaemia) by contacting the cell with
CC	the novel nucleic acid molecule, cleaving RNA of a GRID gene by
CC	contacting the cell with the novel nucleic acid molecule, an expression
CC	vector comprising a nucleic acid sequences (encoding at least the novel
CC	nucleic acid molecule in a manner that allows its expression), a
CC	mammalian cell including the expression vector and an enzymatic nucleic
CC	acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid
CC	molecule is useful for treating a condition associated with the level of
CC	GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is
CC	a target region for the enzymatic nucleic acids of the invention.
XX	
XX	Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
SQ	
	Query Match 1.7%; Score 12.8; DB 1; Length 17;
	Best Local Similarity 81.2%; Pred. No. 7.2e+02;
	Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY	393 TCCAAGCGCACCACGAG 408
Dd	:
	2 UCCGGGCACGCCAGAG 17
RESULT 1100	
ADM54086	
ID	ADM54086 standard; mRNA; 17 BP.
XX	ADM54086;
XX	03-JUN-2004 (first entry)
DT	
XX	Human GRID mRNA substrate sequence #361.
DE	
XX	Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
KW	NCH ribozyme; G-cleaver ribozyme; Zinzyme; DNazyme; amberzyme; Inozyme;
KW	hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
XX	Homo sapiens.
OS	
XX	US2003134806-A1.
PN	
XX	17-JUL-2003.
PD	
XX	23-FEB-2001; 2001US-00792818.
PF	
XX	10-FEB-2000; 2000US-0181594P.
PR	
XX	JARV(/) JARVIS T.
PA	(CARL/) CARLOWITZ I V.
PA	(MCSW/) MCSWIGGEN J.
PA	(HAMB/) HAMBLIN P A.
PA	(ELLI/) ELLIS J H.
XX	Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;
PI	
XX	WPI; 2003-829646/77.
DR	
XX	

PT New nucleic acid molecule that down-regulates expression of Grb2-related
 PT with insert domain (GRID) gene, useful for treating a condition
 PT associated with the level of GRID, e.g. tissue/graft rejection and
 leukemia.
 XX
 XX
 PS Claim 4; SEQ ID NO 361; 74pp; English.
 XX
 XX The invention relates to a nucleic acid molecule that down-regulates
 CC expression of Grb2-related with insert domain (GRID) gene, e.g. a
 CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNazyme,
 CC amberzyme, Inozyme or hairpin ribozyme. Also include are a mammalian cell
 CC including the novel nucleic acid molecule, reducing GRID activity in a
 CC cell by contacting the cell with the novel nucleic acid molecule,
 CC treating a patient having a condition associated with the level of GRID
 CC (e.g. tissue/graft rejection or leukaemia) by contacting the cell with
 CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by
 CC contacting the cell with the novel nucleic acid molecule; an expression
 CC vector comprising a nucleic acid sequences (encoding at least the novel
 CC nucleic acid molecule in a manner that allows its expression), a
 CC mammalian cell including the expression vector and an enzymatic nucleic
 CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid
 CC molecule is useful for treating a condition associated with the level of
 CC GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is
 CC a target region for the enzymatic nucleic acids of the invention.
 XX
 SQ Sequence 17 BP; 5 A; 8 C; 4 G; 0 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0
 Qy 718 GCTGCAGCAGCAGCAC 733
 Db 1 GCAGCAGCAGCAGCAC 16
 RESULT 1101
 ADM54561
 ID ADM54561 standard; mRNA; 17 BP.
 XX
 AC ADM54561;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE Human GRID mRNA substrate sequence #871.
 XX
 KW Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;
 KW NCH ribozyme; G-cleaver ribozyme; Zinzyme; DNazyme; Inozyme;
 KW hairpin ribozyme; tissue rejection; graft rejection; leukaemia.
 XX
 OS Homo sapiens.
 XX
 EN US2003134806-A1.
 XX
 PD 17-JUL-2003.
 XX
 PF 23-FEB-2001; 2001US-00792818.
 XX
 PR 10-FEB-2000; 2000US-0181594P.
 XX
 PA (JARV/) JARVIS T.
 PA (CARL/) CARLOWITZ I V.
 PA (MCSW/) MCSWIGGEN J.
 PA (HAMB/) HAMELIN P A.
 PA (ELLI/) ELLIS J H.
 XX
 PI Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;
 XX
 DR WPI; 2003-829646/77.
 XX
 PT New nucleic acid molecule that down-regulates expression of Grb2-related
 PT with insert domain (GRID) gene, useful for treating a condition
 PT associated with the level of GRID, e.g. tissue/graft rejection and

PT leukemia.

XX Claim 4; SEQ ID NO 874; 74pp; English.

XX

CC The invention relates to a nucleic acid molecule that down-regulates

CC expression of Grb2-related with insert domain (GRID) gene, e.g. a

CC hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNazyme,

CC amberzyme, inozyme or hairpin ribozyme. Also include are a mammalian cell

CC including the novel nucleic acid molecule, reducing GRID activity in a

CC cell by contacting the cell with the novel nucleic acid molecule,

CC treating a patient having a condition associated with the level of GRID

CC (e.g. tissue/graft rejection or leukaemia) by contacting the cell with

CC the novel nucleic acid molecule, cleaving RNA of a GRID gene by

CC contacting the cell with the novel nucleic acid molecule, an expression

CC vector comprising a nucleic acid sequences (encoding at least the novel

CC nucleic acid molecule in a manner that allows its expression), a

CC mammalian cell including the expression vector and an enzymatic nucleic

CC acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid

CC molecule is useful for treating a condition associated with the level of

CC GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is

CC a target region for the enzymatic nucleic acids of the invention.

XX

SQ Sequence 17 BP; 3 A; 3 C; 9 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 7.2e+02;

Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 731 CACAGCGTGCAGGTGG 746

Db 1 CACAGCGGGAGGUGG 16

RESULT 1102

ADM54297

ID ADM54297 standard; mRNA; 17 BP.

AC ADM54297;

XX

XX 03-JUN-2004 (first entry)

DE Human GRID mRNA substrate sequence #607.

XX

XX Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;

XX NCH ribozyme; G-cleaver ribozyme; Zinzyme; DNazyme; inozyme;

XX hairpin ribozyme; tissue rejection; graft rejection; leukaemia.

XX

OS Homo sapiens.

XX

XX US2003134806-A1.

XX

XX 17-JUL-2003.

XX

XX 23-FEB-2001; 2001US-00792818.

XX

XX 10-FEB-2000; 2000US-0181594P.

XX

XX (JARVIS) JARVIS T.

XX (CARL) CARLOWITZ I V.

XX (MCSW) MCSWIGGEN J.

XX (HAMB) HAMLIN P A.

XX (ELLI) ELLIS J H.

XX

XX Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;

XX WPI; 2003-829646/77.

XX

XX New nucleic acid molecule that down-regulates expression of Grb2-related

XX with insert domain (GRID) gene, useful for treating a condition

XX associated with the level of GRID, e.g. tissue/graft rejection and

XX leukemia.

XX

XX Claim 4; SEQ ID NO 607; 74pp; English.

PS

XX

XX The invention relates to a nucleic acid molecule that down-regulates

XX expression of Grb2-related with insert domain (GRID) gene, e.g. a

XX hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNazyme,

XX amberzyme, inozyme or hairpin ribozyme. Also include are a mammalian cell

XX including the novel nucleic acid molecule, reducing GRID activity in a

XX cell by contacting the cell with the novel nucleic acid molecule,

XX treating a patient having a condition associated with the level of GRID

XX (e.g. tissue/graft rejection or leukaemia) by contacting the cell with

XX the novel nucleic acid molecule, cleaving RNA of a GRID gene by

XX contacting the cell with the novel nucleic acid molecule, an expression

XX vector comprising a nucleic acid sequences (encoding at least the novel

XX nucleic acid molecule in a manner that allows its expression), a

XX mammalian cell including the expression vector and an enzymatic nucleic

XX acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid

XX molecule is useful for treating a condition associated with the level of

XX GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is

XX a target region for the enzymatic nucleic acids of the invention.

XX

SQ Sequence 17 BP; 4 A; 9 C; 3 G; 0 T; 1 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 7.2e+02;

Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 717 CGCTGAGCAGCAGCA 732

Db 2 CCCGCGCAGCAGCACCA 17

RESULT 1103

ADF92040

ID ADF92040 standard; DNA; 17 BP.

XX

XX ADF92040;

XX

XX 26-FEB-2004 (first entry)

DE Human cytokeratin 18-derived RLC DNA - SEQ ID 128.

XX

XX human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;

XX tumour metastasis; prostate cancer; lymphoma; human; CK18; ss; primer;

XX PCR; RLC; probe.

XX

XX Homo sapiens.

XX

XX WO2003097878-A1.

XX

XX 27-NOV-2003.

XX

XX 20-MAY-2003; 2003WO-JP006256.

XX

XX 21-MAY-2002; 2002JP-00145689.

XX

XX 17-JUN-2002; 2002JP-00175271.

XX

XX 09-JUL-2002; 2002JP-00199759.

XX

XX (SYSM-) SYSMEX CORP.

XX

XX Tada S, Akai Y, Imura Y, Abe S, Minekawa H;

XX WPI; 2004-012543/01.

XX

XX LAMP nucleic acid amplification primers for detection of cytokeratin

XX expression as indicator in diagnosis of tumour metastasis.

XX

XX Claim 3; SEQ ID NO 128; 266pp; Japanese.

XX

XX The invention relates to novel nucleic acid amplification primers for the

XX detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP

XX (loop mediated isothermal amplification) method. The primers of the

XX invention may be useful for the detecting cytokeratin 18-20 expression as

XX an indicator for the diagnosis of tumour metastasis, particularly

XX prostate cancer and lymphoma. The amplification using the primers is

CC

CC highly efficient and allows very sensitive detection of tumour
CC metastasis. The current sequence is that of the human CK18-derived DNA of
CC the invention.

SX Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 400 CAGCCAGAGGAGGAG 415
Db 2 CAGCCAGAGGAGGAGTG 17

RESULT 1104
ADF92290/c
ID ADF92290 standard; DNA; 17 BP.

XX ADF92290;

XX 26-FEB-2004 (first entry)

XX Human cytokeratin 19-related R3 PCR primer - SEQ ID 378.

XX human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;
KW tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;
KW PCR; R3.
XX Homo sapiens.

OS WO2003097878-A1.

XX 27-NOV-2003.

XX 20-MAY-2003; 2003WO-JP006256.

XX 21-MAY-2002; 2002JP-00145689.

PR 17-JUN-2002; 2002JP-00175271.

PR 09-JUL-2002; 2002JP-00199759.

XX (SYSM-) SYSMEX CORP.

XX Tada S, Akai Y, Imura Y, Abe S, Minekawa H;

XX WPI; 2004-012543/01.

XX LAMP nucleic acid amplification primers for detection of cytokeratin
PT expression as indicator in diagnosis of tumour metastasis.

XX Claim 19; SEQ ID NO 378; 266pp; Japanese.

XX The invention relates to novel nucleic acid amplification primers for the
CC detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP
CC (loop mediated isothermal amplification) method. The primers of the
CC invention may be useful for the detecting cytokeratin 18-20 expression as
CC an indicator for the diagnosis of tumour metastasis, particularly
CC prostate cancer and lymphoma. The amplification using the primers is
CC highly efficient and allows very sensitive detection of tumour
CC metastasis. The current sequence is that of the human CK19-related PCR
CC primer of the invention.

SX Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 498 AGAAGGAGGAGGCTCT 513
Db 16 AGACGGAGGAGGCTCT 1

RESULT 1105
ADK95913
ID ADK95913 standard; DNA; 17 BP.

XX ADK95913;

XX 06-MAY-2004 (first entry)

XX Primer of the invention #1633.

XX human; single nucleotide polymorphism; SNP; ss; primer.

XX Synthetic.

XX JP2003259875-A.

XX 16-SEP-2003.

XX 08-MAR-2002; 2002JP-00064373.

XX 08-MAR-2002; 2002JP-00064373.

XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.

XX WPI; 2004-093977/10.

XX Novel polynucleotide useful for PCR amplification along with two DNA
PT fragment from another set of sequences, or for detecting single
PT nucleotide polymorphism in human gene.

XX Claim 2; SEQ ID NO 4942; 2627pp; Japanese.

XX The present invention relates to a polynucleotide isolated from a human
CC gene and is useful for detecting a single nucleotide polymorphism in a
CC human gene or for diagnosing of disease. The invention enables the
CC detection of a single nucleotide polymorphism in a human gene. The
CC present sequence represents a primer of the invention.

XX Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 648 GCCAGGCTCTGGAGGG 663

Db 1 GCCTGGCTCTGGAGG 16

RESULT 1106
ADM59282/c
ID ADM59282 standard; RNA; 17 BP.

XX ADM59282;

XX 03-JUN-2004 (first entry)

XX Hepatitis B virus (HBV) RNA target sequence #1416.

XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatotropic; antiinflammatory; cytostatic.

XX Hepatitis B virus.

XX US2004054156-A1.

XX 18-MAR-2004.

XX 15-JAN-2003; 2003US-00342902.

XX 14-MAY-1992; 92US-00882712.

```

PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00636385.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (MORR/) MORRISSEY D.
XX
PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX WPI; 2004-247781/23.
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
XX specifically cleaving RNA derived from hepatitis B virus and comprising
XX one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 1416; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
XX specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX comprising one or more binding arms, without requiring the presence of a
XX 2'-OH group within the molecule for activity. The nucleic acids are
XX useful for treating hepatitis B virus infection, hepatitis,
XX hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX combination with other therapies such as lamivudine and interferons. The
XX nucleic acids are useful as diagnostic tools to examine genetic drift and
XX mutations within diseased cells, for detecting the presence of HBV RNA in
XX a cell, for the study of RNA and for down-regulating gene expression of
XX target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX sequence represents an HBV RNA target sequence, used in the scope of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 17 BP; 0 A; 10 C; 2 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 406 GAGGAGGAGGAGGAG 421
Db 17 GAGGAGGAGGAGGAG 2
RESULT 1107
ADM58553/c
ID ADM58553 standard; RNA; 17 BP.
XX
XX ADM58553;
AC
XX
XX 03-JUN-2004 (first entry)
DT
XX
XX Hepatitis B virus (HBV) RNA target sequence #687.
DE
XX
XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
XX hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
XX cirrhosis; liver failure; lamivudine; interferon; genetic drift;
XX virucide; hepatotropic; antiinflammatory; cytostatic.
XX
XX Hepatitis B virus.
OS
XX
XX US2004054156-A1.
PN
XX
XX 18-MAR-2004.
PD
XX
XX 15-JAN-2003; 2003US-00342902.
PF
XX
XX 14-MAY-1992; 92US-0082712.
PR
XX 07-FEB-1994; 94US-00193627.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00636385.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (MORR/) MORRISSEY D.
XX
PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX WPI; 2004-247781/23.
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
XX specifically cleaving RNA derived from hepatitis B virus and comprising
XX one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 1416; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
XX specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX comprising one or more binding arms, without requiring the presence of a
XX 2'-OH group within the molecule for activity. The nucleic acids are
XX useful for treating hepatitis B virus infection, hepatitis,
XX hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX combination with other therapies such as lamivudine and interferons. The
XX nucleic acids are useful as diagnostic tools to examine genetic drift and
XX mutations within diseased cells, for detecting the presence of HBV RNA in
XX a cell, for the study of RNA and for down-regulating gene expression of
XX target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX sequence represents an HBV RNA target sequence, used in the scope of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 17 BP; 0 A; 10 C; 2 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 406 GAGGAGGAGGAGGAG 421
Db 17 GAGGAGGAGGAGGAG 2
RESULT 1108
AD186585/c
ID AD186585 standard; RNA; 17 BP.
XX
XX AD186585;
AC
XX
XX 03-JUN-2004 (first entry)
DT
XX
XX HCV DNazyme substrate sequence #3831.
DE
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
XX HCV infection; type I interferon; DNazyme.
XX
XX Hepatitis C virus.
OS
XX
XX US2003125270-A1.
PN
XX
XX 03-JUL-2003.
PD
XX
XX 18-DEC-2000; 2000US-00740332.
PF
XX
XX 18-DEC-2000; 2000US-00740332.
PR
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.

```

PA (PAVC/) PAVCO P A.
 PA (MACE/) MACEJACK D.
 PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
 XX WPI; 2004-031273/03.
 DR
 XX
 XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
 PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
 PT especially in combination with type I interferon therapy.
 XX
 XX Claim 1; SEQ ID NO 3831; 198pp; English.
 PS
 CC The invention relates to an enzymatic nucleic acid molecule which
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
 CC the binding arms of the enzymatic nucleic acid molecule comprises
 CC sequences complementary to any of the defined substrate sequences given
 CC in the specification. The nucleic acid molecule may be administered for
 CC the treatment of HCV infections, especially in combination with type I
 CC interferons. The present sequence represents a HCV DNzyme substrate
 CC sequence.
 XX
 XX Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
 SQ
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 829 GGCCAGTTCAGGTG 844
 DB 16 GGCCAGTTCAGGTG 1
 RESULT 1109
 ADI82969/C
 ID ADI82969 standard; RNA; 17 BP.
 XX
 AC ADI82969;
 XX
 XX 03-JUN-2004 (first entry)
 DT
 DE HCV DNzyme substrate sequence #215.
 XX
 XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
 KW HCV infection; type I interferon; DNzyme.
 KW
 XX Hepatitis C virus.
 OS
 XX US2003125270-A1.
 PN
 XX 03-JUL-2003.
 PD
 XX 18-DEC-2000; 2000US-00740332.
 PF
 XX 18-DEC-2000; 2000US-00740332.
 PR
 XX (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (ROBE/) ROBERTS E.
 PA (PAVC/) PAVCO P A.
 PA (MACE/) MACEJACK D.
 XX
 PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
 XX WPI; 2004-031273/03.
 DR
 XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
 PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
 PT especially in combination with type I interferon therapy.
 XX
 XX Claim 1; SEQ ID NO 215; 198pp; English.
 PS
 CC The invention relates to an enzymatic nucleic acid molecule which

CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
 CC the binding arms of the enzymatic nucleic acid molecule comprises
 CC sequences complementary to any of the defined substrate sequences given
 CC in the specification. The nucleic acid molecule may be administered for
 CC the treatment of HCV infections, especially in combination with type I
 CC interferons. The present sequence represents a HCV DNzyme substrate
 CC sequence.
 XX
 XX Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
 SQ
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 181 TGAGATGGTGCAGCCC 196
 DB 17 TGACATGGTACAGCCC 2
 RESULT 1110
 ADI86321
 ID ADI86321 standard; RNA; 17 BP.
 XX
 AC ADI86321;
 XX
 XX 03-JUN-2004 (first entry)
 DT
 DE HCV DNzyme substrate sequence #3567.
 XX
 XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
 KW HCV infection; type I interferon; DNzyme.
 KW
 XX Hepatitis C virus.
 OS
 XX US2003125270-A1.
 PN
 XX 03-JUL-2003.
 PD
 XX 18-DEC-2000; 2000US-00740332.
 PF
 XX 18-DEC-2000; 2000US-00740332.
 PR
 XX (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (ROBE/) ROBERTS E.
 PA (PAVC/) PAVCO P A.
 PA (MACE/) MACEJACK D.
 XX
 PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
 XX WPI; 2004-031273/03.
 DR
 XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
 PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
 PT especially in combination with type I interferon therapy.
 XX
 XX Claim 1; SEQ ID NO 3567; 198pp; English.
 PS
 CC The invention relates to an enzymatic nucleic acid molecule which
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
 CC the binding arms of the enzymatic nucleic acid molecule comprises
 CC sequences complementary to any of the defined substrate sequences given
 CC in the specification. The nucleic acid molecule may be administered for
 CC the treatment of HCV infections, especially in combination with type I
 CC interferons. The present sequence represents a HCV DNzyme substrate
 CC sequence.
 XX
 XX Sequence 17 BP; 2 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
 SQ
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 7.2e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

```

QY 735 GCGTGACAGGTGGACCA 750
Db 1 GCGUGAGGUGGGACCA 16

RESULT 1111
ADI83869
ID ADI83869 standard; RNA; 17 BP.
XX
XX ADI83869;
AC
XX
XX 03-JUN-2004 (first entry)
DE HCV DNzyme substrate sequence #1115.
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNzyme.
XX
XX Hepatitis C virus.
XX
XX US2003125270-A1.
XX
XX 03-JUL-2003.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (ROBE/) ROBERTS E.
XX (PAVC/) PAVCO P A.
XX (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 1115; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNzyme substrate
CC sequence.
XX
XX Sequence 17 BP; 4 A; 6 C; 2 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 7.2e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 383 CTTCTGCAATTCACAG 398
Db 1 CUCUGCAUUCACAG 16

RESULT 1112
ADI84116/C
ID ADI84116 standard; RNA; 17 BP.
XX
XX ADI84116;
AC
XX
XX 03-JUN-2004 (first entry)
DE HCV DNzyme substrate sequence #1362.

XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNzyme.
XX
XX Hepatitis C virus.
XX
XX US2003125270-A1.
XX
XX 03-JUL-2003.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (ROBE/) ROBERTS E.
XX (PAVC/) PAVCO P A.
XX (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 1115; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNzyme substrate
CC sequence.
XX
XX Sequence 17 BP; 4 A; 6 C; 2 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 7.2e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 594 TGCTCGGGGAGCTGCA 609
Db 16 TGCTCGGGGAGGTGGA 1

RESULT 1113
ADO30697
ID ADO30697 standard; DNA; 17 BP.
XX
XX ADO30697;
AC
XX
XX 15-JUL-2004 (first entry)
DE
XX
XX Quadruplex modulator detection method test quadruplex molecule #9.
XX
XX ss; cytotstatic; quadruplex DNA; stabilization;
KW cell proliferative disorder; colorectal cancer; leukemia;
KW Hodgkin's disease.
XX
XX Synthetic.
XX
XX WO2004019283-A2.
XX
XX 04-MAR-2004.
XX
XX 20-AUG-2003; 2003WO-US026267.
XX
XX 20-AUG-2002; 2002US-0404965P.
XX

```

XX (CYTE-) CYTERNEX INC.
XX Ebbinghaus SW, Hurley LH, Siddiqui-Jain A, Memmott R;
XX WPI; 2004-239051/22.
XX
XX Identifying molecule that modulates biological activity of native
PT quadruplex DNA, by contacting test quadruplex DNA with candidate
PT molecule, determining presence or absence of interaction between the
PT molecule and test quadruplex DNA.
XX
XX Claim 2; Page 36; 43pp; English.
XX
XX The invention relates to a method of identifying (M1) a molecule that
CC modulates biological activity of native quadruplex DNA, by contacting
CC test quadruplex DNA with candidate molecule, and determining presence or
CC absence of interaction between candidate molecule and test quadruplex
CC DNA, where candidate molecule that interacts with test quadruplex DNA is
CC identified as molecule that modulates biological activity of native
CC quadruplex DNA. (M1) is useful for identifying molecule that modulates
CC biological activity of native quadruplex DNA (claimed). (M1) is useful
CC for identifying molecule that modulates biological activity of native
CC quadruplex DNA, where the identified molecule stabilizes quadruplex
CC structure which can exert a therapeutic effect for certain cell
CC proliferative disorders e.g., colorectal cancer, leukemia's, Hodgkin's
CC disease, etc. This sequence corresponds to a test quadruplex molecule
CC used in the method of the invention.
XX
SQ Sequence 17 BP; 7 A; 0 C; 10 G; 0 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 490 GAAGAGGCGAAGAGG 505
Db . 2 GAAGAGGCGAAGAGG 17
RESULT 1114
ADN44954
ID ADN44954 standard; DNA; 17 BP.
XX
XX AC ADN44954;
XX
XX 15-JUL-2004 (first entry)
XX
XX Mutant cell identification-related mutagenic oligonucleotide SeqID1623.
XX
XX cell identification; oligonucleotide-directed sequence alteration;
KW selectable phenotype; transgenic plant; herbicide resistance;
KW sterile plant; abiotic stress tolerance; albino plant;
KW amino acid production; ss.
XX
XX Oryza sativa.
OS
XX Synthetic.
OS
XX WO2004033708-A2.
PN
XX 22-APR-2004.
XX
XX 07-OCT-2003; 2003WO-US031862.
PF
XX 07-OCT-2002; 2002US-0416983P.
PR
XX 07-MAR-2003; 2003US-0453360P.
PR
XX (UYDE) UNIV DELAWARE.
PA
XX (NAPR-) NAPRO BIO THERAPEUTICS INC.
PA
XX Kmiec EB, Van Brabant A;
XX
XX WPI; 2004-340941/31.

XX Identifying a cell with a desired oligonucleotide-directed sequence
PT alteration at a nucleic acid target site within the cell by identifying
PT the desired sequence alteration in cells selected for the presence of a
PT selectable phenotype.
XX
XX Example 28; SEQ ID NO 1623; 303pp; English.
XX
XX This invention relates to a novel method of identifying a cell having a
CC desired oligonucleotide-directed sequence alteration at a first nucleic
CC acid target site within the cell. The method comprises identifying the
CC desired sequence alteration in cells that have been selected for the
CC presence of a selectable phenotype conferred by a concurrent
CC oligonucleotide-directed sequence alteration at a second nucleic acid
CC target site within the cells. The method is useful in identifying a cell
CC having a desired oligonucleotide-directed sequence alteration at a first
CC nucleic acid target site within the cell. The method may be useful for
CC the production of plants with herbicide resistance, male or female
CC sterile plants, abiotic stress tolerance, albino plants or plants with
CC altered amino acid production as well as for use in mammalian cell lines.
CC The present sequence is that of a mutagenic oligonucleotide which was
CC used in the exemplification of the invention.
XX
SQ Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 409 GGAGGAGAGGAGGTTTC 424
Db . 2 GGAGGAGAGGAGGTTTC 17
RESULT 1115
ADN44955/C
ID ADN44955 standard; DNA; 17 BP.
XX
XX AC ADN44955;
XX
XX 15-JUL-2004 (first entry)
XX
XX Mutant cell identification-related mutagenic oligonucleotide SeqID1624.
XX
XX cell identification; oligonucleotide-directed sequence alteration;
KW selectable phenotype; transgenic plant; herbicide resistance;
KW sterile plant; abiotic stress tolerance; albino plant;
KW amino acid production; ss.
XX
XX Oryza sativa.
OS
XX Synthetic.
OS
XX WO2004033708-A2.
PN
XX 22-APR-2004.
XX
XX 07-OCT-2003; 2003WO-US031862.
PF
XX 07-OCT-2002; 2002US-0416983P.
PR
XX 07-MAR-2003; 2003US-0453360P.
PR
XX (UYDE) UNIV DELAWARE.
PA
XX (NAPR-) NAPRO BIO THERAPEUTICS INC.
PA
XX Kmiec EB, Van Brabant A;
XX
XX WPI; 2004-340941/31.
XX
XX Identifying a cell with a desired oligonucleotide-directed sequence
PT alteration at a nucleic acid target site within the cell by identifying
PT the desired sequence alteration in cells selected for the presence of a
PT selectable phenotype.
XX

PS Example 28; SEQ ID NO 1624; 303pp; English.

XX This invention relates to a novel method of identifying a cell having a

CC desired oligonucleotide-directed sequence alteration at a first nucleic

CC acid target site within the cell. The method comprises identifying the

CC desired sequence alteration in cells that have been selected for the

CC presence of a selectable phenotype conferred by a concurrent

CC oligonucleotide-directed sequence alteration at a second nucleic acid

CC target site within the cells. The method is useful in identifying a cell

CC having a desired oligonucleotide-directed sequence alteration at a first

CC nucleic acid target site within the cell. The method may be useful for

CC the production of plants with herbicide resistance, male or female

CC sterile plants, abiotic stress tolerance, albino plants or plants with

CC altered amino acid production as well as for use in mammalian cell lines.

CC The present sequence is that of a mutagenic oligonucleotide which was

CC used in the exemplification of the invention.

XX

SQ Sequence 17 BP; 3 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 409 GGAGGAGGAGGAGTTC 424

DB 16 GGAGGAGGAGGAGTTC 1

RESULT 1116

ACN64621/c

ID ACN64621 standard; DNA; 17 BP.

XX

AC ACN64621;

XX

DT 02-DEC-2004 (first entry)

XX

DE Human GDMPLP-1 probe SEQ ID NO:1523.

XX

KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;

KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;

KW skeletal muscle function.

XX

OS Homo sapiens.

XX

PN US2004137589-A1.

XX

PD 15-JUL-2004.

XX

PF 26-NOV-2003; 2003US-00723361.

XX

PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001US-0266806P.

PR 25-MAY-2001; 2001US-00866108.

XX

(GUY/) GU Y.

PA (JIY/) JI Y.

PA (PENN/) PENN S G.

PA (HANZ/) HANZEL D K.

PA (RANK/) RANK D.

PA (CHEN/) CHEN W.

PA (SHAN/) SHANNON M E.

XX

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX

DR WPI; 2004-533378/51.

XX

PT Novel myosin-like protein-1, useful for treating or preventing disorder

PT associated with decreased expression or activity of human genome-derived

PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle

PT function.

XX

PS Disclosure; SEQ ID NO 1523; Opp; English.

XX

CC The invention relates to a novel polypeptide (I) comprising a sequence

CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of

CC (S1), 95% deviation from (S1) which are conservative substitutions, and

CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or

CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A

CC pharmaceutical composition of the invention is useful for treating or

CC preventing a disorder associated with decreased expression or activity of

CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.

CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63102

XX

SQ Sequence 17 BP; 5 A; 2 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 846 CCTATCACCAGCTCTT 861

DB 17 CCTATCACCAGCTCTT 2

RESULT 1117

ACN65094/c

ID ACN65094 standard; DNA; 17 BP.

XX

AC ACN65094;

XX

DT 02-DEC-2004 (first entry)

XX

DE Human GDMPLP-1 probe SEQ ID NO:1996.

XX

KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;

KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;

KW skeletal muscle function.

XX

OS Homo sapiens.

XX

PN US2004137589-A1.

XX

PD 15-JUL-2004.

XX

PF 26-NOV-2003; 2003US-00723361.

XX

PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001US-0266806P.

XX

PR 25-MAY-2001; 2001US-00866108.
 XX (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 1996; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.3%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 309 GCCTGGAGGAGATCA 324
 DB 17 GGCTGGAGGACATCA 2
 XX
 RESULT 1118
 ACN70797/c
 ID ACN70797 standard; DNA; 17 BP.
 XX
 AC ACN70797;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:7699.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 KW
 OS Homo sapiens.
 XX
 XX US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 XX 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 7699; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 6 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 827 CTGGCCCGAGTTCAGG 842
 DB 16 CTGGCCCGAGTTCAGG 1
 XX
 RESULT 1119
 ACN64622/c
 ID ACN64622 standard; DNA; 17 BP.
 XX
 AC ACN64622;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:1524.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 KW
 OS Homo sapiens.
 XX
 XX US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 XX 26-NOV-2003; 2003US-00723361.
 XX

```

XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PR 25-MAY-2001; 2001US-00866108.
XX PA (GUYV/) GU Y.
XX PA (JIYV/) JI Y.
XX PA (PENNV/) PENN S G.
XX PA (HANZ/) HANZEL D K.
XX PA (RANK/) RANK D.
XX PA (CHEN/) CHEN W.
XX PA (SHAN/) SHANNON M E.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX Disclosure; SEQ ID NO 1524; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (SI) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (SI), 95% deviation from (SI) which are conservative substitutions, and
XX 65% identity to (SI). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63102
XX SQ Sequence 17 BP; 5 A; 1 C; 9 G; 2 T; 0 U; 0 Other;
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 846 CCTATCACCAGCTCTT 861
XX |||||
XX 16 CCCATCAGCTGCTCTT 1
XX Db
XX RESULT 1120
XX ACN64818/c
XX ID ACN64818 standard; DNA; 17 BP.
XX AC ACN64818;
XX XX
XX DT 02-DEC-2004 (first entry)
XX XX
XX DE Human GDMLP-1 probe SEQ ID NO:1720.
XX KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX KW skeletal muscle function.
XX OS Homo sapiens.
XX PN US2004137589-A1.
XX XX
XX PD 15-JUL-2004.
XX PF
XX PR 26-NOV-2003; 2003US-00723361.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PR 25-MAY-2001; 2001US-00866108.
XX PA (GUYV/) GU Y.
XX PA (JIYV/) JI Y.
XX PA (PENNV/) PENN S G.
XX PA (HANZ/) HANZEL D K.
XX PA (RANK/) RANK D.
XX PA (CHEN/) CHEN W.
XX PA (SHAN/) SHANNON M E.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX Disclosure; SEQ ID NO 1720; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (SI) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (SI), 95% deviation from (SI) which are conservative substitutions, and
XX 65% identity to (SI). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63102
XX SQ Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 392 TTCCAAGCCAGCCAGA 407
XX |||||
XX 17 TTCTGAGCCAGCCAGA 2
XX Db
XX RESULT 1121
XX ACN70912
XX ID ACN70912 standard; DNA; 17 BP.
XX XX
XX AC ACN70912;

```


XX 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:7814.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 7814; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (SI) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (SI), 95% deviation from (SI) which are conservative substitutions, and
CC 65% identity to (SI). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmacological composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
|||||
494 AGGCAAGAGGAGGAGG 509

Db 1 AAGCAAAAGGAGGAGG 16
RESULT 1122
ACN63452/C
ID ACN63452 standard; DNA; 17 BP.
XX ACN63452;
XX
XX 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:354.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX US2004137589-A1.
XX 15-JUL-2004.
XX 26-NOV-2003; 2003US-00723361.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 354; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (SI) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (SI), 95% deviation from (SI) which are conservative substitutions, and
CC 65% identity to (SI). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmacological composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX

SQ Sequence 17 BP; 4 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 482 CTCGATCTGAAGAGGC 497
 ||||| ||||| |||||
 Db 17 CTCGTTCTGGAGAGGC 2

RESULT 1123
 ACN69989/c

ID ACN69989 standard; DNA; 17 BP.

XX ACN69989;

AC ACN69989;

DT 02-DEC-2004 (first entry)

XX Human GDMPLP-1 probe SEQ ID NO:6891.

DE Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.

XX Homo sapiens.

OS US2004137589-A1.

PN 15-JUL-2004.

PD 26-NOV-2003; 2003US-00723361.

PF 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.
 PA (JIVY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 PI WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.

XX Disclosure; SEQ ID NO 6891; Opp; English.

PS The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and

CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103

XX SQ Sequence 17 BP; 1 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 306 GCTGCCTGGAGAGAA 321
 ||||| ||||| |||||
 Db 16 GCCGCTGGAGAGAA 1

RESULT 1124
 ACN64819/c

ID ACN64819 standard; DNA; 17 BP.

XX ACN64819;

AC ACN64819;

DT 02-DEC-2004 (first entry)

XX Human GDMPLP-1 probe SEQ ID NO:1721.

DE Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.

XX Homo sapiens.

OS US2004137589-A1.

PN 15-JUL-2004.

PD 26-NOV-2003; 2003US-00723361.

PF 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.
 PA (JIVY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 PI WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.

XX Disclosure; SEQ ID NO 6891; Opp; English.

PS The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and

PT function.
 PS Disclosure; SEQ ID NO 1721; Opp; English.
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 392 TTCCAGCCAGCCAGCA 407
 Db 16 TTCTGAGCCAGCCAGCA 1
 RESULT 1125
 ACN71521
 ID ACN71521 standard; DNA; 17 BP.
 AC ACN71521;
 DT 02-DEC-2004 (first entry)
 XX Human GDMPLP-1 probe SEQ ID NO:8423.
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX Homo sapiens.
 XX US2004137589-A1.
 XX 15-JUL-2004.
 XX 26-NOV-2003; 2003US-00723361.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001WO-US000670.
 PR 25-MAY-2001; 2001US-0266860P.
 XX (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX Disclosure; SEQ ID NO 8423; Opp; English.
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 491 AAGAGCGCAGAGGAGC 506
 Db 1 AAGAGCGCAGAGGAGTGC 16
 RESULT 1126
 ACN63771/C
 ID ACN63771 standard; DNA; 17 BP.
 AC ACN63771;
 DT 02-DEC-2004 (first entry)
 XX Human GDMPLP-1 probe SEQ ID NO:673.
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX Homo sapiens.
 XX US2004137589-A1.
 XX 15-JUL-2004.
 XX 26-NOV-2003; 2003US-00723361.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001WO-US000670.
 PR 25-MAY-2001; 2001US-0266860P.
 XX (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.


```

PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX
Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX
Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX
Disclosure; SEQ ID NO 7697; Opp; English.
XX
XX
The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX
Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 828 TGGCCAGTTCAGGT 843
Db 17 TGGCCAGTTCAGGT 2
XX
XX
RESULT 1129
ACN71132
ID ACN71132 standard; DNA; 17 BP.
XX
XX
AC ACN71132;
XX
XX
02-DEC-2004 (first entry)
XX
XX
Human GDMPLP-1 probe SEQ ID NO:8034.
XX
XX
Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX

```

```

OS Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX
(GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX
Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX
Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX
Disclosure; SEQ ID NO 8034; Opp; English.
XX
XX
The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX
Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 696 AGCTGGAGAGTGAGCG 711
Db 1 AGCTGGAGATCGAGCG 16
XX
XX
RESULT 1130
ACN65095/c
ID ACN65095 standard; DNA; 17 BP.
XX
XX
AC ACN65095;
XX

```

DT 02-DEC-2004 (first entry)
XX Human GDMPLP-1 probe SEQ ID NO:1997.
XX
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PEN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 1997; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63102
XX
XX Sequence 17 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 7.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 309 GCCTGGAGGAGCAATCA 324
XX 16 GCCTGGAGGAGCAATCA 1

RESULT 1131
ACN71131
ID ACN71131 standard; DNA; 17 BP.
XX
XX ACN71131;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMPLP-1 probe SEQ ID NO:8033.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PEN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 8033; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGAGAGTGCAGCG 711
 |||||
 Db 2 AGCTGGAGATCGAGCG 17

RESULT 1132
 ACN63770/C
 ID ACN63770 standard; DNA; 17 BP.
 AC ACN63770;
 XX
 XX
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:672.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 XX Homo sapiens.
 XX
 XX US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001WO-US000670.
 PR 25-MAY-2001; 2001US-0266860P.
 XX
 XX (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 PT
 PT Disclosure; SEQ ID NO 672; Opp; English.
 PS
 PS The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or

CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102
 XX
 SQ Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
 |||||
 Db 17 GATGAGTCTCTCTGG 2

RESULT 1133
 ACN70776
 ID ACN70776 standard; DNA; 17 BP.
 XX
 AC ACN70776;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:7678.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 XX Homo sapiens.
 XX
 XX US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001WO-US000670.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 XX (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.

XX Disclosure; SEQ ID NO 7678; Opp; English.

XX The invention relates to a novel polypeptide (I) comprising a sequence

CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of

CC (S1), 95% deviation from (S1) which are conservative substitutions, and

CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or

CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A

CC pharmaceutical composition of the invention is useful for treating or

CC preventing a disorder associated with decreased expression or activity of

CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.

CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63103

XX

SQ Sequence 17 BP; 9 A; 1 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGGCGACAGGAG 505

Db 1 GAAGAGGCGACAGGAG 16

RESULT 1134

ACN70910

ID ACN70910 standard; DNA; 17 BP.

XX ACN70910;

XX 02-DEC-2004 (first entry)

DE Human GDMPLP-1 probe SEQ ID NO:7812.

XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;

KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;

KW skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 05-FEB-2001; 2001WO-US000670.

XX 25-MAY-2001; 2001US-0266860P.

XX (GUIYU/) GU Y.

XX (JIYU/) JI Y.

XX (PENN/) PENN S G.

XX (HANZ/) HANZEL D K.

XX (RANK/) RANK D.

XX (CHEN/) CHEN W.

XX (SHAN/) SHANNON M E.

XX

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder

PT associated with decreased expression or activity of human genome-derived

PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle

PT function.

XX Disclosure; SEQ ID NO 7812; Opp; English.

XX The invention relates to a novel polypeptide (I) comprising a sequence

CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of

CC (S1), 95% deviation from (S1) which are conservative substitutions, and

CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or

CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A

CC pharmaceutical composition of the invention is useful for treating or

CC preventing a disorder associated with decreased expression or activity of

CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.

CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63103

XX

SQ Sequence 17 BP; 8 A; 2 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 493 GAGCGAGAGGAGGAG 508

Db 2 GAAGCAAAAGGAGGAG 17

RESULT 1135

ACN63453/C

ID ACN63453 standard; DNA; 17 BP.

XX ACN63453;

XX 02-DEC-2004 (first entry)

DE Human GDMPLP-1 probe SEQ ID NO:355.

XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;

KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;

KW skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 05-FEB-2001; 2001WO-US000670.

XX 25-MAY-2001; 2001US-00866108.

XX

PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 PT
 XX Disclosure; SEQ ID NO 355; Opp; English.
 PS
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1) 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 482 CTCGATCTGAAGAGGC 497
 DB 16 CTCGTTCTGGAGAGC 1
 RESULT 1136
 ACN70775
 ID ACN70775 standard; DNA; 17 BP.
 XX
 AC ACN70775;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMLP-1 probe SEQ ID NO:7677.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
 KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US20041137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 XX (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 PT
 XX Disclosure; SEQ ID NO 7677; Opp; English.
 PS
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1) 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 10 A; 1 C; 6 G; 0 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 490 GAAGAGGCAGAGAGG 505
 DB 2 GAAGAGGCAGAGAGG 17
 RESULT 1137
 ACN69988/C
 ID ACN69988 standard; DNA; 17 BP.
 XX
 AC ACN69988;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMLP-1 probe SEQ ID NO:6890.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
 KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US20041137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 XX 26-MAY-2000; 2000US-0207456P.

```

PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US0000661.
PR 30-JAN-2001; 2001WO-US0000662.
PR 30-JAN-2001; 2001WO-US0000663.
PR 30-JAN-2001; 2001WO-US0000664.
PR 30-JAN-2001; 2001WO-US0000665.
PR 30-JAN-2001; 2001WO-US0000666.
PR 30-JAN-2001; 2001WO-US0000667.
PR 30-JAN-2001; 2001WO-US0000668.
PR 30-JAN-2001; 2001WO-US0000669.
PR 30-JAN-2001; 2001WO-US0000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUYU/) GU Y.
PA (JIYU/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 6890; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 1 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
XX
Query Match 1.7%; Score 12.6; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 306 GCTGCTGTGGAGGAGAA 321
DB 17 GCCGCTGTGGAGGAGAA 2
RESULT 1138
ADR74662/C
XX ADR74662 standard; DNA; 17 BP.
XX
AC ADR74662;
XX
DT 16-DEC-2004 (first entry)
XX
DE Allele specific primer B for human stenosis associated marker hCV1997488.
XX
XX Human; ss; PCR; primer; Allele specific primer; coronary stenosis;
KW angina; ischaemic chest pain; myocardial infarction;
KW sudden cardiac death; SNP; single nucleotide polymorphism.
XX
OS Homo sapiens.

```

```

XX WO2004081186-A2.
XX 23-SEP-2004.
XX
PF 10-MAR-2004; 2004WO-US0007140.
XX
PR 10-MAR-2003; 2003US-0453050P.
PR 30-APR-2003; 2003US-0466437P.
XX
XX (APPL-) APPLERA CORP.
XX
XX Cargill M, Devlin JJ, Luke MM;
XX WPI; 2004-668949/65.
XX
PT Identifying an individual who has altered risk for developing stenosis
PT comprises detecting single nucleotide polymorphism (SNP), in the
PT individual's nucleic acids.
XX
PS Claim 19; SEQ ID NO 67974; 146pp; English.
XX
CC The invention relates to identifying an individual who has altered risk
CC for developing coronary stenosis comprising detecting a single nucleotide
CC polymorphism (SNP) in any one of the 67073 nucleotide sequences (not
CC given in the specification), in the individual's nucleic acids, where the
CC presence of the SNP is correlated with an altered risk for stenosis in
CC the individual. Also included are an isolated nucleic acid molecule
CC comprising at least 8 contiguous nucleotides where one of the
CC nucleotides is an SNP as cited above, or their complement, an isolated
CC polypeptide comprising an amino acid sequence selected from any of the
CC 696 amino acid sequences (not defined in the specification), an antibody
CC that specifically binds to the polypeptide (or its antigen-binding
CC fragment), an amplified polynucleotide containing the SNP as cited (where
CC the amplified polynucleotide is between about 16 and about 1,000
CC nucleotides in length), an isolated polynucleotide which specifically
CC hybridises to a nucleic acid molecule containing the SNP, a kit for
CC detecting a SNP in a nucleic acid, detecting a SNP in a nucleic acid
CC molecule, detecting a variant polypeptide and identifying an agent useful
CC in therapeutically or prophylactically treating stenosis. The detection
CC step of the method is carried out by a process selected from allele-
CC specific probe hybridisation, allele-specific primer extension, allele-
CC specific amplification, sequencing, 5' nuclease digestion, molecular
CC beacon assay, oligonucleotide ligation assay, size analysis, and single-
CC stranded conformation polymorphism. The method is useful for identifying
CC an individual who has altered risk for developing coronary stenosis,
CC which can lead to angina (ischaemic chest pain), myocardial infarction
CC and ultimately sudden cardiac death. The present sequence is an allele
CC specific primer for amplifying a SNP-containing region of a human marker
CC gene associated with stenosis. NOTE: SEQ ID 1-67771 are not shown in the
CC specification but are provided on a CD-R named CL001510CDR which was not
CC supplied with the specification.
XX
XX Sequence 17 BP; 2 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
XX
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 603 AGCTGAGGAGGAGGCA 618
DB 16 AGCTTCAGCAGAGGCA 1

```

Search completed: April 8, 2005, 08:45:30
Job time : 15 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 8, 2005, 08:39:07 ; Search time 3 Seconds
(without alignments)
3.120 Million cell updates/sec

Title: US-10-628-841-3

Perfect score: 755

Sequence: 1 tctggaagagcaactgtgt.....tgggcagtgagcgaagcga 755

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 361 seqs, 6198 residues

Total number of hits satisfying chosen parameters: 722

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 361 summaries

Database : fetch3rge.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	17	2.3	18	1	ACCESSION:AX930601
2	15.8	2.1	19	1	ACCESSION:A68936
3	15.8	2.1	19	1	ACCESSION:AR102011
4	15.8	2.1	19	1	ACCESSION:AR139162
5	15.8	2.1	19	1	ACCESSION:AR342346
6	15.8	2.1	19	1	ACCESSION:BD006049
7	15.8	2.1	20	1	ACCESSION:A32036
8	15.8	2.1	20	1	ACCESSION:A44459
9	15.8	2.1	20	1	ACCESSION:Q0818178
10	15.8	2.1	20	1	ACCESSION:AR215451
11	15.8	2.1	21	1	ACCESSION:AX764372
12	15.4	2.0	17	1	ACCESSION:Q0622506
13	15.4	2.0	17	1	ACCESSION:Q0622710
14	15.4	2.0	17	1	ACCESSION:AR463569
15	15.4	2.0	17	1	ACCESSION:AR463773
16	15.4	2.0	18	1	ACCESSION:AR018170
17	15.4	2.0	18	1	ACCESSION:AR080884
18	15.4	2.0	18	1	ACCESSION:AR080887
19	15.4	2.0	18	1	ACCESSION:AR080889
20	15.4	2.0	18	1	ACCESSION:AR152352
21	15.4	2.0	18	1	ACCESSION:I71081
22	15.4	2.0	18	1	ACCESSION:AR236347
23	15.4	2.0	18	1	ACCESSION:BD107650
24	15.4	2.0	18	1	BD107653
25	15.4	2.0	18	1	BD107655
26	15.4	2.0	19	1	AR017595
27	15.4	2.0	19	1	AR068241
28	15.4	2.0	19	1	BD014243
29	15.4	2.0	20	1	I03563
30	15.4	2.0	20	1	ACCESSION:AR208100
31	15.2	2.0	20	1	A65119
32	15.2	2.0	20	1	ACCESSION:AR156208
33	15.2	2.0	20	1	BD228536

c	34	15.2	2.0	20	1	AR225911
	35	15.2	2.0	20	1	AR359761
	36	15.2	2.0	20	1	AR454156
	37	15.2	2.0	20	1	AR490587
	38	15.2	2.0	20	1	AX202443
	39	15.2	2.0	20	1	AX296834
c	40	15.2	2.0	20	1	AX323070
	41	15.2	2.0	20	1	AX816171
	42	15	2.0	17	1	C0622504
	43	15	2.0	17	1	C0622505
	44	15	2.0	17	1	AR463567
	45	15	2.0	17	1	AR463568
	46	15	2.0	17	1	AR463567
	47	15	2.0	17	1	AX730387
	48	15	2.0	17	1	AX736200
	49	15	2.0	17	1	AX762433
c	50	15	2.0	18	1	AR134262
	51	15	2.0	19	1	AX287102
	52	15	2.0	20	1	AX473022
	53	14.8	2.0	18	1	AR296947
	54	14.8	2.0	19	1	BD205460
	55	14.8	2.0	19	1	AX481359
	56	14.4	1.9	17	1	BD104776
	57	14.4	1.9	17	1	C0622507
	58	14.4	1.9	17	1	C0622709
	59	14.4	1.9	17	1	C0622711
c	60	14.4	1.9	17	1	C0624230
	61	14.4	1.9	17	1	C0624231
	62	14.4	1.9	17	1	AR463570
	63	14.4	1.9	17	1	AR463772
	64	14.4	1.9	17	1	AR463774
	65	14.4	1.9	17	1	AR465293
	66	14.4	1.9	17	1	AR465294
	67	14.4	1.9	18	1	AR134263
	68	14.4	1.9	18	1	AR299235
	69	14	1.9	19	1	AR035629
	70	14	1.9	17	1	C0622503
	71	14	1.9	17	1	C0624232
	72	14	1.9	17	1	C0624233
	73	14	1.9	17	1	AR463566
	74	14	1.9	17	1	AR465295
	75	14	1.9	17	1	AR465296
	76	14	1.9	17	1	AX673623
	77	13.8	1.8	18	1	AR106794
	78	13.8	1.8	17	1	AR045391
	79	13.8	1.8	17	1	BD254195
	80	13.8	1.8	17	1	BD254196
	81	13.8	1.8	17	1	C0622083
	82	13.8	1.8	17	1	C0622958
	83	13.8	1.8	17	1	C0623073
	84	13.8	1.8	17	1	C0623681
	85	13.8	1.8	17	1	C0623682
	86	13.8	1.8	17	1	I52443
	87	13.8	1.8	17	1	AR190504
	88	13.8	1.8	17	1	AR325427
	89	13.8	1.8	17	1	AR327369
	90	13.8	1.8	17	1	AR329402
	91	13.8	1.8	17	1	AR463146
	92	13.8	1.8	17	1	AR464021
	93	13.8	1.8	17	1	AR464136
	94	13.8	1.8	17	1	AR464744
	95	13.8	1.8	17	1	AR464745
	96	13.8	1.8	17	1	AX266063
	97	13.8	1.8	17	1	AX266064
	98	13.8	1.8	17	1	AX530794
	99	13.8	1.8	17	1	AX578640
	100	13.8	1.8	17	1	AX687997
	101	13.8	1.8	17	1	AX687998
	102	13.8	1.8	17	1	AX757153
	103	13.8	1.8	17	1	AX757735
	104	13.8	1.8	17	1	AX781735
	105	13.8	1.8	17	1	AX781740
	106	13.8	1.8	17	1	AX783694
						AX783781

						ACCESSION:AR225911
						ACCESSION:AR359761
						ACCESSION:AR454156
						ACCESSION:AR490587
						ACCESSION:AX202443
						ACCESSION:AX296834
						ACCESSION:AX323070
						ACCESSION:AX816171
						ACCESSION:C0622504
						ACCESSION:C0622505
						ACCESSION:AR463567
						ACCESSION:AR463568
						ACCESSION:AX730387
						ACCESSION:AX736200
						ACCESSION:AX762433
						ACCESSION:AR134262
						ACCESSION:AX287102
						ACCESSION:AX473022
						ACCESSION:AR296947
						ACCESSION:BD205460
						ACCESSION:AX481359
						ACCESSION:BD104776
						ACCESSION:C0622507
						ACCESSION:C0622709
						ACCESSION:C0622711
						ACCESSION:C0624230
						ACCESSION:C0624231
						ACCESSION:AR463570
						ACCESSION:AR463772
						ACCESSION:AR463774
						ACCESSION:AR465293
						ACCESSION:AR465294
						ACCESSION:AR134263
						ACCESSION:AR299235
						ACCESSION:AR035629
						ACCESSION:C0622503
						ACCESSION:C0624232
						ACCESSION:C0624233
						ACCESSION:AR463566
						ACCESSION:AR465295
						ACCESSION:AR465296
						ACCESSION:AX673623
						ACCESSION:AR106794
						ACCESSION:AR045391
						ACCESSION:BD254195
						ACCESSION:BD254196
						ACCESSION:C0622083
						ACCESSION:C0622958
						ACCESSION:C0623073
						ACCESSION:C0623681
						ACCESSION:C0623682
						ACCESSION:I52443
						ACCESSION:AR190504
						ACCESSION:AR325427
						ACCESSION:AR327369
						ACCESSION:AR329402
						ACCESSION:AR463146
						ACCESSION:AR464021
						ACCESSION:AR464136
						ACCESSION:AR464744
						ACCESSION:AR464745
						ACCESSION:AX266063
						ACCESSION:AX266064
						ACCESSION:AX530794
						ACCESSION:AX578640
						ACCESSION:AX687997
						ACCESSION:AX687998
						ACCESSION:AX757153
						ACCESSION:AX757735
						ACCESSION:AX781735
						ACCESSION:AX781740
						ACCESSION:AX783694
						ACCESSION:AX783781

107	13.8	1.8	17	1	AX783782	ACCESSION:AX783782	C 180	12.8	1.7	16	1	BD083852	ACCESSION:BD083852
108	13.8	1.8	17	1	BD104959	ACCESSION:BD104959	C 181	12.8	1.7	16	1	BD083870	ACCESSION:BD083870
C 109	13.8	1.8	17	1	AR064931	ACCESSION:AR064931	182	12.8	1.7	17	1	A12195	ACCESSION:A12195
C 110	13.8	1.8	18	1	AR096403	ACCESSION:AR096403	183	12.8	1.7	17	1	A34251	ACCESSION:A34251
C 111	13.8	1.8	18	1	AR098802	ACCESSION:AR098802	184	12.8	1.7	17	1	AR045383	ACCESSION:AR045383
C 112	13.8	1.8	18	1	AR105438	ACCESSION:AR105438	185	12.8	1.7	17	1	AR057435	ACCESSION:AR057435
C 113	13.8	1.8	18	1	BD196769	ACCESSION:BD196769	186	12.8	1.7	17	1	AR057586	ACCESSION:AR057586
C 114	13.8	1.8	18	1	BD217451	ACCESSION:BD217451	187	12.8	1.7	17	1	AR057597	ACCESSION:AR057597
C 115	13.8	1.8	18	1	AR129834	ACCESSION:AR129834	188	12.8	1.7	17	1	AR057619	ACCESSION:AR057619
C 116	13.8	1.8	18	1	AR326578	ACCESSION:AR326578	189	12.8	1.7	17	1	AR057664	ACCESSION:AR057664
C 117	13.8	1.8	18	1	AR359325	ACCESSION:AR359325	190	12.8	1.7	17	1	AR115193	ACCESSION:AR115193
C 118	13.8	1.8	18	1	AR354884	ACCESSION:AR354884	191	12.8	1.7	17	1	AR115344	ACCESSION:AR115344
C 119	13.8	1.8	18	1	AX004444	ACCESSION:AX004444	192	12.8	1.7	17	1	AR115355	ACCESSION:AR115355
C 120	13.8	1.8	18	1	AX015708	ACCESSION:AX015708	193	12.8	1.7	17	1	AR115377	ACCESSION:AR115377
C 121	13.8	1.8	18	1	AX114463	ACCESSION:AX114463	194	12.8	1.7	17	1	AR115422	ACCESSION:AR115422
C 122	13.8	1.8	18	1	AX164504	ACCESSION:AX164504	195	12.8	1.7	17	1	AR197639	ACCESSION:AR197639
C 123	13.8	1.8	18	1	AX587328	ACCESSION:AX587328	196	12.8	1.7	17	1	BD197639	ACCESSION:BD197639
C 124	13.8	1.8	18	1	AR124643	ACCESSION:AR124643	197	12.8	1.7	17	1	BD200587	ACCESSION:BD200587
C 125	13.6	1.8	17	1	BD194721	ACCESSION:BD194721	198	12.8	1.7	17	1	BD202923	ACCESSION:BD202923
C 126	13.6	1.8	17	1	AR026174	ACCESSION:AR026174	199	12.8	1.7	17	1	BD241701	ACCESSION:BD241701
C 127	13.6	1.8	17	1	BD064161	ACCESSION:BD064161	200	12.8	1.7	17	1	BD254084	ACCESSION:BD254084
C 128	13.4	1.8	15	1	AR132396	ACCESSION:AR132396	201	12.8	1.7	17	1	BD254283	ACCESSION:BD254283
C 129	13.4	1.8	15	1	BD208731	ACCESSION:BD208731	202	12.8	1.7	17	1	BD254816	ACCESSION:BD254816
C 130	13.4	1.8	16	1	AR057415	ACCESSION:AR057415	203	12.8	1.7	17	1	BD254816	ACCESSION:BD254816
C 131	13.4	1.8	16	1	AR115173	ACCESSION:AR115173	204	12.8	1.7	17	1	BD257476	ACCESSION:BD257476
C 132	13.4	1.8	16	1	CO797647	ACCESSION:CO797647	205	12.8	1.7	17	1	BD272834	ACCESSION:BD272834
C 133	13.4	1.8	16	1	AX634461	ACCESSION:AX634461	206	12.8	1.7	17	1	CO615614	ACCESSION:CO615614
C 134	13.4	1.8	16	1	AX08221	ACCESSION:AX08221	207	12.8	1.7	17	1	CO615932	ACCESSION:CO615932
C 135	13.4	1.8	17	1	CO622084	ACCESSION:CO622084	208	12.8	1.7	17	1	CO615933	ACCESSION:CO615933
C 136	13.4	1.8	17	1	CO622085	ACCESSION:CO622085	209	12.8	1.7	17	1	CO616783	ACCESSION:CO616783
C 137	13.4	1.8	17	1	CO622508	ACCESSION:CO622508	210	12.8	1.7	17	1	CO616784	ACCESSION:CO616784
C 138	13.4	1.8	17	1	CO622708	ACCESSION:CO622708	211	12.8	1.7	17	1	CO616980	ACCESSION:CO616980
C 139	13.4	1.8	17	1	CO622712	ACCESSION:CO622712	212	12.8	1.7	17	1	CO616981	ACCESSION:CO616981
C 140	13.4	1.8	17	1	CO623679	ACCESSION:CO623679	213	12.8	1.7	17	1	CO617256	ACCESSION:CO617256
C 141	13.4	1.8	17	1	CO623680	ACCESSION:CO623680	214	12.8	1.7	17	1	CO617257	ACCESSION:CO617257
C 142	13.4	1.8	17	1	CO624229	ACCESSION:CO624229	215	12.8	1.7	17	1	CO622082	ACCESSION:CO622082
C 143	13.4	1.8	17	1	IG2755	ACCESSION:IG2755	216	12.8	1.7	17	1	CO622150	ACCESSION:CO622150
C 144	13.4	1.8	17	1	AR192534	ACCESSION:AR192534	217	12.8	1.7	17	1	CO622151	ACCESSION:CO622151
C 145	13.4	1.8	17	1	AR286285	ACCESSION:AR286285	218	12.8	1.7	17	1	CO622337	ACCESSION:CO622337
C 146	13.4	1.8	17	1	AR326403	ACCESSION:AR326403	219	12.8	1.7	17	1	CO622338	ACCESSION:CO622338
C 147	13.4	1.8	17	1	AR398275	ACCESSION:AR398275	220	12.8	1.7	17	1	CO622957	ACCESSION:CO622957
C 148	13.4	1.8	17	1	AR463147	ACCESSION:AR463147	221	12.8	1.7	17	1	CO622959	ACCESSION:CO622959
C 149	13.4	1.8	17	1	AR463148	ACCESSION:AR463148	222	12.8	1.7	17	1	CO623072	ACCESSION:CO623072
C 150	13.4	1.8	17	1	AR463371	ACCESSION:AR463371	223	12.8	1.7	17	1	CO623074	ACCESSION:CO623074
C 151	13.4	1.8	17	1	AR463775	ACCESSION:AR463775	224	12.8	1.7	17	1	CO623293	ACCESSION:CO623293
C 152	13.4	1.8	17	1	AR464742	ACCESSION:AR464742	225	12.8	1.7	17	1	CO623294	ACCESSION:CO623294
C 153	13.4	1.8	17	1	AR464743	ACCESSION:AR464743	226	12.8	1.7	17	1	CO623683	ACCESSION:CO623683
C 154	13.4	1.8	17	1	AR465292	ACCESSION:AR465292	227	12.8	1.7	17	1	I34958	ACCESSION:I34958
C 155	13.4	1.8	17	1	AX324837	ACCESSION:AX324837	228	12.8	1.7	17	1	I52435	ACCESSION:I52435
C 156	13.4	1.8	17	1	AX324838	ACCESSION:AX324838	229	12.8	1.7	17	1	AR186446	ACCESSION:AR186446
C 157	13.4	1.8	17	1	AX729247	ACCESSION:AX729247	230	12.8	1.7	17	1	AR192127	ACCESSION:AR192127
C 158	13.4	1.8	17	1	AX738306	ACCESSION:AX738306	231	12.8	1.7	17	1	AR192284	ACCESSION:AR192284
C 159	13.4	1.8	17	1	AX762032	ACCESSION:AX762032	232	12.8	1.7	17	1	AR286106	ACCESSION:AR286106
C 160	13.4	1.8	17	1	AX782446	ACCESSION:AX782446	233	12.8	1.7	17	1	AR286233	ACCESSION:AR286233
C 161	13.4	1.8	17	1	AR349716	ACCESSION:AR349716	234	12.8	1.7	17	1	AR323077	ACCESSION:AR323077
C 162	13	1.8	15	1	AR4045387	ACCESSION:AR4045387	235	12.8	1.7	17	1	AR326154	ACCESSION:AR326154
C 163	13	1.7	17	1	AR045389	ACCESSION:AR045389	236	12.8	1.7	17	1	AR327368	ACCESSION:AR327368
C 164	13	1.7	17	1	CO622502	ACCESSION:CO622502	237	12.8	1.7	17	1	AR363927	ACCESSION:AR363927
C 165	13	1.7	17	1	CO624234	ACCESSION:CO624234	238	12.8	1.7	17	1	AR398096	ACCESSION:AR398096
C 166	13	1.7	17	1	I52439	ACCESSION:I52439	239	12.8	1.7	17	1	AR398223	ACCESSION:AR398223
C 167	13	1.7	17	1	I52441	ACCESSION:I52441	240	12.8	1.7	17	1	AR456677	ACCESSION:AR456677
C 168	13	1.7	17	1	AR463565	ACCESSION:AR463565	241	12.8	1.7	17	1	AR456678	ACCESSION:AR456678
C 169	13	1.7	17	1	AR465297	ACCESSION:AR465297	242	12.8	1.7	17	1	AR456995	ACCESSION:AR456995
C 170	13	1.7	17	1	AX046409	ACCESSION:AX046409	243	12.8	1.7	17	1	AR457846	ACCESSION:AR457846
C 171	13	1.7	17	1	A67075	ACCESSION:A67075	244	12.8	1.7	17	1	AR457847	ACCESSION:AR457847
C 172	12.8	1.7	16	1	CO847645	ACCESSION:CO847645	245	12.8	1.7	17	1	AR458043	ACCESSION:AR458043
C 173	12.8	1.7	16	1	E33195	ACCESSION:E33195	246	12.8	1.7	17	1	AR458044	ACCESSION:AR458044
C 174	12.8	1.7	16	1	E52013	ACCESSION:E52013	247	12.8	1.7	17	1	AR458319	ACCESSION:AR458319
C 175	12.8	1.7	16	1	AR322209	ACCESSION:AR322209	248	12.8	1.7	17	1	AR458320	ACCESSION:AR458320
C 176	12.8	1.7	16	1	AR488577	ACCESSION:AR488577	249	12.8	1.7	17	1	AR463145	ACCESSION:AR463145
C 177	12.8	1.7	16	1	AX128605	ACCESSION:AX128605	250	12.8	1.7	17	1	AR463213	ACCESSION:AR463213
C 178	12.8	1.7	16	1	AX804969	ACCESSION:AX804969	251	12.8	1.7	17	1	AR463214	ACCESSION:AR463214
C 179	12.8	1.7	16	1			252	12.8	1.7	17	1		

```
253 12.8 1.7 17 1 AR464000 ACCESSION:AR464000
254 12.8 1.7 17 1 AR464001 ACCESSION:AR464001
255 12.8 1.7 17 1 AR464020 ACCESSION:AR464020
256 12.8 1.7 17 1 AR464022 ACCESSION:AR464022
257 12.8 1.7 17 1 AR464135 ACCESSION:AR464135
258 12.8 1.7 17 1 AR464137 ACCESSION:AR464137
259 12.8 1.7 17 1 AR464356 ACCESSION:AR464356
260 12.8 1.7 17 1 AR464357 ACCESSION:AR464357
261 12.8 1.7 17 1 AR464746 ACCESSION:AR464746
262 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
263 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
264 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
265 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
266 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
267 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
268 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
269 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
270 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
271 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
272 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
273 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
274 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
275 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
276 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
277 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
278 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
279 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
280 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
281 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
282 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
283 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
284 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
285 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
286 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
287 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
288 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
289 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
290 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
291 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
292 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
293 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
294 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
295 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
296 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
297 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
298 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
299 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
300 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
301 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
302 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
303 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
304 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
305 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
306 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
307 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
308 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
309 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
310 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
311 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
312 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
313 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
314 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
315 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
316 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
317 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
318 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
319 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
320 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
321 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
322 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
323 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
324 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
325 12.8 1.7 17 1 AR483302 ACCESSION:AR483302
```

```
c 326 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
327 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
328 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
329 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
330 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
331 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
332 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
333 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
334 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
335 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
336 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
337 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
338 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
339 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
340 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
341 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
342 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
343 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
344 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
345 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
346 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
347 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
348 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
349 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
350 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
351 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
352 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
353 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
354 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
355 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
356 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
357 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
358 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
359 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
360 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
361 12.8 1.7 17 1 AX736680 ACCESSION:AX736680
```

ALIGNMENTS

```
RESULT 1
AX930601
LOCUS AX930601 18 bp DNA linear PAT 22-DEC-2003
DEFINITION Sequence 73 from Patent WO03087386.
ACCESSION AX930601
VERSION AX930601.1 GI:40312349
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Kroeger,B., Zelder,O., Klopprogge,C., Schroeder,H. and Haefner,S.
TITLE Methods for producing sulphurous fine chemicals
JOURNAL Patent: WO 03087386-A 73 23-OCT-2003;
BASF AKTIENGESSELLSCHAFT (DE)
FEATURES
source
1..18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:3264"
/note="PCR Primer"
Query Match 2.3%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 469 CGGCTCGAGAGCTCG 485
Db 2 CGGCTCGAGAGCTCG 18
RESULT 2
```

JOURNAL Patent: US 6207165-A 10 27-MAR-2001;
FEATURES Location/Qualifiers
source
1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 64;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTGCA 390
|||||
Db 1 GCTGCGAGGAGCATCTGCA 19

RESULT 5
AR342346 19 bp DNA linear PAT 17-AUG-2003
LOCUS
DEFINITION Sequence 8 from patent US 6576243.
ACCESSION AR342346
VERSION AR342346.1 GI:33737313
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Audonnet,J.-C., Bouchardon,A., Baudu,P. and Riviere,M.
TITLE Polynucleotide vaccine formula against porcine reproductive and
respiratory pathologies
JOURNAL Patent: US 6576243-A 8 10-JUN-2003;
FEATURES Location/Qualifiers
source
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 64;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTGCA 390
|||||
Db 1 GCTGCGAGGAGCATCTGCA 19

RESULT 3
AR012011/c 19 bp DNA linear PAT 04-DEC-1998
LOCUS
DEFINITION Sequence 5 from patent US 5763183.
ACCESSION AR012011
VERSION AR012011.1 GI:3970001
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Pesonen,U., Koulou,M., Linnola,M., Goldman,D. and Virkkunen,M.
TITLE Allelic variation of the serotonin 5HT7 receptor
JOURNAL Patent: US 5763183-A 5 09-JUN-1998;
FEATURES Location/Qualifiers
source
1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 64;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 441 AGGAGCCAGGAACCTGGT 459
|||||
Db 19 AGGAGCCAGGAACCTGT 1

RESULT 4
AR139162 19 bp DNA linear PAT 16-JUN-2001
LOCUS
DEFINITION Sequence 10 from patent US 6207165.
ACCESSION AR139162
VERSION AR139162.1 GI:14481658
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Audonnet,J.-C., Bouchardon,A., Baudu,P. and Riviere,M.
TITLE Polynucleotide formula against porcine reproductive and respiratory
pathologies

JOURNAL Patent: US 6207165-A 10 27-MAR-2001;
FEATURES Location/Qualifiers
source
1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 64;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTGCA 390
|||||
Db 1 GCTGCGAGGAGCATCTGCA 19

RESULT 5
AR342346 19 bp DNA linear PAT 17-AUG-2003
LOCUS
DEFINITION Sequence 8 from patent US 6576243.
ACCESSION AR342346
VERSION AR342346.1 GI:33737313
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Audonnet,J.-C., Bouchardon,A., Baudu,P. and Riviere,M.
TITLE Polynucleotide vaccine formula against porcine reproductive and
respiratory pathologies
JOURNAL Patent: US 6576243-A 8 10-JUN-2003;
FEATURES Location/Qualifiers
source
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 64;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTGCA 390
|||||
Db 1 GCTGCGAGGAGCATCTGCA 19

RESULT 6
BD006049 19 bp DNA linear PAT 31-JAN-2002
LOCUS
DEFINITION Polynucleotide vaccine formula for treating porcine respiratory and
reproductive diseases.
ACCESSION BD006049
VERSION BD006049.1 GI:18634420
KEYWORDS JP 2001500111-A/8.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 19)
AUTHORS Audonnet,J.C., Bouchardon,A., Baudu,P. and Rivie,M.
TITLE Polynucleotide vaccine formula for treating porcine respiratory and
reproductive diseases
JOURNAL Patent: JP 2001500111-A 8 09-JAN-2001;
COMMENT Merial
OS PRVGD
PN JP 2001500111-A/8
PD 09-JAN-2001
PF 15-JUL-1997 JP 1998506628
PR 19-JUL-1996 FR 96/09338
PI JEAN CHRISTOPHE AUDONNET,ANNABELLE BOUCHARDON,PHILIPPE BAUDU,
MICHEL RIVIERE
PC C12N15/38,C12N15/44,C12N15/40,C12N15/35,C12N15/31,A61K39/295
CC
FH Key Location/Qualifiers
FT source 1..19
FT /organism='PRVGD'

```

FEATURES
source
Location/Qualifiers
1..19
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 2.1%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTGCA 390
Db 1 GCTGCGAGGAGCATCTGCA 19

RESULT 7
A32036
LOCUS A32036 20 bp DNA linear PAT 08-DEC-1995
DEFINITION Primer DNA U2 from patent EP0395292.
ACCESSION A32036
VERSION A32036.1 GI:1249491
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Barry,T.G., Gannon,B.X. and Powell,R.
TITLE Generation of specific probes for target nucleotide sequences
JOURNAL Patent: EP 0395292-A 6 31-OCT-1990;
Barry, Thomas Gerard; Gannon, Bernard Francis Xavier; BIORESEARCH
IRELAND; Powell, Richard; UNIVERSITY COLLEGE GALWAY; Barry, Thomas
Gerard; Gannon, Bernard Francis Xavier; BIORESEARCH IRELAND;
Powell, Richard; UNIVERSITY COLLEGE GALWAY; Barry, Thomas Gerard;
Gannon, Bernard Francis Xavier; EOLAS (trading as BioResearch
Ireland) - The Irish Science and Technology Agency; Powell,
Richard; UNIVERSITY COLLEGE GALWAY
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 2.1%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 GCCAGCCATGCTGCACCTG 271
Db 1 GACAGCCATGCGACACCTG 19

RESULT 8
A44459
LOCUS A44459 20 bp DNA linear PAT 07-MAR-1997
DEFINITION Sequence 6 from Patent WO9513396.
ACCESSION A44459
VERSION A44459.1 GI:2299285
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Fluit,A.C. and Widojoatmodjo,M.N.
TITLE A METHOD FOR IDENTIFYING MICROORGANISMS, AND AIDS USEFUL THEREOF
JOURNAL Patent: WO 9513396-A 6 18-MAY-1995;
U GENE RESEARCH BV (NL)
COMMENT Other publication NL 9301957 950601.
Location/Qualifiers
1..20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

FEATURES
source
Location/Qualifiers
1..20
/organism="unassigned DNA"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 2.1%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGCGCGA 714
Db 19 AGCCGGAGAGGAGCGCGA 1

RESULT 11
AX764372/c

FEATURES
source
Location/Qualifiers
1..20
/organism="unassigned DNA"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 2.1%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 256 AGCCATGCTGCACCTGCCT 274
Db 1 AGCCATGCGACCTGTCT 19

RESULT 9
CQ818178/c
LOCUS CQ818178 20 bp DNA linear PAT 07-JUN-2004
DEFINITION Sequence 15 from Patent WO200404247.
ACCESSION CQ818178
VERSION CQ818178.1 GI:48426970
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Chaubron,F., Martin-Minvielle,A.C. and Groulon,S.
TITLE One step real-time rt pcr kits for the universal detection of
organisms in industrial products
JOURNAL Patent: WO 200404247-A 15 27-MAY-2004;
Genolife (FR)
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="#Description of artificial sequence:
oligonucleotide primer#"

Query Match
Best Local Similarity 2.1%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 GCCAGCCATGCTGCACCTG 271
Db 20 GACAGCCATGCGACACCTG 2

RESULT 10
AR215451/c
LOCUS AR215451 20 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 16 from patent US 6410322.
ACCESSION AR215451
VERSION AR215451.1 GI:23313707
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Robinson,G.S.
TITLE Antisense oligonucleotide inhibition of vascular endothelial growth
factor expression
JOURNAL Patent: US 6410322-A 16 25-JUN-2002;
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 2.1%; Score 15.8; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGCGCGA 714
Db 19 AGCCGGAGAGGAGCGCGA 1

RESULT 11
AX764372/c

```

```

LOCUS       AX764372               21 bp    DNA             linear      PAT 25-JUN-2003
DEFINITION   Sequence 20 from Patent WO03040296.
ACCESSION    AX764372
VERSION      AX764372.1  GI:32258677
KEYWORDS     synthetic construct
SOURCE       synthetic construct
            other sequences; artificial sequences.
REFERENCE    1
AUTHORS      Eulenbergh,K., Steuernagel,A. and Broenner,G.
TITLE        Men protein, gst2, rab-rpl, csp, f-box protein lilina/Fbl7, abc50,
            coronin, sec61 alpha, or vhhapai-1, or homologous proteins involved
            in the regulation of energy homeostasis
JOURNAL      Patent: WO 03040296-A 20 15-MAY-2003;
            DeveloGen Aktiengesellschaft fuer entwicklungsbiologische Forschung
            (DE)
FEATURES     Location/Qualifiers
            source             1..21
                                /organism="synthetic construct"
                                /mol_type="unassigned DNA"
                                /db_xref="taxon:32630"
                                /note="Mouse Rab38 tagman probe"
            misc_feature       1
                                /note="5/6-FAM"
            misc_feature       21
                                /note="5/6-TAMRA"

Query Match      2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 58;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      839  CAGGTGGCGCTATCACCAGC 857
          ||||| ||||| ||||| |||||
DB      20  CAGGTGGCGGATCACCAGC 2

RESULT 12
LOCUS     CQ622506               17 bp    DNA             linear      PAT 02-FEB-2004
DEFINITION   Sequence 7246 from Patent WO0192524.
ACCESSION    CQ622506
VERSION      CQ622506.1  GI:41672724
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 7246 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
            source             1..17
                                /organism="Homo sapiens"
                                /mol_type="unassigned DNA"
                                /db_xref="taxon:9606"

Query Match      2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 83;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      697  GCTGGAGAGTGAGCGCG 713
          ||||| ||||| ||||| |||||
DB      1  GCTGGAGAGTGAGCGCG 17

RESULT 13
LOCUS     CQ622710               17 bp    DNA             linear      PAT 02-FEB-2004
DEFINITION   Sequence 7450 from Patent WO0192524.
ACCESSION    CQ622710

```

```

VERSION      CQ622710.1  GI:41672928
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 7450 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
            source             1..17
                                /organism="Homo sapiens"
                                /mol_type="unassigned DNA"
                                /db_xref="taxon:9606"

Query Match      2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 83;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      412  GGAGAAGGAGTTCCTCA 428
          ||||| ||||| ||||| |||||
DB      1  GGAGAAGGAGTTCCTCA 17

RESULT 14
LOCUS     AR463569               17 bp    DNA             linear      PAT 20-FEB-2004
DEFINITION   Sequence 7246 from patent US 6686188.
ACCESSION    AR463569
VERSION      AR463569.1  GI:42698626
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
            1 (bases 1 to 17)
            Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE        Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL      Patent: US 6686188-A 7246 03-FEB-2004;
            Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
            source             1..17
                                /organism="unknown"
                                /mol_type="genomic DNA"

Query Match      2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 83;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      697  GCTGGAGAGTGAGCGCG 713
          ||||| ||||| ||||| |||||
DB      1  GCTGGAGAGTGAGCGCG 17

RESULT 15
LOCUS     AR463773               17 bp    DNA             linear      PAT 20-FEB-2004
DEFINITION   Sequence 7450 from patent US 6686188.
ACCESSION    AR463773
VERSION      AR463773.1  GI:42698830
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
            1 (bases 1 to 17)
            Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE        Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL      Patent: US 6686188-A 7450 03-FEB-2004;

```



```
FEATURES
  source      Location/Qualifiers
            1..17      18 bp      DNA      linear      PAT 31-AUG-2000
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 83;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 GGAGAGGAGTTCTCTCA 428
Db 1 GGAGAGGAGTTCTCTCA 17

RESULT 16
LOCUS AR018170      18 bp      DNA      linear      PAT 05-DEC-1998
DEFINITION Sequence 32 from patent US 5780610.
ACCESSION AR018170
VERSION AR018170.1 GI:3973773
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Collins,M.L., Horn,T., Sheridan,P.J., Warner,B.D. and Urdea,M.S.
TITLE Reduction of nonspecific hybridization by using novel base-pairing
schemes
JOURNAL Patent: US 5780610-A 32 14-JUL-1998;
FEATURES
  source      Location/Qualifiers
            1..18      18 bp      DNA      linear      PAT 31-AUG-2000
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACCAACCATC 883
Db 2 AGTACGACCAACCATC 18

RESULT 17
LOCUS AR080884/c      18 bp      DNA      linear      PAT 31-AUG-2000
DEFINITION Sequence 2 from patent US 5969117.
ACCESSION AR080884
VERSION AR080884.1 GI:10007613
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Agrawal,S.
TITLE Modified protein kinase a-specific oligonucleotide
JOURNAL Patent: US 5969117-A 2 19-OCT-1999;
FEATURES
  source      Location/Qualifiers
            1..18      18 bp      DNA      linear      PAT 08-AUG-2001
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCG 693
Db 18 GCCAGCGAGCGCG 2

RESULT 18
LOCUS AR080887      18 bp      DNA      linear      PAT 31-AUG-2000
DEFINITION Sequence 5 from patent US 5969117.
ACCESSION AR080887
VERSION AR080887.1 GI:10007616
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Agrawal,S.
TITLE Modified protein kinase a-specific oligonucleotide
JOURNAL Patent: US 5969117-A 5 19-OCT-1999;
FEATURES
  source      Location/Qualifiers
            1..18      18 bp      DNA      linear      PAT 31-AUG-2000
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCG 693
Db 18 GCCAGCGAGCGCG 2

RESULT 19
LOCUS AR080889/c      18 bp      DNA      linear      PAT 31-AUG-2000
DEFINITION Sequence 7 from patent US 5969117.
ACCESSION AR080889
VERSION AR080889.1 GI:10007618
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Agrawal,S.
TITLE Modified protein kinase a-specific oligonucleotide
JOURNAL Patent: US 5969117-A 7 19-OCT-1999;
FEATURES
  source      Location/Qualifiers
            1..18      18 bp      DNA      linear      PAT 31-AUG-2000
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCG 693
Db 18 GCCAGCGAGCGCG 2

RESULT 20
LOCUS AR152352      18 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION Sequence 32 from patent US 6232462.
ACCESSION AR152352
VERSION AR152352.1 GI:15118402
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Collins,M.L., Horn,T., Sheridan,P.J., Warner,B.D. and Urdea,M.S.
TITLE Reduction of nonspecific hybridization by using novel base-pairing
schemes
JOURNAL Patent: US 6232462-A 32 15-MAY-2001;
FEATURES
  source      Location/Qualifiers
            1..18      18 bp      DNA      linear      PAT 08-AUG-2001
            /organism="unknown"
            /mol_type="unassigned DNA"
```

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
| | | | | | | | | | | | | | | | | |
Db 2 AGTACGACACACATC 18

RESULT 21
LOCUS I71081 18 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 32 from patent US 5681702.
ACCESSION I71081
VERSION I71081.1 GI:3007216
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Collins, M.L., Horn, T., Sheridan, P.J., Warner, B.D. and Urdea, M.S.
TITLE Reduction of nonspecific hybridization by using novel base-pairing schemes
JOURNAL Patent: US 5681702-A 32 28-OCT-1997;
FEATURES
source
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
| | | | | | | | | | | | | | | | | |
Db 2 AGTACGACACACATC 18

RESULT 22
LOCUS AR236347 18 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 3 from patent US 6465175.
ACCESSION AR236347
VERSION AR236347.1 GI:27280275
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Horn, T., Schroeder, H.R., Warner, B.D., Fiss, E., Sells, T. and Law, S.-J.
TITLE Oligonucleotide probes bearing quenchable fluorescent labels, and methods of use thereof
JOURNAL Patent: US 6465175-A 3 15-OCT-2002;
FEATURES
source
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
| | | | | | | | | | | | | | | | | |
Db 2 AGTACGACACACATC 18

RESULT 23
LOCUS BD107650/c 18 bp DNA linear PAT 18-SEP-2002
DEFINITION Modified protein kinase A-specific oligonucleotides and methods of

their use.
ACCESSION BD107650
VERSION BD107650.1 GI:23202468
KEYWORDS JP 2002501370-A/2.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 18)
AUTHORS Agrawal, S.
TITLE Modified protein kinase A-specific oligonucleotides and methods of their use
JOURNAL Patent: JP 2002501370-A 2 15-JAN-2002;
COMMENT HYBRIDON INC
OS Unidentified
PN JP 2002501370-A/2
PD 15-JAN-2002
PF 12-FEB-1998 JP 1998539567
PR 12-MAR-1997 US 60/040740
PI SUDHIR AGRAWAL
PC C12N15/11,A61K31/70,C07H21/04
CC Strandedness: Single;
CC Topology: Linear;
CC Modified protein kinase A-specific oligonucleotides and methods of their use
CC use
FH Key Location/Qualifiers
FT source 1..18
/organism="Unidentified".

FEATURES
source
Location/Qualifiers
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGCG 693
| | | | | | | | | | | | | | | | | |
Db 18 GCCAGCGAGCGCGCG 2

RESULT 24
LOCUS BD107653/c 18 bp DNA linear PAT 18-SEP-2002
DEFINITION Modified protein kinase A-specific oligonucleotides and methods of their use.
ACCESSION BD107653
VERSION BD107653.1 GI:23202471
KEYWORDS JP 2002501370-A/5.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 18)
AUTHORS Agrawal, S.
TITLE Modified protein kinase A-specific oligonucleotides and methods of their use
JOURNAL Patent: JP 2002501370-A 5 15-JAN-2002;
COMMENT HYBRIDON INC
OS Unidentified
PN JP 2002501370-A/5
PD 15-JAN-2002
PF 12-FEB-1998 JP 1998539567
PR 12-MAR-1997 US 60/040740
PI SUDHIR AGRAWAL
PC C12N15/11,A61K31/70,C07H21/04
CC Strandedness: Single;
CC Topology: Linear;
CC Modified protein kinase A-specific oligonucleotides and methods of their use
CC use
FH Key Location/Qualifiers

```
FT source 1. .18 /organism='Unidentified'.
FEATURES
  source 1. .18
    Location/Qualifiers
      /organism="unidentified"
      /mol_type="genomic DNA"
      /db_xref="taxon:32644"

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGG 693
Db 18 GCCAGCGAGCGCGG 2

RESULT 25
BD107655/c
LOCUS 18 bp DNA linear PAT 18-SEP-2002
DEFINITION Modified protein kinase A-specific oligonucleotides and methods of
their use.
ACCESSION BD107655
VERSION JP 2002501370-A/7.
KEYWORDS unclassified
SOURCE unclassified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Agrawal,S.
TITLE Modified protein kinase A-specific oligonucleotides and methods of
their use
JOURNAL Patent: JP 2002501370-A 7 15-JAN-2002;
COMMENT HYBRIDON INC
OS Unidentified
PN JP 2002501370-A/7
PD 15-JAN-2002
PF 12-FEB-1998 JP 1998539567
PR 12-MAR-1997 US 60/040740
PI SUDHIR AGRAWAL
PC C12N15/11,A61K31/70,C07H21/04
CC Strandedness: Single;
CC Topology: Linear;
CC Modified protein kinase A-specific oligonucleotides and CC
methods of their
CC use
FH key Location/Qualifiers
FT source 1. .18 /organism='Unidentified'.
FEATURES
  source 1. .18
    Location/Qualifiers
      /organism="unidentified"
      /mol_type="genomic DNA"
      /db_xref="taxon:32644"

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 78;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGG 693
Db 18 GCCAGCGAGCGCGG 2

RESULT 26
AR017595
LOCUS 19 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 1 from patent US 5780227.
ACCESSION AR017595
VERSION AR017595.1 GI:3973198
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
```

```
REFERENCE 1 (bases 1 to 19)
AUTHORS Sheridan,P.J., Gagne,J.C. and Anderson,M.L.
TITLE Oligonucleotide probe conjugated to a purified hydrophilic alkaline
phosphatase and uses thereof
JOURNAL Patent: US 5780227-A 1 14-JUL-1998;
FEATURES
  source 1. .19
    Location/Qualifiers
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match 2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
Db 2 AGTACGACACACATC 18

RESULT 27
AR068241
LOCUS 19 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5853974.
ACCESSION AR068241
VERSION AR068241.1 GI:6000448
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Sheridan,P.J.
TITLE Enhancement of alkaline phosphatase with SDS in chemiluminescent
substrates
JOURNAL Patent: US 5853974-A 1 29-DEC-1998;
FEATURES
  source 1. .19
    Location/Qualifiers
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match 2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
Db 2 AGTACGACACACATC 18

RESULT 28
BD014243
LOCUS 19 bp DNA linear PAT 27-AUG-2002
DEFINITION Probe for nucleic acid hybridization.
ACCESSION BD014243
VERSION BD014243.1 GI:22554572
KEYWORDS JP 2001095590-A/109.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Adair,M.S.
TITLE Probe for nucleic acid hybridization
JOURNAL Patent: JP 2001095590-A 109 10-APR-2001;
COMMENT BAYER CORP
OS Artificial Sequence
PN JP 2001095590-A/109
PD 10-APR-2001
PF 08-AUG-2000 JP 2000240494
PR 10-JAN-1990 US 463022
PI MICHAEL S ADAIR
PC C12N15/09,C12Q1/68,G01N33/569,G01N33/576,C12N15/00 CC
Description of Artificial Sequence: Probe
FH Key Location/Qualifiers
```

```

FT      source      1. 19
FT      /organism='Artificial Sequence'.
FEATURES
  source
    1. 19
    Location/Qualifiers
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32630"
Query Match      2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      867 AATACGACACCAATC 883
Db      3 AGTACGACACCAATC 19

RESULT 29
LOCUS      I03563      20 bp ss-DNA      linear      PAT 21-MAY-1993
DEFINITION      Sequence 9 from Patent US 4654419.
ACCESSION      I03563
VERSION      I03563.1 GI:313892
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 20)
AUTHORS      Vaughan,J.H.; Carson,D.A.; Rhodes,G. and Houghten,R.
TITLE      Synthetic polypeptides and antibodies related to epstein-barr virus
JOURNAL
COMMENT      Patent: US 4654419-A 9 31-MAR-1987;
Scripps Clinic and Research Foundation; La Jolla, CA
On Jul 30, 1993 this sequence version replaced gi:268684.
FEATURES
  source
    1. 20
    /organism="unknown"
    /mol_type="unassigned DNA"
Query Match      2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      405 AGAGGAGGAGGAGGAG 421
Db      1 AGAGGAGGAGGAGGAG 17

RESULT 30
LOCUS      AR208100      20 bp      DNA      linear      PAT 20-JUN-2002
DEFINITION      Sequence 18 from patent US 6379960.
ACCESSION      AR208100
VERSION      AR208100.1 GI:21508028
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 20)
AUTHORS      Popoff,I. and Wyatt,J.
TITLE      Antisense modulation of damage-specific DNA binding protein 2, p48
JOURNAL
COMMENT      Patent: US 6379960-A 18 30-APR-2002;
expression
Location/Qualifiers
  source
    1. 20
    /organism="unknown"
    /mol_type="unassigned DNA"
Query Match      2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      815 GAGAGGAGGAGGAGGAG 831
```

```

Db      3 GAGTAGAGGAGGAGGAG 19

RESULT 31
LOCUS      A65119      20 bp      DNA      linear      PAT 29-MAR-1999
DEFINITION      Sequence 16 from Patent EP0798378.
ACCESSION      A65119
VERSION      A65119.1 GI:4530984
KEYWORDS
SOURCE      unidentified
ORGANISM      unidentified
REFERENCE      1
AUTHORS      Mosselman,S. and Dijkema,R.
TITLE      Estrogen receptor
JOURNAL      Patent: EP 0798378-A 16 01-OCT-1997;
AKZO NOBEL NV (NL)
COMMENT      Other publication CA 2200423 19970926
Other publication AU 1652197 19971002.
Location/Qualifiers
  source
    1. 20
    /organism="unidentified"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32644"
Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      822 GGAGCTGGCCAGTGGAG 841
Db      1 GGAAGCTGGCTCAGTGGCTG 20

RESULT 32
LOCUS      AR156208      20 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION      Sequence 3 from patent US 6242181.
ACCESSION      AR156208
VERSION      AR156208.1 GI:15124912
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 20)
AUTHORS      Siffert,W.
TITLE      Methods for diagnosing hypertension by detecting a mutation in the
human G protein .beta.3 subunit gene
JOURNAL      Patent: US 6242181-A 3 05-JUN-2001;
Location/Qualifiers
  source
    1. 20
    /organism="unknown"
    /mol_type="unassigned DNA"
Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      513 TGGGGGAGGTGGAGCACTG 532
Db      1 TGGGGGAGATGGAGCAACTG 20

RESULT 33
LOCUS      BD228536      20 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION      IL-17 homologous polypeptide and its application to remedy.
ACCESSION      BD228536
VERSION      BD228536.1 GI:33038306
KEYWORDS      JP 2002515246-A/131.
SOURCE      unidentified
```

ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Chen,J., Filvaroff,E., Goddard,A., Gurney,A.L., Li,H. and Wood,W.I.
TITLE IL-17 homologous polypeptide and its application to remedy
JOURNAL Patent: JP 2002515246-A 131 28-MAY-2002;
GENENTECH INC
COMMENT OS Unidentified
PN JP 2002515246-A/131
PD 28-MAY-2002
PF 14-MAY-1999 JP 2000549734
PR 15-MAY-1998 US 60/085579,23-DEC-1998 US 60/113621 PI
JIAN CHEN,ELLEN FILVAROFF,AUDLEY GODDARD,AUSTIN L GURNEY, PI
HANZHONG LI,
PI WILLIAM I WOOD
PC C12N15/09,A61K38/21,A61K45/00,A61P19/00,C07K14/52,C07K16/24,
C07K19/00,
PC C12N1/19,C12N1/21,C12N5/10,C12P21/02,C12P21/08,C12Q1/00 PC
C12Q1/68,C12N15/00,
PC A61K37/66,C12N5/00
CC Strandedness: Single;
CC Topology: Linear;
CC IL-17 homologous polypeptide and its application to remedy FH
Key source 1..20
Location/Qualifiers
FT source /organism='Unidentified'.
FEATURES
source 1..20
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 471 GCCTGGAGAGCTCGATCTG 490
|||||
Db 1 GCCTGGAGAGCTCGATCTG 20
RESULT 34
AR225911/c
LOCUS 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 61 from patent US 6444464.
ACCESSION AR225911
VERSION AR225911.1 GI:27264065
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Wyatt,J
TITLE Antisense modulation of E2F transcription factor 2 expression
JOURNAL Patent: US 6444464-A 61 03-SEP-2002;
FEATURES
source 1..20
Location/Qualifiers
/organism='unknown'
/mol_type='genomic DNA'
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 548 CAGATGGCTGAGGACCAAGGC 567
|||||
Db 20 CACCTGACTGAGGACCAAGGC 1
RESULT 35
AR359761
LOCUS 20 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 131 from patent US 6593456.

ACCESSION AR359761
VERSION AR359761.1 GI:33766505
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Gatanaga,T. and Granger,G.A.
TITLE Tumor necrosis factor receptor releasing enzyme
JOURNAL Patent: US 6593456-A 131 15-JUL-2003;
FEATURES
source 1..20
Location/Qualifiers
/organism='unknown'
/mol_type='genomic DNA'
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 471 GCCTGGAGAGCTCGATCTG 490
|||||
Db 1 GCCTGGAGAGCTCGATCTG 20
RESULT 36
AR454156
LOCUS 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 16 from patent US 6680368.
ACCESSION AR454156
VERSION AR454156.1 GI:42687192
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mosselman,S. and Dijkema,R.
TITLE Estrogen receptor beta
JOURNAL Patent: US 6680368-A 16 20-JAN-2004;
FEATURES
source 1..20
Location/Qualifiers
/organism='unknown'
/mol_type='genomic DNA'
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 822 GGAGCTGGCCCGCTTGCAG 841
|||||
Db 1 GGAGCTGGCTCACTTCTG 20
RESULT 37
AR490587
LOCUS 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 16 from patent US 6713270.
ACCESSION AR490587
VERSION AR490587.1 GI:47257976
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mosselman,S. and Dijkema,R.
TITLE Method for identifying ligand of estrogen receptor beta
JOURNAL Patent: US 6713270-A 16 30-MAR-2004;
FEATURES
source 1..20
Location/Qualifiers
/organism='unknown'
/mol_type='genomic DNA'
Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 822 GGAAGCTGGCCAGTTCAG 841
|||||
Db 1 GGAAGCTGGCTACTTGCTG 20

RESULT 38
AX202443
LOCUS AX202443 20 bp DNA linear PAT 30-AUG-2001
DEFINITION Sequence 31 from Patent WO0152620.
ACCESSION AX202443
VERSION AX202443.1 GI:15392192
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Barbas, C.F., Stege, J.T., Guan, X. and Dalmia, B.
TITLE Methods and compositions to modulate expression in plants
JOURNAL Patent: WO 0152620-A 31 26-JUL-2001;
The Scripps Research Institute (US); SYNGENTA AGRICULTURAL
DISCOVERY, INC. (CA)

FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer NZlib5"

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 667 GGCCCGGGCGCCAGCGAGC 686
|||||
Db 1 GGCCCGAGCGCCCTCGAGC 20

RESULT 39
AX296834/c
LOCUS AX296834 20 bp DNA linear PAT 21-NOV-2001
DEFINITION Sequence 8596 from Patent WO0179548.
ACCESSION AX296834
VERSION AX296834.1 GI:17058523
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Barany, F., Zirvi, M., Gerry, N.P., Favis, R. and Kliman, R.
TITLE Method of designing addressable array for detection of nucleic acid
sequence differences using ligase detection reaction
JOURNAL Patent: WO 0179548-A 8596 25-OCT-2001;
CORNELL RESEARCH FOUNDATION, INC. (US)

FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Hypothetical Probe Sequence"

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 828 TGGCCAGTTCAGGTGCC 847
|||||
Db 20 TTGCCAAGTTCAGGTGCC 1

RESULT 40
AX23070

LOCUS AX23070 20 bp DNA linear PAT 07-JAN-2002
DEFINITION Sequence 16 from Patent EP1162264.
ACCESSION AX23070
VERSION AX23070.1 GI:18093953
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Mosselman, S. and Dijkema, R.
TITLE Chimeric hormone receptor
JOURNAL Patent: EP 1162264-A 16 12-DEC-2001;
Akzo Nobel N.V. (NL)

FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer/Probe"

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 822 GGAAGCTGGCCAGTTCAG 841
|||||
Db 1 GGAAGCTGGCTACTTGCTG 20

RESULT 41
AX816171
LOCUS AX816171 20 bp DNA linear PAT 09-DEC-2003
DEFINITION Sequence 4 from Patent WO03066888.
ACCESSION AX816171
VERSION AX816171.1 GI:39646730
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Jonasson, J.
TITLE Method and apparatus for microorganism identification
JOURNAL Patent: WO 03066888-A 4 14-AUG-2003;
Pyrosequencing AB (SE)

FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 76;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 251 AAGCCAGCCATGCTGCACCT 270
|||||
Db 1 ACGACGCCATGCGACCT 20

RESULT 42
CO622504
LOCUS CO622504 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7244 from Patent WO0192524.
ACCESSION CO622504
VERSION CO622504.1 GI:41672722
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.

```

TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 7244 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   source
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAGCG 711
Db      3 GCTGGAGAGTGAGCG 17

RESULT 43
CQ622505
LOCUS      CQ622505
DEFINITION Sequence 7245 from Patent WO0192524.
ACCESSION  CQ622505
VERSION     CQ622505.1 GI:41672723
KEYWORDS    .
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 7245 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   source
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAGCG 711
Db      3 GCTGGAGAGTGAGCG 17

RESULT 44
AR463567
LOCUS      AR463567
DEFINITION Sequence 7244 from patent US 6686188.
ACCESSION  AR463567
VERSION     AR463567.1 GI:42698624
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL     Patent: US 6686188-A 7244 03-FEB-2004;
            Aeomica, Inc. (US)
FEATURES   source
            1. .17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAGCG 711
Db      2 GCTGGAGAGTGAGCG 16

RESULT 45
AR463568
LOCUS      AR463568
DEFINITION Sequence 7245 from patent US 6686188.
ACCESSION  AR463568
VERSION     AR463568.1 GI:42698625
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL     Patent: US 6686188-A 7245 03-FEB-2004;
            Aeomica, Inc. (US)
FEATURES   source
            1. .17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAGCG 711
Db      2 GCTGGAGAGTGAGCG 16

RESULT 46
AX730387
LOCUS      AX730387
DEFINITION Sequence 2021 from Patent WO03025175.
ACCESSION  AX730387
VERSION     AX730387.1 GI:30509730
KEYWORDS    .
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijinder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025175-A 2021 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES   source
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      241 TCCTCTGGGGAGGCC 255
Db      3 TCCTCTGGGGAGGCC 17

RESULT 47
AX736200
LOCUS      AX736200

```

```

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAGCG 711
Db      3 GCTGGAGAGTGAGCG 17

RESULT 45
AR463568
LOCUS      AR463568
DEFINITION Sequence 7245 from patent US 6686188.
ACCESSION  AR463568
VERSION     AR463568.1 GI:42698625
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL     Patent: US 6686188-A 7245 03-FEB-2004;
            Aeomica, Inc. (US)
FEATURES   source
            1. .17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAGCG 711
Db      2 GCTGGAGAGTGAGCG 16

RESULT 46
AX730387
LOCUS      AX730387
DEFINITION Sequence 2021 from Patent WO03025175.
ACCESSION  AX730387
VERSION     AX730387.1 GI:30509730
KEYWORDS    .
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijinder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025175-A 2021 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES   source
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      241 TCCTCTGGGGAGGCC 255
Db      3 TCCTCTGGGGAGGCC 17

RESULT 47
AX736200
LOCUS      AX736200

```

Query Match 2.0%; Score 15; DB 1; Length 20;


```

Best Local Similarity 100.0%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 890 AGCGTGGTGGCAGT 904
Db 15 AGCGTGGTGGCAGT 1

RESULT 52
AR296947
LOCUS AR296947 18 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 8682 from patent US 6537751.
ACCESSION AR296947
VERSION AR296947.1 GI:31684231
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 18)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 8682 25-MAR-2003;
FEATURES
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 97;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 492 AGAGCAGGAAGGAGCAGG 509
Db 1 AGAGGAAGAAGGAGCAGG 18

RESULT 53
BD205460/c
LOCUS BD205460 19 bp DNA linear PAT 17-JUL-2003
DEFINITION Recombinant protein of Treponemapallidum and utilization thereof
for syphilis vaccine.
ACCESSION BD205460
VERSION BD205460.1 GI:33015230
KEYWORDS JP 2002511275-A/43.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
1 (bases 1 to 19)
AUTHORS Voothis,W.C.V., Lukehart,S.A., Lara,G.A.C. and Cameron,C.E.S.
TITLE Recombinant protein of Treponemapallidum and utilization thereof
for syphilis vaccine
JOURNAL Patent: JP 2002511275-A 43 16-APR-2002;
UNIVERSITY OF WASHINGTON
COMMENT OS Artificial Sequence
PN JP 2002511275-A/43
PD 16-APR-2002
PF 09-APR-1999 JP 2000543645
PR 10-APR-1998 US 09/058968
PI WESLEY C VAN VOORHIS, SHEILA A LUKEHART, GLABER A CENTURION
LARA,
CAROLINE E STEBECK CAMERON
PC C12N15/09,A61K39/02,A61P37/04,C07K14/20,C12Q1/68,G01N33/571,
PC C12N15/00
CC Description of Artificial Sequence: T7, PCR3.1 CC
Oligonucleotide used for DNA sequencing.
FH Key Location/Qualifiers
FT misc_feature (1)..(19).
1..19
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 92;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 348 AGAGCAACGAGATTCTGC 365
Db 2 AGAACCAACGAGATTCTGC 19

RESULT 55
BD104776
LOCUS BD104776 19 bp DNA linear PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104776
VERSION BD104776.1 GI:22650350
KEYWORDS WO 0192572-A/880.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1 (bases 1 to 19)
AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
Nishida,M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 880 06-DEC-2001;
NISHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
NISHIDA
COMMENT OS Artificial Sequence
PN WO 0192572-A/880
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004562
PR 01-JUN-2000 JP 00P 164798
PI HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
MATSUMURA,
SHOGO MORIYA,MICHIO NISHIDA
PC C12Q1/68,C12M1/00,C12N15/09,G01N33/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source 1..19
/organism='Artificial Sequence'.

```

```
FEATURES
  source
    Location/Qualifiers
      1. .19
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32630"

Query Match      2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 92;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 310 CTTGAGGAGCAATCAAGA 327
Db 1 CTTGAGGAGCAATCGGGA 18

RESULT 56
LOCUS      CQ622507      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 7247 from Patent WO0192524.
ACCESSION  CQ622507
VERSION    CQ622507.1 GI:41672725
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 7247 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 413 GAGAGGAGTTCCTCA 428
Db 1 GAGAGGAGTTCCTCA 16

RESULT 59
LOCUS      CQ624230/c      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8970 from Patent WO0192524.
ACCESSION  CQ624230
VERSION    CQ624230.1 GI:41674448
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 8970 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 851 CACCAGCTCTCCAG 866
Db 17 CACCAGCTCTCCAG 2

RESULT 60
LOCUS      CQ624231/c      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 7449 from Patent WO0192524.
ACCESSION  CQ622709
VERSION    CQ622709.1 GI:41672927
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 7449 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

Qy 851 CACCAGCTCTTCCAAG 866

Db 17 CACGAGCTCTCCATG 2

RESULT 65
AR465294/c
LOCUS AR465294 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8971 from patent US 6686188.
ACCESSION AR465294
VERSION AR465294.1 GI:42700351
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8971 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 851 CACGAGCTCTCCAAAG 866
|||||
Db 16 CACGAGCTCTCCATG 1

RESULT 66
AR134263/c
LOCUS AR134263 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 2688 from patent US 6194150.
ACCESSION AR134263
VERSION AR134263.1 GI:14123168
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stinchcomb, D.T., Jarvis, T. and McSwiggen, J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2688 27-FEB-2001;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 717 CGCTGCAGCAGCAGCA 732
|||||
Db 16 CCCTGCAGCAGCAGCA 1

RESULT 67
AR299235/c
LOCUS AR299235 18 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 10970 from patent US 6537751.
ACCESSION AR299235
VERSION AR299235.1 GI:31686519
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen, D., Chumakov, I. and Blumenfeld, M.

TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 10970 25-MAR-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 811 GGAGGAGAGAGAGAG 826
|||||
Db 17 GGAGGAGAGATCAAG 2

RESULT 68
AR035629
LOCUS AR035629 19 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 61 from patent US 5871920.
ACCESSION AR035629
VERSION AR035629.1 GI:5952297
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Page, D.C. and Reijo, R.
TITLE Daz: a gene associated with azoospermia
JOURNAL Patent: US 5871920-A 61 16-FEB-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 526 GCACCTGAAGAGATGC 541
|||||
Db 1 GCACCTGAAGAGCTGC 16

RESULT 69
CQ622503
LOCUS CQ622503 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7243 from Patent WO0192524.
ACCESSION CQ622503
VERSION CQ622503.1 GI:41672721
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7243 06-DEC-2001;
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGC 710

[illegible]

```

/organism="unknown"
/mol_type="genomic DNA"

Query Match
  1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 851 CACCAGCTCTTCCA 864
Db 14 CACCAGCTCTTCCA 1

RESULT 75
AX673623/c
LOCUS
DEFINITION Sequence 2068 from Patent WO03004526.
ACCESSION AX673623
VERSION AX673623.1 GI:29331971
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
        reversion, apoptosis and/or resistance to viruses and their use as
        medicines
JOURNAL Patent: WO 03004526-A 2068 16-JAN-2003;
        Molecular Engines Laboratories (FR)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 475 GGAGAAGCTCGATC 488
Db 14 GGAGAAGCTCGATC 1

RESULT 76
AR106794/c
LOCUS
DEFINITION Sequence 42 from patent US 6107091.
ACCESSION AR106794
VERSION AR106794.1 GI:12821324
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cowsert,L.M.
TITLE Antisense inhibition of G-alpha-16 expression
JOURNAL Patent: US 6107091-A 42 22-AUG-2000;
FEATURES
  source
    Location/Qualifiers
      1..18
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  1.9%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 308 TGCTGGAGGAGAA 321
Db 14 TGCTGGAGGAGAA 1

/organism="unknown"
/mol_type="genomic DNA"

Query Match
  1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 851 CACCAGCTCTTCCA 864
Db 14 CACCAGCTCTTCCA 1

RESULT 77
AR045391/c
LOCUS
DEFINITION Sequence 184 from patent US 5817796.
ACCESSION AR045391
VERSION AR045391.1 GI:5966856
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
          Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myd ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 184 06-OCT-1998;
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 405 AGAGGAGGAGGAGGAG 421
Db 17 AGAGGAGGAGGAGGAG 1

RESULT 78
BD254195
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254195
VERSION BD254195.1 GI:33063965
KEYWORDS JP 2002541795-A/1988.
SOURCE unidentified
ORGANISM unidentified
          unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 1988 10-DEC-2002;
        RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
        PN JP 2002541795-A/1988
        PD 10-DEC-2002
        PF 11-APR-2000 JP 2000611654
        PR 12-APR-1999 US 60/129390
        PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
        CI2N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/10, PC
        CI2P21/02,
        PC
        CI2P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
        C12R1:91),
        PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
        PC A61K37/02,
        PC (CI2N5/00,C12R1:91)
        CC Regulation of repressor genes using nucleic acid molecules FH
        Key Location/Qualifiers
        FT source 1..17
        FT /organism='Eukaryote'.
        FT Location/Qualifiers
          1..17
          /organism="unidentified"
          /mol_type="genomic DNA"
          /db_xref="taxon:32644"

Query Match
  1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 367 GGAGCGCTCGAGGAGC 383
Db 17 GGAGCGCTCGAGGAGC 1
```

```

Db      1 GGAGTGTCTTCGAGGAGC 17

RESULT 79
BD254196
LOCUS      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION  BD254196
VERSION     BD254196.1 GI:33063966
KEYWORDS    JP 2002541795-A/1989.
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Blatt, L., Zwick, M., Pavco, P. and McSwiggen, J.
TITLE       Regulation of repressor genes using nucleic acid molecules
JOURNAL     Patent: JP 2002541795-A 1989 10-DEC-2002;
RIBOZYME    PHARMACEUTICALS INC
OS          Eukaryote
PN          JP 2002541795-A/1989
PD          10-DEC-2002
PF          11-APR-2000 JP 2000611654
PI          12-APR-1999 US 60/129390
PR          LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
PT          C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
PC          C12P21/02,
PC          C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
PC          C12R1:91),
PC          (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC          A61K37/02, C12R1:91)
PC          (C12N5/00, C12R1:91)
CC          Regulation of repressor genes using nucleic acid molecules FH
KEY          Location/Qualifiers
FT          source
FT          1..17
FT          Location/Qualifiers
FT          1..17
FT          /organism="Eukaryote".
FT          /organism="unidentified"
FT          /mol_type="genomic DNA"
FT          /db_xref="taxon:32644"

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      368 GAGCGCTTCGAGGAGCT 384
Db      1 GAGTGTCTTCGAGGAGCT 17

RESULT 80
CO622083/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 6923 from Patent WO0192524.
ACCESSION  CO622083
VERSION     CO622083.1 GI:41672301
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 6923 06-DEC-2001;
            Aecomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      827 CTGGCCAGTTGCAGGT 843
Db      17 CTGGCCAGTTGCAGGT 1

RESULT 82
CO623073
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 7813 from Patent WO0192524.
ACCESSION  CO623073
VERSION     CO623073.1 GI:41673291
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 7813 06-DEC-2001;
            Aecomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      493 GAGCGAGGAGGAGCAGG 509
Db      1 GAAGCAAAAGGAGCAGG 17

```

```

RESULT 83
CQ623681
LOCUS CQ623681 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8421 from Patent WO0192524.
ACCESSION CQ623681
VERSION CQ623681.1 GI:41673899
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="Homo sapiens (human)"
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
        Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8421 06-DEC-2001;
        Aeomica, Inc. (US)
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGGAG 505
Db 1 TGAAGAGCGCAGAGGTG 17

RESULT 84
CQ623682
LOCUS CQ623682 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8422 from Patent WO0192524.
ACCESSION CQ623682
VERSION CQ623682.1 GI:41673900
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
        Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8422 06-DEC-2001;
        Aeomica, Inc. (US)
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGCAGAGGAGC 506
Db 1 GAAGAGCGCAGAGGTGC 17

RESULT 85
I52443
LOCUS I52443 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 184 from patent US 5646042.
ACCESSION I52443
VERSION I52443.1 GI:2473644
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 184 08-JUL-1997;
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 405 AGAGGGAGGAGAGGAG 421
Db 17 AGAGGGAGGAGAGGAG 1

RESULT 86
AR190504/c
LOCUS AR190504 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence.5992 from patent US 6346398.
ACCESSION AR190504
VERSION AR190504.1 GI:20236469
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
        related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5992 12-FEB-2002;
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 457 GGTGAGACACTCGGCC 473
Db 17 GGTAGACAGACTCGGCC 1

RESULT 87
AR325427/c
LOCUS AR325427 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2829 from patent US 6566127.
ACCESSION AR325427
VERSION AR325427.1 GI:33711235
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
        related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2829 20-MAY-2003;
FEATURES
    source
        location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned RNA"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```


Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
Qy	493	GAGCGAAGAGGAGCAGG	509						
Db	1	GAAGCAAAAGGAGCAGG	17						
RESULT 93									
AR464744									
LOCUS	AR464744			17 bp	DNA	linear -	PAT 20-FEB-2004		
DEFINITION	Sequence 8421 from patent US 6686188.								
ACCESSION	AR464744								
VERSION	AR464744.1	GI:42699801							
KEYWORDS									
SOURCE	Unknown.								
ORGANISM	Unknown.								
REFERENCE	Unclassified.								
AUTHORS	1 (bases 1 to 17)								
TITLE	Gu,Y., J.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.								
JOURNAL	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle								
FEATURES	Patent: US 6686188-A 8421 03-FEB-2004;								
source	Location/Qualifiers								
	1..17								
	/organism="unknown"								
	/mol_type="genomic DNA"								
Query Match	1.8%;	Score 13.8;	DB 1;	Length 17;					
Best Local Similarity	88.2%;	Pred. No. 1.5e+02;							
Matches	15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;				
Qy	489	TGAAGAGCGCAGAGGAGC	505						
Db	1	TGAAGAGCGCAGAGGTG	17						
RESULT 94									
AR464745									
LOCUS	AR464745			17 bp	DNA	linear	PAT 20-FEB-2004		
DEFINITION	Sequence 8422 from patent US 6686188.								
ACCESSION	AR464745								
VERSION	AR464745.1	GI:42699802							
KEYWORDS									
SOURCE	Unknown.								
ORGANISM	Unknown.								
REFERENCE	Unclassified.								
AUTHORS	1 (bases 1 to 17)								
TITLE	Gu,Y., J.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.								
JOURNAL	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle								
FEATURES	Patent: US 6686188-A 8422 03-FEB-2004;								
source	Location/Qualifiers								
	1..17								
	/organism="unknown"								
	/mol_type="genomic DNA"								
Query Match	1.8%;	Score 13.8;	DB 1;	Length 17;					
Best Local Similarity	88.2%;	Pred. No. 1.5e+02;							
Matches	15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;				
Qy	490	GAAGAGCGCAGAGGAGC	506						
Db	1	GAAGAGCGCAGAGGTGC	17						
RESULT 95									
AX266063/c									
LOCUS	AX266063			17 bp	DNA	linear	PAT 26-OCT-2001		
DEFINITION	Sequence 3454 from Patent WO0173002.								
ACCESSION	AX266063								
VERSION	AX266063.1	GI:16514862							

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS 1 Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 3454 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)

FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 374 TGCAGGAGCTTCTGCA 390
|||||

Db 17 TGCAGGCGCTTCTGCA 1
|||||

RESULT 96
AX266064
LOCUS AX266064 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3455 from Patent WO0173002.
ACCESSION AX266064
VERSION AX266064.1 GI:16514863
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS 1 Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 3455 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)

FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 374 TGCAGGAGCTTCTGCA 390
|||||

Db 1 TGCAGGCGCTTCTGCA 17
|||||

RESULT 97
AX530794
LOCUS AX530794 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 303 from Patent EP1239051.
ACCESSION AX530794
VERSION AX530794.1 GI:25253383
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS 1 Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 303 11-SEP-2002;

```
FEATURES
  source
    Aeomica, Inc. (US)
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 471 GCTGAGAGCTCGAT 487
Db 1 GCTTTGAGAGCTCGAT 17

RESULT 98
AX578640
LOCUS AX578640 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 478 from Patent WO0211674.
ACCESSION AX578640
VERSION AX578640.1 GI:27647842
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
  and Grupe, A.
  Method and reagent for the inhibition of calcium activated chloride
  channel-1 (clca-1)
  Patent: WO 0211674-A 478 14-FEB-2002;
  RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
  Thompson, James (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned RNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 476 GAGAGCTCGATCGAA 492
Db 1 GATAAGGTCGATCTGAA 17

RESULT 99
AX587997/c
LOCUS AX587997 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 729 from Patent EP1281758.
ACCESSION AX587997
VERSION AX587997.1 GI:29410695
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Shannon, M., Gu, Y. and Nguyen, C.T.
  Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
  mdz12
  Patent: EP 1281758-A 729 05-FEB-2003;
  Aeomica, Inc. (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

FEATURES
  source
    Aeomica, Inc. (US)
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 268 CCTGCCTTCAGAACAGG 284
Db 17 CCCGCCCTCAGAACAGG 1

RESULT 100
AX587998/c
LOCUS AX587998 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 730 from Patent EP1281758.
ACCESSION AX587998
VERSION AX587998.1 GI:29410696
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Shannon, M., Gu, Y. and Nguyen, C.T.
  Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
  mdz12
  Patent: EP 1281758-A 730 05-FEB-2003;
  Aeomica, Inc. (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 ACCTGCCTTCAGAACAG 283
Db 17 ACCCGCCTGCAGAACAG 1

RESULT 101
AX757153
LOCUS AX757153 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 474 from Patent WO03040369.
ACCESSION AX757153
VERSION AX757153.1 GI:32251769
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Telerman, A., Amson, R. and Tuijnder, M.
  Sequences involved in tumoral suppression, tumoral reversion,
  apoptosis and/or viral resistance phenomena and their use as
  medicines
  Patent: WO 03040369-A 474 15-MAY-2003;
  Molecular Engines Laboratories (FR)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 250 GAAGCCAGCCATGCTGC 266
Db 1 GATCCAGCCATGCTGC 17
```

RESULT 102
AX757735
LOCUS AX757735 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 1056 from Patent WO03040369.
ACCESSION AX757735
VERSION AX757735.1 GI:32252351
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 1056 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 485 GATCTGAAGAGCAGGA 501
|||||
Db 1 GATCTGAAGAGCAGTA 17
RESULT 103
AX781735
LOCUS AX781735 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 66 from Patent WO03050284.
ACCESSION AX781735
VERSION AX781735.1 GI:32949569
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 66 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 672 GGGCGCCGCGGCGAG 688
|||||
Db 1 GGGCTGCGGCGGCGAG 17
RESULT 104
AX781740
LOCUS AX781740 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 71 from Patent WO03050284.
ACCESSION AX781740
VERSION AX781740.1 GI:32949574
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 71 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 677 GCGAGCGAGCGGCGG 693
|||||
Db 1 GCGAGCGAGCGAGCGG 17
RESULT 105
AX783694
LOCUS AX783694 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2025 from Patent WO03050284.
ACCESSION AX783694
VERSION AX783694.1 GI:32951543
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2025 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 333 GAGATGCCATCCGCGAG 349
|||||
Db 1 GAGATGCCATCCGCGAG 17
RESULT 106
AX783781
LOCUS AX783781 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2112 from Patent WO03050284.
ACCESSION AX783781
VERSION AX783781.1 GI:32951630
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2112 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 413 GAGAGGAGTTCCTCAT 429
Db 1 GAGAAGGAATGCCTCAT 17

RESULT 107
AX783782
LOCUS AX783782 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2113 from Patent WO03050284.
ACCESSION AX783782
VERSION AX783782.1 GI:32951631
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2113 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCCTCATG 430
Db 1 AGAAGGAATGCCTCATG 17

RESULT 108
BD104959
LOCUS BD104959 17 bp DNA linear PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104959
VERSION BD104959.1 GI:22650533
KEYWORDS WO 0192572-A/1063.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Inoko,H., Kagiya,T., Ichiwara,T., Matsuura,Y., Moriya,S. and
Nishida,M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 1063 06-DEC-2001;
NISHINOBO INDUSTRIES INC. SYSTEM RESEARCH INC. HIDEOTOSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO
NISHIDA
COMMENT
PS Artificial Sequence
SN WO 0192572-A/1063
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDEOTOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA,MICHIO NISHIDA
PC C12M1/68,C12M1/00,C12N15/09,G01N33/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source
1..17

/organism='Artificial Sequence'.
Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 760 GCAGGGCCAGAGCGTGG 776
Db 1 GCAGGGCCGTCGCTGG 17

RESULT 109
AR064931/c
LOCUS AR064931 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 56 from patent US 5849481.
ACCESSION AR064931
VERSION AR064931.1 GI:5995147
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Urdea,M.S., Horn,T., Chang,C.-A., Warner,B. and Fultz,T.J.
TITLE Nucleic acid hybridization assays employing large comb-type
branched polynucleotides
JOURNAL Patent: US 5849481-A 56 15-DEC-1998;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AATACGACACACATC 883
Db 17 AGTACGACACACATC 1

RESULT 110
AR096403/c
LOCUS AR096403 18 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 74 from patent US 6007995.
ACCESSION AR096403
VERSION AR096403.1 GI:10025178
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Baker,B.F. and Cowseert,L.M.
TITLE Antisense inhibition of TNFR1 expression
JOURNAL Patent: US 6007995-A 74 28-DEC-1999;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 302 CAGCGCTGCCTGGAGGA 318
Db 17 CTGGGCTGCCTGGAGGA 1
```

```
RESULT 111
AR098802
LOCUS
DEFINITION Sequence 57 from patent US 6077672.
ACCESSION AR098802
VERSION AR098802.1 GI:12808568
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Monia,B.P. and Cowsert,L.M.
TITLE Antisense modulation of TRADD expression
JOURNAL Patent: US 6077672-A 57 20-JUN-2000;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 795 AGCGCCAGCGCGCTCG 811
||||| ||| |||||
Db 2 AGCGCCGCGAGCGCTCG 18

RESULT 112
AR105438/c
LOCUS
DEFINITION Sequence 1 from patent US 6096549.
ACCESSION AR105438
VERSION AR105438.1 GI:12819035
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Pelicic,V., Revrat,J.-M., Gicquel,B., Guilhot,C. and Jackson,M.
TITLE Method of selection of allelic exchange mutants
JOURNAL Patent: US 6096549-A 1 01-AUG-2000;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 810 CGGAGGAGAGGAGGAG 826
||||| ||| |||||
Db 17 CGGAGAGAGGAGCGGAG 1

RESULT 113
BD196769
LOCUS
DEFINITION Prostatic cancer gene.
ACCESSION BD196769
VERSION BD196769.1 GI:33006539
KEYWORDS
SOURCE
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen,D., Blumenfeld,M., Chumakov,I. and Bougueleret,L.
TITLE Prostatic cancer gene
JOURNAL Patent: JP 2002516657-A 358 11-JUN-2002;
COMMENT OS Homo sapiens (human)

PN JP 2002516657-A/358
PD 11-JUN-2002
PF 22-DEC-1998 JP 2000525562
PR 22-DEC-1997 US 08/996306,09-SEP-1998 US 60/099658 PI
DANIEL COHEN,MARTA BLUMENFELD,ILYA CHUMAKOV,LYDIE BOUGUELERET PC
C12N15/09,C12N15/09,A01K67/027,C07K14/47,C07K16/18,C12N1/15, PC
C12N1/19,
PC C12N1/21,C12N5/10,C12N5/10,C12P21/08,C12Q1/68,G01N33/50 PC
,C12N15/00,C12N5/00,
PC C12N5/00,C12N15/00
CC downstream amplification primer for SEQ
190, SEQ 267, SEQ 191,
CC
FH Key Location/Qualifiers
FT primer bind 1..18.
Location/Qualifiers
1..18
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 372 GCTGCGAGGAGCTTCTG 388
||||| ||| |||||
Db 2 GCTGAGAGGAGCTTTG 18

RESULT 114
BD217451/c
LOCUS
DEFINITION Antisense modulation of TNFR1 expression.
ACCESSION BD217451
VERSION BD217451.1 GI:33027221
KEYWORDS
SOURCE
ORGANISM
unidentified
unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Baker,B.F. and Cowsert,L.M.
TITLE Antisense modulation of TNFR1 expression
JOURNAL Patent: JP 2002519015-A 74 02-JUL-2002;
COMMENT OS Unidentified
PN JP 2002519015-A/74
PD 02-JUL-2002
PF 17-JUN-1999 JP 2000557265
PR 26-JUN-1998 US 09/106038
PI BRENDA F BAKER,LEX M COWSERT
PC
C12N15/09,A61K31/7105,A61K48/00,A61P29/00,A61P43/00, PC
C12Q1/68,
PC C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Antisense modulation of TNFR1 expression
FH Key Location/Qualifiers
FT source 1..18
/organism="Unidentified".
Location/Qualifiers
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 302 CAGCGCTGCTGGAGGA 318
||||| ||| |||||
```

Db 17 CTGGGCTGCTGGAGGA 1 linear PAT 20-APR-2002

RESULT 115
ARI92834/c 18 bp DNA
LOCUS Sequence 8322 from patent US 6346398.
DEFINITION ARI92834
ACCESSION ARI92834
VERSION ARI92834.1 GI:20238799
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 8322 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 688 GGCGGGCAGCTGGAGA 704
Db 18 GGCGGGCAGCTGTAGA 2

RESULT 116
AR326578/c 18 bp RNA
LOCUS Sequence 3980 from patent US 6566127.
DEFINITION AR326578
ACCESSION AR326578
VERSION AR326578.1 GI:33712386
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3980 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 688 GGCGGGCAGCTGGAGA 704
Db 18 GGCGGGCAGCTGTAGA 2

RESULT 117
AR359325 18 bp DNA
LOCUS Sequence 38 from patent US 6593133.
DEFINITION AR359325
ACCESSION AR359325
VERSION AR359325.1 GI:33765538
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Johansen,T.E., Blom,N. and Hansen,C.

TITLE Neurotrophic factors
JOURNAL Patent: US 6593133-A 38 15-JUL-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 GCTGGCCCGCTGCAGG 842
Db 1 GCTGGCCCGCTGCAGG 17

RESULT 118
AR534884 18 bp DNA
LOCUS Sequence 38 from patent US 6734284.
DEFINITION AR534884
ACCESSION AR534884
VERSION AR534884.1 GI:53925596
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Johansen,T.E., Blom,N. and Hansen,C.
TITLE Neublastin neurotrophic factors
JOURNAL Patent: US 6734284-A 38 11-MAY-2004;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 GCTGGCCCGCTGCAGG 842
Db 1 GCTGGCCCGCTGCAGG 17

RESULT 119
AX004444 18 bp DNA
LOCUS Sequence 26 from Patent WO9916899.
DEFINITION AX004444
ACCESSION AX004444
VERSION AX004444.1 GI:9927903
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 other sequences; artificial sequences.
AUTHORS Anctil,J.L. and Cote,G.
TITLE Molecular diagnostic of glaucomas associated with chromosomes 2 and 6
JOURNAL Patent: WO 9916899-A 26 08-APR-1999;
FEATURES ANCTIL JEAN LOUIS (CA); COTE GILLES (CA)
Location/Qualifiers
source 1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="OLIGONUCLEOTIDE"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 558 AGGACAAGGCCTCTGTG 574
|||||

```

Db      1 AGGCCAAGACCTCTGTG 17

RESULT 120
LOCUS   AX015708/c
DEFINITION Sequence 10 from Patent WO950421.
ACCESSION AX015708
VERSION   AX015708.1 GI:10041536
KEYWORDS Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens

REFERENCE
AUTHORS   Markham,A.F. and Robinson,P.A.
TITLE      Ubiquitin conjugating enzyme
JOURNAL    Patent: WO 950421-A 10 07-OCT-1999;
            UNIV LEEDS (GB); MARKHAM ALEXANDER FRED (GB); ROBINSON PHILIP ALAN
            (GB)

FEATURES
source    Location/Qualifiers
            1..18
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      719 CTGCAGCAGCAGCACAG 735
Db      17 CTGTAGCTGCAGCACAG 1

RESULT 121
LOCUS   AX114463
DEFINITION Sequence 132 from Patent WO0129257.
ACCESSION AX114463
VERSION   AX114463.1 GI:14031427
KEYWORDS Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens

REFERENCE
AUTHORS   Schork,N. and Skierczynski,B.
TITLE      Methods of genetic cluster analysis and use thereof
JOURNAL    Patent: WO 0129257-A 132 26-APR-2001;
            GENSET (FR)

FEATURES
source    Location/Qualifiers
            1..18
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

primer_bind 1..18
            /notes="downstream amplification primer 4-22 for SEQ 6, in complement"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      372 GCTGCGAGGAGCTTCTG 388
Db      2 GCTGAGAGGAGCTTTTG 18

RESULT 122
LOCUS   AX164504/c
DEFINITION Sequence 334 from Patent WO0138564.

```

```

ACCESSION AX164504
VERSION   AX164504.1 GI:14545438
KEYWORDS synthetic construct
SOURCE    synthetic construct
ORGANISM  other sequences; artificial sequences.

REFERENCE
AUTHORS   Rouleau,G.A., Lafreniere,R.G., Rochefort,D., Cossette,P. and
            Ragsdale,D.
TITLE      Loci for idiopathic generalized epilepsy, mutations thereof and
            method using same to assess, diagnose, prognose or treat epilepsy
            Patent: WO 0138564-A 334 31-MAY-2001;
            McGill University (CA)
JOURNAL    McGill University (CA)
FEATURES
source    Location/Qualifiers
            1..18
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="synthetic oligonucleotide"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      617 CAGAGTCGCTTGGAGGC 633
Db      18 CAGATCGCTTGGGGGC 2

RESULT 123
LOCUS   AX587328
DEFINITION Sequence 104 from Patent WO0236761.
ACCESSION AX587328
VERSION   AX587328.1 GI:27656193
KEYWORDS synthetic construct
SOURCE    synthetic construct
ORGANISM  other sequences; artificial sequences.

REFERENCE
AUTHORS   D'Andrea,A.D., Taniguchi,T., Timmers,C. and Grompe,M.
TITLE      Methods and compositions for the diagnosis of cancer
            susceptibilities and defective dna repair mechanisms and treatment
            thereof
JOURNAL    Patent: WO 0236761-A 104 10-MAY-2002;
            DANA FARBBER CANCER INSTITUTE (US)
FEATURES
source    Location/Qualifiers
            1..18
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="MG476"

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      647 TGCAGGCTCTGGAGGG 663
Db      2 TGCACACTCTGTGGG 18

RESULT 124
LOCUS   AR124643
DEFINITION Sequence 44 from patent US 6172041.
ACCESSION AR124643
VERSION   AR124643.1 GI:14110004
KEYWORDS Unknown.
SOURCE    Unknown.
ORGANISM  Unclassified.

REFERENCE
1 (bases 1 to 17)

```


McCabe, R. Tyler.; Zhou, L.-M.; Laver, R. T.; Olivera, B. M. and

RESULT 128	AR132396/c	AR132396	Sequence 821 from patent US 6194150.	15 bp	DNA	linear	PAT 16-MAY-2001
LOCUS		AR132396					
DEFINITION		AR132396					
ACCESSION		AR132396.1	GI:14121301				
VERSION							
KEYWORDS							
SOURCE		Unknown.					
ORGANISM		Unknown.					
		Unclassified.					
REFERENCE		1 (bases 1 to 15)					

```

AUTHORS      Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE        Nucleic acid based inhibition of CD40
JOURNAL      Patent: US 6194150-A 821 27-FEB-2001;
FEATURES     Location/Qualifiers
             source
             1..15
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 579 CCCAGGTGACGTCT 593
Db 15 CCCAGGTGAAGTCT 1

RESULT 129
BD208731/c
LOCUS          15 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION     Enzymatic nucleic acid treatment of diseases or conditions related
                to hepatitis C virus infection.
ACCESSION      BD208731
VERSION        BD208731.1 GI:33018501
KEYWORDS       JP 2002512791-A/2321.
SOURCE         unidentified
ORGANISM       unclassified.
REFERENCE      1 (bases 1 to 15)
AUTHORS        Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE          Enzymatic nucleic acid treatment of diseases or conditions related
                to hepatitis C virus infection
JOURNAL        Patent: JP 2002512791-A 2321 08-MAY-2002;
                RIBOZYME PHARMACEUTICALS INC
COMMENT        OS Hepatitis virus (hepatitis C virus)
                PN JP 2002512791-A/2321
                PD 08-MAY-2002
                PP 26-APR-1999 JP 2000545991
                PR 27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR
                25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI
                LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A PI
                PAVCO, DENNIS MACEJAK
                PI C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
                PC A61K37/66,
                PC C12N15/00
                CC Enzymatic nucleic acid treatment of diseases or conditions CC
                related to
                CC hepatitis C virus infection.
                FH Key Location/Qualifiers
                FT source 1..15
                FT virus',
                /organism='Hepatitis virus (hepatitis C FT
                /organism='Hepatitis virus (hepatitis C FT

FEATURES     source
             1..15
             /organism="unidentified"
             /mol_type="genomic RNA"
             /db_xref="taxon:32644"

Query Match      1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 595 GCTCGGGAGCTGCA 609
Db 15 GCTCGGGAGCTGCA 1

RESULT 130
AR057415
LOCUS          16 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION     Sequence 1619 from patent US 5837542.
ACCESSION      AR057415

AUTHORS        Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE        Nucleic acid based inhibition of CD40
JOURNAL      Patent: US 6194150-A 821 27-FEB-2001;
FEATURES     Location/Qualifiers
             source
             1..15
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 304 GCGCTGCCTGGAGGA 318
Db 1 GCGCTGCCTGGTGA 15

RESULT 131
AR115173
LOCUS          16 bp      DNA      linear      PAT 16-MAY-2001
DEFINITION     Sequence 1619 from patent US 6132967.
ACCESSION      AR115173
VERSION        AR115173.1 GI:14095495
KEYWORDS       Unknown.
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
                Draper,K.G.
TITLE          Ribozyme treatment of diseases or conditions related to levels of
                intercellular adhesion molecule-1 (ICAM-1)
JOURNAL        Patent: US 6132967-A 1619 17-OCT-2000;
                Location/Qualifiers
FEATURES     source
             1..16
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 304 GCGCTGCCTGGAGGA 318
Db 1 GCGCTGCCTGGTGA 15

RESULT 132
CQ797647/c
LOCUS          16 bp      DNA      linear      PAT 20-APR-2004
DEFINITION     Sequence 27 from Patent WO2004029299.
ACCESSION      CQ797647
VERSION        CQ797647.1 GI:46425927
KEYWORDS       Klebsiella oxytoca
SOURCE         Klebsiella oxytoca
ORGANISM       Klebsiella oxytoca
                Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
                Enterobacteriaceae; Klebsiella.
REFERENCE      1
AUTHORS        Weizenegger,M. and Bollen,M.
TITLE          Methods for detecting and differentiating bacteria
JOURNAL        Patent: WO 2004029299-A 27 08-APR-2004;
                Hain Lifescience GmbH (DE)
FEATURES     source
             1..16
             /organism="Klebsiella oxytoca"

```

```

/mol_type="unassigned DNA"
/db_xref="taxon:571"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 592 CTTGCTCGGGAGCT 606
Db 15 CTTGCTCGGGAGCT 1

RESULT 133
LOCUS AX634461
DEFINITION Sequence 1600 from Patent EP1260586.
ACCESSION AX634461
VERSION AX634461.1 GI:28470075
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Wolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL Patent: EP 1260586-A 1600 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1. .16
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 1.8%; Score 13.4; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 304 GCGCTCGCTGGAGGA 318
Db 1 GCGCTCGCTGGTGA 15

RESULT 134
LOCUS A08221/c
DEFINITION synthetic oligonucleotide primer III.
ACCESSION A08221
VERSION A08221.1 GI:413426
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 17)
AUTHORS Seemann,G., Bosslet,K. and Sedlacek,H.H.
TITLE Antigens composed of major histocompatibility complex class I
antigens and specific carrier molecules, their production and use
JOURNAL Patent: EP 0352761-A 3 31-JAN-1990;
BEHRINGERWERKE Aktiengesellschaft
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 293 GAGACCTCCAGCGC 307
Db 17 GAGACGCTCCAGCGC 3

RESULT 135
LOCUS CQ622084/c
DEFINITION Sequence 6824 from Patent WO0192524.
ACCESSION CQ622084
VERSION CQ622084.1 GI:41672302
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6824 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 16 CACCTGCCTTGAGAA 2

RESULT 136
LOCUS CQ622085/c
DEFINITION Sequence 6825 from Patent WO0192524.
ACCESSION CQ622085
VERSION CQ622085.1 GI:41672303
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6825 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 15 CACCTGCCTTGAGAA 1

RESULT 137
LOCUS CQ622508
DEFINITION Sequence 7248 from Patent WO0192524.

```

```
ACCESSION      CQ622508
VERSION        CQ622508.1  GI:41672726
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS       Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
               Shannon, M.E.
TITLE         Myosin-like gene expressed in human heart and muscle
JOURNAL       Patent: WO 0192524-A 7448 06-DEC-2001;
               Aeomica, Inc. (US)
FEATURES      1. .17
               Location/Qualifiers
               source
               1. .17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match   1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 699 TGGAGAGTGAGCGG 713
      |||||
Db 1 TGGAGAGTGAGCGG 15

RESULT 138
CQ622708
LOCUS         CQ622708 17 bp DNA linear PAT 02-FEB-2004
DEFINITION   Sequence 7448 from Patent WO0192524.
ACCESSION    CQ622708
VERSION      CQ622708.1 GI:41672926
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
               Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 7448 06-DEC-2001;
               Aeomica, Inc. (US)
FEATURES    1. .17
               Location/Qualifiers
               source
               1. .17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match   1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 412 GGAGAGGAGTTCCT 426
      |||||
Db 3 GGAGAGGAGTTCCT 17

RESULT 139
CQ622712
LOCUS         CQ622712 17 bp DNA linear PAT 02-FEB-2004
DEFINITION   Sequence 7452 from Patent WO0192524.
ACCESSION    CQ622712
VERSION      CQ622712.1 GI:41672930
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
               Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 7448 06-DEC-2001;
               Aeomica, Inc. (US)
FEATURES    1. .17
               Location/Qualifiers
               source
               1. .17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match   1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 412 GGAGAGGAGTTCCT 426
      |||||
Db 3 GGAGAGGAGTTCCT 17

RESULT 140
CQ623679
LOCUS         CQ623679 17 bp DNA linear PAT 02-FEB-2004
DEFINITION   Sequence 8419 from Patent WO0192524.
ACCESSION    CQ623679
VERSION      CQ623679.1 GI:41673897
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
               Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 8419 06-DEC-2001;
               Aeomica, Inc. (US)
FEATURES    1. .17
               Location/Qualifiers
               source
               1. .17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match   1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 414 AGAAGGAGTTCCTCA 428
      |||||
Db 1 AGAAGGAGTTCCTCA 15

RESULT 141
CQ623680
LOCUS         CQ623680 17 bp DNA linear PAT 02-FEB-2004
DEFINITION   Sequence 8420 from Patent WO0192524.
ACCESSION    CQ623680
VERSION      CQ623680.1 GI:41673898
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
               Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 8420 06-DEC-2001;
               Aeomica, Inc. (US)
FEATURES    1. .17
               Location/Qualifiers
               source
               1. .17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
```

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGACGCGAAGG 503
Db 2 TGAAGACGCGAAGG 16

RESULT 142
CO624229/c
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8969 from Patent WO0192524.
ACCESSION CO624229
VERSION CO624229.1 GI:41674447
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
AUTHORS Gu, Y., Ji, Y., Penn, S. G., Hanzel, D. K., Rank, D. R., Chen, W. and
Shannon, M. E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8969 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 852 ACCAGCTCTTCCAAG 866
Db 17 ACCAGCTCTTCCATG 3

RESULT 143
I62755/c
LOCUS 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 1 from patent US 5660983.
ACCESSION I62755
VERSION I62755.1 GI:2480463
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Levings, C. S. III and Dewey, R.
TITLE Maize cytoplasmic male sterility type T (cms-T) mitochondria DNA
JOURNAL Patent: US 5660983-A 1 26-AUG-1997;
FEATURES
source 1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 754 GCGCATGCGAGGCCA 768
Db 17 GCTCATGCGAGGCCA 3

RESULT 144
AR192534/c
LOCUS 17 bp DNA linear PAT 20-APR-2002

DEFINITION Sequence 8022 from patent US 6346398.
ACCESSION AR192534
VERSION AR192534.1 GI:20238499
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 8022 12-FEB-2002;
FEATURES
source 1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGC 710
Db 16 AGCTGGAGAGGGAGC 2

RESULT 145
AR286285/c
LOCUS 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 657 from patent US 6528640.
ACCESSION AR286285
VERSION AR286285.1 GI:29723881
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman, L., Burgin, A., Beaudry, A., Karpeisky, A.,
Matulic-Adamic, J., Sweedler, D. and Zinnen, S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 657 04-MAR-2003;
FEATURES
source 1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 642 AGGAATGCCAGGCTC 656
Db 16 AGAATGCCAGGCTC 2

RESULT 146
AR326403/c
LOCUS 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3805 from patent US 6566127.
ACCESSION AR326403
VERSION AR326403.1 GI:33712211
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3805 20-MAY-2003;
FEATURES
source 1. .17
Location/Qualifiers
/organism="unknown"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGGAGAGTGAGC 710
Db 16 AGCTGGAGAGGAGC 2

RESULT 147
AR398275/c
LOCUS AR398275 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 656 from patent US 6617438.
ACCESSION AR398275
VERSION AR398275.1 GI:40135951
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 656 09-SEP-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 642 AGCAATGCCAGGCTC 656
Db 16 AGAAATGCCAGGCTC 2

RESULT 148
AR463147/c
LOCUS AR463147 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6824 from patent US 6686188.
ACCESSION AR463147
VERSION AR463147.1 GI:42698204
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL Patent: US 6686188-A 6824 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 16 CACCTGCCTTCAGAA 2

RESULT 149
AR463148/c
LOCUS AR463148 17 bp DNA linear PAT 20-FEB-2004

DEFINITION Sequence 6825 from patent US 6686188.
ACCESSION AR463148
VERSION AR463148.1 GI:42698205
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL Patent: US 6686188-A 6825 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 15 CACCTGCCTTCAGAA 1

RESULT 150
AR463571
LOCUS AR463571 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7248 from patent US 6686188.
ACCESSION AR463571
VERSION AR463571.1 GI:42698628
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL Patent: US 6686188-A 7248 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 699 TGGAGAGTGAGCGCG 713
Db 1 TGGAGAGTGAGCGGG 15

RESULT 151
AR463771
LOCUS AR463771 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7448 from patent US 6686188.
ACCESSION AR463771
VERSION AR463771.1 GI:42698828
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL Patent: US 6686188-A 7448 03-FEB-2004;

```

FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="unknown"
        /mol_type="genomic DNA"

  Query Match
    Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

  QY 412 GCAGAGGAGTTCCT 426
  Db 3 GCAGAGGAGTTCCT 17

RESULT 152
LOCUS AR463775 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7452 from patent US 6686188.
ACCESSION AR463775
VERSION AR463775.1 GI:42698832
KEYWORDS
SOURCE
  ORGANISM
    Unknown.
  REFERENCE
    1 (bases 1 to 17)
    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
    Shannon, M.E.
  TITLE
    Polynucleotide encoding a human myosin-like polypeptide expressed
    predominantly in heart and muscle
  JOURNAL
    Patent: US 6686188-A 7452 03-FEB-2004;
  FEATURES
    Location/Qualifiers
      1..17
        /organism="unknown"
        /mol_type="genomic DNA"

  Query Match
    Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

  QY 414 AGAAGGAGTTCCTCA 428
  Db 1 AGAAGGAGTTCCTCA 15

RESULT 153
LOCUS AR464742 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8419 from patent US 6686188.
ACCESSION AR464742
VERSION AR464742.1 GI:42699799
KEYWORDS
SOURCE
  ORGANISM
    Unknown.
  REFERENCE
    1 (bases 1 to 17)
    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
    Shannon, M.E.
  TITLE
    Polynucleotide encoding a human myosin-like polypeptide expressed
    predominantly in heart and muscle
  JOURNAL
    Patent: US 6686188-A 8419 03-FEB-2004;
  FEATURES
    Location/Qualifiers
      1..17
        /organism="unknown"
        /mol_type="genomic DNA"

  Query Match
    Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

  QY 489 TGAAGAGCGAAGG 503
  Db 3 TGAAGAGCGAAGG 17

RESULT 154
LOCUS AR464743 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8420 from patent US 6686188.
ACCESSION AR464743
VERSION AR464743.1 GI:42699800
KEYWORDS
SOURCE
  ORGANISM
    Unknown.
  REFERENCE
    1 (bases 1 to 17)
    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
    Shannon, M.E.
  TITLE
    Polynucleotide encoding a human myosin-like polypeptide expressed
    predominantly in heart and muscle
  JOURNAL
    Patent: US 6686188-A 8420 03-FEB-2004;
  FEATURES
    Location/Qualifiers
      1..17
        /organism="unknown"
        /mol_type="genomic DNA"

  Query Match
    Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

  QY 489 TGAAGAGCGAAGG 503
  Db 2 TGAAGAGCGAAGG 16

RESULT 155
LOCUS AR465292 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8969 from patent US 6686188.
ACCESSION AR465292
VERSION AR465292.1 GI:42700349
KEYWORDS
SOURCE
  ORGANISM
    Unknown.
  REFERENCE
    1 (bases 1 to 17)
    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
    Shannon, M.E.
  TITLE
    Polynucleotide encoding a human myosin-like polypeptide expressed
    predominantly in heart and muscle
  JOURNAL
    Patent: US 6686188-A 8969 03-FEB-2004;
  FEATURES
    Location/Qualifiers
      1..17
        /organism="unknown"
        /mol_type="genomic DNA"

  Query Match
    Best Local Similarity 1.8%; Score 13.4; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

  QY 852 ACCAGCTCTTCCAG 866
  Db 17 ACCAGCTCTTCCATG 3

RESULT 156
LOCUS AX324837 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 975 from Patent WO0192512.
ACCESSION AX324837
VERSION AX324837.1 GI:18095590
KEYWORDS
SOURCE
  ORGANISM
    Oryza sativa
    Oryza sativa
    Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
    Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
    Ehrhartoideae; Oryzaceae; Oryza.

```

```

source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 493 GAGGCAGAGGAGCA 507
|||||
Db 17 GAGGCAGAGGAGGA 3

RESULT 159
AX738306 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 3896 from Patent WO03025177.
ACCESSION AX738306
VERSION AX738306.1 GI:30517594
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 3896 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 215 GATCAGGACGTACTG 229
|||||
Db 1 GATCAGGACGTACTG 15

RESULT 160
AX762032 17 bp DNA linear PAT 25-JUN-2003
LOCUS
DEFINITION Sequence 5353 from Patent WO03040369.
ACCESSION AX762032
VERSION AX762032.1 GI:32256648
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 5353 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```



```

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAG 709
Db      5 GCTGGAGAGTGAG 17

RESULT 166
LOCUS      CQ624234/c
DEFINITION Sequence 8974 from Patent WO0192524.
ACCESSION  CQ624234
VERSION     CQ624234.1 GI:41674452
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM
REFERENCE 1
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 8974 06-DEC-2001;
            Aecomica, Inc. (US)
FEATURES   source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      851 CACCAGCTCTTCC 863
Db      13 CACCAGCTCTTCC 1

RESULT 167
LOCUS      I52439/c
DEFINITION Sequence 180 from patent US 5646042.
ACCESSION  I52439
VERSION     I52439.1 GI:2473640
KEYWORDS
SOURCE      Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS    Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.
TITLE      C-myb targeted ribozymes
JOURNAL    Patent: US 5646042-A 180 08-JUL-1997;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      409 GGAGGAGAGGAG 421
Db      16 GGAGGAGAGGAG 4

RESULT 168
LOCUS      I52441/c
DEFINITION Sequence 182 from patent US 5646042.
ACCESSION  I52441
VERSION     I52441.1 GI:2473642
KEYWORDS
SOURCE      Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS    Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.
TITLE      C-myb targeted ribozymes
JOURNAL    Patent: US 5646042-A 182 08-JUL-1997;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      409 GGAGGAGAGGAG 421
Db      15 GGAGGAGAGGAG 3

RESULT 169
LOCUS      AR463565
DEFINITION Sequence 7242 from patent US 6686188.
ACCESSION  AR463565
VERSION     AR463565.1 GI:42698622
KEYWORDS
SOURCE      Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL    Patent: US 6686188-A 7242 03-FEB-2004;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAG 709
Db      5 GCTGGAGAGTGAG 17

RESULT 170
LOCUS      AR465297/c
DEFINITION Sequence 8974 from patent US 6686188.
ACCESSION  AR465297
VERSION     AR465297.1 GI:42700354
KEYWORDS
SOURCE      Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL    Patent: US 6686188-A 8974 03-FEB-2004;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      409 GGAGGAGAGGAG 421
Db      16 GGAGGAGAGGAG 4

RESULT 168
LOCUS      I52441/c
DEFINITION Sequence 182 from patent US 5646042.
ACCESSION  I52441
VERSION     I52441.1 GI:2473642
KEYWORDS
SOURCE      Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS    Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.
TITLE      C-myb targeted ribozymes
JOURNAL    Patent: US 5646042-A 182 08-JUL-1997;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      851 CACCAGCTCTTCC 863
Db      13 CACCAGCTCTTCC 1

RESULT 167
LOCUS      I52439/c
DEFINITION Sequence 180 from patent US 5646042.
ACCESSION  I52439
VERSION     I52439.1 GI:2473640
KEYWORDS
SOURCE      Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS    Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.
TITLE      C-myb targeted ribozymes
JOURNAL    Patent: US 5646042-A 180 08-JUL-1997;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      409 GGAGGAGAGGAG 421
Db      16 GGAGGAGAGGAG 4

RESULT 168
LOCUS      I52441/c
DEFINITION Sequence 182 from patent US 5646042.
ACCESSION  I52441
VERSION     I52441.1 GI:2473642
KEYWORDS
SOURCE      Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS    Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.
TITLE      C-myb targeted ribozymes
JOURNAL    Patent: US 5646042-A 182 08-JUL-1997;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      409 GGAGGAGAGGAG 421
Db      15 GGAGGAGAGGAG 3

RESULT 169
LOCUS      AR463565
DEFINITION Sequence 7242 from patent US 6686188.
ACCESSION  AR463565
VERSION     AR463565.1 GI:42698622
KEYWORDS
SOURCE      Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL    Patent: US 6686188-A 7242 03-FEB-2004;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGGAGAGTGAG 709
Db      5 GCTGGAGAGTGAG 17

RESULT 170
LOCUS      AR465297/c
DEFINITION Sequence 8974 from patent US 6686188.
ACCESSION  AR465297
VERSION     AR465297.1 GI:42700354
KEYWORDS
SOURCE      Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE      Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL    Patent: US 6686188-A 8974 03-FEB-2004;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

```

```

/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.7%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCC 863
Db 13 CACCAGCTCTTCC 1

RESULT 171
AX046409/c
LOCUS AX046409 17 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 76 from Patent WO0011168.
ACCESSION AX046409
VERSION AX046409.1 GI:11344379
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Lemischka, I. and Moore, K.
TITLE Genes that regulate hematopoietic blood forming stem cells and uses thereof
JOURNAL Patent: WO 0011168-A 76 02-MAR-2000;
Princeton University (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match
Best Local Similarity 1.7%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 667 GGCCCGGGCGGCC 679
Db 17 GGCCCGGGCGGCC 5

RESULT 172
A67075/c
LOCUS A67075 16 bp DNA linear PAT 29-MAR-1999
DEFINITION Sequence 242 from Patent WO9740193.
ACCESSION A67075
VERSION A67075.1 GI:4538446
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Stuyver, L., Rossau, R. and Maertens, G.
TITLE METHOD FOR TYPING AND DETECTING HBV
JOURNAL Patent: WO 9740193-A 242 30-OCT-1997;
INNOGENETICS NV (BE)
FEATURES
source
1..16
Location/Qualifiers
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 395 CAAGCCAGCCAGGG 410
Db 16 CAAGCCAGCAGTGGG 1

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Annealed Sequence"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 690 CGCGCAGCTGGAGAG 705
Db 1 CGGCGCAGCTGGAGGG 16

RESULT 174
E33195/c
LOCUS E33195 16 bp DNA linear PAT 18-JUN-2001
DEFINITION Reagent for detecting gene polymorphism of apolipoprotein E gene and alpha-1antichymotrypsin gene and detection method.
ACCESSION E33195
VERSION E33195.1 GI:13022358
KEYWORDS JP 2000050898-A/7.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Norinobu, K. and Toshiaki, B.
TITLE Reagent for detecting gene polymorphism of apolipoprotein E gene and alpha-1antichymotrypsin gene and detection method
JOURNAL Patent: JP 2000050898-A 7 22-FEB-2000;
NISHIO CORP
COMMENT OS Unidentified
PN JP 2000050898-A/7
PD 22-FEB-2000
PP 06-AUG-1998 JP 1998235033
PR
PI NORINOBU KUSABA, TOSHIAKI BABA
PC C12Q1/68, A61B5/00, C12N15/09, G01N33/566, C12N15/00 CC
Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source
1..16
Location/Qualifiers
/organism="Unidentified".
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 373 CTGCGAGGAGCTTCTG 388
Db 1 CTGCGAGGAGCTTCTG 388

```

Db 16 CTCCGAGCGCTTCTG 1

RESULT 175
E52013
LOCUS IL-6 receptor/IL-6 directly fused protein. 16 bp DNA linear PAT 31-JAN-2002
DEFINITION
E52013
ACCESSION
E52013.1 GI:18629574
KEYWORDS JP 2001008690-A/10.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 16)
AUTHORS Ekita,T., Iegame,H., Ida,H., Yasukawa,K., Tsuchiya,S. and Ide,T.
TITLE IL-6 receptor/IL-6 directly fused protein
JOURNAL Patent: JP 2001008690-A 10 16-JAN-2001;
TOSOH CORP
OS Artificial Sequence
PN JP 2001008690-A/10
PD 16-JAN-2001
PF 02-JUL-1999 JP 1999188650
PR TEIJI EKITA,HARUO IEGAME,HIROSHI IDA,KIYOSHI YASUKAWA, PT
SHIGEO TSUCHIYA,
PI TERUHIKO IDE
PC C12N15/09,A61K31/00,A61K38/00,C07K14/715,
C07K19/00,
PC C12N1/19,C12P21/02//((C12N1/19,C12R1:84),(C12P21/02,C12R1:84),
C12N15/00,
PC A61K37/02
CC
FH Key Location/Qualifiers
FT source 1..16
/organism="Artificial Sequence".
FEATURES
source
1..16
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 690 CGCGGCGAGCTGGAGAG 705
Db 1 CGGCGGCGAGCTGGAGGG 16
RESULT 176
AR322209/c
LOCUS AR322209 16 bp DNA linear PAT 17-AUG-2003
DEFINITION
AR322209 Sequence 18 from patent US 6566064.
ACCESSION
AR322209
VERSION AR322209.1 GI:33707773
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Shiraki,M., Ouchi,Y., Hosoi,T., Kusaba,N., Baba,T. and Yoshida,H.
TITLE Method for anticipating sensitivity to medicine for osteoporosis
JOURNAL Patent: US 6566064-A 18 20-MAY-2003;
FEATURES
source
1..16
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 690 CGCGGCGAGCTGGAGAG 705
Db 1 CGGCGGCGAGCTGGAGGG 16
RESULT 177
AR488577/c
LOCUS AR488577 16 bp DNA linear PAT 15-MAY-2004
DEFINITION
AR488577 Sequence 242 from patent US 6709812.
ACCESSION
AR488577
VERSION AR488577.1 GI:47254629
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Stuyver,L., Rossau,R. and Maertens,G.
TITLE Method for typing and detecting HBV
JOURNAL Patent: US 6709812-A 242 23-MAR-2004;
FEATURES
source
1..16
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 395 CAAGCCGCGCAGAGGG 410
Db 16 CAAGCCGCGCAGAGTGGG 1
RESULT 178
AX128605/c
LOCUS AX128605 16 bp DNA linear PAT 15-MAY-2001
DEFINITION
AX128605 Sequence 5 from Patent WO0130989.
ACCESSION
AX128605
VERSION AX128605.1 GI:14135067
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Renner,W.A. and Nieba,L.
TITLE Method for creating divergent populations of nucleic acid molecules
and proteins
JOURNAL Patent: WO 0130989-A 5 03-MAY-2001;
Cytos Biotechnology AG (CH) ; Renner, Wolfgang Andreas (CH) ;
Nieba, Lars (CH)
FEATURES
source
1..16
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 749 CAGTCGCGCATGCAGG 764
Db 16 CAGATGAGCATGCAGG 1
RESULT 179
AX804969/c
LOCUS AX804969 16 bp DNA linear PAT 25-NOV-2003
DEFINITION
AX804969 Sequence 1137 from Patent WO03060160.
ACCESSION
AX804969
VERSION AX804969.1 GI:38522110
KEYWORDS

```

SOURCE      Oreochromis niloticus (Nile tilapia)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
            Acanthopterygii; Acanthopterygii; Perciformes; Perciformes;
            Labroidae; Cichlidae; Oreochromis.

REFERENCE   Lie,Y., Slettan,A., Hoeyum,M. and Lingaas,F.
AUTHORS    Verification of food origin based on nucleic acid pattern
TITLE      recognition
JOURNAL     Patent: WO 03060160-A 1137 24-JUL-2003;
            Genomar ASA (NO)
FEATURES    source
            Location/Qualifiers
            /organism="Oreochromis niloticus"
            /mol_type="unassigned DNA"
            /db_xref="taxon:8128"

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 622 TCGCTTGAGGCTGCC 637
DB 16 TTGCTTGGAGACTGCC 1

RESULT 180
BD083852/c
LOCUS      BD083852
DEFINITION Method for predicting sensitivity to osteoporosis drug and reagent
            kit therefor.
ACCESSION  BD083852
VERSION    BD083852.1 GI:22629462
KEYWORDS   JP 2001333799-A/18.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            1 (bases 1 to 16)
AUTHORS    Shiraki,M., Ouchi,Y. and Hosoi,T.
TITLE      Method for predicting sensitivity to osteoporosis drug and reagent
            kit therefor
JOURNAL     Patent: JP 2001333799-A 18 04-DEC-2001;
            NISSHO CORP
COMMENT     OS Homo sapiens (human)
            PN JP 2001333799-A/18
            PD 04-DEC-2001
            PF 26-MAY-2000 JP 2000155993
            PI MASATAKA SHIRAKI,YASUYOSHI OUCHI,TAKAYUKI HOSOI PC
            C12Q1/68,C12N15/09,G01N33/53,G01N33/566,C12N15/00 CC A part of
            the base sequence of apolipoprotein E gene FH Key
            Location/Qualifiers
            FT source      1..16
            /organism="Homo sapiens (human)"

FEATURES    source
            Location/Qualifiers
            1..16
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 373 CTGCGAGGAGCTTCTG 388
DB 16 CTGCCAGGCGCTTCTG 1

RESULT 181
BD083870/c
LOCUS      BD083870
DEFINITION Reagent and method for the simultaneous detection of gene
            polymorphisms in vitamin D receptor gene, apolipoprotein E gene and
            estrogen receptor gene.
ACCESSION  BD083870
VERSION    BD083870.1 GI:22629480
KEYWORDS   JP 2001333798-A/5.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            1 (bases 1 to 16)
AUTHORS    Kusaba,N., Baba,T. and Yoshida,H.
TITLE      Reagent and method for the simultaneous detection of gene
            polymorphisms in vitamin D receptor gene, apolipoprotein E gene and
            estrogen receptor gene
JOURNAL     Patent: JP 2001333798-A 5 04-DEC-2001;
            NISSHO CORP
COMMENT     OS Homo sapiens (human)
            PN JP 2001333798-A/5
            PD 04-DEC-2001
            PF 26-MAY-2000 JP 2000155871
            PI NORINOBU KUSABA,TOSHITAKI BABA,HIROSHI YOSHIDA PC
            C12Q1/68,A61K45/00,A61P19/08,C12N15/09,G01N33/15,G01N33/50, PC
            G01N33/53.
            PC G01N33/566,C12N15/00
            CC Part of base sequence of apolipoprotein E gene FH Key
            Location/Qualifiers
            FT source      1..16
            /organism="Homo sapiens (human)"

FEATURES    source
            Location/Qualifiers
            1..16
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 373 CTGCGAGGAGCTTCTG 388
DB 16 CTGCCAGGCGCTTCTG 1

RESULT 182
BD083870/c
LOCUS      BD083870
DEFINITION Reagent and method for the simultaneous detection of gene
            polymorphisms in vitamin D receptor gene, apolipoprotein E gene and
            estrogen receptor gene.
ACCESSION  BD083870
VERSION    BD083870.1 GI:22629480
KEYWORDS   JP 2001333798-A/5.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            1 (bases 1 to 17)
AUTHORS    Heckl,K., Spevak,W., Ostermann,E., Zoepfel,A., Krystek,E.,
            Maurer-Fogy,I., Wiche-Castanon,M.J., Stratowa,C. and Hauptmann,R.
            Human manganese superoxide dismutase (hMn-SOD)
            Patent: EP 0282899-A 18 21-SEP-1988;
            BOEHRINGER INGELHEIM INTERNATIONAL GmbH
            Location/Qualifiers
            FT source      1..17
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 GAGATGTCAGCCCA 197
DB 2 GAGATGTCAGCCCA 17

```

RESULT 183
A34251
LOCUS A34251 17 bp DNA linear PAT 03-JUL-2002
DEFINITION Synthetic sequencing primer.
ACCESSION A34251
VERSION A34251.1 GI:21694203
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Odink,K.G., Tarcsey,L., Brueggen,J., Wiesendanger,W., Cerletti,N.,
Sorg,C., DeWolf-Peters,C. and Delabie,J.
TITLE Novel cytokines
JOURNAL Patent: EP 0412050-A 11 06-FEB-1991;
CIBA-GEIGY AG
FEATURES
source Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 438 TCCAGGAGGCCAGGAA 453
Db 1 TCCAGGAGGCCCTGAA 16
RESULT 184
AR045383/c
LOCUS AR045383 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 176 from patent US 5817796.
ACCESSION AR045383
VERSION AR045383.1 GI:5966848
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylyate residues
JOURNAL Patent: US 5817796-A 176 06-OCT-1998;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 405 AGAGGAGGAGGAGGAGGA 420
Db 17 AGAAGGAGGAGGAGGAGGA 2
RESULT 185
AR057435
LOCUS AR057435 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1639 from patent US 5837542.
ACCESSION AR057435
VERSION AR057435.1 GI:5983012
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and

Draper,K.G.
Intercellular adhesion molecule-1 (ICAM-1) ribozymes
Patent: US 5837542-A 1639 17-NOV-1998;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACTCGGCTGG 16
RESULT 186
AR057586
LOCUS AR057586 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1790 from patent US 5837542.
ACCESSION AR057586
VERSION AR057586.1 GI:5983163
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
Draper,K.G.
Intercellular adhesion molecule-1 (ICAM-1) ribozymes
Patent: US 5837542-A 1790 17-NOV-1998;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACTCGGCTGG 16
RESULT 187
AR057597
LOCUS AR057597 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1801 from patent US 5837542.
ACCESSION AR057597
VERSION AR057597.1 GI:5983174
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
Draper,K.G.
Intercellular adhesion molecule-1 (ICAM-1) ribozymes
Patent: US 5837542-A 1801 17-NOV-1998;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACTCGGCTGG 16

```
RESULT 188
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    AR057619
    Sequence 1823 from patent US 5837542.
    AR057619
    AR057619.1 GI:5983196
    Unknown.
    SOURCE
    ORGANISM
    Unclassified.
    1 (bases 1 to 17)
    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
    Draper,K.G.
    Intercellular adhesion molecule-1 (ICAM-1) ribozymes
    Patent: US 5837542-A 1823 17-NOV-1998;
    Location/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
    Query Match
    Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16

RESULT 189
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    AR057664
    Sequence 1868 from patent US 5837542.
    AR057664
    AR057664.1 GI:5983241
    Unknown.
    SOURCE
    ORGANISM
    Unclassified.
    1 (bases 1 to 17)
    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
    Draper,K.G.
    Intercellular adhesion molecule-1 (ICAM-1) ribozymes
    Patent: US 5837542-A 1868 17-NOV-1998;
    Location/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
    Query Match
    Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16

RESULT 190
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    AR115193
    Sequence 1639 from patent US 6132967.
    AR115193
    AR115193.1 GI:14095515
    Unknown.
    SOURCE
    ORGANISM
    Unclassified.
    1 (bases 1 to 17)
    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
    Draper,K.G.
    Intercellular adhesion molecule-1 (ICAM-1) ribozymes
    Patent: US 6132967-A 1639 17-OCT-2000;
    Location/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
    Query Match
    Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16

RESULT 191
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    AR115344
    Sequence 1790 from patent US 6132967.
    AR115344
    AR115344.1 GI:14095666
    Unknown.
    SOURCE
    ORGANISM
    Unclassified.
    1 (bases 1 to 17)
    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
    Draper,K.G.
    Ribozyme treatment of diseases or conditions related to levels of
    intercellular adhesion molecule-1 (ICAM-1)
    Patent: US 6132967-A 1790 17-OCT-2000;
    Location/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
    Query Match
    Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16

RESULT 192
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    AR115355
    Sequence 1801 from patent US 6132967.
    AR115355
    AR115355.1 GI:14095677
    Unknown.
    SOURCE
    ORGANISM
    Unclassified.
    1 (bases 1 to 17)
    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
    Draper,K.G.
    Ribozyme treatment of diseases or conditions related to levels of
    intercellular adhesion molecule-1 (ICAM-1)
    Patent: US 6132967-A 1801 17-OCT-2000;
    Location/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
    Query Match
    Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16

RESULT 193
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
    AR115193
    Sequence 1639 from patent US 6132967.
    AR115193
    AR115193.1 GI:14095515
    Unknown.
    SOURCE
    ORGANISM
    Unclassified.
    1 (bases 1 to 17)
    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
    Draper,K.G.
    Intercellular adhesion molecule-1 (ICAM-1) ribozymes
    Patent: US 6132967-A 1639 17-OCT-2000;
    Location/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
    Query Match
    Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
    Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
Db 1 GAGAACCTCGGCTGG 16
```

[illegible]


```

DEFINITION      Method and reagent for treating diseases or conditions concerning
ACCESSION      BD200587
VERSION        BD200587.1 GI:33010357
KEYWORDS       JP 2002509721-A/3613.
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 17)
AUTHORS       Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE         Method and reagent for treating diseases or conditions concerning
                molecule participating in vasculogenic response
JOURNAL       RIBOZYME PHARMACEUTICALS INC
COMMENT       Patent: JP 2002509721-A 3613 02-APR-2002;
                OS Homo sapiens (human)
                PN JP 2002509721-A/3613
                PD 02-APR-2002
                PF 24-MAR-1999 JP 2000541291
                PR 27-MAR-1998 US 60/079678
                PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
                PI JAMES A MCSWIGGEN
                PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Homo sapiens (human)'.
FEATURES
source
Query Match 1..7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 676 GCCCAGCGGAGCGGC 691
Db 16 GCCCAGCGGAGCGGC 1
|||||
|||||

RESULT 198
BD202923/c
LOCUS      17 bp RNA linear PAT 17-JUL-2003
DEFINITION      Method and reagent for treating diseases or conditions concerning
ACCESSION      BD202923
VERSION        BD202923.1 GI:33012693
KEYWORDS       JP 2002509721-A/5949.
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 17)
AUTHORS       Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE         Method and reagent for treating diseases or conditions concerning
                molecule participating in vasculogenic response
JOURNAL       RIBOZYME PHARMACEUTICALS INC
COMMENT       Patent: JP 2002509721-A 5949 02-APR-2002;
                OS Homo sapiens (human)
                PN JP 2002509721-A/5949
                PD 02-APR-2002
                PF 24-MAR-1999 JP 2000541291
                PR 27-MAR-1998 US 60/079678
                PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
                PI JAMES A MCSWIGGEN

```

```

PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Homo sapiens (human)'.
FEATURES
source
Query Match 1..7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 493 GAGCGCAGGAGGAGCAG 508
Db 16 GAGCGCAGGAGTGCAG 1
|||||
|||||

RESULT 199
BD241701
LOCUS      17 bp DNA linear PAT 17-JUL-2003
DEFINITION      Methods and products related to genotyping and DNA analysis.
ACCESSION      BD241701
VERSION        BD241701.1 GI:33051471
KEYWORDS       JP 2002525127-A/648.
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 17)
AUTHORS       Landers,J.S., Jordan,B., Housman,D.E. and Charest,A.
TITLE         Methods and products related to genotyping and DNA analysis
JOURNAL       Patent: JP 2002525127-A 648 13-AUG-2002;
                MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT       OS Homo sapiens (human)
                PN JP 2002525127-A/648
                PD 13-AUG-2002
                PF 24-SEP-1999 JP 2000572407
                PR 25-SEP-1998 US 60/101757
                PI JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
                C12N15/09,C12Q1/68,G01N33/53,G01N33/56,G01N33/58,G01N37/00, PC
                G01N37/00,
                PC C12N15/00
                CC Methods and products related to genotyping and DNA analysis FH
                Key source 1..17
                Location/Qualifiers
                FT /organism='Homo sapiens (human)'.
                FEATURES
                source
                Query Match 1..7%; Score 12.8; DB 1; Length 17;
                Best Local Similarity 87.5%; Pred. No. 2.1e+02;
                Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
                QY 397 ACCGAGCGGAGGAG 412
                Db 1 AGGCAGCTAGAGGAG 16
                |||||
                |||||

RESULT 200
BD254084/c
LOCUS      17 bp DNA linear PAT 17-JUL-2003

```

PC	(C12N5/00,C12R1:91)
CC	Regulation of repressor genes using nucleic acid molecules FH
Key	Location/Qualifiers
FT	1. .17
FT	/organism='Eukaryote'.
FEATURES	Location/Qualifiers
source	1. .17
Query Match	1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity	87.5%; Pred. No. 2.1e+02;
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0
Qy	812 GAGGAGAAGAGGAGC 827
Db	17 GAGGAGAAGAGGGTGC 2
RESULT 202	
BD254816/c	
LOCUS	BD254816 17 bp DNA linear PAT 17-JUL-2003
DEFINITION	Regulation of repressor genes using nucleic acid molecules.
ACCESSION	BD254816
VERSION	BD254816.1 GI:33064586
KEYWORDS	JP 2002541795-A/2609.
SOURCE	unidentified
ORGANISM	unclassified.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
TITLE	Regulation of repressor genes using nucleic acid molecules
JOURNAL	Patent: JP 200541795-A 2609 10-DEC-2002;
COMMENT	RIBOZYME PHARMACEUTICALS INC
OS	Eukaryote
PN	JP 2002541795-A/2609
PD	10-DEC-2002
PF	11-APR-2000 JP 2000611654
PR	12-APR-1999 US 60/129390
PI	LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC	
C12P21/02,	
PC	C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),	
PC	C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC	A61K37/02,
PC	C12N5/00,C12R1:91)
CC	Regulation of repressor genes using nucleic acid molecules FH
Key	Location/Qualifiers
FT	1. .17
FT	/organism='Eukaryote'.
FEATURES	Location/Qualifiers
source	1. .17
Query Match	1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity	87.5%; Pred. No. 2.1e+02;
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy	510 CTCGCGGAGGTGGA 525
Db	17 CTCGCGGAGGCGGA 2
RESULT 203	
BD257476/c	
LOCUS	BD257476 17 bp DNA linear PAT 17-JUL-2003
DEFINITION	Regulation of repressor genes using nucleic acid molecules.
ACCESSION	BD257476

```

VERSION      BD257476.1  GI:33067246
KEYWORDS     JP 2002541795-A/5269.
SOURCE       unidentifed
ORGANISM     unidentifed
REFERENCE    1 (bases 1 to 17)
AUTHORS      Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE        Regulation of repressor genes using nucleic acid molecules
JOURNAL      Patent: JP 2002541795-A 5269 10-DEC-2002;
              RIBOZYME PHARMACEUTICALS INC
COMMENT      OS Eukaryote
              PN JP 2002541795-A/5269
              PD 10-DEC-2002
              PF 11-APR-2000 JP 2000611654
              PR 12-APR-1999 US 60/129390
              PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
              C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
              C12P21/02,
              PC
              C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
              C12R1:91),
              PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
              PC A61K37/02,
              PC (C12N5/00,C12R1:91)
              CC Regulation of repressor genes using nucleic acid molecules FH
              Key
              FT source
              FT Location/Qualifiers
              FT 1..17
              FT Location/Qualifiers
              FT /organism='Eukaryote'.
              FT 1..17
              FT /organism="unidentifed"
              FT /mol_type="genomic DNA"
              FT /db_xref="taxon:32644"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 GGAGGAGAGAGGAG 826
Db 16 GGAGGGGAGGGGAG 1

RESULT 204
LOCUS      BD272834
DEFINITION Cancer-susceptible mutation in BRCA2.
ACCESSION BD272834
VERSION    BD272834.1 GI:33082602
KEYWORDS   JP 2002533054-A/3.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Lescalliet,J.L., Lawrence,T., Allen,A.P., Olson,S.J., Thurber,D.B.
            and White,M.B.
TITLE      Cancer-susceptible mutation in BRCA2
JOURNAL    Patent: JP 2002533054-A 3 08-OCT-2002;
            GENE LOGIC INC
COMMENT    OS Homo sapiens (human)
            PN JP 2002533054-A/3
            PD 08-OCT-2002
            PF 02-DEC-1998 JP 2000523381
            PR 02-DEC-1997 US 08/984034
            PI JENNIFER L LESCALLETT,TAMMY LAWRENCE,ANTONETTE P ALLEN,SHERI J
            OLSON,
            PI DENISE B THURBER,MARGA B WHITE
            PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,C12Q1/68,G01N33/53, PC
            G01N37/00,
            PC C12N15/00,C12N15/00
            CC Cancer-susceptible mutation in BRCA2

FEATURES             source
source
FH Key               Location/Qualifiers
FT source            1..17
                        /organism='Homo sapiens (human)'.
FEATURES             source
source
FH Key               Location/Qualifiers
FT source            1..17
                        /organism="Homo sapiens"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:9606"
Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 166 GAAGAGCCCACTGTGT 181
Db 2 GAAGAACCACCTTTGT 17

RESULT 205
LOCUS      CQ615614/c
DEFINITION Sequence 354 from Patent WO0192524.
ACCESSION CQ615614
VERSION    CQ615614.1 GI:41665832
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 354 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             source
source
FH Key               Location/Qualifiers
FT source            1..17
                        /organism="Homo sapiens"
                        /mol_type="unassigned DNA"
                        /db_xref="taxon:9606"
Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTCGAGAGGC 497
Db 17 CTCGTTCTGGAGAGGC 2

RESULT 206
LOCUS      CQ615615/c
DEFINITION Sequence 355 from Patent WO0192524.
ACCESSION CQ615615
VERSION    CQ615615.1 GI:41665833
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 355 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             source
source
FH Key               Location/Qualifiers
FT source            1..17
                        /organism="Homo sapiens"
                        /mol_type="unassigned DNA"
                        /db_xref="taxon:9606"
```

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTGAGAGGC 497
Db 16 CTCGTTCTGGAGAGC 1

RESULT 207
CO615932/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 672 from Patent WO0192524.
ACCESSION  CO615932
VERSION     CO615932.1 GI:41666150
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 672 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
Db 17 GATGAGTCTCTCTGG 2

RESULT 208
CO615933/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 673 from Patent WO0192524.
ACCESSION  CO615933
VERSION     CO615933.1 GI:41666151
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 673 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
Db 16 GATGAGTCTCTCTGG 1

RESULT 209
CO616783/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 1523 from Patent WO0192524.
ACCESSION  CO616783
VERSION     CO616783.1 GI:41667001
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 1523 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 846 CCTATCACCAGCTCTT 861
Db 17 CCATCACCCTGCTCTT 2

RESULT 210
CO616784/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 1524 from Patent WO0192524.
ACCESSION  CO616784
VERSION     CO616784.1 GI:41667002
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 1524 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 846 CCTATCACCAGCTCTT 861
Db 16 CCATCACCCTGCTCTT 1

RESULT 211
CO616980/c
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 1720 from Patent WO0192524.
ACCESSION  CO616980
VERSION     CO616980.1 GI:41667198
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
```

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1720 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCAGCCAGA 407
Db 17 TTCTGAGCCAGCCAGA 2

RESULT 212
CQ616981/c
LOCUS CQ616981 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1721 from Patent WO0192524.
ACCESSION CQ616981
VERSION CQ616981.1 GI:41667199
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1721 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCAGCCAGA 407
Db 17 TTCTGAGCCAGCCAGA 2

RESULT 213
CQ617256/c
LOCUS CQ617256 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1996 from Patent WO0192524.
ACCESSION CQ617256
VERSION CQ617256.1 GI:41667474
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1996 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCAGCCAGA 407
Db 16 TTCTGAGCCAGCCAGA 1

RESULT 214
CQ617257/c
LOCUS CQ617257 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1997 from Patent WO0192524.
ACCESSION CQ617257
VERSION CQ617257.1 GI:41667475
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1997 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGCAATCA 324
Db 16 GCCTGGAGGAGCAATCA 1

RESULT 215
CQ622082/c
LOCUS CQ622082 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 6822 from Patent WO0192524.
ACCESSION CQ622082
VERSION CQ622082.1 GI:41672300
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 6822 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGCAATCA 324
Db 16 GCCTGGAGGAGCAATCA 1

```

ACCESSION	CQ622937
VERSION	CQ622937.1 GI:41673155
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS	Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE	Myosin-like gene expressed in human heart and muscle
JOURNAL	Patent: WO 0192524-A 7677 06-DEC-2001;
FEATURES	Aeomica, Inc. (US) source Location/Qualifiers 1..17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
Query Match	1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity	87.5%; Pred. No. 2.le+02;
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy	490 GAAGAGGCGAAGAAG 505 2 GAAGAGGCGAAGAAG 17
Db	
RESULT 219	
CQ622938	
LOCUS	CQ622938 17 bp DNA linear PAT 02-FEB-2004
DEFINITION	Sequence 7678 from Patent WO0192524.
ACCESSION	CQ622938
VERSION	CQ622938.1 GI:41673156
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS	Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE	Myosin-like gene expressed in human heart and muscle
JOURNAL	Patent: WO 0192524-A 7678 06-DEC-2001;
FEATURES	Aeomica, Inc. (US) source Location/Qualifiers 1..17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
Query Match	1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity	87.5%; Pred. No. 2.le+02;
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy	490 GAAGAGGCGAAGAAG 505 1 GAAGAGGCGAAGAAG 16
Db	
RESULT 220	
CQ622957/c	
LOCUS	CQ622957 17 bp DNA linear PAT 02-FEB-2004
DEFINITION	Sequence 7697 from Patent WO0192524.
ACCESSION	CQ622957
VERSION	CQ622957.1 GI:41673175
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS	Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and

```
Shannon,M.E.
Myosin-like gene expressed in human heart and muscle
Patent: WO 0192524-A 7697 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 828 TGGCCAGTTCGAGGT 843
Db 17 TGGCCAGTTCGAGGT 2

RESULT 221
LOCUS CQ622959/c 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7699 from Patent WO0192524.
ACCESSION CQ622959
VERSION CQ622959.1 GI:41673177
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7699 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 827 CTGGCCAGTTCGAGG 842
Db 16 CTGGCCAGTTCGAGG 1

RESULT 222
LOCUS CQ623072 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7812 from Patent WO0192524.
ACCESSION CQ623072
VERSION CQ623072.1 GI:41673290
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7812 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Shannon,M.E.
Myosin-like gene expressed in human heart and muscle
Patent: WO 0192524-A 7697 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 493 GAGCGAAGGAGCAGG 508
Db 2 GAGCGAAGGAGCAGG 17

RESULT 223
LOCUS CQ623074 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 7814 from Patent WO0192524.
ACCESSION CQ623074
VERSION CQ623074.1 GI:41673292
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 7814 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 494 AGCGAAGGAGCAGG 509
Db 1 AAGCGAAGGAGCAGG 16

RESULT 224
LOCUS CQ623293 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8033 from Patent WO0192524.
ACCESSION CQ623293
VERSION CQ623293.1 GI:41673511
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8033 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 696 AGCTGGAGAGTGAGCG 711
Db 2 AGCTGGAGAGTGAGCG 17
```

```
RESULT 225
CQ623294
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8034 from Patent WO0192524.
ACCESSION  CQ623294
VERSION     CQ623294.1 GI:41673512
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 8034 06-DEC-2001;
            Aecomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      696 AGCTGGAGAGTGAGCG 711
Db      1 AGCTGGAGATCGAGCG 16
            |||||
            |||||

RESULT 226
CQ623683
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8423 from Patent WO0192524.
ACCESSION  CQ623683
VERSION     CQ623683.1 GI:41673901
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 8423 06-DEC-2001;
            Aecomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      696 AGCTGGAGAGTGAGCG 711
Db      1 AGCTGGAGATCGAGCG 16
            |||||
            |||||

RESULT 227
I34958
LOCUS      17 bp      DNA      linear      PAT 13-MAY-1997
DEFINITION Sequence 44 from patent US 5599704.
ACCESSION  I34958
VERSION     I34958.1 GI:2087926
KEYWORDS
SOURCE      Unknown.

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      491 AAGACGCAGAGGATGTC 506
Db      1 AAGACGCAGAGGATGTC 16
            |||||
            |||||

RESULT 228
I52435/c
LOCUS      17 bp      DNA      linear      PAT 07-OCT-1997
DEFINITION Sequence 176 from patent US 5646042.
ACCESSION  I52435
VERSION     I52435.1 GI:2473636
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
            Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE       C-myb targeted ribozymes
JOURNAL     Patent: US 5646042-A 176 08-JUL-1997;
            Location/Qualifiers
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      405 AGAGGAGGAGGAGGA 420
Db      17 AGAAGGAGGAGGAGGA 2
            |||||
            |||||

RESULT 229
AR186446
LOCUS      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 1934 from patent US 6346398.
ACCESSION  AR186446
VERSION     AR186446.1 GI:20232411
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
            Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL     Patent: US 6346398-A 1934 12-FEB-2002;
            Location/Qualifiers
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      875 AACCATCATCAGAGCA 890
```



```
Db      1  AACTACCTCAAGAGCA 16
|||||
RESULT 230
AR192127  AR192127 17 bp DNA linear PAT 20-APR-2002
LOCUS     Sequence 7615 from patent US 6346398.
DEFINITION AR192127
ACCESSION  AR192127
VERSION    AR192127.1 GI:20238092
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE     Method and reagent for the treatment of diseases or conditions
          related to levels of vascular endothelial growth factor receptor
JOURNAL   Patent: US 6346398-A 7615 12-FEB-2002;
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      875  AACCATCAAGAGCA 890
|||||
Db      1  AACTACCTCAAGAGCA 16
|||||
RESULT 231
AR192284/c AR192284 17 bp DNA linear PAT 20-APR-2002
LOCUS     Sequence 7772 from patent US 6346398.
DEFINITION AR192284
ACCESSION  AR192284
VERSION    AR192284.1 GI:20238249
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE     Method and reagent for the treatment of diseases or conditions
          related to levels of vascular endothelial growth factor receptor
JOURNAL   Patent: US 6346398-A 7772 12-FEB-2002;
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      815  GAGAAGGAGGAGCTGG 830
|||||
Db      17  GAGAAGGAGGAGCTGG 2
|||||
RESULT 232
AR286106  AR286106 17 bp RNA linear PAT 10-APR-2003
LOCUS     Sequence 478 from patent US 6528640.
DEFINITION AR286106
ACCESSION  AR286106
VERSION    AR286106.1 GI:29723702
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)

QY      875  AACCATCAAGAGCA 890
|||||
```

```
AUTHORS   Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
          Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE     Synthetic ribonucleic acids with RNase activity
JOURNAL   Patent: US 6528640-A 478 04-MAR-2003;
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="unknown"
                /mol_type="unassigned RNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      263  CTGCACCTGCTTCAG 278
|||||
Db      1  CTCTCTCTGCTTCAG 16
|||||
RESULT 233
AR286233  AR286233 17 bp RNA linear PAT 10-APR-2003
LOCUS     Sequence 605 from patent US 6528640.
DEFINITION AR286233
ACCESSION  AR286233
VERSION    AR286233.1 GI:29723829
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
          Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE     Synthetic ribonucleic acids with RNase activity
JOURNAL   Patent: US 6528640-A 605 04-MAR-2003;
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="unknown"
                /mol_type="unassigned RNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      512  CTGCGGAGGTGAGC 527
|||||
Db      1  CTGCGGAGGTGAGC 16
|||||
RESULT 234
AR323077  AR323077 17 bp RNA linear PAT 17-AUG-2003
LOCUS     Sequence 479 from patent US 6566127.
DEFINITION AR323077
ACCESSION  AR323077
VERSION    AR323077.1 GI:33708885
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE     Method and reagent for the treatment of diseases or conditions
          related to levels of vascular endothelial growth factor receptor
JOURNAL   Patent: US 6566127-A 479 20-MAY-2003;
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="unknown"
                /mol_type="unassigned RNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      875  AACCATCAAGAGCA 890
|||||
```

Db 1 AACTACCTCAAGACCA 16

RESULT 235
AR326154/c

LOCUS AR326154 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3556 from patent US 6566127.
ACCESSION AR326154
VERSION AR326154.1 GI:33711962
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3556 20-MAY-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GAGAGAGGAGGCTGG 830
||||| |||||||
Db 17 GAGAGCAGAGCTGG 2

RESULT 236
AR327368

LOCUS AR327368 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 4770 from patent US 6566127.
ACCESSION AR327368
VERSION AR327368.1 GI:33713176
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4770 20-MAY-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACCATCAAGAGC 889
||||| |||||||
Db 2 CAATACCTCAAGAGC 17

RESULT 237
AR363927

LOCUS AR363927 17 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 22 from patent US 5240847.
ACCESSION AR363927
VERSION AR363927.1 GI:34426034
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Heckl,K., Spevak,W., Ostermann,E., Zophel,A., Krystek,E.,

TITLE Maurer-Fogy,I., Wiche-Castanon,M.J., Stratowa,C. and Hauptmann,R.
JOURNAL Human manganese superoxide dismutase (hMn-SOD)
FEATURES
source
1. .17
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 182 GAGATGTCAGCCCA 197
||||| |||||||
Db 2 GAGATGTTACAGCCCA 17

RESULT 238
AR398096

LOCUS AR398096 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 477 from patent US 6617438.
ACCESSION AR398096
VERSION AR398096.1 GI:40135629
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A., Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 477 09-SEP-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 263 CTCACCTGCCTTCAG 278
||||| |||||||
Db 1 CTCCTCTGCCTTCAG 16

RESULT 239
AR398223

LOCUS AR398223 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 604 from patent US 6617438.
ACCESSION AR398223
VERSION AR398223.1 GI:40135860
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A., Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 604 09-SEP-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 512 CTGCGGAGGTGGAGC 527
||||| |||||||
Db 1 CTGCGGAGGTGGAGC 16

RESULT 240
LOCUS AR456677/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 354 from patent US 6686188.
ACCESSION AR456677
VERSION AR456677.1 GI:42691734
KEYWORDS SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 354 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTGAAGAGGC 497
Db 17 CTCGTTCTGGAGGC 2

RESULT 241
LOCUS AR456678/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 355 from patent US 6686188.
ACCESSION AR456678
VERSION AR456678.1 GI:42691735
KEYWORDS SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 355 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTGAAGAGGC 497
Db 16 CTCGTTCTGGAGGC 1

RESULT 242
LOCUS AR456995/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 672 from patent US 6686188.
ACCESSION AR456995
VERSION AR456995.1 GI:42692052
KEYWORDS SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1523 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 672 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
Db 17 GATGAGTCTCTCTGG 2

RESULT 243
LOCUS AR456996/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 673 from patent US 6686188.
ACCESSION AR456996
VERSION AR456996.1 GI:42692053
KEYWORDS SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 673 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
Db 16 GATGAGTCTCTCTGG 1

RESULT 244
LOCUS AR457846/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1523 from patent US 6686188.
ACCESSION AR457846
VERSION AR457846.1 GI:42692903
KEYWORDS SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1523 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 846 CCTATCACCGCTCTT 861
Db 17 CCCATCACCTGCTCTT 2

RESULT 245
AR457847/c
LOCUS AR457847 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1524 from patent US 6686188.
ACCESSION AR457847
VERSION AR457847.1 GI:42692904
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1524 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 846 CCTATCACCGCTCTT 861
Db 16 CCCATCACCTGCTCTT 1

RESULT 246
AR458043/c
LOCUS AR458043 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1720 from patent US 6686188.
ACCESSION AR458043
VERSION AR458043.1 GI:42693100
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1720 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCAGCCAGA 407
Db 17 TTCTGAGCCAGCCAGA 2

RESULT 247
AR458044/c
LOCUS AR458044 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1721 from patent US 6686188.
ACCESSION AR458044
VERSION AR458044.1 GI:42693101
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1721 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAGCCAGCCAGA 407
Db 16 TTCTGAGCCAGCCAGA 1

RESULT 248
AR458319/c
LOCUS AR458319 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1996 from patent US 6686188.
ACCESSION AR458319
VERSION AR458319.1 GI:42693376
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1996 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGAGGAGCAATCA 324
Db 17 GGCTGAGGAGCAATCA 2

RESULT 249
AR458320/c
LOCUS AR458320 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1997 from patent US 6686188.
ACCESSION AR458320
VERSION AR458320.1 GI:42693377
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1997 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCTGGAGGAGATCA 324
Db 16 GGCTGGAGGACATCA 1

RESULT 250
AR463145/C
LOCUS AR463145 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6822 from patent US 6686188.
ACCESSION AR463145
VERSION AR463145.1 GI:42698202
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6822 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 ACCTGCTTCAGAAC 282
Db 17 ACCTGCTTCAGAAAA 2

RESULT 251
AR463213/C
LOCUS AR463213 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6890 from patent US 6686188.
ACCESSION AR463213
VERSION AR463213.1 GI:42698270
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6890 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGGAGGAG 321
Db 17 GCCGCTGGAGAGAA 2

RESULT 252
AR463214/C
LOCUS AR463214 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 6822 from patent US 6686188.
ACCESSION AR463214
VERSION AR463214.1 GI:42698271
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6822 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGGAGGAG 321
Db 16 GCCGCTGGAGAGAA 1

RESULT 253
AR464000
LOCUS AR464000 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7677 from patent US 6686188.
ACCESSION AR464000
VERSION AR464000.1 GI:42699057
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7677 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGAGAGAG 505
Db 2 GAAGAAGCAGAGAGAG 17

RESULT 254
AR464001
LOCUS AR464001 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7678 from patent US 6686188.
ACCESSION AR464001
VERSION AR464001.1 GI:42699058
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7678 03-FEB-2004;

DEFINITION Sequence 6891 from patent US 6686188.
ACCESSION AR463214
VERSION AR463214.1 GI:42698271
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 6891 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGGAGGAG 321
Db 16 GCCGCTGGAGAGAA 1

RESULT 253
AR464000
LOCUS AR464000 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7677 from patent US 6686188.
ACCESSION AR464000
VERSION AR464000.1 GI:42699057
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7677 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGAGAGAG 505
Db 2 GAAGAAGCAGAGAGAG 17

RESULT 254
AR464001
LOCUS AR464001 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7678 from patent US 6686188.
ACCESSION AR464001
VERSION AR464001.1 GI:42699058
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7678 03-FEB-2004;

```
FEATURES
source
Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGGCGAGGAG 505
||||| ||||| ||||| |||||
Db 1 GAAGAGCAGAGAG 16

RESULT 255
AR464020/c
LOCUS AR464020 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7697 from patent US 6686188.
ACCESSION AR464020
VERSION AR464020.1 GI:42699077
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7697 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 828 TGGCCAGGTGCAGGT 843
||||| ||||| ||||| |||||
Db 17 TGGCCAGCTGCAGGT 2

RESULT 256
AR464022/c
LOCUS AR464022 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7699 from patent US 6686188.
ACCESSION AR464022
VERSION AR464022.1 GI:42699079
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7699 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 827 CTGGCCAGGTGCAGG 842
||||| ||||| ||||| |||||
Db 16 CTGGCCAGCTGCAGG 1

RESULT 257
AR464135
LOCUS AR464135 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7812 from patent US 6686188.
ACCESSION AR464135
VERSION AR464135.1 GI:42699192
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7812 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 493 GAGCGAAGAGGAGCAG 508
||||| ||||| ||||| |||||
Db 2 GAAGCAAGAGGAGCAG 17

RESULT 258
AR464137
LOCUS AR464137 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 7814 from patent US 6686188.
ACCESSION AR464137
VERSION AR464137.1 GI:42699194
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 7814 03-FEB-2004;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 259
AR464356
LOCUS AR464356 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8033 from patent US 6686188.
ACCESSION AR464356
VERSION AR464356.1 GI:42699413
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
```

Shannon,M.E.
 Polynucleotide encoding a human myosin-like polypeptide expressed
 predominantly in heart and muscle
 Patent: US 6686188-A 8033 03-FEB-2004;
 FEATURES
 Location/Qualifiers
 1..17
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 696 AGCTGGAGATCGAGCG 711
 Db 2 AGCTGGAGATCGAGCG 17

RESULT 260
 AR464357
 LOCUS
 DEFINITION Sequence 8034 from patent US 6686188.
 ACCESSION AR464357
 VERSION AR464357.1 GI:42699414
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 8034 03-FEB-2004;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 696 AGCTGGAGATCGAGCG 711
 Db 1 AGCTGGAGATCGAGCG 16

RESULT 261
 AR464746
 LOCUS
 DEFINITION Sequence 8423 from patent US 6686188.
 ACCESSION AR464746
 VERSION AR464746.1 GI:42699803
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 8423 03-FEB-2004;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 696 AGCTGGAGATCGAGCG 711
 Db 1 AGCTGGAGATCGAGCG 16

Shannon,M.E.
 Polynucleotide encoding a human myosin-like polypeptide expressed
 predominantly in heart and muscle
 Patent: US 6686188-A 8033 03-FEB-2004;
 FEATURES
 Location/Qualifiers
 1..17
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 696 AGCTGGAGATCGAGCG 711
 Db 2 AGCTGGAGATCGAGCG 17

RESULT 260
 AR464357
 LOCUS
 DEFINITION Sequence 8034 from patent US 6686188.
 ACCESSION AR464357
 VERSION AR464357.1 GI:42699414
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 8034 03-FEB-2004;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 696 AGCTGGAGATCGAGCG 711
 Db 1 AGCTGGAGATCGAGCG 16

RESULT 261
 AR464746
 LOCUS
 DEFINITION Sequence 8423 from patent US 6686188.
 ACCESSION AR464746
 VERSION AR464746.1 GI:42699803
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 8423 03-FEB-2004;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 696 AGCTGGAGATCGAGCG 711
 Db 1 AGCTGGAGATCGAGCG 16

QY 491 AAGAGCGCAGAGGAGC 506
 Db 1 AAGAGCGCAGAGGAGTGC 16

RESULT 262
 AR483202
 LOCUS
 DEFINITION Sequence 648 from patent US 6703228.
 ACCESSION AR483202
 VERSION AR483202.1 GI:47245725
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Landers,J., Jordan,B., Housman,D.E. and Charest,A.
 TITLE Methods and products related to genotyping and DNA analysis
 JOURNAL Patent: US 6703228-A 648 09-MAR-2004;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 397 AGCCAGCCAGAGGGAG 412
 Db 1 AGCCAGCTAGAGGGAG 16

RESULT 263
 AX214573
 LOCUS
 DEFINITION Sequence 15 from Patent WO0159103.
 ACCESSION AX214573
 VERSION AX214573.1 GI:15524616
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.
 REFERENCE 1
 AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 15 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES Location/Qualifiers
 source 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"
 Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 233 GAAGAGTCTCTCTCGG 248
 Db 2 GACCAGTCTCTCTCGG 17

RESULT 264
 AX215343
 LOCUS
 DEFINITION Sequence 785 from Patent WO0159103.
 ACCESSION AX215343
 VERSION AX215343.1 GI:15525386
 KEYWORDS

SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression

JOURNAL Patent: WO 0159103-A 785 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)

FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 233 GAGAGTCTCTCTGG 248
Db 1 GACCAGTCTCTCTGG 16
|||||

RESULT 265
AX216496 17 bp RNA linear PAT 07-SEP-2001
LOCUS AX216496
DEFINITION Sequence 1938 from Patent WO0159103.
ACCESSION AX216496
VERSION AX216496.1 GI:15526557
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression

JOURNAL Patent: WO 0159103-A 1938 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)

FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 487 TCTGAGAGGCGAAG 502
Db 1 TTTCAGAGTCAGAAG 16
|||||

RESULT 266
AX217098 17 bp RNA linear PAT 07-SEP-2001
LOCUS AX217098
DEFINITION Sequence 2540 from Patent WO0159103.
ACCESSION AX217098
VERSION AX217098.1 GI:15527159
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression

JOURNAL Patent: WO 0159103-A 2540 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)

FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 486 ATCTGAAGAGCGAGAA 501
Db 2 ATTGAAGAGTCAGAA 17
|||||

RESULT 267
AX226754/c 17 bp RNA linear PAT 10-SEP-2001
LOCUS AX226754
DEFINITION Sequence 126 from Patent WO0157206.
ACCESSION AX226754
VERSION AX226754.1 GI:15555895
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Fattaey, A.R., Jarvis, T., Mcswiggen, J., Boher, R.N. and Holman, P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme

JOURNAL Patent: WO 0157206-A 126 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)

FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 606 TGCAGAGAGCCAGAG 621
Db 16 TGCAGAGAGCTAGAG 1
|||||

RESULT 268
AX227107/c 17 bp RNA linear PAT 10-SEP-2001
LOCUS AX227107
DEFINITION Sequence 479 from Patent WO0157206.
ACCESSION AX227107
VERSION AX227107.1 GI:15556248
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Fattaey, A.R., Jarvis, T., Mcswiggen, J., Boher, R.N. and Holman, P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme

JOURNAL Patent: WO 0157206-A 479 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)

FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 1.7%; Score 12.8; DB 1; Length 17;


```

Best Local Similarity 87.5%; Pred. No. 2.1e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 14; Conservative 0;

QY 606 TGCAGGAGCCGAG 621
Db 17 TGCAGGAGCTAG 2

RESULT 269
AX262960
LOCUS AX262960 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 351 from Patent WO0173002.
ACCESSION AX262960
VERSION AX262960.1 GI:16511759
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Kmiec, E.B., Gamper, H.B. and Rice, M.C.
AUTHORS Targeted chromosomal genomic alterations with modified single
TITLE stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 351 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTCGAG 379
Db 2 GCGTGGAGCGCTCGAG 17

RESULT 270
AX262961/c
LOCUS AX262961 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 352 from Patent WO0173002.
ACCESSION AX262961
VERSION AX262961.1 GI:16511760
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Kmiec, E.B., Gamper, H.B. and Rice, M.C.
AUTHORS Targeted chromosomal genomic alterations with modified single
TITLE stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 352 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTCGAG 379
Db 16 GCGTGGAGCGCTCGAG 1

RESULT 271
AX262961/c
LOCUS AX262961 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 352 from Patent WO0173002.
ACCESSION AX262961
VERSION AX262961.1 GI:16511760
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Kmiec, E.B., Gamper, H.B. and Rice, M.C.
AUTHORS Targeted chromosomal genomic alterations with modified single
TITLE stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 352 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTCGAG 379
Db 16 GCGTGGAGCGCTCGAG 1

RESULT 272
AX263985
LOCUS AX263985 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 1376 from Patent WO0173002.
ACCESSION AX263985
VERSION AX263985.1 GI:16512784
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Kmiec, E.B., Gamper, H.B. and Rice, M.C.
AUTHORS Targeted chromosomal genomic alterations with modified single
TITLE stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 1376 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGC 736
Db 17 GCAGCAGCAGCTCCGC 2

RESULT 273
AX263985
LOCUS AX263985 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 1376 from Patent WO0173002.
ACCESSION AX263985
VERSION AX263985.1 GI:16512784
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Kmiec, E.B., Gamper, H.B. and Rice, M.C.
AUTHORS Targeted chromosomal genomic alterations with modified single
TITLE stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 1376 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGC 736
Db 1 GCAGCAGCAGCTCCGC 16

RESULT 273
AX265711
LOCUS AX265711 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3102 from Patent WO0173002.
ACCESSION AX265711
VERSION AX265711.1 GI:16514510
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Kmiec, E.B., Gamper, H.B. and Rice, M.C.
AUTHORS Targeted chromosomal genomic alterations with modified single
TITLE stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 3102 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3102 GCAGCAGCAGCAGC 3117
Db 1 GCAGCAGCAGCTCCGC 16

```

```
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
  source
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Kniec,E.B., Gamper,H.B. and Rice,M.C.
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3102 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
  1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 724 GCAGCAGCAGCGTG 739
Db 1 GCAGCAGCAGCATCGAG 16

RESULT 274
AX265712/c
LOCUS AX265712 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3103 from Patent WO0173002.
ACCESSION AX265712
VERSION AX265712.1 GI:16514511
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
  source
Kniec,E.B., Gamper,H.B. and Rice,M.C.
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3103 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
  1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 724 GCAGCAGCAGCGTG 739
Db 1 GCAGCAGCAGCATCGAG 2

RESULT 275
AX266023
LOCUS AX266023 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3414 from Patent WO0173002.
ACCESSION AX266023
VERSION AX266023.1 GI:16514822
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
  source
Kniec,E.B., Gamper,H.B. and Rice,M.C.
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3414 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
  1. .17
```

```
Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 757 CATGCAGGCCAGAGC 772
Db 1 CATGCTCGGCCAGAGC 16

RESULT 276
AX266024/c
LOCUS AX266024 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 3415 from Patent WO0173002.
ACCESSION AX266024
VERSION AX266024.1 GI:16514823
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
  source
Kniec,E.B., Gamper,H.B. and Rice,M.C.
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3415 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
  1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 757 CATGCAGGCCAGAGC 772
Db 17 CATGCTCGGCCAGAGC 2

RESULT 277
AX272702
LOCUS AX272702 17 bp RNA linear PAT 29-OCT-2001
DEFINITION Sequence 271 from Patent WO0162911.
ACCESSION AX272702
VERSION AX272702.1 GI:16545439
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
  source
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and
Ellis,J.H.
Method and reagent for the inhibition of grid
Patent: WO 0162911-A 271 30-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
Location/Qualifiers
  1. .17
  /organism="Homo sapiens"
  /mol_type="unassigned RNA"
  /db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 393 TCCAGCCAGCCAGAGC 408
```

Db	2	TCCGGGCCAGCCAG 17			
RESULT 278					
AX272703					
LOCUS	AX272703	17 bp RNA linear PAT 29-OCT-2001			
DEFINITION	Sequence 272 from Patent WO0162911.				
ACCESSION	AX272703				
VERSION	AX272703.1 GI:16545440				
KEYWORDS	Homo sapiens (human)				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE	1	Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and Ellis,J.H.			
AUTHORS	Method and reagent for the inhibition of grid				
TITLE	Patent: WO 0162911-A 272 30-AUG-2001;				
JOURNAL	RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)				
FEATURES	Location/Qualifiers				
source	1..17				
	/organism="Homo sapiens"				
	/mol_type="unassigned RNA"				
	/db_xref="taxon:9606"				
Query Match	1.7%; Score 12.8; DB 1; Length 17;				
Best Local Similarity	87.5%; Pred. No. 2.1e+02;				
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
Qy	393 TCCAAGCCAGCCAG 408				
Db	1 TCCGGGCCAGCCAG 16				
RESULT 279					
AX272792					
LOCUS	AX272792	17 bp RNA linear PAT 29-OCT-2001			
DEFINITION	Sequence 361 from Patent WO0162911.				
ACCESSION	AX272792				
VERSION	AX272792.1 GI:16545529				
KEYWORDS	Homo sapiens (human)				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE	1	Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and Ellis,J.H.			
AUTHORS	Method and reagent for the inhibition of grid				
TITLE	Patent: WO 0162911-A 361 30-AUG-2001;				
JOURNAL	RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)				
FEATURES	Location/Qualifiers				
source	1..17				
	/organism="Homo sapiens"				
	/mol_type="unassigned RNA"				
	/db_xref="taxon:9606"				
Query Match	1.7%; Score 12.8; DB 1; Length 17;				
Best Local Similarity	87.5%; Pred. No. 2.1e+02;				
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
Qy	718 GCTGCAGCAGCAC 733				
Db	1 GCAGCGCCAGCAC 16				
RESULT 280					
AX273038					
LOCUS	AX273038	17 bp RNA linear PAT 29-OCT-2001			
DEFINITION	Sequence 607 from Patent WO0162911.				
ACCESSION	AX273038				
VERSION	AX273038.1 GI:16545440				
KEYWORDS	Homo sapiens (human)				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE	1	Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and Ellis,J.H.			
AUTHORS	Method and reagent for the inhibition of grid				
TITLE	Patent: WO 0162911-A 607 30-AUG-2001;				
JOURNAL	RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)				
FEATURES	Location/Qualifiers				
source	1..17				
	/organism="Homo sapiens"				
	/mol_type="unassigned RNA"				
	/db_xref="taxon:9606"				
Query Match	1.7%; Score 12.8; DB 1; Length 17;				
Best Local Similarity	87.5%; Pred. No. 2.1e+02;				
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
Qy	717 CGTCGACGACGAC 732				
Db	2 CCCTGCAGCAGCA 17				
RESULT 281					
AX273304					
LOCUS	AX273304	17 bp RNA linear PAT 29-OCT-2001			
DEFINITION	Sequence 873 from Patent WO0162911.				
ACCESSION	AX273304				
VERSION	AX273304.1 GI:16546041				
KEYWORDS	Homo sapiens (human)				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE	1	Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and Ellis,J.H.			
AUTHORS	Method and reagent for the inhibition of grid				
TITLE	Patent: WO 0162911-A 873 30-AUG-2001;				
JOURNAL	RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)				
FEATURES					

[illegible]

```

TITLE      Method and reagent for the inhibition of grid
JOURNAL    Patent: WO 0162911-A 874 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      731 CACAGCGTGCAGGTGG 746
Db      1 CACAGCGGGGAGGTGG 16
            ||||| |||||
            ||||| |||||

RESULT 283
AX325485
LOCUS      AX325485                17 bp    DNA        linear    PAT 02-SEP-2002
DEFINITION Sequence 1623 from Patent WO0192512.
ACCESSION  AX325485
VERSION     AX325485.1 GI:18096242
KEYWORDS
SOURCE      Oryza sativa
ORGANISM    Oryza sativa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1
AUTHORS    Kniec,E.B., Gamber,H.B., Rice,M.C. and Kim,J.
TITLE      Targeted chromosomal genomic alterations in plants using modified
            single stranded oligonucleotides
JOURNAL    Patent: WO 0192512-A 1623 06-DEC-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="Oryza sativa"
            /mol_type="unassigned DNA"
            /db_xref="taxon:4530"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      409 GGAGGAGAGGAGTTC 424
Db      2 GGAGGCCAAGGAGTTC 17
            ||||| |||||
            ||||| |||||

RESULT 284
AX325486/c
LOCUS      AX325486                17 bp    DNA        linear    PAT 02-SEP-2002
DEFINITION Sequence 1624 from Patent WO0192512.
ACCESSION  AX325486
VERSION     AX325486.1 GI:18096243
KEYWORDS
SOURCE      Oryza sativa
ORGANISM    Oryza sativa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1
AUTHORS    Kniec,E.B., Gamber,H.B., Rice,M.C. and Kim,J.
TITLE      Targeted chromosomal genomic alterations in plants using modified
            single stranded oligonucleotides
JOURNAL    Patent: WO 0192512-A 1624 06-DEC-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="Oryza sativa"
            /mol_type="unassigned DNA"

TITLE      Method and reagent for the inhibition of grid
JOURNAL    Patent: WO 0162911-A 874 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      409 GGAGGAGAGGAGTTC 424
Db      16 GGAGGCCAAGGAGTTC 1
            ||||| |||||
            ||||| |||||

RESULT 285
AX422460/c
LOCUS      AX422460                17 bp    RNA        linear    PAT 18-JUN-2002
DEFINITION Sequence 796 from Patent WO0188124.
ACCESSION  AX422460
VERSION     AX422460.1 GI:21525842
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 796 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      795 AGCGCCAGCGCGCTC 810
Db      16 AGCGCGGGCGCACCTC 1
            ||||| |||||
            ||||| |||||

RESULT 286
AX422538/c
LOCUS      AX422538                17 bp    RNA        linear    PAT 18-JUN-2002
DEFINITION Sequence 874 from Patent WO0188124.
ACCESSION  AX422538
VERSION     AX422538.1 GI:21525920
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 874 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      656 CTGGAGGTCGGGGCC 671
Db      17 CTGGAGGGTGGGGCGC 2
            ||||| |||||
            ||||| |||||
```

```
RESULT 287
AX422543
LOCUS          17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION     Sequence 879 from Patent WO0188124.
ACCESSION      AX422543
VERSION        AX422543.1 GI:21525925
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS        Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
               Randi,A.M.
TITLE          Method and reagent for the inhibition of erg
JOURNAL        Patent: WO 0188124-A 879 22-NOV-2001;
               RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 87.5%; Pred. No. 2.1e+02; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 296 ACCCTCCAGCGCTGCC 311
Db 2 ACCCTCCAGCGCTGCC 17

RESULT 288
AX423120/C
LOCUS          17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION     Sequence 1456 from Patent WO0188124.
ACCESSION      AX423120
VERSION        AX423120.1 GI:21526502
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS        Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
               Randi,A.M.
TITLE          Method and reagent for the inhibition of erg
JOURNAL        Patent: WO 0188124-A 1456 22-NOV-2001;
               RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 87.5%; Pred. No. 2.1e+02; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 796 GCGCCAGCGCGCTCG 811
Db 17 GCGCCAGCGCGCTCG 2

RESULT 289
AX423137
LOCUS          17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION     Sequence 1473 from Patent WO0188124.
ACCESSION      AX423137
VERSION        AX423137.1 GI:21526519
KEYWORDS
```

```
SOURCE         Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS        Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
               Randi,A.M.
TITLE          Method and reagent for the inhibition of erg
JOURNAL        Patent: WO 0188124-A 1473 22-NOV-2001;
               RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 87.5%; Pred. No. 2.1e+02; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 296 ACCCTCCAGCGCTGCC 311
Db 1 ACCCTCCAGCGCTGCC 16

RESULT 290
AX423503
LOCUS          17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION     Sequence 1839 from Patent WO0188124.
ACCESSION      AX423503
VERSION        AX423503.1 GI:21526885
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS        Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
               Randi,A.M.
TITLE          Method and reagent for the inhibition of erg
JOURNAL        Patent: WO 0188124-A 1839 22-NOV-2001;
               RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 87.5%; Pred. No. 2.1e+02; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGGAGGAGAA 321
Db 2 GCTGCTGGAGGAGAA 17

RESULT 291
AX423504
LOCUS          17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION     Sequence 1840 from Patent WO0188124.
ACCESSION      AX423504
VERSION        AX423504.1 GI:21526886
KEYWORDS
SOURCE         Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS        Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
               Randi,A.M.
TITLE          Method and reagent for the inhibition of erg
JOURNAL        Patent: WO 0188124-A 1840 22-NOV-2001;
```

RIBOZYME PHARMACEUTICALS, INC. (US) • GLAXO GROUP LIMITED (GB)

```
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M.
TITLE       Human posh-like protein 1
JOURNAL     Aeomica, Inc. (US)
            Patent: EP 1239051-A 302 11-SEP-2002;
FEATURES    Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 471 GCTGGAGAAGCTCGA 486
Db 2 GCTTGAGAAGCTCGA 17
RESULT 297
AX530795
LOCUS       AX530795                17 bp    DNA
DEFINITION Sequence 304 from Patent EP1239051.
ACCESSION  AX530795
VERSION     AX530795.1 GI:25253385
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M.
TITLE       Human posh-like protein 1
JOURNAL     Aeomica, Inc. (US)
            Patent: EP 1239051-A 304 11-SEP-2002;
FEATURES    Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 472 CCTGGAGAAGCTCGAT 487
Db 1 CTTTGAGAAGCTCGAT 16
RESULT 298
AX530796
LOCUS       AX530796                17 bp    DNA
DEFINITION Sequence 305 from Patent EP1239051.
ACCESSION  AX530796
VERSION     AX530796.1 GI:25253387
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M.
TITLE       Human posh-like protein 1
JOURNAL     Aeomica, Inc. (US)
            Patent: EP 1239051-A 305 11-SEP-2002;
FEATURES    Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 473 CCTGGAGAAGCTCGAT 487
Db 1 CTTTGAGAAGCTCGAT 16
RESULT 299
AX530797
LOCUS       AX530797                17 bp    DNA
DEFINITION Sequence 306 from Patent EP1239051.
ACCESSION  AX530797
VERSION     AX530797.1 GI:25253389
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M.
TITLE       Human posh-like protein 1
JOURNAL     Aeomica, Inc. (US)
            Patent: EP 1239051-A 306 11-SEP-2002;
FEATURES    Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 474 TGGAGAAGCTCGATCT 489
Db 2 TTGAGAAGCTCGATGT 17
RESULT 300
AX530798
LOCUS       AX530798                17 bp    DNA
DEFINITION Sequence 307 from Patent EP1239051.
ACCESSION  AX530798
VERSION     AX530798.1 GI:25253391
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M.
TITLE       Human posh-like protein 1
JOURNAL     Aeomica, Inc. (US)
            Patent: EP 1239051-A 307 11-SEP-2002;
FEATURES    Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 475 TGGAGAAGCTCGATCT 489
Db 1 TTGAGAAGCTCGATGT 16
RESULT 301
AX530799
LOCUS       AX530799                17 bp    DNA
DEFINITION Sequence 308 from Patent EP1239051.
ACCESSION  AX530799
VERSION     AX530799.1 GI:25253393
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M.
TITLE       Human posh-like protein 1
JOURNAL     Aeomica, Inc. (US)
            Patent: EP 1239051-A 308 11-SEP-2002;
FEATURES    Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 476 GAGAAGCTCGATCTGA 491
Db 1 TTGAGAAGCTCGATGT 16
```

```
Db      2 GAGAGCTCGATGTCA 17

RESULT 301
AX530799
LOCUS      AX530799      17 bp      DNA      linear      PAT 22-NOV-2002
DEFINITION Sequence 308 from Patent EP1239051.
ACCESSION  AX530799
VERSION     AX530799.1 GI:25253393
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            Shannon.M.
            Human posh-like protein 1
            Patent: EP 1239051-A 308 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES
    source
        1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
REFERENCE
    AUTHORS
        Shannon.M.
    TITLE
        Human posh-like protein 1
    JOURNAL
        Patent: EP 1239051-A 308 11-SEP-2002;
        Aeomica, Inc. (US)
FEATURES
    source
        1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      476 GAGAGCTCGATGTGA 491
        |||||
Db      1 GAGAGCTCGATGTCA 16

RESULT 302
AX531537
LOCUS      AX531537      17 bp      DNA      linear      PAT 22-NOV-2002
DEFINITION Sequence 1046 from Patent EP1239051.
ACCESSION  AX531537
VERSION     AX531537.1 GI:25254845
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            Shannon.M.
            Human posh-like protein 1
            Patent: EP 1239051-A 1046 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES
    source
        1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      253 GCCAGCCATCTGCAC 268
        |||||
Db      2 GCCAGTCATCTGCAC 17

RESULT 303
AX531538
LOCUS      AX531538      17 bp      DNA      linear      PAT 22-NOV-2002
DEFINITION Sequence 1047 from Patent EP1239051.
ACCESSION  AX531538
VERSION     AX531538.1 GI:25254847
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            Gu, Y. and Nguyen, C.T.
            Human lcc1-domain containing protein
            Patent: EP 1262488-A 311 04-DEC-2002;
            Aeomica, Inc. (US)
```

```
ORGANISM Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
    1
AUTHORS
    Shannon.M.
TITLE
    Human posh-like protein 1
JOURNAL
    Patent: EP 1239051-A 1047 11-SEP-2002;
    Aeomica, Inc. (US)
FEATURES
    Location/Qualifiers
        1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      253 GCCAGCCATCTGCAC 268
        |||||
Db      1 GCCAGTCATCTGCAC 16

RESULT 304
AX579515
LOCUS      AX579515      17 bp      RNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 1353 from Patent WO0211674.
ACCESSION  AX579515
VERSION     AX579515.1 GI:27648717
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
            and Grube, A.
            Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
            Patent: WO 0211674-A 1353 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES
    Location/Qualifiers
        1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      477 AGAAGCTCGATCTGAA 492
        |||||
Db      1 ATAAGTCGATCTGAA 16

RESULT 305
AX615504
LOCUS      AX615504      17 bp      DNA      linear      PAT 20-FEB-2003
DEFINITION Sequence 311 from Patent EP1262488.
ACCESSION  AX615504
VERSION     AX615504.1 GI:28446550
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            Gu, Y. and Nguyen, C.T.
            Human lcc1-domain containing protein
            Patent: EP 1262488-A 311 04-DEC-2002;
            Aeomica, Inc. (US)
```



```

FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 500 AAGGACGAGCTCTGC 515
    ||| ||||| |||
Db 2 AAGAGCAGGCTATGC 17

RESULT 306
AX615505
LOCUS AX615505 17 bp DNA linear PAT 20-FEB-2003
DEFINITION Sequence 312 from Patent EP1262488.
ACCESSION AX615505
VERSION AX615505.1 GI:28446551
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
  1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Gu, Y. and Nguyen, C.T.
TITLE Human lcc1-domain containing protein
JOURNAL Patent: EP 1262488-A 312 04-DEC-2002;
  Aeomica, Inc. (US)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 500 AAGGACGAGCTCTGC 515
    ||| ||||| |||
Db 1 AAGAGCAGGCTATGC 16

RESULT 307
AX634500
LOCUS AX634500 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1639 from Patent EP1260586.
ACCESSION AX634500
VERSION AX634500.1 GI:28470114
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
  1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
  Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
  Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
  Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
  Woolf,T.
  Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 1639 27-NOV-2002;
  RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    1..17
      /organism="unidentified"
      /mol_type="unassigned RNA"
      /db_xref="taxon:32644"

Query Match
  Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 500 AAGGACGAGCTCTGC 515
    ||| ||||| |||
Db 1 AAGAGCAGGCTATGC 16

RESULT 308
AX634623
LOCUS AX634623 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1762 from Patent EP1260586.
ACCESSION AX634623
VERSION AX634623.1 GI:28470237
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
  1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
  Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
  Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
  Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
  Woolf,T.
  Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 1762 27-NOV-2002;
  RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    1..17
      /organism="unidentified"
      /mol_type="unassigned RNA"
      /db_xref="taxon:32644"

Query Match
  Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
    ||| ||||| |||
Db 1 GAGAACCTCGGCTGG 16

RESULT 309
AX634645
LOCUS AX634645 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1784 from Patent EP1260586.
ACCESSION AX634645
VERSION AX634645.1 GI:28470259
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
  1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
  Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
  Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
  Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
  Woolf,T.
  Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 1784 27-NOV-2002;
  RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    1..17
      /organism="unidentified"
      /mol_type="unassigned RNA"
      /db_xref="taxon:32644"

Query Match
  Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGG 476
    ||| ||||| |||
Db 1 GAGAACCTCGGCTGG 16

```

Qy 461 GAGAGACTCGGCTGG 476
|||||
Db 1 GAGAACCTCGGCTGG 16

RESULT 310
AX634681
LOCUS AX634681 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1820 from Patent EP1260586.
ACCESSION AX634681
VERSION AX634681.1 GI:28470295
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., Meswigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.B. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 1820 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source 1..17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 461 GAGAGACTCGGCTGG 476
|||||
Db 1 GAGAACCTCGGCTGG 16

RESULT 311
AX634688
LOCUS AX634688 17 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 1827 from Patent EP1260586.
ACCESSION AX634688
VERSION AX634688.1 GI:28470302
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., Meswigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.B. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 1827 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source 1..17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 461 GAGAGACTCGGCTGG 476
|||||
Db 1 GAGAACCTCGGCTGG 16

RESULT 312
AX648396
LOCUS AX648396 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 236 from Patent EP1273660.
ACCESSION AX648396
VERSION AX648396.1 GI:29151214
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 236 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 448 CAGGAACTCGTGGAG 463
|||||
Db 2 CATGAACTCGGAG 17

RESULT 313
AX648397
LOCUS AX648397 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 237 from Patent EP1273660.
ACCESSION AX648397
VERSION AX648397.1 GI:29151215
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 237 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 448 CAGGAACTCGTGGAG 463
|||||
Db 1 CATGAACTCGGAG 16

RESULT 314
AX649636/c
LOCUS AX649636/c 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 1476 from Patent EP1273660.
ACCESSION AX649636
VERSION AX649636.1 GI:29152454
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 Gu, Y.
Human sodium-hydrogen exchanger like protein 1
Patent: EP 1273660-A 1476 08-JAN-2003;
JOURNAL Aeomica, Inc. (US)

FEATURES

source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 884 AGAGCAGCGTGTGG 899

Db 17 AGGAGCAGCGTAGTGG 2

RESULT 315

AX649637/c
LOCUS AX649637 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 1477 from Patent EP1273660.
ACCESSION AX649637
VERSION AX649637.1 GI:29152455

KEYWORDS

source Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Gu, Y.
Human sodium-hydrogen exchanger like protein 1
Patent: EP 1273660-A 1477 08-JAN-2003;
JOURNAL Aeomica, Inc. (US)

FEATURES

source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 884 AGAGCAGCGTGTGG 899

Db 16 AGGAGCAGCGTAGTGG 1

RESULT 316

AX674370/c
LOCUS AX674370 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 2815 from Patent WO03004526.
ACCESSION AX674370
VERSION AX674370.1 GI:29332718

KEYWORDS

source Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Telerman, A., Anson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 2815 16-JAN-2003;
JOURNAL Molecular Engines Laboratories (FR)

FEATURES

source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 203 GGCCCGGCGAGCAGATC 218

Db 16 GGCTGGCAGCAGATC 1

RESULT 317

AX674379/c
LOCUS AX674379 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 2824 from Patent WO03004526.
ACCESSION AX674379
VERSION AX674379.1 GI:29332727

KEYWORDS

source Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Telerman, A., Anson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 2824 16-JAN-2003;
JOURNAL Molecular Engines Laboratories (FR)

FEATURES

source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 537 GATGCCAGCAGCAGAT 552

Db 17 GCTGCCAGAGCAGAT 2

RESULT 318

AX687996/c
LOCUS AX687996 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 728 from Patent EP1281758.
ACCESSION AX687996
VERSION AX687996.1 GI:29410694

KEYWORDS

source Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Shannon, M., Gu, Y. and Nguyen, C.T.
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
Patent: EP 1281758-A 728 05-FEB-2003;
JOURNAL Aeomica, Inc. (US)

FEATURES

source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

source

Qy 269 CTGCCTTCAGAACAGG 284
Db 17 CCGCGCTGCAGAACAGG 2

RESULT 319
AX687999/c
LOCUS AX726310 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 731 from Patent EP1281758.
ACCESSION AX687999
VERSION AX687999.1 GI:29410697
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 731 05-FEB-2003;
Acomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 267 ACCTGCCTTCAGAAC 282
Db 16 ACCGCGCTGCAGAAC 1

RESULT 320
AX726310
LOCUS AX726310 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3997 from Patent WO03025175.
ACCESSION AX726310
VERSION AX726310.1 GI:30505653
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 3997 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 485 GATCTGAAGGCGACA 500
Db 1 GATCTGAAGTGCACA 16

RESULT 321
AX726360/c
LOCUS AX726360 17 bp DNA linear PAT 08-MAY-2003

DEFINITION Sequence 4047 from Patent WO03025176.
ACCESSION AX726360
VERSION AX726360.1 GI:30505703
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 4047 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 570 CTGTGAAGCCAGGT 585
Db 17 CTGTGACAGCCAGAT 2

RESULT 322
AX729841/c
LOCUS AX729841 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1475 from Patent WO03025175.
ACCESSION AX729841
VERSION AX729841.1 GI:30509184
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 1475 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 601 GGAGCTGCAGGAGC 616
Db 16 GGAGCTGCAGTAGATC 1

RESULT 323
AX730931
LOCUS AX730931 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2565 from Patent WO03025175.
ACCESSION AX730931
VERSION AX730931.1 GI:30510274
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS 1 Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 2565 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 881 ATCAAGCAGCGCTGG 896
Db 2 ATCTAGCAGCAGCTGG 17
RESULT 324
AX731926/c
LOCUS AX731926 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3560 from Patent WO03025175.
ACCESSION AX731926
VERSION AX731926.1 GI:30511269
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS 1 Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 3560 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 203 GGCCCGCAGCAGATC 218
Db 16 GGCTGGCAGCAGATC 1
RESULT 325
AX736229
LOCUS AX736229 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1819 from Patent WO03025177.
ACCESSION AX736229
VERSION AX736229.1 GI:30515506
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS 1 Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL Patent: WO 03025177-A 1819 27-MAR-2003;

FEATURES Molecular Engines Laboratories (FR)
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 215 GATCAGGACGTACTGG 230
Db 1 GATCAGGACGTACTGG 16
RESULT 326
AX736680/c
LOCUS AX736680 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2270 from Patent WO03025177.
ACCESSION AX736680
VERSION AX736680.1 GI:30515968
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS 1 Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL Patent: WO 03025177-A 2270 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 473 CTGGAGAGCTCGATC 488
Db 16 CTGGAGAGCTAGATC 1
RESULT 327
AX738167
LOCUS AX738167 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3757 from Patent WO03025177.
ACCESSION AX738167
VERSION AX738167.1 GI:30517455
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS 1 Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL Patent: WO 03025177-A 3757 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

```

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 341 ATCCGCGACAGCAACC 356
Db 2 ATCTCGACAGCATCC 17

RESULT 328
AX759796/c
LOCUS AX759796 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 3117 from Patent WO03040369.
ACCESSION AX759796
VERSION AX759796.1 GI:32254412
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 3117 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 345 GGCAGACCAACCAT 360
Db 17 GGAAGACCAAGCAT 2

RESULT 329
AX760038/c
LOCUS AX760038 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 3359 from Patent WO03040369.
ACCESSION AX760038
VERSION AX760038.1 GI:32254654
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 3359 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACCAATCAAGAC 889
Db 16 CACCACATCAAGATC 1

```

```

RESULT 330
AX760481/c
LOCUS AX760481 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 3802 from Patent WO03040369.
ACCESSION AX760481
VERSION AX760481.1 GI:32255097
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 3802 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 203 GGCCCGCAGCAGATC 218
Db 16 GGGCTGCAGCAGATC 1

RESULT 331
AX761627/c
LOCUS AX761627 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 4948 from Patent WO03040369.
ACCESSION AX761627
VERSION AX761627.1 GI:32256243
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 4948 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 537 GATCCCGCAGCAGAT 552
Db 17 GCTGCCAGAGCAGAT 2

RESULT 332
AX781734
LOCUS AX781734 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 65 from Patent WO03050284.
ACCESSION AX781734

```

```

VERSION      AX781734.1  GI:32949568
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE    1
AUTHORS      Guo,J.
TITLE        Human prostate cancer candidate protein 1
JOURNAL      Patent: WO 03050284-A 65 19-JUN-2003;
             Amersham Biosciences (SV) Corp. (US)

FEATURES     source
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match  1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  672  GGGCGGCCAGCGAGCA 687
Db    2  GGGCTGGAGCGAGCA 17

RESULT 333
AX781736
LOCUS       AX781736             17 bp  DNA  linear  PAT 17-JUL-2003
DEFINITION Sequence 67 from Patent WO03050284.
ACCESSION  AX781736
VERSION     AX781736.1  GI:32949570
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE    1
AUTHORS      Guo,J.
TITLE        Human prostate cancer candidate protein 1
JOURNAL      Patent: WO 03050284-A 67 19-JUN-2003;
             Amersham Biosciences (SV) Corp. (US)

FEATURES     source
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match  1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  673  GGGCGGCCAGCGAGCAG 688
Db    1  GGCTGGAGCGAGCAG 16

RESULT 334
AX781739
LOCUS       AX781739             17 bp  DNA  linear  PAT 17-JUL-2003
DEFINITION Sequence 70 from Patent WO03050284.
ACCESSION  AX781739
VERSION     AX781739.1  GI:32949573
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE    1
AUTHORS      Guo,J.
TITLE        Human prostate cancer candidate protein 1
JOURNAL      Patent: WO 03050284-A 70 19-JUN-2003;
             Amersham Biosciences (SV) Corp. (US)

```

```

FEATURES     source
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match  1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  677  GCGAGCGAGCGAGCGCG 692
Db    2  GCGAGCGAGCGAGCGC 17

RESULT 335
AX781741
LOCUS       AX781741             17 bp  DNA  linear  PAT 17-JUL-2003
DEFINITION Sequence 72 from Patent WO03050284.
ACCESSION  AX781741
VERSION     AX781741.1  GI:32949575
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE    1
AUTHORS      Guo,J.
TITLE        Human prostate cancer candidate protein 1
JOURNAL      Patent: WO 03050284-A 72 19-JUN-2003;
             Amersham Biosciences (SV) Corp. (US)

FEATURES     source
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match  1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  678  CCAGCGAGCGAGCGCG 693
Db    1  CGAGCGAGCGAGCGCG 16

RESULT 336
AX783693
LOCUS       AX783693             17 bp  DNA  linear  PAT 17-JUL-2003
DEFINITION Sequence 2024 from Patent WO03050284.
ACCESSION  AX783693
VERSION     AX783693.1  GI:32951542
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE    1
AUTHORS      Guo,J.
TITLE        Human prostate cancer candidate protein 1
JOURNAL      Patent: WO 03050284-A 2024 19-JUN-2003;
             Amersham Biosciences (SV) Corp. (US)

FEATURES     source
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match  1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  678  CCAGCGAGCGAGCGCG 693
Db    1  CGAGCGAGCGAGCGCG 16

RESULT 336
AX783693
LOCUS       AX783693             17 bp  DNA  linear  PAT 17-JUL-2003
DEFINITION Sequence 2024 from Patent WO03050284.
ACCESSION  AX783693
VERSION     AX783693.1  GI:32951542
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE    1
AUTHORS      Guo,J.
TITLE        Human prostate cancer candidate protein 1
JOURNAL      Patent: WO 03050284-A 2024 19-JUN-2003;
             Amersham Biosciences (SV) Corp. (US)

FEATURES     source
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match  1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  333  GAGATGCCATCCGCA 348

```

```
Db 2 GAGATGGCATCCTGCA 17
||||| ||||| |||
RESULT 337
AX783695
LOCUS AX783695 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2026 from Patent WO03050284.
ACCESSION AX783695
VERSION AX783695.1 GI:32951544
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2026 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 334 AGATGCCATCCGGCAG 349
||||| ||||| |||||
Db 1 AGATGGCATCCTGCAG 16
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 334 AGATGCCATCCGGCAG 349
||||| ||||| |||||
Db 1 AGATGGCATCCTGCAG 16
RESULT 338
AX783780
LOCUS AX783780 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2111 from Patent WO03050284.
ACCESSION AX783780
VERSION AX783780.1 GI:32951629
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2111 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 413 GAGAAGGAGTTCTCTCA 428
||||| ||||| |||||
Db 2 GAGAAGGAATGCCTCA 17
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 413 GAGAAGGAGTTCTCTCA 428
||||| ||||| |||||
Db 2 GAGAAGGAATGCCTCA 17
RESULT 339
AX783783
LOCUS AX783783 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2114 from Patent WO03050284.
ACCESSION AX783783
VERSION AX783783.1 GI:32951632
KEYWORDS
```

```
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2114 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 415 GAAGGAGTTCTCTCATG 430
||||| ||||| |||||
Db 1 GAAGGAATGCCTCATG 16
RESULT 340
AX802176/c
LOCUS AX802176 17 bp DNA linear PAT 24-NOV-2003
DEFINITION Sequence 39 from Patent WO03057727.
ACCESSION AX802176
VERSION AX802176.1 GI:38501075
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Karatzas,C.N. and Turcotte,C.
TITLE Methods of producing silk polypeptides and products thereof
JOURNAL Patent: WO 03057727-A 39 17-JUL-2003;
Nexia Biotechnologies, Inc. (CA)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Linker sequence"
Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 718 GCTGCAGCAGCAGCAC 733
||||| ||||| |||||
Db 16 GCCGCAGCAGCAGCCCC 1
RESULT 341
AX802177/c
LOCUS AX802177 17 bp DNA linear PAT 24-NOV-2003
DEFINITION Sequence 40 from Patent WO03057727.
ACCESSION AX802177
VERSION AX802177.1 GI:38501076
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Karatzas,C.N. and Turcotte,C.
TITLE Methods of producing silk polypeptides and products thereof
JOURNAL Patent: WO 03057727-A 40 17-JUL-2003;
Nexia Biotechnologies, Inc. (CA)
FEATURES
source
1..17
/organism="synthetic construct"
```



```

/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 718 GCTGCAGCAGCAGCAC 733
Db 16 GCCGCAGCAGCAGCCC 1

RESULT 342
136992/c
LOCUS 136992 14 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 5 from patent US 5612215.
ACCESSION 136992
VERSION 136992.1 GI:2084952
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 5 18-MAR-1997;
FEATURES
source
1..14
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.6%; Score 12.4; DB 1; Length 14;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 380 GAGCTTCTGCATTT 393
Db 14 GAACCTTCTGCATTT 1

RESULT 343
193842/c
LOCUS 193842 14 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 5 from patent US 5731395.
ACCESSION 193842
VERSION 193842.1 GI:3938312
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 5 24-MAR-1998;
FEATURES
source
1..14
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.6%; Score 12.4; DB 1; Length 14;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 380 GAGCTTCTGCATTT 393
Db 14 GAACCTTCTGCATTT 1

RESULT 344
ARI32395/c
LOCUS ARI32395 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 820 from patent US 6194150.
ACCESSION ARI32395
VERSION ARI32395.1 GI:14121300
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 820 27-FEB-2001;
FEATURES
source
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.6%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 580 CCAGGTGACGTCCT 593
Db 15 CCAGGTGAAGTCCT 2

RESULT 345
ARI32460/c
LOCUS ARI32460 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 885 from patent US 6194150.
ACCESSION ARI32460
VERSION ARI32460.1 GI:14121365
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 885 27-FEB-2001;
FEATURES
source
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.6%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 CTTCAGAACAGGC 286
Db 15 CTTCAGAAAGGC 2

RESULT 346
ARI32461/c
LOCUS ARI32461 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 886 from patent US 6194150.
ACCESSION ARI32461
VERSION ARI32461.1 GI:14121366
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 886 27-FEB-2001;
FEATURES
source
1..15
/organism="unknown"
/mol_type="unassigned DNA"

```

```
Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 273 CTTTCAGACAGGCG 286
Db 14 CTTTCAGAAAGGCG 1

RESULT 347
BD238450      15 bp      DNA      linear      PAT 17-JUL-2003
LOCUS      Nucleic acids provided for modulating cellular activation.
DEFINITION      BD238450
ACCESSION      BD238450.1 GI:33048220
VERSION      JP 2002517181-A/6.
KEYWORDS      synthetic construct
SOURCE      other sequences; artificial sequences.
ORGANISM      1 (bases 1 to 15)
REFERENCE      Nucleic acids provided for modulating cellular activation
AUTHORS      Abken,H.
TITLE      Patent: JP 2002517181-A 6 18-JUN-2002;
JOURNAL      CURACYTE AG
COMMENT      OS Artificial Sequence
PN JP 2002517181-A/6
PD 18-JUN-2002
PF 05-FEB-1999 JP 2000530601
PR 06-FEB-1998 DE 198 38 967.1,22-DEC-1998 DE 198 59 056.3 PI
PC HINRICH ABKEN
C12N15/09,A61K31/7105,A61K31/711,A61P35/00,A61P37/02,A61P43/00, PC
C12N15/00
CC Description of Artificial Sequence:synthetic DNA FH Key
FT source
FT 1. .15
   Location/Qualifiers
   /organism='Artificial Sequence'.
   /mol_type='genomic DNA'
   /db_xref='taxon:32630'

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 369 AGCGCTGGAGGAG 382
Db 2 AGCGCGGCGAGGAG 15

RESULT 348
BD266203/c    15 bp      DNA      linear      PAT 17-JUL-2003
LOCUS      Universal arrays.
DEFINITION      BD266203
ACCESSION      BD266203.1 GI:33075971
VERSION      JP 2002539849-A/203.
KEYWORDS      synthetic construct
SOURCE      other sequences; artificial sequences.
ORGANISM      1 (bases 1 to 15)
REFERENCE      Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
AUTHORS      Lockhart,D.J., Ryder,T. and Sklar,P.
TITLE      Universal arrays
JOURNAL      Patent: JP 2002539849-A 203 26-NOV-2002;
COMMENT      WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC
OS Artificial Sequence
PN JP 2002539849-A/203
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 27-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI

JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG,PAUL KAPLAN,ERIC
PI S LANDER,
PC DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C12Q1/68,C12M1/00,C12N15/09,C12N15/09,C12N15/09,G01N33/53, PC
G01N33/566,
PC G01N37/00,C12N15/00,C12N15/00,C12N15/00
CC Primer
FH Key
FT source
FT 1. .15
   Location/Qualifiers
   /organism='Artificial Sequence'.
   /mol_type='genomic DNA'
   /db_xref='taxon:32630'

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 397 AGCCAGCGAGGG 410
Db 15 AGCCAGCGAGGG 2

RESULT 349
I39091/c      15 bp      DNA      linear      PAT 13-MAY-1997
LOCUS      Sequence 129 from patent US 5616488.
DEFINITION      I39091
ACCESSION      I39091
VERSION      I39091.1 GI:2083571
KEYWORDS      Unknown.
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Sullivan,S., Draper,K.G., McSwiggen,J. and Stinchcomb,D.T.
TITLE      IL-5 targeted ribozymes
JOURNAL      Patent: US 5616488-A 129 01-APR-1997;
FEATURES      Location/Qualifiers
      source
      1. .15
        /organism='unknown'
        /mol_type='unassigned DNA'

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 308 TGCCTGGAGGAGAA 321
Db 14 TGCCTGGAGGAGAA 1

RESULT 350
I64669/c      15 bp      DNA      linear      PAT 07-OCT-1997
LOCUS      Sequence 18 from patent US 5665580.
DEFINITION      I64669
ACCESSION      I64669
VERSION      I64669.1 GI:2481563
KEYWORDS      Unknown.
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Crooke,S.T., Mirabelli,C.K., Ecker,D.J. and Cowseert,L.M.
TITLE      Antisense oligonucleotide inhibition of papillomavirus transformed
JOURNAL      cells
COMMENT      Patent: US 5665580-A 18 09-SEP-1997;
OS Artificial Sequence
PN JP 2002539849-A/203
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 27-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI
```

```

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 404 CAGAGGAGGAGGAA 417
    ||||| ||||| |||||
Db 14 CAGAGGTAGGAGAA 1

RESULT 351
LOCUS AR242016 15 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 304 from patent US 6472154.
ACCESSION AR242016
VERSION AR242016.1 GI:27287828
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.
TITLE Polymorphic repeats in human genes
JOURNAL Patent: US 6472154-A 304 29-OCT-2002;
FEATURES Location/Qualifiers
    source
        1..15
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 719 CTGCAGCAGCAGCA 732
    ||||| ||||| |||||
Db 1 CAGCAGCAGCAGCA 14

RESULT 352
LOCUS AX019392 15 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 8 from Patent WO9940187.
ACCESSION AX019392
VERSION AX019392.1 GI:10043362
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Abken,H.
TITLE Nucleic acids provided for modulating cellular activation
JOURNAL Patent: WO 9940187-A 8 12-AUG-1999;
FEATURES Location/Qualifiers
    source
        1..15
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="synthetische"

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 369 AGCGCTGGAGGAG 382
    ||||| ||||| |||||
Db 2 AGCGCGGAGGAG 15

RESULT 353
LOCUS AX635410 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 2549 from Patent EP1260586.

```

```

ACCESSION AX635410
VERSION AX635410.1 GI:28471024
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL Patent: EP 1260586-A 2549 27-NOV-2002;
FEATURES Location/Qualifiers
    source
        1..15
            /organism="unidentified"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32644"

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 308 TGCTGGAGGAGAA 321
    ||||| ||||| |||||
Db 14 TGCTGGAGGAGAA 1

RESULT 354
LOCUS BD266350 16 bp DNA linear PAT 17-JUL-2003
DEFINITION Universal arrays.
ACCESSION BD266350
VERSION BD266350.1 GI:33076118
KEYWORDS JP 2002539849-A/350.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 16)
AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
Lockhart,D.J., Ryder,T. and Sklar,P.
TITLE Universal arrays
JOURNAL Patent: JP 2002539849-A 350 26-NOV-2002;
COMMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC
    OS Artificial Sequence
    PN JP 2002539849-A/350
    PD 26-NOV-2002
    PR 27-MAR-2000 JP 2000608794
    PI 60/126473,23-JUN-1999 US 60/140359 PI
    JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
    HUANG,PAUL,KAPLAN,ERIC
    PI S LANDER,
    PI DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
    PC C12Q1/68,C12M1/00,C12N15/09,C12N15/09,C12N15/09,G01N33/53, PC
    GOIN33/566,
    PC GOIN37/00,C12N15/00,C12N15/00,C12N15/00
    CC Primer
    FH Key
    FT source
    FT source
    FT Location/Qualifiers
        1..16
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"

FEATURES
    source
        1..16
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"

Query Match      1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```
Qy 496 GCAGAAGGAGCAGG 509
Db 16 GCAGCAGGAGCAGG 3

RESULT 355
LOCUS AR211619 16 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 38 from patent US 6399340.
ACCESSION AR211619
VERSION AR211619.1 GI:21514989
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE
AUTHORS Saito,Y., Noguchi,Y., Yoshikawa,K. and Soeda,S.
TITLE Vector derivatives of gluconobacter plasmid pF4
JOURNAL Patent: US 6399340-A 38 04-JUN-2002;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 741 AGGTGGACCACTG 754
Db 1 AGGTGGACCACTG 14

RESULT 356
LOCUS AR305487/c 16 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 445 from patent US 6545137.
ACCESSION AR305487
VERSION AR305487.1 GI:31694797
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE
AUTHORS Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D.,
Hammond,H., Hey,P., Kawaguchi,Y., Merriman,T.R., Metzker,M.L.,
Nakagawa,Y., Phillips,M.S. and Twells,R.C.J.
TITLE LDL-receptor
JOURNAL Patent: US 6555654-A 445 29-APR-2003;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 508 GGCTCTGCGGGAGG 521
Db 14 GGCTCTGCGGGAGG 1

RESULT 357
LOCUS AR309591/c 16 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 445 from patent US 6555654.
ACCESSION AR309591
VERSION AR309591.1 GI:31701596
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE
AUTHORS Remacle,J., Hamels,S., Zammateo,N., Lockman,L., Dufour,S.,
Alexandre,I. and de Longueville,F.
TITLE Identification of biological (micro) organisms by detection of the
JOURNAL ir homologous nucleotide sequences on arrays
Patent: WO 0177372-A 150 18-OCT-2001;
FEATURES
source
1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db xref="taxon:32630"
/note="Antisense consensus Primer subtypes 5A, 5B"

REFERENCE 1 (bases 1 to 16)
AUTHORS Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D.,
Hammond,H., Hey,P., Kawaguchi,Y., Merriman,T.R., Metzker,M.L.,
Nakagawa,Y., Phillips,M.S. and Twells,R.C.J.
TITLE LDL-receptor
JOURNAL Patent: US 6555654-A 445 29-APR-2003;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 705 GTGAGCGCGAGCGG 718
Db 16 GTGAGCGCGAGCGG 3

RESULT 359
LOCUS AX278613 16 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 150 from Patent WO0177372.
ACCESSION AX278613
VERSION AX278613.1 GI:16606067
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Remacle,J., Hamels,S., Zammateo,N., Lockman,L., Dufour,S.,
Alexandre,I. and de Longueville,F.
TITLE Identification of biological (micro) organisms by detection of the
JOURNAL ir homologous nucleotide sequences on arrays
Patent: WO 0177372-A 150 18-OCT-2001;
FEATURES
source
1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db xref="taxon:32630"
/note="Antisense consensus Primer subtypes 5A, 5B"
```

```

Query Match      1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 406 GAGGGAGGAGGAGG 419
Db 14 GAGGGAGGAGGAGG 1

RESULT 360
AX659627
LOCUS AX659627 16 bp DNA linear PAT 03-APR-2003
DEFINITION Sequence 21 from Patent WO02103014.
ACCESSION AX659627
VERSION AX659627.1 GI:29161809
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
1
AUTHORS Al-Mahmood,S.
TITLE Antisense oligonucleotides which can inhibit the formation of
capillary tubes by endothelial cells
JOURNAL Patent: WO 02103014-A 21 27-DEC-2002;
Al-Mahmood, Salman (PR)
FEATURES
source
1..16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide anti-sens."

Query Match      1.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 253 GCACGCCATGCTGC 266
Db 2 GCCTGCCATGCTGC 15

RESULT 361
BD106398/c
LOCUS BD106398 16 bp DNA linear PAT 18-SEP-2002
DEFINITION Novel LDL-receptor.
ACCESSION BD106398
VERSION BD106398.1 GI:23201216
KEYWORDS JP 2002501376-A/413.
SOURCE Chlamydia sp.
ORGANISM Chlamydia sp.
REFERENCE 1
AUTHORS Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D., Hammond,H.
and Hey,P.
TITLE Novel LDL-receptor
JOURNAL Patent: JP 2002501376-A 413 15-JAN-2002;
THE WELLCOME TRUST LTD AS TRUSTEE TO THE WELLCOME TRUST, MERCK & CO
INC
COMMENT
PN JP 2002501376-A/413
PD 15-JAN-2002
PF 15-APR-1998 JP 1998543635
PR 15-APR-1997 US 60/043553,05-JUN-1997 US 60/048740 PI
JOHN ANDREW TODD,JOHN WILFRED HESS,CHARLES
THOMAS CASKEY,ROGER
PI DAVID COX
PI DAVID GERHOLD,HOLLY HAMMOND,PATRICIA HEY
PC C12N15/12,C12N15/11,C12Q1/68,C07K14/705,C07K16/28,A61K38/17,
A61K39/395,
PC A61K48/00
CC Strandedness: Double;
CC Topology: Linear;
PH Key Location/Qualifiers.

FEATURES
source
1..16
/organism="Chlamydia sp."
/mol_type="genomic DNA"
/db_xref="taxon:35827"

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 16;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 508 GGCTCTGGGGGAGG 521
Db 14 GGCTCTGGGGGAGG 1

Search completed: April 8, 2005, 08:39:11
Job time : 4 secs

```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 8, 2005, 08:53:42 ; Search time 1 Seconds
(without alignments)
0.630 Million cell updates/sec

Title: US-10-628-841-3
Perfect score: 755
Sequence: 1 tctggaagagccaactgtgt.....tgggcagtgcggaagcga 755

Scoring table: IDENTITY NUC
Gapop 10_0 , Gapext 0.5

Searched: 31 seqs, 417 residues

Total number of hits satisfying chosen parameters: 62

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 32 summaries

Database : fetch3rst.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
C 1	16.8	2.2	22	1	BG926061	ACCESSION:BG926061
2	12.8	1.7	17	1	CF305567	ACCESSION:CF305567
3	12	1.6	12	1	AJ593912	ACCESSION:AJ593912
4	12	1.6	12	1	AJ594491	ACCESSION:AJ594491
5	12	1.6	13	1	AJ590284	ACCESSION:AJ590284
6	12	1.6	13	1	AJ592721	ACCESSION:AJ592721
7	12	1.6	13	1	AJ593693	ACCESSION:AJ593693
8	12	1.6	13	1	AJ593750	ACCESSION:AJ593750
9	12	1.6	13	1	AJ594409	ACCESSION:AJ594409
10	12	1.6	14	1	AJ587585	ACCESSION:AJ587585
11	12	1.6	14	1	AJ592722	ACCESSION:AJ592722
12	12	1.6	14	1	AJ592942	ACCESSION:AJ592942
13	12	1.6	15	1	AJ593961	ACCESSION:AJ593961
14	12	1.6	16	1	AJ588998	ACCESSION:AJ588998
15	11.4	1.5	15	1	AJ595331	ACCESSION:AJ595331
16	11	1.5	13	1	AJ591455	ACCESSION:AJ591455
C 17	10.6	1.4	17	1	CF305567	ACCESSION:CF305567
18	10.4	1.4	12	1	AJ587934	ACCESSION:AJ587934
19	10.4	1.4	12	1	AJ593993	ACCESSION:AJ593993
20	10.4	1.4	13	1	AJ593342	ACCESSION:AJ593342
21	10.4	1.4	13	1	AJ594410	ACCESSION:AJ594410
22	10.4	1.4	13	1	AJ598779	ACCESSION:AJ598779
23	10.4	1.4	13	1	AJ598718	ACCESSION:AJ598718
24	10.4	1.4	13	1	AJ599128	ACCESSION:AJ599128
25	10.4	1.4	13	1	AJ599161	ACCESSION:AJ599161
26	10	1.3	10	1	AJ592517	ACCESSION:AJ592517
27	10	1.3	11	1	BM395068	ACCESSION:BM395068
C 28	9.8	1.3	13	1	AJ650760	ACCESSION:AJ650760
C 29	9.8	1.3	13	1	AJ687457	ACCESSION:AJ687457
C 30	9.8	1.3	13	1	BG926067	ACCESSION:BG926067
31	9.8	1.3	13	1	CF921303	ACCESSION:CF921303
C 32	9.8	1.3	13	1	AJ588600	ACCESSION:AJ588600

ALIGNMENTS

```
RESULT 1
BG926061/c
LOCUS      BG926061
DEFINITION HNC23-1-E2.R HNC (Human Normal Cartilage) Homo sapiens cDNA, mRNA
sequence.
ACCESSION  BG926061
VERSION    BG926061.1
KEYWORDS   EST
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1 (bases 1 to 22)
AUTHORS   Kumar,S., Connor,J.R., Dodds,R.A., Halsey,W., Van Horn,M., Mao,J.,
Sache,C., Mui,P., Agarwal,P., Badger,A.M., Lee,J.C., Gowen,M. and
Lark,M.W.
TITLE      Identification and initial characterization of 5000 expressed
sequenced tags (ESTs) each from adult human normal and
osteoarthritis cartilage cDNA libraries
JOURNAL    Osteoarthritis. Cartil. 9 (7), 641-653 (2001)
MEDLINE    21482651
PUBMED     11597177
COMMENT    Contact: Sanjay Kumar
          UW2109
          GlaxoSmithKline
          709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406, USA
          Tel: 610-270-7245
          Fax: 610-270-5598
          Email: sanjay.kumar-1@gsk.com
          Seq primer: 17.
          Location/Qualifiers
            1..22
              /organism="Homo sapiens"
              /mol_type="mRNA"
              /db_xref="taxon:9606"
              /tissue_type="cartilage"
              /lab_host="E.coli DH10 B"
              /clone_lib="HNC (Human Normal Cartilage)"
              /note="Vector: pSPORT 1; Site_1: SalI; Site_2: NotI;
              Directional"
          Query Match      2.2%; Score 16.8; DB 1; Length 22;
          Best Local Similarity 90.0%; Pred. No. 1.2;
          Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      402 GCCAGAGGAGGAGGAGGAG 421
          |||||
Db      21  GCGCGAGGAGGAGGAGGAG 2

RESULT 2
CF305567
LOCUS      CF305567
DEFINITION HDAL--01-B07.g1 OshDAC1-overexpressing transgenic rice lambda phage
cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA
clone HDAL--01-B07, mRNA sequence.
ACCESSION  CF305567
VERSION    CF305567.1
KEYWORDS   EST
SOURCE     Oryza sativa (japonica cultivar-group)
ORGANISM   Oryza sativa (japonica cultivar-group)
REFERENCE  1 (bases 1 to 17)
AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE      Large-scale Sequencing Analysis of Rice ESTs
          Unpublished (2003)
```

COMMENT

Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Gyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

Location/Qualifiers

source

```

1. .17
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39347"
/clone="HDAL-01-B07"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OSHDAC1-overexpressing transgenic rice lambda
phage cDNA library I (HDAL)"
/notes="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1 hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice histone deacetylase overexpression line."

```

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.2;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 709 GCGGAGGCGTGCAG 724

Db 2 GCACGAGCGCTGCG 17

RESULT 3

AJ593912

LOCUS

DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone

389E12, genomic survey sequence.

ACCESSION AJ593912

VERSION AJ593912.1 Gi:37943536

KEYWORDS GSS; left border; T-DNA flanking sequence.

SOURCE Arabidopsis thaliana (thale cress)

ORGANISM

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE

AUTHORS

1 Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.

T-DNA integration into the Arabidopsis genome depends on sequences

of pre-insertion sites

EMBO Rep. 3 (12), 1152-1157 (2002)

2363535

12446565

2 (bases 1 to 12)

Balzerque, S.

Direct Submission

Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue

Gaston Cremieux, 91057 Evry cedex, FRANCE

PCR was performed on DNA from transformants of Arabidopsis thaliana

plants from INRA (Versailles). The DNA fragment(s) resulting from

the PCR were directly sequenced from the left or the right border

to determine the genomic sequence flanking the insertion. T-DNA

derived sequences were removed. Information to order the

corresponding mutant line and a link to a database providing a

graphical display of the insertion site are available at

http://dbsgap.versailles.inra.fr/publiclines/. This sequence has

been generated in the framework of the French plant genomics

program 'Genoplante' (http://www.genoplante.com and

http://genoplante-info.infobiogen.fr).

Location/Qualifiers

FEATURES

source

```

1. .12
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskija"
/db_xref="taxon:3702"
/clone="389E12"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
/notes="T-DNA flanking sequence
left border"

```

Query Match 1.6%; Score 12; DB 1; Length 12;

Best Local Similarity 100.0%; Pred. No. 6.3;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 669 CCCGCGCGGCCA 680

Db 1 CCCGCGCGGCCA 12

RESULT 4

AJ594491

LOCUS

DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone

399F03, genomic survey sequence.

ACCESSION AJ594491

VERSION AJ594491.1 Gi:37944115

KEYWORDS GSS; left border; T-DNA flanking sequence.

SOURCE Arabidopsis thaliana (thale cress)

ORGANISM

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE

AUTHORS

1 Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.

T-DNA integration into the Arabidopsis genome depends on sequences

of pre-insertion sites

EMBO Rep. 3 (12), 1152-1157 (2002)

2363535

12446565

2 (bases 1 to 12)

Balzerque, S.

Direct Submission

Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue

Gaston Cremieux, 91057 Evry cedex, FRANCE

PCR was performed on DNA from transformants of Arabidopsis thaliana

plants from INRA (Versailles). The DNA fragment(s) resulting from

the PCR were directly sequenced from the left or the right border

to determine the genomic sequence flanking the insertion. T-DNA

derived sequences were removed. Information to order the

corresponding mutant line and a link to a database providing a

graphical display of the insertion site are available at

http://dbsgap.versailles.inra.fr/publiclines/. This sequence has

been generated in the framework of the French plant genomics

program 'Genoplante' (http://www.genoplante.com and

http://genoplante-info.infobiogen.fr).

Location/Qualifiers

FEATURES

source

```

1. .12
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskija"
/db_xref="taxon:3702"
/clone="399F03"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
/notes="T-DNA flanking sequence
left border"

```

misc_feature

1. .12
/notes="T-DNA flanking sequence
left border"

Query Match 1.6%; Score 12; DB 1; Length 12;

Best Local Similarity 100.0%; Pred. No. 6.3;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```

QY      669  CCGGCGCGGCCA 680
Db      |||||
1  CCGGCGCGGCCA 12

RESULT 5
AJ590284
LOCUS   Arabidopsis thaliana T-DNA flanking sequence, left border, clone
DEFINITION
566D05, genomic survey sequence.
ACCESSION AJ590284
VERSION   1 GI:37939908
KEYWORDS  GSS; left border; T-DNA flanking sequence.
SOURCE    Arabidopsis thaliana (thale cress)
ORGANISM  Arabidopsis thaliana
          Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
          Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
          rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE
1  Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,
    Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
    Lepiniec, L., Caboche, M. and Lecharny, A.
    T-DNA integration into the Arabidopsis genome depends on sequences
    of pre-insertion sites
    EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL  22363535
MEDLINE  12446565
PUBMED   12446565
AUTHORS  Balzergue, S.
TITLE    Direct Submision
JOURNAL  Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
COMMENT  PCR was performed on DNA from transformants of Arabidopsis thaliana
          plants from INRA (Versailles). The DNA fragment(s) resulting from
          the PCR were directly sequenced from the left or the right border
          to determine the genomic sequence flanking the insertion. T-DNA
          derived sequences were removed. Information to order the
          corresponding mutant line and a link to a database providing a
          graphical display of the insertion site are available at
          http://dbgap.versailles.inra.fr/publiclines/. This sequence has
          been generated in the framework of the French plant genomics
          program 'Genoplatane' (http://www.genoplatane.com and
          http://genoplatane-info.infobiogen.fr).

FEATURES             Location/Qualifiers
     source           1..13
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="631A03"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature     1..13
                     /note="T-DNA flanking sequence
                     right border"

Query Match      1.6%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 7.2;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      669  CCGGCGCGGCCA 680
Db      |||||
2  CCGGCGCGGCCA 13

RESULT 7
AJ593693
LOCUS   Arabidopsis thaliana T-DNA flanking sequence, left border, clone
DEFINITION
385F05, genomic survey sequence.
ACCESSION AJ593693
VERSION   1 GI:37943317
KEYWORDS  GSS; left border; T-DNA flanking sequence.
SOURCE    Arabidopsis thaliana (thale cress)
ORGANISM  Arabidopsis thaliana
          Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
          Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
          rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE
1  Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,
    Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
    Lepiniec, L., Caboche, M. and Lecharny, A.
    T-DNA integration into the Arabidopsis genome depends on sequences
    of pre-insertion sites
    EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL  22363535
MEDLINE  12446565
PUBMED   12446565
AUTHORS  Balzergue, S.
TITLE    Direct Submision
JOURNAL  Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
COMMENT  PCR was performed on DNA from transformants of Arabidopsis thaliana
          plants from INRA (Versailles). The DNA fragment(s) resulting from
          the PCR were directly sequenced from the left or the right border
          to determine the genomic sequence flanking the insertion. T-DNA
          derived sequences were removed. Information to order the
          corresponding mutant line and a link to a database providing a
          graphical display of the insertion site are available at
          http://dbgap.versailles.inra.fr/publiclines/. This sequence has
          been generated in the framework of the French plant genomics
          program 'Genoplatane' (http://www.genoplatane.com and
          http://genoplatane-info.infobiogen.fr).

FEATURES             Location/Qualifiers
     source           1..13
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="566D05"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature     1..13
                     /note="T-DNA flanking sequence
                     left border"

Query Match      1.6%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 7.2;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      669  CCGGCGCGGCCA 680
Db      |||||
2  CCGGCGCGGCCA 13

RESULT 6
AJ592721
LOCUS   Arabidopsis thaliana T-DNA flanking sequence, right border, clone
DEFINITION
631A03, genomic survey sequence.
ACCESSION AJ592721
VERSION   1 GI:37942345
KEYWORDS  GSS; right border; T-DNA flanking sequence.

```

```

SOURCE             Arabidopsis thaliana (thale cress)
ORGANISM           Arabidopsis thaliana
                  Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
                  Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
                  rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE
1  Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,
    Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
    Lepiniec, L., Caboche, M. and Lecharny, A.
    T-DNA integration into the Arabidopsis genome depends on sequences
    of pre-insertion sites
    EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL  22363535
MEDLINE  12446565
PUBMED   12446565
AUTHORS  Balzergue, S.
TITLE    Direct Submision
JOURNAL  Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
COMMENT  PCR was performed on DNA from transformants of Arabidopsis thaliana
          plants from INRA (Versailles). The DNA fragment(s) resulting from
          the PCR were directly sequenced from the left or the right border
          to determine the genomic sequence flanking the insertion. T-DNA
          derived sequences were removed. Information to order the
          corresponding mutant line and a link to a database providing a
          graphical display of the insertion site are available at
          http://dbgap.versailles.inra.fr/publiclines/. This sequence has
          been generated in the framework of the French plant genomics
          program 'Genoplatane' (http://www.genoplatane.com and
          http://genoplatane-info.infobiogen.fr).

FEATURES             Location/Qualifiers
     source           1..13
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="631A03"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature     1..13
                     /note="T-DNA flanking sequence
                     right border"

Query Match      1.6%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 7.2;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      669  CCGGCGCGGCCA 680
Db      |||||
2  CCGGCGCGGCCA 13

RESULT 7
AJ593693
LOCUS   Arabidopsis thaliana T-DNA flanking sequence, left border, clone
DEFINITION
385F05, genomic survey sequence.
ACCESSION AJ593693
VERSION   1 GI:37943317
KEYWORDS  GSS; left border; T-DNA flanking sequence.
SOURCE    Arabidopsis thaliana (thale cress)
ORGANISM  Arabidopsis thaliana
          Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
          Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
          rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE
1  Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,
    Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
    Lepiniec, L., Caboche, M. and Lecharny, A.
    T-DNA integration into the Arabidopsis genome depends on sequences
    of pre-insertion sites
    EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL  22363535
MEDLINE  12446565
PUBMED   12446565
AUTHORS  Balzergue, S.
TITLE    Direct Submision
JOURNAL  Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
COMMENT  PCR was performed on DNA from transformants of Arabidopsis thaliana
          plants from INRA (Versailles). The DNA fragment(s) resulting from
          the PCR were directly sequenced from the left or the right border
          to determine the genomic sequence flanking the insertion. T-DNA
          derived sequences were removed. Information to order the
          corresponding mutant line and a link to a database providing a
          graphical display of the insertion site are available at
          http://dbgap.versailles.inra.fr/publiclines/. This sequence has
          been generated in the framework of the French plant genomics
          program 'Genoplatane' (http://www.genoplatane.com and
          http://genoplatane-info.infobiogen.fr).

FEATURES             Location/Qualifiers
     source           1..13
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="566D05"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature     1..13
                     /note="T-DNA flanking sequence
                     left border"

Query Match      1.6%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 7.2;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      669  CCGGCGCGGCCA 680
Db      |||||
2  CCGGCGCGGCCA 13

RESULT 6
AJ592721
LOCUS   Arabidopsis thaliana T-DNA flanking sequence, right border, clone
DEFINITION
631A03, genomic survey sequence.
ACCESSION AJ592721
VERSION   1 GI:37942345
KEYWORDS  GSS; right border; T-DNA flanking sequence.

```

```

REFERENCE
AUTHORS      2 (bases 1 to 13)
TITLE        Balzergue,S.
JOURNAL      Direct Submission
COMMENT      Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).

FEATURES             source
   Location/Qualifiers
       1..13
           /organism="Arabidopsis thaliana"
           /mol_type="genomic DNA"
           /cultivar="Wassilewskija"
           /db_xref="taxon:3702"
           /clone="385F05"
           /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
       misc_feature
           1..13
               /note="T-DNA flanking sequence
               left border"

Query Match      1.6%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 7.2;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      669 CCGGGCGGGCCA 680
Db      2 CCGGGCGGGCCA 13
          |||||
RESULT 9
AJ594409
LOCUS
DEFINITION  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
SOURCE      398B08, genomic survey sequence.
ACCESSION   AJ594409
VERSION     AJ594409.1 GI:37944033
KEYWORDS    GSS; left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
ORGANISM    Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
AUTHORS     Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
            T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL     MEDLINE
PUBMED     22363535
REFERENCE   2 (bases 1 to 13)
AUTHORS     Balzergue,S.
TITLE       Direct Submission
JOURNAL     Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
COMMENT     PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.infobiogen.fr).

FEATURES             source
   Location/Qualifiers
       1..13
           /organism="Arabidopsis thaliana"
           /mol_type="genomic DNA"
           /cultivar="Wassilewskija"
           /db_xref="taxon:3702"
           /clone="385F05"
           /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
       misc_feature
           1..13
               /note="T-DNA flanking sequence
               left border"

Query Match      1.6%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 7.2;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      669 CCGGGCGGGCCA 680
Db      2 CCGGGCGGGCCA 13
          |||||
RESULT 8
AJ593750
LOCUS
DEFINITION  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
SOURCE      385F02, genomic survey sequence.
ACCESSION   AJ593750
VERSION     AJ593750.1 GI:37943374
KEYWORDS    GSS; left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
ORGANISM    Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
AUTHORS     Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
            T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL     MEDLINE
PUBMED     22363535
REFERENCE   2 (bases 1 to 13)
AUTHORS     Balzergue,S.
TITLE       Direct Submission
JOURNAL     Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
COMMENT     PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics

```

program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES source

Location/Qualifiers
1..13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassilewskija"
/db_xref="taxon:3702"
/clone="386F02"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
1..13
/note="T-DNA flanking sequence
left border"

misc_feature

Query Match 1.6%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 7.2;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 CCGGGCGGGCCA 680
Db 2 CCGGGCGGGCCA 13
|||||

RESULT 9

AJ594409
LOCUS
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone
398B08, genomic survey sequence.

ACCESSION AJ594409
VERSION AJ594409.1 GI:37944033
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)

ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE

AUTHORS Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
Lepiniec,L., Caboche,M. and Lecharny,A.

T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites

EMBO Rep. 3 (12), 1152-1157 (2002)

JOURNAL MEDLINE

PUBMED 22363535

REFERENCE 2 (bases 1 to 13)

AUTHORS Balzergue,S.

TITLE Direct Submission

JOURNAL Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE

COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
<http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (<http://www.genoplante.com> and
<http://genoplante-info.infobiogen.fr>).

FEATURES

source

Location/Qualifiers
1..13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassilewskija"
/db_xref="taxon:3702"
/clone="398B08"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"

misc_feature

1..13
/note="T-DNA flanking sequence
left border"

```

Query Match      1.6%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 7.2;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
Db 2 CCGGGCGGCCA 13

RESULT 10
AJ587585
LOCUS
DEFINITION
  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
  296A05, genomic survey sequence.
ACCESSION
  AJ587585
VERSION
  1 GI:37937209
KEYWORDS
  GSS; left border; T-DNA flanking sequence.
SOURCE
  Arabidopsis thaliana (thale cress)
ORGANISM
  Arabidopsis thaliana
  Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
  Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
  rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
1
  Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
  Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
  Lepiniec, L., Caboche, M. and Lecharny, A.
  T-DNA integration into the Arabidopsis genome depends on sequences
  of pre-insertion sites
  EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL
MEDLINE
  22363535
PUBMED
  12446565
REFERENCE
2 (bases 1 to 14)
  Balzerque, S.
  Direct Submission
  Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
  Gaston Cremieux, 91057 Evry cedex, FRANCE
  PCR was performed on DNA from transformants of Arabidopsis thaliana
  plants from INRA (Versailles). The DNA fragment(s) resulting from
  the PCR were directly sequenced from the left or the right border
  to determine the genomic sequence flanking the insertion. T-DNA
  derived sequences were removed. Information to order the
  corresponding mutant line and a link to a database providing a
  graphical display of the insertion site are available at
  http://dbgap.versailles.inra.fr/publiclines/. This sequence has
  been generated in the framework of the French plant genomics
  program 'Genoplatte' (http://www.genoplatte.com and
  http://genoplatte-info.infobiogen.fr).

FEATURES
    source
    1..14
    /organism="Arabidopsis thaliana"
    /mol_type="genomic DNA"
    /cultivar="Wassiljewskija"
    /db_xref="taxon:3702"
    /clone="296A05"
    /clone_lib="Arabidopsis thaliana T-DNA insertion lines"

    misc_feature
    1..14
    /note="T-DNA flanking sequence
    left border"

    Query Match      1.6%; Score 12; DB 1; Length 14;
    Best Local Similarity 100.0%; Pred. No. 8.1;
    Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

    QY 669 CCGGGCGGCCA 680
    Db 1 CCGGGCGGCCA 12

RESULT 12
AJ592942
LOCUS
DEFINITION
  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
  372B12, genomic survey sequence.
ACCESSION
  AJ592942
VERSION
  1 GI:37942566
KEYWORDS
  GSS; left border; T-DNA flanking sequence.
SOURCE
  Arabidopsis thaliana (thale cress)
ORGANISM
  Arabidopsis thaliana
  Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
  Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
  rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
1
  Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
  Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
  Lepiniec, L., Caboche, M. and Lecharny, A.
  T-DNA integration into the Arabidopsis genome depends on sequences
  of pre-insertion sites

    Query Match      1.6%; Score 12; DB 1; Length 13;
    Best Local Similarity 100.0%; Pred. No. 7.2;
    Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

    QY 669 CCGGGCGGCCA 680
    Db 2 CCGGGCGGCCA 13

RESULT 11
AJ592722
LOCUS
DEFINITION
  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
  369E05, genomic survey sequence.

```

```

JOURNAL      EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE      22363535
PUBMED       12446565
REFERENCE     2 (bases 1 to 14)
AUTHORS       Balzergue, S.
JOURNAL      Direct Submission
COMMENT       Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
              Gaston Cremieux, 91057 Evry cedex, FRANCE
              PCR was performed on DNA from transformants of Arabidopsis thaliana
              plants from INRA (Versailles). The DNA fragment(s) resulting from
              the PCR were directly sequenced from the left or the right border
              to determine the genomic sequence flanking the insertion. T-DNA
              derived sequences were removed. Information to order the
              corresponding mutant line and a link to a database providing a
              graphical display of the insertion site are available at
              http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
              been generated in the framework of the French plant genomics
              program 'Genoplante' (http://www.genoplante.com and
              http://genoplante-info.infobiogen.fr).
FEATURES     Location/Qualifiers
             1..14
             /organism="Arabidopsis thaliana"
             /mol_type="genomic DNA"
             /cultivar="Wassiljewskija"
             /db_xref="taxon:3702"
             /clone="372B12"
             /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
             misc_feature 1..14
             /note="T-DNA flanking sequence
             /left border"

Query Match      1.6%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 8.1;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      669 CCGGGCGGCCA 680
Db      1 CCGGGCGGCCA 12

RESULT 13
AJ593961
LOCUS      Arabidopsis thaliana T-DNA flanking sequence, left border, clone
DEFINITION 390C05, genomic survey sequence.
ACCESSION  AJ593961
VERSION     AJ593961.1 GI:37943585
KEYWORDS    GSS; left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana
ORGANISM    Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
            Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,
            Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
            Lepiniec, L., Caboche, M. and Lecharny, A.
            T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
            EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL     22363535
MEDLINE     12446565
PUBMED      12446565
REFERENCE   2 (bases 1 to 15)
AUTHORS     Balzergue, S.
JOURNAL     Direct Submission
COMMENT     Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
              Gaston Cremieux, 91057 Evry cedex, FRANCE
              PCR was performed on DNA from transformants of Arabidopsis thaliana
              plants from INRA (Versailles). The DNA fragment(s) resulting from
              the PCR were directly sequenced from the left or the right border
              to determine the genomic sequence flanking the insertion. T-DNA
              derived sequences were removed. Information to order the
              corresponding mutant line and a link to a database providing a

```

```

graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).
FEATURES     Location/Qualifiers
             1..15
             /organism="Arabidopsis thaliana"
             /mol_type="genomic DNA"
             /cultivar="Wassiljewskija"
             /db_xref="taxon:3702"
             /clone="390C05"
             /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
             misc_feature 1..15
             /note="T-DNA flanking sequence
             /left border"

Query Match      1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 9;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      669 CCGGGCGGCCA 680
Db      1 CCGGGCGGCCA 12

RESULT 14
AJ588998
LOCUS      Arabidopsis thaliana T-DNA flanking sequence, right border, clone
DEFINITION 542F02, genomic survey sequence.
ACCESSION  AJ588998
VERSION     AJ588998.1 GI:37938622
KEYWORDS    GSS; right border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
ORGANISM    Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
            Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F.,
            Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
            Lepiniec, L., Caboche, M. and Lecharny, A.
            T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
            EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL     22363535
MEDLINE     12446565
PUBMED      12446565
REFERENCE   2 (bases 1 to 16)
AUTHORS     Balzergue, S.
JOURNAL     Direct Submission
COMMENT     Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
              Gaston Cremieux, 91057 Evry cedex, FRANCE
              PCR was performed on DNA from transformants of Arabidopsis thaliana
              plants from INRA (Versailles). The DNA fragment(s) resulting from
              the PCR were directly sequenced from the left or the right border
              to determine the genomic sequence flanking the insertion. T-DNA
              derived sequences were removed. Information to order the
              corresponding mutant line and a link to a database providing a
              graphical display of the insertion site are available at
              http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
              been generated in the framework of the French plant genomics
              program 'Genoplante' (http://www.genoplante.com and
              http://genoplante-info.infobiogen.fr).
FEATURES     Location/Qualifiers
             1..16
             /organism="Arabidopsis thaliana"
             /mol_type="genomic DNA"
             /cultivar="Wassiljewskija"
             /db_xref="taxon:3702"
             /clone="542F02"
             /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
             misc_feature 1..16

```

```

/note="T-DNA flanking sequence
right border"

Query Match      1.6%; Score 12; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 10;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 668 GCCCGGGCGGCCA 680
    ||||| |||||
Db 4 GCCCGGCGGCCA 16

RESULT 15
AJ595331
LOCUS      Arabidopsis thaliana T-DNA flanking sequence, left border, clone
DEFINITION
VERSION    AJ595331.1 GI:37944955
KEYWORDS   GSS; left border; T-DNA flanking sequence.
SOURCE     Arabidopsis thaliana (thale cress)
ORGANISM   Arabidopsis thaliana
REFERENCE  1
AUTHORS    Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
TITLE      T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
JOURNAL    EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE    22363535
PUBMED     12446565
REFERENCE  2 (bases 1 to 15)
AUTHORS    Balzergue,S.
TITLE      Direct Submission
JOURNAL    Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
COMMENT    PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.inbio.gen.fr).
FEATURES   source
            1..15
            /organism="Arabidopsis thaliana"
            /mol_type="genomic DNA"
            /cultivar="Wassillewskija"
            /db_xref="taxon:3702"
            /clone="415C10"
            /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
            misc_feature 1..15
            /note="T-DNA flanking sequence
            left border"

Query Match      1.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 12;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 669 CCCGGGGCGCCAGC 683
    ||||| |||||
Db 1 CCCGGGGCGCCCTNNG 15

RESULT 16
AJ591455
LOCUS      Arabidopsis thaliana T-DNA flanking sequence, left border, clone
DEFINITION
VERSION    AJ591455.1 GI:37941079
KEYWORDS   GSS; left border; T-DNA flanking sequence.
SOURCE     Arabidopsis thaliana (thale cress)
ORGANISM   Arabidopsis thaliana
REFERENCE  1
AUTHORS    Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
TITLE      T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
JOURNAL    EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE    22363535
PUBMED     12446565
REFERENCE  2 (bases 1 to 13)
AUTHORS    Balzergue,S.
TITLE      Direct Submission
JOURNAL    Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
COMMENT    PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.inbio.gen.fr).
FEATURES   source
            1..13
            /organism="Arabidopsis thaliana"
            /mol_type="genomic DNA"
            /cultivar="Wassillewskija"
            /db_xref="taxon:3702"
            /clone="585E11"
            /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
            misc_feature 1..13
            /note="T-DNA flanking sequence
            left border"

Query Match      1.5%; Score 11; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCCGGGGCGGCCA 680
    ||||| |||||
Db 2 CCCGGGCGGCCA 13

RESULT 17
CF305567/c
LOCUS      HDAL--01-B07.g1 OsHDA1-overexpressing transgenic rice lambda phage
DEFINITION  cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA
            clone HDAL--01-B07, mRNA sequence.
ACCESSION   CF305567
VERSION     CF305567.1 GI:33677328
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
            Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE   1 (bases 1 to 17)
AUTHORS    Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,

```

Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
 Large-scale Sequencing Analysis of Rice ESTs
 Unpublished (2003)
 Contact: Nahm B.H.
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
 of Bioscience and Bioinformatics, Myongji University
 Yongin, Kyeonggi, Korea
 Tel: 82 31 330 6193
 Fax: 82 31 321 6355
 Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

TITLE JOURNAL COMMENT

FEATURES source

```

1. .17
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="rRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HDAL-01-B07"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OSHDA1-overexpressing transgenic rice lambda
phage cDNA library I (HDAL)"
/notes="vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."

```

Query Match 1.4%; Score 10.6; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 21;
 Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 725 CAGCAGCAGCGTGCA 741
 Db 17 CGCAGCGCTCGTGCA 1

RESULT 18 AJ587934

LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone, 342D03, genomic survey sequence.
 DEFINITION

ACCESSION AJ587934.1 GI:37937558
 VERSION
 KEYWORDS GSS; left border; T-DNA flanking sequence.
 SOURCE Arabidopsis thaliana (thale cress)

ORGANISM

Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE AUTHORS

1
 Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, P.,
 Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
 Lepiniec, L., Caboche, M. and Lecharny, A.

TITLE T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites

JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)

MEDLINE

PUBMED 22363535

REFERENCE

2 (bases 1 to 12)

AUTHORS

Balzerque, S.

TITLE

JOURNAL Direct Submission
 Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
 Gaston Cremieux, 91057 Evry cedex, FRANCE

COMMENT

PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics

program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES

source

```

1. .12
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiliewskija"
/db_xref="taxon:3702"
/clone="342D03"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
/misc_feature 1. .12
/notes="T-DNA flanking sequence
left border"

```

Query Match 1.4%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 15;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 511 TCTGCGGGAGGT 522

Db 1 TCGCGGGAGGT 12

RESULT 19

AJ593983

LOCUS

Arabidopsis thaliana T-DNA flanking sequence, left border, clone 390F01, genomic survey sequence.
 DEFINITION

ACCESSION AJ593983

VERSION AJ593983.1 GI:37943607

KEYWORDS GSS; left border; T-DNA flanking sequence.

SOURCE Arabidopsis thaliana (thale cress)

ORGANISM

Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE

AUTHORS

1
 Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, P.,
 Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
 Lepiniec, L., Caboche, M. and Lecharny, A.

TITLE T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites

JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)

MEDLINE

PUBMED 22363535

REFERENCE

2 (bases 1 to 12)

AUTHORS

Balzerque, S.

TITLE

JOURNAL Direct Submission
 Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
 Gaston Cremieux, 91057 Evry cedex, FRANCE

PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics

program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES

source

```

1. .12
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiliewskija"
/db_xref="taxon:3702"
/clone="390F01"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
/misc_feature 1. .12
/notes="T-DNA flanking sequence
left border"

```

```

Query Match          1.4%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 15;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
    ||||| |||||
Db 1 CCGGGCGGCCA 12

RESULT 20
AJ594410
LOCUS          13 bp      DNA      linear      GSS 15-JAN-2004
DEFINITION    Arabidopsis thaliana T-DNA flanking sequence, left border, clone
378003, genomic survey sequence.
ACCESSION    AJ593342
VERSION      AJ593342.1 GI:37942966
KEYWORDS     GSS; left border; T-DNA flanking sequence.
SOURCE       Arabidopsis thaliana (thale cress)
ORGANISM     Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.

REFERENCE
AUTHORS      Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
              Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
              Lepintec,L., Caboche,M. and Lecharny,A.
TITLE        T-DNA integration into the Arabidopsis genome depends on sequences
              of pre-insertion sites
JOURNAL      EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE      22363535
PubMed      12446565
AUTHORS      Balzerque,S.
TITLE        Direct Submission
JOURNAL      Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
              Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT      PCR was performed on DNA from transformants of Arabidopsis thaliana
              plants from INRA (Versailles). The DNA fragment(s) resulting from
              the PCR were directly sequenced from the left or the right border
              to determine the genomic sequence flanking the insertion. T-DNA
              derived sequences were removed. Information to order the
              corresponding mutant line and a link to a database providing a
              graphical display of the insertion site are available at
              http://dbgap.versailles.inra.fr/publiclines/. This sequence has
              been generated in the framework of the French plant genomics
              program 'Genoplante' (http://www.genoplante.com and
              http://genoplante-info.infobiogen.fr).

FEATURES
source
    1..13
    /organism="Arabidopsis thaliana"
    /mol_type="genomic DNA"
    /cultivar="Wassillewskija"
    /db_xref="taxon:3702"
    /clone="398B09"
    /clone_lib="Arabidopsis thaliana T-DNA insertion lines"

misc_feature
    1..13
    /note="T-DNA flanking sequence
    left border"

Query Match          1.4%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 17;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
    ||||| |||||
Db 2 CCGGGCGGCCA 13

RESULT 22
AJ597879
LOCUS          13 bp      DNA      linear      GSS 15-JAN-2004
DEFINITION    Arabidopsis thaliana T-DNA flanking sequence, left border, clone
458C03, genomic survey sequence.
ACCESSION    AJ597879
VERSION      AJ597879.1 GI:37947507
KEYWORDS     GSS; left border; T-DNA flanking sequence.
SOURCE       Arabidopsis thaliana (thale cress)
ORGANISM     Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.

REFERENCE
AUTHORS      Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
              Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
              Lepintec,L., Caboche,M. and Lecharny,A.
TITLE        T-DNA integration into the Arabidopsis genome depends on sequences
              of pre-insertion sites

```

JOURNAL
MEDLINE
PUBMED
REFERENCE
AUTHORS
TITLE
JOURNAL

EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
12446565
2 (bases 1 to 13)
Balzerque, S.
Direct Submission
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplatane' (http://www.genoplatane.com and
http://genoplatane-info.infobiogen.fr).

FEATURES
source
1. .13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="458C03"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1. .13
/note="T-DNA flanking sequence
left border"

Query Match 1.4%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 17;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCCGGCGCGCCA 680
|||||
Db 2 CCCGGCGCGCCA 13

RESULT 24
AJ599128
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
481805, genomic survey sequence.

ACCESSION
AJ599128
VERSION
AJ599128.1 GI:37948756
KEYWORDS
GSS; left border; T-DNA flanking sequence.
SOURCE
Arabidopsis thaliana
ORGANISM
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
AUTHORS
Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
12446565
2 (bases 1 to 13)
Balzerque, S.
Direct Submission
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplatane' (http://www.genoplatane.com and
http://genoplatane-info.infobiogen.fr).

FEATURES
source
1. .13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="481B05"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1. .13

Query Match 1.4%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 17;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCCGGCGCGCCA 680
|||||
Db 2 CCCGGCGCGCCA 13

RESULT 23
AJ598718
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
473E08, genomic survey sequence.

ACCESSION
AJ598718
VERSION
AJ598718.1 GI:37948346
KEYWORDS
GSS; left border; T-DNA flanking sequence.
SOURCE
Arabidopsis thaliana
ORGANISM
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
AUTHORS
Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
12446565
2 (bases 1 to 13)
Balzerque, S.
Direct Submission
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a

graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplatane' (http://www.genoplatane.com and
http://genoplatane-info.infobiogen.fr).

FEATURES
source

1. .13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="473E08"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1. .13
/note="T-DNA flanking sequence
left border"

Query Match 1.4%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 17;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCCGGCGCGCCA 680
|||||
Db 2 CCCGGCGCGCCA 13

RESULT 24
AJ599128
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
481805, genomic survey sequence.

ACCESSION
AJ599128
VERSION
AJ599128.1 GI:37948756
KEYWORDS
GSS; left border; T-DNA flanking sequence.
SOURCE
Arabidopsis thaliana
ORGANISM
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
AUTHORS
Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
12446565
2 (bases 1 to 13)
Balzerque, S.
Direct Submission
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplatane' (http://www.genoplatane.com and
http://genoplatane-info.infobiogen.fr).

FEATURES
source

1. .13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="481B05"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1. .13

FEATURES
source

1. .13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="481B05"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1. .13


```

/Note="T-DNA flanking sequence
left border"

Query Match      1.4%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 17;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
      ||||| |||||
DB 2 CCGGGCGGCCA 13

RESULT 25
AJ599161
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
481F10, genomic survey sequence.
ACCESSION
AJ599161.1 GI:37948789
VERSION
GSS; left border; T-DNA flanking sequence.
KEYWORDS
Arabidopsis thaliana (thale cress)
SOURCE
Arabidopsis thaliana
ORGANISM
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE
1
AUTHORS
Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
PUBMED
12446565
REFERENCE
2 (bases 1 to 13)
AUTHORS
Balzerque, S.
TITLE
Direct Submission
JOURNAL
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Crenieux, 91057 Evry cedex, FRANCE
COMMENT
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplatte' (http://www.genoplatte.com and
http://genoplatte-info.infobiogen.fr).
FEATURES
Location/Qualifiers
1..13
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="481F10"
/misc_feature 1..13
/Note="T-DNA flanking sequence
left border"

Query Match      1.4%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 17;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 669 CCGGGCGGCCA 680
      ||||| |||||
DB 2 CCGGGCGGCCA 13

RESULT 26
AJ592517
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, right border, clone
621G09, genomic survey sequence.
ACCESSION
AJ592517.1 GI:37942141
VERSION
GSS; right border; T-DNA flanking sequence.
KEYWORDS
Arabidopsis thaliana (thale cress)
SOURCE
Arabidopsis thaliana
ORGANISM
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE
1
AUTHORS
Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepiniec, L., Caboche, M. and Lecharny, A.
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
22363535
PUBMED
12446565
REFERENCE
2 (bases 1 to 10)
AUTHORS
Balzerque, S.
TITLE
Direct Submission
JOURNAL
Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Crenieux, 91057 Evry cedex, FRANCE
COMMENT
PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplatte' (http://www.genoplatte.com and
http://genoplatte-info.infobiogen.fr).
FEATURES
Location/Qualifiers
1..10
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="621G09"
/misc_feature 1..10
/Note="T-DNA flanking sequence
right border"

Query Match      1.3%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 672 GGGCGGCCAG 681
      ||||| |||||
DB 1 GGGCGGCCAG 10

RESULT 27
BM395068
LOCUS
DEFINITION
Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION
BM395068
VERSION
EST.
KEYWORDS
Tetrahymena thermophila
ORGANISM
Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
Hymenostomatida; Tetrahymenina; Tetrahymenidae; Tetrahymena.
REFERENCE
1 (bases 1 to 11)
AUTHORS
Turkewitz, A.P., Karrer, K.M., Jahn, C., Orlas, E., Kirk, K.E.,
Frankel, J. and Klobutcher, L.
EST from Tetrahymena thermophila, strain CU428.1, growing cells

```

```

JOURNAL      Unpublished (2002)
COMMENT      Contact: Turkewitz AP
              Molecular Genetics and Cell Biology
              University of Chicago
              920 E. 58th Street, Chicago, IL 60637, USA
              Tel: 773 702 4374
              Fax: 773 702 3172
              Email: apturkew@midway.uchicago.edu
              Seq primer: T3.

FEATURES
  source
    1..11
      /organism="Tetrahymena thermophila"
      /mol_type="mRNA"
      /strain="CU428.1"
      /db_xref="taxon:5911"
      /clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
      /note="Vector: Bluescript2 SK-; Details on library
      preparation can be found in Chilcoat and Turkewitz (2001)
      Proc. Natl. Acad. Sci USA, 98: 8709-8713."

  Query Match      1.3%; Score 10; DB 1; Length 11;
  Best Local Similarity 100.0%; Pred. No. 16;
  Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      662 GGTGGGGCCC 671
Db      2 GGTGGGGCCC 11

RESULT 28
AJ650760/c
LOCUS
DEFINITION      AJ650760 CSEQRAN19 Sus scrofa cDNA clone C0003276_E04, mRNA
                  13 bp mRNA linear EST 07-JUL-2004
                  sequence.

ACCESSION      AJ650760
VERSION
KEYWORDS
SOURCE
ORGANISM
  Sus scrofa
  Sus scrofa (pig)
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.

REFERENCE
  1 (bases 1 to 13)
  Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
  Development of cDNA and EST resources for studying reproduction and
  embryo development in pigs and cattle
  Unpublished (2004)

JOURNAL
COMMENT      Contact: Anderson SI
              Genomics and Bioinformatics
              Roslin Institute
              Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
              Single pass sequencing. Bases called and trimmed with phred
              v0.020425.c. Vector identified by cross match with the -minscore 20
              and -mismatch 12 options. Vector: pBluescriptII (KS+) R. Site1: EcoRI
              R. Site2: NotI 5' Seq Primer M13F Normalised library constructed
              from pooled ovaries. Clones available from UK Centre for Functional
              Genomics in Farm Animals, Roslin Institute, Roslin, Midlothian, UK,
              EH25 9PS, www.ark-genomics.org.

FEATURES
  source
    1..13
      /organism="Sus scrofa"
      /mol_type="mRNA"
      /db_xref="taxon:9823"
      /clone="C0003276_E04"
      /tissue_type="ovary"
      /clone_lib="CSEQRAN19"
      /note="Vector: pBluescriptII (KS+); Site 1: EcoRI; Site 2:
      NotI; Single pass sequencing; Normalised library
      constructed from pooled ovaries"

  Query Match      1.3%; Score 9.8; DB 1; Length 13;
  Best Local Similarity 84.6%; Pred. No. 22;
  Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      489 TGAAGAGGCGAGAA 501
Db      13 TGAAGAGGCGAGAA 1

RESULT 30
BG926067/c
LOCUS
DEFINITION      BG926067 HNC23-1-E8.R HNC (Human Normal Cartilage) Homo sapiens cDNA, mRNA
                  13 bp mRNA linear EST 06-NOV-2001
                  sequence.

ACCESSION      BG926067
VERSION
KEYWORDS
SOURCE
ORGANISM
  Homo sapiens (human)
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
  1 (bases 1 to 13)
  Kumar,S., Connor,J.R., Dodds,R.A., Halsey,W., Van Horn,M., Mao,J.,
  Sathie,G., Mui,P., Agarwal,P., Badger,A.M., Lee,J.C., Gowen,M. and
  Lark,M.W.
  Identification and initial characterization of 5000 expressed
  sequenced tags (ESTs) each from adult human normal and
  osteoarthritic cartilage cDNA libraries

```

Query Match 1.3%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 22;

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 8, 2005, 08:52:33 ; Search time 7 Seconds
(without alignments)
4.110 Million cell updates/sec

Title: US-10-628-841-3
Perfect score: 755
Sequence: 1 tctggaagagcccaactgtg.....tgggcagtgcgcggaagcga 755

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 1089 seqs, 19055 residues

Total number of hits satisfying chosen parameters: 2178

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1090 summaries

Database : fetchrnpb.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	29	3.8	29	1	US-09-972-607-6
2	29	3.8	29	1	US-10-628-841-6
3	27	3.6	27	1	US-10-972-607-24
4	22	2.9	22	1	US-09-863-049A-61
5	21	2.8	21	1	US-10-444-795B-711
6	21	2.8	21	1	US-10-444-795B-721
7	20	2.6	20	1	US-09-972-607-5
8	20	2.6	20	1	US-09-972-607-16
9	20	2.6	20	1	US-09-972-607-17
10	20	2.6	20	1	US-09-972-607-18
11	20	2.6	20	1	US-09-972-607-19
12	20	2.6	20	1	US-09-972-607-20
13	20	2.6	20	1	US-09-972-607-21
14	20	2.6	20	1	US-09-972-607-22
15	20	2.6	20	1	US-09-972-607-23
16	20	2.6	20	1	US-09-972-607-24
17	20	2.6	20	1	US-09-972-607-25
18	20	2.6	20	1	US-09-972-607-26
19	20	2.6	20	1	US-09-972-607-27
20	20	2.6	20	1	US-09-972-607-28
21	20	2.6	20	1	US-09-972-607-29
22	20	2.6	20	1	US-09-972-607-30
23	20	2.6	20	1	US-09-972-607-31
24	20	2.6	20	1	US-09-972-607-32
25	20	2.6	20	1	US-09-972-607-33
26	20	2.6	20	1	US-09-972-607-34
27	20	2.6	20	1	US-09-972-607-35
28	20	2.6	20	1	US-09-972-607-36
29	20	2.6	20	1	US-09-972-607-37
30	20	2.6	20	1	US-09-972-607-38
31	20	2.6	20	1	US-09-972-607-39
32	20	2.6	20	1	US-09-972-607-40
33	20	2.6	20	1	US-09-972-607-41

Sequence 42, Appl
Sequence 43, Appl
Sequence 44, Appl
Sequence 45, Appl
Sequence 46, Appl
Sequence 47, Appl
Sequence 48, Appl
Sequence 49, Appl
Sequence 5, Appl
Sequence 16, Appl
Sequence 17, Appl
Sequence 18, Appl
Sequence 19, Appl
Sequence 20, Appl
Sequence 21, Appl
Sequence 22, Appl
Sequence 23, Appl
Sequence 24, Appl
Sequence 25, Appl
Sequence 26, Appl
Sequence 27, Appl
Sequence 28, Appl
Sequence 29, Appl
Sequence 30, Appl
Sequence 31, Appl
Sequence 32, Appl
Sequence 33, Appl
Sequence 34, Appl
Sequence 35, Appl
Sequence 36, Appl
Sequence 37, Appl
Sequence 38, Appl
Sequence 39, Appl
Sequence 40, Appl
Sequence 41, Appl
Sequence 42, Appl
Sequence 43, Appl
Sequence 44, Appl
Sequence 45, Appl
Sequence 46, Appl
Sequence 47, Appl
Sequence 48, Appl
Sequence 49, Appl
Sequence 53, Appl
Sequence 13872, A
Sequence 55, Appl
Sequence 716, Appl
Sequence 63, Appl
Sequence 590469,
Sequence 707, App
Sequence 708, App
Sequence 712, App
Sequence 713, App
Sequence 717, App
Sequence 718, App
Sequence 722, App
Sequence 723, App
Sequence 706, App
Sequence 709, App
Sequence 710, App
Sequence 714, App
Sequence 715, App
Sequence 719, App
Sequence 720, App
Sequence 724, App
Sequence 725, App
Sequence 123, App
Sequence 124, App
Sequence 127, App
Sequence 128, App
Sequence 131, App
Sequence 132, App
Sequence 123, App

19	19	2.5	21	1	US-10-757-803-124	Sequence 124, App	180	17	2.3	17	1	US-10-156-306-4810	Sequence 4810, Ap
107	107	2.5	21	1	US-10-757-803-127	Sequence 127, App	181	17	2.3	17	1	US-10-156-306-4811	Sequence 4811, Ap
108	108	2.5	21	1	US-10-757-803-128	Sequence 128, App	182	17	2.3	17	1	US-10-156-306-4812	Sequence 4812, Ap
109	109	2.5	21	1	US-10-757-803-131	Sequence 131, App	183	17	2.3	17	1	US-10-156-306-4813	Sequence 4813, Ap
110	110	2.5	21	1	US-10-757-803-132	Sequence 132, App	184	17	2.3	17	1	US-10-156-306-4814	Sequence 4814, Ap
111	111	2.5	21	1	US-10-826-966-123	Sequence 123, App	185	17	2.3	17	1	US-10-156-306-4815	Sequence 4815, Ap
112	112	2.5	21	1	US-10-826-966-124	Sequence 124, App	186	17	2.3	17	1	US-10-156-306-4816	Sequence 4816, Ap
113	113	2.5	21	1	US-10-826-966-127	Sequence 127, App	187	17	2.3	17	1	US-10-156-306-4817	Sequence 4817, Ap
114	114	2.5	21	1	US-10-826-966-128	Sequence 128, App	188	17	2.3	17	1	US-10-156-306-4818	Sequence 4818, Ap
115	115	2.5	21	1	US-10-826-966-131	Sequence 131, App	189	17	2.3	17	1	US-10-156-306-4819	Sequence 4819, Ap
116	116	2.5	21	1	US-10-826-966-132	Sequence 132, App	190	17	2.3	17	1	US-10-156-306-4820	Sequence 4820, Ap
117	117	2.5	21	1	US-10-826-966-137	Sequence 37, Appl	191	17	2.3	17	1	US-10-156-306-4821	Sequence 4821, Ap
118	18.4	2.4	20	1	US-10-210-280-37	Sequence 37, Appl	192	17	2.3	17	1	US-10-156-306-4822	Sequence 4822, Ap
119	18.4	2.4	20	1	US-10-210-802-37	Sequence 9484, Ap	193	17	2.3	17	1	US-10-156-306-4823	Sequence 4823, Ap
120	17.4	2.3	21	1	US-10-751-736-9484	Sequence 9485, Ap	194	17	2.3	17	1	US-10-156-306-4824	Sequence 4824, Ap
121	17.4	2.3	21	1	US-10-751-736-9485	Sequence 4383, Ap	195	17	2.3	17	1	US-10-156-306-4825	Sequence 4825, Ap
122	17	2.3	17	1	US-10-156-306-4383	Sequence 4384, Ap	196	17	2.3	17	1	US-10-156-306-4826	Sequence 4826, Ap
123	17	2.3	17	1	US-10-156-306-4384	Sequence 4385, Ap	197	17	2.3	17	1	US-10-156-306-4827	Sequence 4827, Ap
124	17	2.3	17	1	US-10-156-306-4385	Sequence 4386, Ap	198	17	2.3	17	1	US-10-156-306-4828	Sequence 4828, Ap
125	17	2.3	17	1	US-10-156-306-4386	Sequence 4387, Ap	199	17	2.3	17	1	US-10-156-306-4829	Sequence 4829, Ap
126	17	2.3	17	1	US-10-156-306-4387	Sequence 4388, Ap	200	17	2.3	17	1	US-10-156-306-4830	Sequence 4830, Ap
127	17	2.3	17	1	US-10-156-306-4388	Sequence 4389, Ap	201	17	2.3	17	1	US-10-156-306-4831	Sequence 4831, Ap
128	17	2.3	17	1	US-10-156-306-4389	Sequence 4390, Ap	202	17	2.3	17	1	US-10-156-306-4832	Sequence 4832, Ap
129	17	2.3	17	1	US-10-156-306-4390	Sequence 4391, Ap	203	17	2.3	17	1	US-10-156-306-4833	Sequence 4833, Ap
130	17	2.3	17	1	US-10-156-306-4391	Sequence 4392, Ap	204	17	2.3	17	1	US-10-156-306-4834	Sequence 4834, Ap
131	17	2.3	17	1	US-10-156-306-4392	Sequence 4393, Ap	205	17	2.3	17	1	US-10-156-306-4835	Sequence 4835, Ap
132	17	2.3	17	1	US-10-156-306-4393	Sequence 4394, Ap	206	17	2.3	17	1	US-10-156-306-4836	Sequence 4836, Ap
133	17	2.3	17	1	US-10-156-306-4394	Sequence 4395, Ap	207	17	2.3	17	1	US-10-156-306-4837	Sequence 4837, Ap
134	17												

253	17	2.3	17	2.3	17	1	US-10-156-306-4883	Sequence 4883, Ap	326	17	2.3	17	1	US-10-156-306-4956	Sequence 4956, Ap
254	17	2.3	17	2.3	17	1	US-10-156-306-4884	Sequence 4884, Ap	327	17	2.3	17	1	US-10-156-306-4957	Sequence 4957, Ap
255	17	2.3	17	2.3	17	1	US-10-156-306-4885	Sequence 4885, Ap	328	17	2.3	17	1	US-10-156-306-4958	Sequence 4958, Ap
256	17	2.3	17	2.3	17	1	US-10-156-306-4886	Sequence 4886, Ap	329	17	2.3	17	1	US-10-156-306-4959	Sequence 4959, Ap
257	17	2.3	17	2.3	17	1	US-10-156-306-4887	Sequence 4887, Ap	330	17	2.3	17	1	US-10-156-306-4960	Sequence 4960, Ap
258	17	2.3	17	2.3	17	1	US-10-156-306-4888	Sequence 4888, Ap	331	17	2.3	17	1	US-10-156-306-4961	Sequence 4961, Ap
259	17	2.3	17	2.3	17	1	US-10-156-306-4889	Sequence 4889, Ap	332	17	2.3	17	1	US-10-156-306-4962	Sequence 4962, Ap
260	17	2.3	17	2.3	17	1	US-10-156-306-4890	Sequence 4890, Ap	333	17	2.3	17	1	US-10-156-306-4963	Sequence 4963, Ap
261	17	2.3	17	2.3	17	1	US-10-156-306-4891	Sequence 4891, Ap	334	17	2.3	17	1	US-10-156-306-4964	Sequence 4964, Ap
262	17	2.3	17	2.3	17	1	US-10-156-306-4892	Sequence 4892, Ap	335	17	2.3	17	1	US-10-156-306-4965	Sequence 4965, Ap
263	17	2.3	17	2.3	17	1	US-10-156-306-4893	Sequence 4893, Ap	336	17	2.3	17	1	US-10-156-306-4966	Sequence 4966, Ap
264	17	2.3	17	2.3	17	1	US-10-156-306-4894	Sequence 4894, Ap	337	17	2.3	17	1	US-10-156-306-4967	Sequence 4967, Ap
265	17	2.3	17	2.3	17	1	US-10-156-306-4895	Sequence 4895, Ap	338	17	2.3	17	1	US-10-156-306-4968	Sequence 4968, Ap
266	17	2.3	17	2.3	17	1	US-10-156-306-4896	Sequence 4896, Ap	339	17	2.3	17	1	US-10-156-306-4969	Sequence 4969, Ap
267	17	2.3	17	2.3	17	1	US-10-156-306-4897	Sequence 4897, Ap	340	17	2.3	17	1	US-10-156-306-4970	Sequence 4970, Ap
268	17	2.3	17	2.3	17	1	US-10-156-306-4898	Sequence 4898, Ap	341	17	2.3	17	1	US-10-156-306-4971	Sequence 4971, Ap
269	17	2.3	17	2.3	17	1	US-10-156-306-4899	Sequence 4899, Ap	342	17	2.3	17	1	US-10-156-306-4972	Sequence 4972, Ap
270	17	2.3	17	2.3	17	1	US-10-156-306-4900	Sequence 4900, Ap	343	17	2.3	17	1	US-10-156-306-4973	Sequence 4973, Ap
271	17	2.3	17	2.3	17	1	US-10-156-306-4901	Sequence 4901, Ap	344	17	2.3	17	1	US-10-156-306-4974	Sequence 4974, Ap
272	17	2.3	17	2.3	17	1	US-10-156-306-4902	Sequence 4902, Ap	345	17	2.3	17	1	US-10-156-306-4975	Sequence 4975, Ap
273	17	2.3	17	2.3	17	1	US-10-156-306-4903	Sequence 4903, Ap	346	17	2.3	17	1	US-10-156-306-4976	Sequence 4976, Ap
274	17	2.3	17	2.3	17	1	US-10-156-306-4904	Sequence 4904, Ap	347	17	2.3	17	1	US-10-156-306-4977	Sequence 4977, Ap
275	17	2.3	17	2.3	17	1	US-10-156-306-4905	Sequence 4905, Ap	348	17	2.3	17	1	US-10-156-306-4978	Sequence 4978, Ap
276	17	2.3	17	2.3	17	1	US-10-156-306-4906	Sequence 4906, Ap	349	17	2.3	17	1	US-10-156-306-4979	Sequence 4979, Ap
277	17	2.3	17	2.3	17	1	US-10-156-306-4907	Sequence 4907, Ap	350	17	2.3	17	1	US-10-156-306-4980	Sequence 4980, Ap
278	17	2.3	17	2.3	17	1	US-10-156-306-4								

399	17	2.3	1	US-10-156-306-5841	Sequence 5841, Ap	472	17	2.3	1	US-10-156-306-6339	Sequence 6339, Ap
400	17	2.3	1	US-10-156-306-5842	Sequence 5842, Ap	473	17	2.3	1	US-10-156-306-6814	Sequence 6814, Ap
401	17	2.3	1	US-10-156-306-5843	Sequence 5843, Ap	474	17	2.3	1	US-10-156-306-6815	Sequence 6815, Ap
402	17	2.3	1	US-10-156-306-5844	Sequence 5844, Ap	475	17	2.3	1	US-10-156-306-6816	Sequence 6816, Ap
403	17	2.3	1	US-10-156-306-5845	Sequence 5845, Ap	476	17	2.3	1	US-10-156-306-6817	Sequence 6817, Ap
404	17	2.3	1	US-10-156-306-5846	Sequence 5846, Ap	477	17	2.3	1	US-10-156-306-6818	Sequence 6818, Ap
405	17	2.3	1	US-10-156-306-5847	Sequence 5847, Ap	478	17	2.3	1	US-10-156-306-6819	Sequence 6819, Ap
406	17	2.3	1	US-10-156-306-5848	Sequence 5848, Ap	479	17	2.3	1	US-10-156-306-6820	Sequence 6820, Ap
407	17	2.3	1	US-10-156-306-5849	Sequence 5849, Ap	480	17	2.3	1	US-10-156-306-6821	Sequence 6821, Ap
408	17	2.3	1	US-10-156-306-5850	Sequence 5850, Ap	481	17	2.3	1	US-10-156-306-6822	Sequence 6822, Ap
409	17	2.3	1	US-10-156-306-5851	Sequence 5851, Ap	482	17	2.3	1	US-10-156-306-6823	Sequence 6823, Ap
410	17	2.3	1	US-10-156-306-5852	Sequence 5852, Ap	483	17	2.3	1	US-10-156-306-6824	Sequence 6824, Ap
411	17	2.3	1	US-10-156-306-5853	Sequence 5853, Ap	484	17	2.3	1	US-10-156-306-6825	Sequence 6825, Ap
412	17	2.3	1	US-10-156-306-5854	Sequence 5854, Ap	485	17	2.3	1	US-10-156-306-6826	Sequence 6826, Ap
413	17	2.3	1	US-10-156-306-5855	Sequence 5855, Ap	486	17	2.3	1	US-10-156-306-6827	Sequence 6827, Ap
414	17	2.3	1	US-10-156-306-5856	Sequence 5856, Ap	487	17	2.3	1	US-10-156-306-6828	Sequence 6828, Ap
415	17	2.3	1	US-10-156-306-5857	Sequence 5857, Ap	488	17	2.3	1	US-10-156-306-6829	Sequence 6829, Ap
416	17	2.3	1	US-10-156-306-5858	Sequence 5858, Ap	489	17	2.3	1	US-10-156-306-6830	Sequence 6830, Ap
417	17	2.3	1	US-10-156-306-5859	Sequence 5859, Ap	490	17	2.3	1	US-10-156-306-6831	Sequence 6831, Ap
418	17	2.3	1	US-10-156-306-5860	Sequence 5860, Ap	491	17	2.3	1	US-10-156-306-6832	Sequence 6832, Ap
419	17	2.3	1	US-10-156-306-5861	Sequence 5861, Ap	492	17	2.3	1	US-10-156-306-6833	Sequence 6833, Ap
420	17	2.3	1	US-10-156-306-5862	Sequence 5862, Ap	493	17	2.3	1	US-10-156-306-6834	Sequence 6834, Ap
421	17	2.3	1	US-10-156-306-5863	Sequence 5863, Ap	494	17	2.3	1	US-10-156-306-6835	Sequence 6835, Ap
422	17	2.3	1	US-10-156-306-5864	Sequence 5864, Ap	495	17	2.3	1	US-10-156-306-6836	Sequence 6836, Ap
423	17	2.3	1	US-10-156-306-5865	Sequence 5865, Ap	496	17	2.3	1	US-10-156-306-6837	Sequence 6837, Ap
424	17	2.3	1	US-10-156-306-5866	Sequence 5866, Ap	497	17	2.3	1	US-10-156-306-6838	Sequence 6838, Ap
425	17	2.3	1	US-10-156-306-5867	Sequence 5867, Ap	498	17	2.3	1	US-10-156-306-6840	Sequence 6840, Ap
426	17	2.3	1	US-10-156-306-5868	Sequence 5868, Ap	499	17	2.3	1	US-10-156-306-6841	Sequence 6841, Ap
427	17	2.3	1	US-10-156-306-5869	Sequence 5869, Ap	500	17	2.3	1	US-10-156-306-6842	Sequence 6842, Ap
428	17	2.3	1	US-10-156-306-5870	Sequence 5870, Ap	501	17	2.3	1	US-10-156-306-6843	Sequence 6843, Ap
429	17	2.3	1	US-10-156-306-5871	Sequence 5871, Ap	502	17	2.3	1	US-10-156-306-6844	Sequence 6844, Ap

545	17	2.3	17	1	US-10-156-306-6886	Sequence 6886, Ap	618	17	2.3	17	1	US-10-156-306-6959	Sequence 6959, Ap
546	17	2.3	17	1	US-10-156-306-6887	Sequence 6887, Ap	619	17	2.3	17	1	US-10-156-306-6960	Sequence 6960, Ap
547	17	2.3	17	1	US-10-156-306-6888	Sequence 6888, Ap	620	17	2.3	17	1	US-10-156-306-6961	Sequence 6961, Ap
548	17	2.3	17	1	US-10-156-306-6889	Sequence 6889, Ap	621	17	2.3	17	1	US-10-156-306-6962	Sequence 6962, Ap
549	17	2.3	17	1	US-10-156-306-6890	Sequence 6890, Ap	622	17	2.3	17	1	US-10-156-306-6963	Sequence 6963, Ap
550	17	2.3	17	1	US-10-156-306-6891	Sequence 6891, Ap	623	16.8	2.2	21	1	US-10-786-720-11195	Sequence 11195, A
551	17	2.3	17	1	US-10-156-306-6892	Sequence 6892, Ap	c 624	16.8	2.2	21	1	US-10-490-080-12	Sequence 12, Appl
552	17	2.3	17	1	US-10-156-306-6893	Sequence 6893, Ap	c 625	16.8	2.2	21	1	US-10-490-080-18	Sequence 18, Appl
553	17	2.3	17	1	US-10-156-306-6894	Sequence 6894, Ap	c 626	16.8	2.2	21	1	US-10-751-736-18624	Sequence 18624, A
554	17	2.3	17	1	US-10-156-306-6895	Sequence 6895, Ap	c 627	16.8	2.2	21	1	US-10-751-736-49885	Sequence 49885, A
555	17	2.3	17	1	US-10-156-306-6896	Sequence 6896, Ap	c 628	16.4	2.2	21	1	US-10-751-736-9649	Sequence 9649, Ap
556	17	2.3	17	1	US-10-156-306-6897	Sequence 6897, Ap	c 629	16.4	2.2	21	1	US-10-751-736-9650	Sequence 9650, Ap
557	17	2.3	17	1	US-10-156-306-6898	Sequence 6898, Ap	c 630	16.2	2.1	21	1	US-10-786-720-11196	Sequence 11196, A
558	17	2.3	17	1	US-10-156-306-6899	Sequence 6899, Ap	c 631	16.2	2.1	21	1	US-10-751-736-39475	Sequence 39475, A
559	17	2.3	17	1	US-10-156-306-6900	Sequence 6900, Ap	c 632	16.2	2.1	21	1	US-10-751-736-39478	Sequence 39478, A
560	17	2.3	17	1	US-10-156-306-6901	Sequence 6901, Ap	c 633	16	2.1	17	1	US-10-156-306-6813	Sequence 6813, Ap
561	17	2.3	17	1	US-10-156-306-6902	Sequence 6902, Ap	c 634	16	2.1	17	1	US-10-156-306-6964	Sequence 6964, Ap
562	17	2.3	17	1	US-10-156-306-6903	Sequence 6903, Ap	c 635	15.8	2.1	19	1	US-10-224-836-290	Sequence 290, App
563	17	2.3	17	1	US-10-156-306-6904	Sequence 6904, Ap	c 636	15.8	2.1	19	1	US-10-670-011-56	Sequence 56, Appl
564	17	2.3	17	1	US-10-156-306-6905	Sequence 6905, Ap	c 637	15.8	2.1	19	1	US-10-670-011-152	Sequence 152, App
565	17	2.3	17	1	US-10-156-306-6906	Sequence 6906, Ap	c 638	15.8	2.1	19	1	US-10-764-957-56	Sequence 56, Appl
566	17	2.3	17	1	US-10-156-306-6907	Sequence 6907, Ap	c 639	15.8	2.1	19	1	US-10-764-957-152	Sequence 152, App
567	17	2.3	17	1	US-10-156-306-6908	Sequence 6908, Ap	c 640	15.8	2.1	21	1	US-10-083-720A-10	Sequence 10, Appl
568	17	2.3	17	1	US-10-156-306-6909	Sequence 6909, Ap	c 641	15.8	2.1	21	1	US-10-186-180-20	Sequence 20, Appl
569	17	2.3	17	1	US-10-156-306-6910	Sequence 6910, Ap	c 642	15.8	2.1	21	1	US-10-005-956-1033	Sequence 1033, Ap
570	17	2.3	17	1	US-10-156-306-6911	Sequence 6911, Ap	c 643	15.8	2.1	21	1	US-10-786-720-11194	Sequence 11194, A
571	17	2.3	17	1	US-10-156-306-6912	Sequence 6912, Ap	c 644	15.8	2.1	21	1	US-10-683-990-202	Sequence 202, App
572	17	2.3	17	1	US-10-156-306-6913	Sequence 6913, Ap	c 645	15.8	2.1	21	1	US-10-683-990-206	Sequence 206, App
573	17	2.3	17	1	US-10-156-306-6914	Sequence 6914, Ap	c 646	15.8	2.1	21	1	US-10-683-990-210	Sequence 210, App
574	17	2.3	17	1	US-10-156-306-6915	Sequence 6915, Ap	c 647	15.8	2.1	21	1	US-10-683-990-214	Sequence 214, App
575	17	2.3	17	1	US-10-156-306-6916	Sequence 6916, Ap	c 648	15.8	2.1	21	1	US-10-683-990-218	Sequence 218, App
576	17	2.3	17	1	US-10-156-306-6917	Sequence 6917, Ap	c 649	15.8	2.1	21	1	US-10-683-990-222	Sequence 222, App
577	17	2.3	17	1	US-10-156-306-6918	Sequence 6918, Ap	c 650	15.8	2.1	21	1	US-10-683-990-226	Sequence 226, App
578	17	2.3	17	1	US-10-156-306-6919	Sequence 6919, Ap	c 651	15.8	2.1	21	1	US-10-683-990-230	Sequence 230, App
579	17	2.3	17	1	US-10-156-306-6920	Sequence 6920, Ap	c 652	15.8	2.1	21	1	US-10-683-990-234	Sequence 234, App
580	17	2.3	17	1	US-10-156-306-6921	Sequence 6921, Ap	c 653	15.8	2.1	21	1	US-10-683-990-238	Sequence 238, App
581	17	2.3	17	1	US-10-156-306-6922	Sequence 6922, Ap	c 654	15.8	2.1	21	1	US-10-751-736-16993	Sequence 16993, A
582	17	2.3	17	1	US-10-156-306-6923	Sequence 6923, Ap	c 655	15.8	2.1	21	1	US-10-751-736-18963	Sequence 18963, A
583	17	2.3	17	1	US-10-156-306-6924	Sequence 6924, Ap	c 656	15.8	2.1	21	1	US-10-751-736-49882	Sequence 49882, A
584	17	2.3	17	1	US-10-156-306-6925	Sequence 6925, Ap	c 657	15.8	2.1	21	1	US-10-751-736-49883	Sequence 49883, A
585	17	2.3	17	1	US-10-156-306-6926	Sequence 6926, Ap	c 658	15.8	2.1	21	1	US-10-916-256-10	Sequence 10, Appl
586	17	2.3	17	1	US-10-156-306-6927	Sequence 6927, Ap	c 659	15.8	2.1	21	1	US-10-494-921-20	Sequence 20, Appl
587	17	2.3	17	1	US-10-156-306-6928	Sequence 6928, Ap	c 660	15.4	2.0	17	1	US-09-866-108-7246	Sequence 7246, Ap
588	17	2.3	17	1	US-10-156-306-6929	Sequence 6929, Ap	c 661	15.4	2.0	17	1	US-09-866-108-7450	Sequence 7450, Ap
589	17	2.3	17	1	US-10-156-306-6930	Sequence 6930, Ap	c 662	15.4	2.0	17	1	US-10-723-361-7246	Sequence 7246, Ap
590	17	2.3	17	1	US-10-156-306-6931	Sequence 6931, Ap	c 663	15.4	2.0	17	1	US-10-723-361-7450	Sequence 7450, Ap
591	17	2.3	17	1	US-10-156-306-6932	Sequence 6932, Ap	c 664	15.4	2.0	17	1	US-10-454-246-336	Sequence 336, App
592	17	2.3	17	1	US-10-156-306-6933	Sequence 6933, Ap	c 665	15.4	2.0	18	1	US-09-146-157-3	Sequence 3, Appli
593	17	2.3	17	1	US-10-156-306-6934	Sequence 6934, Ap	c 666	15.4	2.0	18	1	US-09-412-947-2	Sequence 2, Appli
594	17	2.3	17	1	US-10-156-306-6935	Sequence 6935, Ap	c 667	15.4	2.0	18	1	US-09-412-947-5	Sequence 5, Appli
595	17	2.3	17	1	US-10-156-306-6936	Sequence 6936, Ap	c 668	15.4	2.0	18	1	US-09-412-947-7	Sequence 7, Appli
596	17	2.3	17	1	US-10-156-306-6937	Sequence 6937, Ap	c 669	15.4	2.0	18	1	US-10-641-521-2	Sequence 2, Appli
597	17	2.3	17	1	US-10-156-306-6938	Sequence 6938, Ap	c 670	15.4	2.0	18	1	US-10-641-521-5	Sequence 5, Appli
598	17	2.3	17	1	US-10-156-306-6939	Sequence 6939, Ap	c 671	15.4	2.0	18	1	US-10-641-521-7	Sequence 7, Appli
599	17	2.3	17	1	US-10-156-306-6940	Sequence 6940, Ap	c 672	15.4	2.0	18	1	US-10-854-989-2	Sequence 2, Appli
600	17	2.3	17	1	US-10-156-306-6941	Sequence 6941, Ap	c 673	15.4	2.0	18	1	US-10-854-989-5	Sequence 5, Appli
601	17	2.3	17	1	US-10-156-306-6942	Sequence 6942, Ap	c 674	15.4	2.0	18	1	US-10-854-989-7	Sequence 7, Appli
602	17	2.3	17	1	US-10-156-306-6943	Sequence 6943, Ap	c 675	15.4	2.0	20	1	US-09-863-049A-13	Sequence 13, Appl
603	17	2.3	17	1	US-10-156-306-6944	Sequence 6944, Ap	c 676	15.4	2.0	20	1	US-10-211-028-145	Sequence 145, App
604	17	2.3	17	1	US-10-156-306-6945	Sequence 6945, Ap	c 677	15.2	2.0	20	1	US-09-752-639-131	Sequence 131, App
605	17	2.3	17	1	US-10-156-306-6946	Sequence 6946, Ap	c 678	15.2	2.0	20	1	US-09-984-198-131	Sequence 131, App
606	17	2.3	17	1	US-10-156-306-6947	Sequence 6947, Ap	c 679	15.2	2.0	20	1	US-09-836-697-3	Sequence 3, Appli
607	17	2.3	17	1	US-10-156-306-6948	Sequence 6948, Ap	c 680	15.2	2.0	20	1	US-09-765-555-31	Sequence 31, Appl
608	17	2.3	17	1	US-10-156-306-6949	Sequence 6949, Ap	c 681	15.2	2.0	20	1	US-10-160-807-122	Sequence 122, App
609	17	2.3	17	1	US-10-156-306-6950	Sequence 6950, Ap	c 682	15.2	2.0	20	1	US-10-160-807-261	Sequence 261, App
610	17	2.3	17	1	US-10-156-306-6951	Sequence 6951, Ap	c 683	15.2	2.0	20	1	US-10-161-983-15	Sequence 15, Appl
611	17	2.3	17	1	US-10-156-306-6952	Sequence 6952, Ap	c 684	15.2	2.0	20	1	US-10-161-983-52	Sequence 52, Appl
612	17	2.3	17	1	US-10-156-306-6953	Sequence 6953, Ap	c 685	15.2	2.0	20	1	US-10-303-199A-7	Sequence 7, Appli
613	17	2.3	17	1	US-10-156-306-6954	Sequence 6954, Ap	c 686	15.2	2.0	20	1	US-10-380-125-61	Sequence 61, Appl
614	17	2.3	17	1	US-10-156-306-6955	Sequence 6955, Ap	c 687	15.2	2.0	20	1	US-10-655-847-122	Sequence 122, App
615	17	2.3	17	1	US-10-156-306-6956	Sequence 6956, Ap	c 688	15.2	2.0	20	1	US-10-655-847-261	Sequence 261, App
616	17	2.3	17	1	US-10-156-306-6957	Sequence 6957, Ap	c 689	15.2	2.0	20	1	US-10-688-706-2714	Sequence 2714, Ap
617	17	2.3	17	1	US-10-156-306-6958	Sequence 6958, Ap	c 690	15	2.0	15	1	US-09-863-049A-62	Sequence 62, Appl


```

; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; PRIOR FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 6
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-10-628-841-6

Query Match          3.8%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 162 TCTGGAAGAGCCCACTGTGTGAGATGGTG 190
DB 1 TCTGGAAGAGCCCACTGTGTGAGATGGTG 29

RESULT 3
US-10-792-063-24/c
; Sequence 24, Application US/10792063
; Publication No. US20040175797A1
; GENERAL INFORMATION:
; APPLICANT: Johnson, Jason
; APPLICANT: Garrett-Engle, Phillip
; APPLICANT: Kan, Zhengyan
; TITLE OF INVENTION: IKKKG
; FILE REFERENCE: R03-011-208PV
; CURRENT APPLICATION NUMBER: US/10/792,063
; CURRENT FILING DATE: 2004-03-03
; PRIOR APPLICATION NUMBER: US 06/452,293
; PRIOR FILING DATE: 2003-03-04
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 24
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-792-063-24

Query Match          3.6%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 880 CATCAAGACGAGCGTGGTGGGCAAGTGA 906
DB 27 CATCAAGACGAGCGTGGTGGGCAAGTGA 1

RESULT 4
US-09-863-049A-61
; Sequence 61, Application US/09863049A
; Publication No. US20030032055A1
; GENERAL INFORMATION:
; APPLICANT: Kenrick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Aradhyia, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Asmae
; APPLICANT: Israel, Alain
; APPLICANT: Foustcka, Annemarie
; APPLICANT: Lewis, Richard A

```

```

; APPLICANT: Levy, Moise
; APPLICANT: Heiss, Nina
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Defe
; FILE REFERENCE: NFKAPPA B (NF-kB) Activation
; FILE REFERENCE: HO-P01961U51
; CURRENT APPLICATION NUMBER: US/09/863,049A
; CURRENT FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 61
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(22)
; OTHER INFORMATION: Primer
US-09-863-049A-61

Query Match          2.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 344 CGGCAGACCAACAGATTCTGC 365
DB 1 CGGCAGACCAACAGATTCTGC 22

RESULT 5
US-10-444-795B-711
; Sequence 711, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 711
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.2
US-10-444-795B-711

Query Match          2.8%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCTCTCATGTGCAAGTT 438
DB 1 GGAGUCCUCCAUUGUGCAAGTT 21

RESULT 6
US-10-444-795B-721/c
; Sequence 721, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449

```

;; CURRENT APPLICATION NUMBER: US/10/444,795B
;; CURRENT FILING DATE: 2003-05-23
;; NUMBER OF SEQ ID NOS: 842
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 721
;; LENGTH: 21
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Small interfering RNA - IKK.4
US-10-444-795B-721

Query Match 2.8%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 875 AACCATCAAGACGACGGT 895
Db 21 AACCATCAAGACGACGGT 1

RESULT 7

US-09-972-607-5/c
; Sequence 5, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-972-607-5

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 215 GATCAGGACGTACTGGCGA 234
Db 20 GATCAGGACGTACTGGCGA 1

RESULT 8

US-09-972-607-16/c
; Sequence 16, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-16

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 162 TCTGGAAGGCCAACTGTGT 181
Db 20 TCTGGAAGGCCAACTGTGT 1

RESULT 9

US-09-972-607-17/c
; Sequence 17, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-17

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 195 CCAGTGTGCGCCGCGCAGCA 214
Db 20 CCAGTGTGCGCCGCGCAGCA 1

RESULT 10

US-09-972-607-18/c
; Sequence 18, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-18

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 231 GCGAAGAGTCTCTCTGGG 250
Db 20 GCGAAGAGTCTCTCTGGG 1

RESULT 11

US-09-972-607-19/c
; Sequence 19, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191

; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-19

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 270 TGCCTTCAGAACAGGGCGCT 289
DB 20 TGCCTTCAGAACAGGGCGCT 1

RESULT 12
US-09-972-607-20/c
; Sequence 20, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-20

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 275 TCAGAACAGGGCGCTCTCTGA 294
DB 20 TCAGAACAGGGCGCTCTCTGA 1

RESULT 13
US-09-972-607-21/c
; Sequence 21, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-21

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 279 AACAGGGCGCTCTCTGAGACC 298
DB 20 AACAGGGCGCTCTCTGAGACC 1

RESULT 14
US-09-972-607-22/c
; Sequence 22, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-22

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 313 GGAGGAGAAATCAAGAGCTCC 332
DB 20 GGAGGAGAAATCAAGAGCTCC 1

RESULT 15
US-09-972-607-23/c
; Sequence 23, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-23

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 344 CGCAGAGCAACCAAGATTCT 363
DB 20 CGCAGAGCAACCAAGATTCT 1

RESULT 16
US-09-972-607-24/c
; Sequence 24, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607

```

; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-24

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 385 TCTGCAATTCACGCCAGCC 404
Db 20 TCTGCAATTCACGCCAGCC 1

RESULT 17
US-09-972-607-25/c
; Sequence 25, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-25

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 TTTCACAGCCAGCCAGGG 410
Db 20 TTTCACAGCCAGCCAGGG 1

RESULT 18
US-09-972-607-26/c
; Sequence 26, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-26

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 GAGTTCCTCATGTGCAAGTT 438

```

```

Db 20 GAGTTCCTCATGTGCAAGTT 1

RESULT 19
US-09-972-607-27/c
; Sequence 27, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-27

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 451 GAAACTGGTGGAGAGACTCG 470
Db 20 GAAACTGGTGGAGAGACTCG 1

RESULT 20
US-09-972-607-28/c
; Sequence 28, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-28

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 465 GACTCGGCCTGGAGAGCTC 484
Db 20 GACTCGGCCTGGAGAGCTC 1

RESULT 21
US-09-972-607-29/c
; Sequence 29, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06

```


; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-29

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 483 TCGATCTGAAGAGCGCAGAAG 502
|||||
Db 20 TCGATCTGAAGAGCGCAGAAG 1

RESULT 22

US-09-972-607-30/c
; Sequence 30, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia

; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION

; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607

; CURRENT FILING DATE: 2001-10-06

; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 30
; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-30

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGGAGCAG 508
|||||
Db 20 TGAAGAGCGCAGAGGAGCAG 1

RESULT 23

US-09-972-607-31/c
; Sequence 31, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia

; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION

; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607

; CURRENT FILING DATE: 2001-10-06

; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 31
; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-31

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 507 AGGCTCTGCGGAGGTGGAG 526
|||||

Db 20 AGGCTCTGCGGAGGTGGAG 1

RESULT 24

US-09-972-607-32/c
; Sequence 32, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia

; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION

; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607

; CURRENT FILING DATE: 2001-10-06

; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 32
; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-32

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 534 AGAGATGCCAGCAGCAGATG 553
|||||
Db 20 AGAGATGCCAGCAGCAGATG 1

RESULT 25

US-09-972-607-33/c
; Sequence 33, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia

; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION

; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607

; CURRENT FILING DATE: 2001-10-06

; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 33
; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-33

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGAGCCAGATC 623
|||||
Db 20 GCTGCAGGAGAGCCAGATC 1

RESULT 26

US-09-972-607-34/c
; Sequence 34, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia

; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION

; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607

; CURRENT FILING DATE: 2001-10-06

; NUMBER OF SEQ ID NOS: 88

```

; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-972-607-34

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      616 CCAGAGTCGCTGGAGGCTG 635
Db      20 CCAGAGTCGCTGGAGGCTG 1

RESULT 27
US-09-972-607-35/c
; Sequence 35, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972.607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-972-607-35

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      686 CAGCGCGCGAGCTGGAGAG 705
Db      20 CAGCGCGCGAGCTGGAGAG 1

RESULT 28
US-09-972-607-36/c
; Sequence 36, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972.607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-972-607-36

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      715 GCGGCTGCAGCAGCAGCACA 734
Db      20 GCGGCTGCAGCAGCAGCACA 1

```

```

RESULT 29
US-09-972-607-37/c
; Sequence 37, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972.607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-972-607-37

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      724 GCAGCAGCACAGCGTGCAGG 743
Db      20 GCAGCAGCACAGCGTGCAGG 1

RESULT 30
US-09-972-607-38/c
; Sequence 38, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972.607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-972-607-38

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      725 CAGCAGCACAGCGTGCAGGT 744
Db      20 CAGCAGCACAGCGTGCAGGT 1

RESULT 31
US-09-972-607-39/c
; Sequence 39, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972.607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 39

```

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-39

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 726 AGCAGCACAGCGTCAGGTG 745
|||||
Db 20 AGCAGCACAGCGTCAGGTG 1

RESULT 32
US-09-972-607-40/c
; Sequence 40, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-40

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 776 GAGGCGCGCTCCGCATGGA 795
|||||
Db 20 GAGGCGCGCTCCGCATGGA 1

RESULT 33
US-09-972-607-41/c
; Sequence 41, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-41

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 792 TGGAGCGCCAGCGCCGCTCG 811
|||||
Db 20 TGGAGCGCCAGCGCCGCTCG 1

RESULT 34
US-09-972-607-42/c
; Sequence 42, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-42

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 800 CAGGCCGCTCGGAGGAGAA 819
|||||
Db 20 CAGGCCGCTCGGAGGAGAA 1

RESULT 35
US-09-972-607-43/c
; Sequence 43, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-43

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 803 GCGCGCTCGGAGGAGAGAG 822
|||||
Db 20 GCGCGCTCGGAGGAGAGAG 1

RESULT 36
US-09-972-607-44/c
; Sequence 44, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 44
; LENGTH: 20

```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-44
Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 830 GCCAGTTCAGGTGGCCTA 849
      |||||
Db 20 GCCAGTTCAGGTGGCCTA 1

RESULT 37
US-09-972-607-45/c
; Sequence 45, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-45
Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 AGGTGGCTATCACCAGCTC 859
      |||||
Db 20 AGGTGGCTATCACCAGCTC 1

RESULT 38
US-09-972-607-46/c
; Sequence 46, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-46
Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 843 TGGCCTATCACCAGCTCTTC 862
      |||||
Db 20 TGGCCTATCACCAGCTCTTC 1
```

```

RESULT 39
US-09-972-607-47/c
; Sequence 47, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-47
Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 882 TCAAGAGCAGCGTGGTGGC 901
      |||||
Db 20 TCAAGAGCAGCGTGGTGGC 1

RESULT 40
US-09-972-607-48/c
; Sequence 48, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-48
Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 885 AGACGACGCGTGGGCGAGT 904
      |||||
Db 20 AGACGACGCGTGGGCGAGT 1

RESULT 41
US-09-972-607-49/c
; Sequence 49, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-49

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 897 TGGCAGTGGCGGAGCGCA 916
Db 20 TGGCAGTGGCGGAGCGCA 1
|||||

RESULT 42

US-10-628-841-5/c
; Sequence 5, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-628-841-5

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 215 GATCAGGAGTACTGGCGCA 234
Db 20 GATCAGGAGTACTGGCGCA 1
|||||

RESULT 43

US-10-628-841-16/c
; Sequence 16, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-16

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 162 TCTGAAGAGCCCACTGTGT 181
|||||

Db 20 TCTGAAGAGCCCACTGTGT 1

RESULT 44

US-10-628-841-17/c
; Sequence 17, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-17

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 195 CCAGTGGTGGCCCGGCGCA 214
Db 20 CCAGTGGTGGCCCGGCGCA 1
|||||

RESULT 45

US-10-628-841-18/c
; Sequence 18, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-18

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 231 GCGAAGAGTCTCTCTGGGG 250
Db 20 GCGAAGAGTCTCTCTGGGG 1
|||||

RESULT 46

US-10-628-841-19/c
; Sequence 19, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:

; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION

```
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-19

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 270 TGCCTTCAGAACAGGGCGCT 289
Db 20 TGCCTTCAGAACAGGGCGCT 1

RESULT 47
US-10-628-841-20/c
; Sequence 20, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-20

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 275 TCAGAACAGGGCGCTCTCTGA 294
Db 20 TCAGAACAGGGCGCTCTCTGA 1

RESULT 48
US-10-628-841-21/c
; Sequence 21, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-21

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 279 AACAGGGCGCTCTCTGAGACC 298
Db 20 AACAGGGCGCTCTCTGAGACC 1

RESULT 49
US-10-628-841-22/c
; Sequence 22, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-22

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 313 GGAGGAGAAATCAAGAGCTCC 332
Db 20 GGAGGAGAAATCAAGAGCTCC 1

RESULT 50
US-10-628-841-23/c
; Sequence 23, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-23

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 344 CGGACAGCAACACAGATTCT 363
Db 20 CGGACAGCAACACAGATTCT 1
```

```
RESULT 51
US-10-628-841-24/c
; Sequence 24, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; PRIOR FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-24

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 385 TCTGCATTTCACAGCCAGCC 404
DB 20 TCTGCATTTCACAGCCAGCC 1

RESULT 52
US-10-628-841-25/c
; Sequence 25, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; PRIOR FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-25

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 TTTCCAGCCAGCCAGGG 410
DB 20 TTTCCAGCCAGCCAGGG 1

RESULT 53
US-10-628-841-26/c
; Sequence 26, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
```

```
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-26

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 GAGTTCCTCATGTGCAAGTT 438
DB 20 GAGTTCCTCATGTGCAAGTT 1

RESULT 54
US-10-628-841-27/c
; Sequence 27, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-27

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 451 GAAACTGGTGGAGAGACTCG 470
DB 20 GAAACTGGTGGAGAGACTCG 1

RESULT 55
US-10-628-841-28/c
; Sequence 28, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-28
```

```
Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 465 GACTCGGCTGGAGAGCTC 484
Db 20 GACTCGGCTGGAGAGCTC 1

RESULT 56
US-10-628-841-29/c
; Sequence 29, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-29

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 483 TCGATCTGAAGAGGCGAGAAG 502
Db 20 TCGATCTGAAGAGGCGAGAAG 1

RESULT 57
US-10-628-841-30/c
; Sequence 30, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-30

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 489 TGAAGAGGCGAGAAGGAGCAG 508
Db 20 TGAAGAGGCGAGAAGGAGCAG 1

RESULT 58
```

```
US-10-628-841-31/c
; Sequence 31, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-31

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 507 AGGCTCTGGGAGGTGGAG 526
Db 20 AGGCTCTGGGAGGTGGAG 1

RESULT 59
US-10-628-841-32/c
; Sequence 32, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-32

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 534 AGAGATCCGAGCAGCATG 553
Db 20 AGAGATCCGAGCAGCATG 1

RESULT 60
US-10-628-841-33/c
; Sequence 33, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
```



```
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-33

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGAGCCAGAGTC 623
Db 20 GCTGCAGGAGAGCCAGAGTC 1

RESULT 61
US-10-628-841-34/c
; Sequence 34, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-34

Query Match          2.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 616 CCAGAGTCGCTTGAGGCTG 635
Db 20 CCAGAGTCGCTTGAGGCTG 1

RESULT 62
US-10-628-841-35/c
; Sequence 35, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-35

Query Match          2.6%; Score 20; DB 1; Length 20;
```

```
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 686 CAGGCGCGCAGCTGGAGAG 705
Db 20 CAGGCGCGCAGCTGGAGAG 1

RESULT 63
US-10-628-841-36/c
; Sequence 36, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-36

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 715 GCGCTGCAGCAGCAGCACA 734
Db 20 GCGCTGCAGCAGCAGCACA 1

RESULT 64
US-10-628-841-37/c
; Sequence 37, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-37

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCGTCGAGG 743
Db 20 GCAGCAGCAGCGTCGAGG 1

RESULT 65
US-10-628-841-38/c
; Sequence 38, Application US/10628841
```

```

; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; PRIOR FILING DATE: 2003-07-28
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-38

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 725 CAGCAGCACGCGTGCAGGT 744
Db 20 CAGCAGCACGCGTGCAGGT 1

RESULT 66
US-10-628-841-39/c
; Sequence 39, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-39

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 726 AGCAGCACGCGTGCAGGTG 745
Db 20 AGCAGCACGCGTGCAGGTG 1

RESULT 67
US-10-628-841-40/c
; Sequence 40, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88

```

```

; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-40

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 776 GAGCGCGCGCTCCGCATGGA 795
Db 20 GAGCGCGCGCTCCGCATGGA 1

RESULT 68
US-10-628-841-41/c
; Sequence 41, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-41

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 792 TGGAGCGCCAGCGCGCTCG 811
Db 20 TGGAGCGCCAGCGCGCTCG 1

RESULT 69
US-10-628-841-42/c
; Sequence 42, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-42

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```
QY      800 CAGGCCGCTCGAGGAGAA 819
      |||||
Db      20 CAGGCCGCTCGAGGAGAA 1

RESULT 70
US-10-628-841-43/c
; Sequence 43, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-43

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      803 GCCGCTCGAGGAGAAG 822
      |||||
Db      20 GCCGCTCGAGGAGAAG 1

RESULT 71
US-10-628-841-44/c
; Sequence 44, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-44

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      830 GCCAGTTGCAGTGGCCTA 849
      |||||
Db      20 GCCAGTTGCAGTGGCCTA 1

RESULT 72
US-10-628-841-45/c
; Sequence 45, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-45

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      840 AGGTGGCTATCACCAGCTC 859
      |||||
Db      20 AGGTGGCTATCACCAGCTC 1

RESULT 73
US-10-628-841-46/c
; Sequence 46, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-46

Query Match      2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      843 TGGCCTATCACCAGCTCTTC 862
      |||||
Db      20 TGGCCTATCACCAGCTCTTC 1

RESULT 74
US-10-628-841-47/c
; Sequence 47, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 47
; LENGTH: 20
```

```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-47

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 882 TCAAGACGCGGTGGGC 901
      |||||
Db 20 TCAAGACGCGGTGGGC 1

RESULT 75
US-10-628-841-48/c
; Sequence 48, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RUS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-48

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 885 AGAGCAGCGTGGTGGCAGT 904
      |||||
Db 20 AGAGCAGCGTGGTGGCAGT 1

RESULT 76
US-10-628-841-49/c
; Sequence 49, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RUS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; PRIOR FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-49

Query Match          2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 897 TGGGCACTGAGCGGACCGA 916
      |||||
Db 20 TGGGCACTGAGCGGACCGA 1

RESULT 77
US-09-863-049A-53/c
; Sequence 53, Application US/09863049A
; Publication No. US20030032055A1
; GENERAL INFORMATION:
; APPLICANT: Kenrick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Arachya, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Asmae
; APPLICANT: Israeli, Alain
; APPLICANT: Poustka, Annemarie
; APPLICANT: Lewis, Richard A
; APPLICANT: Levy, Moise
; APPLICANT: Heiss, Nina
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Def
; FILE REFERENCE: HO-P01961U51
; CURRENT APPLICATION NUMBER: US/09/863,049A
; CURRENT FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 53
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Human
US-09-863-049A-53

Query Match          2.6%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 645 AATGCCAGGCTCTGGAGGGT 664
      |||||
Db 20 AATGCCAGGCTCTGGAGGGT 1

RESULT 78
US-10-809-189-13872
; Sequence 13872, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13872
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-13872

Query Match          2.6%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 897 TGGGCACTGAGCGGACCGA 916
      |||||
Db 20 TGGGCACTGAGCGGACCGA 1
```

QY 733 CACGCTGACAGGTGGACCACTGC 755
 |||||
 Db 3 CACGCTGACAGGTGGCCCACTGC 25

RESULT 79

US-09-863-049A-55/c
 ; Sequence 55, Application US/09863049A
 ; Publication No. US20030032055A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kenrick, Sue J.
 ; APPLICANT: Nelson, David L.
 ; APPLICANT: Aradnya, Swaroop
 ; APPLICANT: D'Urso, Michele
 ; APPLICANT: Woffendin, Hayley
 ; APPLICANT: Munnich, Arnold
 ; APPLICANT: Smahi, Asmae
 ; APPLICANT: Israel, Alain
 ; APPLICANT: Poustka, Annemarie
 ; APPLICANT: Lewis, Richard A
 ; APPLICANT: Levy, Moise
 ; APPLICANT: Heiss, Nina
 ; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Def
 ; TITLE OF INVENTION: NFKAPPA B (NF-KB) Activation
 ; FILE REFERENCE: HO-P01961US1
 ; CURRENT APPLICATION NUMBER: US/09/863,049A
 ; PRIOR FILING DATE: 2001-05-22
 ; PRIOR APPLICATION NUMBER: US 60/206,223
 ; PRIOR FILING DATE: 2000-05-22
 ; NUMBER OF SEQ ID NOS: 77
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 55
 ; LENGTH: 21
 ; TYPE: DNA
 ; ORGANISM: Human
 ; US-09-863-049A-55

Query Match 2.6%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 473 CTGGAAGCTCGATCTGAAG 493
 |||||
 Db 21 CTCGAGAAGCTCGATCTGAAG 1

RESULT 80

US-10-444-795B-716
 ; Sequence 716, Application US/10444795B
 ; Publication No. US2004007757A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Klinghoffer, Richard
 ; APPLICANT: Lewis, Stephen Patrick
 ; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
 ; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
 ; FILE REFERENCE: 200125.449
 ; CURRENT APPLICATION NUMBER: US/10/444,795B
 ; CURRENT FILING DATE: 2003-05-23
 ; NUMBER OF SEQ ID NOS: 842
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 716
 ; LENGTH: 21
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Small interfering RNA - IKK.3
 ; US-10-444-795B-716

Query Match 2.6%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 81.0%; Pred. No. 1.9e+02;
 Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAAGCCCAAGT 585
 |||||
 Db 1 GGCCUCUGUGAAAGCCCAAGT 21

RESULT 81

US-09-863-049A-63
 ; Sequence 63, Application US/09863049A
 ; Publication No. US20030032055A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kenrick, Sue J.
 ; APPLICANT: Nelson, David L.
 ; APPLICANT: Aradnya, Swaroop
 ; APPLICANT: D'Urso, Michele
 ; APPLICANT: Woffendin, Hayley
 ; APPLICANT: Munnich, Arnold
 ; APPLICANT: Smahi, Asmae
 ; APPLICANT: Israel, Alain
 ; APPLICANT: Poustka, Annemarie
 ; APPLICANT: Lewis, Richard A
 ; APPLICANT: Levy, Moise
 ; APPLICANT: Heiss, Nina
 ; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Def
 ; TITLE OF INVENTION: NFKAPPA B (NF-KB) Activation
 ; FILE REFERENCE: HO-P01961US1
 ; CURRENT APPLICATION NUMBER: US/09/863,049A
 ; PRIOR FILING DATE: 2001-05-22
 ; PRIOR APPLICATION NUMBER: US 60/206,223
 ; PRIOR FILING DATE: 2000-05-22
 ; NUMBER OF SEQ ID NOS: 77
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 63
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: Human
 ; US-09-863-049A-63

Query Match 2.6%; Score 19.4; DB 1; Length 25;
 Best Local Similarity 95.2%; Pred. No. 2.4e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 263 CTGCACCTGCCTTCAGAACAG 283
 |||||
 Db 5 CTTACCTGCCTTCAGAACAG 25

RESULT 82

US-10-719-900-590469
 ; Sequence 590469, Application US/10719900
 ; Publication No. US20050026164A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Xue Mei Zhou
 ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
 ; FILE REFERENCE: 3528.1
 ; CURRENT APPLICATION NUMBER: US/10/719,900
 ; CURRENT FILING DATE: 2003-11-20
 ; PRIOR APPLICATION NUMBER: 60/427,808
 ; PRIOR FILING DATE: 2002 11 20
 ; NUMBER OF SEQ ID NOS: 982514
 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
 ; SEQ ID NO 590469
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: Mus musculus
 ; US-10-719-900-590469

Query Match 2.5%; Score 19.2; DB 1; Length 25;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 559 GGACAAAGCCTCTGTGAAAGCCCA 582
 |||||
 Db 1 GGACATGGCCTGTGTGAAAGCCCA 24

```

RESULT 83
US-10-444-795B-707
; Sequence 707, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 707
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.1
US-10-444-795B-707

Query Match          2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.8e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 236 GAGTCTCTCTGGGGAAGC 254
      |||:|:|:|:|:|:|
DB 1 GAGUCUCCUGGGGAAGC 19

RESULT 84
US-10-444-795B-708/c
; Sequence 708, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 708
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.1
US-10-444-795B-708

Query Match          2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 236 GAGTCTCTCTGGGGAAGC 254
      |||:|:|:|:|:|:|
DB 19 GAGTCTCTCTGGGGAAGC 1

RESULT 85
US-10-444-795B-712
; Sequence 712, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE

```

US-10-444-795B-717

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.8e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAGCCCGAG 583
||||:|:|||||
Db 1 GGCCUCUGUGAAGCCCGAG 19

RESULT 88

US-10-444-795B-718/c
; Sequence 718, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 718
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.3
US-10-444-795B-718

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAGCCCGAG 583
||||:|:|||||
Db 19 GGCCCTCTGTGAAGCCCGAG 1

RESULT 89

US-10-444-795B-722/c
; Sequence 722, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 722
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.4
US-10-444-795B-722

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 877 CCACATCAAGACGCGTG 895
||||:|:|||||
Db 19 CCACATCAAGACGCGTG 1

RESULT 90

US-10-444-795B-723
; Sequence 723, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 723
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.4
US-10-444-795B-723

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 877 CCACATCAAGACGCGTG 895
||||:|:|||||
Db 1 CCACATCAAGACGCGUG 19

RESULT 91

US-10-444-795B-706
; Sequence 706, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 706
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.1
US-10-444-795B-706

Query Match 2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 2.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 236 GAGTCTCTCTGGGGAAGC 254
||||:|:|||||
Db 1 GAGUCUCUCUGGGAAGC 19

RESULT 92

US-10-444-795B-709
; Sequence 709, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B

```

; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 709
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.1
; NAME/KEY: misc feature
; LOCATION: 20..21
; OTHER INFORMATION: n = A,T,C,G or U
; US-10-444-795B-709

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 2.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      236 GAGTCTCTCTGGGGAAGC 254
      |||:|:|:|:|:|:|
Db      1 GAGUCUCUCUGGGGAAGC 19

RESULT 93
US-10-444-795B-710/c
; Sequence 710, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 710
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.1
; NAME/KEY: misc_feature
; LOCATION: 1, 2
; OTHER INFORMATION: n = A,T,C,G or U
; US-10-444-795B-710

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      236 GAGTCTCTCTGGGGAAGC 254
      |||:|:|:|:|:|:|
Db      21 GAGTCTCTCTGGGGAAGC 3

RESULT 94
US-10-444-795B-714
; Sequence 714, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0

```

```

; SEQ ID NO 714
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.2
; NAME/KEY: misc feature
; LOCATION: 20..21
; OTHER INFORMATION: n = A,T,C,G or U
; US-10-444-795B-714

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 2.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      418 GGAGTTCTCTCATGTGCAAG 436
      |||:|:|:|:|:|:|
Db      1 GGAGUUCUCCAUUGUGCAAG 19

RESULT 95
US-10-444-795B-715/c
; Sequence 715, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 715
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.2
; NAME/KEY: misc feature
; LOCATION: 1, 2
; OTHER INFORMATION: n = A,T,C,G or U
; US-10-444-795B-715

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      418 GGAGTTCTCTCATGTGCAAG 436
      |||:|:|:|:|:|:|
Db      21 GGAGTTCTCTCATGTGCAAG 3

RESULT 96
US-10-444-795B-719
; Sequence 719, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 719
; LENGTH: 21
; TYPE: DNA

```



```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.3
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 20, 21
; OTHER INFORMATION: n = A,T,C,G or U
US-10-444-795B-719

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAGCCCGAG 583
Db 1 GGCCTCTGTGAAGCCCGAG 19

RESULT 97
US-10-444-795B-720/c
; Sequence 720, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 720
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.3
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1, 2
; OTHER INFORMATION: n = A,T,C,G or U
US-10-444-795B-720

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAGCCCGAG 583
Db 21 GGCCTCTGTGAAGCCCGAG 3

RESULT 98
US-10-444-795B-724/c
; Sequence 724, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 724
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.4

```

```

; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 20, 21
; OTHER INFORMATION: n = A,T,C,G or U
US-10-444-795B-724

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 877 CCACATCAAGACGCGGTG 895
Db 19 CCACATCAAGACGCGGTG 1

RESULT 99
US-10-444-795B-725
; Sequence 725, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 725
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Small interfering RNA - IKK.4
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1, 2
; OTHER INFORMATION: n = A,T,C,G or U
US-10-444-795B-725

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 877 CCACATCAAGACGCGGTG 895
Db 3 CCACATCAAGACGCGGTG 21

RESULT 100
US-10-444-853A-123
; Sequence 123, Application US/10444853A
; Publication No. US20040192626A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haeblerli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Mokier, Victor
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/114 (MBH03-465)
; CURRENT APPLICATION NUMBER: US/10/444,853A
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012

```



```
/ PRIOR FILING DATE: 2002-09-05
/ PRIOR APPLICATION NUMBER: US 60/409,293
/ PRIOR FILING DATE: 2002-09-09
/ PRIOR APPLICATION NUMBER: US 60/440,129
/ PRIOR FILING DATE: 2003-01-15
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 626
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 127
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
/ NAME/KEY: misc feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-444-853A-127

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGCTCCGAGATGCC 340
Db 1 UCAAGAGCTCCGAGATGCC 19

RESULT 103
US-10-444-853A-128/c
/ Sequence 128, Application US/10444853A
/ Publication No. US20040192626A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Haerberli, Peter
/ APPLICANT: McSwiggen, James
/ APPLICANT: Beigelman, Leonid
/ APPLICANT: Macejak, Dennis
/ APPLICANT: Zinnen, Shawn
/ APPLICANT: Pavco, Pamela
/ APPLICANT: Morrissey, David
/ APPLICANT: Fosnaugh, Kathy
/ APPLICANT: Mokler, Victor
/ APPLICANT: Jamison, Sharon
/ APPLICANT: Vaish, Narendra
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
/ FILE REFERENCE: 400/114 (MBHB03-465)
/ CURRENT APPLICATION NUMBER: US/10/444,853A
/ CURRENT FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/417,012
/ PRIOR FILING DATE: 2003-04-16
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ PRIOR APPLICATION NUMBER: US 60/408,378
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/409,293
/ PRIOR FILING DATE: 2002-09-05
/ PRIOR APPLICATION NUMBER: US 60/409,293
/ PRIOR FILING DATE: 2002-09-09
/ PRIOR APPLICATION NUMBER: US 60/440,129
/ PRIOR FILING DATE: 2003-01-15
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 626
```

```
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 128
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
/ NAME/KEY: misc feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-444-853A-128

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGCTCCGAGATGCC 340
Db 19 TCAAGAGCTCCGAGATGCC 1

RESULT 104
US-10-444-853A-131
/ Sequence 131, Application US/10444853A
/ Publication No. US20040192626A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Haerberli, Peter
/ APPLICANT: McSwiggen, James
/ APPLICANT: Beigelman, Leonid
/ APPLICANT: Macejak, Dennis
/ APPLICANT: Zinnen, Shawn
/ APPLICANT: Pavco, Pamela
/ APPLICANT: Morrissey, David
/ APPLICANT: Fosnaugh, Kathy
/ APPLICANT: Mokler, Victor
/ APPLICANT: Jamison, Sharon
/ APPLICANT: Vaish, Narendra
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
/ FILE REFERENCE: 400/114 (MBHB03-465)
/ CURRENT APPLICATION NUMBER: US/10/444,853A
/ CURRENT FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/417,012
/ PRIOR FILING DATE: 2003-04-16
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ PRIOR APPLICATION NUMBER: US 60/408,378
/ PRIOR FILING DATE: 2002-09-05
/ PRIOR APPLICATION NUMBER: US 60/409,293
/ PRIOR FILING DATE: 2002-09-09
/ PRIOR APPLICATION NUMBER: US 60/440,129
/ PRIOR FILING DATE: 2003-01-15
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 626
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 131
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
```

```

;
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-444-853A-131

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.le+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 547 GCAGATGGCTGAGGACAAG 565
Db 1 GCAGAUGGCGAGGACAAG 19

RESULT 105
US-10-444-853A-132/c
; Sequence 132, Application US/10444853A
; Publication No. US20040192628A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Mokler, Victor
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/114 (MEH803-465)
; CURRENT APPLICATION NUMBER: US/10/444,853A
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 626
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 132
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-444-853A-132

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.le+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 547 GCAGATGGCTGAGGACAAG 565
Db 1 GCAGAUGGCGAGGACAAG 19

RESULT 105
US-10-444-853A-132/c
; Sequence 132, Application US/10444853A
; Publication No. US20040192628A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Mokler, Victor
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/114 (MEH803-465)
; CURRENT APPLICATION NUMBER: US/10/444,853A
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 626
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 132
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-444-853A-132

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.le+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 547 GCAGATGGCTGAGGACAAG 565
Db 1 GCAGAUGGCGAGGACAAG 19

RESULT 105
US-10-757-803-123
; Sequence 123, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; APPLICANT: Chowrira, Bharat
; APPLICANT: Usman, Nassim
; APPLICANT: James, Thompson
; APPLICANT: Vargeese, Chandra
; APPLICANT: Wang, Weimen
; APPLICANT: Tongqian, Chen
; TITLE OF INVENTION: Chemically Modified Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/142 (03-465-C)
; CURRENT APPLICATION NUMBER: US/10/757,803
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 123
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-757-803-123

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 2.le+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```

;
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-444-853A-131

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.le+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 547 GCAGATGGCTGAGGACAAG 565
Db 1 GCAGAUGGCGAGGACAAG 19

RESULT 105
US-10-757-803-123
; Sequence 123, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; APPLICANT: Chowrira, Bharat
; APPLICANT: Usman, Nassim
; APPLICANT: James, Thompson
; APPLICANT: Vargeese, Chandra
; APPLICANT: Wang, Weimen
; APPLICANT: Tongqian, Chen
; TITLE OF INVENTION: Chemically Modified Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/142 (03-465-C)
; CURRENT APPLICATION NUMBER: US/10/757,803
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 123
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-757-803-123

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 2.le+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

QY 418 GGAGTTCTCATGTGCAAG 436
 Db 1 GGAGUUCUUGUGCAAG 19

RESULT 107

US-10-757-803-124/c
 ; Sequence 124, Application US/10757803
 ; Publication No. US20050020525A1

GENERAL INFORMATION:

APPLICANT: Sirna Therapeutics, Inc.
 APPLICANT: Haerberli, Peter
 APPLICANT: McSwiggen, James
 APPLICANT: Beigelman, Leonid
 APPLICANT: Macejak, Dennis
 APPLICANT: Zinnen, Shawn
 APPLICANT: Pavco, Pamela
 APPLICANT: Morrissey, David
 APPLICANT: Fosnaugh, Kathy
 APPLICANT: Jamison, Sharon
 APPLICANT: Vaish, Nerendra
 APPLICANT: Chowrira, Bharat
 APPLICANT: Usman, Nassim
 APPLICANT: James, Thompson
 APPLICANT: Vargeese, Chandra
 APPLICANT: Wang, Weimen
 APPLICANT: Tonggian, Chen

TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using Artificially Modified Short Interfering Nucleic Acid (siRNA)

FILE REFERENCE: 400/142 (03-465-C)

CURRENT APPLICATION NUMBER: US/10/757,803

PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059

PRIOR FILING DATE: 2003-10-23

PRIOR APPLICATION NUMBER: US 10/444,853

PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: US 10/652,791

PRIOR FILING DATE: 2003-08-29

PRIOR APPLICATION NUMBER: US 10/422,704

PRIOR FILING DATE: 2003-04-24

PRIOR APPLICATION NUMBER: US 10/417,012

PRIOR FILING DATE: 2003-04-16

PRIOR APPLICATION NUMBER: US 10/427,160

PRIOR FILING DATE: 2003-04-30

PRIOR APPLICATION NUMBER: PCT/US03/05346

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: PCT/US03/05028

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/358,580

PRIOR FILING DATE: 2002-02-20

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 669

SOFTWARE: PatentIn version 3.3

SEQ ID NO 124

LENGTH: 21

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region

FEATURE:

NAME/KEY: misc feature

LOCATION: (20)..(21)

OTHER INFORMATION: n stands for thymidine

US-10-757-803-124

Query Match 2.5%; Score 19; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 2.1e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCTCATGTGCAAG 436

Db 19 GGAGTTCTCATGTGCAAG 1

RESULT 108

US-10-757-803-127

; Sequence 127, Application US/10757803

; Publication No. US20050020525A1

GENERAL INFORMATION:

APPLICANT: Sirna Therapeutics, Inc.
 APPLICANT: Haerberli, Peter
 APPLICANT: McSwiggen, James
 APPLICANT: Beigelman, Leonid
 APPLICANT: Macejak, Dennis
 APPLICANT: Zinnen, Shawn
 APPLICANT: Pavco, Pamela
 APPLICANT: Morrissey, David
 APPLICANT: Fosnaugh, Kathy
 APPLICANT: Jamison, Sharon
 APPLICANT: Vaish, Nerendra
 APPLICANT: Chowrira, Bharat
 APPLICANT: Usman, Nassim
 APPLICANT: James, Thompson
 APPLICANT: Vargeese, Chandra
 APPLICANT: Wang, Weimen
 APPLICANT: Tonggian, Chen

TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using Artificially Modified Short Interfering Nucleic Acid (siRNA)

FILE REFERENCE: 400/142 (03-465-C)

CURRENT APPLICATION NUMBER: US/10/757,803

PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059

PRIOR FILING DATE: 2003-10-23

PRIOR APPLICATION NUMBER: US 10/444,853

PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: US 10/652,791

PRIOR FILING DATE: 2003-08-29

PRIOR APPLICATION NUMBER: US 10/422,704

PRIOR FILING DATE: 2003-04-24

PRIOR APPLICATION NUMBER: US 10/417,012

PRIOR FILING DATE: 2003-04-16

PRIOR APPLICATION NUMBER: US 10/427,160

PRIOR FILING DATE: 2003-04-30

PRIOR APPLICATION NUMBER: PCT/US03/05346

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: PCT/US03/05028

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/358,580

PRIOR FILING DATE: 2002-02-20

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 669

SOFTWARE: PatentIn version 3.3

SEQ ID NO 127

LENGTH: 21

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: siRNA sense region

FEATURE:

NAME/KEY: misc feature

LOCATION: (20)..(21)

OTHER INFORMATION: n stands for thymidine

US-10-757-803-127

Query Match 2.5%; Score 19; DB 1; Length 21;

Best Local Similarity 84.2%; Pred. No. 2.1e+02;

Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGTCCGAGATGCC 340

Db 1 UCAAGAGTCCGAGATGCC 19

```
RESULT 110
US-10-757-803-131
; Sequence 131, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; APPLICANT: Chowrira, Bharat
; APPLICANT: Usman, Nassim
; APPLICANT: James, Thompson
; APPLICANT: Vargeese, Chandra
; APPLICANT: Wang, Weimen
; APPLICANT: Tongqian, Chen
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/142 (03-465-C)
; CURRENT FILING DATE: 2004-01-14
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 131
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-757-803-131
Query Match 2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.le+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 547 GCAGATGGCTCGAGACAAG 565
Db 1 GCAGAGGCGGAGACAAG 19
RESULT 111
US-10-757-803-132/c
```

```
RESULT 109
US-10-757-803-128/c
; Sequence 128, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; APPLICANT: Chowrira, Bharat
; APPLICANT: Usman, Nassim
; APPLICANT: James, Thompson
; APPLICANT: Vargeese, Chandra
; APPLICANT: Wang, Weimen
; APPLICANT: Tongqian, Chen
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/142 (03-465-C)
; CURRENT FILING DATE: 2004-01-14
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 128
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-757-803-128
Query Match 2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 322 TCAAGAGCTCCGAGATGCC 340
Db 19 TCAAGAGCTCCGAGATGCC 1
```

```

; Sequence 132, Application US/10757803
; Publication No. US20050020525A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Macejak, Dennis
; APPLICANT: Zinnen, Shawn
; APPLICANT: Pavco, Pamela
; APPLICANT: Morrissey, David
; APPLICANT: Posnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Vaish, Narendra
; APPLICANT: Chowrira, Bharat
; APPLICANT: Usman, Nassim
; APPLICANT: James, Thompson
; APPLICANT: Vargeese, Chandra
; APPLICANT: Wang, Weimen
; APPLICANT: Tongqian, Chen
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/142 (03-465-C)
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US/10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 132
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-757-803-132

Query Match 2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 547 GCAGATGGCTGAGGACAAG 565
Db 19 GCAGATGGCTGAGGACAAG 1

RESULT 112
US-10-826-966-123
; Sequence 123, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT FILING DATE: 2004-04-16
; CURRENT APPLICATION NUMBER: US/10/826,966
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 132
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-757-803-132

```

```

; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT FILING DATE: 2004-04-16
; CURRENT APPLICATION NUMBER: US/10/826,966
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 123
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-826-966-123

Query Match 2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 2.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTTCTCTCATGTGCAAG 436
Db 1 GGAGTUCCUCAUGGCAAG 19

RESULT 113
US-10-826-966-124/c
; Sequence 124, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT FILING DATE: 2004-04-16
; CURRENT APPLICATION NUMBER: US/10/826,966
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 123
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-826-966-123

```

```

; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 124
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; US-10-826-966-124

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418 GGAGTCTCTCATGTGCGAAG 436
      |||||
DB 19 GGAGTCTCTCATGTGCGAAG 1

RESULT 114
US-10-826-966-127
; Sequence 127, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT APPLICATION NUMBER: US/10/826,966
; CURRENT FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 124
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; US-10-826-966-124

```

```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 127
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; US-10-826-966-127

Query Match          2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGCTCCGAGATGCC 340
      |||||
DB 1 UCAAGAGCUCCGAGAUGC 19

RESULT 115
US-10-826-966-128/c
; Sequence 128, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT APPLICATION NUMBER: US/10/826,966
; CURRENT FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 128
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; US-10-826-966-128

```



```

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGCTCCGAGATGCC 340
Db 19 TCAAGAGCTCCGAGATGCC 1

RESULT 116
US-10-826-966-131
; Sequence 131, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT APPLICATION NUMBER: US/10/826,966
; CURRENT FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/422,791
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 131
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-826-966-131

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 547 GCAGATGGCTGAGGACAAG 565
Db 1 GCAGATGGCTGAGGACAAG 19

RESULT 117
US-10-826-966-132/c
; Sequence 132, Application US/10826966
; Publication No. US20050032733A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.

```

```

; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/151 (03-465-D)
; CURRENT APPLICATION NUMBER: US/10/826,966
; CURRENT FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 669
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 132
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-826-966-132

Query Match      2.5%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 547 GCAGATGGCTGAGGACAAG 565
Db 19 GCAGATGGCTGAGGACAAG 1

RESULT 118
US-10-210-290-37/c
; Sequence 37, Application US/10210290
; Publication No. US20040023378A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Eric G. Marcussen
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: ANTISENSE MODULATION OF KIAA1531 PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0367
; CURRENT APPLICATION NUMBER: US/10/210,290
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-290-37

```

```

Query Match      2.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 877 CCACATCAAGAGCGGTGG 896
Db 20 CCACATCAAGAGCGGTGG 1

RESULT 119
US-10-210-802-37/c
; Sequence 37, Application US/10210802
; Publication No. US20040087523A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF KIA1531 PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0367
; CURRENT APPLICATION NUMBER: US/10/210,802
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 134
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide.
US-10-210-802-37

Query Match      2.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 877 CCACATCAAGAGCGGTGG 896
Db 20 CCACATCAAGAGCGGTGG 1

RESULT 120
US-10-751-736-9484/c
; Sequence 9484, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9484
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-9484

Query Match      2.3%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 376 CGAGGAGCTTCTGCATTTC 394
Db 21 CGAGGAACCTCTGCATTTC 3

RESULT 121
US-10-751-736-9485/c

```

```

; Sequence 9485, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9485
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-9485

Query Match      2.3%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 376 CGAGGAGCTTCTGCATTTC 394
Db 19 CGAGGAACCTCTGCATTTC 1

RESULT 122
US-10-156-306-4383
; Sequence 4383, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4383
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4383

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 210 CAGCAGATCAGGACGTA 226
Db 1 CAGCAGAUACAGGACGUA 17

RESULT 123
US-10-156-306-4384
; Sequence 4384, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013

```

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4384
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4384

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 218 CAGGACGTACTGGCGCA 234
|||:|:|:|:|:|:|
Db 1 CAGGACGUACUGGGCGA 17

RESULT 124

US-10-156-306-4385
; Sequence 4385, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4385
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4385

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 232 CGAAGAGTCCTCTCGG 248
|||:|:|:|:|:|:|
Db 1 CGAAGAGUCUCCUCUGG 17

RESULT 125

US-10-156-306-4386
; Sequence 4386, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4386
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4386

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 234 AAGAGTCCTCTGGGG 250
|||:|:|:|:|:|:|
Db 1 AAGAGUCUCCUCUGGG 17

RESULT 126

US-10-156-306-4387
; Sequence 4387, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4387
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4387

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 237 AGTCCTCTCTGGGAAG 253
|||:|:|:|:|:|:|
Db 1 AGUCUCCUCUGGGGAAG 17

RESULT 127

US-10-156-306-4388
; Sequence 4388, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4388
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4388

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 267 ACCTGCCTTCAGAACAG 283
|||:|:|:|:|:|:|
Db 1 ACCUGCCUUCAGAACAG 17

RESULT 128

US-10-156-306-4389
; Sequence 4389, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0

```

; SEQ ID NO 4389
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4389

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.2%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 268 CCTGCCTTCAGAACAGG 284
      |||:::|||||
Db 1 CCUGCCUUCAGACAGG 17

RESULT 129
US-10-156-306-4390
; Sequence 4390, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4390
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4390

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 282 AGGGCGCTCTGAGACC 298
      |||:::|||||
Db 1 AGGGCGCUUCGAGACC 17

RESULT 130
US-10-156-306-4391
; Sequence 4391, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4391
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4391

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 293 GAGACCTTCAGCGTGG 309
      |||:::|||||
Db 1 GAGACCUUCAGCGGUG 17
```

```

RESULT 131
US-10-156-306-4392
; Sequence 4392, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4392
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4392

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 315 AGGAGAATCAAGAGCTC 331
      |||:::|||||
Db 1 AGGAGAAUCAAGAGCUC 17

RESULT 132
US-10-156-306-4393
; Sequence 4393, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4393
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4393

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 323 CAAGAGCTCCGAGATGC 339
      |||:::|||||
Db 1 CAAGAGCUCCGAGAUGC 17

RESULT 133
US-10-156-306-4394
; Sequence 4394, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4394
```

```

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4394

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 335 GATCCATCGGCGAG 351
    |||||:|||||
    1 GAUGCAUCCGCGAG 17

RESULT 134
US-10-156-306-4395
; Sequence 4395, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4395
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4395

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 353 AACAGATTCTGCGGA 369
    |||||:|||||
    1 AACAGAUUCGCGGA 17

RESULT 135
US-10-156-306-4396
; Sequence 4396, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4396
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4396

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 354 ACCAGATTCTGCGGAG 370
    |||||:|||||
    1 ACCAGAUUCGCGGAG 17

RESULT 136

```

```

US-10-156-306-4397
; Sequence 4397, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4397
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4397

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 377 GAGGAGCTTGCATT 393
    |||||:|||||
    1 GAGGAGCUUCGCAU 17

RESULT 137
US-10-156-306-4398
; Sequence 4398, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4398
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4398

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 378 AGGAGCTTGCATT 394
    |||||:|||||
    1 AGGAGCUUCGCAU 17

RESULT 138
US-10-156-306-4399
; Sequence 4399, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4399
; LENGTH: 17

```

```

; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4399

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 384 TTTCGATTTCACAGCC 400
Db 1 UUCGCAUUCACAGCC 17
      :|||:|||||
      :|||:|||||

RESULT 139
US-10-156-306-4400
; Sequence 4400, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4400
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4400

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 385 TCTGCATTTCACAGCCA 401
Db 1 UUCGCAUUCACAGCCA 17
      :|||:|||||
      :|||:|||||

RESULT 140
US-10-156-306-4401
; Sequence 4401, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4401
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4401

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 386 CTGCAATTTCACAGCCAG 402
Db 1 CUGCAUUCACAGCCAG 17
      :|||:|||||
      :|||:|||||

RESULT 141
US-10-156-306-4402

```

```

; Sequence 4402, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4402
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4402

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 415 GAAGGAGTTCTCATGT 431
Db 1 GAAGGAGUUCUCAUGU 17
      :|||:|||||
      :|||:|||||

RESULT 142
US-10-156-306-4403
; Sequence 4403, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4403
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4403

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 416 AAGGAGTTCTCATGTG 432
Db 1 AAGGAGUUCUCAUGUG 17
      :|||:|||||
      :|||:|||||

RESULT 143
US-10-156-306-4404
; Sequence 4404, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4404
; LENGTH: 17
; TYPE: RNA

```

```
; ORGANISM: Homo sapiens
US-10-156-306-4404

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 419 GAGTTCTCATGTGCAA 435
      |||:||||:|||||
Db 1 GAGUUCUCAUGGCAA 17

RESULT 144
US-10-156-306-4405
; Sequence 4405, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4405
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4405

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 430 GTGCAAGTTCAGGAGG 446
      |:|||||:|||||
Db 1 GUGCAAGUCCAGGAGG 17

RESULT 145
US-10-156-306-4406
; Sequence 4406, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4406
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4406

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 431 TGCAGTTCAGGAGGC 447
      :|||||:|||||
Db 1 UGCAAGUCCAGGAGGC 17

RESULT 146
US-10-156-306-4407
; Sequence 4407, Application US/10156306
```

```
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4407
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4407

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 461 GAGAGACTCGGCTGGA 477
      |||||:||||:|
Db 1 GAGAGACUCGGCCUGGA 17

RESULT 147
US-10-156-306-4408
; Sequence 4408, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4408
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4408

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 476 GAGAAGCTCGATCTGAA 492
      |||||:||||:|
Db 1 GAGAAGCUCGACUGAA 17

RESULT 148
US-10-156-306-4409
; Sequence 4409, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4409
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-10-156-306-4409

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 480 AGCTGATCTGAGAGG 496
|||||:|:|:|:|:|:|
Db 1 AGCUGAUCUGAAGG 17

RESULT 149

US-10-156-306-4410
; Sequence 4410, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4410

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4410

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 504 AGCAGGCTCTCGGGAG 520
|||||:|:|:|:|:|:|
Db 1 AGCAGGCUUCGGGAG 17

RESULT 150

US-10-156-306-4411

; Sequence 4411, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4411

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4411

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 562 CAAGGCCCTCTGGAAG 578
|||||:|:|:|:|:|:|
Db 1 CAAGGCCUCUGAAG 17

RESULT 151

US-10-156-306-4412

; Sequence 4412, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4412

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4412

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 583 GGTGAGCTCTTGCTCG 599
|||||:|:|:|:|:|:|
Db 1 GSGAGCUUCUGCUG 17

RESULT 152

US-10-156-306-4413

; Sequence 4413, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4413

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4413

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 586 GAGTCTCTGCTCGGG 602
|||||:|:|:|:|:|:|
Db 1 GACGCUUCUGCUGGG 17

RESULT 153

US-10-156-306-4414

; Sequence 4414, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4414

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4414


```

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 590 TCCTTGCTGGGAGCT 606
    :||:|||||:
Db 1 UCCUUGCUGGGAGCU 17

RESULT 154
US-10-156-306-4415
; Sequence 4415, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4415
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4415

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 615 GCCAGAGTCGCTGGAG 631
    |||||:|||||:
Db 1 GCCAGAGUCGCUUGAG 17

RESULT 155
US-10-156-306-4416
; Sequence 4416, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4416
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4416

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 619 GAGTCGCTGGAGGCTG 635
    ||||:|||||:
Db 1 GAGUCCUUGGGGCG 17

RESULT 156
US-10-156-306-4417
; Sequence 4417, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4417
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4417

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 633 CTGCCACTAAGGAATGC 649
    |:|||||:|||||:
Db 1 CUGCCACUAGGGAUGC 17

RESULT 157
US-10-156-306-4418
; Sequence 4418, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4418
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4418

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 648 GCCAGGCTCTGGAGGT 664
    |||||:|||||:
Db 1 GCCAGGCUCUGGAGGCU 17

RESULT 158
US-10-156-306-4419
; Sequence 4419, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4419
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4419

```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 657 TGGAGGCTCGGGCCGG 673
Db 1 UGGAGGGUCCGGCCGG 17

RESULT 159
US-10-156-306-4420
; Sequence 4420, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4420
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4420

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 779 GCCGCGCTCCGATGGA 795
Db 1 GCCGCGCTCCGCAUGGA 17

RESULT 160
US-10-156-306-4421
; Sequence 4421, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4421
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4421

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 802 GCGCGCTCGGAGGAGA 818
Db 1 GCGCGCCUCCGAGGAGA 17

RESULT 161
US-10-156-306-4422
; Sequence 4422, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4422
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4422

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 829 GGCCCATGTTGCAGGTGG 845
Db 1 GGCCCAUUGCAGGUGG 17

RESULT 162
US-10-156-306-4423
; Sequence 4423, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4423
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4423

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 841 GGTGGCTATCACCAGC 857
Db 1 GGUGGCCUAUACCAGC 17

RESULT 163
US-10-156-306-4424
; Sequence 4424, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4424
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4424

Query Match      2.3%; Score 17; DB 1; Length 17;
```

```
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 843 TGGCTTATCACCAGCTC 859
Db 1 UGCCUAUACCAAGCUC 17

RESULT 164
US-10-156-306-4425
; Sequence 4425, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4425
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4425

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACGCTCTTCCAAGA 867
Db 1 CACGAGCUUCCAAAGA 17

RESULT 165
US-10-156-306-4426
; Sequence 4426, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4426
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4426

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 853 CCAGCTCTTCCAAGAT 869
Db 1 CCAGCUUCCAAAGAU 17

RESULT 166
US-10-156-306-4427
; Sequence 4427, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4427
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4427

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 854 CAGCTCTTCCAAGATA 870
Db 1 CAGCUCUCCAAAGAAU 17

RESULT 167
US-10-156-306-4428
; Sequence 4428, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4428
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4428

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 862 CCAAGATACGACAACC 878
Db 1 CCAAGAAUACGACAACC 17

RESULT 168
US-10-156-306-4429
; Sequence 4429, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4429
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4429

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
```

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 875 AACACATCAAGACGAG 891
|||||:|||||

Db 1 AACCAACAAGACGAG 17

RESULT 169
US-10-156-306-4799
; Sequence 4799, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4799
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4799

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 165 GGAAGAGCCCACTGTGT 181
|||||:|||||

Db 1 GGAAGAGCCCACTGTGT 17

RESULT 170
US-10-156-306-4800
; Sequence 4800, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4800
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4800

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 166 GAAGAGCCCACTGTGTG 182
|||||:|||||

Db 1 GAAGAGCCCACTGTGTG 17

RESULT 171
US-10-156-306-4801
; Sequence 4801, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4801
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4801

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 169 GAGCCCACTGTGTGAGA 185
|||||:|||||

Db 1 GAGCCCACTGTGTGAGA 17

RESULT 172
US-10-156-306-4802
; Sequence 4802, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4802
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4802

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 184 GATGTCGACCCAGTG 200
|||||:|||||

Db 1 GAUGGUGCAGCCAGTG 17

RESULT 173
US-10-156-306-4803
; Sequence 4803, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4803
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4803

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```

QY 187 GGTGAGCCAGTGTGG 203
||:|||||:|:|
Db 1 GGUGAGCCAGUGGUG 17

RESULT 174
US-10-156-306-4804
; Sequence 4804, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4804
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4804

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 188 GTGAGCCAGTGTGG 204
||:|||||:|:|
Db 1 GUGAGCCAGUGGUG 17

RESULT 175
US-10-156-306-4805
; Sequence 4805, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4805
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4805

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 189 TGCAGCCAGTGTGG 205
||:|||||:|:|
Db 1 UGCAGCCAGUGGUG 17

RESULT 176
US-10-156-306-4806
; Sequence 4806, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

```

```

; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4806
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4806

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 198 GTGTGGCCCGCAGCA 214
||:|||||:|:|
Db 1 GUGUGCCCGCAGCA 17

RESULT 177
US-10-156-306-4807
; Sequence 4807, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4807
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4807

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 199 TGTGTGGCCCGCAGCA 215
||:|||||:|:|
Db 1 UGUGGCCCGCAGCA 17

RESULT 178
US-10-156-306-4808
; Sequence 4808, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4808
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4808

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

Qy 203 GGCCCGGCGACGATCA 219
 Db 1 GGCCCGGCGACGAUCA 17

RESULT 179
 US-10-156-306-4809
 ; Sequence 4809, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MBH01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4809
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-4809

Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.6e+02;
 Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 206 CCGGCGACGATCAGGA 222
 Db 1 CCGGCGACGATCAGGA 17

RESULT 180
 US-10-156-306-4810
 ; Sequence 4810, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MBH01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4810
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-4810

Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.6e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 211 AGCAGATCAGGATGAC 227
 Db 1 AGCAGATCAGGATGAC 17

RESULT 181
 US-10-156-306-4811
 ; Sequence 4811, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4811
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-4811

Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2.6e+02;
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 220 GGACGTACTGGCGAAG 236
 Db 1 GGACGTACTGGCGAAG 17

RESULT 182
 US-10-156-306-4812
 ; Sequence 4812, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MBH01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4812
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-4812

Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.6e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 233 GAAGAGTCCTCTGGG 249
 Db 1 GAAGAGTCCTCTGGG 17

RESULT 183
 US-10-156-306-4813
 ; Sequence 4813, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MBH01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4813
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-4813

Query Match 2.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2.6e+02;
 Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 235 AGAGTCCTCTGGGA 251

```
||||:|:|:|:|:|:|
Db      1 AGAGUCUCCUGGGGA 17

RESULT 184
US-10-156-306-4814
; Sequence 4814, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4814
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4814

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      236 GAGTCCTCCTCGGGAA 252
Db      1 GAGUCUCCUGGGGAA 17

RESULT 185
US-10-156-306-4815
; Sequence 4815, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4815
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4815

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      238 GTCTCCTCTGGGAAGC 254
Db      1 GUCUCCUCCUGGGGAAGC 17

RESULT 186
US-10-156-306-4816
; Sequence 4816, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
```

```
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4816
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4816

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      247 GGGGAAGCCAGCCATGC 263
Db      1 GGGGAAGCCAGCCAUCC 17

RESULT 187
US-10-156-306-4817
; Sequence 4817, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4817
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4817

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      248 GGGGAAGCCAGCCATGCT 264
Db      1 GGGGAAGCCAGCCAUCC 17

RESULT 188
US-10-156-306-4818
; Sequence 4818, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4818
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4818

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      251 AAGCCAGCCATGCTGCA 267
Db      1 AAGCCAGCCATGCTGCA 267
```

```
Db      1 AAGCCAGCCAUGCUGCA 17

RESULT 189
US-10-156-306-4819
; Sequence 4819, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4819
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4819

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      252 AGCCAGCCATGCTGCAC 268
        |||||:||||:||||:
Db      1 AGCCAGCCATGCTGCAC 17

RESULT 190
US-10-156-306-4820
; Sequence 4820, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4820
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4820

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy      256 AGCCATGCTGCACCTGC 272
        |||||:||||:||||:
Db      1 AGCCATGCTGCACCTGC 17

RESULT 191
US-10-156-306-4821
; Sequence 4821, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
```

```
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4821
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4821

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      259 CATGCTGCACCTGCCTT 275
        ||:||||:||||:
Db      1 CAUGCUGCACCUGCCUU 17

RESULT 192
US-10-156-306-4822
; Sequence 4822, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4822
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4822

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      261 TGCTGCACCTGCCTTCA 277
        :||:||||:||||:
Db      1 UGCUGCACCUGCCUUGCA 17

RESULT 193
US-10-156-306-4823
; Sequence 4823, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4823
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4823

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      262 GCTGCACCTGCCTTCAG 278
        ||:||||:||||:
Db      1 GCUGCACCUGCCUUCAG 17
```



```
RESULT 194
US-10-156-306-4824
; Sequence 4824, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4824
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4824

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 265 GCACCTGCCTTCAGAAC 281
Db 1 GCACCGCCUUCAGAAC 17

RESULT 195
US-10-156-306-4825
; Sequence 4825, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4825
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4825

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAAC 282
Db 1 CACCGCCUUCAGAAC 17

RESULT 196
US-10-156-306-4826
; Sequence 4826, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4826
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4826

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 269 CTGCCTTCAGACAGGG 285
Db 1 CUGCCUUCAGACAGGG 17

RESULT 197
US-10-156-306-4827
; Sequence 4827, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4827
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4827

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 274 TTCAGAACAGGGCGCTC 290
Db 1 UUCAGAACAGGGCGCUC 17

RESULT 198
US-10-156-306-4828
; Sequence 4828, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4828
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4828

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 281 CAGGGCGCTCTCAGAC 297
Db 1 CAGGGCGCCUUCAGAC 17
```

```
RESULT 199
US-10-156-306-4829
; Sequence 4829, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4829
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4829

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 283 GGGCGCTCCTGAGACCC 299
Db 1 GGGCGCUCCUGAGACCC 17

RESULT 200
US-10-156-306-4830
; Sequence 4830, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4830
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4830

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 283 GGGCGCTCCTGAGACCC 299
Db 1 GGGCGCUCCUGAGACCC 17

RESULT 201
US-10-156-306-4831
; Sequence 4831, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4831

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 291 CTGAGACCCCTCCAGCGC 307
Db 1 CUGAGACCCUCCAGCGC 17

RESULT 202
US-10-156-306-4832
; Sequence 4832, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4832
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4832

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 290 CCTGAGACCCCTCCAGCG 306
Db 1 CCTGAGACCCUCCAGCG 17

RESULT 203
US-10-156-306-4833
; Sequence 4833, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4833
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4833

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 284 GGGCGCTCCTGAGACCC 300
Db 1 GGGCGCUCCUGAGACCC 17

RESULT 204
US-10-156-306-4834
; Sequence 4834, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4834
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4834

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 292 TGAGACCCCTCCAGCGCT 308
Db 1 UGAGACCCUCCAGCGCU 17
```

```
; SEQ ID NO 4831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4831

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 290 CCTGAGACCCCTCCAGCG 306
Db 1 CCTGAGACCCUCCAGCG 17

RESULT 202
US-10-156-306-4832
; Sequence 4832, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4832
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4832

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 291 CTGAGACCCCTCCAGCGC 307
Db 1 CUGAGACCCUCCAGCGC 17

RESULT 203
US-10-156-306-4833
; Sequence 4833, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4833
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4833

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 292 TGAGACCCCTCCAGCGCT 308
Db 1 UGAGACCCUCCAGCGCU 17
```

```
RESULT 204
US-10-156-306-4834
; Sequence 4834, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4834
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4834

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 294 AGACCTCCAGCGCTGC 310
      |||||:|||||:|||||
Db 1 AGACCCUCCAGCGCUGC 17

RESULT 205
US-10-156-306-4835
; Sequence 4835, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4835
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4835

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 295 GACCTCCAGCGCTGCC 311
      |||||:|||||:|||||
Db 1 GACCCUCCAGCGCUGC 17

RESULT 206
US-10-156-306-4836
; Sequence 4836, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4836
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4836

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 300 TCCAGCGCTCCCTGGAG 316
      :|||||:|||||:|||||
Db 1 UCCAGCGCUGCCUGGAG 17

RESULT 207
US-10-156-306-4837
; Sequence 4837, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4837
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4837

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 303 AGCGCTGCCTGGAGGAG 319
      |||||:|||||:|||||
Db 1 AGCGCUGCCUGGAGGAG 17

RESULT 208
US-10-156-306-4838
; Sequence 4838, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4838
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4838

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 304 GCGCTGCCTGGAGGAGA 320
      :|||||:|||||:|||||
Db 1 GCGCUGCCUGGAGGAGA 17

RESULT 209
```

US-10-156-306-4839
; Sequence 4839, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4839
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4839

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 316 GGAGATCAAGAGTCC 332
|||||:|||||:
Db 1 GGAGAUCCAGAGCUCC 17

RESULT 210
US-10-156-306-4840
; Sequence 4840, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4840
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4840

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGATCCGAGATG 338
:|||||:|||||:
Db 1 UCAAGAGCUCCGAGAUG 17

RESULT 211
US-10-156-306-4841
; Sequence 4841, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4841
; LENGTH: 17

; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4841

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 324 AAGAGCTCCGAGATGCC 340
|||||:|||||:
Db 1 AAGAGCUCCGAGAUGCC 17

RESULT 212
US-10-156-306-4842
; Sequence 4842, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4842
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4842

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 332 CGAGATGCCATCCGGCA 348
|||||:|||||:
Db 1 CGAGAUCCCAUGCGCA 17

RESULT 213
US-10-156-306-4843
; Sequence 4843, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4843
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4843

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 333 GAGATGCCATCCGGCAG 349
|||||:|||||:
Db 1 GAGAUCCCAUGCGCAG 17

RESULT 214
US-10-156-306-4844

```
; Sequence 4844, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4844
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4844

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 336 ATCCCATCCGCGAGAC 352
Db 1 AUGCCCAUCCGCGAGAC 17

RESULT 215
US-10-156-306-4845
; Sequence 4845, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4845

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 340 CATCCGCGAGACCAACC 356
Db 1 CAUCCGCGAGAGCAACC 17

RESULT 216
US-10-156-306-4846
; Sequence 4846, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4846
```

```
; ORGANISM: Homo sapiens
US-10-156-306-4846

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 345 GCGAGAGCAACGAGATT 361
Db 1 GCGAGAGCAACGAGAUU 17

RESULT 217
US-10-156-306-4847
; Sequence 4847, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4847
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4847

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 348 AGAGCAACGAGATTCTG 364
Db 1 AGAGCAACGAGAUUCUG 17

RESULT 218
US-10-156-306-4848
; Sequence 4848, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4848
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4848

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 349 GAGCAACGAGATTCTGC 365
Db 1 GAGCAACGAGAUUCUGC 17

RESULT 219
US-10-156-306-4849
; Sequence 4849, Application US/10156306
```

Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4849
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4849

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 355 CCAGATTCTCGGGAGC 371
|||||:|:|:|:|:|:|
Db 1 CCAGAUUCUGGGAGC 17

RESULT 220
US-10-156-306-4850
; Sequence 4850, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4850
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4850

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 366 GGGAGCGCTCGGAGGAG 382
|||||:|:|:|:|:|:|
Db 1 GGGAGCGCUGCGGAGG 17

RESULT 221
US-10-156-306-4851
; Sequence 4851, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4851
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

US-10-156-306-4851

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 376 CGAGGAGCTTCGCAATT 392
|||||:|:|:|:|:|:|
Db 1 CGAGGAGCTUCUGCAU 17

RESULT 222
US-10-156-306-4852
; Sequence 4852, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4852
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4852

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 379 GGAGCTTCTGCATTTCC 395
|||||:|:|:|:|:|:|
Db 1 GGAGCUUCUGCAUUC 17

RESULT 223
US-10-156-306-4853
; Sequence 4853, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4853
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4853

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 382 GCTTCTGCAATTCAG 398
|||||:|:|:|:|:|:|
Db 1 GCUUCUGCAUUCUCAA 17

RESULT 224
US-10-156-306-4854
; Sequence 4854, Application US/10156306
; Publication No. US20030119017A1

```
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4854
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4854

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 387 TGCATTTCGAAGCCAGC 403
DB 1 UGCAUUCGAGCCAGC 17

RESULT 225
US-10-156-306-4855
; Sequence 4855, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4855
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4855

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 388 GCATTTCGAAGCCAGCC 404
DB 1 GCAUUCGAGCCAGCC 17

RESULT 226
US-10-156-306-4856
; Sequence 4856, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4856
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4856
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 392 TTCGAAGCCAGCCAGC 408
DB 1 UUCAAGCCAGCCAGC 17

RESULT 227
US-10-156-306-4857
; Sequence 4857, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4857
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4857

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 393 TCCAAGCCAGCCAGG 409
DB 1 UCCAAGCCAGCCAGG 17

RESULT 228
US-10-156-306-4858
; Sequence 4858, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4858
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4858

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 396 AAGCCAGCCAGGGAG 412
DB 1 AAGCCAGCCAGGGAG 17

RESULT 229
US-10-156-306-4859
; Sequence 4859, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4859
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4859

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 397 AGCCAGCCAGGAGG 413
Db 1 AGCCAGCCAGGAGG 17

RESULT 230
US-10-156-306-4860
; Sequence 4860, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4860
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4860

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 417 AGGAGTTCCTCATGTGC 433
Db 1 AGGAGUCCUCAUGGUC 17

RESULT 231
US-10-156-306-4861
; Sequence 4861, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4861
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4861

```

```

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 418 GGAGTTCTCTCATGTGCA 434
Db 1 GGAGUCCUCAUGGCA 17

RESULT 232
US-10-156-306-4862
; Sequence 4862, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4862
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4862

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 420 AGTTCCTCATGTGCAAG 436
Db 1 AGUUCUCCUCAUGGCAAG 17

RESULT 233
US-10-156-306-4863
; Sequence 4863, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4863
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4863

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 426 TCATGTGCAAGTTCACG 442
Db 1 UCAUGUGCAAGUCCAG 17

RESULT 234
US-10-156-306-4864
; Sequence 4864, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```



```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4864
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4864

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 432 GCAAGTTCAGGAGGCC 448
      |||||:|||||
Db 1 GCAAGUCCAGGAGGCC 17

RESULT 235
US-10-156-306-4865
; Sequence 4865, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4865
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4865

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 433 CAAGTTCAGGAGGCCA 449
      |||||:|||||
Db 1 CAAGUCCAGGAGGCCA 17

RESULT 236
US-10-156-306-4866
; Sequence 4866, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4866
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4866

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 434 GCAAGTTCAGGAGGCC 448
      |||||:|||||
Db 1 GCAAGUCCAGGAGGCC 17

RESULT 237
US-10-156-306-4867
; Sequence 4867, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4867
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4867

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 440 CAGGAGCCAGGAAACT 456
      |||||:|||||
Db 1 CAGGAGCCAGGAAACU 17

RESULT 238
US-10-156-306-4868
; Sequence 4868, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4868
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4868

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 448 CAGGAAACTGGTGGAGA 464
      |||||:|||||
Db 1 CAGGAAACUGGUGGAGA 17

RESULT 239
US-10-156-306-4869
; Sequence 4869, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 440 CAGGAGCCAGGAAACT 456
      |||||:|||||
Db 1 CAGGAGCCAGGAAACU 17

RESULT 237
US-10-156-306-4867
; Sequence 4867, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4867
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4867

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 441 AGGAGCCAGGAAACTG 457
      |||||:|||||
Db 1 AGGAGCCAGGAAACUG 17

RESULT 238
US-10-156-306-4868
; Sequence 4868, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4868
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4868

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 448 CAGGAAACTGGTGGAGA 464
      |||||:|||||
Db 1 CAGGAAACUGGUGGAGA 17

RESULT 239
US-10-156-306-4869
; Sequence 4869, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

Matches	15;	Conservative	2;	Mismatches	0;	Indels	0;	Gaps	0;
QY	466	ACTCGGCTCGAGAAGC	482						
		:							
Db	1	ACUCGGCCUGGAGAAGC	17						
RESULT 242									
US-10-156-306-4872									
; Sequence 4872, Application US/10156306									
; Publication No. US20030119017A1									
; GENERAL INFORMATION:									
; APPLICANT: McSwiggen, James									
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions									
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR									
; FILE REFERENCE: MEH01-664-A (400/050)									
; CURRENT APPLICATION NUMBER: US/10/156,306									
; CURRENT FILING DATE: 2002-05-28									
; NUMBER OF SEQ ID NOS: 8013									
; SOFTWARE: PatentIn version 3.0									
; SEQ ID NO 4872									
; LENGTH: 17									
; TYPE: RNA									
; ORGANISM: Homo sapiens									
US-10-156-306-4872									
Query Match 2.3%; Score 17; DB 1; Length 17;									
Best Local Similarity 82.4%; Pred. No. 2.6e+02;									
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;									
QY	475	GGAGAAGCTCGATCTGA	491						
		:							
Db	1	GGAGAAGCUCGAUCUGA	17						
RESULT 243									
US-10-156-306-4873									
; Sequence 4873, Application US/10156306									
; Publication No. US20030119017A1									
; GENERAL INFORMATION:									
; APPLICANT: McSwiggen, James									
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions									
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR									
; FILE REFERENCE: MEH01-664-A (400/050)									
; CURRENT APPLICATION NUMBER: US/10/156,306									
; CURRENT FILING DATE: 2002-05-28									
; NUMBER OF SEQ ID NOS: 8013									
; SOFTWARE: PatentIn version 3.0									
; SEQ ID NO 4873									
; LENGTH: 17									
; TYPE: RNA									
; ORGANISM: Homo sapiens									
US-10-156-306-4873									
Query Match 2.3%; Score 17; DB 1; Length 17;									
Best Local Similarity 82.4%; Pred. No. 2.6e+02;									
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;									
QY	481	GCTCGATCTCGAAGGC	497						
		:							
Db	1	GCUCGAUCGAAGAGGC	17						
RESULT 244									
US-10-156-306-4874									
; Sequence 4874, Application US/10156306									
; Publication No. US20030119017A1									
; GENERAL INFORMATION:									
; APPLICANT: McSwiggen, James									
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions									

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4874
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4874

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 490 GAAGAGCAGCAGGAGC 506
Db 1 GAAGAGCAGCAGGAGC 17

RESULT 245
US-10-156-306-4875
; Sequence 4875, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4875
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4875

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 499 GAAGGAGCAGGCTCTGC 515
Db 1 GAAGGAGCAGGCUUCG 17

RESULT 246
US-10-156-306-4876
; Sequence 4876, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4876
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4876

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 503 GAGCAGGCTCTCGCGGA 519
Db 1 GAGCAGGCTCTCGCGGA 17

RESULT 247
US-10-156-306-4877
; Sequence 4877, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4877
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4877

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 505 GCAGGCTCTCGCGGAGG 521
Db 1 GCAGGCTCTCGCGGAGG 17

RESULT 248
US-10-156-306-4878
; Sequence 4878, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4878
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4878

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 520 GGTGAGCAGCCTGAAGA 536
Db 1 GGTGAGCAGCCTGAAGA 17

RESULT 249
US-10-156-306-4879
; Sequence 4879, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4879
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4879

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 522 TGGAGCACCTGAGAGAGA 538
Db 1 UGGAGCACCUAGAGAGA 17
:|||||:|||||

RESULT 250
US-10-156-306-4880
; Sequence 4880, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4880
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4880

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 523 GGAGCACCTGAGAGAT 539
Db 1 GGAGCACCUAGAGAU 17
|||||:|||||

RESULT 251
US-10-156-306-4881
; Sequence 4881, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4881
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4881

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 534 AGAGATGCCAGCAGCAG 550
Db 1 AGAGAUGCCAGCAGCAG 17
|||||:|||||

RESULT 252
US-10-156-306-4882
; Sequence 4882, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4882
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4882

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 535 GAGATGCCAGCAGCAGA 551
Db 1 GAGAUGCCAGCAGCAGA 17
|||||:|||||

RESULT 253
US-10-156-306-4883
; Sequence 4883, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4883
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4883

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 538 ATGCCAGCAGCAGATGG 554
Db 1 AUGCCAGCAGCAGAU 17
:|||||:|||||

RESULT 254
US-10-156-306-4884
; Sequence 4884, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB01-664-A (400/050)


```
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4889
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4889

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 563 AAGCCCTCTGGAAGC 579
Db 1 AAGCCCUUGUGAAGC 17

RESULT 260
US-10-156-306-4890
; Sequence 4890, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4890
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4890

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 572 GTGAAGCCCGAGGTGAC 588
Db 1 GUGAAGCCCGAGGUGAC 17

RESULT 261
US-10-156-306-4891
; Sequence 4891, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4891
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4891

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 573 TGAAGCCCGAGGTGACG 589
Db 1 TGAAGCCCGAGGTGACG 589
```

```
Db 1 UGAAAGCCCGAGGUGACG 17

RESULT 262
US-10-156-306-4892
; Sequence 4892, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4892
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4892

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 574 GAAAGCCCGAGGTGACGT 590
Db 1 GAAAGCCCGAGGUGACGU 17

RESULT 263
US-10-156-306-4893
; Sequence 4893, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4893
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4893

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 584 GTGACGTCCTTGCTCGG 600
Db 1 GUGACGUCCUUGCTCGG 17

RESULT 264
US-10-156-306-4894
; Sequence 4894, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
```

; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4894
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4894

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 585 TCAGTCCTGTCGCGG 601
:||||:||||:||||
Db 1 UGAGGUCUUGCGCGG 17

RESULT 265
US-10-156-306-4895
; Sequence 4895, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4895
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4895

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 589 GTCCTGCTCGGGGAGC 605
:||||:||||:||||
Db 1 GUCCUUGCUGCGGAGC 17

RESULT 266
US-10-156-306-4896
; Sequence 4896, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4896
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4896

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 598 CGGGAGCTGCAGGAGA 614
:||||:||||:||||
Db 1 CGGGAGCUGCAGGAGA 17

RESULT 267
US-10-156-306-4897
; Sequence 4897, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4897
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4897

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 601 GGAGCTGCAGGAGGCC 617
:||||:||||:||||
Db 1 GGAGCUGCAGGAGGCC 17

RESULT 268
US-10-156-306-4898
; Sequence 4898, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4898
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4898

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 609 AGGAGGCCAGAGTCGC 625
:||||:||||:||||
Db 1 AGGAGGCCAGAGTCGC 17

RESULT 269
US-10-156-306-4899
; Sequence 4899, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4899
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4899

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 609 AGGAGGCCAGAGTCGC 625
:||||:||||:||||
Db 1 AGGAGGCCAGAGTCGC 17

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4899
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4899

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 610 GGAGAGCCAGAGCGCT 626
Db 1 GGAGAGCCAGAGUGCU 17

RESULT 270
US-10-156-306-4900
; Sequence 4900, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4900
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4900

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 618 AGAGTCGCTTGAGGCT 634
Db 1 AGAGTCGCTTGAGGCU 17

RESULT 271
US-10-156-306-4901
; Sequence 4901, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4901
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4901

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 626 TTGAGGCTGCCACTAA 642
Db 1 UUGAGGCGCCACUAA 17
```

```
RESULT 272
US-10-156-306-4902
; Sequence 4902, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4902
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4902

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 629 GAGGCTGCCACTAAGGA 645
Db 1 GAGGCTGCCACTAAGGA 17

RESULT 273
US-10-156-306-4903
; Sequence 4903, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4903
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4903

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 630 AGGTCGCCACTAAGGAA 646
Db 1 AGGTCGCCACTAAGGAA 17

RESULT 274
US-10-156-306-4904
; Sequence 4904, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
```


; SEQ ID NO 4904
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4904

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 632 GCTGCCACTAAGGAATG 648
||:|||||:|||||:
Db 1 GCGGCCACUAGGAUG 17

RESULT 275
US-10-156-306-4905
; Sequence 4905, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4905
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4905

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 642 AGGAATGCCAGGCTCTG 658
|||||:|||||:
Db 1 AGGAUCCAGGCUCUG 17

RESULT 276
US-10-156-306-4906
; Sequence 4906, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4906
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4906

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 643 GGAATGCCAGGCTCTGG 659
|||||:|||||:
Db 1 GGAUCCAGGCUCUG 17

RESULT 277
US-10-156-306-4907
; Sequence 4907, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4907
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4907

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 647 TGCCAGGCTCTGGAGGG 663
:|||||:|||||:
Db 1 UGCCAGGCUCUGAGGG 17

RESULT 278
US-10-156-306-4908
; Sequence 4908, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4908
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4908

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 649 CCAGGCTCTGGAGGTC 665
|||||:|||||:
Db 1 CCAGGCUCUGAGGGUC 17

RESULT 279
US-10-156-306-4909
; Sequence 4909, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4909

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4909

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 662 GGTGGGCGCCGGCGGC 678
Db 1 GGUCGGGCGCCGGCGGC 17

RESULT 280
US-10-156-306-4910
; Sequence 4910, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4910
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4910

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 663 GTCGGGCGCCGGCGGC 679
Db 1 GUCGCGGCGCCGGCGGC 17

RESULT 281
US-10-156-306-4911
; Sequence 4911, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4911
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4911

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 671 CGGCGGCGCCGAGCA 687
Db 1 CGGCGGCGCCGAGCA 17

RESULT 282
```

```
US-10-156-306-4912
; Sequence 4912, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4912
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4912

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 672 GGGCGCCGAGCGGCGC 688
Db 1 GGGCGCCGAGCGGCGC 17

RESULT 283
US-10-156-306-4913
; Sequence 4913, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4913
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4913

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 679 CAGCGAGCAGCGCGGC 695
Db 1 CAGCGAGCAGCGCGGC 17

RESULT 284
US-10-156-306-4914
; Sequence 4914, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4914
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4914

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 688 GCGCGCGCAGCTGGAGA 704
      |||||:|||||
Db 1 GCGCGCGCAGCUGGAGA 17

RESULT 285
US-10-156-306-4915
; Sequence 4915, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4915
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4915

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 691 GCGCGCAGCTGGAGAGTG 707
      |||||:|||||
Db 1 GCGCGCAGCUGGAGAGUG 17

RESULT 286
US-10-156-306-4916
; Sequence 4916, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4916
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4916

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 712 CGAGCGCTGCAGCAGC 728
      |||||:|||||
Db 1 CGAGCGCUGCAGCAGC 17

RESULT 287
US-10-156-306-4917
```

```
; Sequence 4917, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4917
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4917

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 715 GCGCGCTGCAGCAGCAGC 731
      |||||:|||||
Db 1 GCGCGCUGCAGCAGCAGC 17

RESULT 288
US-10-156-306-4918
; Sequence 4918, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4918
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4918

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 718 GCTGCAGCAGCAGCAGCA 734
      |||||:|||||
Db 1 GCUGCAGCAGCAGCAGCA 17

RESULT 289
US-10-156-306-4919
; Sequence 4919, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4919
; LENGTH: 17
; TYPE: RNA
```

```

; ORGANISM: Homo sapiens
US-10-156-306-4919

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 721 GCAGCAGCAGCAGCG 737
Db 1 GCAGCAGCAGCAGCG 17

RESULT 290
US-10-156-306-4920
; Sequence 4920, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4920
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4920

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 724 GCAGCAGCAGCAGCGTGC 740
Db 1 GCAGCAGCAGCAGCGUGC 17

RESULT 291
US-10-156-306-4921
; Sequence 4921, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4921
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4921

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 726 AGCAGCAGCAGCGTGCAG 742
Db 1 AGCAGCAGCAGCGUGCAG 17

RESULT 292
US-10-156-306-4922
; Sequence 4922, Application US/10156306

```

```

; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4922
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4922

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 733 CAGCGTGACGAGTGGACC 749
Db 1 CAGCGUGCAGGUGGACC 17

RESULT 293
US-10-156-306-4923
; Sequence 4923, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4923
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4923

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 741 AGGTGGACACGAGTGGCG 757
Db 1 AGGUGGACACGAGCUGCG 17

RESULT 294
US-10-156-306-4924
; Sequence 4924, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4924
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4924

```

US-10-156-306-4924

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 742 GGTGGACCACTGCCGA 758
||:|||||:|||||
Db 1 GGUGGACCACTGCCGA 17

RESULT 295

US-10-156-306-4925
; Sequence 4925, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4925

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4925

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 745 GGACCACTGCCATGC 761
||:|||||:|||||
Db 1 GGACCACTGCCATGC 17

RESULT 296

US-10-156-306-4926
; Sequence 4926, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4926

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4926

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 750 AGCTGCCATGCCGCGC 766
||:|||||:|||||
Db 1 AGCTGCCATGCCGCGC 17

RESULT 297

US-10-156-306-4927
; Sequence 4927, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4927

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4927

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 754 GGCATGCCAGGCCAGA 770
||:|||||:|||||
Db 1 GGCATGCCAGGCCAGA 17

RESULT 298

US-10-156-306-4928
; Sequence 4928, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4928

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4928

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 759 TGCAGGCCAGCGGTG 775
||:|||||:|||||
Db 1 TGCAGGCCAGCGGTG 17

RESULT 299

US-10-156-306-4929
; Sequence 4929, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4929

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4929

```

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 760 GCAGGGCCAGAGCGTGG 776
    |||||:|||||:|||||
Db 1 GCAGGGCCAGAGCGUGG 17

RESULT 300
US-10-156-306-4930
; Sequence 4930, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4930
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4930

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 773 GTGGAGCGCGCGCTCCG 789
    |:|||||:|||||:|||||
Db 1 GUGGAGCGCGCGCUCCG 17

RESULT 301
US-10-156-306-4931
; Sequence 4931, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4931
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4931

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 778 GCGCGCGTCCGATGG 794
    |||||:|||||:|||||
Db 1 GCGCGCGTCCGCAUGG 17

RESULT 302
US-10-156-306-4932
; Sequence 4932, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4932
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4932

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 780 CCGCGCTCCGATGGAG 796
    |||||:|||||:|||||
Db 1 CCGCGCTCCGCAUGGAG 17

RESULT 303
US-10-156-306-4933
; Sequence 4933, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4933
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4933

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 783 CGCTCCGATGGAGCGC 799
    |||||:|||||:|||||
Db 1 CGCTCCGATGGAGCGC 17

RESULT 304
US-10-156-306-4934
; Sequence 4934, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4934
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4934

```

```

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 792 TGGAGCGCCAGCGCCGC 808
Db 1 UGGAGCGCCAGCGCCGC 17

RESULT 305
US-10-156-306-4935
; Sequence 4935, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4935
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4935

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 793 GGAGCGCCAGCGCCGC 809
Db 1 GGAGCGCCAGCGCCGC 17

RESULT 306
US-10-156-306-4936
; Sequence 4936, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4936
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4936

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 797 CGCAGCGCCGCTCGGA 813
Db 1 CGCAGCGCCGCTCGGA 17

RESULT 307
US-10-156-306-4937
; Sequence 4937, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```

```

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4937
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4937

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 800 CAGCGCGCTCGGAGGA 816
Db 1 CAGCGCGCTCGGAGGA 17

RESULT 308
US-10-156-306-4938
; Sequence 4938, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4938
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4938

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 801 AGCGCGCTCGGAGGAG 817
Db 1 AGCGCGCTCGGAGGAG 17

RESULT 309
US-10-156-306-4939
; Sequence 4939, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4939
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4939

Query Match          2.3%; Score 17; DB 1; Length 17;

```

```

Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 820 GAGGAAGCTGCCAGT 836
    |||||:|||||:
Db 1 GAGGAAGCUGGCCAGU 17

RESULT 310
US-10-156-306-4940
; Sequence 4940, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4940
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4940

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 824 AAGCTGCCAGTTCGA 840
    |||||:|||||:
Db 1 AAGCUGGCCAGUUGCA 17

RESULT 311
US-10-156-306-4941
; Sequence 4941, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4941
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4941

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 825 AGCTGCCAGTTCAG 841
    |||||:|||||:
Db 1 AGCUGGCCAGUUGCAG 17

RESULT 312
US-10-156-306-4942
; Sequence 4942, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James

```

```

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4942
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4942

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 826 GCTGGCCAGTTCAGG 842
    |||||:|||||:
Db 1 GCTGGCCAGUUGCAGG 17

RESULT 313
US-10-156-306-4943
; Sequence 4943, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4943
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4943

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 832 CCAGTTCAGTGCCT 848
    |||||:|||||:
Db 1 CCAGUUGCAGUUGCCU 17

RESULT 314
US-10-156-306-4944
; Sequence 4944, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4944
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4944

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;

```



```
QY      850 TCACCAGCTTCCAG 866
      :|||||:|:|
Db      1 UCACCAGCUCUCCAAG 17

RESULT 320
US-10-156-306-4950
; Sequence 4950, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4950
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4950

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      852 ACCAGCTCTTCCAGAA 868
      :|||||:|:|
Db      1 ACCAGCUCUCCAAGAA 17

RESULT 321
US-10-156-306-4951
; Sequence 4951, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4951
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4951

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      855 AGCTTCTCCAGATAC 871
      :|||||:|:|
Db      1 AGCUCUCCAAGAUAC 17

RESULT 322
US-10-156-306-4952
; Sequence 4952, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
```

```
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4952
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4952

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      856 GCTCTCCAGATACG 872
      :|:|:|:|:|:|:|
Db      1 GCUCUCCAAGAUACG 17

RESULT 323
US-10-156-306-4953
; Sequence 4953, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4953
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4953

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      867 AATACGACACCAATC 883
      :|:|:|:|:|:|:|
Db      1 AAUACGACACCAAC 17

RESULT 324
US-10-156-306-4954
; Sequence 4954, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4954
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4954

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

QY 870 ACACAACCATCAAG 886
|||||||:|:|:|
Db 1 ACACAACCATCAAG 17

RESULT 325

US-10-156-306-4955
; Sequence 4955, Application US/10156306
; Publication No. US20030119017A1

GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4955

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4955

Query Match

Best Local Similarity 2.3%; Score 17; DB 1; Length 17;

Mismatches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 871 CGACAACCATCAAGA 887

Db 1 CGACAACCATCAAGA 17

RESULT 326

US-10-156-306-4956
; Sequence 4956, Application US/10156306
; Publication No. US20030119017A1

GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4956

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4956

Query Match

Best Local Similarity 2.3%; Score 17; DB 1; Length 17;

Mismatches 1; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 873 ACAACCATCAAGAC 889

Db 1 ACAACCATCAAGAC 17

RESULT 327

US-10-156-306-4957
; Sequence 4957, Application US/10156306
; Publication No. US20030119017A1

GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4957
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4957

Query Match

Best Local Similarity 2.3%; Score 17; DB 1; Length 17;

Mismatches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 876 ACCACATCAAGACGAC 892

Db 1 ACCACATCAAGACGAC 17

RESULT 328

US-10-156-306-4958

; Sequence 4958, Application US/10156306

; Publication No. US20030119017A1

GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4958

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4958

Query Match

Best Local Similarity 2.3%; Score 17; DB 1; Length 17;

Mismatches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 882 TCAAGACGACGCTGGTG 898

Db 1 UCAAGACGACGCTGGTG 17

RESULT 329

US-10-156-306-4959

; Sequence 4959, Application US/10156306

; Publication No. US20030119017A1

GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4959

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-4959

Query Match

Best Local Similarity 2.3%; Score 17; DB 1; Length 17;

Mismatches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 894 TGGTGGCAGTCAGCGG 910

```

Db      1 UGUGGCGCAGUGAGCG 17
      :||:|||||:|||||
RESULT 330
US-10-156-306-5772
; Sequence 5772, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5772
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5772

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      163 CTGAGAGGCGCACTGT 179
      :|||||:|||||:
Db      1 CUGGAGAGCGCAACUG 17

RESULT 331
US-10-156-306-5773
; Sequence 5773, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5773
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5773

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      170 AGCCAACTGTGTGAGAT 186
      :|||||:|||||:
Db      1 AGCCAACTGTGTGAGAU 17

RESULT 332
US-10-156-306-5774
; Sequence 5774, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306

```

```

; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5774
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5774

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      172 CCAACTGTGTGAGATGG 188
      :|||||:|||||:
Db      1 CCAACUGUGAGAGUGG 17

RESULT 333
US-10-156-306-5775
; Sequence 5775, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5775
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5775

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      180 GTCAGATGTGTGAGCCC 196
      :|||||:|||||:
Db      1 GUGAGAGUGGUGAGAGCCC 17

RESULT 334
US-10-156-306-5776
; Sequence 5776, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5776
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5776

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      182 GAGATGTGTGAGAGCCCAG 198
      :|||||:|||||:

```

```

; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5779
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5779

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 193 GCCCAGTGTGGCCCGG 209
      |||||:|||||
Db 1 GCCCAGUGGCGCCCGG 17

RESULT 338
US-10-156-306-5780
; Sequence 5780, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwiggan, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5780
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5780

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 196 CAGTGTGGCCCGCAG 212
      ||||:|||||
Db 1 CAGUGGUGGCCCGCAG 17

RESULT 339
US-10-156-306-5781
; Sequence 5781, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwiggan, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5781
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5781

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 201 GTGCCCGCGCAGCAT 217
      .:|||||
Db 1 GUGGCCCGCGCAGCAU 17

```

```
RESULT 340
US-10-156-306-5782
; Sequence 5782, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5782
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5782

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 204 GCCCGGCGAGCATGAC 220
      |||||
Db 1 GCCCGGCGAGCAUCAG 17

RESULT 341
US-10-156-306-5783
; Sequence 5783, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5783
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5783

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 216 ATCAGGACGTAAGGCG 232
      |||||
Db 1 AUCAGGAGUACUGGCG 17

RESULT 342
US-10-156-306-5784
; Sequence 5784, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5784
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5784

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 223 CGTACTGGCGGAGAGT 239
      |||||
Db 1 CGUACUGGCGGAGAGU 17

RESULT 343
US-10-156-306-5785
; Sequence 5785, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5785
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5785

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 230 GGCGAAGAGTCTCTCT 246
      |||||
Db 1 GGCGAAGAGUCCUCCU 17

RESULT 344
US-10-156-306-5786
; Sequence 5786, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5786
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5786

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 245 CTGGGGAAGCCAGCCAT 261
      |||||
Db 1 CUGGGGAGCCAGCCAU 17
```

```
RESULT 345
US-10-156-306-5787
; Sequence 5787, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5787
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5787

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 249 GGAAGCCAGCCATGCTG 265
      |||||:|||||:|:|
Db 1 GGAAGCCAGCCAGCUG 17

RESULT 346
US-10-156-306-5788
; Sequence 5788, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5788
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5788

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 254 CCAGCCATGCTGCACCT 270
      |||||:|||||:|
Db 1 CCAGCCAGCUGCAGCCU 17

RESULT 347
US-10-156-306-5789
; Sequence 5789, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 5789
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5789

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 257 GCCATGCTGCACCTGCC 273
      |||||:|||||:|
Db 1 GCCAUGCUGCACCUGCC 17

RESULT 348
US-10-156-306-5790
; Sequence 5790, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5790
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5790

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 263 CTGCACCTGCCTTCAGA 279
      |||||:|||||:|
Db 1 CUGCACCUGCCUUCAGA 17

RESULT 349
US-10-156-306-5791
; Sequence 5791, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5791
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5791

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 277 AGAACAGGCGCTCCTG 293
      |||||:|||||:|
Db 1 AGAACAGGCGCCUCCUG 17
```

```
RESULT 350
US-10-156-306-5792
; Sequence 5792, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5792
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5792

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      279 AACAGGGCGCTCTCGAG 295
      |||||:|||||:|||||
Db      1 AACAGGGCGCUCUGAG 17

RESULT 351
US-10-156-306-5793
; Sequence 5793, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5793
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5793

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      279 AACAGGGCGCTCTCGAG 295
      |||||:|||||:|||||
Db      1 AACAGGGCGCUCUGAG 17

RESULT 352
US-10-156-306-5794
; Sequence 5794, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5794
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5794

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      298 CCTCCAGCGCTCGCTGG 314
      ||:|||||:|||||:|||||
Db      1 CCUCCAGCGCGCUGCCUGG 17

RESULT 353
US-10-156-306-5795
; Sequence 5795, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5795
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5795

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      301 CCAGCGCTCGCTGGAGG 317
      |||||:|||||:|||||
Db      1 CCAGCGCGCUGCCUGGAGG 17

RESULT 354
US-10-156-306-5796
; Sequence 5796, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5796
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5796

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      320 AATCAAGAGCTCCGAGA 336
      ||:|||||:|||||:|||||
Db      1 AAUCAAGAGCUCGCGAGA 17

RESULT 355
```


US-10-156-306-5797
; Sequence 5797, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5797
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5797

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 330 TCCGAGATGCCATCCGG 346
:|||||:|||||
Db 1 UCCGAGAUCCGCAUCCGG 17

RESULT 356
US-10-156-306-5798
; Sequence 5798, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5798
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5798

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 338 GCCATCCGCGCAGACCA 354
:|||||:|||||
Db 1 GCCAUCCGCGCAGACCA 17

RESULT 357
US-10-156-306-5799
; Sequence 5799, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5799
; LENGTH: 17

; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5799

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 343 CCGCGCAGACCAACCAGA 359
:|||||:|||||
Db 1 CCGCGCAGACCAACCAGA 17

RESULT 358
US-10-156-306-5800
; Sequence 5800, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5800
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5800

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 356 CAGATTCTCGGGAGCG 372
:|||||:|||||
Db 1 CAGAUUCUGCGGAGCG 17

RESULT 359
US-10-156-306-5801
; Sequence 5801, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5801
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5801

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 362 CTGCGGGAGCGTGCGA 378
:|||||:|||||
Db 1 CTGCGGGAGCGTGCGA 17

RESULT 360
US-10-156-306-5802

; Sequence 5802, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5802
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5802

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 364 GCGGAGCGCTGCGAGG 380
Db 1 GCGGAGCGCUGCAGG 17
|||||:|||||:|||||

RESULT 361
US-10-156-306-5803
; Sequence 5803, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5803
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5803

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 367 GGAGCGCTGCGAGGAGC 383
Db 1 GGAGCGCUGCAGGAGC 17
|||||:|||||:|||||

RESULT 362
US-10-156-306-5804
; Sequence 5804, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5804
; LENGTH: 17
; TYPE: RNA

; ORGANISM: Homo sapiens
US-10-156-306-5804

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 374 TGCAGGAGCTTCTGCA 390
Db 1 UGCGAGGAGCUCUGCA 17
:|||||:|||||:|||||

RESULT 363
US-10-156-306-5805
; Sequence 5805, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5805
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5805

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 380 GAGCTTCTGCATTTCGA 396
Db 1 GAGCUCUGCAUUCUCA 17
|||||:|||||:|||||

RESULT 364
US-10-156-306-5806
; Sequence 5806, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5806
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5806

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 390 ATTCCAGCCAGCCAG 406
Db 1 AUUCCAAGCCAGCCAG 17
|:|||||:|||||

RESULT 365
US-10-156-306-5807
; Sequence 5807, Application US/10156306

```
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5807
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5807

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      394 CCAAGCCAGCCAGG 410
Db      1 CCAAGCCAGCCAGG 17

RESULT 366
US-10-156-306-5808
; Sequence 5808, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5808
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5808

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      413 GAGAAGGAGTCTCAT 429
Db      1 GAGAAGGAGUCCAU 17

RESULT 367
US-10-156-306-5809
; Sequence 5809, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5809
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

```
US-10-156-306-5809

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.6e+02;
Matches 10; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      422 TTCCTCATGTGCAAGTT 438
Db      1 UUCUCAUGUGCAAGUU 17

RESULT 368
US-10-156-306-5810
; Sequence 5810, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5810
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5810

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      424 CCTCATGTGCAAGTTCC 440
Db      1 CCUCAUGUGCAAGUCC 17

RESULT 369
US-10-156-306-5811
; Sequence 5811, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5811
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5811

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      428 ATGTGCAAGTTCAGGA 444
Db      1 AUGUCAAGUCCAGGA 17

RESULT 370
US-10-156-306-5812
; Sequence 5812, Application US/10156306
; Publication No. US20030119017A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5812
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5812

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      438  TCCAGGAGGCCAGGAAA 454
Db      1      UCCAGGAGGCCAGGAAA 17
          :|||||:|||||:
          :|||||:|||||:

RESULT 371
US-10-156-306-5813
; Sequence 5813, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5813
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5813

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      450  GGAACTGGTGGAGAGA 466
Db      1      GGAAACUGGUGAGAGA 17
          :|||||:|||||:
          :|||||:|||||:

RESULT 372
US-10-156-306-5814
; Sequence 5814, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5814
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5814
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      463  GAGACTCGCGCTGGAGA 479
Db      1      GAGACUGCGCCUGGAGA 17
          :|||||:|||||:
          :|||||:|||||:

RESULT 373
US-10-156-306-5815
; Sequence 5815, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5815
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5815

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      473  CTGGAGAAGCTCGATCT 489
Db      1      CUGGAGAAGCUCGAGUCU 17
          |:|||||:|||||:
          |:|||||:|||||:

RESULT 374
US-10-156-306-5816
; Sequence 5816, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5816
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5816

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      488  CTGAAGAGGCGAGAAGGA 504
Db      1      CUGAAGAGGCGAGAAGGA 17
          |:|||||:|||||:
          |:|||||:|||||:

RESULT 375
US-10-156-306-5817
; Sequence 5817, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5817
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5817

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 497 CAGAAGCAGCAGGCTCT 513
Db 1 CAGAAGCAGCAGGCGUCU 17

RESULT 376
US-10-156-306-5818
; Sequence 5818, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5818
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5818

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 501 AGGAGCAGGCTCTGCGG 517
Db 1 AGGAGCAGGCGUCUGCGG 17

RESULT 377
US-10-156-306-5819
; Sequence 5819, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5819
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5819
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 506 CAGGCTCTCGGCGAGGT 522
Db 1 CAGGCTCTCGGCGAGGU 17

RESULT 378
US-10-156-306-5820
; Sequence 5820, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5820
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5820

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 513 TCGCGGAGGTGGAGCAC 529
Db 1 UCGCGGAGGUGGAGCAC 17

RESULT 379
US-10-156-306-5821
; Sequence 5821, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5821
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5821

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 518 GAGGTGGAGCAGCTGAA 534
Db 1 GAGGTGGAGCAGCUGAA 17

RESULT 380
US-10-156-306-5822
; Sequence 5822, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5822
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5822

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 532 GAAGAGATGCCAGCAGC 548
Db 1 GAAGAGAUGCAGCAGC 17

RESULT 381
US-10-156-306-5823
; Sequence 5823, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5823
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5823

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 536 AGATGCCAGCAGCAGAT 552
Db 1 AGAUGCCAGCAGCAGAU 17

RESULT 382
US-10-156-306-5824
; Sequence 5824, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5824
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5824

Query Match      2.3%; Score 17; DB 1; Length 17;
```

```
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 539 TGCCAGCAGCAGATGGC 555
Db 1 UGCCAGCAGCAGGAUGC 17

RESULT 383
US-10-156-306-5825
; Sequence 5825, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5825
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5825

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 546 AGCAGATGGCTGAGGAC 562
Db 1 AGCAGAUGCUCGAGGAC 17

RESULT 384
US-10-156-306-5826
; Sequence 5826, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5826
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5826

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 558 AGGACAAGGCCTCTGTG 574
Db 1 AGGACAAGGCUCUGUG 17

RESULT 385
US-10-156-306-5827
; Sequence 5827, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
```

```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5827
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5827

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 564 AGCCCTCTGTGAAGCC 580
      |||||:|:|:|:|:|
Db 1 AGCCUCUGUGAAAGCC 17

RESULT 386
US-10-156-306-5828
; Sequence 5828, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5828
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5828

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 570 CTGTGAAGCCCGAGTG 586
      |:|:|:|:|:|:|:|
Db 1 CUGUGAAAGCCCGAGGUG 17

RESULT 387
US-10-156-306-5829
; Sequence 5829, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5829
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5829

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
```

```
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 576 AAGCCAGGTGACGTCC 592
      |||||:|:|:|:|:|
Db 1 AAGCCAGGUGAGCGUCC 17

RESULT 388
US-10-156-306-5830
; Sequence 5830, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5830
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5830

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 581 CAGGTGACGTCTTGCT 597
      |||||:|:|:|:|:|
Db 1 CAGGUGAGCGUCCUGCU 17

RESULT 389
US-10-156-306-5831
; Sequence 5831, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5831

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 587 ACGTCTCTGCTCGGGA 603
      |||||:|:|:|:|:|
Db 1 AGGUCCUUGCUCGGGA 17

RESULT 390
US-10-156-306-5832
; Sequence 5832, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
```

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5832
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5832

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 596 CTCGGGAGCTGCAGGA 612
|:|||||:|||||:
Db 1 CUCGGGAGCGCAGGA 17

RESULT 391
US-10-156-306-5833
; Sequence 5833, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5833
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5833

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 599 GGGGAGCTGCAGGAGAG 615
|:|||||:|||||:
Db 1 GGGGAGCGCAGGAGAG 17

RESULT 392
US-10-156-306-5834
; Sequence 5834, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5834
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5834

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 607 GCAGGAGCCAGATC 623
|:|||||:|||||:
Db 1 GCAGGAGAGCCAGAGUC 17

RESULT 393
US-10-156-306-5835
; Sequence 5835, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5835
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5835

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 613 GAGCCAGATCGCTTGG 629
|:|||||:|||||:
Db 1 GAGCCAGAGCGCUGG 17

RESULT 394
US-10-156-306-5836
; Sequence 5836, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5836
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5836

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 616 CCAGATCGCTTGGAGG 632
|:|||||:|||||:
Db 1 CCAGAGCGCUGGAGG 17

RESULT 395
US-10-156-306-5837
; Sequence 5837, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5837
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5837

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0;

QY 624 GCTTGAGGCTGCACT 640
DB 1 GCUUGGAGGCGCCACU 17

RESULT 396
US-10-156-306-5838
; Sequence 5838, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5838
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5838

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0;

QY 627 TGGAGGCTGCCTAAG 643
DB 1 UGAGGCGCGCCUAAG 17

RESULT 397
US-10-156-306-5839
; Sequence 5839, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5839
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5839

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0;

QY 640 TAAGGAATGCCAGGCTC 656
DB 1 UAAAGGAUCCAGGCUC 17

RESULT 398
US-10-156-306-5840
; Sequence 5840, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5840
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5840

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 645 AATGCCAGGCTCGAG 661
DB 1 AAUGCCAGGCGUCUGAG 17

RESULT 399
US-10-156-306-5841
; Sequence 5841, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5841
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5841

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 655 TCTGAGGCTCGGCC 671
DB 1 UCUGGAGGCGCGGCC 17

RESULT 400
US-10-156-306-5842
; Sequence 5842, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5842
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5842

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 660 AGGTGCGGCGCGCGCG 676
|||||

Db 1 AGGUGCGGCGCGCGCG 17

RESULT 401

US-10-156-306-5843
; Sequence 5843, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5843
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5843

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 666 GGGCCCGCGCGCGCAGC 682
|||||

Db 1 GGGCCCGCGCGCGCAGC 17

RESULT 402

US-10-156-306-5844
; Sequence 5844, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5844
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5844

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 CCCGGCGCGCGCAGCAG 685

Db 1 CCCGGCGCGCGCAGCAG 17
|||||

RESULT 403

US-10-156-306-5845
; Sequence 5845, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5845

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 673 GCGCGCCAGCGAGCAGG 689
|||||

Db 1 GCGCGCCAGCGAGCAGG 17

RESULT 404

US-10-156-306-5846
; Sequence 5846, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5846

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 677 GCGCGCGAGCGCGCG 693
|||||

Db 1 GCGCGCGAGCGCGCG 17

RESULT 405

US-10-156-306-5847
; Sequence 5847, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5847
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5847

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 681 GCGAGCAGCGCGGCAG 697
|||:|||||:|||||
Db 1 GCGAGCAGCGCGGCAG 17

RESULT 406

US-10-156-306-5848
; Sequence 5848, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5848
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5848

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 683 GAGCAGCGCGGCAGCT 699
|||:|||||:|||||
Db 1 GAGCAGCGCGGCAGCT 17

RESULT 407

US-10-156-306-5849
; Sequence 5849, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5849
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5849

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 686 CAGGCGCGCGAGCTGGA 702
|||:|||||:|||||

Db 1 CAGGCGCGCGAGCTUGGA 17

RESULT 408

US-10-156-306-5850
; Sequence 5850, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5850
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5850

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 689 GCGCGCGCAGCTGGAGAG 705
|||:|||||:|||||
Db 1 GCGCGCGCAGCTGGAGAG 17

RESULT 409

US-10-156-306-5851
; Sequence 5851, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5851
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5851

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCGCG 713
|||:|||||:|||||
Db 1 GCUGGAGAGUGAGCGCG 17

RESULT 410

US-10-156-306-5852
; Sequence 5852, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5852
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5852

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 701 GAGAGTGGCGGCGGC 717
||||:|||||||
Db 1 GAGAGGAGCGCGAGGC 17

RESULT 411

US-10-156-306-5853
; Sequence 5853, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5853
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5853

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 703 GAGTGGCGGCGGCGC 719
||||:|||||||
Db 1 GAGUGAGCGGAGGCGC 17

RESULT 412

US-10-156-306-5854
; Sequence 5854, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5854
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5854

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 708 AGCGGAGCGGCGGCGAG 724
||||:|||||||
Db 1 AGCGGAGCGGCGGCGAG 17

RESULT 413

US-10-156-306-5855
; Sequence 5855, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5855
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5855

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 710 CGCGAGCGCGTCGACGA 726
||||:|||||||
Db 1 CGCGAGCGCGTCGACGA 17

RESULT 414

US-10-156-306-5856
; Sequence 5856, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5856
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5856

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 713 GAGGCGCTCGACGACGA 729
||||:|||||||
Db 1 GAGGCGCTCGACGACGA 17

RESULT 415

US-10-156-306-5857
; Sequence 5857, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5857
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5857

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 716 GCGCTGCAGCAGCA 732
|||||:|||||:
Db 1 GCGCUGCAGCAGCA 17

RESULT 416
US-10-156-306-5858
; Sequence 5858, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5858
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5858

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 719 CTGCAGCAGCAGCAG 735
|:|||||:|||||:
Db 1 CUGCAGCAGCAGCAG 17

RESULT 417
US-10-156-306-5859
; Sequence 5859, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5859
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5859

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 722 CAGCAGCAGCAGCCT 738
|||||:|||||:
Db 1 CAGCAGCAGCAGCGU 17

RESULT 418

US-10-156-306-5860
; Sequence 5860, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5860
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5860

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 727 GCAGCAGCGGTGCAGG 743
|||||:|||||:
Db 1 GCAGCAGCAGCGUGCAGG 17

RESULT 419
US-10-156-306-5861
; Sequence 5861, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5861
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5861

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 729 AGCAGCAGCGTCAGGTG 745
|||||:|||||:
Db 1 AGCAGCAGCGUGCAGGUG 17

RESULT 420
US-10-156-306-5862
; Sequence 5862, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0

```
; SEQ ID NO 5862
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5862

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 731 CACAGCGTGCAGTGGA 747
|||||:|||||:||||
Db 1 CACAGCGUGCAGGUGGA 17

RESULT 421
US-10-156-306-5863
; Sequence 5863, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5863
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5863

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 735 GCGTGCAGGTGGACCAG 751
|||||:|||||:|||||
Db 1 GCGUGCAGGUGGACCAG 17

RESULT 422
US-10-156-306-5864
; Sequence 5864, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5864
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5864

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 743 GTGACCAAGTGGCGCAT 759
|:|||||:|||||:
Db 1 GUGGACCAGCUGGCGCAU 17
```

```
RESULT 423
US-10-156-306-5865
; Sequence 5865, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5865
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5865

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 746 GACCAGCTGCGCATGCA 762
|||||:|||||:||||
Db 1 GACCAGCUGCGCAUGCA 17

RESULT 424
US-10-156-306-5866
; Sequence 5866, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5866
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5866

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 748 CCAGCTGCCGATGCAGG 764
|||||:|||||:||||
Db 1 CCAGCUGCGCAUGCAGG 17

RESULT 425
US-10-156-306-5867
; Sequence 5867, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5867
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5867

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 752 CTGCGCATGCGAGGCCA 768
   |||||:|||||
Db 1 CUGCGCAUGCAGGCGCCA 17

RESULT 426
US-10-156-306-5868
; Sequence 5868, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5868
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5868

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 757 CATGCGAGGCCAGAGCG 773
   ||:|||||:|||||
Db 1 CAUGCAGGCGCCAGAGCG 17

RESULT 427
US-10-156-306-5869
; Sequence 5869, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5869
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5869

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 763 GCGCCAGAGCGTGGAGG 779
   |||||:|||||
Db 1 GCGCCAGAGCGGAGG 17

RESULT 428
```

```
US-10-156-306-5870
; Sequence 5870, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5870
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5870

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 765 GCCAGAGCGTGGAGGCC 781
   |||||:|||||
Db 1 GCCAGAGCGGAGGCC 17

RESULT 429
US-10-156-306-5871
; Sequence 5871, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5871
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5871

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 771 GCGTGGAGCGCGGCTC 787
   |||:|||||:|
Db 1 GCGUGGAGGCGCGGCUC 17

RESULT 430
US-10-156-306-5872
; Sequence 5872, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5872
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5872

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 774 TGGAGCGCGCTCCGC 790
Db 1 UGGAGCGCGCUCCGC 17

RESULT 431
US-10-156-306-5873
; Sequence 5873, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5873
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5873

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 776 GAGCGCGCGCTCCGCAT 792
Db 1 GAGCGCGCGCUCCGAU 17

RESULT 432
US-10-156-306-5874
; Sequence 5874, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5874
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5874

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 781 CGCGCTCCGCATGGAGC 797
Db 1 CGCGCUCCGCAUGGAGC 17

RESULT 433
US-10-156-306-5875
```

```
; Sequence 5875, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5875
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5875

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 788 CGCATGGAGCGCCAGCG 804
Db 1 CGCAUGGAGCGCCAGCG 17

RESULT 434
US-10-156-306-5876
; Sequence 5876, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5876
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5876

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 790 CATGGAGCGCCAGCGCG 806
Db 1 CAUGGAGCGCCAGCGCG 17

RESULT 435
US-10-156-306-5877
; Sequence 5877, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5877
; LENGTH: 17
; TYPE: RNA
```



```
; ORGANISM: Homo sapiens
US-10-156-306-5877

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 795 AGCGCAGCGCCCTCG 811
      |||||
Db 1 AGCGCAGCGCCCGUG 17

RESULT 436
US-10-156-306-5878
; Sequence 5878, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5878
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5878

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 798 GCCAGCGCCCTCGGAG 814
      |||||
Db 1 GCCAGCGCCCGUGGAG 17

RESULT 437
US-10-156-306-5879
; Sequence 5879, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5879
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5879

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 818 AAGAGGAAGTCGCCCA 834
      |||||
Db 1 AAGAGGAAGTCGCCCA 17

RESULT 438
US-10-156-306-5880
; Sequence 5880, Application US/10156306
```

```
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5880
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5880

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 822 GGAAGCTGCCCGAGTTG 838
      |||||
Db 1 GGAAGCTGCCCGAGUUG 17

RESULT 439
US-10-156-306-5881
; Sequence 5881, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5881
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5881

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 827 CTGGCCCGAGTTGCAGGT 843
      |||||
Db 1 CUGGCCCGAGUUGCAGGU 17

RESULT 440
US-10-156-306-5882
; Sequence 5882, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5882
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-10-156-306-5882

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 830 GCCAGTTCGAGTGGC 846
|||||:|||||:|||||
Db 1 GCCCAGUUGCAGGUGGC 17

RESULT 441

US-10-156-306-5883
; Sequence 5883, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5883
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5883

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 834 AGTTCGAGTGGCCTAT 850
|||||:|||||:|||||
Db 1 AGUUGCAGGUGGCUAU 17

RESULT 442

US-10-156-306-5884
; Sequence 5884, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5884
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5884

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 837 TGCAGGTGGCCTATCAC 853
|||||:|||||:|||||
Db 1 UGCAGGUGGCUAUAC 17

RESULT 443

US-10-156-306-5885
; Sequence 5885, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5885
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5885

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 848 TATCACCAGCTCTTCCA 864
|||||:|||||:|||||
Db 1 UAUCACCAGCUCUCCA 17

RESULT 444

US-10-156-306-5886
; Sequence 5886, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5886
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5886

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 880 CATCAAGAGCAGCGTGG 896
|||||:|||||:|||||
Db 1 CAUCAAGAGCAGCGUGG 17

RESULT 445

US-10-156-306-5887
; Sequence 5887, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5887
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5887

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 883 CAAGACGCGGTGG 899
|||||:|||||:|||||
Db 1 CAAGACGCGGUGG 17

RESULT 446
US-10-156-306-5888
; Sequence 5888, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5888
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5888

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 885 AGAGCAGCGGTGGCG 901
|||||:|||||:|||||
Db 1 AGAGCAGCGGUGGCG 17

RESULT 447
US-10-156-306-5889
; Sequence 5889, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5889
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5889

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 888 GCAGCGGTGGCGAGT 904
|||||:|||||:|||||
Db 1 GCAGCGGUGGUGGCGAGU 17

RESULT 448
US-10-156-306-5890
; Sequence 5890, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5890
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5890

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 892 CGTGTGGCGAGTGAGC 908
|||||:|||||:|||||
Db 1 CGUGGUGGCGAGUGAGC 17

RESULT 449
US-10-156-306-5891
; Sequence 5891, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5891
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5891

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 895 GGTGGCGAGTGAGCGGA 911
|||||:|||||:|||||
Db 1 GGUGGCGAGUGAGCGGA 17

RESULT 450
US-10-156-306-5892
; Sequence 5892, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5892
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5892
```

```

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 899 GGCAGTGAGCGGAAGCG 915
      |||||:|||||:|||||
Db 1 GGCAGUGAGCGGAAGCG 17

RESULT 451
US-10-156-306-6318
; Sequence 6318, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6318
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6318

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 167 AAGAGCCAACTGTGTGA 183
      |||||:|||||:|||||
Db 1 AAGAGCCAACTGTGTGA 17

RESULT 452
US-10-156-306-6319
; Sequence 6319, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6319
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6319

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 177 TGTGTGAGATGGTGCAG 193
      :||:|||||:|||||
Db 1 UGUGUGAGUGGUGCAG 17

RESULT 453
US-10-156-306-6320
; Sequence 6320, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```

```

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6320
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6320

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 208 GGCAGCAGATCAGGAGC 224
      |||||:|||||:|||||
Db 1 GGCAGCAGATCAGGAGC 17

RESULT 454
US-10-156-306-6321
; Sequence 6321, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6321
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6321

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 214 AGATCAGGAGCTACTGG 230
      |||||:|||||:|||||
Db 1 AGAUCAGGAGGAGUACUGG 17

RESULT 455
US-10-156-306-6322
; Sequence 6322, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6322
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6322

Query Match          2.3%; Score 17; DB 1; Length 17;

```

```
Best Local Similarity 88.2%; Pred. No. 2.6e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 2;

QY 272 CCTCAGAACAGGGCCG 288
||:|||||
Db 1 CCUCAGAACAGGGCCG 17

RESULT 456
US-10-156-306-6323
; Sequence 6323, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6323
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6323

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 14; Conservative 3;

QY 288 CTCCTGAGACCTCCAG 304
||:|||||
Db 1 CUCCUGAGACCUCCAG 17

RESULT 457
US-10-156-306-6324
; Sequence 6324, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6324
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6324

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 16; Conservative 1;

QY 313 GGAGGAGAAATCAAGAGC 329
|||||
Db 1 GGAGGAGAAUACAGAGC 17

RESULT 458
US-10-156-306-6325
; Sequence 6325, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
```

```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6325
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6325

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 14; Conservative 3;

QY 328 GCTCCGAGATGCCATCC 344
||:|||||
Db 1 GCUCGAGAUCCAUCC 17

RESULT 459
US-10-156-306-6326
; Sequence 6326, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6326
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6326

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 2;

QY 346 GCAGAGCAACCATTC 362
|||||
Db 1 GCAGAGCAACCATTC 17

RESULT 460
US-10-156-306-6327
; Sequence 6327, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6327
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6327

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 15; Conservative 2;
```

```

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 351 GCAACCATGATCTGCGG 367
      |||||:|:|:|:|:|
Db 1 GCAACCAUAUCUGCGG 17

RESULT 461
US-10-156-306-6328
; Sequence 6328, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6328
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6328

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 446 GCCAGGAACCTGTGGG 462
      |||||:|:|:|:|:|
Db 1 GCCAGGAACUGUGGA 17

RESULT 462
US-10-156-306-6329
; Sequence 6329, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6329
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6329

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 458 GTGAGAGACTCGCCT 474
      |||||:|:|:|:|:|
Db 1 GUGGAGAGACUGGCCU 17

RESULT 463
US-10-156-306-6330
; Sequence 6330, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

```

```

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6330
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6330

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 478 GAAGCTCGATCTGAAGA 494
      |||||:|:|:|:|:|
Db 1 GAAGCUCAUGCUGAAGA 17

RESULT 464
US-10-156-306-6331
; Sequence 6331, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6331
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6331

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 530 CTGAAGATGCCAGCA 546
      |||||:|:|:|:|:|
Db 1 CUGAAGAGUAGCCAGCA 17

RESULT 465
US-10-156-306-6332
; Sequence 6332, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6332
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6332

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```

QY 543 AGCAGCAGATGGCTGAG 559
|||||:||||:
Db 1 AGCAGCAGAUCCUGAG 17

RESULT 466
US-10-156-306-6333
; Sequence 6333, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6333
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6333

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 15; Conservative 2; Mismatches 0;

QY 553 GCGTGGAGCAGGCTT 569
|||||:||||:
Db 1 GCGUGAGCAGAGCCU 17

RESULT 467
US-10-156-306-6334
; Sequence 6334, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6334
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6334

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 13; Conservative 4; Mismatches 0;

QY 579 CCCAGGTGAGTCTTG 595
|||||:||||:
Db 1 CCCAGGAGCAGCUUG 17

RESULT 468
US-10-156-306-6335
; Sequence 6335, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 14; Conservative 3; Mismatches 0;

; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6335
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6335

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 15; Conservative 2; Mismatches 0;

QY 638 ACTAAGGAATGCCAGGC 654
|||||:||||:
Db 1 ACUAGGAUGCCAGGC 17

RESULT 469
US-10-156-306-6336
; Sequence 6336, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6336
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6336

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 15; Conservative 2; Mismatches 0;

QY 739 GCAGGTGACACGCTGC 755
|||||:||||:
Db 1 GCAGGUGGACGAGCUGC 17

RESULT 470
US-10-156-306-6337
; Sequence 6337, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6337
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6337

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02; Indels 0; Gaps 0;
Matches 14; Conservative 3; Mismatches 0;

QY 860 TTCCAAGAAATACGACAA 876
:|||||:|||||
Db 1 UUCAAGAAUACGACAA 17

RESULT 471
US-10-156-306-6338
; Sequence 6338, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6338
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6338

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 865 AGAATACGACCAACACA 881
:|||||:|||||
Db 1 AGAAUACGACCAACACA 17

RESULT 472
US-10-156-306-6339
; Sequence 6339, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6339
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6339

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 868 ATACGACCAACCAATCA 884
:|||||:|||||
Db 1 AUACGACCAACCAUCA 17

RESULT 473
US-10-156-306-6814
; Sequence 6814, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6814
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6814

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 174 AACTGTGTGAGATGGTG 190
:|||||:|||||
Db 1 AACUGUGAGAUUGGUG 17

RESULT 474
US-10-156-306-6815
; Sequence 6815, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6815
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6815

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 176 CTGTGTGAGATGGTGCA 192
:|||||:|||||
Db 1 CUGUGAGAUUGGUGCA 17

RESULT 475
US-10-156-306-6816
; Sequence 6816, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6816
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6816

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 179 TGTGAGATGGTGACGCC 195


```

Db      1  UGUGAGUGGCGAGCC 17
          :|:||||:|:|:|||||
RESULT 476
US-10-156-306-6817
; Sequence 6817, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6817
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6817

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      192  AGCCGAGTGTGTCGCG 208
          |||||:|:|:|||||
Db      1  AGCCGAGUGGUGGCGCG 17

RESULT 477
US-10-156-306-6818
; Sequence 6818, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6818
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6818

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      195  CCAGTGTGTCGCGGCA 211
          |||||:|:|:|||||
Db      1  CCAGUGGUGGCGCGCA 17

RESULT 478
US-10-156-306-6819
; Sequence 6819, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306

```

```

; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6819
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6819

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      200  CGTGGCCCGCAGCAGA 216
          .||:|||||:|||||
Db      1  GGUGGCCCGCAGCAGA 17

RESULT 479
US-10-156-306-6820
; Sequence 6820, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6820
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6820

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      207  CGGCAGCAGATCAGGAC 223
          |||||:|:|:|||||
Db      1  CGGCAGCAGCAUCAGGAC 17

RESULT 480
US-10-156-306-6821
; Sequence 6821, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6821
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6821

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      212  GCAGATCAGGACGTACT 228
          |||||:|:|:|||||:|:

```

```
Db      1 GCAGACAGGACGACU 17

RESULT 481
US-10-156-306-6822
; Sequence 6822, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6822
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6822

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      213 CAGATCAGGACGACTG 229
      |||||:|||||:|:|:|
Db      1 CAGACAGGACGACU 17

RESULT 482
US-10-156-306-6823
; Sequence 6823, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6823
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6823

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      221 GAGTACTGGCGGAAGA 237
      |||||:|||||:|:|:|
Db      1 GACGACUGGCGGAG 17

RESULT 483
US-10-156-306-6824
; Sequence 6824, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
```

```
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6824
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6824

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      222 ACGTACTGGCGGAAGAG 238
      |||||:|||||:|:|:|
Db      1 ACUACUGGCGGAAGAG 17

RESULT 484
US-10-156-306-6825
; Sequence 6825, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6825
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6825

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      225 TACTGGCGGAAGTCT 241
      :||:|||||:|:|:|
Db      1 UACUGGCGGAAGAGUCU 17

RESULT 485
US-10-156-306-6826
; Sequence 6826, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6826
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6826

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      228 TGGCGGAGAGTCTCT 244
      :|||||:|:|:|
Db      1 UGGCGGAGAGUCUCU 17
```

```
RESULT 486
US-10-156-306-6827
; Sequence 6827, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6827
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6827

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 239 TCCTCTCTGGGGAAGCC 255
      :||:|||||
Db 1 UCUCUCUGGGGAAGCC 17

RESULT 487
US-10-156-306-6828
; Sequence 6828, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6828
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6828

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 240 CTCCTCTGGGGAAGCCA 256
      :||:|||||
Db 1 UCUCUCUGGGGAAGCCA 17

RESULT 488
US-10-156-306-6829
; Sequence 6829, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6829
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6829

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 241 TCCTCTGGGGAAGCCAG 257
      :||:|||||
Db 1 UCUCUCUGGGGAAGCCAG 17

RESULT 489
US-10-156-306-6830
; Sequence 6830, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6830
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6830

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 242 CCTCTGGGGAAGCCAGC 258
      :||:|||||
Db 1 CCUCUGGGGAAGCCAGC 17

RESULT 490
US-10-156-306-6831
; Sequence 6831, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6831

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 270 TGCCTTCAGAACAGGCG 286
      :||:|||||
Db 1 UGCCUUCAGAACAGGCG 17
```

```
RESULT 491
US-10-156-306-6832
; Sequence 6832, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6832
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6832

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      275 TCAGAACAGGGCGCTCC 291
Db      1 UCAGAACAGGGCGGUCC 17

RESULT 492
US-10-156-306-6833
; Sequence 6833, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6833
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6833

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      276 CAGAACAGGGCGCTCT 292
Db      1 CAGAACAGGGCGGUCCU 17

RESULT 493
US-10-156-306-6834
; Sequence 6834, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 6834
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6834

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      285 GCGCTCTGAGACCCCTC 301
Db      1 GCGCUCCUGAGACCCUC 17

RESULT 494
US-10-156-306-6835
; Sequence 6835, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6835
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6835

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      287 GCTCTGAGACCTCCA 303
Db      1 GCUCCUGAGACCCUCA 17

RESULT 495
US-10-156-306-6836
; Sequence 6836, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6836
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6836

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      305 CGCTGCTGGAGAGAA 321
Db      1 CGCUGCCUGAGAGAA 17
```

```

RESULT 496
US-10-156-306-6837
; Sequence 6837, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6837
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6837

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 306 GCTGCTGAGGAGAAAT 322
||:||||:||||:||||:
Db 1 GCGUGCCUGGAGGAGAAU 17

RESULT 497
US-10-156-306-6838
; Sequence 6838, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6838
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6838

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 308 TGCTCGAGGAGAAATCA 324
||:||||:||||:||||:
Db 1 UGCGUGGAGGAGAAUCA 17

RESULT 498
US-10-156-306-6839
; Sequence 6839, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6839

```

```

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6839

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGAAATCAA 325
||:||||:||||:||||:
Db 1 GCGUGGAGGAGAAUCA 17

RESULT 499
US-10-156-306-6840
; Sequence 6840, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6840
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6840

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 311 CTGGAGGAGAAATCAAGA 327
||:||||:||||:||||:
Db 1 CUGGAGGAGAAUCAAGA 17

RESULT 500
US-10-156-306-6841
; Sequence 6841, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6841
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6841

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 318 AGAATCAAGAGCTCCGA 334
||:||||:||||:||||:
Db 1 AGAAUCAAGAGCTCCGA 17

RESULT 501

```

```
US-10-156-306-6842
; Sequence 6842, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6842
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6842

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      325 AGAGCTCCGAGATGCCA 341
Db      1 AGAGCUCCGAGAUCCCA 17

RESULT 502
US-10-156-306-6843
; Sequence 6843, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6843
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6843

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      327 AGCTCCGAGATGCCATC 343
Db      1 AGCUCCGAGAUCCCAUC 17

RESULT 503
US-10-156-306-6844
; Sequence 6844, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6844
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6844

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      327 AGCTCCGAGATGCCATC 343
Db      1 AGCUCCGAGAUCCCAUC 17

RESULT 504
US-10-156-306-6845
; Sequence 6845, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6845

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      341 ATCCGGCAGAGCAACCA 357
Db      1 AUCCGGCAGAGCAACCA 17

RESULT 505
US-10-156-306-6846
; Sequence 6846, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6846

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      350 AGCAACCGAGATTCTCGC 366
Db      1 AGCAACCGAGAUUCUGCG 17

RESULT 506
US-10-156-306-6847
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6844

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      337 TGCCATCCGCGCAGACCA 353
Db      1 UGCCAUCCGCGCAGACCA 17

RESULT 504
US-10-156-306-6845
; Sequence 6845, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6845

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      341 ATCCGGCAGAGCAACCA 357
Db      1 AUCCGGCAGAGCAACCA 17

RESULT 505
US-10-156-306-6846
; Sequence 6846, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6846

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      350 AGCAACCGAGATTCTCGC 366
Db      1 AGCAACCGAGAUUCUGCG 17

RESULT 506
US-10-156-306-6847
```

```
; Sequence 6847, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6847
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6847

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 358 GATTCTGCGGAGCGCTG 374
DB 1 GAUUCUGCGGAGCGCU 17

RESULT 507
US-10-156-306-6848
; Sequence 6848, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6848
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6848

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 359 ATTCTGCGGAGCGCTG 375
DB 1 AUUCUGCGGAGCGCUG 17

RESULT 508
US-10-156-306-6849
; Sequence 6849, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6849
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6849

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 360 TTCTGCGGAGCGCTGC 376
DB 1 UUCUGCGGAGCGCUG 17

RESULT 509
US-10-156-306-6850
; Sequence 6850, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6850
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6850

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 369 ACGCTGCGGAGGAGCTT 385
DB 1 AGCGCUGCGAGGAGCUU 17

RESULT 510
US-10-156-306-6851
; Sequence 6851, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6851
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6851

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 371 CGCTGCGGAGGAGCTTCT 387
DB 1 CGCUGCGGAGGAGCUUCU 17

RESULT 511
US-10-156-306-6852
; Sequence 6852, Application US/10156306
```

```

; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6852
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6852

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTG 388
Db 1 GCUGCGAGGAGCUUCUG 17

RESULT 512
US-10-156-306-6853
; Sequence 6853, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6853
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6853

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 398 GCCAGCCAGAGGGAGGA 414
Db 1 GCCAGCCAGAGGGAGGA 17

RESULT 513
US-10-156-306-6854
; Sequence 6854, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6854
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6854

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 398 GCCAGCCAGAGGGAGGA 414
Db 1 GCCAGCCAGAGGGAGGA 17

RESULT 514
US-10-156-306-6855
; Sequence 6855, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6855
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6855

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 401 AGCCAGAGGGAGGAGAA 417
Db 1 AGCCAGAGGGAGGAGAA 17

RESULT 515
US-10-156-306-6856
; Sequence 6856, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6856
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6856

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 402 GCCAGAGGGAGGAGAG 418
Db 1 GCCAGAGGGAGGAGAG 17

RESULT 516
US-10-156-306-6857
; Sequence 6857, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6857
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6857
```

```

US-10-156-306-6854

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 400 CAGCCAGAGGGAGGAGA 416
Db 1 CAGCCAGAGGGAGGAGA 17

RESULT 514
US-10-156-306-6855
; Sequence 6855, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6855
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6855

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 401 AGCCAGAGGGAGGAGAA 417
Db 1 AGCCAGAGGGAGGAGAA 17

RESULT 515
US-10-156-306-6856
; Sequence 6856, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6856
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6856

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 402 GCCAGAGGGAGGAGAG 418
Db 1 GCCAGAGGGAGGAGAG 17

RESULT 516
US-10-156-306-6857
; Sequence 6857, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6857
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6857
```



```
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6857
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6857

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 404 CAGAGGGAGGAGGAGGA 420
    |||||
Db 1 CAGAGGGAGGAGGAGGA 17

RESULT 517
US-10-156-306-6858
; Sequence 6858, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6858
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6858

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 405 AGAGGGAGGAGGAGGAG 421
    |||||
Db 1 AGAGGGAGGAGGAGGAG 17

RESULT 518
US-10-156-306-6859
; Sequence 6859, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6859
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6859
```

```
Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 407 AGGGAGGAGGAGGAGTT 423
    |||||
Db 1 AGGGAGGAGGAGGAGUU 17

RESULT 519
US-10-156-306-6860
; Sequence 6860, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6860
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6860

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 410 GAGGAGGAGGAGGTCCT 426
    |||||
Db 1 GAGGAGGAGGAGGUCCU 17

RESULT 520
US-10-156-306-6861
; Sequence 6861, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6861
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6861

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 411 AGGAGAGGAGGTCCTC 427
    |||||
Db 1 AGGAGAGGAGGUCCUC 17

RESULT 521
US-10-156-306-6862
; Sequence 6862, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6862
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6862

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 434 AAGTCCAGGAGGCCAG 450
|||:|||||
Db 1 AAGUCCAGGAGGCCAG 17

RESULT 522

US-10-156-306-6863
; Sequence 6863, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6863
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6863

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 435 AGTTCAGGAGGCCAGG 451
|||:|||||
Db 1 AAGUCCAGGAGGCCAGG 17

RESULT 523

US-10-156-306-6864
; Sequence 6864, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6864
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6864

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 437 TTCCAGGAGGCCAGGAA 453
|||:|||||
Db 1 UUCCAGGAGGCCAGGAA 17

RESULT 524

US-10-156-306-6865
; Sequence 6865, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6865
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6865

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 442 GGAGGCCAGGAAACTGG 458
|||:|||||
Db 1 GGAGGCCAGGAAACUGG 17

RESULT 525

US-10-156-306-6866
; Sequence 6866, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6866
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6866

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 443 GAGGCCAGGAAACTGGT 459
|||:|||||
Db 1 GAGGCCAGGAAACUGGU 17

RESULT 526

US-10-156-306-6867
; Sequence 6867, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6867
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6867

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 449 AGGAACTGCTGGAGAG 465
      |||||:|||||
Db 1 AGGAACTGCTGGAGAG 17

RESULT 527
US-10-156-306-6868
; Sequence 6868, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6868
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6868

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 452 AAACGTGCTGGAGACT 468
      |||||:|||||
Db 1 AAACGTGCTGGAGACT 17

RESULT 528
US-10-156-306-6869
; Sequence 6869, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6869
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6869

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 452 AAACGTGCTGGAGACT 468
      |||||:|||||
Db 1 AAACGTGCTGGAGACT 17

RESULT 529
US-10-156-306-6870
; Sequence 6870, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6870
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6870

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 455 CTGGTGGAGAGACTCGG 471
      |||||:|||||
Db 1 CUGGUGGAGAGACUGGC 17

RESULT 530
US-10-156-306-6871
; Sequence 6871, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6871
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6871

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 457 GGTGGAGAGACTCGGCC 473
      |||||:|||||
Db 1 GGUGGAGAGACUGGCC 17

RESULT 531
US-10-156-306-6872
; Sequence 6872, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
```

```
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 453 AACTGCTGGAGAGACTC 469
      |||||:|||||
Db 1 AACUGGUGGAGAGACUC 17

RESULT 529
US-10-156-306-6870
; Sequence 6870, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6870
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6870

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 455 CTGGTGGAGAGACTCGG 471
      |||||:|||||
Db 1 CUGGUGGAGAGACUGGC 17

RESULT 530
US-10-156-306-6871
; Sequence 6871, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6871
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6871

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 457 GGTGGAGAGACTCGGCC 473
      |||||:|||||
Db 1 GGUGGAGAGACUGGCC 17

RESULT 531
US-10-156-306-6872
; Sequence 6872, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
```

Matches	14;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	468	TCGGCCTGGAGAAGCTC	484						
Db	1	UCGGCCUGGAGAGCUC	17						
RESULT 534									
US-10-156-306-6875									
; Sequence 6875, Application US/10156306									
; Publication No. US20030119017A1									
; GENERAL INFORMATION:									
; APPLICANT: Ribozyme Pharmaceuticals, Inc.									
; APPLICANT: McSwiggen, James									
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related									
; TITLE OF INVENTION: Levels of IKK-gamma and PKR									
; FILE REFERENCE: MEHB01-664-A (400/050)									
; CURRENT APPLICATION NUMBER: US/10/156,306									
; CURRENT FILING DATE: 2002-05-28									
; NUMBER OF SEQ ID NOS: 8013									
; SOFTWARE: PatentIn version 3.0									
; SEQ ID NO 6875									
; LENGTH: 17									
; TYPE: RNA									
; ORGANISM: Homo sapiens									
US-10-156-306-6875									
Query Match 2.3%; Score 17; DB 1; Length 17;									
Best Local Similarity 88.2%; Pred. No. 2.6e+02;									
Matches	15;	Conservative	2;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	470	GGCCTGGAGAAGCTCGA	486						
Db	1	GGCCUGGAGAGCUCGA	17						
RESULT 535									
US-10-156-306-6876									
; Sequence 6876, Application US/10156306									
; Publication No. US20030119017A1									
; GENERAL INFORMATION:									
; APPLICANT: Ribozyme Pharmaceuticals, Inc.									
; APPLICANT: McSwiggen, James									
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related									
; TITLE OF INVENTION: Levels of IKK-gamma and PKR									
; FILE REFERENCE: MEHB01-664-A (400/050)									
; CURRENT APPLICATION NUMBER: US/10/156,306									
; CURRENT FILING DATE: 2002-05-28									
; NUMBER OF SEQ ID NOS: 8013									
; SOFTWARE: PatentIn version 3.0									
; SEQ ID NO 6876									
; LENGTH: 17									
; TYPE: RNA									
; ORGANISM: Homo sapiens									
US-10-156-306-6876									
Query Match 2.3%; Score 17; DB 1; Length 17;									
Best Local Similarity 82.4%; Pred. No. 2.6e+02;									
Matches	14;	Conservative	3;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	477	AGAAAGCTCGATCTGAAG	493						
Db	1	AGAAGCUCGAGCUCGAG	17						
RESULT 536									
US-10-156-306-6877									
; Sequence 6877, Application US/10156306									
; Publication No. US20030119017A1									
; GENERAL INFORMATION:									
; APPLICANT: Ribozyme Pharmaceuticals, Inc.									
; APPLICANT: McSwiggen, James									
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related									

```
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6882
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6882

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 495 GGCAGAGGAGGAGGCT 511
Db 1 GGCAGAGGAGGAGGCU 17

RESULT 542
US-10-156-306-6883
; Sequence 6883, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6883
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6883

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 500 AAGGAGCAGGCTCTGCG 516
Db 1 AAGGAGCAGGCUUGCG 17

RESULT 543
US-10-156-306-6884
; Sequence 6884, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6884
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6884

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 508 GGCCTGCGGAGGTGG 524
Db 1 GGCUCUGCGGAGGUGG 17

RESULT 544
US-10-156-306-6885
; Sequence 6885, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6885
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6885

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 509 GCTCTGCGGAGGTGGA 525
Db 1 GCUCUGCGGAGGUGGA 17

RESULT 545
US-10-156-306-6886
; Sequence 6886, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6886
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6886

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 510 CTCCTGCGGAGGTGGAG 526
Db 1 CUCUGCGGAGGUGGAG 17

RESULT 546
US-10-156-306-6887
; Sequence 6887, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6887
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6887

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 512 CTGCGGAGGTGGAGCA 528
|:|||||:|||||
Db 1 CUGCGGAGGUGGAGCA 17

RESULT 547
US-10-156-306-6888
; Sequence 6888, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6888
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6888

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 515 CCGGAGGTGGAGCACT 531
|||||:|||||
Db 1 CCGGAGGUGGAGCACCU 17

RESULT 548
US-10-156-306-6889
; Sequence 6889, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6889
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6889

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 516 GCGAGGTGGAGCACTG 532

Db 1 GCGAGGUGGAGCACCU 17
|||||:|||||:|

RESULT 549
US-10-156-306-6890
; Sequence 6890, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6890
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6890

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 524 GAGCACTGAGAGATG 540
|||||:|||||
Db 1 GAGCACCGAGAGAGAU 17

RESULT 550
US-10-156-306-6891
; Sequence 6891, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6891
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6891

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 527 CACCTGAAGAGATGCCA 543
|||||:|||||
Db 1 CACCGAGAGAGAUCCA 17

RESULT 551
US-10-156-306-6892
; Sequence 6892, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6892
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6892

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 529 CCTGAAGAGATGCCAGC 545
||:|||||:|||||
Db 1 CCUGAAGAGAUCCAGC 17

RESULT 552
US-10-156-306-6893
; Sequence 6893, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6893
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6893

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 542 CAGCAGCAGATGGCTGA 558
|||||:|||||:|||||
Db 1 CAGCAGCAGAUCCUGA 17

RESULT 553
US-10-156-306-6894
; Sequence 6894, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6894
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6894

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 545 CAGCAGATGGCTGAGGA 561
|||||:|||||:|||||

Db 1 CAGCAGAUCCUGAGGA 17
RESULT 554
US-10-156-306-6895
; Sequence 6895, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6895
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6895

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 549 AGATGGCTGAGGACAAG 565
|||||:|||||:|||||
Db 1 AGAUGGUGAGGACAAG 17

RESULT 555
US-10-156-306-6896
; Sequence 6896, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6896
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6896

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 551 ATGGCTGAGGACAAGGC 567
||:|||||:|||||
Db 1 AUGGUGAGGACAAGGC 17

RESULT 556
US-10-156-306-6897
; Sequence 6897, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6897
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6897

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 552 TGCCTGAGGACCAAGGCC 568
:||||:|||||
Db 1 UGCGUGAGGACCAAGGCC 17

RESULT 557
US-10-156-306-6898
; Sequence 6898, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6898
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6898

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 557 GAGGACAGGCTCTCT 573
:|||||:|
Db 1 GAGGACAGGCTCTCT 17

RESULT 558
US-10-156-306-6899
; Sequence 6899, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6899
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6899

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 566 GCCTCTGTGAAGGCCA 582
:|:|:|:|
Db 1 GCCTCTGTGAAGGCCA 17

RESULT 559
US-10-156-306-6900
; Sequence 6900, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6900
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6900

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 575 AAAGCCCAGGTGACGTC 591
:|||||:|
Db 1 AAAGCCCAGGTGACGTC 17

RESULT 560
US-10-156-306-6901
; Sequence 6901, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6901
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6901

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 578 GCCCAGGTGACGTCCTT 594
:|||||:|
Db 1 GCCCAGGTGACGTCCTT 17

RESULT 561
US-10-156-306-6902
; Sequence 6902, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6902
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6902

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 591 CCTTGCTCGGGAGCTG 607
||:|||||:
Db 1 CCUUGCUCGGGAGCUG 17

RESULT 562
US-10-156-306-6903
; Sequence 6903, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6903
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6903

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 592 CTGCTCGGGAGCTGC 608
||:|||||:
Db 1 CUUGCUCGGGAGCUG 17

RESULT 563
US-10-156-306-6904
; Sequence 6904, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6904
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6904

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 593 TTGCTCGGGAGCTGCA 609
||:|||||:
Db 1 UUGCUCGGGAGCUGCA 17

RESULT 564
US-10-156-306-6905
; Sequence 6905, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6905
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6905

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 594 TGCTCGGGAGCTGCAG 610
||:|||||:
Db 1 UGCUCGGGAGCUGCAG 17

RESULT 565
US-10-156-306-6906
; Sequence 6906, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6906
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6906

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 602 GAGCTCGAGGAGGCCA 618
||:|||||:
Db 1 GAGCUCGAGGAGGCCA 17

RESULT 566
US-10-156-306-6907
; Sequence 6907, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0

```
; SEQ ID NO 6907
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6907

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 603 AGTCGAGGAGCCAG 619
DB 1 ACUGCAGGAGCCAG 17

RESULT 567
US-10-156-306-6908
; Sequence 6908, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6908
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6908

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 605 CTGCGAGGAGCCAGAG 621
DB 1 CUGCAGGAGCCAGAG 17

RESULT 568
US-10-156-306-6909
; Sequence 6909, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6909
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6909

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 611 GAGAGCCAGAGTCGCTT 627
DB 1 GAGAGCCAGAGGCGCUU 17
```

```
RESULT 569
US-10-156-306-6910
; Sequence 6910, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6910
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6910

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 620 AGTCGCTTGAGGCTGC 636
DB 1 AGUCGCUUGGAGGCTGC 17

RESULT 570
US-10-156-306-6911
; Sequence 6911, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6911
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6911

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 621 GTCGCTTGAGGCTGCC 637
DB 1 GUCGCUUGGAGGCGGCC 17

RESULT 571
US-10-156-306-6912
; Sequence 6912, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6912
```

```

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6912
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 2.6e+02;
    Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 623 CGCTGGAGGCTCCAC 639
    |||:|||||:|||||
Db 1 CGCUGGAGGCUCGCG 17

RESULT 572
US-10-156-306-6913
; Sequence 6913, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6913
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6913
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 88.2%; Pred. No. 2.6e+02;
    Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 635 GCCACTAAGGAATGCCA 651
    |||||:|||||:|||||
Db 1 GCCACUAGGAUGCCCA 17

RESULT 573
US-10-156-306-6914
; Sequence 6914, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6914
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6914
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 88.2%; Pred. No. 2.6e+02;
    Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 636 CCACTAAGGAATGCCAG 652
    |||||:|||||:|||||
Db 1 CCACUAGGAUGCCAG 17

RESULT 574
US-10-156-306-6915
; Sequence 6915, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6915
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6915
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 2.6e+02;
    Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 644 GAATGCCAGGCTCTCGA 660
    |||:|||||:|||||
Db 1 GAAUGCCAGGCUCUGGA 17

RESULT 575
US-10-156-306-6916
; Sequence 6916, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6916
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6916
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 2.6e+02;
    Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 650 CAGGCTCTGGAGGTCG 666
    |||||:|||||:|||||
Db 1 CAGGCUCUGGAGGUGCG 17

RESULT 576
US-10-156-306-6917
; Sequence 6917, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6917
; LENGTH: 17
```

```

US-10-156-306-6915
; Sequence 6915, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6915
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6915
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 2.6e+02;
    Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 644 GAATGCCAGGCTCTCGA 660
    |||:|||||:|||||
Db 1 GAAUGCCAGGCUCUGGA 17

RESULT 575
US-10-156-306-6916
; Sequence 6916, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6916
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6916
    Query Match      2.3%; Score 17; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 2.6e+02;
    Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 650 CAGGCTCTGGAGGTCG 666
    |||||:|||||:|||||
Db 1 CAGGCUCUGGAGGUGCG 17

RESULT 576
US-10-156-306-6917
; Sequence 6917, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6917
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6917

Query Match
Best Local Similarity 2.3%; Score 17; DB 1; Length 17;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 651 AGGCTCTGAGGAGGTCGG 667
||||:|||||:||||
Db 1 AGGCUCGAGGAGGUCGG 17

RESULT 577
US-10-156-306-6918
; Sequence 6918, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6918
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6918

Query Match
Best Local Similarity 2.3%; Score 17; DB 1; Length 17;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 653 GCTCTGGAGGAGGTCGGGC 669
||||:|||||:||||
Db 1 GCUCUGAGGAGGUCGGGC 17

RESULT 578
US-10-156-306-6919
; Sequence 6919, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6919
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6919

Query Match
Best Local Similarity 2.3%; Score 17; DB 1; Length 17;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 654 CTCTGAGGAGGTCGGGCC 670
|:|:|||||:|||||
Db 1 CUCUGAGGAGGUCGGGCC 17

RESULT 579
US-10-156-306-6920
```

```
; Sequence 6920, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6920
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6920

Query Match
Best Local Similarity 2.3%; Score 17; DB 1; Length 17;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 658 GGAGGTCGGGCCCGGG 674
|||||:|||||:||||
Db 1 GGAGGUCGGGCCCGGG 17

RESULT 580
US-10-156-306-6921
; Sequence 6921, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6921
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6921

Query Match
Best Local Similarity 2.3%; Score 17; DB 1; Length 17;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 659 GAGGTCGGGCCCGGGC 675
|||||:|||||:||||
Db 1 GAGGUCGGGCCCGGGC 17

RESULT 581
US-10-156-306-6922
; Sequence 6922, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6922
; LENGTH: 17
; TYPE: RNA
```

```
; ORGANISM: Homo sapiens
US-10-156-306-6922

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 664 TCGGGCCCGGGCGGCCA 680
      :|||||
Db 1 UCGGGCCCGGGCGGCCA 17

RESULT 582
US-10-156-306-6923
; Sequence 6923, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6923
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6923

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 665 CGGGCCCGGGCGGCCAG 681
      :|||||
Db 1 CGGGCCCGGGCGGCCAG 17

RESULT 583
US-10-156-306-6924
; Sequence 6924, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6924
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6924

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 668 GCCCGGGCGGCCAGCCA 684
      :|||||
Db 1 GCCCGGGCGGCCAGCCA 17

RESULT 584
US-10-156-306-6925
; Sequence 6925, Application US/10156306
```

```
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6925
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6925

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 675 CGGCCAGCGCAGCGCG 691
      :|||||
Db 1 CGGCCAGCGCAGCGCG 17

RESULT 585
US-10-156-306-6926
; Sequence 6926, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6926
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6926

Query Match      2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 680 AGCGAGCAGCGCGGCA 696
      :|||||
Db 1 AGCGAGCAGCGCGGCA 17

RESULT 586
US-10-156-306-6927
; Sequence 6927, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6927
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-10-156-306-6927

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 685 GCAGGCGCGGACGTGG 701
|||:|||||:|||||:
Db 1 GCAGGCGCGGACGUGG 17

RESULT 587

US-10-156-306-6928
; Sequence 6928, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6928

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6928

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 692 CGGCGCTGGAGAGTGA 708
|||:|||||:|||||:
Db 1 CGGCGCUGGAGAGUGA 17

RESULT 588

US-10-156-306-6929
; Sequence 6929, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6929

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6929

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 693 GCGAGCTGGAGAGTGA 709
|||:|||||:|||||:
Db 1 GCGAGCUGGAGAGUGA 17

RESULT 589

US-10-156-306-6930
; Sequence 6930, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6930

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6930

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 695 CAGCTGGAGAGTGACG 711
|||:|||||:|||||:
Db 1 CAGCUGGAGAGUGACG 17

RESULT 590

US-10-156-306-6931

; Sequence 6931, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6931

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6931

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 699 TGGAGAGTGACGCGAG 715
|||:|||||:|||||:
Db 1 UGGAGAGUGAGCGCGAG 17

RESULT 591

US-10-156-306-6932

; Sequence 6932, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6932

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6932

```
Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 705 GTGAGCGGAGGCGCTG 721
Db 1 GUGAGCGGAGGCGCUG 17

RESULT 592
US-10-156-306-6933
; Sequence 6933, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6933
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6933

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.4%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 707 GAGCGGAGGCGGTGCA 723
Db 1 GAGCGGAGGCGGUGCA 17

RESULT 593
US-10-156-306-6934
; Sequence 6934, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6934
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6934

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 734 AGCGTGCGAGTGACCA 750
Db 1 AGCGUGCAGGUGGACCA 17

RESULT 594
US-10-156-306-6935
; Sequence 6935, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6935
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6935

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 737 GTGCGAGTGGACCACTG 753
Db 1 GUGCAGGUGGACCACTG 17

RESULT 595
US-10-156-306-6936
; Sequence 6936, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6936
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6936

Query Match          2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 738 TGCAGGTGGACCACTG 754
Db 1 UGCAGGUGGACCACTG 17

RESULT 596
US-10-156-306-6937
; Sequence 6937, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6937
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6937
```


Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 755 CGCATCGAGGCCAGAG 771
|||||:|||||
Db 1 CGCAUGCAGGCCAGAG 17

RESULT 597

US-10-156-306-6938
; Sequence 6938, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6938

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6938

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 756 GCATCGAGGCCAGAGC 772
|||||:|||||
Db 1 GCAUGCAGGCCAGAGC 17

RESULT 598

US-10-156-306-6939
; Sequence 6939, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6939

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6939

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 761 CAGGCGCAGAGCGTGA 777
|||||:|||||
Db 1 CAGGCGCAGAGCGUGA 17

RESULT 599

US-10-156-306-6940
; Sequence 6940, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6940
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6940

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.6e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 767 CAGAGCGTGAGGCCGC 783
|||||:|||||
Db 1 CAGAGCGUGAGGCCGC 17

RESULT 600

US-10-156-306-6941
; Sequence 6941, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6941

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6941

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.6e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 768 AGAGCGTGAGGCCGC 784
|||||:|||||
Db 1 AGAGCGUGAGGCCGC 17

RESULT 601

US-10-156-306-6942
; Sequence 6942, Application US/10156306
; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of IKK-Gamma and PKR

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6942

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6942

Query Match 2.3%; Score 17; DB 1; Length 17;

```
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 770 AGCGTGGAGCGCGGCT 786
||||:|||||
Db 1 AGCGUGGAGCGCGGCU 17

RESULT 602
US-10-156-306-6943
; Sequence 6943, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6943
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6943

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 785 CTCGCATGGAGCGCCA 801
|:||||:|||||
Db 1 CUCCGAUGGAGCGCCA 17

RESULT 603
US-10-156-306-6944
; Sequence 6944, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6944
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6944

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 786 TCCGCATGGAGCGCCAG 802
||||:|||||
Db 1 UCCGCAUGGAGCGCCAG 17

RESULT 604
US-10-156-306-6945
; Sequence 6945, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6945
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6945

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6945
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6945

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 794 GAGCGCCAGCGCGCTC 810
|||||:|||||
Db 1 GAGCGCCAGCGCGCTC 17

RESULT 605
US-10-156-306-6946
; Sequence 6946, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6946
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6946

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 803 GCGCGCTCGGAGGAGAA 819
|||||:|||||
Db 1 GCGCGCTCGGAGGAGAA 17

RESULT 606
US-10-156-306-6947
; Sequence 6947, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6947
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6947

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 804 GCGCGCTCGGAGGAGAA 819
|||||:|||||
Db 1 GCGCGCTCGGAGGAGAA 17

RESULT 607
US-10-156-306-6948
; Sequence 6948, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6948
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6948

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 804 CCGCTCGGAGGAGAG 820
      |||||:|||||
Db 1 CCGCCUCCGAGGAGAG 17

RESULT 607
US-10-156-306-6948
; Sequence 6948, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6948
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6948

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 806 GCCTCGGAGGAGAGAG 822
      |||||:|||||
Db 1 GCUCGAGGAGAGAGAG 17

RESULT 608
US-10-156-306-6949
; Sequence 6949, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6949
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6949

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 807 CCTCGGAGGAGAGAGG 823
      |||||:|||||
Db 1 CCUCGAGGAGAGAGG 17

RESULT 609
US-10-156-306-6950
; Sequence 6950, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
```

```
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6950
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6950

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 809 TCGGAGGAGAGAGGAA 825
      .|||||:|||||
Db 1 UCGGAGGAGAGAGGAA 17

RESULT 610
US-10-156-306-6951
; Sequence 6951, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6951
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6951

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 812 GAGGAGAGAGAGGAGCT 828
      |||||:|||||
Db 1 GAGGAGAGAGAGGAGCU 17

RESULT 611
US-10-156-306-6952
; Sequence 6952, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6952
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6952

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 814 GGAGAGGAGGAGCTGG 830
      |||||
Db 1 GGAGAGGAGGAGGCGG 17

RESULT 612
US-10-156-306-6953
; Sequence 6953, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6953
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6953

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 815 GAGAGGAGGAGCTGGC 831
      |||||
Db 1 GAGAGGAGGAGGCGGC 17

RESULT 613
US-10-156-306-6954
; Sequence 6954, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6954
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6954

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.6e+02;
Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 821 AGGAGCTGGCCGAGTT 837
      |||||
Db 1 AGGAGCGGCCGAGUU 17

RESULT 614
US-10-156-306-6955
; Sequence 6955, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
```

```
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6955
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6955

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 833 CAGTTGCAGGTGGCCTA 849
      |||||
Db 1 CAGUUGCAGGUGGCCUA 17

RESULT 615
US-10-156-306-6956
; Sequence 6956, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6956
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6956

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 836 TTGCAGGTGGCCTATCA 852
      |||||
Db 1 UUGCAGGUGGCCUAUCA 17

RESULT 616
US-10-156-306-6957
; Sequence 6957, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6957
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6957

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

QY 858 TCTTCAGAAATACGAC 874
:|:|||||:|||||
Db 1 UCUUCCAAGAAUACGAC 17

RESULT 617

US-10-156-306-6958
; Sequence 6958, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6958

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6958

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.6e+02;

Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 864 AAGATACGACCAACCAC 880

|||||:|||||:|||||
Db 1 AAGAAUACGACCAACCAC 17

RESULT 618

US-10-156-306-6959
; Sequence 6959, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6959

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6959

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.6e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 878 CACATCAGACGCGT 894

|||||:|||||:|||||
Db 1 CACAUCAGACGCGGU 17

RESULT 619

US-10-156-306-6960
; Sequence 6960, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6960

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6960

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.6e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 878 CACATCAGACGCGT 894

|||||:|||||:|||||
Db 1 CACAUCAGACGCGGU 17

RESULT 620

US-10-156-306-6961

; Sequence 6961, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6961

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6961

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.6e+02;

Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 887 AGCAGCGTGGTGGCAG 903

|||||:|||||:|||||
Db 1 AGCAGCGUGUGGCAG 17

RESULT 621

US-10-156-306-6962

; Sequence 6962, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6962

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6962

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.6e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 891 GCGTGGTGGCAGTGAG 907

|||||:|||||:|||||

RESULT 622

US-10-156-306-6963

; Sequence 6963, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to

; FILE REFERENCE: MBH01-664-A (400/050)

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6963

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-156-306-6963

Query Match 2.3%; Score 17; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 2.6e+02;

Matches 14; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 891 GCGTGGTGGCAGTGAG 907

|||||:|||||:|||||

```
Db 1 GCGUGGUGGCGAGUGAG 17
||||:||||:||||:||||:||||:
RESULT 622
US-10-156-306-6963
; Sequence 6963, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6963
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6963

Query Match 2.3%; Score 17; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 897 TGGGCGAGTGGCGGAAG 913
||||:||||:||||:||||:||||:
Db 1 UGGGCGAGUGGCGGAAG 17

RESULT 623
US-10-786-720-11195
; Sequence 11195, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AMI01331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11195
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-11195

Query Match 2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 3.6e+02;
Matches 14; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 468 TCGGCTGGGAGAGCTCGAT 487
||||:||||:||||:||||:||||:
Db 1 UCAGCCUGGAGAGCUGGAU 20

RESULT 624
US-10-490-080-12/c
; Sequence 12, Application US/10490080
; Publication No. US20040253597A1
; GENERAL INFORMATION:
; APPLICANT: Takeda Chemical Industries, Ltd.
; TITLE OF INVENTION: Novel Protein and its DNA
; FILE REFERENCE: P02-0109PCT
; CURRENT APPLICATION NUMBER: US/10/490,080
; CURRENT FILING DATE: 2004-03-17
```

```
; PRIOR APPLICATION NUMBER: JP 2001-281992
; PRIOR FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: JP 2001-306873
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: JP 2002-113279
; PRIOR FILING DATE: 2002-04-16
; NUMBER OF SEQ ID NOS: 42
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer F1 for sequencing
US-10-490-080-12

Query Match 2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 423 TCCTCATGTGCAAGTTCCAG 442
||||:||||:||||:||||:||||:
Db 20 TCCTCTTGTGCAGGTTCCAG 1

RESULT 625
US-10-490-080-18
; Sequence 18, Application US/10490080
; Publication No. US20040253597A1
; GENERAL INFORMATION:
; APPLICANT: Takeda Chemical Industries, Ltd.
; TITLE OF INVENTION: Novel Protein and its DNA
; FILE REFERENCE: P02-0109PCT
; CURRENT APPLICATION NUMBER: US/10/490,080
; CURRENT FILING DATE: 2004-03-17
; PRIOR APPLICATION NUMBER: JP 2001-281992
; PRIOR FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: JP 2001-306873
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: JP 2002-113279
; PRIOR FILING DATE: 2002-04-16
; NUMBER OF SEQ ID NOS: 42
; SEQ ID NO 18
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer R1 for sequencing
US-10-490-080-18

Query Match 2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 423 TCCTCATGTGCAAGTTCCAG 442
||||:||||:||||:||||:||||:
Db 2 TCCTCTTGTGCAGGTTCCAG 21

RESULT 626
US-10-751-736-18624/c
; Sequence 18624, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AMI00927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
```

```
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18624
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-18624

Query Match          2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 166 GAAGACCAACTGCTGTGAGA 185
Db 21 GAAGAGTCACCTGTGTGTGAGA 2

RESULT 627
US-10-751-736-49885
; Sequence 49885, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49885
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-49885

Query Match          2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 518 GAGGTGAGCACCCTGAAGAG 537
Db 1 GAGGTGAGCAGATGAAGAG 20

RESULT 628
US-10-751-736-9649/c
; Sequence 9649, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9649
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
```

```
US-10-751-736-9649

Query Match          2.2%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 377 GAGGAGCTTCTGCATTTC 394
Db 21 GAGGAACCTCTGCATTTC 4

RESULT 629
US-10-751-736-9650/c
; Sequence 9650, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9650
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-9650

Query Match          2.2%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 377 GAGGAGCTTCTGCATTTC 394
Db 19 GAGGAACCTCTGCATTTC 2

RESULT 630
US-10-786-720-11196/c
; Sequence 11196, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11196
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-11196

Query Match          2.1%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 466 ACTCGGCTCTGGAGAGCTCGA 486
Db 21 AATCAGCCTGGAGAGCTGGA 1
```

```
RESULT 631
US-10-751-736-39475/c
; Sequence 39475, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39475
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-39475

Query Match      2.1%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 440 CAGAGGCCGAGGAACCTGGTG 460
      ||||| | ||||| |||||
Db 21 CAGGAAGTGAGGAACCTGGTG 1

RESULT 632
US-10-751-736-39478/c
; Sequence 39478, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39478
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-39478

Query Match      2.1%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 4.2e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 437 TTCAGGAGCCGAGGAACCTG 457
      ||||| | ||||| |||||
Db 21 TTCAGGAAGTGAGGAACCTG 1

RESULT 633
US-10-156-306-6813
; Sequence 6813, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6813
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6813

Query Match      2.1%; Score 16; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.4e+02;
Matches 13; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 162 TCTGGAAGAGCCAACT 177
      :||:||||| |||||
Db 2 UCUGGAAGAGCCAACT 17

RESULT 634
US-10-156-306-6964
; Sequence 6964, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6964
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6964

Query Match      2.1%; Score 16; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.4e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 901 CAGTGAGCGGAAGCGA 916
      |||:||||| |||||
Db 1 CAGUGAGCGGAAGCGA 16

RESULT 635
US-10-224-836-290
; Sequence 290, Application US/10224836
; Publication No. US20030082598A1
; GENERAL INFORMATION:
; APPLICANT: Ecker, David J.
; TITLE OF INVENTION: Molecular Interaction Sites Of 23S Ribosomal RNA And Methods Of
; FILE REFERENCE: IBIS0402
; CURRENT APPLICATION NUMBER: US/10/224,836
; CURRENT FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: 60/314,251
; PRIOR FILING DATE: 2001-08-22
; NUMBER OF SEQ ID NOS: 327
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 290
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-224-836-290
```



```
Query Match          2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.1e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 652 GGCTCTGGAGGTCGGGCC 670
Db 1 GGCGGAGGCGCGCGGCC 19

RESULT 636
US-10-670-011-56
; Sequence 56, Application US/10670011
; Publication No. US20040209832A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/132 (MBHB02-742-G)
; CURRENT APPLICATION NUMBER: US/10/670,011
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 427
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-670-011-56

Query Match          2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 701 GAGAGTGAGCGCGAGCGGC 719
Db 1 GAGAGGAGCGCGAGCGGC 19

RESULT 637
US-10-670-011-152/c
; Sequence 152, Application US/10670011
; Publication No. US20040209832A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
```

```
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/132 (MBHB02-742-G)
; CURRENT APPLICATION NUMBER: US/10/670,011
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 427
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 152
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-670-011-152

Query Match          2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 701 GAGAGTGAGCGCGAGCGGC 719
Db 19 GAGAGGAGCGCGAGCGGC 1

RESULT 638
US-10-764-957-56
; Sequence 56, Application US/10764957
; Publication No. US20050054596A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Pavco, Pamela
; APPLICANT: Beigelman, Leo
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/144 (MBHB02-742-O)
; CURRENT APPLICATION NUMBER: US/10/764,957
; CURRENT FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US60/386,782
; PRIOR FILING DATE: 2002-06-06
```

```
; PRIOR APPLICATION NUMBER: US60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US60/408,378
; PRIOR FILING DATE: 2002-09-05
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 473
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 56
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense region
US-10-764-957-56

Query Match      2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      701 GAGAGTGCAGCGCGAGCGGC 719
Db      1 GAGAGGAGCGCGAGCGGC 19

RESULT 639
US-10-764-957-152/c
; Sequence 152, Application US/10764957
; Publication No. US20050054596A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Pavco, Pamela
; APPLICANT: Beigelman, Leo
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/144 (MBHB02-742-0)
; CURRENT APPLICATION NUMBER: US/10/764,957
; CURRENT FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US60/408,378
; PRIOR FILING DATE: 2002-09-05
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 473
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 152
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-764-957-152
```

```
Query Match      2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      701 GAGAGTGCAGCGCGAGCGGC 719
Db      19 GAGAGGAGCGCGAGCGGC 1

RESULT 640
US-10-083-720A-10
; Sequence 10, Application US/10083720A
; Publication No. US20030073199A1
; GENERAL INFORMATION:
; APPLICANT: de Waal Malefyt, Rene
; APPLICANT: Fleckenstein, Helmut
; APPLICANT: Fleckenstein, Bernhard
; APPLICANT: Knappe, Andrea
; TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
; FILE REFERENCE: DX0644KBK
; CURRENT APPLICATION NUMBER: US/10/083,720A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 09/363,993
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: 08/934,959
; PRIOR FILING DATE: 1997-09-22
; PRIOR APPLICATION NUMBER: 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: 60/302,176
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: 60/027,368
; PRIOR FILING DATE: 1996-09-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: IL-10 forward.
; NAME/KEY: misc_feature
; LOCATION: (1)..(21)
; OTHER INFORMATION: IL-10 forward.
US-10-083-720A-10

Query Match      2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      325 AGAGCTCCGAGATGCATC 343
Db      2 AGATCTCCGAGATGCCTTC 20

RESULT 641
US-10-186-180-20
; Sequence 20, Application US/10186180
; Publication No. US20030108958A1
; GENERAL INFORMATION:
; APPLICANT: De Waal Malefyt, Rene
; APPLICANT: Nagalakshmi, Marehalli
; APPLICANT: Moore, Kevin
; APPLICANT: Fickensher, Helmut
; TITLE OF INVENTION: BIOLOGICAL ACTIVITY OF AK155
; FILE REFERENCE: DX01168
; CURRENT APPLICATION NUMBER: US/10/186,180
; CURRENT FILING DATE: 2002-06-27
; PRIOR APPLICATION NUMBER: U.S. Provisional 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: U.S. Provisional 60/302,176
; PRIOR FILING DATE: 2001-06-28
```

```

RESULT 643
US-10-786-720-11194
; Sequence 11194, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11194
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-11194

```

RESULT: 645
US-10-683-990-206/c
; Sequence 206, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics

```

; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 206
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-683-990-206

Query Match 2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 303 AGCGCTGCCTGGAGGAGAA 321
Db 19 AGAGCTGCCTGGATGAGAA 1

RESULT 646
US-10-683-990-210
; Sequence 210, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782

```

```

; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 210
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (8)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
US-10-683-990-210

Query Match 2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 4.6e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 303 AGCGCTGCCTGGAGGAGAA 321
Db 1 AGAGCTGCCTGGAGGAGAA 19

RESULT 647
US-10-683-990-214/c
; Sequence 214, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20

```

```
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/440,129
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 214
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-683-990-214

Query Match      2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 303 AGCGTGCCTGGAGGAGAA 321
DB 19 AGAGCTGCCTGGATGAGAA 1

RESULT 648
US-10-683-990-218
; Sequence 218, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
US-10-683-990-218

; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/440,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 218
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(4)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (8)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (11)..(13)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(19)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
US-10-683-990-218
```

```

Query Match      2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 4.6e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 303 AGCGTGCCTGGAGGAGAA 321
    |||:|||||:|||||
Db 1 AGAGCUGCCUGGAUGAGAA 19

RESULT 649
US-10-683-990-222/c
; Sequence 222, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 222
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (10)..(12)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro

```

```

; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (14)..(15)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-683-990-222

Query Match      2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 303 AGCGTGCCTGGAGGAGAA 321
    |||:|||||:|||||
Db 19 AGAGTGCCTGGATGAGAA 1

RESULT 650
US-10-683-990-226
; Sequence 226, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 226
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(4)

```

```

; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(13)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(19)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; US-10-683-990-226

```

```

Query Match          2.1%  Score 15.8;  DB 1;  Length 21;
Best Local Similarity 78.9%;  Pred. No. 4.6e+02;
Matches 15;  Conservative 2;  Mismatches 2;  Indels 0;  Gaps 0;

```

```

Qy 303 AGCGTGCCTGGAGGAGAA 321
    |||:|||||
Db 1 AGAGCUGCCUGAUGAGAA 19

```

```

RESULT 651
US-10-683-990-230/c
; Sequence 230, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; PRIOR FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348

```

```

; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 230
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(12)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(15)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; US-10-683-990-230

```

```

Query Match          2.1%  Score 15.8;  DB 1;  Length 21;
Best Local Similarity 89.5%;  Pred. No. 4.6e+02;
Matches 17;  Conservative 0;  Mismatches 2;  Indels 0;  Gaps 0;

```

```

Qy 303 AGCGTGCCTGGAGGAGAA 321
    |||:|||||
Db 19 AGAGTGCCTGGATGAGAA 1

```

```

RESULT 652
US-10-683-990-234
; Sequence 234, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim

```

```
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 234
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-683-990-234

Query Match          2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 4.6e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 303 AGCGCTGCTGGAGGAGAA 321
   |||:|||||
Db 1 AGAGUGCCUGGAGAGAA 19

RESULT 653
US-10-683-990-238/c
; Sequence 238, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: siRNA Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usgan, Naasim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
```

```
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 238
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-683-990-238

Query Match          2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 303 AGCGTGCCTGGAGGAGAA 321
   |||:|||||
Db 19 AGAGCTGCCTGGATGAGAA 1

RESULT 654
US-10-751-736-16993
; Sequence 16993, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16993
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-16993

Query Match          2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 4.6e+02;
```


Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 543 AGCAGCAGATGCTGAGGA 561
 ||||| ||||| ||||| |||||
 Db 2 AGCAGCAGGAGCTGAGGA 20

RESULT 655
 US-10-751-736-18963/c
 ; Sequence 18963, Application US/10751736
 ; Publication No. US20040265230A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Wyeth
 ; APPLICANT: Martinez, Robert
 ; APPLICANT: Brown, Eugene
 ; APPLICANT: Liu, Wei
 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
 ; FILE REFERENCE: AM100927 (031896-002000)
 ; CURRENT APPLICATION NUMBER: US/10751,736
 ; CURRENT FILING DATE: 2003-01-06
 ; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
 ; PRIOR FILING DATE: 2003-01-06
 ; NUMBER OF SEQ ID NOS: 54873
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 18963
 ; LENGTH: 21
 ; TYPE: RNA
 ; ORGANISM: RNAi
 US-10-751-736-18963

Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 167 AAGAGCCACTGTGTGAGA 185
 ||||| ||||| ||||| |||||
 Db 21 AAGAGTCACCTGTGTGAGA 3

RESULT 656
 US-10-751-736-49882
 ; Sequence 49882, Application US/10751736
 ; Publication No. US20040265230A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Wyeth
 ; APPLICANT: Martinez, Robert
 ; APPLICANT: Brown, Eugene
 ; APPLICANT: Liu, Wei
 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
 ; FILE REFERENCE: AM100927 (031896-002000)
 ; CURRENT APPLICATION NUMBER: US/10751,736
 ; CURRENT FILING DATE: 2003-01-06
 ; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
 ; PRIOR FILING DATE: 2003-01-06
 ; NUMBER OF SEQ ID NOS: 54873
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 49882
 ; LENGTH: 21
 ; TYPE: DNA
 ; ORGANISM: homo sapiens
 US-10-751-736-49882

Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 4.6e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 517 GGAGGTGGAGCCTGGAAG 535
 ||||| ||||| ||||| |||||
 Db 3 GGAGGTGGAGCAGATGAAG 21

RESULT 657
 US-10-751-736-49883
 ; Sequence 49883, Application US/10751736
 ; Publication No. US20040265230A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Wyeth
 ; APPLICANT: Martinez, Robert
 ; APPLICANT: Brown, Eugene
 ; APPLICANT: Liu, Wei
 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
 ; FILE REFERENCE: AM100927 (031896-002000)
 ; CURRENT APPLICATION NUMBER: US/10751,736
 ; CURRENT FILING DATE: 2003-01-06
 ; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
 ; PRIOR FILING DATE: 2003-01-06
 ; NUMBER OF SEQ ID NOS: 54873
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 49883
 ; LENGTH: 21
 ; TYPE: RNA
 ; ORGANISM: RNAi
 US-10-751-736-49883

Query Match 2.1%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 78.9%; Pred. No. 4.6e+02;
 Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 517 GGAGGTGGAGCCTGGAAG 535
 ||||| ||||| ||||| |||||
 Db 1 GGAGGTGGAGCAGATGAAG 19

RESULT 658
 US-10-916-256-10
 ; Sequence 10, Application US/10916256
 ; Publication No. US20050009106A1
 ; GENERAL INFORMATION:
 ; APPLICANT: de Waal Malefyt, Rene
 ; APPLICANT: Fickenscher, Helmut
 ; APPLICANT: Fleckenstein, Bernhard
 ; APPLICANT: Knappe, Andrea
 ; TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
 ; FILE REFERENCE: DX0644KBK
 ; CURRENT APPLICATION NUMBER: US/10/916,256
 ; CURRENT FILING DATE: 2004-08-10
 ; PRIOR APPLICATION NUMBER: US/10/083,720
 ; PRIOR FILING DATE: 2002-02-28
 ; PRIOR APPLICATION NUMBER: 09/363,993
 ; PRIOR FILING DATE: 1999-07-29
 ; PRIOR APPLICATION NUMBER: 08/934,959
 ; PRIOR FILING DATE: 1997-09-22
 ; PRIOR APPLICATION NUMBER: 60/345,690
 ; PRIOR FILING DATE: 2002-01-03
 ; PRIOR APPLICATION NUMBER: 60/302,176
 ; PRIOR FILING DATE: 2001-06-28
 ; PRIOR APPLICATION NUMBER: 60/027,368
 ; PRIOR FILING DATE: 1996-09-23
 ; NUMBER OF SEQ ID NOS: 21
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 10
 ; LENGTH: 21
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: IL-10 forward.
 ; NAME/KEY: misc feature
 ; LOCATION: (1)..(21)
 ; OTHER INFORMATION: IL-10 forward.
 US-10-916-256-10

Query Match 2.1%; Score 15.8; DB 1; Length 21;

; CURRENT APPLICATION NUMBER: US/09/866,108
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00670
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: US 60/234,687
 ; PRIOR FILING DATE: 2000-09-21
 ; PRIOR APPLICATION NUMBER: US 60/266,860
 ; PRIOR FILING DATE: 2001-02-05
 ; NUMBER OF SEQ ID NOS: 15752
 ; SOFTWARE: Aecomica Sequence Listing Engine
 ; SEQ ID NO 7450
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-866-108-7450

Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 3.9e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 GGAGAGGAGTTCCTCA 428
 |||||
 Db 1 GGAGACGAGTTCCTCA 17

RESULT 662
 US-10-723-361-7246
 ; Sequence 7246, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
 ; FILE REFERENCE: PB0105
 ; CURRENT APPLICATION NUMBER: US/10/723,361
 ; CURRENT FILING DATE: 2003-11-26
 ; PRIOR APPLICATION NUMBER: US 09/866,108
 ; PRIOR FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Aecomica Sequence Listing Engine
 ; SEQ ID NO 7246
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-723-361-7246

Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 3.9e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCGG 713
 |||||
 Db 1 GCTGGAGAGTGAGCGG 17

RESULT 663
 US-10-723-361-7450
 ; Sequence 7450, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
 ; FILE REFERENCE: PB0105
 ; CURRENT APPLICATION NUMBER: US/10/723,361
 ; CURRENT FILING DATE: 2003-11-26
 ; PRIOR APPLICATION NUMBER: US 09/866,108
 ; PRIOR FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Aecomica Sequence Listing Engine
 ; SEQ ID NO 7450
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens

```

US-10-723-361-7450
Query Match      2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 3.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 GGAGAGGAGTCTCTCA 428
    ||||| ||||| |||||
Db 1 GGAGAGGAGTCTCTCA 17

RESULT 664
US-10-454-246-336/c
; Sequence 336, Application US/10454246
; Publication No. US20050053930A1
; GENERAL INFORMATION:
; APPLICANT: Anderson, et al.
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-589 B
; CURRENT APPLICATION NUMBER: US/10/454,246
; CURRENT FILING DATE: 2003-06-03
; PRIOR APPLICATION NUMBER: 03/898,994
; PRIOR FILING DATE: 2001-07-03
; PRIOR APPLICATION NUMBER: 60/218,903
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: 10/016,248
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: 60/255,648
; PRIOR FILING DATE: 2000-12-14
; PRIOR APPLICATION NUMBER: 10/028,248
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 60/256,619
; PRIOR FILING DATE: 2000-12-19
; PRIOR APPLICATION NUMBER: 10/044,564
; PRIOR FILING DATE: 2002-01-11
; PRIOR APPLICATION NUMBER: 60/261,013
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 10/136,071
; PRIOR FILING DATE: 2002-05-01
; PRIOR APPLICATION NUMBER: 60/289,087
; PRIOR FILING DATE: 2001-05-07
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 339
; SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 336
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-454-246-336

Query Match      2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 3.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 556 TGAGGACAGGCTCTG 572
    ||||| ||||| |||||
Db 17 TGAGGACAGGCTCTG 1

RESULT 665
US-09-146-157-3
; Sequence 3, Application US/09146157
; Patent No. US20010009760A1
; GENERAL INFORMATION:
; APPLICANT: HORN, Thomas
; APPLICANT: SCHROEDER, Hartmut R.
; APPLICANT: WARNER, Brian D.
; APPLICANT: FISS, Ellen
; APPLICANT: SELLS, Todd
; APPLICANT: LAW, Say-Jong
; TITLE OF INVENTION: OLIGONUCLEOTIDE PROBES BEARING QUENCHABLE FLUORESCENT LABELS,

```

```

; TITLE OF INVENTION: AND METHODS OF USE THEREOF
; FILE REFERENCE: 1411.002
; CURRENT APPLICATION NUMBER: US/09/146,157
; CURRENT FILING DATE: 1998-09-03
; EARLIER APPLICATION NUMBER: 60/057,810
; EARLIER FILING DATE: 1997-09-04
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: This information
; OTHER INFORMATION: is not available.
US-09-146-157-3

Query Match      2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 867 AATAGACACACATC 883
    ||||| ||||| |||||
Db 2 AGTAGACACACATC 18

RESULT 666
US-09-412-947-2/c
; Sequence 2, Application US/09412947
; Publication No. US20030105035A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, Sudhir
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CP2
; CURRENT APPLICATION NUMBER: US/09/412,947
; CURRENT FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: US 60/103,098
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: mismatched
; OTHER INFORMATION: control synthetic oligonucleotide
US-09-412-947-2

Query Match      2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCAGGAGCGCG 693
    ||||| ||||| |||||
Db 18 GCCAGCAGGAGCGCG 2

RESULT 667
US-09-412-947-5/c
; Sequence 5, Application US/09412947
; Publication No. US20030105035A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, Sudhir
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CP2
; CURRENT APPLICATION NUMBER: US/09/412,947
; CURRENT FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: US 60/103,098
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 8

```

```
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:single
; OTHER INFORMATION: stranded nucleic acid
; OTHER INFORMATION: Description of Artificial Sequence:mismatched
; OTHER INFORMATION: hybrid synthetic oligonucleotide
US-09-412-947-5
Query Match          2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCAGCGCG 693
|||||
DB 18 GCCAGCGAGGAGCGCG 2

RESULT 668
US-09-412-947-7/c
; Sequence 7, Application US/09412947
; Publication No. US20030105035A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, Sudhir
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CP2
; CURRENT APPLICATION NUMBER: US/09/412,947
; CURRENT FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: US 60/103,098
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:single
; OTHER INFORMATION: stranded nucleic acid
; OTHER INFORMATION: Description of Artificial Sequence:mismatched
; OTHER INFORMATION: inverted hybrid synthetic oligonucleotide
US-09-412-947-7
Query Match          2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCAGCGCG 693
|||||
DB 18 GCCAGCGAGGAGCGCG 2

RESULT 669
US-10-641-521-2/c
; Sequence 2, Application US/10641521
; Publication No. US20040106570A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, SUDHIR
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CIPDV-47508.766
; CURRENT APPLICATION NUMBER: US/10/641,521
; CURRENT FILING DATE: 2003-08-15
; PRIOR APPLICATION NUMBER: 09/022,965
; PRIOR FILING DATE: 1998-02-12
; PRIOR APPLICATION NUMBER: 60/040,740
; PRIOR FILING DATE: 1997-03-12
; PRIOR APPLICATION NUMBER: 08/532,979
; PRIOR FILING DATE: 1995-09-22

; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-641-521-5
Query Match          2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCAGCGCG 693
|||||
DB 18 GCCAGCGAGGAGCGCG 2

RESULT 671
US-10-641-521-7/c
; Sequence 7, Application US/10641521
; Publication No. US20040106570A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, SUDHIR
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CIPDV-47508.766
```

; CURRENT APPLICATION NUMBER: US/10/641,521
; CURRENT FILING DATE: 2003-08-15
; PRIOR APPLICATION NUMBER: 09/022,965
; PRIOR FILING DATE: 1998-02-12
; PRIOR APPLICATION NUMBER: 60/040,740
; PRIOR FILING DATE: 1997-03-12
; PRIOR APPLICATION NUMBER: 08/532,979
; PRIOR FILING DATE: 1995-09-22
; PRIOR APPLICATION NUMBER: 08/516,454
; PRIOR FILING DATE: 1995-08-17
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-641-521-7

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGCG 693
Db 18 GCCAGCGAGCGCGCG 2

RESULT 672
US-10-854-989-2/c
; Sequence 2, Application US/10854989
; Publication No. US20050054600A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, SUDHIR
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CP3 (47508.766)
; CURRENT APPLICATION NUMBER: US/10/854,989
; CURRENT FILING DATE: 2004-05-27
; PRIOR APPLICATION NUMBER: 09/708,786
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 09/412,947
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: 08/532,979
; PRIOR FILING DATE: 1995-09-22
; PRIOR APPLICATION NUMBER: 08/516,454
; PRIOR FILING DATE: 1995-08-17
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-854-989-2

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGCG 693
Db 18 GCCAGCGAGCGCGCG 2

RESULT 673
US-10-854-989-5/c
; Sequence 5, Application US/10854989
; Publication No. US20050054600A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, SUDHIR
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CP3 (47508.766)
; CURRENT APPLICATION NUMBER: US/10/854,989
; CURRENT FILING DATE: 2004-05-27
; PRIOR APPLICATION NUMBER: 09/708,786
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 09/412,947
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: 60/164,182
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/103,098
; PRIOR FILING DATE: 1998-10-05
; PRIOR APPLICATION NUMBER: 09/022,965
; PRIOR FILING DATE: 1998-02-12
; PRIOR APPLICATION NUMBER: 08/532,979
; PRIOR FILING DATE: 1995-09-22
; PRIOR APPLICATION NUMBER: 08/516,454
; PRIOR FILING DATE: 1995-08-17
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-854-989-5

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGCG 693
Db 18 GCCAGCGAGCGCGCG 2

RESULT 674
US-10-854-989-7/c
; Sequence 7, Application US/10854989
; Publication No. US20050054600A1
; GENERAL INFORMATION:
; APPLICANT: AGRAWAL, SUDHIR
; TITLE OF INVENTION: MODIFIED PROTEIN KINASE A-SPECIFIC OLIGONUCLEOTIDES AND
; FILE REFERENCE: HYZ-050CP3 (47508.766)
; CURRENT APPLICATION NUMBER: US/10/854,989
; CURRENT FILING DATE: 2004-05-27
; PRIOR APPLICATION NUMBER: 09/708,786
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 09/412,947
; PRIOR FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: 60/164,182
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/103,098
; PRIOR FILING DATE: 1998-10-05
; PRIOR APPLICATION NUMBER: 09/022,965

; PRIOR FILING DATE: 1998-02-12
; PRIOR APPLICATION NUMBER: 08/532,979
; PRIOR FILING DATE: 1995-09-22
; PRIOR APPLICATION NUMBER: 08/516,454
; PRIOR FILING DATE: 1995-08-17
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-854-989-7

Query Match 2.0%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 4.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGCG 593
DB 18 GCCAGCGAGCGCGCG 2

RESULT 675
US-09-863-049A-13
; Sequence 13, Application US/09863049A
; Publication No. US20030032055A1
; GENERAL INFORMATION:
; APPLICANT: Kenrick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Aradhyia, Swareop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Asmaa
; APPLICANT: Israel, Alain
; APPLICANT: Poustka, Annemarie
; APPLICANT: Lewis, Richard A
; APPLICANT: Levy, Meise
; APPLICANT: Heiss, Nina
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Def
; FILE REFERENCE: HO-P01961US1
; CURRENT APPLICATION NUMBER: US/09/863,049A
; PRIOR FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Human
US-09-863-049A-13

Query Match 2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 541 CCAGCGAGCGATGCTG 557
DB 4 CCTGCAGCGATGCTG 20

RESULT 676
US-10-211-028-145/c
; Sequence 145, Application US/10211028
; Publication No. US20050027113A1

; GENERAL INFORMATION:
; APPLICANT: CUBIST PHARMACEUTICALS, INC.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS RELATING TO THE DAPTOMYCIN
; FILE REFERENCE: BIOSYNTHETIC GENE CLUSTER
; FILE REFERENCE: CUB-12 PCT CIP
; CURRENT APPLICATION NUMBER: US/10/211,028
; CURRENT FILING DATE: 2002-07-31
; PRIOR APPLICATION NUMBER: PCT/US02/24310
; PRIOR FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: PCT/US01/32354
; PRIOR FILING DATE: 2001-10-17
; PRIOR APPLICATION NUMBER: 60/310,385
; PRIOR FILING DATE: 2001-08-06
; PRIOR APPLICATION NUMBER: 60/379,866
; PRIOR FILING DATE: 2002-05-10
; NUMBER OF SEQ ID NOS: 170
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 145
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Streptomyces roseosporus
US-10-211-028-145

Query Match 2.0%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 546 AGCAGATGGCTGAGGAC 562
DB 18 AGGAGATGGCTGAGGAC 2

RESULT 677
US-09-752-639-131
; Sequence 131, Application US/09752639
; Patent No. US20020091243A1
; GENERAL INFORMATION:
; APPLICANT: Gatanaga, T.
; APPLICANT: Granger, G.A.
; TITLE OF INVENTION: Factors Altering Tumor Necrosis
; TITLE OF INVENTION: Factor Receptor Releasing Enzyme Activity, and Methods
; TITLE OF INVENTION: of Use Thereof
; NUMBER OF SEQUENCES: 154
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/752,639
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US99/10793
; FILING DATE:
; APPLICATION NUMBER: 09/081,385
; FILING DATE:
; APPLICATION NUMBER: 08/964,747
; FILING DATE: 05-NOV-1997
; APPLICATION NUMBER: 60/030,761
; FILING DATE: 06-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Wu, Frank
; REGISTRATION NUMBER: 41,386
; REFERENCE/DOCKET NUMBER: 22000-20577.21
; TELECOMMUNICATION INFORMATION:

```

; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 131:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-752-639-131

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 471 GCCTGGAGAGCTCGATCTG 490
Db 1 GCCTGGAGAGCCCGACTG 20

RESULT 678
US-09-984-198-131
; Sequence 131, Application US/09984198
; Patent No. US20020106679A1
; GENERAL INFORMATION:
; APPLICANT: Gatanaga, T.
; TITLE OF INVENTION: Factors Altering Tumor Necrosis
; TITLE OF INVENTION: Factor Receptor Releasing Enzyme Activity, and Methods
; TITLE OF INVENTION: of Use Thereof
; NUMBER OF SEQUENCES: 154
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; APPLICATION DATA:
; APPLICATION NUMBER: US/09/984,198
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US99/10793
; FILING DATE:
; FILING DATE:
; APPLICATION NUMBER: 09/081,385
; APPLICATION NUMBER: 08/964,747
; FILING DATE: 05-NOV-1997
; APPLICATION NUMBER: 60/030,761
; FILING DATE: 06-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Wu, Frank
; REGISTRATION NUMBER: 41,386
; REFERENCE/DOCKET NUMBER: 22000-20577.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 131:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-984-198-131

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 471 GCCTGGAGAGCTCGATCTG 490
Db 1 GCCTGGAGAGCCCGACTG 20

RESULT 679
US-09-836-697-3
; Sequence 3, Application US/09836697
; Patent No. US20020142311A1
; GENERAL INFORMATION:
; APPLICANT: Siffert, Winfried
; TITLE OF INVENTION: THE USE OF A GENETIC MODIFICATION IN THE GENE FOR HUMAN
; TITLE OF INVENTION: G PROTEIN b3 SUBUNIT FOR THE DIAGNOSIS OF DISEASES
; FILE REFERENCE: 1135-2
; CURRENT APPLICATION NUMBER: US/09/836,697
; CURRENT FILING DATE: 2001-04-16
; PRIOR APPLICATION NUMBER: 09/180,783
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: DE 19619362.1
; PRIOR FILING DATE: 1996-05-14
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-836-697-3

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 513 TCGGGAGGTGAGCACCTG 532
Db 1 TGGGGAGATGAGCAACTG 20

RESULT 680
US-09-765-555-31
; Sequence 31, Application US/09765555
; Publication No. US20030037355A1
; GENERAL INFORMATION:
; APPLICANT: The Scripps Research Institute
; TITLE OF INVENTION: Methods and compositions to modulate
; TITLE OF INVENTION: expression in plants
; FILE REFERENCE: 27801-20014.40
; CURRENT APPLICATION NUMBER: US/09/765,555
; CURRENT FILING DATE: 2002-05-24
; PRIOR APPLICATION NUMBER: US 09/620,897
; PRIOR FILING DATE: 2000-01-21
; PRIOR APPLICATION NUMBER: US 60/177,468
; PRIOR FILING DATE: 2000-01-21
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer NZlib5'
US-09-765-555-31

Query Match 2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 667 GCGCCGGCGGCCGAGCAGC 686
Db 1 GCGCCAGGCGGCCCTCGAGC 20

```



```
RESULT 681
US-10-160-807-122/c
; Sequence 122, Application US/10160807
; Publication No. US20030224514A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/160,807
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 122
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-807-122

Query Match          2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 826 GCTGCCCGGAGTTCAGGTGG 845
      ||||| ||||| ||||| |||||
DB 20 GCTGGACCGAGCTGCAGATGG 1

RESULT 682
US-10-160-807-261
; Sequence 261, Application US/10160807
; Publication No. US20030224514A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/160,807
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 261
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
US-10-160-807-261

Query Match          2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 826 GCTGCCCGGAGTTCAGGTGG 845
      ||||| ||||| ||||| |||||
DB 20 GCTGGACCGAGCTGCAGATGG 1

RESULT 683
US-10-161-983-15
; Sequence 15, Application US/10161983
; Publication No. US20030225015A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF RB2/PI30 EXPRESSION
; FILE REFERENCE: HTS-0020
; CURRENT APPLICATION NUMBER: US/10/161,983
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 74
; SEQ ID NO 15
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-161-983-15

Query Match          2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCTCTCATGTGC 433
      ||||| ||||| ||||| |||||
DB 1 AGTAGGAGTTTCTCTCTGTGC 20

RESULT 684
US-10-161-983-52/c
; Sequence 52, Application US/10161983
; Publication No. US20030225015A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF RB2/PI30 EXPRESSION
; FILE REFERENCE: HTS-0020
; CURRENT APPLICATION NUMBER: US/10/161,983
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 74
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-161-983-52

Query Match          2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCTCTCATGTGC 433
      ||||| ||||| ||||| |||||
DB 20 AGTAGGAGTTTCTCTCTGTGC 1

RESULT 685
US-10-303-199A-7
; Sequence 7, Application US/10303199A
; Publication No. US20040023209A1
; GENERAL INFORMATION:
; APPLICANT: Pyrosequencing AB
; TITLE OF INVENTION: Method for Identifying Microorganisms based on Sequencing Gene Frag
; FILE REFERENCE: 27.76010/002
; CURRENT APPLICATION NUMBER: US/10/303,199A
; CURRENT FILING DATE: 2002-11-25
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: ().?)
; OTHER INFORMATION: Primer: B-V3.AS
US-10-303-199A-7

Query Match          2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 251 AAGCCAGCCATGCTGCACCT 270
      ||||| ||||| ||||| |||||
DB 1 ACGACAGCCATGCGACGACCT 20
```

```

RESULT 686
US-10-380-125-61/c
; Sequence 61, Application US/10380125
; Publication No. US20040048818A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Ian Popoff
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF E2F TRANSCRIPTION FACTOR 2 EXPRESSION
; FILE REFERENCE: R1SP-0176
; CURRENT APPLICATION NUMBER: US/10/380,125
; PRIOR FILING DATE: 2003-03-10
; PRIOR APPLICATION NUMBER: 09/658,679
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-125-61

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 548 CAGATGGCTGAGGACGAGGC 567
Db 20 CACCTGACTGAGGACGAGGC 1

RESULT 687
US-10-655-847-122/c
; Sequence 122, Application US/10655847
; Publication No. US20040063129A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/655,847
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: US/10/160,807
; PRIOR FILING DATE: 2003-09-05
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 122
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-655-847-122

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 826 GCTGGCCCACTTGCAGGTGG 845
Db 20 GCTGGACCAGCTGCAGATGG 1

RESULT 688
US-10-655-847-261
; Sequence 261, Application US/10655847
; Publication No. US20040063129A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Susan M. Freier

```

```

; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPAR-DELTA EXPRESSION
; FILE REFERENCE: RTS-0189
; CURRENT APPLICATION NUMBER: US/10/655,847
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: US/10/160,807
; PRIOR FILING DATE: 2003-09-05
; NUMBER OF SEQ ID NOS: 296
; SEQ ID NO 261
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
US-10-655-847-261

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 826 GCTGGCCCACTTGCAGGTGG 845
Db 1 GCTGGACCAGCTGCAGATGG 20

RESULT 689
US-10-688-706-2714
; Sequence 2714, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2714
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-2714

Query Match      2.0%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 162 TCTGGAAGAGCCCACTGTGT 181
Db 1 TATGGAAGTCCCACTGTGT 20

RESULT 690
US-09-863-049A-62
; Sequence 62, Application US/09863049A
; Publication No. US20030032055A1
; GENERAL INFORMATION:
; APPLICANT: Kenrick, Sue J.
; APPLICANT: Nelson, David L.
; APPLICANT: Aradhya, Swaroop
; APPLICANT: D'Urso, Michele
; APPLICANT: Woffendin, Hayley
; APPLICANT: Munnich, Arnold
; APPLICANT: Smahi, Asmae
; APPLICANT: Israel, Alain
; APPLICANT: Poustka, Annemarie
; APPLICANT: Lewis, Richard A
; APPLICANT: Levy, Moise
; APPLICANT: Heiss, Nina

```

```
; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Def
; TITLE OF INVENTION: NFKBPA B (NF-KB) Activation
; FILE REFERENCE: HO-P01961US1
; CURRENT APPLICATION NUMBER: US/09/863,049A
; CURRENT FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 62
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Human
US-09-863-049A-62

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 269 CTGCCTTCAGAACAG 283
      |||||
Db 1 CTGCCTTCAGAACAG 15

RESULT 691
US-10-156-306-7813
; Sequence 7813, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7813
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7813

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 3.7e+02;
Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 420 AGTTCCTCATGTGCA 434
      ||::|||
Db 1 AGUUCUCAUGUGCA 15

RESULT 692
US-10-156-306-7826
; Sequence 7826, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7826
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7826

; TITLE OF INVENTION: Diagnosis and Treatment of Medical Conditions Associated with Def
; TITLE OF INVENTION: NFKBPA B (NF-KB) Activation
; FILE REFERENCE: HO-P01961US1
; CURRENT APPLICATION NUMBER: US/09/863,049A
; CURRENT FILING DATE: 2001-05-22
; PRIOR APPLICATION NUMBER: US 60/206,223
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 62
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Human
US-09-863-049A-62

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 269 CTGCCTTCAGAACAG 283
      |||||
Db 1 CTGCCTTCAGAACAG 15

RESULT 691
US-10-156-306-7813
; Sequence 7813, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7813
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7813

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 3.7e+02;
Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 420 AGTTCCTCATGTGCA 434
      ||::|||
Db 1 AGUUCUCAUGUGCA 15

RESULT 692
US-10-156-306-7826
; Sequence 7826, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7826
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7826
```

```
Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 317 GAGAAATCAAGAGCTC 331
      |||||
Db 1 GAGAAUCAAAGAGCUC 15

RESULT 693
US-10-156-306-7828
; Sequence 7828, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7828
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7828

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 549 AGATGGCTGAGGACA 563
      ||::|||
Db 1 AGAUGGCUAGAGACA 15

RESULT 694
US-10-156-306-7829
; Sequence 7829, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7829
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7829

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.7e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 561 ACAAGGCCTCTGTGA 575
      |||||
Db 1 ACNAGGCCUCUGUGA 15

RESULT 695
US-10-156-306-7831
; Sequence 7831, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7831
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7831

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 573 TGAAGCCCGAGTGA 587
Db 1 UGAAAGCCCGAGGUA 15

RESULT 696
US-10-156-306-7847
; Sequence 7847, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7847
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7847

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 297 CCCTCAGCGCTGCC 311
Db 1 CCCUCCAGCGCCUGCC 15

RESULT 697
US-10-156-306-7848
; Sequence 7848, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7848
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7848

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 297 CCCTCAGCGCTGCC 311
Db 1 CCCUCCAGCGCCUGCC 15

RESULT 698
US-10-156-306-7851
; Sequence 7851, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7851
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7851

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 321 ATCAAGAGCTCCGAG 335
Db 1 AUCRAAGAGCUCCGAG 15

RESULT 699
US-10-156-306-7853
; Sequence 7853, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7853
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7853

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.7e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAAGC 579
Db 1 GGCUCUCUGGAAAGC 15

RESULT 700
US-10-156-306-7861
; Sequence 7861, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
```

```
Best Local Similarity 80.0%; Pred. No. 3.7e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 299 CTCACAGCGCTGCTG 313
Db 1 CUCCAGCGCUGCCUG 15

RESULT 698
US-10-156-306-7851
; Sequence 7851, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7851
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7851

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 321 ATCAAGAGCTCCGAG 335
Db 1 AUCRAAGAGCUCCGAG 15

RESULT 699
US-10-156-306-7853
; Sequence 7853, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7853
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7853

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.7e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCCTCTGTGAAAGC 579
Db 1 GGCUCUCUGGAAAGC 15

RESULT 700
US-10-156-306-7861
; Sequence 7861, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
```

```

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7861
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7861

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.7e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 431 TCACAGTTCAGGAG 445
      :|||||:|||||
Db 1 UGCAAGUCCAGGAG 15

RESULT 701
US-10-156-306-7866
; Sequence 7866, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7866
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7866

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 734 AGCGTCAGGTGAG 748
      :|||||:|||||
Db 1 AGCGUCAGGUGGAC 15

RESULT 702
US-10-156-306-7876
; Sequence 7876, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7876
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7876

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Indels 0; Gaps 0;

```

```

Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 209 GCAGCAGATCAGGAC 223
      :|||||:|||||
Db 1 GCAGCAGAUCCAGGAC 15

RESULT 703
US-10-156-306-7877
; Sequence 7877, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7877
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7877

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 531 TGAAGAGATGCCAGC 545
      :|||||:|||||
Db 1 UGAAGAGAUCCAGC 15

RESULT 704
US-10-156-306-7878
; Sequence 7878, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7878
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7878

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 861 TCCAAGAATACGACA 875
      :|||||:|||||
Db 1 UCCAAGAAUCCAGCA 15

RESULT 705
US-10-156-306-7880
; Sequence 7880, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

```

```
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 7880
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7880

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.7e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 208 GGCAGCAGATCAGCA 222
Db 1 GGCAGCAGATCAGCA 15

RESULT 706
US-10-156-306-7881
; Sequence 7881, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MEHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 7881
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7881

Query Match      2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 810 CGGAGGAGAGAGAGGA 824
Db 1 CGGAGGAGAGAGAGGA 15

RESULT 707
US-09-866-108-7244
; Sequence 7244, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7244
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7244

Query Match      2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCG 711
Db 3 GCTGGAGAGTGAGCG 17

RESULT 708
US-09-866-108-7245
; Sequence 7245, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
```

; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00670
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: US 60/234,687
 ; PRIOR FILING DATE: 2000-09-21
 ; PRIOR APPLICATION NUMBER: US 60/266,860
 ; PRIOR FILING DATE: 2001-02-05
 ; NUMBER OF SEQ ID NOS: 15752
 ; SOFTWARE: Aecomica Sequence Listing Engine
 ; SEQ ID NO 7245
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-866-108-7245

Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCG 711
 |||||
 Db 2 GCTGGAGAGTGAGCG 16

RESULT 709
 US-10-156-306-6965
 ; Sequence 6965, Application US/10156306
 ; Publication No. US20030119017A1
 ; GENERAL INFORMATION:
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
 ; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
 ; FILE REFERENCE: MEH01-664-A (400/050)
 ; CURRENT APPLICATION NUMBER: US/10/156,306
 ; CURRENT FILING DATE: 2002-05-28
 ; NUMBER OF SEQ ID NOS: 8013
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 6965
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-156-306-6965

Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 4.3e+02;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 902 AGTGAGCGAAGCGA 916
 |||||
 Db 1 AGUGAGCGAAGCGA 15

RESULT 710
 US-10-723-361-7244
 ; Sequence 7244, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
 ; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361
 ; CURRENT FILING DATE: 2003-11-26
 ; PRIOR APPLICATION NUMBER: US 09/866,108
 ; PRIOR FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Aecomica Sequence Listing Engine
 ; SEQ ID NO 7244
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-723-361-7244

Query Match 2.0%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCG 711
 |||||
 Db 3 GCTGGAGAGTGAGCG 17

RESULT 711
 US-10-723-361-7245
 ; Sequence 7245, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
 ; FILE REFERENCE: PB0105
 ; CURRENT APPLICATION NUMBER: US/10/723,361
 ; CURRENT FILING DATE: 2003-11-26
 ; PRIOR APPLICATION NUMBER: US 09/866,108
 ; PRIOR FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7245
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7245

Query Match          2.0%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGCG 711
Db 2 GCTGGAGAGTGAGCG 16

RESULT 712
US-10-440-850-1112/c
; Sequence 1112, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Reversal
; TITLE OF INVENTION: Immune Responses
; FILE REFERENCE: 250/130 (MBHB00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1112
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-440-850-1112

Query Match          2.0%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 719 CTGCAGCAGCAGCAC 733
Db 17 CTGCAGCAGCAGCAC 3

RESULT 713
US-09-940-227-71/c
; Sequence 71, Application US/09940227
; Publication No. US20030017468A1
; GENERAL INFORMATION:
; APPLICANT: Chen, Sei Yu
; APPLICANT: Macina, Roberto
; APPLICANT: Sun, Yongming
; APPLICANT: Recipon, Hervé
; TITLE OF INVENTION: Compositions and Methods Relating to Lung Specific
; FILE REFERENCE: DEX-0230
; CURRENT APPLICATION NUMBER: US/09/940,227
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: 60/041182
; PRIOR FILING DATE: 1997-03-21
; NUMBER OF SEQ ID NOS: 10
```

```
; CURRENT FILING DATE: 2001-08-27
; PRIOR APPLICATION NUMBER: 60/228,378
; PRIOR FILING DATE: 2000-08-28
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-940-227-71

Query Match          2.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 890 AGCGTGGTGGCAGT 904
Db 15 AGCGTGGTGGCAGT 1

RESULT 714
US-10-933-058-71/c
; Sequence 71, Application US/10933058
; Publication No. US20050026211A1
; GENERAL INFORMATION:
; APPLICANT: Chen, Sei Yu
; APPLICANT: Macina, Roberto
; APPLICANT: Sun, Yongming
; APPLICANT: Recipon, Hervé
; TITLE OF INVENTION: Compositions and Methods Relating to Lung Specific
; FILE REFERENCE: DEX-0230
; CURRENT APPLICATION NUMBER: US/10/933,058
; CURRENT FILING DATE: 2004-09-02
; PRIOR APPLICATION NUMBER: US/09/940,227
; PRIOR FILING DATE: 2001-08-27
; PRIOR APPLICATION NUMBER: 60/228,378
; PRIOR FILING DATE: 2000-08-28
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-933-058-71

Query Match          2.0%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 890 AGCGTGGTGGCAGT 904
Db 15 AGCGTGGTGGCAGT 1

RESULT 715
US-09-863-777-3/c
; Sequence 3, Application US/09863777
; Patent No. US20020019359A1
; GENERAL INFORMATION:
; APPLICANT: Olson, Karen A.
; APPLICANT: Fett, James W.
; TITLE OF INVENTION: Antisense Inhibition of Angiogenin Expression
; FILE REFERENCE: 10498/05286
; CURRENT APPLICATION NUMBER: US/09/863,777
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: 60/041182
; PRIOR FILING DATE: 1997-03-21
; NUMBER OF SEQ ID NOS: 10
```



```

; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: phosphorothioate oligodeoxynucleotide
US-09-863-777-3

```

```

Query Match          2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 845 GCCTATCACCGCTCTTC 862
    ||| ||||| |||||
DB 18 GCCCATCACCATCTCTTC 1

```

```

RESULT 716
US-09-863-777-4
; Sequence 4, Application US/09863777
; Patent No. US20020019359A1
; GENERAL INFORMATION:
; APPLICANT: Fett, James W.
; APPLICANT: Olson, Karen A.
; TITLE OF INVENTION: Antisense Inhibition of Angiogenin Expression
; FILE REFERENCE: 10498/05286
; CURRENT APPLICATION NUMBER: US/09/863,777
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: 60/041182
; PRIOR FILING DATE: 1997-03-21
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: phosphorothioate oligodeoxynucleotide
US-09-863-777-4

```

```

Query Match          2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 845 GCCTATCACCGCTCTTC 862
    ||| ||||| |||||
DB 1  GCCCATCACCATCTCTTC 18

```

```

RESULT 717
US-10-349-143-8682
; Sequence 8682, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796

```

```

; SEQ ID NO 8682
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-17522 for SEQ 817, in complemer
US-10-349-143-8682

```

```

Query Match          2.0%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 492 AGAGCGAGAGGAGCAGG 509
    ||||| ||||| |||||
DB 1  AGAGGAGAGGAGGAGCAGG 18

```

```

RESULT 718
US-10-297-068-880
; Sequence 880, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 13140P1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 880
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-880

```

```

Query Match          2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 310 CCTGGAGGAGGAATCAAGA 327
    ||||| ||||| |||||
DB 1  CCTGGAGGAGGAATCGGGA 18

```

```

RESULT 719
US-10-444-795B-213/c
; Sequence 213, Application US/10444795B
; Publication No. US2004007574A1
; GENERAL INFORMATION:
; APPLICANT: Klinghoffer, Richard
; APPLICANT: Lewis, Stephen Patrick
; TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
; TITLE OF INVENTION: TRANSDUCTION BY RNA INTERFERENCE
; FILE REFERENCE: 200125.449
; CURRENT APPLICATION NUMBER: US/10/444,795B
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 842
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 213
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence

```

```
;
; FEATURE:
; OTHER INFORMATION: Small interfering RNA
US-10-444-795B-213

Query Match      2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 215 GATCAGGACGTACTGGGC 232
Db 19 GATCAGATGTACTGGGC 2

RESULT 720
US-10-665-951-1036
; Sequence 1036, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1036
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-665-951-1036

Query Match      2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 5.2e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 811 GGAGGAGAGAGGAAGCT 828
Db 1 GUAGAGAGAGAGGAGCU 18

RESULT 721
US-10-665-951-1360/c
; Sequence 1360, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1360
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-665-951-1360

Query Match      2.0%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 GGAGGAGAGAGGAAGCT 828
Db 19 GTAGAGAGAGAGGAAGCT 2

RESULT 722
US-09-866-108-7247
; Sequence 7247, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7247
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7247
```

```
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 698 CTGGAGAGTGAGCGG 713
Db 1 CTGGAGAGTGAGCGG 16
|||||
```

```
RESULT 723
US-09-866-108-7449
; Sequence 7449, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7449
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7449
```

```
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 412 GGAGAAGGAGTTCTTC 427
Db 2 GGAGAAGGAGTTCTTC 17
|||||
```

```
RESULT 724
US-09-866-108-7451
; Sequence 7451, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
```

; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7451
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7451

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02; Mismatches 0; Gaps 0;
Matches 15; Conservative 0; Indels 1; Indels 0; Gaps 0;

Qy 413 GAGAACGAGTCTCTCA 428
Db 1 GAGAACGAGTCTCTCA 16

RESULT 725

US-09-866-108-8970/c
; Sequence 8970, Application US/09866108
; Patent No. US20020048800A1

GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: Aeomica Sequence Listing Engine

; SEQ ID NO 8970

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108-8970

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02; Mismatches 0; Gaps 0;
Matches 15; Conservative 0; Indels 1; Indels 0; Gaps 0;

Qy 851 CACGAGCTCTTCCAAG 866
Db 17 CACGAGCTCTTCCATG 2

RESULT 726

US-09-866-108-8971/c
; Sequence 8971, Application US/09866108
; Patent No. US20020048800A1

GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: Aeomica Sequence Listing Engine

; SEQ ID NO 8971

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108-8971

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02; Mismatches 0; Gaps 0;
Matches 15; Conservative 0; Indels 1; Indels 0; Gaps 0;

Qy 851 CACGAGCTCTTCCAAG 866
Db 16 CACGAGCTCTTCCATG 1

RESULT 727

US-09-740-332-1362/c
; Sequence 1362, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1362
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1362

Query Match 1.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 5e+02; Mismatches 0; Gaps 0; Indels 1;

QY 594 TGCTCGGGAGCTGCA 609
Db 16 TGCTCGGGAGCTGCA 1

RESULT 728

US-09-817-879-1362/c
; Sequence 1362, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBH800-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1362
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1362

Query Match 1.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 5e+02; Mismatches 0; Gaps 0; Indels 1;

QY 594 TGCTCGGGAGCTGCA 609
Db 16 TGCTCGGGAGCTGCA 1

RESULT 729

US-10-669-841-3955/c
; Sequence 3955, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen

; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS
; FILE REFERENCE: 400/042US (MBH802-249-B)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3955
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-3955
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02; Mismatches 0; Gaps 0; Indels 1;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 594 TGCTCGGGAGCTGCA 609
Db 16 TGCTCGGGAGCTGCA 1
RESULT 730
US-10-723-361-7247
; Sequence 7247, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AND SKELETAL MUSCLE
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456

```
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7247
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7247
```

```
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 698 CTGAGAGTGCAGCG 713
DB 1 CTGAGAGTGCAGCG 16
```

```
RESULT 731
US-10-723-361-7449
; Sequence 7449, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
```

```
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7449
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7449
```

```
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 412 GGAGAGGAGTTCCTC 427
DB 2 GGAGAGGAGTTCCTC 17
```

```
RESULT 732
US-10-723-361-7451
; Sequence 7451, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7451
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7451
```

```
Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 413 GAGAGGAGTTCCTCA 428
DB 1 GAGAGGAGTTCCTCA 16
```

```
RESULT 733
US-10-723-361-8970/c
; Sequence 8970, Application US/10723361
```

```

; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8970
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8970

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCCAG 866
Db 17 CACCAGCTCTTCCATG 2

RESULT 734
US-10-723-361-8971/c
; Sequence 8971, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04

```

```

; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8971
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8971

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCCAG 866
Db 16 CACCAGCTCTTCCATG 1

RESULT 735
US-09-995-529-188/c
; Sequence 188, Application US/09995529
; Publication No. US20030099655A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; APPLICANT: Tang, Ying
; APPLICANT: Huse, William D.
; TITLE OF INVENTION: Humanized Collagen Antibodies and
; TITLE OF INVENTION: Related Methods
; FILE REFERENCE: P-IX 4976
; CURRENT APPLICATION NUMBER: US/09/995,529
; CURRENT FILING DATE: 2001-11-26
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 188
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-995-529-188

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 5.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 347 CAGAGCAACCAGATTC 362
Db 17 CAGAGCAACCAGATTC 2

RESULT 736
US-09-995-529-188/c
; Sequence 188, Application US/09995529
; Publication No. US20040091482A9
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; APPLICANT: Huse, William D.
; APPLICANT: Tang, Ying
; TITLE OF INVENTION: Humanized Collagen Antibodies and

```

```

; TITLE OF INVENTION: Related Methods
; FILE REFERENCE: P-IX 4976
; CURRENT APPLICATION NUMBER: US/09/995,529
; CURRENT FILING DATE: 2001-11-26
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 188
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; US-09-995-529-188

Query Match          1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 5.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 347 CAGAGCAACGATTC 362
Db 17 CAGAGCAACGATTC 2

RESULT 737
US-10-440-850-1113/c
; Sequence 1113, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Stinchcomb, Dan
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Reversal
; FILE REFERENCE: 250/130 (MBHB00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR FILING DATE: 2000-08-28
; PRIOR FILING DATE: 1998-03-11
; PRIOR FILING DATE: 1996-01-12
; PRIOR FILING DATE: 1995-07-07
; PRIOR FILING DATE: 1995-07-07
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1113
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-440-850-1113

Query Match          1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 5.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 717 CGCTGCAGCAGCAGCA 732
Db 16 CCTGCAGCAGCAGCA 1

RESULT 738
US-10-349-143-10970/c
; Sequence 10970, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
```

```

; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 10970
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-23427 for SEQ 3105, in complement
; US-10-349-143-10970

Query Match          1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 5.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 811 GGAGGAGAGGAGGAG 826
Db 17 GGAGGAGAGGAGGAG 2

RESULT 739
US-10-226-992-70
; Sequence 70, Application US/10226992
; Publication No. US20030148507A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Fornaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Prostaglandin D2 Receptor
; TITLE OF INVENTION: and Prostaglandin D2 Synthetase (PTGDS) Gene Expression Using Sh
; FILE REFERENCE: 400/055 (MBHB01-1110-B)
; CURRENT APPLICATION NUMBER: US/10/226,992
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 70
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
; US-10-226-992-70

Query Match          1.9%; Score 14.4; DB 1; Length 19;
Best Local Similarity 81.2%; Pred. No. 5.7e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 487 TCTGAGAGGCGAGAAG 502
Db 3 UCUGAAGAGCAGAGAAG 18

RESULT 740
US-10-226-992-153/c
; Sequence 153, Application US/10226992
; Publication No. US20030148507A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Fornaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Prostaglandin D2 Receptor
```



```

; TITLE OF INVENTION: and Prostaglandin D2 Synthetase (PTGDS) Gene Expression Using SH
; FILE REFERENCE: 400/055 (MBH01-1110-B)
; CURRENT APPLICATION NUMBER: US/10/226,992
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 153
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-226-992-153

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 487 TCTGAAGAGCAGAG 502
17 TCTGAAGAGCAGAG 2

Db

RESULT 741
US-10-830-287A-8/c
; Sequence 8, Application US/10830287A
; Publication No. US20050038238A1
; GENERAL INFORMATION:
; APPLICANT: Kriesel, John D.
; APPLICANT: Jones, Brandt B.
; APPLICANT: Grissom, Charles B.
; APPLICANT: Herpin, Geoff
; APPLICANT: Glazer, Peter M.
; TITLE OF INVENTION: OLIGONUCLEOTIDE COMPLEXES FOR USE AS ANTI-VIRAL THERAPEUTICS
; FILE REFERENCE: 007180-19
; CURRENT APPLICATION NUMBER: US/10/830,287A
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,270
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Variola virus
US-10-830-287A-8

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 405 AGAGGAGGAGGAGGA 420
16 AGAGGAGGAGGAGGA 1

Db

RESULT 742
US-09-866-108-7243
; Sequence 7243, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7

```

```

; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7243
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7243

Query Match
Best Local Similarity 1.9%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGAGTGAGC 710
4 GCTGGAGAGTGAGC 17

Db

RESULT 743
US-09-866-108-8972/c
; Sequence 8972, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30

```

; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00670
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: US 60/234,697
 ; PRIOR FILING DATE: 2000-09-21
 ; PRIOR APPLICATION NUMBER: US 60/266,860
 ; PRIOR FILING DATE: 2001-02-05
 ; NUMBER OF SEQ ID NOS: 15752
 ; SOFTWARE: Aeomica Sequence Listing Engine
 ; SEQ ID NO 8972
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-866-108-8972

Query Match 1.9%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 5.5e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCCA 864
 DB 15 CACCAGCTCTTCCA 2

RESULT 744
 US-09-866-108-8973/c
 ; Sequence 8973, Application US/09866108
 ; Patent No. US20020048800A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: AEOMICA-7
 ; CURRENT APPLICATION NUMBER: US/09/866,108
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00670
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: US 60/234,687
 ; PRIOR FILING DATE: 2000-09-21
 ; PRIOR APPLICATION NUMBER: US 60/266,860
 ; PRIOR FILING DATE: 2001-02-05
 ; NUMBER OF SEQ ID NOS: 15752
 ; SOFTWARE: Aeomica Sequence Listing Engine
 ; SEQ ID NO 8973
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-866-108-8973

Query Match 1.9%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 5.5e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCCA 864
 DB 14 CACCAGCTCTTCCA 1

RESULT 745
 US-10-084-839-3739
 ; Sequence 3739, Application US/10084839
 ; Publication No. US20030186238A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Third Wave Technologies
 ; APPLICANT: Allawi, Hatim
 ; APPLICANT: Argue, Brad T.
 ; APPLICANT: Bartholomay, Christian T.
 ; APPLICANT: Chehak, LuAnne
 ; APPLICANT: Curtis, Michelle L.
 ; APPLICANT: Eis, Peggy S.
 ; APPLICANT: Hall, Jeff G.
 ; APPLICANT: Ip, Hon S.
 ; APPLICANT: Ji, Lin
 ; APPLICANT: Kaiser, Michael
 ; APPLICANT: Kwiatkowski, Jr., Robert W.
 ; APPLICANT: Lukowiak, Andrew A.
 ; APPLICANT: Lyamichev, Victor
 ; APPLICANT: Lymaicheva, Natalie E.
 ; APPLICANT: Ma, WuPo
 ; APPLICANT: Neri, Bruce P.
 ; APPLICANT: Olson, Sarah M.
 ; APPLICANT: Olson-Munoz, Marilyn C.
 ; APPLICANT: Schaefer, James J.
 ; APPLICANT: Skrzypczynski, Zbigniew
 ; APPLICANT: Takova, Tssetska Y.
 ; APPLICANT: Thompson, Lisa C.
 ; APPLICANT: Vedvik, Kevin L.
 ; TITLE OF INVENTION: RNA Detection Assays
 ; FILE REFERENCE: FORS-06666
 ; CURRENT APPLICATION NUMBER: US/10/084,839
 ; CURRENT FILING DATE: 2002-02-26
 ; NUMBER OF SEQ ID NOS: 4004
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 3739
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic
 US-10-084-839-3739

Query Match 1.9%; Score 14; DB 1; Length 17;

```

Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 187 GGTGAGCCAGTG 200
Db 1 GGTGAGCCAGTG 14

RESULT 746
US-10-723-361-7243
; Sequence 7243, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7243
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7243

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 GCTGGAGTGAGC 710
Db 4 GCTGGAGTGAGC 17

RESULT 747
US-10-723-361-8972/c
; Sequence 8972, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7243
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7243

```

```

; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8972
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8972

Query Match 1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCCA 864
Db 15 CACCAGCTCTTCCA 2

RESULT 748
US-10-723-361-8973/c
; Sequence 8973, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30

```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8973
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8973

Query Match      1.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      851 CACCAGCTCTCCA 864
Db      14 CACCAGCTCTCCA 1

RESULT 749
US-09-866-108-6823/c
; Sequence 6823, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8973
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7698

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6823

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      266 CACCTGCCTTCAGACA 282
Db      17 CACCTGCCTTCAGAAAA 1

RESULT 750
US-09-866-108-7698/c
; Sequence 7698, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7698
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7698

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 827 CTGGCCCGAGTTCAGGT 843

Db 17 CTGGGCCAGCTCAGGT 1

RESULT 751

US-09-866-108-7813
; Sequence 7813, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/266,860
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7813
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7813

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 493 GAGCAGCAGGAGCAGG 509

Db 1 GAAGCAAAAGGAGCAGG 17

RESULT 752

US-09-866-108-8421
; Sequence 8421, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8421
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8421

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAGGAG 505

Db 1 TGAAGAGCGCAGAGGAGTG 17

RESULT 753

US-09-866-108-8422
; Sequence 8422, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25

Query Match	1.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	64.7%;	Pred. No. 5.8e+02;		

Best Local Similarity 88.2%; Pred. NO. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TGCAGGAGCTTCTGCA 390
 ||||| :|||:|:|
 Db 17 TGCAGGCGCTTCTGCA 1

RESULT 757
 US-09-818-875-3455
 ; Sequence 3455, Application US/09818875
 ; Publication No. US20030051270A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Howard B.
 ; APPLICANT: Gamper, Howard B.
 ; APPLICANT: Rice, Michael C.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; TITLE OF INVENTION: Stranded Oligonucleotides
 ; FILE REFERENCE: Napro-4
 ; CURRENT APPLICATION NUMBER: US/09/818,875
 ; CURRENT FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3455
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-818-875-3455

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TGCAGGAGCTTCTGCA 390
 ||||| :|||:|:|
 Db 1 TGCAGGCGCTTCTGCA 17

RESULT 758
 US-09-927-046-478
 ; Sequence 478, Application US/09927046
 ; Publication No. US20030064946A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Thompson, Jim
 ; APPLICANT: McKenzie, Tim
 ; APPLICANT: Ayers, Dave
 ; APPLICANT: Grupe, Andrew
 ; APPLICANT: Szymkowski, Edmund
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
 ; TITLE OF INVENTION: Channel-1
 ; FILE REFERENCE: 249/021
 ; CURRENT APPLICATION NUMBER: US/09/927,046
 ; CURRENT FILING DATE: 2001-08-09
 ; NUMBER OF SEQ ID NOS: 5450
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 478
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-927-046-478

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 5.8e+02;
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 476 GAGAAGCTCGATCTGAA 492

Db 1 GAUAAGGUCAUCUGAA 17
 ||||| :|||:|:|

RESULT 759
 US-09-827-395A-168/c
 ; Sequence 168, Application US/09827395A
 ; Publication No. US20030113891A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowira
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; TITLE OF INVENTION: MBH00-878-C (400/017)
 ; FILE REFERENCE: MBH00-878-C (400/017)
 ; CURRENT APPLICATION NUMBER: US/09/827,395A
 ; CURRENT FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 168
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-827-395A-168

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 685 GCAGGCGCGCAGCTGG 701
 ||||| :|||:|:|
 Db 17 GCAGGCGCGCAGCTGG 1

RESULT 760
 US-09-827-395A-936/c
 ; Sequence 936, Application US/09827395A
 ; Publication No. US20030113891A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowira
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; TITLE OF INVENTION: MBH00-878-C (400/017)
 ; FILE REFERENCE: MBH00-878-C (400/017)
 ; CURRENT APPLICATION NUMBER: US/09/827,395A
 ; CURRENT FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 936
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-827-395A-936

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 800 CAGGCGCGCTCGAGGA 816
 ||||| :|||:|:|
 Db 17 CAGGCGCGCTCGAGGA 1

RESULT 761

[illegible]

Db 1 GAGAGAGAGGAGCUCCU 17
||| ||||| :||:
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 766
US-10-061-201-303
; Sequence 303, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 303
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-303

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 471 GCCTGAGAGCTCGAT 487
||| ||||| :||:
Db 1 GCTTTGAGAGCTCGAT 17

RESULT 767
US-10-230-006-2067/c
; Sequence 2067, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2067
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2067

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 705 GTGAGCGGAGGCGCTG 721
||| ||||| :||:
Db 17 GTGAGCGGCTGGCGCTG 1

RESULT 768
US-10-430-882-168/c
; Sequence 168, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 168
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-168

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 685 GCAGGCGGAGGAGCTGG 701
||| ||||| :||:
Db 17 GCAGGCGGAGGAGCTGG 1

RESULT 769
US-10-430-882-936/c
; Sequence 936, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512

```

; PRIOR FILING DATE: 2002-04-03
;
; NUMBER OF SEQ ID NOS: 2617
;
; SOFTWARE: PatentIn version 3.0
;
; SEQ ID NO 936
;
; LENGTH: 17
;
; TYPE: RNA
;
; ORGANISM: Homo sapiens
;
US-10-430-882-936

```

Query Match	1.8%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 5.8e+02;		
Matches 15;	Conservative	0;	Mismatches 2;	Indels 0;
Gaps				0;

QY 800 CAGGCCGCTCGGAGGA 816
||| | |||||
Db 17 CAGGGCACCTCGGAGGA 1

```

RESULT 770
US-10-209-787-3454/c
; Sequence 3454, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3454
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3454

```

Query Match	1.8%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No 5.8e+02;		
Matches 15;	Conservative	0;	Mismatches2;	
			Indels	0;
			Gaps	0;

QY 374 TGCAGGAGCCTTCTGCA 390
Db 17 TGCCAGGCGCTTCTGCA 1

RESULT 771
US-10-209-787-3455
; Sequence 3455, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27

```

; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3455
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3455

```

Query Match	1.8t;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 5.8e+02;		
Matches 15;	Conservative	0;	Mismatches 2;	Indels 0;
				Gaps 0;

Qy 374 TCGAGGAGGCTTCTGCA 390
||| ||| ||| ||| ||| ||| ||| |||
Db 1 TGCCAGGGCGCTTCTGCA 17

```

RESULT 772
US-10-297-068-1063
; Sequence 1063, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 1314OP1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1063
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:captu
US-10-297-068-1063

```

Query Match	1.8%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.3%;	Pred. No. 5.8e+02;		
Matches 15;	Conservative	0;	Mismatches 2;	Indels 0;
				Gaps 0;

QY 760 GCAGGGCCAGAGCGTGG 776
|||
Db 1 GCAGGGCCGTCGCTGG 17

RESULT 773
US-10-261-185-3454/c
Sequence 3454, Application US/10261185
Publication No. US20040014057A1
GENERAL INFORMATION:
APPLICANT: Kniec, Eric B.
APPLICANT: Gampier, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosome
TITLE OF INVENTION: Stranded Oligonucleotides
FILE REFERENCE: NaPro-4CON
CURRENT APPLICATION NUMBER: US/10/261185

```

/ AFFILIATION: RICE, MICHAEL C.
/ TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
/ TITLE OF INVENTION: Stranded Oligonucleotides
/ FILE REFERENCE: NaPro-4CON
/ CURRENT APPLICATION NUMBER: US/10/261.185
/

```

; CURRENT FILING DATE: 2002-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/09761
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3454
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-261-185-3454

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TCGGAGGAGCTTCTGCA 390
 |||||
 Db 17 TGCCAGGCGCTTCTGCA 1

RESULT 774
 US-10-261-185-3455
 ; Sequence 3455, Application US/10261185
 ; Publication No. US20040014057A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamber, Howard B.
 ; APPLICANT: Rice, Michael C.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; FILE REFERENCE: Napro-4CON
 ; CURRENT APPLICATION NUMBER: US/10/261,185
 ; CURRENT FILING DATE: 2002-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/09761
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3455
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-261-185-3455

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TCGGAGGAGCTTCTGCA 390
 |||||
 Db 1 TGCCAGGCGCTTCTGCA 17

RESULT 775
 US-10-138-674-2829/c
 ; Sequence 2829, Application US/10138674
 ; Publication No. US20040077565A1
 ; GENERAL INFORMATION:

; APPLICANT: Ribozyne Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
 ; FILE REFERENCE: MBHB00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/138,674
 ; CURRENT FILING DATE: 2002-05-03
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 2829
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Mus musculus
 US-10-138-674-2829

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 457 GGTGAGAGACTCGGCC 473
 |||||
 Db 17 GTGAGACAGACTCGGCC 1

RESULT 776
 US-10-138-674-4771
 ; Sequence 4771, Application US/10138674
 ; Publication No. US20040077565A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyne Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
 ; FILE REFERENCE: MBHB00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/138,674
 ; CURRENT FILING DATE: 2002-05-03
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 4771
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-138-674-4771

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACCATCAAGAGCA 890
 |||||
 Db 1 CAACUACCUCAAGAGCA 17

RESULT 777
 US-10-138-674-6804/c
 ; Sequence 6804, Application US/10138674
 ; Publication No. US20040077565A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyne Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
 ; FILE REFERENCE: MBHB00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6804
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6804

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 337 TGCCATCCGCGAGCA 353
Db 17 TGCCATCCTGCTGAGCA 1

RESULT 778

US-10-287-949A-2829/c
; Sequence 2829, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2829
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2829

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 457 GGTGGAGAGACTCGGCC 473
Db 17 GGTAGACAGACTCGGCC 1

RESULT 779

US-10-287-949A-4771
; Sequence 4771, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4771
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4771

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACACATCAAGCA 890
Db 1 CAACUACCUAAGCA 17

RESULT 780

US-10-287-949A-6804/c
; Sequence 6804, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6804
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6804

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 337 TGCCATCCGCGAGCA 353
Db 17 TGCCATCCTGCTGAGCA 1

RESULT 781

US-10-712-672-60/c
; Sequence 60, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 60
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-60

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 810 CGGAGGAGAGGAG 826

```
Db      17  CTGAGGAGTAGGGAAG 1
|      ||||| ||||| |||||
RESULT 782
US-10-712-672-508/c
; Sequence 508, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 508
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-508

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      712  CGAGGCGCTGCAGCAGC 728
|      ||||| ||||| |||||
Db      17  CGCGGCGCAGCAGCAGC 1

RESULT 783
US-10-669-841-6933
; Sequence 6933, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (MHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      712  CGAGGCGCTGCAGCAGC 728
|      ||||| ||||| |||||
Db      17  CGCGGCGCAGCAGCAGC 1

RESULT 784
US-10-723-361-6823/c
; Sequence 6823, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 6823
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6933
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6933
```

```
Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 5.8e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      180  GTGATGTTGTCAGCCC 196
|      |::|::|::|::|::|
Db      1  GUGACAUGGUACAGCCC 17
```

```
RESULT 784
US-10-723-361-6823/c
; Sequence 6823, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 6823
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
```

US-10-723-361-6823

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 266 CACCTGCTTCAGAACCA 282
|||||
DB 17 CACCTGCTTCAGAAAA 1

RESULT 785

US-10-723-361-7698/c
; Sequence 7698, Application US/10723361
; Publication No. US20040137589A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361

; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aeonica Sequence Listing Engine

; SEQ ID NO 7698

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-723-361-7698

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 827 CTGGCCAGTTGAGGT 843
|||||
DB 17 CTGGCCAGTTGAGGT 1

RESULT 786

US-10-723-361-7813

; Sequence 7813, Application US/10723361

; Publication No. US20040137589A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aeonica Sequence Listing Engine

; SEQ ID NO 7813

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-723-361-7813

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 493 GAGGAGAGGAGGAGG 509
|||||
DB 1 GAAGCAAAAGGAGCAGG 17

RESULT 787

US-10-723-361-8421

; Sequence 8421, Application US/10723361

; Publication No. US20040137589A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361

; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8421
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8421

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 489 TGAAGAGGCGAGGAGGAG 505
||||| ||||| ||||| ||||| |||||
Db 1 TGAAGAGGCGAGGAGGAG 17

RESULT 788
US-10-723-361-8422
; Sequence 8422, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8422
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8422

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 490 GAAGAGCGAGGAGGAGC 506
||||| ||||| ||||| ||||| |||||
Db 1 GAAGAGCGAGGAGGAGTGC 17

RESULT 789
US-10-681-074-3454/c
; Sequence 3454, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3454
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3454

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TCCGAGGAGCTTCTGCA 390
||||| ||||| ||||| ||||| |||||
Db 17 TCCGAGGCGCTTCTGCA 1

RESULT 790
US-10-681-074-3455
; Sequence 3455, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3455
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3455

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 TCCGAGGAGCTTCTGCA 390
||||| ||||| ||||| ||||| |||||
Db 1 TCCGAGGCGCTTCTGCA 17

```
RESULT 791
US-10-498-462-66
; Sequence 66, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 66
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-66

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      672 GGGCGCGCAGCGGCG 688
Db      1 GGGCTGCGAGCGAGCAG 17

RESULT 792
US-10-498-462-71
; Sequence 71, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 71
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-71

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      677 GCCAGCGAGCGGCGG 693
Db      1 GCGAGCGAGCGAGCGG 17

RESULT 793
US-10-498-462-2025
; Sequence 2025, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2025
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2025

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      413 GAGAGGAGGTTCTCTCAT 429
Db      1 GAGAGGGAATGCTCAT 17

RESULT 794
US-10-498-462-2112
; Sequence 2112, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2112
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2112

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      413 GAGAGGAGGTTCTCTCAT 429
Db      1 GAGAGGGAATGCTCAT 17

RESULT 795
US-10-498-462-2113
; Sequence 2113, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2113
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2113
```



```
Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCTCATG 430
    ||||| ||||| |||||
Db 1 AGAAGGAGTTCTCATG 17

RESULT 796
US-10-741-600-73509/c
; Sequence 73509, Application US/10741600
; Publication No. US20050026169A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001499
; CURRENT APPLICATION NUMBER: US/10/741,600
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 73997
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 73509
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-741-600-73509

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 720 TGCAGCAGCAGCAGCAGC 736
    ||||| ||||| |||||
Db 17 TGTACCAGCAGCAGCAGC 1

RESULT 797
US-09-901-484A-384
; Sequence 384, Application US/09901484A
; Patent No. US20020119460A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: Prostate Cancer Gene
; FILE REFERENCE: GEN-T11XC3D2
; CURRENT APPLICATION NUMBER: US/09/901,484A
; CURRENT FILING DATE: 2001-07-09
; PRIOR APPLICATION NUMBER: US 08/996,306
; PRIOR FILING DATE: 1997-12-22
; PRIOR APPLICATION NUMBER: US 60/099,658
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: US 09/218,207
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: US 09/338,907
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/853,526
; PRIOR FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 384
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer for SEQ 190, SEQ 267, SEQ 191,
US-09-901-484A-384
```

```
Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTG 388
    ||||| ||||| |||||
Db 2 GCTGAGAGGAGCTTTTG 18

RESULT 798
US-09-853-526-384
; Sequence 384, Application US/09853526
; Patent No. US20020165345A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: PROSTATE CANCER GENE
; FILE REFERENCE: GENSET.18CP1CP
; CURRENT APPLICATION NUMBER: US/09/853,526
; CURRENT FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: 09/338,907
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 08/996,306
; PRIOR FILING DATE: 1997-12-22
; PRIOR APPLICATION NUMBER: 60/099,658
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 09/218,207
; PRIOR FILING DATE: 1998-12-22
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 384
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer for SEQ 190, SEQ 267, SEQ 191,
US-09-853-526-384

Query Match      1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 GCTGCGAGGAGCTTCTG 388
    ||||| ||||| |||||
Db 2 GCTGAGAGGAGCTTTTG 18

RESULT 799
US-09-881-012-194
; Sequence 194, Application US/09881012
; Publication No. US20020192655A1
; GENERAL INFORMATION:
; APPLICANT: Ginns, Edward I.
; APPLICANT: Egeland, Janice A.
; APPLICANT: Paul, Steven M.
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by The Secretary of the
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Susceptibility and Resistance Genes for
; FILE REFERENCE: 015280-248110US
; CURRENT APPLICATION NUMBER: US/09/881,012
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/175,158
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: US 60/062,924
; PRIOR FILING DATE: 1997-10-20
; NUMBER OF SEQ ID NOS: 240
```

; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 194
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: D6S1713 reverse primer
US-09-881-012-194

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 558 AGGCAAGGCTCTGTG 574
Db 1 AGGCCAAGACCTCTGTG 17

RESULT 800

US-09-881-012-194
; Sequence 194, Application US/09881012
; Publication No. US20040248086A9
; GENERAL INFORMATION:
; APPLICANT: Ginn, Edward I.
; APPLICANT: Egeland, Janice A.
; APPLICANT: Paul, Steven M.
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by the Secretary of the
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Susceptibility and Resistance Genes for
; TITLE OF INVENTION: Bipolar Affective Disorder
; FILE REFERENCE: 015280-248100S
; CURRENT APPLICATION NUMBER: US/09/881,012
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/175,158
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: US 60/062,924
; PRIOR FILING DATE: 1997-10-20
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 194
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: D6S1713 reverse primer
US-09-881-012-194

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 558 AGGCAAGGCTCTGTG 574
Db 1 AGGCCAAGACCTCTGTG 17

RESULT 801

US-09-998-027-104
; Sequence 104, Application US/09998027
; Publication No. US20030093819A1
; GENERAL INFORMATION:
; APPLICANT: D'Andrea et al.
; TITLE OF INVENTION: Methods and Compositions for the
; TITLE OF INVENTION: Diagnosis and Treatment of Cancers Associated with Defective
; TITLE OF INVENTION: DNA Repair Mechanisms
; FILE REFERENCE: 2486/101
; CURRENT APPLICATION NUMBER: US/09/998,027
; CURRENT FILING DATE: 2001-11-02
; NUMBER OF SEQ ID NOS: 191
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 104
; LENGTH: 18

; TYPE: DNA
; ORGANISM: MG476
US-09-998-027-104

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 647 TGCCAGGCTCTGGAGG 663
Db 2 TGCCAGACTCTGTGGG 18

RESULT 802

US-10-314-657-204
; Sequence 204, Application US/10314657
; Publication No. US20030175888A1
; GENERAL INFORMATION:
; APPLICANT: SHEN, Ben
; APPLICANT: CHENG, Yi-Qiang
; APPLICANT: TANG, Gong-Li
; TITLE OF INVENTION: Discrete Acyltransferases Associated with Type I Polyketide
; TITLE OF INVENTION: Synthases and Methods of Use
; FILE REFERENCE: 054030-0021
; CURRENT APPLICATION NUMBER: US/10/314,657
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: PCT/US02/08937
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: US 60/278,935
; PRIOR FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 214
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 204
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Streptomyces atroolivaceus
US-10-314-657-204

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 275 TCAGACAGGCGCTCC 291
Db 1 TCAGATCAGGCGCGCC 17

RESULT 803

US-10-165-099-104
; Sequence 104, Application US/10165099
; Publication No. US20030188326A1
; GENERAL INFORMATION:
; APPLICANT: D'Andrea, Alan
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF CANCER SUSCEPTIBILITY
; TITLE OF INVENTION: DEFECTIVE DNA REPAIR MECHANISMS AND TREATMENT THEREOF
; FILE REFERENCE: 7032/2055
; CURRENT APPLICATION NUMBER: US/10/165,099
; CURRENT FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 09/998,027
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: US 60/245,756
; PRIOR FILING DATE: 2000-11-03
; NUMBER OF SEQ ID NOS: 352
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 104
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-165-099-104

Query Match 1.8%; Score 13.8; DB 1; Length 18;

; Sequence 57, Application US/10765500
; Publication No. US20040137501A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia and Lex M. Cowseert
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRADD EXPRESSION
; FILE REFERENCE: RISP-0100
; CURRENT APPLICATION NUMBER: US/10/765,500
; CURRENT FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US/09/763,748
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: 09/143,212
; PRIOR FILING DATE: 1998-08-28
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 57
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
; US-10-765-500-57

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 AGCGCCGCGCGCTCG 811
Db 2 AGCGCCGCGCGCTCG 18

RESULT 809
US-10-664-603-334/c
; Sequence 334, Application US/10664603
; Publication No. US20040214195A1
; GENERAL INFORMATION:
; APPLICANT: Rouleau, Guy A.
; APPLICANT: Lafreniere, Ronald G.
; TITLE OF INVENTION: LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND
; FILE REFERENCE: GQUD-023USD1
; CURRENT APPLICATION NUMBER: US/10/664,603
; CURRENT FILING DATE: 2003-09-17
; PRIOR APPLICATION NUMBER: 09/718,355
; PRIOR FILING DATE: 2000-11-24
; PRIOR APPLICATION NUMBER: 60/167,623
; PRIOR FILING DATE: 1999-11-26
; NUMBER OF SEQ ID NOS: 408
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 334
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic oligonucleotide
; US-10-664-603-334

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 617 CAGAGTCGCTTGAGGC 633
Db 18 CAGAGTCGCTTGAGGC 2

RESULT 810
US-10-660-122-143
; Sequence 143, Application US/10660122
; Publication No. US20040219517A1
; GENERAL INFORMATION:
; APPLICANT: Ecker, David J.
; APPLICANT: Griffey, Richard H.

; APPLICANT: Sampath, Rangarajan
; APPLICANT: Hofstadler, Steven
; APPLICANT: McNeil, John
; APPLICANT: Crooke, Stanley T.
; TITLE OF INVENTION: Methods For Rapid Identification Of Pathogens In Humans And Animals
; FILE REFERENCE: IBIS0061-100
; CURRENT APPLICATION NUMBER: US/10/660,122
; CURRENT FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 10/323,233
; PRIOR FILING DATE: 2002-12-18
; PRIOR APPLICATION NUMBER: 09/798,007
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/431,319
; PRIOR FILING DATE: 2002-12-06
; PRIOR APPLICATION NUMBER: 60/443,443
; PRIOR FILING DATE: 2003-01-29
; PRIOR APPLICATION NUMBER: 60/443,788
; PRIOR FILING DATE: 2003-01-30
; PRIOR APPLICATION NUMBER: 60/447,529
; PRIOR FILING DATE: 2003-02-14
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 143
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
; US-10-660-122-143

Query Match 1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 258 CCATGCTGCACCTGCCT 274
Db 1 CCATGCTGCACCTGTCT 17

RESULT 811
US-10-806-793-38
; Sequence 38, Application US/10806793
; Publication No. US20040230043A1
; GENERAL INFORMATION:
; APPLICANT: Johansen, Teit E.
; APPLICANT: Blom, Nikolaj
; APPLICANT: Hansen, Claus
; TITLE OF INVENTION: Novel Neurotrophic Factors
; FILE REFERENCE: 19313-001 DIV
; CURRENT APPLICATION NUMBER: US/10/806,793
; CURRENT FILING DATE: 2004-03-22
; PRIOR APPLICATION NUMBER: US/09/662,183
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: DANISH 1998 00904
; PRIOR FILING DATE: 1998-07-06
; PRIOR APPLICATION NUMBER: USSN 60/692,229
; PRIOR FILING DATE: 1998-07-09
; PRIOR APPLICATION NUMBER: DANISH 1998 01048
; PRIOR FILING DATE: 1998-08-19
; PRIOR APPLICATION NUMBER: USSN 60/097,774
; PRIOR FILING DATE: 1998-08-25
; PRIOR APPLICATION NUMBER: DANISH 1998 01260
; PRIOR FILING DATE: 1998-10-05
; PRIOR APPLICATION NUMBER: USSN 60/103,908
; PRIOR FILING DATE: 1998-10-13
; PRIOR APPLICATION NUMBER: DANISH 1998 01265
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 09/347,613
; PRIOR FILING DATE: 2000-07-02
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 38
; LENGTH: 18

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-806-793-38

Query Match          1.8%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 6.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 GCTGGCCCGAGTTCGAGG 842
      ||||| | | | | |
DB 1 GCTGGCCCGCTGCAGG 17

RESULT 812
US-10-809-189-13872/c
; Sequence 13872, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13872
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-13872

Query Match          1.8%; Score 13.8; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 8.4e+02;
Matches 18; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 823 GAAGCTGGCCCGAGTTCGAGTGGCC 847
      ||||| | | | | |
DB 25 GCAGCTGGCCCGAGTTCGAGTGGC 1

RESULT 813
US-10-357-467-44
; Sequence 44, Application US/10357467
; Publication No. US20030194729A1
; GENERAL INFORMATION:
; APPLICANT: Abogadie, Fe C.
; APPLICANT: Cruz, Lourdes J.
; APPLICANT: Olivera, Baldomero M.
; APPLICANT: Walker, Craig
; APPLICANT: Colledge, Clark
; APPLICANT: Hillyard, David R.
; APPLICANT: Jimenez, Elsie
; APPLICANT: TITLE OF INVENTION: Conantokins.
; NUMBER OF SEQUENCES: 71
; CORRESPONDENCE ADDRESS:
; ADDRESSES: Rothwell, Figg, Ernst & Manbeck, P.C.
; STREET: 1425 K Street, N.W., Suite 800
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

```
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/357,467
; FILING DATE: 04-Feb-2003
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 09/142,080
; FILING DATE: 15-MAY-2000
; APPLICATION NUMBER: WO US97/12618
; FILING DATE: 21-JUL-1997
; APPLICATION NUMBER: US 08/684,742
; FILING DATE: 22-JUL-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 2314-256.A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-783-6040
; TELEFAX: 202-783-6031
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "probe"
; SEQUENCE DESCRIPTION: SEQ ID NO: 44:
US-10-357-467-44

Query Match          1.8%; Score 13.6; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 6.1e+02;
Matches 10; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 315 AGGAGATCAAGAGCT 330
      |::|::|::|::|::|
DB 2 ARGARAAVCARGAYT 17

RESULT 814
US-09-504-231A-988/c
; Sequence 988, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATEI
; FILE REFERENCE: Ipi 247/282
; CURRENT APPLICATION NUMBER: US/09/504,231A
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 988
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-988

Query Match          1.8%; Score 13.4; DB 1; Length 15;
```

Best Local Similarity 93.3%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 595 GCTCGGGAGCTGCA 609
Db 15 GCTCGGGAGCTGCA 1

RESULT 815
US-09-274-553D-988/c
; Sequence 988, Application US/09274553D
; Patent No. US20020082225A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION
; FILE REFERENCE: fpi 247/282
; CURRENT APPLICATION NUMBER: US/09/274,553D
; CURRENT FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3148
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 988
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target

US-09-274-553D-988

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 595 GCTCGGGAGCTGCA 609
Db 15 GCTCGGGAGCTGCA 1

RESULT 816
US-09-907-111-18
; Sequence 18, Application US/09907111
; Publication No. US20030003461A1
; GENERAL INFORMATION:
; APPLICANT: Pagratis, Nikos
; APPLICANT: Gold, Larry
; APPLICANT: Shtatland, Timur
; APPLICANT: Javornik, Brenda
; TITLE OF INVENTION: Truncation SELEX Method
; FILE REFERENCE: NEX 79
; CURRENT APPLICATION NUMBER: US/09/907,111
; CURRENT FILING DATE: 2001-07-17
; PRIOR APPLICATION NUMBER: 09/275,850
; PRIOR FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 351
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 18
; LENGTH: 15
; TYPE: RNA
; ORGANISM: E. coli
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-907-111-18

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 5.5e+02;

Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 720 TGCAGCAGCAGCACA 734
Db 1 UGCAGCAGCAGCGCA 15

RESULT 817
US-10-440-850-387/c
; Sequence 387, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Revert
; TITLE OF INVENTION: Immune Responses
; FILE REFERENCE: 250/130 (MEHB00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 387
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-440-850-387

Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 579 CCCAGGTGACGTCCT 593
Db 15 CCCAGGTGAAGTCCT 1

RESULT 818
US-10-407-818-7/c
; Sequence 7, Application US/10407818
; Publication No. US20040198971A1
; GENERAL INFORMATION:
; APPLICANT: RABBANI, ELAZAR
; APPLICANT: STAVRIANOFULOS, JANNIS G.
; APPLICANT: DONEGAN, JAMES J.
; TITLE OF INVENTION: MULTISIGNAL LABELING REAGENTS, AND PROCESSES AND USES
; FILE REFERENCE: ENZ-65
; CURRENT APPLICATION NUMBER: US/10/407,818
; CURRENT FILING DATE: 2003-04-03
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-407-818-7

Query Match 1.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 5.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 718 GCTGAGCAGCAGCA 732
 DB 15 GCAGCAGCAGCAGCA 1

RESULT 819

US-10-307-928A-36/c
 ; Sequence 36, Application US/10307928A
 ; Publication No. US2003029016A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Alsobrook, John P.
 ; APPLICANT: Anderson, David W.
 ; APPLICANT: Boldog, Ferenc L.
 ; APPLICANT: Burgess, Catherine E.
 ; APPLICANT: Catterton, Elina
 ; APPLICANT: Edinger, Shlomit R.
 ; APPLICANT: Gorman, Linda
 ; APPLICANT: Guo, Xiaojia (Sasha)
 ; APPLICANT: Ji, Weizhen
 ; APPLICANT: Kekuda, Ramesh
 ; APPLICANT: Li, Li
 ; APPLICANT: Patturajan, Meera
 ; APPLICANT: Rieger, Daniel K.
 ; APPLICANT: Shenoy, Suresh G.
 ; APPLICANT: Spytek, Kimberly A.
 ; APPLICANT: Vernet, Corine A.M.
 ; APPLICANT: Voss, Edward Z.
 ; APPLICANT: Zhong, Mei
 ; TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS
 ; FILE REFERENCE: 24102-502D
 ; CURRENT APPLICATION NUMBER: US/10/307,928A
 ; PRIOR FILING DATE: 2002-12-02
 ; PRIOR APPLICATION NUMBER: 60/341,477
 ; PRIOR FILING DATE: 2001-12-17
 ; PRIOR APPLICATION NUMBER: 60/341,540
 ; PRIOR FILING DATE: 2001-12-17
 ; PRIOR APPLICATION NUMBER: 60/342,592
 ; PRIOR FILING DATE: 2001-12-20
 ; PRIOR APPLICATION NUMBER: 60/344,903
 ; PRIOR FILING DATE: 2001-12-31
 ; PRIOR APPLICATION NUMBER: 60/373,288
 ; PRIOR FILING DATE: 2002-04-17
 ; PRIOR APPLICATION NUMBER: 60/380,981
 ; PRIOR FILING DATE: 2002-05-15
 ; PRIOR APPLICATION NUMBER: 60/381,495
 ; PRIOR FILING DATE: 2002-05-17
 ; PRIOR APPLICATION NUMBER: 60/383,744
 ; PRIOR FILING DATE: 2002-05-28
 ; PRIOR APPLICATION NUMBER: 60/384,024
 ; PRIOR FILING DATE: 2002-05-29
 ; PRIOR APPLICATION NUMBER: 60/401,788
 ; PRIOR FILING DATE: 2002-08-07
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 53
 ; SOFTWARE: CuraseqList version 0.1
 ; SEQ ID NO 36
 ; LENGTH: 16
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
 US-10-307-928A-36

Query Match 1.8%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 6e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 201 GTGGCCCGCAGCAG 215

DB 15 GTGGCCCTGCAGCAG 1

RESULT 820

US-09-866-108-6824/c
 ; Sequence 824, Application US/09866108
 ; Patent No. US20020048800A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: AEWICA-7
 ; CURRENT APPLICATION NUMBER: US/09/866,108
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00670
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: US 60/234,687
 ; PRIOR FILING DATE: 2000-09-21
 ; PRIOR APPLICATION NUMBER: US 60/266,860
 ; PRIOR FILING DATE: 2001-02-05
 ; NUMBER OF SEQ ID NOS: 15752
 ; SOFTWARE: Aecmica Sequence Listing Engine
 ; SEQ ID NO 6824
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-866-108-6824

Query Match 1.8%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 6.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280

DB 16 CACCTGCCTTCAGAA 2

RESULT 821

US-09-866-108-6825/c
 ; Sequence 825, Application US/09866108
 ; Patent No. US20020048800A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIORITY FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 6825
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-6825

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 15 CACCTGCCTTCAGAA 1
|||||

RESULT 822
US-09-866-108-7248
Sequence 7248, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 7248
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-7248

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 699 TGGAGAGTGAGCGCG 713
Db 1 TGGAGAGTGAGCGCG 15
|||||

RESULT 823
US-09-866-108-7448
Sequence 7448, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7448
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7448

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred.No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 412 GGAGAGGAGTTCTC 426
||||| |||||
Db 3 GGAGACGAGTTCT 17

RESULT 824
US-09-866-108-7452
; Sequence 7452, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7452
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7452

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred.No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 AGAAGGAGTTCTCA 428
||||| |||||
Db 1 AGACGAGTTCTCA 15

RESULT 825
US-09-866-108-8419
; Sequence 8419, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8419
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8419

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAAGG 503
Db 3 TGAAGAGCGCAGAAGG 17

RESULT 826

US-09-866-108-8420
; Sequence 8420, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8420
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8420

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 489 TGAAGAGCGCAGAAGG 503
Db 2 TGAAGAGCGCAGAAGG 16

RESULT 827

US-09-866-108-8969/c
; Sequence 8969, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8969
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8969

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 852 ACCAGCTCTTCCAAG 866
Db 17 ACCAGCTCTTCCATG 3

RESULT 828

US-09-864-785-124
; Sequence 124, Application US/09864785

```

; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 124
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-124

Query Match          1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      884 AAGAGCAGCGTGGTG 898
Db      3 AAGAGCAGCGUGGG 17

RESULT 829
US-09-864-785-1475
; Sequence 1475, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1475
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1475

Query Match          1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      884 AAGAGCAGCGTGGTG 898
Db      2 AAGAGCAGCGUGGG 16

RESULT 830
US-09-825-805-656/c
; Sequence 656, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic

```

```

; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MBHB00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 656
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-656

Query Match          1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      642 AGGAATGCCAGGCTC 656
Db      16 AGAATGCCAGGCTC 2

RESULT 831
US-09-740-332-3193
; Sequence 3193, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3193
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3193

Query Match          1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 6.4e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      594 TCCTCGGGGAGCTGC 608
Db      3 UGCUCGGCGAGCUGC 17

RESULT 832
US-09-817-879-3193
; Sequence 3193, Application US/09817879
; Publication No. US20030171311A1

```

```

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-P
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3193
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3193

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 6.4e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      594 TGCTCGGGGAGCTGC 608
      :||:|||||:|:|:|
Db      3 UGCTCGCGGAGCGTC 17

RESULT 833
US-10-163-552-306/c
; Sequence 306, Application US/10163552
; Publication No. US2003010501A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 306
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-306

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      642 AGGAATGCCAGGCTC 656
      ||| ||||| |||||
Db      16 AGAATGCCAGGCTC 2

RESULT 834
US-10-339-782-104/c
; Sequence 104, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Goodman, Laurie J
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
; FILE REFERENCE: 37-000110US
; CURRENT APPLICATION NUMBER: US/10/339, 782
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 495
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 104
; LENGTH: 17

```

```

; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-782-104

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      492 AGAGGCAGAGGAGC 506
      ||||| ||||| |||||
Db      15 AGAGGCAGAGGATC 1

RESULT 835
US-10-339-782-127
; Sequence 127, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Goodman, Laurie J
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
; FILE REFERENCE: 37-000110US
; CURRENT APPLICATION NUMBER: US/10/339,782
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 495
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 127
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-782-127

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      241 TCCTCTGGGGAGGCC 255
      ||||| ||||| |||||
Db      3 TCCTGTGGGGAGGCC 17

RESULT 836
US-10-230-006-1418
; Sequence 1418, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1418
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1418

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      488 CTGAAGAGCGCAGAG 502
      :||| |||||
Db      1 CUGAAGAGCAGAG 15

```

```

RESULT 837
US-10-230-006-2221
; Sequence 2221, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2221
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2221

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 487 TCTGAAGAGCGCAGAA 501
Db 3 UCUGAAGAGCGCAGAA 17

RESULT 838
US-10-307-005-975
; Sequence 975, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kniec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: US/10/307,005
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 975
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Oryza sativa
US-10-307-005-975

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 899 GGCAGTGAGCGGAAG 913
Db 1 GGCAGTGAGCGGAAG 15

RESULT 839
US-10-307-005-976
; Sequence 976, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kniec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 976
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Oryza sativa
US-10-307-005-976

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 899 GGCAGTGAGCGGAAG 913
Db 17 GGCAGTGAGCGGAAG 3

RESULT 840
US-10-138-674-3805/c
; Sequence 3805, Application US/10138674
; Publication No. US2004007565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jalme
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3805
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3805

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGAGAGTGAGC 710
Db 16 AGCTGAGAGTGAGC 2

RESULT 841
US-10-138-674-7939
; Sequence 7939, Application US/10138674

```

; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7939
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7939

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 540 GCCAGCAGCAGATGG 554
||||| ||||| |||||
Db 2 GCCAGGAGCAGAUGG 16

RESULT 842
US-10-412-672-3/c
; Sequence 3, Application US/10412672
; Publication No. US20040091488A1
; GENERAL INFORMATION:
; APPLICANT: SERMAN, GERHARD
; TITLE OF INVENTION: ANTIGENIC CONSTRUCTS OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I ANTIGENS WITH SPECIFIC CARRIER
; FILE REFERENCE: SCH-1977D1
; CURRENT APPLICATION NUMBER: US/10/412,672
; CURRENT FILING DATE: 2003-04-14
; PRIOR APPLICATION NUMBER: 08/460,569
; PRIOR FILING DATE: 1995-06-02
; PRIOR APPLICATION NUMBER: 07/912,677
; PRIOR FILING DATE: 1992-07-14
; PRIOR APPLICATION NUMBER: 07/385,532
; PRIOR FILING DATE: 1989-07-26
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
US-10-412-672-3

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 293 GAGACCCCTCCAGCGC 307
||||| ||||| |||||
Db 17 GAGACGCTCCAGCGC 3

RESULT 843
US-10-287-949A-3805/c
; Sequence 3805, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3805
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3805

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 696 AGCTGCGAGAGTGAGC 710
||||| ||||| |||||
Db 16 AGCTGCGAGAGTGAGC 2

RESULT 844
US-10-287-949A-7939
; Sequence 7939, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7939
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7939

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 540 GCCAGCAGCAGATGG 554
||||| ||||| |||||
Db 2 GCCAGGAGCAGAUGG 16

RESULT 845
US-10-712-672-59/c
; Sequence 59, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31

APPLICANT: ELISABETH, ROBERTS
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS REPLICATION

; PRIOR APPLICATION NUMBER: PCI/USOI/0066
: PRIOR FILING DATE: 2001-01-30

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 6824
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6824

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 266 CACCTGCCTTCAGAA 280
Db 16 CACCTGCCTTCAGAA 2

RESULT 849
US-10-723-361-6825/c
; Sequence 6825, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 6825
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6825

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 266 CACCTGCCTTCAGAA 280
Db 15 CACCTGCCTTCAGAA 1

RESULT 850

US-10-723-361-7248
; Sequence 7248, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 7248
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7248

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 699 TGGAGAGTGGCGG 713
Db 1 TGGAGAGTGGCGG 15

RESULT 851

US-10-723-361-7448
; Sequence 7448, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.


```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7452
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7452

Query Match      1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 1

QY      414 AGAAGGAGTTCCTCA 428
      |||||
Db       1 AGAACGAGTTCCTCA 15

RESULT 853
US-10-723-361-8419
; Sequence 8419, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.

```

```

> APPLICANT: CHEN, Wensheng
> APPLICANT: SHANNON, Mark
> TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN MUSCLE
> FILE REFERENCE: PB0105
> CURRENT APPLICATION NUMBER: US/10/723,361
> CURRENT FILING DATE: 2003-11-26
> PRIOR APPLICATION NUMBER: US 09/866,108
> PRIOR FILING DATE: 2001-05-25
> PRIOR APPLICATION NUMBER: US 60/207,456
> PRIOR FILING DATE: 2000-05-26
> PRIOR APPLICATION NUMBER: GB 24263.6
> PRIOR FILING DATE: 2000-10-04
> PRIOR APPLICATION NUMBER: US 60/236,359
> PRIOR FILING DATE: 2000-09-27
> PRIOR APPLICATION NUMBER: PCT/US01/00666
> PRIOR FILING DATE: 2001-01-30
> PRIOR APPLICATION NUMBER: PCT/US01/00667
> PRIOR FILING DATE: 2001-01-30
> PRIOR APPLICATION NUMBER: PCT/US01/00664
> PRIOR FILING DATE: 2001-01-30
> PRIOR APPLICATION NUMBER: PCT/US01/00669
> PRIOR FILING DATE: 2001-01-30
> PRIOR APPLICATION NUMBER: PCT/US01/00665
> PRIOR FILING DATE: 2001-01-30
> PRIOR APPLICATION NUMBER: PCT/US01/00668
> PRIOR FILING DATE: 2001-01-30
> REMAINING Prior Application data removed - See File Wrapper or PALM
> NUMBER OF SEQ ID NOS: 15755
> SOFTWARE: Aecmica Sequence Listing Engine
> SEQ ID NO 8419
> LENGTH: 17
> TYPE: DNA
> ORGANISM: Homo sapiens
>
US-10-723-361-8419

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0;

```

```

QY 489 TGAAGAGCGCAGAAGG 503
Db 3 TGAAGAGCGCAGAAGG 17

RESULT 854
US-10-723-361-8420
; Sequence 8420, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8420
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8420

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAAGG 503
Db 2 TGAAGAGCGCAGAAGG 16

RESULT 855
US-10-723-361-8969/c
; Sequence 8969, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8420
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8420

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 489 TGAAGAGCGCAGAAGG 503
Db 2 TGAAGAGCGCAGAAGG 16

RESULT 856
US-10-712-633-1089
; Sequence 1089, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0

```

; SEQ ID NO 1089
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-1089

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 6.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 540 GCAGCAGCAGATGG 554
||||| |||||:|
Db 2 GCCAGAGCAGAUGG 16

RESULT 857

US-10-498-462-777
; Sequence 777, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 777
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-777

Query Match 1.8%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 GAGAGAGAGAGCTG 829
| | | | | | | | | |
Db 3 GTGAGAGAGAGCTG 17

RESULT 858

US-10-156-306-7822
; Sequence 7822, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7822
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7822

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 189 TGCAGCCCACTGG 201
: | | | | | | | | | |
Db 1 UGCAGCCCACTGG 13

RESULT 859

US-10-156-306-7823
; Sequence 7823, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7823
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7823

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 190 GCAGCCCACTGGT 202
| | | | | | | | | |
Db 1 GCAGCCCACTGGU 13

RESULT 860

US-10-156-306-7824
; Sequence 7824, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7824
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7824

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 297 CCCTCCAGCGCTG 309
| | | | | | | | | |
Db 1 CCCUCCAGCGCUG 13

RESULT 861

US-10-156-306-7825
; Sequence 7825, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7825
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7825

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 318 AGAATCAAGACT 330
|||||:|||||:
Db 1 AGAAUCAAGACU 13

RESULT 862
US-10-156-306-7827
; Sequence 7827, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7827
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7827

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 550 GATGGCTGAGGAC 562
||:|||||:
Db 1 GAUGGUCGAGGAC 13

RESULT 863
US-10-156-306-7830
; Sequence 7830, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7830
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7830

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 5.1e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 565 GGCTCTGTGAAA 577
|||||:|||||:
Db 1 GGCCUCUGAGAA 13

RESULT 864
US-10-156-306-7832
; Sequence 7832, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7832
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7832

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 743 GTGGACCACTGC 755
|:|||||:
Db 1 GUGGACCACTGC 13

RESULT 865
US-10-156-306-7849
; Sequence 7849, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7849
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7849

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 303 AGCGTGCTGGA 315
|||||:|||||:
Db 1 AGCGTGCTGGA 13

RESULT 866
US-10-156-306-7850
; Sequence 7850, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 7850
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7850

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 322 TCAAGAGTCCGA 334
:|||||:||||
Db 1 UCAAGAGGUCCGA 13

RESULT 867

US-10-156-306-7852
; Sequence 7852, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7852
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7852

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 76.9%; Pred. No. 5.1e+02;
Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 566 GCCTCTGTGAAAG 578
|||:|:|:|:|
Db 1 GCCUCUGUGAAAG 13

RESULT 868

US-10-156-306-7854
; Sequence 7854, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7854
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7854

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 5.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 699 TGGAGAGTGAGCG 711
:|||||:||||
Db 1 UGGAGAGUGAGCG 13

RESULT 869

US-10-257-017B-129695/c
; Sequence 129695, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 129695
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0032456

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 ACAACCATCAAA 885
|||||:|:|:|
Db 13 ACAACCATCAAA 1

RESULT 870

US-10-257-017B-129696
; Sequence 129696, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 129696
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0032456

Query Match 1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 ACAACCATCAAA 885
|||||:|:|:|
Db 1 ACAACCATCAAA 13

RESULT 871

US-10-257-017B-130515
; Sequence 130515, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock

```
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 130515
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0032599
US-10-257-017B-130515

Query Match      1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      407 AGGAGGAGGAGG 419
Db      1 AGGAGGAGGAGG 13

RESULT 872
US-10-257-017B-130516/c
; Sequence 130516, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 130516
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0032599
US-10-257-017B-130516

Query Match      1.7%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      407 AGGAGGAGGAGG 419
Db      13 AGGAGGAGGAGG 1

RESULT 873
US-09-811-286-11
; Sequence 11, Application US/09811286
; Patent No. US20010051712A1
; GENERAL INFORMATION:
; APPLICANT: Drysdale, Connie M
; APPLICANT: Judson, Richard S
; APPLICANT: Liggett, Stephen B
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Stack, Catherine B.
; APPLICANT: Stephens, J. Claiborne
; TITLE OF INVENTION: Association of beta2-adrenergic receptor haplotypes
; FILE REFERENCE: MWH-0303US1
```

```
; CURRENT APPLICATION NUMBER: US/09/811,286
; CURRENT FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-811-286-11

Query Match      1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      196 CAGTGGTGCCCG 208
Db      3 CAGTGGTGCCCG 15

RESULT 874
US-09-979-593-20
; Sequence 20, Application US/09979593
; Publication No. US20030082555A1
; GENERAL INFORMATION:
; APPLICANT: Genaisance Pharmaceuticals, Inc.
; APPLICANT: Chew, Anne
; APPLICANT: Choi, Julie Y
; APPLICANT: Denton, R. Rex
; APPLICANT: Kliem, Stefanie E
; APPLICANT: Lee, Helen H
; APPLICANT: Nandabalan, Krishnan
; TITLE OF INVENTION: HAPLOTYPES OF THE ICAM2 GENE
; FILE REFERENCE: MWH-0425 PCT ICAM2
; CURRENT APPLICATION NUMBER: US/09/979,593
; CURRENT FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: PCT/US01/14714
; PRIOR FILING DATE: 2001-05-07
; PRIOR APPLICATION NUMBER: 60/201,946
; PRIOR FILING DATE: 2000-05-05
; NUMBER OF SEQ ID NOS: 83
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapien
US-09-979-593-20

Query Match      1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 6.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      210 CAGCAGATCAGGACG 224
Db      1 CAGCAGATCAGGGYG 15

RESULT 875
US-09-811-285-11
; Sequence 11, Application US/09811285
; Publication No. US20030091998A1
; GENERAL INFORMATION:
; APPLICANT: Drysdale, Connie M
; APPLICANT: Judson, Richard S
; APPLICANT: Liggett, Stephen B
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Stephens, J. Claiborne
; TITLE OF INVENTION: Association of beta2-adrenergic receptor haplotypes
; FILE REFERENCE: MWH-0303US2
; CURRENT APPLICATION NUMBER: US/09/811,285
; CURRENT FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
```

```
; SEQ ID NO 11
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-811-285-11

Query Match      1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 196 CAGTGGTGCCCG 208
Db      |||||
3 CAGTGGTGCCCG 15

RESULT 876
US-10-852-943-37
; Sequence 37, Application US/10852943
; Publication No. US20050037388A1
; GENERAL INFORMATION:
; APPLICANT: University of Geneva
; APPLICANT: Stylianos, Antonarakis
; APPLICANT: Deutech, Samuel
; TITLE OF INVENTION: METHOD FOR DETECTING DISEASES CAUSED BY CHROMOSOMAL IMBALANCES
; FILE REFERENCE: 27067/2005
; CURRENT APPLICATION NUMBER: US/10/852,943
; CURRENT FILING DATE: 2004-05-25
; PRIOR APPLICATION NUMBER: US 60/300,266
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: US 10/177,063
; PRIOR FILING DATE: 2002-06-21
; NUMBER OF SEQ ID NOS: 98
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 37
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PRIMER
US-10-852-943-37

Query Match      1.7%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 6.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 451 GAAACTGGTGGAG 463
Db      |||||
1 GAAACTGGTGGAG 13

RESULT 877
US-09-866-108-7242
; Sequence 7242, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7242
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7242

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 697 GCTGGAGAGTGAG 709
Db      |||||
5 GCTGGAGAGTGAG 17

RESULT 878
US-09-866-108-8974/c
; Sequence 8974, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 8974
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8974

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02; 0; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

QY 851 CACCAGCTCTTCC 863
Db 13 CACCAGCTCTTCC 1

RESULT 879

US-09-789-919-76/c
; Sequence 76, Application US/09789919
; Patent No. US20020064855A1
; GENERAL INFORMATION:
; APPLICANT: Lemischka, Ibor
; TITLE OF INVENTION: GENES THAT REGULATE HEMATOPOIETIC BLOOD FORMING STEM
; TITLE OF INVENTION: CELLS AND USES THEREOF
; FILE REFERENCE: 2275-1-005
; CURRENT APPLICATION NUMBER: US/09/789,919
; CURRENT FILING DATE: 2001-02-21
; NUMBER OF SEQ ID NOS: 96
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 76
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-789-919-76

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02; 0; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

QY 667 GGCCCGGGCGGCC 679
Db 17 GGCCCGGGCGGCC 5

RESULT 880

US-09-864-785-1474
; Sequence 1474, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBH00-812-D)

; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1474
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1474

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 7e+02; 0; Indels 0; Gaps 0;
Matches 12; Conservative 1; Mismatches 0;

QY 884 AAGAGCAGCGTGG 896
Db 5 AAGAGCAGCGUGG 17

RESULT 881

US-09-740-332-1584/c
; Sequence 1584, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1584
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1584

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02; 0; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

QY 782 GCGCTCCGATGG 794
Db 17 GCGCTCCGATGG 5

RESULT 882

US-09-740-332-2971
; Sequence 2971, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2971
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:

; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2971

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 7e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 782 GCGCTCCGCATGG 794
||||:|||||:
Db 2 GCGCUCCGAUGG 14

RESULT 883

US-09-817-879-1584/c

; Sequence 1584, Application US/09817879

; Publication No. US20030171311A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: Hepatitis C Virus Infection

; CURRENT APPLICATION NUMBER: US/09/817,879

; CURRENT FILING DATE: 2001-03-26

; NUMBER OF SEQ ID NOS: 9703

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1584

; LENGTH: 17

; TYPE: RNA

; ORGANISM: artificial sequence

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION:

; OTHER INFORMATION: oligonucleotide substrate

US-09-817-879-1584

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 782 GCGCTCCGCATGG 794
||||:|||||:
Db 17 GCGCTCCGCATGG 5

RESULT 884

US-09-817-879-2971

; Sequence 2971, Application US/09817879

; Publication No. US20030171311A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: Hepatitis C Virus Infection

; CURRENT APPLICATION NUMBER: US/09/817,879

; CURRENT FILING DATE: 2001-03-26

; NUMBER OF SEQ ID NOS: 9703

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 2971

; LENGTH: 17

; TYPE: RNA

; ORGANISM: artificial sequence

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION:

; OTHER INFORMATION: oligonucleotide substrate

US-09-817-879-2971

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 7e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 782 GCGCTCCGCATGG 794
||||:|||||:
Db 2 GCGCUCCGAUGG 14

Db 2 GCGCUCCGAUGG 14

RESULT 885

US-10-156-306-6812

; Sequence 6812, Application US/10156306

; Publication No. US20030119017A1

; GENERAL INFORMATION:

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: Levels of IKK-Gamma and PKR

; CURRENT APPLICATION NUMBER: US/10/156,306

; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6812

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

; US-10-156-306-6812

Query Match 1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 7e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 162 TCTGGAAGAGCCA 174
||:|||||:
Db 5 UCUGGAAGAGCCA 17

RESULT 886

US-10-669-841-4177/c

; Sequence 4177, Application US/10669841

; Publication No. US20040127446A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: Lawrence, Blatt

; APPLICANT: Dennis, Macejak

; APPLICANT: James, McSwiggen

; APPLICANT: David, Morrissey

; APPLICANT: Pamela, Pavco

; APPLICANT: Patricia, Lee

; APPLICANT: Kenneth, Draper

; APPLICANT: Elisabeth, Roberts

; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT

; FILE REFERENCE: VIRUS REPLICATION

; CURRENT APPLICATION NUMBER: US/10/669,841

; CURRENT FILING DATE: 2003-09-23

; PRIOR APPLICATION NUMBER: PCT/US02/09187

; PRIOR FILING DATE: 2002-03-26

; PRIOR APPLICATION NUMBER: US 60/296,876

; PRIOR FILING DATE: 2001-06-08

; PRIOR APPLICATION NUMBER: US 60/335,059

; PRIOR FILING DATE: 2001-10-24

; PRIOR APPLICATION NUMBER: US 60/337,055

; PRIOR FILING DATE: 2001-12-05

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 09/817,879

; PRIOR FILING DATE: 2001-03-26

; PRIOR APPLICATION NUMBER: US 09/740,332

; PRIOR FILING DATE: 2000-12-18

; PRIOR APPLICATION NUMBER: US 09/611,931

; PRIOR FILING DATE: 2000-07-07

; PRIOR APPLICATION NUMBER: US 09/504,321

; PRIOR FILING DATE: 2000-02-15

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 16207

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4177
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4177

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      782 GCGCTCGCATGG 794
Db      17 GCGCTCGCATGG 5

RESULT 887
US-10-669-841-5564
; Sequence 5564, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5564
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
```

```
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5564

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 7e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      782 GCGCTCGCATGG 794
Db      2 GCGCUCGCAUGG 14

RESULT 888
US-10-723-361-7242
; Sequence 7242, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AND
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7242
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7242

Query Match      1.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      697 GCTGAGAGTGAG 709
Db      5 GCTGAGAGTGAG 17

RESULT 889
US-10-723-361-8974/c
; Sequence 8974, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

```

; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8974
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8974

Query Match
Best Local Similarity 100.0%; Score 13; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 851 CACCAGCTCTTCC 863
DB 13 CACCAGCTCTTCC 1

RESULT 890
US-10-227-719D-12/c
; Sequence 12, Application US/10227719D
; Publication No. US20030143578A1
; GENERAL INFORMATION:
; APPLICANT: Pruitt, Steven
; TITLE OF INVENTION: A High Throughput Method for Identification of Sequence Tags
; FILE REFERENCE: 03551.0108
; CURRENT APPLICATION NUMBER: US/10/227,719D
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: US/60/314,991
; PRIOR FILING DATE: 2001-08-24
; NUMBER OF SEQ ID NOS: 13
; SEQ ID NO 12
; LENGTH: 16
; TYPE: DNA
; ORGANISM: mus musculus
; FEATURES:
; OTHER INFORMATION: exon from actin binding protein
US-10-227-719D-12

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 407 AGGAGGAGGAGGAGT 422
DB 16 AGGAGGAGGAGGAGT 410

RESULT 892
US-10-712-672-1520/c
; Sequence 1520, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim

```

```

DB 16 AGGAGGAGGAGTGTAGT 1
|||||
RESULT 891
US-10-453-792-242/c
; Sequence 242, Application US/10453792
; Publication No. US20040029110A1
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: ROSSAU, RUDI
; APPLICANT: MAERTENS, GEERT
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/453,792
; FILING DATE: 04-Jun-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/155,885A
; FILING DATE: 08-Oct-1998
; APPLICATION NUMBER: PCT/EP97/02002
; FILING DATE: 21-APR-1997
; APPLICATION NUMBER: EP 96870053.4
; FILING DATE: 19-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B.J.
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 2551-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 242:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 242:
US-10-453-792-242

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 395 CAAGCCAGCAGGAGGG 410
DB 16 CAAGCCAGCAGGAGGG 1
|||||
RESULT 892
US-10-712-672-1520/c
; Sequence 1520, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim

```

```

; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEH800-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1520
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1520

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      712 CGAGGCGCTGCACGAG 727
Db      16 CGCGGCGCAGCAGCAG 1

RESULT 893
US-10-806-422-10
; Sequence 10, Application US/10806422
; Publication No. US20040170604A1
; GENERAL INFORMATION:
; APPLICANT: Tosoh Corporation
; TITLE OF INVENTION: IL-6 RECEPTOR IL-6 DIRECT FUSION PROTEIN
; FILE REFERENCE: Q62375
; CURRENT APPLICATION NUMBER: US/10/806,422
; CURRENT FILING DATE: 2004-03-23
; PRIOR APPLICATION NUMBER: US/09/743,239
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: JP Hei. No. 10-190597
; PRIOR FILING DATE: 1998-07-06
; PRIOR APPLICATION NUMBER: JP Hei. No. 11-21788
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: JP Hei. No. 11-123411
; PRIOR FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Annealed Sequence
US-10-806-422-10

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      690 CGCGGCGCTGCAGAG 705
Db      1 CGCGGCGCAGTGGAGG 16

RESULT 894
US-10-643-775-1137/c
; Sequence 1137, Application US/10643775
; Publication No. US20050026156A1
; GENERAL INFORMATION:
; APPLICANT: Lie, Oystein
; APPLICANT: Slettan, Audun
; APPLICANT: Hoyum, Morten

```

```

; APPLICANT: Lingaas, Frode
; TITLE OF INVENTION: Verification of Food Origin Based on
; FILE REFERENCE: 66849-019
; CURRENT APPLICATION NUMBER: US/10/643,775
; CURRENT FILING DATE: 2003-08-18
; PRIOR APPLICATION NUMBER: US 60/404,200
; PRIOR FILING DATE: 2002-08-16
; NUMBER OF SEQ ID NOS: 1377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1137
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Oreochromis niloticus
US-10-643-775-1137

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 6.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      622 TCGCTTGGAGGTGCC 637
Db      16 TTGCTTGGAGACTGCC 1

RESULT 895
US-09-866-108-354/c
; Sequence 354, Application US/09866108
; Patent No. US20020049800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Shaaron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine

```

; SEQ ID NO 354
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-354

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTGAAGAGGC 497
Db 17 CTCGTTCTGGAGAGGC 2

RESULT 896

US-09-866-108-355/c
; Sequence 355, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-355

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTGAAGAGGC 497
Db 16 CTCGTTCTGGAGAGGC 1

RESULT 897

US-09-866-108-672/c
; Sequence 672, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 672
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-672

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTCG 248
Db 17 GATGAGTCTCTCTCG 2

RESULT 898

US-09-866-108-673/c
; Sequence 673, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:

APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 673
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-673

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
DB 16 GATGAGTCTCTCTGG 1

RESULT 899
US-09-866-108-1523/c
Sequence 1523, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108

CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 1523
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-1523

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 846 CCTATCACCAGCTCTT 861
DB 17 CCCATCACCTGCTCTT 2

RESULT 900
US-09-866-108-1524/c
Sequence 1524, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667

```

US/09-866-108-1720/c
; Sequence 1720, Application US/09866108
; Patent No. US20020048900A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRES
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/006654
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006659
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006651
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006658
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663

```

;
PRIOR APPLICATION NUMBER:

[illegible]

US-09-866-108-1997/c
; Sequence 1997, Application US/09866108
; Patent No. US20020048800A1

APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN. Sharon G.

```

, APPLICANT: CHEN, WENSHONG
, APPLICANT: SHANNON, MARK
, TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
, FILE REFERENCE: AEMICA-7
, CURRENT APPLICATION NUMBER: US/09/866,108
, CURRENT FILING DATE: 2001-05-25
, PRIOR APPLICATION NUMBER: US 60/207,456
, PRIOR FILING DATE: 2000-05-26
, PRIOR APPLICATION NUMBER: GB 24263.6
, PRIOR FILING DATE: 2000-10-04
, PRIOR APPLICATION NUMBER: US 60/236,359
, PRIOR FILING DATE: 2000-09-27
, PRIOR APPLICATION NUMBER: PCT/US01/00666
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00667

```

```

, PRIOR FILING DATE: 2000-09-27
, PRIOR APPLICATION NUMBER: PCT/US01/00666
,
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00667
,
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00664
,
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00669
,
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00665
,
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00668
,
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00663
,
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00662
,

```

```

; PRIOR FILLING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILLING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILLING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILLING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1997
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1997

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OV          309 GCCTGGAGGAGAATCA 324

```

DD 16 GGC1GGAGGACAAATCA 1

US-09-866-108-6822/c

; Sequence 6822, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6822
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6822

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 ACCTGCTTCAGAAC 282
||| ||||| ||||| |||||
DB 17 ACCTGCTTCAGAGAAA 2

RESULT 906
US-09-866-108-6890/c
; Sequence 6890, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6890
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6890

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTCGAGAGAA 321
||| ||||| ||||| |||||
DB 17 GCCGCTCGAGAGAA 2

RESULT 907
US-09-866-108-6891/c
; Sequence 6891, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6891
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6891

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGTGAGAGAA 321
||| ||||| |||||
Db 16 GCCGCTGTGAGAGAA 1

RESULT 908
US-09-866-108-7677
; Sequence 7677, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7677
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7677

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGGCAGAGAGAG 505
||||| ||||| |||||
Db 2 GAAGAGGCAGAGAGAG 17

RESULT 909
US-09-866-108-7678
; Sequence 7678, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30

US-09-866-108-7697

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 828 TGGCCCGAGTTCAGGT 843
DB 17 TGGCCCGAGTTCAGGT 2

US-09-866-108-7697

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGCAGAGGAG 505
DB 1 GAAGAGCGCAGAGGAG 16

RESULT 910

US-09-866-108-7697/c
; Sequence 7697, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108-7699/c
; Sequence 7699, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 827 CTGCGCCAGTTCAGG 842
DB 16 CTGCGCCAGTTCAGG 1

```

RESULT 912
US-09-866-108-7812      1.7%; Score 12.8; DB 1; Length 17;
Sequence 7812, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866.108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 7812
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-7814

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy    494 AGGCAGAAAGGACGAGCAG 509
Db     1 AAGCAAAAAGGACGAGG 16
| ||||| ||||| |
| ||||| ||||| |

RESULT 914
US-09-866-108-8033
Sequence 8033, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866.108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 7812
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-7812

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy    493 GAGCGAGAAGGACGACGAG 508
Db     2 GAAGCAAAGGACGACGAG 17
| ||||| ||||| |
| ||||| ||||| |

RESULT 913
US-09-866-108-7814
Sequence 7814, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
```

; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8033
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8033

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGAGAGTGAGCG 711
|||||
DB 2 AGCTGAGATCGAGCG 17

RESULT 915
US-09-866-108-8034
; Sequence 8034, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8034
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8034

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGAGAGTGAGCG 711
|||||
DB 1 AGCTGAGATCGAGCG 16

RESULT 916
US-09-866-108-8423
; Sequence 8423, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8423
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8423

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 491 AAGAGCGAGAGGAGCG 506
|||||
Db 1 AAGACGCGAAGGTGC 16

RESULT 917

US-09-864-785-404
; Sequence 404, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MH800-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 404
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-404

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 713 GAGGCGCTGCAGCAGC 728
|||||
Db 2 GAGGCCCGCUGCAGC 17

RESULT 918

US-09-864-785-405
; Sequence 405, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MH800-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 405
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-405

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 257 GCCATGCTGCACCTGC 272
|||||
Db 2 GCCCGCUGCAGCUGC 17

RESULT 919

US-09-864-785-1589
; Sequence 1589, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MH800-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1589
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1589

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 713 GAGGCGCTGCAGCAGC 728
|||||
Db 1 GAGGCCCGCUGCAGC 16

RESULT 920

US-09-864-785-1590
; Sequence 1590, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MH800-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1590
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1590

```
Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 257 GCCATGCTGCACCTGC 272
DB 1 GCCUCGUGCAGCAGC 16

RESULT 921
US-09-864-785-1704/c
; Sequence 1704, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1704
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1704

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 530 CTGAGAGATGCCAGC 545
DB 17 CTGGAGAGCTGCCAGC 2

RESULT 922
US-09-864-785-2754
; Sequence 2754, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2754
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2754

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.3e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 175 ACTGTGTGAGATGGT 190
DB 175 ACTGTGTGAGATGGT 190
```

```
Db 2 ACUGUGUGACAAGGUG 17

RESULT 923
US-09-825-805-477
; Sequence 477, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 477
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-477

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.3e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 263 CTGCACCTGCCTTCAG 278
DB 1 CUCCUCGUGCCUUCAG 16

RESULT 924
US-09-825-805-604
; Sequence 604, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
```

```

; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 604
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-604

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 512 CTGCGGAGGTGGAGC 527
|:|||||||:||||
Db 1 CUGCGGAGCUGCAGC 16

RESULT 925
US-09-818-875-351
; Sequence 351, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-351

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGGAGCGTGGCAG 379
|||||||:||||
Db 2 GCGTGAGCGTTCGAG 17

RESULT 926
US-09-818-875-352/c
; Sequence 352, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-351

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGGAGCGTGGCAG 379
|||||||:||||
Db 2 GCGTGAGCGTTCGAG 17

RESULT 928
US-09-818-875-1376
; Sequence 1376, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1375
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-1375

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGC 736
|||||||:||||
Db 17 GCAGCAGCAGCTCCGC 2

RESULT 928
US-09-818-875-1376
; Sequence 1376, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1375
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-1375

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGC 736
|||||||:||||
Db 17 GCAGCAGCAGCTCCGC 2

```



```

; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1376
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-1376

```

```

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 721 GCAGCAGCAGCAGC 736
Db 1 GCAGCAGCAGCAGC 16

```

RESULT 929

```

US-09-818-875-3102
; Sequence 3102, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3102
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3102

```

```

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 724 GCAGCAGCAGCAGC 739
Db 1 GCAGCAGCAGCAGC 16

```

RESULT 930

```

US-09-818-875-3103/c
; Sequence 3103, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3103
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3103

```

```

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 724 GCAGCAGCAGCAGC 739
Db 17 GCAGCAGCAGCAGC 2

```

RESULT 931

```

US-09-818-875-3414
; Sequence 3414, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3414
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3414

```

```

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 757 CATGCTCGGCCAGAGC 772
Db 1 CATGCTCGGCCAGAGC 16

```

RESULT 932

```

US-09-818-875-3415/c

```

; Sequence 3415, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Knitec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3415
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3415

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 757 CATGCTGGCCAGAGC 772
Db 17 CATGCTGGCCAGAGC 2

RESULT 933
US-09-780-533A-15
; Sequence 15, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 15
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-15

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.3e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 233 GAAGAGTCTCTCTGG 248
Db 2 GACCAGUCCUCCUGG 17

RESULT 934
US-09-780-533A-785
; Sequence 785, Application US/09780533A
; Publication No. US20030060611A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 785
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-785

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 7.3e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 233 GAAGAGTCTCTCTGG 248
Db 1 GACCAGUCCUCCUGG 16

RESULT 935
US-09-780-533A-1938
; Sequence 1938, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1938
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1938

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 487 TCTGAAGGCGCAGAAG 502
Db 1 UUGAAGAGUCAGAAG 16

RESULT 936
US-09-780-533A-2540
; Sequence 2540, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene

```

; FILE REFERENCE: MBHB00.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2540
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2540

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 486 ATCTGAAGAGGAGGAG 501
Db 2 AUUUGAAGAGUCAGAA 17

RESULT 937
US-09-927-046-1353
; Sequence 1353, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride
; TITLE OF INVENTION: Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1353
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1353

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 477 AGAAGCTCGATCTGAA 492
Db 1 AUAAGUCGACUCAGAA 16

RESULT 938
US-09-877-478-687/c
; Sequence 687, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1416
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1416

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 GAGGAGGAGGAGGAG 421
Db 16 GAGGAGGAGGAGGAG 1

RESULT 939
US-09-877-478-1416/c
; Sequence 1416, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1416
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1416

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 GAGGAGGAGGAGGAG 421

```

```

; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 687
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-687

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 GAGGAGGAGGAGGAG 421
Db 16 GAGGAGGAGGAGGAG 1

RESULT 939
US-09-877-478-1416/c
; Sequence 1416, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1416
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1416

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 GAGGAGGAGGAGGAG 421

```

Db 17 GAGCAGGAGGAGGAG 2
||||| ||||| |||||

RESULT 940

US-09-848-754A-2408
; Sequence 2408, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBH00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2408
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2408

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 600 GGCAGGCTGCAGGAGGAG 615
|||:|||||
Db 2 GCGUGUGCAGGAGGAG 17

RESULT 941

US-09-848-754A-3399
; Sequence 3399, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBH00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3399
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3399

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGGAGCCAG 619
||:|||||
Db 2 GCUGCAGGAGGAGGAG 17

RESULT 942

US-09-776-474-126/c
; Sequence 126, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Bocher, Robert
; APPLICANT: Holman, Patricia
; APPLICANT: Fattaey, Ali
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK-1)
; CURRENT APPLICATION NUMBER: US/09/827,395A

; FILE REFERENCE: MBH00-955-A (400/008)
; CURRENT APPLICATION NUMBER: US/09/776,474
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,983
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 2992
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 126
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-776-474-126

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 606 TGCAGGAGAGCCAGAG 621
||||| ||||| |||||
Db 16 TGCAGCAGAGCTAGAG 1

RESULT 943

US-09-776-474-479/c
; Sequence 479, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Bocher, Robert
; APPLICANT: Holman, Patricia
; APPLICANT: Fattaey, Ali
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK-1)
; CURRENT APPLICATION NUMBER: US/09/776,474
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,983
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 2992
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-776-474-479

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 606 TGCAGGAGAGCCAGAG 621
||||| ||||| |||||
Db 17 TGCAGCAGAGCTAGAG 2

RESULT 944

US-09-827-395A-12/c
; Sequence 12, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A

; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-12

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 686 CAGGCGCGCAGCTGG 701
Db 17 CAGGCGCGGAGCTGG 2

RESULT 945
US-09-827-395A-19/c
; Sequence 19, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 19
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-19

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGGCCAG 619
Db 16 GCTCCAGGAGGCCAG 1

RESULT 946
US-09-827-395A-65/c
; Sequence 65, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11

; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 65
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-65

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 CCCTCGGAGGAGGAG 820
Db 16 CACCTCGGAGGAGGAG 1

RESULT 947
US-09-827-395A-195/c
; Sequence 195, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 195
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-195

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGGCCAG 619
Db 17 GCTCCAGGAGGCCAG 2

RESULT 948
US-09-827-395A-367/c
; Sequence 367, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 367
; LENGTH: 17
; TYPE: RNA

```
; ORGANISM: Homo sapiens
US-09-827-395A-367

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 CGCCTCGGAGGAGAG 820
Db 17 CACCTCGGAGGAGG 2

RESULT 949
US-09-827-395A-377/c
; Sequence 377, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 377
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-377

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 506 CAGCGTCTGCGGAGG 521
Db 16 CAGCGTGTGCGGAGG 1

RESULT 950
US-09-827-395A-596/c
; Sequence 596, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 596
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-596

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
```

```
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 685 GCAGGCGCGCAGCTG 700
Db 16 GCAGGACCGAGAGCTG 1

RESULT 951
US-09-827-395A-695/c
; Sequence 695, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 695
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-695

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 800 CAGGCGCGCTCGGAGG 815
Db 16 CAGGCGACCTCGGAGG 1

RESULT 952
US-09-827-395A-935/c
; Sequence 935, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 935
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-935

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 802 GCGCGCTCGGAGGAG 817
Db 17 GGCACCTCGGAGGAG 2
```

```
RESULT 953
US-09-740-332-215/c
; Sequence 215, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 215
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-215

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 181 TCAGATGGTGCAGCCC 196
    ||| ||| ||| |||
Db 17 TCACATGGTACAGCCC 2

RESULT 954
US-09-740-332-1115
; Sequence 1115, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1115
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1115

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 7.3e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 383 CTTCTGCATTTCCAAG 398
    ||| ||| ||| |||
Db 1 CUUCUGCCAUCCAAG 16

RESULT 955
US-09-740-332-3567
; Sequence 3567, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
```

```
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3567
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3567

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 735 GCGTCAGGTGGACCA 750
    ||| ||| ||| |||
Db 1 GCGUGAGGUGGGCCA 16

RESULT 956
US-09-740-332-3831/c
; Sequence 3831, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3831

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 829 GGCCCAAGTTCAGGTG 844
    ||| ||| ||| ||| |||
Db 16 GGCCCAAGTTCAGGTG 1

RESULT 957
US-09-792-818-271
; Sequence 271, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insertion of a Gene
; FILE REFERENCE: MEH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
```

; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 271
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-271

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 393 TCCAAGCCAGCCAGAG 408
Db 2 UCCGGGCCAGCCAGAG 17
||| ||||| |||||

RESULT 958

US-09-792-818-272
; Sequence 272, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 272
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-272

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 393 TCCAAGCCAGCCAGAG 408
Db 1 UCCGGGCCAGCCAGAG 16
:||| ||||| |||||

RESULT 959

US-09-792-818-361
; Sequence 361, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 361
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-361

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 718 GCTGCAGCAGCAGCAC 733
Db 1 GCAGCAGCAGCAGCAC 16
||| ||||| |||||

RESULT 960

US-09-792-818-607
; Sequence 607, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 607
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-607

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 717 CGCTGCAGCAGCAGCA 732
Db 2 CCUGCAGCAGCAGCA 17
|:| ||||| |||||

RESULT 961

US-09-792-818-873
; Sequence 873, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 873
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-873

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 731 CACAGGTCAGGTGG 746
||| ||||| |||||

Db 2 CACAGCGGGGAGGUGG 17

RESULT 962

US-09-818-874

Sequence 874, Application US/09792818

Publication No. US20030134806A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Jarvis, Thale

APPLICANT: Von Carlowitz, Ira

APPLICANT: McSwiggen, Jim

APPLICANT: Hamblin, Paul

APPLICANT: Ellis, Jonathan

TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insertion

TITLE OF INVENTION: (GRID) Gene

FILE REFERENCE: MBH00-901-A (400/013)

CURRENT APPLICATION NUMBER: US/09/792,818

CURRENT FILING DATE: 2001-02-23

NUMBER OF SEQ ID NOS: 2304

SOFTWARE: PatentIn version 3.0

SEQ ID NO 874

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-792-818-874

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 7.3e+02;

Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 731 CACAGCGTGCAGGTGG 746

Db 1 CACAGCGGGGAGGUGG 16

RESULT 963

US-09-817-879-215/c

Sequence 215, Application US/09817879

Publication No. US20030171311A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals Inc.

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection

FILE REFERENCE: MBH00-801-F

CURRENT APPLICATION NUMBER: US/09/817,879

CURRENT FILING DATE: 2001-03-26

NUMBER OF SEQ ID NOS: 9703

SOFTWARE: PatentIn version 3.0

SEQ ID NO 215

LENGTH: 17

TYPE: RNA

ORGANISM: artificial sequence

FEATURE:

NAME/KEY: misc_feature

LOCATION:

OTHER INFORMATION: oligonucleotide substrate

US-09-817-879-215

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 7.3e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 181 TCAGATGGTGCAGCCC 196

Db 17 TCAGATGGTGCAGCCC 2

RESULT 964

US-09-817-879-1115

Sequence 1115, Application US/09817879

Publication No. US20030171311A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals Inc.

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection

FILE REFERENCE: MBH00-801-F

CURRENT APPLICATION NUMBER: US/09/817,879

CURRENT FILING DATE: 2001-03-26

NUMBER OF SEQ ID NOS: 9703

SOFTWARE: PatentIn version 3.0

SEQ ID NO 1115

LENGTH: 17

TYPE: RNA

ORGANISM: artificial sequence

FEATURE:

NAME/KEY: misc_feature

LOCATION:

OTHER INFORMATION: oligonucleotide substrate

US-09-817-879-1115

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 56.2%; Pred. No. 7.3e+02;

Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 383 CTCTGTCATTCCCAAG 398

Db 1 CUUCUGCAUCCCAAG 16

RESULT 965

US-09-817-879-3567

Sequence 3567, Application US/09817879

Publication No. US20030171311A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals Inc.

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection

FILE REFERENCE: MBH00-801-F

CURRENT APPLICATION NUMBER: US/09/817,879

CURRENT FILING DATE: 2001-03-26

NUMBER OF SEQ ID NOS: 9703

SOFTWARE: PatentIn version 3.0

SEQ ID NO 3567

LENGTH: 17

TYPE: RNA

ORGANISM: artificial sequence

FEATURE:

NAME/KEY: misc_feature

LOCATION:

OTHER INFORMATION: oligonucleotide substrate

US-09-817-879-3567

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 7.3e+02;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 735 GCGTGCAGGTGGACCA 750

Db 1 GCGUGAGGUGGGCCA 16

RESULT 966

US-09-817-879-3831/c

Sequence 3831, Application US/09817879

Publication No. US20030171311A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals Inc.

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection

FILE REFERENCE: MBH00-801-F

CURRENT APPLICATION NUMBER: US/09/817,879

CURRENT FILING DATE: 2001-03-26

NUMBER OF SEQ ID NOS: 9703

SOFTWARE: PatentIn version 3.0

SEQ ID NO 3831

LENGTH: 17

TYPE: RNA

ORGANISM: artificial sequence

FEATURE:

NAME/KEY: misc_feature

LOCATION:

OTHER INFORMATION: oligonucleotide substrate

US-09-817-879-3831

Query Match 1.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 7.3e+02;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 735 GCGTGCAGGTGGACCA 750

Db 1 GCGUGAGGUGGGCCA 16

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3831

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      829  GGCCAGTTCAGGTG 844
Db       16  GGCCAGTTCAGGTG 1

RESULT 967
US-10-060-830-311
; Sequence 311, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 311
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-311

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      500  AAGGAGCAGGCTCTGC 515
Db       2   AAGAGCAGGCTATGC 17

RESULT 968
US-10-060-830-312
; Sequence 312, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 312
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-312

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      500  AAGGAGCAGGCTCTGC 515
Db       1   AAGAAGCAGGCTATGC 16

RESULT 969
US-10-060-998-236
; Sequence 236, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 236
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-236

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      448  CAGGAACCTGGTGGAG 463
Db       2   CATGAACCTGGAGGAG 17

RESULT 970
US-10-060-998-237
; Sequence 237, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
```

```

; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 237
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-237

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 448 CAGGAACCTGGTGGAG 463
|| |||||
Db 1 CATGAACCTGGAGGAG 16

RESULT 971
US-10-060-998-1476/c
; Sequence 1476, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1476
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1476

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 884 AAGACGACGCTGGTGG 899
|| |||||
Db 17 AGGAGCAGCGTAGTGG 2

RESULT 972
US-10-060-998-1477/c
; Sequence 1477, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23

```

```

; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1477
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1477

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 884 AAGACGACGCTGGTGG 899
|| |||||
Db 16 AGGAGCAGCGTAGTGG 1

RESULT 973
US-10-163-552-135
; Sequence 135, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 135
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-135

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 512 CTGCGGAGCGTGGAGC 527
|| |||||
Db 1 CUGCGGAGCGUGCAGC 16

RESULT 974
US-10-163-552-870
; Sequence 870, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 870
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-870

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 263 CTGCACCTGCCTTCAG 278

```

```
Db      1 CUCCUCCGCGUUCAG 16
      |:|:|:|:|:|:|:|
RESULT 975
US-10-156-306-1663/c
; Sequence 1663, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1663
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1663

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      493 GAGGCAGAGGAGGAGC 508
      |||||
Db      17 GAGGCAGAGGAGGAGC 2

RESULT 976
US-10-156-306-1664/c
; Sequence 1664, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1664
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1664

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      491 AAGAGGCAGAGGAGC 506
      |||||
Db      16 AAGAGGCAGAGGAGTGC 1

RESULT 977
US-10-156-306-5007
; Sequence 5007, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
```

```
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5007
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5007
```

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      694 GCAGCTGGAGAGTGAG 709
      |||||
Db      1 GCAGCUGCAGAGGGAG 16
```

RESULT 978

```
US-10-156-306-5121/c
; Sequence 5121, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5121
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5121
```

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      190 GCAGCCGAGTGCTGCG 205
      |||||
Db      16 GCATCCGAGTGTGCG 1
```

RESULT 979

```
US-10-156-306-5922/c
; Sequence 5922, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5922
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5922
```

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      748 CCAGCTGGCGCATGCG 763
      |||||
```

```
Dbb 16 CCAGCTGCTCTGCAG 1

RESULT 980
US-10-156-306-5924
; Sequence 5924, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5924
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5924

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 740 CAGGTGGACGACTGC 755
|||:|||||:|
Db 1 CAGCUGGACGACGUCG 16

RESULT 981
US-10-156-306-5925
; Sequence 5925, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5925
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5925

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 522 TGGAGCACCTGAAGAG 537
:|||||:|:|
Db 2 UGAGCAGCUGCAGAG 17

RESULT 982
US-10-156-306-6361/c
; Sequence 6361, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
```

```
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6361
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6361

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 191 CAGCCAGTGTGGCC 206
|||:|||||:|
Db 17 CATCCAGTTGTGGCC 2

RESULT 983
US-10-156-306-7019
; Sequence 7019, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7019
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7019

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 411 AGGAGAGGAGTTCCT 426
|||:|||||:|
Db 1 AGAAGAGGAGCUCUC 16

RESULT 984
US-10-156-306-7021/c
; Sequence 7021, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7021
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7021

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 749 CAGCTGGCAGTCAGG 764
|||:|||||:|
Db 17 CAGCTGCTCCTGCAGG 2
```

```
RESULT 985
US-10-156-306-7023
; Sequence 7023, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7023
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7023

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 739 GCAGGTGGACGACGCTG 754
|||||:|||||:|
Db 2 GCAGCUGGAGCAGCUG 17

RESULT 986
US-10-156-306-7038
; Sequence 7038, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7038
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7038

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 812 GAGGACAGAGGAGGAGC 827
|||||:|||||:|
Db 1 GAGGACAGAGGAGGAGC 16

RESULT 987
US-10-238-700-3318/c
; Sequence 3318, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH801-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
```

```
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3318
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3318

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 571 TGTGAAGGCCAGGTG 586
|||||:|||||:|
Db 17 TGTGAAGGCCAGGAG 2

RESULT 988
US-10-238-700-3356/c
; Sequence 3356, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels
; FILE REFERENCE: 400/057 (MBH801-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3356
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3356

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 740 CAGGTGGACGACGCTG 755
|||||:|||||:|
Db 17 CAGACGGACGACGCTG 2

RESULT 989
US-10-061-201-51
; Sequence 51, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
```

; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 51
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-51

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 617 CAGAGTCGCTTGAGG 632
||| |||||
Db 2 CAGCGCGCTTGAGG 17

RESULT 990

US-10-061-201-52
; Sequence 52, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 52
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-52

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 617 CAGAGTCGCTTGAGG 632
||| |||||
Db 1 CAGCGCGCTTGAGG 16

RESULT 991

US-10-061-201-302
; Sequence 302, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 302
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-302

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 471 GCTCGAGAGCTCGA 486
||| |||||
Db 2 GCTTGAGAGCTCGA 17

RESULT 992

US-10-061-201-304
; Sequence 304, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 304
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-304

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 991

; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 304
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-304

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 472 CCTGGAAGCTCGAT 487
Db 1 CTTTGAAGCTCGAT 16

RESULT 993
US-10-061-201-305
; Sequence 305, Application US/10061201
; Publication No. US2003016229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 305
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-305

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 474 TGGGAAGCTCGATCT 489
Db 2 TTGGAAGCTCGATGT 17

RESULT 994
US-10-061-201-306
; Sequence 306, Application US/10061201
; Publication No. US2003016229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark

; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 306
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-306

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 474 TGGGAAGCTCGATCT 489
Db 1 TTGGAAGCTCGATGT 16

RESULT 995
US-10-061-201-307
; Sequence 307, Application US/10061201
; Publication No. US2003016229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 307
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-307

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 474 TGGGAAGCTCGATCT 489
Db 2 TTGGAAGCTCGATGT 17

RESULT 996
US-10-061-201-308
; Sequence 308, Application US/10061201
; Publication No. US2003016229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark


```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1046
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1046

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 GCCAGCCATGCTGCAC 268
      ||||| ||| |||||
Db 2 GCCAGTCATCTGCAC 17

RESULT 998
US-10-061-201-1047
; Sequence 1047, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1047
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1047

```

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 253 GCCAGCATGCTGCAC 268
      ||||| ||||| |||||
Db 1 GCCAGTCATCTGCAC 16

RESULT 999
US-10-084-839-3484
; Sequence 3484, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lyamacheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3484
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3484

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 784 GCTCCGATGCTGCAC 799
      ||||| ||||| |||||
Db 2 GATCCGATGCTGCAC 17

RESULT 1000
US-10-230-006-107/c
; Sequence 107, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 683
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-683
```

```
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 107
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-107

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGC 692
      ||||| ||||| |||||
Db 17 GCCAGGAGAGCGCGC 2

RESULT 1001
US-10-230-006-487/c
; Sequence 487, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 487
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-487

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 706 TGAGCGCGAGCGCTG 721
      ||||| ||||| |||||
Db 17 TGAGCGCTGCGCGCTG 2

RESULT 1002
US-10-230-006-683/c
; Sequence 683, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 683
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-683
```

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 677 GCCAGCGAGCGCGC 692
Db 16 GCCAGGAGAGCGCGC 1

RESULT 1003
US-10-230-006-1226/c
; Sequence 1226, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1226
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1226

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 705 GTGAGCGCGAGCGCCT 720
Db 16 GTGAGCGCGCTGGCGCT 1

RESULT 1004
US-10-230-006-1316
; Sequence 1316, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1316
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1316

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 353 AACCGAGTCTCGGG 368
Db 2 AACCGAGUCUGCGG 17

RESULT 1005
US-10-230-006-1403
```

```
; Sequence 1403, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1403
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1403

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 473 CTGGAGAGCTCGATC 488
Db 1 CUGGAGGAGCUGGAUC 16

RESULT 1006
US-10-230-006-2205
; Sequence 2205, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2205
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2205

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 7.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 472 CCTGGAGAGCTCGAT 487
Db 2 CCUGGAGGAGCUGGAU 17

RESULT 1007
US-10-430-882-12/c
; Sequence 12, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haeblerl
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
```

; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-12

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 686 CAGCGCGGCGAGCTGG 701
||||| ||||| ||||| |||||
Db 17 CAGGCACGGAAGCTGG 2

RESULT 1008
US-10-430-882-19/c
; Sequence 19, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 19
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-19

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGGCGCAG 619
||||| ||||| ||||| |||||
Db 16 GCTCCAGGAGGCGCAG 1

RESULT 1009
US-10-430-882-65/c
; Sequence 65, Application US/10430882
; Publication No. US20030203870A1

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 65
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-65

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 CGCTCGGAGGAGAG 820
||||| ||||| ||||| |||||
Db 16 CACCTCGGAGGAGAG 1

RESULT 1010
US-10-430-882-195/c
; Sequence 195, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 195
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-195

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 604 GCTGCAGGAGGCCAG 619
 DB 17 GCTCCAGGAGGCCAG 2

RESULT 1011
 US-10-430-882-367/c
 ; Sequence 367, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowrira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; CURRENT FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: PCT/US01/04273
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; PRIOR APPLICATION NUMBER: PCT/US02/10512
 ; PRIOR FILING DATE: 2002-04-03
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 367
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-367

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 805 CGCTCGGAGGAGAG 820
 DB 17 CACCTCGGAGGAGG 2

RESULT 1012
 US-10-430-882-377/c
 ; Sequence 377, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowrira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; CURRENT FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: PCT/US01/04273
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; PRIOR APPLICATION NUMBER: PCT/US02/10512
 ; PRIOR FILING DATE: 2002-04-03
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 377

; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-377

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 506 CAGGCTCTGCGGAGG 521
 DB 16 CAGGCGTTGCGGAGG 1

RESULT 1013
 US-10-430-882-596/c
 ; Sequence 596, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowrira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; CURRENT FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: PCT/US01/04273
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; PRIOR APPLICATION NUMBER: PCT/US02/10512
 ; PRIOR FILING DATE: 2002-04-03
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 596
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-596

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 685 GCAGCGCGGAGGCTG 700
 DB 16 GCAGGCGAGGAGCTG 1

RESULT 1014
 US-10-430-882-695/c
 ; Sequence 695, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowrira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; CURRENT FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; CURRENT APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 695
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-695

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 800 CAGGCCGCTCGAGG 815
||| |||||
Db 16 CAGGCACCTCGGAGG 1

RESULT 1015
US-10-430-882-935/c
; Sequence 935, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haeblerli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor
; FILE REFERENCE: MEH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 935
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-935

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 802 GCGCGCTCGAGG 817
||| |||||
Db 17 GGCACCTCGGAGG 2

RESULT 1016
US-10-209-787-351
; Sequence 351, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single

; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-351

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTCGAG 379
||| |||||
Db 2 GCGTGGCGCTTCGAG 17

RESULT 1017
US-10-209-787-352/c
; Sequence 352, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-352

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTCGAG 379
||| |||||
Db 16 GCGTGGCGCTTCGAG 1

RESULT 1018
US-10-209-787-1375/c

; Sequence 1375, Application US/10209787
 ; Publication No. US20030217377A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamper, Howard B.
 ; APPLICANT: Rice, Michael C.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; TITLE OF INVENTION: Stranded Oligonucleotides
 ; FILE REFERENCE: Napro-4
 ; CURRENT APPLICATION NUMBER: US/10/209,787
 ; CURRENT FILING DATE: 2002-07-30
 ; PRIOR APPLICATION NUMBER: US 09/818,875
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 1375
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-209-787-1375

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGCAGC 736
 DB 17 GCAGCAGCAGCTCCGC 2

RESULT 1019
 US-10-209-787-1376
 ; Sequence 1376, Application US/10209787
 ; Publication No. US20030217377A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamper, Howard B.
 ; APPLICANT: Rice, Michael C.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; TITLE OF INVENTION: Stranded Oligonucleotides
 ; FILE REFERENCE: Napro-4
 ; CURRENT APPLICATION NUMBER: US/10/209,787
 ; CURRENT FILING DATE: 2002-07-30
 ; PRIOR APPLICATION NUMBER: US 09/818,875
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 1376
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-209-787-1376

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGCAGC 736
 DB 1 GCAGCAGCAGCTCCGC 16

RESULT 1020
 US-10-209-787-3102
 ; Sequence 3102, Application US/10209787
 ; Publication No. US20030217377A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamper, Howard B.
 ; APPLICANT: Rice, Michael C.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; TITLE OF INVENTION: Stranded Oligonucleotides
 ; FILE REFERENCE: Napro-4
 ; CURRENT APPLICATION NUMBER: US/10/209,787
 ; CURRENT FILING DATE: 2002-07-30
 ; PRIOR APPLICATION NUMBER: US 09/818,875
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3102
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-209-787-3102

Query Match 1.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 7.3e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCGTG 739
 DB 1 GCAGCAGCAGCATCGAG 16

RESULT 1021
 US-10-209-787-3103/c
 ; Sequence 3103, Application US/10209787
 ; Publication No. US20030217377A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamper, Howard B.
 ; APPLICANT: Rice, Michael C.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; TITLE OF INVENTION: Stranded Oligonucleotides
 ; FILE REFERENCE: Napro-4
 ; CURRENT APPLICATION NUMBER: US/10/209,787
 ; CURRENT FILING DATE: 2002-07-30
 ; PRIOR APPLICATION NUMBER: US 09/818,875
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3103
 ; LENGTH: 17
 ; TYPE: DNA

```
; ORGANISM: Homo sapiens
US-10-209-787-3103

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCACAGCGTG 739
Db 17 GCAGCAGCACATCGAG 2

RESULT 1022
US-10-209-787-3414
; Sequence 3414, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3414
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3414

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 757 CATCGAGGCCAGCAGC 772
Db 1 CATGCTCGGCCAGCAGC 16

RESULT 1023
US-10-209-787-3415/c
; Sequence 3415, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
```

```
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3415
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3415

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 757 CATCGAGGCCAGCAGC 772
Db 17 CATGCTCGGCCAGCAGC 2

RESULT 1024
US-10-307-005-1623
; Sequence 1623, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; TITLE OF INVENTION: Using Modified Single Stranded Oligonucleotides
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1623
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Oryza sativa
US-10-307-005-1623

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 409 GGAGGAGAGGAGGATTC 424
Db 2 GGAGGCAAGAGGATTC 17

RESULT 1025
US-10-307-005-1624/c
; Sequence 1624, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; TITLE OF INVENTION: Using Modified Single Stranded Oligonucleotides
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
```



```
RESULT 1029
US-10-261-185-1376
; Sequence 1376, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1376
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-1376

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      721 GCAGCAGCAGCAGCAGC 736
Db      1 GCAGCAGCAGCTCCGC 16

RESULT 1030
US-10-261-185-3102
; Sequence 3102, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3102
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3102

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      721 GCAGCAGCAGCAGCAGC 736
Db      1 GCAGCAGCAGCTCCGC 16

RESULT 1031
US-10-261-185-3103/C
; Sequence 3103, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3103
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3103

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      724 GCAGCAGCAGCAGCGTG 739
Db      1 GCAGCAGCAGCATCGAG 16

RESULT 1032
US-10-261-185-3414
; Sequence 3414, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3414
```

```
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      724 GCAGCAGCAGCAGCGTG 739
Db      1 GCAGCAGCAGCATCGAG 16

RESULT 1031
US-10-261-185-3103/C
; Sequence 3103, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3103
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3103

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      724 GCAGCAGCAGCAGCGTG 739
Db      17 GCAGCAGCAGCATCGAG 2

RESULT 1032
US-10-261-185-3414
; Sequence 3414, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3414
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3414

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 757 CATGCTCGGCCAGAGC 772
    ||||| ||||| |||||
Db 1 CATGCTCGGCCAGAGC 16

RESULT 1033
US-10-261-185-3415/c
; Sequence 3415, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3415
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3415

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 757 CATGCTCGGCCAGAGC 772
    ||||| ||||| |||||
Db 17 CATGCTCGGCCAGAGC 2

RESULT 1034
US-10-342-902-687/c
; Sequence 687, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/596,347
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1416
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1416

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 GAGGCGAGGAGGAGGAG 421
    ||||| ||||| |||||
Db 17 GAGGCGAGGAGGAGGAG 2

RESULT 1036
US-10-138-674-479
```

```
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 687
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-687

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 GAGGCGAGGAGGAGGAG 421
    ||||| ||||| |||||
Db 16 GAGGCGAGGAGGAGGAG 1

RESULT 1035
US-10-342-902-1416/c
; Sequence 1416, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/596,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1416
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1416

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 GAGGCGAGGAGGAGGAG 421
    ||||| ||||| |||||
Db 17 GAGGCGAGGAGGAGGAG 2

RESULT 1036
US-10-138-674-479
```

```
; Sequence 479, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-479

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 875 AACACACATCAAGAGCA 890
||| ||| : ||| |||
Db 1 AACUACCUCAAGAGCA 16

RESULT 1037
US-10-138-674-3556/c
; Sequence 3556, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3556
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3556

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GAGAAGAGGAGGCTGG 830
||||| ||| ||| |||
Db 17 GAGAAGCAGAGGCTGG 2

RESULT 1038
US-10-138-674-4770
; Sequence 4770, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
```

```
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4770
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4770

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACACATCAAGAGC 889
||||| ||| : ||| |||
Db 2 CAACUACCUCAAGAGC 17

RESULT 1039
US-10-676-154-648
; Sequence 648, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; FILE REFERENCE: M0656/7045 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/676,154
; CURRENT FILING DATE: 2003-09-29
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 648
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-10-676-154-648

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 397 AGCCAGCCAGAGGGAG 412
||||| ||| ||| |||
Db 1 AGGCAGCTAGAGGGAG 16

RESULT 1040
US-10-287-949A-479
; Sequence 479, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
```

; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-479

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 875 AACACATCAAGGCA 890
||| | : |||||
Db 1 AACUACCUCAAGGCA 16

RESULT 1041
US-10-287-949A-3556/c
; Sequence 3556, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3556
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3556

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GAGAAGGAGGAGCTGG 830
||| | : |||||
Db 17 GAGAAGCAGAGCTGG 2

RESULT 1042
US-10-287-949A-4770
; Sequence 4770, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4770
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4770

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 7.3e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 874 CAACCATCAAGAGC 889
||| | : |||||
Db 2 CAACUACCUCAAGAGC 17

RESULT 1043
US-10-712-672-1992
; Sequence 1992, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1992
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1992

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 624 GCTTGGAGGCTGCCAC 639
||| | : |||||
Db 2 GCUCGGCGGCGGCCAC 17

RESULT 1044
US-10-669-841-687/c
; Sequence 687, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11


```
RESULT 1047
US-10-669-841-3708
; Sequence 3708, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3708
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; FEATURE:
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-3708

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 7.3e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 383 CTTCTGCAATTCACG 398
Db 1 CUUCUGCCAUCACG 16

RESULT 1048
US-10-669-841-6160
; Sequence 6160, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3708
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; FEATURE:
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-3708

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 7.3e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 383 CTTCTGCAATTCACG 398
Db 1 CUUCUGCCAUCACG 16

RESULT 1049
US-10-669-841-6424/c
; Sequence 6424, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6160
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; FEATURE:
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6160

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 735 GCGTCAGGTGGACCA 750
Db 1 GCGUGAGGUGGGCCA 16

RESULT 1049
US-10-669-841-6424/c
; Sequence 6424, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6160
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; FEATURE:
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6160

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 7.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 735 GCGTCAGGTGGACCA 750
Db 1 GCGUGAGGUGGGCCA 16
```

```

; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6424
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6424

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 829 GGCGCAGTTCAGGTG 844
Db 16 GGCGCAGTTCAGGTG 1

RESULT 1050
US-10-723-361-354/c
; Sequence 354, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-355

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 354
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-354

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 482 CTCGATCTCGAAGGC 497
Db 17 CTCGTTCTGAGAGGC 2

RESULT 1051
US-10-723-361-355/c
; Sequence 355, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-355

Query Match          1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```


QY 482 CTCGATCTCAAGAGGC 497
Db 16 CTCGTTCTCGAGGC 1

RESULT 1052

US-10-723-361-672/c
; Sequence 672, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 672
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-672

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
Db 17 GATGAGTCTCTCTGG 2

RESULT 1053

US-10-723-361-673/c
; Sequence 673, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 673
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-673

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 233 GAAGAGTCTCTCTGG 248
Db 16 GATGAGTCTCTCTGG 1

RESULT 1054

US-10-723-361-1523/c
; Sequence 1523, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aescamca Sequence Listing Engine
; SEQ ID NO 1523
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1523

```

Query Match	1.7%	Score 12.8;	DB 1;	Length 17;
Best Local Similarity	87.5%;	Pred. No. 7.3e+02;		
Matches 14;	Conservative	0;	Mismatches 2;	Indels 0;
Gaps	0;			

RESULT 1055
US-10-723-361-1524/c
; Sequence 1524, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

Query Match	1.7%	Score 12.8;	DB 1;	Length 17;
Best Local Similarity	87.5%;	Pred. No. 7.3e+02;		
Matches 14;	Conservative	0;	Mismatches 2;	Indels 0;
Gaps 0;				

RESULT 1056
US-10-723-361-1720/c
; Sequence 1720, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AND
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1720
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-1720

Query Match	1.7%	Score 12.8;	DB 1;	Length 17;
Best Local Similarity	87.5%;	Pred. No.	7.3e+02;	
Matches 14;	Conservative	0;	Mismatches 2;	Indels 0; Gaps 0;
Qy	392	TTCCAAGCCAGCCAGA	407	
Db	17	TTCTGAGCCAGCCAGA	2	

```

RESULT 1057
US/10-723-361-1721/c
; Sequence 1721, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,1

```

```
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1721
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-1721

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 392 TTCCAAGCCAGCCAGA 407
Db 16 TTCTGAGCCAGCCAGA 1

RESULT 1058
US-10-723-361-1996/c
; Sequence 1996, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
```

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1996
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-1996

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGCAATCA 324
Db 17 GCCTGGAGGAGCAATCA 2

RESULT 1059
US-10-723-361-1997/c
; Sequence 1997, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1997
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-1997

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 309 GCCTGGAGGAGCAATCA 324
Db 16 GCCTGGAGGAGCAATCA 1

RESULT 1060
```

US-10-723-361-6822/c
; Sequence 6822, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6822
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6822

Query Match 1.7% Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 ACCTGCTTCAGAAC 282
Db 17 ACCTGCTTCAGAAAA 2

RESULT 1061
US-10-723-361-6890/c
; Sequence 6890, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6890
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6890

Query Match 1.7% Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTTCGAGAGAA 321
Db 17 GCCGCTTGAAGAGAA 2

RESULT 1062

US-10-723-361-6891/c
; Sequence 6891, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine

; SEQ ID NO 6891
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6891

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 GCTGCTGGAGGAGAA 321
||| ||||| |||||
Db 16 GCCGCTGGAGAGAA 1

RESULT 1063
US-10-723-361-7677
; Sequence 7677, Application US/10723361
; Publication No. US20040137589A1

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7677
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7678

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGAGAGGAG 505
||||| ||||| |||||
Db 2 GAAGAAGCAGAGAGAG 17

RESULT 1064
US-10-723-361-7678
; Sequence 7678, Application US/10723361
; Publication No. US20040137589A1

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7677
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7677

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGAGAGGAG 505
||||| ||||| |||||
Db 2 GAAGAAGCAGAGAGAG 17

RESULT 1064
US-10-723-361-7678
; Sequence 7678, Application US/10723361
; Publication No. US20040137589A1

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7678
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7678

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGAGCGAGAGGAG 505
||||| ||||| |||||
Db 1 GAAGAAGCAGAGAGAG 16

RESULT 1065
US-10-723-361-7697/c
; Sequence 7697, Application US/10723361
; Publication No. US20040137589A1

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359

```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7697

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 828 TGGCCCGAGTTCAGGT 843
Db 17 TGGCCCGAGTTCAGGT 2

RESULT 1066
US-10-723-361-7699/c
; Sequence 7699, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7699
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7699/c
```

```
; ORGANISM: Homo sapiens
US-10-723-361-7699

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 827 CTGGCCCGAGTTCAGG 842
Db 16 CTGGCCCGAGTTCAGG 1

RESULT 1067
US-10-723-361-7812
; Sequence 7812, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7812
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7812

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 493 GAGGCAGAGGAGCAG 508
Db 2 GAAGCAAGAGGAGCAG 17

RESULT 1068
US-10-723-361-7814
; Sequence 7814, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

```
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7814
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7814

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 494 AGCGAGAGGAGCAGG 509
DB 1 AAGCAAAGGAGCAGG 16

RESULT 1069
US-10-723-361-8033
; Sequence 8033, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8034
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8034
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8033
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8033

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 696 AGCTGGAGATCGAGCG 711
DB 2 AGCTGGAGATCGAGCG 17

RESULT 1070
US-10-723-361-8034
; Sequence 8034, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8034
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8034
```

```
Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 596 AGCTGGAGAGTGCAGC 711
Db 1 AGCTGGAGATCGAGC 16

RESULT 1071
US-10-723-361-8423
; Sequence 8423, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8423
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8423

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 491 AAGACGAGAGGAGC 506
Db 1 AAGACGAGAGGAGTC 16

RESULT 1072
US-10-645-471A-22
; Sequence 22, Application US/10645471A
; Publication No. US20040171022A1
; GENERAL INFORMATION:
; APPLICANT: Ebbinhaus, Scot W.
; APPLICANT: Hurley, Laurence H.
; APPLICANT: Siddiqui-Jain, Adam
; APPLICANT: Memmott, Regan
; TITLE OF INVENTION: METHODS FOR REGULATING TRANSCRIPTION BY
```

```
; TITLE OF INVENTION: TARGETING QUADRUPEX DNA
; FILE REFERENCE: 532232000500
; CURRENT APPLICATION NUMBER: US/10/645,471A
; CURRENT FILING DATE: 2003-08-20
; PRIOR APPLICATION NUMBER: 60/404,965
; PRIOR FILING DATE: 2002-08-20
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-645-471A-22

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 490 GAAGGCGCAGAAGGAG 505
Db 2 GAAGGCGGAGGAGGAG 17

RESULT 1073
US-10-681-074-351
; Sequence 351, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: Napro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-351

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTCGAG 379
Db 2 GCGTGAGCGCTTCGAG 17

RESULT 1074
US-10-681-074-352/c
; Sequence 352, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: Napro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
```



```
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-352

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 364 GCGGAGCGCTCCGAG 379
DB 16 GCGTGAGCGCTTCGAG 1

RESULT 1075
US-10-681-074-1375/c
; Sequence 1375, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEIC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1375
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-1375

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 GCAGCAGCAGCAGCAGC 736
DB 17 GCAGCAGCAGCAGCTCCGC 2

RESULT 1076
US-10-681-074-1376
; Sequence 1376, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEIC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1376
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-10-681-074-1376

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCGTG 739
DB 1 GCAGCAGCAGCAGCTCGAG 16

RESULT 1078
US-10-681-074-3103/c
; Sequence 3103, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEIC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3103
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3103

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCGTG 739
DB 1 GCAGCAGCAGCAGCTCGAG 16

RESULT 1079
US-10-681-074-3102
; Sequence 3102, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEIC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3102
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3102

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCGTG 739
DB 1 GCAGCAGCAGCAGCTCGAG 16

RESULT 1080
US-10-681-074-3101
; Sequence 3101, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEIC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: NaPro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3101
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3101

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 724 GCAGCAGCAGCAGCGTG 739
DB 1 GCAGCAGCAGCAGCTCGAG 16
```

```
Db      17 GCAGCAGCACATCGAG 2
|||||
RESULT 1079
US-10-681-074-3414
; Sequence 3414, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3414
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3414

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      757 CATCGAGGGCCAGAGC 772
|||||
Db      1 CATGCTCGGCCAGAGC 16
|||||

RESULT 1080
US-10-681-074-3415/c
; Sequence 3415, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3415
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3415

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      757 CATCGAGGGCCAGAGC 772
|||||
Db      17 CATGCTCGGCCAGAGC 2
|||||

RESULT 1081
US-10-498-462-65
; Sequence 65, Application US/10498462
```

```
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 65
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-65

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      672 GCGCGCCGCGAGCA 687
|||||
Db      2 GCGCTCGCGAGCA 17
|||||

RESULT 1082
US-10-498-462-67
; Sequence 67, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 67
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-67

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      673 GCGCGCCGCGAGCA 688
|||||
Db      1 GCGCTCGCGAGCA 16
|||||

RESULT 1083
US-10-498-462-70
; Sequence 70, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
```

```
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 70
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-70

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 677 GCGAGCGAGCAGCGCG 692
Db 2 GCGAGCGAGCAGCGCG 17

RESULT 1084
US-10-498-462-72
; Sequence 72, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 72
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-72

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 678 CCAGCGCAGCAGCGCG 693
Db 1 CCAGCGCAGCAGCGCG 16

RESULT 1085
US-10-498-462-2024
; Sequence 2024, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2024
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2024

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 679 GCGAGCGAGCAGCGCG 692
Db 1 GCGAGCGAGCAGCGCG 16

RESULT 1086
US-10-498-462-2026
; Sequence 2026, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2026
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2026

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 AGATGCCATCCGGCAG 349
Db 1 AGATGCCATCCGGCAG 16

RESULT 1087
US-10-498-462-2111
; Sequence 2111, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2111
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2111

Query Match      1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 413 GAGAGGAGTTCCTCA 428
Db 2 GAGAGGAGTTCCTCA 17

RESULT 1088
US-10-498-462-2114
; Sequence 2114, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
```

; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 2114
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2114

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 415 GAAGGAGTTCCTCATG 430
|||||
Db 1 GAAGGAATGCCCTCATG 16
|||||

RESULT 1089
US-10-741-600-73370
; Sequence 73370, Application US/10741600
; Publication No. US20050026169A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001499
; CURRENT APPLICATION NUMBER: US/10/741,600
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 73997
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 73370
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-741-600-73370

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 601 GGAGCTGCAGGAGGC 616
|||||
Db 2 GGAGCTGCAGGTGATC 17
|||||

RESULT 1090
US-10-845-667-390/c
; Sequence 390, Application US/10845667
; Publication No. US20050026183A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Bibikova, Marina
; TITLE OF INVENTION: Methods and Compositions For Diagnosing
; TITLE OF INVENTION: Conditions Associated With Specific DNA Methylation Patterns
; FILE REFERENCE: 67234-091
; CURRENT APPLICATION NUMBER: US/10/845,667
; CURRENT FILING DATE: 2004-05-14
; PRIOR APPLICATION NUMBER: 60/471,488
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 1506
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 390
; LENGTH: 17
; TYPE: DNA

; ORGANISM: Homo sapiens
US-10-845-667-390

Query Match 1.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 7.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 811 GGAGGAGAAGAGGAAG 826
|||||
Db 16 GGAGGAGACGAGGAGG 1
|||||

Search completed: April 8, 2005, 08:52:46
Job time : 12 secs